sentence	label
The recent development of BC6ENTG antagonists devoid of clinical sedative effects has enabled the administration of doses of BC6OTHER - antihistamines which achieve a greater degree of BC6OTHER blockade within the airways , thus permitting a better appraisal of the role of BC6ENTC in this condition.	CPR:5
The recent development of BC6OTHER antagonists devoid of clinical sedative effects has enabled the administration of doses of BC6ENTG - antihistamines which achieve a greater degree of BC6OTHER blockade within the airways , thus permitting a better appraisal of the role of BC6ENTC in this condition.	False
The recent development of BC6OTHER antagonists devoid of clinical sedative effects has enabled the administration of doses of BC6OTHER - antihistamines which achieve a greater degree of BC6ENTG blockade within the airways , thus permitting a better appraisal of the role of BC6ENTC in this condition.	CPR:5
BC6ENTG antagonists have been utilized , following their initial chemical synthesis in 1933 , both in the treatment of conditions in which BC6OTHER is considered to be of pathogenic importance and conversely to help elucidate the role of BC6ENTC in disease , through an evaluation of their influence on disease expression.	CPR:5
Thus while both these agents offer the potential of an oral therapy for asthma based on an BC6ENTG antagonist , their additional actions do not make them ideally suited to the exploration of the role of BC6ENTC in asthma.	False
While there is considerable indirect evidence to implicate BC6ENTC in the pathogenesis of asthma , a critical evaluation of BC6ENTG antagonism in this condition has , until recently , proved difficult , as many of the early BC6OTHER antagonists possessed additional actions , such as anti - cholinergic , local anaesthetic , BC6OTHER antagonistic and anti - CHEM activity.	CPR:5
While there is considerable indirect evidence to implicate BC6ENTC in the pathogenesis of asthma , a critical evaluation of BC6OTHER antagonism in this condition has , until recently , proved difficult , as many of the early BC6ENTG antagonists possessed additional actions , such as anti - cholinergic , local anaesthetic , BC6OTHER antagonistic and anti - CHEM activity.	CPR:5
While there is considerable indirect evidence to implicate BC6ENTC in the pathogenesis of asthma , a critical evaluation of BC6OTHER antagonism in this condition has , until recently , proved difficult , as many of the early BC6OTHER antagonists possessed additional actions , such as anti - cholinergic , local anaesthetic , BC6ENTG antagonistic and anti - CHEM activity.	False
 BC6ENTC and asthma: an appraisal based on specific BC6ENTG antagonism.	False
BC6ENTC (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6OTHER [ BC6OTHER ] , the BC6OTHER transport inhibitor BC6OTHER , and the CB antagonist BC6OTHER did not have diuretic effects.	False
BC6OTHER (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6ENTC [ BC6OTHER ] , the BC6OTHER transport inhibitor BC6OTHER , and the CB antagonist BC6OTHER did not have diuretic effects.	CPR:5
BC6OTHER (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6OTHER [ BC6ENTC ] , the BC6OTHER transport inhibitor BC6OTHER , and the CB antagonist BC6OTHER did not have diuretic effects.	CPR:5
BC6OTHER (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6OTHER [ BC6OTHER ] , the BC6ENTC transport inhibitor BC6OTHER , and the CB antagonist BC6OTHER did not have diuretic effects.	False
BC6OTHER (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6OTHER [ BC6OTHER ] , the BC6OTHER transport inhibitor BC6ENTC , and the CB antagonist BC6OTHER did not have diuretic effects.	CPR:5
BC6OTHER (10.0 mg / kg) had lesser effect than other CB agonists , and the BC6ENTG agonist BC6OTHER [ BC6OTHER ] , the BC6OTHER transport inhibitor BC6OTHER , and the CB antagonist BC6ENTC did not have diuretic effects.	False
In further studies , the diuretic effects of the BC6ENTG agonist BC6ENTC were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	CPR:5
In further studies , the diuretic effects of the BC6OTHER agonist BC6ENTC were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTG antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6ENTC were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6ENTC , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	CPR:6
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6ENTC , but not by the BC6ENTG antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6ENTC , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTC receptor type I antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTC receptor type I antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6ENTC , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTG antagonist BC6ENTC , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	CPR:6
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6ENTC , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6ENTC antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTG antagonist BC6OTHER , nor were the effects of BC6ENTC antagonized by the BC6OTHER antagonist BC6OTHER [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6ENTC antagonized by the BC6ENTG antagonist BC6OTHER [ BC6OTHER ].	CPR:5
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6ENTC [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTG antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6ENTC [ BC6OTHER ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6ENTC [ BC6OTHER ].	CPR:6
In further studies , the diuretic effects of the BC6ENTG agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6ENTC ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6ENTG antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6OTHER antagonist BC6OTHER [ BC6ENTC ].	False
In further studies , the diuretic effects of the BC6OTHER agonist BC6OTHER were similar in male and female rats , displayed a relatively rapid onset to action , and were dose - dependently antagonized by 30 minutes pretreatment with BC6OTHER , but not by the BC6OTHER antagonist BC6OTHER , nor were the effects of BC6OTHER antagonized by the BC6ENTG antagonist BC6OTHER [ BC6ENTC ].	CPR:6
Direct - acting BC6ENTG agonists , including BC6ENTC , BC6OTHER [ BC6OTHER ] , BC6OTHER [ BC6OTHER ] , and BC6OTHER [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6ENTC [ BC6OTHER ] , BC6OTHER [ BC6OTHER ] , and BC6OTHER [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6OTHER [ BC6ENTC ] , BC6OTHER [ BC6OTHER ] , and BC6OTHER [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6OTHER [ BC6OTHER ] , BC6ENTC [ BC6OTHER ] , and BC6OTHER [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6OTHER [ BC6OTHER ] , BC6OTHER [ BC6ENTC ] , and BC6OTHER [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6OTHER [ BC6OTHER ] , BC6OTHER [ BC6OTHER ] , and BC6ENTC [ BC6OTHER ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
Direct - acting BC6ENTG agonists , including BC6OTHER , BC6OTHER [ BC6OTHER ] , BC6OTHER [ BC6OTHER ] , and BC6OTHER [ BC6ENTC ] , produced dose - dependent increases in diuresis and decreases in colonic temperature , with slightly lower ED(50) values for diuresis than for hypothermia.	CPR:5
The protein is formed by an BC6ENTC - terminal helicase - like domain , a BC6ENTG , and a BC6OTHER that spans between the two.	False
The protein is formed by an BC6ENTC - terminal helicase - like domain , a BC6OTHER , and a BC6ENTG that spans between the two.	False
The protein is formed by an BC6ENTG , a BC6ENTC - terminal DNA polymerase domain , and a BC6OTHER that spans between the two.	False
The protein is formed by an BC6OTHER , a BC6ENTC - terminal DNA polymerase domain , and a BC6ENTG that spans between the two.	False
BC6ENTC / BC6OTHER N1 - acetyltransferase ( BC6ENTG ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6OTHER and BC6OTHER triggers export or degradation.	False
CHEM / BC6ENTC N1 - acetyltransferase ( BC6ENTG ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6OTHER and BC6OTHER triggers export or degradation.	False
BC6ENTG was found to self - BC6ENTC BC6OTHER - 26 in the presence of BC6OTHER and absence of substrate , a reaction apparently catalzyed by BC6OTHER bound in the second channel of the asymmetric dimer.	False
BC6ENTG was found to self - BC6OTHER BC6ENTC - 26 in the presence of BC6OTHER and absence of substrate , a reaction apparently catalzyed by BC6OTHER bound in the second channel of the asymmetric dimer.	False
BC6ENTG was found to self - BC6OTHER BC6OTHER - 26 in the presence of BC6ENTC and absence of substrate , a reaction apparently catalzyed by BC6OTHER bound in the second channel of the asymmetric dimer.	False
BC6ENTG was found to self - BC6OTHER BC6OTHER - 26 in the presence of BC6OTHER and absence of substrate , a reaction apparently catalzyed by BC6ENTC bound in the second channel of the asymmetric dimer.	False
BC6ENTG ( BC6OTHER ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6ENTC and BC6OTHER triggers export or degradation.	CPR:9
CHEM / BC6OTHER N1 - acetyltransferase ( BC6ENTG ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6ENTC and BC6OTHER triggers export or degradation.	False
BC6ENTG ( BC6OTHER ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6OTHER and BC6ENTC triggers export or degradation.	CPR:9
CHEM / BC6OTHER N1 - acetyltransferase ( BC6ENTG ) is a key enzyme in the control of BC6OTHER levels in human cells , as acetylation of BC6OTHER and BC6ENTC triggers export or degradation.	False
These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating BC6ENTG activity or stability as a part of BC6ENTC homeostasis.	CPR:9
Sequence signatures group BC6ENTG with proteins that appear to have BC6ENTC Nepsilon - acetyltransferase activity.	False
Increased intracellular BC6ENTC levels accompany several types of cancers as well as other human diseases , and compounds that affect the expression , activity , or stability of BC6ENTG are being explored as potential therapeutic drugs.	False
We have expressed BC6ENTG from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6OTHER , as the free dimer and in binary and ternary complexes with BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6OTHER from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6ENTG , as the free dimer and in binary and ternary complexes with BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6ENTG from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6OTHER , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6ENTC ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6OTHER from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6ENTG , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6ENTC ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6ENTG from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6OTHER , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6ENTC ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6OTHER from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6ENTG , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6ENTC ) , BC6OTHER , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6ENTG from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6OTHER , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6OTHER from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6ENTG , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC , and the inhibitor BC6OTHER (CHEM).	False
We have expressed BC6ENTG from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6OTHER , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6ENTC (CHEM).	False
We have expressed BC6OTHER from the cloned cDNA in Escherichia coli and have determined high - resolution structures of wild - type and mutant BC6ENTG , as the free dimer and in binary and ternary complexes with BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , and the inhibitor BC6ENTC (CHEM).	False
BC6ENTG ( BC6OTHER ) is a key enzyme in the control of BC6ENTC levels in human cells , as acetylation of BC6OTHER and BC6OTHER triggers export or degradation.	CPR:9
CHEM / BC6OTHER N1 - acetyltransferase ( BC6ENTG ) is a key enzyme in the control of BC6ENTC levels in human cells , as acetylation of BC6OTHER and BC6OTHER triggers export or degradation.	False
Structures of wild - type and mutant BC6ENTG BC6ENTC N1 - acetyltransferase , a potential therapeutic drug target.	False
We report here that BC6ENTC , a drug clinically used for lowering BC6OTHER levels , inhibits the interaction of BC6ENTG with its counter - receptor BC6OTHER .	CPR:4
We report here that BC6ENTC , a drug clinically used for lowering BC6OTHER levels , inhibits the interaction of BC6OTHER with its counter - receptor BC6ENTG .	CPR:4
We report here that BC6OTHER , a drug clinically used for lowering BC6ENTC levels , inhibits the interaction of BC6ENTG with its counter - receptor BC6OTHER .	False
We report here that BC6OTHER , a drug clinically used for lowering BC6ENTC levels , inhibits the interaction of BC6OTHER with its counter - receptor BC6ENTG .	False
Structural basis for BC6ENTG inhibition upon BC6ENTC binding to the BC6OTHER .	CPR:4
Structural basis for BC6OTHER inhibition upon BC6ENTC binding to the BC6ENTG .	False
Similar partial correlations for antipsychotic drug dose and serum levels of BC6ENTC BC6ENTG - blocking activity with performance of the trail - making and picture completion tests (negative) and the block - design task (positive) showed the functional importance of BC6OTHER - related activity.	False
Similar partial correlations for antipsychotic drug dose and serum levels of BC6OTHER BC6ENTG - blocking activity with performance of the trail - making and picture completion tests (negative) and the block - design task (positive) showed the functional importance of BC6ENTC - related activity.	False
High estimates of central BC6ENTC BC6ENTG - occupancy were related to impaired verbal fluency but were associated with improved recall of stories , especially in paranoid patients.	False
 This , the first study of its kind , tentatively imputes a role for BC6ENTC BC6ENTG - related activity in left frontal (e.g. CB , verbal fluency) and temporal lobe functions (verbal recall) as well as in some non - verbal abilities mediated more in the right hemisphere in patients with schizophrenia.	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6ENTC equivalents , BC6OTHER ) , the antipsychotic serum concentration of BC6ENTG - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6ENTC equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6ENTG occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6ENTC equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6ENTC ) , the antipsychotic serum concentration of BC6ENTG - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6ENTC ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6ENTG occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6ENTC ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of BC6ENTC ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6ENTG occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of BC6ENTC ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6ENTC ) D2 - blocking activity and the approximated central BC6OTHER BC6ENTG occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6ENTC ) D2 - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6OTHER BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of BC6ENTG - blocking activity and the approximated central BC6ENTC BC6OTHER occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6ENTC BC6ENTG occupancy ( BC6OTHER BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6ENTC BC6OTHER occupancy ( BC6OTHER BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of BC6ENTG - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6ENTC BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6ENTG occupancy ( BC6ENTC BC6OTHER - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We describe here the putative influence of the dose of antipsychotic medication ( BC6OTHER equivalents , BC6OTHER ) , the antipsychotic serum concentration of CHEM ( BC6OTHER ) D2 - blocking activity and the approximated central BC6OTHER BC6OTHER occupancy ( BC6ENTC BC6ENTG - occupancy) , on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery , in 108 patients with schizophrenia (compared with 62 healthy controls).	False
We tested the hypothesis that allelic variants of the BC6ENTG genotype are associated with (i) BC6ENTC D2 antagonist CHEM dose in treatment of BC6OTHER withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50).	False
We tested the hypothesis that allelic variants of the human BC6OTHER D2 receptor E8 genotype are associated with (i) BC6ENTG antagonist CHEM dose in treatment of BC6ENTC withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50).	False
We tested the hypothesis that allelic variants of the BC6ENTG genotype are associated with (i) BC6OTHER antagonist CHEM dose in treatment of BC6ENTC withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50).	False
BC6ENTG A / A genotype was associated with increased dose of BC6ENTC during a 9 - day detoxification therapy and with increased anxiety and depression scores on admission and 2 weeks later.	False
We tested the hypothesis that allelic variants of the human BC6ENTC D2 receptor E8 genotype are associated with (i) BC6ENTG antagonist CHEM dose in treatment of BC6OTHER withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50).	False
In an earlier report , BC6ENTG E8 A / A genotype was associated with reduced responsiveness to the BC6ENTC D2 agonist BC6OTHER ; however , it is not clear whether both findings share the same biological basis.	False
In an earlier report , BC6ENTG E8 A / A genotype was associated with reduced responsiveness to the BC6OTHER agonist BC6ENTC ; however , it is not clear whether both findings share the same biological basis.	False
In an earlier report , BC6OTHER E8 A / A genotype was associated with reduced responsiveness to the BC6ENTG agonist BC6ENTC ; however , it is not clear whether both findings share the same biological basis.	CPR:5
Influence of the BC6ENTG genotype on efficacy of BC6OTHER and clinical outcome of BC6ENTC withdrawal.	False
Influence of the BC6ENTG genotype on efficacy of BC6ENTC and clinical outcome of BC6OTHER withdrawal.	False
CONCLUSION: BC6ENTG receptors are involved in the regulation of BC6ENTC stimulated orocaecal transit; BC6OTHER tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.	False
CONCLUSION: BC6ENTG receptors are involved in the regulation of BC6OTHER stimulated orocaecal transit; BC6ENTC tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.	False
METHODS: Part A compared the effects of placebo to four doses of a BC6ENTG receptor antagonist ( BC6ENTC ) on the BC6OTHER mediated increase in plasma BC6OTHER (a BC6OTHER mediated response) and orocaecal transit in 18 subjects.	CPR:6
METHODS: Part A compared the effects of placebo to four doses of a BC6OTHER receptor antagonist ( BC6ENTC ) on the BC6OTHER mediated increase in plasma BC6OTHER (a BC6ENTG mediated response) and orocaecal transit in 18 subjects.	CPR:6
METHODS: Part A compared the effects of placebo to four doses of a BC6ENTG receptor antagonist ( BC6OTHER ) on the BC6ENTC mediated increase in plasma BC6OTHER (a BC6OTHER mediated response) and orocaecal transit in 18 subjects.	CPR:5
METHODS: Part A compared the effects of placebo to four doses of a BC6OTHER receptor antagonist ( BC6OTHER ) on the BC6ENTC mediated increase in plasma BC6OTHER (a BC6ENTG mediated response) and orocaecal transit in 18 subjects.	False
METHODS: Part A compared the effects of placebo to four doses of a BC6ENTG receptor antagonist ( BC6OTHER ) on the BC6OTHER mediated increase in plasma BC6ENTC (a BC6OTHER mediated response) and orocaecal transit in 18 subjects.	False
METHODS: Part A compared the effects of placebo to four doses of a BC6OTHER receptor antagonist ( BC6OTHER ) on the BC6OTHER mediated increase in plasma BC6ENTC (a BC6ENTG mediated response) and orocaecal transit in 18 subjects.	False
Effects of a BC6ENTG antagonist BC6ENTC on gastrointestinal motor and sensory function in humans.	CPR:6
BC6ENTC , a BC6ENTG antagonist , inhibited gastric acid secretion in pylorus - ligated rats (ED50 = 4.9 mg / kg intraduodenal; 3.4 mg / kg p.o.	CPR:6
The nonspecific inhibition of gastric acid by BC6ENTC supports the existence of interdependence between BC6ENTG on the parietal cell surface.	False
Effects of BC6ENTC , other BC6ENTG antagonists and BC6OTHER on gastric acid secretory states in rats and dogs.	CPR:6
Effects of BC6OTHER , other BC6ENTG antagonists and BC6ENTC on gastric acid secretory states in rats and dogs.	False
A series of BC6OTHER were synthesized and investigated in vitro as inhibitors of pancreatic BC6ENTC esterase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
A series of BC6OTHER were synthesized and investigated in vitro as inhibitors of pancreatic BC6ENTC esterase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
A series of BC6OTHER were synthesized and investigated in vitro as inhibitors of pancreatic BC6ENTC esterase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
A series of BC6ENTC were synthesized and investigated in vitro as inhibitors of pancreatic BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:4
A series of BC6ENTC were synthesized and investigated in vitro as inhibitors of pancreatic BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:4
A series of BC6ENTC were synthesized and investigated in vitro as inhibitors of pancreatic BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:4
A series of BC6ENTC were synthesized and investigated in vitro as inhibitors of pancreatic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:4
The results showed that most of the synthesized compounds exhibited nanomolar potency against BC6ENTG , much better than the parent BC6ENTC .	CPR:4
Furthermore , these BC6ENTC demonstrated good to high selectivity for BC6ENTG over BC6OTHER , which only showed micromolar potency inhibition of BC6OTHER .	CPR:4
Furthermore , these BC6ENTC demonstrated good to high selectivity for BC6OTHER over BC6ENTG , which only showed micromolar potency inhibition of BC6OTHER .	CPR:4
Furthermore , these BC6ENTC demonstrated good to high selectivity for BC6OTHER over BC6OTHER , which only showed micromolar potency inhibition of BC6ENTG .	CPR:4
The structure - activity relationships revealed that the free BC6ENTC group at position 5 and BC6OTHER group at position 7 of the BC6OTHER are favorable to the inhibition of BC6ENTG .	CPR:4
The structure - activity relationships revealed that the free BC6OTHER group at position 5 and BC6ENTC group at position 7 of the BC6OTHER are favorable to the inhibition of BC6ENTG .	CPR:4
The structure - activity relationships revealed that the free BC6OTHER group at position 5 and BC6OTHER group at position 7 of the BC6ENTC are favorable to the inhibition of BC6ENTG .	CPR:4
Synthesis and biological evaluation of BC6ENTC as potent and selective inhibitors of BC6ENTG .	CPR:4
Compared with placebo , both reversible BC6ENTG inhibitors decreased the plasma concentration of BC6ENTC and BC6OTHER .	False
Compared with placebo , both reversible BC6ENTG inhibitors decreased the plasma concentration of BC6OTHER and BC6ENTC .	False
The effects of two reversible , predominantly BC6ENTG ( BC6OTHER ) inhibitors , BC6OTHER (150 mg three times daily) and BC6ENTC (400 - 200 - 400 mg day - 1) on BC6OTHER metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	CPR:4
The effects of two reversible , predominantly BC6OTHER ( BC6ENTG ) inhibitors , BC6OTHER (150 mg three times daily) and BC6ENTC (400 - 200 - 400 mg day - 1) on BC6OTHER metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	False
Before the next drug intake , BC6ENTG inhibition , as judged by the decrease of plasma BC6ENTC concentration , was significantly different from placebo with BC6OTHER but not with BC6OTHER .	False
Before the next drug intake , BC6ENTG inhibition , as judged by the decrease of plasma BC6OTHER concentration , was significantly different from placebo with BC6ENTC but not with BC6OTHER .	CPR:4
Before the next drug intake , BC6ENTG inhibition , as judged by the decrease of plasma BC6OTHER concentration , was significantly different from placebo with BC6OTHER but not with BC6ENTC .	CPR:4
The effects of two reversible , predominantly BC6ENTG ( BC6OTHER ) inhibitors , BC6OTHER (150 mg three times daily) and BC6OTHER (400 - 200 - 400 mg day - 1) on BC6ENTC metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	False
The effects of two reversible , predominantly BC6OTHER ( BC6ENTG ) inhibitors , BC6OTHER (150 mg three times daily) and BC6OTHER (400 - 200 - 400 mg day - 1) on BC6ENTC metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	False
The effects of two reversible , predominantly BC6ENTC oxidase - A ( BC6ENTG ) inhibitors , BC6OTHER (150 mg three times daily) and BC6OTHER (400 - 200 - 400 mg day - 1) on BC6OTHER metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	False
The effects of two reversible , predominantly BC6ENTG ( BC6OTHER ) inhibitors , BC6ENTC (150 mg three times daily) and BC6OTHER (400 - 200 - 400 mg day - 1) on BC6OTHER metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	CPR:4
The effects of two reversible , predominantly BC6OTHER ( BC6ENTG ) inhibitors , BC6ENTC (150 mg three times daily) and BC6OTHER (400 - 200 - 400 mg day - 1) on BC6OTHER metabolites and psychometric performance were compared in a double - blind placebo controlled crossover study in 12 healthy subjects.	False
Comparison of the BC6ENTG inhibiting properties of two reversible and selective BC6OTHER inhibitors BC6ENTC and BC6OTHER , and assessment of their effect on psychometric performance in healthy subjects.	CPR:4
Comparison of the BC6OTHER inhibiting properties of two reversible and selective BC6ENTG inhibitors BC6ENTC and BC6OTHER , and assessment of their effect on psychometric performance in healthy subjects.	CPR:4
Comparison of the BC6ENTG inhibiting properties of two reversible and selective BC6OTHER inhibitors BC6OTHER and BC6ENTC , and assessment of their effect on psychometric performance in healthy subjects.	CPR:4
Comparison of the BC6OTHER inhibiting properties of two reversible and selective BC6ENTG inhibitors BC6OTHER and BC6ENTC , and assessment of their effect on psychometric performance in healthy subjects.	CPR:4
Comparison of the BC6ENTC oxidase inhibiting properties of two reversible and selective BC6ENTG inhibitors BC6OTHER and BC6OTHER , and assessment of their effect on psychometric performance in healthy subjects.	False
Comparison of the BC6ENTG inhibiting properties of two reversible and selective BC6ENTC oxidase - A inhibitors BC6OTHER and BC6OTHER , and assessment of their effect on psychometric performance in healthy subjects.	False
Variations in BC6ENTG binding have been shown to correlate with an animal's sensitivity to BC6ENTC - induced seizures and sensory gating.	False
Inbred mouse strains display significant differences in their levels of brain alpha7 nicotinic BC6ENTC receptor ( BC6ENTG ) expression , as measured by binding of the alpha7 - selective antagonist CHEM.	False
BC6ENTG activity was strongly increased and BC6ENTC kinase activity was moderately reduced in all of the resistant variants , resulting in reduced accumulation of BC6OTHER analogues.	False
BC6ENTG activity was strongly increased and BC6OTHER activity was moderately reduced in all of the resistant variants , resulting in reduced accumulation of BC6ENTC analogues.	False
BC6OTHER activity was strongly increased and BC6ENTG activity was moderately reduced in all of the resistant variants , resulting in reduced accumulation of BC6ENTC analogues.	False
In addition a deletion in one of the alleles of the BC6ENTG was detected in the BC6ENTC - resistant line.	False
BC6ENTG activity was found to be strongly increased in the BC6ENTC - selected line and BC6OTHER was increased in the BC6OTHER - selected line.	CPR:3
BC6OTHER activity was found to be strongly increased in the BC6ENTC - selected line and BC6ENTG was increased in the BC6OTHER - selected line.	False
BC6ENTG activity was found to be strongly increased in the BC6OTHER - selected line and BC6OTHER was increased in the BC6ENTC - selected line.	False
BC6OTHER activity was found to be strongly increased in the BC6OTHER - selected line and BC6ENTG was increased in the BC6ENTC - selected line.	CPR:3
BC6ENTC withdrawal significantly increased the packing density of BC6ENTG - and BC6OTHER - IR astrocytes in the PLC of P rats as compared with P rats with continuous access to CHEM.	False
BC6ENTC withdrawal significantly increased the packing density of BC6OTHER - and BC6ENTG - IR astrocytes in the PLC of P rats as compared with P rats with continuous access to CHEM.	False
In addition , there was a positive correlation between the pre - withdrawal BC6ENTC consumption and the packing density of BC6ENTG - IR astrocytes.	False
The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free - choice BC6ENTC consumption and point to differential adaptations of BC6ENTG and BC6OTHER to prolonged BC6OTHER drinking in the PLC of P rats.	False
The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free - choice BC6ENTC consumption and point to differential adaptations of BC6OTHER and BC6ENTG to prolonged BC6OTHER drinking in the PLC of P rats.	False
The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free - choice BC6OTHER consumption and point to differential adaptations of BC6ENTG and BC6OTHER to prolonged BC6ENTC drinking in the PLC of P rats.	False
The present results suggest the involvement of astrocytes in the regulation of the glutamatergic activation associated with withdrawal from free - choice BC6OTHER consumption and point to differential adaptations of BC6OTHER and BC6ENTG to prolonged BC6ENTC drinking in the PLC of P rats.	False
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released BC6ENTC and its conversion to BC6OTHER through the enzyme BC6ENTG ( BC6OTHER ).	CPR:9
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released BC6ENTC and its conversion to BC6OTHER through the enzyme BC6OTHER ( BC6ENTG ).	CPR:9
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released BC6OTHER and its conversion to BC6ENTC through the enzyme BC6ENTG ( BC6OTHER ).	CPR:9
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released BC6OTHER and its conversion to BC6ENTC through the enzyme BC6OTHER ( BC6ENTG ).	CPR:9
Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released BC6OTHER and its conversion to BC6OTHER through the enzyme BC6ENTC synthetase ( BC6ENTG ).	False
However , it is unclear if withdrawal from free - choice BC6ENTC drinking causes changes in the numbers of astrocytes expressing BC6ENTG or the cytoskeletal protein of astrocytes BC6OTHER ( BC6OTHER ).	False
However , it is unclear if withdrawal from free - choice BC6ENTC drinking causes changes in the numbers of astrocytes expressing BC6OTHER or the cytoskeletal protein of astrocytes BC6ENTG ( BC6OTHER ).	False
However , it is unclear if withdrawal from free - choice BC6ENTC drinking causes changes in the numbers of astrocytes expressing BC6OTHER or the cytoskeletal protein of astrocytes BC6OTHER ( BC6ENTG ).	False
Withdrawal from free - choice BC6OTHER consumption results in increased packing density of BC6ENTG - immunoreactive astrocytes in the prelimbic cortex of BC6ENTC - preferring rats.	False
Withdrawal from free - choice BC6ENTC consumption results in increased packing density of BC6ENTG - immunoreactive astrocytes in the prelimbic cortex of BC6OTHER - preferring rats.	CPR:3
Based on the results of the hydrolysis and inhibition of the BC6ENTC substrates , it was difficult to have an exact decision on the BC6ENTG type in the vaginal homogenates from the species studied.	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6ENTC of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6ENTC for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTC aminopeptidase , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6ENTC aminopeptidase , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTC aminopeptidase , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTC aminopeptidase , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6ENTC of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6ENTC of BC6OTHER for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6ENTC for BC6OTHER and BC6OTHER of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6ENTG and BC6OTHER of BC6OTHER for BC6OTHER .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6ENTC for BC6OTHER and BC6OTHER of BC6OTHER for BC6ENTG .	False
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6ENTC of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6ENTC of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6ENTC of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6ENTC of BC6OTHER for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6ENTC of BC6OTHER for BC6ENTG .	CPR:9
Different substrates were used as the relative specific substrates for the determination of BC6ENTG enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6ENTC for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6ENTC for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6ENTC for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6ENTG and BC6OTHER of BC6ENTC for BC6OTHER .	False
Different substrates were used as the relative specific substrates for the determination of BC6OTHER enzymatic activity: BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER , BC6OTHER of BC6OTHER for BC6OTHER and BC6OTHER of BC6ENTC for BC6ENTG .	CPR:9
The specific enzymatic activity of four different BC6OTHER ( BC6OTHER , BC6ENTC aminopeptidase , BC6ENTG and BC6OTHER ) in vaginal homogenates from rabbit , rat , guinea - pig , sheep and humans was compared.	False
The specific enzymatic activity of four different BC6OTHER ( BC6OTHER , BC6ENTC aminopeptidase , BC6OTHER and BC6ENTG ) in vaginal homogenates from rabbit , rat , guinea - pig , sheep and humans was compared.	False
The specific enzymatic activity of four different BC6ENTG ( BC6OTHER , BC6ENTC aminopeptidase , BC6OTHER and BC6OTHER ) in vaginal homogenates from rabbit , rat , guinea - pig , sheep and humans was compared.	False
The specific enzymatic activity of four different BC6OTHER ( BC6ENTG , BC6ENTC aminopeptidase , BC6OTHER and BC6OTHER ) in vaginal homogenates from rabbit , rat , guinea - pig , sheep and humans was compared.	False
The inhibition of BC6ENTG activity in the presence of BC6ENTC and BC6OTHER inhibitors was also investigated.	CPR:4
The inhibition of BC6ENTG activity in the presence of BC6OTHER and BC6ENTC inhibitors was also investigated.	CPR:4
BC6ENTC reductase ( BC6ENTG ) catalyzes the reduction of toxic lipid BC6OTHER to their BC6OTHER products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).	False
BC6ENTC ( BC6OTHER ) , a recently described BC6ENTG inhibitor , was purified from extracts of the Indian gooseberry (Emblica officinalis).	CPR:4
BC6OTHER ( BC6ENTC ) , a recently described BC6ENTG inhibitor , was purified from extracts of the Indian gooseberry (Emblica officinalis).	CPR:4
In this study , we found that BC6ENTC showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited BC6ENTG activity as measured by a decrease in BC6OTHER accumulation.	CPR:4
In this study , we found that BC6OTHER showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited BC6ENTG activity as measured by a decrease in BC6ENTC accumulation.	False
In addition , BC6ENTC - mediated inhibition of BC6ENTG prevented LPS - induced activation of BC6OTHER and BC6OTHER and lowered ROS levels , which could inhibit LPS - induced apoptosis.	CPR:4
In addition , BC6ENTC - mediated inhibition of BC6OTHER prevented LPS - induced activation of BC6ENTG and BC6OTHER and lowered ROS levels , which could inhibit LPS - induced apoptosis.	CPR:4
In addition , BC6ENTC - mediated inhibition of BC6OTHER prevented LPS - induced activation of BC6OTHER and BC6ENTG and lowered ROS levels , which could inhibit LPS - induced apoptosis.	CPR:4
BC6ENTG ( BC6OTHER ) catalyzes the reduction of toxic lipid BC6ENTC to their BC6OTHER products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the reduction of toxic lipid BC6ENTC to their BC6OTHER products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).	CPR:9
BC6ENTG ( BC6OTHER ) catalyzes the reduction of toxic lipid BC6OTHER to their BC6ENTC products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the reduction of toxic lipid BC6OTHER to their BC6ENTC products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).	CPR:9
 BC6ENTC reduces the expression of lipopolysaccharide - induced inflammatory markers by inhibition of BC6ENTG in murine macrophages and ocular tissues.	CPR:4
BC6ENTG ( BC6OTHER ) BC6ENTC phosphorylation is a time - controlled physiological feedback mechanism in BC6OTHER signaling that is hijacked by metabolic and inflammatory stresses to promote BC6OTHER resistance.	False
BC6OTHER ( BC6OTHER ) BC6ENTC phosphorylation is a time - controlled physiological feedback mechanism in BC6ENTG signaling that is hijacked by metabolic and inflammatory stresses to promote BC6OTHER resistance.	False
BC6OTHER ( BC6OTHER ) BC6ENTC phosphorylation is a time - controlled physiological feedback mechanism in BC6OTHER signaling that is hijacked by metabolic and inflammatory stresses to promote BC6ENTG resistance.	False
BC6OTHER ( BC6ENTG ) BC6ENTC phosphorylation is a time - controlled physiological feedback mechanism in BC6OTHER signaling that is hijacked by metabolic and inflammatory stresses to promote BC6OTHER resistance.	False
BC6ENTG , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , activated by the inducers of BC6ENTG resistance induce uncontrolled BC6OTHER BC6ENTC phosphorylation.	False
BC6OTHER , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , activated by the inducers of BC6OTHER resistance induce uncontrolled BC6ENTG BC6ENTC phosphorylation.	False
Cellular mechanisms of BC6OTHER resistance: role of stress - regulated BC6OTHER kinases and BC6OTHER ( BC6ENTG ) BC6ENTC phosphorylation.	False
Cellular mechanisms of BC6ENTG resistance: role of stress - regulated BC6OTHER kinases and BC6OTHER ( BC6OTHER ) BC6ENTC phosphorylation.	False
Cellular mechanisms of BC6OTHER resistance: role of BC6ENTG and BC6OTHER ( BC6OTHER ) BC6ENTC phosphorylation.	False
Cellular mechanisms of BC6OTHER resistance: role of stress - regulated BC6OTHER kinases and BC6ENTG ( BC6OTHER ) BC6ENTC phosphorylation.	False
Cellular mechanisms of BC6OTHER resistance: role of stress - regulated BC6ENTC kinases and BC6OTHER ( BC6ENTG ) BC6OTHER phosphorylation.	False
Cellular mechanisms of BC6ENTG resistance: role of stress - regulated BC6ENTC kinases and BC6OTHER ( BC6OTHER ) BC6OTHER phosphorylation.	False
Cellular mechanisms of BC6OTHER resistance: role of stress - regulated BC6ENTC kinases and BC6ENTG ( BC6OTHER ) BC6OTHER phosphorylation.	False
Only five tumors failed to express BC6ENTG but four of these expressed BC6OTHER , suggesting BC6ENTC resistance.	False
Only five tumors failed to express BC6OTHER but four of these expressed BC6ENTG , suggesting BC6ENTC resistance.	False
PURPOSE: The BC6ENTC ( BC6OTHER ) is converted to BC6OTHER ( BC6OTHER ) by BC6OTHER ( BC6ENTG ) inside target tissues.	CPR:9
PURPOSE: The BC6ENTC ( BC6OTHER ) is converted to BC6OTHER ( BC6OTHER ) by BC6ENTG ( BC6OTHER ) inside target tissues.	CPR:9
BC6ENTC interferes with DNA synthesis by blocking BC6ENTG ( BC6OTHER ) but is inactivated by BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC interferes with DNA synthesis by blocking BC6OTHER ( BC6ENTG ) but is inactivated by BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC interferes with DNA synthesis by blocking BC6OTHER ( BC6OTHER ) but is inactivated by BC6ENTG ( BC6OTHER ).	False
BC6ENTC interferes with DNA synthesis by blocking BC6OTHER ( BC6OTHER ) but is inactivated by BC6OTHER ( BC6ENTG ).	False
The results support the hypothesis that BC6ENTC is activated in the majority of differentiated thyroid cancers and that 32% have favorable expression of all three enzymes ( BC6ENTG , BC6OTHER , and BC6OTHER ).	False
The results support the hypothesis that BC6ENTC is activated in the majority of differentiated thyroid cancers and that 32% have favorable expression of all three enzymes ( BC6OTHER , BC6ENTG , and BC6OTHER ).	False
The results support the hypothesis that BC6ENTC is activated in the majority of differentiated thyroid cancers and that 32% have favorable expression of all three enzymes ( BC6OTHER , BC6OTHER , and BC6ENTG ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6ENTC synthase ( BC6ENTG ) but is inactivated by BC6OTHER ( BC6OTHER ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6ENTC synthase ( BC6OTHER ) but is inactivated by BC6ENTG ( BC6OTHER ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6ENTC synthase ( BC6OTHER ) but is inactivated by BC6OTHER ( BC6ENTG ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6ENTG ( BC6OTHER ) but is inactivated by BC6ENTC dehydrogenase ( BC6OTHER ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6OTHER ( BC6ENTG ) but is inactivated by BC6ENTC dehydrogenase ( BC6OTHER ).	False
BC6OTHER interferes with DNA synthesis by blocking BC6OTHER ( BC6OTHER ) but is inactivated by BC6ENTC dehydrogenase ( BC6ENTG ).	False
Favorable enzyme profiles (high BC6ENTG and low BC6OTHER ) generate high intratumor levels of BC6ENTC that are effective against many tumors , especially those with low BC6OTHER .	CPR:9
Favorable enzyme profiles (high BC6OTHER and low BC6ENTG ) generate high intratumor levels of BC6ENTC that are effective against many tumors , especially those with low BC6OTHER .	CPR:9
Favorable enzyme profiles (high BC6OTHER and low BC6OTHER ) generate high intratumor levels of BC6ENTC that are effective against many tumors , especially those with low BC6ENTG .	False
PURPOSE: The BC6OTHER ( BC6ENTC ) is converted to BC6OTHER ( BC6OTHER ) by BC6OTHER ( BC6ENTG ) inside target tissues.	CPR:9
PURPOSE: The BC6OTHER ( BC6ENTC ) is converted to BC6OTHER ( BC6OTHER ) by BC6ENTG ( BC6OTHER ) inside target tissues.	CPR:9
BC6ENTC has not been tested against thyroid cancers , and it is not known to what extent thyroid cancers express BC6ENTG , BC6OTHER or BC6OTHER .	False
BC6ENTC has not been tested against thyroid cancers , and it is not known to what extent thyroid cancers express BC6OTHER , BC6ENTG or BC6OTHER .	False
BC6ENTC has not been tested against thyroid cancers , and it is not known to what extent thyroid cancers express BC6OTHER , BC6OTHER or BC6ENTG .	False
PURPOSE: The BC6OTHER ( BC6OTHER ) is converted to BC6ENTC ( BC6OTHER ) by BC6OTHER ( BC6ENTG ) inside target tissues.	CPR:9
PURPOSE: The BC6OTHER ( BC6OTHER ) is converted to BC6ENTC ( BC6OTHER ) by BC6ENTG ( BC6OTHER ) inside target tissues.	CPR:9
PURPOSE: The BC6OTHER ( BC6OTHER ) is converted to BC6OTHER ( BC6ENTC ) by BC6OTHER ( BC6ENTG ) inside target tissues.	CPR:9
PURPOSE: The BC6OTHER ( BC6OTHER ) is converted to BC6OTHER ( BC6ENTC ) by BC6ENTG ( BC6OTHER ) inside target tissues.	CPR:9
PURPOSE: The BC6OTHER ( BC6OTHER ) is converted to BC6OTHER ( BC6OTHER ) by BC6ENTC phosphorylase ( BC6ENTG ) inside target tissues.	False
BC6ENTC regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6ENTG ( BC6OTHER ) and CHEM / BC6OTHER - ATPase subunits.	False
BC6ENTC regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6ENTG ) and CHEM / BC6OTHER - ATPase subunits.	False
BC6ENTC regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6OTHER ) and BC6ENTG subunits.	False
This study reveals a novel mechanism for rapid regulation of BC6ENTG and the BC6ENTC / BC6OTHER - ATPase , via directed trafficking through BC6OTHER - BC6OTHER signalling at the level of the TGN.	False
This study reveals a novel mechanism for rapid regulation of BC6OTHER and the BC6ENTC / BC6OTHER - ATPase , via directed trafficking through BC6ENTG - BC6OTHER signalling at the level of the TGN.	False
This study reveals a novel mechanism for rapid regulation of BC6OTHER and the BC6ENTC / BC6OTHER - ATPase , via directed trafficking through BC6OTHER - BC6ENTG signalling at the level of the TGN.	False
This study reveals a novel mechanism for rapid regulation of BC6ENTG and the CHEM / BC6ENTC - ATPase , via directed trafficking through BC6OTHER - BC6OTHER signalling at the level of the TGN.	False
This study reveals a novel mechanism for rapid regulation of BC6OTHER and the CHEM / BC6ENTC - ATPase , via directed trafficking through BC6ENTG - BC6OTHER signalling at the level of the TGN.	False
This study reveals a novel mechanism for rapid regulation of BC6OTHER and the CHEM / BC6ENTC - ATPase , via directed trafficking through BC6OTHER - BC6ENTG signalling at the level of the TGN.	False
BC6OTHER regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6ENTG ( BC6OTHER ) and BC6ENTC / BC6OTHER - ATPase subunits.	False
BC6OTHER regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6ENTG ) and BC6ENTC / BC6OTHER - ATPase subunits.	False
BC6OTHER regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6ENTG ( BC6OTHER ) and CHEM / BC6ENTC - ATPase subunits.	False
BC6OTHER regulates BC6OTHER transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6ENTG ) and CHEM / BC6ENTC - ATPase subunits.	False
BC6ENTC also induces the rapid phosphorylation of BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC also induces the rapid phosphorylation of BC6OTHER ( BC6ENTG ).	CPR:3
BC6OTHER regulates BC6ENTC transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6ENTG ( BC6OTHER ) and CHEM / BC6OTHER - ATPase subunits.	False
BC6OTHER regulates BC6ENTC transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6ENTG ) and CHEM / BC6OTHER - ATPase subunits.	False
BC6OTHER regulates BC6ENTC transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial BC6OTHER ( BC6OTHER ) and BC6ENTG subunits.	False
BC6ENTG isoforms regulate protein trafficking , by the control of vesicle fission from the trans Golgi network (TGN) through activation of BC6ENTC 4 - kinaseIIIβ ( BC6OTHER ).	False
BC6OTHER isoforms regulate protein trafficking , by the control of vesicle fission from the trans Golgi network (TGN) through activation of BC6ENTC 4 - kinaseIIIβ ( BC6ENTG ).	False
In BC6ENTG - deficient cells , the BC6ENTC - sensitive current was significantly reduced and CHEM / BC6OTHER - ATPase α and β subunits showed aberrant localization.	False
In BC6OTHER - deficient cells , the BC6ENTC - sensitive current was significantly reduced and BC6ENTG subunits showed aberrant localization.	False
In BC6ENTG - deficient cells , the BC6OTHER - sensitive current was significantly reduced and BC6ENTC / BC6OTHER - ATPase α and β subunits showed aberrant localization.	False
In BC6ENTG - deficient cells , the BC6OTHER - sensitive current was significantly reduced and CHEM / BC6ENTC - ATPase α and β subunits showed aberrant localization.	False
BC6ENTG and BC6OTHER localize to the TGN , and BC6ENTC induced an interaction between BC6OTHER and BC6OTHER following BC6OTHER treatment.	False
BC6OTHER and BC6ENTG localize to the TGN , and BC6ENTC induced an interaction between BC6OTHER and BC6OTHER following BC6OTHER treatment.	False
BC6OTHER and BC6OTHER localize to the TGN , and BC6ENTC induced an interaction between BC6ENTG and BC6OTHER following BC6OTHER treatment.	False
BC6OTHER and BC6OTHER localize to the TGN , and BC6ENTC induced an interaction between BC6OTHER and BC6ENTG following BC6OTHER treatment.	False
BC6ENTG and BC6OTHER localize to the TGN , and BC6OTHER induced an interaction between BC6OTHER and BC6OTHER following BC6ENTC treatment.	False
BC6OTHER and BC6ENTG localize to the TGN , and BC6OTHER induced an interaction between BC6OTHER and BC6OTHER following BC6ENTC treatment.	False
BC6OTHER and BC6OTHER localize to the TGN , and BC6OTHER induced an interaction between BC6ENTG and BC6OTHER following BC6ENTC treatment.	False
BC6OTHER and BC6OTHER localize to the TGN , and BC6OTHER induced an interaction between BC6OTHER and BC6ENTG following BC6ENTC treatment.	False
 BC6ENTC - induced BC6ENTG and basal CHEM / BC6OTHER - ATPase trafficking via BC6OTHER - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	CPR:3
 BC6ENTC - induced BC6OTHER and basal BC6ENTG trafficking via BC6OTHER - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	CPR:3
 BC6ENTC - induced BC6OTHER and basal CHEM / BC6OTHER - ATPase trafficking via BC6ENTG - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6ENTC - induced BC6OTHER and basal CHEM / BC6OTHER - ATPase trafficking via BC6OTHER - BC6ENTG trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6ENTG and basal BC6ENTC / BC6OTHER - ATPase trafficking via BC6OTHER - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal BC6ENTC / BC6OTHER - ATPase trafficking via BC6ENTG - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal BC6ENTC / BC6OTHER - ATPase trafficking via BC6OTHER - BC6ENTG trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6ENTG and basal CHEM / BC6ENTC - ATPase trafficking via BC6OTHER - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal CHEM / BC6ENTC - ATPase trafficking via BC6ENTG - BC6OTHER trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal CHEM / BC6ENTC - ATPase trafficking via BC6OTHER - BC6ENTG trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6ENTG and basal CHEM / BC6OTHER - ATPase trafficking via BC6OTHER - BC6ENTC 4 - kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal BC6ENTG trafficking via BC6OTHER - BC6ENTC 4 - kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.	False
 BC6OTHER - induced BC6OTHER and basal CHEM / BC6OTHER - ATPase trafficking via BC6ENTG - BC6ENTC 4 - kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.	False
The channel activators BC6ENTC and BC6OTHER usually retain their inhibitory potency in the BC6ENTG subunit mutants.	CPR:4
The channel activators BC6OTHER and BC6ENTC usually retain their inhibitory potency in the BC6ENTG subunit mutants.	CPR:4
The non - competitive blocker site of the BC6ENTG in normal susceptible strains of Drosophila melanogaster and simulans binds BC6ENTC ( BC6OTHER ) at specific sites with KdS of 1.6 - 1.9 nM and BmaxS of 171 - 181 fmol / mg protein.	False
In contrast , the BC6ENTC - - > BC6OTHER replacement has less impact in protecting the BC6ENTG from the action of insecticidal blockers.	False
In contrast , the BC6OTHER - - > BC6ENTC replacement has less impact in protecting the BC6ENTG from the action of insecticidal blockers.	False
The non - competitive blocker site of the BC6ENTG in normal susceptible strains of Drosophila melanogaster and simulans binds BC6OTHER ( BC6ENTC ) at specific sites with KdS of 1.6 - 1.9 nM and BmaxS of 171 - 181 fmol / mg protein.	False
BC6ENTC resistance in D. melanogaster has been attributed to a mutation resulting in an BC6ENTG replacement in the Rdl BC6OTHER receptor subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6OTHER replacement.	False
BC6ENTC resistance in D. melanogaster has been attributed to a mutation resulting in an CHEM BC6OTHER replacement in the BC6ENTG subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an CHEM302 - - > BC6ENTC replacement in the BC6ENTG subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an BC6ENTG replacement in the Rdl BC6ENTC receptor subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an BC6ENTG replacement in the Rdl BC6OTHER receptor subunit and in D. simulans to an homologous BC6ENTC - - > BC6OTHER or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an CHEM BC6OTHER replacement in the BC6ENTG subunit and in D. simulans to an homologous BC6ENTC - - > BC6OTHER or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an BC6ENTG replacement in the Rdl BC6OTHER receptor subunit and in D. simulans to an homologous BC6OTHER - - > BC6ENTC or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an CHEM BC6OTHER replacement in the BC6ENTG subunit and in D. simulans to an homologous BC6OTHER - - > BC6ENTC or BC6OTHER replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an BC6ENTG replacement in the Rdl BC6OTHER receptor subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6ENTC replacement.	False
BC6OTHER resistance in D. melanogaster has been attributed to a mutation resulting in an CHEM BC6OTHER replacement in the BC6ENTG subunit and in D. simulans to an homologous BC6OTHER - - > BC6OTHER or BC6ENTC replacement.	False
 BC6ENTG BC6OTHER channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6OTHER or BC6ENTC mutants of BC6OTHER subunit.	False
Drosophila BC6OTHER - gated BC6OTHER channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6OTHER or BC6ENTC mutants of BC6ENTG subunit.	False
Drosophila BC6ENTC - gated BC6OTHER channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6OTHER or BC6OTHER mutants of BC6ENTG subunit.	False
 BC6ENTG BC6ENTC channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6OTHER or BC6OTHER mutants of BC6OTHER subunit.	False
Drosophila BC6OTHER - gated BC6ENTC channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6OTHER or BC6OTHER mutants of BC6ENTG subunit.	False
 BC6ENTG BC6OTHER channel: modified BC6ENTC binding site associated with BC6OTHER - - > BC6OTHER or BC6OTHER mutants of BC6OTHER subunit.	False
Drosophila BC6OTHER - gated BC6OTHER channel: modified BC6ENTC binding site associated with BC6OTHER - - > BC6OTHER or BC6OTHER mutants of BC6ENTG subunit.	False
 BC6ENTG BC6OTHER channel: modified BC6OTHER binding site associated with BC6ENTC - - > BC6OTHER or BC6OTHER mutants of BC6OTHER subunit.	False
Drosophila BC6OTHER - gated BC6OTHER channel: modified BC6OTHER binding site associated with BC6ENTC - - > BC6OTHER or BC6OTHER mutants of BC6ENTG subunit.	False
 BC6ENTG BC6OTHER channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6ENTC or BC6OTHER mutants of BC6OTHER subunit.	False
Drosophila BC6OTHER - gated BC6OTHER channel: modified BC6OTHER binding site associated with BC6OTHER - - > BC6ENTC or BC6OTHER mutants of BC6ENTG subunit.	False
Administration of C3 (16 mg / kg) offered 70% protection against BC6ENTG - and BC6ENTC - induced pulmonary thromboembolism and 30% protection against BC6OTHER - induced death in mice , without adversely affecting bleeding time.	False
Administration of C3 (16 mg / kg) offered 70% protection against BC6ENTG - and BC6OTHER - induced pulmonary thromboembolism and 30% protection against BC6ENTC - induced death in mice , without adversely affecting bleeding time.	False
In rat PRP , C3 reduced BC6ENTC and BC6ENTG - induced platelet aggregation.	False
C3 fed hamsters showed reduced whole - blood aggregation response to BC6ENTC and BC6ENTG compared to HC - fed hamsters.	False
In mechanistic studies , BC6ENTC decreased the protein level of BC6ENTG , which might be the possible molecular mechanism of BC6OTHER efficacy on the growth inhibition in SGC - 7901 cells.	CPR:4
In mechanistic studies , BC6OTHER decreased the protein level of BC6ENTG , which might be the possible molecular mechanism of BC6ENTC efficacy on the growth inhibition in SGC - 7901 cells.	False
In addition , BC6ENTC caused an increase in BC6ENTG and BC6OTHER protein level as well as mRNA levels.	CPR:3
In addition , BC6ENTC caused an increase in BC6OTHER and BC6ENTG protein level as well as mRNA levels.	CPR:3
BC6ENTC is absorbed in the small bowel and is rapidly catabolized by BC6ENTG ( BC6OTHER ) and CHEM - BC6OTHER - methyltransferase ( BC6OTHER ).	CPR:9
BC6ENTC is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6ENTG ) and CHEM - BC6OTHER - methyltransferase ( BC6OTHER ).	CPR:9
BC6ENTC is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:9
BC6ENTC is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6OTHER ) and CHEM - BC6OTHER - methyltransferase ( BC6ENTG ).	CPR:9
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6ENTC decarboxylase ( BC6ENTG ) and CHEM - BC6OTHER - methyltransferase ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6ENTC decarboxylase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6ENTC decarboxylase ( BC6OTHER ) and CHEM - BC6OTHER - methyltransferase ( BC6ENTG ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by BC6ENTG ( BC6OTHER ) and BC6ENTC - BC6OTHER - methyltransferase ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6ENTG ) and BC6ENTC - BC6OTHER - methyltransferase ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6OTHER ) and BC6ENTC - BC6OTHER - methyltransferase ( BC6ENTG ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by BC6ENTG ( BC6OTHER ) and CHEM - BC6ENTC - methyltransferase ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6ENTG ) and CHEM - BC6ENTC - methyltransferase ( BC6OTHER ).	False
BC6OTHER is absorbed in the small bowel and is rapidly catabolized by aromatic - BC6OTHER decarboxylase ( BC6OTHER ) and CHEM - BC6ENTC - methyltransferase ( BC6ENTG ).	False
Because gastric BC6ENTG and BC6OTHER degrade BC6ENTC , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	CPR:9
Because gastric BC6OTHER and BC6ENTG degrade BC6ENTC , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	CPR:9
Because gastric BC6OTHER and BC6OTHER degrade BC6ENTC , the drug is given with inhibitors of BC6ENTG ( BC6OTHER or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	False
Because gastric BC6OTHER and BC6OTHER degrade BC6ENTC , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6OTHER ) , and inhibitors of BC6ENTG will also enter clinical use.	False
Because gastric BC6ENTG and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6ENTC or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	False
Because gastric BC6OTHER and BC6ENTG degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6ENTC or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	False
Because gastric BC6OTHER and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6ENTG ( BC6ENTC or BC6OTHER ) , and inhibitors of BC6OTHER will also enter clinical use.	CPR:4
Because gastric BC6OTHER and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6ENTC or BC6OTHER ) , and inhibitors of BC6ENTG will also enter clinical use.	False
Because gastric BC6ENTG and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6ENTC ) , and inhibitors of BC6OTHER will also enter clinical use.	False
Because gastric BC6OTHER and BC6ENTG degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6ENTC ) , and inhibitors of BC6OTHER will also enter clinical use.	False
Because gastric BC6OTHER and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6ENTG ( BC6OTHER or BC6ENTC ) , and inhibitors of BC6OTHER will also enter clinical use.	CPR:4
Because gastric BC6OTHER and BC6OTHER degrade BC6OTHER , the drug is given with inhibitors of BC6OTHER ( BC6OTHER or BC6ENTC ) , and inhibitors of BC6ENTG will also enter clinical use.	False
Although the exact site of decarboxylation of exogenous BC6ENTC to BC6OTHER in the brain is unknown , most striatal BC6ENTG is located in nigrostriatal dopaminergic nerve terminals.	False
Although the exact site of decarboxylation of exogenous BC6OTHER to BC6ENTC in the brain is unknown , most striatal BC6ENTG is located in nigrostriatal dopaminergic nerve terminals.	False
Newly synthesized CHEM is stored in the terminals and then released , stimulating postsynaptic BC6ENTG and mediating the antiparkinsonian action of BC6ENTC .	False
BC6ENTC agonists act directly on postsynaptic BC6ENTG , thus obviating the need for metabolic conversion , storage , and release.	False
However , the agonist - bound state provides an uncertain template for modeling the activated conformation of other BC6ENTG , as a BC6ENTC D2 receptor ( BC6OTHER ) activated model templated on the activated BC6OTHER structure returned few hits of only marginal potency.	False
However , the agonist - bound state provides an uncertain template for modeling the activated conformation of other BC6OTHER , as a BC6ENTC D2 receptor ( BC6ENTG ) activated model templated on the activated BC6OTHER structure returned few hits of only marginal potency.	False
However , the agonist - bound state provides an uncertain template for modeling the activated conformation of other BC6OTHER , as a BC6ENTC D2 receptor ( BC6OTHER ) activated model templated on the activated BC6ENTG structure returned few hits of only marginal potency.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6OTHER , and BC6OTHER , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTC channel inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6OTHER , and BC6OTHER , a novel mixed BC6OTHER blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTG inactivation and amplifies late I( BC6ENTC ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6OTHER , and BC6OTHER , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6OTHER inactivation and amplifies late I( BC6ENTC ) greatly , mimicking LQT3.	False
The BC6ENTC channel block caused by BC6OTHER and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6ENTG expressed in HEK cells.	False
The BC6ENTG block caused by BC6ENTC and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6OTHER expressed in HEK cells.	CPR:4
The BC6OTHER block caused by BC6ENTC and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6ENTG expressed in HEK cells.	False
The BC6ENTG block caused by BC6OTHER and BC6ENTC can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6OTHER expressed in HEK cells.	CPR:4
The BC6OTHER block caused by BC6OTHER and BC6ENTC can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6ENTG expressed in HEK cells.	False
The BC6ENTG block caused by BC6OTHER and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6ENTC current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6OTHER expressed in HEK cells.	False
The BC6OTHER block caused by BC6OTHER and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6ENTC current (I( BC6OTHER )) , recorded at 22 degrees C using whole - cell patch clamp of BC6ENTG expressed in HEK cells.	False
The BC6ENTG block caused by BC6OTHER and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6ENTC )) , recorded at 22 degrees C using whole - cell patch clamp of BC6OTHER expressed in HEK cells.	False
The BC6OTHER block caused by BC6OTHER and BC6OTHER can be through the open or inactivated states of the channel , but both equivalently inhibit a late component of BC6OTHER current (I( BC6ENTC )) , recorded at 22 degrees C using whole - cell patch clamp of BC6ENTG expressed in HEK cells.	False
However , pretreatment with agents that block late I( BC6ENTC ) , like BC6OTHER , BC6OTHER , and BC6OTHER , a novel mixed BC6OTHER blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTG inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6ENTC ) , like BC6OTHER , BC6OTHER , and BC6OTHER , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6OTHER inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6ENTC , BC6OTHER , and BC6OTHER , a novel mixed BC6OTHER blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTG inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6ENTC , BC6OTHER , and BC6OTHER , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6OTHER inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6ENTC , and BC6OTHER , a novel mixed BC6OTHER blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTG inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6ENTC , and BC6OTHER , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6OTHER inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6OTHER , and BC6ENTC , a novel mixed BC6OTHER blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6ENTG inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	False
However , pretreatment with agents that block late I( BC6OTHER ) , like BC6OTHER , BC6OTHER , and BC6ENTC , a novel mixed BC6ENTG blocker for the rapid pharmacologic conversion of atrial fibrillation , significantly attenuates the prolonging effects of Class III agents or those induced by ATX - II , a specific toxin that delays BC6OTHER inactivation and amplifies late I( BC6OTHER ) greatly , mimicking LQT3.	CPR:4
A series of BC6OTHER have been synthesised , characterised and tested for their in vitro BC6ENTG BC6ENTC kinase inhibitory activity.	False
A series of BC6ENTC have been synthesised , characterised and tested for their in vitro BC6OTHER BC6ENTG inhibitory activity.	CPR:4
A series of BC6ENTC have been synthesised , characterised and tested for their in vitro BC6ENTG BC6OTHER inhibitory activity.	CPR:4
Synthesis and in vitro evaluation of BC6ENTC derivatives as potent BC6ENTG inhibitors.	CPR:4
In this study , a novel series of BC6ENTC derivatives were synthesized and evaluated for inhibiting BC6ENTG BC6OTHER activity and suppressing cancer cell invasion.	CPR:4
In this study , a novel series of BC6ENTC derivatives were synthesized and evaluated for inhibiting BC6OTHER BC6ENTG activity and suppressing cancer cell invasion.	CPR:4
In this study , a novel series of BC6OTHER derivatives were synthesized and evaluated for inhibiting BC6ENTG BC6ENTC protease activity and suppressing cancer cell invasion.	False
These derivatives demonstrated good inhibitory activity against BC6ENTG BC6ENTC protease , which correlated with the promising anti - invasive activity of colon cancer cells overexpressing BC6OTHER .	False
These derivatives demonstrated good inhibitory activity against BC6OTHER BC6ENTC protease , which correlated with the promising anti - invasive activity of colon cancer cells overexpressing BC6ENTG .	False
Discovery of novel BC6ENTC derivatives as BC6ENTG inhibitors.	CPR:4
BC6ENTG is a 54 - BC6ENTC peptide which is encoded by the BC6OTHER gene and activates the BC6OTHER BC6OTHER .	False
BC6OTHER is a 54 - BC6ENTC peptide which is encoded by the BC6OTHER gene and activates the BC6OTHER BC6ENTG .	False
BC6OTHER is a 54 - BC6ENTC peptide which is encoded by the BC6ENTG gene and activates the BC6OTHER BC6OTHER .	False
BC6OTHER is a 54 - BC6ENTC peptide which is encoded by the BC6OTHER gene and activates the BC6ENTG BC6OTHER .	False
Central and peripheral administration of BC6ENTG stimulates the hypothalamic - pituitary - gonadal (HPG) axis whilst pre - administration of a BC6ENTC ( BC6OTHER ) antagonist abolishes this effect.	CPR:4
Central and peripheral administration of BC6OTHER stimulates the hypothalamic - pituitary - gonadal (HPG) axis whilst pre - administration of a BC6ENTC ( BC6ENTG ) antagonist abolishes this effect.	False
Central and peripheral administration of BC6ENTG stimulates the hypothalamic - pituitary - gonadal (HPG) axis whilst pre - administration of a BC6OTHER ( BC6ENTC ) antagonist abolishes this effect.	CPR:4
Central and peripheral administration of BC6OTHER stimulates the hypothalamic - pituitary - gonadal (HPG) axis whilst pre - administration of a BC6ENTG ( BC6ENTC ) antagonist abolishes this effect.	False
In healthy human volunteers , the acute intravenous administration of kisspeptin potently increases plasma BC6ENTG ( BC6OTHER ) levels and significantly increases plasma BC6OTHER ( BC6OTHER ) and BC6ENTC without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle.	False
In healthy human volunteers , the acute intravenous administration of kisspeptin potently increases plasma BC6OTHER ( BC6ENTG ) levels and significantly increases plasma BC6OTHER ( BC6OTHER ) and BC6ENTC without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle.	False
In healthy human volunteers , the acute intravenous administration of kisspeptin potently increases plasma BC6OTHER ( BC6OTHER ) levels and significantly increases plasma BC6ENTG ( BC6OTHER ) and BC6ENTC without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle.	False
In healthy human volunteers , the acute intravenous administration of kisspeptin potently increases plasma BC6OTHER ( BC6OTHER ) levels and significantly increases plasma BC6OTHER ( BC6ENTG ) and BC6ENTC without side effects in both males and in females particularly in the preovulatatory phase of the menstrual cycle.	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ).	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ).	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ).	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ).	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ).	False
BC6ENTC - terminal amidation , a required post - translational modification for the bioactivation of many neuropeptides , entails sequential enzymic action by BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ).	False
Stereochemical studies established that BC6ENTG inactivation by BC6ENTC is stereospecific with respect to the moiety at the P(2) position , which is consistent with previous results with substrates and reversible inhibitors.	CPR:4
In contrast , BC6ENTC , which is a competitive inhibitor with respect to BC6OTHER , exhibits a low degree of stereospecificity in binding to the BC6OTHER sites of both BC6ENTG and BC6OTHER .	CPR:4
In contrast , BC6ENTC , which is a competitive inhibitor with respect to BC6OTHER , exhibits a low degree of stereospecificity in binding to the BC6OTHER sites of both BC6OTHER and BC6ENTG .	CPR:4
In contrast , BC6OTHER , which is a competitive inhibitor with respect to BC6ENTC , exhibits a low degree of stereospecificity in binding to the BC6OTHER sites of both BC6ENTG and BC6OTHER .	False
In contrast , BC6OTHER , which is a competitive inhibitor with respect to BC6ENTC , exhibits a low degree of stereospecificity in binding to the BC6OTHER sites of both BC6OTHER and BC6ENTG .	False
In contrast , BC6OTHER , which is a competitive inhibitor with respect to BC6OTHER , exhibits a low degree of stereospecificity in binding to the BC6ENTC sites of both BC6ENTG and BC6OTHER .	False
In contrast , BC6OTHER , which is a competitive inhibitor with respect to BC6OTHER , exhibits a low degree of stereospecificity in binding to the BC6ENTC sites of both BC6OTHER and BC6ENTG .	False
In contrast , BC6OTHER , which is a competitive inhibitor with respect to BC6OTHER , exhibits a low degree of stereospecificity in binding to the BC6OTHER sites of both BC6ENTG and BC6ENTC - beta - hydroxylase.	False
Kinetic parameters for BC6ENTG inactivation by BC6ENTC were obtained by using both the conventional dilution assay method and the more complex progress curve method.	CPR:4
Nevertheless , an external application of BC6ENTC or BC6OTHER over decapsulized kidney of rat resulted in a significant accumulation of BC6OTHER - labelled BC6ENTG .	False
Nevertheless , an external application of BC6OTHER or BC6ENTC over decapsulized kidney of rat resulted in a significant accumulation of BC6OTHER - labelled BC6ENTG .	False
Nevertheless , an external application of BC6OTHER or BC6OTHER over decapsulized kidney of rat resulted in a significant accumulation of BC6ENTC - labelled BC6ENTG .	False
The activation may be accelerated by an acute inflammatory process provoked by BC6ENTC , which is supported by such clinical manifestations as mild fever , retrosternal pain leukocytosis and an increase in plasma BC6ENTG level which was observed in all during the period.	CPR:3
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6ENTC ( BC6OTHER ) , by means of serial determination of plasma BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6ENTC ( BC6OTHER ) , by means of serial determination of plasma BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6ENTC ( BC6OTHER ) , by means of serial determination of plasma BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6ENTC ( BC6OTHER ) , by means of serial determination of plasma BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6ENTC ) , by means of serial determination of plasma BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6ENTC ) , by means of serial determination of plasma BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6ENTC ) , by means of serial determination of plasma BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6ENTC ) , by means of serial determination of plasma BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6OTHER ) , by means of serial determination of plasma BC6ENTG ( BC6OTHER ) and BC6ENTC beta 15 - 42 ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6OTHER ) , by means of serial determination of plasma BC6OTHER ( BC6ENTG ) and BC6ENTC beta 15 - 42 ( BC6OTHER ).	False
Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices , who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent BC6OTHER ( BC6OTHER ) , by means of serial determination of plasma BC6OTHER ( BC6OTHER ) and BC6ENTC beta 15 - 42 ( BC6ENTG ).	False
In vitro studies , however , revealed that BC6ENTC inhibits BC6ENTG clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6OTHER formation in vitro.	CPR:4
In vitro studies , however , revealed that BC6ENTC inhibits BC6OTHER clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6ENTG formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6ENTG clot formation because of the BC6ENTC - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6OTHER formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6OTHER clot formation because of the BC6ENTC - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6ENTG formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6ENTG clot formation because of the BC6OTHER - chelating ability of its constituent BC6ENTC , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6OTHER formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6OTHER clot formation because of the BC6OTHER - chelating ability of its constituent BC6ENTC , although BC6OTHER or BC6OTHER exhibited procoagulant activity in BC6ENTG formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6ENTG clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6ENTC or BC6OTHER exhibited procoagulant activity in BC6OTHER formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6OTHER clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6ENTC or BC6OTHER exhibited procoagulant activity in BC6ENTG formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6ENTG clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6ENTC exhibited procoagulant activity in BC6OTHER formation in vitro.	False
In vitro studies , however , revealed that BC6OTHER inhibits BC6OTHER clot formation because of the BC6OTHER - chelating ability of its constituent BC6OTHER , although BC6OTHER or BC6ENTC exhibited procoagulant activity in BC6ENTG formation in vitro.	False
The obtained data demonstrate that the adenosinergic system is involved in BC6ENTC withdrawal signs in mice , and BC6ENTG plays an important role in this process.	False
The aim of the present experiment was to assess the involvement of BC6ENTG antagonists in BC6ENTC ( BC6OTHER ) withdrawal signs , observed as the seizure susceptibility in mice.	False
The aim of the present experiment was to assess the involvement of BC6ENTG antagonists in BC6OTHER ( BC6ENTC ) withdrawal signs , observed as the seizure susceptibility in mice.	False
The concomitant application of subconvulsive dose of BC6ENTC (55.0 mg / kg) with low dose of BC6OTHER (5.0 mg / kg) - a BC6ENTG antagonist , immediately induced BC6OTHER withdrawal signs in these animals.	False
The concomitant application of subconvulsive dose of BC6OTHER (55.0 mg / kg) with low dose of BC6ENTC (5.0 mg / kg) - a BC6ENTG antagonist , immediately induced BC6OTHER withdrawal signs in these animals.	CPR:6
The concomitant application of subconvulsive dose of BC6OTHER (55.0 mg / kg) with low dose of BC6OTHER (5.0 mg / kg) - a BC6ENTG antagonist , immediately induced BC6ENTC withdrawal signs in these animals.	False
The non - selective BC6ENTC receptor antagonist ( BC6OTHER ) , and the selective BC6ENTG antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6ENTG antagonist ( BC6ENTC ) , and the selective BC6OTHER antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	CPR:6
The non - selective BC6OTHER antagonist ( BC6ENTC ) , and the selective BC6ENTG antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6ENTG antagonist ( BC6OTHER ) , and the selective BC6ENTC A1 receptor antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6ENTG antagonist ( BC6OTHER ) , and the selective BC6OTHER antagonist ( BC6ENTC ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6OTHER antagonist ( BC6OTHER ) , and the selective BC6ENTG antagonist ( BC6ENTC ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	CPR:6
The non - selective BC6ENTG antagonist ( BC6OTHER ) , and the selective BC6OTHER antagonist ( BC6OTHER ) , injected 15 min before the application of BC6ENTC and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6OTHER antagonist ( BC6OTHER ) , and the selective BC6ENTG antagonist ( BC6OTHER ) , injected 15 min before the application of BC6ENTC and BC6OTHER , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6ENTG antagonist ( BC6OTHER ) , and the selective BC6OTHER antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6ENTC , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6OTHER antagonist ( BC6OTHER ) , and the selective BC6ENTG antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6ENTC , were able to intensify BC6OTHER withdrawal signs in mice.	False
The non - selective BC6ENTG antagonist ( BC6OTHER ) , and the selective BC6OTHER antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6ENTC withdrawal signs in mice.	False
The non - selective BC6OTHER antagonist ( BC6OTHER ) , and the selective BC6ENTG antagonist ( BC6OTHER ) , injected 15 min before the application of BC6OTHER and BC6OTHER , were able to intensify BC6ENTC withdrawal signs in mice.	False
The most apparent effects were observed after administration of BC6ENTC , indicating that the BC6ENTG may play a more important role in these effects.	False
 BC6ENTG antagonists intensify the BC6ENTC withdrawal signs in mice.	False
These values are here given for BC6ENTC D2 and D4 receptors , as well as for BC6ENTG .	False
These values are here given for BC6ENTG , as well as for BC6ENTC 5 - HT2A receptors.	False
For example , BC6ENTC revealed a radioligand - independent value of 1.6 nM at the BC6ENTG , agreeing with the value directly measured with BC6OTHER at BC6OTHER .	False
For example , BC6ENTC revealed a radioligand - independent value of 1.6 nM at the BC6OTHER , agreeing with the value directly measured with BC6OTHER at BC6ENTG .	False
For example , BC6OTHER revealed a radioligand - independent value of 1.6 nM at the BC6ENTC D4 receptor , agreeing with the value directly measured with BC6OTHER at BC6ENTG .	False
For example , BC6OTHER revealed a radioligand - independent value of 1.6 nM at the BC6ENTG , agreeing with the value directly measured with BC6ENTC at BC6OTHER .	False
For example , BC6OTHER revealed a radioligand - independent value of 1.6 nM at the BC6OTHER , agreeing with the value directly measured with BC6ENTC at BC6ENTG .	False
However , because BC6ENTC competes with endogenous BC6OTHER , the in vivo concentration of BC6OTHER (to occupy BC6ENTG ) can be derived to be about 13 nM , agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.	False
However , because BC6OTHER competes with endogenous BC6ENTC , the in vivo concentration of BC6OTHER (to occupy BC6ENTG ) can be derived to be about 13 nM , agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.	False
However , because BC6OTHER competes with endogenous BC6OTHER , the in vivo concentration of BC6ENTC (to occupy BC6ENTG ) can be derived to be about 13 nM , agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.	False
The atypical neuroleptics BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had low affinity for the BC6OTHER BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
The atypical neuroleptics BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had low affinity for the BC6OTHER BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
The atypical neuroleptics BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had low affinity for the BC6OTHER BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
The atypical neuroleptics BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had low affinity for the BC6OTHER BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
The atypical neuroleptics BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had low affinity for the BC6OTHER BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
The atypical neuroleptics BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had low affinity for the BC6ENTC BC6ENTG (radioligand - independent dissociation constants of 30 to 90 nM).	False
Most typical neuroleptics have radioligand - independent values of 0.3 to 5 nM at BC6ENTG , making them more resistant to displacement by endogenous BC6ENTC .	False
Thus , the atypical neuroleptics appear to fall into two groups , those that have a low affinity for BC6ENTC D2 receptors and those that are selective for BC6ENTG .	False
Thus , the atypical neuroleptics appear to fall into two groups , those that have a low affinity for BC6ENTG and those that are selective for BC6ENTC D4 receptors.	False
Atypical neuroleptics have low affinity for BC6ENTC D2 receptors or are selective for BC6ENTG .	False
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:4
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6ENTG ( BC6OTHER / BC6OTHER ) and BC6OTHER .	CPR:3
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6ENTG / BC6OTHER ) and BC6OTHER .	CPR:3
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6ENTG ) and BC6OTHER .	CPR:3
BC6ENTC inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) , and the upregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and BC6ENTG .	CPR:3
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6ENTG ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6ENTG ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6ENTG / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6ENTG ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6ENTG ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTG ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6ENTG ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6ENTG / BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6ENTG ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6ENTG ) signaling pathway.	CPR:4
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6ENTG ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6ENTG ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6ENTG / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6ENTG ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6ENTG ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6ENTG ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6ENTG / BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6ENTG ( BC6OTHER ) signaling pathway.	False
BC6OTHER was also found to attenuate the activation of proteins involved in f BC6OTHER ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6OTHER ) signaling , and BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER / BC6OTHER ( BC6ENTG ) signaling pathway.	False
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6ENTG , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6ENTG / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6ENTG / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6ENTG signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6ENTG - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
Subsequently , BC6ENTC suppressed the nuclear translocation of BC6OTHER , one of downstream molecules of BC6OTHER / BC6OTHER / BC6OTHER signaling , and these events led to the sequential downregulation of BC6OTHER - mediated transcription of target genes including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Suppression of BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER signaling by BC6ENTC inhibits the growth of human colorectal cancer cells.	CPR:4
Suppression of BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER signaling by BC6ENTC inhibits the growth of human colorectal cancer cells.	CPR:4
Suppression of BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER signaling by BC6ENTC inhibits the growth of human colorectal cancer cells.	CPR:4
Suppression of BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG signaling by BC6ENTC inhibits the growth of human colorectal cancer cells.	CPR:4
BC6OTHER was adducted in CHEM - MB - 231 breast cancer cells treated with BC6OTHER as judged by click chemistry conjugation with BC6ENTC followed by streptavidin - based pulldown and Western blotting with anti - BC6ENTG antibody.	False
BC6ENTG was adducted in CHEM - MB - 231 breast cancer cells treated with BC6OTHER as judged by click chemistry conjugation with BC6ENTC followed by streptavidin - based pulldown and Western blotting with anti - BC6OTHER antibody.	False
Furthermore , orbitrap MS data support the adduction of BC6ENTC - 113 in the BC6ENTG active site upon BC6OTHER treatment of CHEM - MB - 231 cells.	False
Furthermore , orbitrap MS data support the adduction of BC6OTHER - 113 in the BC6ENTG active site upon BC6ENTC treatment of CHEM - MB - 231 cells.	False
siRNA knockdown of BC6ENTG in CHEM - MB - 231 cells partially protected the cells from BC6ENTC - induced toxicity.	False
Recent studies indicate that BC6ENTG is an important molecular target for the chemopreventive effects of green tea BC6ENTC .	False
Here , we demonstrate that peptidyl - BC6ENTC cis / trans - isomerase A1 ( BC6ENTG ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6OTHER - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	False
Here , we demonstrate that BC6ENTG ( BC6OTHER ) , an enzyme that catalyzes the conversion of the peptide bond of BC6ENTC / BC6OTHER - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that peptidyl - BC6OTHER cis / trans - isomerase A1 ( BC6ENTG ) , an enzyme that catalyzes the conversion of the peptide bond of BC6ENTC / BC6OTHER - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that BC6ENTG ( BC6OTHER ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6ENTC - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that peptidyl - BC6OTHER cis / trans - isomerase A1 ( BC6ENTG ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6ENTC - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that BC6ENTG ( BC6OTHER ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6OTHER - BC6ENTC moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that peptidyl - BC6OTHER cis / trans - isomerase A1 ( BC6ENTG ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6OTHER - BC6ENTC moieties in signaling proteins from cis to trans , is highly susceptible to BC6OTHER modification.	CPR:9
Here , we demonstrate that BC6ENTG ( BC6OTHER ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6OTHER - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6ENTC modification.	False
Here , we demonstrate that peptidyl - BC6OTHER cis / trans - isomerase A1 ( BC6ENTG ) , an enzyme that catalyzes the conversion of the peptide bond of BC6OTHER / BC6OTHER - BC6OTHER moieties in signaling proteins from cis to trans , is highly susceptible to BC6ENTC modification.	False
Incubation of purified BC6ENTG with BC6ENTC followed by MALDI - TOF / TOF mass spectrometry resulted in detection of Michael adducts at the active site residues BC6OTHER - 157 and BC6OTHER - 113.	False
Incubation of purified BC6ENTG with BC6OTHER followed by MALDI - TOF / TOF mass spectrometry resulted in detection of Michael adducts at the active site residues BC6ENTC - 157 and BC6OTHER - 113.	False
Incubation of purified BC6ENTG with BC6OTHER followed by MALDI - TOF / TOF mass spectrometry resulted in detection of Michael adducts at the active site residues BC6OTHER - 157 and BC6ENTC - 113.	False
BC6OTHER was adducted in CHEM - MB - 231 breast cancer cells treated with BC6ENTC as judged by click chemistry conjugation with BC6OTHER followed by streptavidin - based pulldown and Western blotting with anti - BC6ENTG antibody.	False
BC6ENTG was adducted in CHEM - MB - 231 breast cancer cells treated with BC6ENTC as judged by click chemistry conjugation with BC6OTHER followed by streptavidin - based pulldown and Western blotting with anti - BC6OTHER antibody.	False
Peptidyl - BC6ENTC cis / trans - isomerase A1 ( BC6ENTG ) is a target for modification by lipid electrophiles.	False
In conclusion , BC6ENTG production and neutrophil infiltration are increased in high - BC6ENTC environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.	CPR:3
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6ENTC environment enhanced BC6ENTG production via BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6OTHER species (ROS) - dependent manner in keratinocytes.	CPR:3
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6ENTC environment enhanced BC6OTHER production via BC6ENTG ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6OTHER species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6ENTC environment enhanced BC6OTHER production via BC6OTHER ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6OTHER species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6ENTC environment enhanced BC6OTHER production via BC6OTHER ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) pathway in a reactive BC6OTHER species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6ENTC environment enhanced BC6OTHER production via BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) pathway in a reactive BC6OTHER species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6OTHER environment enhanced BC6ENTG production via BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6ENTC species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6OTHER environment enhanced BC6OTHER production via BC6ENTG ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6ENTC species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6OTHER environment enhanced BC6OTHER production via BC6OTHER ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) pathway in a reactive BC6ENTC species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6OTHER environment enhanced BC6OTHER production via BC6OTHER ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) pathway in a reactive BC6ENTC species (ROS) - dependent manner in keratinocytes.	False
Using cultured human keratinocytes and diabetic rat model , the current study showed that high - BC6OTHER environment enhanced BC6OTHER production via BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) pathway in a reactive BC6ENTC species (ROS) - dependent manner in keratinocytes.	False
High - BC6ENTC environment enhanced oxidative stress and increased BC6ENTG secretion from keratinocytes: New insights on impaired diabetic wound healing.	CPR:3
We have shown that this approach well predicts the longitudinal BC6ENTG response in a 12 - week study using only information from a 1 - week study where BC6ENTC and BC6OTHER concentrations were measured.	False
We have shown that this approach well predicts the longitudinal BC6OTHER response in a 12 - week study using only information from a 1 - week study where BC6ENTC and BC6ENTG concentrations were measured.	False
In this paper , we present a model - based approach for predicting BC6ENTG ( BC6OTHER ) in late phase using BC6ENTC and BC6OTHER concentrations from an early - phase study , investigating an anti - diabetic treatment.	False
In this paper , we present a model - based approach for predicting BC6OTHER ( BC6ENTG ) in late phase using BC6ENTC and BC6OTHER concentrations from an early - phase study , investigating an anti - diabetic treatment.	False
In this paper , we present a model - based approach for predicting BC6OTHER ( BC6OTHER ) in late phase using BC6ENTC and BC6ENTG concentrations from an early - phase study , investigating an anti - diabetic treatment.	False
Two previously published models were used; an integrated BC6ENTC and BC6ENTG (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6OTHER from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6ENTC and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6ENTG (IGRH) model predicting the formation of BC6OTHER from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6ENTC and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6ENTG from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6ENTG (IGI) model for meal tolerance tests and an integrated BC6ENTC - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6OTHER from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6ENTC - red blood cell - BC6ENTG (IGRH) model predicting the formation of BC6OTHER from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6ENTC - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6ENTG from the average BC6OTHER concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6ENTG (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6OTHER from the average BC6ENTC concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6ENTG (IGRH) model predicting the formation of BC6OTHER from the average BC6ENTC concentration (Cg , av ).	False
Two previously published models were used; an integrated BC6OTHER and BC6OTHER (IGI) model for meal tolerance tests and an integrated BC6OTHER - red blood cell - BC6OTHER (IGRH) model predicting the formation of BC6ENTG from the average BC6ENTC concentration (Cg , av ).	False
A Model - Based Approach to Predict Longitudinal BC6ENTG , Using Early Phase BC6ENTC Data From Type 2 Diabetes Mellitus Patients After Anti - Diabetic Treatment.	False
To determine the role of these sites , we examined the effect of CHEM on the transcription of the BC6ENTG gene , where only intragenic BC6ENTC receptor - binding sites ( BC6OTHER ) were identified.	False
To determine the role of these sites , we examined the effect of CHEM on the transcription of the BC6OTHER gene , where only intragenic BC6ENTC receptor - binding sites ( BC6ENTG ) were identified.	False
 BC6ENTC receptor induces BC6ENTG expression through BC6OTHER favoring BC6OTHER elongation.	False
 BC6ENTC receptor induces BC6OTHER expression through BC6ENTG favoring BC6OTHER elongation.	False
 BC6ENTC receptor induces BC6OTHER expression through BC6OTHER favoring BC6ENTG elongation.	False
Synthesis and antitumor activity of BC6ENTC possessing BC6OTHER moiety as a novel class of potent BC6ENTG inhibitors.	CPR:4
Synthesis and antitumor activity of BC6OTHER possessing BC6ENTC moiety as a novel class of potent BC6ENTG inhibitors.	CPR:4
Acute BC6ENTC did not increase sociability in BALB / cByJ; however , sub - chronic BC6ENTG had significant prosocial effects in both BALB / cByJ and C58 / J.	False
Acute BC6ENTG did not increase sociability in BALB / cByJ; however , sub - chronic BC6ENTC had significant prosocial effects in both BALB / cByJ and C58 / J.	False
Increased sociability was observed 24 hours following the final BC6ENTG dose in BALB / cByJ , while prosocial effects of BC6ENTC emerged 1 - 2 weeks post - treatment in C58 / J.	False
The aim of the present study was to investigate the role of central BC6ENTG receptors on the control of blood BC6ENTC in stressed and non - stressed rats in both fasted and fed states.	False
Injections of BC6ENTC , a selective BC6ENTG receptor agonist , induced a significant increase in blood BC6OTHER in non - stressed rats in both fasted and in fed states.	CPR:5
Injections of BC6OTHER , a selective BC6ENTG receptor agonist , induced a significant increase in blood BC6ENTC in non - stressed rats in both fasted and in fed states.	False
The hyperglycemic effect of BC6ENTC central administration was blocked by pretreatment with CHEM , a specific BC6ENTG receptor antagonist , indicating that the effects here obtained with BC6OTHER were a result of its interaction with BC6OTHER receptors.	CPR:5
The hyperglycemic effect of BC6ENTC central administration was blocked by pretreatment with CHEM , a specific BC6OTHER receptor antagonist , indicating that the effects here obtained with BC6OTHER were a result of its interaction with BC6ENTG receptors.	False
The hyperglycemic effect of BC6OTHER central administration was blocked by pretreatment with CHEM , a specific BC6ENTG receptor antagonist , indicating that the effects here obtained with BC6ENTC were a result of its interaction with BC6OTHER receptors.	False
The hyperglycemic effect of BC6OTHER central administration was blocked by pretreatment with CHEM , a specific BC6OTHER receptor antagonist , indicating that the effects here obtained with BC6ENTC were a result of its interaction with BC6ENTG receptors.	False
Central BC6ENTG receptor stimulation by BC6ENTC increases blood BC6OTHER in rats.	CPR:3
Central BC6ENTG receptor stimulation by BC6OTHER increases blood BC6ENTC in rats.	False
BACKGROUND: BC6ENTC , a BC6ENTG ( BC6OTHER ) antagonist , inhibits not only airway smooth muscle contraction , but also allergic inflammation.	CPR:6
BACKGROUND: BC6ENTC , a BC6OTHER ( BC6ENTG ) antagonist , inhibits not only airway smooth muscle contraction , but also allergic inflammation.	CPR:6
BC6ENTC - induced inhibition of BC6ENTG mRNA expression was noted in various cells , irrespective of their BC6OTHER mRNA expression status.	CPR:4
BC6ENTC - induced inhibition of BC6OTHER mRNA expression was noted in various cells , irrespective of their BC6ENTG mRNA expression status.	False
In addition , BC6ENTC per se failed to upregulate the BC6ENTG production.	False
CONCLUSION: Our results indicate that BC6ENTC inhibits BC6ENTG synthesis via a mechanism distinct from BC6OTHER antagonism.	CPR:4
CONCLUSION: Our results indicate that BC6ENTC inhibits BC6OTHER synthesis via a mechanism distinct from BC6ENTG antagonism.	CPR:6
The aim of this study was to determine the mechanism of BC6ENTC - induced BC6ENTG ( BC6OTHER ) inhibition in allergic inflammation.	CPR:4
The aim of this study was to determine the mechanism of BC6ENTC - induced BC6OTHER ( BC6ENTG ) inhibition in allergic inflammation.	CPR:4
BACKGROUND: BC6OTHER , a BC6ENTC receptor 1 ( BC6ENTG ) antagonist , inhibits not only airway smooth muscle contraction , but also allergic inflammation.	False
RESULTS: Pretreatment of lung tissues with BC6ENTC alone significantly decreased the amount of BC6ENTG protein in the culture medium by 40%.	CPR:4
 BC6ENTC , a BC6OTHER antagonist , inhibits BC6OTHER production via a mechanism distinct from BC6ENTG antagonism.	CPR:6
 BC6ENTC , a BC6ENTG antagonist , inhibits BC6OTHER production via a mechanism distinct from BC6OTHER antagonism.	CPR:6
 BC6ENTC , a BC6OTHER antagonist , inhibits BC6ENTG production via a mechanism distinct from BC6OTHER antagonism.	CPR:4
 BC6OTHER , a BC6ENTG antagonist , inhibits BC6OTHER production via a mechanism distinct from BC6ENTC receptor antagonism.	False
 BC6OTHER , a BC6OTHER antagonist , inhibits BC6ENTG production via a mechanism distinct from BC6ENTC receptor antagonism.	False
 BC6OTHER , a BC6ENTC receptor antagonist , inhibits BC6OTHER production via a mechanism distinct from BC6ENTG antagonism.	False
 BC6OTHER , a BC6ENTC receptor antagonist , inhibits BC6ENTG production via a mechanism distinct from BC6OTHER antagonism.	False
Taken together , the results of the present study have characterized BC6ENTG as an inhibitor of BC6OTHER that modulates the synthesis of BC6OTHER and provides new insights into the regulatory mechanism of BC6ENTC homoeostasis , with clinical importance for a treatment of BC6OTHER overload diseases.	False
Taken together , the results of the present study have characterized BC6OTHER as an inhibitor of BC6ENTG that modulates the synthesis of BC6OTHER and provides new insights into the regulatory mechanism of BC6ENTC homoeostasis , with clinical importance for a treatment of BC6OTHER overload diseases.	False
Taken together , the results of the present study have characterized BC6OTHER as an inhibitor of BC6OTHER that modulates the synthesis of BC6ENTG and provides new insights into the regulatory mechanism of BC6ENTC homoeostasis , with clinical importance for a treatment of BC6OTHER overload diseases.	False
Taken together , the results of the present study have characterized BC6ENTG as an inhibitor of BC6OTHER that modulates the synthesis of BC6OTHER and provides new insights into the regulatory mechanism of BC6OTHER homoeostasis , with clinical importance for a treatment of BC6ENTC overload diseases.	False
Taken together , the results of the present study have characterized BC6OTHER as an inhibitor of BC6ENTG that modulates the synthesis of BC6OTHER and provides new insights into the regulatory mechanism of BC6OTHER homoeostasis , with clinical importance for a treatment of BC6ENTC overload diseases.	False
Taken together , the results of the present study have characterized BC6OTHER as an inhibitor of BC6OTHER that modulates the synthesis of BC6ENTG and provides new insights into the regulatory mechanism of BC6OTHER homoeostasis , with clinical importance for a treatment of BC6ENTC overload diseases.	False
BC6ENTG , a recently identified cell surface BC6OTHER , is the key enzyme of BC6ENTC homoeostasis modulating the expression of the liver peptide hormone BC6OTHER .	False
BC6OTHER , a recently identified cell surface BC6OTHER , is the key enzyme of BC6ENTC homoeostasis modulating the expression of the liver peptide hormone BC6ENTG .	False
BC6OTHER , a recently identified cell surface BC6ENTG , is the key enzyme of BC6ENTC homoeostasis modulating the expression of the liver peptide hormone BC6OTHER .	False
SS rats had lower plasma BC6ENTC concentrations than CTL rats (p=0.05) , but did not differ in BC6ENTG , BC6OTHER , or BC6OTHER immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6ENTC concentrations than CTL rats (p=0.05) , but did not differ in BC6OTHER , BC6ENTG , or BC6OTHER immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6ENTC concentrations than CTL rats (p=0.05) , but did not differ in BC6OTHER , BC6OTHER , or BC6ENTG immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6OTHER concentrations than CTL rats (p=0.05) , but did not differ in BC6ENTC receptor , BC6ENTG , or BC6OTHER immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6OTHER concentrations than CTL rats (p=0.05) , but did not differ in BC6ENTC receptor , BC6OTHER , or BC6ENTG immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6OTHER concentrations than CTL rats (p=0.05) , but did not differ in BC6ENTG , BC6ENTC receptor alpha , or BC6OTHER immunoreactive cell counts in the medial preoptic area.	False
SS rats had lower plasma BC6OTHER concentrations than CTL rats (p=0.05) , but did not differ in BC6OTHER , BC6ENTC receptor alpha , or BC6ENTG immunoreactive cell counts in the medial preoptic area.	False
BC6ENTC uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest BC6OTHER uptake activity , at an increment of 21% in the BC6ENTG - resistant FL83B mouse hepatocytes as compared with the BC6OTHER - treated control group.	False
BC6ENTC uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest BC6OTHER uptake activity , at an increment of 21% in the BC6OTHER - resistant FL83B mouse hepatocytes as compared with the BC6ENTG - treated control group.	False
BC6OTHER uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest BC6ENTC uptake activity , at an increment of 21% in the BC6ENTG - resistant FL83B mouse hepatocytes as compared with the BC6OTHER - treated control group.	False
BC6OTHER uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest BC6ENTC uptake activity , at an increment of 21% in the BC6OTHER - resistant FL83B mouse hepatocytes as compared with the BC6ENTG - treated control group.	False
This compound , at the concentration of 6.25 µg / mL , exhibits the same BC6ENTC uptake improvement in BC6ENTG - resistant cells as PWFE at a 100 - µg / mL dose.	False
We postulate that BC6ENTC is an active component in PWFE that may alleviate the BC6ENTG resistance in mouse hepatocytes.	False
Effect of water extracts from edible myrtaceae plants on uptake of BC6ENTC in BC6ENTG - treated FL83B mouse hepatocytes.	False
A series of BC6ENTC linked prodrugs of 1 ( BC6OTHER ) , a clinical BC6ENTG inhibitor , were synthesized and evaluated.	CPR:4
A series of BC6OTHER linked prodrugs of 1 ( BC6ENTC ) , a clinical BC6ENTG inhibitor , were synthesized and evaluated.	CPR:4
Synthesis and evaluation of BC6ENTC linked prodrugs of BC6OTHER , a clinical BC6ENTG inhibitor.	CPR:4
Synthesis and evaluation of BC6OTHER linked prodrugs of BC6ENTC , a clinical BC6ENTG inhibitor.	CPR:4
BC6ENTC nonresponsive CHEM (CHEM , mut complementation class) results from mutations in the nuclear gene BC6ENTG , which codes for the mitochondrial enzyme BC6OTHER ( BC6OTHER ).	False
BC6ENTC nonresponsive CHEM (CHEM , mut complementation class) results from mutations in the nuclear gene BC6OTHER , which codes for the mitochondrial enzyme BC6ENTG ( BC6OTHER ).	False
BC6ENTC nonresponsive CHEM (CHEM , mut complementation class) results from mutations in the nuclear gene BC6OTHER , which codes for the mitochondrial enzyme BC6OTHER ( BC6ENTG ).	False
BC6OTHER nonresponsive CHEM (CHEM , mut complementation class) results from mutations in the nuclear gene BC6ENTG , which codes for the mitochondrial enzyme BC6ENTC mutase ( BC6OTHER ).	False
BC6OTHER nonresponsive CHEM (CHEM , mut complementation class) results from mutations in the nuclear gene BC6OTHER , which codes for the mitochondrial enzyme BC6ENTC mutase ( BC6ENTG ).	False
BC6ENTG density and function (agonist - induced BC6ENTC production) was measured in myometrial samples from both groups.	False
The failure of the myometrium to respond to BC6ENTC (desensitization) was associated with significant reductions in agonist - induced BC6OTHER production and BC6ENTG concentration in myometrial tissue collected from these animals compared with the saline solution - treated controls.	CPR:4
The failure of the myometrium to respond to BC6OTHER (desensitization) was associated with significant reductions in agonist - induced BC6ENTC production and BC6ENTG concentration in myometrial tissue collected from these animals compared with the saline solution - treated controls.	False
These findings demonstrate that cinnamon BC6ENTC can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti - oxidative capacity , as well as attenuating cytotoxicity via inhibition of BC6ENTG , BC6OTHER activation.	CPR:4
These findings demonstrate that cinnamon BC6ENTC can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti - oxidative capacity , as well as attenuating cytotoxicity via inhibition of BC6OTHER , BC6ENTG activation.	CPR:4
As revealed by BC6ENTC oxidase (GOD) and radioimmunoassay (RIA) , both BC6OTHER (DC , 0.6gkg( - 1)d( - 1)) and CHEM (0.3 , 0.6 , 1.2gkg( - 1)d( - 1)) treatments significantly resulted in down - regulation of blood BC6OTHER and BC6ENTG levels in serum , while the levels of oxidative stress markers were markedly lowered through ELISA assay.	False
As revealed by BC6ENTG (GOD) and radioimmunoassay (RIA) , both BC6ENTC (DC , 0.6gkg( - 1)d( - 1)) and CHEM (0.3 , 0.6 , 1.2gkg( - 1)d( - 1)) treatments significantly resulted in down - regulation of blood BC6OTHER and BC6OTHER levels in serum , while the levels of oxidative stress markers were markedly lowered through ELISA assay.	False
As revealed by BC6OTHER (GOD) and radioimmunoassay (RIA) , both BC6ENTC (DC , 0.6gkg( - 1)d( - 1)) and CHEM (0.3 , 0.6 , 1.2gkg( - 1)d( - 1)) treatments significantly resulted in down - regulation of blood BC6OTHER and BC6ENTG levels in serum , while the levels of oxidative stress markers were markedly lowered through ELISA assay.	CPR:4
As revealed by BC6ENTG (GOD) and radioimmunoassay (RIA) , both BC6OTHER (DC , 0.6gkg( - 1)d( - 1)) and CHEM (0.3 , 0.6 , 1.2gkg( - 1)d( - 1)) treatments significantly resulted in down - regulation of blood BC6ENTC and BC6OTHER levels in serum , while the levels of oxidative stress markers were markedly lowered through ELISA assay.	False
As revealed by BC6OTHER (GOD) and radioimmunoassay (RIA) , both BC6OTHER (DC , 0.6gkg( - 1)d( - 1)) and CHEM (0.3 , 0.6 , 1.2gkg( - 1)d( - 1)) treatments significantly resulted in down - regulation of blood BC6ENTC and BC6ENTG levels in serum , while the levels of oxidative stress markers were markedly lowered through ELISA assay.	False
BC6ENTC and its ortho - halogenated ( BC6OTHER , BC6OTHER , BC6OTHER ) derivatives are first - generation dual BC6ENTG and BC6OTHER inhibitors (DASIs).	CPR:4
BC6ENTC and its ortho - halogenated ( BC6OTHER , BC6OTHER , BC6OTHER ) derivatives are first - generation dual BC6OTHER and BC6ENTG inhibitors (DASIs).	CPR:4
BC6OTHER and its ortho - halogenated ( BC6OTHER , BC6ENTC , BC6OTHER ) derivatives are first - generation dual BC6ENTG and BC6OTHER inhibitors (DASIs).	CPR:4
BC6OTHER and its ortho - halogenated ( BC6OTHER , BC6ENTC , BC6OTHER ) derivatives are first - generation dual BC6OTHER and BC6ENTG inhibitors (DASIs).	CPR:4
BC6OTHER and its ortho - halogenated ( BC6OTHER , BC6OTHER , BC6ENTC ) derivatives are first - generation dual BC6ENTG and BC6OTHER inhibitors (DASIs).	CPR:4
BC6OTHER and its ortho - halogenated ( BC6OTHER , BC6OTHER , BC6ENTC ) derivatives are first - generation dual BC6OTHER and BC6ENTG inhibitors (DASIs).	CPR:4
The most potent in vitro DASI discovered is an BC6ENTC derivative with IC50 values against BC6ENTG and BC6OTHER in a JEG - 3 cell preparation of 0.2 and 2.5 nM , respectively.	CPR:4
The most potent in vitro DASI discovered is an BC6ENTC derivative with IC50 values against BC6OTHER and BC6ENTG in a JEG - 3 cell preparation of 0.2 and 2.5 nM , respectively.	CPR:4
The most potent in vitro DASI discovered is an BC6OTHER derivative with IC50 values against BC6ENTG and BC6ENTC sulfatase in a JEG - 3 cell preparation of 0.2 and 2.5 nM , respectively.	False
The parent BC6ENTC of this compound inhibits BC6ENTG with an IC50 value of 0.028 nM in the same assay.	CPR:4
BC6OTHER and its ortho - halogenated ( BC6ENTC , BC6OTHER , BC6OTHER ) derivatives are first - generation dual BC6ENTG and BC6OTHER inhibitors (DASIs).	CPR:4
BC6OTHER and its ortho - halogenated ( BC6ENTC , BC6OTHER , BC6OTHER ) derivatives are first - generation dual BC6OTHER and BC6ENTG inhibitors (DASIs).	CPR:4
Synthesis and Structure - Activity Relationship Studies of Derivatives of the Dual BC6ENTG - BC6OTHER Inhibitor BC6ENTC .	CPR:4
Synthesis and Structure - Activity Relationship Studies of Derivatives of the Dual BC6OTHER - BC6ENTG Inhibitor BC6ENTC .	CPR:4
We analyzed clinical and genetic factors contributing to infections in 457 subjects with early rheumatoid arthritis (RA) enrolled in a prospective , 1 - year clinical trial of BC6ENTC and the BC6ENTG inhibitor CHEM.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6ENTG - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6ENTG ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6ENTG ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6ENTG + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6ENTG BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6ENTG 131 H / R; BC6OTHER 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6ENTG 176 F / V; and BC6OTHER NA 1 / 2 and genotypes were correlated with infections.	False
Subjects were genotyped for the following single BC6ENTC polymorphisms (SNPs): ( BC6OTHER - 308 ,  - 238 , and + 488); BC6OTHER ( BC6OTHER ) ( BC6OTHER + 249 , + 365 , and + 720); and BC6OTHER BC6OTHER 131 H / R; BC6OTHER 176 F / V; and BC6ENTG NA 1 / 2 and genotypes were correlated with infections.	False
Here we report that BC6ENTG null mice are lean and protected from diet - induced obesity and BC6ENTC intolerance.	False
The activation of the BC6OTHER cascade , a cornerstone of the innate immune response , produces a number of small (74 - 77 BC6ENTC ) fragments , originally termed BC6ENTG , that are potent chemoattractants and secretagogues that act on a wide variety of cell types.	False
The activation of the BC6ENTG cascade , a cornerstone of the innate immune response , produces a number of small (74 - 77 BC6ENTC ) fragments , originally termed BC6OTHER , that are potent chemoattractants and secretagogues that act on a wide variety of cell types.	False
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) enzymes , may have a better cardiovascular profile that BC6ENTG inhibitors due to BC6OTHER blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	False
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) enzymes , may have a better cardiovascular profile that BC6OTHER inhibitors due to BC6ENTG blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	CPR:4
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) enzymes , may have a better cardiovascular profile that BC6OTHER inhibitors due to BC6OTHER blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	CPR:4
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) enzymes , may have a better cardiovascular profile that BC6OTHER inhibitors due to BC6OTHER blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	CPR:4
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) enzymes , may have a better cardiovascular profile that BC6OTHER inhibitors due to BC6OTHER blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	CPR:4
BC6ENTC , a dual anti - inflammatory drug that inhibits BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) enzymes , may have a better cardiovascular profile that BC6OTHER inhibitors due to BC6OTHER blockade - mediated antithrombotic effect and a better gastrointestinal tolerability.	CPR:4
Moreover , BC6ENTC inhibited BC6ENTG and BC6OTHER protein expression in vascular lesions.	CPR:4
Moreover , BC6ENTC inhibited BC6OTHER and BC6ENTG protein expression in vascular lesions.	CPR:4
BC6ENTC only diminished BC6ENTG protein expression and BC6OTHER gene expression in vascular atheroma.	CPR:4
BC6ENTC only diminished BC6OTHER protein expression and BC6ENTG gene expression in vascular atheroma.	CPR:4
BC6ENTC almost abolished BC6ENTG activity by inhibiting BC6OTHER generation in rabbit neutrophils and prevented platelet BC6OTHER production from whole blood.	CPR:4
BC6OTHER almost abolished BC6ENTG activity by inhibiting BC6ENTC generation in rabbit neutrophils and prevented platelet BC6OTHER production from whole blood.	CPR:9
BC6OTHER almost abolished BC6ENTG activity by inhibiting BC6OTHER generation in rabbit neutrophils and prevented platelet BC6ENTC production from whole blood.	CPR:9
We examined the anti - inflammatory effect of BC6ENTC on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of BC6ENTG , BC6OTHER .	False
We examined the anti - inflammatory effect of BC6OTHER on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of BC6ENTG , BC6ENTC .	CPR:4
BC6ENTC reduced intima / media ratio in injured arteries , the macrophages infiltration in the neointimal area , BC6ENTG ( BC6OTHER ) gene expression , and the activation of BC6OTHER in rabbit atheroma.	CPR:4
BC6ENTC reduced intima / media ratio in injured arteries , the macrophages infiltration in the neointimal area , BC6OTHER ( BC6ENTG ) gene expression , and the activation of BC6OTHER in rabbit atheroma.	CPR:4
BC6ENTC reduced intima / media ratio in injured arteries , the macrophages infiltration in the neointimal area , BC6OTHER ( BC6OTHER ) gene expression , and the activation of BC6ENTG in rabbit atheroma.	CPR:4
 BC6ENTC , a balanced inhibitor of BC6ENTG and BC6OTHER , reduces inflammation in a rabbit model of atherosclerosis.	CPR:4
 BC6ENTC , a balanced inhibitor of BC6OTHER and BC6ENTG , reduces inflammation in a rabbit model of atherosclerosis.	CPR:4
Further studies in BC6ENTG - null mice indicated that GS - BC6ENTC and its metabolites in nasal - wash fluid were generated in the nasal mucosa , rather than in other organs.	False
The tissue - selective toxicity of BC6ENTC in mouse nasal mucosa is largely dependent on target tissue bioactivation by BC6ENTG .	False
The human orthologues of BC6ENTG , BC6OTHER and BC6OTHER , are both expressed in nasal mucosa and are capable of activating BC6ENTC .	False
The human orthologues of BC6OTHER , BC6ENTG and BC6OTHER , are both expressed in nasal mucosa and are capable of activating BC6ENTC .	False
The human orthologues of BC6OTHER , BC6OTHER and BC6ENTG , are both expressed in nasal mucosa and are capable of activating BC6ENTC .	False
The activity of the human nasal mucosa microsomes was inhibited by BC6ENTC , a known BC6ENTG inhibitor.	CPR:4
Activation of endogenous BC6ENTC receptor subtype 2 ( BC6ENTG ) by BC6OTHER or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6OTHER (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6ENTC receptor subtype 2 ( BC6OTHER ) by BC6OTHER or activation of transiently transfected BC6ENTG ( BC6OTHER (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6ENTC receptor subtype 2 ( BC6OTHER ) by BC6OTHER or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6ENTG (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6ENTG ( BC6OTHER ) by BC6ENTC or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6OTHER (long)) by BC6OTHER had no effect.	CPR:3
Activation of endogenous BC6OTHER ( BC6ENTG ) by BC6ENTC or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6OTHER (long)) by BC6OTHER had no effect.	CPR:3
Activation of endogenous BC6OTHER ( BC6OTHER ) by BC6ENTC or activation of transiently transfected BC6ENTG ( BC6OTHER (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6OTHER ( BC6OTHER ) by BC6ENTC or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6ENTG (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6ENTG ( BC6OTHER ) by BC6OTHER or activation of transiently transfected rat D2 BC6ENTC receptors ( BC6OTHER (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6OTHER ( BC6ENTG ) by BC6OTHER or activation of transiently transfected rat D2 BC6ENTC receptors ( BC6OTHER (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6OTHER ( BC6OTHER ) by BC6OTHER or activation of transiently transfected rat D2 BC6ENTC receptors ( BC6ENTG (long)) by BC6OTHER had no effect.	False
Activation of endogenous BC6ENTG ( BC6OTHER ) by BC6OTHER or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6OTHER (long)) by BC6ENTC had no effect.	False
Activation of endogenous BC6OTHER ( BC6ENTG ) by BC6OTHER or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6OTHER (long)) by BC6ENTC had no effect.	False
Activation of endogenous BC6OTHER ( BC6OTHER ) by BC6OTHER or activation of transiently transfected BC6ENTG ( BC6OTHER (long)) by BC6ENTC had no effect.	CPR:3
Activation of endogenous BC6OTHER ( BC6OTHER ) by BC6OTHER or activation of transiently transfected rat D2 BC6OTHER receptors ( BC6ENTG (long)) by BC6ENTC had no effect.	CPR:3
In contrast , in the same system , BC6ENTC - type currents , formed from transiently transfected alpha(1B) / CHEM , showed strong BC6ENTG - mediated inhibition.	CPR:4
Furthermore , the I - II loop from the alpha(1D) clone , expressed as a BC6ENTC - BC6OTHER - transferase ( BC6ENTG ) fusion protein , did not bind Gbetagamma , unlike the BC6OTHER fusion protein.	False
Furthermore , the I - II loop from the alpha(1D) clone , expressed as a BC6ENTC - BC6OTHER - transferase ( BC6OTHER ) fusion protein , did not bind Gbetagamma , unlike the BC6ENTG fusion protein.	False
Furthermore , the I - II loop from the alpha(1D) clone , expressed as a CHEM - BC6ENTC - transferase ( BC6ENTG ) fusion protein , did not bind Gbetagamma , unlike the BC6OTHER fusion protein.	False
Furthermore , the I - II loop from the alpha(1D) clone , expressed as a CHEM - BC6ENTC - transferase ( BC6OTHER ) fusion protein , did not bind Gbetagamma , unlike the BC6ENTG fusion protein.	False
To investigate the biophysical and pharmacological properties and role of BC6ENTG modulation of alpha(1D) BC6ENTC channels , we have examined BC6OTHER currents formed by the BC6OTHER subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
To investigate the biophysical and pharmacological properties and role of BC6OTHER modulation of alpha(1D) BC6ENTC channels , we have examined BC6ENTG currents formed by the BC6OTHER subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
To investigate the biophysical and pharmacological properties and role of BC6OTHER modulation of alpha(1D) BC6ENTC channels , we have examined BC6OTHER currents formed by the BC6ENTG subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
To investigate the biophysical and pharmacological properties and role of BC6ENTG modulation of alpha(1D) BC6OTHER channels , we have examined BC6ENTC channel currents formed by the BC6OTHER subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
To investigate the biophysical and pharmacological properties and role of BC6OTHER modulation of BC6ENTG , we have examined BC6ENTC channel currents formed by the BC6OTHER subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
To investigate the biophysical and pharmacological properties and role of BC6OTHER modulation of alpha(1D) BC6OTHER channels , we have examined BC6ENTC channel currents formed by the BC6ENTG subunit , co - expressed with CHEM , stably expressed in a human embryonic kidney (HEK) 293 cell line , using whole cell and perforated patch - clamp techniques.	False
Biophysical properties , pharmacology , and modulation of human , neuronal L - type ( BC6ENTG , BC6OTHER ) voltage - dependent BC6ENTC currents.	False
Biophysical properties , pharmacology , and modulation of human , neuronal L - type ( BC6OTHER , BC6ENTG ) voltage - dependent BC6ENTC currents.	False
The CHEM - sensitive BC6OTHER channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6ENTG ) and a BC6ENTC receptor subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTC receptor subunit ( BC6ENTG ).	False
The CHEM - sensitive BC6OTHER channel ( BC6ENTG ) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTC receptor subunit ( BC6OTHER ).	False
The BC6ENTG (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTC receptor subunit ( BC6OTHER ).	False
Sulfhydration of BC6ENTC receptor 2B ( BC6ENTG ) was induced by BC6OTHER and colonic inflammation.	False
Sulfhydration of BC6ENTG ( BC6OTHER ) was induced by BC6ENTC and colonic inflammation.	CPR:3
Sulfhydration of BC6OTHER ( BC6ENTG ) was induced by BC6ENTC and colonic inflammation.	CPR:3
These data suggest that sulfhydration of BC6ENTG induces allosteric modulation of BC6ENTC ( BC6OTHER ) currents in colonic inflammation.	False
These data suggest that sulfhydration of BC6ENTG induces allosteric modulation of BC6OTHER ( BC6ENTC ) currents in colonic inflammation.	False
The CHEM - sensitive BC6ENTC channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6ENTG ) and a BC6OTHER subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6ENTC channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTG subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6ENTC channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6ENTG ).	False
The CHEM - sensitive BC6ENTC channel ( BC6ENTG ) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel ( BC6ENTC ( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6ENTG ) and a BC6OTHER subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel ( BC6ENTC ( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTG subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel ( BC6ENTC ( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6ENTG ).	False
The BC6ENTG ( BC6ENTC ( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel (K( BC6ENTC )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6ENTG ) and a BC6OTHER subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel (K( BC6ENTC )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTG subunit ( BC6OTHER ).	False
The CHEM - sensitive BC6OTHER channel (K( BC6ENTC )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6ENTG ).	False
The BC6ENTG (K( BC6ENTC )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6OTHER ).	False
The BC6ENTC - sensitive BC6OTHER channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6ENTG ) and a BC6OTHER subunit ( BC6OTHER ).	False
The BC6ENTC - sensitive BC6OTHER channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6ENTG subunit ( BC6OTHER ).	False
The BC6ENTC - sensitive BC6OTHER channel (K( BC6OTHER )) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6ENTG ).	False
The BC6ENTC - sensitive BC6OTHER channel ( BC6ENTG ) in mouse colonic smooth muscle cell is a complex containing a pore - forming subunit ( BC6OTHER ) and a BC6OTHER subunit ( BC6OTHER ).	False
The concentration response to BC6ENTC ( BC6OTHER ) , a BC6ENTG opener , was significantly shifted to the left in the inflamed smooth - muscle cells.	CPR:3
The concentration response to BC6OTHER ( BC6ENTC ) , a BC6ENTG opener , was significantly shifted to the left in the inflamed smooth - muscle cells.	CPR:3
 BC6ENTC as an allosteric modulator of BC6ENTG in colonic inflammation.	False
This mini - review evaluates the theoretical potential of a pharmacological enhancement strategy of cognitive remediation training with nicotinic BC6ENTC receptor ( BC6ENTG ) agonists.	False
Moreover , the production of intracellular reactive BC6ENTC species (ROS) elicited by AGE was also suppressed by BC6OTHER treatment , through dual action of reducing ROS itself and inhibiting BC6ENTG activity.	False
Moreover , the production of intracellular reactive BC6OTHER species (ROS) elicited by AGE was also suppressed by BC6ENTC treatment , through dual action of reducing ROS itself and inhibiting BC6ENTG activity.	CPR:4
Our findings indicate that BC6ENTC suppresses AGE - mediated inflammation by inhibiting ROS production and BC6ENTG activity.	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6OTHER synthase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ).	False
BC6OTHER reduced the expression of pro - inflammatory mediates , such as BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , inducible BC6ENTC synthase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ).	False
Promoter and electromobility shift assays showed that transcriptional activation of BC6ENTG was significantly reduced by BC6ENTC treatment , while BC6OTHER was not.	CPR:4
Promoter and electromobility shift assays showed that transcriptional activation of BC6OTHER was significantly reduced by BC6ENTC treatment , while BC6ENTG was not.	False
BC6ENTC also suppressed AGE - induced phosphorylation of BC6OTHER , degradation of BC6OTHER and the nuclear localization of BC6ENTG .	CPR:4
BC6ENTC also suppressed AGE - induced phosphorylation of BC6ENTG , degradation of BC6OTHER and the nuclear localization of BC6OTHER .	CPR:4
BC6ENTC also suppressed AGE - induced phosphorylation of BC6OTHER , degradation of BC6ENTG and the nuclear localization of BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTG ) is a cystolic enzyme that stereospecifically catalyzes the transformation of BC6ENTC to BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) is a cystolic enzyme that stereospecifically catalyzes the transformation of BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) is a cystolic enzyme that stereospecifically catalyzes the transformation of BC6OTHER to BC6ENTC .	CPR:9
BC6ENTG ( BC6OTHER ) is a cystolic enzyme that stereospecifically catalyzes the transformation of BC6OTHER to BC6ENTC .	CPR:9
This paper describes the identification and synthesis of substituted BC6ENTC as BC6ENTG inhibitors.	CPR:4
BC6ENTC 28 showed dose responsive target engagement and provides a useful tool to explore a BC6ENTG inhibitor for the treatment of inflammatory diseases , such as asthma and inflammatory bowel disease (IBD).	CPR:4
BC6ENTC hydrolase ( BC6ENTG ) is a cystolic enzyme that stereospecifically catalyzes the transformation of BC6OTHER to BC6OTHER .	False
Identification of BC6ENTC central cores for the inhibition of BC6ENTG .	CPR:4
Optimization of HTS hit 1 for BC6ENTG binding affinity , BC6OTHER inhibition , solubility and metabolic stability led to the identification of some orally available BC6ENTC - linker derivatives for in vivo study.	False
Optimization of HTS hit 1 for BC6OTHER binding affinity , BC6ENTG inhibition , solubility and metabolic stability led to the identification of some orally available BC6ENTC - linker derivatives for in vivo study.	False
Identification of a novel BC6ENTC derivative as a highly potent BC6ENTG antagonist with an anti - obesity profile.	CPR:6
Plasma BC6ENTC , BC6OTHER and BC6ENTG were also significantly reduced (P<0.05).	False
Plasma BC6OTHER , BC6ENTC and BC6ENTG were also significantly reduced (P<0.05).	False
As BC6ENTG agonism has been found to elicit behaviors associated with visceral illness in rodents , we also examined the effect of peripheral exenatide on BC6ENTC consumption and locomotor activity.	False
We begin by capturing BC6ENTG using a complementary BC6ENTC oligonucleotide tethered to beads.	False
Two ongoing large randomized placebo - controlled studies will prospectively define fracture outcomes in men with prostate cancer and assess the efficacy of novel pharmacologic interventions (CHEM , BC6ENTC ) during BC6ENTG agonist treatment.	False
BC6ENTC play a central role in homeostasis of the normal male skeleton , and BC6OTHER deficiency rather than BC6OTHER deficiency seems to be primarily responsible for the adverse skeletal effects of BC6ENTG agonists.	False
BC6OTHER play a central role in homeostasis of the normal male skeleton , and BC6ENTC deficiency rather than BC6OTHER deficiency seems to be primarily responsible for the adverse skeletal effects of BC6ENTG agonists.	False
BC6OTHER play a central role in homeostasis of the normal male skeleton , and BC6OTHER deficiency rather than BC6ENTC deficiency seems to be primarily responsible for the adverse skeletal effects of BC6ENTG agonists.	False
In randomized controlled trials , BC6ENTC ( BC6OTHER and BC6OTHER ) and selective BC6ENTG modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6OTHER agonist - treated men.	False
In randomized controlled trials , BC6ENTC ( BC6OTHER and BC6OTHER ) and selective BC6OTHER modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6ENTG agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6ENTC and BC6OTHER ) and selective BC6ENTG modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6OTHER agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6ENTC and BC6OTHER ) and selective BC6OTHER modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6ENTG agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6ENTC ) and selective BC6ENTG modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6OTHER agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6ENTC ) and selective BC6OTHER modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6ENTG agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6OTHER ) and selective BC6ENTC receptor modulators ( BC6OTHER and BC6OTHER ) increased bone mineral density in BC6ENTG agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6OTHER ) and selective BC6ENTG modulators ( BC6ENTC and BC6OTHER ) increased bone mineral density in BC6OTHER agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6OTHER ) and selective BC6OTHER modulators ( BC6ENTC and BC6OTHER ) increased bone mineral density in BC6ENTG agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6OTHER ) and selective BC6ENTG modulators ( BC6OTHER and BC6ENTC ) increased bone mineral density in BC6OTHER agonist - treated men.	False
In randomized controlled trials , BC6OTHER ( BC6OTHER and BC6OTHER ) and selective BC6OTHER modulators ( BC6OTHER and BC6ENTC ) increased bone mineral density in BC6ENTG agonist - treated men.	False
Such resistance is related to an overall reduction of BC6ENTC receptor ( BC6ENTG ) density or to a differentiated expression of BC6OTHER subtypes.	False
Such resistance is related to an overall reduction of BC6ENTC receptor ( BC6OTHER ) density or to a differentiated expression of BC6ENTG subtypes.	False
BC6ENTG and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6ENTC and BC6OTHER bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6ENTG are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6ENTC and BC6OTHER bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6ENTG - secreting pituitary tumors , and both BC6ENTC and BC6OTHER bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6ENTC and BC6OTHER bind preferentially to BC6ENTG and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6ENTC and BC6OTHER bind preferentially to BC6OTHER and , to a lesser extent , to BC6ENTG .	False
BC6ENTG and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6OTHER and BC6ENTC bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6ENTG are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6OTHER and BC6ENTC bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6ENTG - secreting pituitary tumors , and both BC6OTHER and BC6ENTC bind preferentially to BC6OTHER and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6OTHER and BC6ENTC bind preferentially to BC6ENTG and , to a lesser extent , to BC6OTHER .	False
BC6OTHER and BC6OTHER are usually expressed in BC6OTHER - secreting pituitary tumors , and both BC6OTHER and BC6ENTC bind preferentially to BC6OTHER and , to a lesser extent , to BC6ENTG .	False
"The development of specific BC6ENTC subtypes analogs , mainly for BC6ENTG , of a BC6OTHER - BC6OTHER bispecific compound , and of a ""universal"" analog with high affinity to BC6OTHER showed preliminary , albeit promising results for the treatment of resistant somatotropic adenomas."	False
"The development of specific BC6ENTC subtypes analogs , mainly for BC6OTHER , of a BC6ENTG - BC6OTHER bispecific compound , and of a ""universal"" analog with high affinity to BC6OTHER showed preliminary , albeit promising results for the treatment of resistant somatotropic adenomas."	False
"The development of specific BC6ENTC subtypes analogs , mainly for BC6OTHER , of a BC6OTHER - BC6ENTG bispecific compound , and of a ""universal"" analog with high affinity to BC6OTHER showed preliminary , albeit promising results for the treatment of resistant somatotropic adenomas."	False
"The development of specific BC6ENTC subtypes analogs , mainly for BC6OTHER , of a BC6OTHER - BC6OTHER bispecific compound , and of a ""universal"" analog with high affinity to BC6ENTG showed preliminary , albeit promising results for the treatment of resistant somatotropic adenomas."	False
BC6ENTC ( BC6OTHER ) and its prodrug BC6OTHER ( BC6OTHER ) are highly potent BC6ENTG agonists often used in asthma patients.	CPR:5
BC6OTHER ( BC6ENTC ) and its prodrug BC6OTHER ( BC6OTHER ) are highly potent BC6ENTG agonists often used in asthma patients.	CPR:5
BC6OTHER ( BC6OTHER ) and its prodrug BC6ENTC ( BC6OTHER ) are highly potent BC6ENTG agonists often used in asthma patients.	CPR:5
BC6OTHER ( BC6OTHER ) and its prodrug BC6OTHER ( BC6ENTC ) are highly potent BC6ENTG agonists often used in asthma patients.	CPR:5
Recent studies have demonstrated the association between BC6ENTG *58:01 allele and BC6ENTC - induced SCARs , which might explain ethnic differences in their incidences.	False
Women who developed GDM had lower 1st - trimester BC6ENTG levels (9.67 ± 3.84 vs. 11.92 ± 4.59 µg / mL in women with normal BC6ENTC tolerance).	False
After adjustment for confounding factors , we found no significant association with HOMA - B and AUC( BC6ENTG / BC6ENTC ).CONCLUSIONSPregnant women with lower BC6OTHER levels at 1st trimester have higher levels of BC6OTHER resistance and are more likely to develop GDM independently of adiposity or glycemic measurements.	False
After adjustment for confounding factors , we found no significant association with HOMA - B and AUC( BC6OTHER / BC6ENTC ).CONCLUSIONSPregnant women with lower BC6ENTG levels at 1st trimester have higher levels of BC6OTHER resistance and are more likely to develop GDM independently of adiposity or glycemic measurements.	False
After adjustment for confounding factors , we found no significant association with HOMA - B and AUC( BC6OTHER / BC6ENTC ).CONCLUSIONSPregnant women with lower BC6OTHER levels at 1st trimester have higher levels of BC6ENTG resistance and are more likely to develop GDM independently of adiposity or glycemic measurements.	False
BC6ENTG was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6OTHER resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6OTHER sensitivity (Matsuda index) , BC6OTHER secretion (AUC( BC6OTHER / BC6ENTC )) , and β - cell compensation ( BC6OTHER secretion sensitivity index - 2).	False
BC6OTHER was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6ENTG resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6OTHER sensitivity (Matsuda index) , BC6OTHER secretion (AUC( BC6OTHER / BC6ENTC )) , and β - cell compensation ( BC6OTHER secretion sensitivity index - 2).	False
BC6OTHER was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6OTHER resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6ENTG sensitivity (Matsuda index) , BC6OTHER secretion (AUC( BC6OTHER / BC6ENTC )) , and β - cell compensation ( BC6OTHER secretion sensitivity index - 2).	False
BC6OTHER was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6OTHER resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6OTHER sensitivity (Matsuda index) , BC6ENTG secretion (AUC( BC6OTHER / BC6ENTC )) , and β - cell compensation ( BC6OTHER secretion sensitivity index - 2).	False
BC6OTHER was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6OTHER resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6OTHER sensitivity (Matsuda index) , BC6OTHER secretion (AUC( BC6ENTG / BC6ENTC )) , and β - cell compensation ( BC6OTHER secretion sensitivity index - 2).	False
BC6OTHER was measured (ELISA; Luminex) to estimate homeostasis model assessment of BC6OTHER resistance (HOMA - IR) , β - cell function (HOMA - B) , BC6OTHER sensitivity (Matsuda index) , BC6OTHER secretion (AUC( BC6OTHER / BC6ENTC )) , and β - cell compensation ( BC6ENTG secretion sensitivity index - 2).	False
BC6ENTC aminopeptidase - 2 ( BC6ENTG ) is a novel target for cancer therapy.	False
As part of an effort to discover orally active reversible inhibitors of BC6ENTG , a series of BC6ENTC with micromolar affinities for BC6OTHER were identified using affinity selection by mass spectrometry (ASMS) screening.	False
As part of an effort to discover orally active reversible inhibitors of BC6OTHER , a series of BC6ENTC with micromolar affinities for BC6ENTG were identified using affinity selection by mass spectrometry (ASMS) screening.	False
Modifications based on structural information on the binding of lead compounds to both BC6ENTG and BC6OTHER allowed the identification of compounds with significant improvements in both parameters , which showed good cellular activity in both proliferation and BC6ENTC processing assays.	False
Modifications based on structural information on the binding of lead compounds to both BC6OTHER and BC6ENTG allowed the identification of compounds with significant improvements in both parameters , which showed good cellular activity in both proliferation and BC6ENTC processing assays.	False
Discovery and optimization of BC6ENTC as inhibitors of BC6OTHER : a structural basis for the reduction of BC6ENTG binding.	CPR:4
Discovery and optimization of BC6ENTC as inhibitors of BC6ENTG : a structural basis for the reduction of BC6OTHER binding.	False
Discovery and optimization of BC6OTHER as inhibitors of BC6ENTC aminopeptidase - 2: a structural basis for the reduction of BC6ENTG binding.	False
Treatment of HDP cells with a c - Jun BC6ENTC - terminal kinase ( BC6ENTG ) inhibitor also reduced BC6OTHER - induced BC6OTHER expression , and BC6OTHER treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6OTHER - induced BC6ENTG expression , and BC6OTHER treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6OTHER - induced BC6OTHER expression , and BC6OTHER treatment led to increased BC6ENTG phosphorylation.	False
Treatment of HDP cells with a BC6ENTG ( BC6OTHER ) inhibitor also reduced BC6ENTC - induced BC6OTHER expression , and BC6OTHER treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6ENTG ) inhibitor also reduced BC6ENTC - induced BC6OTHER expression , and BC6OTHER treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6ENTC - induced BC6ENTG expression , and BC6OTHER treatment led to increased BC6OTHER phosphorylation.	CPR:3
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6ENTC - induced BC6OTHER expression , and BC6OTHER treatment led to increased BC6ENTG phosphorylation.	False
Treatment of HDP cells with a BC6ENTG ( BC6OTHER ) inhibitor also reduced BC6OTHER - induced BC6OTHER expression , and BC6ENTC treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6ENTG ) inhibitor also reduced BC6OTHER - induced BC6OTHER expression , and BC6ENTC treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6OTHER - induced BC6ENTG expression , and BC6ENTC treatment led to increased BC6OTHER phosphorylation.	False
Treatment of HDP cells with a c - Jun BC6OTHER - terminal kinase ( BC6OTHER ) inhibitor also reduced BC6OTHER - induced BC6OTHER expression , and BC6ENTC treatment led to increased BC6ENTG phosphorylation.	CPR:3
BC6ENTC also increased BC6ENTG ( BC6OTHER ) protein expression and BC6OTHER activity.	CPR:3
BC6ENTC also increased BC6OTHER ( BC6ENTG ) protein expression and BC6OTHER activity.	CPR:3
BC6ENTC also increased BC6OTHER ( BC6OTHER ) protein expression and BC6ENTG activity.	CPR:3
BC6OTHER also increased BC6ENTC oxygenase - 1 ( BC6ENTG ) protein expression and BC6OTHER activity.	False
BC6OTHER also increased BC6ENTC oxygenase - 1 ( BC6OTHER ) protein expression and BC6ENTG activity.	False
In addition , BC6ENTC - dependent BC6ENTG expression was required for the inhibition of BC6OTHER - induced cell death and ROS generation.	False
In addition , BC6OTHER - dependent BC6ENTG expression was required for the inhibition of BC6ENTC - induced cell death and ROS generation.	False
Furthermore , BC6ENTC treatment caused nuclear accumulation of BC6OTHER ( BC6OTHER ) and increased the promoter activity of BC6ENTG ( BC6OTHER ).	CPR:3
Furthermore , BC6ENTC treatment caused nuclear accumulation of BC6OTHER ( BC6OTHER ) and increased the promoter activity of BC6OTHER ( BC6ENTG ).	CPR:3
Furthermore , BC6ENTC treatment caused nuclear accumulation of BC6ENTG ( BC6OTHER ) and increased the promoter activity of BC6OTHER ( BC6OTHER ).	CPR:3
Furthermore , BC6ENTC treatment caused nuclear accumulation of BC6OTHER ( BC6ENTG ) and increased the promoter activity of BC6OTHER ( BC6OTHER ).	CPR:3
 BC6ENTC protects human dental pulp cells from BC6OTHER - induced oxidative toxicity via BC6OTHER pathway - dependent BC6ENTG expressions.	False
 BC6ENTC protects human dental pulp cells from BC6OTHER - induced oxidative toxicity via BC6ENTG pathway - dependent BC6OTHER expressions.	False
 BC6OTHER protects human dental pulp cells from BC6ENTC - induced oxidative toxicity via BC6OTHER pathway - dependent BC6ENTG expressions.	False
 BC6OTHER protects human dental pulp cells from BC6ENTC - induced oxidative toxicity via BC6ENTG pathway - dependent BC6OTHER expressions.	False
Moreover , these results support the concept that BC6ENTG BC6ENTC receptors represent a novel target for antiepileptic drug development.	False
The drug has been reported to interact with various BC6ENTG types , including BC6ENTC / BC6OTHER receptors.	False
The drug has been reported to interact with various BC6ENTG types , including CHEM / BC6ENTC receptors.	False
In whole - cell voltage - clamp recordings from principal neurons of the rat basolateral amygdala , BC6ENTC at low concentrations (IC50 , approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by BC6ENTG containing the BC6OTHER subunit.	CPR:4
In whole - cell voltage - clamp recordings from principal neurons of the rat basolateral amygdala , BC6ENTC at low concentrations (IC50 , approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by BC6OTHER containing the BC6ENTG subunit.	CPR:4
In whole - cell voltage - clamp recordings from principal neurons of the rat basolateral amygdala , BC6OTHER at low concentrations (IC50 , approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by BC6ENTC receptors containing the BC6ENTG subunit.	False
BC6ENTC also partially depressed predominantly BC6ENTG - mediated EPSCs , but with lower efficacy.	CPR:4
Inhibition of BC6ENTG BC6ENTC receptors could represent a key mechanism underlying the anticonvulsant activity of BC6OTHER .	False
Inhibition of BC6ENTG BC6OTHER could represent a key mechanism underlying the anticonvulsant activity of BC6ENTC .	CPR:4
Inhibition of BC6OTHER BC6ENTG could represent a key mechanism underlying the anticonvulsant activity of BC6ENTC .	CPR:4
Selective antagonism of BC6ENTG BC6ENTC - receptor - mediated synaptic currents by BC6OTHER in rat basolateral amygdala neurons.	False
Selective antagonism of BC6ENTG BC6OTHER - mediated synaptic currents by BC6ENTC in rat basolateral amygdala neurons.	CPR:6
Selective antagonism of BC6OTHER BC6ENTG - mediated synaptic currents by BC6ENTC in rat basolateral amygdala neurons.	CPR:6
Therefore , we investigated the hippocampal gene expression of BC6ENTC receptors α and β ( BC6ENTG ) in 8 - week - old , 12 - week - old and 24 - week - old male rats.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTC receptor genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTG genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6ENTG ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6ENTG ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTC receptors , BC6OTHER ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTG genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTG , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6ENTG ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTC receptors ( BC6OTHER ) , BC6OTHER - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were also measured.	False
To control for possible interactions between the expression of the BC6ENTG genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were also measured.	False
To control for possible interactions between the expression of the BC6OTHER genes and other learning - related BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC - binding BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were also measured.	False
We provided evidence of a novel link among BC6ENTC oxidase and BC6ENTG signaling , mediated by BC6OTHER , BC6OTHER , and BC6OTHER .	False
We provided evidence of a novel link among BC6ENTC oxidase and BC6OTHER signaling , mediated by BC6ENTG , BC6OTHER , and BC6OTHER .	False
We provided evidence of a novel link among BC6ENTC oxidase and BC6OTHER signaling , mediated by BC6OTHER , BC6ENTG , and BC6OTHER .	False
We provided evidence of a novel link among BC6ENTC oxidase and BC6OTHER signaling , mediated by BC6OTHER , BC6OTHER , and BC6ENTG .	False
BC6ENTC activates BC6ENTG .	CPR:3
ROS produced by this BC6ENTG activates BC6OTHER , enable that in turn , transactivates BC6OTHER that activates BC6OTHER in BC6ENTC , allowing its dimerization.	False
ROS produced by this BC6OTHER activates BC6ENTG , enable that in turn , transactivates BC6OTHER that activates BC6OTHER in BC6ENTC , allowing its dimerization.	False
ROS produced by this BC6OTHER activates BC6OTHER , enable that in turn , transactivates BC6ENTG that activates BC6OTHER in BC6ENTC , allowing its dimerization.	False
ROS produced by this BC6OTHER activates BC6OTHER , enable that in turn , transactivates BC6OTHER that activates BC6ENTG in BC6ENTC , allowing its dimerization.	False
Also , ROS from BC6ENTC oxidase favors BC6ENTG activation that phosphorylates BC6OTHER in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6OTHER exposure times.	False
Also , ROS from BC6ENTC oxidase favors BC6OTHER activation that phosphorylates BC6ENTG in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6OTHER exposure times.	False
Also , ROS from BC6ENTC oxidase favors BC6OTHER activation that phosphorylates BC6OTHER in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6ENTG in short BC6OTHER exposure times.	False
Also , ROS from BC6ENTG favors BC6OTHER activation that phosphorylates BC6OTHER in BC6ENTC , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6OTHER exposure times.	False
Also , ROS from BC6OTHER favors BC6ENTG activation that phosphorylates BC6OTHER in BC6ENTC , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6OTHER exposure times.	False
Also , ROS from BC6OTHER favors BC6OTHER activation that phosphorylates BC6ENTG in BC6ENTC , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6OTHER exposure times.	False
Also , ROS from BC6OTHER favors BC6OTHER activation that phosphorylates BC6OTHER in BC6ENTC , resulting in a compensatory or adaptive survival response such as production of BC6ENTG in short BC6OTHER exposure times.	False
Also , ROS from BC6ENTG favors BC6OTHER activation that phosphorylates BC6OTHER in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6ENTC exposure times.	False
Also , ROS from BC6OTHER favors BC6ENTG activation that phosphorylates BC6OTHER in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6ENTC exposure times.	False
Also , ROS from BC6OTHER favors BC6OTHER activation that phosphorylates BC6ENTG in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6OTHER in short BC6ENTC exposure times.	False
Also , ROS from BC6OTHER favors BC6OTHER activation that phosphorylates BC6OTHER in BC6OTHER , resulting in a compensatory or adaptive survival response such as production of BC6ENTG in short BC6ENTC exposure times.	False
However , after 12h BC6ENTC treatment , cell viability diminished in 50% , accompanied by a drastic decrease of BC6ENTG production , and an increase in BC6OTHER activation and the pro - apoptotic protein BC6OTHER .	CPR:4
However , after 12h BC6ENTC treatment , cell viability diminished in 50% , accompanied by a drastic decrease of BC6OTHER production , and an increase in BC6ENTG activation and the pro - apoptotic protein BC6OTHER .	CPR:3
However , after 12h BC6ENTC treatment , cell viability diminished in 50% , accompanied by a drastic decrease of BC6OTHER production , and an increase in BC6OTHER activation and the pro - apoptotic protein BC6ENTG .	CPR:3
Hepatocytes display a compensatory survival response against BC6ENTC toxicity by a mechanism mediated by BC6ENTG and BC6OTHER .	False
Hepatocytes display a compensatory survival response against BC6ENTC toxicity by a mechanism mediated by BC6OTHER and BC6ENTG .	False
Alkaptonuria , a rare autosomal recessive disorder caused by mutations in the BC6ENTG gene and deficiency of BC6ENTC 1 , 2 dioxygenase , is characterized by ochronosis , arthritis , and daily excretion of gram quantities of BC6OTHER ( BC6OTHER ).	False
Alkaptonuria , a rare autosomal recessive disorder caused by mutations in the BC6OTHER gene and deficiency of BC6ENTG , is characterized by ochronosis , arthritis , and daily excretion of gram quantities of BC6ENTC ( BC6OTHER ).	False
Alkaptonuria , a rare autosomal recessive disorder caused by mutations in the BC6ENTG gene and deficiency of BC6OTHER , is characterized by ochronosis , arthritis , and daily excretion of gram quantities of BC6ENTC ( BC6OTHER ).	False
Alkaptonuria , a rare autosomal recessive disorder caused by mutations in the BC6OTHER gene and deficiency of BC6ENTG , is characterized by ochronosis , arthritis , and daily excretion of gram quantities of BC6OTHER ( BC6ENTC ).	False
Alkaptonuria , a rare autosomal recessive disorder caused by mutations in the BC6ENTG gene and deficiency of BC6OTHER , is characterized by ochronosis , arthritis , and daily excretion of gram quantities of BC6OTHER ( BC6ENTC ).	False
CHEM , an inhibitor of the enzyme BC6ENTG , can drastically reduce urinary excretion of BC6ENTC in individuals with alkaptonuria.	False
Even though the activities of BC6ENTG and BC6OTHER were elevated , the concentration of liver BC6ENTC was decreased (24% , p<0.001) and BC6OTHER increased (113% , p<0.001) in the dwarf mice.	CPR:9
Even though the activities of BC6OTHER and BC6ENTG were elevated , the concentration of liver BC6ENTC was decreased (24% , p<0.001) and BC6OTHER increased (113% , p<0.001) in the dwarf mice.	CPR:9
Even though the activities of BC6ENTG and BC6OTHER were elevated , the concentration of liver BC6OTHER was decreased (24% , p<0.001) and BC6ENTC increased (113% , p<0.001) in the dwarf mice.	CPR:9
Even though the activities of BC6OTHER and BC6ENTG were elevated , the concentration of liver BC6OTHER was decreased (24% , p<0.001) and BC6ENTC increased (113% , p<0.001) in the dwarf mice.	CPR:9
The specific activity of liver BC6ENTC adenosyltransferase ( BC6ENTG ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6ENTC adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTG (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6ENTC adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6ENTG (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6ENTC adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTG ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6ENTC adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6ENTG , 91% , p<0.001) activities.	False
The specific activity of BC6ENTG ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTC synthase (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6ENTG ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTC synthase (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTC synthase (50% , p<0.01) , BC6ENTG (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTC synthase (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTG ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTC synthase (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6OTHER - methyltransferase ( BC6ENTG , 91% , p<0.001) activities.	False
The specific activity of BC6ENTG ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTC BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6ENTG ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTC BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTG (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTC BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6ENTG (83% , p<0.001) , and BC6ENTC BC6OTHER - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and BC6ENTC BC6OTHER - methyltransferase ( BC6ENTG , 91% , p<0.001) activities.	False
The specific activity of BC6ENTG ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6ENTC - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6ENTG ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6ENTC - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6ENTG (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6ENTC - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6ENTG (83% , p<0.001) , and CHEM BC6ENTC - methyltransferase ( BC6OTHER , 91% , p<0.001) activities.	False
The specific activity of liver BC6OTHER adenosyltransferase ( BC6OTHER ) was significantly elevated (205% , p<0.0001) in the dwarf mice , as were BC6OTHER (50% , p<0.01) , BC6OTHER (83% , p<0.001) , and CHEM BC6ENTC - methyltransferase ( BC6ENTG , 91% , p<0.001) activities.	False
To ascertain whether developmental activation of the BC6ENTC - R and BC6ENTG subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTC - R and BC6OTHER subunit gene expression is BC6ENTG dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTC - R and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6ENTG action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTC - R and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6ENTG antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTG and BC6OTHER subunit gene expression is BC6ENTC dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6ENTG subunit gene expression is BC6ENTC dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6ENTC dependent , we have studied the effect of blocking the endogenous BC6ENTG action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6ENTC dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6ENTG antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTG and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6ENTC action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6ENTG subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6ENTC action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6ENTG dependent , we have studied the effect of blocking the endogenous BC6ENTC action by treating developing male rats with the specific BC6OTHER antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6ENTC action by treating developing male rats with the specific BC6ENTG antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6ENTG and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6ENTC antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6ENTG subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6ENTC antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6ENTG dependent , we have studied the effect of blocking the endogenous BC6OTHER action by treating developing male rats with the specific BC6ENTC antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
To ascertain whether developmental activation of the BC6OTHER and BC6OTHER subunit gene expression is BC6OTHER dependent , we have studied the effect of blocking the endogenous BC6ENTG action by treating developing male rats with the specific BC6ENTC antagonist CHEM (1.5 mg / kg body weight / week , s.c.) through the infantile (Days 5 - 20) and the juvenile periods (Days 20 - 35).	False
BC6ENTC completely blocked the rise of levels of the two most abundant species , 5.0 kb and 4.5 kb , of the BC6ENTG mRNA , during both the infantile and the juvenile periods.	CPR:4
BC6ENTC also abolished the developmental rise of the BC6ENTG subunit mRNAs during the two periods of the study.	CPR:4
These data demonstrate that sexual maturation of male rats is accompanied by a progressive and concerted induction of BC6ENTC - R and BC6ENTG subunit gene expression.	False
Developmental activation of BC6ENTC - R and BC6ENTG subunit genes is BC6OTHER dependent.	False
Developmental activation of BC6ENTC - R and BC6OTHER subunit genes is BC6ENTG dependent.	False
Developmental activation of BC6ENTG and BC6OTHER subunit genes is BC6ENTC dependent.	False
Developmental activation of BC6OTHER and BC6ENTG subunit genes is BC6ENTC dependent.	False
The apparent BC6ENTC - independent regulation of the BC6ENTG subunit mRNA levels may be due to the contribution of thyrotropes and perhaps to the presence of exclusive regulatory signals for this gene.	False
Appropriate expression of the BC6ENTC receptor ( BC6OTHER ) in gonadotropes is critical for BC6OTHER signaling and hence for BC6ENTG secretion and sexual development.	False
Appropriate expression of the BC6ENTC receptor ( BC6ENTG ) in gonadotropes is critical for BC6OTHER signaling and hence for BC6OTHER secretion and sexual development.	False
Appropriate expression of the BC6ENTC receptor ( BC6OTHER ) in gonadotropes is critical for BC6ENTG signaling and hence for BC6OTHER secretion and sexual development.	False
Appropriate expression of the BC6OTHER ( BC6ENTC - R) in gonadotropes is critical for BC6OTHER signaling and hence for BC6ENTG secretion and sexual development.	False
Appropriate expression of the BC6ENTG ( BC6ENTC - R) in gonadotropes is critical for BC6OTHER signaling and hence for BC6OTHER secretion and sexual development.	False
Appropriate expression of the BC6OTHER ( BC6ENTC - R) in gonadotropes is critical for BC6ENTG signaling and hence for BC6OTHER secretion and sexual development.	False
In addition , the role of the endogenous BC6ENTC on the maturational changes of BC6ENTG and BC6OTHER subunit gene expression was investigated.	False
In addition , the role of the endogenous BC6ENTC on the maturational changes of BC6OTHER and BC6ENTG subunit gene expression was investigated.	False
In addition , the role of the endogenous BC6ENTG on the maturational changes of BC6ENTC - R and BC6OTHER subunit gene expression was investigated.	False
In addition , the role of the endogenous BC6OTHER on the maturational changes of BC6ENTC - R and BC6ENTG subunit gene expression was investigated.	False
Appropriate expression of the BC6OTHER ( BC6OTHER ) in gonadotropes is critical for BC6ENTC signaling and hence for BC6ENTG secretion and sexual development.	False
Appropriate expression of the BC6ENTG ( BC6OTHER ) in gonadotropes is critical for BC6ENTC signaling and hence for BC6OTHER secretion and sexual development.	False
Appropriate expression of the BC6OTHER ( BC6ENTG ) in gonadotropes is critical for BC6ENTC signaling and hence for BC6OTHER secretion and sexual development.	False
BC6ENTC are BC6ENTG inhibitors broadly used for the control of hypercholesterolemia.	CPR:4
Computational modeling showed the direct interaction of the BC6ENTC moiety of CHEM with the catalytic site of BC6ENTG .	False
In the subsequent enzymatic assay , it was shown that BC6ENTC inhibited BC6ENTG activity competitively with a K(i) value of 31.6 micromol / L.	CPR:4
 BC6ENTC increase BC6OTHER through inhibition of BC6OTHER activity and release of promoter - associated BC6ENTG .	CPR:3
 BC6ENTC increase BC6ENTG through inhibition of BC6OTHER activity and release of promoter - associated BC6OTHER .	CPR:3
 BC6ENTC increase BC6OTHER through inhibition of BC6ENTG activity and release of promoter - associated BC6OTHER .	CPR:4
BACKGROUND: In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of BC6ENTG - BC6ENTC - BC6OTHER system - mediated impairment of renal BC6OTHER excretion.	False
BACKGROUND: In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of BC6ENTG - BC6OTHER - BC6ENTC system - mediated impairment of renal BC6OTHER excretion.	False
BACKGROUND: In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of BC6OTHER - BC6ENTG - BC6ENTC system - mediated impairment of renal BC6OTHER excretion.	False
BACKGROUND: In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of BC6ENTG - BC6OTHER - BC6OTHER system - mediated impairment of renal BC6ENTC excretion.	False
BACKGROUND: In essential hypertension an elevated renal vascular resistance (RVR) may be a marker of BC6OTHER - BC6ENTG - BC6OTHER system - mediated impairment of renal BC6ENTC excretion.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6ENTG - BC6ENTC - BC6OTHER system (RAAS) blockade by BC6OTHER - inhibitor BC6OTHER could be predicted from pretreatment renal vascular tone.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6OTHER - BC6ENTC - BC6OTHER system (RAAS) blockade by BC6ENTG - inhibitor BC6OTHER could be predicted from pretreatment renal vascular tone.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6ENTG - BC6OTHER - BC6ENTC system (RAAS) blockade by BC6OTHER - inhibitor BC6OTHER could be predicted from pretreatment renal vascular tone.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6OTHER - BC6ENTG - BC6ENTC system (RAAS) blockade by BC6OTHER - inhibitor BC6OTHER could be predicted from pretreatment renal vascular tone.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6OTHER - BC6OTHER - BC6ENTC system (RAAS) blockade by BC6ENTG - inhibitor BC6OTHER could be predicted from pretreatment renal vascular tone.	False
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6ENTG - BC6OTHER - BC6OTHER system (RAAS) blockade by BC6OTHER - inhibitor BC6ENTC could be predicted from pretreatment renal vascular tone.	CPR:4
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6OTHER - BC6ENTG - BC6OTHER system (RAAS) blockade by BC6OTHER - inhibitor BC6ENTC could be predicted from pretreatment renal vascular tone.	CPR:4
This hypothesis was tested by investigating whether , in subjects with essential hypertension , the natriuretic response to specific BC6OTHER - BC6OTHER - BC6OTHER system (RAAS) blockade by BC6ENTG - inhibitor BC6ENTC could be predicted from pretreatment renal vascular tone.	CPR:4
BC6ENTC is an important regulatory molecule implicated in a variety of biological processes in response to stress and BC6ENTG .	False
In a further study to analyse the downstream mediator of BC6ENTG in the BC6ENTC - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6ENTC - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6ENTG ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6ENTC - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6ENTG ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6ENTC - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6ENTG activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6ENTC - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6ENTG in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6ENTG in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6ENTC , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6ENTC , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6ENTG ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6ENTC , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6ENTG ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6ENTC , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6ENTG activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6ENTC , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6ENTG in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6ENTG in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6ENTC - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6ENTG ( BC6OTHER ) oligonucleotide repressed the BC6ENTC - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6ENTG ) oligonucleotide repressed the BC6ENTC - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6ENTC - induced BC6ENTG activation selectively , implying a critical role of BC6OTHER in BC6OTHER - induced signalling to nucleus.	CPR:3
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6ENTC - induced BC6OTHER activation selectively , implying a critical role of BC6ENTG in BC6OTHER - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6ENTG in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6ENTC - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6ENTG ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6ENTC - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6ENTG ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6OTHER in BC6ENTC - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6ENTG activation selectively , implying a critical role of BC6OTHER in BC6ENTC - induced signalling to nucleus.	False
In a further study to analyse the downstream mediator of BC6OTHER in the BC6OTHER - signalling pathway , we observed that either pretreatment with BC6OTHER , a potent and specific inhibitor of phospholipase A2 , or co - transfection with antisense BC6OTHER ( BC6OTHER ) oligonucleotide repressed the BC6OTHER - induced BC6OTHER activation selectively , implying a critical role of BC6ENTG in BC6ENTC - induced signalling to nucleus.	False
Consistent with these results , the translocation of BC6ENTG protein as well as the release of BC6ENTC , a principal product of BC6OTHER , was rapidly induced by the addition of BC6OTHER in a BC6OTHER - dependent manner.	False
Consistent with these results , the translocation of BC6OTHER protein as well as the release of BC6ENTC , a principal product of BC6ENTG , was rapidly induced by the addition of BC6OTHER in a BC6OTHER - dependent manner.	CPR:9
Consistent with these results , the translocation of BC6OTHER protein as well as the release of BC6ENTC , a principal product of BC6OTHER , was rapidly induced by the addition of BC6OTHER in a BC6ENTG - dependent manner.	False
Consistent with these results , the translocation of BC6ENTG protein as well as the release of BC6OTHER , a principal product of BC6OTHER , was rapidly induced by the addition of BC6ENTC in a BC6OTHER - dependent manner.	False
Consistent with these results , the translocation of BC6OTHER protein as well as the release of BC6OTHER , a principal product of BC6ENTG , was rapidly induced by the addition of BC6ENTC in a BC6OTHER - dependent manner.	False
Consistent with these results , the translocation of BC6OTHER protein as well as the release of BC6OTHER , a principal product of BC6OTHER , was rapidly induced by the addition of BC6ENTC in a BC6ENTG - dependent manner.	False
Together , our findings suggest the critical role of ' BC6ENTG and subsequent activation of BC6OTHER ' in BC6ENTC - signalling to nucleus.	False
Together , our findings suggest the critical role of ' BC6OTHER and subsequent activation of BC6ENTG ' in BC6ENTC - signalling to nucleus.	CPR:3
To understand the signal transduction pathway of BC6ENTC to the nucleus , in the present study , we examined whether BC6OTHER , a cell permeable BC6OTHER , activates BC6ENTG ( BC6OTHER ).	False
To understand the signal transduction pathway of BC6ENTC to the nucleus , in the present study , we examined whether BC6OTHER , a cell permeable BC6OTHER , activates BC6OTHER ( BC6ENTG ).	False
To understand the signal transduction pathway of BC6OTHER to the nucleus , in the present study , we examined whether BC6ENTC , a cell permeable BC6OTHER , activates BC6ENTG ( BC6OTHER ).	False
To understand the signal transduction pathway of BC6OTHER to the nucleus , in the present study , we examined whether BC6ENTC , a cell permeable BC6OTHER , activates BC6OTHER ( BC6ENTG ).	False
To understand the signal transduction pathway of BC6OTHER to the nucleus , in the present study , we examined whether BC6OTHER , a cell permeable BC6ENTC , activates BC6ENTG ( BC6OTHER ).	False
To understand the signal transduction pathway of BC6OTHER to the nucleus , in the present study , we examined whether BC6OTHER , a cell permeable BC6ENTC , activates BC6OTHER ( BC6ENTG ).	False
Treatment of Rat - 2 fibroblast cells with BC6ENTC caused the stimulation of BC6ENTG - dependent reporter gene activity in a dose - and time - dependent manner by transient transfection analysis.	CPR:3
Next , we examined the role of BC6ENTG family BC6OTHER in the BC6ENTC - induced signalling to BC6OTHER activation.	False
Next , we examined the role of BC6OTHER family BC6ENTG in the BC6ENTC - induced signalling to BC6OTHER activation.	False
Next , we examined the role of BC6OTHER family BC6OTHER in the BC6ENTC - induced signalling to BC6ENTG activation.	CPR:3
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6ENTG , BC6OTHER or BC6OTHER , BC6ENTC - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6OTHER to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6ENTG or BC6OTHER , BC6ENTC - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6OTHER to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6ENTG , BC6ENTC - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6OTHER to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6ENTC - induced BC6ENTG activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6OTHER to the nucleus.	CPR:3
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6ENTC - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6ENTG , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6OTHER to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6ENTC - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6ENTG activity is essential for the signalling cascade of BC6OTHER to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6ENTG , BC6OTHER or BC6OTHER , BC6OTHER - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6ENTG or BC6OTHER , BC6OTHER - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6ENTG , BC6OTHER - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6OTHER - induced BC6ENTG activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6OTHER - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6ENTG , suggesting that BC6OTHER activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of BC6OTHER , BC6OTHER or BC6OTHER , BC6OTHER - induced BC6OTHER activation was shown to be selectively repressed by pEXV - RacN17 encoding a dominant negative mutant of BC6OTHER , suggesting that BC6ENTG activity is essential for the signalling cascade of BC6ENTC to the nucleus.	False
Exogenous BC6ENTC activates BC6ENTG via BC6OTHER - dependent signalling pathway.	CPR:3
Exogenous BC6ENTC activates BC6OTHER via BC6ENTG - dependent signalling pathway.	False
Many lung cancers also express BC6ENTG RNA and BC6OTHER protein and biosynthesize BC6ENTC , which correlates with their metastatic potential.	False
Many lung cancers also express BC6OTHER RNA and BC6ENTG protein and biosynthesize BC6ENTC , which correlates with their metastatic potential.	False
In this report , we evaluated the growth - inhibitory effects of BC6ENTC , a BC6ENTG and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	CPR:4
In this report , we evaluated the growth - inhibitory effects of BC6ENTC , a BC6OTHER and BC6ENTG inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	CPR:4
In this report , we evaluated the growth - inhibitory effects of BC6ENTC , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6ENTG enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6ENTC , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6ENTG inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6ENTG and BC6OTHER inhibitor; BC6ENTC ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6ENTG inhibitor; BC6ENTC ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6ENTC ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6ENTG enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6ENTC ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6ENTG inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6ENTG and BC6OTHER inhibitor; BC6OTHER ( BC6ENTC ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6ENTG inhibitor; BC6OTHER ( BC6ENTC ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6ENTC ) , a novel proapoptotic agent that does not inhibit BC6ENTG enzymes; and BC6OTHER ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6ENTC ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6OTHER ) , a BC6ENTG inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6ENTG and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6ENTC ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6ENTG inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6ENTC ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6ENTG enzymes; and BC6ENTC ( BC6OTHER ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6ENTC ( BC6OTHER ) , a BC6ENTG inhibitor on human lung cancer cell lines.	CPR:4
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6ENTG and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6ENTC ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6ENTG inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6ENTC ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6ENTG enzymes; and BC6OTHER ( BC6ENTC ) , a BC6OTHER inhibitor on human lung cancer cell lines.	False
In this report , we evaluated the growth - inhibitory effects of BC6OTHER , a BC6OTHER and BC6OTHER inhibitor; BC6OTHER ( BC6OTHER ) , a novel proapoptotic agent that does not inhibit BC6OTHER enzymes; and BC6OTHER ( BC6ENTC ) , a BC6ENTG inhibitor on human lung cancer cell lines.	CPR:4
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6ENTC BC6OTHER and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6ENTC and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6OTHER and BC6ENTC for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6OTHER and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6ENTC and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6OTHER and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6ENTC as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6OTHER and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6ENTC and BC6OTHER as baseline immunosuppression (n = 5).	False
BC6ENTG expression was examined on peripheral blood small lymphocytes in three groups of patients who received: BC6OTHER BC6OTHER and BC6OTHER for baseline immunosuppression (n = 9); (B) anti - Tac with BC6OTHER and BC6OTHER as baseline immunosuppression (n = 12); and (C) anti - Tac with BC6OTHER and BC6ENTC as baseline immunosuppression (n = 5).	False
These results suggested that the activation and degradation pattern of BC6ENTC plays an important role in the efficacy of BC6OTHER and that it is possible to use the BC6ENTG / BC6OTHER ratio to predict response to BC6OTHER therapy.	False
These results suggested that the activation and degradation pattern of BC6ENTC plays an important role in the efficacy of BC6OTHER and that it is possible to use the BC6OTHER / BC6ENTG ratio to predict response to BC6OTHER therapy.	False
These results suggested that the activation and degradation pattern of BC6OTHER plays an important role in the efficacy of BC6ENTC and that it is possible to use the BC6ENTG / BC6OTHER ratio to predict response to BC6OTHER therapy.	False
These results suggested that the activation and degradation pattern of BC6OTHER plays an important role in the efficacy of BC6ENTC and that it is possible to use the BC6OTHER / BC6ENTG ratio to predict response to BC6OTHER therapy.	False
These results suggested that the activation and degradation pattern of BC6OTHER plays an important role in the efficacy of BC6OTHER and that it is possible to use the BC6ENTG / BC6OTHER ratio to predict response to BC6ENTC therapy.	False
These results suggested that the activation and degradation pattern of BC6OTHER plays an important role in the efficacy of BC6OTHER and that it is possible to use the BC6OTHER / BC6ENTG ratio to predict response to BC6ENTC therapy.	False
In conclusion , BC6ENTG and BC6ENTC effects on BC6OTHER play important roles in the cytotoxic action of BC6OTHER , and it is possible to use the BC6OTHER / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6ENTC effects on BC6ENTG play important roles in the cytotoxic action of BC6OTHER , and it is possible to use the BC6OTHER / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6ENTC effects on BC6OTHER play important roles in the cytotoxic action of BC6OTHER , and it is possible to use the BC6ENTG / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6ENTC effects on BC6OTHER play important roles in the cytotoxic action of BC6OTHER , and it is possible to use the BC6OTHER / BC6ENTG ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6ENTG and BC6OTHER effects on BC6OTHER play important roles in the cytotoxic action of BC6ENTC , and it is possible to use the BC6OTHER / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6OTHER effects on BC6ENTG play important roles in the cytotoxic action of BC6ENTC , and it is possible to use the BC6OTHER / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6OTHER effects on BC6OTHER play important roles in the cytotoxic action of BC6ENTC , and it is possible to use the BC6ENTG / BC6OTHER ratio to predict more precisely individual resistance or sensitivity.	False
In conclusion , BC6OTHER and BC6OTHER effects on BC6OTHER play important roles in the cytotoxic action of BC6ENTC , and it is possible to use the BC6OTHER / BC6ENTG ratio to predict more precisely individual resistance or sensitivity.	False
BC6ENTC currently undergoing clinical trials , has been demonstrated to have at least two mechanisms , inhibition of BC6ENTG and incorporation into DNA.	CPR:4
In the present study , we measured the enzyme activity of BC6ENTC kinase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTC kinase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTG ( BC6OTHER ) , BC6ENTC phosphorylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6ENTG ) , BC6ENTC phosphorylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6ENTC phosphorylase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6ENTC phosphorylase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6ENTC phosphorylase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6ENTC synthase ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC synthase ( BC6ENTG ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6OTHER .	False
In the present study , we measured the enzyme activity of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	False
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	CPR:4
In the present study , we measured the enzyme activity of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of BC6ENTC .	CPR:4
Antitumor activity of BC6ENTC appears to be associated with BC6ENTG , tumor growth and BC6OTHER .	False
Antitumor activity of BC6ENTC appears to be associated with BC6OTHER , tumor growth and BC6ENTG .	False
 BC6ENTC kinase and BC6ENTG level as the main predictive parameter for sensitivity to BC6OTHER in a mouse model.	False
 BC6ENTG and BC6OTHER level as the main predictive parameter for sensitivity to BC6ENTC in a mouse model.	False
 BC6OTHER and BC6ENTG level as the main predictive parameter for sensitivity to BC6ENTC in a mouse model.	False
 BC6ENTG and BC6ENTC phosphorylase level as the main predictive parameter for sensitivity to BC6OTHER in a mouse model.	False
In addition , several receptor BC6ENTC kinases , acting upstream of BC6ENTG , were found either mutated or overexpressed in human tumors.	False
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6ENTG family ( BC6OTHER and BC6OTHER ) and BC6OTHER family ( BC6OTHER and BC6OTHER ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6OTHER family ( BC6ENTG and BC6OTHER ) and BC6OTHER family ( BC6OTHER and BC6OTHER ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6OTHER family ( BC6OTHER and BC6ENTG ) and BC6OTHER family ( BC6OTHER and BC6OTHER ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6OTHER family ( BC6OTHER and BC6OTHER ) and BC6ENTG family ( BC6OTHER and BC6OTHER ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6OTHER family ( BC6OTHER and BC6OTHER ) and BC6OTHER family ( BC6ENTG and BC6OTHER ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Further characterization of BC6ENTC revealed that this molecule was a multikinase inhibitor that targeted the BC6OTHER family ( BC6OTHER and BC6OTHER ) and BC6OTHER family ( BC6OTHER and BC6ENTG ) , which play key roles in tumor progression and angiogenesis.	CPR:4
Thus , BC6ENTC may inhibit tumor growth by a dual mechanism , acting either directly on the tumor (through inhibition of BC6ENTG and BC6OTHER signaling) and / or on tumor angiogenesis (through inhibition of BC6OTHER and BC6OTHER signaling).	CPR:4
Thus , BC6ENTC may inhibit tumor growth by a dual mechanism , acting either directly on the tumor (through inhibition of BC6OTHER and BC6ENTG signaling) and / or on tumor angiogenesis (through inhibition of BC6OTHER and BC6OTHER signaling).	CPR:4
Thus , BC6ENTC may inhibit tumor growth by a dual mechanism , acting either directly on the tumor (through inhibition of BC6OTHER and BC6OTHER signaling) and / or on tumor angiogenesis (through inhibition of BC6ENTG and BC6OTHER signaling).	CPR:4
Thus , BC6ENTC may inhibit tumor growth by a dual mechanism , acting either directly on the tumor (through inhibition of BC6OTHER and BC6OTHER signaling) and / or on tumor angiogenesis (through inhibition of BC6OTHER and BC6ENTG signaling).	CPR:4
A novel class of BC6ENTC that inhibits BC6ENTG BC6OTHER was discovered using a combination of medicinal and combinatorial chemistry approaches.	CPR:4
A novel class of BC6ENTC that inhibits BC6OTHER BC6ENTG was discovered using a combination of medicinal and combinatorial chemistry approaches.	CPR:4
BC6ENTC inhibited the BC6ENTG activity of both BC6OTHER and BC6OTHER (wild type and BC6OTHER mutant).	CPR:4
BC6ENTC inhibited the BC6OTHER activity of both BC6ENTG and BC6OTHER (wild type and BC6OTHER mutant).	CPR:4
BC6ENTC inhibited the BC6OTHER activity of both BC6OTHER and BC6ENTG (wild type and BC6OTHER mutant).	CPR:4
BC6ENTC inhibited the BC6OTHER activity of both BC6OTHER and BC6OTHER (wild type and BC6ENTG mutant).	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTG BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6ENTG / BC6OTHER in tumor vasculature.	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6ENTG in tumor vasculature.	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6ENTG / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6ENTG / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6ENTC ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6ENTG pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTC kinases BC6ENTG / BC6OTHER in tumor vasculature.	False
 BC6OTHER ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTC kinases BC6OTHER / BC6ENTG in tumor vasculature.	False
 BC6OTHER ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6ENTG / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTC kinases BC6OTHER / BC6OTHER in tumor vasculature.	False
 BC6OTHER ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6ENTG / BC6OTHER pathway in tumor cells and BC6ENTC kinases BC6OTHER / BC6OTHER in tumor vasculature.	False
 BC6OTHER ( BC6OTHER , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6ENTG pathway in tumor cells and BC6ENTC kinases BC6OTHER / BC6OTHER in tumor vasculature.	False
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTG BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6ENTG / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6ENTG in tumor vasculature.	CPR:4
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6ENTG / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6ENTG / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6ENTC , BC6OTHER ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6ENTG pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6ENTG BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6ENTG / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6ENTG in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6ENTG / BC6OTHER / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6OTHER / BC6ENTG / BC6OTHER pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
 BC6OTHER ( BC6OTHER , BC6ENTC ) , a dual - action inhibitor that targets BC6OTHER / BC6OTHER / BC6ENTG pathway in tumor cells and BC6OTHER BC6OTHER / BC6OTHER in tumor vasculature.	CPR:4
In the rabbit pulmonary artery , BC6OTHER and BC6OTHER are potent full agonists , whereas in the human atrial appendages they are antagonists at the BC6ENTG , sharing this property with BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:6
In the rabbit pulmonary artery , BC6OTHER and BC6OTHER are potent full agonists , whereas in the human atrial appendages they are antagonists at the BC6ENTG , sharing this property with BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:6
In the rabbit pulmonary artery , BC6OTHER and BC6OTHER are potent full agonists , whereas in the human atrial appendages they are antagonists at the BC6ENTG , sharing this property with BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:6
In addition , a partial nucleotide and BC6ENTC sequence of the BC6ENTG (a region known to substantially influence the pharmacological characteristics of the BC6OTHER ) revealed marked differences between the rabbit and the human BC6OTHER .	False
In addition , a partial nucleotide and BC6ENTC sequence of the BC6OTHER (a region known to substantially influence the pharmacological characteristics of the BC6ENTG ) revealed marked differences between the rabbit and the human BC6OTHER .	False
In addition , a partial nucleotide and BC6ENTC sequence of the BC6OTHER (a region known to substantially influence the pharmacological characteristics of the BC6OTHER ) revealed marked differences between the rabbit and the human BC6ENTG .	False
The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with BC6ENTG , at which , however , both BC6ENTC and BC6OTHER exhibit different properties (antagonism and agonism , respectively).	CPR:6
The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with BC6ENTG , at which , however , both BC6OTHER and BC6ENTC exhibit different properties (antagonism and agonism , respectively).	CPR:5
The antagonistic property of BC6ENTC at BC6ENTG indicates that in contrast to the suggestion based on rabbit data , the hypotensive property of the drug in humans is not due to activation of BC6OTHER but other , presumably I(1) - BC6OTHER receptors , are probably involved.	CPR:6
The antagonistic property of BC6ENTC at BC6OTHER indicates that in contrast to the suggestion based on rabbit data , the hypotensive property of the drug in humans is not due to activation of BC6ENTG but other , presumably I(1) - BC6OTHER receptors , are probably involved.	False
The antagonistic property of BC6ENTC at BC6OTHER indicates that in contrast to the suggestion based on rabbit data , the hypotensive property of the drug in humans is not due to activation of BC6OTHER but other , presumably BC6ENTG , are probably involved.	False
The antagonistic property of BC6OTHER at BC6ENTG indicates that in contrast to the suggestion based on rabbit data , the hypotensive property of the drug in humans is not due to activation of BC6OTHER but other , presumably I(1) - BC6ENTC receptors , are probably involved.	False
The antagonistic property of BC6OTHER at BC6OTHER indicates that in contrast to the suggestion based on rabbit data , the hypotensive property of the drug in humans is not due to activation of BC6ENTG but other , presumably I(1) - BC6ENTC receptors , are probably involved.	False
A prerequisite for this hypothesis was the unproved assumption that rabbit and human BC6ENTG are equally activated by BC6ENTC .	CPR:3
On the basis of data obtained in rabbits , the BC6ENTC receptor ligand BC6OTHER has been suggested to decrease blood pressure in humans by activating central BC6ENTG .	False
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of BC6ENTG agonists in inhibiting the electrically (2 Hz) evoked BC6ENTC release and of antagonists in counteracting the BC6OTHER - mediated inhibition induced by BC6OTHER .	False
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of BC6OTHER agonists in inhibiting the electrically (2 Hz) evoked BC6ENTC release and of antagonists in counteracting the BC6ENTG - mediated inhibition induced by BC6OTHER .	False
On the basis of data obtained in rabbits , the BC6OTHER ligand BC6ENTC has been suggested to decrease blood pressure in humans by activating central BC6ENTG .	CPR:3
On the basis of data obtained in rabbits , the BC6ENTG ligand BC6ENTC has been suggested to decrease blood pressure in humans by activating central BC6OTHER .	False
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of BC6ENTG agonists in inhibiting the electrically (2 Hz) evoked BC6OTHER release and of antagonists in counteracting the BC6OTHER - mediated inhibition induced by BC6ENTC .	False
Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of BC6OTHER agonists in inhibiting the electrically (2 Hz) evoked BC6OTHER release and of antagonists in counteracting the BC6ENTG - mediated inhibition induced by BC6ENTC .	CPR:4
In the rabbit pulmonary artery , BC6ENTC and BC6OTHER are potent full agonists , whereas in the human atrial appendages they are antagonists at the BC6ENTG , sharing this property with BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:6
In the rabbit pulmonary artery , BC6OTHER and BC6ENTC are potent full agonists , whereas in the human atrial appendages they are antagonists at the BC6ENTG , sharing this property with BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:6
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the BC6ENTC transfer step in BC6ENTG ( BC6OTHER ).	CPR:9
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the BC6ENTC transfer step in CHEM BC6OTHER - methyltransferase ( BC6ENTG ).	CPR:9
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the BC6OTHER transfer step in BC6ENTC BC6OTHER - methyltransferase ( BC6ENTG ).	False
Density functional theory calculations using the hybrid functional B3LYP have been performed to study the BC6OTHER transfer step in CHEM BC6ENTC - methyltransferase ( BC6ENTG ).	False
The starting point for the calculations is the recent X - ray crystal structure of BC6ENTG complexed with BC6ENTC and CHEM.	CPR:9
 BC6ENTC transfer in BC6ENTG .	False
BC6ENTC is a semisynthetic BC6OTHER that inhibit tumor growth by induction of microtubule stabilization and promotion of BC6ENTG inactivation , which induce apoptosis.	CPR:4
BC6OTHER is a semisynthetic BC6ENTC that inhibit tumor growth by induction of microtubule stabilization and promotion of BC6ENTG inactivation , which induce apoptosis.	CPR:4
Cys2 - His2 BC6ENTC finger proteins ( BC6ENTG ) are the largest group of transcription factors in higher metazoans.	False
To confirm the utility of our finger recognition models , we employed subsets of Drosophila fingers in combination with an existing archive of artificial BC6ENTC finger modules to create BC6ENTG with novel DNA - binding specificity.	False
Global analysis of BC6ENTG BC6ENTC 2 BC6OTHER finger proteins reveals a multitude of novel recognition motifs and binding determinants.	False
Global analysis of BC6ENTG BC6OTHER 2 BC6ENTC finger proteins reveals a multitude of novel recognition motifs and binding determinants.	False
BC6ENTC [ BC6OTHER ; BC6OTHER ] is a potent irreversible BC6ENTG ( BC6OTHER ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6ENTC [ BC6OTHER ; BC6OTHER ] is a potent irreversible BC6OTHER ( BC6ENTG ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6OTHER [ BC6ENTC ; BC6OTHER ] is a potent irreversible BC6ENTG ( BC6OTHER ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6OTHER [ BC6ENTC ; BC6OTHER ] is a potent irreversible BC6OTHER ( BC6ENTG ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6ENTC does not modify CNS BC6OTHER tissue levels or BC6OTHER - induced behavioural syndromes at doses which selectively inhibit BC6ENTG but not BC6OTHER .	CPR:4
BC6ENTC does not modify CNS BC6OTHER tissue levels or BC6OTHER - induced behavioural syndromes at doses which selectively inhibit BC6OTHER but not BC6ENTG .	CPR:4
BC6OTHER does not modify CNS BC6ENTC tissue levels or BC6OTHER - induced behavioural syndromes at doses which selectively inhibit BC6ENTG but not BC6OTHER .	False
BC6OTHER does not modify CNS BC6ENTC tissue levels or BC6OTHER - induced behavioural syndromes at doses which selectively inhibit BC6OTHER but not BC6ENTG .	False
BC6OTHER does not modify CNS BC6OTHER tissue levels or BC6ENTC - induced behavioural syndromes at doses which selectively inhibit BC6ENTG but not BC6OTHER .	False
BC6OTHER does not modify CNS BC6OTHER tissue levels or BC6ENTC - induced behavioural syndromes at doses which selectively inhibit BC6OTHER but not BC6ENTG .	False
BC6ENTC - induced ptosis was reversed by BC6OTHER at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6ENTG as well as BC6OTHER , but not at BC6OTHER - selective doses.	False
BC6ENTC - induced ptosis was reversed by BC6OTHER at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6OTHER as well as BC6ENTG , but not at BC6OTHER - selective doses.	False
BC6ENTC - induced ptosis was reversed by BC6OTHER at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6OTHER as well as BC6OTHER , but not at BC6ENTG - selective doses.	False
BC6OTHER [ BC6OTHER ; BC6ENTC ] is a potent irreversible BC6ENTG ( BC6OTHER ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6OTHER [ BC6OTHER ; BC6ENTC ] is a potent irreversible BC6OTHER ( BC6ENTG ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	CPR:4
BC6OTHER - induced ptosis was reversed by BC6ENTC at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6ENTG as well as BC6OTHER , but not at BC6OTHER - selective doses.	CPR:4
BC6OTHER - induced ptosis was reversed by BC6ENTC at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6OTHER as well as BC6ENTG , but not at BC6OTHER - selective doses.	CPR:4
BC6OTHER - induced ptosis was reversed by BC6ENTC at doses above 2 mg x kg( - 1) i.p. , which inhibit BC6OTHER as well as BC6OTHER , but not at BC6ENTG - selective doses.	False
BC6OTHER [ BC6OTHER ; BC6OTHER ] is a potent irreversible BC6ENTC oxidase ( BC6ENTG ) inhibitor with selectivity for type B of the enzyme , which is being developed for treatment of Parkinson's disease.	False
) , did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both BC6ENTG and BC6OTHER by BC6ENTC together with the BC6OTHER precursors.	CPR:4
) , did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both BC6OTHER and BC6ENTG by BC6ENTC together with the BC6OTHER precursors.	CPR:4
) , did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both BC6ENTG and BC6OTHER by BC6OTHER together with the BC6ENTC precursors.	CPR:4
) , did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both BC6OTHER and BC6ENTG by BC6OTHER together with the BC6ENTC precursors.	CPR:4
BC6ENTG inhibition modeled by iHOMA2 resulted in a decrease in mean BC6ENTC of 1.1 mmol / L.	False
Manipulation of iHOMA2s renal excretion threshold variable suggested that a decrease of 17% was required to obtain a 0.9 mmol / L decrease in mean BC6ENTC .CONCLUSIONSiHOMA2 is an extended mathematical model for the assessment of BC6ENTG resistance and β - cell function.	False
The model can be used to evaluate therapeutic agents and predict effects on fasting BC6ENTC and insulin and on β - cell function and BC6ENTG sensitivity.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6ENTG sensitivity with BC6ENTC and changes in renal threshold with CHEM BC6OTHER transporter ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6ENTC and changes in renal threshold with BC6ENTG ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6ENTC and changes in renal threshold with CHEM BC6OTHER transporter ( BC6ENTG ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6ENTG sensitivity with BC6OTHER and changes in renal threshold with BC6ENTC BC6OTHER transporter ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6OTHER and changes in renal threshold with BC6ENTC BC6OTHER transporter ( BC6ENTG ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6ENTG sensitivity with BC6OTHER and changes in renal threshold with CHEM BC6ENTC transporter ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6OTHER and changes in renal threshold with CHEM BC6ENTC transporter ( BC6ENTG ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6OTHER and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6ENTG sensitivity with BC6OTHER and changes in renal threshold with CHEM BC6OTHER transporter ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6ENTC and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6OTHER and changes in renal threshold with BC6ENTG ( BC6OTHER ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6ENTC and hormonal compartments.	False
OBJECTIVETo describe and make available an interactive , 24 - variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model , enabling the modeling of physiology and treatment effects , to present equations of the HOMA2 and iHOMA2 models , and to exemplify iHOMA2 in two widely differing scenarios: changes in BC6OTHER sensitivity with BC6OTHER and changes in renal threshold with CHEM BC6OTHER transporter ( BC6ENTG ) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the BC6ENTC and hormonal compartments.	False
We exemplify this with BC6ENTG inhibition modeling (by changing the renal threshold parameters) using published data of renal effect , showing that the modeled effect is concordant with the effects on fasting BC6ENTC from independent data.RESULTSiHOMA2 modeling of BC6OTHER effect suggested that changes in insulin sensitivity in the fasting state are predominantly hepatic.	False
We exemplify this with BC6ENTG inhibition modeling (by changing the renal threshold parameters) using published data of renal effect , showing that the modeled effect is concordant with the effects on fasting BC6OTHER from independent data.RESULTSiHOMA2 modeling of BC6ENTC effect suggested that changes in insulin sensitivity in the fasting state are predominantly hepatic.	False
The approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the center of a laminar - flow microfluidic channel , where they are exposed to overlapping , opposed gradients of inducers of the BC6ENTC - and BC6OTHER - terminal BC6ENTG fragments.	False
The approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the center of a laminar - flow microfluidic channel , where they are exposed to overlapping , opposed gradients of inducers of the BC6OTHER - and BC6ENTC - terminal BC6ENTG fragments.	False
The centerpiece of the AND gate is a bisected BC6ENTC - tRNA synthetase ( BC6ENTG ) that charges the BC6OTHER surrogate BC6OTHER ( BC6OTHER ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6ENTG ( BC6OTHER ) that charges the BC6ENTC surrogate BC6OTHER ( BC6OTHER ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6OTHER ( BC6ENTG ) that charges the BC6ENTC surrogate BC6OTHER ( BC6OTHER ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6ENTG ( BC6OTHER ) that charges the BC6OTHER surrogate BC6ENTC ( BC6OTHER ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6OTHER ( BC6ENTG ) that charges the BC6OTHER surrogate BC6ENTC ( BC6OTHER ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6ENTG ( BC6OTHER ) that charges the BC6OTHER surrogate BC6OTHER ( BC6ENTC ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6OTHER ( BC6ENTG ) that charges the BC6OTHER surrogate BC6OTHER ( BC6ENTC ) to tRNA( BC6OTHER ).	False
The centerpiece of the AND gate is a bisected BC6ENTG ( BC6OTHER ) that charges the BC6OTHER surrogate BC6OTHER ( BC6OTHER ) to tRNA( BC6ENTC ).	False
The centerpiece of the AND gate is a bisected BC6OTHER ( BC6ENTG ) that charges the BC6OTHER surrogate BC6OTHER ( BC6OTHER ) to tRNA( BC6ENTC ).	False
Cellular protein labeling occurs only upon activation of two different promoters that drive expression of the BC6ENTC - and BC6OTHER - terminal fragments of the bisected BC6ENTG .	False
Cellular protein labeling occurs only upon activation of two different promoters that drive expression of the BC6OTHER - and BC6ENTC - terminal fragments of the bisected BC6ENTG .	False
BC6ENTC ( BC6OTHER , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6ENTG BC6OTHER ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6ENTG ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6ENTG ) to its cognate receptor BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6OTHER ) to its cognate receptor BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6ENTG BC6OTHER ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6ENTG ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6ENTG ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC , Genzyme Corporation) is a BC6OTHER molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6OTHER ) to its cognate receptor BC6ENTG .	CPR:4
BC6OTHER ( BC6OTHER , Genzyme Corporation) is a BC6ENTC molecule that antagonizes the binding of the BC6ENTG BC6OTHER ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER , Genzyme Corporation) is a BC6ENTC molecule that antagonizes the binding of the BC6OTHER BC6ENTG ( BC6OTHER ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER , Genzyme Corporation) is a BC6ENTC molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6ENTG ) to its cognate receptor BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER , Genzyme Corporation) is a BC6ENTC molecule that antagonizes the binding of the BC6OTHER BC6OTHER ( BC6OTHER ) to its cognate receptor BC6ENTG .	CPR:4
BC6ENTC results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with BC6ENTG .	False
In clinical studies of autologous stem cell transplantation , the combination of BC6ENTC and BC6ENTG allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail BC6OTHER mobilization alone.	False
In clinical studies of autologous stem cell transplantation , the combination of BC6ENTC and BC6OTHER allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail BC6ENTG mobilization alone.	False
 BC6ENTC , a BC6ENTG antagonist for the mobilization of hematopoietic stem cells.	CPR:6
In this sample of neuroleptic - refractory schizophrenic patients , BC6ENTC and BC6OTHER showed a different pattern of occupancy of BC6ENTG despite a common lack of extrapyramidal side - effects.	False
In this sample of neuroleptic - refractory schizophrenic patients , BC6OTHER and BC6ENTC showed a different pattern of occupancy of BC6ENTG despite a common lack of extrapyramidal side - effects.	False
We report the results of a double - blind , randomized prospective trial on BC6ENTG occupancy and the clinical effects of BC6ENTC versus BC6OTHER in a sample of neuroleptic - refractory schizophrenic patients.	False
We report the results of a double - blind , randomized prospective trial on BC6ENTG occupancy and the clinical effects of BC6OTHER versus BC6ENTC in a sample of neuroleptic - refractory schizophrenic patients.	False
Cerebral BC6ENTG occupancy in Schizophrenic patients treated with BC6ENTC or BC6OTHER .	False
Cerebral BC6ENTG occupancy in Schizophrenic patients treated with BC6OTHER or BC6ENTC .	False
Several members of a new family of non - BC6ENTC - type BC6ENTG inhibitors , bearing a BC6OTHER moiety and various substituent at the CHEM position , were synthesized and their activities were investigated.	False
Structure - activity relationship studies indicated that BC6ENTC moiety is a favorable scaffold to exert the BC6ENTG inhibitory activity and substituents at the CHEM position have considerable influence on the efficacy of the inhibition activities.	CPR:4
Several members of a new family of non - BC6OTHER - type BC6ENTG inhibitors , bearing a BC6ENTC moiety and various substituent at the CHEM position , were synthesized and their activities were investigated.	CPR:4
A new series of BC6ENTC analogues as BC6ENTG inhibitors.	CPR:4
The other endogenous BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , had considerably lower BC6ENTG transport rates.	False
The other endogenous BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , had considerably lower BC6ENTG transport rates.	False
The other endogenous BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , had considerably lower BC6ENTG transport rates.	False
The other endogenous BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , had considerably lower BC6ENTG transport rates.	False
The other endogenous BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , had considerably lower BC6ENTG transport rates.	False
The rates of BC6ENTG transport for the exogenous BC6ENTC BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6ENTC and similar to those of the endogenous BC6OTHER BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6ENTC BC6OTHER and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6ENTC and BC6OTHER .	False
The rates of BC6ENTG transport for the exogenous BC6OTHER BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) are lower than that of BC6OTHER and similar to those of the endogenous BC6OTHER BC6OTHER and BC6ENTC .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6ENTG ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6OTHER ( BC6ENTG ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6ENTG and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6ENTG and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6ENTG and BC6OTHER .	False
Here , translocation studies using the human BC6ENTC receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6OTHER (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6ENTG .	False
Here , translocation studies using the BC6ENTG ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6ENTG ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6OTHER ( BC6ENTG ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6ENTG and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	CPR:3
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6ENTG and how glucocorticoid ligands were interacting with the BC6OTHER and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6ENTG and BC6OTHER .	False
Here , translocation studies using the human BC6OTHER receptor ( BC6OTHER ) and the BC6OTHER ( BC6OTHER ) were performed to aid in identifying the mechanism by which anabolic - androgenic BC6ENTC (AAS) were activating BC6OTHER and potentially interacting with BC6OTHER and how glucocorticoid ligands were interacting with the BC6OTHER and BC6ENTG .	False
BC6ENTC ( BC6OTHER ) had the fastest translocation rate for the BC6ENTG of 0.0525 min( - 1).	False
BC6OTHER ( BC6ENTC ) had the fastest translocation rate for the BC6ENTG of 0.0525 min( - 1).	False
Effect of anabolic - androgenic BC6ENTC and glucocorticoids on the kinetics of BC6ENTG and BC6OTHER nucleocytoplasmic translocation.	False
Effect of anabolic - androgenic BC6ENTC and glucocorticoids on the kinetics of BC6OTHER and BC6ENTG nucleocytoplasmic translocation.	False
CONCLUSIONS: In the maximum registered dosage , BC6ENTC inhibits BC6OTHER production much more than CHEM , signifying less BC6ENTG selectivity of the former.	CPR:4
CONCLUSIONS: In the maximum registered dosage , BC6OTHER inhibits BC6ENTC production much more than CHEM , signifying less BC6ENTG selectivity of the former.	False
AIMS: To compare the effects of BC6ENTC and BC6OTHER , two BC6OTHER ( BC6OTHER ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6ENTG activity and platelet function.	False
AIMS: To compare the effects of BC6ENTC and BC6OTHER , two BC6ENTG ( BC6OTHER ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6OTHER activity and platelet function.	False
AIMS: To compare the effects of BC6ENTC and BC6OTHER , two BC6OTHER ( BC6ENTG ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6OTHER activity and platelet function.	False
AIMS: To compare the effects of BC6OTHER and BC6ENTC , two BC6OTHER ( BC6OTHER ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6ENTG activity and platelet function.	False
AIMS: To compare the effects of BC6OTHER and BC6ENTC , two BC6ENTG ( BC6OTHER ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6OTHER activity and platelet function.	False
AIMS: To compare the effects of BC6OTHER and BC6ENTC , two BC6OTHER ( BC6ENTG ) preferential nonsteroidal anti - inflammatory drugs (NSAIDs) , on platelet BC6OTHER activity and platelet function.	False
BC6ENTG inhibition was measured as percentage inhibition of serum BC6ENTC generation in clotting whole blood , and as closure time with use of the platelet function analyser CHEM - 100.	CPR:9
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6ENTC ( BC6OTHER )] and nonsteroidal [CHEM and BC6OTHER ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6OTHER in the ovariectomized mouse and immature rat.	False
Overall , these findings suggest that BC6ENTC and BC6OTHER probably act through the same mechanism of action via the BC6ENTG .	False
Overall , these findings suggest that BC6OTHER and BC6ENTC probably act through the same mechanism of action via the BC6ENTG .	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6ENTC )] and nonsteroidal [CHEM and BC6OTHER ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6OTHER in the ovariectomized mouse and immature rat.	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6OTHER )] and nonsteroidal [CHEM and BC6ENTC ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6OTHER in the ovariectomized mouse and immature rat.	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6OTHER )] and nonsteroidal [CHEM and BC6OTHER ( BC6ENTC )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6OTHER in the ovariectomized mouse and immature rat.	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6OTHER )] and nonsteroidal [CHEM and BC6OTHER ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6ENTC and BC6OTHER in the ovariectomized mouse and immature rat.	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6OTHER , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6OTHER )] and nonsteroidal [CHEM and BC6OTHER ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6ENTC in the ovariectomized mouse and immature rat.	False
The aim of the study was to determine whether the dihydroxylated antiestrogen BC6ENTC , with a high affinity for the BC6ENTG and low intrinsic estrogenic activity , could inhibit the uterotropic actions of CHEM [ BC6OTHER ( BC6OTHER )] and nonsteroidal [CHEM and BC6OTHER ( BC6OTHER )] CHEM in immature rats and also the uterotropic actions of BC6OTHER and BC6OTHER in the ovariectomized mouse and immature rat.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6ENTG , BC6OTHER and BC6OTHER , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6ENTG and BC6OTHER , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6ENTG , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6ENTG and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6OTHER and BC6ENTG .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTC regulatory element - binding protein - 1 , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6ENTG , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6ENTC acyltransferase - 2 and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6ENTG and BC6OTHER , and significantly increased BC6OTHER , BC6ENTC acyltransferase - 2 and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6ENTG , and significantly increased BC6OTHER , BC6ENTC acyltransferase - 2 and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTG , BC6ENTC acyltransferase - 2 and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6ENTC acyltransferase - 2 and BC6ENTG .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6ENTC acyltransferase - 2 and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6ENTG , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6ENTC synthase.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6ENTG and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6ENTC synthase.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6ENTG , and significantly increased BC6OTHER , BC6OTHER and BC6ENTC synthase.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTG , BC6OTHER and BC6ENTC synthase.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6OTHER transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6ENTG and BC6ENTC synthase.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6ENTC synthase.	False
RESULTS: ORX mice fed HFD showed increased hepatic steatosis , markedly decreased serum BC6ENTC (TG) and TG - BC6ENTG content , and increased serum very small - BC6OTHER content.	False
RESULTS: ORX mice fed HFD showed increased hepatic steatosis , markedly decreased serum BC6ENTC (TG) and TG - BC6OTHER content , and increased serum very small - BC6ENTG content.	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6ENTG , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6OTHER , BC6ENTG and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6OTHER , BC6OTHER and BC6ENTG , and significantly increased BC6OTHER , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6ENTG , BC6OTHER and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6ENTG and BC6OTHER .	False
Gene expression analysis revealed that ORX mice fed HFD showed significantly decreased expression of microsomal BC6ENTC transfer protein , BC6OTHER , BC6OTHER and BC6OTHER , and significantly increased BC6OTHER , BC6OTHER and BC6ENTG .	False
 BC6ENTC deficiency induces markedly decreased serum BC6OTHER , increased small dense BC6ENTG , and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high - fat diet.	False
 BC6OTHER deficiency induces markedly decreased serum BC6ENTC , increased small dense BC6ENTG , and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high - fat diet.	False
It inhibits the activity of BC6ENTG , BC6OTHER , inducible form of BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER BC6OTHER ( BC6OTHER ).	False
It inhibits the activity of BC6OTHER , BC6ENTG , inducible form of BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER BC6OTHER ( BC6OTHER ).	False
It inhibits the activity of BC6OTHER , BC6OTHER , inducible form of BC6ENTC synthetase ( BC6ENTG ) and BC6OTHER BC6OTHER ( BC6OTHER ).	False
It inhibits the activity of BC6OTHER , BC6OTHER , inducible form of BC6ENTC synthetase ( BC6OTHER ) and BC6ENTG BC6OTHER ( BC6OTHER ).	False
It inhibits the activity of BC6OTHER , BC6OTHER , inducible form of BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER BC6ENTG ( BC6OTHER ).	False
It inhibits the activity of BC6OTHER , BC6OTHER , inducible form of BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER BC6OTHER ( BC6ENTG ).	False
We find that BC6ENTC inhibits mitochondrial permeability - transition - mediated BC6ENTG release.	CPR:4
BC6ENTC - mediated inhibition of BC6ENTG release is demonstrated in vivo , in cells , and in isolated mitochondria.	CPR:4
 BC6ENTC inhibits BC6ENTG release and delays progression of amyotrophic lateral sclerosis in mice.	CPR:4
We have identified >50 potential BC6ENTG substrates of both cytosolic and mitochondrial origin that bear hallmark BC6ENTC - terminal BC6OTHER binding motifs.	False
We have identified >50 potential BC6OTHER substrates of both cytosolic and mitochondrial origin that bear hallmark BC6ENTC - terminal BC6ENTG binding motifs.	False
The structure - activity relationship of a series of BC6ENTC BC6ENTG inhibitors is described.	CPR:4
Structure - based design of novel BC6OTHER BC6ENTG inhibitors that do not engage the catalytic BC6ENTC .	False
Structure - based design of novel BC6ENTC BC6ENTG inhibitors that do not engage the catalytic BC6OTHER .	CPR:4
BC6ENTG aggregation results showed that all compounds exhibited remarkable BC6OTHER fibril aggregation inhibition activity with a nearly similar potential as the reference compound BC6ENTC , which makes them promising anti - Alzheimer drug candidates.	False
BC6OTHER aggregation results showed that all compounds exhibited remarkable BC6ENTG fibril aggregation inhibition activity with a nearly similar potential as the reference compound BC6ENTC , which makes them promising anti - Alzheimer drug candidates.	CPR:4
To develop new drugs for treatment of Alzheimer's disease , a group of BC6ENTC was designed , synthesized and tested for their ability to inhibit BC6ENTG , BC6OTHER and aggregation of BC6OTHER .	CPR:4
To develop new drugs for treatment of Alzheimer's disease , a group of BC6ENTC was designed , synthesized and tested for their ability to inhibit BC6OTHER , BC6ENTG and aggregation of BC6OTHER .	CPR:4
To develop new drugs for treatment of Alzheimer's disease , a group of BC6ENTC was designed , synthesized and tested for their ability to inhibit BC6OTHER , BC6OTHER and aggregation of BC6ENTG .	False
Synthesis , molecular modeling and evaluation of novel BC6ENTC derivatives as dual inhibitors for BC6ENTG and BC6OTHER aggregation.	CPR:4
Synthesis , molecular modeling and evaluation of novel BC6ENTC derivatives as dual inhibitors for BC6OTHER and BC6ENTG aggregation.	CPR:4
CHEM ( BC6ENTC reductase inhibitors) have consistently been shown to decrease both BC6ENTG - C and CVD risk in almost all patient categories , with the exception of heart and kidney failure as well as advanced aortic stenosis.	False
It is widely recognised that BC6ENTG BC6ENTC ( BC6OTHER - C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD).	False
It is widely recognised that BC6OTHER BC6ENTC ( BC6ENTG - C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD).	False
 In patients who do not reach the BC6ENTG - C target , combination therapy with additional BC6OTHER - C lowering drugs (e.g. BC6ENTC , BC6OTHER sequestrants or BC6OTHER ) should be considered.	False
 In patients who do not reach the BC6OTHER - C target , combination therapy with additional BC6ENTG - C lowering drugs (e.g. BC6ENTC , BC6OTHER sequestrants or BC6OTHER ) should be considered.	CPR:4
 In patients who do not reach the BC6ENTG - C target , combination therapy with additional BC6OTHER - C lowering drugs (e.g. BC6OTHER , BC6ENTC sequestrants or BC6OTHER ) should be considered.	False
 In patients who do not reach the BC6OTHER - C target , combination therapy with additional BC6ENTG - C lowering drugs (e.g. BC6OTHER , BC6ENTC sequestrants or BC6OTHER ) should be considered.	CPR:4
 In patients who do not reach the BC6ENTG - C target , combination therapy with additional BC6OTHER - C lowering drugs (e.g. BC6OTHER , BC6OTHER sequestrants or BC6ENTC ) should be considered.	False
 In patients who do not reach the BC6OTHER - C target , combination therapy with additional BC6ENTG - C lowering drugs (e.g. BC6OTHER , BC6OTHER sequestrants or BC6ENTC ) should be considered.	CPR:4
 BC6ENTG BC6ENTC Goals in High - Risk Patients: How Low Do We Go and How Do We Get There?	False
Treatment with BC6ENTC resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated BC6ENTG after 6 hr , indicating that BC6OTHER may cause apoptosis of neuronal cells via activation of the BC6OTHER cascade.	CPR:3
Treatment with BC6ENTC resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated BC6OTHER after 6 hr , indicating that BC6OTHER may cause apoptosis of neuronal cells via activation of the BC6ENTG cascade.	False
Treatment with BC6OTHER resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated BC6ENTG after 6 hr , indicating that BC6ENTC may cause apoptosis of neuronal cells via activation of the BC6OTHER cascade.	False
Treatment with BC6OTHER resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated BC6OTHER after 6 hr , indicating that BC6ENTC may cause apoptosis of neuronal cells via activation of the BC6ENTG cascade.	CPR:3
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6ENTC or BC6OTHER in patients with a mutation in the BC6ENTG - coding gene BC6OTHER ( BC6OTHER ).	CPR:4
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6ENTC or BC6OTHER in patients with a mutation in the BC6OTHER - coding gene BC6ENTG ( BC6OTHER ).	CPR:4
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6ENTC or BC6OTHER in patients with a mutation in the BC6OTHER - coding gene BC6OTHER ( BC6ENTG ).	CPR:4
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6OTHER or BC6ENTC in patients with a mutation in the BC6ENTG - coding gene BC6OTHER ( BC6OTHER ).	CPR:4
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6OTHER or BC6ENTC in patients with a mutation in the BC6OTHER - coding gene BC6ENTG ( BC6OTHER ).	CPR:4
Pharmacological treatment has been studied and it could be demonstrated , that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as , e.g. , BC6OTHER or BC6ENTC in patients with a mutation in the BC6OTHER - coding gene BC6OTHER ( BC6ENTG ).	CPR:4
Herein , we report the pharmacological actions of BC6ENTC , a novel , selective , and brain - penetrant positive allosteric modulator (PAM) of the BC6ENTG receptor in the stress - induced hyperthermia (SIH) , four - plate , marble - burying and Vogel's conflict tests.	False
The anti - hyperthermic effect of BC6ENTC (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6ENTC (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6ENTC (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTC receptor antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTC receptor antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6ENTC (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	CPR:6
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6ENTC (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6ENTC (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6ENTC - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6ENTC - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6ENTC - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6ENTC - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6ENTC - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6ENTC - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTC (1A) receptors by BC6OTHER , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTC (1A) receptors by BC6OTHER , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6ENTC , or BC6OTHER receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6ENTC , or BC6OTHER receptors by BC6OTHER .	CPR:4
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6ENTC , or BC6ENTG receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTC (2A / 2C) receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6ENTC (2A / 2C) receptors by BC6OTHER .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6ENTG antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6OTHER receptors by BC6ENTC .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6ENTG receptors by BC6OTHER , or BC6OTHER receptors by BC6ENTC .	False
The anti - hyperthermic effect of BC6OTHER (5 mg / kg) in the SIH test was inhibited by the BC6OTHER antagonist BC6OTHER (10 mg / kg) and was not BC6OTHER - dependent , as it persisted in BC6OTHER - deficient mice and upon blockade of either BC6OTHER receptors by BC6OTHER , or BC6ENTG receptors by BC6ENTC .	CPR:4
Previous studies demonstrated that the BC6ENTG - selective orthosteric agonist , BC6ENTC produced anxiolytic - but not antidepressant - like effects upon peripheral administration.	CPR:5
Anxiolytic - but not antidepressant - like activity of BC6ENTC , a novel , selective positive allosteric modulator of the BC6ENTG receptor.	False
In four (10 %) patients the peak BC6ENTG - stimulated BC6ENTC values were lower than 18 μg / dL.	CPR:9
However , the predictors of CFC , FCI , and BC6ENTC - S levels were serum BC6OTHER levels in hyperthyroidism , and both BC6OTHER and BC6ENTG levels in euthyroidism.	False
However , the predictors of CFC , FCI , and BC6OTHER - S levels were serum BC6ENTC levels in hyperthyroidism , and both BC6OTHER and BC6ENTG levels in euthyroidism.	False
However , the predictors of CFC , FCI , and BC6OTHER - S levels were serum BC6OTHER levels in hyperthyroidism , and both BC6ENTC and BC6ENTG levels in euthyroidism.	False
BC6ENTG - stimulated peak BC6ENTC , BC6OTHER , and BC6OTHER - S levels are decreased during hyperthyroidism , probably due to increased turnover.	CPR:9
BC6ENTG - stimulated peak BC6OTHER , BC6ENTC , and BC6OTHER - S levels are decreased during hyperthyroidism , probably due to increased turnover.	CPR:9
BC6ENTG - stimulated peak BC6OTHER , BC6OTHER , and BC6ENTC - S levels are decreased during hyperthyroidism , probably due to increased turnover.	CPR:9
Baseline BC6ENTC (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6ENTC (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6ENTC (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , CHEM ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , CHEM ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , CHEM ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6ENTC - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6ENTC - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6ENTC - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTC binding globulin ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTC binding globulin ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6ENTC (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6ENTC (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6ENTC (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6ENTC index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6ENTC index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6ENTC index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6ENTC (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6ENTC (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6ENTC (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6ENTC - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6ENTC - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6ENTC - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6ENTC - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6ENTC - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6ENTC - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6ENTC ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6ENTC ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6ENTC ( BC6OTHER ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6ENTC ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6ENTC ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6ENTC ) , BC6OTHER - S ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , CHEM ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , CHEM ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , CHEM ( BC6OTHER - S) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6ENTG ( BC6OTHER ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( CHEM) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6ENTG ) , BC6OTHER , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( CHEM) responses were evaluated.	False
Baseline BC6OTHER (Cor0) , BC6OTHER - S ( BC6OTHER - S0) , BC6OTHER ( BC6OTHER ) , BC6ENTG , calculated free BC6OTHER (by Coolen's equation = CFC) , free BC6OTHER index (FCI) , 60 - min BC6OTHER (Cor60) , and BC6OTHER - S ( BC6OTHER - S60) , BC6OTHER ( BC6OTHER ) , BC6OTHER - S ( CHEM) responses were evaluated.	False
The affinities of a number of BC6OTHER antagonists were determined by displacement of BC6ENTC binding from cloned BC6ENTG (previously designated cloned alpha 1c subtype) , CHEM and BC6OTHER , stably expressed in rat - 1 fibroblasts.	False
The affinities of a number of BC6OTHER antagonists were determined by displacement of BC6ENTC binding from cloned BC6OTHER (previously designated cloned alpha 1c subtype) , CHEM and BC6ENTG , stably expressed in rat - 1 fibroblasts.	False
The affinities of a number of BC6ENTG antagonists were determined by displacement of BC6ENTC binding from cloned BC6OTHER (previously designated cloned alpha 1c subtype) , CHEM and BC6OTHER , stably expressed in rat - 1 fibroblasts.	False
Functional affinities for compounds determined against BC6ENTC - mediated contractions of rat aorta correlated well with binding affinities at cloned BC6ENTG (r = 0.96) , but not with alpha 1A (r = 0.61) or alpha 1B (r = 0.46) subtypes.	False
The results of this study suggest that BC6ENTC predominantly , but not exclusively , mediates contraction of rat aorta through the activation of an BC6ENTG .	CPR:3
BC6ENTC displayed high affinity for cloned BC6ENTG (pKi = 8.2 + / - 0.10) and was selective over alpha 1A (pKi = 6.2 + / - 0.10) and alpha 1B subtypes (6.7 + / - 0.11).	False
CHEM , BC6ENTC and BC6OTHER displayed high affinity for BC6ENTG compared to the alpha 1B subtype.	False
CHEM , BC6OTHER and BC6ENTC displayed high affinity for BC6ENTG compared to the alpha 1B subtype.	False
BC6ENTC displayed high affinity and selectivity for BC6ENTG (pKi 8.8 + / - 0.16).	False
BC6ENTC was selective for cloned BC6ENTG .	False
Characterization of an BC6ENTG mediating the contractile response of rat aorta to BC6ENTC .	False
Cytotoxic BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6ENTG and a BC6OTHER .	False
Cytotoxic BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6OTHER and a BC6ENTG .	False
Cytotoxic BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6ENTG and a BC6OTHER .	False
Cytotoxic BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6OTHER and a BC6ENTG .	False
Cytotoxic BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6ENTG and a BC6OTHER .	False
Cytotoxic BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6OTHER and a BC6ENTG .	False
Cytotoxic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6ENTG and a BC6OTHER .	False
Cytotoxic BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) lesions induced in DNA and RNA in vitro and in pre - damaged DNA and RNA bacteriophages in vivo are repaired by the BC6OTHER and a BC6ENTG .	False
Here , we demonstrate BC6ENTG - mediated repair of endogenous RNA in vivo by measuring differences in lesion - accumulation in two independent BC6OTHER - proficient and deficient E. coli strains during exposure to BC6ENTC ( BC6OTHER ).	False
Here , we demonstrate BC6OTHER - mediated repair of endogenous RNA in vivo by measuring differences in lesion - accumulation in two independent BC6ENTG - proficient and deficient E. coli strains during exposure to BC6ENTC ( BC6OTHER ).	False
Here , we demonstrate BC6ENTG - mediated repair of endogenous RNA in vivo by measuring differences in lesion - accumulation in two independent BC6OTHER - proficient and deficient E. coli strains during exposure to BC6OTHER ( BC6ENTC ).	False
Here , we demonstrate BC6OTHER - mediated repair of endogenous RNA in vivo by measuring differences in lesion - accumulation in two independent BC6ENTG - proficient and deficient E. coli strains during exposure to BC6OTHER ( BC6ENTC ).	False
The activity of BC6OTHER containing mutations known to confer resistance to BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6ENTC eight to 14 times higher than those required to inhibit wild - type BC6ENTG .	CPR:4
The activity of BC6ENTG containing mutations known to confer resistance to BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6ENTC eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	CPR:4
The activity of BC6OTHER containing mutations known to confer resistance to BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6ENTC eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	CPR:4
The activity of BC6OTHER containing mutations known to confer resistance to BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) was inhibited by concentrations of BC6ENTC eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	CPR:4
The activity of BC6OTHER containing mutations known to confer resistance to BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) was inhibited by concentrations of BC6ENTC eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	CPR:4
Phenotypic characterisation of the BC6OTHER BC6OTHER is a useful tool for testing for mutations in the BC6ENTG gene thought to render HCMV resistant to BC6ENTC .	False
Phenotypic characterisation of the BC6ENTG BC6OTHER is a useful tool for testing for mutations in the BC6OTHER gene thought to render HCMV resistant to BC6ENTC .	False
Phenotypic characterisation of the BC6OTHER BC6ENTG is a useful tool for testing for mutations in the BC6OTHER gene thought to render HCMV resistant to BC6ENTC .	False
In this study , an in - house non - isotopic method for assessing polymerase enzymatic activity in the presence and absence of BC6ENTC was developed and its utility for BC6ENTG phenotyping evaluated.	False
BC6ENTG activity was assessed by monitoring the incorporation of BC6ENTC - labelled CHEM into the growing DNA chain and BC6OTHER concentrations inhibiting enzymatic activity by 50% were determined.	False
BC6ENTG activity was assessed by monitoring the incorporation of BC6OTHER - labelled CHEM into the growing DNA chain and BC6ENTC concentrations inhibiting enzymatic activity by 50% were determined.	False
The activity of BC6OTHER containing mutations known to confer resistance to BC6ENTC ( BC6OTHER , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6OTHER eight to 14 times higher than those required to inhibit wild - type BC6ENTG .	False
The activity of BC6ENTG containing mutations known to confer resistance to BC6ENTC ( BC6OTHER , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6OTHER eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	False
The activity of BC6OTHER containing mutations known to confer resistance to BC6ENTC ( BC6ENTG , BC6OTHER and BC6OTHER ) was inhibited by concentrations of BC6OTHER eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	False
The activity of BC6OTHER containing mutations known to confer resistance to BC6ENTC ( BC6OTHER , BC6ENTG and BC6OTHER ) was inhibited by concentrations of BC6OTHER eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	False
The activity of BC6OTHER containing mutations known to confer resistance to BC6ENTC ( BC6OTHER , BC6OTHER and BC6ENTG ) was inhibited by concentrations of BC6OTHER eight to 14 times higher than those required to inhibit wild - type BC6OTHER .	False
Development and validation of a non - radioactive BC6ENTG assay for studying cytomegalovirus resistance to BC6ENTC .	CPR:4
BC6ENTC receptor antagonists block BC6OTHER and reduce the pressor effects of BC6ENTG in the vasculature.	False
BC6ENTC receptor antagonists block BC6ENTG and reduce the pressor effects of BC6OTHER in the vasculature.	False
In clinical trials BC6ENTC has proven to be at least as effective as the BC6ENTG inhibitor CHEM in reducing BP , but with a significantly lower incidence of side effects.	CPR:4
BC6ENTG antagonists block BC6OTHER and reduce the pressor effects of BC6ENTC in the vasculature.	False
BC6OTHER antagonists block BC6ENTG and reduce the pressor effects of BC6ENTC in the vasculature.	False
By this mechanism , they induce similar pharmacological effects to BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors , resulting in a lowering of blood pressure (BP).	False
BC6ENTG antagonists block BC6ENTC type 1 (AT1) receptors and reduce the pressor effects of BC6OTHER in the vasculature.	False
BC6OTHER antagonists block BC6ENTC type 1 (AT1) receptors and reduce the pressor effects of BC6ENTG in the vasculature.	False
BC6ENTC acts not only at vascular BC6ENTG receptors but also at presynaptic BC6OTHER receptors , causing inhibition of sympathetically stimulated BC6OTHER release.	False
BC6ENTC acts not only at vascular BC6OTHER receptors but also at presynaptic BC6ENTG receptors , causing inhibition of sympathetically stimulated BC6OTHER release.	False
BC6OTHER acts not only at vascular BC6ENTG receptors but also at presynaptic BC6OTHER receptors , causing inhibition of sympathetically stimulated BC6ENTC release.	False
BC6OTHER acts not only at vascular BC6OTHER receptors but also at presynaptic BC6ENTG receptors , causing inhibition of sympathetically stimulated BC6ENTC release.	False
BC6ENTC is not metabolized by BC6ENTG enzymes and therefore has a low potential for metabolic drug interactions , which may be of importance when treating the elderly and patients on multiple drugs.	False
The clinical profile of the BC6ENTG blocker BC6ENTC .	CPR:4
These findings show that BC6ENTG inhibition dramatically increases basal levels of BC6ENTC .	False
Here we studied the effects of the recently developed BC6ENTG inhibitor BC6ENTC on basal and stress - induced BC6OTHER levels in male CD1 mice , and found that this compound dramatically increased basal levels without affecting stress responses.	CPR:4
Here we studied the effects of the recently developed BC6ENTG inhibitor BC6OTHER on basal and stress - induced BC6ENTC levels in male CD1 mice , and found that this compound dramatically increased basal levels without affecting stress responses.	False
 BC6ENTG inhibition - induced changes in plasma BC6ENTC levels , anxiety and locomotor activity in male CD1 mice.	False
The effects of several BC6ENTC ( BC6OTHER ) - elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against BC6ENTG ( BC6OTHER ).	False
The effects of several BC6ENTC ( BC6OTHER ) - elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against BC6OTHER ( BC6ENTG ).	False
The effects of several BC6OTHER ( BC6ENTC ) - elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against BC6ENTG ( BC6OTHER ).	False
The effects of several BC6OTHER ( BC6ENTC ) - elevating agents on the proliferation of cultured rat microglia were investigated by immunocytochemical staining with an antibody against BC6OTHER ( BC6ENTG ).	False
These findings suggest that the beta - agonists suppress the proliferation of microglia by elevating intracellular BC6ENTC level through an action on BC6ENTG .	False
Our findings suggest that null mutations in BC6ENTG which cause Parkinsonism potentiate BC6ENTC toxicity and increase susceptibility to develop BC6OTHER .	False
Our findings suggest that null mutations in BC6ENTG which cause Parkinsonism potentiate BC6OTHER toxicity and increase susceptibility to develop BC6ENTC .	False
Genes linked to early onset of Parkinsonism which includes BC6ENTG and BC6OTHER have already been suggested to promote development of BC6ENTC toxicity.	False
Genes linked to early onset of Parkinsonism which includes BC6OTHER and BC6ENTG have already been suggested to promote development of BC6ENTC toxicity.	False
Of the other Parkinson - linked genes , mutations in BC6ENTG , an autosomal dominant gene , represent another likely candidate involved in the development of BC6ENTC .	False
In this paper the effect of shRNA BC6ENTG knock - down on BC6ENTC toxicity was examined in control and BC6OTHER transfected HEK293 cells.	False
In this paper the effect of shRNA BC6OTHER knock - down on BC6ENTC toxicity was examined in control and BC6ENTG transfected HEK293 cells.	False
Results demonstrate that BC6ENTG down - regulation potentiates BC6ENTC toxicity in both control and BC6OTHER - transfected cell as well as potentiates DA toxicity.	False
Results demonstrate that BC6OTHER down - regulation potentiates BC6ENTC toxicity in both control and BC6ENTG - transfected cell as well as potentiates DA toxicity.	False
Combined treatment of BC6ENTC and DA further augments cell toxicity , ROS production and BC6OTHER phosphorylation in BC6ENTG deficient cells compared to controls.	False
Combined treatment of BC6ENTC and DA further augments cell toxicity , ROS production and BC6ENTG phosphorylation in BC6OTHER deficient cells compared to controls.	CPR:3
Down - regulation of BC6ENTG in control and BC6OTHER transfected HEK cells increases BC6ENTC - induced oxidative stress and cell toxicity.	False
Down - regulation of BC6OTHER in control and BC6ENTG transfected HEK cells increases BC6ENTC - induced oxidative stress and cell toxicity.	False
BC6ENTC , a BC6ENTG inhibitor is currently in phase II clinical trials.	CPR:4
BC6ENTC , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6ENTG , and receptor - associated BC6OTHER kinases has completed phase II trials.	False
BC6ENTC , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6OTHER , and BC6ENTG has completed phase II trials.	False
BC6OTHER , is a synthetic BC6ENTC that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6ENTG , and receptor - associated BC6OTHER kinases has completed phase II trials.	False
BC6OTHER , is a synthetic BC6ENTC that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6OTHER , and BC6ENTG has completed phase II trials.	False
BC6OTHER , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6ENTC synthesis , BC6ENTG , and receptor - associated BC6OTHER kinases has completed phase II trials.	False
BC6OTHER , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6ENTC synthesis , BC6OTHER , and BC6ENTG has completed phase II trials.	False
BC6OTHER , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6ENTC dehydrogenase , and BC6ENTG has completed phase II trials.	False
BC6OTHER , is a synthetic BC6OTHER that targets the critical enzyme of the de novo BC6OTHER synthesis , BC6ENTG , and receptor - associated BC6ENTC kinases has completed phase II trials.	False
BC6ENTC ( BC6OTHER ) , a synthetic BC6ENTG modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.	False
BC6OTHER ( BC6ENTC ) , a synthetic BC6ENTG modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.	False
BC6ENTC - induced autophagy via BC6ENTG and BC6OTHER pathways may provide a protective mechanism for cell survival against BC6OTHER - induced apoptosis to act as a cytoprotective reaction.	False
BC6ENTC - induced autophagy via BC6OTHER and BC6ENTG pathways may provide a protective mechanism for cell survival against BC6OTHER - induced apoptosis to act as a cytoprotective reaction.	False
BC6OTHER - induced autophagy via BC6ENTG and BC6OTHER pathways may provide a protective mechanism for cell survival against BC6ENTC - induced apoptosis to act as a cytoprotective reaction.	False
BC6OTHER - induced autophagy via BC6OTHER and BC6ENTG pathways may provide a protective mechanism for cell survival against BC6ENTC - induced apoptosis to act as a cytoprotective reaction.	False
Results from BC6ENTC and annexin - V / PI double - staining assay showed that BC6ENTG - and BC6OTHER - dependent , and dose - dependent apoptoses were detected after a 24 - h BC6OTHER treatment.	False
Results from BC6ENTC and annexin - V / PI double - staining assay showed that BC6OTHER - and BC6ENTG - dependent , and dose - dependent apoptoses were detected after a 24 - h BC6OTHER treatment.	False
Results from BC6OTHER and annexin - V / PI double - staining assay showed that BC6ENTG - and BC6OTHER - dependent , and dose - dependent apoptoses were detected after a 24 - h BC6ENTC treatment.	False
Results from BC6OTHER and annexin - V / PI double - staining assay showed that BC6OTHER - and BC6ENTG - dependent , and dose - dependent apoptoses were detected after a 24 - h BC6ENTC treatment.	False
Meanwhile , autophagy was detected as early as 12 h after an exposure to low - dose BC6ENTC , as indicated by an up - regulated expression of BC6ENTG and BC6OTHER proteins.	CPR:3
Meanwhile , autophagy was detected as early as 12 h after an exposure to low - dose BC6ENTC , as indicated by an up - regulated expression of BC6OTHER and BC6ENTG proteins.	CPR:3
Treatment of A549 and H1299 cells with BC6ENTC caused a dose - dependent increase in BC6OTHER and BC6ENTG activity , accompanied with a decreased BC6OTHER expression and decreased phosphorylation of BC6OTHER and BC6OTHER .	CPR:3
Treatment of A549 and H1299 cells with BC6ENTC caused a dose - dependent increase in BC6OTHER and BC6OTHER activity , accompanied with a decreased BC6ENTG expression and decreased phosphorylation of BC6OTHER and BC6OTHER .	CPR:4
Treatment of A549 and H1299 cells with BC6ENTC caused a dose - dependent increase in BC6OTHER and BC6OTHER activity , accompanied with a decreased BC6OTHER expression and decreased phosphorylation of BC6ENTG and BC6OTHER .	CPR:4
Treatment of A549 and H1299 cells with BC6ENTC caused a dose - dependent increase in BC6OTHER and BC6OTHER activity , accompanied with a decreased BC6OTHER expression and decreased phosphorylation of BC6OTHER and BC6ENTG .	CPR:4
Treatment of A549 and H1299 cells with BC6ENTC caused a dose - dependent increase in BC6ENTG and BC6OTHER activity , accompanied with a decreased BC6OTHER expression and decreased phosphorylation of BC6OTHER and BC6OTHER .	CPR:3
 BC6ENTC - induced autophagy mitigates cell apoptosis through modulation of BC6ENTG / BC6OTHER and BC6OTHER and BC6OTHER signaling pathways in human lung cancer cell lines.	False
 BC6ENTC - induced autophagy mitigates cell apoptosis through modulation of BC6OTHER / BC6ENTG and BC6OTHER and BC6OTHER signaling pathways in human lung cancer cell lines.	False
 BC6ENTC - induced autophagy mitigates cell apoptosis through modulation of BC6OTHER / BC6OTHER and BC6ENTG and BC6OTHER signaling pathways in human lung cancer cell lines.	False
 BC6ENTC - induced autophagy mitigates cell apoptosis through modulation of BC6OTHER / BC6OTHER and BC6OTHER and BC6ENTG signaling pathways in human lung cancer cell lines.	False
The present review will consider the advantages and challenges associated with allosteric BC6ENTG ligands , and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free BC6ENTC sensitive BC6OTHER .	False
The present review will consider the advantages and challenges associated with allosteric BC6OTHER ligands , and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free BC6ENTC sensitive BC6ENTG .	False
The therapeutic potential of allosteric ligands for free BC6ENTC sensitive BC6ENTG .	False
In recent years , BC6ENTC receptor blockers (ARBs) have emerged as effective and well - tolerated alternatives to an BC6ENTG inhibitor (ACEi) for RAAS blockade.	False
In recent years , BC6ENTG blockers (ARBs) have emerged as effective and well - tolerated alternatives to an BC6ENTC - converting enzyme inhibitor (ACEi) for RAAS blockade.	False
UNLABELLED: Therapeutic interventions that block the BC6ENTG - BC6ENTC - BC6OTHER system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases.	False
UNLABELLED: Therapeutic interventions that block the BC6ENTG - BC6OTHER - BC6ENTC system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases.	False
UNLABELLED: Therapeutic interventions that block the BC6OTHER - BC6ENTG - BC6ENTC system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases.	False
FINDINGS: Compared with other ARBs , BC6ENTC demonstrates the strongest binding affinity to the BC6ENTG .	False
Clinical trials have demonstrated that BC6ENTC is well tolerated in combination with diuretics or BC6ENTG blockers (CCBs) , making it a suitable treatment option for patients whose hypertension is not adequately controlled by monotherapy.	False
OBJECTIVE: This randomized , double - blind study tested the hypothesis that BC6OTHER , a drug that specifically inhibits BC6ENTG , would cause fewer gastroduodenal ulcers than BC6ENTC (in a multicenter trial) , and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).	False
OBJECTIVE: This randomized , double - blind study tested the hypothesis that BC6ENTC , a drug that specifically inhibits BC6ENTG , would cause fewer gastroduodenal ulcers than BC6OTHER (in a multicenter trial) , and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).	CPR:4
Comparison of the effect of BC6ENTC (a BC6ENTG inhibitor) , BC6OTHER , and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized , double - blind , placebo - controlled trial.	CPR:4
Comparison of the effect of BC6OTHER (a BC6ENTG inhibitor) , BC6ENTC , and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized , double - blind , placebo - controlled trial.	False
Furthermore , the expression of these BC6ENTC was correlated with the expression of BC6ENTG .	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6ENTG ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6ENTG ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6ENTG ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTG ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6ENTG ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6ENTG ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6ENTG ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTC ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6ENTG levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTG ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6ENTG ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6ENTG ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTG ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6ENTG ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6ENTG ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6ENTG ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTC ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6OTHER ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6ENTG levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6ENTG ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6ENTG ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6ENTG ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6ENTG ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6ENTG ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6ENTG ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6ENTG ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , as well as the pituitary and plasma BC6OTHER levels between 50 and 300 days post - hatching (dph).	False
A likely endocrine control mechanism for sexual differentiation in size - graded populations of European sea bass (Dicentrarchus labrax) is proposed by evaluating the brain expression and pituitary content of two forms of BC6OTHER ( BC6OTHER ) , namely sea bream ( BC6OTHER ) and salmon ( BC6OTHER ) , the pituitary expression of one subtype of BC6ENTC receptor ( BC6OTHER ) and the three BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , as well as the pituitary and plasma BC6ENTG levels between 50 and 300 days post - hatching (dph).	False
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	CPR:4
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	CPR:4
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	CPR:4
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6ENTG unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	CPR:4
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6ENTG (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	CPR:4
BC6ENTC treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6ENTG .	CPR:3
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6ENTG ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6OTHER ( BC6ENTG ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6ENTG BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6ENTG unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6ENTG (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6ENTC , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6OTHER ) with an elevation in plasma BC6ENTG .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6ENTG unit (in pancreas) and BC6OTHER (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6ENTG (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6ENTC ( BC6OTHER ) with an elevation in plasma BC6ENTG .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6ENTG unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6ENTG (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6OTHER .	False
BC6OTHER treatment showed a significant decline in the levels of blood BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER BC6OTHER unit (in pancreas) and BC6OTHER (plasma) , serum BC6OTHER ( BC6ENTC ) with an elevation in plasma BC6ENTG .	False
Here , we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing BC6ENTG to a BC6OTHER and removing the intrinsic heparan BC6ENTC - binding activity of BC6OTHER .	False
Here , we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing BC6OTHER to a BC6ENTG and removing the intrinsic heparan BC6ENTC - binding activity of BC6OTHER .	False
Here , we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing BC6OTHER to a BC6OTHER and removing the intrinsic heparan BC6ENTC - binding activity of BC6ENTG .	False
All drugs reduced peak current and stabilized the inactivated state of voltage - gated BC6ENTC channel BC6ENTG , with similar effects in dorsal root ganglion neurons.	False
We compared the effect of BC6ENTC on BC6OTHER currents using in vitro patch clamp in cells expressing the BC6ENTG BC6OTHER isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6OTHER .	False
We compared the effect of BC6ENTC on BC6OTHER currents using in vitro patch clamp in cells expressing the voltage - gated BC6OTHER channel BC6ENTG isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6ENTC currents using in vitro patch clamp in cells expressing the BC6ENTG BC6OTHER isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6ENTC currents using in vitro patch clamp in cells expressing the voltage - gated BC6OTHER channel BC6ENTG isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6OTHER currents using in vitro patch clamp in cells expressing the voltage - gated BC6ENTC channel BC6ENTG isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6OTHER currents using in vitro patch clamp in cells expressing the BC6ENTG BC6OTHER isoform and on dissociated dorsal root ganglion neurons to BC6ENTC and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6OTHER currents using in vitro patch clamp in cells expressing the voltage - gated BC6OTHER channel BC6ENTG isoform and on dissociated dorsal root ganglion neurons to BC6ENTC and BC6OTHER .	False
We compared the effect of BC6OTHER on BC6OTHER currents using in vitro patch clamp in cells expressing the BC6ENTG BC6OTHER isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6ENTC .	False
We compared the effect of BC6OTHER on BC6OTHER currents using in vitro patch clamp in cells expressing the voltage - gated BC6OTHER channel BC6ENTG isoform and on dissociated dorsal root ganglion neurons to BC6OTHER and BC6ENTC .	False
 BC6ENTC attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes BC6ENTG inactivated state.	False
These data demonstrate that BC6ENTG is a positive modulator of osteoclast differentiation via BC6OTHER - dependent BC6ENTC signaling.	False
These data demonstrate that BC6OTHER is a positive modulator of osteoclast differentiation via BC6ENTG - dependent BC6ENTC signaling.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6OTHER ) - mediated induction of BC6ENTG ( BC6OTHER ) , which is further activated via increased intracellular BC6ENTC ([ BC6OTHER ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6OTHER ) - mediated induction of BC6OTHER ( BC6ENTG ) , which is further activated via increased intracellular BC6ENTC ([ BC6OTHER ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6ENTG ( BC6OTHER ) - mediated induction of BC6OTHER ( BC6OTHER ) , which is further activated via increased intracellular BC6ENTC ([ BC6OTHER ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6ENTG ) - mediated induction of BC6OTHER ( BC6OTHER ) , which is further activated via increased intracellular BC6ENTC ([ BC6OTHER ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6OTHER ) - mediated induction of BC6ENTG ( BC6OTHER ) , which is further activated via increased intracellular BC6OTHER ([ BC6ENTC ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6OTHER ) - mediated induction of BC6OTHER ( BC6ENTG ) , which is further activated via increased intracellular BC6OTHER ([ BC6ENTC ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6ENTG ( BC6OTHER ) - mediated induction of BC6OTHER ( BC6OTHER ) , which is further activated via increased intracellular BC6OTHER ([ BC6ENTC ](i)) oscillation.	False
Osteoclast maturation and function primarily depend on BC6OTHER ( BC6ENTG ) - mediated induction of BC6OTHER ( BC6OTHER ) , which is further activated via increased intracellular BC6OTHER ([ BC6ENTC ](i)) oscillation.	False
Here , we identified BC6ENTG ( BC6OTHER ) as a regulator of BC6ENTC oscillation during osteoclastogenesis.	False
Here , we identified BC6OTHER ( BC6ENTG ) as a regulator of BC6ENTC oscillation during osteoclastogenesis.	False
Consequently , BC6OTHER deficiency significantly diminishes BC6OTHER - induced [ BC6ENTC ](i) oscillation , which results in reduced BC6OTHER and mitochondrial ROS , both of which contribute to achieving the BC6ENTG activity necessary for osteoclast formation.	False
Consequently , BC6ENTG deficiency significantly diminishes BC6OTHER - induced [ BC6ENTC ](i) oscillation , which results in reduced BC6OTHER and mitochondrial ROS , both of which contribute to achieving the BC6OTHER activity necessary for osteoclast formation.	False
Consequently , BC6OTHER deficiency significantly diminishes BC6ENTG - induced [ BC6ENTC ](i) oscillation , which results in reduced BC6OTHER and mitochondrial ROS , both of which contribute to achieving the BC6OTHER activity necessary for osteoclast formation.	False
Consequently , BC6OTHER deficiency significantly diminishes BC6OTHER - induced [ BC6ENTC ](i) oscillation , which results in reduced BC6ENTG and mitochondrial ROS , both of which contribute to achieving the BC6OTHER activity necessary for osteoclast formation.	False
Consequently , BC6OTHER deficiency significantly diminishes BC6OTHER - induced [ BC6OTHER ](i) oscillation , which results in reduced BC6ENTC / calmodulin - dependent protein kinases (CaMK) IV and mitochondrial ROS , both of which contribute to achieving the BC6ENTG activity necessary for osteoclast formation.	False
Consequently , BC6ENTG deficiency significantly diminishes BC6OTHER - induced [ BC6OTHER ](i) oscillation , which results in reduced BC6ENTC / calmodulin - dependent protein kinases (CaMK) IV and mitochondrial ROS , both of which contribute to achieving the BC6OTHER activity necessary for osteoclast formation.	False
Consequently , BC6OTHER deficiency significantly diminishes BC6ENTG - induced [ BC6OTHER ](i) oscillation , which results in reduced BC6ENTC / calmodulin - dependent protein kinases (CaMK) IV and mitochondrial ROS , both of which contribute to achieving the BC6OTHER activity necessary for osteoclast formation.	False
 BC6ENTG modulates BC6ENTC signaling during BC6OTHER - mediated osteoclast differentiation.	False
 BC6OTHER modulates BC6ENTC signaling during BC6ENTG - mediated osteoclast differentiation.	False
The BC6ENTG antagonist , BC6ENTC , is selective for BC6OTHER .	CPR:6
The BC6OTHER antagonist , BC6ENTC , is selective for BC6ENTG .	CPR:6
Intravenous treatment , during coronary artery occlusion , with the BC6ENTG analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6ENTG (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6ENTG ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6ENTG [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6ENTG ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6ENTG and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6ENTG levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6ENTG and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6ENTG were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6ENTG and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6ENTC (4) , BC6OTHER (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6ENTG , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6ENTG analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6ENTG (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6ENTG ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6ENTG [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6ENTG ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6ENTG and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6ENTG levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6ENTG and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6ENTG were associated with over - expression of the pro - survival proteins BC6OTHER and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6ENTG and BC6OTHER , and marked decrease of the myocardial infarct size.	False
Intravenous treatment , during coronary artery occlusion , with the BC6OTHER analogs [ BC6OTHER (4) , BC6ENTC (7)] BC6OTHER (CHEM - BC6OTHER ) and BC6OTHER [ BC6OTHER ] , induced a left ventricle up - regulation of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER - dependent) , and a reduction in BC6OTHER and BC6OTHER levels; these effects of CHEM - BC6OTHER and BC6OTHER were associated with over - expression of the pro - survival proteins BC6OTHER and BC6ENTG , and marked decrease of the myocardial infarct size.	False
Blockade of BC6ENTG and BC6OTHER pathways with BC6ENTC and BC6OTHER , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6OTHER .	CPR:4
Blockade of BC6OTHER and BC6ENTG pathways with BC6ENTC and BC6OTHER , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6OTHER .	False
Blockade of BC6OTHER and BC6OTHER pathways with BC6ENTC and BC6OTHER , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6ENTG .	False
Blockade of BC6ENTG and BC6OTHER pathways with BC6OTHER and BC6ENTC , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6OTHER .	False
Blockade of BC6OTHER and BC6ENTG pathways with BC6OTHER and BC6ENTC , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6OTHER .	CPR:4
Blockade of BC6OTHER and BC6OTHER pathways with BC6OTHER and BC6ENTC , respectively , abrogated the myocardial infarct size reduction by CHEM - BC6ENTG .	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6ENTG ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6ENTG ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6ENTG and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6ENTG ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6ENTG , as well as of the cardioprotective enzyme BC6OTHER ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6ENTG ( BC6OTHER ) , was performed in the left ventricle and spleen.	False
At the end of the 2 - h reperfusion , western blot analysis of the cardioprotective transcription factors BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , the inflammatory mediator BC6OTHER ( BC6OTHER ) , the pro - apoptotic factors BC6OTHER and c - jun BC6ENTC - terminal kinases ( BC6OTHER ) , the anti - apoptotic protein BC6OTHER , as well as of the cardioprotective enzyme BC6OTHER ( BC6ENTG ) , was performed in the left ventricle and spleen.	False
The most potent compound , BC6ENTC ( BC6OTHER , BC6OTHER ) , has a great affinity for the pancreatic BC6ENTG and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6ENTC ( BC6OTHER , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6ENTG antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	CPR:6
The most potent compound , BC6ENTC ( BC6OTHER , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6ENTG - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6ENTC ( BC6OTHER , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6ENTG secretion of isolated pancreatic acini.	False
Derivatives of BC6ENTC are a new class of non - peptide BC6OTHER ( BC6ENTG ) antagonists.	CPR:6
Derivatives of BC6ENTC are a new class of non - peptide BC6ENTG ( BC6OTHER ) antagonists.	CPR:6
The most potent compound , BC6OTHER ( BC6ENTC , BC6OTHER ) , has a great affinity for the pancreatic BC6ENTG and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6OTHER ( BC6ENTC , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6ENTG antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	CPR:6
The most potent compound , BC6OTHER ( BC6ENTC , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6ENTG - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6OTHER ( BC6ENTC , BC6OTHER ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6ENTG secretion of isolated pancreatic acini.	False
The most potent compound , BC6OTHER ( BC6OTHER , BC6ENTC ) , has a great affinity for the pancreatic BC6ENTG and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6OTHER ( BC6OTHER , BC6ENTC ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6ENTG antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6OTHER secretion of isolated pancreatic acini.	CPR:6
The most potent compound , BC6OTHER ( BC6OTHER , BC6ENTC ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6ENTG - induced BC6OTHER secretion of isolated pancreatic acini.	False
The most potent compound , BC6OTHER ( BC6OTHER , BC6ENTC ) , has a great affinity for the pancreatic BC6OTHER and is a competitive , specific and potent BC6OTHER antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the BC6OTHER - induced BC6ENTG secretion of isolated pancreatic acini.	False
 In vivo BC6ENTC antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. BC6ENTG or BC6OTHER ( BC6OTHER ).	CPR:6
 In vivo BC6OTHER antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. BC6ENTG or BC6ENTC ( BC6OTHER ).	False
 In vivo BC6OTHER antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. BC6ENTG or BC6OTHER ( BC6ENTC ).	False
It antagonizes the satiety effect of BC6ENTG in the rat and is protective against BC6ENTC - , BC6OTHER - and diet - induced pancreatitis.	False
It antagonizes the satiety effect of BC6ENTG in the rat and is protective against BC6OTHER - , BC6ENTC - and diet - induced pancreatitis.	False
BC6ENTC is therefore a useful pharmacological tool to study the functions of BC6ENTG .	False
For its pharmacological properties , its relatively low toxicity and because it is active also after oral administration , BC6ENTC is a candidate for diagnostic or therapeutic use in man when an involvement of BC6ENTG is suspected.	False
Pharmacological properties of BC6ENTC as a member of a new class of BC6ENTG antagonists.	CPR:6
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6ENTC ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
We concluded that BC6ENTG has no direct role in the regulation of the above two pathways of BC6ENTC synthesis; the breakdown of BC6OTHER to BC6OTHER by the BC6OTHER reaction is the primary and preferred fate of the organic acid in Arabidopsis.	False
We concluded that BC6OTHER has no direct role in the regulation of the above two pathways of BC6ENTC synthesis; the breakdown of BC6OTHER to BC6OTHER by the BC6ENTG reaction is the primary and preferred fate of the organic acid in Arabidopsis.	False
We concluded that BC6ENTG has no direct role in the regulation of the above two pathways of BC6OTHER synthesis; the breakdown of BC6ENTC to BC6OTHER by the BC6OTHER reaction is the primary and preferred fate of the organic acid in Arabidopsis.	False
We concluded that BC6OTHER has no direct role in the regulation of the above two pathways of BC6OTHER synthesis; the breakdown of BC6ENTC to BC6OTHER by the BC6ENTG reaction is the primary and preferred fate of the organic acid in Arabidopsis.	CPR:9
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6ENTC ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
We concluded that BC6ENTG has no direct role in the regulation of the above two pathways of BC6OTHER synthesis; the breakdown of BC6OTHER to BC6ENTC by the BC6OTHER reaction is the primary and preferred fate of the organic acid in Arabidopsis.	False
We concluded that BC6OTHER has no direct role in the regulation of the above two pathways of BC6OTHER synthesis; the breakdown of BC6OTHER to BC6ENTC by the BC6ENTG reaction is the primary and preferred fate of the organic acid in Arabidopsis.	CPR:9
The ratio between the BC6ENTG / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6ENTG and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6ENTG pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6ENTG / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6ENTG and C1 - BC6ENTC synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6ENTG pathways of BC6OTHER synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6ENTC synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6ENTC synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	CPR:9
The ratio between the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways of BC6ENTC synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways of BC6ENTC synthesis from BC6OTHER and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	CPR:9
The ratio between the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6ENTC and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	CPR:9
The ratio between the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6ENTC and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways of BC6OTHER synthesis from BC6ENTC and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways of BC6OTHER synthesis from BC6ENTC and BC6OTHER , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6ENTC , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6ENTC , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
The ratio between the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways of BC6OTHER synthesis from BC6OTHER and BC6ENTC , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	CPR:9
The ratio between the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways of BC6OTHER synthesis from BC6OTHER and BC6ENTC , respectively , in Arabidopsis shoots was 21 : 1; in roots , 9 : 1.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTC decarboxylase complex ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTC decarboxylase complex ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTC decarboxylase complex ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTC decarboxylase complex ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTC decarboxylase complex ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
In shoots , therefore , the pathway from BC6ENTC plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the BC6ENTG / BC6OTHER route than in shoots.	False
In shoots , therefore , the pathway from BC6ENTC plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the C1 - BC6OTHER synthase / BC6ENTG route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6ENTC synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the BC6ENTG / BC6OTHER route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6ENTC synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the C1 - BC6OTHER synthase / BC6ENTG route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6ENTC through both pathways together with a relatively higher contribution from the BC6ENTG / BC6OTHER route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6ENTC through both pathways together with a relatively higher contribution from the C1 - BC6OTHER synthase / BC6ENTG route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the BC6ENTC - BC6OTHER synthase / BC6ENTG route than in shoots.	False
In shoots , therefore , the pathway from BC6OTHER plays only a small role in BC6OTHER synthesis; in the case of roots , results indicated that the 9 : 1 ratio was as a result of greater fluxes of BC6OTHER through both pathways together with a relatively higher contribution from the C1 - BC6ENTC synthase / BC6ENTG route than in shoots.	False
We also examined the synthesis of BC6ENTC in a BC6ENTG - deficient mutant of Arabidopsis ( BC6OTHER ) where the BC6OTHER / BC6OTHER pathway was impaired.	False
We also examined the synthesis of BC6ENTC in a BC6OTHER - deficient mutant of Arabidopsis ( BC6OTHER ) where the BC6ENTG / BC6OTHER pathway was impaired.	False
We also examined the synthesis of BC6ENTC in a BC6OTHER - deficient mutant of Arabidopsis ( BC6OTHER ) where the BC6OTHER / BC6ENTG pathway was impaired.	False
We also examined the synthesis of BC6OTHER in a BC6ENTG - deficient mutant of Arabidopsis ( BC6ENTC ) where the BC6OTHER / BC6OTHER pathway was impaired.	False
We also examined the synthesis of BC6OTHER in a BC6OTHER - deficient mutant of Arabidopsis ( BC6ENTC ) where the BC6ENTG / BC6OTHER pathway was impaired.	False
We also examined the synthesis of BC6OTHER in a BC6OTHER - deficient mutant of Arabidopsis ( BC6ENTC ) where the BC6OTHER / BC6ENTG pathway was impaired.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6ENTC hydroxymethyltransferase ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6ENTC hydroxymethyltransferase ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6ENTC hydroxymethyltransferase ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC hydroxymethyltransferase ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC hydroxymethyltransferase ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	False
On the other hand , the accumulation of BC6ENTC through the BC6ENTG / BC6OTHER pathway in BC6OTHER plants was 2.5 - fold greater than that in WT plants.	False
On the other hand , the accumulation of BC6ENTC through the C1 - BC6OTHER synthase / BC6ENTG pathway in BC6OTHER plants was 2.5 - fold greater than that in WT plants.	CPR:9
On the other hand , the accumulation of BC6OTHER through the BC6ENTC - BC6OTHER synthase / BC6ENTG pathway in BC6OTHER plants was 2.5 - fold greater than that in WT plants.	False
On the other hand , the accumulation of BC6OTHER through the C1 - BC6ENTC synthase / BC6ENTG pathway in BC6OTHER plants was 2.5 - fold greater than that in WT plants.	False
On the other hand , the accumulation of BC6OTHER through the BC6ENTG / BC6OTHER pathway in BC6ENTC plants was 2.5 - fold greater than that in WT plants.	False
On the other hand , the accumulation of BC6OTHER through the C1 - BC6OTHER synthase / BC6ENTG pathway in BC6ENTC plants was 2.5 - fold greater than that in WT plants.	False
Our experiments confirmed that the BC6ENTG / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6ENTG and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6ENTG pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6ENTG / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6ENTG pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTG / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTC - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6ENTG pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6ENTG / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6ENTG and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6ENTG pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6ENTG / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6ENTG pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTG / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6ENTC synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6ENTG pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6ENTG / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6ENTG pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTC - BC6OTHER synthase / BC6ENTG pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6ENTG / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6ENTG pathway is impaired the alternative C1 - BC6ENTC synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6ENTC synthase / BC6ENTG pathway can partially compensate for deficiencies in the synthesis of BC6OTHER .	False
Our experiments confirmed that the BC6ENTG / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6ENTG and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6ENTG pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6ENTG / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6ENTG pathway is impaired the alternative C1 - BC6OTHER synthase / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative BC6ENTG / BC6OTHER pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
Our experiments confirmed that the BC6OTHER / BC6OTHER and C1 - BC6OTHER synthase / BC6OTHER pathways normally operate independently in Arabidopsis plants but that when the primary BC6OTHER / BC6OTHER pathway is impaired the alternative C1 - BC6OTHER synthase / BC6ENTG pathway can partially compensate for deficiencies in the synthesis of BC6ENTC .	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6ENTC ( BC6OTHER ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6ENTC ) as one - BC6OTHER ( BC6OTHER ) source.	CPR:9
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6ENTC ( BC6OTHER ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG , BC6OTHER ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
One major route involves the BC6OTHER ( BC6OTHER ) - dependent activities of the BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTG ) with BC6OTHER ( BC6OTHER ) as one - BC6OTHER ( BC6ENTC ) source.	False
An alternative BC6ENTC - dependent pathway involves the BC6ENTG / BC6OTHER activities with BC6OTHER as BC6OTHER source.	False
An alternative BC6ENTC - dependent pathway involves the C1 - BC6OTHER synthase / BC6ENTG activities with BC6OTHER as BC6OTHER source.	False
An alternative BC6OTHER - dependent pathway involves the BC6ENTC - BC6OTHER synthase / BC6ENTG activities with BC6OTHER as BC6OTHER source.	False
An alternative BC6OTHER - dependent pathway involves the C1 - BC6ENTC synthase / BC6ENTG activities with BC6OTHER as BC6OTHER source.	False
An alternative BC6OTHER - dependent pathway involves the BC6ENTG / BC6OTHER activities with BC6ENTC as BC6OTHER source.	CPR:9
An alternative BC6OTHER - dependent pathway involves the C1 - BC6OTHER synthase / BC6ENTG activities with BC6ENTC as BC6OTHER source.	CPR:9
An alternative BC6OTHER - dependent pathway involves the BC6ENTG / BC6OTHER activities with BC6OTHER as BC6ENTC source.	False
An alternative BC6OTHER - dependent pathway involves the C1 - BC6OTHER synthase / BC6ENTG activities with BC6OTHER as BC6ENTC source.	False
Firstly , transgenic plants overexpressing BC6ENTC dehydrogenase ( BC6ENTG , BC6OTHER ) were used to continue our previous studies on the function of BC6OTHER in BC6OTHER metabolism.	False
Firstly , transgenic plants overexpressing BC6ENTC dehydrogenase ( BC6OTHER , BC6ENTG ) were used to continue our previous studies on the function of BC6OTHER in BC6OTHER metabolism.	False
Firstly , transgenic plants overexpressing BC6ENTC dehydrogenase ( BC6OTHER , BC6OTHER ) were used to continue our previous studies on the function of BC6ENTG in BC6OTHER metabolism.	False
Firstly , transgenic plants overexpressing BC6ENTG ( BC6OTHER , BC6OTHER ) were used to continue our previous studies on the function of BC6OTHER in BC6ENTC metabolism.	CPR:9
Firstly , transgenic plants overexpressing BC6OTHER ( BC6ENTG , BC6OTHER ) were used to continue our previous studies on the function of BC6OTHER in BC6ENTC metabolism.	CPR:9
Firstly , transgenic plants overexpressing BC6OTHER ( BC6OTHER , BC6ENTG ) were used to continue our previous studies on the function of BC6OTHER in BC6ENTC metabolism.	CPR:9
Firstly , transgenic plants overexpressing BC6OTHER ( BC6OTHER , BC6OTHER ) were used to continue our previous studies on the function of BC6ENTG in BC6ENTC metabolism.	CPR:9
Excessive level of BC6OTHER is considered as a main cause of breast cancer , therefore , many studies have focused on BC6ENTC receptor ( BC6ENTG ) - positive breast cancer , even though BC6OTHER - negative cancer has a poor prognosis than BC6OTHER - positive breast cancer.	False
Excessive level of BC6OTHER is considered as a main cause of breast cancer , therefore , many studies have focused on BC6ENTC receptor ( BC6OTHER ) - positive breast cancer , even though BC6ENTG - negative cancer has a poor prognosis than BC6OTHER - positive breast cancer.	False
Excessive level of BC6OTHER is considered as a main cause of breast cancer , therefore , many studies have focused on BC6ENTC receptor ( BC6OTHER ) - positive breast cancer , even though BC6OTHER - negative cancer has a poor prognosis than BC6ENTG - positive breast cancer.	False
Excessive level of BC6ENTC is considered as a main cause of breast cancer , therefore , many studies have focused on BC6ENTG ( BC6OTHER ) - positive breast cancer , even though BC6OTHER - negative cancer has a poor prognosis than BC6OTHER - positive breast cancer.	False
Excessive level of BC6ENTC is considered as a main cause of breast cancer , therefore , many studies have focused on BC6OTHER ( BC6ENTG ) - positive breast cancer , even though BC6OTHER - negative cancer has a poor prognosis than BC6OTHER - positive breast cancer.	False
Excessive level of BC6ENTC is considered as a main cause of breast cancer , therefore , many studies have focused on BC6OTHER ( BC6OTHER ) - positive breast cancer , even though BC6ENTG - negative cancer has a poor prognosis than BC6OTHER - positive breast cancer.	False
Excessive level of BC6ENTC is considered as a main cause of breast cancer , therefore , many studies have focused on BC6OTHER ( BC6OTHER ) - positive breast cancer , even though BC6OTHER - negative cancer has a poor prognosis than BC6ENTG - positive breast cancer.	False
BC6ENTC ( BC6OTHER ) is a BC6ENTG ( BC6OTHER ) inhibitor chemotherapeutic agent.	CPR:4
BC6ENTC ( BC6OTHER ) is a BC6OTHER ( BC6ENTG ) inhibitor chemotherapeutic agent.	CPR:4
Apoptosis studies ( BC6ENTC staining and BC6ENTG activity) showed a marked increase in the presence of BC6OTHER and BC6OTHER compared to BC6OTHER alone.	False
BC6OTHER ( BC6ENTC ) is a BC6ENTG ( BC6OTHER ) inhibitor chemotherapeutic agent.	CPR:4
BC6OTHER ( BC6ENTC ) is a BC6OTHER ( BC6ENTG ) inhibitor chemotherapeutic agent.	CPR:4
Apoptosis studies ( BC6OTHER staining and BC6ENTG activity) showed a marked increase in the presence of BC6ENTC and BC6OTHER compared to BC6OTHER alone.	CPR:3
Apoptosis studies ( BC6OTHER staining and BC6ENTG activity) showed a marked increase in the presence of BC6OTHER and BC6ENTC compared to BC6OTHER alone.	CPR:3
Apoptosis studies ( BC6OTHER staining and BC6ENTG activity) showed a marked increase in the presence of BC6OTHER and BC6OTHER compared to BC6ENTC alone.	CPR:3
BC6ENTC induced the release of BC6ENTG , and addition of BC6OTHER reduced enhanced release and the spontaneous release of BC6OTHER from the cells.	False
BC6ENTC induced the release of BC6OTHER , and addition of BC6OTHER reduced enhanced release and the spontaneous release of BC6ENTG from the cells.	False
BC6OTHER induced the release of BC6ENTG , and addition of BC6ENTC reduced enhanced release and the spontaneous release of BC6OTHER from the cells.	False
BC6OTHER induced the release of BC6OTHER , and addition of BC6ENTC reduced enhanced release and the spontaneous release of BC6ENTG from the cells.	False
In conclusion , the results suggest that the enhancement in the reduction of BC6ENTG activity by the combined BC6ENTC / BC6OTHER treatments was probably due to the increase in the level of the DNA - enzyme cleavable complexes formed by both drugs.	CPR:4
In conclusion , the results suggest that the enhancement in the reduction of BC6ENTG activity by the combined BC6OTHER / BC6ENTC treatments was probably due to the increase in the level of the DNA - enzyme cleavable complexes formed by both drugs.	CPR:4
The aim of this study was to investigate the effects of BC6ENTC ( BC6OTHER ) and BC6OTHER on cellular BC6ENTG activity in drug - treated cells and evaluate the influence of BC6OTHER on the mode of action of BC6OTHER , on proliferation and apoptosis of HT - 29 cells.	False
The aim of this study was to investigate the effects of BC6OTHER ( BC6ENTC ) and BC6OTHER on cellular BC6ENTG activity in drug - treated cells and evaluate the influence of BC6OTHER on the mode of action of BC6OTHER , on proliferation and apoptosis of HT - 29 cells.	False
The aim of this study was to investigate the effects of BC6OTHER ( BC6OTHER ) and BC6ENTC on cellular BC6ENTG activity in drug - treated cells and evaluate the influence of BC6OTHER on the mode of action of BC6OTHER , on proliferation and apoptosis of HT - 29 cells.	False
The aim of this study was to investigate the effects of BC6OTHER ( BC6OTHER ) and BC6OTHER on cellular BC6ENTG activity in drug - treated cells and evaluate the influence of BC6ENTC on the mode of action of BC6OTHER , on proliferation and apoptosis of HT - 29 cells.	False
The aim of this study was to investigate the effects of BC6OTHER ( BC6OTHER ) and BC6OTHER on cellular BC6ENTG activity in drug - treated cells and evaluate the influence of BC6OTHER on the mode of action of BC6ENTC , on proliferation and apoptosis of HT - 29 cells.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6ENTC ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6OTHER staining and BC6ENTG activity) and BC6OTHER and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6ENTC ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6OTHER staining and BC6OTHER activity) and BC6ENTG and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6ENTC ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6OTHER staining and BC6OTHER activity) and BC6OTHER and BC6ENTG secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6ENTC - BC6OTHER staining and BC6ENTG activity) and BC6OTHER and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6ENTC - BC6OTHER staining and BC6OTHER activity) and BC6ENTG and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6ENTC - BC6OTHER staining and BC6OTHER activity) and BC6OTHER and BC6ENTG secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6ENTC staining and BC6ENTG activity) and BC6OTHER and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6ENTC staining and BC6OTHER activity) and BC6ENTG and BC6OTHER secretion were determined.	False
Decatenation assay , band depletion and Western blot analysis , cytotoxic assay ( BC6OTHER ) , flow cytometric studies (cell cycle and survivin expression) , apoptosis ( BC6OTHER - BC6ENTC staining and BC6OTHER activity) and BC6OTHER and BC6ENTG secretion were determined.	False
BC6ENTC or BC6OTHER slightly affected cellular BC6ENTG activity in nuclear extracts derived from drug - treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of BC6OTHER .	False
BC6ENTC or BC6OTHER slightly affected cellular BC6OTHER activity in nuclear extracts derived from drug - treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of BC6ENTG .	CPR:4
BC6OTHER or BC6ENTC slightly affected cellular BC6ENTG activity in nuclear extracts derived from drug - treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of BC6OTHER .	False
BC6OTHER or BC6ENTC slightly affected cellular BC6OTHER activity in nuclear extracts derived from drug - treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of BC6ENTG .	CPR:4
 BC6ENTC enhances BC6OTHER - induced cytotoxic , apoptotic and anti - BC6ENTG effects in a human colon carcinoma cell line.	False
 BC6OTHER enhances BC6ENTC - induced cytotoxic , apoptotic and anti - BC6ENTG effects in a human colon carcinoma cell line.	False
In consecutive sections , the small BC6ENTG - immunoreactive cell clusters also showed immunoreactivity to BC6ENTC hydroxylase , suggesting that these cells contain the enzymes for both BC6OTHER and BC6OTHER synthesis.	False
In consecutive sections , the small BC6OTHER - immunoreactive cell clusters also showed immunoreactivity to BC6ENTG , suggesting that these cells contain the enzymes for both BC6ENTC and BC6OTHER synthesis.	False
In consecutive sections , the small BC6ENTG - immunoreactive cell clusters also showed immunoreactivity to BC6OTHER , suggesting that these cells contain the enzymes for both BC6ENTC and BC6OTHER synthesis.	False
In consecutive sections , the small BC6OTHER - immunoreactive cell clusters also showed immunoreactivity to BC6ENTG , suggesting that these cells contain the enzymes for both BC6OTHER and BC6ENTC synthesis.	False
In consecutive sections , the small BC6ENTG - immunoreactive cell clusters also showed immunoreactivity to BC6OTHER , suggesting that these cells contain the enzymes for both BC6OTHER and BC6ENTC synthesis.	False
The location of BC6ENTC decarboxylase and BC6ENTG immunoreactivity in the superior cervical ganglion and in the coeliac - superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy , with specific antisera raised in rabbits against the corresponding enzymes.	False
In light microscopy , several BC6ENTC decarboxylase - or BC6ENTG - immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac - superior mesenteric ganglion complex.	False
In light microscopy , several BC6ENTG - or BC6ENTC - transaminase - immunoreactive principal nerve cells were detected in the superior cervical ganglion and coeliac - superior mesenteric ganglion complex.	False
The location of BC6ENTG and BC6ENTC ( BC6OTHER ) - transaminase immunoreactivity in the superior cervical ganglion and in the coeliac - superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy , with specific antisera raised in rabbits against the corresponding enzymes.	False
The location of BC6ENTG and CHEM ( BC6ENTC ) - transaminase immunoreactivity in the superior cervical ganglion and in the coeliac - superior mesenteric ganglion complex of the rat was studied by an indirect immunofluorescence method and by immunoelectron microscopy , with specific antisera raised in rabbits against the corresponding enzymes.	False
In addition , numerous small cells in both the superior cervical ganglion and coeliac - superior mesenteric ganglion complex showed intense immunoreactivity to BC6ENTC decarboxylase or BC6ENTG .	False
In addition , numerous small cells in both the superior cervical ganglion and coeliac - superior mesenteric ganglion complex showed intense immunoreactivity to BC6ENTG or BC6ENTC - transaminase.	False
In consecutive sections , the small BC6ENTC decarboxylase - immunoreactive cell clusters also showed immunoreactivity to BC6ENTG , suggesting that these cells contain the enzymes for both BC6OTHER and BC6OTHER synthesis.	False
Localization of BC6ENTC decarboxylase and BC6ENTG immunoreactivity in the sympathetic ganglia of the rat.	False
Localization of BC6ENTG and BC6ENTC transaminase immunoreactivity in the sympathetic ganglia of the rat.	False
RESULTS: In an animal study with BC6ENTC - labeled BC6ENTG in Han - Wistar rats , an increase of BC6OTHER - BC6OTHER is observed after dose administration.	False
RESULTS: In an animal study with BC6ENTC - labeled BC6OTHER in Han - Wistar rats , an increase of BC6OTHER - BC6ENTG is observed after dose administration.	False
RESULTS: In an animal study with BC6OTHER - labeled BC6ENTG in Han - Wistar rats , an increase of BC6ENTC - BC6OTHER is observed after dose administration.	False
RESULTS: In an animal study with BC6OTHER - labeled BC6OTHER in Han - Wistar rats , an increase of BC6ENTC - BC6ENTG is observed after dose administration.	False
 BC6ENTC microdosing for protein and peptide drug development: BC6ENTG as a case study.	False
As a result , we demonstrated that the BC6OTHER significantly protects these cells from BC6OTHER - induced reduction in BC6ENTC uptake , but neither BC6ENTG nor BC6OTHER does.	False
As a result , we demonstrated that the BC6OTHER significantly protects these cells from BC6OTHER - induced reduction in BC6ENTC uptake , but neither BC6OTHER nor BC6ENTG does.	False
As a result , we demonstrated that the BC6ENTG significantly protects these cells from BC6OTHER - induced reduction in BC6ENTC uptake , but neither BC6OTHER nor BC6OTHER does.	False
In accord with a rise in BC6ENTC uptake activity , the mRNA and protein levels of BC6ENTG were apparently up - regulated in the presence of BC6OTHER .	False
In accord with a rise in BC6ENTC uptake activity , the mRNA and protein levels of BC6OTHER were apparently up - regulated in the presence of BC6ENTG .	False
Furthermore , we found that the uptake of BC6ENTC is decreased by BC6ENTG , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6ENTC is decreased by BC6OTHER , and that BC6ENTG showed obvious protection against the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6ENTC is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6ENTG ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6ENTC is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6OTHER ( BC6ENTG ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6ENTG , and that BC6OTHER showed obvious protection against the BC6ENTC - dependent BC6OTHER ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6ENTG showed obvious protection against the BC6ENTC - dependent BC6OTHER ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6ENTC - dependent BC6ENTG ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6ENTC - dependent BC6OTHER ( BC6ENTG ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6ENTG , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6ENTG showed obvious protection against the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6ENTC ( BC6ENTG ) release from LLC - PK1 cells.	False
CHEM , a family of BC6ENTG related to the BC6OTHER , is a major pathway for proximal tubular BC6ENTC accumulation.	CPR:9
CHEM , a family of BC6OTHER related to the BC6ENTG , is a major pathway for proximal tubular BC6ENTC accumulation.	CPR:9
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6ENTG , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6ENTG showed obvious protection against the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) release from LLC - PK1 cells.	False
Furthermore , we found that the uptake of BC6OTHER is decreased by BC6OTHER , and that BC6OTHER showed obvious protection against the BC6OTHER - dependent BC6ENTG ( BC6ENTC ) release from LLC - PK1 cells.	False
Thus , these results indicate that BC6ENTG could be a valuable tool for the prevention of BC6ENTC nephrotoxicity.	False
We previously reported that BC6ENTC antibiotics reduce BC6ENTG - dependent BC6OTHER transport in pig proximal tubular epithelial LLC - PK1 cells in parallel with the order of their nephrotoxicity.	CPR:4
We previously reported that BC6OTHER antibiotics reduce BC6ENTG - dependent BC6ENTC transport in pig proximal tubular epithelial LLC - PK1 cells in parallel with the order of their nephrotoxicity.	False
In this study , using a model of BC6ENTC ( BC6OTHER ) - induced reduction in BC6ENTG activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6OTHER - induced reduction in BC6OTHER activity.	CPR:4
In this study , using a model of BC6ENTC ( BC6OTHER ) - induced reduction in BC6OTHER activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6OTHER - induced reduction in BC6ENTG activity.	False
In this study , using a model of BC6OTHER ( BC6ENTC ) - induced reduction in BC6ENTG activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6OTHER - induced reduction in BC6OTHER activity.	CPR:4
In this study , using a model of BC6OTHER ( BC6ENTC ) - induced reduction in BC6OTHER activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6OTHER - induced reduction in BC6ENTG activity.	False
In this study , using a model of BC6OTHER ( BC6OTHER ) - induced reduction in BC6ENTG activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6ENTC - induced reduction in BC6OTHER activity.	False
In this study , using a model of BC6OTHER ( BC6OTHER ) - induced reduction in BC6OTHER activity , we examined whether ligands for megalin protect LLC - PK1 cells from the BC6ENTC - induced reduction in BC6ENTG activity.	CPR:4
Then the cells were treated with various concentrations of BC6ENTG , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6ENTC , and the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6ENTG and BC6OTHER with or without 100 microg / ml of BC6ENTC , and the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6ENTG with or without 100 microg / ml of BC6ENTC , and the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6ENTC , and the BC6ENTG - dependent BC6OTHER ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6ENTC , and the BC6OTHER - dependent BC6OTHER ( BC6OTHER ) uptake and levels of BC6ENTG expression were determined.	False
Then the cells were treated with various concentrations of BC6ENTG , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6ENTG and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6ENTG with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6ENTG - dependent BC6ENTC ( BC6OTHER ) uptake and levels of BC6OTHER expression were determined.	CPR:9
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6ENTC ( BC6OTHER ) uptake and levels of BC6ENTG expression were determined.	False
Then the cells were treated with various concentrations of BC6ENTG , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6ENTG and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6ENTG with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) uptake and levels of BC6OTHER expression were determined.	False
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6ENTG - dependent BC6OTHER ( BC6ENTC ) uptake and levels of BC6OTHER expression were determined.	CPR:9
Then the cells were treated with various concentrations of BC6OTHER , BC6OTHER and BC6OTHER with or without 100 microg / ml of BC6OTHER , and the BC6OTHER - dependent BC6OTHER ( BC6ENTC ) uptake and levels of BC6ENTG expression were determined.	False
As a result , we demonstrated that the BC6OTHER significantly protects these cells from BC6ENTC - induced reduction in BC6OTHER uptake , but neither BC6ENTG nor BC6OTHER does.	False
As a result , we demonstrated that the BC6OTHER significantly protects these cells from BC6ENTC - induced reduction in BC6OTHER uptake , but neither BC6OTHER nor BC6ENTG does.	False
As a result , we demonstrated that the BC6ENTG significantly protects these cells from BC6ENTC - induced reduction in BC6OTHER uptake , but neither BC6OTHER nor BC6OTHER does.	False
 BC6ENTG ( BC6OTHER ) safeguards pig proximal tubular LLC - PK1 cells against reduction in BC6OTHER activity induced by BC6ENTC .	False
 BC6OTHER ( BC6ENTG ) safeguards pig proximal tubular LLC - PK1 cells against reduction in BC6OTHER activity induced by BC6ENTC .	False
 BC6OTHER ( BC6OTHER ) safeguards pig proximal tubular LLC - PK1 cells against reduction in BC6ENTG activity induced by BC6ENTC .	CPR:4
BC6ENTC , a small CHEM molecule approved for the treatment of Gaucher disease , reversibly inhibits BC6ENTG , which catalyses the first committed step in CHEM synthesis.	CPR:4
BC6ENTC oxidoreductase 2 ( BC6ENTG ) purified from human red blood cells was recently shown to be a potential target of the BC6OTHER antimalarial compounds [Graves et al. , (2002) Mol.	False
BC6ENTG ( BC6OTHER ) purified from human red blood cells was recently shown to be a potential target of the BC6ENTC antimalarial compounds [Graves et al. , (2002) Mol.	False
BC6OTHER ( BC6ENTG ) purified from human red blood cells was recently shown to be a potential target of the BC6ENTC antimalarial compounds [Graves et al. , (2002) Mol.	False
Our studies shed light on the possible in vivo potency of the BC6ENTC and provide a foundation for future studies aimed at creating more potent BC6ENTG inhibitors and at understanding the physiological significance of BC6OTHER .	CPR:4
Our studies shed light on the possible in vivo potency of the BC6ENTC and provide a foundation for future studies aimed at creating more potent BC6OTHER inhibitors and at understanding the physiological significance of BC6ENTG .	False
BC6ENTG catalyzes the two - electron reduction of BC6ENTC via the oxidation of BC6OTHER or BC6OTHER .	CPR:9
BC6ENTG catalyzes the two - electron reduction of BC6OTHER via the oxidation of BC6ENTC or BC6OTHER .	CPR:9
BC6ENTG catalyzes the two - electron reduction of BC6OTHER via the oxidation of BC6OTHER or BC6ENTC .	CPR:9
To investigate the mechanism and consequences of inhibition of BC6ENTG by the BC6ENTC further , we have used steady - state and transient - state kinetics to define the mechanism of BC6OTHER .	CPR:4
To investigate the mechanism and consequences of inhibition of BC6OTHER by the BC6ENTC further , we have used steady - state and transient - state kinetics to define the mechanism of BC6ENTG .	CPR:4
Kinetic mechanism of BC6ENTG and its inhibition by the antimalarial BC6ENTC .	CPR:4
The functional protein contains 1160 BC6OTHER with a large central BC6OTHER , three consensus sites for glycosaminoglycan attachment , two epidermal growth factor - like repeats , a putative BC6ENTG , and a potential transmembrane domain near the BC6ENTC - terminal.	False
The functional protein contains 1160 BC6OTHER with a large central BC6ENTG , three consensus sites for glycosaminoglycan attachment , two epidermal growth factor - like repeats , a putative BC6OTHER , and a potential transmembrane domain near the BC6ENTC - terminal.	False
Removal of BC6ENTC - and BC6OTHER - linked CHEM reduces the M(r) to approximately 160 , 000 , suggesting that approximately 60% of the mass of BC6ENTG is BC6OTHER .	False
Removal of BC6OTHER - and BC6ENTC - linked CHEM reduces the M(r) to approximately 160 , 000 , suggesting that approximately 60% of the mass of BC6ENTG is BC6OTHER .	False
Removal of BC6OTHER - and BC6OTHER - linked CHEM reduces the M(r) to approximately 160 , 000 , suggesting that approximately 60% of the mass of BC6ENTG is BC6ENTC .	False
BC6ENTG was cloned from a human BC6ENTC cDNA library and the gene localized to chromosome 3q11.2.	False
The functional protein contains 1160 BC6ENTC with a large central BC6OTHER , three consensus sites for glycosaminoglycan attachment , two epidermal growth factor - like repeats , a putative BC6ENTG , and a potential transmembrane domain near the BC6OTHER - terminal.	False
The functional protein contains 1160 BC6ENTC with a large central BC6ENTG , three consensus sites for glycosaminoglycan attachment , two epidermal growth factor - like repeats , a putative BC6OTHER , and a potential transmembrane domain near the BC6OTHER - terminal.	False
The newly synthesized compounds were tested for their in vitro BC6ENTG inhibition and in vivo carrageenan induced hind paw edema in rats and BC6ENTC induced vascular permeability in mice.	False
The BC6ENTC and BC6OTHER - BC6OTHER are major factors that are prominently involved in interaction with BC6ENTG active site.	False
The BC6OTHER and BC6ENTC - BC6OTHER are major factors that are prominently involved in interaction with BC6ENTG active site.	False
The BC6OTHER and BC6OTHER - BC6ENTC are major factors that are prominently involved in interaction with BC6ENTG active site.	False
The expression of dominant cardiac BC6ENTC channel subunit , BC6ENTG , was consistently detected throughout the culture periods.	False
Antiarrhythmic effects of BC6ENTC , a novel BC6ENTG agonist in cultured neonatal rat ventricular myocytes.	CPR:5
The early BC6ENTG response to oral BC6ENTC was reduced in mice on HFD + GRA (1 , 890 + / - 160 vs 3 , 040 + / - 420 pmol / l; p = 0.012) , but BC6OTHER excursions were improved.	False
The early BC6ENTG response to oral BC6OTHER was reduced in mice on HFD + GRA (1 , 890 + / - 160 vs 3 , 040 + / - 420 pmol / l; p = 0.012) , but BC6ENTC excursions were improved.	False
Intravenous BC6ENTC significantly increased the acute BC6ENTG response (129 + / - 12 vs 36 + / - 6 ng / l in controls; p < 0.01) , notably without affecting plasma BC6OTHER .	CPR:3
Intravenous BC6OTHER significantly increased the acute BC6ENTG response (129 + / - 12 vs 36 + / - 6 ng / l in controls; p < 0.01) , notably without affecting plasma BC6ENTC .	False
Isolated islets displayed improved BC6ENTC - stimulated BC6ENTG secretion after GRA treatment (0.061 + / - 0.007 vs 0.030 + / - 0.004 pmol islet( - 1) h( - 1) at 16.7 mmol / l BC6OTHER ; p < 0.001) , without affecting islet BC6OTHER oxidation.	CPR:3
Isolated islets displayed improved BC6OTHER - stimulated BC6ENTG secretion after GRA treatment (0.061 + / - 0.007 vs 0.030 + / - 0.004 pmol islet( - 1) h( - 1) at 16.7 mmol / l BC6ENTC ; p < 0.001) , without affecting islet BC6OTHER oxidation.	False
Isolated islets displayed improved BC6OTHER - stimulated BC6ENTG secretion after GRA treatment (0.061 + / - 0.007 vs 0.030 + / - 0.004 pmol islet( - 1) h( - 1) at 16.7 mmol / l BC6OTHER ; p < 0.001) , without affecting islet BC6ENTC oxidation.	False
CONCLUSIONS / INTERPRETATION: Chronic BC6ENTG antagonism in HFD - fed mice improves islet sensitivity to BC6ENTC and increases BC6OTHER secretion , suggesting improvement of key defects underlying impaired BC6OTHER tolerance and type 2 diabetes.	False
CONCLUSIONS / INTERPRETATION: Chronic BC6OTHER antagonism in HFD - fed mice improves islet sensitivity to BC6ENTC and increases BC6ENTG secretion , suggesting improvement of key defects underlying impaired BC6OTHER tolerance and type 2 diabetes.	False
CONCLUSIONS / INTERPRETATION: Chronic BC6ENTG antagonism in HFD - fed mice improves islet sensitivity to BC6OTHER and increases BC6OTHER secretion , suggesting improvement of key defects underlying impaired BC6ENTC tolerance and type 2 diabetes.	False
CONCLUSIONS / INTERPRETATION: Chronic BC6OTHER antagonism in HFD - fed mice improves islet sensitivity to BC6OTHER and increases BC6ENTG secretion , suggesting improvement of key defects underlying impaired BC6ENTC tolerance and type 2 diabetes.	False
BC6ENTG secretion was studied after oral and intravenous administration of BC6ENTC and BC6OTHER secretion after intravenous BC6OTHER .	False
BC6OTHER secretion was studied after oral and intravenous administration of BC6ENTC and BC6ENTG secretion after intravenous BC6OTHER .	False
BC6ENTG secretion was studied after oral and intravenous administration of BC6OTHER and BC6OTHER secretion after intravenous BC6ENTC .	False
BC6OTHER secretion was studied after oral and intravenous administration of BC6OTHER and BC6ENTG secretion after intravenous BC6ENTC .	False
AIMS / HYPOTHESIS: Increased BC6OTHER secretion predicts deterioration of BC6ENTC tolerance , and high BC6ENTG levels contribute to hyperglycaemia in type 2 diabetes.	False
AIMS / HYPOTHESIS: Increased BC6ENTG secretion predicts deterioration of BC6ENTC tolerance , and high BC6OTHER levels contribute to hyperglycaemia in type 2 diabetes.	False
Islet morphology was examined and BC6ENTG secretion and BC6ENTC oxidation were measured in isolated islets.	False
The acute BC6ENTG response to intravenous BC6ENTC was augmented (1 , 300 + / - 110 vs 790 + / - 64 pmol / l; p < 0.001).	False
Affinities for the major nonadrenergic BC6ENTC binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ).	False
Affinities for the major nonadrenergic BC6OTHER binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ).	False
Affinities for the major nonadrenergic BC6OTHER binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER ).	False
Affinities for the major nonadrenergic BC6OTHER binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER ).	False
Affinities for the major nonadrenergic BC6OTHER binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER ).	False
Affinities for the major nonadrenergic BC6OTHER binding site were highly comparable to BC6ENTG sites in the brain stem (rank order: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC ).	False
Finally , a third nonadrenergic internal membrane site , labeled by BC6ENTC , was consistent with a BC6ENTG site (rank order: BC6OTHER > IDX >> BC6OTHER > BC6OTHER > BC6OTHER ).	False
Finally , a third nonadrenergic internal membrane site , labeled by BC6OTHER , was consistent with a BC6ENTG site (rank order: BC6ENTC > IDX >> BC6OTHER > BC6OTHER > BC6OTHER ).	False
Finally , a third nonadrenergic internal membrane site , labeled by BC6OTHER , was consistent with a BC6ENTG site (rank order: BC6OTHER > IDX >> BC6ENTC > BC6OTHER > BC6OTHER ).	False
Finally , a third nonadrenergic internal membrane site , labeled by BC6OTHER , was consistent with a BC6ENTG site (rank order: BC6OTHER > IDX >> BC6OTHER > BC6ENTC > BC6OTHER ).	False
Finally , a third nonadrenergic internal membrane site , labeled by BC6OTHER , was consistent with a BC6ENTG site (rank order: BC6OTHER > IDX >> BC6OTHER > BC6OTHER > BC6ENTC ).	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTC receptors ( BC6ENTG and subtype - I2 BC6OTHER receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTC receptors (subtype - I1 BC6OTHER receptor and BC6ENTG ) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTC receptors (subtype - I1 BC6OTHER receptor and subtype - I2 BC6OTHER receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6ENTG .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTG (subtype - I1 BC6ENTC receptor and subtype - I2 BC6OTHER receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER (subtype - I1 BC6ENTC receptor and BC6ENTG ) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER (subtype - I1 BC6ENTC receptor and subtype - I2 BC6OTHER receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6ENTG .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTG (subtype - I1 BC6OTHER receptor and subtype - I2 BC6ENTC receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER ( BC6ENTG and subtype - I2 BC6ENTC receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER (subtype - I1 BC6OTHER receptor and subtype - I2 BC6ENTC receptor) , plus a novel BC6OTHER - sensitive site , as well as an BC6ENTG .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6ENTG (subtype - I1 BC6OTHER receptor and subtype - I2 BC6OTHER receptor) , plus a novel BC6ENTC - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER ( BC6ENTG and subtype - I2 BC6OTHER receptor) , plus a novel BC6ENTC - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER (subtype - I1 BC6OTHER receptor and BC6ENTG ) , plus a novel BC6ENTC - sensitive site , as well as an BC6OTHER .	False
Thus , based on differential subcellular distributions and affinity constants , human platelets appear to possess BC6OTHER (subtype - I1 BC6OTHER receptor and subtype - I2 BC6OTHER receptor) , plus a novel BC6ENTC - sensitive site , as well as an BC6ENTG .	False
These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to BC6ENTC and endogenous BC6OTHER - displacing substance(s) , and may serve as markers of BC6ENTG in humans.	CPR:3
These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to BC6OTHER and endogenous BC6ENTC - displacing substance(s) , and may serve as markers of BC6ENTG in humans.	False
These nonadrenergic sites were radiolabeled even in the presence of a 10 microM BC6ENTC mask of BC6ENTG .	False
Human platelets are shown to possess at least two high - affinity , BC6ENTC - preferring binding sites that are pharmacologically distinct from BC6ENTG .	False
Introduction: BC6ENTG ( BC6OTHER ) is a crucial enzyme of the BC6ENTC (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of BC6OTHER , the BC6OTHER .	CPR:9
Introduction: BC6OTHER ( BC6OTHER ) is a crucial enzyme of the BC6ENTC (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of BC6ENTG , the BC6OTHER .	False
Introduction: BC6OTHER ( BC6OTHER ) is a crucial enzyme of the BC6ENTC (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of BC6OTHER , the BC6ENTG .	False
Introduction: BC6OTHER ( BC6ENTG ) is a crucial enzyme of the BC6ENTC (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of BC6OTHER , the BC6OTHER .	CPR:9
BC6ENTC is a novel , potent , and irreversible BC6ENTG ( BC6OTHER ) inhibitor which has been approved for treatment of PD.	CPR:4
BC6ENTC is a novel , potent , and irreversible BC6OTHER ( BC6ENTG ) inhibitor which has been approved for treatment of PD.	CPR:4
BC6OTHER is a novel , potent , and irreversible BC6ENTC oxidase type B ( BC6ENTG ) inhibitor which has been approved for treatment of PD.	False
BC6ENTC inhibits BC6ENTG more potently than CHEM and has the advantage of once - daily dosing.	CPR:4
Synthesis and structure - activity relationship of BC6OTHER derivatives as potent and selective BC6ENTC : BC6OTHER acyltransferase 2 ( BC6ENTG ) inhibitors: Part 2.	False
Synthesis and structure - activity relationship of BC6OTHER derivatives as potent and selective CHEM: BC6ENTC acyltransferase 2 ( BC6ENTG ) inhibitors: Part 2.	False
Synthesis and structure - activity relationship of BC6ENTC derivatives as potent and selective BC6ENTG ( BC6OTHER ) inhibitors: Part 2.	CPR:4
Synthesis and structure - activity relationship of BC6ENTC derivatives as potent and selective CHEM: BC6OTHER acyltransferase 2 ( BC6ENTG ) inhibitors: Part 2.	CPR:4
The inhibition of BC6ENTG synthesis and BC6OTHER down - regulation by BC6ENTC and BC6OTHER indicates that these BC6OTHER metabolites possess antiprogestational properties.	CPR:4
The inhibition of BC6OTHER synthesis and BC6ENTG down - regulation by BC6ENTC and BC6OTHER indicates that these BC6OTHER metabolites possess antiprogestational properties.	CPR:3
The inhibition of BC6ENTG synthesis and BC6OTHER down - regulation by BC6OTHER and BC6ENTC indicates that these BC6OTHER metabolites possess antiprogestational properties.	CPR:4
The inhibition of BC6OTHER synthesis and BC6ENTG down - regulation by BC6OTHER and BC6ENTC indicates that these BC6OTHER metabolites possess antiprogestational properties.	CPR:4
The inhibition of BC6ENTG synthesis and BC6OTHER down - regulation by BC6OTHER and BC6OTHER indicates that these BC6ENTC metabolites possess antiprogestational properties.	CPR:4
The inhibition of BC6OTHER synthesis and BC6ENTG down - regulation by BC6OTHER and BC6OTHER indicates that these BC6ENTC metabolites possess antiprogestational properties.	CPR:4
The effects of these metabolites on the expression of BC6ENTG ( BC6OTHER ) and BC6ENTC receptor ( BC6OTHER ) genes , both regulated by BC6OTHER , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6OTHER ( BC6ENTG ) and BC6ENTC receptor ( BC6OTHER ) genes , both regulated by BC6OTHER , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6OTHER ( BC6OTHER ) and BC6ENTC receptor ( BC6ENTG ) genes , both regulated by BC6OTHER , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) genes , both regulated by BC6ENTC , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes , both regulated by BC6ENTC , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes , both regulated by BC6ENTC , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
The effects of these metabolites on the expression of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes , both regulated by BC6ENTC , were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.	False
As determined by Western and Northern blot analyses , BC6ENTC inhibited the P4 - induced BC6ENTG gene expression in a dose - dependent manner.	CPR:4
The estrogenic agent BC6ENTC and BC6OTHER at a dose of 1.0 mg also inhibited the BC6ENTG gene expression induced by P4.	CPR:4
The estrogenic agent BC6OTHER and BC6ENTC at a dose of 1.0 mg also inhibited the BC6ENTG gene expression induced by P4.	CPR:4
Both BC6ENTC and BC6OTHER blocked the BC6ENTG down - regulation induced by P4 as assessed by Western and Northern blot methods.	CPR:3
Both BC6OTHER and BC6ENTC blocked the BC6ENTG down - regulation induced by P4 as assessed by Western and Northern blot methods.	CPR:3
 BC6ENTC metabolites modulate the BC6ENTG and BC6OTHER gene expression in prepubertal rabbits.	False
 BC6ENTC metabolites modulate the BC6OTHER and BC6ENTG gene expression in prepubertal rabbits.	False
 BC6OTHER metabolites modulate the BC6ENTG and BC6ENTC receptor gene expression in prepubertal rabbits.	False
OBJECTIVES: The alkaloid BC6ENTC ( BC6OTHER ) , which exhibits a combined BC6ENTG and direct parasympathomimetic mechanism of action , is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.	CPR:4
OBJECTIVES: The CHEM BC6OTHER ( BC6ENTC ) , which exhibits a combined BC6ENTG and direct parasympathomimetic mechanism of action , is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.	CPR:4
 RESULTS: Following administration of the highest of the BC6ENTC doses used (2.5; 5; 10 mg / kg i.m.) , BC6ENTG activity decreased mainly in the frontal cortex , hippocampus and hypophysis.	CPR:4
In the interaction of BC6ENTC and BC6ENTG , BC6OTHER inhibition was stronger but without any statistical significance.	False
In the interaction of BC6ENTC and BC6OTHER , BC6ENTG inhibition was stronger but without any statistical significance.	CPR:4
In the interaction of BC6OTHER and BC6ENTC , BC6ENTG inhibition was stronger but without any statistical significance.	False
Effect of BC6OTHER on BC6ENTG and BC6OTHER activities in the presence of BC6ENTC in rat selected brain and peripheral tissues.	False
Effect of BC6OTHER on BC6OTHER and BC6ENTG activities in the presence of BC6ENTC in rat selected brain and peripheral tissues.	False
Effect of BC6ENTC on BC6ENTG and BC6OTHER activities in the presence of BC6OTHER in rat selected brain and peripheral tissues.	False
Effect of BC6ENTC on BC6OTHER and BC6ENTG activities in the presence of BC6OTHER in rat selected brain and peripheral tissues.	False
BC6ENTG ( BC6OTHER ; BC6OTHER ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC hormone synthesis in mammalian tissues.	CPR:9
BC6OTHER ( BC6ENTG ; BC6OTHER ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC hormone synthesis in mammalian tissues.	CPR:9
BC6OTHER ( BC6OTHER ; BC6ENTG ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC hormone synthesis in mammalian tissues.	CPR:9
BC6ENTG ( BC6OTHER ; BC6OTHER ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC synthesis in mammalian tissues.	CPR:9
BC6OTHER ( BC6ENTG ; BC6OTHER ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC synthesis in mammalian tissues.	CPR:9
BC6OTHER ( BC6OTHER ; BC6ENTG ) is an BC6OTHER - BC6OTHER protein that is involved in various metabolic processes , including BC6ENTC synthesis in mammalian tissues.	CPR:9
BC6ENTG ( BC6OTHER ; BC6OTHER ) is an BC6ENTC - BC6OTHER protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
BC6OTHER ( BC6ENTG ; BC6OTHER ) is an BC6ENTC - BC6OTHER protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
BC6OTHER ( BC6OTHER ; BC6ENTG ) is an BC6ENTC - BC6OTHER protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
BC6ENTG ( BC6OTHER ; BC6OTHER ) is an BC6OTHER - BC6ENTC protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
BC6OTHER ( BC6ENTG ; BC6OTHER ) is an BC6OTHER - BC6ENTC protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
BC6OTHER ( BC6OTHER ; BC6ENTG ) is an BC6OTHER - BC6ENTC protein that is involved in various metabolic processes , including BC6OTHER synthesis in mammalian tissues.	False
Luciferase reporter assays showed that transcription of BC6ENTG was synergistically activated by the BC6OTHER family and BC6ENTC treatment through two BC6OTHER binding sites and a BC6OTHER - like sequence in a human ovarian granulosa cell line , KGN.	CPR:3
Luciferase reporter assays showed that transcription of BC6OTHER was synergistically activated by the BC6ENTG family and BC6ENTC treatment through two BC6OTHER binding sites and a BC6OTHER - like sequence in a human ovarian granulosa cell line , KGN.	False
Luciferase reporter assays showed that transcription of BC6OTHER was synergistically activated by the BC6OTHER family and BC6ENTC treatment through two BC6ENTG binding sites and a BC6OTHER - like sequence in a human ovarian granulosa cell line , KGN.	False
Luciferase reporter assays showed that transcription of BC6OTHER was synergistically activated by the BC6OTHER family and BC6ENTC treatment through two BC6OTHER binding sites and a BC6ENTG - like sequence in a human ovarian granulosa cell line , KGN.	False
Knockdown of BC6ENTG attenuated BC6ENTC production in KGN cells.	False
These results indicate transcription of BC6ENTG is regulated by the BC6OTHER family and BC6ENTC signaling , and participates in BC6OTHER hormone production in ovarian granulosa cells.	CPR:3
These results indicate transcription of BC6OTHER is regulated by the BC6ENTG family and BC6ENTC signaling , and participates in BC6OTHER hormone production in ovarian granulosa cells.	False
These results indicate transcription of BC6ENTG is regulated by the BC6OTHER family and BC6OTHER signaling , and participates in BC6ENTC hormone production in ovarian granulosa cells.	CPR:9
These results indicate transcription of BC6OTHER is regulated by the BC6ENTG family and BC6OTHER signaling , and participates in BC6ENTC hormone production in ovarian granulosa cells.	False
BC6ENTG are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6ENTC and BC6OTHER as well as BC6OTHER BC6OTHER and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6ENTC and BC6OTHER as well as BC6ENTG BC6OTHER and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6ENTC and BC6OTHER as well as BC6OTHER BC6ENTG and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6ENTC and BC6OTHER as well as BC6OTHER BC6OTHER and BC6ENTG .	False
BC6ENTG are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6ENTC as well as BC6OTHER BC6OTHER and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6ENTC as well as BC6ENTG BC6OTHER and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6ENTC as well as BC6OTHER BC6ENTG and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6ENTC as well as BC6OTHER BC6OTHER and BC6ENTG .	False
BC6ENTG are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6OTHER as well as BC6OTHER BC6ENTC and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6OTHER as well as BC6ENTG BC6ENTC and BC6OTHER .	False
BC6OTHER are the membrane proteins that mediate the pain - relieving effect of CHEM drugs , such as BC6OTHER and BC6OTHER as well as BC6OTHER BC6ENTC and BC6ENTG .	False
BC6ENTC are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6ENTG ( BC6OTHER ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6OTHER and lipid metabolism.	False
BC6ENTC are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6OTHER ( BC6ENTG ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6OTHER and lipid metabolism.	False
BC6ENTC are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6OTHER ( BC6OTHER ) and stimulating the expression of BC6ENTG - responsive genes involved in BC6OTHER and lipid metabolism.	CPR:3
BC6ENTC are a new class of anti - diabetic agents which increase BC6ENTG sensitivity by binding to the BC6OTHER ( BC6OTHER ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6OTHER and lipid metabolism.	CPR:3
The effect of BC6OTHER on BC6OTHER was BC6ENTG - independent and kinetic studies revealed that BC6ENTC was a competitive inhibitor of BC6OTHER .	False
The effect of BC6OTHER on BC6OTHER was BC6OTHER - independent and kinetic studies revealed that BC6ENTC was a competitive inhibitor of BC6ENTG .	CPR:4
The effect of BC6OTHER on BC6ENTG was BC6OTHER - independent and kinetic studies revealed that BC6ENTC was a competitive inhibitor of BC6OTHER .	False
The difference in structure of BC6ENTC did not account for its inhibitory effect on BC6ENTG because BC6OTHER did not inhibit BC6OTHER uptake by HASMCs.	CPR:4
The difference in structure of BC6OTHER did not account for its inhibitory effect on BC6ENTG because BC6ENTC did not inhibit BC6OTHER uptake by HASMCs.	False
The difference in structure of BC6OTHER did not account for its inhibitory effect on BC6ENTG because BC6OTHER did not inhibit BC6ENTC uptake by HASMCs.	False
Using the BC6ENTG deficient PK15NTD cells stably expressing BC6OTHER and BC6OTHER , it was found that BC6ENTC inhibited BC6OTHER but had no effect on BC6OTHER .	False
Using the BC6OTHER deficient PK15NTD cells stably expressing BC6ENTG and BC6OTHER , it was found that BC6ENTC inhibited BC6OTHER but had no effect on BC6OTHER .	False
Using the BC6OTHER deficient PK15NTD cells stably expressing BC6OTHER and BC6ENTG , it was found that BC6ENTC inhibited BC6OTHER but had no effect on BC6OTHER .	False
Using the BC6OTHER deficient PK15NTD cells stably expressing BC6OTHER and BC6OTHER , it was found that BC6ENTC inhibited BC6ENTG but had no effect on BC6OTHER .	CPR:4
Using the BC6OTHER deficient PK15NTD cells stably expressing BC6OTHER and BC6OTHER , it was found that BC6ENTC inhibited BC6OTHER but had no effect on BC6ENTG .	False
From these results , it is suggested that BC6ENTC may enhance the vasodilatory effect of BC6OTHER by inhibiting BC6ENTG .	CPR:4
From these results , it is suggested that BC6OTHER may enhance the vasodilatory effect of BC6ENTC by inhibiting BC6ENTG .	False
Pharmacologically , BC6ENTC is a novel inhibitor of BC6ENTG .	CPR:4
BC6OTHER are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6ENTG ( BC6OTHER ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6ENTC and lipid metabolism.	False
BC6OTHER are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6OTHER ( BC6ENTG ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6ENTC and lipid metabolism.	False
BC6OTHER are a new class of anti - diabetic agents which increase BC6OTHER sensitivity by binding to the BC6OTHER ( BC6OTHER ) and stimulating the expression of BC6ENTG - responsive genes involved in BC6ENTC and lipid metabolism.	False
BC6OTHER are a new class of anti - diabetic agents which increase BC6ENTG sensitivity by binding to the BC6OTHER ( BC6OTHER ) and stimulating the expression of BC6OTHER - responsive genes involved in BC6ENTC and lipid metabolism.	False
The present study studied the effects of three BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , on BC6ENTG in the human aortic smooth muscle cells (HASMCs).	False
The present study studied the effects of three BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , on BC6ENTG in the human aortic smooth muscle cells (HASMCs).	False
The present study studied the effects of three BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , on BC6ENTG in the human aortic smooth muscle cells (HASMCs).	False
The present study studied the effects of three BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , on BC6ENTG in the human aortic smooth muscle cells (HASMCs).	False
Although incubating HASMCs for 48h with BC6ENTC had no effect on BC6ENTG mRNA and protein levels , BC6OTHER acutely inhibited BC6OTHER uptake and BC6OTHER binding of HASMCs with IC50 values of 2.35+ / - 0.35 and 3.99+ / - 0.57microM , respectively.	False
Although incubating HASMCs for 48h with BC6OTHER had no effect on BC6ENTG mRNA and protein levels , BC6ENTC acutely inhibited BC6OTHER uptake and BC6OTHER binding of HASMCs with IC50 values of 2.35+ / - 0.35 and 3.99+ / - 0.57microM , respectively.	False
Although incubating HASMCs for 48h with BC6OTHER had no effect on BC6ENTG mRNA and protein levels , BC6OTHER acutely inhibited BC6ENTC uptake and BC6OTHER binding of HASMCs with IC50 values of 2.35+ / - 0.35 and 3.99+ / - 0.57microM , respectively.	False
Although incubating HASMCs for 48h with BC6OTHER had no effect on BC6ENTG mRNA and protein levels , BC6OTHER acutely inhibited BC6OTHER uptake and BC6ENTC binding of HASMCs with IC50 values of 2.35+ / - 0.35 and 3.99+ / - 0.57microM , respectively.	False
The effect of BC6ENTC on BC6OTHER was BC6ENTG - independent and kinetic studies revealed that BC6OTHER was a competitive inhibitor of BC6OTHER .	False
The effect of BC6ENTC on BC6OTHER was BC6OTHER - independent and kinetic studies revealed that BC6OTHER was a competitive inhibitor of BC6ENTG .	False
The effect of BC6ENTC on BC6ENTG was BC6OTHER - independent and kinetic studies revealed that BC6OTHER was a competitive inhibitor of BC6OTHER .	False
Effect of BC6ENTC on BC6ENTG in human aortic smooth muscle cells.	False
Using BC6ENTC imaging on BC6ENTG receptors heterologously expressed in the human embryonic kidney (HEK) 293 cells and on dissociated primary sensory neurons , we find that in both systems , AS activate BC6OTHER receptors , and , moreover , they sensitize these channels to acid and heat.	False
Using BC6ENTC imaging on BC6OTHER receptors heterologously expressed in the human embryonic kidney (HEK) 293 cells and on dissociated primary sensory neurons , we find that in both systems , AS activate BC6ENTG receptors , and , moreover , they sensitize these channels to acid and heat.	False
We also found that BC6ENTG receptors are activated by BC6ENTC , BC6OTHER , and BC6OTHER , three salts known to produce a metallic taste sensation.	CPR:3
We also found that BC6ENTG receptors are activated by BC6OTHER , BC6ENTC , and BC6OTHER , three salts known to produce a metallic taste sensation.	CPR:3
We also found that BC6ENTG receptors are activated by BC6OTHER , BC6OTHER , and BC6ENTC , three salts known to produce a metallic taste sensation.	CPR:3
Recently , it has been shown that the activation of particular BC6ENTG bitter taste receptors is partially involved with the bitter aftertaste sensation of BC6ENTC and BC6OTHER .	CPR:3
Recently , it has been shown that the activation of particular BC6ENTG bitter taste receptors is partially involved with the bitter aftertaste sensation of BC6OTHER and BC6ENTC .	CPR:3
BC6ENTG activation induced by BC6OTHER - independent signaling components , BC6OTHER and BC6OTHER , was also downregulated by BC6ENTC .	CPR:4
BC6OTHER activation induced by BC6ENTG - independent signaling components , BC6OTHER and BC6OTHER , was also downregulated by BC6ENTC .	False
BC6OTHER activation induced by BC6OTHER - independent signaling components , BC6ENTG and BC6OTHER , was also downregulated by BC6ENTC .	CPR:4
BC6OTHER activation induced by BC6OTHER - independent signaling components , BC6OTHER and BC6ENTG , was also downregulated by BC6ENTC .	CPR:4
Our results first demonstrate that BC6ENTC suppresses the multiple steps in BC6ENTG signaling , especially the homodimerization of BC6OTHER .	CPR:4
Our results first demonstrate that BC6ENTC suppresses the multiple steps in BC6OTHER signaling , especially the homodimerization of BC6ENTG .	CPR:4
The results suggest that the suppression of BC6ENTG activity by BC6ENTC may be the molecular mechanism through which BC6OTHER exerts anti - rheumatic activity.	CPR:4
The results suggest that the suppression of BC6ENTG activity by BC6OTHER may be the molecular mechanism through which BC6ENTC exerts anti - rheumatic activity.	CPR:4
Our results demonstrated that BC6ENTC suppressed BC6ENTG - mediated activation of transcription factors , BC6OTHER and BC6OTHER , and expression of BC6OTHER , a pro - inflammatory enzyme.	CPR:4
Our results demonstrated that BC6ENTC suppressed BC6OTHER - mediated activation of transcription factors , BC6ENTG and BC6OTHER , and expression of BC6OTHER , a pro - inflammatory enzyme.	CPR:4
Our results demonstrated that BC6ENTC suppressed BC6OTHER - mediated activation of transcription factors , BC6OTHER and BC6ENTG , and expression of BC6OTHER , a pro - inflammatory enzyme.	CPR:4
Our results demonstrated that BC6ENTC suppressed BC6OTHER - mediated activation of transcription factors , BC6OTHER and BC6OTHER , and expression of BC6ENTG , a pro - inflammatory enzyme.	CPR:4
This suppression was well correlated with the inhibitory effect of BC6ENTC on the homodimerization of BC6ENTG induced by an agonist.	CPR:4
Furthermore , BC6ENTC inhibited BC6ENTG activation induced by BC6OTHER - dependent downstream signaling components of BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Furthermore , BC6ENTC inhibited BC6OTHER activation induced by BC6ENTG - dependent downstream signaling components of BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Furthermore , BC6ENTC inhibited BC6OTHER activation induced by BC6OTHER - dependent downstream signaling components of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
Furthermore , BC6ENTC inhibited BC6OTHER activation induced by BC6OTHER - dependent downstream signaling components of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
Furthermore , BC6ENTC inhibited BC6OTHER activation induced by BC6OTHER - dependent downstream signaling components of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
Furthermore , BC6ENTC inhibited BC6OTHER activation induced by BC6OTHER - dependent downstream signaling components of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
 BC6ENTC , as an anti - rheumatic gold compound , suppresses LPS - induced homodimerization of BC6ENTG .	CPR:4
Increased phosphorylation of BC6ENTG and BC6OTHER in response to BC6OTHER was abrogated to varying degrees by BC6ENTC .	CPR:4
Increased phosphorylation of BC6OTHER and BC6ENTG in response to BC6OTHER was abrogated to varying degrees by BC6ENTC .	CPR:4
Increased phosphorylation of BC6OTHER and BC6OTHER in response to BC6ENTG was abrogated to varying degrees by BC6ENTC .	False
Thus , BC6ENTG represents a target for therapeutic intervention , and one that is sensitive to BC6ENTC therapy.	False
The expression of the BC6ENTC terminally truncated BC6OTHER receptor ( BC6OTHER ) in breast cancer correlates with metastatic disease progression compared with the expression of full - length BC6ENTG .	False
The expression of the BC6ENTC terminally truncated BC6ENTG receptor ( BC6OTHER ) in breast cancer correlates with metastatic disease progression compared with the expression of full - length BC6OTHER .	False
The expression of the BC6ENTC terminally truncated BC6OTHER receptor ( BC6ENTG ) in breast cancer correlates with metastatic disease progression compared with the expression of full - length BC6OTHER .	False
BC6ENTC , a reversible small molecule inhibitor of BC6ENTG and BC6OTHER BC6OTHER , inhibits baseline BC6OTHER phosphorylation in BT474 cells and tumor xenografts.	CPR:4
BC6ENTC , a reversible small molecule inhibitor of BC6OTHER and BC6ENTG BC6OTHER , inhibits baseline BC6OTHER phosphorylation in BT474 cells and tumor xenografts.	CPR:4
BC6ENTC , a reversible small molecule inhibitor of BC6OTHER and BC6OTHER BC6ENTG , inhibits baseline BC6OTHER phosphorylation in BT474 cells and tumor xenografts.	CPR:4
BC6ENTC , a reversible small molecule inhibitor of BC6OTHER and BC6OTHER BC6OTHER , inhibits baseline BC6ENTG phosphorylation in BT474 cells and tumor xenografts.	CPR:4
BC6OTHER , a reversible small molecule inhibitor of BC6ENTG and BC6OTHER BC6ENTC kinases , inhibits baseline BC6OTHER phosphorylation in BT474 cells and tumor xenografts.	False
BC6OTHER , a reversible small molecule inhibitor of BC6OTHER and BC6ENTG BC6ENTC kinases , inhibits baseline BC6OTHER phosphorylation in BT474 cells and tumor xenografts.	False
BC6OTHER , a reversible small molecule inhibitor of BC6OTHER and BC6OTHER BC6ENTC kinases , inhibits baseline BC6ENTG phosphorylation in BT474 cells and tumor xenografts.	False
Inhibition of BC6ENTG , BC6OTHER , and BC6OTHER phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6OTHER , CHEM - BC6OTHER , and BC6OTHER steady - state protein levels.	CPR:4
Inhibition of BC6OTHER , BC6ENTG , and BC6OTHER phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6OTHER , CHEM - BC6OTHER , and BC6OTHER steady - state protein levels.	CPR:4
Inhibition of BC6OTHER , BC6OTHER , and BC6ENTG phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6OTHER , CHEM - BC6OTHER , and BC6OTHER steady - state protein levels.	CPR:4
Inhibition of BC6OTHER , BC6OTHER , and BC6OTHER phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6ENTG , CHEM - BC6OTHER , and BC6OTHER steady - state protein levels.	CPR:4
Inhibition of BC6OTHER , BC6OTHER , and BC6OTHER phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6OTHER , CHEM - BC6ENTG , and BC6OTHER steady - state protein levels.	CPR:4
Inhibition of BC6OTHER , BC6OTHER , and BC6OTHER phosphorylation by BC6ENTC resulted in the inhibition of downstream CHEM - BC6OTHER , CHEM - BC6OTHER , and BC6ENTG steady - state protein levels.	CPR:4
Truncated BC6ENTG receptor ( BC6OTHER ) is regulated by BC6OTHER through heterodimer formation with BC6OTHER yet remains sensitive to the dual BC6OTHER / BC6OTHER kinase inhibitor BC6ENTC .	False
Truncated BC6OTHER receptor ( BC6OTHER ) is regulated by BC6OTHER through heterodimer formation with BC6OTHER yet remains sensitive to the dual BC6ENTG / BC6OTHER kinase inhibitor BC6ENTC .	False
Truncated BC6OTHER receptor ( BC6OTHER ) is regulated by BC6OTHER through heterodimer formation with BC6OTHER yet remains sensitive to the dual BC6OTHER / BC6ENTG kinase inhibitor BC6ENTC .	CPR:4
Truncated BC6OTHER receptor ( BC6ENTG ) is regulated by BC6OTHER through heterodimer formation with BC6OTHER yet remains sensitive to the dual BC6OTHER / BC6OTHER kinase inhibitor BC6ENTC .	False
Truncated BC6OTHER receptor ( BC6OTHER ) is regulated by BC6ENTG through heterodimer formation with BC6OTHER yet remains sensitive to the dual BC6OTHER / BC6OTHER kinase inhibitor BC6ENTC .	False
Truncated BC6OTHER receptor ( BC6OTHER ) is regulated by BC6OTHER through heterodimer formation with BC6ENTG yet remains sensitive to the dual BC6OTHER / BC6OTHER kinase inhibitor BC6ENTC .	False
Taken together , these results suggest that BC6ENTC partially inhibits CHEM - MB - 231 cell growth by inducing autophagy through the BC6ENTG - BC6OTHER pathway and may be a promising anti - tumor agent.	False
Taken together , these results suggest that BC6ENTC partially inhibits CHEM - MB - 231 cell growth by inducing autophagy through the BC6OTHER - BC6ENTG pathway and may be a promising anti - tumor agent.	False
We report that BC6ENTC triggered the formation of BC6ENTG ( BC6OTHER ) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in CHEM - MB - 231 cells.	False
We report that BC6ENTC triggered the formation of BC6OTHER ( BC6ENTG ) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in CHEM - MB - 231 cells.	False
The results showed that BC6ENTC promotes the expression of BC6ENTG and BC6OTHER .	CPR:3
The results showed that BC6ENTC promotes the expression of BC6OTHER and BC6ENTG .	CPR:3
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6ENTG ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6ENTG ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6ENTG involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6ENTG ( BC6OTHER ) signaling pathway.	False
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6ENTG ) signaling pathway.	False
BC6ENTC also suppressed the activation of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6ENTC also suppressed the activation of mammalian target of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	CPR:4
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6ENTG ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6ENTG ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6ENTG involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6ENTG ( BC6OTHER ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6ENTG ) signaling pathway.	False
BC6OTHER also suppressed the activation of mammalian target of BC6ENTC ( BC6ENTG ) and BC6OTHER ( BC6OTHER by regulating the expression of the BC6OTHER ( BC6OTHER ) and BC6OTHER involved BC6OTHER ( BC6OTHER ) signaling pathway.	False
 BC6ENTC induces autophagy in CHEM - MB - 231 cells by regulating BC6ENTG - BC6OTHER pathway.	False
 BC6ENTC induces autophagy in CHEM - MB - 231 cells by regulating BC6OTHER - BC6ENTG pathway.	False
In this review , the various elements that participate in non - canonical BC6ENTG signaling , including BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTC , are discussed , focusing on their effect on ASM phenotype and function.	False
In this review , the various elements that participate in non - canonical BC6OTHER signaling , including BC6ENTG , BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTC , are discussed , focusing on their effect on ASM phenotype and function.	False
In this review , the various elements that participate in non - canonical BC6OTHER signaling , including BC6OTHER , BC6ENTG , BC6OTHER / BC6OTHER , and BC6ENTC , are discussed , focusing on their effect on ASM phenotype and function.	False
In this review , the various elements that participate in non - canonical BC6OTHER signaling , including BC6OTHER , BC6OTHER , BC6ENTG / BC6OTHER , and BC6ENTC , are discussed , focusing on their effect on ASM phenotype and function.	False
In this review , the various elements that participate in non - canonical BC6OTHER signaling , including BC6OTHER , BC6OTHER , BC6OTHER / BC6ENTG , and BC6ENTC , are discussed , focusing on their effect on ASM phenotype and function.	False
Chelation of BC6ENTC ions by BC6OTHER or blockade of BC6ENTG activation by BC6OTHER also prevented the BC6OTHER effects.	False
Chelation of BC6OTHER ions by BC6ENTC or blockade of BC6ENTG activation by BC6OTHER also prevented the BC6OTHER effects.	False
Chelation of BC6OTHER ions by BC6OTHER or blockade of BC6ENTG activation by BC6ENTC also prevented the BC6OTHER effects.	CPR:4
Chelation of BC6OTHER ions by BC6OTHER or blockade of BC6ENTG activation by BC6OTHER also prevented the BC6ENTC effects.	False
Thus prolonged activation of BC6ENTC receptors in hippocampal neurons reduced BC6ENTG expression through BC6OTHER entry and at least in part by BC6OTHER activation.	False
Thus prolonged activation of BC6ENTC receptors in hippocampal neurons reduced BC6OTHER expression through BC6OTHER entry and at least in part by BC6ENTG activation.	False
Thus prolonged activation of BC6ENTG in hippocampal neurons reduced BC6OTHER expression through BC6ENTC entry and at least in part by BC6OTHER activation.	False
Thus prolonged activation of BC6OTHER in hippocampal neurons reduced BC6ENTG expression through BC6ENTC entry and at least in part by BC6OTHER activation.	CPR:4
Thus prolonged activation of BC6OTHER in hippocampal neurons reduced BC6OTHER expression through BC6ENTC entry and at least in part by BC6ENTG activation.	False
Neurosteroids are endogenous allosteric modulators of BC6ENTC type A receptors ( BC6OTHER ) , and enhance BC6ENTG - mediated inhibition.	False
Neurosteroids are endogenous allosteric modulators of BC6ENTC type A receptors ( BC6ENTG ) , and enhance BC6OTHER - mediated inhibition.	False
 BC6ENTC Receptor Activation Down - Regulates Expression of BC6ENTG in Cultured Hippocampal Neurons.	False
 BC6ENTG Activation Down - Regulates Expression of δ Subunit - Containing BC6ENTC - A Receptors in Cultured Hippocampal Neurons.	False
BC6ENTC is an BC6OTHER antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by BC6ENTG .	CPR:9
BC6ENTC is an BC6ENTG antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by BC6OTHER .	CPR:6
In summary , BC6OTHER had no clinically significant effect on the pharmacokinetics or safety profile of BC6ENTC ; therefore , no changes in BC6OTHER dose should be necessary when the drug is administered concomitantly with known BC6ENTG inhibitors.	False
In summary , BC6OTHER had no clinically significant effect on the pharmacokinetics or safety profile of BC6OTHER ; therefore , no changes in BC6ENTC dose should be necessary when the drug is administered concomitantly with known BC6ENTG inhibitors.	False
The potential for BC6ENTC , the archetypal strong inhibitor of BC6ENTG , to alter the pharmacokinetic profile of BC6OTHER and its oxidative metabolite , BC6OTHER , was assessed in an open - label , nonrandomized , 2 - period , single - sequence study in 16 healthy men.	CPR:4
The potential for BC6OTHER , the archetypal strong inhibitor of BC6ENTG , to alter the pharmacokinetic profile of BC6ENTC and its oxidative metabolite , BC6OTHER , was assessed in an open - label , nonrandomized , 2 - period , single - sequence study in 16 healthy men.	False
The potential for BC6OTHER , the archetypal strong inhibitor of BC6ENTG , to alter the pharmacokinetic profile of BC6OTHER and its oxidative metabolite , BC6ENTC , was assessed in an open - label , nonrandomized , 2 - period , single - sequence study in 16 healthy men.	False
In summary , BC6ENTC had no clinically significant effect on the pharmacokinetics or safety profile of BC6OTHER ; therefore , no changes in BC6OTHER dose should be necessary when the drug is administered concomitantly with known BC6ENTG inhibitors.	CPR:4
Hence , it is proposed that a conformational change is induced when BC6ENTG interacts with BC6OTHER or BC6OTHER , resulting in an increase of BC6OTHER affinity for BC6ENTC and the activation of BC6OTHER .	False
Hence , it is proposed that a conformational change is induced when BC6OTHER interacts with BC6ENTG or BC6OTHER , resulting in an increase of BC6OTHER affinity for BC6ENTC and the activation of BC6OTHER .	False
Hence , it is proposed that a conformational change is induced when BC6OTHER interacts with BC6OTHER or BC6ENTG , resulting in an increase of BC6OTHER affinity for BC6ENTC and the activation of BC6OTHER .	False
Hence , it is proposed that a conformational change is induced when BC6OTHER interacts with BC6OTHER or BC6OTHER , resulting in an increase of BC6ENTG affinity for BC6ENTC and the activation of BC6OTHER .	False
Hence , it is proposed that a conformational change is induced when BC6OTHER interacts with BC6OTHER or BC6OTHER , resulting in an increase of BC6OTHER affinity for BC6ENTC and the activation of BC6ENTG .	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6ENTG ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6ENTG ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6ENTG - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6ENTG ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6ENTG , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6ENTG ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6ENTG ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTG ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6ENTG ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) isoforms , 65 - kDa BC6ENTC decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6ENTG ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , BC6ENTG ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6ENTG ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6ENTG - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6ENTG ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6ENTG , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6ENTG ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6ENTG ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6ENTG ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTC BC6OTHER - transferase ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6ENTG ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , BC6ENTG ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6ENTG ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6ENTG - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6ENTG ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6ENTG , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6ENTG ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6ENTG ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6ENTG ) - human BC6OTHER decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6ENTC - transferase ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
The activation appears to be due to an increase of BC6ENTG affinity for its cofactor , BC6ENTC ( BC6OTHER ).	False
The activation appears to be due to an increase of BC6ENTG affinity for its cofactor , BC6OTHER ( BC6ENTC ).	False
Firstly , the V(max) of BC6ENTG was increased when BC6OTHER was present whereas the affinity for the substrate , BC6ENTC , was not affected.	CPR:9
Firstly , the V(max) of BC6OTHER was increased when BC6ENTG was present whereas the affinity for the substrate , BC6ENTC , was not affected.	False
Secondly , the affinity of BC6ENTG for BC6ENTC was increased in the presence of BC6OTHER .	False
Secondly , the affinity of BC6OTHER for BC6ENTC was increased in the presence of BC6ENTG .	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6ENTG ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , BC6ENTG ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6ENTG ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6ENTG - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6ENTG ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6ENTG , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6ENTG ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6ENTG ) to an extent of 60%.	False
In this work , we report that the recombinant BC6ENTG ( BC6OTHER ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
In this work , we report that the recombinant CHEM BC6OTHER - transferase ( BC6ENTG ) - human BC6ENTC decarboxylase ( BC6OTHER ) isoforms , 65 - kDa BC6OTHER decarboxylase ( BC6OTHER ) ( BC6OTHER - BC6OTHER ) fusion protein or free truncated BC6OTHER , were activated by BC6OTHER ( BC6OTHER ) to an extent of 60%.	False
Effect of BC6ENTG on recombinant human brain BC6ENTC decarboxylase.	False
BC6ENTC ( BC6OTHER ) is a BC6OTHER that selectively induces cell death in human cancer cells through BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) is a BC6OTHER that selectively induces cell death in human cancer cells through CHEM: BC6OTHER oxidoreductase - 1 ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) is a BC6OTHER that selectively induces cell death in human cancer cells through BC6ENTC : BC6OTHER oxidoreductase - 1 ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) is a BC6OTHER that selectively induces cell death in human cancer cells through CHEM: BC6ENTC oxidoreductase - 1 ( BC6ENTG ).	False
BC6OTHER ( BC6ENTC ) is a BC6OTHER that selectively induces cell death in human cancer cells through BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) is a BC6OTHER that selectively induces cell death in human cancer cells through CHEM: BC6OTHER oxidoreductase - 1 ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) is a BC6ENTC that selectively induces cell death in human cancer cells through BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) is a BC6ENTC that selectively induces cell death in human cancer cells through CHEM: BC6OTHER oxidoreductase - 1 ( BC6ENTG ).	False
The beta - adrenergic / BC6ENTG receptor antagonist BC6ENTC and the selective BC6OTHER antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6OTHER .	CPR:6
The beta - adrenergic / BC6OTHER receptor antagonist BC6ENTC and the selective BC6ENTG antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6OTHER .	False
The beta - adrenergic / BC6ENTG receptor antagonist BC6OTHER and the selective BC6OTHER antagonist BC6ENTC produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6OTHER .	False
The beta - adrenergic / BC6OTHER receptor antagonist BC6OTHER and the selective BC6ENTG antagonist BC6ENTC produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6OTHER .	False
The beta - adrenergic / BC6ENTG receptor antagonist BC6OTHER and the selective BC6OTHER antagonist BC6OTHER produced no significant augmentation of BC6ENTC - induced changes in either BC6OTHER or BC6OTHER .	False
The beta - adrenergic / BC6OTHER receptor antagonist BC6OTHER and the selective BC6ENTG antagonist BC6OTHER produced no significant augmentation of BC6ENTC - induced changes in either BC6OTHER or BC6OTHER .	False
The beta - adrenergic / BC6ENTG receptor antagonist BC6OTHER and the selective BC6OTHER antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6ENTC or BC6OTHER .	False
The beta - adrenergic / BC6OTHER receptor antagonist BC6OTHER and the selective BC6ENTG antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6ENTC or BC6OTHER .	False
The beta - adrenergic / BC6ENTG receptor antagonist BC6OTHER and the selective BC6OTHER antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6ENTC .	False
The beta - adrenergic / BC6OTHER receptor antagonist BC6OTHER and the selective BC6ENTG antagonist BC6OTHER produced no significant augmentation of BC6OTHER - induced changes in either BC6OTHER or BC6ENTC .	False
Using the BC6ENTG antagonists , BC6ENTC and BC6OTHER , we also demonstrate the role of the BC6OTHER in the augmentation of BC6OTHER - induced changes.	False
Using the BC6OTHER antagonists , BC6ENTC and BC6OTHER , we also demonstrate the role of the BC6ENTG in the augmentation of BC6OTHER - induced changes.	False
Using the BC6ENTG antagonists , BC6OTHER and BC6ENTC , we also demonstrate the role of the BC6OTHER in the augmentation of BC6OTHER - induced changes.	False
Using the BC6OTHER antagonists , BC6OTHER and BC6ENTC , we also demonstrate the role of the BC6ENTG in the augmentation of BC6OTHER - induced changes.	False
Using the BC6ENTG antagonists , BC6OTHER and BC6OTHER , we also demonstrate the role of the BC6OTHER in the augmentation of BC6ENTC - induced changes.	False
Using the BC6OTHER antagonists , BC6OTHER and BC6OTHER , we also demonstrate the role of the BC6ENTG in the augmentation of BC6ENTC - induced changes.	False
Preclinically , BC6ENTC has been shown to potently inhibit dorsal raphe neuronal (DRN) firing through a BC6ENTG mediated mechanism , in a similar manner to SSRIs.	False
Combination treatment with the selective BC6ENTG antagonist BC6ENTC produced a dose - dependent augmentation of BC6OTHER - induced (3 - 30 mg / kg s.c) extracellular BC6OTHER concentrations , but had no further effect on BC6OTHER above that produced by BC6OTHER alone.	CPR:6
Combination treatment with the selective BC6ENTG antagonist BC6OTHER produced a dose - dependent augmentation of BC6ENTC - induced (3 - 30 mg / kg s.c) extracellular BC6OTHER concentrations , but had no further effect on BC6OTHER above that produced by BC6OTHER alone.	False
Combination treatment with the selective BC6ENTG antagonist BC6OTHER produced a dose - dependent augmentation of BC6OTHER - induced (3 - 30 mg / kg s.c) extracellular BC6ENTC concentrations , but had no further effect on BC6OTHER above that produced by BC6OTHER alone.	False
Combination treatment with the selective BC6ENTG antagonist BC6OTHER produced a dose - dependent augmentation of BC6OTHER - induced (3 - 30 mg / kg s.c) extracellular BC6OTHER concentrations , but had no further effect on BC6ENTC above that produced by BC6OTHER alone.	False
Combination treatment with the selective BC6ENTG antagonist BC6OTHER produced a dose - dependent augmentation of BC6OTHER - induced (3 - 30 mg / kg s.c) extracellular BC6OTHER concentrations , but had no further effect on BC6OTHER above that produced by BC6ENTC alone.	False
Effects of BC6ENTC on extracellular concentrations of BC6OTHER and BC6OTHER in the rat frontal cortex: augmentation via BC6ENTG receptor antagonism.	False
Effects of BC6OTHER on extracellular concentrations of BC6ENTC and BC6OTHER in the rat frontal cortex: augmentation via BC6ENTG receptor antagonism.	False
Effects of BC6OTHER on extracellular concentrations of BC6OTHER and BC6ENTC in the rat frontal cortex: augmentation via BC6ENTG receptor antagonism.	False
RESULTS: The BC6ENTG mutation caused a significant decrease in the BC6ENTC channel expression.	False
In addition to this pronounced loss of function , BC6ENTG also showed a 10 - fold increase in the persistent late BC6ENTC current.	CPR:3
CONCLUSIONS: These findings suggest that BC6ENTG - BC6OTHER channel dysfunction may contribute to the basis of lethal arrhythmias , displays an overlapping electrophysiological phenotype , and represents the first BC6ENTC channelopathy rescued by drug.	False
CONCLUSIONS: These findings suggest that BC6OTHER - BC6ENTG channel dysfunction may contribute to the basis of lethal arrhythmias , displays an overlapping electrophysiological phenotype , and represents the first BC6ENTC channelopathy rescued by drug.	False
OBJECTIVE: Mutations in the cardiac BC6ENTC channel gene , BC6ENTG , cause congenital long QT syndrome (LQT3) , Brugada syndrome , idiopathic ventricular fibrillation , and conduction disease by distinct cellular and clinical electrophysiological phenotypes.	False
A novel BC6OTHER arrhythmia mutation , BC6ENTG , with expression defect rescued by BC6ENTC .	False
A novel BC6ENTG arrhythmia mutation , BC6OTHER , with expression defect rescued by BC6ENTC .	False
Interestingly , all exchanges identified involved BC6ENTC which are conserved in the BC6ENTG of yeasts and mammals.	False
Two mutations that were generated by PCR mutagenesis of the BC6ENTG gene and that conferred BC6ENTC resistance mapped in the same regions of the BC6OTHER protein , with one resulting in an BC6OTHER exchange and the other resulting in an BC6OTHER exchange.	False
Two mutations that were generated by PCR mutagenesis of the BC6OTHER gene and that conferred BC6ENTC resistance mapped in the same regions of the BC6ENTG protein , with one resulting in an BC6OTHER exchange and the other resulting in an BC6OTHER exchange.	False
Two mutations that were generated by PCR mutagenesis of the BC6OTHER gene and that conferred BC6ENTC resistance mapped in the same regions of the BC6OTHER protein , with one resulting in an BC6ENTG exchange and the other resulting in an BC6OTHER exchange.	False
Two mutations that were generated by PCR mutagenesis of the BC6OTHER gene and that conferred BC6ENTC resistance mapped in the same regions of the BC6OTHER protein , with one resulting in an BC6OTHER exchange and the other resulting in an BC6ENTG exchange.	False
The results strongly indicate that these regions are responsible for the interaction of BC6ENTG with BC6ENTC .	False
Molecular analysis of these mutants revealed single base pair exchanges in the BC6ENTG gene coding for BC6ENTC epoxidase , the target of BC6OTHER .	False
Molecular analysis of these mutants revealed single base pair exchanges in the BC6ENTG gene coding for BC6OTHER , the target of BC6ENTC .	False
Molecular analysis of these mutants revealed single base pair exchanges in the BC6OTHER gene coding for BC6ENTG , the target of BC6ENTC .	False
BC6ENTC resistance was transmitted with the mutated alleles in gene replacement experiments , proving that single BC6OTHER substitutions in the BC6ENTG protein were sufficient to confer the resistance phenotype.	False
BC6OTHER resistance was transmitted with the mutated alleles in gene replacement experiments , proving that single BC6ENTC substitutions in the BC6ENTG protein were sufficient to confer the resistance phenotype.	False
The BC6ENTC changes caused by the point mutations were clustered in two regions of the BC6ENTG protein.	False
Seven mutants carried the BC6ENTC substitutions BC6OTHER (one mutant) , BC6OTHER (one mutant) , and BC6OTHER (five mutants) in the BC6OTHER - terminal part of the protein; and three mutants carried an BC6ENTG exchange in the central part of the protein.	False
Seven mutants carried the BC6ENTC substitutions BC6ENTG (one mutant) , BC6OTHER (one mutant) , and BC6OTHER (five mutants) in the BC6OTHER - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
Seven mutants carried the BC6ENTC substitutions BC6OTHER (one mutant) , BC6ENTG (one mutant) , and BC6OTHER (five mutants) in the BC6OTHER - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
Seven mutants carried the BC6ENTC substitutions BC6OTHER (one mutant) , BC6OTHER (one mutant) , and BC6ENTG (five mutants) in the BC6OTHER - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
Seven mutants carried the BC6OTHER substitutions BC6OTHER (one mutant) , BC6OTHER (one mutant) , and BC6OTHER (five mutants) in the BC6ENTC - terminal part of the protein; and three mutants carried an BC6ENTG exchange in the central part of the protein.	False
Seven mutants carried the BC6OTHER substitutions BC6ENTG (one mutant) , BC6OTHER (one mutant) , and BC6OTHER (five mutants) in the BC6ENTC - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
Seven mutants carried the BC6OTHER substitutions BC6OTHER (one mutant) , BC6ENTG (one mutant) , and BC6OTHER (five mutants) in the BC6ENTC - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
Seven mutants carried the BC6OTHER substitutions BC6OTHER (one mutant) , BC6OTHER (one mutant) , and BC6ENTG (five mutants) in the BC6ENTC - terminal part of the protein; and three mutants carried an BC6OTHER exchange in the central part of the protein.	False
In the livers of db / db mice , CHEM promoted BC6ENTC - activated protein kinase activity and restored metabolic process and BC6ENTG signaling pathways.	False
The sustained model raised the average plasma BC6ENTC concentration from 70 mg / dL to 180 mg / dL and led to decreased gene expression of BC6ENTG BC6OTHER .	False
The sustained model raised the average plasma BC6ENTC concentration from 70 mg / dL to 180 mg / dL and led to decreased gene expression of BC6OTHER BC6ENTG .	False
The sustained model raised the average plasma BC6OTHER concentration from 70 mg / dL to 180 mg / dL and led to decreased gene expression of BC6ENTC transporter BC6ENTG .	False
BC6ENTC has higher affinity to BC6ENTG ( BC6OTHER ) than BC6OTHER and lower administered dosage for the treatment of erectile dysfunction.	False
BC6ENTC has higher affinity to BC6OTHER ( BC6ENTG ) than BC6OTHER and lower administered dosage for the treatment of erectile dysfunction.	False
Reported here is a crystal structure of the fully active and nonmutated BC6ENTG in complex with BC6ENTC .	False
The structure shows that the conformation of the CHEM - loop in the BC6ENTG - BC6ENTC complex is different from those of any known structures of the unliganded BC6OTHER and its complexes with the inhibitors.	False
The structure shows that the conformation of the CHEM - loop in the BC6OTHER - BC6ENTC complex is different from those of any known structures of the unliganded BC6ENTG and its complexes with the inhibitors.	False
In addition , the molecular configuration of BC6ENTC differs from that of BC6OTHER when bound to BC6ENTG .	False
In addition , the molecular configuration of BC6OTHER differs from that of BC6ENTC when bound to BC6ENTG .	False
BC6OTHER has higher affinity to BC6ENTG ( BC6OTHER ) than BC6ENTC and lower administered dosage for the treatment of erectile dysfunction.	False
BC6OTHER has higher affinity to BC6OTHER ( BC6ENTG ) than BC6ENTC and lower administered dosage for the treatment of erectile dysfunction.	False
It is noteworthy that the binding of BC6ENTC causes loss of the divalent metal ions that have been observed in all the previously published BC6ENTG structures.	False
Conformational variations of both BC6ENTG and inhibitors provide the structural basis for the physiological effects of BC6ENTC and BC6OTHER .	False
Conformational variations of both BC6ENTG and inhibitors provide the structural basis for the physiological effects of BC6OTHER and BC6ENTC .	CPR:4
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6ENTG target genes in response to BC6OTHER inducers ( BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6ENTG inducers ( BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6OTHER inducers ( BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) showed that the BC6ENTG is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6ENTG target genes in response to BC6OTHER inducers ( BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6ENTG inducers ( BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6OTHER inducers ( BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) showed that the BC6ENTG is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6ENTG target genes in response to BC6OTHER inducers ( BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6ENTG inducers ( BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6OTHER inducers ( BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) showed that the BC6ENTG is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6ENTG target genes in response to BC6OTHER inducers ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6ENTG inducers ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) showed that the BC6OTHER is highly inducible by all treatments.	CPR:3
Firstly , in the normal human renal epithelial HK - 2 cells , the measurement of the expression of 30 previously reported BC6OTHER target genes in response to BC6OTHER inducers ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) showed that the BC6ENTG is highly inducible by all treatments.	CPR:3
The treatment of U937 cells with BC6ENTG inducers including BC6ENTC effectively elevated the expression of BC6OTHER .	CPR:3
The treatment of U937 cells with BC6OTHER inducers including BC6ENTC effectively elevated the expression of BC6ENTG .	CPR:3
Whereas , the levels of both the basal and BC6ENTC - inducible expression of BC6ENTG were significantly reduced in BC6OTHER - silenced stable U937 cells compared to the control cells.	CPR:3
Whereas , the levels of both the basal and BC6ENTC - inducible expression of BC6OTHER were significantly reduced in BC6ENTG - silenced stable U937 cells compared to the control cells.	False
We report here the optimization of BC6ENTG inhibitors in the BC6ENTC class by varying the size of the linker (n equals 0 and 2) between the BC6OTHER moiety and the BC6OTHER group.	CPR:4
We report here the optimization of BC6ENTG inhibitors in the BC6OTHER class by varying the size of the linker (n equals 0 and 2) between the BC6ENTC moiety and the BC6OTHER group.	False
We report here the optimization of BC6ENTG inhibitors in the BC6OTHER class by varying the size of the linker (n equals 0 and 2) between the BC6OTHER moiety and the BC6ENTC group.	False
While none of the BC6ENTC (n = 2) were active , most of the BC6OTHER (n = 0) turned out to moderately or strongly inhibit BC6ENTG .	False
While none of the BC6OTHER (n = 2) were active , most of the BC6ENTC (n = 0) turned out to moderately or strongly inhibit BC6ENTG .	CPR:4
The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and the BC6ENTC receptors α and β.	False
The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and the BC6ENTC receptors α and β.	False
The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and the BC6ENTC receptors α and β.	False
The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and the BC6ENTC receptors α and β.	False
The four most active compounds showed an IC₅₀ of around 60 nM and a very good selectivity toward BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and the BC6ENTC receptors α and β.	False
Structural optimization of BC6ENTC as highly potent and selective BC6ENTG inhibitors for the treatment of osteoporosis.	CPR:4
We conclude that CHEM564 blocks the entry of medium - and long - chain BC6ENTC to the catalytic site of BC6ENTG .	CPR:9
BC6ENTC acetyltransferases ( BC6ENTG ) catalyze the reversible conversion of BC6OTHER and BC6OTHER to BC6OTHER and free CoA.	False
We show for the first time that a single BC6ENTC is able to determine the substrate specificity of BC6ENTG and BC6OTHER .	False
We show for the first time that a single BC6ENTC is able to determine the substrate specificity of BC6OTHER and BC6ENTG .	False
BC6ENTG ( BC6OTHER ) catalyze the reversible conversion of BC6ENTC and BC6OTHER to BC6OTHER and free CoA.	CPR:9
BC6OTHER ( BC6ENTG ) catalyze the reversible conversion of BC6ENTC and BC6OTHER to BC6OTHER and free CoA.	CPR:9
BC6ENTG ( BC6OTHER ) catalyze the reversible conversion of BC6OTHER and BC6ENTC to BC6OTHER and free CoA.	CPR:9
BC6OTHER ( BC6ENTG ) catalyze the reversible conversion of BC6OTHER and BC6ENTC to BC6OTHER and free CoA.	CPR:9
BC6ENTG ( BC6OTHER ) catalyze the reversible conversion of BC6OTHER and BC6OTHER to BC6ENTC and free CoA.	CPR:9
BC6OTHER ( BC6ENTG ) catalyze the reversible conversion of BC6OTHER and BC6OTHER to BC6ENTC and free CoA.	CPR:9
The BC6ENTG mutated BC6OTHER showed higher activity toward longer chain BC6ENTC : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6OTHER mutated BC6ENTG showed higher activity toward longer chain BC6ENTC : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6OTHER mutated BC6OTHER showed higher activity toward longer chain BC6ENTC : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6ENTG , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6ENTG mutated BC6OTHER showed higher activity toward longer chain BC6OTHER : activity toward BC6ENTC was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6OTHER mutated BC6ENTG showed higher activity toward longer chain BC6OTHER : activity toward BC6ENTC was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6OTHER mutated BC6OTHER showed higher activity toward longer chain BC6OTHER : activity toward BC6ENTC was 1250 - fold higher than that of the wild - type BC6ENTG , and lower activity toward its natural substrate , BC6OTHER .	CPR:9
The BC6ENTG mutated BC6OTHER showed higher activity toward longer chain BC6OTHER : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6ENTC .	CPR:9
The BC6OTHER mutated BC6ENTG showed higher activity toward longer chain BC6OTHER : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6OTHER , and lower activity toward its natural substrate , BC6ENTC .	CPR:9
The BC6OTHER mutated BC6OTHER showed higher activity toward longer chain BC6OTHER : activity toward BC6OTHER was 1250 - fold higher than that of the wild - type BC6ENTG , and lower activity toward its natural substrate , BC6ENTC .	CPR:9
Kinetic constants of the mutant BC6ENTG showed modification in favor of longer BC6ENTC as substrates.	CPR:9
In the reverse case , mutation of the orthologous BC6ENTC (CHEM553) to BC6OTHER in BC6ENTG ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous BC6ENTC (CHEM553) to BC6OTHER in BC6OTHER ( BC6ENTG ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6ENTC in BC6ENTG ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6ENTC in BC6OTHER ( BC6ENTG ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous BC6ENTG in BC6ENTC octanoyltransferase ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6OTHER in BC6ENTC octanoyltransferase ( BC6ENTG ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous BC6ENTG in BC6OTHER ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6ENTC , and increased activity toward short - chain BC6OTHER .	False
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6OTHER in BC6ENTG ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6ENTC , and increased activity toward short - chain BC6OTHER .	CPR:9
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6OTHER in BC6OTHER ( BC6ENTG ) decreased activity toward its natural substrates , medium - and long - chain BC6ENTC , and increased activity toward short - chain BC6OTHER .	CPR:9
In the reverse case , mutation of the orthologous BC6ENTG in BC6OTHER ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6ENTC .	False
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6OTHER in BC6ENTG ( BC6OTHER ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6ENTC .	CPR:9
In the reverse case , mutation of the orthologous CHEM (CHEM553) to BC6OTHER in BC6OTHER ( BC6ENTG ) decreased activity toward its natural substrates , medium - and long - chain BC6OTHER , and increased activity toward short - chain BC6ENTC .	CPR:9
BC6ENTC decreased BC6ENTG ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	CPR:4
BC6ENTC decreased BC6OTHER ( BC6ENTG ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	CPR:4
BC6ENTC decreased BC6OTHER ( BC6OTHER ) protein contents and BC6ENTG mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	CPR:4
BC6ENTC decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6ENTG activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	CPR:4
BC6ENTC decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6ENTG contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6ENTC decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6ENTG activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6ENTG ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6ENTG ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6ENTG mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6ENTG activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6OTHER activity of purified myosin , implicating that the decrease of BC6ENTG contents and inhibition of BC6OTHER activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6ENTC - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6ENTG activity are involved in the BC6OTHER - induced inhibitory effects.	False
BC6OTHER decreased BC6ENTG ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6ENTC - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6ENTG ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6ENTC - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6ENTG mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6ENTC - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6ENTG activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6OTHER activity are involved in the BC6ENTC - induced inhibitory effects.	False
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6ENTG contents and inhibition of BC6OTHER activity are involved in the BC6ENTC - induced inhibitory effects.	CPR:4
BC6OTHER decreased BC6OTHER ( BC6OTHER ) protein contents and BC6OTHER mRNA expression in IJS , and inhibited both phosphorylation and BC6OTHER - BC6OTHER activity of purified myosin , implicating that the decrease of BC6OTHER contents and inhibition of BC6ENTG activity are involved in the BC6ENTC - induced inhibitory effects.	CPR:4
The inhibitory effects of BC6ENTC were correlated with the stimulation of BC6ENTG since these inhibitory effects were significantly blocked in the presence of BC6OTHER and BC6OTHER respectively.	False
The inhibitory effects of BC6OTHER were correlated with the stimulation of BC6ENTG since these inhibitory effects were significantly blocked in the presence of BC6ENTC and BC6OTHER respectively.	False
The inhibitory effects of BC6OTHER were correlated with the stimulation of BC6ENTG since these inhibitory effects were significantly blocked in the presence of BC6OTHER and BC6ENTC respectively.	False
The reactivation experiments were performed in a four - step procedure ( BC6OTHER - inhibition at 0 degree and pH 10 , aging at 37 degrees and pH 7.3 , reactivation by the BC6ENTC HI 6 at 37 degrees and pH 7.3 followed by BC6ENTG assay).	False
BC6ENTG ( BC6OTHER ) inhibited by the BC6OTHER BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6ENTC due to dealkylation of the BC6OTHER - enzyme complex.	CPR:3
BC6OTHER ( BC6ENTG ) inhibited by the BC6OTHER BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6ENTC due to dealkylation of the BC6OTHER - enzyme complex.	CPR:3
If the effectors were added after 5 min of aging they increased the activity of BC6ENTC - inhibited BC6ENTG , but to a considerably smaller extent than HI 6.	CPR:4
BC6ENTG ( BC6OTHER ) inhibited by the BC6OTHER BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6ENTC - enzyme complex.	False
BC6OTHER ( BC6ENTG ) inhibited by the BC6OTHER BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6ENTC - enzyme complex.	False
The effect of the four BC6ENTC compounds BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER and BC6OTHER on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6OTHER ( BC6OTHER ) , BC6ENTC , BC6OTHER and BC6OTHER on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC and BC6OTHER on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6ENTC on the reactivatability of BC6OTHER - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	False
The effect of the four BC6OTHER compounds BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER on the reactivatability of BC6ENTC - inhibited , solubilized BC6ENTG from human erythrocytes was investigated in vitro.	CPR:4
BC6ENTG ( BC6OTHER ) inhibited by the BC6ENTC BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
BC6OTHER ( BC6ENTG ) inhibited by the BC6ENTC BC6OTHER ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
BC6ENTG ( BC6OTHER ) inhibited by the BC6OTHER BC6ENTC ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
BC6OTHER ( BC6ENTG ) inhibited by the BC6OTHER BC6ENTC ( BC6OTHER ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
BC6ENTG ( BC6OTHER ) inhibited by the BC6OTHER BC6OTHER ( BC6ENTC ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
BC6OTHER ( BC6ENTG ) inhibited by the BC6OTHER BC6OTHER ( BC6ENTC ) rapidly becomes resistant to reactivation by BC6OTHER due to dealkylation of the BC6OTHER - enzyme complex.	CPR:4
The reactivation experiments were performed in a four - step procedure ( BC6ENTC - inhibition at 0 degree and pH 10 , aging at 37 degrees and pH 7.3 , reactivation by the BC6OTHER HI 6 at 37 degrees and pH 7.3 followed by BC6ENTG assay).	False
Effects of some BC6ENTC compounds on the reactivatability of BC6OTHER - inhibited BC6ENTG in vitro.	False
Effects of some BC6OTHER compounds on the reactivatability of BC6ENTC - inhibited BC6ENTG in vitro.	CPR:4
Post - translational modifications of BC6ENTG such as phosphorylation , ubiquitination , SUMOylation , methylation and poly( BC6ENTC - ribosyl)ation have been shown to play important roles in telomere function.	False
Here we show that BC6ENTG specifically interacts with the BC6OTHER , and that BC6OTHER acetylates the BC6ENTC residue at position 293 of BC6OTHER .	False
Here we show that BC6OTHER specifically interacts with the BC6ENTG , and that BC6OTHER acetylates the BC6ENTC residue at position 293 of BC6OTHER .	False
Here we show that BC6OTHER specifically interacts with the BC6OTHER , and that BC6ENTG acetylates the BC6ENTC residue at position 293 of BC6OTHER .	False
Here we show that BC6OTHER specifically interacts with the BC6OTHER , and that BC6OTHER acetylates the BC6ENTC residue at position 293 of BC6ENTG .	False
BC6ENTG occupancy was determined by displacement of BC6ENTC ( BC6OTHER ).	False
Similar to BC6ENTC , other local anesthetics bind to the BC6ENTG ( BC6OTHER ) and inhibit BC6OTHER uptake in rodent and monkey brain.	False
Similar to BC6ENTC , other local anesthetics bind to the BC6OTHER ( BC6ENTG ) and inhibit BC6OTHER uptake in rodent and monkey brain.	False
BC6ENTG occupancy was determined by displacement of BC6OTHER ( BC6ENTC ).	False
BC6ENTG occupancy was between 66 and 82% and <10 - 41% for doses of BC6ENTC and BC6OTHER that maintained maximum response rates , respectively.	False
BC6ENTG occupancy was between 66 and 82% and <10 - 41% for doses of BC6OTHER and BC6ENTC that maintained maximum response rates , respectively.	False
There was close correspondence between peak increases in BC6ENTC and BC6ENTG occupancy.	False
Similar to BC6OTHER , other local anesthetics bind to the BC6ENTC transporter ( BC6ENTG ) and inhibit BC6OTHER uptake in rodent and monkey brain.	False
Similar to BC6OTHER , other local anesthetics bind to the BC6ENTG ( BC6OTHER ) and inhibit BC6ENTC uptake in rodent and monkey brain.	False
Similar to BC6OTHER , other local anesthetics bind to the BC6OTHER ( BC6ENTG ) and inhibit BC6ENTC uptake in rodent and monkey brain.	False
The present study examined the reinforcing and BC6ENTG effects of the local anesthetics BC6ENTC , BC6OTHER and BC6OTHER using in vivo techniques.	False
The present study examined the reinforcing and BC6ENTG effects of the local anesthetics BC6OTHER , BC6ENTC and BC6OTHER using in vivo techniques.	False
The present study examined the reinforcing and BC6ENTG effects of the local anesthetics BC6OTHER , BC6OTHER and BC6ENTC using in vivo techniques.	False
Recent evidence suggests that a substantial portion of the passive stiffness of an in vitro preparation of tracheal smooth muscle is BC6ENTC sensitive and is regulated by BC6ENTG , although the underlying mechanism and the details of regulation for the development of this intracellular passive stiffness are still largely unknown.	False
BC6ENTC , an efficacious antidepressant and smoking cessation agent , inhibits CHEM and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively).	CPR:4
BC6ENTC , an efficacious antidepressant and smoking cessation agent , inhibits CHEM and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively).	CPR:4
BC6ENTC , an efficacious antidepressant and smoking cessation agent , inhibits BC6ENTG ( BC6OTHER and BC6OTHER , respectively).	False
Recently , BC6ENTC has been reported to noncompetitively inhibit BC6ENTG expressed in Xenopus oocytes or established cell lines.	False
Thus , BC6ENTC acts as an antagonist at BC6ENTG in rat striatum and hippocampus , respectively , across the same concentration range that inhibits BC6OTHER and BC6OTHER function.	False
Thus , BC6ENTC acts as an antagonist at BC6OTHER in rat striatum and hippocampus , respectively , across the same concentration range that inhibits BC6ENTG and BC6OTHER function.	CPR:4
Thus , BC6ENTC acts as an antagonist at BC6OTHER in rat striatum and hippocampus , respectively , across the same concentration range that inhibits BC6OTHER and BC6ENTG function.	CPR:4
The combination of BC6ENTG and transporter inhibition produced by BC6ENTC may contribute to its clinical efficacy as a smoking cessation agent.	CPR:4
The present study evaluated BC6ENTC - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6ENTC - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6ENTC ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6ENTC ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6ENTC ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6ENTC - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6ENTC ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6ENTC ( BC6OTHER ).	False
The present study evaluated BC6OTHER - induced inhibition of native BC6ENTG using functional neurotransmitter release assays , BC6OTHER - evoked [ BC6OTHER ]overflow from superfused rat striatal slices preloaded with BC6OTHER ( BC6OTHER ) , and BC6OTHER - evoked [ BC6OTHER ]overflow from hippocampal slices preloaded with BC6OTHER ( BC6ENTC ).	False
BC6OTHER , an efficacious antidepressant and smoking cessation agent , inhibits BC6ENTC and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively).	False
BC6OTHER , an efficacious antidepressant and smoking cessation agent , inhibits BC6ENTC and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively).	False
To eliminate the interaction of BC6ENTC with BC6ENTG or BC6OTHER , BC6OTHER or BC6OTHER , respectively , was included in the superfusion buffer.	CPR:4
To eliminate the interaction of BC6ENTC with BC6OTHER or BC6ENTG , BC6OTHER or BC6OTHER , respectively , was included in the superfusion buffer.	CPR:4
To eliminate the interaction of BC6OTHER with BC6ENTG or BC6OTHER , BC6ENTC or BC6OTHER , respectively , was included in the superfusion buffer.	False
To eliminate the interaction of BC6OTHER with BC6OTHER or BC6ENTG , BC6ENTC or BC6OTHER , respectively , was included in the superfusion buffer.	False
To eliminate the interaction of BC6OTHER with BC6ENTG or BC6OTHER , BC6OTHER or BC6ENTC , respectively , was included in the superfusion buffer.	False
To eliminate the interaction of BC6OTHER with BC6OTHER or BC6ENTG , BC6OTHER or BC6ENTC , respectively , was included in the superfusion buffer.	False
BC6OTHER , an efficacious antidepressant and smoking cessation agent , inhibits CHEM and BC6ENTC transporters ( BC6ENTG and BC6OTHER , respectively).	False
BC6OTHER , an efficacious antidepressant and smoking cessation agent , inhibits CHEM and BC6ENTC transporters ( BC6OTHER and BC6ENTG , respectively).	False
CONCLUSIONS: These results suggest that genetic variation in the BC6ENTG gene effects the response time to BC6ENTC and provides complementing evidence to previous reports that this polymorphism affects response time to other SSRIs.	False
RATIONALE: A common polymorphism ( BC6OTHER ) within the promoter region of the BC6OTHER gene ( BC6ENTG ) has been shown to influence response time as well as overall response to selective BC6ENTC reuptake inhibitors (SSRIs) in subjects with major depressive disorder.	False
RATIONALE: A common polymorphism ( BC6ENTG ) within the promoter region of the BC6OTHER gene ( BC6OTHER ) has been shown to influence response time as well as overall response to selective BC6ENTC reuptake inhibitors (SSRIs) in subjects with major depressive disorder.	False
RATIONALE: A common polymorphism ( BC6OTHER ) within the promoter region of the BC6ENTG gene ( BC6OTHER ) has been shown to influence response time as well as overall response to selective BC6ENTC reuptake inhibitors (SSRIs) in subjects with major depressive disorder.	False
OBJECTIVES: We tested the hypothesis that subjects homozygous for the long allele at the BC6ENTG polymorphism would respond more rapidly to BC6ENTC than subjects carrying one or two copies of the short allele.	False
RATIONALE: A common polymorphism ( BC6OTHER ) within the promoter region of the BC6ENTC transporter gene ( BC6ENTG ) has been shown to influence response time as well as overall response to selective BC6OTHER reuptake inhibitors (SSRIs) in subjects with major depressive disorder.	False
RATIONALE: A common polymorphism ( BC6ENTG ) within the promoter region of the BC6ENTC transporter gene ( BC6OTHER ) has been shown to influence response time as well as overall response to selective BC6OTHER reuptake inhibitors (SSRIs) in subjects with major depressive disorder.	False
Genotyping of the BC6ENTG polymorphism was performed to test for correlations with response at each week in the BC6ENTC and placebo groups ( n=206).	False
The BC6ENTC transporter polymorphism , BC6ENTG , is associated with a faster response time to BC6OTHER in an elderly population with major depressive disorder.	False
The BC6OTHER polymorphism , BC6ENTG , is associated with a faster response time to BC6ENTC in an elderly population with major depressive disorder.	False
The BC6ENTG polymorphism , BC6OTHER , is associated with a faster response time to BC6ENTC in an elderly population with major depressive disorder.	False
Two mutations were identified ( BC6OTHER and BC6OTHER ) with DCM properties (decreased BC6OTHER sensitivity , maximal force recovery , and activation of the BC6ENTG at high [ BC6ENTC ]).	False
Two mutations were identified ( BC6ENTG and BC6OTHER ) with DCM properties (decreased BC6OTHER sensitivity , maximal force recovery , and activation of the BC6OTHER at high [ BC6ENTC ]).	False
Two mutations were identified ( BC6OTHER and BC6ENTG ) with DCM properties (decreased BC6OTHER sensitivity , maximal force recovery , and activation of the BC6OTHER at high [ BC6ENTC ]).	False
Steady - state fluorescence was utilized to assess BC6ENTC affinity in isolated BC6ENTG containing BC6OTHER and did not necessarily mirror the fiber BC6OTHER sensitivity.	False
Steady - state fluorescence was utilized to assess BC6ENTC affinity in isolated BC6OTHER containing BC6ENTG and did not necessarily mirror the fiber BC6OTHER sensitivity.	False
Steady - state fluorescence was utilized to assess BC6OTHER affinity in isolated BC6ENTG containing BC6OTHER and did not necessarily mirror the fiber BC6ENTC sensitivity.	False
Steady - state fluorescence was utilized to assess BC6OTHER affinity in isolated BC6OTHER containing BC6ENTG and did not necessarily mirror the fiber BC6ENTC sensitivity.	False
Circular dichroism of mutant BC6ENTG revealed a trend where increased alpha - helical content correlated with increased BC6ENTC sensitivity in skinned fibers and vice versa.	False
The main findings from this study were as follows: 1) BC6ENTG mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6ENTC sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6OTHER sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6ENTG associated with increased BC6ENTC sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6OTHER sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6ENTC sensitivity in skinned fibers was identified; and 3) the BC6ENTG reporter mutation affected BC6OTHER sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6ENTC sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6OTHER sensitivity , maximal force , and BC6ENTG activation of some mutants.	False
The main findings from this study were as follows: 1) BC6ENTG mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6OTHER sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6ENTC sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6ENTG associated with increased BC6OTHER sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6ENTC sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6OTHER sensitivity in skinned fibers was identified; and 3) the BC6ENTG reporter mutation affected BC6ENTC sensitivity , maximal force , and BC6OTHER activation of some mutants.	False
The main findings from this study were as follows: 1) BC6OTHER mutants demonstrated distinct functional phenotypes reminiscent of bona fide HCM , RCM , and DCM mutations; 2) a region in BC6OTHER associated with increased BC6OTHER sensitivity in skinned fibers was identified; and 3) the BC6OTHER reporter mutation affected BC6ENTC sensitivity , maximal force , and BC6ENTG activation of some mutants.	False
Mutations in the BC6ENTC sensor , BC6ENTG ( BC6OTHER ) , were generated to increase / decrease the BC6OTHER sensitivity of cardiac skinned fibers to create the characteristic effects of DCM , HCM , and RCM.	False
Mutations in the BC6ENTC sensor , BC6OTHER ( BC6ENTG ) , were generated to increase / decrease the BC6OTHER sensitivity of cardiac skinned fibers to create the characteristic effects of DCM , HCM , and RCM.	False
Mutations in the BC6OTHER sensor , BC6ENTG ( BC6OTHER ) , were generated to increase / decrease the BC6ENTC sensitivity of cardiac skinned fibers to create the characteristic effects of DCM , HCM , and RCM.	False
Mutations in the BC6OTHER sensor , BC6OTHER ( BC6ENTG ) , were generated to increase / decrease the BC6ENTC sensitivity of cardiac skinned fibers to create the characteristic effects of DCM , HCM , and RCM.	False
One mutant ( BC6ENTG ) was found with HCM - like properties (increased BC6ENTC sensitivity of force and normal levels of BC6OTHER inhibition).	False
One mutant ( BC6OTHER ) was found with HCM - like properties (increased BC6ENTC sensitivity of force and normal levels of BC6ENTG inhibition).	False
Three mutants ( BC6ENTG , BC6OTHER , and BC6OTHER ) were identified with RCM - like properties (a large increase in BC6ENTC sensitivity , partial loss of BC6OTHER inhibition , and increased basal force).	False
Three mutants ( BC6OTHER , BC6ENTG , and BC6OTHER ) were identified with RCM - like properties (a large increase in BC6ENTC sensitivity , partial loss of BC6OTHER inhibition , and increased basal force).	False
Three mutants ( BC6OTHER , BC6OTHER , and BC6ENTG ) were identified with RCM - like properties (a large increase in BC6ENTC sensitivity , partial loss of BC6OTHER inhibition , and increased basal force).	False
Three mutants ( BC6OTHER , BC6OTHER , and BC6OTHER ) were identified with RCM - like properties (a large increase in BC6ENTC sensitivity , partial loss of BC6ENTG inhibition , and increased basal force).	False
Two mutations were identified ( BC6OTHER and BC6OTHER ) with DCM properties (decreased BC6ENTC sensitivity , maximal force recovery , and activation of the BC6ENTG at high [ BC6OTHER ]).	False
Two mutations were identified ( BC6ENTG and BC6OTHER ) with DCM properties (decreased BC6ENTC sensitivity , maximal force recovery , and activation of the BC6OTHER at high [ BC6OTHER ]).	False
Two mutations were identified ( BC6OTHER and BC6ENTG ) with DCM properties (decreased BC6ENTC sensitivity , maximal force recovery , and activation of the BC6OTHER at high [ BC6OTHER ]).	False
Predicting cardiomyopathic phenotypes by altering BC6ENTC affinity of BC6ENTG .	False
Results of RT - PCR analysis showed decrease of BC6ENTG mRNA level and no significant difference in BC6OTHER and BC6OTHER mRNA expressions in BC6ENTC - treated rats.	CPR:4
Results of RT - PCR analysis showed decrease of BC6OTHER mRNA level and no significant difference in BC6ENTG and BC6OTHER mRNA expressions in BC6ENTC - treated rats.	False
Results of RT - PCR analysis showed decrease of BC6OTHER mRNA level and no significant difference in BC6OTHER and BC6ENTG mRNA expressions in BC6ENTC - treated rats.	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTG ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6ENTG ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6ENTG , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6ENTG ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6ENTG , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6ENTC treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6ENTG ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6ENTG ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6ENTG , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6OTHER , BC6ENTG , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6ENTG , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6ENTG ) and cell - survival molecules ( BC6OTHER , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6ENTG , BC6OTHER ).	False
The objective of the current study was to determine whether a low - dose subchronic BC6OTHER treatment (100 μg / kg for 8 consecutive days) exerts long - term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death - promoting molecules ( BC6ENTC polymerase ( BC6OTHER ) , BC6OTHER , BC6OTHER , cleaved BC6OTHER , BC6OTHER ) and cell - survival molecules ( BC6OTHER , BC6ENTG ).	False
In PFC , BC6ENTC caused activation of BC6ENTG , augmentation of pro - survival BC6OTHER protein and enhanced BC6OTHER / BC6OTHER protein ratio , as well BC6OTHER translocation to mitochondria.	CPR:3
In PFC , BC6ENTC caused activation of BC6OTHER , augmentation of pro - survival BC6ENTG protein and enhanced BC6OTHER / BC6OTHER protein ratio , as well BC6OTHER translocation to mitochondria.	CPR:3
In PFC , BC6ENTC caused activation of BC6OTHER , augmentation of pro - survival BC6OTHER protein and enhanced BC6ENTG / BC6OTHER protein ratio , as well BC6OTHER translocation to mitochondria.	CPR:3
In PFC , BC6ENTC caused activation of BC6OTHER , augmentation of pro - survival BC6OTHER protein and enhanced BC6OTHER / BC6ENTG protein ratio , as well BC6OTHER translocation to mitochondria.	CPR:3
In PFC , BC6ENTC caused activation of BC6OTHER , augmentation of pro - survival BC6OTHER protein and enhanced BC6OTHER / BC6OTHER protein ratio , as well BC6ENTG translocation to mitochondria.	False
BC6ENTC , an BC6ENTG inhibitor , delays the absorption of BC6OTHER from the small intestine , thereby reducing postprandial hyperglycemia.	CPR:4
BC6OTHER , an BC6ENTG inhibitor , delays the absorption of BC6ENTC from the small intestine , thereby reducing postprandial hyperglycemia.	False
 Further , recently , BC6ENTC has been shown to improve BC6ENTG resistance in vivo. These findings suggest that BC6OTHER is a promising metabolic modifier that could reduce the risk of CVD in patients with the metabolic syndrome.	False
 Further , recently , CHEM has been shown to improve BC6ENTG resistance in vivo. These findings suggest that BC6ENTC is a promising metabolic modifier that could reduce the risk of CVD in patients with the metabolic syndrome.	False
Clinical utility of BC6ENTC , an BC6ENTG inhibitor in cardiometabolic disorders.	CPR:4
The expression of the neuronal activity marker BC6ENTG was increased 3.7 - fold in PFC by BC6ENTC administration , but was not increased in the striatum or nucleus accumbens , consistent with the regional distribution of increased DA(EX).	False
We investigated the mechanism of action of BC6ENTC in ADHD by evaluating the interaction of BC6OTHER with BC6ENTG , the effects on extracellular levels of BC6OTHER , and the expression of the neuronal activity marker BC6OTHER in brain regions.	False
We investigated the mechanism of action of BC6ENTC in ADHD by evaluating the interaction of BC6OTHER with BC6OTHER , the effects on extracellular levels of BC6OTHER , and the expression of the neuronal activity marker BC6ENTG in brain regions.	False
We investigated the mechanism of action of BC6OTHER in ADHD by evaluating the interaction of BC6ENTC with BC6ENTG , the effects on extracellular levels of BC6OTHER , and the expression of the neuronal activity marker BC6OTHER in brain regions.	False
We investigated the mechanism of action of BC6OTHER in ADHD by evaluating the interaction of BC6ENTC with BC6OTHER , the effects on extracellular levels of BC6OTHER , and the expression of the neuronal activity marker BC6ENTG in brain regions.	False
We investigated the mechanism of action of BC6OTHER in ADHD by evaluating the interaction of BC6OTHER with BC6ENTC transporters , the effects on extracellular levels of BC6OTHER , and the expression of the neuronal activity marker BC6ENTG in brain regions.	False
We investigated the mechanism of action of BC6OTHER in ADHD by evaluating the interaction of BC6OTHER with BC6ENTG , the effects on extracellular levels of BC6ENTC , and the expression of the neuronal activity marker BC6OTHER in brain regions.	False
We investigated the mechanism of action of BC6OTHER in ADHD by evaluating the interaction of BC6OTHER with BC6OTHER , the effects on extracellular levels of BC6ENTC , and the expression of the neuronal activity marker BC6ENTG in brain regions.	False
BC6ENTC inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6OTHER .	False
BC6ENTC inhibited binding of radioligands to clonal cell lines transfected with human BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with human BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6OTHER .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with human BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6OTHER .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with human BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
The selective BC6ENTG inhibitor BC6ENTC (formerly called BC6OTHER or BC6OTHER ) has been shown to alleviate symptoms in Attention Deficit / Hyperactivity Disorder (ADHD).	CPR:4
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6OTHER .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with human BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6OTHER .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with human BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTG .	False
BC6OTHER inhibited binding of radioligands to clonal cell lines transfected with BC6ENTG BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) transporters with dissociation constants (K(i)) values of 5 , 77 and 1451 nM , respectively , demonstrating selectivity for BC6ENTC transporters.	False
The selective BC6ENTG inhibitor BC6OTHER (formerly called BC6ENTC or BC6OTHER ) has been shown to alleviate symptoms in Attention Deficit / Hyperactivity Disorder (ADHD).	CPR:4
The selective BC6ENTG inhibitor BC6OTHER (formerly called BC6OTHER or BC6ENTC ) has been shown to alleviate symptoms in Attention Deficit / Hyperactivity Disorder (ADHD).	CPR:4
Further , BC6ENTC exposure could induce phosphorylation - and ubiquitination - dependent degradation of BC6ENTG , and the translocation of BC6OTHER from the cytosol to the nucleus in this microglial cell line.	CPR:3
Further , BC6ENTC exposure could induce phosphorylation - and ubiquitination - dependent degradation of BC6OTHER , and the translocation of BC6ENTG from the cytosol to the nucleus in this microglial cell line.	False
Thus , the BC6ENTG signaling pathway can be activated after BC6ENTC treatment.	CPR:3
However , BC6ENTC blockers also obviously attenuated BC6ENTG activation and transnuclear transport induced by BC6OTHER .	False
However , BC6OTHER blockers also obviously attenuated BC6ENTG activation and transnuclear transport induced by BC6ENTC .	CPR:3
In concert with these results , we highlighted that the secretion of pro - inflammatory BC6ENTG and BC6OTHER activation induced by BC6ENTC can be mediated by elevation of [ BC6OTHER ]i in HAPI microglial cells.	CPR:3
In concert with these results , we highlighted that the secretion of pro - inflammatory BC6OTHER and BC6ENTG activation induced by BC6ENTC can be mediated by elevation of [ BC6OTHER ]i in HAPI microglial cells.	CPR:3
In concert with these results , we highlighted that the secretion of pro - inflammatory BC6ENTG and BC6OTHER activation induced by BC6OTHER can be mediated by elevation of [ BC6ENTC ]i in HAPI microglial cells.	False
In concert with these results , we highlighted that the secretion of pro - inflammatory BC6OTHER and BC6ENTG activation induced by BC6OTHER can be mediated by elevation of [ BC6ENTC ]i in HAPI microglial cells.	False
In this study , using reverse transcriptase PCR (RT - PCR) and ELISA , we showed that BC6ENTC up - regulated the expression and secretion of BC6ENTG ( BC6OTHER ) in a time - dependent manner in cultured HAPI microglial cells.	CPR:3
In this study , using reverse transcriptase PCR (RT - PCR) and ELISA , we showed that BC6ENTC up - regulated the expression and secretion of BC6OTHER ( BC6ENTG ) in a time - dependent manner in cultured HAPI microglial cells.	CPR:3
BC6ENTC also caused a fast (within 30min as judged by the increase in its mRNA level) activation of BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC also caused a fast (within 30min as judged by the increase in its mRNA level) activation of BC6OTHER ( BC6ENTG ).	CPR:3
This initial action was accompanied by up - regulation of BC6ENTG ( BC6OTHER ) , an important inflammation marker within 1h after BC6ENTC treatment.	CPR:3
This initial action was accompanied by up - regulation of BC6OTHER ( BC6ENTG ) , an important inflammation marker within 1h after BC6ENTC treatment.	CPR:3
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6ENTC and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6ENTC and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6ENTC and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6ENTC and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6ENTC natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6ENTC natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6ENTC natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6ENTC natural products , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
BC6ENTC like the ones investigated here possess a BC6ENTG inhibition mechanism distinct of that of the BC6OTHER / BC6OTHER used clinically or the BC6OTHER .	CPR:4
BC6OTHER like the ones investigated here possess a BC6ENTG inhibition mechanism distinct of that of the BC6ENTC / BC6OTHER used clinically or the BC6OTHER .	CPR:4
BC6OTHER like the ones investigated here possess a BC6ENTG inhibition mechanism distinct of that of the BC6OTHER / BC6ENTC used clinically or the BC6OTHER .	CPR:4
BC6OTHER like the ones investigated here possess a BC6ENTG inhibition mechanism distinct of that of the BC6OTHER / BC6OTHER used clinically or the BC6ENTC .	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6ENTG BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
A series of BC6OTHER and BC6OTHER natural products , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , were investigated for their inhibitory effects against the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
Inhibition of BC6ENTG with a series of natural product BC6ENTC and BC6OTHER .	CPR:4
Inhibition of BC6ENTG with a series of natural product BC6OTHER and BC6ENTC .	CPR:4
In addition , BC6ENTG - induced formation of tube - like structures in vitro and neovascularization in mouse corneas were significantly inhibited by BC6ENTC .	CPR:4
BC6ENTC is specific for the BC6ENTG , and has therapeutic effects in BC6OTHER resistant acute promyelocytic leukemia.	False
BC6OTHER is specific for the BC6ENTG , and has therapeutic effects in BC6ENTC resistant acute promyelocytic leukemia.	False
BC6ENTC slightly inhibited the growth of both myeloma cells and HUVECs , and remarkably inhibited the growth of HUVECs stimulated by BC6ENTG .	CPR:4
BC6ENTC inhibited BC6OTHER - induced phosphorylation of BC6ENTG .	CPR:4
BC6ENTC inhibited BC6ENTG - induced phosphorylation of BC6OTHER .	CPR:4
Particularly , the effects of BC6ENTC used as a non selective BC6ENTG inhibitor in experimental and clinical studies will be discussed.	CPR:4
Notably , BC6ENTC treatment reduced adipose tissue expression of inflammatory BC6ENTG , increased BC6OTHER expression and improved BC6OTHER tolerance parallel to BC6OTHER sensitivity in obese mice.	CPR:4
Notably , BC6ENTC treatment reduced adipose tissue expression of inflammatory BC6OTHER , increased BC6ENTG expression and improved BC6OTHER tolerance parallel to BC6OTHER sensitivity in obese mice.	CPR:3
Notably , BC6ENTC treatment reduced adipose tissue expression of inflammatory BC6OTHER , increased BC6OTHER expression and improved BC6OTHER tolerance parallel to BC6ENTG sensitivity in obese mice.	CPR:3
Notably , BC6OTHER treatment reduced adipose tissue expression of inflammatory BC6ENTG , increased BC6OTHER expression and improved BC6ENTC tolerance parallel to BC6OTHER sensitivity in obese mice.	False
Notably , BC6OTHER treatment reduced adipose tissue expression of inflammatory BC6OTHER , increased BC6ENTG expression and improved BC6ENTC tolerance parallel to BC6OTHER sensitivity in obese mice.	False
Notably , BC6OTHER treatment reduced adipose tissue expression of inflammatory BC6OTHER , increased BC6OTHER expression and improved BC6ENTC tolerance parallel to BC6ENTG sensitivity in obese mice.	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6ENTC and protectins , which derive from the n - 3 BC6OTHER BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6OTHER and protectins , which derive from the n - 3 BC6ENTC BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6OTHER and protectins , which derive from the n - 3 BC6OTHER BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6OTHER and protectins , which derive from the n - 3 BC6OTHER BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6OTHER and protectins , which derive from the n - 3 BC6OTHER BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
Obesity - induced chronic low - grade inflammation originates from adipose tissue and is crucial for obesity - driven metabolic deterioration including BC6ENTG resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation , and could result from a lack of local specialized pro - resolving lipid mediators (SPM) such as BC6OTHER and protectins , which derive from the n - 3 BC6OTHER BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
Dietary BC6ENTC / BC6OTHER treatment restored endogenous biosynthesis of n - 3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving BC6ENTG sensitivity.	CPR:3
Dietary BC6OTHER / BC6ENTC treatment restored endogenous biosynthesis of n - 3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving BC6ENTG sensitivity.	CPR:3
Circulating BC6ENTC and markers of BC6ENTG resistance (IR) were higher in women with PCOS than in controls.	False
Experimental cystathioninuria was induced in rats by administration of the BC6ENTG inhibitor , BC6ENTC .	CPR:4
The human genome codes for 13 members of a family of filament - forming BC6ENTC - binding proteins known as BC6ENTG .	False
This construct ( BC6ENTG - GC) , which includes the BC6ENTC - binding and BC6OTHER - terminal domains , purifies as a BC6OTHER - free monomer , allowing for its characterization in terms of BC6OTHER - binding and hydrolysis.	False
This construct ( BC6ENTG - GC) , which includes the GTP - binding and BC6ENTC - terminal domains , purifies as a BC6OTHER - free monomer , allowing for its characterization in terms of BC6OTHER - binding and hydrolysis.	False
This construct ( BC6ENTG - GC) , which includes the GTP - binding and BC6OTHER - terminal domains , purifies as a BC6ENTC - free monomer , allowing for its characterization in terms of BC6OTHER - binding and hydrolysis.	False
This construct ( BC6OTHER - GC) , which includes the BC6ENTG , purifies as a BC6ENTC - free monomer , allowing for its characterization in terms of BC6OTHER - binding and hydrolysis.	False
This construct ( BC6ENTG - GC) , which includes the GTP - binding and BC6OTHER - terminal domains , purifies as a BC6OTHER - free monomer , allowing for its characterization in terms of BC6ENTC - binding and hydrolysis.	False
This construct ( BC6OTHER - GC) , which includes the BC6ENTG , purifies as a BC6OTHER - free monomer , allowing for its characterization in terms of BC6ENTC - binding and hydrolysis.	False
The BC6ENTG structure , which is composed of seven α - helixes and eleven β - strands , contains the β - strand / ɛSer / α - helix structural motif , which contains the BC6ENTC - X - BC6OTHER - X - BC6OTHER consensus sequence.	False
The BC6ENTG structure , which is composed of seven α - helixes and eleven β - strands , contains the β - strand / ɛSer / α - helix structural motif , which contains the CHEM - X - BC6ENTC - X - BC6OTHER consensus sequence.	False
The BC6ENTG structure , which is composed of seven α - helixes and eleven β - strands , contains the β - strand / ɛSer / α - helix structural motif , which contains the CHEM - X - BC6OTHER - X - BC6ENTC consensus sequence.	False
The BC6OTHER structure , which is composed of seven α - helixes and eleven β - strands , contains the β - strand / ɛSer / α - helix structural motif , which contains the BC6ENTG BC6ENTC consensus sequence.	False
Moreover , the observed insertion of BC6ENTC into the lid domain of the BC6ENTG structure is rare.	False
We therefore propose that this BC6ENTC residue might be involved in the stability and activity of BC6ENTG .	False
The cDNAs of the full - length version of BC6ENTG revealed that the BC6OTHER gene consists of a 1005 - bp ORF , which encodes 334 BC6ENTC residues , and 67 - and 227 - bp 5' and 3' UTRs , respectively.	False
The cDNAs of the full - length version of BC6OTHER revealed that the BC6ENTG gene consists of a 1005 - bp ORF , which encodes 334 BC6ENTC residues , and 67 - and 227 - bp 5' and 3' UTRs , respectively.	False
BC6ENTG was chemically bound via linkers to BC6ENTC - loaded BC6OTHER - NP.	False
BC6OTHER was chemically bound via linkers to BC6ENTC - loaded BC6ENTG - NP.	False
In conclusion , immortalized SHR and WKY PTE cells take up BC6ENTC mainly through a high - affinity BC6ENTG , with functional features of BC6OTHER transport.	CPR:9
In conclusion , immortalized SHR and WKY PTE cells take up BC6ENTC mainly through a high - affinity CHEM - dependent BC6OTHER transporter , with functional features of BC6ENTG transport.	CPR:9
In conclusion , immortalized SHR and WKY PTE cells take up BC6OTHER mainly through a high - affinity BC6ENTC - dependent BC6OTHER transporter , with functional features of BC6ENTG transport.	CPR:3
In conclusion , immortalized SHR and WKY PTE cells take up BC6OTHER mainly through a high - affinity CHEM - dependent BC6ENTC transporter , with functional features of BC6ENTG transport.	CPR:3
This study examined the inward transport of BC6ENTC , an BC6ENTG preferential substrate , in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar - Kyoto (WKY) and spontaneously hypertensive (SHR) rats.	CPR:9
In the presence of the system L inhibitor BCH , BC6ENTC - dependent BC6OTHER uptake in WKY and SHR PTE cells was inhibited by BC6OTHER , BC6OTHER , and BC6OTHER , which is consistent with BC6OTHER transport through BC6ENTG .	False
In the presence of the system L inhibitor BCH , BC6OTHER - dependent BC6ENTC uptake in WKY and SHR PTE cells was inhibited by BC6OTHER , BC6OTHER , and BC6OTHER , which is consistent with BC6OTHER transport through BC6ENTG .	CPR:9
In the presence of the system L inhibitor BCH , BC6OTHER - dependent BC6OTHER uptake in WKY and SHR PTE cells was inhibited by BC6ENTC , BC6OTHER , and BC6OTHER , which is consistent with BC6OTHER transport through BC6ENTG .	CPR:4
In the presence of the system L inhibitor BCH , BC6OTHER - dependent BC6OTHER uptake in WKY and SHR PTE cells was inhibited by BC6OTHER , BC6ENTC , and BC6OTHER , which is consistent with BC6OTHER transport through BC6ENTG .	CPR:4
In the presence of the system L inhibitor BCH , BC6OTHER - dependent BC6OTHER uptake in WKY and SHR PTE cells was inhibited by BC6OTHER , BC6OTHER , and BC6ENTC , which is consistent with BC6OTHER transport through BC6ENTG .	CPR:4
In the presence of the system L inhibitor BCH , BC6OTHER - dependent BC6OTHER uptake in WKY and SHR PTE cells was inhibited by BC6OTHER , BC6OTHER , and BC6OTHER , which is consistent with BC6ENTC transport through BC6ENTG .	CPR:9
Differences in magnitude of BC6ENTC - dependent BC6OTHER uptake through BC6OTHER between WKY and SHR PTE cells correlated positively with differences in BC6ENTG protein expression , this being more abundant in WKY PTE cells.	CPR:3
Differences in magnitude of BC6ENTC - dependent BC6OTHER uptake through BC6ENTG between WKY and SHR PTE cells correlated positively with differences in BC6OTHER protein expression , this being more abundant in WKY PTE cells.	False
Differences in magnitude of BC6OTHER - dependent BC6ENTC uptake through BC6OTHER between WKY and SHR PTE cells correlated positively with differences in BC6ENTG protein expression , this being more abundant in WKY PTE cells.	CPR:3
Differences in magnitude of BC6OTHER - dependent BC6ENTC uptake through BC6ENTG between WKY and SHR PTE cells correlated positively with differences in BC6OTHER protein expression , this being more abundant in WKY PTE cells.	CPR:9
Underexpression of the BC6ENTC - dependent neutral BC6OTHER transporter BC6ENTG in the spontaneously hypertensive rat kidney.	False
Underexpression of the CHEM - dependent neutral BC6ENTC transporter BC6ENTG in the spontaneously hypertensive rat kidney.	False
Constitutive BC6ENTC receptor ( BC6ENTG ) translocates into the nucleus in accordance with BC6OTHER and thus confers transactivation.	False
Constitutive BC6ENTC receptor ( BC6OTHER ) translocates into the nucleus in accordance with BC6ENTG and thus confers transactivation.	False
BC6ENTG ( BC6OTHER ) translocates into the nucleus in accordance with BC6ENTC - activated protein kinase and thus confers transactivation.	False
Constitutive BC6OTHER receptor ( BC6ENTG ) translocates into the nucleus in accordance with BC6ENTC - activated protein kinase and thus confers transactivation.	False
BC6ENTG ( BC6OTHER ) and BC6ENTC - activated protein kinase are often activated under similar physiological conditions.	False
BC6OTHER ( BC6ENTG ) and BC6ENTC - activated protein kinase are often activated under similar physiological conditions.	False
BC6ENTC (PB) , a typical BC6ENTG activator , increased the gene expression of BC6OTHER - target genes in the livers of mice , including BC6OTHER , BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC (PB) , a typical BC6OTHER activator , increased the gene expression of BC6ENTG - target genes in the livers of mice , including BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6ENTC (PB) , a typical BC6OTHER activator , increased the gene expression of BC6OTHER - target genes in the livers of mice , including BC6ENTG , BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC (PB) , a typical BC6OTHER activator , increased the gene expression of BC6OTHER - target genes in the livers of mice , including BC6OTHER , BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC (PB) , a typical BC6OTHER activator , increased the gene expression of BC6OTHER - target genes in the livers of mice , including BC6OTHER , BC6OTHER and BC6ENTG .	CPR:3
BC6ENTC , a typical BC6ENTG activator , induced the gene expression of BC6OTHER - target genes , including BC6OTHER and BC6OTHER , an accumulation of nuclear BC6OTHER and an increase in the BC6OTHER - mediated transactivation in the mouse liver.	CPR:3
BC6ENTC , a typical BC6OTHER activator , induced the gene expression of BC6ENTG - target genes , including BC6OTHER and BC6OTHER , an accumulation of nuclear BC6OTHER and an increase in the BC6OTHER - mediated transactivation in the mouse liver.	False
BC6ENTC , a typical BC6OTHER activator , induced the gene expression of BC6OTHER - target genes , including BC6ENTG and BC6OTHER , an accumulation of nuclear BC6OTHER and an increase in the BC6OTHER - mediated transactivation in the mouse liver.	CPR:3
BC6ENTC , a typical BC6OTHER activator , induced the gene expression of BC6OTHER - target genes , including BC6OTHER and BC6ENTG , an accumulation of nuclear BC6OTHER and an increase in the BC6OTHER - mediated transactivation in the mouse liver.	CPR:3
BC6ENTC , a typical BC6OTHER activator , induced the gene expression of BC6OTHER - target genes , including BC6OTHER and BC6OTHER , an accumulation of nuclear BC6ENTG and an increase in the BC6OTHER - mediated transactivation in the mouse liver.	False
BC6ENTC , a typical BC6OTHER activator , induced the gene expression of BC6OTHER - target genes , including BC6OTHER and BC6OTHER , an accumulation of nuclear BC6OTHER and an increase in the BC6ENTG - mediated transactivation in the mouse liver.	False
Cross - talk between constitutive BC6ENTC receptor and BC6ENTG in the regulation of gene expression.	False
The selective BC6ENTG BC6OTHER agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6OTHER antagonist BC6ENTC .	False
The selective BC6OTHER BC6ENTG agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6OTHER antagonist BC6ENTC .	False
The selective BC6OTHER BC6OTHER agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6ENTG BC6OTHER antagonist BC6ENTC .	CPR:6
The selective BC6OTHER BC6OTHER agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6ENTG antagonist BC6ENTC .	CPR:6
Together , these observations indicate that BC6ENTG BC6ENTC receptors have a unique role in triggering epileptiform activity in the amygdala and could participate in long - term plasticity mechanisms that underlie some forms of epileptogenesis.	False
Accordingly , BC6ENTG BC6ENTC receptors represent a potential target for antiepileptic and antiepileptogenic drug treatments.	False
However , BC6ENTC at low concentrations causes slow inhibition of BC6ENTG BC6OTHER - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6OTHER responses.	CPR:4
However , BC6ENTC at low concentrations causes slow inhibition of BC6OTHER BC6ENTG - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6OTHER responses.	CPR:4
However , BC6ENTC at low concentrations causes slow inhibition of BC6OTHER BC6OTHER - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6ENTG BC6OTHER responses.	CPR:4
However , BC6ENTC at low concentrations causes slow inhibition of BC6OTHER BC6OTHER - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6ENTG responses.	CPR:4
However , BC6OTHER at low concentrations causes slow inhibition of BC6ENTG BC6ENTC receptor - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6OTHER responses.	False
However , BC6OTHER at low concentrations causes slow inhibition of BC6OTHER BC6ENTC receptor - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6ENTG BC6OTHER responses.	False
However , BC6OTHER at low concentrations causes slow inhibition of BC6OTHER BC6ENTC receptor - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6ENTG responses.	False
However , BC6OTHER at low concentrations causes slow inhibition of BC6ENTG BC6OTHER - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6ENTC receptor responses.	False
However , BC6OTHER at low concentrations causes slow inhibition of BC6OTHER BC6ENTG - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6OTHER BC6ENTC receptor responses.	False
However , BC6OTHER at low concentrations causes slow inhibition of BC6OTHER BC6OTHER - mediated synaptic currents in the basolateral amygdala , indicating that it may protect against seizures , at least in part , through suppression of BC6ENTG BC6ENTC receptor responses.	False
Several lines of evidence implicate BC6ENTG ( BC6OTHER ) BC6ENTC receptors , a type of ionotropic BC6OTHER receptor , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Several lines of evidence implicate BC6OTHER ( BC6ENTG ) BC6ENTC receptors , a type of ionotropic BC6OTHER receptor , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Several lines of evidence implicate BC6OTHER ( BC6OTHER ) BC6ENTC receptors , a type of BC6ENTG , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Several lines of evidence implicate BC6ENTG ( BC6OTHER ) BC6OTHER , a type of ionotropic BC6ENTC receptor , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Several lines of evidence implicate BC6OTHER ( BC6ENTG ) BC6OTHER , a type of ionotropic BC6ENTC receptor , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Several lines of evidence implicate BC6OTHER ( BC6OTHER ) BC6ENTG , a type of ionotropic BC6ENTC receptor , in the amygdala's vulnerability to seizures and epileptogenesis.	False
Brain slice recordings indicate that BC6ENTG BC6ENTC receptors mediate a portion of the synaptic excitation of neurons in the rat basolateral amygdala.	False
Whole - cell voltage - clamp studies demonstrate that BC6ENTG BC6ENTC receptor - mediated synaptic currents are inwardly rectifying and are likely to be BC6OTHER permeable.	False
Whole - cell voltage - clamp studies demonstrate that BC6ENTG BC6OTHER - mediated synaptic currents are inwardly rectifying and are likely to be BC6ENTC permeable.	False
Whole - cell voltage - clamp studies demonstrate that BC6OTHER BC6ENTG - mediated synaptic currents are inwardly rectifying and are likely to be BC6ENTC permeable.	False
Prolonged activation of basolateral amygdala BC6ENTG BC6ENTC receptors results in enduring synaptic facilitation through a BC6OTHER - dependent process.	False
Prolonged activation of basolateral amygdala BC6ENTG BC6OTHER results in enduring synaptic facilitation through a BC6ENTC - dependent process.	False
Prolonged activation of basolateral amygdala BC6OTHER BC6ENTG results in enduring synaptic facilitation through a BC6ENTC - dependent process.	False
The selective BC6ENTG BC6ENTC receptor agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6OTHER antagonist BC6OTHER .	False
The selective BC6OTHER BC6ENTC receptor agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6ENTG BC6OTHER antagonist BC6OTHER .	False
The selective BC6OTHER BC6ENTC receptor agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6ENTG antagonist BC6OTHER .	False
The selective BC6ENTG BC6OTHER agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6ENTC receptor antagonist BC6OTHER .	False
The selective BC6OTHER BC6ENTG agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6OTHER BC6ENTC receptor antagonist BC6OTHER .	False
The selective BC6OTHER BC6OTHER agonist CHEM induces spontaneous epileptiform bursting that is sensitive to the BC6ENTG BC6ENTC receptor antagonist BC6OTHER .	False
 BC6ENTG BC6ENTC receptors , seizures , and the amygdala.	False
BC6ENTC is primarily metabolized to BC6OTHER by hepatic BC6ENTG and BC6OTHER - mediated CHEM - demethylation.	CPR:9
BC6ENTC is primarily metabolized to BC6OTHER by hepatic BC6OTHER and BC6ENTG - mediated CHEM - demethylation.	CPR:9
BC6ENTC ( BC6ENTG inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	CPR:4
BC6ENTC ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6ENTG but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6ENTC ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6ENTG inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6ENTC ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6ENTG inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6ENTG inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6ENTC ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6ENTG but not BC6ENTC ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6ENTC ( BC6ENTG inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	CPR:4
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6ENTC ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6ENTG inhibited BC6OTHER N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6ENTG inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6ENTC N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6ENTG but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6ENTC N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6ENTG inhibitor , 25 μM) or the monoclonal antibody against BC6OTHER inhibited BC6ENTC N - demethylation at clinically relevant concentrations.	False
BC6OTHER ( BC6OTHER inhibitor , 25 μM) and the monoclonal antibody against BC6OTHER but not BC6OTHER ( BC6OTHER inhibitor , 25 μM) or the monoclonal antibody against BC6ENTG inhibited BC6ENTC N - demethylation at clinically relevant concentrations.	False
These results indicate a major role of BC6ENTG in BC6ENTC N - demethylation in vitro and a significant impact of the BC6OTHER allele on enzyme - BC6OTHER binding and catalytic activity.	CPR:9
These results indicate a major role of BC6OTHER in BC6ENTC N - demethylation in vitro and a significant impact of the BC6ENTG allele on enzyme - BC6OTHER binding and catalytic activity.	False
These results indicate a major role of BC6ENTG in BC6OTHER N - demethylation in vitro and a significant impact of the BC6OTHER allele on enzyme - BC6ENTC binding and catalytic activity.	False
These results indicate a major role of BC6OTHER in BC6OTHER N - demethylation in vitro and a significant impact of the BC6ENTG allele on enzyme - BC6ENTC binding and catalytic activity.	CPR:9
The BC6ENTG allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in BC6ENTC metabolism.	CPR:9
BC6OTHER is primarily metabolized to BC6ENTC by hepatic BC6ENTG and BC6OTHER - mediated CHEM - demethylation.	False
BC6OTHER is primarily metabolized to BC6ENTC by hepatic BC6OTHER and BC6ENTG - mediated CHEM - demethylation.	False
We examined the CHEM - demethylation of individual BC6ENTC enantiomers using human liver microsomes (HLMs) genotyped for the BC6ENTG allele , insect cell expressed recombinant BC6OTHER and BC6OTHER enzymes and COS - 1 cell expressed recombinant BC6OTHER and BC6OTHER protein variant.	CPR:9
We examined the CHEM - demethylation of individual BC6ENTC enantiomers using human liver microsomes (HLMs) genotyped for the BC6OTHER allele , insect cell expressed recombinant BC6ENTG and BC6OTHER enzymes and COS - 1 cell expressed recombinant BC6OTHER and BC6OTHER protein variant.	False
We examined the CHEM - demethylation of individual BC6ENTC enantiomers using human liver microsomes (HLMs) genotyped for the BC6OTHER allele , insect cell expressed recombinant BC6OTHER and BC6ENTG enzymes and COS - 1 cell expressed recombinant BC6OTHER and BC6OTHER protein variant.	False
We examined the CHEM - demethylation of individual BC6ENTC enantiomers using human liver microsomes (HLMs) genotyped for the BC6OTHER allele , insect cell expressed recombinant BC6OTHER and BC6OTHER enzymes and COS - 1 cell expressed recombinant BC6ENTG and BC6OTHER protein variant.	False
We examined the CHEM - demethylation of individual BC6ENTC enantiomers using human liver microsomes (HLMs) genotyped for the BC6OTHER allele , insect cell expressed recombinant BC6OTHER and BC6OTHER enzymes and COS - 1 cell expressed recombinant BC6OTHER and BC6ENTG protein variant.	False
Effects of BC6ENTG - selective inhibitors on BC6ENTC formation were also determined in HLMs.	False
The intrinsic clearance for both BC6ENTC enantiomers by the high affinity enzyme in HLMs with BC6ENTG / *1 genotype were at least 2 - fold and 6 - fold higher , respectively , than those for BC6OTHER / *6 genotype and BC6OTHER / *6 genotype.	CPR:9
The intrinsic clearance for both BC6ENTC enantiomers by the high affinity enzyme in HLMs with BC6OTHER / *1 genotype were at least 2 - fold and 6 - fold higher , respectively , than those for BC6ENTG / *6 genotype and BC6OTHER / *6 genotype.	False
The intrinsic clearance for both BC6ENTC enantiomers by the high affinity enzyme in HLMs with BC6OTHER / *1 genotype were at least 2 - fold and 6 - fold higher , respectively , than those for BC6OTHER / *6 genotype and BC6ENTG / *6 genotype.	False
The BC6ENTG Allele Significantly Alters the CHEM - demethylation of BC6ENTC Enantiomers In Vitro.	CPR:9
Therefore , if these results are confirmed , BC6ENTG occupancy at the beginning of treatment with BC6ENTC may be a predictor of subsequent clinical response.	False
The objective of the study is to investigate whether BC6ENTG occupancy by BC6ENTC and plasma levels over time can account for therapeutic efficacy and the latency period to response.	False
 BC6ENTG occupancy by BC6ENTC : implications for the timing and magnitude of clinical response.	False
 Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of BC6ENTC ( BC6ENTG ) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing BC6OTHER activity , as well as levels and activity of the downstream translation regulators , BC6OTHER and BC6OTHER , delayed breast cancer progression , onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro.	False
 Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of BC6ENTC ( BC6OTHER ) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing BC6ENTG activity , as well as levels and activity of the downstream translation regulators , BC6OTHER and BC6OTHER , delayed breast cancer progression , onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro.	False
 Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of BC6ENTC ( BC6OTHER ) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing BC6OTHER activity , as well as levels and activity of the downstream translation regulators , BC6ENTG and BC6OTHER , delayed breast cancer progression , onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro.	False
 Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of BC6ENTC ( BC6OTHER ) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing BC6OTHER activity , as well as levels and activity of the downstream translation regulators , BC6OTHER and BC6ENTG , delayed breast cancer progression , onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro.	False
BACKGROUND: Since the introduction of the first BC6ENTG inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6ENTC , BC6OTHER and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6OTHER .	CPR:4
BACKGROUND: Since the introduction of the first BC6OTHER inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6ENTC , BC6OTHER and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6ENTG .	CPR:4
BACKGROUND: Since the introduction of the first BC6ENTG inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6ENTC and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6OTHER .	CPR:4
BACKGROUND: Since the introduction of the first BC6OTHER inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6ENTC and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6ENTG .	CPR:4
BACKGROUND: Since the introduction of the first BC6ENTG inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6OTHER and BC6ENTC , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6OTHER .	CPR:4
BACKGROUND: Since the introduction of the first BC6OTHER inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6OTHER and BC6ENTC , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6OTHER , an important neurotransmitter associated with memory , by blocking the enzyme BC6ENTG .	CPR:4
BACKGROUND: Since the introduction of the first BC6ENTG inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6OTHER and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6ENTC , an important neurotransmitter associated with memory , by blocking the enzyme BC6OTHER .	False
BACKGROUND: Since the introduction of the first BC6OTHER inhibitor (ChEI) in 1997 , most clinicians and probably most patients would consider the cholinergic drugs , BC6OTHER , BC6OTHER and BC6OTHER , to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties , but they all work by inhibiting the breakdown of BC6ENTC , an important neurotransmitter associated with memory , by blocking the enzyme BC6ENTG .	CPR:9
We provide here evidence that BC6ENTG , via its BC6OTHER BC6ENTC triphosphatase - activating activity , controls BC6OTHER - dependent BC6OTHER ( BC6OTHER ) signaling in chondrocytes.	False
We provide here evidence that BC6OTHER , via its BC6ENTG BC6ENTC triphosphatase - activating activity , controls BC6OTHER - dependent BC6OTHER ( BC6OTHER ) signaling in chondrocytes.	False
We provide here evidence that BC6OTHER , via its BC6OTHER BC6ENTC triphosphatase - activating activity , controls BC6ENTG - dependent BC6OTHER ( BC6OTHER ) signaling in chondrocytes.	False
We provide here evidence that BC6OTHER , via its BC6OTHER BC6ENTC triphosphatase - activating activity , controls BC6OTHER - dependent BC6ENTG ( BC6OTHER ) signaling in chondrocytes.	False
We provide here evidence that BC6OTHER , via its BC6OTHER BC6ENTC triphosphatase - activating activity , controls BC6OTHER - dependent BC6OTHER ( BC6ENTG ) signaling in chondrocytes.	False
In contrast , their effects on BC6ENTG varied with two (V - 4 , V - 6) inhibiting BC6OTHER transport (IC50's 2.0 , 9.2 μM) , two (V - 3 , III - 1) stimulating transport (>2 - fold) , while BC6ENTC I - 5 had no effect.	False
Strikingly , although V - 3 and V - 4 had opposite effects on BC6ENTG activity , they are structurally identical except for their BC6ENTC atom ( BC6OTHER versus BC6OTHER ).	False
Strikingly , although V - 3 and V - 4 had opposite effects on BC6ENTG activity , they are structurally identical except for their BC6OTHER atom ( BC6ENTC versus BC6OTHER ).	False
Strikingly , although V - 3 and V - 4 had opposite effects on BC6ENTG activity , they are structurally identical except for their BC6OTHER atom ( BC6OTHER versus BC6ENTC ).	False
This study is the first to identify Class V CHEM with their distinctive BC6ENTC or BC6OTHER linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6ENTG modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6OTHER .	False
This study is the first to identify Class V CHEM with their distinctive BC6ENTC or BC6OTHER linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6OTHER modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6ENTG .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6ENTC linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6ENTG modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6OTHER .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6ENTC linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6OTHER modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6ENTG .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6OTHER linkage between two disubstituted BC6ENTC moieties as a particularly potent class of BC6ENTG modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6OTHER .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6OTHER linkage between two disubstituted BC6ENTC moieties as a particularly potent class of BC6OTHER modulators and also show that within this core structure , differences in the electronegativity associated with a BC6OTHER atom can be the sole determinant of whether a compound will stimulate or inhibit BC6ENTG .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6OTHER linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6ENTG modulators and also show that within this core structure , differences in the electronegativity associated with a BC6ENTC atom can be the sole determinant of whether a compound will stimulate or inhibit BC6OTHER .	False
This study is the first to identify Class V CHEM with their distinctive BC6OTHER or BC6OTHER linkage between two disubstituted BC6OTHER moieties as a particularly potent class of BC6OTHER modulators and also show that within this core structure , differences in the electronegativity associated with a BC6ENTC atom can be the sole determinant of whether a compound will stimulate or inhibit BC6ENTG .	False
Five classes of BC6ENTC dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6OTHER ( BC6OTHER ) (a prototypical BC6ENTG substrate) into BC6OTHER - enriched inside - out membrane vesicles.	False
Five classes of BC6ENTC dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6OTHER ( BC6OTHER ) (a prototypical BC6OTHER substrate) into BC6ENTG - enriched inside - out membrane vesicles.	False
Five classes of BC6OTHER dyes ( BC6ENTC ) were examined for their ability to modulate transport of BC6OTHER ( BC6OTHER ) (a prototypical BC6ENTG substrate) into BC6OTHER - enriched inside - out membrane vesicles.	False
Five classes of BC6OTHER dyes ( BC6ENTC ) were examined for their ability to modulate transport of BC6OTHER ( BC6OTHER ) (a prototypical BC6OTHER substrate) into BC6ENTG - enriched inside - out membrane vesicles.	False
Five classes of BC6OTHER dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6ENTC ( BC6OTHER ) (a prototypical BC6ENTG substrate) into BC6OTHER - enriched inside - out membrane vesicles.	CPR:9
Five classes of BC6OTHER dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6ENTC ( BC6OTHER ) (a prototypical BC6OTHER substrate) into BC6ENTG - enriched inside - out membrane vesicles.	False
Five classes of BC6OTHER dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6OTHER ( BC6ENTC ) (a prototypical BC6ENTG substrate) into BC6OTHER - enriched inside - out membrane vesicles.	CPR:9
Five classes of BC6OTHER dyes ( BC6OTHER ) were examined for their ability to modulate transport of BC6OTHER ( BC6ENTC ) (a prototypical BC6OTHER substrate) into BC6ENTG - enriched inside - out membrane vesicles.	False
Sixteen of 34 BC6ENTC inhibited BC6ENTG - mediated BC6OTHER uptake by >50% (IC50's 0.7 - 7.6 μM).	CPR:4
BC6ENTG ( BC6OTHER ) mediate the BC6ENTC - dependent efflux of structurally diverse compounds , including anticancer drugs and physiological organic anions.	False
BC6OTHER ( BC6ENTG ) mediate the BC6ENTC - dependent efflux of structurally diverse compounds , including anticancer drugs and physiological organic anions.	False
Sixteen of 34 BC6OTHER inhibited BC6ENTG - mediated BC6ENTC uptake by >50% (IC50's 0.7 - 7.6 μM).	CPR:9
Of 9 BC6ENTC with IC50's ≤2 μM , two belonged to Class I , two to Class III and five to Class V. When tested in the intact cells , only 4 of 16 BC6OTHER (at 10 μM) inhibited BC6ENTG - mediated BC6OTHER efflux by >50% (III - 1 , V - 3 ,  - 4 ,  - 6) while a fifth (I - 5) inhibited efflux by just 23%.	False
Of 9 BC6OTHER with IC50's ≤2 μM , two belonged to Class I , two to Class III and five to Class V. When tested in the intact cells , only 4 of 16 BC6ENTC (at 10 μM) inhibited BC6ENTG - mediated BC6OTHER efflux by >50% (III - 1 , V - 3 ,  - 4 ,  - 6) while a fifth (I - 5) inhibited efflux by just 23%.	CPR:4
Of 9 BC6OTHER with IC50's ≤2 μM , two belonged to Class I , two to Class III and five to Class V. When tested in the intact cells , only 4 of 16 BC6OTHER (at 10 μM) inhibited BC6ENTG - mediated BC6ENTC efflux by >50% (III - 1 , V - 3 ,  - 4 ,  - 6) while a fifth (I - 5) inhibited efflux by just 23%.	CPR:9
These five BC6ENTC also inhibited BC6OTHER uptake by BC6ENTG .	CPR:4
These five BC6OTHER also inhibited BC6ENTC uptake by BC6ENTG .	CPR:9
In contrast , their effects on BC6ENTG varied with two (V - 4 , V - 6) inhibiting BC6ENTC transport (IC50's 2.0 , 9.2 μM) , two (V - 3 , III - 1) stimulating transport (>2 - fold) , while BC6OTHER I - 5 had no effect.	False
 BC6ENTC Dyes as Differential Modulators of Organic Anion Transport by BC6ENTG , BC6OTHER and BC6OTHER .	False
 BC6ENTC Dyes as Differential Modulators of Organic Anion Transport by BC6OTHER , BC6ENTG and BC6OTHER .	False
 BC6ENTC Dyes as Differential Modulators of Organic Anion Transport by BC6OTHER , BC6OTHER and BC6ENTG .	False
Leukocyte adhesion during inflammation is initiated by the binding of sialofucosylated BC6ENTC expressed on leukocytes to endothelial BC6ENTG .	False
Results demonstrate that predominantly BC6OTHER , and to a lesser extent BC6OTHER , forms the BC6OTHER - ligand at the BC6ENTC terminus of leukocyte BC6OTHER ( BC6ENTG ) in humans and mice.	False
Results demonstrate that predominantly BC6ENTG , and to a lesser extent BC6OTHER , forms the BC6OTHER - ligand at the BC6ENTC terminus of leukocyte BC6OTHER ( BC6OTHER ) in humans and mice.	False
Results demonstrate that predominantly BC6OTHER , and to a lesser extent BC6ENTG , forms the BC6OTHER - ligand at the BC6ENTC terminus of leukocyte BC6OTHER ( BC6OTHER ) in humans and mice.	False
Results demonstrate that predominantly BC6OTHER , and to a lesser extent BC6OTHER , forms the BC6ENTG - ligand at the BC6ENTC terminus of leukocyte BC6OTHER ( BC6OTHER ) in humans and mice.	False
Results demonstrate that predominantly BC6OTHER , and to a lesser extent BC6OTHER , forms the BC6OTHER - ligand at the BC6ENTC terminus of leukocyte BC6ENTG ( BC6OTHER ) in humans and mice.	False
Furthermore , BC6ENTG did not induce increases of heat pain tolerance thresholds , but of pressure pain tolerance thresholds , which , however , were not reversible by BC6ENTC .	False
In 16 healthy volunteers we studied the effects of 100 microg intravenously administered BC6ENTG in absence or presence of 12 mg BC6ENTC on heat or pressure pain sensitivity , using a double - blind , cross - over and placebo - controlled design.	False
To evaluate analgesic effects of BC6ENTG via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6ENTG derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6ENTG - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6ENTG ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6ENTG ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6ENTG IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6ENTG (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6OTHER (or placebo) injection.	False
To evaluate analgesic effects of BC6OTHER via release of BC6OTHER derivatives , we determined plasma concentrations of BC6OTHER - immunoreactive material (IRM) , authentic BC6OTHER ( BC6OTHER ) and BC6OTHER IRM , in parallel with heat and pressure pain tolerance thresholds before and 15 and 30 min after treatment with BC6OTHER (or placebo) , and 5 min after BC6ENTC (or placebo) administration which was administered 40 min after BC6ENTG (or placebo) injection.	False
The constitutive active / BC6ENTC receptor ( BC6OTHER ) regulates hepatic drug metabolism by activating genes such as BC6ENTG ( BC6OTHER ) and certain BC6OTHER .	False
The constitutive active / BC6ENTC receptor ( BC6OTHER ) regulates hepatic drug metabolism by activating genes such as BC6OTHER ( BC6ENTG ) and certain BC6OTHER .	False
The constitutive active / BC6ENTC receptor ( BC6OTHER ) regulates hepatic drug metabolism by activating genes such as BC6OTHER ( BC6OTHER ) and certain BC6ENTG .	False
The constitutive active / BC6ENTC receptor ( BC6ENTG ) regulates hepatic drug metabolism by activating genes such as BC6OTHER ( BC6OTHER ) and certain BC6OTHER .	False
Here , we have now found that activation of BC6ENTG BC6OTHER by BC6ENTC potentiated induction of BC6OTHER mRNA by BC6OTHER ligand in HepG2 cells to levels observed in ligand - treated human primary hepatocytes.	CPR:3
Here , we have now found that activation of BC6OTHER BC6ENTG by BC6ENTC potentiated induction of BC6OTHER mRNA by BC6OTHER ligand in HepG2 cells to levels observed in ligand - treated human primary hepatocytes.	CPR:3
Here , we have now found that activation of BC6OTHER BC6OTHER by BC6ENTC potentiated induction of BC6ENTG mRNA by BC6OTHER ligand in HepG2 cells to levels observed in ligand - treated human primary hepatocytes.	CPR:3
Here , we have now found that activation of BC6OTHER BC6OTHER by BC6ENTC potentiated induction of BC6OTHER mRNA by BC6ENTG ligand in HepG2 cells to levels observed in ligand - treated human primary hepatocytes.	False
siRNA knockdown of BC6ENTG BC6OTHER abrogated the ability of BC6ENTC to synergistically induce BC6OTHER mRNA.	False
siRNA knockdown of BC6OTHER BC6ENTG abrogated the ability of BC6ENTC to synergistically induce BC6OTHER mRNA.	False
siRNA knockdown of BC6OTHER BC6OTHER abrogated the ability of BC6ENTC to synergistically induce BC6ENTG mRNA.	CPR:3
In addition to BC6ENTG , BC6ENTC co - treatment potentiated an increase in BC6OTHER and BC6OTHER mRNAs but not BC6OTHER or BC6OTHER mRNAs.	CPR:3
In addition to BC6OTHER , BC6ENTC co - treatment potentiated an increase in BC6ENTG and BC6OTHER mRNAs but not BC6OTHER or BC6OTHER mRNAs.	CPR:3
In addition to BC6OTHER , BC6ENTC co - treatment potentiated an increase in BC6OTHER and BC6ENTG mRNAs but not BC6OTHER or BC6OTHER mRNAs.	CPR:3
In addition to BC6OTHER , BC6ENTC co - treatment potentiated an increase in BC6OTHER and BC6OTHER mRNAs but not BC6ENTG or BC6OTHER mRNAs.	False
In addition to BC6OTHER , BC6ENTC co - treatment potentiated an increase in BC6OTHER and BC6OTHER mRNAs but not BC6OTHER or BC6ENTG mRNAs.	False
In addition to BC6ENTG , BC6OTHER co - treatment potentiated an increase in BC6OTHER and BC6OTHER mRNAs but not BC6OTHER or BC6ENTC - glucuronosyltransferase 1A1 mRNAs.	False
In addition to BC6OTHER , BC6OTHER co - treatment potentiated an increase in BC6ENTG and BC6OTHER mRNAs but not BC6OTHER or BC6ENTC - glucuronosyltransferase 1A1 mRNAs.	False
In addition to BC6OTHER , BC6OTHER co - treatment potentiated an increase in BC6OTHER and BC6ENTG mRNAs but not BC6OTHER or BC6ENTC - glucuronosyltransferase 1A1 mRNAs.	False
In addition to BC6OTHER , BC6OTHER co - treatment potentiated an increase in BC6OTHER and BC6OTHER mRNAs but not BC6ENTG or BC6ENTC - glucuronosyltransferase 1A1 mRNAs.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6ENTC (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6ENTC (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6ENTC + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6ENTC + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6ENTC + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6ENTC + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6ENTC and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6ENTC and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6ENTC + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6ENTC + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6ENTC + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6ENTC + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6ENTC produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6OTHER produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6ENTC produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
In addition , by comparing the combined administration of BC6ENTC with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6ENTC with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6ENTC with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6ENTC , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6ENTC , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6ENTC , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6ENTC or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6ENTC or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6ENTC or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6ENTC , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6ENTC , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6ENTC , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6ENTC produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6ENTC produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6ENTC produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	CPR:6
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6ENTC - induced increases in extracellular BC6OTHER via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6ENTC - induced increases in extracellular BC6OTHER via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6ENTC - induced increases in extracellular BC6OTHER via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6ENTC via its action at the BC6ENTG receptor in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6ENTC via its action at the BC6ENTG in addition to any activity it has at the presynaptic BC6OTHER receptor.	False
In addition , by comparing the combined administration of BC6OTHER with either BC6OTHER , BC6OTHER or BC6OTHER , we have determined that BC6OTHER produces much of its acute potentiation of BC6OTHER - induced increases in extracellular BC6ENTC via its action at the BC6OTHER in addition to any activity it has at the presynaptic BC6ENTG receptor.	False
This effect has been attributed to the antagonist effects of BC6ENTC at the BC6ENTG receptor.	CPR:6
In the present study , we compared the pharmacology of BC6ENTC , BC6OTHER (a BC6ENTG antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	CPR:6
In the present study , we compared the pharmacology of BC6ENTC , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6ENTG antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6ENTC , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6ENTG antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6ENTC (a BC6ENTG antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	CPR:6
In the present study , we compared the pharmacology of BC6OTHER , BC6ENTC (a BC6OTHER antagonist) , BC6OTHER (a BC6ENTG antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6ENTC (a BC6OTHER antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6ENTG antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6ENTG antagonist) , BC6ENTC (a BC6OTHER antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6ENTC (a BC6ENTG antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6ENTC (a BC6OTHER antagonist) , and BC6OTHER (a BC6ENTG antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6ENTG antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6ENTC (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6ENTG antagonist) , and BC6ENTC (a BC6OTHER antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6ENTC (a BC6ENTG antagonist) , when given acutely in combination with BC6OTHER , using in vivo microdialysis in the frontal cortex of the freely moving rat.	CPR:6
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6ENTG antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6ENTC , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6ENTG antagonist) , and BC6OTHER (a BC6OTHER antagonist) , when given acutely in combination with BC6ENTC , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
In the present study , we compared the pharmacology of BC6OTHER , BC6OTHER (a BC6OTHER antagonist) , BC6OTHER (a BC6OTHER antagonist) , and BC6OTHER (a BC6ENTG antagonist) , when given acutely in combination with BC6ENTC , using in vivo microdialysis in the frontal cortex of the freely moving rat.	False
 Combination of both BC6ENTG and BC6OTHER autoreceptor antagonists with BC6ENTC produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
 Combination of both BC6OTHER and BC6ENTG autoreceptor antagonists with BC6ENTC produced additive increases in extracellular BC6OTHER (i.e. BC6OTHER + BC6OTHER + BC6OTHER and BC6OTHER + BC6OTHER + BC6OTHER produced a four - and five - fold potentiation , respectively) , suggesting that this strategy may be useful in further augmenting the action of a SSRI in the treatment of depression.	False
The role of BC6ENTG and BC6OTHER on the modulation of acute BC6OTHER - induced changes in extracellular BC6ENTC : the mechanism of action of BC6OTHER .	False
The role of BC6OTHER and BC6ENTG on the modulation of acute BC6OTHER - induced changes in extracellular BC6ENTC : the mechanism of action of BC6OTHER .	False
The role of BC6ENTG and BC6OTHER on the modulation of acute BC6OTHER - induced changes in extracellular BC6OTHER : the mechanism of action of BC6ENTC .	False
The role of BC6OTHER and BC6ENTG on the modulation of acute BC6OTHER - induced changes in extracellular BC6OTHER : the mechanism of action of BC6ENTC .	False
The role of BC6ENTG and BC6OTHER on the modulation of acute BC6ENTC - induced changes in extracellular BC6OTHER : the mechanism of action of BC6OTHER .	False
The role of BC6OTHER and BC6ENTG on the modulation of acute BC6ENTC - induced changes in extracellular BC6OTHER : the mechanism of action of BC6OTHER .	False
In the AG+GG group , males with BC6ENTG BC6ENTC levels <40 mg / dL are less frequent (P = 0.05) and obesity tends to be less prevalent (P = 0.07).	False
In conclusion , we find that BC6ENTC exhibits hepatoprotective and antifibrotic effects against BC6OTHER - induced liver injury , most likely due to its antioxidant activities of scavenging radicals , its capacity to suppress BC6ENTG and its ability to attenuate activation of hepatic stellate cells.	CPR:4
In conclusion , we find that BC6OTHER exhibits hepatoprotective and antifibrotic effects against BC6ENTC - induced liver injury , most likely due to its antioxidant activities of scavenging radicals , its capacity to suppress BC6ENTG and its ability to attenuate activation of hepatic stellate cells.	False
This was accompanied by a significant increase in levels of serum BC6ENTC transaminase , BC6ENTG , and liver BC6OTHER content.	False
This was accompanied by a significant increase in levels of serum BC6ENTG , BC6ENTC transaminase , and liver BC6OTHER content.	False
This was accompanied by a significant increase in levels of serum BC6ENTG , BC6OTHER , and liver BC6ENTC content.	False
This was accompanied by a significant increase in levels of serum BC6OTHER , BC6ENTG , and liver BC6ENTC content.	False
Furthermore , BC6ENTC reduced hepatic BC6OTHER content , which correlated with a reduction in the expression of BC6ENTG mRNA and histological analysis of BC6OTHER in liver tissue.	CPR:4
Furthermore , BC6ENTC reduced hepatic BC6OTHER content , which correlated with a reduction in the expression of BC6OTHER mRNA and histological analysis of BC6ENTG in liver tissue.	False
Furthermore , BC6OTHER reduced hepatic BC6ENTC content , which correlated with a reduction in the expression of BC6ENTG mRNA and histological analysis of BC6OTHER in liver tissue.	False
Furthermore , BC6OTHER reduced hepatic BC6ENTC content , which correlated with a reduction in the expression of BC6OTHER mRNA and histological analysis of BC6ENTG in liver tissue.	False
Additionally , the expression of hepatic fibrosis - related factors such as BC6ENTG and BC6OTHER ( BC6OTHER ) , were reduced in rats treated with BC6ENTC .	CPR:4
Additionally , the expression of hepatic fibrosis - related factors such as BC6OTHER and BC6ENTG ( BC6OTHER ) , were reduced in rats treated with BC6ENTC .	CPR:4
Additionally , the expression of hepatic fibrosis - related factors such as BC6OTHER and BC6OTHER ( BC6ENTG ) , were reduced in rats treated with BC6ENTC .	CPR:4
In this report , we demonstrate the utility of reversed - phase protein chromatography and FT - ICR mass spectrometry in analyzing CHEM ( BC6ENTC , BC6OTHER , MW: 233.7Da) modification of BC6ENTG .	False
In this report , we demonstrate the utility of reversed - phase protein chromatography and FT - ICR mass spectrometry in analyzing CHEM ( BC6OTHER , BC6ENTC , MW: 233.7Da) modification of BC6ENTG .	False
The intracellular routing of EGa1 targeted nanoparticles leads to a successful release of the BC6ENTG inhibitor in the cell and inhibition of proliferation whereas the non - targeted formulations had no antiproliferative effects on BC6ENTC cells.	False
BC6OTHER crosslinked BC6ENTG nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6ENTC - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6ENTG inhibitor BC6ENTC - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	CPR:4
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6ENTC - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6ENTG and is released in a reductive environment.	False
BC6OTHER crosslinked BC6ENTG nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6ENTC - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6ENTG inhibitor BC6OTHER - L(x) - a BC6ENTC - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6ENTC - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6ENTG and is released in a reductive environment.	False
BC6OTHER crosslinked BC6ENTG nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6ENTC analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6ENTG inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6ENTC analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6ENTC analogue - which couples the drug to BC6OTHER residues of BC6ENTG and is released in a reductive environment.	False
BC6OTHER crosslinked BC6ENTG nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6ENTC residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6ENTG inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6ENTC residues of BC6OTHER and is released in a reductive environment.	False
BC6OTHER crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6ENTC residues of BC6ENTG and is released in a reductive environment.	False
BC6ENTG nanoparticles were surface - coated with bifunctional BC6ENTC 3500 ( BC6OTHER ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6OTHER ( BC6OTHER ).	False
BC6OTHER nanoparticles were surface - coated with bifunctional BC6ENTC 3500 ( BC6OTHER ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6ENTG ( BC6OTHER ).	False
BC6OTHER nanoparticles were surface - coated with bifunctional BC6ENTC 3500 ( BC6OTHER ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6OTHER ( BC6ENTG ).	False
BC6ENTG nanoparticles were surface - coated with bifunctional BC6OTHER 3500 ( BC6ENTC ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6OTHER ( BC6OTHER ).	False
BC6OTHER nanoparticles were surface - coated with bifunctional BC6OTHER 3500 ( BC6ENTC ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6ENTG ( BC6OTHER ).	False
BC6OTHER nanoparticles were surface - coated with bifunctional BC6OTHER 3500 ( BC6ENTC ) and a nanobody - the single variable domain of an antibody - (Ega1) against the BC6OTHER ( BC6ENTG ).	False
EGa1 - BC6ENTC functionalized nanoparticles showed a 40 - fold higher binding to BC6ENTG - positive BC6OTHER squamous head and neck cancer cells in comparison to PEGylated nanoparticles.	False
EGa1 - BC6OTHER functionalized nanoparticles showed a 40 - fold higher binding to BC6ENTG - positive BC6ENTC squamous head and neck cancer cells in comparison to PEGylated nanoparticles.	False
BC6ENTC - L(x) loaded EGa1 - BC6OTHER nanoparticles were internalized by BC6ENTG - mediated endocytosis and ultimately digested in lysosomes.	False
BC6OTHER - L(x) loaded EGa1 - BC6ENTC nanoparticles were internalized by BC6ENTG - mediated endocytosis and ultimately digested in lysosomes.	False
BC6ENTC crosslinked BC6ENTG nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6ENTC crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6ENTG inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6OTHER and is released in a reductive environment.	False
BC6ENTC crosslinked BC6OTHER nanoparticles with a size of approximately 100nm were loaded with the BC6OTHER inhibitor BC6OTHER - L(x) - a BC6OTHER - bound BC6OTHER analogue - which couples the drug to BC6OTHER residues of BC6ENTG and is released in a reductive environment.	False
Nanobody - BC6OTHER nanoparticles (NANAPs) for the delivery of a BC6ENTG inhibitor BC6ENTC to BC6OTHER overexpressing tumor cells.	CPR:4
Nanobody - BC6ENTG nanoparticles (NANAPs) for the delivery of a BC6OTHER inhibitor BC6ENTC to BC6OTHER overexpressing tumor cells.	False
Nanobody - BC6OTHER nanoparticles (NANAPs) for the delivery of a BC6OTHER inhibitor BC6ENTC to BC6ENTG overexpressing tumor cells.	False
Key marker of diabetes in cells is the insulin dependent BC6ENTC transporter - 4 ( BC6ENTG ) which also responds to exogenous chemicals , and is over expressed up to 5 - and 4 - fold , by Tinospora cordifolia and BC6OTHER , respectively.	False
Key marker of diabetes in cells is the BC6ENTG ( BC6OTHER ) which also responds to exogenous chemicals , and is over expressed up to 5 - and 4 - fold , by Tinospora cordifolia and BC6ENTC , respectively.	False
Key marker of diabetes in cells is the insulin dependent BC6OTHER transporter - 4 ( BC6ENTG ) which also responds to exogenous chemicals , and is over expressed up to 5 - and 4 - fold , by Tinospora cordifolia and BC6ENTC , respectively.	False
Next to BC6ENTG , the predominant protein influencing BC6ENTC metabolism is BC6OTHER whose expressions were also positively modulated.	CPR:9
Next to BC6OTHER , the predominant protein influencing BC6ENTC metabolism is BC6ENTG whose expressions were also positively modulated.	False
Further , the inhibitors of BC6ENTG pathway prevented BC6ENTC uptake mediated by Tinospora cordifolia and BC6OTHER which shows that the activity is majorly mediated through BC6OTHER pathway.	False
Further , the inhibitors of BC6OTHER pathway prevented BC6ENTC uptake mediated by Tinospora cordifolia and BC6OTHER which shows that the activity is majorly mediated through BC6ENTG pathway.	False
Further , the inhibitors of BC6ENTG pathway prevented BC6OTHER uptake mediated by Tinospora cordifolia and BC6ENTC which shows that the activity is majorly mediated through BC6OTHER pathway.	False
Further , the inhibitors of BC6OTHER pathway prevented BC6OTHER uptake mediated by Tinospora cordifolia and BC6ENTC which shows that the activity is majorly mediated through BC6ENTG pathway.	False
Treatment with BC6ENTG resulted in hypodiploid DNA contents , increased BC6OTHER / BC6OTHER ratio and induction of reactive BC6ENTC species (ROS) production.	False
Treatment with BC6OTHER resulted in hypodiploid DNA contents , increased BC6ENTG / BC6OTHER ratio and induction of reactive BC6ENTC species (ROS) production.	False
Treatment with BC6OTHER resulted in hypodiploid DNA contents , increased BC6OTHER / BC6ENTG ratio and induction of reactive BC6ENTC species (ROS) production.	False
In addition , pretreatment with BC6ENTC ( BC6OTHER ) , a broad spectrum of BC6OTHER inhibitor , could not rescue apoptotic cells from BC6ENTG toxicity.	False
In addition , pretreatment with BC6ENTC ( BC6OTHER ) , a broad spectrum of BC6ENTG inhibitor , could not rescue apoptotic cells from BC6OTHER toxicity.	CPR:4
In addition , pretreatment with BC6OTHER ( BC6ENTC ) , a broad spectrum of BC6OTHER inhibitor , could not rescue apoptotic cells from BC6ENTG toxicity.	False
In addition , pretreatment with BC6OTHER ( BC6ENTC ) , a broad spectrum of BC6ENTG inhibitor , could not rescue apoptotic cells from BC6OTHER toxicity.	CPR:4
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6ENTC at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6ENTC , acted as substrate for BC6ENTG .	CPR:9
BC6ENTC inhibited BC6ENTG activity with a mixed type of inhibition in which the analogue had a 70 - fold higher affinity for the enzyme than the natural substrate , BC6OTHER .	CPR:4
BC6OTHER inhibited BC6ENTG activity with a mixed type of inhibition in which the analogue had a 70 - fold higher affinity for the enzyme than the natural substrate , BC6ENTC .	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by CHEM / CHEM BC6ENTC - acetyltransferase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by CHEM / CHEM BC6ENTC - acetyltransferase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by CHEM / CHEM BC6ENTC - acetyltransferase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by BC6ENTG ( BC6OTHER ) and BC6ENTC oxidase ( BC6OTHER ).	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by CHEM / CHEM BC6OTHER - acetyltransferase ( BC6ENTG ) and BC6ENTC oxidase ( BC6OTHER ).	False
CHEM was rapidly taken up and metabolized to CHEM and an unknown , possibly CHEM , by CHEM / CHEM BC6OTHER - acetyltransferase ( BC6OTHER ) and BC6ENTC oxidase ( BC6ENTG ).	False
BC6ENTC analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6ENTC , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6ENTC and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6ENTC , as well as BC6OTHER analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6ENTC analogues [ BC6OTHER , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6ENTC , a BC6OTHER 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6OTHER analogues of BC6OTHER , such as BC6OTHER and BC6OTHER , as well as BC6OTHER analogues [ BC6OTHER , a BC6ENTC 3 - 7 - 3 analogue] blocked uptake and interconversion of BC6OTHER at micromolar levels and , in the case of BC6OTHER , acted as substrate for BC6ENTG .	False
BC6ENTC increased the amount of BC6ENTG at both mRNA and protein levels , and increased the activity of BC6OTHER , leading to the mineralization.	CPR:3
BC6ENTC increased the amount of BC6OTHER at both mRNA and protein levels , and increased the activity of BC6ENTG , leading to the mineralization.	False
These findings suggest that BC6ENTC activates the BC6ENTG / BC6OTHER signaling pathway leading to the promotion of nuclear translocation of BC6OTHER in osteoblast - like cells , resulting in the upregulation of BC6OTHER and osteoblast differentiation markers including BC6OTHER , probably relating to the inhibition of osteoclast formation and the mineralization , respectively.	CPR:3
These findings suggest that BC6ENTC activates the BC6OTHER / BC6ENTG signaling pathway leading to the promotion of nuclear translocation of BC6OTHER in osteoblast - like cells , resulting in the upregulation of BC6OTHER and osteoblast differentiation markers including BC6OTHER , probably relating to the inhibition of osteoclast formation and the mineralization , respectively.	CPR:3
These findings suggest that BC6ENTC activates the BC6OTHER / BC6OTHER signaling pathway leading to the promotion of nuclear translocation of BC6ENTG in osteoblast - like cells , resulting in the upregulation of BC6OTHER and osteoblast differentiation markers including BC6OTHER , probably relating to the inhibition of osteoclast formation and the mineralization , respectively.	CPR:3
These findings suggest that BC6ENTC activates the BC6OTHER / BC6OTHER signaling pathway leading to the promotion of nuclear translocation of BC6OTHER in osteoblast - like cells , resulting in the upregulation of BC6ENTG and osteoblast differentiation markers including BC6OTHER , probably relating to the inhibition of osteoclast formation and the mineralization , respectively.	CPR:3
These findings suggest that BC6ENTC activates the BC6OTHER / BC6OTHER signaling pathway leading to the promotion of nuclear translocation of BC6OTHER in osteoblast - like cells , resulting in the upregulation of BC6OTHER and osteoblast differentiation markers including BC6ENTG , probably relating to the inhibition of osteoclast formation and the mineralization , respectively.	CPR:3
BC6ENTC activated BC6ENTG ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	CPR:3
BC6ENTC activated BC6OTHER ( BC6ENTG ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	CPR:3
BC6ENTC activated BC6OTHER ( BC6OTHER ) / BC6ENTG signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	CPR:3
BC6ENTC activated BC6OTHER ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6ENTG and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	CPR:4
BC6ENTC activated BC6OTHER ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6ENTG , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6ENTC activated BC6OTHER ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6ENTG / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6ENTC activated BC6OTHER ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6ENTG complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6ENTG ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6OTHER ) / BC6ENTG signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6ENTG and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6ENTG , followed by the increase of the transcriptional activity by BC6OTHER / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6ENTG / BC6OTHER complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
BC6OTHER activated BC6ENTC 3 - kinase ( BC6OTHER ) / BC6OTHER signaling , leading to the inhibition of BC6OTHER and the nuclear translocation of BC6OTHER , followed by the increase of the transcriptional activity by BC6OTHER / BC6ENTG complex formation in both SaOS - 2 cells and MC3T3 - E1 cells.	False
The inhibitors of BC6ENTG and BC6OTHER suppressed BC6ENTC - induced nuclear localization of BC6OTHER .	False
The inhibitors of BC6OTHER and BC6ENTG suppressed BC6ENTC - induced nuclear localization of BC6OTHER .	False
The inhibitors of BC6OTHER and BC6OTHER suppressed BC6ENTC - induced nuclear localization of BC6ENTG .	False
 BC6ENTC promotes the nuclear translocation of BC6ENTG and thereby induces BC6OTHER gene expression in osteoblast - like cell lines.	False
 BC6ENTC promotes the nuclear translocation of BC6OTHER and thereby induces BC6ENTG gene expression in osteoblast - like cell lines.	CPR:3
It remains to be fully elucidated whether use of BC6ENTC , an BC6ENTG sensitizer , and / or BC6OTHER , BC6OTHER secretagogues , affect cancer incidence in subjects with T2DM.	False
It remains to be fully elucidated whether use of BC6ENTC , an BC6OTHER sensitizer , and / or BC6OTHER , BC6ENTG secretagogues , affect cancer incidence in subjects with T2DM.	False
It remains to be fully elucidated whether use of BC6OTHER , an BC6ENTG sensitizer , and / or BC6ENTC , BC6OTHER secretagogues , affect cancer incidence in subjects with T2DM.	False
It remains to be fully elucidated whether use of BC6OTHER , an BC6OTHER sensitizer , and / or BC6ENTC , BC6ENTG secretagogues , affect cancer incidence in subjects with T2DM.	False
RESULTS: In drug discrimination studies , BC6ENTC fully mimicked the BC6ENTG agonist BC6OTHER , only partially substituted for BC6OTHER and BC6OTHER , and failed to substitute for BC6OTHER .	CPR:5
RESULTS: In drug discrimination studies , BC6OTHER fully mimicked the BC6ENTG agonist BC6ENTC , only partially substituted for BC6OTHER and BC6OTHER , and failed to substitute for BC6OTHER .	CPR:5
RESULTS: In drug discrimination studies , BC6OTHER fully mimicked the BC6ENTG agonist BC6OTHER , only partially substituted for BC6ENTC and BC6OTHER , and failed to substitute for BC6OTHER .	False
RESULTS: In drug discrimination studies , BC6OTHER fully mimicked the BC6ENTG agonist BC6OTHER , only partially substituted for BC6OTHER and BC6ENTC , and failed to substitute for BC6OTHER .	False
RESULTS: In drug discrimination studies , BC6OTHER fully mimicked the BC6ENTG agonist BC6OTHER , only partially substituted for BC6OTHER and BC6OTHER , and failed to substitute for BC6ENTC .	False
BC6ENTC produced a significant dose - related increase in flat body posture , forepaw treading , and lower - lip retraction which reflect a modulation of behavior by action at central BC6ENTG receptors.	False
Only pMPPI [ BC6ENTC ] , a selective BC6ENTG antagonist , was effective in inhibiting all BC6OTHER syndrome behaviors produced by BC6OTHER , whereas pMPPI was without effect on any behavior induced by BC6OTHER .	CPR:6
Only pMPPI [ BC6OTHER ] , a selective BC6ENTG antagonist , was effective in inhibiting all BC6ENTC syndrome behaviors produced by BC6OTHER , whereas pMPPI was without effect on any behavior induced by BC6OTHER .	False
Only pMPPI [ BC6OTHER ] , a selective BC6ENTG antagonist , was effective in inhibiting all BC6OTHER syndrome behaviors produced by BC6ENTC , whereas pMPPI was without effect on any behavior induced by BC6OTHER .	False
Only pMPPI [ BC6OTHER ] , a selective BC6ENTG antagonist , was effective in inhibiting all BC6OTHER syndrome behaviors produced by BC6OTHER , whereas pMPPI was without effect on any behavior induced by BC6ENTC .	False
CHEM dose dependently decreased body temperature in rats with a potency similar to that of the selective BC6ENTG agonist BC6ENTC .	CPR:5
Nevertheless , this action has generally been ignored in the mechanism of action of BC6ENTC , in favor of an exclusive role for BC6ENTG in considering its antiparkinsonian effects , or an exclusive role of BC6OTHER receptor activation in hallucinogenesis.	False
Nevertheless , this action has generally been ignored in the mechanism of action of BC6ENTC , in favor of an exclusive role for BC6OTHER in considering its antiparkinsonian effects , or an exclusive role of BC6ENTG receptor activation in hallucinogenesis.	False
CONCLUSION: We have demonstrated that the behavioral effects of low doses of BC6ENTC are clearly mediated by stimulation of BC6ENTG receptors.	False
Nevertheless , this action has generally been ignored in the mechanism of action of BC6OTHER , in favor of an exclusive role for BC6ENTC receptors in considering its antiparkinsonian effects , or an exclusive role of BC6ENTG receptor activation in hallucinogenesis.	False
These conclusions are surprising when one considers that the potent interaction of BC6ENTC with BC6ENTG receptors has been demonstrated in several different laboratories and that activation of BC6OTHER and BC6OTHER receptors can modulate dopaminergically mediated responses.	False
These conclusions are surprising when one considers that the potent interaction of BC6ENTC with BC6OTHER receptors has been demonstrated in several different laboratories and that activation of BC6ENTG and BC6OTHER receptors can modulate dopaminergically mediated responses.	False
These conclusions are surprising when one considers that the potent interaction of BC6ENTC with BC6OTHER receptors has been demonstrated in several different laboratories and that activation of BC6OTHER and BC6ENTG receptors can modulate dopaminergically mediated responses.	False
RATIONALE: There is substantial evidence that BC6ENTC can produce effects linked to BC6ENTG receptor occupancy.	False
Re - evaluation of BC6ENTC pharmacology: BC6ENTG - mediated behavioral effects overlap its other properties in rats.	False
Thus , the findings indicate dysregulations in the BC6ENTC system of patients diagnosed with CHEM with more longitudinal research being necessary to disentangle the relationship between childhood adversities , BC6ENTG system , and psychopathology.	False
Thus , the findings indicate dysregulations in the BC6ENTG system of patients diagnosed with CHEM with more longitudinal research being necessary to disentangle the relationship between childhood adversities , BC6ENTC system , and psychopathology.	False
In the present study , we compared plasma BC6ENTC levels of women with and without CHEM in the follicular phase and assessed the relationship between BC6ENTG concentrations and childhood traumata.	False
In the present study , we compared plasma BC6ENTG levels of women with and without CHEM in the follicular phase and assessed the relationship between BC6ENTC concentrations and childhood traumata.	False
Women diagnosed with CHEM had significantly reduced BC6ENTG concentrations , even after controlling for BC6ENTC , BC6OTHER , and contraceptive intake.	False
Women diagnosed with CHEM had significantly reduced BC6ENTG concentrations , even after controlling for BC6OTHER , BC6ENTC , and contraceptive intake.	False
Due to the ubiquitous nature of the BC6ENTC pathway , general inhibitors of BC6OTHER signaling proteins such as BC6ENTG , BC6OTHER and BC6OTHER would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Due to the ubiquitous nature of the BC6ENTC pathway , general inhibitors of BC6OTHER signaling proteins such as BC6OTHER , BC6ENTG and BC6OTHER would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Due to the ubiquitous nature of the BC6ENTC pathway , general inhibitors of BC6OTHER signaling proteins such as BC6OTHER , BC6OTHER and BC6ENTG would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Due to the ubiquitous nature of the BC6OTHER pathway , general inhibitors of BC6ENTC signaling proteins such as BC6ENTG , BC6OTHER and BC6OTHER would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Due to the ubiquitous nature of the BC6OTHER pathway , general inhibitors of BC6ENTC signaling proteins such as BC6OTHER , BC6ENTG and BC6OTHER would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Due to the ubiquitous nature of the BC6OTHER pathway , general inhibitors of BC6ENTC signaling proteins such as BC6OTHER , BC6OTHER and BC6ENTG would act non - specifically and universally , increasing the likelihood of serious 'off target' effects.	False
Computer modeling suggests that the BC6ENTG BC6OTHER mutation destabilizes the inactive conformation of the BC6OTHER to which BC6ENTC binds , but it is not predicted to impair binding of BC6OTHER by BC6OTHER .	False
Computer modeling suggests that the BC6OTHER BC6ENTG mutation destabilizes the inactive conformation of the BC6OTHER to which BC6ENTC binds , but it is not predicted to impair binding of BC6OTHER by BC6OTHER .	False
Computer modeling suggests that the BC6OTHER BC6OTHER mutation destabilizes the inactive conformation of the BC6ENTG to which BC6ENTC binds , but it is not predicted to impair binding of BC6OTHER by BC6OTHER .	False
Computer modeling suggests that the BC6OTHER BC6OTHER mutation destabilizes the inactive conformation of the BC6OTHER to which BC6ENTC binds , but it is not predicted to impair binding of BC6ENTG by BC6OTHER .	False
Computer modeling suggests that the BC6ENTG BC6OTHER mutation destabilizes the inactive conformation of the BC6OTHER to which BC6OTHER binds , but it is not predicted to impair binding of BC6OTHER by BC6ENTC .	False
Computer modeling suggests that the BC6OTHER BC6ENTG mutation destabilizes the inactive conformation of the BC6OTHER to which BC6OTHER binds , but it is not predicted to impair binding of BC6OTHER by BC6ENTC .	False
Computer modeling suggests that the BC6OTHER BC6OTHER mutation destabilizes the inactive conformation of the BC6ENTG to which BC6OTHER binds , but it is not predicted to impair binding of BC6OTHER by BC6ENTC .	False
Computer modeling suggests that the BC6OTHER BC6OTHER mutation destabilizes the inactive conformation of the BC6OTHER to which BC6OTHER binds , but it is not predicted to impair binding of BC6ENTG by BC6ENTC .	False
Moreover , BC6ENTC may be of clinical utility in other disease settings driven by activating BC6ENTG mutations.	False
This mutation is inherently resistant to BC6ENTC and , to date , there remains no effective curative therapy for systemic mastocytosis associated with BC6ENTG BC6OTHER .	False
This mutation is inherently resistant to BC6ENTC and , to date , there remains no effective curative therapy for systemic mastocytosis associated with BC6OTHER BC6ENTG .	False
BC6ENTC ( BC6OTHER ) is a novel orally bioavailable BC6ENTG / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	CPR:4
BC6ENTC ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6ENTG inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	CPR:4
BC6ENTC ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6ENTG - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6ENTC ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6ENTG isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6ENTC ) is a novel orally bioavailable BC6ENTG / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	CPR:4
BC6OTHER ( BC6ENTC ) is a novel orally bioavailable BC6OTHER / BC6ENTG inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	CPR:4
BC6OTHER ( BC6ENTC ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6ENTG - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6ENTC ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6OTHER - resistant BC6OTHER - BC6ENTG isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6OTHER ) is a novel orally bioavailable BC6ENTG / BC6OTHER inhibitor that has activity against multiple BC6ENTC - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6ENTG inhibitor that has activity against multiple BC6ENTC - resistant BC6OTHER - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6ENTC - resistant BC6ENTG - BC6OTHER isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
BC6OTHER ( BC6OTHER ) is a novel orally bioavailable BC6OTHER / BC6OTHER inhibitor that has activity against multiple BC6ENTC - resistant BC6OTHER - BC6ENTG isoforms in vitro that is presently showing considerable promise in early - phase clinical trials of chronic myeloid leukemia (CML).	False
In this study , we demonstrate significant inhibitory activity of BC6ENTC against both wild - type BC6ENTG and the BC6OTHER BC6OTHER mutation in the nanomolar range in in vitro and cell - based BC6OTHER assays.	CPR:4
In this study , we demonstrate significant inhibitory activity of BC6ENTC against both wild - type BC6OTHER and the BC6ENTG BC6OTHER mutation in the nanomolar range in in vitro and cell - based BC6OTHER assays.	CPR:4
In this study , we demonstrate significant inhibitory activity of BC6ENTC against both wild - type BC6OTHER and the BC6OTHER BC6ENTG mutation in the nanomolar range in in vitro and cell - based BC6OTHER assays.	CPR:4
In this study , we demonstrate significant inhibitory activity of BC6ENTC against both wild - type BC6OTHER and the BC6OTHER BC6OTHER mutation in the nanomolar range in in vitro and cell - based BC6ENTG assays.	False
Additionally , BC6ENTC leads to growth inhibition of a BC6ENTG BC6OTHER - harboring human masto - cytosis cell line.	CPR:4
Additionally , BC6ENTC leads to growth inhibition of a BC6OTHER BC6ENTG - harboring human masto - cytosis cell line.	CPR:4
 BC6ENTC ( BC6OTHER ) inhibits BC6ENTG BC6OTHER , an BC6OTHER - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	CPR:4
 BC6ENTC ( BC6OTHER ) inhibits BC6OTHER BC6ENTG , an BC6OTHER - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	CPR:4
 BC6OTHER ( BC6ENTC ) inhibits BC6ENTG BC6OTHER , an BC6OTHER - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	False
 BC6OTHER ( BC6ENTC ) inhibits BC6OTHER BC6ENTG , an BC6OTHER - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	CPR:4
 BC6OTHER ( BC6OTHER ) inhibits BC6ENTG BC6OTHER , an BC6ENTC - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	False
 BC6OTHER ( BC6OTHER ) inhibits BC6OTHER BC6ENTG , an BC6ENTC - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.	False
Block of BC6ENTG by BC6ENTC also displayed a positive voltage - dependence.	CPR:4
BC6ENTC blocked BC6ENTG channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.	CPR:4
We conclude that BC6ENTG can be blocked by certain antipsychotic drugs like BC6ENTC and BC6OTHER .	CPR:4
We conclude that BC6ENTG can be blocked by certain antipsychotic drugs like BC6OTHER and BC6ENTC .	CPR:4
Inhibition of BC6ENTG or related BC6ENTC channels in the brain may contribute to the efficacy / side effect profiles of some antipsychotic drugs.	False
The antipsychotic drugs BC6OTHER and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6ENTC channel known as BC6ENTG ( BC6OTHER ; BC6OTHER ).	False
The antipsychotic drugs BC6OTHER and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6ENTC channel known as BC6OTHER ( BC6ENTG ; BC6OTHER ).	False
The antipsychotic drugs BC6OTHER and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6ENTC channel known as BC6OTHER ( BC6OTHER ; BC6ENTG ).	False
The antipsychotic drugs BC6ENTC and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the BC6ENTG known as BC6OTHER ( BC6OTHER ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6ENTC and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6ENTG ( BC6OTHER ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6ENTC and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6OTHER ( BC6ENTG ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6ENTC and BC6OTHER are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6OTHER ( BC6OTHER ; BC6ENTG ).	CPR:4
We wished to test whether these drugs also displayed high affinity for the related neuronal BC6ENTC channel BC6ENTG .	False
The antipsychotic drugs BC6OTHER and BC6ENTC are known to prolong the QT interval on the electrocardiogram via a high affinity block of the BC6ENTG known as BC6OTHER ( BC6OTHER ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6OTHER and BC6ENTC are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6ENTG ( BC6OTHER ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6OTHER and BC6ENTC are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6OTHER ( BC6ENTG ; BC6OTHER ).	CPR:4
The antipsychotic drugs BC6OTHER and BC6ENTC are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac BC6OTHER channel known as BC6OTHER ( BC6OTHER ; BC6ENTG ).	CPR:4
Transient expression of BC6ENTG in Chinese hamster ovary cells produced outwardly directed BC6ENTC currents that activated at approximately - 50 mV and produced a large transient component at positive membrane potentials.	False
The antipsychotic drugs BC6ENTC and BC6OTHER block BC6ENTG , a human brain BC6OTHER channel.	CPR:4
The antipsychotic drugs BC6ENTC and BC6OTHER block BC6OTHER , a BC6ENTG .	CPR:4
The antipsychotic drugs BC6OTHER and BC6ENTC block BC6ENTG , a human brain BC6OTHER channel.	CPR:4
The antipsychotic drugs BC6OTHER and BC6ENTC block BC6OTHER , a BC6ENTG .	CPR:4
The antipsychotic drugs BC6OTHER and BC6OTHER block BC6ENTG , a human brain BC6ENTC channel.	False
Our data are consistent with different barriers for BC6OTHER recombination in BC6ENTG and BC6OTHER and the presence of a second BC6ENTC - binding site.	False
Our data are consistent with different barriers for BC6OTHER recombination in BC6OTHER and BC6ENTG and the presence of a second BC6ENTC - binding site.	False
The hypothesis that an additional BC6ENTC - binding cavity is present in BC6ENTG is also consistent with the effect of the BC6OTHER concentration on its rebinding.	False
The hypothesis that an additional BC6OTHER - binding cavity is present in BC6ENTG is also consistent with the effect of the BC6ENTC concentration on its rebinding.	False
The lack of the effect of BC6ENTC concentration on the geminate rebinding in BC6ENTG could be due to an isolated second site.	False
We confirm the existence of a second BC6ENTC site in the BC6ENTG of the BC6OTHER as previously hypothesized [A. Slama - Schwok , M. Negrerie , V. Berka , J.C. Lambry , A.L.	False
We confirm the existence of a second BC6ENTC site in the BC6OTHER of the BC6ENTG as previously hypothesized [A. Slama - Schwok , M. Negrerie , V. Berka , J.C. Lambry , A.L.	False
Martin , BC6ENTC ( BC6OTHER ) traffic in BC6ENTG .	False
Martin , BC6OTHER ( BC6ENTC ) traffic in BC6ENTG .	False
This site requires the presence of BC6ENTC and BC6OTHER ; and we propose that BC6OTHER dynamic and escape from BC6ENTG is regulated by the active site BC6OTHER - bonding network connecting between the CHEM , the substrate , and cofactor.	False
This site requires the presence of BC6OTHER and BC6ENTC ; and we propose that BC6OTHER dynamic and escape from BC6ENTG is regulated by the active site BC6OTHER - bonding network connecting between the CHEM , the substrate , and cofactor.	False
This site requires the presence of BC6OTHER and BC6OTHER ; and we propose that BC6ENTC dynamic and escape from BC6ENTG is regulated by the active site BC6OTHER - bonding network connecting between the CHEM , the substrate , and cofactor.	False
This site requires the presence of BC6OTHER and BC6OTHER ; and we propose that BC6OTHER dynamic and escape from BC6ENTG is regulated by the active site BC6ENTC - bonding network connecting between the CHEM , the substrate , and cofactor.	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , CHEM domain of BC6OTHER Synthase - like proteins) with striking sequence identity to the BC6ENTG of mammalian BC6ENTC synthases ( BC6OTHER ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , CHEM domain of BC6OTHER Synthase - like proteins) with striking sequence identity to the BC6OTHER of mammalian BC6ENTC synthases ( BC6ENTG ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6ENTG , CHEM domain of BC6OTHER Synthase - like proteins) with striking sequence identity to the BC6OTHER of mammalian BC6ENTC synthases ( BC6OTHER ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , BC6ENTG ) with striking sequence identity to the BC6OTHER of mammalian BC6ENTC synthases ( BC6OTHER ).	False
The unique properties of BC6ENTG make it an excellent model system for probing how the CHEM environment tunes BC6ENTC dynamics and for comparing it to the endothelial BC6OTHER synthase CHEM domain ( BC6OTHER ) using ultrafast transient spectroscopy.	False
The unique properties of BC6OTHER make it an excellent model system for probing how the CHEM environment tunes BC6ENTC dynamics and for comparing it to the BC6ENTG ( BC6OTHER ) using ultrafast transient spectroscopy.	False
The unique properties of BC6OTHER make it an excellent model system for probing how the CHEM environment tunes BC6ENTC dynamics and for comparing it to the endothelial BC6OTHER synthase CHEM domain ( BC6ENTG ) using ultrafast transient spectroscopy.	False
The unique properties of BC6ENTG make it an excellent model system for probing how the CHEM environment tunes BC6OTHER dynamics and for comparing it to the endothelial BC6ENTC synthase CHEM domain ( BC6OTHER ) using ultrafast transient spectroscopy.	False
The unique properties of BC6OTHER make it an excellent model system for probing how the CHEM environment tunes BC6OTHER dynamics and for comparing it to the endothelial BC6ENTC synthase CHEM domain ( BC6ENTG ) using ultrafast transient spectroscopy.	False
BC6ENTC rebinding in BC6ENTG from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6OTHER .	False
BC6ENTC rebinding in BC6OTHER from Staphylococcus aureus ( BC6ENTG ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6OTHER .	False
BC6ENTC rebinding in BC6OTHER from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6ENTG ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6OTHER .	False
BC6ENTC rebinding in BC6OTHER from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6ENTG in both oxidized and reduced forms in the presence of BC6OTHER .	False
BC6OTHER rebinding in BC6ENTG from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6ENTC .	False
BC6OTHER rebinding in BC6OTHER from Staphylococcus aureus ( BC6ENTG ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6ENTC .	False
BC6OTHER rebinding in BC6OTHER from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6ENTG ) or for BC6OTHER in both oxidized and reduced forms in the presence of BC6ENTC .	False
BC6OTHER rebinding in BC6OTHER from Staphylococcus aureus ( BC6OTHER ) is faster than that measured for either Bacillus anthracis ( BC6OTHER ) or for BC6ENTG in both oxidized and reduced forms in the presence of BC6ENTC .	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , CHEM domain of BC6ENTC Synthase - like proteins) with striking sequence identity to the BC6ENTG of mammalian BC6OTHER synthases ( BC6OTHER ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , CHEM domain of BC6ENTC Synthase - like proteins) with striking sequence identity to the BC6OTHER of BC6ENTG ( BC6OTHER ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6OTHER , CHEM domain of BC6ENTC Synthase - like proteins) with striking sequence identity to the BC6OTHER of mammalian BC6OTHER synthases ( BC6ENTG ).	False
Some Gram - positive bacterial pathogens harbor a gene that encodes a protein ( BC6ENTG , CHEM domain of BC6ENTC Synthase - like proteins) with striking sequence identity to the BC6OTHER of mammalian BC6OTHER synthases ( BC6OTHER ).	False
Our data are consistent with different barriers for BC6ENTC recombination in BC6ENTG and BC6OTHER and the presence of a second BC6OTHER - binding site.	False
Our data are consistent with different barriers for BC6ENTC recombination in BC6OTHER and BC6ENTG and the presence of a second BC6OTHER - binding site.	False
Dynamics of BC6ENTC rebinding to the BC6ENTG from bacterial pathogens.	False
These results indicate that BC6OTHER prevents lipid accumulation in HepG2 cells by blocking the expression of BC6ENTG and BC6OTHER through BC6OTHER / BC6OTHER activation , suggesting that BC6ENTC is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	False
These results indicate that BC6OTHER prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6ENTG through BC6OTHER / BC6OTHER activation , suggesting that BC6ENTC is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	False
These results indicate that BC6OTHER prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6ENTG / BC6OTHER activation , suggesting that BC6ENTC is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	False
These results indicate that BC6OTHER prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6OTHER / BC6ENTG activation , suggesting that BC6ENTC is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	False
These results indicate that BC6OTHER prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6OTHER / BC6OTHER activation , suggesting that BC6ENTC is a novel BC6ENTG activator with a role in the prevention and treatment of obesity.	CPR:3
BC6ENTC strongly inhibited high BC6OTHER - induced BC6ENTG ( BC6OTHER ) expression by modulating BC6OTHER ( BC6OTHER ) activation.	CPR:4
BC6ENTC strongly inhibited high BC6OTHER - induced BC6OTHER ( BC6ENTG ) expression by modulating BC6OTHER ( BC6OTHER ) activation.	CPR:4
BC6ENTC strongly inhibited high BC6OTHER - induced BC6OTHER ( BC6OTHER ) expression by modulating BC6ENTG ( BC6OTHER ) activation.	False
BC6ENTC strongly inhibited high BC6OTHER - induced BC6OTHER ( BC6OTHER ) expression by modulating BC6OTHER ( BC6ENTG ) activation.	False
BC6OTHER strongly inhibited high BC6ENTC - induced BC6ENTG ( BC6OTHER ) expression by modulating BC6OTHER ( BC6OTHER ) activation.	CPR:3
BC6OTHER strongly inhibited high BC6ENTC - induced BC6OTHER ( BC6ENTG ) expression by modulating BC6OTHER ( BC6OTHER ) activation.	CPR:3
BC6OTHER strongly inhibited high BC6ENTC - induced BC6OTHER ( BC6OTHER ) expression by modulating BC6ENTG ( BC6OTHER ) activation.	False
BC6OTHER strongly inhibited high BC6ENTC - induced BC6OTHER ( BC6OTHER ) expression by modulating BC6OTHER ( BC6ENTG ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6ENTC synthase ( BC6ENTG ) expression by modulating BC6OTHER ( BC6OTHER ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6ENTC synthase ( BC6OTHER ) expression by modulating BC6ENTG ( BC6OTHER ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6ENTC synthase ( BC6OTHER ) expression by modulating BC6OTHER ( BC6ENTG ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6ENTG ( BC6OTHER ) expression by modulating BC6ENTC regulatory element - binding protein - 1c ( BC6OTHER ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6OTHER ( BC6ENTG ) expression by modulating BC6ENTC regulatory element - binding protein - 1c ( BC6OTHER ) activation.	False
BC6OTHER strongly inhibited high BC6OTHER - induced BC6OTHER ( BC6OTHER ) expression by modulating BC6ENTC regulatory element - binding protein - 1c ( BC6ENTG ) activation.	False
Moreover , use of the pharmacological BC6ENTC - activated protein kinase ( BC6ENTG ) inhibitor BC6OTHER revealed that BC6OTHER is essential for suppressing BC6OTHER expression in BC6OTHER - treated cells.	False
Moreover , use of the pharmacological BC6ENTC - activated protein kinase ( BC6OTHER ) inhibitor BC6OTHER revealed that BC6ENTG is essential for suppressing BC6OTHER expression in BC6OTHER - treated cells.	False
Moreover , use of the pharmacological BC6ENTC - activated protein kinase ( BC6OTHER ) inhibitor BC6OTHER revealed that BC6OTHER is essential for suppressing BC6ENTG expression in BC6OTHER - treated cells.	False
Moreover , use of the pharmacological BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC revealed that BC6OTHER is essential for suppressing BC6OTHER expression in BC6OTHER - treated cells.	CPR:4
Moreover , use of the pharmacological BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC revealed that BC6OTHER is essential for suppressing BC6OTHER expression in BC6OTHER - treated cells.	CPR:4
Moreover , use of the pharmacological BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC revealed that BC6ENTG is essential for suppressing BC6OTHER expression in BC6OTHER - treated cells.	CPR:4
Moreover , use of the pharmacological BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC revealed that BC6OTHER is essential for suppressing BC6ENTG expression in BC6OTHER - treated cells.	False
Moreover , use of the pharmacological BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER revealed that BC6OTHER is essential for suppressing BC6OTHER expression in BC6ENTC - treated cells.	False
Moreover , use of the pharmacological BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER revealed that BC6OTHER is essential for suppressing BC6OTHER expression in BC6ENTC - treated cells.	False
Moreover , use of the pharmacological BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER revealed that BC6ENTG is essential for suppressing BC6OTHER expression in BC6ENTC - treated cells.	False
Moreover , use of the pharmacological BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER revealed that BC6OTHER is essential for suppressing BC6ENTG expression in BC6ENTC - treated cells.	False
Finally , we found that BC6ENTG ( BC6OTHER ) phosphorylation is required for the BC6ENTC - enhanced activation of BC6OTHER in HepG2 hepatocytes.	False
Finally , we found that BC6OTHER ( BC6ENTG ) phosphorylation is required for the BC6ENTC - enhanced activation of BC6OTHER in HepG2 hepatocytes.	False
Finally , we found that BC6OTHER ( BC6OTHER ) phosphorylation is required for the BC6ENTC - enhanced activation of BC6ENTG in HepG2 hepatocytes.	CPR:3
These results indicate that BC6ENTC prevents lipid accumulation in HepG2 cells by blocking the expression of BC6ENTG and BC6OTHER through BC6OTHER / BC6OTHER activation , suggesting that BC6OTHER is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	CPR:4
These results indicate that BC6ENTC prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6ENTG through BC6OTHER / BC6OTHER activation , suggesting that BC6OTHER is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	CPR:4
These results indicate that BC6ENTC prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6ENTG / BC6OTHER activation , suggesting that BC6OTHER is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	CPR:3
These results indicate that BC6ENTC prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6OTHER / BC6ENTG activation , suggesting that BC6OTHER is a novel BC6OTHER activator with a role in the prevention and treatment of obesity.	CPR:3
These results indicate that BC6ENTC prevents lipid accumulation in HepG2 cells by blocking the expression of BC6OTHER and BC6OTHER through BC6OTHER / BC6OTHER activation , suggesting that BC6OTHER is a novel BC6ENTG activator with a role in the prevention and treatment of obesity.	False
 BC6ENTC attenuates high BC6OTHER - induced lipid accumulation in human HepG2 hepatocytes through the activation of BC6ENTG / BC6OTHER - dependent signalling.	CPR:3
 BC6ENTC attenuates high BC6OTHER - induced lipid accumulation in human HepG2 hepatocytes through the activation of BC6OTHER / BC6ENTG - dependent signalling.	CPR:3
 BC6OTHER attenuates high BC6OTHER - induced lipid accumulation in human HepG2 hepatocytes through the activation of BC6ENTG / BC6ENTC - activated protein kinase - dependent signalling.	False
 BC6OTHER attenuates high BC6ENTC - induced lipid accumulation in human HepG2 hepatocytes through the activation of BC6ENTG / BC6OTHER - dependent signalling.	False
 BC6OTHER attenuates high BC6ENTC - induced lipid accumulation in human HepG2 hepatocytes through the activation of BC6OTHER / BC6ENTG - dependent signalling.	False
BC6ENTG ( BC6OTHER ) is a nuclear enzyme that removes BC6ENTC groups from BC6OTHER residues in BC6OTHER and other proteins to epigenetically regulate gene expression.	False
BC6OTHER ( BC6OTHER ) is a nuclear enzyme that removes BC6ENTC groups from BC6OTHER residues in BC6ENTG and other proteins to epigenetically regulate gene expression.	False
BC6OTHER ( BC6ENTG ) is a nuclear enzyme that removes BC6ENTC groups from BC6OTHER residues in BC6OTHER and other proteins to epigenetically regulate gene expression.	False
BC6ENTG ( BC6OTHER ) is a nuclear enzyme that removes BC6OTHER groups from BC6ENTC residues in BC6OTHER and other proteins to epigenetically regulate gene expression.	False
BC6OTHER ( BC6OTHER ) is a nuclear enzyme that removes BC6OTHER groups from BC6ENTC residues in BC6ENTG and other proteins to epigenetically regulate gene expression.	False
BC6OTHER ( BC6ENTG ) is a nuclear enzyme that removes BC6OTHER groups from BC6ENTC residues in BC6OTHER and other proteins to epigenetically regulate gene expression.	False
Loss of BC6ENTG , but not BC6OTHER family proteins , which are both involved in regulation of translation , attenuated the effects of BC6ENTC on the quality of newly translated proteins.	False
Loss of BC6OTHER , but not BC6ENTG family proteins , which are both involved in regulation of translation , attenuated the effects of BC6ENTC on the quality of newly translated proteins.	False
Mammalian target of BC6ENTC complex 1 ( BC6ENTG ) regulates cell growth and may regulate organismal aging by controlling mRNA translation.	False
Unable to reverse BC6ENTG phosphorylation , TXM - CB3 ( BC6ENTC ) appeared to function in part , through inhibiting BC6OTHER - BC6OTHER dissociation.	False
Unable to reverse BC6OTHER phosphorylation , TXM - CB3 ( BC6ENTC ) appeared to function in part , through inhibiting BC6ENTG - BC6OTHER dissociation.	False
Unable to reverse BC6OTHER phosphorylation , TXM - CB3 ( BC6ENTC ) appeared to function in part , through inhibiting BC6OTHER - BC6ENTG dissociation.	False
The BC6ENTG mimetics peptides (TXM) protected insulinoma INS 832 / 13 cells from oxidative stress induced by selectively inhibiting BC6OTHER with BC6ENTC ( BC6OTHER ).	False
The BC6OTHER mimetics peptides (TXM) protected insulinoma INS 832 / 13 cells from oxidative stress induced by selectively inhibiting BC6ENTG with BC6ENTC ( BC6OTHER ).	CPR:4
The BC6ENTG mimetics peptides (TXM) protected insulinoma INS 832 / 13 cells from oxidative stress induced by selectively inhibiting BC6OTHER with BC6OTHER ( BC6ENTC ).	False
The BC6OTHER mimetics peptides (TXM) protected insulinoma INS 832 / 13 cells from oxidative stress induced by selectively inhibiting BC6ENTG with BC6OTHER ( BC6ENTC ).	CPR:4
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ) phosphorylation , in correlation with preventing BC6OTHER cleavage and thereby BC6OTHER dissociation.	CPR:3
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ) phosphorylation , in correlation with preventing BC6OTHER cleavage and thereby BC6OTHER dissociation.	CPR:3
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ) phosphorylation , in correlation with preventing BC6OTHER cleavage and thereby BC6OTHER dissociation.	CPR:3
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ) phosphorylation , in correlation with preventing BC6OTHER cleavage and thereby BC6OTHER dissociation.	CPR:3
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) phosphorylation , in correlation with preventing BC6ENTG cleavage and thereby BC6OTHER dissociation.	False
The TXM peptides were effective in inhibiting BC6ENTC - induced BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) phosphorylation , in correlation with preventing BC6OTHER cleavage and thereby BC6ENTG dissociation.	False
 BC6ENTG - mimetic peptides (TXM) reverse BC6ENTC induced apoptosis and restore BC6OTHER secretion in insulinoma cells.	False
 BC6OTHER - mimetic peptides (TXM) reverse BC6ENTC induced apoptosis and restore BC6ENTG secretion in insulinoma cells.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6ENTC synthesis through downregulation of the BC6ENTG gene , which was mediated through reduced expression of the BC6OTHER gene.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6ENTC synthesis through downregulation of the CHEM ( BC6OTHER ) reductase gene , which was mediated through reduced expression of the BC6ENTG gene.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the BC6ENTC ( BC6OTHER ) reductase gene , which was mediated through reduced expression of the BC6ENTG gene.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the CHEM ( BC6ENTC ) reductase gene , which was mediated through reduced expression of the BC6ENTG gene.	False
Taken together , these findings indicate that the inhibition of melanogenesis by BC6ENTC occurs through reduced expression of the BC6ENTG gene , which is mediated by BC6OTHER inhibition and suggest that BC6OTHER may be useful as a hyperpigmentation inhibitor.	CPR:4
Taken together , these findings indicate that the inhibition of melanogenesis by BC6ENTC occurs through reduced expression of the BC6OTHER gene , which is mediated by BC6ENTG inhibition and suggest that BC6OTHER may be useful as a hyperpigmentation inhibitor.	CPR:4
Taken together , these findings indicate that the inhibition of melanogenesis by BC6OTHER occurs through reduced expression of the BC6ENTC reductase gene , which is mediated by BC6ENTG inhibition and suggest that BC6OTHER may be useful as a hyperpigmentation inhibitor.	False
Taken together , these findings indicate that the inhibition of melanogenesis by BC6OTHER occurs through reduced expression of the BC6ENTG gene , which is mediated by BC6OTHER inhibition and suggest that BC6ENTC may be useful as a hyperpigmentation inhibitor.	False
Taken together , these findings indicate that the inhibition of melanogenesis by BC6OTHER occurs through reduced expression of the BC6OTHER gene , which is mediated by BC6ENTG inhibition and suggest that BC6ENTC may be useful as a hyperpigmentation inhibitor.	False
The mRNA levels of BC6ENTG ( BC6OTHER ) and its downstream genes BC6OTHER , BC6OTHER , and BC6OTHER were reduced by BC6ENTC treatment.	CPR:4
The mRNA levels of BC6OTHER ( BC6ENTG ) and its downstream genes BC6OTHER , BC6OTHER , and BC6OTHER were reduced by BC6ENTC treatment.	CPR:4
The mRNA levels of BC6OTHER ( BC6OTHER ) and its downstream genes BC6ENTG , BC6OTHER , and BC6OTHER were reduced by BC6ENTC treatment.	CPR:4
The mRNA levels of BC6OTHER ( BC6OTHER ) and its downstream genes BC6OTHER , BC6ENTG , and BC6OTHER were reduced by BC6ENTC treatment.	CPR:4
The mRNA levels of BC6OTHER ( BC6OTHER ) and its downstream genes BC6OTHER , BC6OTHER , and BC6ENTG were reduced by BC6ENTC treatment.	CPR:4
Additionally , the mRNA levels of melanogenesis - related genes ( BC6ENTG , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) were down - regulated by BC6ENTC .	CPR:4
Additionally , the mRNA levels of melanogenesis - related genes ( BC6OTHER , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) were down - regulated by BC6ENTC .	CPR:4
Additionally , the mRNA levels of melanogenesis - related genes ( BC6OTHER , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) were down - regulated by BC6ENTC .	CPR:4
Additionally , the mRNA levels of melanogenesis - related genes ( BC6OTHER , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) were down - regulated by BC6ENTC .	CPR:4
Additionally , the mRNA levels of melanogenesis - related genes ( BC6OTHER , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) were down - regulated by BC6ENTC .	CPR:4
Furthermore , BC6ENTC production and BC6ENTG ( BC6OTHER ) activity were suppressed by BC6OTHER .	False
Furthermore , BC6ENTC production and BC6OTHER ( BC6ENTG ) activity were suppressed by BC6OTHER .	False
Furthermore , BC6OTHER production and BC6ENTG ( BC6OTHER ) activity were suppressed by BC6ENTC .	CPR:4
Furthermore , BC6OTHER production and BC6OTHER ( BC6ENTG ) activity were suppressed by BC6ENTC .	CPR:4
Moreover , attempts to elucidate a possible mechanism underlying the BC6ENTC - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the BC6ENTG gene , which was mediated through reduced expression of the BC6OTHER gene.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6ENTC - mediated effects revealed that BC6OTHER regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the CHEM ( BC6OTHER ) reductase gene , which was mediated through reduced expression of the BC6ENTG gene.	False
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6ENTC regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the BC6ENTG gene , which was mediated through reduced expression of the BC6OTHER gene.	CPR:4
Moreover , attempts to elucidate a possible mechanism underlying the BC6OTHER - mediated effects revealed that BC6ENTC regulated melanogenesis by inhibiting BC6OTHER synthesis through downregulation of the CHEM ( BC6OTHER ) reductase gene , which was mediated through reduced expression of the BC6ENTG gene.	CPR:4
 BC6ENTC inhibits melanogenesis through downregulation of BC6ENTG - dependent expression of BC6OTHER gene.	CPR:4
 BC6ENTC inhibits melanogenesis through downregulation of BC6OTHER - dependent expression of BC6ENTG gene.	CPR:4
 BC6OTHER inhibits melanogenesis through downregulation of BC6ENTG - dependent expression of BC6ENTC reductase gene.	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6OTHER (HK):siRNA nanoplexes modified with BC6ENTC and a cyclic BC6ENTG ( BC6OTHER ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6OTHER (HK):siRNA nanoplexes modified with BC6ENTC and a cyclic BC6OTHER ( BC6ENTG ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6OTHER (HK):siRNA nanoplexes modified with BC6ENTC and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6ENTG and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6OTHER (HK):siRNA nanoplexes modified with BC6ENTC and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6OTHER and BC6ENTG .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6ENTC - BC6OTHER (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6ENTG ( BC6OTHER ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6ENTC - BC6OTHER (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6ENTG ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6ENTC - BC6OTHER (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6ENTG and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6ENTC - BC6OTHER (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6OTHER and BC6ENTG .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6ENTC (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6ENTG ( BC6OTHER ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6ENTC (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6ENTG ) ligand targeting BC6OTHER and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6ENTC (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6ENTG and BC6OTHER .	False
We characterized in this study the pharmacokinetics and antitumor efficacy of BC6OTHER - BC6ENTC (HK):siRNA nanoplexes modified with BC6OTHER and a cyclic BC6OTHER ( BC6OTHER ) ligand targeting BC6OTHER and BC6ENTG .	False
Somatic BC6ENTC - converting enzyme (s - BC6ENTG ) plays a central role in blood pressure regulation and has been the target of most antihypertensive drugs.	False
The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel BC6ENTG ( BC6OTHER ) selective inhibitor BC6ENTC ( BC6OTHER ) , so that dose recommendations for clinical use can be provided.	CPR:4
The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel BC6OTHER ( BC6ENTG ) selective inhibitor BC6ENTC ( BC6OTHER ) , so that dose recommendations for clinical use can be provided.	CPR:4
The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel BC6ENTG ( BC6OTHER ) selective inhibitor BC6OTHER ( BC6ENTC ) , so that dose recommendations for clinical use can be provided.	CPR:4
The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel BC6OTHER ( BC6ENTG ) selective inhibitor BC6OTHER ( BC6ENTC ) , so that dose recommendations for clinical use can be provided.	CPR:4
No influence of moderate hepatic impairment on the pharmacokinetics of BC6ENTC , an oral BC6ENTG selective inhibitor.	CPR:4
Knockdown of BC6ENTG blocked enhancement in the early stage of cell adhesion by BC6ENTC treatment.	False
Thus , BC6ENTG was identified as the key protein involved in the enhancement of cell adhesion of BC6ENTC under serum - free conditions.	False
In conclusion , BC6ENTC protects HCC cells against serum - starvation - induced cell death by enhancing cell adhesion , and BC6ENTG plays an important role in HCC cell migration and invasion.	False
The most upregulated genes are BC6ENTG ( BC6OTHER ) , BC6ENTC triad nucleotide binding protein 3 ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) , which showed more than fivefold greater expression.	False
The most upregulated genes are BC6OTHER ( BC6ENTG ) , BC6ENTC triad nucleotide binding protein 3 ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) , which showed more than fivefold greater expression.	False
The most upregulated genes are BC6OTHER ( BC6OTHER ) , BC6ENTC triad nucleotide binding protein 3 ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) , which showed more than fivefold greater expression.	False
The most upregulated genes are BC6OTHER ( BC6OTHER ) , BC6ENTC triad nucleotide binding protein 3 ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) , which showed more than fivefold greater expression.	False
The most upregulated genes are BC6OTHER ( BC6OTHER ) , BC6ENTC triad nucleotide binding protein 3 ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) , which showed more than fivefold greater expression.	False
The most upregulated genes are BC6OTHER ( BC6OTHER ) , BC6ENTC triad nucleotide binding protein 3 ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) , which showed more than fivefold greater expression.	False
 BC6ENTC protects hepatocellular carcinoma cells against serum - starvation - induced cell death by upregulating BC6ENTG .	CPR:3
BC6ENTG interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6ENTG ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6ENTG ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6ENTG and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6ENTG  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6ENTG and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6ENTG ( BC6OTHER ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6ENTG ) BC6OTHER ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6ENTG ( BC6OTHER ) pathways.	False
BC6OTHER interacts with BC6OTHER ( BC6OTHER ) , BC6OTHER and other receptor BC6ENTC kinases at the cell membrane and contributes to activation of the BC6OTHER  BC6OTHER and BC6OTHER ( BC6OTHER ) BC6OTHER ( BC6ENTG ) pathways.	False
 These results suggest that the enantioselective disposition of BC6ENTC and its active metabolites are influenced by the altered genetic and environmental factors of BC6ENTG and BC6OTHER activity in vivo.	False
 These results suggest that the enantioselective disposition of BC6ENTC and its active metabolites are influenced by the altered genetic and environmental factors of BC6OTHER and BC6ENTG activity in vivo.	False
In this study , we assessed the effects of BC6OTHER and BC6OTHER , known BC6OTHER and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6ENTC in conjunction with BC6ENTG polymorphisms in humans.	False
In this study , we assessed the effects of BC6OTHER and BC6OTHER , known BC6ENTG and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6ENTC in conjunction with BC6OTHER polymorphisms in humans.	False
In this study , we assessed the effects of BC6OTHER and BC6OTHER , known BC6OTHER and BC6ENTG inhibitors , respectively , on the enantioselective disposition of BC6ENTC in conjunction with BC6OTHER polymorphisms in humans.	False
In this study , we assessed the effects of BC6ENTC and BC6OTHER , known BC6OTHER and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6ENTG polymorphisms in humans.	CPR:4
In this study , we assessed the effects of BC6ENTC and BC6OTHER , known BC6ENTG and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6OTHER polymorphisms in humans.	CPR:4
In this study , we assessed the effects of BC6ENTC and BC6OTHER , known BC6OTHER and BC6ENTG inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6OTHER polymorphisms in humans.	CPR:4
In this study , we assessed the effects of BC6OTHER and BC6ENTC , known BC6OTHER and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6ENTG polymorphisms in humans.	False
In this study , we assessed the effects of BC6OTHER and BC6ENTC , known BC6ENTG and BC6OTHER inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6OTHER polymorphisms in humans.	CPR:4
In this study , we assessed the effects of BC6OTHER and BC6ENTC , known BC6OTHER and BC6ENTG inhibitors , respectively , on the enantioselective disposition of BC6OTHER in conjunction with BC6OTHER polymorphisms in humans.	CPR:4
Exposure to BC6ENTC was higher in subjects with the BC6ENTG *6 / *6 genotype , but no statistical difference was observed among the BC6OTHER genotypes.	False
Exposure to BC6ENTC was higher in subjects with the BC6OTHER *6 / *6 genotype , but no statistical difference was observed among the BC6ENTG genotypes.	False
BC6ENTC is metabolized to its active metabolite , BC6OTHER , mainly by the BC6OTHER enzymes BC6ENTG .	False
BC6ENTC is metabolized to its active metabolite , BC6OTHER , mainly by the BC6ENTG enzymes BC6OTHER .	CPR:9
The BC6ENTG genotype did not influence BC6ENTC , BC6OTHER , or active moiety C / Ds.	False
The BC6ENTG genotype did not influence BC6OTHER , BC6ENTC , or active moiety C / Ds.	False
The BC6ENTG genotype in these 46 patients was again associated with BC6ENTC C / D (P = 0.001) but not with BC6OTHER C / D or active moiety C / D , as previously shown by our group in 37 of these patients.	False
The BC6ENTG genotype in these 46 patients was again associated with BC6OTHER C / D (P = 0.001) but not with BC6ENTC C / D or active moiety C / D , as previously shown by our group in 37 of these patients.	False
Patients homozygous for the BC6ENTG 3435T / 2677T / 1236T haplotype had significantly lower C / Ds of BC6ENTC (P = 0.026) and active moiety (P = 0.028) than patients carrying other BC6OTHER genotypes.	False
Patients homozygous for the BC6OTHER 3435T / 2677T / 1236T haplotype had significantly lower C / Ds of BC6ENTC (P = 0.026) and active moiety (P = 0.028) than patients carrying other BC6ENTG genotypes.	False
In conclusion , our results confirmed the significant effect of BC6ENTG genotype on the steady - state plasma levels of BC6ENTC and showed that BC6OTHER polymorphisms have a moderate effect on those of BC6OTHER and the active moiety.	False
In conclusion , our results confirmed the significant effect of BC6OTHER genotype on the steady - state plasma levels of BC6ENTC and showed that BC6ENTG polymorphisms have a moderate effect on those of BC6OTHER and the active moiety.	False
In conclusion , our results confirmed the significant effect of BC6ENTG genotype on the steady - state plasma levels of BC6OTHER and showed that BC6OTHER polymorphisms have a moderate effect on those of BC6ENTC and the active moiety.	False
In conclusion , our results confirmed the significant effect of BC6OTHER genotype on the steady - state plasma levels of BC6OTHER and showed that BC6ENTG polymorphisms have a moderate effect on those of BC6ENTC and the active moiety.	False
Both BC6ENTC and BC6OTHER are substrates of BC6ENTG ( BC6OTHER ) , a transport protein involved in drug absorption , distribution , and elimination.	CPR:9
Both BC6ENTC and BC6OTHER are substrates of BC6OTHER ( BC6ENTG ) , a transport protein involved in drug absorption , distribution , and elimination.	CPR:9
Both BC6OTHER and BC6ENTC are substrates of BC6ENTG ( BC6OTHER ) , a transport protein involved in drug absorption , distribution , and elimination.	CPR:9
Both BC6OTHER and BC6ENTC are substrates of BC6OTHER ( BC6ENTG ) , a transport protein involved in drug absorption , distribution , and elimination.	CPR:9
BC6OTHER is metabolized to its active metabolite , BC6ENTC , mainly by the BC6OTHER enzymes BC6ENTG .	False
BC6OTHER is metabolized to its active metabolite , BC6ENTC , mainly by the BC6ENTG enzymes BC6OTHER .	CPR:9
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6ENTG and BC6OTHER ( BC6OTHER ) on the steady - state plasma levels of BC6ENTC , BC6OTHER , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6ENTG ( BC6OTHER ) on the steady - state plasma levels of BC6ENTC , BC6OTHER , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6OTHER ( BC6ENTG ) on the steady - state plasma levels of BC6ENTC , BC6OTHER , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6OTHER ( BC6OTHER ) on the steady - state plasma levels of BC6ENTC , BC6OTHER , and the active moiety , taking BC6ENTG genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6ENTG and BC6OTHER ( BC6OTHER ) on the steady - state plasma levels of BC6OTHER , BC6ENTC , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6ENTG ( BC6OTHER ) on the steady - state plasma levels of BC6OTHER , BC6ENTC , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6OTHER ( BC6ENTG ) on the steady - state plasma levels of BC6OTHER , BC6ENTC , and the active moiety , taking BC6OTHER genotype status into account.	False
The aim of the present study was to evaluate the influence of polymorphisms in genes encoding BC6OTHER and BC6OTHER ( BC6OTHER ) on the steady - state plasma levels of BC6OTHER , BC6ENTC , and the active moiety , taking BC6ENTG genotype status into account.	False
 BC6ENTG polymorphisms influence steady - state plasma levels of BC6ENTC and BC6OTHER active moiety.	False
 BC6ENTG polymorphisms influence steady - state plasma levels of BC6OTHER and BC6ENTC active moiety.	False
In the BC6ENTC group , BC6ENTG activity was decreased with statistically high significance compared to group I.	CPR:4
The use of BC6ENTG agonist BC6ENTC attenuates EAP.	CPR:5
Our findings suggest that stimulation of BC6ENTG plays a positive role in the BC6ENTC - induced EAP in rats.	False
The aim of this study is (Ed note: Purpose statements should be in present tense) to evaluate the effects of the BC6ENTG agonist on the course of BC6ENTC - induced experimental acute pancreatitis (EAP).	False
The experiments were performed on 80 male Wistar rats , 58 of which survived , subdivided into 3 groups: C - control rats , I - EAP group , and II - EAP group treated with the BC6ENTG agonist BC6ENTC BC6OTHER at a dose of 0.75 mg / kg b.w.	CPR:5
The experiments were performed on 80 male Wistar rats , 58 of which survived , subdivided into 3 groups: C - control rats , I - EAP group , and II - EAP group treated with the BC6ENTG agonist BC6OTHER BC6ENTC at a dose of 0.75 mg / kg b.w.	CPR:5
The effects of the BC6ENTG agonist BC6ENTC on BC6OTHER - induced experimental acute pancreatitis.	CPR:5
The effects of the BC6ENTG agonist BC6OTHER on BC6ENTC - induced experimental acute pancreatitis.	False
Inhibition studies have suggested that BC6ENTG ( BC6OTHER , EC ) isoforms might regulate the use of BC6ENTC by different metabolic pathways.	False
Inhibition studies have suggested that BC6OTHER ( BC6ENTG , EC ) isoforms might regulate the use of BC6ENTC by different metabolic pathways.	False
BC6OTHER , a competitive inhibitor of both BC6OTHER and BC6OTHER , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6ENTC - sensitive BC6ENTG is present in mitochondria.	False
BC6OTHER , a competitive inhibitor of both BC6ENTG and BC6OTHER , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6ENTC - sensitive BC6OTHER is present in mitochondria.	False
BC6OTHER , a competitive inhibitor of both BC6OTHER and BC6ENTG , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6ENTC - sensitive BC6OTHER is present in mitochondria.	False
BC6OTHER , a competitive inhibitor of both BC6OTHER and BC6OTHER , inhibited BC6ENTG activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6ENTC - sensitive BC6OTHER is present in mitochondria.	False
Re - feeding normal chow or a high BC6ENTC diet for 24 h after a 48 - h fast increased both BC6ENTG and BC6OTHER protein expression 1.5 - 2.0 - fold , consistent with inhibition studies.	CPR:3
Re - feeding normal chow or a high BC6ENTC diet for 24 h after a 48 - h fast increased both BC6OTHER and BC6ENTG protein expression 1.5 - 2.0 - fold , consistent with inhibition studies.	CPR:3
These results suggest that BC6ENTG and BC6OTHER may be linked to BC6ENTC synthesis.	CPR:9
These results suggest that BC6OTHER and BC6ENTG may be linked to BC6ENTC synthesis.	CPR:9
Taken together , the data suggest that BC6ENTC may be functionally channeled to specific metabolic pathways through different BC6ENTG isoforms in unique subcellular locations.	False
Inhibition studies have suggested that BC6ENTC synthetase ( BC6ENTG , EC ) isoforms might regulate the use of BC6OTHER by different metabolic pathways.	False
Consistent with these locations , BC6ENTC , an inhibitor of BC6ENTG , inhibited BC6OTHER activity 47% in MAM and 28% in endoplasmic reticulum.	CPR:4
Consistent with these locations , BC6ENTC , an inhibitor of BC6OTHER , inhibited BC6ENTG activity 47% in MAM and 28% in endoplasmic reticulum.	CPR:4
BC6ENTC , a second BC6ENTG inhibitor , inhibited BC6OTHER activity <10% in microsomes and mitochondria and 45% in MAM.	CPR:4
BC6ENTC , a second BC6OTHER inhibitor , inhibited BC6ENTG activity <10% in microsomes and mitochondria and 45% in MAM.	CPR:4
BC6ENTC , a competitive inhibitor of both BC6OTHER and BC6OTHER , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6OTHER - sensitive BC6ENTG is present in mitochondria.	False
BC6ENTC , a competitive inhibitor of both BC6ENTG and BC6OTHER , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6OTHER - sensitive BC6OTHER is present in mitochondria.	CPR:4
BC6ENTC , a competitive inhibitor of both BC6OTHER and BC6ENTG , inhibited BC6OTHER activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6OTHER - sensitive BC6OTHER is present in mitochondria.	CPR:4
BC6ENTC , a competitive inhibitor of both BC6OTHER and BC6OTHER , inhibited BC6ENTG activity similarly in endoplasmic reticulum , MAM , and mitochondria , suggesting that a hitherto unidentified BC6OTHER - sensitive BC6OTHER is present in mitochondria.	CPR:4
Interestingly , BC6ENTC - labeled BC6ENTG ( BC6OTHER - BC6OTHER ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%).	False
Interestingly , BC6ENTC - labeled BC6OTHER ( BC6OTHER - BC6ENTG ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%).	False
Interestingly , BC6OTHER - labeled BC6ENTG ( BC6ENTC - BC6OTHER ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%).	False
Interestingly , BC6OTHER - labeled BC6OTHER ( BC6ENTC - BC6ENTG ) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%).	False
The in vitro release studies showed that release of BC6ENTC - BC6ENTG was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6OTHER with about 96.8% of BC6OTHER - BC6OTHER released in 22 h from nanogel 1.	False
The in vitro release studies showed that release of BC6ENTC - BC6OTHER was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6OTHER with about 96.8% of BC6OTHER - BC6ENTG released in 22 h from nanogel 1.	False
The in vitro release studies showed that release of BC6OTHER - BC6ENTG was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6ENTC with about 96.8% of BC6OTHER - BC6OTHER released in 22 h from nanogel 1.	False
The in vitro release studies showed that release of BC6OTHER - BC6OTHER was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6ENTC with about 96.8% of BC6OTHER - BC6ENTG released in 22 h from nanogel 1.	False
The in vitro release studies showed that release of BC6OTHER - BC6ENTG was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6OTHER with about 96.8% of BC6ENTC - BC6OTHER released in 22 h from nanogel 1.	False
The in vitro release studies showed that release of BC6OTHER - BC6OTHER was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM BC6OTHER with about 96.8% of BC6ENTC - BC6ENTG released in 22 h from nanogel 1.	False
Confocal microscopy results showed that nanogel 1 delivered and released BC6ENTC - BC6ENTG into the perinuclei region of HeLa cells following 8 h incubation.	False
Peptide sequences selected using MICA4 were rich in basic or BC6ENTC - containing BC6OTHER , and the surface of the BC6ENTG surrounding CHEM358 , which is known to be critical for MICA4 binding , was likewise rich in these BC6OTHER .	False
Peptide sequences selected using MICA4 were rich in basic or BC6OTHER - containing BC6ENTC , and the surface of the BC6ENTG surrounding CHEM358 , which is known to be critical for MICA4 binding , was likewise rich in these BC6OTHER .	False
Peptide sequences selected using MICA4 were rich in basic or BC6OTHER - containing BC6OTHER , and the surface of the BC6ENTG surrounding CHEM358 , which is known to be critical for MICA4 binding , was likewise rich in these BC6ENTC .	False
Also , the two phage most reactive with MICA4 encoded the motif BC6ENTG , and the reverse of this sequence , BC6ENTC , was located in this same region.	False
The BC6OTHER , BC6OTHER ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6ENTC , to the BC6ENTG of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6OTHER , BC6OTHER ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6ENTC , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6ENTG can initiate autoimmune diabetes.	False
The BC6OTHER , BC6ENTG ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6ENTC , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6ENTG , BC6OTHER ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6ENTC , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6OTHER , BC6OTHER ( BC6ENTG ) , contains a region of sequence similarity , including six identical residues BC6ENTC , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
Thus , we have defined the MICA3 and MICA4 epitopes on BC6ENTG using the combination of phage display , molecular modeling , and mutagenesis and have provided compelling evidence for the involvement of the BC6ENTC loop in the MICA3 epitope.	False
The BC6OTHER , BC6ENTC decarboxylase ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6ENTG , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6OTHER , BC6ENTC decarboxylase ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6OTHER , to the BC6ENTG of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6OTHER , BC6ENTC decarboxylase ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6OTHER , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6ENTG can initiate autoimmune diabetes.	False
The BC6ENTG , BC6ENTC decarboxylase ( BC6OTHER ) , contains a region of sequence similarity , including six identical residues BC6OTHER , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The BC6OTHER , BC6ENTC decarboxylase ( BC6ENTG ) , contains a region of sequence similarity , including six identical residues BC6OTHER , to the BC6OTHER of coxsackie B virus , suggesting that cross - reactivity between coxsackie B virus and BC6OTHER can initiate autoimmune diabetes.	False
The identified peptide sequences could be mapped to a homology model of the BC6ENTC ( BC6OTHER ) binding domain of BC6ENTG .	False
The identified peptide sequences could be mapped to a homology model of the CHEM ( BC6ENTC ) binding domain of BC6ENTG .	False
For MICA3 , a surface loop containing the sequence BC6ENTC and two adjacent exposed helixes were identified in the BC6ENTG as well as a region of the BC6OTHER terminus of BC6OTHER that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6ENTC and two adjacent exposed helixes were identified in the BC6OTHER as well as a region of the BC6OTHER terminus of BC6ENTG that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6ENTG and two adjacent exposed helixes were identified in the BC6ENTC binding domain as well as a region of the BC6OTHER terminus of BC6OTHER that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6OTHER and two adjacent exposed helixes were identified in the BC6ENTC binding domain as well as a region of the BC6OTHER terminus of BC6ENTG that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6ENTG and two adjacent exposed helixes were identified in the BC6OTHER as well as a region of the BC6ENTC terminus of BC6OTHER that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6OTHER and two adjacent exposed helixes were identified in the BC6ENTG as well as a region of the BC6ENTC terminus of BC6OTHER that has previously been identified as critical for MICA3 binding.	False
For MICA3 , a surface loop containing the sequence BC6OTHER and two adjacent exposed helixes were identified in the BC6OTHER as well as a region of the BC6ENTC terminus of BC6ENTG that has previously been identified as critical for MICA3 binding.	False
AIM: To assess the efficacy and safety of a 24 - week treatment with BC6ENTC , a highly selective once - daily oral BC6ENTG ( BC6OTHER ) inhibitor , in patients with type 2 diabetes who had inadequate glycaemic control [ BC6OTHER ( BC6OTHER ) >or=7.5% and <or=10.5%] while on CHEM alone or in combination with CHEM.	CPR:4
AIM: To assess the efficacy and safety of a 24 - week treatment with BC6ENTC , a highly selective once - daily oral BC6OTHER ( BC6ENTG ) inhibitor , in patients with type 2 diabetes who had inadequate glycaemic control [ BC6OTHER ( BC6OTHER ) >or=7.5% and <or=10.5%] while on CHEM alone or in combination with CHEM.	CPR:4
AIM: To assess the efficacy and safety of a 24 - week treatment with BC6ENTC , a highly selective once - daily oral BC6OTHER ( BC6OTHER ) inhibitor , in patients with type 2 diabetes who had inadequate glycaemic control [ BC6ENTG ( BC6OTHER ) >or=7.5% and <or=10.5%] while on CHEM alone or in combination with CHEM.	False
AIM: To assess the efficacy and safety of a 24 - week treatment with BC6ENTC , a highly selective once - daily oral BC6OTHER ( BC6OTHER ) inhibitor , in patients with type 2 diabetes who had inadequate glycaemic control [ BC6OTHER ( BC6ENTG ) >or=7.5% and <or=10.5%] while on CHEM alone or in combination with CHEM.	False
Efficacy and safety of the BC6ENTG inhibitor , BC6OTHER , in patients with type 2 diabetes mellitus inadequately controlled on BC6ENTC alone or on BC6OTHER and BC6OTHER .	False
Efficacy and safety of the BC6ENTG inhibitor , BC6OTHER , in patients with type 2 diabetes mellitus inadequately controlled on BC6OTHER alone or on BC6ENTC and BC6OTHER .	False
Efficacy and safety of the BC6ENTG inhibitor , BC6OTHER , in patients with type 2 diabetes mellitus inadequately controlled on BC6OTHER alone or on BC6OTHER and BC6ENTC .	False
Efficacy and safety of the BC6ENTG inhibitor , BC6ENTC , in patients with type 2 diabetes mellitus inadequately controlled on BC6OTHER alone or on BC6OTHER and BC6OTHER .	CPR:4
A great deal of information has now accumulated pertaining to the mechanisms by which BC6ENTG , such as the BC6ENTC receptor , modulate the activity of responsive genes.	False
In addition to studies focused on the mechanisms of BC6ENTG function , additional work has illuminated the mechanism by which BC6ENTC are metabolized in selected tissues.	False
[Trp(7)] BC6ENTG and [Trp(8)] BC6OTHER but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6OTHER than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6ENTG but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6OTHER than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6OTHER but not [His(5)] BC6ENTG exhibit a higher potency in activating wild - type BC6OTHER than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6OTHER but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6ENTG than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6OTHER but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6OTHER than native BC6ENTG , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6OTHER but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6OTHER than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6ENTG are more important than position 5 for differential recognition by BC6OTHER .	False
[Trp(7)] BC6OTHER and [Trp(8)] BC6OTHER but not [His(5)] BC6OTHER exhibit a higher potency in activating wild - type BC6OTHER than native BC6OTHER , indicating that BC6ENTC at positions 7 and 8 of BC6OTHER are more important than position 5 for differential recognition by BC6ENTG .	False
Point - mutation studies indicate that four BC6ENTC , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6ENTC / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6ENTC (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6ENTC / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6ENTC (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6ENTC / BC6OTHER (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6ENTC (7.46) , and BC6OTHER / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6ENTC / BC6OTHER (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Point - mutation studies indicate that four BC6OTHER , BC6OTHER / BC6OTHER (7.38) , BC6OTHER / BC6OTHER (7.43) , BC6OTHER / BC6OTHER (7.46) , and BC6OTHER / BC6ENTC (7.47) in BC6ENTG are critical for ligand selectivity as well as receptor conformation.	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6ENTC (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6ENTC (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6ENTC (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6ENTC in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6ENTC (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6ENTC (7.43) , BC6OTHER (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6ENTC (7.46) , and BC6OTHER (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6ENTG , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6ENTG from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6ENTG .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6ENTG and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6OTHER ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6ENTG ) in BC6OTHER exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
Furthermore , a combinatory mutation ( BC6OTHER (7.31) - BC6OTHER (7.32) - BC6OTHER (7.33) motif to BC6OTHER in BC6OTHER and BC6OTHER (7.38) , BC6OTHER (7.43) , BC6OTHER (7.46) , and BC6ENTC (7.47) to those of BC6OTHER ) in BC6ENTG exhibited an approximately 500 - fold increased sensitivity to BC6OTHER , indicating that these residues are critical for discriminating BC6OTHER from BC6OTHER .	False
These results suggested that BC6ENTC could inhibit invasion and angiogenesis by downregulation of BC6ENTG and BC6OTHER , resulting from the inhibition of BC6OTHER pathway.	CPR:4
These results suggested that BC6ENTC could inhibit invasion and angiogenesis by downregulation of BC6OTHER and BC6ENTG , resulting from the inhibition of BC6OTHER pathway.	CPR:4
These results suggested that BC6ENTC could inhibit invasion and angiogenesis by downregulation of BC6OTHER and BC6OTHER , resulting from the inhibition of BC6ENTG pathway.	CPR:4
Gelatin zymography showed that BC6ENTC inhibited secretion and activity of BC6ENTG .	CPR:4
Western blotting demonstrated that BC6ENTC effectively suppressed the expression of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Western blotting demonstrated that BC6ENTC effectively suppressed the expression of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
Western blotting demonstrated that BC6ENTC effectively suppressed the expression of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
Western blotting demonstrated that BC6ENTC effectively suppressed the expression of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Inhibition of angiogenesis and invasion by BC6ENTC is mediated by downregulation of BC6OTHER and BC6OTHER through BC6ENTG pathway in CHEM - MB - 231 breast cancer cells.	CPR:4
Inhibition of angiogenesis and invasion by BC6ENTC is mediated by downregulation of BC6ENTG and BC6OTHER through BC6OTHER pathway in CHEM - MB - 231 breast cancer cells.	CPR:4
Inhibition of angiogenesis and invasion by BC6ENTC is mediated by downregulation of BC6OTHER and BC6ENTG through BC6OTHER pathway in CHEM - MB - 231 breast cancer cells.	CPR:4
BC6OTHER effectively antagonized the positive inotropic effect of BC6ENTC even after inactivation of BC6ENTG by treatment with BC6OTHER , which is an indication that the BC6OTHER - sensitive subtype belongs to a class resistant to BC6OTHER .	CPR:5
BC6OTHER effectively antagonized the positive inotropic effect of BC6OTHER even after inactivation of BC6ENTG by treatment with BC6ENTC , which is an indication that the BC6OTHER - sensitive subtype belongs to a class resistant to BC6OTHER .	CPR:4
BC6OTHER effectively antagonized the positive inotropic effect of BC6OTHER even after inactivation of BC6ENTG by treatment with BC6OTHER , which is an indication that the BC6ENTC - sensitive subtype belongs to a class resistant to BC6OTHER .	False
BC6OTHER effectively antagonized the positive inotropic effect of BC6OTHER even after inactivation of BC6ENTG by treatment with BC6OTHER , which is an indication that the BC6OTHER - sensitive subtype belongs to a class resistant to BC6ENTC .	False
BC6ENTC , over the range of concentrations at which it antagonized the positive inotropic effect mediated by BC6ENTG , did not affect the accumulation of BC6OTHER that was induced by 10 microM BC6OTHER .	CPR:6
The influence of BC6OTHER , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6ENTC that are induced via BC6ENTG was studied in comparison with that of another BC6OTHER ligand BC6OTHER in the rabbit ventricular myocardium.	False
The influence of BC6OTHER , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6ENTC that are induced via BC6OTHER was studied in comparison with that of another BC6ENTG ligand BC6OTHER in the rabbit ventricular myocardium.	False
The influence of BC6OTHER , a selective BC6ENTG antagonist , on the positive inotropic effect and the accumulation of BC6ENTC that are induced via BC6OTHER was studied in comparison with that of another BC6OTHER ligand BC6OTHER in the rabbit ventricular myocardium.	False
BC6OTHER , over the range of concentrations at which it antagonized the positive inotropic effect mediated by BC6ENTG , did not affect the accumulation of BC6ENTC that was induced by 10 microM BC6OTHER .	False
BC6OTHER , over the range of concentrations at which it antagonized the positive inotropic effect mediated by BC6ENTG , did not affect the accumulation of BC6OTHER that was induced by 10 microM BC6ENTC .	False
The influence of BC6ENTC , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6ENTG was studied in comparison with that of another BC6OTHER ligand BC6OTHER in the rabbit ventricular myocardium.	False
The influence of BC6ENTC , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6OTHER was studied in comparison with that of another BC6ENTG ligand BC6OTHER in the rabbit ventricular myocardium.	False
The influence of BC6ENTC , a selective BC6ENTG antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6OTHER was studied in comparison with that of another BC6OTHER ligand BC6OTHER in the rabbit ventricular myocardium.	CPR:6
These results indicate that the positive inotropic effect , mediated via BC6ENTC - and BC6OTHER - sensitive subtype of BC6ENTG , is exerted by a subcellular mechanism that is independent of the accumulation of BC6OTHER .	CPR:6
These results indicate that the positive inotropic effect , mediated via BC6OTHER - and BC6ENTC - sensitive subtype of BC6ENTG , is exerted by a subcellular mechanism that is independent of the accumulation of BC6OTHER .	CPR:5
These results indicate that the positive inotropic effect , mediated via BC6OTHER - and BC6OTHER - sensitive subtype of BC6ENTG , is exerted by a subcellular mechanism that is independent of the accumulation of BC6ENTC .	False
The influence of BC6OTHER , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6ENTG was studied in comparison with that of another BC6OTHER ligand BC6ENTC in the rabbit ventricular myocardium.	False
The influence of BC6OTHER , a selective BC6OTHER antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6OTHER was studied in comparison with that of another BC6ENTG ligand BC6ENTC in the rabbit ventricular myocardium.	False
The influence of BC6OTHER , a selective BC6ENTG antagonist , on the positive inotropic effect and the accumulation of BC6OTHER that are induced via BC6OTHER was studied in comparison with that of another BC6OTHER ligand BC6ENTC in the rabbit ventricular myocardium.	False
BC6ENTC elicited a concentration - dependent positive inotropic effect via BC6ENTG in the presence of either BC6OTHER or BC6OTHER .	CPR:5
BC6OTHER elicited a concentration - dependent positive inotropic effect via BC6ENTG in the presence of either BC6ENTC or BC6OTHER .	False
BC6OTHER elicited a concentration - dependent positive inotropic effect via BC6ENTG in the presence of either BC6OTHER or BC6ENTC .	False
BC6ENTC effectively antagonized the positive inotropic effect of BC6OTHER even after inactivation of BC6ENTG by treatment with BC6OTHER , which is an indication that the BC6OTHER - sensitive subtype belongs to a class resistant to BC6OTHER .	CPR:6
 BC6ENTC , an BC6ENTG antagonist , inhibits the positive inotropic effect but not the accumulation of BC6OTHER in rabbit heart.	CPR:6
 BC6OTHER , an BC6ENTG antagonist , inhibits the positive inotropic effect but not the accumulation of BC6ENTC in rabbit heart.	False
Rheumatoid synovial cells expressed BC6ENTG mRNA , and the BC6OTHER ligands BC6ENTC and BC6OTHER reduced the proliferation and induced apoptosis in synovial cells.	False
Rheumatoid synovial cells expressed BC6OTHER mRNA , and the BC6ENTG ligands BC6ENTC and BC6OTHER reduced the proliferation and induced apoptosis in synovial cells.	False
Rheumatoid synovial cells expressed BC6ENTG mRNA , and the BC6OTHER ligands BC6OTHER and BC6ENTC reduced the proliferation and induced apoptosis in synovial cells.	False
Rheumatoid synovial cells expressed BC6OTHER mRNA , and the BC6ENTG ligands BC6OTHER and BC6ENTC reduced the proliferation and induced apoptosis in synovial cells.	False
BC6ENTC ( BC6OTHER ) , a selective BC6ENTG inhibitor , also inhibited cell proliferation , whereas it did not cause apoptosis.	CPR:4
BC6OTHER ( BC6ENTC ) , a selective BC6ENTG inhibitor , also inhibited cell proliferation , whereas it did not cause apoptosis.	CPR:4
The positive correlation between BC6ENTC and BC6ENTG concentrations might be the result of the BC6OTHER inductive effect during BC6OTHER synthesis.	CPR:3
The positive correlation between BC6ENTC and BC6OTHER concentrations might be the result of the BC6OTHER inductive effect during BC6ENTG synthesis.	CPR:3
The positive correlation between BC6OTHER and BC6ENTG concentrations might be the result of the BC6ENTC inductive effect during BC6OTHER synthesis.	CPR:3
The positive correlation between BC6OTHER and BC6OTHER concentrations might be the result of the BC6ENTC inductive effect during BC6ENTG synthesis.	CPR:3
The isolated increasing of BC6ENTG in boys with BC6ENTC deficiency has been assigned to the ecosensitiveness of the unfavourable environment.	False
We therefore concluded that , in Ivorian primary - school - aged children with BC6ENTC deficiency , nutritional , immunity and inflammatory proteins which are modified are respectively BC6ENTG , BC6OTHER and BC6OTHER .	False
We therefore concluded that , in Ivorian primary - school - aged children with BC6ENTC deficiency , nutritional , immunity and inflammatory proteins which are modified are respectively BC6OTHER , BC6ENTG and BC6OTHER .	False
We therefore concluded that , in Ivorian primary - school - aged children with BC6ENTC deficiency , nutritional , immunity and inflammatory proteins which are modified are respectively BC6OTHER , BC6OTHER and BC6ENTG .	False
We therefore concluded that , in Ivorian primary - school - aged children with BC6OTHER deficiency , nutritional , immunity and inflammatory proteins which are modified are respectively BC6ENTC binding protein , BC6ENTG and BC6OTHER .	False
We therefore concluded that , in Ivorian primary - school - aged children with BC6OTHER deficiency , nutritional , immunity and inflammatory proteins which are modified are respectively BC6ENTC binding protein , BC6OTHER and BC6ENTG .	False
Results showed that 96 children (36.6%) presented a BC6ENTC deficiency ( BC6OTHER < 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6ENTC deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6ENTC deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6ENTC deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6ENTC < 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6ENTC < 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6ENTC < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6ENTC < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6ENTC ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6ENTC ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6ENTC ( BC6OTHER > or = 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6ENTC ( BC6OTHER > or = 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6ENTC > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6ENTC > or = 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6ENTC > or = 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6ENTC > or = 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6ENTG / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6ENTC Binding Protein / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6ENTG molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6ENTC Binding Protein / BC6OTHER molar ratio = 0.40 + / - 0.08).	False
Results showed that 96 children (36.6%) presented a BC6OTHER deficiency ( BC6OTHER < 200 microg / L with a BC6OTHER / BC6OTHER molar ratio = 0.29 + / - 0.06) while 166 (63.3%) children presented normal blood concentrations of BC6OTHER ( BC6OTHER > or = 200 microg / L with a BC6ENTC Binding Protein / BC6ENTG molar ratio = 0.40 + / - 0.08).	False
This study showed that the BC6ENTC binding protein and the BC6ENTG are lower in children with BC6OTHER deficiency.	False
This study showed that the BC6ENTG and the BC6OTHER are lower in children with BC6ENTC deficiency.	False
This study showed that the BC6OTHER and the BC6ENTG are lower in children with BC6ENTC deficiency.	False
On the other hand , an isolated increase of BC6ENTG has been observed in boys with BC6ENTC deficiency.	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC kinase).	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC kinase).	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC kinase).	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER ( BC6ENTC kinase).	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER ( BC6ENTC kinase).	False
The potential candidate biomarkers screened in ovarian tumors and found to be significantly up - regulated in comparison to normal tissues were as follows: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG ( BC6ENTC kinase).	False
BC6OTHER and BC6OTHER (both at > or = 10( - 7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to BC6OTHER at 10( - 6) M was abolished by BC6ENTC which illustrates that the BC6OTHER - induced attenuation is BC6ENTG mediated.	False
BC6OTHER and BC6OTHER (both at > or = 10( - 7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to BC6OTHER at 10( - 6) M was abolished by BC6OTHER which illustrates that the BC6ENTC - induced attenuation is BC6ENTG mediated.	False
The BC6ENTC attenuation responses of the portal vein were inhibited by BC6OTHER and BC6OTHER (both at > or = 10( - 7) M) and the pA2 value for the BC6OTHER at BC6ENTG was 7.59.	False
The BC6OTHER attenuation responses of the portal vein were inhibited by BC6ENTC and BC6OTHER (both at > or = 10( - 7) M) and the pA2 value for the BC6OTHER at BC6ENTG was 7.59.	False
The BC6OTHER attenuation responses of the portal vein were inhibited by BC6OTHER and BC6ENTC (both at > or = 10( - 7) M) and the pA2 value for the BC6OTHER at BC6ENTG was 7.59.	False
The BC6OTHER attenuation responses of the portal vein were inhibited by BC6OTHER and BC6OTHER (both at > or = 10( - 7) M) and the pA2 value for the BC6ENTC at BC6ENTG was 7.59.	CPR:6
It is concluded that BC6ENTC and BC6OTHER are BC6ENTG selective antagonists.	CPR:6
It is concluded that BC6OTHER and BC6ENTC are BC6ENTG selective antagonists.	CPR:6
BC6ENTC (> or = 3 x 10( - 8) M) and BC6OTHER (> or = 10( - 8) M) caused surmountable antagonism of the BC6OTHER responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6ENTG of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6OTHER .	CPR:6
BC6ENTC (> or = 3 x 10( - 8) M) and BC6OTHER (> or = 10( - 8) M) caused surmountable antagonism of the BC6OTHER responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6OTHER of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6ENTG .	False
BC6OTHER (> or = 3 x 10( - 8) M) and BC6ENTC (> or = 10( - 8) M) caused surmountable antagonism of the BC6OTHER responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6ENTG of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6OTHER .	CPR:6
BC6OTHER (> or = 3 x 10( - 8) M) and BC6ENTC (> or = 10( - 8) M) caused surmountable antagonism of the BC6OTHER responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6OTHER of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6ENTG .	False
BC6OTHER (> or = 3 x 10( - 8) M) and BC6OTHER (> or = 10( - 8) M) caused surmountable antagonism of the BC6ENTC responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6ENTG of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6OTHER .	CPR:5
BC6OTHER (> or = 3 x 10( - 8) M) and BC6OTHER (> or = 10( - 8) M) caused surmountable antagonism of the BC6ENTC responses of the atria and the pA2 values were 8.60 and 8.98 at the BC6OTHER of the rat left atria and 7.90 and 8.31 , respectively , on the guinea - pig left atria which has functional BC6ENTG .	False
BC6ENTC and BC6OTHER (both at > or = 10( - 7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to BC6OTHER at 10( - 6) M was abolished by BC6OTHER which illustrates that the BC6OTHER - induced attenuation is BC6ENTG mediated.	False
BC6OTHER and BC6ENTC (both at > or = 10( - 7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to BC6OTHER at 10( - 6) M was abolished by BC6OTHER which illustrates that the BC6OTHER - induced attenuation is BC6ENTG mediated.	False
BC6OTHER and BC6OTHER (both at > or = 10( - 7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to BC6ENTC at 10( - 6) M was abolished by BC6OTHER which illustrates that the BC6OTHER - induced attenuation is BC6ENTG mediated.	False
The updated BC6OTHER gene sequence revealed inactivation by frame shifts , premature stop codons , and BC6ENTC changes specifying nonconservative replacement of BC6OTHER residues , similar to inactivation of BC6ENTG .	False
The updated BC6ENTG gene sequence revealed inactivation by frame shifts , premature stop codons , and BC6ENTC changes specifying nonconservative replacement of BC6OTHER residues , similar to inactivation of BC6OTHER .	False
The updated BC6OTHER gene sequence revealed inactivation by frame shifts , premature stop codons , and BC6OTHER changes specifying nonconservative replacement of BC6ENTC residues , similar to inactivation of BC6ENTG .	False
The updated BC6ENTG gene sequence revealed inactivation by frame shifts , premature stop codons , and BC6OTHER changes specifying nonconservative replacement of BC6ENTC residues , similar to inactivation of BC6OTHER .	False
These findings , and previous descriptions of inactivation of the BC6ENTG and deletions of prepro - BC6ENTC and BC6OTHER in laboratory rodents , suggest the BC6OTHER system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of prepro - BC6ENTC and BC6ENTG in laboratory rodents , suggest the BC6OTHER system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of prepro - BC6ENTC and BC6OTHER in laboratory rodents , suggest the BC6ENTG system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of prepro - BC6ENTC and BC6OTHER in laboratory rodents , suggest the BC6OTHER system has been replaced by the BC6ENTG system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6ENTG and deletions of prepro - BC6OTHER and BC6OTHER in laboratory rodents , suggest the BC6ENTC system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of BC6ENTG and BC6OTHER in laboratory rodents , suggest the BC6ENTC system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of prepro - BC6OTHER and BC6ENTG in laboratory rodents , suggest the BC6ENTC system has been replaced by the BC6OTHER system or is redundant in certain mammals.	False
These findings , and previous descriptions of inactivation of the BC6OTHER and deletions of prepro - BC6OTHER and BC6OTHER in laboratory rodents , suggest the BC6ENTC system has been replaced by the BC6ENTG system or is redundant in certain mammals.	False
New data for cattle (Bos taurus) indicates a gene encoding BC6ENTG CHEM possessing BC6ENTC (codon: BC6OTHER ) rather than BC6OTHER ( BC6OTHER ) at position three in the mature peptide.	False
New data for cattle (Bos taurus) indicates a gene encoding BC6ENTG CHEM possessing BC6OTHER (codon: BC6ENTC ) rather than BC6OTHER ( BC6OTHER ) at position three in the mature peptide.	False
New data for cattle (Bos taurus) indicates a gene encoding BC6ENTG CHEM possessing BC6OTHER (codon: BC6OTHER ) rather than BC6ENTC ( BC6OTHER ) at position three in the mature peptide.	False
New data for cattle (Bos taurus) indicates a gene encoding BC6ENTG CHEM possessing BC6OTHER (codon: BC6OTHER ) rather than BC6OTHER ( BC6ENTC ) at position three in the mature peptide.	False
A premature stop codon (TGA) replaces the expected BC6ENTC codon at position seven of BC6ENTG in sheep DNA.	False
Thus , both species possess prepro - BC6ENTC genes encoding inactive peptides , as previously described for BC6ENTG .	False
Thus , both species possess BC6ENTG genes encoding inactive peptides , as previously described for chimpanzee BC6ENTC .	False
Bovine and ovine BC6ENTC BC6OTHER ligand precursors and BC6ENTG genes are functionally inactivated.	False
 BC6ENTG BC6ENTC ligand precursors and BC6OTHER genes are functionally inactivated.	False
Bovine and ovine BC6OTHER BC6ENTC ligand precursors and BC6ENTG genes are functionally inactivated.	False
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
Analysis of enzyme activities and gene expression associated with BC6ENTC metabolism indicated that a significant decrease in BC6ENTG activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6ENTC metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6ENTG mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6ENTC metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6ENTG activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6ENTC phosphoribosyltransferase activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6ENTG mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6ENTC phosphoribosyltransferase activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6ENTG activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6ENTG activity in DLD - 1 / BC6ENTC cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6ENTC cells , a 7 - fold increase of BC6ENTG mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6ENTC cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6ENTG activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6ENTG activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6ENTC cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6ENTG mRNA in DLD - 1 / BC6ENTC cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6ENTC cells , and a 37 - fold decrease in BC6ENTG activity of DLD - 1 / BC6OTHER cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6ENTG activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6ENTC cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6ENTG mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6OTHER activity of DLD - 1 / BC6ENTC cells were the major mechanisms of drug resistance.	False
Analysis of enzyme activities and gene expression associated with BC6OTHER metabolism indicated that a significant decrease in BC6OTHER activity in DLD - 1 / BC6OTHER cells , a 7 - fold increase of BC6OTHER mRNA in DLD - 1 / BC6OTHER cells , and a 37 - fold decrease in BC6ENTG activity of DLD - 1 / BC6ENTC cells were the major mechanisms of drug resistance.	False
When DLD - 1 / BC6ENTC cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6ENTC cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6ENTC and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6ENTC and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6ENTC for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6ENTC for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6ENTC cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6ENTC cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6ENTC and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6ENTC and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6ENTC , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6ENTC , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6ENTC is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6ENTC is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6OTHER in the short - time is low compared to that of long - time exposure.	CPR:4
When DLD - 1 / BC6OTHER cells expressing increased BC6ENTG mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6OTHER inhibition , although the cytotoxicity of BC6ENTC in the short - time is low compared to that of long - time exposure.	False
When DLD - 1 / BC6OTHER cells expressing increased BC6OTHER mRNA were treated with BC6OTHER and BC6OTHER for only 4 h , the resistance ratios of DLD - 1 / BC6OTHER cells to parental DLD - 1 cells were markedly different for BC6OTHER and BC6OTHER , suggesting that the cytotoxicity with short - time exposure to BC6OTHER is due to a mechanism other than BC6ENTG inhibition , although the cytotoxicity of BC6ENTC in the short - time is low compared to that of long - time exposure.	False
In conclusion , BC6ENTC , an antimetabolite that inhibits BC6ENTG activity , may be effective against BC6OTHER and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6OTHER .	CPR:4
In conclusion , BC6ENTC , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6OTHER and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6ENTG and / or deletion of BC6OTHER .	False
In conclusion , BC6ENTC , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6OTHER and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6ENTG .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6ENTG activity , may be effective against BC6ENTC and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6OTHER .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6ENTC and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6ENTG and / or deletion of BC6OTHER .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6ENTC and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6ENTG .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6ENTG activity , may be effective against BC6OTHER and / or BC6ENTC - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6OTHER .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6OTHER and / or BC6ENTC - resistance in colorectal cancer cells caused by amplification of BC6ENTG and / or deletion of BC6OTHER .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6OTHER and / or BC6ENTC - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6ENTG .	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6ENTG activity , may be effective against BC6OTHER and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6OTHER and / or deletion of BC6ENTC phosphoribosyltransferase.	False
In conclusion , BC6OTHER , an antimetabolite that inhibits BC6OTHER activity , may be effective against BC6OTHER and / or BC6OTHER - resistance in colorectal cancer cells caused by amplification of BC6ENTG and / or deletion of BC6ENTC phosphoribosyltransferase.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTC synthase ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6ENTG ( BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of BC6OTHER ( BC6ENTG ).	CPR:4
Infrared spectroscopic studies revealed a reduced thermal stability both of the apo - and the holo - BC6ENTG on binding of BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Infrared spectroscopic studies revealed a reduced thermal stability both of the apo - and the holo - BC6ENTG on binding of BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Infrared spectroscopic studies revealed a reduced thermal stability both of the apo - and the holo - BC6ENTG on binding of BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Thus , our studies provide new insight into the regulation of BC6ENTG by the concentration of BC6ENTC which may have significant implications for the physiological regulation of BC6OTHER biosynthesis in neuroendocrine cells.	False
Thus , our studies provide new insight into the regulation of BC6ENTG by the concentration of BC6OTHER which may have significant implications for the physiological regulation of BC6ENTC biosynthesis in neuroendocrine cells.	False
Kinetic studies of tetrameric recombinant human BC6ENTC hydroxylase isoform 1 ( BC6ENTG ) have revealed properties so far not reported for this enzyme.	False
On phosphorylation of BC6ENTC by BC6ENTG , the affinity for BC6OTHER increased ([S]0.5 = 11 + / - 2 microM) and the negative cooperativity was amplified (h = 0.27 + / - 0.03).	CPR:9
On phosphorylation of BC6OTHER by BC6ENTG , the affinity for BC6ENTC increased ([S]0.5 = 11 + / - 2 microM) and the negative cooperativity was amplified (h = 0.27 + / - 0.03).	False
The dimeric BC6ENTC - terminal deletion mutant (CHEM) of BC6ENTG also showed negative cooperativity of BC6OTHER binding (h = 0.4).	False
The dimeric BC6OTHER - terminal deletion mutant (CHEM) of BC6ENTG also showed negative cooperativity of BC6ENTC binding (h = 0.4).	False
 BC6ENTG binds BC6ENTC cofactor with negative cooperativity , as shown by kinetic analyses and surface plasmon resonance detection.	False
The pretreatment with 20 mg L( - 1) BC6ENTC could alleviate the effects of UV - B radiation on the activities of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	CPR:4
The pretreatment with 20 mg L( - 1) BC6ENTC could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	CPR:4
The pretreatment with 20 mg L( - 1) BC6ENTC could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	CPR:4
The pretreatment with 20 mg L( - 1) BC6ENTC could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	CPR:4
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTC reductase , BC6ENTG , BC6OTHER , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTC reductase , BC6OTHER , BC6ENTG , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTC reductase , BC6OTHER , BC6OTHER , and BC6ENTG , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTG , BC6ENTC synthetase , BC6OTHER , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTC synthetase , BC6ENTG , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTC synthetase , BC6OTHER , and BC6ENTG , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTG , BC6OTHER , BC6ENTC synthase , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTG , BC6ENTC synthase , and BC6OTHER , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6ENTC synthase , and BC6ENTG , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTG , BC6OTHER , BC6OTHER , and BC6ENTC dehydrogenase , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTG , BC6OTHER , and BC6ENTC dehydrogenase , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6ENTG , and BC6ENTC dehydrogenase , promoting BC6OTHER conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , promoting BC6ENTC conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , promoting BC6ENTC conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , promoting BC6ENTC conversion and protein synthesis in soybean seedlings.	False
The pretreatment with 20 mg L( - 1) BC6OTHER could alleviate the effects of UV - B radiation on the activities of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , promoting BC6ENTC conversion and protein synthesis in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTC reductase , BC6ENTG , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTC reductase , BC6OTHER , BC6ENTG ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTG , BC6ENTC synthetase , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6ENTC synthetase , BC6ENTG ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTG , BC6OTHER , BC6ENTC synthase) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6ENTG , BC6ENTC synthase) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTG , BC6OTHER , BC6OTHER ) in the BC6ENTC assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6ENTG , BC6OTHER ) in the BC6ENTC assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6OTHER , BC6ENTG ) in the BC6ENTC assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTG , BC6OTHER , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6ENTC and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6ENTG , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6ENTC and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6OTHER , BC6ENTG ) in the BC6OTHER assimilation , the decrease in the contents of BC6ENTC and soluble proteins , as well as the increase in the content of BC6OTHER in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6ENTG , BC6OTHER , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6ENTC in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6ENTG , BC6OTHER ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6ENTC in soybean seedlings.	False
UV - B radiation led to the inhibition in the activities of the key enzymes ( BC6OTHER , BC6OTHER , BC6ENTG ) in the BC6OTHER assimilation , the decrease in the contents of BC6OTHER and soluble proteins , as well as the increase in the content of BC6ENTC in soybean seedlings.	False
With the use of BC6ENTC , it has been clearly , clinically demonstrated that the selective inhibition of BC6ENTG is an appropriate , effective , safe method for the treatment of ED of all aetiologies and severities.	CPR:4
The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of BC6ENTG that breaks down BC6ENTC , the key pathway for the production of erectile function in humans.	CPR:9
Many clinical studies , both pre - and post - marketing , have demonstrated the clinical efficacy and safety of BC6ENTC ( BC6OTHER , Pfizer) - the first approved selective BC6ENTG inhibitor for the treatment of ED.	CPR:4
Many clinical studies , both pre - and post - marketing , have demonstrated the clinical efficacy and safety of BC6OTHER ( BC6ENTC , Pfizer) - the first approved selective BC6ENTG inhibitor for the treatment of ED.	CPR:4
BC6ENTC is inhibitory of BC6ENTG at a rate tenfold higher than for the next BC6OTHER ( BC6OTHER ) , which produces visual changes through the CHEM rods.	CPR:4
BC6ENTC is inhibitory of BC6OTHER at a rate tenfold higher than for the next BC6ENTG ( BC6OTHER ) , which produces visual changes through the CHEM rods.	CPR:4
BC6ENTC is inhibitory of BC6OTHER at a rate tenfold higher than for the next BC6OTHER ( BC6ENTG ) , which produces visual changes through the CHEM rods.	CPR:4
The inhibition of BC6ENTC binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described BC6ENTG subtype.	False
In HEK - 293 cells stably transfected with this receptor , BC6ENTC elicits a potent stimulation of BC6ENTG activity , which is blocked by antipsychotic and antidepressant drugs.	CPR:3
We have used the polymerase chain reaction technique to selectively amplify a BC6ENTG cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned BC6ENTC receptors.	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTC [ BC6OTHER ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6ENTC ( BC6OTHER )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following BC6ENTG BC6ENTC )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG > BC6OTHER .	False
Within these hydrophobic regions , this receptor was found to be 41 - 36% identical to the following CHEM [ BC6OTHER ( BC6ENTC )] receptors: BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTG .	False
We have used the polymerase chain reaction technique to selectively amplify a BC6ENTC - binding protein - coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned BC6ENTG .	False
Cloning and expression of a novel BC6ENTG with high affinity for BC6ENTC psychotropic drugs.	False
To begin to examine whether these changes are mediated by alterations in gene expression for BC6ENTC hydroxylase ( BC6ENTG ) , the rate - limiting enzyme in BC6OTHER biosynthesis , we quantitated its mRNA levels by competitive reverse transcription - polymerase chain reaction (RT - PCR).	False
To begin to examine whether these changes are mediated by alterations in gene expression for BC6ENTG ( BC6OTHER ) , the rate - limiting enzyme in BC6ENTC biosynthesis , we quantitated its mRNA levels by competitive reverse transcription - polymerase chain reaction (RT - PCR).	CPR:9
To begin to examine whether these changes are mediated by alterations in gene expression for BC6OTHER ( BC6ENTG ) , the rate - limiting enzyme in BC6ENTC biosynthesis , we quantitated its mRNA levels by competitive reverse transcription - polymerase chain reaction (RT - PCR).	CPR:9
In contrast , there was little change in mRNA levels for BC6ENTG ( BC6OTHER ) , the rate limiting enzyme in synthesis of the BC6ENTC ( BC6OTHER ) , the obligate cofactor for BC6OTHER .	CPR:9
In contrast , there was little change in mRNA levels for BC6OTHER ( BC6ENTG ) , the rate limiting enzyme in synthesis of the BC6ENTC ( BC6OTHER ) , the obligate cofactor for BC6OTHER .	CPR:9
In contrast , there was little change in mRNA levels for BC6OTHER ( BC6OTHER ) , the rate limiting enzyme in synthesis of the BC6ENTC ( BC6OTHER ) , the obligate cofactor for BC6ENTG .	False
In contrast , there was little change in mRNA levels for BC6ENTG ( BC6OTHER ) , the rate limiting enzyme in synthesis of the BC6OTHER ( BC6ENTC ) , the obligate cofactor for BC6OTHER .	CPR:9
In contrast , there was little change in mRNA levels for BC6OTHER ( BC6ENTG ) , the rate limiting enzyme in synthesis of the BC6OTHER ( BC6ENTC ) , the obligate cofactor for BC6OTHER .	CPR:9
In contrast , there was little change in mRNA levels for BC6OTHER ( BC6OTHER ) , the rate limiting enzyme in synthesis of the BC6OTHER ( BC6ENTC ) , the obligate cofactor for BC6ENTG .	False
Inhibition studies revealed that the BC6ENTG ( BC6OTHER ) are involved in the transport of BC6ENTC conjugates.	CPR:9
Inhibition studies revealed that the BC6OTHER ( BC6ENTG ) are involved in the transport of BC6ENTC conjugates.	CPR:9
Stable BC6ENTG , BC6OTHER and BC6OTHER knockdown cell lines were generated , thus making it possible to demonstrate that BC6OTHER mediates the basolateral and BC6OTHER the apical excretion of BC6ENTC conjugates.	CPR:9
Stable BC6OTHER , BC6ENTG and BC6OTHER knockdown cell lines were generated , thus making it possible to demonstrate that BC6OTHER mediates the basolateral and BC6OTHER the apical excretion of BC6ENTC conjugates.	CPR:9
Stable BC6OTHER , BC6OTHER and BC6ENTG knockdown cell lines were generated , thus making it possible to demonstrate that BC6OTHER mediates the basolateral and BC6OTHER the apical excretion of BC6ENTC conjugates.	False
Stable BC6OTHER , BC6OTHER and BC6OTHER knockdown cell lines were generated , thus making it possible to demonstrate that BC6ENTG mediates the basolateral and BC6OTHER the apical excretion of BC6ENTC conjugates.	CPR:9
Stable BC6OTHER , BC6OTHER and BC6OTHER knockdown cell lines were generated , thus making it possible to demonstrate that BC6OTHER mediates the basolateral and BC6ENTG the apical excretion of BC6ENTC conjugates.	CPR:9
The ultimate carcinogenic Phase I BP metabolite anti - BC6ENTC ( BC6OTHER ) can be detoxified by BC6OTHER conjugate formation catalyzed by BC6ENTG .	False
The ultimate carcinogenic Phase I BP metabolite anti - BC6OTHER ( BC6ENTC ) can be detoxified by BC6OTHER conjugate formation catalyzed by BC6ENTG .	False
The ultimate carcinogenic Phase I BP metabolite anti - BC6OTHER ( BC6OTHER ) can be detoxified by BC6ENTC conjugate formation catalyzed by BC6ENTG .	CPR:9
In the present study , differentiated human intestinal Caco - 2 cells were used as a model for the human small intestine to investigate the detoxification of BC6ENTC and excretion of stereoisomeric BC6OTHER conjugates in the presence of an inhibitor of the BC6ENTG BC6OTHER at the cell surface.	False
In the present study , differentiated human intestinal Caco - 2 cells were used as a model for the human small intestine to investigate the detoxification of BC6ENTC and excretion of stereoisomeric BC6OTHER conjugates in the presence of an inhibitor of the BC6OTHER BC6ENTG at the cell surface.	False
In the present study , differentiated human intestinal Caco - 2 cells were used as a model for the human small intestine to investigate the detoxification of BC6OTHER and excretion of stereoisomeric BC6ENTC conjugates in the presence of an inhibitor of the BC6ENTG BC6OTHER at the cell surface.	False
In the present study , differentiated human intestinal Caco - 2 cells were used as a model for the human small intestine to investigate the detoxification of BC6OTHER and excretion of stereoisomeric BC6ENTC conjugates in the presence of an inhibitor of the BC6OTHER BC6ENTG at the cell surface.	False
In the present study , differentiated human intestinal Caco - 2 cells were used as a model for the human small intestine to investigate the detoxification of BC6OTHER and excretion of stereoisomeric BC6OTHER conjugates in the presence of an inhibitor of the BC6ENTC - cleaving enzyme BC6ENTG at the cell surface.	False
 BC6ENTG are involved in the transport of the BC6OTHER conjugates of the ultimate carcinogen of BC6ENTC in human Caco - 2 cells.	False
 BC6ENTG are involved in the transport of the BC6ENTC conjugates of the ultimate carcinogen of BC6OTHER in human Caco - 2 cells.	CPR:9
This inhibition was blocked when mice were pretreated with the selective BC6ENTG agonist BC6ENTC (10 mg / kg).	CPR:5
RATIONALE: Growing evidence supports a role for the central histaminergic system to have a modulatory influence on drug addiction in general and BC6ENTC - use disorders in particular through BC6ENTG ( BC6OTHER ).	False
RATIONALE: Growing evidence supports a role for the central histaminergic system to have a modulatory influence on drug addiction in general and BC6ENTC - use disorders in particular through BC6OTHER ( BC6ENTG ).	False
Lastly , the results add to the growing literature on BC6ENTG modulation in the pharmacotherapy of BC6ENTC addiction.	False
RATIONALE: Growing evidence supports a role for the central histaminergic system to have a modulatory influence on drug addiction in general and BC6OTHER - use disorders in particular through BC6ENTC H3 receptors ( BC6ENTG ).	False
OBJECTIVE: In the present study , the effects of systemic injection of the newly synthesized BC6ENTG antagonist CHEM on BC6ENTC ( BC6OTHER ) voluntary intake and BC6OTHER - conditioned reward in mice have been investigated.	False
OBJECTIVE: In the present study , the effects of systemic injection of the newly synthesized BC6ENTG antagonist CHEM on BC6OTHER ( BC6ENTC ) voluntary intake and BC6OTHER - conditioned reward in mice have been investigated.	False
OBJECTIVE: In the present study , the effects of systemic injection of the newly synthesized BC6ENTG antagonist CHEM on BC6OTHER ( BC6OTHER ) voluntary intake and BC6ENTC - conditioned reward in mice have been investigated.	False
Influence of the novel BC6ENTG antagonist CHEM on voluntary BC6OTHER consumption and BC6ENTC - induced place preference in mice.	False
Influence of the novel BC6ENTG antagonist CHEM on voluntary BC6ENTC consumption and BC6OTHER - induced place preference in mice.	False
The results suggested that both the BC6ENTC extract and BC6OTHER were able to activate BC6ENTG , and Rhizoma Coptis contains potential natural agonists of BC6OTHER besides BC6OTHER .	CPR:5
The results suggested that both the BC6ENTC extract and BC6OTHER were able to activate BC6OTHER , and Rhizoma Coptis contains potential natural agonists of BC6ENTG besides BC6OTHER .	False
The results suggested that both the BC6OTHER extract and BC6ENTC were able to activate BC6ENTG , and Rhizoma Coptis contains potential natural agonists of BC6OTHER besides BC6OTHER .	CPR:5
The results suggested that both the BC6OTHER extract and BC6ENTC were able to activate BC6OTHER , and Rhizoma Coptis contains potential natural agonists of BC6ENTG besides BC6OTHER .	False
The results suggested that both the BC6OTHER extract and BC6OTHER were able to activate BC6ENTG , and Rhizoma Coptis contains potential natural agonists of BC6OTHER besides BC6ENTC .	CPR:5
The results suggested that both the BC6OTHER extract and BC6OTHER were able to activate BC6OTHER , and Rhizoma Coptis contains potential natural agonists of BC6ENTG besides BC6ENTC .	CPR:5
As is the case with BLTs , BC6ENTC increased the apparent affinity of BC6ENTG binding to BC6OTHER .	False
As is the case with BLTs , BC6ENTC increased the apparent affinity of BC6OTHER binding to BC6ENTG .	False
The reciprocal inhibition of BC6ENTG and BC6OTHER by BLT - 4 and BC6ENTC raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.	CPR:4
The reciprocal inhibition of BC6OTHER and BC6ENTG by BLT - 4 and BC6ENTC raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.	CPR:4
BC6ENTG is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6ENTC from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6OTHER from cells to BC6OTHER .	CPR:9
BC6OTHER is a receptor that binds BC6ENTG with high affinity and mediates both the selective lipid uptake of BC6ENTC from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6OTHER from cells to BC6OTHER .	False
BC6OTHER is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6ENTC from lipid - rich BC6ENTG to cells and the efflux of unesterified BC6OTHER from cells to BC6OTHER .	False
BC6OTHER is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6ENTC from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6OTHER from cells to BC6ENTG .	False
BC6ENTG is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6OTHER from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6ENTC from cells to BC6OTHER .	CPR:9
BC6OTHER is a receptor that binds BC6ENTG with high affinity and mediates both the selective lipid uptake of BC6OTHER from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6ENTC from cells to BC6OTHER .	False
BC6OTHER is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6OTHER from lipid - rich BC6ENTG to cells and the efflux of unesterified BC6ENTC from cells to BC6OTHER .	False
BC6OTHER is a receptor that binds BC6OTHER with high affinity and mediates both the selective lipid uptake of BC6OTHER from lipid - rich BC6OTHER to cells and the efflux of unesterified BC6ENTC from cells to BC6ENTG .	False
BC6ENTG mediates the efflux of unesterified BC6ENTC and phospholipids from cells to lipid - poor BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER mediates the efflux of unesterified BC6ENTC and phospholipids from cells to lipid - poor BC6ENTG ( BC6OTHER ).	False
BC6OTHER mediates the efflux of unesterified BC6ENTC and phospholipids from cells to lipid - poor BC6OTHER ( BC6ENTG ).	False
The activities of BC6ENTG and other BC6ENTC binding cassette superfamily members are inhibited by the drug BC6OTHER , and BC6OTHER - mediated lipid transport is blocked by small molecule inhibitors called BLTs.	False
The activities of BC6OTHER and other BC6ENTC binding cassette superfamily members are inhibited by the drug BC6OTHER , and BC6ENTG - mediated lipid transport is blocked by small molecule inhibitors called BLTs.	False
The activities of BC6ENTG and other BC6OTHER members are inhibited by the drug BC6ENTC , and BC6OTHER - mediated lipid transport is blocked by small molecule inhibitors called BLTs.	CPR:4
The activities of BC6OTHER and other BC6ENTG members are inhibited by the drug BC6ENTC , and BC6OTHER - mediated lipid transport is blocked by small molecule inhibitors called BLTs.	CPR:4
The activities of BC6OTHER and other BC6OTHER members are inhibited by the drug BC6ENTC , and BC6ENTG - mediated lipid transport is blocked by small molecule inhibitors called BLTs.	False
Here , we show that one BC6ENTC , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6ENTG - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6ENTC , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6ENTG at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	False
Here , we show that one BC6ENTC , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6ENTG (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6OTHER , [ BC6ENTC ] ( BC6OTHER ) , blocked BC6ENTG - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6OTHER , [ BC6ENTC ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6ENTG at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	False
Here , we show that one BC6OTHER , [ BC6ENTC ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6ENTG (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6ENTC ) , blocked BC6ENTG - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6ENTC ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6ENTG at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	False
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6ENTC ) , blocked BC6OTHER - mediated BC6OTHER efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6ENTG (IC(50) approximately 55 - 60 microM).	CPR:4
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6ENTG - mediated BC6ENTC efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	CPR:9
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6ENTC efflux to lipid - poor BC6ENTG at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 55 - 60 microM).	False
Here , we show that one BC6OTHER , [ BC6OTHER ] ( BC6OTHER ) , blocked BC6OTHER - mediated BC6ENTC efflux to lipid - poor BC6OTHER at a potency similar to that for its inhibition of BC6ENTG (IC(50) approximately 55 - 60 microM).	False
Reciprocally , BC6ENTC blocked BC6OTHER - mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of BC6ENTG (IC(50) approximately 275 - 300 microM).	CPR:4
Reciprocally , BC6ENTC blocked BC6ENTG - mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of BC6OTHER (IC(50) approximately 275 - 300 microM).	CPR:4
Cross - inhibition of BC6ENTG - and BC6OTHER - mediated BC6OTHER transport by the small molecules BLT - 4 and BC6ENTC .	CPR:4
Cross - inhibition of BC6OTHER - and BC6ENTG - mediated BC6OTHER transport by the small molecules BLT - 4 and BC6ENTC .	CPR:4
Cross - inhibition of BC6ENTG - and BC6OTHER - mediated BC6ENTC transport by the small molecules BLT - 4 and BC6OTHER .	CPR:9
Cross - inhibition of BC6OTHER - and BC6ENTG - mediated BC6ENTC transport by the small molecules BLT - 4 and BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTC , BC6OTHER ) is an established BC6ENTG blocker and is a useful anticonvulsant and class 1b antiarrhythmic , and has been effectively used in the treatment of neuropathic pain.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is an established BC6ENTG blocker and is a useful anticonvulsant and class 1b antiarrhythmic , and has been effectively used in the treatment of neuropathic pain.	CPR:4
BC6ENTG BC6ENTC ) channels are a critical component of electrically excitable cells.	CPR:9
In this study , we have synthesized novel BC6ENTC analogues of BC6OTHER and examined their ability to inhibit BC6ENTG BC6OTHER expressed in Chinese Hamster Ovary (CHO - K1) cells.	CPR:4
In this study , we have synthesized novel BC6ENTC analogues of BC6OTHER and examined their ability to inhibit BC6OTHER BC6ENTG expressed in Chinese Hamster Ovary (CHO - K1) cells.	CPR:4
In this study , we have synthesized novel BC6OTHER analogues of BC6ENTC and examined their ability to inhibit BC6ENTG BC6OTHER expressed in Chinese Hamster Ovary (CHO - K1) cells.	CPR:4
In this study , we have synthesized novel BC6OTHER analogues of BC6ENTC and examined their ability to inhibit BC6OTHER BC6ENTG expressed in Chinese Hamster Ovary (CHO - K1) cells.	CPR:4
In this study , we have synthesized novel BC6OTHER analogues of BC6OTHER and examined their ability to inhibit BC6ENTG BC6ENTC channels expressed in Chinese Hamster Ovary (CHO - K1) cells.	CPR:9
In comparison to BC6ENTC , the novel BC6OTHER - substituted BC6OTHER compounds produced as much as a 20 - fold greater tonic and frequency - dependent blockade of BC6ENTG channels with an IC(50) value of 14.5 microM.	CPR:4
In comparison to BC6OTHER , the novel BC6ENTC - substituted BC6OTHER compounds produced as much as a 20 - fold greater tonic and frequency - dependent blockade of BC6ENTG channels with an IC(50) value of 14.5 microM.	CPR:4
In comparison to BC6OTHER , the novel BC6OTHER - substituted BC6ENTC compounds produced as much as a 20 - fold greater tonic and frequency - dependent blockade of BC6ENTG channels with an IC(50) value of 14.5 microM.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is an established BC6ENTG blocker and is a useful anticonvulsant and class 1b antiarrhythmic , and has been effectively used in the treatment of neuropathic pain.	CPR:4
Block of BC6ENTG BC6ENTC channels by novel BC6OTHER analogues of BC6OTHER .	CPR:9
Block of BC6OTHER BC6ENTG by novel BC6ENTC analogues of BC6OTHER .	CPR:4
Block of BC6ENTG BC6OTHER by novel BC6ENTC analogues of BC6OTHER .	CPR:4
Block of BC6OTHER BC6ENTG by novel BC6OTHER analogues of BC6ENTC .	CPR:4
Block of BC6ENTG BC6OTHER by novel BC6OTHER analogues of BC6ENTC .	CPR:4
In addition , BC6ENTC inhibits BC6ENTG - dependent inflammatory responses by modulating BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) - BC6OTHER signaling.	CPR:4
In addition , BC6ENTC inhibits BC6OTHER - dependent inflammatory responses by modulating BC6ENTG ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) - BC6OTHER signaling.	False
In addition , BC6ENTC inhibits BC6OTHER - dependent inflammatory responses by modulating BC6OTHER ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) - BC6OTHER signaling.	False
In addition , BC6ENTC inhibits BC6OTHER - dependent inflammatory responses by modulating BC6OTHER ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) - BC6OTHER signaling.	False
In addition , BC6ENTC inhibits BC6OTHER - dependent inflammatory responses by modulating BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) - BC6OTHER signaling.	False
In addition , BC6ENTC inhibits BC6OTHER - dependent inflammatory responses by modulating BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) - BC6ENTG signaling.	False
Consistent with these results , BC6ENTC significantly reduced serum levels of inflammatory BC6ENTG and mortality in mice challenged with lipopolysaccharide.	CPR:4
Inducible BC6ENTC synthase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) expressions were determined by western blot and or realtime - PCR (RT - PCR).	False
Promoter assay revealed that BC6ENTC inhibits LPS - induced BC6OTHER and BC6OTHER production through the suppression of BC6ENTG and BC6OTHER at the transcriptional level.	CPR:4
Promoter assay revealed that BC6ENTC inhibits LPS - induced BC6OTHER and BC6OTHER production through the suppression of BC6OTHER and BC6ENTG at the transcriptional level.	CPR:4
Promoter assay revealed that BC6OTHER inhibits LPS - induced BC6ENTC and BC6OTHER production through the suppression of BC6ENTG and BC6OTHER at the transcriptional level.	False
Promoter assay revealed that BC6OTHER inhibits LPS - induced BC6ENTC and BC6OTHER production through the suppression of BC6OTHER and BC6ENTG at the transcriptional level.	False
Promoter assay revealed that BC6OTHER inhibits LPS - induced BC6OTHER and BC6ENTC production through the suppression of BC6ENTG and BC6OTHER at the transcriptional level.	False
Promoter assay revealed that BC6OTHER inhibits LPS - induced BC6OTHER and BC6ENTC production through the suppression of BC6OTHER and BC6ENTG at the transcriptional level.	False
Anti - inflammatory effect of BC6ENTC via the suppression of BC6ENTG pathway.	CPR:4
Here we report the solution structure of the BC6ENTG of BC6ENTC - terminal Src kinase ( BC6OTHER ) in complex with a longer phosphopeptide from BC6OTHER ( BC6OTHER ).	False
Here we report the solution structure of the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6ENTG ) in complex with a longer phosphopeptide from BC6OTHER ( BC6OTHER ).	False
Here we report the solution structure of the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) in complex with a longer phosphopeptide from BC6ENTG ( BC6OTHER ).	False
Here we report the solution structure of the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) in complex with a longer phosphopeptide from BC6OTHER ( BC6ENTG ).	False
Proteins with BC6ENTG play major roles in BC6ENTC kinase signaling.	False
This structure , together with biochemical experiments , revealed the existence of a novel binding region in addition to the canonical BC6ENTC - 314 binding site of BC6ENTG .	False
Identification of a new interaction mode between the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ).	False
Identification of a new interaction mode between the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER ).	False
Identification of a new interaction mode between the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER ).	False
Identification of a new interaction mode between the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6ENTG ( BC6OTHER ).	False
Identification of a new interaction mode between the BC6OTHER of BC6ENTC - terminal Src kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6ENTG ).	False
Identification of a new interaction mode between the BC6ENTG of BC6ENTC - terminal Src kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ).	False
To establish the relative importance of these subtypes , we compared the effects of BC6ENTC with those of a selective BC6ENTG receptor agonist ( BC6OTHER ) on BC6OTHER protein expression in the trigeminal nucleus caudalis.	False
To establish the relative importance of these subtypes , we compared the effects of BC6ENTC with those of a selective BC6OTHER receptor agonist ( BC6OTHER ) on BC6ENTG protein expression in the trigeminal nucleus caudalis.	False
To establish the relative importance of these subtypes , we compared the effects of BC6OTHER with those of a selective BC6ENTG receptor agonist ( BC6ENTC ) on BC6OTHER protein expression in the trigeminal nucleus caudalis.	CPR:5
To establish the relative importance of these subtypes , we compared the effects of BC6OTHER with those of a selective BC6OTHER receptor agonist ( BC6ENTC ) on BC6ENTG protein expression in the trigeminal nucleus caudalis.	False
BC6ENTG expression was induced in BC6ENTC - anaesthetized rats by intracisternal BC6OTHER administration.	False
BC6ENTG expression was induced in BC6OTHER - anaesthetized rats by intracisternal BC6ENTC administration.	CPR:3
BC6ENTC and BC6OTHER decreased the number of BC6OTHER - induced BC6ENTG - like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg( - 1)).	CPR:4
BC6OTHER and BC6ENTC decreased the number of BC6OTHER - induced BC6ENTG - like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg( - 1)).	CPR:4
BC6OTHER and BC6OTHER decreased the number of BC6ENTC - induced BC6ENTG - like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg( - 1)).	CPR:3
The effect of BC6ENTC , but not of BC6OTHER , was prevented by pretreatment with the antagonist BC6OTHER , which displays high affinity for BC6ENTG receptors.	False
The effect of BC6OTHER , but not of BC6ENTC , was prevented by pretreatment with the antagonist BC6OTHER , which displays high affinity for BC6ENTG receptors.	False
The effect of BC6OTHER , but not of BC6OTHER , was prevented by pretreatment with the antagonist BC6ENTC , which displays high affinity for BC6ENTG receptors.	CPR:6
BC6ENTC appears to attenuate c - fos - like immunoreactivity via BC6ENTG receptors , while BC6OTHER acts via BC6OTHER receptors.	False
BC6ENTC appears to attenuate c - fos - like immunoreactivity via BC6OTHER receptors , while BC6OTHER acts via BC6ENTG receptors.	False
BC6OTHER appears to attenuate c - fos - like immunoreactivity via BC6ENTG receptors , while BC6ENTC acts via BC6OTHER receptors.	False
BC6OTHER appears to attenuate c - fos - like immunoreactivity via BC6OTHER receptors , while BC6ENTC acts via BC6ENTG receptors.	False
The effects of BC6OTHER and BC6ENTC on expression of BC6ENTG and BC6OTHER were abolished by BC6OTHER .	False
The effects of BC6OTHER and BC6ENTC on expression of BC6OTHER and BC6ENTG were abolished by BC6OTHER .	False
The effects of BC6OTHER and BC6OTHER on expression of BC6ENTG and BC6OTHER were abolished by BC6ENTC .	CPR:4
The effects of BC6OTHER and BC6OTHER on expression of BC6OTHER and BC6ENTG were abolished by BC6ENTC .	CPR:4
We investigated the involvement of the BC6ENTG ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6ENTC ( BC6OTHER ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6ENTG ) , a BC6OTHER for CHEM , in the BC6ENTC ( BC6OTHER ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6ENTG for CHEM , in the BC6ENTC ( BC6OTHER ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6ENTC ( BC6OTHER ) - induced expression of BC6ENTG and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	CPR:3
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6ENTC ( BC6OTHER ) - induced expression of BC6OTHER and BC6ENTG in normal rat gastric epithelial cells (RGM - 1 cells).	CPR:3
We investigated the involvement of the BC6ENTG ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6OTHER ( BC6ENTC ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6ENTG ) , a BC6OTHER for CHEM , in the BC6OTHER ( BC6ENTC ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6ENTG for CHEM , in the BC6OTHER ( BC6ENTC ) - induced expression of BC6OTHER and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	False
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6OTHER ( BC6ENTC ) - induced expression of BC6ENTG and BC6OTHER in normal rat gastric epithelial cells (RGM - 1 cells).	CPR:3
We investigated the involvement of the BC6OTHER ( BC6OTHER ) , a BC6OTHER for CHEM , in the BC6OTHER ( BC6ENTC ) - induced expression of BC6OTHER and BC6ENTG in normal rat gastric epithelial cells (RGM - 1 cells).	CPR:3
RGM - 1 cells were treated with BC6ENTC or BC6OTHER , an BC6ENTG agonist , in the presence or absence of BC6OTHER , an BC6OTHER antagonist.	CPR:5
RGM - 1 cells were treated with BC6ENTC or BC6OTHER , an BC6OTHER agonist , in the presence or absence of BC6OTHER , an BC6ENTG antagonist.	False
RGM - 1 cells were treated with BC6OTHER or BC6ENTC , an BC6ENTG agonist , in the presence or absence of BC6OTHER , an BC6OTHER antagonist.	CPR:5
RGM - 1 cells were treated with BC6OTHER or BC6ENTC , an BC6OTHER agonist , in the presence or absence of BC6OTHER , an BC6ENTG antagonist.	False
RGM - 1 cells were treated with BC6OTHER or BC6OTHER , an BC6ENTG agonist , in the presence or absence of BC6ENTC , an BC6OTHER antagonist.	False
RGM - 1 cells were treated with BC6OTHER or BC6OTHER , an BC6OTHER agonist , in the presence or absence of BC6ENTC , an BC6ENTG antagonist.	CPR:6
BC6ENTC induced dose - dependent expression of BC6ENTG and BC6OTHER at both the mRNA and protein levels.	CPR:3
BC6ENTC induced dose - dependent expression of BC6OTHER and BC6ENTG at both the mRNA and protein levels.	CPR:3
The maximum stimulation of BC6ENTG and BC6OTHER mRNA induced by BC6ENTC was observed at 3 h and by 6 h , respectively.	CPR:3
The maximum stimulation of BC6OTHER and BC6ENTG mRNA induced by BC6ENTC was observed at 3 h and by 6 h , respectively.	CPR:3
The effects of BC6ENTC and BC6OTHER on expression of BC6ENTG and BC6OTHER were abolished by BC6OTHER .	False
The effects of BC6ENTC and BC6OTHER on expression of BC6OTHER and BC6ENTG were abolished by BC6OTHER .	False
Remarkably , BC6OTHER binding results in the assembly of five BC6ENTC - BC6ENTG / TFP dimers into a tightly packed pentameric ring.	False
Within each pentamer most of the contacts between BC6ENTG dimers occurs through the BC6ENTC moieties.	False
The BC6ENTC - BC6ENTG / BC6OTHER ( BC6OTHER ) complex exhibits a similar pentameric assembly.	False
The BC6OTHER - BC6ENTG / BC6ENTC ( BC6OTHER ) complex exhibits a similar pentameric assembly.	False
The BC6OTHER - BC6ENTG / BC6OTHER ( BC6ENTC ) complex exhibits a similar pentameric assembly.	False
Equilibrium sedimentation and cross - linking studies demonstrate the cooperative formation of a similarly sized BC6ENTG / BC6ENTC oligomer in solution.	False
Assays examining the ability of BC6ENTC to block BC6ENTG - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6OTHER concentrations that promote BC6OTHER oligomerization.	CPR:4
Assays examining the ability of BC6ENTC to block BC6OTHER - mediated disassembly of BC6ENTG filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6OTHER concentrations that promote BC6OTHER oligomerization.	CPR:4
Assays examining the ability of BC6ENTC to block BC6OTHER - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6ENTG function occurs only at BC6OTHER concentrations that promote BC6OTHER oligomerization.	False
Assays examining the ability of BC6ENTC to block BC6OTHER - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6OTHER concentrations that promote BC6ENTG oligomerization.	False
Assays examining the ability of BC6OTHER to block BC6ENTG - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6ENTC concentrations that promote BC6OTHER oligomerization.	False
Assays examining the ability of BC6OTHER to block BC6OTHER - mediated disassembly of BC6ENTG filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6ENTC concentrations that promote BC6OTHER oligomerization.	False
Assays examining the ability of BC6OTHER to block BC6OTHER - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6ENTG function occurs only at BC6ENTC concentrations that promote BC6OTHER oligomerization.	CPR:4
Assays examining the ability of BC6OTHER to block BC6OTHER - mediated disassembly of BC6OTHER filaments demonstrate that significant inhibition of BC6OTHER function occurs only at BC6ENTC concentrations that promote BC6ENTG oligomerization.	CPR:3
Together these studies support a unique mode of inhibition in which BC6ENTC disrupt the BC6ENTG / BC6OTHER interaction by sequestering BC6OTHER via small molecule - induced oligomerization.	CPR:4
Together these studies support a unique mode of inhibition in which BC6ENTC disrupt the BC6OTHER / BC6ENTG interaction by sequestering BC6OTHER via small molecule - induced oligomerization.	CPR:4
Together these studies support a unique mode of inhibition in which BC6ENTC disrupt the BC6OTHER / BC6OTHER interaction by sequestering BC6ENTG via small molecule - induced oligomerization.	False
BC6ENTG , a member of the BC6OTHER family of BC6ENTC - binding proteins , regulates carcinoma cell motility via interactions with BC6OTHER .	False
BC6OTHER , a member of the BC6OTHER family of BC6ENTC - binding proteins , regulates carcinoma cell motility via interactions with BC6ENTG .	False
BC6OTHER , a member of the BC6ENTG family of BC6ENTC - binding proteins , regulates carcinoma cell motility via interactions with BC6OTHER .	False
Using a unique biosensor - based assay , BC6ENTC ( BC6OTHER ) was identified as an inhibitor that disrupts the BC6ENTG / BC6OTHER interaction.	CPR:4
Using a unique biosensor - based assay , BC6ENTC ( BC6OTHER ) was identified as an inhibitor that disrupts the BC6OTHER / BC6ENTG interaction.	CPR:4
Using a unique biosensor - based assay , BC6OTHER ( BC6ENTC ) was identified as an inhibitor that disrupts the BC6ENTG / BC6OTHER interaction.	CPR:4
Using a unique biosensor - based assay , BC6OTHER ( BC6ENTC ) was identified as an inhibitor that disrupts the BC6OTHER / BC6ENTG interaction.	CPR:4
To examine the interaction of BC6ENTG with BC6ENTC , we determined the 2.3 A crystal structure of human BC6OTHER - BC6OTHER bound to BC6OTHER .	False
To examine the interaction of BC6OTHER with BC6ENTC , we determined the 2.3 A crystal structure of human BC6OTHER - BC6ENTG bound to BC6OTHER .	False
To examine the interaction of BC6ENTG with BC6OTHER , we determined the 2.3 A crystal structure of human BC6ENTC - BC6OTHER bound to BC6OTHER .	False
To examine the interaction of BC6OTHER with BC6OTHER , we determined the 2.3 A crystal structure of human BC6ENTC - BC6ENTG bound to BC6OTHER .	False
To examine the interaction of BC6ENTG with BC6OTHER , we determined the 2.3 A crystal structure of human BC6OTHER - BC6OTHER bound to BC6ENTC .	False
To examine the interaction of BC6OTHER with BC6OTHER , we determined the 2.3 A crystal structure of human BC6OTHER - BC6ENTG bound to BC6ENTC .	False
Two BC6ENTC molecules bind within the hydrophobic target binding pocket of BC6OTHER - BC6ENTG with no significant conformational changes observed in the protein upon complex formation.	False
Two BC6OTHER molecules bind within the hydrophobic target binding pocket of BC6ENTC - BC6ENTG with no significant conformational changes observed in the protein upon complex formation.	False
NMR chemical shift perturbations are consistent with the crystal structure and demonstrate that BC6ENTC binds to the target binding cleft of BC6ENTG in solution.	False
Remarkably , BC6ENTC binding results in the assembly of five BC6OTHER - BC6ENTG / TFP dimers into a tightly packed pentameric ring.	False
 BC6ENTC inhibit BC6ENTG function by inducing protein oligomerization.	CPR:4
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6OTHER ) encoding BC6OTHER , the enzyme that synthesizes BC6ENTC , BC6ENTG , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	CPR:9
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6OTHER ) encoding BC6OTHER , the enzyme that synthesizes BC6ENTC , BC6OTHER , is expressed in liver , whereas BC6ENTG is expressed in extrahepatic tissues.	False
BACKGROUND & AIMS: Of the 2 genes ( BC6ENTG , BC6OTHER ) encoding BC6OTHER , the enzyme that synthesizes BC6ENTC , BC6OTHER , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	CPR:9
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6ENTG ) encoding BC6OTHER , the enzyme that synthesizes BC6ENTC , BC6OTHER , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	CPR:9
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6OTHER ) encoding BC6ENTG , the enzyme that synthesizes BC6ENTC , BC6OTHER , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	CPR:9
CONCLUSIONS: Our findings indicate that beta subunit associates with cirrhosis and cancer providing a proliferative advantage in hepatoma cells through its interaction with BC6ENTG and down - regulation of BC6ENTC levels.	False
The beta subunit has been cloned and shown to lower the K(m) of BC6ENTC adenosyltransferase II alpha2 (the BC6ENTG product) for BC6OTHER and to render the enzyme more susceptible to BC6OTHER inhibition.	False
The beta subunit has been cloned and shown to lower the K(m) of BC6ENTG (the BC6OTHER product) for BC6ENTC and to render the enzyme more susceptible to BC6OTHER inhibition.	CPR:9
The beta subunit has been cloned and shown to lower the K(m) of BC6OTHER (the BC6ENTG product) for BC6ENTC and to render the enzyme more susceptible to BC6OTHER inhibition.	CPR:9
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6OTHER ) encoding BC6ENTC adenosyltransferase , the enzyme that synthesizes BC6OTHER , BC6ENTG , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	False
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6OTHER ) encoding BC6ENTC adenosyltransferase , the enzyme that synthesizes BC6OTHER , BC6OTHER , is expressed in liver , whereas BC6ENTG is expressed in extrahepatic tissues.	False
BACKGROUND & AIMS: Of the 2 genes ( BC6ENTG , BC6OTHER ) encoding BC6ENTC adenosyltransferase , the enzyme that synthesizes BC6OTHER , BC6OTHER , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	False
BACKGROUND & AIMS: Of the 2 genes ( BC6OTHER , BC6ENTG ) encoding BC6ENTC adenosyltransferase , the enzyme that synthesizes BC6OTHER , BC6OTHER , is expressed in liver , whereas BC6OTHER is expressed in extrahepatic tissues.	False
The beta subunit has been cloned and shown to lower the K(m) of BC6ENTG (the BC6OTHER product) for BC6OTHER and to render the enzyme more susceptible to BC6ENTC inhibition.	CPR:4
The beta subunit has been cloned and shown to lower the K(m) of BC6OTHER (the BC6ENTG product) for BC6OTHER and to render the enzyme more susceptible to BC6ENTC inhibition.	CPR:4
Consistent with this , we find that BC6ENTG null mice exhibit a significant decrease in the volume and number of neurons (40% decrease) in SNr , whereas the volume and number of BC6OTHER + neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal BC6ENTC neurons.	False
Consistent with this , we find that BC6OTHER null mice exhibit a significant decrease in the volume and number of neurons (40% decrease) in SNr , whereas the volume and number of BC6ENTG + neurons in SNc is not significantly affected nor are there changes in the distribution of nigrostriatal BC6ENTC neurons.	False
In situ hybridization data and a direct comparison of SN neurons expressing BC6ENTC hydroxylase ( BC6ENTG ) and / or the beta - gal marker for BC6OTHER revealed that BC6OTHER is not expressed in BC6OTHER + neurons of pars compacta (SNc) , but is restricted to neurons in pars reticulata (SNr).	False
In situ hybridization data and a direct comparison of SN neurons expressing BC6ENTC hydroxylase ( BC6OTHER ) and / or the beta - gal marker for BC6ENTG revealed that BC6OTHER is not expressed in BC6OTHER + neurons of pars compacta (SNc) , but is restricted to neurons in pars reticulata (SNr).	False
In situ hybridization data and a direct comparison of SN neurons expressing BC6ENTC hydroxylase ( BC6OTHER ) and / or the beta - gal marker for BC6OTHER revealed that BC6ENTG is not expressed in BC6OTHER + neurons of pars compacta (SNc) , but is restricted to neurons in pars reticulata (SNr).	False
In situ hybridization data and a direct comparison of SN neurons expressing BC6ENTC hydroxylase ( BC6OTHER ) and / or the beta - gal marker for BC6OTHER revealed that BC6OTHER is not expressed in BC6ENTG + neurons of pars compacta (SNc) , but is restricted to neurons in pars reticulata (SNr).	False
BC6ENTG BC6ENTC kinases are potential participants in this process as they regulate development of other CNS regions and are expressed in basal ganglia nuclei , such as the substantia nigra (SN) and striatum.	False
Furthermore , compared with control groups , the plaque endothelium level of BC6ENTG was 3 - fold increased and the liver level of BC6OTHER was 17.4 - fold increased by BC6ENTC - HD.	CPR:3
Furthermore , compared with control groups , the plaque endothelium level of BC6OTHER was 3 - fold increased and the liver level of BC6ENTG was 17.4 - fold increased by BC6ENTC - HD.	CPR:3
Meanwhile , the serum level of KC (a functional homolog of BC6ENTG and the main proinflammatory BC6OTHER in mice) in BC6OTHER ( - / - ) mice was up to 357pg / ml in BC6ENTC - HD treated group.	CPR:3
Meanwhile , the serum level of KC (a functional homolog of BC6OTHER and the main proinflammatory BC6ENTG in mice) in BC6OTHER ( - / - ) mice was up to 357pg / ml in BC6ENTC - HD treated group.	CPR:3
Meanwhile , the serum level of KC (a functional homolog of BC6OTHER and the main proinflammatory BC6OTHER in mice) in BC6ENTG ( - / - ) mice was up to 357pg / ml in BC6ENTC - HD treated group.	False
Thus , BC6ENTC contributes to the instability of atherosclerotic plaque in BC6ENTG ( - / - ) mice through activating BC6OTHER and BC6OTHER and cell apoptosis in plaque.	False
Thus , BC6ENTC contributes to the instability of atherosclerotic plaque in BC6OTHER ( - / - ) mice through activating BC6ENTG and BC6OTHER and cell apoptosis in plaque.	CPR:3
Thus , BC6ENTC contributes to the instability of atherosclerotic plaque in BC6OTHER ( - / - ) mice through activating BC6OTHER and BC6ENTG and cell apoptosis in plaque.	CPR:3
In this study , we investigated BC6ENTC - induced atherosclerotic plaque vulnerability (possibility of rupture) in BC6ENTG - knockout ( BC6OTHER ( - / - )) mice.	False
In this study , we investigated BC6ENTC - induced atherosclerotic plaque vulnerability (possibility of rupture) in BC6OTHER - knockout ( BC6ENTG ( - / - )) mice.	False
 BC6ENTC induces atherosclerotic plaque vulnerability in BC6ENTG - knockout mice.	False
Moreover , BC6ENTC - induced increases in BC6ENTG and BC6OTHER BC6OTHER in the brain were also attenuated by BC6OTHER .	CPR:3
Moreover , BC6ENTC - induced increases in BC6OTHER and BC6ENTG BC6OTHER in the brain were also attenuated by BC6OTHER .	CPR:3
Moreover , BC6ENTC - induced increases in BC6OTHER and BC6OTHER BC6ENTG in the brain were also attenuated by BC6OTHER .	CPR:3
Moreover , BC6OTHER - induced increases in BC6ENTG and BC6OTHER BC6OTHER in the brain were also attenuated by BC6ENTC .	CPR:4
Moreover , BC6OTHER - induced increases in BC6OTHER and BC6ENTG BC6OTHER in the brain were also attenuated by BC6ENTC .	CPR:4
Moreover , BC6OTHER - induced increases in BC6OTHER and BC6OTHER BC6ENTG in the brain were also attenuated by BC6ENTC .	CPR:4
These results suggest that BC6ENTC increases BC6ENTG burden via activation of BC6OTHER , which further affects BC6OTHER levels and activity of β - and γ - secretases via the BC6OTHER pathway.	CPR:3
These results suggest that BC6ENTC increases BC6OTHER burden via activation of BC6ENTG , which further affects BC6OTHER levels and activity of β - and γ - secretases via the BC6OTHER pathway.	CPR:3
These results suggest that BC6ENTC increases BC6OTHER burden via activation of BC6OTHER , which further affects BC6ENTG levels and activity of β - and γ - secretases via the BC6OTHER pathway.	False
These results suggest that BC6ENTC increases BC6OTHER burden via activation of BC6OTHER , which further affects BC6OTHER levels and activity of β - and γ - secretases via the BC6ENTG pathway.	False
The results demonstrated that intracerebral infusions of BC6ENTC (1 ng / mouse) produced memory impairment as determined by Morris water maze test and Y - maze test in mice , and caused the accumulation of BC6ENTG and BC6OTHER in the hippocampus and cortex through increased activity of β - and γ - secretases accompanied with increased expression of BC6OTHER ( BC6OTHER ).	CPR:3
The results demonstrated that intracerebral infusions of BC6ENTC (1 ng / mouse) produced memory impairment as determined by Morris water maze test and Y - maze test in mice , and caused the accumulation of BC6OTHER and BC6ENTG in the hippocampus and cortex through increased activity of β - and γ - secretases accompanied with increased expression of BC6OTHER ( BC6OTHER ).	CPR:3
The results demonstrated that intracerebral infusions of BC6ENTC (1 ng / mouse) produced memory impairment as determined by Morris water maze test and Y - maze test in mice , and caused the accumulation of BC6OTHER and BC6OTHER in the hippocampus and cortex through increased activity of β - and γ - secretases accompanied with increased expression of BC6ENTG ( BC6OTHER ).	CPR:3
The results demonstrated that intracerebral infusions of BC6ENTC (1 ng / mouse) produced memory impairment as determined by Morris water maze test and Y - maze test in mice , and caused the accumulation of BC6OTHER and BC6OTHER in the hippocampus and cortex through increased activity of β - and γ - secretases accompanied with increased expression of BC6OTHER ( BC6ENTG ).	CPR:3
BC6ENTC also induced expression of BC6ENTG ( BC6OTHER ) and BC6OTHER BC6OTHER in the hippocampus and cortex.	CPR:3
BC6ENTC also induced expression of BC6OTHER ( BC6ENTG ) and BC6OTHER BC6OTHER in the hippocampus and cortex.	CPR:3
BC6ENTC also induced expression of BC6OTHER ( BC6OTHER ) and BC6ENTG BC6OTHER in the hippocampus and cortex.	CPR:3
BC6ENTC also induced expression of BC6OTHER ( BC6OTHER ) and BC6OTHER BC6ENTG in the hippocampus and cortex.	CPR:3
BC6OTHER also induced expression of BC6ENTC receptor 1 ( BC6ENTG ) and BC6OTHER BC6OTHER in the hippocampus and cortex.	False
BC6OTHER also induced expression of BC6ENTC receptor 1 ( BC6OTHER ) and BC6ENTG BC6OTHER in the hippocampus and cortex.	False
BC6OTHER also induced expression of BC6ENTC receptor 1 ( BC6OTHER ) and BC6OTHER BC6ENTG in the hippocampus and cortex.	False
Pretreatment with BC6ENTC (1.5 ng / mouse , intracerebroventricularly) , a BC6ENTG antagonist , blocked BC6OTHER - induced amyloidogenesis , memory deficits.	CPR:6
Pretreatment with BC6OTHER (1.5 ng / mouse , intracerebroventricularly) , a BC6ENTG antagonist , blocked BC6ENTC - induced amyloidogenesis , memory deficits.	False
 BC6ENTC induces cognitive impairment through enhancement of BC6ENTG - mediated BC6OTHER generation in mice.	CPR:3
 BC6ENTC induces cognitive impairment through enhancement of BC6OTHER - mediated BC6ENTG generation in mice.	CPR:3
After 30min of treatment , CHEM induced a rapid increase in the intracellular BC6ENTC concentration and activation of BC6ENTG , which was maintained for at least 6h.	False
CHEM - treatment of astrocytes with BC6ENTC and the intracellular BC6OTHER chelator BC6OTHER prevented downregulation of BC6ENTG and inhibition of GJIC.	CPR:4
CHEM - treatment of astrocytes with BC6OTHER and the intracellular BC6ENTC chelator BC6OTHER prevented downregulation of BC6ENTG and inhibition of GJIC.	False
CHEM - treatment of astrocytes with BC6OTHER and the intracellular BC6OTHER chelator BC6ENTC prevented downregulation of BC6ENTG and inhibition of GJIC.	CPR:3
Moreover , co - treatment with BC6ENTC and a specific BC6ENTG inhibitor prevented endocytosis of gap junctions , downregulation of BC6OTHER , and inhibition of GJIC.	False
Moreover , co - treatment with BC6ENTC and a specific BC6OTHER inhibitor prevented endocytosis of gap junctions , downregulation of BC6ENTG , and inhibition of GJIC.	CPR:4
Taken together , these findings indicate that BC6ENTC induces BC6ENTG gap junction disassembly by the BC6OTHER signaling pathway.	False
Taken together , these findings indicate that BC6ENTC induces BC6OTHER gap junction disassembly by the BC6ENTG signaling pathway.	CPR:3
Levels of BC6ENTG protein were also decreased in a dose - and time - dependent manner following BC6ENTC treatment.	CPR:4
Double - labeling immunofluorescence microscopy showed that BC6ENTC (10ng / ml) induced endocytosis of surface gap junctions into the cytoplasm , where BC6ENTG was co - localized with the early endosome marker BC6OTHER .	False
Double - labeling immunofluorescence microscopy showed that BC6ENTC (10ng / ml) induced endocytosis of surface gap junctions into the cytoplasm , where BC6OTHER was co - localized with the early endosome marker BC6ENTG .	False
Inhibition of lysosomes or proteasomes by co - treatment with BC6ENTC and their respective specific inhibitors , BC6OTHER or BC6OTHER , partially inhibited the CHEM - induced decrease in BC6ENTG protein levels , but did not inhibit the CHEM - induced inhibition of GJIC.	False
Inhibition of lysosomes or proteasomes by co - treatment with BC6OTHER and their respective specific inhibitors , BC6ENTC or BC6OTHER , partially inhibited the CHEM - induced decrease in BC6ENTG protein levels , but did not inhibit the CHEM - induced inhibition of GJIC.	False
Inhibition of lysosomes or proteasomes by co - treatment with BC6OTHER and their respective specific inhibitors , BC6OTHER or BC6ENTC , partially inhibited the CHEM - induced decrease in BC6ENTG protein levels , but did not inhibit the CHEM - induced inhibition of GJIC.	False
 BC6ENTC - induced BC6ENTG gap junction disassembly in rat astrocytes involves BC6OTHER .	False
 BC6ENTC - induced BC6OTHER gap junction disassembly in rat astrocytes involves BC6ENTG .	False
Two mechanisms of action have been identified for BC6ENTC : inhibition of BC6ENTG ( BC6OTHER ) and inhibition of BC6OTHER .	CPR:4
Two mechanisms of action have been identified for BC6ENTC : inhibition of BC6OTHER ( BC6ENTG ) and inhibition of BC6OTHER .	CPR:4
Two mechanisms of action have been identified for BC6ENTC : inhibition of BC6OTHER ( BC6OTHER ) and inhibition of BC6ENTG .	CPR:4
Two mechanisms of action have been identified for BC6OTHER : inhibition of BC6ENTC dehydrogenase ( BC6ENTG ) and inhibition of BC6OTHER .	False
Two mechanisms of action have been identified for BC6OTHER : inhibition of BC6ENTC dehydrogenase ( BC6OTHER ) and inhibition of BC6ENTG .	False
Two mechanisms of action have been identified for BC6OTHER : inhibition of BC6ENTG ( BC6OTHER ) and inhibition of BC6ENTC kinases.	False
Two mechanisms of action have been identified for BC6OTHER : inhibition of BC6OTHER ( BC6ENTG ) and inhibition of BC6ENTC kinases.	False
BC6ENTG inhibition occurs at lower concentrations of BC6ENTC than that of BC6OTHER and is currently considered the major mode of action.	CPR:4
BC6OTHER inhibition occurs at lower concentrations of BC6ENTC than that of BC6ENTG and is currently considered the major mode of action.	CPR:4
BC6ENTG inhibition occurs at lower concentrations of BC6OTHER than that of BC6ENTC kinases and is currently considered the major mode of action.	False
When HUVECs were stimulated by BC6ENTG in the presence of 100 microM BC6ENTC , BC6OTHER activity and BC6OTHER release were similar in untreated and BC6OTHER - treated cells.	False
When HUVECs were stimulated by BC6OTHER in the presence of 100 microM BC6ENTC , BC6ENTG activity and BC6OTHER release were similar in untreated and BC6OTHER - treated cells.	False
When HUVECs were stimulated by BC6ENTG in the presence of 100 microM BC6OTHER , BC6OTHER activity and BC6ENTC release were similar in untreated and BC6OTHER - treated cells.	False
When HUVECs were stimulated by BC6OTHER in the presence of 100 microM BC6OTHER , BC6ENTG activity and BC6ENTC release were similar in untreated and BC6OTHER - treated cells.	False
When HUVECs were stimulated by BC6ENTG in the presence of 100 microM BC6OTHER , BC6OTHER activity and BC6OTHER release were similar in untreated and BC6ENTC - treated cells.	False
When HUVECs were stimulated by BC6OTHER in the presence of 100 microM BC6OTHER , BC6ENTG activity and BC6OTHER release were similar in untreated and BC6ENTC - treated cells.	False
However , despite activation of BC6ENTC uptake , the inhibition of BC6ENTG activity by BC6OTHER was still significant.	False
However , despite activation of BC6OTHER uptake , the inhibition of BC6ENTG activity by BC6ENTC was still significant.	CPR:4
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6ENTC , the common substrate of BC6ENTG ( BC6OTHER ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6ENTC , the common substrate of constitutive BC6OTHER synthase ( BC6ENTG ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6ENTC , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6ENTG and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6ENTC , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6OTHER and BC6ENTG .	CPR:9
These data suggest that endothelial BC6ENTC synthesis depends on the activity of BC6ENTG in mitochondria and BC6OTHER carriers in cell membrane.	CPR:9
These data suggest that endothelial BC6OTHER synthesis depends on the activity of BC6ENTG in mitochondria and BC6ENTC carriers in cell membrane.	False
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6ENTC synthase ( BC6ENTG ) and cytosolic BC6OTHER and BC6OTHER .	False
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6ENTC synthase ( BC6OTHER ) and cytosolic BC6ENTG and BC6OTHER .	False
Reduced synthesis of BC6OTHER ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6ENTC synthase ( BC6OTHER ) and cytosolic BC6OTHER and BC6ENTG .	False
Reduced synthesis of BC6ENTC ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of BC6ENTG ( BC6OTHER ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6ENTC ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6ENTG ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6ENTC ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6ENTG and BC6OTHER .	CPR:9
Reduced synthesis of BC6ENTC ( BC6OTHER ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6OTHER and BC6ENTG .	CPR:9
To determine whether BC6ENTG modulate the endothelial BC6ENTC synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	CPR:9
To determine whether BC6OTHER modulate the endothelial BC6ENTC synthesis , we investigated the effects of the competitive BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6ENTC synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6ENTG , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6ENTC synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6ENTG , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6ENTC synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTG and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
Reduced synthesis of BC6OTHER ( BC6ENTC ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of BC6ENTG ( BC6OTHER ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6ENTC ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6ENTG ) and cytosolic BC6OTHER and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6ENTC ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6ENTG and BC6OTHER .	CPR:9
Reduced synthesis of BC6OTHER ( BC6ENTC ) contributes to the endothelial dysfunction and may be related to limited availability of BC6OTHER , the common substrate of constitutive BC6OTHER synthase ( BC6OTHER ) and cytosolic BC6OTHER and BC6ENTG .	CPR:9
To determine whether BC6ENTG modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	CPR:4
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) on the activity of BC6ENTG , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) on the activity of BC6OTHER , BC6ENTG , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTG and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6ENTG modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	CPR:4
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) on the activity of BC6ENTG , BC6OTHER , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) on the activity of BC6OTHER , BC6ENTG , and BC6OTHER and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTG and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6ENTG modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTC transporter and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTC transporter and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6ENTG , BC6OTHER , and BC6ENTC transporter and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6ENTG , and BC6ENTC transporter and on BC6OTHER release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6ENTG modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6ENTC release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6OTHER and on BC6ENTC release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6ENTG , BC6OTHER , and BC6OTHER and on BC6ENTC release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6ENTG , and BC6OTHER and on BC6ENTC release at surface of human umbilical vein endothelial cells (HUVECs).	False
To determine whether BC6OTHER modulate the endothelial BC6OTHER synthesis , we investigated the effects of the competitive BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) on the activity of BC6OTHER , BC6OTHER , and BC6ENTG and on BC6ENTC release at surface of human umbilical vein endothelial cells (HUVECs).	False
In unstimulated cells , BC6ENTC dose - dependently reduced the BC6ENTG activity with maximal inhibition at 20 microM.	CPR:4
When HUVECs were stimulated by BC6ENTG without extracellular BC6ENTC , BC6OTHER dose - dependently increased the BC6OTHER activity and the BC6OTHER release with maximal effects at 20 microM.	False
When HUVECs were stimulated by BC6OTHER without extracellular BC6ENTC , BC6OTHER dose - dependently increased the BC6ENTG activity and the BC6OTHER release with maximal effects at 20 microM.	False
When HUVECs were stimulated by BC6ENTG without extracellular BC6OTHER , BC6ENTC dose - dependently increased the BC6OTHER activity and the BC6OTHER release with maximal effects at 20 microM.	False
When HUVECs were stimulated by BC6OTHER without extracellular BC6OTHER , BC6ENTC dose - dependently increased the BC6ENTG activity and the BC6OTHER release with maximal effects at 20 microM.	CPR:3
When HUVECs were stimulated by BC6ENTG without extracellular BC6OTHER , BC6OTHER dose - dependently increased the BC6OTHER activity and the BC6ENTC release with maximal effects at 20 microM.	False
When HUVECs were stimulated by BC6OTHER without extracellular BC6OTHER , BC6OTHER dose - dependently increased the BC6ENTG activity and the BC6ENTC release with maximal effects at 20 microM.	False
Extracellular BC6ENTC also dose - dependently increased BC6OTHER release and BC6ENTG activity.	CPR:3
Extracellular BC6OTHER also dose - dependently increased BC6ENTC release and BC6ENTG activity.	False
 BC6ENTG modulates BC6ENTC synthesis through nonfreely exchangeable BC6OTHER pools in human endothelial cells.	CPR:9
 BC6ENTG modulates BC6OTHER synthesis through nonfreely exchangeable BC6ENTC pools in human endothelial cells.	CPR:9
OBJECTIVE: BC6ENTC and BC6OTHER are two relatively new nonsteroidal anti - inflammatory drugs (NSAIDs) that selectively inhibit the BC6ENTG ( BC6OTHER ) isoenzyme at therapeutic concentrations.	CPR:4
OBJECTIVE: BC6ENTC and BC6OTHER are two relatively new nonsteroidal anti - inflammatory drugs (NSAIDs) that selectively inhibit the BC6OTHER ( BC6ENTG ) isoenzyme at therapeutic concentrations.	CPR:4
OBJECTIVE: BC6OTHER and BC6ENTC are two relatively new nonsteroidal anti - inflammatory drugs (NSAIDs) that selectively inhibit the BC6ENTG ( BC6OTHER ) isoenzyme at therapeutic concentrations.	CPR:4
OBJECTIVE: BC6OTHER and BC6ENTC are two relatively new nonsteroidal anti - inflammatory drugs (NSAIDs) that selectively inhibit the BC6OTHER ( BC6ENTG ) isoenzyme at therapeutic concentrations.	CPR:4
This study was conducted in order to understand the association between acute renal failure and the two BC6ENTG inhibitors BC6ENTC and BC6OTHER .	CPR:4
This study was conducted in order to understand the association between acute renal failure and the two BC6ENTG inhibitors BC6OTHER and BC6ENTC .	CPR:4
Unlike BC6ENTG ( BC6OTHER ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6ENTC to produce either BC6OTHER or BC6OTHER , respectively.	False
Unlike BC6OTHER ( BC6ENTG ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6ENTC to produce either BC6OTHER or BC6OTHER , respectively.	False
Unlike BC6OTHER ( BC6OTHER ) , BC6ENTG had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6ENTC to produce either BC6OTHER or BC6OTHER , respectively.	CPR:9
Unlike BC6ENTG ( BC6OTHER ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6ENTC or BC6OTHER , respectively.	False
Unlike BC6OTHER ( BC6ENTG ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6ENTC or BC6OTHER , respectively.	False
Unlike BC6OTHER ( BC6OTHER ) , BC6ENTG had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6ENTC or BC6OTHER , respectively.	CPR:9
Unlike BC6ENTG ( BC6OTHER ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6OTHER or BC6ENTC , respectively.	False
Unlike BC6OTHER ( BC6ENTG ) , BC6OTHER had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6OTHER or BC6ENTC , respectively.	False
Unlike BC6OTHER ( BC6OTHER ) , BC6ENTG had an altered bond specificity saturating either the 13 - 14 or 7 - 8 double bonds of BC6OTHER to produce either BC6OTHER or BC6ENTC , respectively.	CPR:9
Metabolism of BC6OTHER , BC6OTHER , leads to the formation of BC6OTHER , the visual chromophore , and BC6ENTC , which is involved in the regulation of gene expression through the BC6ENTG .	False
BC6ENTG also saturated the 13 - 14 or 7 - 8 double bonds of BC6ENTC ( BC6OTHER ) , a second endogenous form of BC6OTHER in zebrafish.	CPR:9
BC6ENTG also saturated the 13 - 14 or 7 - 8 double bonds of BC6OTHER ( BC6ENTC ) , a second endogenous form of BC6OTHER in zebrafish.	CPR:9
BC6ENTG also saturated the 13 - 14 or 7 - 8 double bonds of BC6OTHER ( BC6OTHER ) , a second endogenous form of BC6ENTC in zebrafish.	False
Metabolism of BC6ENTC , BC6OTHER , leads to the formation of BC6OTHER , the visual chromophore , and BC6OTHER , which is involved in the regulation of gene expression through the BC6ENTG .	False
The dual enzymatic activity of BC6ENTG displays a newly acquired specificity for the 13 - 14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial BC6ENTC desaturases and BC6OTHER .	False
The dual enzymatic activity of BC6OTHER displays a newly acquired specificity for the 13 - 14 double bond retained in higher vertebrates and also the evolutionarily preserved activity of bacterial BC6ENTC desaturases and BC6ENTG .	False
Exogenous BC6ENTC , BC6OTHER , or BC6OTHER led to the strong induction of the expression of the BC6OTHER - metabolizing enzyme , BC6ENTG , arguing for an active signaling function of BC6OTHER metabolites in zebrafish.	False
Exogenous BC6OTHER , BC6ENTC , or BC6OTHER led to the strong induction of the expression of the BC6OTHER - metabolizing enzyme , BC6ENTG , arguing for an active signaling function of BC6OTHER metabolites in zebrafish.	False
Exogenous BC6OTHER , BC6OTHER , or BC6ENTC led to the strong induction of the expression of the BC6OTHER - metabolizing enzyme , BC6ENTG , arguing for an active signaling function of BC6OTHER metabolites in zebrafish.	False
Exogenous BC6OTHER , BC6OTHER , or BC6OTHER led to the strong induction of the expression of the BC6ENTC - metabolizing enzyme , BC6ENTG , arguing for an active signaling function of BC6OTHER metabolites in zebrafish.	False
Exogenous BC6OTHER , BC6OTHER , or BC6OTHER led to the strong induction of the expression of the BC6OTHER - metabolizing enzyme , BC6ENTG , arguing for an active signaling function of BC6ENTC metabolites in zebrafish.	False
These findings point to a conserved function but altered specificity of BC6ENTG in vertebrates , leading to the generation of various BC6ENTC compounds , some of which could have signaling functions.	False
Metabolism of BC6OTHER , BC6ENTC , leads to the formation of BC6OTHER , the visual chromophore , and BC6OTHER , which is involved in the regulation of gene expression through the BC6ENTG .	False
Specifically , BC6ENTC is transiently oxidized to BC6OTHER before being oxidized further by BC6ENTG enzymes.	CPR:9
Specifically , BC6OTHER is transiently oxidized to BC6ENTC before being oxidized further by BC6ENTG enzymes.	False
Metabolism of BC6OTHER , BC6OTHER , leads to the formation of BC6ENTC , the visual chromophore , and BC6OTHER , which is involved in the regulation of gene expression through the BC6ENTG .	False
Here , we report the identification of two putative BC6ENTG homologues in zebrafish , one of which , BC6OTHER ( BC6OTHER ) , also had BC6ENTC saturase activity , whereas BC6OTHER ( BC6OTHER ) was inactive under similar conditions.	False
Here , we report the identification of two putative BC6OTHER homologues in zebrafish , one of which , BC6ENTG ( BC6OTHER ) , also had BC6ENTC saturase activity , whereas BC6OTHER ( BC6OTHER ) was inactive under similar conditions.	False
Here , we report the identification of two putative BC6OTHER homologues in zebrafish , one of which , BC6OTHER ( BC6ENTG ) , also had BC6ENTC saturase activity , whereas BC6OTHER ( BC6OTHER ) was inactive under similar conditions.	False
Here , we report the identification of two putative BC6OTHER homologues in zebrafish , one of which , BC6OTHER ( BC6OTHER ) , also had BC6ENTC saturase activity , whereas BC6ENTG ( BC6OTHER ) was inactive under similar conditions.	False
Here , we report the identification of two putative BC6OTHER homologues in zebrafish , one of which , BC6OTHER ( BC6OTHER ) , also had BC6ENTC saturase activity , whereas BC6OTHER ( BC6ENTG ) was inactive under similar conditions.	False
Specificity of BC6ENTG : formation of BC6ENTC and BC6OTHER .	CPR:9
Specificity of BC6ENTG : formation of BC6OTHER and BC6ENTC .	CPR:9
The influence of BC6ENTC antagonists on BC6ENTG activity was assessed.	False
Increased BC6ENTG activity in the serum was inhibited by both BC6ENTC and BC6OTHER by over 90%.	CPR:4
Increased BC6ENTG activity in the serum was inhibited by both BC6OTHER and BC6ENTC by over 90%.	CPR:4
CONCLUSIONS: BC6ENTC produced after antigen provocation sequentially induced BC6ENTG production from some immune component cells via BC6OTHER receptor activation.	False
CONCLUSIONS: BC6ENTC produced after antigen provocation sequentially induced BC6OTHER production from some immune component cells via BC6ENTG receptor activation.	CPR:3
Thus , it is likely that BC6ENTC indirectly cause antigen - induced eosinophilia through BC6ENTG production.	False
BACKGROUND: Allergic airway eosinophilia is suppressed by BC6ENTG ( BC6OTHER receptor) antagonists in several species including humans and guinea - pigs , suggesting that BC6ENTC are directly or indirectly involved in induction of the response.	False
BACKGROUND: Allergic airway eosinophilia is suppressed by CHEM leukotriene ( BC6OTHER ) receptor ( BC6ENTG receptor) antagonists in several species including humans and guinea - pigs , suggesting that BC6ENTC are directly or indirectly involved in induction of the response.	False
OBJECTIVE: We examined the effect of BC6ENTC antagonists ( BC6OTHER and BC6OTHER ) on antigen inhalation - induced eosinophilia in peripheral blood and lung , and on BC6ENTG activity in serum during late increase of airway resistance (late asthmatic response , LAR) in sensitized guinea - pigs.	False
OBJECTIVE: We examined the effect of BC6OTHER antagonists ( BC6ENTC and BC6OTHER ) on antigen inhalation - induced eosinophilia in peripheral blood and lung , and on BC6ENTG activity in serum during late increase of airway resistance (late asthmatic response , LAR) in sensitized guinea - pigs.	False
OBJECTIVE: We examined the effect of BC6OTHER antagonists ( BC6OTHER and BC6ENTC ) on antigen inhalation - induced eosinophilia in peripheral blood and lung , and on BC6ENTG activity in serum during late increase of airway resistance (late asthmatic response , LAR) in sensitized guinea - pigs.	False
BACKGROUND: Allergic airway eosinophilia is suppressed by BC6ENTC ( BC6OTHER ) receptor ( BC6ENTG receptor) antagonists in several species including humans and guinea - pigs , suggesting that BC6OTHER are directly or indirectly involved in induction of the response.	False
METHODS: Guinea - pigs inhaled BC6ENTG ( BC6OTHER ) + BC6ENTC and BC6OTHER mists alternately for sensitization and challenge , respectively , once every 2 weeks.	False
METHODS: Guinea - pigs inhaled BC6OTHER ( BC6ENTG ) + BC6ENTC and BC6OTHER mists alternately for sensitization and challenge , respectively , once every 2 weeks.	False
METHODS: Guinea - pigs inhaled BC6OTHER ( BC6OTHER ) + BC6ENTC and BC6ENTG mists alternately for sensitization and challenge , respectively , once every 2 weeks.	False
At the fifth challenge , the effects of BC6ENTC antagonists and an anti - BC6ENTG antibody (TRFK - 5) on the occurrence of LAR , and blood and lung eosinophilia , which appeared at 5 h after challenge , were examined.	False
BACKGROUND: Allergic airway eosinophilia is suppressed by CHEM leukotriene ( BC6ENTC ) receptor ( BC6ENTG receptor) antagonists in several species including humans and guinea - pigs , suggesting that BC6OTHER are directly or indirectly involved in induction of the response.	False
 BC6ENTC - dependent BC6ENTG production leading to eosinophilia during late asthmatic response in guinea - pigs.	False
In contrast , an BC6ENTC - terminal deletion mutant of BC6ENTG promoted the formation of intracellular aggregates even in the absence of BC6OTHER overexpression.	False
In contrast , an BC6ENTC - terminal deletion mutant of BC6OTHER promoted the formation of intracellular aggregates even in the absence of BC6ENTG overexpression.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6ENTG ( BC6OTHER ) and BC6OTHER and are present in hepatocytes of individuals with BC6ENTC liver disease , BC6OTHER steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6OTHER ( BC6ENTG ) and BC6OTHER and are present in hepatocytes of individuals with BC6ENTC liver disease , BC6OTHER steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6OTHER ( BC6OTHER ) and BC6ENTG and are present in hepatocytes of individuals with BC6ENTC liver disease , BC6OTHER steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6ENTG ( BC6OTHER ) and BC6OTHER and are present in hepatocytes of individuals with BC6OTHER liver disease , BC6ENTC steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6OTHER ( BC6ENTG ) and BC6OTHER and are present in hepatocytes of individuals with BC6OTHER liver disease , BC6ENTC steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Mallory bodies (MBs) are cytoplasmic inclusions that contain BC6OTHER ( BC6OTHER ) and BC6ENTG and are present in hepatocytes of individuals with BC6OTHER liver disease , BC6ENTC steatohepatitis , or benign or malignant hepatocellular neoplasia.	False
Culture of HepG2 cells with BC6ENTC has now been shown to induce both the formation of intracellular aggregates containing BC6ENTG as well as an increase in the abundance of BC6OTHER mRNA.	CPR:3
Culture of HepG2 cells with BC6ENTC has now been shown to induce both the formation of intracellular aggregates containing BC6OTHER as well as an increase in the abundance of BC6ENTG mRNA.	CPR:3
Overexpression of BC6ENTG in HepG2 , HeLa , or COS - 7 cells also induced the formation of intracellular aggregates that stained with antibodies to BC6OTHER and with BC6ENTC (characteristics of MBs formed in vivo) , eventually leading to cell death.	False
Overexpression of BC6OTHER in HepG2 , HeLa , or COS - 7 cells also induced the formation of intracellular aggregates that stained with antibodies to BC6ENTG and with BC6ENTC (characteristics of MBs formed in vivo) , eventually leading to cell death.	False
We topically applied the BC6OTHER ( BC6ENTG ) inhibitor , BC6ENTC , on sciatic nerve and observed reduced inhibition of NBF in EDN , which was correctable with a BC6OTHER diet.	CPR:4
We topically applied the BC6ENTG ( BC6OTHER ) inhibitor , BC6ENTC , on sciatic nerve and observed reduced inhibition of NBF in EDN , which was correctable with a BC6OTHER diet.	CPR:4
We topically applied the BC6OTHER ( BC6ENTG ) inhibitor , BC6OTHER , on sciatic nerve and observed reduced inhibition of NBF in EDN , which was correctable with a BC6ENTC diet.	False
We topically applied the BC6ENTG ( BC6OTHER ) inhibitor , BC6OTHER , on sciatic nerve and observed reduced inhibition of NBF in EDN , which was correctable with a BC6ENTC diet.	False
These results suggest that diabetic neuropathy may have an increasing vasopressor action with BC6ENTC and this is likely to be the mechanism of BC6ENTG inhibition.	False
We evaluated the effects of BC6ENTC and an BC6ENTG inhibitor ( BC6OTHER ) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.	False
We evaluated the effects of BC6ENTG and an BC6ENTC - converting enzyme inhibitor ( BC6OTHER ) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.	False
We evaluated the effects of BC6ENTG and an BC6OTHER inhibitor ( BC6ENTC ) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.	CPR:4
We evaluated the effects of BC6OTHER and an BC6ENTG inhibitor ( BC6ENTC ) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.	CPR:4
We topically applied the BC6ENTC synthase ( BC6ENTG ) inhibitor , BC6OTHER , on sciatic nerve and observed reduced inhibition of NBF in EDN , which was correctable with a BC6OTHER diet.	False
Altered vasoreactivity to BC6ENTG in experimental diabetic neuropathy: role of BC6ENTC .	False
Accordingly , the production rates of BC6ENTG and BC6ENTC , as well as BC6OTHER activity , were significantly higher in the 3D versus the 2D cultures.	False
Accordingly , the production rates of BC6OTHER and BC6ENTC , as well as BC6ENTG activity , were significantly higher in the 3D versus the 2D cultures.	False
BC6ENTG and BC6OTHER genes were downregulated in dTGR and were increased by BC6ENTC and BC6OTHER treatments , whereas no changes in the expression of BC6OTHER and BC6OTHER receptor genes were observed.	CPR:3
BC6OTHER and BC6ENTG genes were downregulated in dTGR and were increased by BC6ENTC and BC6OTHER treatments , whereas no changes in the expression of BC6OTHER and BC6OTHER receptor genes were observed.	CPR:3
BC6OTHER and BC6OTHER genes were downregulated in dTGR and were increased by BC6ENTC and BC6OTHER treatments , whereas no changes in the expression of BC6ENTG and BC6OTHER receptor genes were observed.	False
BC6OTHER and BC6OTHER genes were downregulated in dTGR and were increased by BC6ENTC and BC6OTHER treatments , whereas no changes in the expression of BC6OTHER and BC6ENTG receptor genes were observed.	False
BC6ENTG and BC6OTHER genes were downregulated in dTGR and were increased by BC6OTHER and BC6ENTC treatments , whereas no changes in the expression of BC6OTHER and BC6OTHER receptor genes were observed.	CPR:3
BC6OTHER and BC6ENTG genes were downregulated in dTGR and were increased by BC6OTHER and BC6ENTC treatments , whereas no changes in the expression of BC6OTHER and BC6OTHER receptor genes were observed.	CPR:3
BC6OTHER and BC6OTHER genes were downregulated in dTGR and were increased by BC6OTHER and BC6ENTC treatments , whereas no changes in the expression of BC6ENTG and BC6OTHER receptor genes were observed.	False
BC6OTHER and BC6OTHER genes were downregulated in dTGR and were increased by BC6OTHER and BC6ENTC treatments , whereas no changes in the expression of BC6OTHER and BC6ENTG receptor genes were observed.	False
BC6ENTG expression was increased by BC6ENTC but not by BC6OTHER .	CPR:3
BC6ENTG expression was increased by BC6OTHER but not by BC6ENTC .	False
Neither inducible BC6ENTC synthase nor BC6ENTG gene expression was affected by drug treatments.	False
Neither BC6ENTG nor neural BC6ENTC synthase gene expression was affected by drug treatments.	False
Therefore , submaximal BC6ENTG inhibition enhanced BC6ENTC excretion mainly by increasing RBF and GFR , whereas submaximal BC6OTHER receptor blockade decreased tubular BC6OTHER and water reabsorption.	False
Therefore , submaximal BC6OTHER inhibition enhanced BC6ENTC excretion mainly by increasing RBF and GFR , whereas submaximal BC6ENTG receptor blockade decreased tubular BC6OTHER and water reabsorption.	False
Therefore , submaximal BC6ENTG inhibition enhanced BC6OTHER excretion mainly by increasing RBF and GFR , whereas submaximal BC6OTHER receptor blockade decreased tubular BC6ENTC and water reabsorption.	False
Therefore , submaximal BC6OTHER inhibition enhanced BC6OTHER excretion mainly by increasing RBF and GFR , whereas submaximal BC6ENTG receptor blockade decreased tubular BC6ENTC and water reabsorption.	False
The pressure - natriuresis and - diuresis relationships in response to chronic BC6ENTC - converting enzyme ( BC6ENTG ) inhibition and BC6OTHER receptor blockade were evaluated.	False
The pressure - natriuresis and - diuresis relationships in response to chronic BC6ENTC - converting enzyme ( BC6OTHER ) inhibition and BC6ENTG receptor blockade were evaluated.	False
The BC6ENTG inhibitor effects may involve increased endothelial BC6ENTC synthase expression , perhaps related to the inhibition of BC6OTHER degradation.	False
The BC6OTHER inhibitor effects may involve increased endothelial BC6ENTC synthase expression , perhaps related to the inhibition of BC6ENTG degradation.	False
The BC6ENTG inhibitor effects may involve increased endothelial BC6OTHER synthase expression , perhaps related to the inhibition of BC6ENTC degradation.	False
The BC6OTHER inhibitor effects may involve increased BC6ENTG expression , perhaps related to the inhibition of BC6ENTC degradation.	False
BC6ENTG - BC6ENTC and BC6OTHER ( BC6OTHER ) system gene expression was also investigated.	False
BC6ENTG - BC6OTHER and BC6ENTC ( BC6OTHER ) system gene expression was also investigated.	False
BC6OTHER - BC6ENTG and BC6ENTC ( BC6OTHER ) system gene expression was also investigated.	False
BC6ENTG - BC6OTHER and BC6OTHER ( BC6ENTC ) system gene expression was also investigated.	False
BC6OTHER - BC6ENTG and BC6OTHER ( BC6ENTC ) system gene expression was also investigated.	False
 BC6ENTC - converting enzyme inhibition and BC6OTHER receptor blockade modify the pressure - natriuresis relationship by additive mechanisms in rats with BC6ENTG and BC6OTHER genes.	False
 BC6ENTC - converting enzyme inhibition and BC6OTHER receptor blockade modify the pressure - natriuresis relationship by additive mechanisms in rats with BC6OTHER and BC6ENTG genes.	False
 BC6ENTC - converting enzyme inhibition and BC6ENTG receptor blockade modify the pressure - natriuresis relationship by additive mechanisms in rats with BC6OTHER and BC6OTHER genes.	False
BC6ENTC was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of BC6ENTG ( BC6OTHER ).	CPR:9
BC6ENTC was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of CHEM - BC6OTHER - transferase ( BC6ENTG ).	CPR:9
BC6OTHER was metabolised by BC6ENTC to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of BC6ENTG ( BC6OTHER ).	False
BC6OTHER was metabolised by BC6ENTC to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of CHEM - BC6OTHER - transferase ( BC6ENTG ).	False
BC6OTHER was metabolised by BC6OTHER to form a BC6ENTC conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of BC6ENTG ( BC6OTHER ).	False
BC6OTHER was metabolised by BC6OTHER to form a BC6ENTC conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of CHEM - BC6OTHER - transferase ( BC6ENTG ).	False
BC6OTHER was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6ENTC ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6ENTC ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of CHEM - BC6OTHER - transferase ( BC6ENTG ).	CPR:9
BC6OTHER was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of BC6ENTC - BC6OTHER - transferase ( BC6ENTG ).	False
BC6OTHER was metabolised by BC6OTHER to form a BC6OTHER conjugate ( BC6OTHER ) in RAW 264.7 cells , via a potential mechanism involving the catalytic activity of CHEM - BC6ENTC - transferase ( BC6ENTG ).	False
A significant decrease in BC6ENTC (T180) and BC6OTHER (T90 and T180) , as well as a significant increase in BC6OTHER , accompanied intake of AGE - BC6ENTG .	False
A significant decrease in BC6OTHER (T180) and BC6ENTC (T90 and T180) , as well as a significant increase in BC6OTHER , accompanied intake of AGE - BC6ENTG .	False
A significant decrease in BC6OTHER (T180) and BC6OTHER (T90 and T180) , as well as a significant increase in BC6ENTC , accompanied intake of AGE - BC6ENTG .	False
These studies suggest that BC6OTHER - overexpressing tumors are particularly susceptible to the inhibition of BC6ENTG family BC6ENTC kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.	False
These studies suggest that BC6ENTG - overexpressing tumors are particularly susceptible to the inhibition of BC6OTHER family BC6ENTC kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.	False
"BC6ENTC ("" BC6OTHER "") , a CHEM BC6ENTG inhibitor selective for the BC6OTHER , has shown good activity in preclinical studies and in the early phase of clinical trials."	CPR:4
"BC6ENTC ("" BC6OTHER "") , a CHEM BC6OTHER inhibitor selective for the BC6ENTG , has shown good activity in preclinical studies and in the early phase of clinical trials."	CPR:4
"BC6OTHER ("" BC6ENTC "") , a CHEM BC6ENTG inhibitor selective for the BC6OTHER , has shown good activity in preclinical studies and in the early phase of clinical trials."	CPR:4
"BC6OTHER ("" BC6ENTC "") , a CHEM BC6OTHER inhibitor selective for the BC6ENTG , has shown good activity in preclinical studies and in the early phase of clinical trials."	CPR:4
"BC6OTHER ("" BC6OTHER "") , a BC6ENTC kinase inhibitor selective for the BC6ENTG , has shown good activity in preclinical studies and in the early phase of clinical trials."	False
In a panel of human breast cancer and other epithelial tumor cell lines , BC6ENTG - overexpressing tumors were particularly sensitive to BC6ENTC .	False
Growth inhibition of these tumor cell lines was associated with the dephosphorylation of BC6ENTG , BC6OTHER , and BC6OTHER , accompanied by the loss of association of HER3 with BC6ENTC 3 - kinase , and down - regulation of BC6OTHER activity.	False
Growth inhibition of these tumor cell lines was associated with the dephosphorylation of BC6OTHER , BC6ENTG , and BC6OTHER , accompanied by the loss of association of HER3 with BC6ENTC 3 - kinase , and down - regulation of BC6OTHER activity.	False
Growth inhibition of these tumor cell lines was associated with the dephosphorylation of BC6OTHER , BC6OTHER , and BC6ENTG , accompanied by the loss of association of HER3 with BC6ENTC 3 - kinase , and down - regulation of BC6OTHER activity.	False
Growth inhibition of these tumor cell lines was associated with the dephosphorylation of BC6OTHER , BC6OTHER , and BC6OTHER , accompanied by the loss of association of HER3 with BC6ENTC 3 - kinase , and down - regulation of BC6ENTG activity.	False
"The BC6OTHER inhibitor BC6ENTC ("" BC6OTHER "") inhibits BC6OTHER - driven signaling and suppresses the growth of BC6ENTG - overexpressing tumor cells."	False
"The BC6ENTG inhibitor BC6ENTC ("" BC6OTHER "") inhibits BC6OTHER - driven signaling and suppresses the growth of BC6OTHER - overexpressing tumor cells."	CPR:4
"The BC6OTHER inhibitor BC6ENTC ("" BC6OTHER "") inhibits BC6ENTG - driven signaling and suppresses the growth of BC6OTHER - overexpressing tumor cells."	CPR:4
"The BC6OTHER inhibitor BC6OTHER ("" BC6ENTC "") inhibits BC6OTHER - driven signaling and suppresses the growth of BC6ENTG - overexpressing tumor cells."	CPR:4
"The BC6ENTG inhibitor BC6OTHER ("" BC6ENTC "") inhibits BC6OTHER - driven signaling and suppresses the growth of BC6OTHER - overexpressing tumor cells."	CPR:4
"The BC6OTHER inhibitor BC6OTHER ("" BC6ENTC "") inhibits BC6ENTG - driven signaling and suppresses the growth of BC6OTHER - overexpressing tumor cells."	CPR:4
"The BC6ENTC kinase inhibitor BC6OTHER ("" BC6OTHER "") inhibits BC6OTHER - driven signaling and suppresses the growth of BC6ENTG - overexpressing tumor cells."	False
"The BC6ENTC kinase inhibitor BC6OTHER ("" BC6OTHER "") inhibits BC6ENTG - driven signaling and suppresses the growth of BC6OTHER - overexpressing tumor cells."	False
The current U.S. military and civilian BC6ENTC countermeasure , BC6OTHER ( BC6OTHER ) , is under consideration for replacement with a more effective BC6ENTG reactivator , BC6OTHER ( BC6OTHER ).	False
The current U.S. military and civilian BC6OTHER countermeasure , BC6ENTC ( BC6OTHER ) , is under consideration for replacement with a more effective BC6ENTG reactivator , BC6OTHER ( BC6OTHER ).	False
The current U.S. military and civilian BC6OTHER countermeasure , BC6OTHER ( BC6ENTC ) , is under consideration for replacement with a more effective BC6ENTG reactivator , BC6OTHER ( BC6OTHER ).	False
The current U.S. military and civilian BC6OTHER countermeasure , BC6OTHER ( BC6OTHER ) , is under consideration for replacement with a more effective BC6ENTG reactivator , BC6ENTC ( BC6OTHER ).	CPR:3
The current U.S. military and civilian BC6OTHER countermeasure , BC6OTHER ( BC6OTHER ) , is under consideration for replacement with a more effective BC6ENTG reactivator , BC6OTHER ( BC6ENTC ).	CPR:3
Based on a previous model structure for the BC6ENTC BC6OTHER , the model includes key sites of BC6ENTG inhibition (brain and diaphragm) , as well as fat , kidney , liver , rapidly perfused tissues and slowly perfused tissues.	False
Based on a previous model structure for the BC6OTHER BC6ENTC , the model includes key sites of BC6ENTG inhibition (brain and diaphragm) , as well as fat , kidney , liver , rapidly perfused tissues and slowly perfused tissues.	False
OBJECTIVES: We sought to assess plasma concentrations of the CHEM ( BC6OTHER ) - terminal portion of pro - brain natriuretic peptide ( BC6ENTC - BNP) and BC6ENTG for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the BC6ENTG ( BC6ENTC - BNP) and BC6OTHER for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
BC6ENTC reduced the risk of death or heart failure in patients with above - median levels of BC6ENTG or BC6OTHER , or both , to rates not significantly different from those observed in patients with levels below the median value.	CPR:4
BC6ENTC reduced the risk of death or heart failure in patients with above - median levels of BC6OTHER or BC6ENTG , or both , to rates not significantly different from those observed in patients with levels below the median value.	CPR:4
BC6OTHER reduced the risk of death or heart failure in patients with above - median levels of BC6ENTC - BNP or BC6ENTG , or both , to rates not significantly different from those observed in patients with levels below the median value.	False
CONCLUSIONS: In patients with established ischemic LV dysfunction , plasma BC6ENTC - BNP and BC6ENTG are independent predictors of mortality and heart failure.	False
BC6ENTC reduced mortality and heart failure in patients with higher pre - treatment plasma BC6ENTG and BC6OTHER .	CPR:4
BC6ENTC reduced mortality and heart failure in patients with higher pre - treatment plasma BC6OTHER and BC6ENTG .	CPR:4
BC6OTHER reduced mortality and heart failure in patients with higher pre - treatment plasma BC6ENTC - BNP and BC6ENTG .	False
OBJECTIVES: We sought to assess plasma concentrations of the CHEM ( BC6OTHER ) - terminal portion of pro - brain natriuretic peptide ( BC6ENTG ) and BC6OTHER for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6ENTC or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the CHEM ( BC6OTHER ) - terminal portion of pro - brain natriuretic peptide ( BC6OTHER ) and BC6ENTG for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6ENTC or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the BC6ENTG ( BC6OTHER ) and BC6OTHER for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6ENTC or placebo.	False
BACKGROUND: Although neurohormonal status has known prognostic significance in heart failure , the predictive power of either BC6ENTC - BNP or BC6ENTG in chronic ischemic LV dysfunction has not been previously reported.	False
METHODS: Plasma BC6ENTC - BNP and BC6ENTG were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to BC6OTHER or placebo , added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without CHEM).	False
OBJECTIVES: We sought to assess plasma concentrations of the BC6ENTC ( BC6OTHER ) - terminal portion of pro - brain natriuretic peptide ( BC6ENTG ) and BC6OTHER for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the BC6ENTC ( BC6OTHER ) - terminal portion of pro - brain natriuretic peptide ( BC6OTHER ) and BC6ENTG for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the CHEM ( BC6ENTC ) - terminal portion of pro - brain natriuretic peptide ( BC6ENTG ) and BC6OTHER for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
OBJECTIVES: We sought to assess plasma concentrations of the CHEM ( BC6ENTC ) - terminal portion of pro - brain natriuretic peptide ( BC6OTHER ) and BC6ENTG for prediction of adverse outcomes and responses to treatment in 297 patients with ischemic left ventricular (LV) dysfunction who were randomly assigned to receive BC6OTHER or placebo.	False
METHODS: Plasma BC6ENTG and BC6OTHER were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to BC6ENTC or placebo , added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without CHEM).	False
METHODS: Plasma BC6OTHER and BC6ENTG were measured in 297 patients with chronic ischemic (LV) dysfunction before randomization to BC6ENTC or placebo , added to established treatment with a converting enzyme inhibitor and loop diuretic (with or without CHEM).	False
RESULTS: Above - median BC6ENTC - BNP and BC6ENTG levels conferred increased risks (all p < 0.001) of mortality (risk ratios [95% confidence intervals]: 4.67 [2 - 10.9] and 3.92 [1.76 - 8.7] , respectively) and hospital admission with heart failure (4.7 [2.2 - 10.3] and 2.4 [1.3 - 4.5] , respectively).	False
Plasma BC6OTHER and BC6ENTG : prognostic utility and prediction of benefit from BC6ENTC in chronic ischemic left ventricular dysfunction.	False
Plasma BC6ENTG and BC6OTHER : prognostic utility and prediction of benefit from BC6ENTC in chronic ischemic left ventricular dysfunction.	False
Plasma BC6ENTC - terminal pro - brain natriuretic peptide and BC6ENTG : prognostic utility and prediction of benefit from BC6OTHER in chronic ischemic left ventricular dysfunction.	False
Our results showed that low dose BC6OTHER and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6ENTG and BC6OTHER proteins , while only BC6ENTC could downregulate the expression of BC6OTHER protein.	False
Our results showed that low dose BC6OTHER and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6OTHER and BC6ENTG proteins , while only BC6ENTC could downregulate the expression of BC6OTHER protein.	False
Our results showed that low dose BC6OTHER and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6OTHER and BC6OTHER proteins , while only BC6ENTC could downregulate the expression of BC6ENTG protein.	CPR:4
Our results showed that low dose BC6ENTC and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6ENTG and BC6OTHER proteins , while only BC6OTHER could downregulate the expression of BC6OTHER protein.	CPR:3
Our results showed that low dose BC6ENTC and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6OTHER and BC6ENTG proteins , while only BC6OTHER could downregulate the expression of BC6OTHER protein.	CPR:3
Our results showed that low dose BC6ENTC and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of BC6OTHER and BC6OTHER proteins , while only BC6OTHER could downregulate the expression of BC6ENTG protein.	False
Monodemethylated BC6ENTC bound to BC6ENTG with higher affinity than monodemethylated BC6OTHER or BC6OTHER .	False
Monodemethylated BC6OTHER bound to BC6ENTG with higher affinity than monodemethylated BC6ENTC or BC6OTHER .	False
Monodemethylated BC6OTHER bound to BC6ENTG with higher affinity than monodemethylated BC6OTHER or BC6ENTC .	False
T47D - CO cells were used to assess inhibition of CHEM - stimulated endogenous BC6ENTG activity and transactivation of the BC6OTHER - BC6ENTC kinase ( BC6OTHER ) - luciferase (LUC) reporter plasmid in transient transfections.	False
T47D - CO cells were used to assess inhibition of CHEM - stimulated endogenous BC6OTHER activity and transactivation of the BC6ENTG - BC6ENTC kinase ( BC6OTHER ) - luciferase (LUC) reporter plasmid in transient transfections.	False
T47D - CO cells were used to assess inhibition of CHEM - stimulated endogenous BC6OTHER activity and transactivation of the BC6OTHER - BC6ENTC kinase ( BC6ENTG ) - luciferase (LUC) reporter plasmid in transient transfections.	False
At 10( - 6)M in transcription assays , none of these compounds showed BC6ENTC agonist activity , whereas BC6OTHER and its monodemethylated metabolite manifested slight BC6ENTG agonist activity.	False
At 10( - 6)M in transcription assays , none of these compounds showed BC6ENTG agonist activity , whereas BC6ENTC and its monodemethylated metabolite manifested slight BC6OTHER agonist activity.	False
At 10( - 6)M in transcription assays , none of these compounds showed BC6OTHER agonist activity , whereas BC6ENTC and its monodemethylated metabolite manifested slight BC6ENTG agonist activity.	CPR:5
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTC receptors ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTC receptors ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTC receptors ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6ENTC , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6ENTC , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6ENTC , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6ENTC , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6ENTC , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6ENTC , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6ENTC , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6ENTC , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6ENTC and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6ENTC and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6ENTC and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6ENTC and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6ENTC and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6ENTC and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6ENTC and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6ENTC and CHEM - ring derivatives of BC6OTHER and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6ENTC and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6ENTC and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6ENTC and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6ENTC and BC6OTHER .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6ENTC .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6ENTC .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6ENTC .	False
We have examined the functional activities and potencies , in various cell - based assays , and relative binding affinities (RBAs) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) of the putative CHEM metabolites of BC6OTHER , BC6OTHER , and BC6OTHER and of the BC6OTHER and CHEM - ring derivatives of BC6OTHER and BC6ENTC .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6ENTG and BC6OTHER binding of the putative metabolites and synthetic derivatives of BC6ENTC , BC6OTHER , and BC6OTHER .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6OTHER and BC6ENTG binding of the putative metabolites and synthetic derivatives of BC6ENTC , BC6OTHER , and BC6OTHER .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6ENTG and BC6OTHER binding of the putative metabolites and synthetic derivatives of BC6OTHER , BC6ENTC , and BC6OTHER .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6OTHER and BC6ENTG binding of the putative metabolites and synthetic derivatives of BC6OTHER , BC6ENTC , and BC6OTHER .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6ENTG and BC6OTHER binding of the putative metabolites and synthetic derivatives of BC6OTHER , BC6OTHER , and BC6ENTC .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6OTHER and BC6ENTG binding of the putative metabolites and synthetic derivatives of BC6OTHER , BC6OTHER , and BC6ENTC .	False
In vitro antiprogestational / antiglucocorticoid activity and BC6ENTC and BC6ENTG binding of the putative metabolites and synthetic derivatives of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6ENTG , a member of the family of two - pore BC6OTHER , is specifically induced in the livers of male mice after BC6ENTC treatment.	CPR:3
BC6OTHER , a member of the family of two - pore BC6ENTG , is specifically induced in the livers of male mice after BC6ENTC treatment.	CPR:3
Here , we have determined the molecular mechanism of this male - specific activation of the BC6ENTG gene and characterized BC6OTHER as a BC6ENTC - inducible antihyperplasia factor.	CPR:3
Here , we have determined the molecular mechanism of this male - specific activation of the BC6OTHER gene and characterized BC6ENTG as a BC6ENTC - inducible antihyperplasia factor.	CPR:3
Upon activation by BC6ENTC , BC6ENTG BC6OTHER binds the 97 - bp response element ( CHEM) within the BC6OTHER .	CPR:3
Upon activation by BC6ENTC , BC6OTHER BC6ENTG binds the 97 - bp response element ( CHEM) within the BC6OTHER .	CPR:3
Upon activation by BC6ENTC , BC6OTHER BC6OTHER binds the 97 - bp response element ( CHEM) within the BC6ENTG .	False
BC6ENTG , a member of the family of two - pore BC6ENTC ion channels , is specifically induced in the livers of male mice after BC6OTHER treatment.	False
Hyperplasia further progressed in the livers of BC6ENTG ( - / - ) male mice compared with those of BC6OTHER ( + / + ) males after BC6ENTC treatment.	False
Hyperplasia further progressed in the livers of BC6OTHER ( - / - ) male mice compared with those of BC6ENTG ( + / + ) males after BC6ENTC treatment.	False
Thus , BC6ENTG suppresses BC6ENTC - induced hyperplasia.	False
These results indicate that BC6ENTC treatment induces BC6ENTG to elicit a male - specific and growth - suppressing signal.	CPR:3
 BC6ENTG BC6OTHER specifically activates the two - pore BC6OTHER BC6OTHER gene in male mouse livers , which attenuates BC6ENTC - induced hepatic hyperplasia.	False
 BC6OTHER BC6ENTG specifically activates the two - pore BC6OTHER BC6OTHER gene in male mouse livers , which attenuates BC6ENTC - induced hepatic hyperplasia.	False
 BC6OTHER BC6OTHER specifically activates the two - pore BC6ENTG BC6OTHER gene in male mouse livers , which attenuates BC6ENTC - induced hepatic hyperplasia.	False
 BC6OTHER BC6OTHER specifically activates the two - pore BC6OTHER BC6ENTG gene in male mouse livers , which attenuates BC6ENTC - induced hepatic hyperplasia.	False
 BC6ENTG BC6OTHER specifically activates the two - pore BC6ENTC channel BC6OTHER gene in male mouse livers , which attenuates BC6OTHER - induced hepatic hyperplasia.	False
 BC6OTHER BC6ENTG specifically activates the two - pore BC6ENTC channel BC6OTHER gene in male mouse livers , which attenuates BC6OTHER - induced hepatic hyperplasia.	False
 BC6OTHER BC6OTHER specifically activates the two - pore BC6ENTC channel BC6ENTG gene in male mouse livers , which attenuates BC6OTHER - induced hepatic hyperplasia.	False
This study was aimed to compare the in vitro effects of BC6ENTC ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6ENTC ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6ENTC ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6ENTC ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6ENTC ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6ENTC ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6ENTC (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6ENTC (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6ENTC ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6ENTC ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTC deaminase ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6ENTC ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6ENTC ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6ENTC ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6ENTC ) and nonprotein BC6OTHER (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6ENTC (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6ENTC (NP - BC6OTHER ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6ENTG ( BC6OTHER ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6ENTC ) content in the cerebral cortex slices of the young rats.	False
This study was aimed to compare the in vitro effects of BC6OTHER ( BC6OTHER ; BC6OTHER ) and BC6OTHER (inorganic BC6OTHER ) on BC6OTHER ( BC6ENTG ) activity , cell viability , lipid peroxidation , scavenger of BC6OTHER ( BC6OTHER ) and nonprotein BC6OTHER (NP - BC6ENTC ) content in the cerebral cortex slices of the young rats.	False
A decrease in BC6ENTG activity was observed when the slices were exposed to BC6ENTC at the concentrations of 1 , 10 and 30 µM.	CPR:4
Differential effects of organic and inorganic BC6ENTC compounds on BC6ENTG activity and scavenger capacity in cerebral cortex slices of young rats.	False
Two migraine patients were studied by in vivo SPECT using the BC6ENTG specific radioligand BC6ENTC ( BC6OTHER ) during BC6OTHER abuse and after withdrawal.	False
Two migraine patients were studied by in vivo SPECT using the BC6ENTG specific radioligand BC6OTHER ( BC6ENTC ) during BC6OTHER abuse and after withdrawal.	False
Two migraine patients were studied by in vivo SPECT using the BC6ENTG specific radioligand BC6OTHER ( BC6OTHER ) during BC6ENTC abuse and after withdrawal.	False
Preliminary evidence suggests that BC6ENTC may not occupy striatal BC6ENTG to a large extent and thus may not cross the blood brain barrier in large quantities.	False
 BC6ENTG imaging with BC6OTHER SPECT in migraine patients abusing BC6OTHER : does BC6ENTC cross the blood brain barrier?	False
 BC6ENTG imaging with BC6ENTC SPECT in migraine patients abusing BC6OTHER : does BC6OTHER cross the blood brain barrier?	False
 BC6ENTG imaging with BC6OTHER SPECT in migraine patients abusing BC6ENTC : does BC6OTHER cross the blood brain barrier?	False
RESULTS: The plant ethanolic extracts effectively suppressed BC6ENTC , BC6ENTG and BC6OTHER release with an IC50 less than 50μg / ml.	False
RESULTS: The plant ethanolic extracts effectively suppressed BC6ENTC , BC6OTHER and BC6ENTG release with an IC50 less than 50μg / ml.	False
This was confirmed by their ability to selectively abrogate the induction of BC6ENTG transcription , whereas the BC6OTHER gene , which is not transcribed selectively by an BC6OTHER complex containing a form of BC6OTHER phosphorylated on BC6ENTC 536 , did not change.	False
This was confirmed by their ability to selectively abrogate the induction of BC6OTHER transcription , whereas the BC6ENTG gene , which is not transcribed selectively by an BC6OTHER complex containing a form of BC6OTHER phosphorylated on BC6ENTC 536 , did not change.	False
This was confirmed by their ability to selectively abrogate the induction of BC6OTHER transcription , whereas the BC6OTHER gene , which is not transcribed selectively by an BC6ENTG complex containing a form of BC6OTHER phosphorylated on BC6ENTC 536 , did not change.	False
This was confirmed by their ability to selectively abrogate the induction of BC6OTHER transcription , whereas the BC6OTHER gene , which is not transcribed selectively by an BC6OTHER complex containing a form of BC6ENTG phosphorylated on BC6ENTC 536 , did not change.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6ENTC ( BC6OTHER ) production in RAW264.7 mouse macrophages , and BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6ENTC ( BC6OTHER ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6ENTC ( BC6OTHER ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6ENTC ( BC6OTHER ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTC ) production in RAW264.7 mouse macrophages , and BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTC ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTC ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) production in human U937 monocytes.	False
MATERIALS AND METHODS: The plant ethanolic extracts were initially tested against lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTC ) production in RAW264.7 mouse macrophages , and BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) production in human U937 monocytes.	False
 BC6ENTC extract of Adiantum capillus - veneris L. suppresses the production of inflammatory mediators by inhibiting BC6ENTG activation.	False
Uncoupling from this channel was achieved by co - expression of an BC6ENTG BC6ENTC - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6OTHER into the BC6OTHER / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6ENTC - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6ENTG into the BC6OTHER / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6ENTC - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6OTHER into the BC6ENTG / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6ENTC - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6OTHER into the BC6OTHER / BC6ENTG signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6ENTC - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6OTHER into the BC6OTHER / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6ENTG .	False
Uncoupling from this channel was achieved by co - expression of an BC6ENTG BC6OTHER - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6ENTC (V2.1) into the BC6OTHER / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6OTHER - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6ENTC (V2.1) into the BC6ENTG / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6OTHER - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6ENTC (V2.1) into the BC6OTHER / BC6ENTG signaling complex , thereby preserving modulation in the presence of scaffolding BC6OTHER .	False
Uncoupling from this channel was achieved by co - expression of an BC6OTHER BC6OTHER - terminal protein designed to disrupt a previously described direct interaction between these two proteins , suggesting that this interaction allows incorporation of BC6ENTC (V2.1) into the BC6OTHER / BC6OTHER signaling complex , thereby preserving modulation in the presence of scaffolding BC6ENTG .	False
Group I metabotropic BC6ENTC receptors ( BC6ENTG ) are BC6OTHER that regulate neuronal activity in a number of ways.	False
Group I metabotropic BC6ENTC receptors ( BC6OTHER ) are BC6ENTG that regulate neuronal activity in a number of ways.	False
This localization is in turn dependent on the BC6ENTG family of scaffolding proteins which bind to a small motif on the distal BC6ENTC - termini of BC6OTHER , localize the receptors near the PSD , strengthen coupling to post - synaptic effectors and simultaneously uncouple the BC6OTHER from extra - synaptic effectors such as BC6OTHER .	False
This localization is in turn dependent on the BC6OTHER family of scaffolding proteins which bind to a small motif on the distal BC6ENTC - termini of BC6ENTG , localize the receptors near the PSD , strengthen coupling to post - synaptic effectors and simultaneously uncouple the BC6OTHER from extra - synaptic effectors such as BC6OTHER .	False
This localization is in turn dependent on the BC6OTHER family of scaffolding proteins which bind to a small motif on the distal BC6ENTC - termini of BC6OTHER , localize the receptors near the PSD , strengthen coupling to post - synaptic effectors and simultaneously uncouple the BC6ENTG from extra - synaptic effectors such as BC6OTHER .	False
This localization is in turn dependent on the BC6OTHER family of scaffolding proteins which bind to a small motif on the distal BC6ENTC - termini of BC6OTHER , localize the receptors near the PSD , strengthen coupling to post - synaptic effectors and simultaneously uncouple the BC6OTHER from extra - synaptic effectors such as BC6ENTG .	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6ENTG to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6ENTG from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTG ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6ENTC channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6ENTG ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6ENTG to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6ENTG from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple BC6ENTG including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6ENTG ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6ENTG ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6ENTG , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTG ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTC (V2.2) ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6OTHER ( BC6ENTG ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6ENTG to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6ENTG from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple BC6ENTG including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTG ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6ENTG ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6ENTG , and BC6OTHER ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6ENTG ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTC (V3.2) ( BC6OTHER , and BC6OTHER ( BC6ENTG ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6ENTG to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6ENTG from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple BC6ENTG including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG , and BC6ENTC (V2.1) ( BC6OTHER ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
Here the selectivity of this uncoupling process was examined by testing the ability of BC6OTHER to uncouple BC6OTHER from multiple voltage dependent BC6OTHER channels including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , and BC6ENTC (V2.1) ( BC6ENTG ) expressed in rat sympathetic neurons from the superior cervical ganglion (SCG).	False
The interaction between BC6OTHER and the BC6ENTC channel BC6OTHER preserves coupling in the presence of BC6ENTG .	False
The interaction between BC6ENTG and the BC6ENTC channel BC6OTHER preserves coupling in the presence of BC6OTHER .	False
The interaction between BC6OTHER and the BC6ENTC channel BC6ENTG preserves coupling in the presence of BC6OTHER .	False
 BC6ENTC : Synthetic Methodologies and Pharmaceutical Applications as BC6ENTG Inhibitors.	CPR:4
In the kidney , BC6ENTC is reabsorbed along the proximal convoluted tubule (PCT) , transported by basolateral carriers , and produced by BC6ENTG ( BC6OTHER ).	False
In the kidney , BC6ENTC is reabsorbed along the proximal convoluted tubule (PCT) , transported by basolateral carriers , and produced by BC6OTHER ( BC6ENTG ).	False
Because BC6ENTG and BC6OTHER proteins overlapped in PST mitochondria , BC6ENTC - derived BC6OTHER may be preferentially converted to BC6OTHER , as proven by BC6OTHER oxidation.	False
Because BC6OTHER and BC6ENTG proteins overlapped in PST mitochondria , BC6ENTC - derived BC6OTHER may be preferentially converted to BC6OTHER , as proven by BC6OTHER oxidation.	False
Because BC6ENTG and BC6OTHER proteins overlapped in PST mitochondria , BC6OTHER - derived BC6ENTC may be preferentially converted to BC6OTHER , as proven by BC6OTHER oxidation.	False
Because BC6OTHER and BC6ENTG proteins overlapped in PST mitochondria , BC6OTHER - derived BC6ENTC may be preferentially converted to BC6OTHER , as proven by BC6OTHER oxidation.	False
Because BC6ENTG and BC6OTHER proteins overlapped in PST mitochondria , BC6OTHER - derived BC6OTHER may be preferentially converted to BC6ENTC , as proven by BC6OTHER oxidation.	False
Because BC6OTHER and BC6ENTG proteins overlapped in PST mitochondria , BC6OTHER - derived BC6OTHER may be preferentially converted to BC6ENTC , as proven by BC6OTHER oxidation.	False
Because BC6ENTG and BC6OTHER proteins overlapped in PST mitochondria , BC6OTHER - derived BC6OTHER may be preferentially converted to BC6OTHER , as proven by BC6ENTC oxidation.	False
Because BC6OTHER and BC6ENTG proteins overlapped in PST mitochondria , BC6OTHER - derived BC6OTHER may be preferentially converted to BC6OTHER , as proven by BC6ENTC oxidation.	False
However , the coexpression of BC6ENTG , BC6ENTC decarboxylase , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6ENTC decarboxylase , and BC6ENTG in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6ENTG , BC6OTHER , and BC6ENTC synthetase in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6ENTG , and BC6ENTC synthetase in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6ENTG , BC6OTHER , and BC6OTHER in PST suggests that BC6ENTC can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6ENTG , and BC6OTHER in PST suggests that BC6ENTC can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6OTHER , and BC6ENTG in PST suggests that BC6ENTC can also be metabolized to BC6OTHER , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6ENTG , BC6OTHER , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6ENTC , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6ENTG , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6ENTC , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6OTHER , and BC6ENTG in PST suggests that BC6OTHER can also be metabolized to BC6ENTC , BC6OTHER , and BC6OTHER .	False
However , the coexpression of BC6ENTG , BC6OTHER , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6ENTC , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6ENTG , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6ENTC , and BC6OTHER .	False
However , the coexpression of BC6OTHER , BC6OTHER , and BC6ENTG in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6ENTC , and BC6OTHER .	False
However , the coexpression of BC6ENTG , BC6OTHER , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6ENTC .	False
However , the coexpression of BC6OTHER , BC6ENTG , and BC6OTHER in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6ENTC .	False
However , the coexpression of BC6OTHER , BC6OTHER , and BC6ENTG in PST suggests that BC6OTHER can also be metabolized to BC6OTHER , BC6OTHER , and BC6ENTC .	False
BC6ENTC aminotransferase ( BC6ENTG ) and BC6OTHER were localized using specific antibodies.	False
BC6ENTC aminotransferase ( BC6OTHER ) and BC6ENTG were localized using specific antibodies.	False
BC6ENTC decarboxylase ( BC6ENTG ) mRNAs were localized by in situ hybridization.	False
 BC6ENTC metabolism in male and female rat kidney: mitochondrial expression of BC6OTHER and BC6ENTG .	False
 BC6ENTC metabolism in male and female rat kidney: mitochondrial expression of BC6ENTG and BC6OTHER .	False
 BC6OTHER metabolism in male and female rat kidney: mitochondrial expression of BC6ENTC aminotransferase and BC6ENTG .	False
Isolated neutrophils and platelets resuspended in heparin - anticoagulated plasma were recirculated with and without blocking antibodies to BC6ENTG , BC6OTHER , or BC6OTHER ( BC6OTHER ) in BC6ENTC tubing using a roller pump.	False
Isolated neutrophils and platelets resuspended in heparin - anticoagulated plasma were recirculated with and without blocking antibodies to BC6OTHER , BC6ENTG , or BC6OTHER ( BC6OTHER ) in BC6ENTC tubing using a roller pump.	False
Isolated neutrophils and platelets resuspended in heparin - anticoagulated plasma were recirculated with and without blocking antibodies to BC6OTHER , BC6OTHER , or BC6ENTG ( BC6OTHER ) in BC6ENTC tubing using a roller pump.	False
Isolated neutrophils and platelets resuspended in heparin - anticoagulated plasma were recirculated with and without blocking antibodies to BC6OTHER , BC6OTHER , or BC6OTHER ( BC6ENTG ) in BC6ENTC tubing using a roller pump.	False
Molecular modeling of the BC6ENTG of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6ENTG ( BC6OTHER ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6ENTG ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6ENTG showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6ENTG / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6ENTG BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6ENTC but efficient binding to BC6OTHER , a novel BC6OTHER / BC6OTHER BC6ENTG inhibitor.	False
Molecular modeling of the BC6ENTG of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6ENTG ( BC6OTHER ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6ENTG ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6ENTG showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6OTHER BC6OTHER inhibitor.	False
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6ENTG / BC6OTHER BC6OTHER inhibitor.	CPR:4
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6ENTG BC6OTHER inhibitor.	CPR:4
Molecular modeling of the BC6OTHER of mutant BC6OTHER ( BC6OTHER ) and BC6OTHER showed no binding to BC6OTHER but efficient binding to BC6ENTC , a novel BC6OTHER / BC6OTHER BC6ENTG inhibitor.	CPR:4
Gene expression profiling (GEP) of GIST CHEM , GIST - R cells and two BC6ENTC resistant GIST patients demonstrated that BC6ENTG is downregulated implying a major role in BC6OTHER resistance.	CPR:4
Gene expression profiling (GEP) of GIST CHEM , GIST - R cells and two BC6OTHER resistant GIST patients demonstrated that BC6ENTG is downregulated implying a major role in BC6ENTC resistance.	CPR:4
Instead , GIST - R cells have acquired BC6ENTC resistance by overexpressing the BC6ENTG - BC6OTHER - in a ' BC6OTHER switch'.	False
Instead , GIST - R cells have acquired BC6ENTC resistance by overexpressing the oncogenic receptor BC6OTHER kinase - BC6ENTG - in a ' BC6OTHER switch'.	False
Instead , GIST - R cells have acquired BC6ENTC resistance by overexpressing the oncogenic receptor BC6OTHER kinase - BC6OTHER - in a ' BC6ENTG switch'.	False
Instead , GIST - R cells have acquired BC6OTHER resistance by overexpressing the oncogenic receptor BC6ENTC kinase - BC6ENTG - in a ' BC6OTHER switch'.	False
Instead , GIST - R cells have acquired BC6OTHER resistance by overexpressing the oncogenic receptor BC6ENTC kinase - BC6OTHER - in a ' BC6ENTG switch'.	False
Further , the two BC6ENTC resistant GIST patients express BC6ENTG and not BC6OTHER , seen by immunohistochemistry (IHC).	False
Further , the two BC6ENTC resistant GIST patients express BC6OTHER and not BC6ENTG , seen by immunohistochemistry (IHC).	False
In GIST - R , BC6OTHER is BC6ENTC phosphorylated and its ligand BC6ENTG is overexpressed implying autocrine activation.	False
In GIST - R , BC6ENTG is BC6ENTC phosphorylated and its ligand BC6OTHER is overexpressed implying autocrine activation.	False
A novel BC6ENTG switch is a mechanism of BC6ENTC resistance in gastrointestinal stromal tumors.	False
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6ENTC (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6ENTC (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6ENTC (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6ENTC (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG inhibitory activity is only significant in compounds 11 and 14 , ten - fold less active than BC6ENTC .	CPR:4
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6ENTC (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6ENTC (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6ENTC (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6ENTC (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6ENTC (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6ENTC (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6ENTC (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6ENTC (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6ENTC (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6ENTC (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6ENTC (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6ENTC (14) , BC6OTHER (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6ENTC (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6ENTC (15) / BC6OTHER (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6ENTC (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6ENTC (15) / BC6OTHER (16) are described.	CPR:4
The BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6ENTC (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6ENTC (16) are described.	CPR:4
The BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6ENTC (16) are described.	CPR:4
The BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) inhibitory activities of a series of BC6OTHER (2 , 3) , BC6OTHER (5 , 6) , BC6OTHER (11 - 13) / BC6OTHER (14) , BC6OTHER (15) / BC6ENTC (16) are described.	CPR:4
These compounds are competitive and , in a few cases , non - competitive inhibitors for BC6ENTG , the most potent being compound (14) , though three - fold less active than BC6ENTC .	CPR:4
This study investigated the effect of a structured self - monitoring of blood BC6ENTC (SMBG) protocol and the resulting improvements in glycemic control on changes in high - sensitivity BC6ENTG ( BC6OTHER ) in BC6OTHER - naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective , cluster - randomized , multicenter trial in which 483 poorly controlled , BC6OTHER - naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG.	False
This study investigated the effect of a structured self - monitoring of blood BC6ENTC (SMBG) protocol and the resulting improvements in glycemic control on changes in high - sensitivity BC6OTHER ( BC6ENTG ) in BC6OTHER - naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective , cluster - randomized , multicenter trial in which 483 poorly controlled , BC6OTHER - naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG.	False
This study investigated the effect of a structured self - monitoring of blood BC6ENTC (SMBG) protocol and the resulting improvements in glycemic control on changes in high - sensitivity BC6OTHER ( BC6OTHER ) in BC6ENTG - naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective , cluster - randomized , multicenter trial in which 483 poorly controlled , BC6OTHER - naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG.	False
This study investigated the effect of a structured self - monitoring of blood BC6ENTC (SMBG) protocol and the resulting improvements in glycemic control on changes in high - sensitivity BC6OTHER ( BC6OTHER ) in BC6OTHER - naïve patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe Structured Testing Program (STeP) study was a prospective , cluster - randomized , multicenter trial in which 483 poorly controlled , BC6ENTG - naïve patients with type 2 diabetes were randomized to active control (ACG) or structured testing (STG) that included quarterly structured SMBG.	False
Brain tissue analyses revealed that neonatal BC6ENTC treatment produced a significant decrease in hippocampal BC6ENTG , BC6OTHER and BC6OTHER that was eliminated by BC6OTHER treatment.	CPR:4
Brain tissue analyses revealed that neonatal BC6ENTC treatment produced a significant decrease in hippocampal BC6OTHER , BC6ENTG and BC6OTHER that was eliminated by BC6OTHER treatment.	CPR:4
Brain tissue analyses revealed that neonatal BC6ENTC treatment produced a significant decrease in hippocampal BC6OTHER , BC6OTHER and BC6ENTG that was eliminated by BC6OTHER treatment.	CPR:4
Brain tissue analyses revealed that neonatal BC6OTHER treatment produced a significant decrease in hippocampal BC6ENTG , BC6OTHER and BC6OTHER that was eliminated by BC6ENTC treatment.	CPR:3
Brain tissue analyses revealed that neonatal BC6OTHER treatment produced a significant decrease in hippocampal BC6OTHER , BC6ENTG and BC6OTHER that was eliminated by BC6ENTC treatment.	CPR:3
Brain tissue analyses revealed that neonatal BC6OTHER treatment produced a significant decrease in hippocampal BC6OTHER , BC6OTHER and BC6ENTG that was eliminated by BC6ENTC treatment.	CPR:3
Neonatal BC6ENTC treatment produced a significant decrease in BC6ENTG and BC6OTHER in the frontal cortex that was unaffected by BC6OTHER treatment.	CPR:4
Neonatal BC6ENTC treatment produced a significant decrease in BC6OTHER and BC6ENTG in the frontal cortex that was unaffected by BC6OTHER treatment.	CPR:4
Neonatal BC6OTHER treatment produced a significant decrease in BC6ENTG and BC6OTHER in the frontal cortex that was unaffected by BC6ENTC treatment.	False
Neonatal BC6OTHER treatment produced a significant decrease in BC6OTHER and BC6ENTG in the frontal cortex that was unaffected by BC6ENTC treatment.	False
These results show that BC6ENTC eliminates BC6ENTG priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by BC6OTHER priming in the hippocampus.	CPR:4
These results show that BC6ENTC eliminates BC6OTHER priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by BC6ENTG priming in the hippocampus.	False
BC6ENTC D2 receptor priming was verified through a yawning behavioural test , a BC6ENTG - mediated event , before BC6OTHER was administered as well as after BC6OTHER treatment and behavioural testing were complete.	False
BC6ENTG priming was verified through a yawning behavioural test , a BC6OTHER - mediated event , before BC6ENTC was administered as well as after BC6OTHER treatment and behavioural testing were complete.	False
BC6OTHER priming was verified through a yawning behavioural test , a BC6ENTG - mediated event , before BC6ENTC was administered as well as after BC6OTHER treatment and behavioural testing were complete.	False
BC6ENTG priming was verified through a yawning behavioural test , a BC6OTHER - mediated event , before BC6OTHER was administered as well as after BC6ENTC treatment and behavioural testing were complete.	False
BC6OTHER priming was verified through a yawning behavioural test , a BC6ENTG - mediated event , before BC6OTHER was administered as well as after BC6ENTC treatment and behavioural testing were complete.	False
Results showed that neonatal BC6ENTC treatment induced BC6ENTG priming that was eliminated by BC6OTHER treatment.	CPR:3
Results showed that neonatal BC6OTHER treatment induced BC6ENTG priming that was eliminated by BC6ENTC treatment.	CPR:4
On the MWM place version , BC6ENTG - primed rats demonstrated a significant impairment that was eliminated by BC6ENTC treatment , but BC6OTHER treatment to animals neonatally treated with saline produced a significant deficit on the place version of the MWM.	False
On the MWM place version , BC6ENTG - primed rats demonstrated a significant impairment that was eliminated by BC6OTHER treatment , but BC6ENTC treatment to animals neonatally treated with saline produced a significant deficit on the place version of the MWM.	False
The effects of adulthood BC6OTHER treatment on cognitive performance and BC6ENTG content in male and female rats neonatally treated with BC6ENTC .	False
The effects of adulthood BC6ENTC treatment on cognitive performance and BC6ENTG content in male and female rats neonatally treated with BC6OTHER .	False
A significant decrease in BC6ENTG expression was observed in the AP and fractionated BC6ENTC - treated cells in the presence of BC6OTHER ( BC6OTHER ) , but no effect on BC6OTHER expression was observed.	CPR:4
A significant decrease in BC6OTHER expression was observed in the AP and fractionated BC6ENTC - treated cells in the presence of BC6ENTG ( BC6OTHER ) , but no effect on BC6OTHER expression was observed.	False
A significant decrease in BC6OTHER expression was observed in the AP and fractionated BC6ENTC - treated cells in the presence of BC6OTHER ( BC6ENTG ) , but no effect on BC6OTHER expression was observed.	False
A significant decrease in BC6OTHER expression was observed in the AP and fractionated BC6ENTC - treated cells in the presence of BC6OTHER ( BC6OTHER ) , but no effect on BC6ENTG expression was observed.	False
Furthermore , the up - regulation of BC6ENTG and BC6OTHER was found in the BC6ENTC trimers - treated cells in the presence of BC6OTHER .	CPR:3
Furthermore , the up - regulation of BC6OTHER and BC6ENTG was found in the BC6ENTC trimers - treated cells in the presence of BC6OTHER .	CPR:3
Furthermore , the up - regulation of BC6OTHER and BC6OTHER was found in the BC6ENTC trimers - treated cells in the presence of BC6ENTG .	False
Apple BC6ENTC suppress antigen presentation of BC6ENTG by CHEM - 1 - derived dendritic cells.	CPR:4
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of BC6ENTC , a selective inhibitor of both BC6ENTG and BC6OTHER ( BC6OTHER ) , which has shown clinical efficacy in some BC6OTHER - dependent hematological cancers.	CPR:4
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of BC6ENTC , a selective inhibitor of both BC6OTHER and BC6ENTG ( BC6OTHER ) , which has shown clinical efficacy in some BC6OTHER - dependent hematological cancers.	CPR:4
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of BC6ENTC , a selective inhibitor of both BC6OTHER and BC6OTHER ( BC6ENTG ) , which has shown clinical efficacy in some BC6OTHER - dependent hematological cancers.	CPR:4
The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of BC6ENTC , a selective inhibitor of both BC6OTHER and BC6OTHER ( BC6OTHER ) , which has shown clinical efficacy in some BC6ENTG - dependent hematological cancers.	False
Here we report the re - engineering of BC6ENTC to create a highly potent , orally bioavailable and BC6ENTG - selective inhibitor , BC6OTHER .	CPR:4
Here we report the re - engineering of BC6OTHER to create a highly potent , orally bioavailable and BC6ENTG - selective inhibitor , BC6ENTC .	CPR:4
A single dose of BC6ENTC in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BC6ENTG shows promise for the treatment of BC6OTHER - dependent hematological cancers.	False
A single dose of BC6ENTC in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BC6OTHER shows promise for the treatment of BC6ENTG - dependent hematological cancers.	False
 BC6ENTC , a potent and selective BC6ENTG inhibitor , achieves antitumor activity while sparing platelets.	CPR:4
Furthermore , BC6ENTC treatment directly inhibited the phosphorylation of BC6ENTG at BC6OTHER 1007 and the downstream activation of BC6OTHER .	CPR:4
Furthermore , BC6ENTC treatment directly inhibited the phosphorylation of BC6OTHER at BC6OTHER 1007 and the downstream activation of BC6ENTG .	CPR:4
Furthermore , BC6OTHER treatment directly inhibited the phosphorylation of BC6ENTG at BC6ENTC 1007 and the downstream activation of BC6OTHER .	False
Furthermore , BC6OTHER treatment directly inhibited the phosphorylation of BC6OTHER at BC6ENTC 1007 and the downstream activation of BC6ENTG .	False
BC6ENTC also down - regulated the expression of BC6ENTG target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6ENTG and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6ENTG , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6ENTG , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6ENTG , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6ENTG , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6ENTG ) and BC6OTHER inhibitors such as BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6ENTG inhibitors such as BC6OTHER and BC6OTHER .	False
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC also down - regulated the expression of BC6OTHER target genes , including the anti - apoptotic proteins BC6OTHER and BC6OTHER , leading to the up - regulation of mitochondrial apoptosis pathway - related proteins ( BC6OTHER , BC6OTHER , cytosolic BC6OTHER , and cleaved BC6OTHER ) and BC6OTHER inhibitors such as BC6OTHER and BC6ENTG .	CPR:3
BC6ENTC , used in combination with a known BC6ENTG / BC6OTHER inhibitor , BC6OTHER , further decreased the viability of osteosarcoma cells.	False
BC6ENTC , used in combination with a known BC6OTHER / BC6ENTG inhibitor , BC6OTHER , further decreased the viability of osteosarcoma cells.	False
BC6OTHER , used in combination with a known BC6ENTG / BC6OTHER inhibitor , BC6ENTC , further decreased the viability of osteosarcoma cells.	CPR:4
BC6OTHER , used in combination with a known BC6OTHER / BC6ENTG inhibitor , BC6ENTC , further decreased the viability of osteosarcoma cells.	CPR:4
Taken together , BC6ENTC is a potent inhibitor of osteosarcoma cell growth that targets the BC6ENTG / BC6OTHER signaling pathway.	CPR:4
Taken together , BC6ENTC is a potent inhibitor of osteosarcoma cell growth that targets the BC6OTHER / BC6ENTG signaling pathway.	CPR:4
These data suggest that inhibition of BC6ENTG / BC6OTHER signaling is a novel mechanism of action for BC6ENTC during therapeutic intervention in osteosarcoma cancers.	CPR:4
These data suggest that inhibition of BC6OTHER / BC6ENTG signaling is a novel mechanism of action for BC6ENTC during therapeutic intervention in osteosarcoma cancers.	CPR:4
In this study , we assessed the antitumor activity of BC6ENTC against human osteosarcoma cells and explored the role of BC6ENTG / BC6OTHER and apoptosis - related signaling pathways on the activity of BC6OTHER .	False
In this study , we assessed the antitumor activity of BC6ENTC against human osteosarcoma cells and explored the role of BC6OTHER / BC6ENTG and apoptosis - related signaling pathways on the activity of BC6OTHER .	False
In this study , we assessed the antitumor activity of BC6OTHER against human osteosarcoma cells and explored the role of BC6ENTG / BC6OTHER and apoptosis - related signaling pathways on the activity of BC6ENTC .	False
In this study , we assessed the antitumor activity of BC6OTHER against human osteosarcoma cells and explored the role of BC6OTHER / BC6ENTG and apoptosis - related signaling pathways on the activity of BC6ENTC .	False
 BC6ENTC exerts antitumor activity against human osteosarcoma cells by inhibiting the BC6ENTG / BC6OTHER signaling pathway.	CPR:4
 BC6ENTC exerts antitumor activity against human osteosarcoma cells by inhibiting the BC6OTHER / BC6ENTG signaling pathway.	CPR:4
An amphiphile with branched BC6ENTC architecture also activated the BC6ENTG pathway but only through L - ficolin recognition.	CPR:3
CNTs with linear BC6ENTC amphiphiles trigger the BC6ENTG pathway of the complement through both L - ficolin and mannan - binding BC6OTHER recognition.	False
CNTs with linear BC6ENTC amphiphiles trigger the BC6OTHER pathway of the complement through both L - ficolin and mannan - binding BC6ENTG recognition.	False
BC6ENTC transporter ( BC6ENTG ) has been associated with drugs of abuse like BC6OTHER ( BC6OTHER ).	False
BC6ENTC is well known to produce effects on the BC6OTHER systems but it is unclear how BC6OTHER affects BC6ENTG and memory.	False
In untrained and trained treated animals with the amnesic dose (1.0mg / kg) of BC6ENTC BC6ENTG binding in several areas including hippocampus and cortex decreased , more remarkably in the trained animals.	False
In contrast , CHEM improved memory , increased BC6ENTG binding , prevented the BC6ENTC amnesic effect and re - established the BC6OTHER binding.	False
In contrast , CHEM improved memory , increased BC6OTHER binding , prevented the BC6ENTC amnesic effect and re - established the BC6ENTG binding.	False
BC6OTHER is well known to produce effects on the BC6ENTC systems but it is unclear how BC6OTHER affects BC6ENTG and memory.	False
BC6OTHER is well known to produce effects on the BC6OTHER systems but it is unclear how BC6ENTC affects BC6ENTG and memory.	False
BC6ENTG ( BC6OTHER ) has been associated with drugs of abuse like BC6ENTC ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) has been associated with drugs of abuse like BC6ENTC ( BC6OTHER ).	False
A comparative autoradiography study of the relationship between the binding pattern of BC6ENTG in autoshaping new untrained vs. trained treated ( BC6ENTC , BC6OTHER , or both) animals was made.	False
A comparative autoradiography study of the relationship between the binding pattern of BC6ENTG in autoshaping new untrained vs. trained treated ( BC6OTHER , BC6ENTC , or both) animals was made.	False
BC6ENTG ( BC6OTHER ) has been associated with drugs of abuse like BC6OTHER ( BC6ENTC ).	False
BC6OTHER ( BC6ENTG ) has been associated with drugs of abuse like BC6OTHER ( BC6ENTC ).	False
These illnesses are a result of BC6ENTC 's ability to bind to the BC6ENTG , blocking the passage of nerve impulses and leading to death via respiratory paralysis.	False
Recent advances in BC6ENTC research are discussed , including the molecular biology of toxin synthesis , new protein targets , association with BC6ENTG and methods of detection.	False
These compounds interact with BC6ENTG BC6ENTC and BC6OTHER channels and modulate the flux of these ions into various cell types.	False
These compounds interact with BC6ENTG BC6OTHER and BC6ENTC channels and modulate the flux of these ions into various cell types.	False
BC6ENTG inhibitors currently under investigation include the small molecules BC6ENTC ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTC ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6ENTC ( BC6OTHER , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6ENTC , BC6OTHER ).	CPR:4
BC6ENTG inhibitors currently under investigation include the small molecules BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) , as well as monoclonal antibodies such as BC6OTHER ( BC6OTHER , BC6ENTC ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6ENTC , an irreversible pan - BC6ENTG BC6OTHER inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6ENTC , an irreversible pan - BC6OTHER BC6ENTG inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6ENTC , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6ENTG inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6ENTC , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6ENTG and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6ENTC , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6ENTG ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6ENTG BC6ENTC kinase inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6ENTC kinase inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6ENTG inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6ENTC kinase inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6ENTG and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6ENTC kinase inhibitor , and BC6OTHER and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6ENTG ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6ENTG BC6OTHER inhibitor , and BC6ENTC and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6ENTG inhibitor , and BC6ENTC and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6ENTC and BC6OTHER , both examples of dual BC6ENTG inhibitors (inhibiting BC6OTHER and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6ENTC and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6ENTG and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6ENTC and BC6OTHER , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6ENTG ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6ENTG BC6OTHER inhibitor , and BC6OTHER and BC6ENTC , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6ENTG inhibitor , and BC6OTHER and BC6ENTC , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6OTHER ).	False
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6ENTC , both examples of dual BC6ENTG inhibitors (inhibiting BC6OTHER and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6ENTC , both examples of dual BC6OTHER inhibitors (inhibiting BC6ENTG and BC6OTHER ).	CPR:4
Agents that have only begun to undergo clinical evaluation include BC6OTHER , an irreversible pan - BC6OTHER BC6OTHER inhibitor , and BC6OTHER and BC6ENTC , both examples of dual BC6OTHER inhibitors (inhibiting BC6OTHER and BC6ENTG ).	CPR:4
Algorithms incorporating genetic ( BC6ENTG and BC6OTHER ) , demographic , and clinical factors to estimate the BC6ENTC dosage , could potentially minimize the risk of over dose during BC6OTHER induction.	False
Algorithms incorporating genetic ( BC6OTHER and BC6ENTG ) , demographic , and clinical factors to estimate the BC6ENTC dosage , could potentially minimize the risk of over dose during BC6OTHER induction.	False
Algorithms incorporating genetic ( BC6ENTG and BC6OTHER ) , demographic , and clinical factors to estimate the BC6OTHER dosage , could potentially minimize the risk of over dose during BC6ENTC induction.	False
Algorithms incorporating genetic ( BC6OTHER and BC6ENTG ) , demographic , and clinical factors to estimate the BC6OTHER dosage , could potentially minimize the risk of over dose during BC6ENTC induction.	False
Pharmacogenetic analysis of two genes , the BC6ENTC metabolic enzyme BC6ENTG and BC6OTHER target enzyme , BC6OTHER BC6OTHER , confirmed their influence on BC6OTHER maintenance dose.	CPR:9
Pharmacogenetic analysis of two genes , the BC6ENTC metabolic enzyme BC6OTHER and BC6OTHER target enzyme , BC6ENTG BC6OTHER , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6ENTC metabolic enzyme BC6OTHER and BC6OTHER target enzyme , BC6OTHER BC6ENTG , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6ENTG and BC6ENTC target enzyme , BC6OTHER BC6OTHER , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6OTHER and BC6ENTC target enzyme , BC6ENTG BC6OTHER , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6OTHER and BC6ENTC target enzyme , BC6OTHER BC6ENTG , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6ENTG and BC6OTHER target enzyme , BC6ENTC reductase complex 1 BC6OTHER , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6OTHER and BC6OTHER target enzyme , BC6ENTC reductase complex 1 BC6ENTG , confirmed their influence on BC6OTHER maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6ENTG and BC6OTHER target enzyme , BC6OTHER BC6OTHER , confirmed their influence on BC6ENTC maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6OTHER and BC6OTHER target enzyme , BC6ENTG BC6OTHER , confirmed their influence on BC6ENTC maintenance dose.	False
Pharmacogenetic analysis of two genes , the BC6OTHER metabolic enzyme BC6OTHER and BC6OTHER target enzyme , BC6OTHER BC6ENTG , confirmed their influence on BC6ENTC maintenance dose.	False
Possession of BC6ENTG *2 or BC6OTHER *3 variant alleles , which result in decreased enzyme activity , is associated with a significant decrease in the mean BC6ENTC dose.	CPR:9
Possession of BC6OTHER *2 or BC6ENTG *3 variant alleles , which result in decreased enzyme activity , is associated with a significant decrease in the mean BC6ENTC dose.	CPR:9
Several single BC6ENTC polymorphisms (SNPs) in BC6ENTG are associated with BC6OTHER dose across the normal dose range.	False
Several single BC6OTHER polymorphisms (SNPs) in BC6ENTG are associated with BC6ENTC dose across the normal dose range.	False
Haplotypes based on these SNPs explain a large fraction of the interindividual variation in BC6ENTC dose , and BC6OTHER has an approximately three - fold greater effect than BC6ENTG .	False
Haplotypes based on these SNPs explain a large fraction of the interindividual variation in BC6ENTC dose , and BC6ENTG has an approximately three - fold greater effect than BC6OTHER .	False
 BC6ENTC dose and the pharmacogenomics of BC6ENTG and BC6OTHER - rationale and perspectives.	False
 BC6ENTC dose and the pharmacogenomics of BC6OTHER and BC6ENTG - rationale and perspectives.	False
The higher affinity of BC6ENTC block of BC6ENTG containing the BC6OTHER subunit could be accounted for by more rapid association and slower dissociation from these sites.	CPR:4
The higher affinity of BC6ENTC block of BC6OTHER containing the BC6ENTG subunit could be accounted for by more rapid association and slower dissociation from these sites.	CPR:4
The higher affinity of BC6OTHER block of BC6ENTC receptors containing the BC6ENTG subunit could be accounted for by more rapid association and slower dissociation from these sites.	False
We conclude that BC6ENTC exhibits modest selectivity for BC6ENTG composed of BC6OTHER / BC6OTHER subunits.	CPR:4
We conclude that BC6ENTC exhibits modest selectivity for BC6OTHER composed of BC6ENTG / BC6OTHER subunits.	CPR:4
We conclude that BC6ENTC exhibits modest selectivity for BC6OTHER composed of BC6OTHER / BC6ENTG subunits.	CPR:4
We conclude that BC6OTHER exhibits modest selectivity for BC6ENTC receptors composed of BC6ENTG / BC6OTHER subunits.	False
We conclude that BC6OTHER exhibits modest selectivity for BC6ENTC receptors composed of BC6OTHER / BC6ENTG subunits.	False
This selectivity could , in part , account for the more favorable clinical profile of BC6ENTC in comparison with BC6ENTG antagonists that do not show subunit selectivity.	CPR:6
The anticonvulsant BC6OTHER blocks BC6ENTG but fails to exhibit the neurobehavioral toxicity characteristic of other BC6ENTC receptor antagonists.	False
The anticonvulsant BC6ENTC blocks CHEM ( BC6OTHER ) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other BC6ENTG antagonists.	CPR:6
The anticonvulsant BC6ENTC blocks BC6ENTG but fails to exhibit the neurobehavioral toxicity characteristic of other BC6OTHER antagonists.	CPR:4
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6ENTC receptor subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6ENTG composed of the BC6OTHER subunit and various BC6OTHER subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6ENTC receptor subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6OTHER composed of the BC6ENTG subunit and various BC6OTHER subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6ENTC receptor subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6OTHER composed of the BC6OTHER subunit and various BC6ENTG subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6ENTG subtype selectivity , we examined the specificity of BC6ENTC block of recombinant BC6OTHER composed of the BC6OTHER subunit and various BC6OTHER subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6OTHER subtype selectivity , we examined the specificity of BC6ENTC block of recombinant BC6ENTG composed of the BC6OTHER subunit and various BC6OTHER subunits.	CPR:4
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6OTHER subtype selectivity , we examined the specificity of BC6ENTC block of recombinant BC6OTHER composed of the BC6ENTG subunit and various BC6OTHER subunits.	CPR:4
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6OTHER subtype selectivity , we examined the specificity of BC6ENTC block of recombinant BC6OTHER composed of the BC6OTHER subunit and various BC6ENTG subunits.	CPR:4
The anticonvulsant BC6OTHER blocks BC6ENTC ( BC6OTHER ) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other BC6ENTG antagonists.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6ENTG subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6ENTC receptors composed of the BC6OTHER subunit and various BC6OTHER subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6OTHER subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6ENTC receptors composed of the BC6ENTG subunit and various BC6OTHER subunits.	False
To investigate the possibility that CHEM's favorable toxicity profile could be related to BC6OTHER subtype selectivity , we examined the specificity of BC6OTHER block of recombinant BC6ENTC receptors composed of the BC6OTHER subunit and various BC6ENTG subunits.	False
BC6ENTC produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6ENTG subunit , and either the BC6OTHER , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	CPR:4
BC6ENTC produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6ENTG , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	CPR:4
BC6ENTC produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6ENTG or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	CPR:4
BC6ENTC produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6OTHER or BC6ENTG subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	CPR:4
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6ENTC and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6ENTG subunit , and either the BC6OTHER , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6ENTC and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6ENTG , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6ENTC and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6ENTG or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6ENTC and 10 microM BC6OTHER in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6OTHER or BC6ENTG subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6ENTC in human embryonic kidney 293 cells expressing the BC6ENTG subunit , and either the BC6OTHER , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6ENTC in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6ENTG , BC6OTHER or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6ENTC in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6ENTG or BC6OTHER subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
BC6OTHER produced a rapid , concentration - dependent block of currents evoked by 50 microM BC6OTHER and 10 microM BC6ENTC in human embryonic kidney 293 cells expressing the BC6OTHER subunit , and either the BC6OTHER , BC6OTHER or BC6ENTG subunits; the IC50 values for block were 2.6 , 0.52 and 2.4 mM , respectively (holding potential ,  - 60 mV).	False
The anticonvulsant BC6OTHER blocks CHEM ( BC6ENTC ) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other BC6ENTG antagonists.	False
 BC6ENTC block of recombinant BC6ENTG : selectivity for the BC6OTHER subunit.	CPR:4
 BC6ENTC block of recombinant BC6OTHER : selectivity for the BC6ENTG subunit.	CPR:4
 BC6OTHER block of recombinant BC6ENTC receptors: selectivity for the BC6ENTG subunit.	False
Proximal tubule cells extract CHEM from filtrate and blood , using cotransporters located in the brush border [ BC6ENTC CHEM cotransporter ( BC6ENTG )] and basolateral cell membrane ( BC6OTHER ).	False
Proximal tubule cells extract CHEM from filtrate and blood , using cotransporters located in the brush border [ BC6ENTC CHEM cotransporter ( BC6OTHER )] and basolateral cell membrane ( BC6ENTG ).	False
As opposed to the rat and flounder orthologs , BC6ENTG was hardly inhibited by BC6ENTC concentrations up to 5 mM.	CPR:4
The narrow substrate specificity prevents interaction of drugs with CHEM - like structure with BC6ENTG and ensures sufficient support of the proximal tubule cells with BC6ENTC for anion secretion via BC6OTHER .	False
The narrow substrate specificity prevents interaction of drugs with CHEM - like structure with BC6OTHER and ensures sufficient support of the proximal tubule cells with BC6ENTC for anion secretion via BC6ENTG .	False
Substrate specificity of the human renal BC6ENTC CHEM cotransporter , BC6ENTG , under voltage - clamp conditions.	False
We report herein the location of the binding site for the inhaled anesthetic BC6ENTC at the BC6OTHER residue level of resolution in the ligand binding cavity in a prototypical BC6ENTG , BC6OTHER .	False
We report herein the location of the binding site for the inhaled anesthetic BC6ENTC at the BC6OTHER residue level of resolution in the ligand binding cavity in a prototypical BC6OTHER , BC6ENTG .	False
We report herein the location of the binding site for the inhaled anesthetic BC6OTHER at the BC6ENTC residue level of resolution in the ligand binding cavity in a prototypical BC6ENTG , BC6OTHER .	False
We report herein the location of the binding site for the inhaled anesthetic BC6OTHER at the BC6ENTC residue level of resolution in the ligand binding cavity in a prototypical BC6OTHER , BC6ENTG .	False
Radiosequence analysis of BC6ENTC - labeled BC6ENTG revealed that BC6OTHER contacts an BC6OTHER residue (CHEM265) lining the ligand binding cavity in the transmembrane core of the receptor.	False
Radiosequence analysis of BC6OTHER - labeled BC6ENTG revealed that BC6ENTC contacts an BC6OTHER residue (CHEM265) lining the ligand binding cavity in the transmembrane core of the receptor.	False
Radiosequence analysis of BC6OTHER - labeled BC6ENTG revealed that BC6OTHER contacts an BC6ENTC residue (CHEM265) lining the ligand binding cavity in the transmembrane core of the receptor.	False
BC6ENTG shows little transport of other BC6ENTC and is BC6OTHER and BC6OTHER dependent.	False
BC6ENTG shows little transport of other BC6OTHER and is BC6ENTC and BC6OTHER dependent.	False
BC6ENTG shows little transport of other BC6OTHER and is BC6OTHER and BC6ENTC dependent.	False
A BC6ENTC - sensitive , high - affinity Drosophila BC6OTHER ( BC6OTHER ; BC6OTHER ) transporter cDNA , denoted BC6ENTG , was isolated and characterized in oocytes.	False
A BC6ENTC - sensitive , high - affinity BC6ENTG BC6OTHER ; BC6OTHER ) transporter cDNA , denoted BC6OTHER , was isolated and characterized in oocytes.	False
Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among BC6ENTG and mammalian BC6ENTC , BC6OTHER , and BC6OTHER transporters.	False
Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among BC6ENTG and mammalian BC6OTHER , BC6ENTC , and BC6OTHER transporters.	False
Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among BC6OTHER and BC6ENTG BC6ENTC , and BC6OTHER transporters.	False
Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among BC6ENTG and mammalian BC6OTHER , BC6OTHER , and BC6ENTC transporters.	False
Sequence analysis indicates 12 putative transmembrane domains and strong homologies (approximately 50%) among BC6OTHER and BC6ENTG BC6OTHER , and BC6ENTC transporters.	False
A BC6OTHER - sensitive , high - affinity Drosophila BC6ENTC ( BC6OTHER ; BC6OTHER ) transporter cDNA , denoted BC6ENTG , was isolated and characterized in oocytes.	False
Interestingly , the pharmacological properties of BC6ENTG , including sensitivity to antidepressants , are more similar to those of mammalian BC6ENTC transporters than to mammalian BC6OTHER transporters.	False
Interestingly , the pharmacological properties of BC6OTHER , including sensitivity to antidepressants , are more similar to those of mammalian BC6ENTC transporters than to BC6ENTG .	False
A BC6OTHER - sensitive , high - affinity Drosophila BC6OTHER ( BC6ENTC ; BC6OTHER ) transporter cDNA , denoted BC6ENTG , was isolated and characterized in oocytes.	False
A BC6OTHER - sensitive , high - affinity BC6ENTG BC6ENTC ; BC6OTHER ) transporter cDNA , denoted BC6OTHER , was isolated and characterized in oocytes.	False
Interestingly , the pharmacological properties of BC6ENTG , including sensitivity to antidepressants , are more similar to those of mammalian BC6OTHER transporters than to mammalian BC6ENTC transporters.	False
Interestingly , the pharmacological properties of BC6OTHER , including sensitivity to antidepressants , are more similar to those of BC6ENTG than to mammalian BC6ENTC transporters.	False
A BC6OTHER - sensitive , high - affinity Drosophila BC6OTHER ( BC6OTHER ; BC6ENTC ) transporter cDNA , denoted BC6ENTG , was isolated and characterized in oocytes.	False
A BC6OTHER - sensitive , high - affinity BC6ENTG BC6OTHER ; BC6ENTC ) transporter cDNA , denoted BC6OTHER , was isolated and characterized in oocytes.	False
Cloning and characterization of BC6ENTG adds significantly to our knowledge of the diversity of BC6ENTC transporters with regard to primary sequence , pharmacological profile , and permeation properties.	False
A BC6ENTC - sensitive BC6ENTG : cloning , expression , and electrophysiological characterization.	False
BC6ENTC treatment inhibited adipocyte differentiation , consistent with the negative effect of BC6OTHER on BC6ENTG .	False
BC6OTHER treatment inhibited adipocyte differentiation , consistent with the negative effect of BC6ENTC on BC6ENTG .	CPR:4
The inhibitory effect of BC6ENTC on adipogenesis is dependent of BC6ENTG activity , suggesting that BC6OTHER inhibits adipogenesis and the accumulation of intracellular BC6OTHER during adipocyte differentiation by targeting BC6OTHER signaling.	False
The inhibitory effect of BC6ENTC on adipogenesis is dependent of BC6OTHER activity , suggesting that BC6OTHER inhibits adipogenesis and the accumulation of intracellular BC6OTHER during adipocyte differentiation by targeting BC6ENTG signaling.	False
The inhibitory effect of BC6OTHER on adipogenesis is dependent of BC6ENTG activity , suggesting that BC6ENTC inhibits adipogenesis and the accumulation of intracellular BC6OTHER during adipocyte differentiation by targeting BC6OTHER signaling.	False
The inhibitory effect of BC6OTHER on adipogenesis is dependent of BC6OTHER activity , suggesting that BC6ENTC inhibits adipogenesis and the accumulation of intracellular BC6OTHER during adipocyte differentiation by targeting BC6ENTG signaling.	False
The inhibitory effect of BC6OTHER on adipogenesis is dependent of BC6ENTG activity , suggesting that BC6OTHER inhibits adipogenesis and the accumulation of intracellular BC6ENTC during adipocyte differentiation by targeting BC6OTHER signaling.	False
The inhibitory effect of BC6OTHER on adipogenesis is dependent of BC6OTHER activity , suggesting that BC6OTHER inhibits adipogenesis and the accumulation of intracellular BC6ENTC during adipocyte differentiation by targeting BC6ENTG signaling.	False
In this study , we have demonstrated that BC6ENTC prevents diet - induced obesity through regulation of the signaling of BC6ENTG ( BC6OTHER ) , a central mediator of cellular growth , cellular proliferation and lipid biosynthesis.	False
In this study , we have demonstrated that BC6ENTC prevents diet - induced obesity through regulation of the signaling of mammalian target of BC6OTHER complex 1 ( BC6ENTG ) , a central mediator of cellular growth , cellular proliferation and lipid biosynthesis.	False
We also observed that BC6ENTC efficiently suppressed the phosphorylation of BC6ENTG , BC6OTHER and BC6OTHER in adipose tissue.	CPR:4
We also observed that BC6ENTC efficiently suppressed the phosphorylation of BC6OTHER , BC6ENTG and BC6OTHER in adipose tissue.	CPR:4
We also observed that BC6ENTC efficiently suppressed the phosphorylation of BC6OTHER , BC6OTHER and BC6ENTG in adipose tissue.	CPR:4
Collectively , these results suggest that inhibition of BC6ENTG signaling by BC6ENTC prevents adipocyte differentiation of 3T3 - L1 preadipocytes and obesity in HFD - fed mice.	CPR:4
In this study , we have demonstrated that BC6OTHER prevents diet - induced obesity through regulation of the signaling of mammalian target of BC6ENTC complex 1 ( BC6ENTG ) , a central mediator of cellular growth , cellular proliferation and lipid biosynthesis.	False
To evaluate whether BC6ENTC regulates BC6ENTG signaling , we investigated the phosphorylation and BC6OTHER activity of the BC6OTHER ( BC6OTHER ) and BC6OTHER in 3T3 - L1 preadipocytes.	False
To evaluate whether BC6ENTC regulates BC6OTHER signaling , we investigated the phosphorylation and BC6ENTG activity of the BC6OTHER ( BC6OTHER ) and BC6OTHER in 3T3 - L1 preadipocytes.	False
To evaluate whether BC6ENTC regulates BC6OTHER signaling , we investigated the phosphorylation and BC6OTHER activity of the BC6ENTG ( BC6OTHER ) and BC6OTHER in 3T3 - L1 preadipocytes.	False
To evaluate whether BC6ENTC regulates BC6OTHER signaling , we investigated the phosphorylation and BC6OTHER activity of the BC6OTHER ( BC6ENTG ) and BC6OTHER in 3T3 - L1 preadipocytes.	False
To evaluate whether BC6ENTC regulates BC6OTHER signaling , we investigated the phosphorylation and BC6OTHER activity of the BC6OTHER ( BC6OTHER ) and BC6ENTG in 3T3 - L1 preadipocytes.	False
BC6ENTC treatment of preadipocytes reduced the phosphorylation of BC6ENTG and BC6OTHER in a time - and concentration - dependent manner.	CPR:4
BC6ENTC treatment of preadipocytes reduced the phosphorylation of BC6OTHER and BC6ENTG in a time - and concentration - dependent manner.	CPR:4
To further our understanding of how BC6ENTC negatively regulates BC6ENTG signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6OTHER in BC6OTHER - treated BC6OTHER - knockdown cells.	CPR:4
To further our understanding of how BC6ENTC negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6ENTG , BC6OTHER and BC6OTHER in BC6OTHER - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6ENTC negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6ENTG and BC6OTHER in BC6OTHER - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6ENTC negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6ENTG in BC6OTHER - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6ENTC negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6OTHER in BC6OTHER - treated BC6ENTG - knockdown cells.	False
To further our understanding of how BC6OTHER negatively regulates BC6ENTG signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6OTHER in BC6ENTC - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6OTHER negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6ENTG , BC6OTHER and BC6OTHER in BC6ENTC - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6OTHER negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6ENTG and BC6OTHER in BC6ENTC - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6OTHER negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6ENTG in BC6ENTC - treated BC6OTHER - knockdown cells.	False
To further our understanding of how BC6OTHER negatively regulates BC6OTHER signaling , we analyzed the phosphorylation of BC6OTHER , BC6OTHER and BC6OTHER in BC6ENTC - treated BC6ENTG - knockdown cells.	False
The results suggested that BC6ENTC treatment inhibits BC6ENTG activity in an BC6OTHER - dependent manner.	CPR:4
The results suggested that BC6ENTC treatment inhibits BC6OTHER activity in an BC6ENTG - dependent manner.	CPR:4
 BC6ENTC regulates obesity by targeting BC6ENTG signaling.	False
BC6ENTG , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an BC6ENTC - terminal BC6OTHER phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6ENTG , comprises an BC6ENTC - terminal BC6OTHER phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an BC6ENTC - terminal BC6OTHER phosphatase domain ( BC6ENTG - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an BC6ENTC - terminal BC6OTHER phosphatase domain ( BC6OTHER - BC6ENTG ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6ENTG - specific general transcription factor BC6OTHER , comprises an BC6ENTC - terminal BC6OTHER phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6ENTG , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an CHEM - terminal BC6ENTC phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6ENTG , comprises an CHEM - terminal BC6ENTC phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an CHEM - terminal BC6ENTC phosphatase domain ( BC6ENTG - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6OTHER - specific general transcription factor BC6OTHER , comprises an CHEM - terminal BC6ENTC phosphatase domain ( BC6OTHER - BC6ENTG ) whose catalytic activity and cellular function is poorly understood.	False
BC6OTHER , a subunit of the BC6ENTG - specific general transcription factor BC6OTHER , comprises an CHEM - terminal BC6ENTC phosphatase domain ( BC6OTHER - BC6OTHER ) whose catalytic activity and cellular function is poorly understood.	False
We solved the crystal structures of BC6ENTG - BC6OTHER and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6ENTC and BC6OTHER containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6ENTG and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6ENTC and BC6OTHER containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6OTHER and its closely related paralogue BC6ENTG and used in silico docking methods to identify BC6ENTC and BC6OTHER containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6OTHER and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6ENTC and BC6OTHER containing peptides as possible substrates that were subsequently validated using in vitro BC6ENTG assays.	False
We solved the crystal structures of BC6ENTG - BC6OTHER and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6OTHER and BC6ENTC containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6ENTG and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6OTHER and BC6ENTC containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6OTHER and its closely related paralogue BC6ENTG and used in silico docking methods to identify BC6OTHER and BC6ENTC containing peptides as possible substrates that were subsequently validated using in vitro BC6OTHER assays.	False
We solved the crystal structures of BC6OTHER - BC6OTHER and its closely related paralogue BC6OTHER and used in silico docking methods to identify BC6OTHER and BC6ENTC containing peptides as possible substrates that were subsequently validated using in vitro BC6ENTG assays.	False
A comparative BC6ENTC - proteomic study identified additional CHEM as possible targets , which show the involvement of these two BC6ENTG in the regulation of a variety of cellular functions.	False
CLA treatment increased serum BC6ENTG ( BC6OTHER ) significantly (p=0.0172) , while serum BC6ENTC concentration was not changed by CLA.	False
CLA treatment increased serum BC6OTHER ( BC6ENTG ) significantly (p=0.0172) , while serum BC6ENTC concentration was not changed by CLA.	False
In conclusion , BC6ENTC - induced constitutive BC6ENTG activity reduces BC6OTHER agonist - and BC6OTHER - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6OTHER .	CPR:3
In conclusion , BC6ENTC - induced constitutive BC6OTHER activity reduces BC6ENTG agonist - and BC6OTHER - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6OTHER .	False
In conclusion , BC6OTHER - induced constitutive BC6ENTG activity reduces BC6OTHER agonist - and BC6ENTC - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6OTHER .	False
In conclusion , BC6OTHER - induced constitutive BC6OTHER activity reduces BC6ENTG agonist - and BC6ENTC - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6OTHER .	False
In the present study , we investigated the effect of BC6OTHER - induced constitutive BC6OTHER activity on BC6ENTG agonist - and BC6ENTC - induced bovine tracheal smooth muscle contractions.	False
In the present study , we investigated the effect of BC6OTHER - induced constitutive BC6ENTG activity on BC6OTHER agonist - and BC6ENTC - induced bovine tracheal smooth muscle contractions.	False
In conclusion , BC6OTHER - induced constitutive BC6ENTG activity reduces BC6OTHER agonist - and BC6OTHER - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6ENTC .	CPR:5
In conclusion , BC6OTHER - induced constitutive BC6OTHER activity reduces BC6ENTG agonist - and BC6OTHER - induced contractions of bovine tracheal smooth muscle , which can be reversed by the inverse agonist BC6ENTC .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6ENTC or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6ENTG agonist BC6OTHER , the partial BC6OTHER agonist BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6ENTC or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6OTHER agonist BC6OTHER , the partial BC6ENTG agonist BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6ENTG agonist BC6ENTC , the partial BC6OTHER agonist BC6OTHER ( BC6OTHER ) and BC6OTHER .	CPR:5
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6OTHER agonist BC6ENTC , the partial BC6ENTG agonist BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
In the present study , we investigated the effect of BC6ENTC - induced constitutive BC6OTHER activity on BC6ENTG agonist - and BC6OTHER - induced bovine tracheal smooth muscle contractions.	False
In the present study , we investigated the effect of BC6ENTC - induced constitutive BC6ENTG activity on BC6OTHER agonist - and BC6OTHER - induced bovine tracheal smooth muscle contractions.	CPR:3
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6ENTG agonist BC6OTHER , the partial BC6OTHER agonist BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6OTHER agonist BC6OTHER , the partial BC6ENTG agonist BC6ENTC ( BC6OTHER ) and BC6OTHER .	CPR:5
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6ENTG agonist BC6OTHER , the partial BC6OTHER agonist BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6OTHER agonist BC6OTHER , the partial BC6ENTG agonist BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6ENTG agonist BC6OTHER , the partial BC6OTHER agonist BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
Bovine tracheal smooth muscle strips were incubated with 10 microM BC6OTHER or vehicle for various periods of time (5 , 30 min , 18 h) at 37 degrees C. After extensive washout (3 h , 37 degrees C) , isometric contractions were measured to the full BC6OTHER agonist BC6OTHER , the partial BC6ENTG agonist BC6OTHER ( BC6OTHER ) and BC6ENTC .	CPR:5
Effect of BC6ENTC - induced constitutive BC6ENTG activity on contractile receptor function in airway smooth muscle.	CPR:3
The modulation of BC6ENTG by the BC6OTHER series ( BC6OTHER and BC6ENTC ) was studied in the paratracheal ganglion cells.	False
The inhibitory effect of BC6ENTC or BC6OTHER was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6ENTC or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6ENTC or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6ENTC or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6ENTC or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6ENTC was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6ENTC was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6ENTC was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6ENTC was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6ENTC was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6ENTC ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6ENTC ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6ENTC ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6ENTC ( BC6OTHER ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6ENTC ( BC6OTHER ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6ENTC ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6OTHER ( BC6ENTC ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6OTHER ( BC6ENTC ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6ENTC ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6ENTC ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC blocked the action of BC6OTHER .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC blocked the action of BC6OTHER .	CPR:4
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC blocked the action of BC6OTHER .	CPR:4
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6ENTG [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6ENTC .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6ENTG ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6ENTC .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6ENTG )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6ENTC .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER blocked the action of BC6ENTC .	False
The inhibitory effect of BC6OTHER or BC6OTHER was prevented by pretreatment with BC6OTHER [ BC6OTHER ( BC6OTHER )] or BC6OTHER ( BC6OTHER ) , and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER blocked the action of BC6ENTC .	False
It was concluded that BC6ENTC selectively reduces both N - and R - type BC6OTHER currents by activating a BC6ENTG probably through the BC6OTHER in paratracheal ganglion cells.	CPR:3
It was concluded that BC6ENTC selectively reduces both N - and R - type BC6OTHER currents by activating a BC6OTHER probably through the BC6ENTG in paratracheal ganglion cells.	False
It was concluded that BC6OTHER selectively reduces both N - and R - type BC6ENTC currents by activating a BC6ENTG probably through the BC6OTHER in paratracheal ganglion cells.	False
It was concluded that BC6OTHER selectively reduces both N - and R - type BC6ENTC currents by activating a BC6OTHER probably through the BC6ENTG in paratracheal ganglion cells.	False
BC6ENTC BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6ENTC BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6ENTC BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6ENTC (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6ENTC (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6ENTC (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6ENTC ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6ENTC ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6ENTC ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6ENTC (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:5
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6ENTC (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6ENTC (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6ENTC (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6ENTC (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:5
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6ENTC (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6ENTC current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6ENTC current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6ENTC current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6ENTC channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6ENTC channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6ENTC > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6ENTC > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6ENTC > BC6OTHER , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6ENTC , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6ENTC , BC6OTHER > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6ENTC , BC6OTHER > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6ENTC > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6ENTC > BC6OTHER >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6ENTC > BC6OTHER >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6ENTC >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6ENTC >> BC6OTHER .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6ENTC >> BC6OTHER .	CPR:4
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6ENTG - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6ENTC .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6ENTG - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit HVA BC6OTHER channels was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6ENTC .	False
BC6OTHER BC6OTHER (a stable analogue of BC6OTHER ) , BC6OTHER (an BC6OTHER - selective agonist) and BC6OTHER (an BC6OTHER - selective agonist) inhibited the CHEM BC6OTHER current (CHEM ICa) dose - dependently , and the rank order of potency to inhibit BC6ENTG was BC6OTHER > BC6OTHER , BC6OTHER > BC6OTHER >> BC6ENTC .	CPR:4
BC6ENTC (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6OTHER .	CPR:6
BC6ENTC (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the BC6ENTG is possibly mediated by the BC6OTHER .	False
BC6ENTC (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6ENTG .	False
BC6OTHER (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6ENTC - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6ENTC - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the BC6ENTG is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6ENTC - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6ENTG .	False
BC6OTHER (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6OTHER - or BC6ENTC - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6ENTC - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the BC6ENTG is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6ENTC - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6ENTG .	False
BC6OTHER (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6ENTC - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6ENTC - and BC6OTHER - induced inhibition of the BC6ENTG is possibly mediated by the BC6OTHER .	CPR:4
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6ENTC - and BC6OTHER - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6ENTG .	False
BC6OTHER (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6ENTC - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6ENTC - induced inhibition of the BC6ENTG is possibly mediated by the BC6OTHER .	CPR:4
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6ENTC - induced inhibition of the CHEM BC6OTHER channels is possibly mediated by the BC6ENTG .	False
BC6OTHER (10( - 5) M) , a selective BC6ENTG antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6ENTC channels is possibly mediated by the BC6OTHER .	False
BC6OTHER (10( - 5) M) , a selective BC6OTHER antagonist , showed no effect on the BC6OTHER - or BC6OTHER - induced inhibition of the CHEM , thereby indicating that BC6OTHER - and BC6OTHER - induced inhibition of the CHEM BC6ENTC channels is possibly mediated by the BC6ENTG .	False
The modulation of BC6ENTG by the BC6ENTC series ( BC6OTHER and BC6OTHER ) was studied in the paratracheal ganglion cells.	False
BC6ENTC and BC6OTHER also inhibited the remaining ICa in a saturating concentration of BC6OTHER , omega - conotoxin - GVIA and omega - conotoxin - MVIIC , suggesting that BC6ENTG are involved.	False
BC6OTHER and BC6ENTC also inhibited the remaining ICa in a saturating concentration of BC6OTHER , omega - conotoxin - GVIA and omega - conotoxin - MVIIC , suggesting that BC6ENTG are involved.	False
The modulation of BC6ENTG by the BC6OTHER series ( BC6ENTC and BC6OTHER ) was studied in the paratracheal ganglion cells.	False
BC6OTHER and BC6OTHER also inhibited the remaining ICa in a saturating concentration of BC6ENTC , omega - conotoxin - GVIA and omega - conotoxin - MVIIC , suggesting that BC6ENTG are involved.	False
The BC6ENTC series modulates BC6ENTG probably through the BC6OTHER in rat paratracheal ganglia.	False
The BC6ENTC series modulates high - voltage - activated BC6OTHER channels probably through the BC6ENTG in rat paratracheal ganglia.	False
The BC6OTHER series modulates high - voltage - activated BC6ENTC channels probably through the BC6ENTG in rat paratracheal ganglia.	False
Guided by the BC6ENTG inhibiting activity , the BC6ENTC BC6OTHER was isolated from a stem extract of Tabernaemontana divaricata , a plant used in Thailand in traditional rejuvenation remedies for improving the memory.	CPR:4
Guided by the BC6ENTG inhibiting activity , the BC6OTHER BC6ENTC was isolated from a stem extract of Tabernaemontana divaricata , a plant used in Thailand in traditional rejuvenation remedies for improving the memory.	CPR:4
 BC6ENTC , a potent BC6ENTG inhibitor from Tabernaemontana divaricata.	CPR:4
Thus , in 158N cells , the ability of BC6ENTC to trigger a mode of cell death by apoptosis involving BC6ENTG and BC6OTHER activation is independent of the increase in the BC6OTHER level and of their accumulation in lipid raft microdomains.	CPR:3
Thus , in 158N cells , the ability of BC6ENTC to trigger a mode of cell death by apoptosis involving BC6OTHER and BC6ENTG activation is independent of the increase in the BC6OTHER level and of their accumulation in lipid raft microdomains.	CPR:3
Thus , in 158N cells , the ability of BC6OTHER to trigger a mode of cell death by apoptosis involving BC6ENTG and BC6OTHER activation is independent of the increase in the BC6ENTC level and of their accumulation in lipid raft microdomains.	False
Thus , in 158N cells , the ability of BC6OTHER to trigger a mode of cell death by apoptosis involving BC6OTHER and BC6ENTG activation is independent of the increase in the BC6ENTC level and of their accumulation in lipid raft microdomains.	False
To this end , 158N murine oligodendrocytes were treated with BC6ENTC or BC6OTHER inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6ENTG and BC6OTHER , mitochondrial depolarization involving BC6OTHER , and BC6OTHER activation.	False
To this end , 158N murine oligodendrocytes were treated with BC6ENTC or BC6OTHER inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6ENTG , mitochondrial depolarization involving BC6OTHER , and BC6OTHER activation.	False
To this end , 158N murine oligodendrocytes were treated with BC6ENTC or BC6OTHER inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6OTHER , mitochondrial depolarization involving BC6ENTG , and BC6OTHER activation.	CPR:3
To this end , 158N murine oligodendrocytes were treated with BC6ENTC or BC6OTHER inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6OTHER , mitochondrial depolarization involving BC6OTHER , and BC6ENTG activation.	CPR:3
To this end , 158N murine oligodendrocytes were treated with BC6OTHER or BC6ENTC inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6ENTG and BC6OTHER , mitochondrial depolarization involving BC6OTHER , and BC6OTHER activation.	False
To this end , 158N murine oligodendrocytes were treated with BC6OTHER or BC6ENTC inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6ENTG , mitochondrial depolarization involving BC6OTHER , and BC6OTHER activation.	False
To this end , 158N murine oligodendrocytes were treated with BC6OTHER or BC6ENTC inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6OTHER , mitochondrial depolarization involving BC6ENTG , and BC6OTHER activation.	CPR:3
To this end , 158N murine oligodendrocytes were treated with BC6OTHER or BC6ENTC inducing an apoptotic mode of cell death characterized by condensation / fragmentation of the nuclei , dephosphorylation of BC6OTHER and BC6OTHER , mitochondrial depolarization involving BC6OTHER , and BC6ENTG activation.	CPR:3
Absence of correlation between BC6ENTC accumulation in BC6ENTG , BC6OTHER increase , and apoptosis induction on 158N murine oligodendrocytes.	False
Absence of correlation between BC6OTHER accumulation in BC6ENTG , BC6ENTC increase , and apoptosis induction on 158N murine oligodendrocytes.	False
Effects of chronic social defeat stress on behavior and BC6ENTC CHEM , 78 - kDa BC6OTHER - regulated protein , and BC6ENTG in adult mice.	False
Effects of chronic social defeat stress on behavior and BC6ENTC acetyltransferase , BC6ENTG , and BC6OTHER in adult mice.	False
Effects of chronic social defeat stress on behavior and BC6OTHER , 78 - kDa BC6ENTC - regulated protein , and BC6ENTG in adult mice.	False
Effects of chronic social defeat stress on behavior and BC6ENTG , 78 - kDa BC6ENTC - regulated protein , and BC6OTHER in adult mice.	False
BC6ENTC ( BC6OTHER ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6OTHER BC6ENTG / BC6OTHER receptor agonist.	CPR:5
BC6ENTC ( BC6OTHER ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6OTHER BC6OTHER / BC6ENTG receptor agonist.	CPR:5
BC6OTHER ( BC6ENTC ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6OTHER BC6ENTG / BC6OTHER receptor agonist.	False
BC6OTHER ( BC6ENTC ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6OTHER BC6OTHER / BC6ENTG receptor agonist.	False
BC6OTHER ( BC6OTHER ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6ENTC BC6ENTG / BC6OTHER receptor agonist.	False
BC6OTHER ( BC6OTHER ; Takeda Pharmaceutical Company Limited , Osaka , Japan) is an orally active , highly selective BC6ENTC BC6OTHER / BC6ENTG receptor agonist.	False
"Unlike the sedative hypnotics that target BC6ENTG complexes , BC6ENTC is a chronohypnotic that acts on the BC6OTHER BC6OTHER and BC6OTHER receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	False
"Unlike the sedative hypnotics that target BC6OTHER complexes , BC6ENTC is a chronohypnotic that acts on the BC6OTHER BC6ENTG and BC6OTHER receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	CPR:5
"Unlike the sedative hypnotics that target BC6OTHER complexes , BC6ENTC is a chronohypnotic that acts on the BC6OTHER BC6OTHER and BC6ENTG receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	CPR:5
"Unlike the sedative hypnotics that target BC6ENTG complexes , BC6OTHER is a chronohypnotic that acts on the BC6ENTC BC6OTHER and BC6OTHER receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	False
"Unlike the sedative hypnotics that target BC6OTHER complexes , BC6OTHER is a chronohypnotic that acts on the BC6ENTC BC6ENTG and BC6OTHER receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	False
"Unlike the sedative hypnotics that target BC6OTHER complexes , BC6OTHER is a chronohypnotic that acts on the BC6ENTC BC6OTHER and BC6ENTG receptors , which are primarily located in the suprachiasmatic nucleus , the body's ""master clock."""	False
Pharmacology of BC6ENTC , a selective BC6ENTG / BC6OTHER receptor agonist: a novel therapeutic drug for sleep disorders.	CPR:5
Pharmacology of BC6ENTC , a selective BC6OTHER / BC6ENTG receptor agonist: a novel therapeutic drug for sleep disorders.	CPR:5
This suggests that plant BC6ENTC racemases represent a distinct group in the eukaryotic BC6ENTG family and can be clustered into monocot and dicot types.	False
This suggests that plant BC6ENTG represent a distinct group in the eukaryotic BC6ENTC racemase family and can be clustered into monocot and dicot types.	False
In this study , we cloned and sequenced a cDNA encoding a BC6ENTG from barley which contained an open reading frame encoding 337 BC6ENTC residues.	False
The deduced BC6ENTC sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6OTHER ( BC6OTHER ) - binding BC6OTHER and BC6OTHER - interacting BC6OTHER residues.	False
The deduced BC6OTHER sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6ENTC ( BC6OTHER ) - binding BC6OTHER and BC6OTHER - interacting BC6OTHER residues.	False
The deduced BC6OTHER sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6OTHER ( BC6ENTC ) - binding BC6OTHER and BC6OTHER - interacting BC6OTHER residues.	False
The deduced BC6OTHER sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6OTHER ( BC6OTHER ) - binding BC6ENTC and BC6OTHER - interacting BC6OTHER residues.	False
The deduced BC6OTHER sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6OTHER ( BC6OTHER ) - binding BC6OTHER and BC6ENTC - interacting BC6OTHER residues.	False
The deduced BC6OTHER sequence showed significant identity to plant and mammalian BC6ENTG and contained conserved BC6OTHER ( BC6OTHER ) - binding BC6OTHER and BC6OTHER - interacting BC6ENTC residues.	False
The enzyme requires BC6ENTC and divalent cations such as BC6OTHER , BC6OTHER , or BC6OTHER , but not BC6OTHER , whereas mammalian BC6ENTG activity is increased by BC6OTHER .	False
The enzyme requires BC6OTHER and divalent cations such as BC6ENTC , BC6OTHER , or BC6OTHER , but not BC6OTHER , whereas mammalian BC6ENTG activity is increased by BC6OTHER .	False
The enzyme requires BC6OTHER and divalent cations such as BC6OTHER , BC6ENTC , or BC6OTHER , but not BC6OTHER , whereas mammalian BC6ENTG activity is increased by BC6OTHER .	False
The enzyme requires BC6OTHER and divalent cations such as BC6OTHER , BC6OTHER , or BC6ENTC , but not BC6OTHER , whereas mammalian BC6ENTG activity is increased by BC6OTHER .	False
The enzyme requires BC6OTHER and divalent cations such as BC6OTHER , BC6OTHER , or BC6OTHER , but not BC6ENTC , whereas mammalian BC6ENTG activity is increased by BC6OTHER .	False
The enzyme requires BC6OTHER and divalent cations such as BC6OTHER , BC6OTHER , or BC6OTHER , but not BC6OTHER , whereas mammalian BC6ENTG activity is increased by BC6ENTC .	CPR:3
In addition to the results regarding the effect of BC6ENTC on enzyme activity and the phylogenetic analysis of eukaryotic BC6ENTG , the antiserum against Arabidopsis BC6OTHER racemase did not form a precipitate with barley and rice BC6OTHER .	False
In addition to the results regarding the effect of BC6ENTC on enzyme activity and the phylogenetic analysis of eukaryotic BC6OTHER , the antiserum against BC6ENTG did not form a precipitate with barley and rice BC6OTHER .	False
In addition to the results regarding the effect of BC6ENTC on enzyme activity and the phylogenetic analysis of eukaryotic BC6OTHER , the antiserum against Arabidopsis BC6OTHER racemase did not form a precipitate with barley and rice BC6ENTG .	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6ENTC racemases , the antiserum against BC6ENTG did not form a precipitate with barley and rice BC6OTHER .	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6ENTC racemases , the antiserum against Arabidopsis BC6OTHER racemase did not form a precipitate with barley and rice BC6ENTG .	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6ENTG , the antiserum against Arabidopsis BC6ENTC racemase did not form a precipitate with barley and rice BC6OTHER .	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6OTHER , the antiserum against Arabidopsis BC6ENTC racemase did not form a precipitate with barley and rice BC6ENTG .	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6ENTG , the antiserum against Arabidopsis BC6OTHER racemase did not form a precipitate with barley and rice BC6ENTC racemases.	False
In addition to the results regarding the effect of BC6OTHER on enzyme activity and the phylogenetic analysis of eukaryotic BC6OTHER , the antiserum against BC6ENTG did not form a precipitate with barley and rice BC6ENTC racemases.	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:6
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:6
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:6
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6ENTC ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:6
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6ENTC (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:4
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6ENTC (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6ENTC (0.01 - 1 microM) , or the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	False
The effects of BC6OTHER in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6ENTG antagonist BC6ENTC (0.01 - 1 microM).	CPR:6
In contrast , the BC6ENTC - induced responses were potently and concentration - dependently antagonized by the mixed BC6ENTG and BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	CPR:5
In contrast , the BC6ENTC - induced responses were potently and concentration - dependently antagonized by the mixed BC6OTHER and BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	CPR:5
In contrast , the BC6OTHER - induced responses were potently and concentration - dependently antagonized by the mixed BC6ENTG and BC6OTHER antagonist BC6ENTC (0.01 - 1 microM).	CPR:6
In contrast , the BC6OTHER - induced responses were potently and concentration - dependently antagonized by the mixed BC6OTHER and BC6ENTG antagonist BC6ENTC (0.01 - 1 microM).	CPR:6
It is concluded that BC6ENTC contracts the canine basilar artery by stimulating BC6ENTG unrelated to either the BC6OTHER or BC6OTHER receptor subtypes.	CPR:3
It is concluded that BC6ENTC contracts the canine basilar artery by stimulating BC6OTHER unrelated to either the BC6ENTG or BC6OTHER receptor subtypes.	CPR:3
It is concluded that BC6ENTC contracts the canine basilar artery by stimulating BC6OTHER unrelated to either the BC6OTHER or BC6ENTG receptor subtypes.	CPR:3
The contractile effects of BC6ENTC in the basilar artery were compared with those produced by BC6OTHER ( BC6OTHER ) and the BC6ENTG agonist BC6OTHER .	False
The contractile effects of BC6OTHER in the basilar artery were compared with those produced by BC6ENTC ( BC6OTHER ) and the BC6ENTG agonist BC6OTHER .	False
The contractile effects of BC6OTHER in the basilar artery were compared with those produced by BC6OTHER ( BC6ENTC ) and the BC6ENTG agonist BC6OTHER .	False
The contractile effects of BC6OTHER in the basilar artery were compared with those produced by BC6OTHER ( BC6OTHER ) and the BC6ENTG agonist BC6ENTC .	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6ENTG receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6ENTG receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6ENTG blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6ENTG and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6ENTG binding sites BC6OTHER (0.01 - 1 microM) , or the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM).	False
The effects of BC6ENTC in the basilar artery were not modified by incubation with either the BC6OTHER antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER and BC6OTHER receptor antagonist CHEM ( BC6OTHER ; 0.1 - 10 microM) , the BC6OTHER receptor antagonist BC6OTHER (0.01 - 1 microM) , the BC6OTHER blocker with high affinity for BC6OTHER and BC6OTHER binding sites BC6OTHER (0.01 - 1 microM) , or the BC6ENTG antagonist BC6OTHER (0.01 - 1 microM).	False
 BC6ENTC ( BC6OTHER ): a novel agonist at BC6ENTG in the canine basilar artery.	CPR:5
 BC6OTHER ( BC6ENTC ): a novel agonist at BC6ENTG in the canine basilar artery.	CPR:5
For our primary outcome , we calculated the quantitative BC6OTHER sensitivity check index (QUICKI) using the end - of - period fasting serum BC6ENTC and BC6ENTG .	False
For our primary outcome , we calculated the quantitative BC6ENTG sensitivity check index (QUICKI) using the end - of - period fasting serum BC6ENTC and BC6OTHER .	False
CONCLUSIONS A diet that partially replaces BC6ENTC with unsaturated fat may improve BC6ENTG sensitivity in a population at risk for cardiovascular disease.	CPR:3
The purpose of this study is to determine the effects on BC6ENTG sensitivity of a BC6ENTC - rich diet ( BC6OTHER ; similar to the Dietary Approaches to Stop Hypertension [DASH] diet) , a protein - rich diet (PROT; protein predominantly from plant sources) , and an unsaturated fat - rich diet (UNSAT; predominantly monounsaturated).	False
The purpose of this study is to determine the effects on BC6ENTG sensitivity of a BC6OTHER - rich diet ( BC6ENTC ; similar to the Dietary Approaches to Stop Hypertension [DASH] diet) , a protein - rich diet (PROT; protein predominantly from plant sources) , and an unsaturated fat - rich diet (UNSAT; predominantly monounsaturated).	False
The Effects of BC6ENTC , Unsaturated Fat , and Protein Intake on Measures of BC6ENTG Sensitivity: Results from the OmniHeart Trial.	False
The modification of the inhibitor scaffold of 1 and 2 from a BC6ENTC core to a BC6OTHER core led to discovery of a new series of potent BC6ENTG inhibitors with excellent physicochemical properties.	CPR:4
The modification of the inhibitor scaffold of 1 and 2 from a BC6OTHER core to a BC6ENTC core led to discovery of a new series of potent BC6ENTG inhibitors with excellent physicochemical properties.	CPR:4
The structure - based design , synthesis , and biological evaluation of a new BC6ENTC series of irreversible BC6ENTG inhibitors are described herein.	CPR:4
 BC6ENTC as a template for structure - based drug design: identification of new BC6OTHER series of irreversible BC6ENTG inhibitors with improved lipophilic efficiency.	CPR:4
 BC6OTHER as a template for structure - based drug design: identification of new BC6ENTC series of irreversible BC6ENTG inhibitors with improved lipophilic efficiency.	CPR:4
BC6ENTC transporters ( BC6ENTG ) play an essential role in the termination and regulation of BC6OTHER signaling in the brain.	False
In functional transport assays , we found that one of the identified molecules , ATM7 , increased the reuptake of BC6ENTC , possibly by facilitating the interaction of BC6OTHER with transport - ready conformations of BC6ENTG when concentrations of BC6OTHER were low and rate limiting.	CPR:9
In functional transport assays , we found that one of the identified molecules , ATM7 , increased the reuptake of BC6OTHER , possibly by facilitating the interaction of BC6ENTC with transport - ready conformations of BC6ENTG when concentrations of BC6OTHER were low and rate limiting.	CPR:9
In functional transport assays , we found that one of the identified molecules , ATM7 , increased the reuptake of BC6OTHER , possibly by facilitating the interaction of BC6OTHER with transport - ready conformations of BC6ENTG when concentrations of BC6ENTC were low and rate limiting.	CPR:9
"In addition , ATM7 potentiates BC6ENTC ( BC6OTHER , ""Ecstasy"") - induced reversed transport by BC6ENTG ."	False
"In addition , ATM7 potentiates BC6OTHER ( BC6ENTC , ""Ecstasy"") - induced reversed transport by BC6ENTG ."	False
Using the structure of the bacterial transporter homologue BC6ENTC transporter as a template , we developed a structural model of BC6ENTG .	False
BC6ENTG ( BC6OTHER ) play an essential role in the termination and regulation of BC6ENTC signaling in the brain.	False
BC6OTHER ( BC6ENTG ) play an essential role in the termination and regulation of BC6ENTC signaling in the brain.	False
BC6ENTG ( BC6OTHER ) , a dimeric glycoprotein synthesized in the anterior pituitary gland , is important for the production of sex BC6ENTC and gametes.	CPR:9
BC6OTHER ( BC6ENTG ) , a dimeric glycoprotein synthesized in the anterior pituitary gland , is important for the production of sex BC6ENTC and gametes.	CPR:9
Humans with BC6ENTG gene mutations tend to have a more severe phenotype than those with BC6OTHER gene mutations , although infertility and varying degrees of impaired sex BC6ENTC production occur in both types of mutations.	CPR:9
Humans with BC6OTHER gene mutations tend to have a more severe phenotype than those with BC6ENTG gene mutations , although infertility and varying degrees of impaired sex BC6ENTC production occur in both types of mutations.	False
 BC6OTHER - dependent and - independent mechanisms underlying in vitro antiglioma action of compound C. We investigated the effect of compound C , a well - known inhibitor of the intracellular energy sensor BC6ENTC - activated protein kinase ( BC6ENTG ) , on proliferation and viability of human U251 and rat C6 glioma cell lines.	False
 BC6ENTG - dependent and - independent mechanisms underlying in vitro antiglioma action of compound C. We investigated the effect of compound C , a well - known inhibitor of the intracellular energy sensor BC6ENTC - activated protein kinase ( BC6OTHER ) , on proliferation and viability of human U251 and rat C6 glioma cell lines.	False
Compound C caused G(2) / M cell cycle block , accompanied by apoptotic glioma cell death characterized by BC6ENTG activation , BC6ENTC exposure and DNA fragmentation.	False
Compound C diminished BC6ENTG phosphorylation and enzymatic activity , resulting in reduced phosphorylation of its target BC6ENTC carboxylase.	False
BC6ENTG activators BC6ENTC and BC6OTHER partly prevented the cell cycle block , oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of BC6OTHER mimicked compound C - induced G(2) / M cell cycle arrest , but failed to induce oxidative stress and apoptosis in U251 glioma cells.	CPR:3
BC6OTHER activators BC6ENTC and BC6OTHER partly prevented the cell cycle block , oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of BC6ENTG mimicked compound C - induced G(2) / M cell cycle arrest , but failed to induce oxidative stress and apoptosis in U251 glioma cells.	False
BC6ENTG activators BC6OTHER and BC6ENTC partly prevented the cell cycle block , oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of BC6OTHER mimicked compound C - induced G(2) / M cell cycle arrest , but failed to induce oxidative stress and apoptosis in U251 glioma cells.	CPR:3
BC6OTHER activators BC6OTHER and BC6ENTC partly prevented the cell cycle block , oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of BC6ENTG mimicked compound C - induced G(2) / M cell cycle arrest , but failed to induce oxidative stress and apoptosis in U251 glioma cells.	False
 BC6ENTC - activated protein kinase - dependent and - independent mechanisms underlying in vitro antiglioma action of compound C. We investigated the effect of compound C , a well - known inhibitor of the intracellular energy sensor BC6ENTG ( BC6OTHER ) , on proliferation and viability of human U251 and rat C6 glioma cell lines.	False
 BC6ENTC - activated protein kinase - dependent and - independent mechanisms underlying in vitro antiglioma action of compound C. We investigated the effect of compound C , a well - known inhibitor of the intracellular energy sensor BC6OTHER ( BC6ENTG ) , on proliferation and viability of human U251 and rat C6 glioma cell lines.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6ENTC - beta - synthase.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6ENTC - beta - synthase.	False
RESULTS: Only single BC6ENTC polymorphisms (SNPs) in BC6ENTG were significantly associated in the overall data set; this significance was strongest when mothers took BC6OTHER - containing nutritional supplements before conception.	False
RESULTS: Only single BC6OTHER polymorphisms (SNPs) in BC6ENTG were significantly associated in the overall data set; this significance was strongest when mothers took BC6ENTC - containing nutritional supplements before conception.	False
Other SNPs in BC6ENTC pathway genes were marginally significant in some analyses when stratified by maternal supplementation , BC6ENTG , or BC6OTHER allele transmission.	False
Other SNPs in BC6ENTC pathway genes were marginally significant in some analyses when stratified by maternal supplementation , BC6OTHER , or BC6ENTG allele transmission.	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTC receptor 1 , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTC receptor 2 , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase 1 , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase BC6ENTC reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , BC6ENTG , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC methyltransferase , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC - BC6OTHER methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , BC6ENTG ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6ENTC methyltransferase reductase , betaine - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , BC6ENTC - BC6OTHER methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6ENTG .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , 5 , 10 - CHEM reductase ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , betaine - BC6ENTC methyltransferase ( BC6OTHER ) , and BC6OTHER .	False
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly , we examined 28 polymorphisms in 11 genes: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , CHEM CHEM - transferase 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , 5 - CHEM - BC6OTHER methyltransferase reductase , betaine - BC6ENTC methyltransferase ( BC6ENTG ) , and BC6OTHER .	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is the first oral inhibitor of BC6ENTG (mammalian target of BC6OTHER ) to reach the oncology clinic.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is the first oral inhibitor of BC6OTHER ( BC6ENTG ) to reach the oncology clinic.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER ) is the first oral inhibitor of BC6ENTG (mammalian target of BC6ENTC ) to reach the oncology clinic.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is the first oral inhibitor of BC6ENTG (mammalian target of BC6OTHER ) to reach the oncology clinic.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is the first oral inhibitor of BC6OTHER ( BC6ENTG ) to reach the oncology clinic.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is the first oral inhibitor of BC6ENTG (mammalian target of BC6OTHER ) to reach the oncology clinic.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is the first oral inhibitor of BC6OTHER ( BC6ENTG ) to reach the oncology clinic.	CPR:4
A phase III randomized placebo - controlled trial has examined the impact of BC6ENTC in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6ENTG BC6OTHER inhibitors BC6OTHER and / or BC6OTHER .	False
A phase III randomized placebo - controlled trial has examined the impact of BC6ENTC in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6OTHER BC6ENTG inhibitors BC6OTHER and / or BC6OTHER .	False
A phase III randomized placebo - controlled trial has examined the impact of BC6OTHER in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6ENTG BC6ENTC kinase inhibitors BC6OTHER and / or BC6OTHER .	False
A phase III randomized placebo - controlled trial has examined the impact of BC6OTHER in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6ENTG BC6OTHER inhibitors BC6ENTC and / or BC6OTHER .	CPR:4
A phase III randomized placebo - controlled trial has examined the impact of BC6OTHER in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6OTHER BC6ENTG inhibitors BC6ENTC and / or BC6OTHER .	CPR:4
A phase III randomized placebo - controlled trial has examined the impact of BC6OTHER in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6ENTG BC6OTHER inhibitors BC6OTHER and / or BC6ENTC .	CPR:4
A phase III randomized placebo - controlled trial has examined the impact of BC6OTHER in patients with clear cell renal cancers and progressive disease on or within 6 months of the BC6OTHER BC6ENTG inhibitors BC6OTHER and / or BC6ENTC .	CPR:4
BC6ENTG ( BC6OTHER ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a class I BC6ENTC - tRNA synthetase ( BC6OTHER ) that does not proofread its products.	False
Human mitochondrial BC6OTHER - tRNA synthetase ( BC6OTHER ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a class I BC6ENTC - tRNA synthetase ( BC6ENTG ) that does not proofread its products.	False
Human mitochondrial BC6OTHER - tRNA synthetase ( BC6ENTG ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a class I BC6ENTC - tRNA synthetase ( BC6OTHER ) that does not proofread its products.	False
Human mitochondrial BC6ENTC - tRNA synthetase ( BC6OTHER ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a BC6ENTG ( BC6OTHER ) that does not proofread its products.	False
Human mitochondrial BC6ENTC - tRNA synthetase ( BC6OTHER ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a class I BC6OTHER - tRNA synthetase ( BC6ENTG ) that does not proofread its products.	False
Human mitochondrial BC6ENTC - tRNA synthetase ( BC6ENTG ) achieves high aminoacylation fidelity without a functional editing active site , representing a rare example of a class I BC6OTHER - tRNA synthetase ( BC6OTHER ) that does not proofread its products.	False
Here we describe studies indicating that this particular residue (K600 in BC6ENTG and L570 in BC6OTHER ) strongly impacts aminoacylation in two ways: it affects both BC6ENTC discrimination and transfer RNA (tRNA) binding.	False
Here we describe studies indicating that this particular residue (K600 in BC6OTHER and L570 in BC6ENTG ) strongly impacts aminoacylation in two ways: it affects both BC6ENTC discrimination and transfer RNA (tRNA) binding.	False
A single residue in BC6ENTG affecting BC6ENTC specificity and tRNA aminoacylation.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its BC6ENTC - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its BC6ENTC - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its BC6ENTC - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6ENTC mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6ENTC mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6ENTC mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its BC6ENTG mutant ( BC6OTHER ) have been studied by monitoring BC6ENTC burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6ENTC burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6ENTC burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6ENTC burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its BC6ENTG mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6ENTC ( BC6OTHER ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6ENTC ( BC6OTHER ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6ENTC ( BC6OTHER ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6ENTC ( BC6OTHER ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its BC6ENTG mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6ENTC ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6ENTC ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6ENTC ) inhibitor binding.	CPR:4
The refolding kinetics of BC6OTHER - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6ENTC ) inhibitor binding.	CPR:4
The refolding kinetics of BC6ENTC - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its BC6ENTG mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6ENTC - denatured BC6OTHER - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6ENTC - denatured BC6OTHER - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6ENTC - denatured BC6OTHER - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The folding rate for wild - type BC6ENTG is faster in the presence of the inhibitor BC6ENTC than in its absence , indicating that the transition - state structure in the rate - determining step is stabilized by BC6OTHER .	CPR:4
The folding rate for wild - type BC6ENTG is faster in the presence of the inhibitor BC6OTHER than in its absence , indicating that the transition - state structure in the rate - determining step is stabilized by BC6ENTC .	False
The refolding kinetics of BC6OTHER - denatured BC6ENTC - intact BC6OTHER ( BC6OTHER ) and its BC6ENTG mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6ENTC - intact BC6OTHER ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6ENTG ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6ENTC - intact BC6ENTG ( BC6OTHER ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The refolding kinetics of BC6OTHER - denatured BC6ENTC - intact BC6OTHER ( BC6ENTG ) and its CHEM - 42 - to - BC6OTHER mutant ( BC6OTHER ) have been studied by monitoring BC6OTHER burial and BC6OTHER ( BC6OTHER ) inhibitor binding.	False
The folding rate monitored by BC6ENTC binding to the major slow - folding species of BC6ENTG BC6OTHER is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6ENTC binding to the major slow - folding species of BC6OTHER BC6ENTG is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6ENTC binding to the major slow - folding species of BC6OTHER BC6OTHER is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6ENTG fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6ENTG BC6OTHER is faster than the folding rate monitored by BC6ENTC burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6OTHER BC6ENTG is faster than the folding rate monitored by BC6ENTC burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6OTHER BC6OTHER is faster than the folding rate monitored by BC6ENTC burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6OTHER burial , indicating that the major and minor slow - folding species of BC6ENTG fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6ENTG BC6OTHER is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6ENTC burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6OTHER BC6ENTG is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6ENTC burial , indicating that the major and minor slow - folding species of BC6OTHER fold to the native state with different transition - state conformations in the rate - determining step.	False
The folding rate monitored by BC6OTHER binding to the major slow - folding species of BC6OTHER BC6OTHER is faster than the folding rate monitored by BC6OTHER burial; however , the folding rate monitored by inhibitor binding to the minor slow - folding species is decreased significantly over the folding rate monitored by BC6ENTC burial , indicating that the major and minor slow - folding species of BC6ENTG fold to the native state with different transition - state conformations in the rate - determining step.	False
Folding pathway of BC6ENTC - denatured BC6OTHER - intact wild - type and mutant BC6ENTG .	False
Folding pathway of BC6OTHER - denatured BC6ENTC - intact wild - type and mutant BC6ENTG .	False
An increase in the BC6ENTC / BC6OTHER ratio opens BC6ENTG , leading to membrane hyperpolarization.	CPR:3
An increase in the BC6OTHER / BC6ENTC ratio opens BC6ENTG , leading to membrane hyperpolarization.	CPR:3
BC6ENTG BC6ENTC ( BC6OTHER )) channels are weak , inward rectifiers that couple metabolic status to cell membrane electrical activity , thus modulating many cellular functions.	False
BC6ENTG BC6OTHER ( BC6ENTC )) channels are weak , inward rectifiers that couple metabolic status to cell membrane electrical activity , thus modulating many cellular functions.	False
In vivo animal studies confirmed that knocking out the BC6ENTG subunit of the BC6ENTC ( BC6OTHER ) channels increases ischemic infarction , and overexpression of the BC6OTHER subunit reduces neuronal injury from ischemic insults.	False
In vivo animal studies confirmed that knocking out the BC6OTHER subunit of the BC6ENTC ( BC6OTHER ) channels increases ischemic infarction , and overexpression of the BC6ENTG subunit reduces neuronal injury from ischemic insults.	False
In vivo animal studies confirmed that knocking out the BC6ENTG subunit of the K( BC6ENTC ) channels increases ischemic infarction , and overexpression of the BC6OTHER subunit reduces neuronal injury from ischemic insults.	False
In vivo animal studies confirmed that knocking out the BC6OTHER subunit of the K( BC6ENTC ) channels increases ischemic infarction , and overexpression of the BC6ENTG subunit reduces neuronal injury from ischemic insults.	False
The anti - amnesic effect of BC6ENTC on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6ENTC - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6ENTC ( BC6OTHER ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6ENTC ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6ENTC , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6OTHER , and by a BC6ENTC precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6ENTC , whereas a BC6ENTG - selective agonist , BC6OTHER , was inactive.	False
The anti - amnesic effect of BC6OTHER on the BC6OTHER - induced memory impairment was also antagonized by a BC6OTHER ( BC6OTHER ) releaser , BC6OTHER , and by a BC6OTHER precursor , BC6OTHER , whereas a BC6ENTG - selective agonist , BC6ENTC , was inactive.	CPR:5
The memory - improving effect of BC6ENTC on BC6OTHER - induced amnesia was potentiated by a selective BC6ENTG antagonist , BC6OTHER .	False
The memory - improving effect of BC6OTHER on BC6ENTC - induced amnesia was potentiated by a selective BC6ENTG antagonist , BC6OTHER .	False
The memory - improving effect of BC6OTHER on BC6OTHER - induced amnesia was potentiated by a selective BC6ENTG antagonist , BC6ENTC .	CPR:6
These results suggest that the beneficial effect of BC6ENTC on BC6OTHER - induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems ( BC6ENTG ).	False
These results suggest that the beneficial effect of BC6OTHER on BC6ENTC - induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems ( BC6ENTG ).	False
BC6ENTC ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6ENTG by itself , is well tolerated by these patients.	False
BC6ENTC ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6ENTG ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	CPR:4
BC6ENTC ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6ENTG ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	CPR:4
Although the precise mechanism of the protective action of BC6ENTC is unknown , our data support the possibility of interaction between BC6OTHER and BC6OTHER on BC6ENTG locus in the respiratory tract in BC6OTHER - intolerant patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6ENTC - intolerant patients , while BC6OTHER , hardly active on BC6ENTG by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6ENTG ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6ENTC - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6ENTG ) inhibitors , precipitate asthmatic attacks in BC6ENTC - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
Although the precise mechanism of the protective action of BC6OTHER is unknown , our data support the possibility of interaction between BC6ENTC and BC6OTHER on BC6ENTG locus in the respiratory tract in BC6OTHER - intolerant patients.	CPR:4
Although the precise mechanism of the protective action of BC6OTHER is unknown , our data support the possibility of interaction between BC6OTHER and BC6ENTC on BC6ENTG locus in the respiratory tract in BC6OTHER - intolerant patients.	CPR:4
Although the precise mechanism of the protective action of BC6OTHER is unknown , our data support the possibility of interaction between BC6OTHER and BC6OTHER on BC6ENTG locus in the respiratory tract in BC6ENTC - intolerant patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6ENTC , hardly active on BC6ENTG by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6ENTG ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6ENTC , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6ENTG ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6ENTC , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
However , BC6ENTC moiety appears to interfere with BC6OTHER inhibitory action on platelets and vascular BC6ENTG .	False
BC6OTHER ( BC6OTHER ) and other non - BC6ENTC anti - inflammatory drugs , which are BC6OTHER ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6ENTG by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6ENTC anti - inflammatory drugs , which are BC6ENTG ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6OTHER ) and other non - BC6ENTC anti - inflammatory drugs , which are BC6OTHER ( BC6ENTG ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	False
However , BC6OTHER moiety appears to interfere with BC6ENTC inhibitory action on platelets and vascular BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6ENTG by itself , is well tolerated by these patients.	False
BC6OTHER ( BC6ENTC ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6ENTG ( BC6OTHER ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	CPR:4
BC6OTHER ( BC6ENTC ) and other non - BC6OTHER anti - inflammatory drugs , which are BC6OTHER ( BC6ENTG ) inhibitors , precipitate asthmatic attacks in BC6OTHER - intolerant patients , while BC6OTHER , hardly active on BC6OTHER by itself , is well tolerated by these patients.	CPR:4
BC6ENTC derived from Zingiber officinale Roscoe (ginger) was identified as a novel BC6ENTG antagonist , with an IC50 value of 8.173 µM.	CPR:6
The major ingredient of ginger , BC6ENTC , could inhibit BC6ENTG activation , which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.	CPR:4
 BC6ENTC : a novel BC6ENTG antagonist for the treatment of cardiovascular disease.	CPR:6
After only 10 - min ischemia followed by 24 - h reperfusion , BC6ENTG was significantly elevated by 13 - fold , whereas serum BC6ENTC (sCr) , blood BC6OTHER BC6OTHER , BC6OTHER ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6ENTC (sCr) , blood BC6OTHER BC6OTHER , BC6ENTG ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6ENTC (sCr) , blood BC6OTHER BC6OTHER , BC6OTHER ( BC6ENTG ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6ENTG was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6ENTC BC6OTHER , BC6OTHER ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6ENTC BC6OTHER , BC6ENTG ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6ENTC BC6OTHER , BC6OTHER ( BC6ENTG ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6ENTG was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6OTHER BC6ENTC , BC6OTHER ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6OTHER BC6ENTC , BC6ENTG ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6OTHER BC6ENTC , BC6OTHER ( BC6ENTG ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6ENTG was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6OTHER BC6OTHER , BC6ENTC - β - glucosaminidase ( BC6OTHER ) , and proteinuria levels did not change.	False
After only 10 - min ischemia followed by 24 - h reperfusion , BC6OTHER was significantly elevated by 13 - fold , whereas serum BC6OTHER (sCr) , blood BC6OTHER BC6OTHER , BC6ENTC - β - glucosaminidase ( BC6ENTG ) , and proteinuria levels did not change.	False
Here , we report the development and validation of two different assays for quantitative assessment of BC6ENTG ( BC6OTHER ) and compare the sensitivity of BC6OTHER relative to other standard markers in ischemia reperfusion and BC6ENTC (AA) - induced kidney injury in mice.	False
Here , we report the development and validation of two different assays for quantitative assessment of BC6OTHER ( BC6ENTG ) and compare the sensitivity of BC6OTHER relative to other standard markers in ischemia reperfusion and BC6ENTC (AA) - induced kidney injury in mice.	False
Here , we report the development and validation of two different assays for quantitative assessment of BC6OTHER ( BC6OTHER ) and compare the sensitivity of BC6ENTG relative to other standard markers in ischemia reperfusion and BC6ENTC (AA) - induced kidney injury in mice.	False
Toxicity of the flame - retardant BC6ENTC on brain mitochondria and neuronal progenitor striatal cells enhanced by a BC6ENTG - deficient background.	False
The BC6ENTG pathway generates inflammatory BC6ENTC , while the BC6OTHER pathway generates inflammatory BC6OTHER .	CPR:9
The BC6OTHER pathway generates inflammatory BC6ENTC , while the BC6ENTG pathway generates inflammatory BC6OTHER .	False
The BC6ENTG pathway generates inflammatory BC6OTHER , while the BC6OTHER pathway generates inflammatory BC6ENTC .	False
The BC6OTHER pathway generates inflammatory BC6OTHER , while the BC6ENTG pathway generates inflammatory BC6ENTC .	CPR:9
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6ENTC ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	CPR:4
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6ENTC ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	CPR:4
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	CPR:4
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6ENTC ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6ENTC ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6ENTC ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6ENTC , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6ENTC and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6ENTC ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6ENTC ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER .	CPR:4
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6ENTC ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER .	False
They included the BC6ENTG inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
They included the BC6OTHER inhibitor CHEM; the BC6ENTG inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6ENTG / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6ENTG inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6ENTG inhibitor BC6OTHER ; and the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC .	False
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC .	CPR:4
They included the BC6OTHER inhibitor CHEM; the BC6OTHER inhibitor BC6OTHER ; the mixed BC6OTHER / BC6OTHER inhibitor BC6OTHER ; the BC6OTHER ( BC6OTHER ) derivatives of BC6OTHER , BC6OTHER and BC6OTHER ; the BC6OTHER inhibitor BC6OTHER ; and the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC .	CPR:4
In contrast , in the presence of BC6ENTC UFH accelerated the inhibition of BC6ENTG by BC6OTHER 10 - fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and CHEM.	CPR:4
In contrast , in the presence of BC6ENTC UFH accelerated the inhibition of BC6OTHER by BC6ENTG 10 - fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and CHEM.	CPR:4
Thus our data suggest that the BC6ENTG preference of BC6ENTC observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.	CPR:4
The effects of BC6ENTC were compared with those of BC6OTHER , a nonselective BC6ENTG inhibitor.	CPR:4
The effects of BC6OTHER were compared with those of BC6ENTC , a nonselective BC6ENTG inhibitor.	CPR:4
METHODS: BC6ENTG inhibition was determined by measuring BC6ENTC ( BC6OTHER ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6OTHER and 75 mg BC6OTHER and at steady state (15 mg BC6OTHER daily and 150 mg BC6OTHER daily).	False
METHODS: BC6ENTG inhibition was determined by measuring BC6OTHER ( BC6ENTC ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6OTHER and 75 mg BC6OTHER and at steady state (15 mg BC6OTHER daily and 150 mg BC6OTHER daily).	False
METHODS: BC6ENTG inhibition was determined by measuring BC6OTHER ( BC6OTHER ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6ENTC and 75 mg BC6OTHER and at steady state (15 mg BC6OTHER daily and 150 mg BC6OTHER daily).	CPR:4
METHODS: BC6ENTG inhibition was determined by measuring BC6OTHER ( BC6OTHER ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6OTHER and 75 mg BC6ENTC and at steady state (15 mg BC6OTHER daily and 150 mg BC6OTHER daily).	CPR:4
METHODS: BC6ENTG inhibition was determined by measuring BC6OTHER ( BC6OTHER ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6OTHER and 75 mg BC6OTHER and at steady state (15 mg BC6ENTC daily and 150 mg BC6OTHER daily).	CPR:4
METHODS: BC6ENTG inhibition was determined by measuring BC6OTHER ( BC6OTHER ) - generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg BC6OTHER and 75 mg BC6OTHER and at steady state (15 mg BC6OTHER daily and 150 mg BC6ENTC daily).	CPR:4
OBJECTIVE: To evaluate the extent of BC6OTHER ( BC6OTHER ) inhibition by BC6ENTC , which has been reported to preferentially inhibit BC6ENTG ( BC6OTHER ).	CPR:4
OBJECTIVE: To evaluate the extent of BC6OTHER ( BC6OTHER ) inhibition by BC6ENTC , which has been reported to preferentially inhibit BC6OTHER ( BC6ENTG ).	CPR:4
OBJECTIVE: To evaluate the extent of BC6ENTG ( BC6OTHER ) inhibition by BC6ENTC , which has been reported to preferentially inhibit BC6OTHER ( BC6OTHER ).	CPR:4
OBJECTIVE: To evaluate the extent of BC6OTHER ( BC6ENTG ) inhibition by BC6ENTC , which has been reported to preferentially inhibit BC6OTHER ( BC6OTHER ).	CPR:4
 BC6ENTC is the first example of a marketed BC6OTHER inhibitor of the BC6OTHER class , and it is reported to be the most selective CHEM in vivo. However , the molecular basis of its BC6ENTG inhibition has not been completely defined.	False
 BC6ENTC is the first example of a marketed BC6ENTG inhibitor of the BC6OTHER class , and it is reported to be the most selective CHEM in vivo. However , the molecular basis of its BC6OTHER inhibition has not been completely defined.	CPR:4
The chemical identity and position of the substituents on the lower BC6ENTC ring were important in determining the potency and extent of BC6ENTG inhibition as well as BC6OTHER selectivity.	CPR:4
The chemical identity and position of the substituents on the lower BC6ENTC ring were important in determining the potency and extent of BC6OTHER inhibition as well as BC6ENTG selectivity.	False
Mutation of BC6ENTC - 530 to BC6OTHER or BC6ENTG BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of BC6ENTC - 530 to BC6OTHER or CHEM to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6ENTG and key BC6OTHER analogs.	False
Mutation of CHEM to BC6ENTC or BC6ENTG BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of CHEM to BC6ENTC or CHEM to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6ENTG and key BC6OTHER analogs.	False
Mutation of BC6ENTG or BC6ENTC - 349 to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of CHEM to BC6OTHER or BC6ENTC - 349 to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6ENTG and key BC6OTHER analogs.	False
Mutation of BC6ENTG or CHEM to BC6ENTC or BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of CHEM to BC6OTHER or CHEM to BC6ENTC or BC6OTHER abolished the potent inhibition observed with wild - type BC6ENTG and key BC6OTHER analogs.	False
Mutation of BC6ENTG or CHEM to BC6OTHER or BC6ENTC abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of CHEM to BC6OTHER or BC6ENTG BC6ENTC abolished the potent inhibition observed with wild - type BC6OTHER and key BC6OTHER analogs.	False
Mutation of CHEM to BC6OTHER or CHEM to BC6OTHER or BC6ENTC abolished the potent inhibition observed with wild - type BC6ENTG and key BC6OTHER analogs.	False
Mutation of BC6ENTG or CHEM to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6ENTC analogs.	False
Mutation of CHEM to BC6OTHER or BC6ENTG BC6OTHER abolished the potent inhibition observed with wild - type BC6OTHER and key BC6ENTC analogs.	False
Mutation of CHEM to BC6OTHER or CHEM to BC6OTHER or BC6OTHER abolished the potent inhibition observed with wild - type BC6ENTG and key BC6ENTC analogs.	CPR:4
Interestingly , a BC6ENTC - 349 to CHEM mutant was inhibited with equal potency to BC6ENTG with BC6OTHER - , BC6OTHER - , or BC6OTHER - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	False
Interestingly , a BC6ENTG mutant was inhibited with equal potency to BC6OTHER with BC6ENTC - , BC6OTHER - , or BC6OTHER - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6OTHER mutant was inhibited with equal potency to BC6ENTG with BC6ENTC - , BC6OTHER - , or BC6OTHER - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6ENTG mutant was inhibited with equal potency to BC6OTHER with BC6OTHER - , BC6ENTC - , or BC6OTHER - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6OTHER mutant was inhibited with equal potency to BC6ENTG with BC6OTHER - , BC6ENTC - , or BC6OTHER - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6ENTG mutant was inhibited with equal potency to BC6OTHER with BC6OTHER - , BC6OTHER - , or BC6ENTC - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6OTHER mutant was inhibited with equal potency to BC6ENTG with BC6OTHER - , BC6OTHER - , or BC6ENTC - substituted inhibitors and , in the case of BC6OTHER , actually showed an increase in potency.	CPR:4
Interestingly , a BC6ENTG mutant was inhibited with equal potency to BC6OTHER with BC6OTHER - , BC6OTHER - , or BC6OTHER - substituted inhibitors and , in the case of BC6ENTC , actually showed an increase in potency.	CPR:4
Interestingly , a BC6OTHER mutant was inhibited with equal potency to BC6ENTG with BC6OTHER - , BC6OTHER - , or BC6OTHER - substituted inhibitors and , in the case of BC6ENTC , actually showed an increase in potency.	CPR:4
Taken together with a recent crystal structure of a BC6ENTC - BC6ENTG complex , the kinetic analyses presented herein of the inhibition of mutant BC6OTHER by BC6OTHER allows the definition of the molecular basis of BC6OTHER inhibition.	False
Taken together with a recent crystal structure of a BC6ENTC - BC6OTHER complex , the kinetic analyses presented herein of the inhibition of mutant BC6ENTG by BC6OTHER allows the definition of the molecular basis of BC6OTHER inhibition.	False
Taken together with a recent crystal structure of a BC6ENTC - BC6OTHER complex , the kinetic analyses presented herein of the inhibition of mutant BC6OTHER by BC6OTHER allows the definition of the molecular basis of BC6ENTG inhibition.	False
Taken together with a recent crystal structure of a BC6OTHER - BC6ENTG complex , the kinetic analyses presented herein of the inhibition of mutant BC6OTHER by BC6ENTC allows the definition of the molecular basis of BC6OTHER inhibition.	False
Taken together with a recent crystal structure of a BC6OTHER - BC6OTHER complex , the kinetic analyses presented herein of the inhibition of mutant BC6ENTG by BC6ENTC allows the definition of the molecular basis of BC6OTHER inhibition.	CPR:4
Taken together with a recent crystal structure of a BC6OTHER - BC6OTHER complex , the kinetic analyses presented herein of the inhibition of mutant BC6OTHER by BC6ENTC allows the definition of the molecular basis of BC6ENTG inhibition.	False
Using standard assays , BC6ENTC was found to be a poor inhibitor of purified BC6ENTG and a relatively weak inhibitor of purified BC6OTHER .	CPR:4
Using standard assays , BC6ENTC was found to be a poor inhibitor of purified BC6OTHER and a relatively weak inhibitor of purified BC6ENTG .	CPR:4
Kinetic studies with BC6ENTC demonstrated that it was a time - dependent and slowly reversible inhibitor of BC6ENTG that exhibited at least two binding steps during inhibition.	CPR:4
 BC6OTHER is the first example of a marketed BC6OTHER inhibitor of the BC6ENTC class , and it is reported to be the most selective CHEM in vivo. However , the molecular basis of its BC6ENTG inhibition has not been completely defined.	False
 BC6OTHER is the first example of a marketed BC6ENTG inhibitor of the BC6ENTC class , and it is reported to be the most selective CHEM in vivo. However , the molecular basis of its BC6OTHER inhibition has not been completely defined.	CPR:4
Inhibition studies demonstrated that the BC6ENTC group on the BC6OTHER ring is required for BC6ENTG selectivity.	CPR:4
Inhibition studies demonstrated that the BC6OTHER group on the BC6ENTC ring is required for BC6ENTG selectivity.	CPR:4
Molecular determinants for the selective inhibition of BC6ENTG by BC6ENTC .	CPR:4
BC6ENTC was found to bind the BC6ENTG , which provides a plausible mechanism for QTc interval prolongation / arrhythmia.	False
Other QTc interval - prolonging / arrhythmic drugs that also bind to BC6ENTG provided an analogy for BC6ENTC causing QTc interval prolongation / arrhythmia via this mechanism.	False
Cytotoxicity assays demonstrated that BC6ENTC ( BC6OTHER ) and most of compounds 1 - 6 killed preferentially BC6ENTG - expressing CHO cells.	CPR:9
Cytotoxicity assays demonstrated that BC6OTHER ( BC6ENTC ) and most of compounds 1 - 6 killed preferentially BC6ENTG - expressing CHO cells.	CPR:9
BC6ENTC , 1 , and 3 were the most potent cytotoxic compounds , with BC6OTHER and 3 selectively killing BC6ENTG - expressing cells.	False
BC6OTHER , 1 , and 3 were the most potent cytotoxic compounds , with BC6ENTC and 3 selectively killing BC6ENTG - expressing cells.	CPR:9
Given that BC6ENTG is expressed in several cancers , BC6ENTC and some of the BC6OTHER derivatives studied might be promising lead compounds for the development of novel anticancer drugs.	False
Given that BC6ENTG is expressed in several cancers , BC6OTHER and some of the BC6ENTC derivatives studied might be promising lead compounds for the development of novel anticancer drugs.	False
BC6ENTC such as green tea BC6OTHER and BC6OTHER have been shown to modulate the function of some BC6ENTG .	False
BC6OTHER such as green tea BC6ENTC and BC6OTHER have been shown to modulate the function of some BC6ENTG .	False
BC6OTHER such as green tea BC6OTHER and BC6ENTC have been shown to modulate the function of some BC6ENTG .	False
In the present study , the extent to which six substituted BC6ENTC derivatives (1 - 6) affected the function of BC6ENTG and BC6OTHER was investigated.	False
In the present study , the extent to which six substituted BC6ENTC derivatives (1 - 6) affected the function of BC6OTHER and BC6ENTG was investigated.	False
Uptake of the radiolabeled model substrates BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6ENTG or BC6OTHER .	CPR:9
Uptake of the radiolabeled model substrates BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6OTHER or BC6ENTG .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6ENTG or BC6OTHER .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6OTHER or BC6ENTG .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6ENTG or BC6OTHER .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6OTHER or BC6ENTG .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6ENTG or BC6OTHER .	CPR:9
Uptake of the radiolabeled model substrates BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC ) was determined in the absence and presence of compounds 1 - 6 using Chinese hamster ovary (CHO) cells stably expressing either BC6OTHER or BC6ENTG .	CPR:9
Compound 6 stimulated BC6OTHER - mediated BC6ENTC uptake by increasing the apparent affinity of BC6ENTG for its substrate.	CPR:9
Compound 6 stimulated BC6ENTG - mediated BC6ENTC uptake by increasing the apparent affinity of BC6OTHER for its substrate.	CPR:9
Transport by BC6ENTG and BC6OTHER enhances the cytotoxicity of BC6OTHER and several BC6ENTC derivatives.	CPR:9
Transport by BC6OTHER and BC6ENTG enhances the cytotoxicity of BC6OTHER and several BC6ENTC derivatives.	CPR:9
Transport by BC6ENTG and BC6OTHER enhances the cytotoxicity of BC6ENTC and several BC6OTHER derivatives.	CPR:9
Transport by BC6OTHER and BC6ENTG enhances the cytotoxicity of BC6ENTC and several BC6OTHER derivatives.	CPR:9
BC6ENTC ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTG inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by BC6ENTG BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6ENTG (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6ENTG , and BC6OTHER .	False
BC6ENTC ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC (®) , AstraZeneca) is a once - daily oral BC6ENTG inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by BC6ENTG BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6ENTC (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6ENTG (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6ENTC (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6ENTG , and BC6OTHER .	False
BC6OTHER ( BC6ENTC (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6ENTG .	CPR:4
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTC kinase inhibitor that selectively inhibits signalling mediated by BC6ENTG BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTC kinase inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6ENTG (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTC kinase inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6ENTG , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTC kinase inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6OTHER kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6ENTG .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6ENTG inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6ENTC kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6ENTC kinase BC6ENTG (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6ENTC kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6ENTG , and BC6OTHER .	False
BC6OTHER ( BC6OTHER (®) , AstraZeneca) is a once - daily oral BC6OTHER inhibitor that selectively inhibits signalling mediated by growth - factor receptor BC6ENTC kinase BC6OTHER (constitutively activated in roughly 60 % of all MTCs) , BC6OTHER , and BC6ENTG .	False
In muscle and liver , BC6ENTC (10 ng / kg / day) induced increases in methylation and decreases in mRNA expression of BC6ENTG .	CPR:4
These results show that the robust effects of BC6ENTC on the mRNA expression of BC6ENTG , BC6OTHER and BC6OTHER genes in the sperm and of BC6OTHER in the muscle and liver are unrelated to changes in methylation in their respective genes.	False
These results show that the robust effects of BC6ENTC on the mRNA expression of BC6OTHER , BC6ENTG and BC6OTHER genes in the sperm and of BC6OTHER in the muscle and liver are unrelated to changes in methylation in their respective genes.	False
These results show that the robust effects of BC6ENTC on the mRNA expression of BC6OTHER , BC6OTHER and BC6ENTG genes in the sperm and of BC6OTHER in the muscle and liver are unrelated to changes in methylation in their respective genes.	False
These results show that the robust effects of BC6ENTC on the mRNA expression of BC6OTHER , BC6OTHER and BC6OTHER genes in the sperm and of BC6ENTG in the muscle and liver are unrelated to changes in methylation in their respective genes.	False
BACKGROUND: BC6ENTG ( BC6OTHER ) is the rate - limiting step in the BC6OTHER ( BC6ENTC ) biosynthetic pathway.	False
BACKGROUND: BC6OTHER ( BC6ENTG ) is the rate - limiting step in the BC6OTHER ( BC6ENTC ) biosynthetic pathway.	False
The BC6ENTG deletion was not associated with MI and did not significantly modify the association between adipose tissue BC6ENTC and the risk of MI.	False
CONCLUSIONS: The BC6ENTG deletion may prevent the conversion of BC6ENTC into BC6OTHER .	False
CONCLUSIONS: The BC6ENTG deletion may prevent the conversion of BC6OTHER into BC6ENTC .	False
OBJECTIVE: The aim was to test whether the common deletion [T / - ] in the promoter of BC6ENTG affects the BC6ENTC biosynthetic pathway and consequently modifies the effect of BC6OTHER ( BC6OTHER ) on myocardial infarction (MI).	CPR:9
OBJECTIVE: The aim was to test whether the common deletion [T / - ] in the promoter of BC6ENTG affects the BC6OTHER biosynthetic pathway and consequently modifies the effect of BC6ENTC ( BC6OTHER ) on myocardial infarction (MI).	CPR:9
OBJECTIVE: The aim was to test whether the common deletion [T / - ] in the promoter of BC6ENTG affects the BC6OTHER biosynthetic pathway and consequently modifies the effect of BC6OTHER ( BC6ENTC ) on myocardial infarction (MI).	CPR:9
BACKGROUND: BC6ENTG ( BC6OTHER ) is the rate - limiting step in the BC6ENTC ( BC6OTHER ) biosynthetic pathway.	False
BACKGROUND: BC6OTHER ( BC6ENTG ) is the rate - limiting step in the BC6ENTC ( BC6OTHER ) biosynthetic pathway.	False
 BC6ENTC , BC6ENTG gene polymorphism , and the risk of nonfatal myocardial infarction.	False
OBJECTIVE: BC6OTHER is an atypical antipsychotic drug that shows a higher affinity for BC6OTHER BC6ENTC (2) receptors compared with BC6ENTG in vitro.	False
OBJECTIVE: BC6ENTC is an atypical antipsychotic drug that shows a higher affinity for BC6OTHER BC6ENTG compared with BC6OTHER in vitro.	False
OBJECTIVE: BC6ENTC is an atypical antipsychotic drug that shows a higher affinity for BC6OTHER BC6OTHER compared with BC6ENTG in vitro.	False
CONCLUSIONS: These data affirm that BC6ENTC is similar to other novel antipsychotics in having greater BC6ENTG than BC6OTHER occupancy at therapeutic doses and suggest that the optimal effective dose of BC6OTHER is closer to 120 mg / day than to the lower doses suggested by previous PET studies.	False
CONCLUSIONS: These data affirm that BC6ENTC is similar to other novel antipsychotics in having greater BC6OTHER than BC6ENTG occupancy at therapeutic doses and suggest that the optimal effective dose of BC6OTHER is closer to 120 mg / day than to the lower doses suggested by previous PET studies.	False
CONCLUSIONS: These data affirm that BC6OTHER is similar to other novel antipsychotics in having greater BC6ENTG than BC6OTHER occupancy at therapeutic doses and suggest that the optimal effective dose of BC6ENTC is closer to 120 mg / day than to the lower doses suggested by previous PET studies.	False
CONCLUSIONS: These data affirm that BC6OTHER is similar to other novel antipsychotics in having greater BC6OTHER than BC6ENTG occupancy at therapeutic doses and suggest that the optimal effective dose of BC6ENTC is closer to 120 mg / day than to the lower doses suggested by previous PET studies.	False
OBJECTIVE: BC6OTHER is an atypical antipsychotic drug that shows a higher affinity for BC6OTHER BC6ENTG compared with BC6ENTC D(2) receptors in vitro.	False
The relatively high BC6ENTG occupancy , even at trough plasma levels , suggests that BC6ENTC is more similar to BC6OTHER and CHEM in receptor occupancy profile than to BC6OTHER and BC6OTHER .	False
The relatively high BC6ENTG occupancy , even at trough plasma levels , suggests that BC6OTHER is more similar to BC6ENTC and CHEM in receptor occupancy profile than to BC6OTHER and BC6OTHER .	False
The relatively high BC6ENTG occupancy , even at trough plasma levels , suggests that BC6OTHER is more similar to BC6OTHER and CHEM in receptor occupancy profile than to BC6ENTC and BC6OTHER .	False
The relatively high BC6ENTG occupancy , even at trough plasma levels , suggests that BC6OTHER is more similar to BC6OTHER and CHEM in receptor occupancy profile than to BC6OTHER and BC6ENTC .	False
METHOD: The authors conducted a PET study to evaluate BC6ENTG occupancy (using BC6ENTC ) and BC6OTHER occupancy (using BC6OTHER ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6OTHER , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6OTHER occupancy (using BC6ENTC ) and BC6ENTG occupancy (using BC6OTHER ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6OTHER , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6ENTG occupancy (using BC6OTHER ) and BC6ENTC (2) occupancy (using BC6OTHER ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6OTHER , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6ENTG occupancy (using BC6OTHER ) and BC6OTHER occupancy (using BC6ENTC ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6OTHER , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6OTHER occupancy (using BC6OTHER ) and BC6ENTG occupancy (using BC6ENTC ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6OTHER , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6ENTG occupancy (using BC6OTHER ) and BC6OTHER occupancy (using BC6OTHER ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6ENTC , which reflected the recommended dose range.	False
METHOD: The authors conducted a PET study to evaluate BC6OTHER occupancy (using BC6OTHER ) and BC6ENTG occupancy (using BC6OTHER ) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40 , 80 , 120 , or 160 mg / day of BC6ENTC , which reflected the recommended dose range.	False
RESULTS: The mean BC6ENTC (2) receptor occupancy was significantly higher than the mean BC6ENTG occupancy (mean=76% , SD=15% , and mean=56% , SD=18% , respectively).	False
OBJECTIVE: BC6OTHER is an atypical antipsychotic drug that shows a higher affinity for BC6ENTC BC6ENTG compared with BC6OTHER in vitro.	False
OBJECTIVE: BC6OTHER is an atypical antipsychotic drug that shows a higher affinity for BC6ENTC BC6OTHER compared with BC6ENTG in vitro.	False
The estimated plasma BC6ENTC concentration associated with 50% maximal BC6ENTG receptor occupancy was almost four times lower than that for BC6OTHER occupancy.	False
The estimated plasma BC6ENTC concentration associated with 50% maximal BC6OTHER receptor occupancy was almost four times lower than that for BC6ENTG occupancy.	False
A PET study of BC6ENTG occupancy in patients with schizophrenia treated with therapeutic doses of BC6ENTC .	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6ENTG producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6ENTG production partially and enhanced BC6OTHER expression and proliferation.	CPR:4
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6ENTG expression and proliferation.	CPR:3
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6ENTG production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6ENTG expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6ENTG producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6ENTG production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6ENTG expression and proliferation; 2) In high BC6OTHER producers BC6ENTC inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Anti - BC6ENTG and anti - BC6OTHER blocked the BC6ENTC - induced increase in proliferation.	False
Anti - BC6OTHER and anti - BC6ENTG blocked the BC6ENTC - induced increase in proliferation.	False
In conclusion , the production of BC6ENTG and BC6OTHER by T - cell clones (derived either from BAL or blood) was more sensitive to inhibition by BC6ENTC than that of BC6OTHER , which may account for the therapeutic effects of CHEM in patients with asthma.	CPR:4
In conclusion , the production of BC6OTHER and BC6ENTG by T - cell clones (derived either from BAL or blood) was more sensitive to inhibition by BC6ENTC than that of BC6OTHER , which may account for the therapeutic effects of CHEM in patients with asthma.	CPR:4
In conclusion , the production of BC6OTHER and BC6OTHER by T - cell clones (derived either from BAL or blood) was more sensitive to inhibition by BC6ENTC than that of BC6ENTG , which may account for the therapeutic effects of CHEM in patients with asthma.	CPR:4
The differential effects of BC6ENTC on the proliferation of high and low BC6ENTG producers in vitro may implicate a selective outgrowth of Th1 - like T cells in vivo in patients treated with BC6OTHER .	False
The differential effects of BC6OTHER on the proliferation of high and low BC6ENTG producers in vitro may implicate a selective outgrowth of Th1 - like T cells in vivo in patients treated with BC6ENTC .	False
In vitro studies with blood - derived T cells , however , show inhibition of all three BC6ENTG by BC6ENTC .	CPR:4
BC6ENTC ( BC6OTHER ) inhibited the anti - BC6ENTG - induced production of BC6OTHER , BC6OTHER and BC6OTHER in all 20 clones tested.	CPR:4
BC6ENTC ( BC6OTHER ) inhibited the anti - BC6OTHER - induced production of BC6ENTG , BC6OTHER and BC6OTHER in all 20 clones tested.	CPR:4
BC6ENTC ( BC6OTHER ) inhibited the anti - BC6OTHER - induced production of BC6OTHER , BC6ENTG and BC6OTHER in all 20 clones tested.	CPR:4
BC6ENTC ( BC6OTHER ) inhibited the anti - BC6OTHER - induced production of BC6OTHER , BC6OTHER and BC6ENTG in all 20 clones tested.	CPR:4
BC6OTHER ( BC6ENTC ) inhibited the anti - BC6ENTG - induced production of BC6OTHER , BC6OTHER and BC6OTHER in all 20 clones tested.	CPR:4
BC6OTHER ( BC6ENTC ) inhibited the anti - BC6OTHER - induced production of BC6ENTG , BC6OTHER and BC6OTHER in all 20 clones tested.	CPR:4
BC6OTHER ( BC6ENTC ) inhibited the anti - BC6OTHER - induced production of BC6OTHER , BC6ENTG and BC6OTHER in all 20 clones tested.	CPR:4
BC6OTHER ( BC6ENTC ) inhibited the anti - BC6OTHER - induced production of BC6OTHER , BC6OTHER and BC6ENTG in all 20 clones tested.	CPR:4
BC6ENTC therapy results in reduced mRNA expression of BC6ENTG ( BC6OTHER ) and BC6OTHER in cells from bronchoalveolar lavage (BAL) but not of BC6OTHER .	CPR:4
BC6ENTC therapy results in reduced mRNA expression of BC6OTHER ( BC6ENTG ) and BC6OTHER in cells from bronchoalveolar lavage (BAL) but not of BC6OTHER .	CPR:4
BC6ENTC therapy results in reduced mRNA expression of BC6OTHER ( BC6OTHER ) and BC6ENTG in cells from bronchoalveolar lavage (BAL) but not of BC6OTHER .	CPR:4
BC6ENTC therapy results in reduced mRNA expression of BC6OTHER ( BC6OTHER ) and BC6OTHER in cells from bronchoalveolar lavage (BAL) but not of BC6ENTG .	False
BC6ENTC enhanced the ratio BC6ENTG / BC6OTHER (mean + / - SEM: control , 28.7 + / - 17.6; with 10 - 7 M DEX , 55.0 + / - 27.5 , P<0.005).	CPR:3
BC6ENTC enhanced the ratio BC6OTHER / BC6ENTG (mean + / - SEM: control , 28.7 + / - 17.6; with 10 - 7 M DEX , 55.0 + / - 27.5 , P<0.005).	CPR:3
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6ENTG producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6ENTG production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6ENTG expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6ENTG production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6ENTG expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6ENTG producers BC6OTHER blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6ENTG production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6ENTC on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6OTHER blocked BC6OTHER production and decreased BC6ENTG expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6ENTG producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6ENTG production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6ENTG expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6ENTG production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6ENTG expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6ENTG producers BC6ENTC blocked BC6OTHER production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	False
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6ENTG production and decreased BC6OTHER expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	CPR:4
Interestingly , two categories of clones were distinguished based on the effects of BC6OTHER on BC6OTHER production and BC6OTHER expression and proliferation; 1) In low BC6OTHER producers BC6ENTC blocked BC6OTHER production and decreased BC6ENTG expression and proliferation; 2) In high BC6OTHER producers BC6OTHER inhibited BC6OTHER production partially and enhanced BC6OTHER expression and proliferation.	CPR:4
Recent studies highlight the capacity of BC6ENTC to bind BC6ENTG ( BC6OTHER ) and deliver it in high concentration to the ulcer.	False
Recent studies highlight the capacity of BC6ENTC to bind BC6OTHER ( BC6ENTG ) and deliver it in high concentration to the ulcer.	False
Additionally , experiments with the non - desensitizing site - directed mutant BC6ENTG ( BC6OTHER ) (Stern - Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the BC6OTHER binding site blocks desensitization of BC6ENTC receptors.	False
Additionally , experiments with the non - desensitizing site - directed mutant BC6OTHER ( BC6ENTG ) (Stern - Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the BC6OTHER binding site blocks desensitization of BC6ENTC receptors.	False
Neuron , 21 (1998) 907 - 918) further confirms that BC6ENTC enhances BC6ENTG responses by reducing desensitization , since CHEM's effects are reversed in this mutant.	CPR:3
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6ENTC produces a large potentiation of the BC6ENTG splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	CPR:3
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6ENTC produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTG function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTG BC6OTHER expressed in Xenopus oocytes has shown that BC6ENTC produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6ENTG expressed in Xenopus oocytes has shown that BC6ENTC produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
CHEM's effects on BC6ENTG desensitization are distinct from the effects of BC6ENTC on desensitization.	False
Specifically , BC6ENTC , which potentiates wild - type BC6ENTG , is ineffective on the non - desensitizing BC6OTHER ( BC6OTHER ) mutant , but has synergistic effects with BC6OTHER on wild - type receptors.	CPR:3
Specifically , BC6ENTC , which potentiates wild - type BC6OTHER , is ineffective on the non - desensitizing BC6ENTG ( BC6OTHER ) mutant , but has synergistic effects with BC6OTHER on wild - type receptors.	False
Specifically , BC6ENTC , which potentiates wild - type BC6OTHER , is ineffective on the non - desensitizing BC6OTHER ( BC6ENTG ) mutant , but has synergistic effects with BC6OTHER on wild - type receptors.	False
Specifically , BC6OTHER , which potentiates wild - type BC6ENTC receptors , is ineffective on the non - desensitizing BC6ENTG ( BC6OTHER ) mutant , but has synergistic effects with BC6OTHER on wild - type receptors.	False
Specifically , BC6OTHER , which potentiates wild - type BC6ENTC receptors , is ineffective on the non - desensitizing BC6OTHER ( BC6ENTG ) mutant , but has synergistic effects with BC6OTHER on wild - type receptors.	False
Specifically , BC6OTHER , which potentiates wild - type BC6ENTG , is ineffective on the non - desensitizing BC6OTHER ( BC6OTHER ) mutant , but has synergistic effects with BC6ENTC on wild - type receptors.	False
Specifically , BC6OTHER , which potentiates wild - type BC6OTHER , is ineffective on the non - desensitizing BC6ENTG ( BC6OTHER ) mutant , but has synergistic effects with BC6ENTC on wild - type receptors.	CPR:3
Specifically , BC6OTHER , which potentiates wild - type BC6OTHER , is ineffective on the non - desensitizing BC6OTHER ( BC6ENTG ) mutant , but has synergistic effects with BC6ENTC on wild - type receptors.	CPR:3
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6ENTG splice variant and suggested that BC6ENTC might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	CPR:3
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6ENTC might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTG function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTG BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6ENTC might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6ENTG expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6ENTC might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6ENTG splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6ENTC on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6ENTC on BC6ENTG function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTG BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6ENTC on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6ENTG expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6ENTC on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6ENTG splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTC receptor function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTG BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTC receptor function.	False
Analysis of splice variants and site - directed mutants of the BC6OTHER BC6ENTG expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTC receptor function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTC receptor BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6ENTG splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTC receptor BC6OTHER expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6ENTG function.	False
Analysis of splice variants and site - directed mutants of the BC6ENTC receptor BC6ENTG expressed in Xenopus oocytes has shown that BC6OTHER produces a large potentiation of the BC6OTHER splice variant and suggested that BC6OTHER might inhibit rapid desensitization , which is characteristic of this receptor (Karkanias , N. and Papke , R. , Subtype - specific effects of BC6OTHER on BC6OTHER function.	False
Science , 9(266) (1994) 1709 - 1713) greatly attenuates the BC6ENTC - induced potentiation of BC6ENTG .	CPR:3
Additionally , experiments with the non - desensitizing site - directed mutant BC6OTHER ( BC6OTHER ) (Stern - Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the BC6ENTC binding site blocks desensitization of BC6ENTG .	False
Additionally , experiments with the non - desensitizing site - directed mutant BC6ENTG ( BC6OTHER ) (Stern - Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the BC6ENTC binding site blocks desensitization of BC6OTHER .	False
Additionally , experiments with the non - desensitizing site - directed mutant BC6OTHER ( BC6ENTG ) (Stern - Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the BC6ENTC binding site blocks desensitization of BC6OTHER .	False
 BC6ENTC modulates desensitization of the BC6ENTG subtype BC6OTHER in Xenopus oocytes.	False
 BC6ENTC modulates desensitization of the BC6OTHER subtype BC6ENTG in Xenopus oocytes.	False
 BC6OTHER modulates desensitization of the BC6ENTC receptor subtype BC6ENTG in Xenopus oocytes.	False
The reduction of BC6ENTG expression levels was reversed by the proteasomal inhibitor BC6ENTC .	CPR:3
The present study investigated the role of BC6ENTC / calmodulin - dependent BC6OTHER protein kinase BC6ENTG in interacting and controlling BC6OTHER expression and function in mouse trigeminal ganglia.	False
The present study investigated the role of BC6ENTC / calmodulin - dependent BC6OTHER protein kinase BC6OTHER in interacting and controlling BC6ENTG expression and function in mouse trigeminal ganglia.	False
The present study investigated the role of CHEM / calmodulin - dependent BC6ENTC protein kinase BC6ENTG in interacting and controlling BC6OTHER expression and function in mouse trigeminal ganglia.	False
The present study investigated the role of CHEM / calmodulin - dependent BC6ENTC protein kinase BC6OTHER in interacting and controlling BC6ENTG expression and function in mouse trigeminal ganglia.	False
Recombinant BC6ENTG / BC6OTHER expression in HEK cells increased BC6ENTC phosphorylation of BC6OTHER receptors , typically associated with receptor upregulation.	False
Recombinant BC6OTHER / BC6ENTG expression in HEK cells increased BC6ENTC phosphorylation of BC6OTHER receptors , typically associated with receptor upregulation.	False
Recombinant BC6OTHER / BC6OTHER expression in HEK cells increased BC6ENTC phosphorylation of BC6ENTG receptors , typically associated with receptor upregulation.	False
Although generally highly specific for BC6ENTG , some ARBs , particularly BC6ENTC , are partial agonists at BC6OTHER .	CPR:6
Although generally highly specific for BC6OTHER , some ARBs , particularly BC6ENTC , are partial agonists at BC6ENTG .	CPR:5
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6ENTC of BC6OTHER 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6OTHER of BC6ENTC 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6ENTC of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6OTHER of BC6ENTC 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
They are homozygous for a point mutation at codon 307 ( BC6ENTG → BC6OTHER ) resulting in the substitution of BC6ENTC 307 by BC6OTHER .	False
They are homozygous for a point mutation at codon 307 ( BC6OTHER → BC6ENTG ) resulting in the substitution of BC6ENTC 307 by BC6OTHER .	False
They are homozygous for a point mutation at codon 307 ( BC6ENTG → BC6OTHER ) resulting in the substitution of CHEM 307 by BC6ENTC .	False
They are homozygous for a point mutation at codon 307 ( BC6OTHER → BC6ENTG ) resulting in the substitution of CHEM 307 by BC6ENTC .	False
The distance between δ BC6ENTC of BC6OTHER 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6ENTC 438 to ε BC6OTHER of BC6OTHER 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6ENTC of BC6OTHER 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
The distance between δ BC6OTHER of BC6OTHER 438 to ε BC6OTHER of BC6ENTC 325 and ε BC6OTHER of BC6OTHER 438 to γ BC6OTHER of BC6OTHER 198 were highly altered in BC6ENTG mutant than the wild and other three variants throughout the simulation.	False
BC6ENTC (DA) receptor transmission through either BC6ENTG or BC6OTHER - like subtypes is involved critically in the processing of emotional information within the medial prefrontal cortex (mPFC).	False
BC6ENTC (DA) receptor transmission through either BC6OTHER or BC6ENTG - like subtypes is involved critically in the processing of emotional information within the medial prefrontal cortex (mPFC).	False
Interestingly , both intra - PLC BC6ENTG mediated block of either fear - related or reward - related associative memories were dependent upon downstream BC6ENTC ( BC6OTHER ) signaling as both effects were rescued by co - administration of a BC6OTHER signaling inhibitor.	False
Interestingly , both intra - PLC BC6ENTG mediated block of either fear - related or reward - related associative memories were dependent upon downstream BC6OTHER ( BC6ENTC ) signaling as both effects were rescued by co - administration of a BC6OTHER signaling inhibitor.	False
Interestingly , both intra - PLC BC6ENTG mediated block of either fear - related or reward - related associative memories were dependent upon downstream BC6OTHER ( BC6OTHER ) signaling as both effects were rescued by co - administration of a BC6ENTC signaling inhibitor.	False
Furthermore , using an unbiased place conditioning procedure (CPP) , intra - PLC BC6ENTG activation blocks the spontaneous expression of an associative BC6ENTC (5 mg / kg; i.p.)	False
Supra - normal stimulation of BC6ENTG in the prelimbic cortex blocks behavioral expression of both aversive and rewarding associative memories through a BC6ENTC - dependent signaling pathway.	False
BC6ENTC ( BC6OTHER ) , a selective BC6ENTG antagonist , is a potent inhibitor of gastric acid secretion.	CPR:6
BC6OTHER ( BC6ENTC ) , a selective BC6ENTG antagonist , is a potent inhibitor of gastric acid secretion.	CPR:6
 Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of BC6ENTC , BC6OTHER and BC6ENTG , BC6OTHER was , respectively , 6.5 , 5 and 4.7 times as active as BC6OTHER by i.v. administration.	False
 Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of BC6OTHER , BC6ENTC and BC6ENTG , BC6OTHER was , respectively , 6.5 , 5 and 4.7 times as active as BC6OTHER by i.v. administration.	False
 Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of BC6OTHER , BC6OTHER and BC6ENTG , BC6ENTC was , respectively , 6.5 , 5 and 4.7 times as active as BC6OTHER by i.v. administration.	False
 Against acid secretion from the vagally innervated gastric fistula and Heidenhain pouch of dogs stimulated with submaximal doses of BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER was , respectively , 6.5 , 5 and 4.7 times as active as BC6ENTC by i.v. administration.	False
Actions of BC6ENTC , a selective BC6ENTG antagonist , on gastric acid secretion in dogs , rats and frogs.	CPR:6
Local LC BC6OTHER effect was abolished by LC presence of the BC6ENTG receptor antagonist BC6ENTC (1 μM) but not the BC6OTHER receptor antagonist BC6OTHER (1 μM).	CPR:6
Local LC BC6OTHER effect was abolished by LC presence of the BC6OTHER receptor antagonist BC6ENTC (1 μM) but not the BC6ENTG receptor antagonist BC6OTHER (1 μM).	False
Local LC BC6OTHER effect was abolished by LC presence of the BC6ENTG receptor antagonist BC6OTHER (1 μM) but not the BC6OTHER receptor antagonist BC6ENTC (1 μM).	False
Local LC BC6OTHER effect was abolished by LC presence of the BC6OTHER receptor antagonist BC6OTHER (1 μM) but not the BC6ENTG receptor antagonist BC6ENTC (1 μM).	CPR:6
CONCLUSIONS: The SSRI BC6ENTC modulates central noradrenergic neurotransmission by activation , through endogenous BC6OTHER , of BC6ENTG receptors expressed in the somatodendritic (LC) and terminal (PFC) areas , which subsequently promote an enhancement of local NA.	False
CONCLUSIONS: The SSRI BC6OTHER modulates central noradrenergic neurotransmission by activation , through endogenous BC6ENTC , of BC6ENTG receptors expressed in the somatodendritic (LC) and terminal (PFC) areas , which subsequently promote an enhancement of local NA.	False
In the local presence into the LC of the BC6ENTG antagonist BC6ENTC (1 μM) , systemic BC6OTHER increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).	CPR:6
In the local presence into the LC of the BC6ENTG antagonist BC6OTHER (1 μM) , systemic BC6ENTC increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).	False
Local LC BC6ENTC effect was abolished by LC presence of the BC6ENTG receptor antagonist BC6OTHER (1 μM) but not the BC6OTHER receptor antagonist BC6OTHER (1 μM).	False
Local LC BC6ENTC effect was abolished by LC presence of the BC6OTHER receptor antagonist BC6OTHER (1 μM) but not the BC6ENTG receptor antagonist BC6OTHER (1 μM).	False
Involvement of BC6ENTC BC6ENTG receptors in the modulation of noradrenergic transmission by BC6OTHER reuptake inhibitors: a microdialysis study in rat brain.	False
Involvement of BC6OTHER BC6ENTG receptors in the modulation of noradrenergic transmission by BC6ENTC reuptake inhibitors: a microdialysis study in rat brain.	False
Western blot analyses showed significant effects of BC6ENTC exposure on BC6ENTG , BC6OTHER , and BC6OTHER expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6OTHER exposure.	False
Western blot analyses showed significant effects of BC6ENTC exposure on BC6OTHER , BC6ENTG , and BC6OTHER expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6OTHER exposure.	False
Western blot analyses showed significant effects of BC6ENTC exposure on BC6OTHER , BC6OTHER , and BC6ENTG expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6OTHER exposure.	False
Western blot analyses showed significant effects of BC6OTHER exposure on BC6ENTG , BC6OTHER , and BC6OTHER expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6ENTC exposure.	False
Western blot analyses showed significant effects of BC6OTHER exposure on BC6OTHER , BC6ENTG , and BC6OTHER expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6ENTC exposure.	False
Western blot analyses showed significant effects of BC6OTHER exposure on BC6OTHER , BC6OTHER , and BC6ENTG expression , with effects often seen at the lowest level of exposure and modified by sex and developmental window of BC6ENTC exposure.	False
These data suggest potential epigenetic effects of developmental BC6ENTC exposure on DNA methylation mediated at least in part through dysregulation of BC6ENTG .	False
Since DNA methylation is regulated by BC6ENTG and BC6ENTC - binding proteins , this study assessed the extent to which developmental BC6OTHER exposure might affect expression of these proteins in the hippocampus.	False
Since DNA methylation is regulated by BC6ENTG and BC6OTHER , this study assessed the extent to which developmental BC6ENTC exposure might affect expression of these proteins in the hippocampus.	False
Since DNA methylation is regulated by BC6OTHER and BC6ENTG , this study assessed the extent to which developmental BC6ENTC exposure might affect expression of these proteins in the hippocampus.	False
Influence of developmental lead exposure on expression of BC6ENTG and BC6ENTC - binding proteins in hippocampus.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6ENTG , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6ENTG and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6ENTG ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6ENTG , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6ENTG , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6ENTG and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6ENTG ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6ENTG , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC - rich domain structure.	False
The noticeable characteristic that distinguished the different classes was their size (molecular weight) differences and domain structure: Class I (P - I) , the small BC6OTHER , have molecular masses of 20 - 30 kDa , contain only a BC6OTHER and the BC6OTHER ; Class II (P - II) , the medium size BC6OTHER , molecular masses of 30 - 60 kDa , contain the BC6OTHER , BC6OTHER and BC6OTHER ; Class III (P - III) , the large BC6OTHER , have molecular masses of 60 - 100 kDa , contain BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC - rich domain structure.	False
The active site of the BC6ENTG has a consensus BC6OTHER sequence and a BC6ENTC - turn.	False
The active site of the BC6OTHER has a consensus BC6ENTG sequence and a BC6ENTC - turn.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6ENTC oxidase ( BC6ENTG ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6ENTC oxidase ( BC6OTHER ) inhibitors , the present study examines the BC6ENTG inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6ENTG ( BC6OTHER ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6ENTC [ BC6OTHER ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6ENTG ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6ENTC [ BC6OTHER ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6OTHER ) inhibitors , the present study examines the BC6ENTG inhibitory properties of a series of BC6ENTC [ BC6OTHER ] analogues.	CPR:4
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6ENTG ( BC6OTHER ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6ENTC ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6ENTG ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6ENTC ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6OTHER ) inhibitors , the present study examines the BC6ENTG inhibitory properties of a series of BC6OTHER [ BC6ENTC ] analogues.	CPR:4
BC6ENTC is structurally related to BC6OTHER and BC6OTHER and it is demonstrated here that substitution at C6 of the BC6OTHER moiety yields compounds endowed with high binding affinities to both BC6ENTG isoforms.	False
BC6OTHER is structurally related to BC6ENTC and BC6OTHER and it is demonstrated here that substitution at C6 of the BC6OTHER moiety yields compounds endowed with high binding affinities to both BC6ENTG isoforms.	False
BC6OTHER is structurally related to BC6OTHER and BC6ENTC and it is demonstrated here that substitution at C6 of the BC6OTHER moiety yields compounds endowed with high binding affinities to both BC6ENTG isoforms.	False
BC6OTHER is structurally related to BC6OTHER and BC6OTHER and it is demonstrated here that substitution at C6 of the BC6ENTC moiety yields compounds endowed with high binding affinities to both BC6ENTG isoforms.	False
Based on recent reports that the small molecules , BC6ENTC and BC6OTHER , are suitable scaffolds for the design of high potency BC6ENTG ( BC6OTHER ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	CPR:4
Based on recent reports that the small molecules , BC6ENTC and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6ENTG ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	CPR:4
Based on recent reports that the small molecules , BC6ENTC and BC6OTHER , are suitable scaffolds for the design of high potency BC6OTHER ( BC6OTHER ) inhibitors , the present study examines the BC6ENTG inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	False
Based on recent reports that the small molecules , BC6OTHER and BC6ENTC , are suitable scaffolds for the design of high potency BC6ENTG ( BC6OTHER ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	CPR:4
Based on recent reports that the small molecules , BC6OTHER and BC6ENTC , are suitable scaffolds for the design of high potency BC6OTHER ( BC6ENTG ) inhibitors , the present study examines the BC6OTHER inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	CPR:4
Based on recent reports that the small molecules , BC6OTHER and BC6ENTC , are suitable scaffolds for the design of high potency BC6OTHER ( BC6OTHER ) inhibitors , the present study examines the BC6ENTG inhibitory properties of a series of BC6OTHER [ BC6OTHER ] analogues.	False
In most instances , C6 - substituted BC6ENTC exhibit BC6ENTG specific inhibition.	CPR:4
The results also show that the binding modes of representative BC6ENTC are reversible and competitive at both BC6ENTG isoforms.	CPR:4
Inhibition of BC6ENTG by BC6ENTC analogues.	CPR:4
BC6ENTC [ BC6OTHER , BC6OTHER ] is one of several cofactors of BC6ENTG ( BC6OTHER ).	False
BC6ENTC [ BC6OTHER , BC6OTHER ] is one of several cofactors of BC6OTHER ( BC6ENTG ).	False
BC6OTHER [ BC6OTHER , BC6OTHER ] is one of several cofactors of BC6ENTC synthases ( BC6ENTG ).	False
BC6ENTC derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	CPR:9
BC6ENTC derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6ENTC derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6ENTG , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTC reductase and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTC reductase and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6ENTG , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6ENTC hydroxylase: BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTC hydroxylase: BC6OTHER - and BC6OTHER inhibited BC6ENTG , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6ENTC - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6ENTC - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6ENTC - and BC6OTHER inhibited BC6ENTG , whereas BC6OTHER - and BC6OTHER had no effect.	CPR:4
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6ENTC inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6ENTC inhibited BC6OTHER , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6ENTC inhibited BC6ENTG , whereas BC6OTHER - and BC6OTHER had no effect.	CPR:4
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6ENTC hydroxylase , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6OTHER inhibited BC6ENTC hydroxylase , whereas BC6OTHER - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6ENTC - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6ENTC - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6ENTG , whereas BC6ENTC - and BC6OTHER had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6ENTG and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6ENTC had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6ENTG : BC6OTHER - and BC6OTHER inhibited BC6OTHER , whereas BC6OTHER - and BC6ENTC had no effect.	False
BC6OTHER derivatives were not oxidized to products serving as substrates for BC6OTHER and , depending on the substituent , were competitive inhibitors of BC6OTHER : BC6OTHER - and BC6OTHER inhibited BC6ENTG , whereas BC6OTHER - and BC6ENTC had no effect.	False
Our data demonstrate differences in the mechanism of stimulation of BC6ENTC hydroxylase and BC6ENTG by BC6OTHER .	False
Our data demonstrate differences in the mechanism of stimulation of BC6ENTG and BC6ENTC synthase by BC6OTHER .	False
Our data demonstrate differences in the mechanism of stimulation of BC6ENTG and BC6OTHER by BC6ENTC .	CPR:4
Our data demonstrate differences in the mechanism of stimulation of BC6OTHER and BC6ENTG by BC6ENTC .	False
Here we compared the action of BC6ENTC - substituted derivatives on recombinant BC6ENTG with their effects on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6ENTC - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6ENTC - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6ENTC - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6ENTC - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the well - studied classical BC6OTHER - dependent reactions.	False
They are compatible with a novel , non - classical , redox - active contribution of BC6ENTC to the catalysis of the BC6ENTG reaction.	False
BC6OTHER [ BC6ENTC , BC6OTHER ] is one of several cofactors of BC6ENTG ( BC6OTHER ).	False
BC6OTHER [ BC6ENTC , BC6OTHER ] is one of several cofactors of BC6OTHER ( BC6ENTG ).	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6ENTC synthase with their effects on BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6ENTC synthase with their effects on BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6ENTC synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6ENTC synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant BC6ENTG with their effects on BC6ENTC reductase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTC reductase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTC reductase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTC reductase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant BC6ENTG with their effects on BC6OTHER ( BC6OTHER ) and BC6ENTC hydroxylase ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTG ( BC6OTHER ) and BC6ENTC hydroxylase ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6ENTG ) and BC6ENTC hydroxylase ( BC6OTHER ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6ENTC hydroxylase ( BC6ENTG ) , the well - studied classical BC6OTHER - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant BC6ENTG with their effects on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6ENTC - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6ENTC - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the well - studied classical BC6ENTC - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the well - studied classical BC6ENTC - dependent reactions.	False
Here we compared the action of BC6OTHER - substituted derivatives on recombinant rat neuronal BC6OTHER synthase with their effects on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the well - studied classical BC6ENTC - dependent reactions.	False
Substitution at BC6ENTC occurs at a position critical to the redox cycle of the cofactor in BC6ENTG / BC6OTHER .	False
Substitution at BC6ENTC occurs at a position critical to the redox cycle of the cofactor in BC6OTHER / BC6ENTG .	False
BC6OTHER [ BC6OTHER , BC6ENTC ] is one of several cofactors of BC6ENTG ( BC6OTHER ).	False
BC6OTHER [ BC6OTHER , BC6ENTC ] is one of several cofactors of BC6OTHER ( BC6ENTG ).	False
Substitution at BC6OTHER occurs at a position critical to the redox cycle of the cofactor in BC6ENTC hydroxylase / BC6ENTG .	False
Substitution at BC6OTHER occurs at a position critical to the redox cycle of the cofactor in BC6ENTG / BC6ENTC reductase.	False
As compared with BC6ENTC , BC6OTHER bound with twice the capacity but stimulated BC6ENTG to a lesser extent.	False
As compared with BC6OTHER , BC6ENTC bound with twice the capacity but stimulated BC6ENTG to a lesser extent.	False
Contrasting effects of BC6OTHER derivatives on BC6OTHER , BC6ENTC reductase and BC6ENTG .	False
Contrasting effects of BC6OTHER derivatives on BC6ENTG , BC6ENTC reductase and BC6OTHER .	False
Contrasting effects of BC6OTHER derivatives on BC6OTHER , BC6ENTG and BC6ENTC synthase.	False
Contrasting effects of BC6OTHER derivatives on BC6ENTG , BC6OTHER and BC6ENTC synthase.	False
Contrasting effects of BC6ENTC derivatives on BC6OTHER , BC6ENTG and BC6OTHER .	False
Contrasting effects of BC6ENTC derivatives on BC6OTHER , BC6OTHER and BC6ENTG .	False
Contrasting effects of BC6ENTC derivatives on BC6ENTG , BC6OTHER and BC6OTHER .	False
Contrasting effects of BC6OTHER derivatives on BC6ENTC hydroxylase , BC6ENTG and BC6OTHER .	False
Contrasting effects of BC6OTHER derivatives on BC6ENTC hydroxylase , BC6OTHER and BC6ENTG .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6ENTG , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6ENTG that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6ENTG signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6ENTG ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6ENTG ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6ENTG signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6ENTG signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6ENTG signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6ENTG ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6ENTG and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6ENTG ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6ENTG signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6ENTG , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6ENTG , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6ENTG , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6ENTG target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6ENTC .	False
Thus , the BC6ENTC - induced reduction in canonical BC6ENTG signaling is associated with a decrease in activators ( BC6OTHER and BC6OTHER ) rather than an increase in inhibitors ( BC6OTHER and BC6OTHER ) of the pathway.	CPR:4
Thus , the BC6ENTC - induced reduction in canonical BC6OTHER signaling is associated with a decrease in activators ( BC6ENTG and BC6OTHER ) rather than an increase in inhibitors ( BC6OTHER and BC6OTHER ) of the pathway.	CPR:4
Thus , the BC6ENTC - induced reduction in canonical BC6OTHER signaling is associated with a decrease in activators ( BC6OTHER and BC6ENTG ) rather than an increase in inhibitors ( BC6OTHER and BC6OTHER ) of the pathway.	CPR:4
Thus , the BC6ENTC - induced reduction in canonical BC6OTHER signaling is associated with a decrease in activators ( BC6OTHER and BC6OTHER ) rather than an increase in inhibitors ( BC6ENTG and BC6OTHER ) of the pathway.	CPR:4
Thus , the BC6ENTC - induced reduction in canonical BC6OTHER signaling is associated with a decrease in activators ( BC6OTHER and BC6OTHER ) rather than an increase in inhibitors ( BC6OTHER and BC6ENTG ) of the pathway.	CPR:4
This study focuses on determining whether treatment of BC6ENTC - exposed UGS organ cultures with BC6ENTG and / or BC6OTHER is capable of rescuing the inhibitory effects of BC6OTHER on canonical BC6OTHER signaling and prostatic bud formation.	False
This study focuses on determining whether treatment of BC6ENTC - exposed UGS organ cultures with BC6OTHER and / or BC6ENTG is capable of rescuing the inhibitory effects of BC6OTHER on canonical BC6OTHER signaling and prostatic bud formation.	False
This study focuses on determining whether treatment of BC6ENTC - exposed UGS organ cultures with BC6OTHER and / or BC6OTHER is capable of rescuing the inhibitory effects of BC6OTHER on canonical BC6ENTG signaling and prostatic bud formation.	False
This study focuses on determining whether treatment of BC6OTHER - exposed UGS organ cultures with BC6ENTG and / or BC6OTHER is capable of rescuing the inhibitory effects of BC6ENTC on canonical BC6OTHER signaling and prostatic bud formation.	False
This study focuses on determining whether treatment of BC6OTHER - exposed UGS organ cultures with BC6OTHER and / or BC6ENTG is capable of rescuing the inhibitory effects of BC6ENTC on canonical BC6OTHER signaling and prostatic bud formation.	False
This study focuses on determining whether treatment of BC6OTHER - exposed UGS organ cultures with BC6OTHER and / or BC6OTHER is capable of rescuing the inhibitory effects of BC6ENTC on canonical BC6ENTG signaling and prostatic bud formation.	CPR:4
We discovered that each BC6ENTG alone or in combination partially rescues BC6ENTC inhibition of both canonical BC6OTHER signaling and prostatic bud formation.	False
We discovered that each BC6OTHER alone or in combination partially rescues BC6ENTC inhibition of both canonical BC6ENTG signaling and prostatic bud formation.	CPR:4
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6ENTG , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6ENTG that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6ENTG signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6ENTG ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6ENTG ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6ENTG signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6ENTG signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6ENTG signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6ENTG ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6ENTG and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6ENTG ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6ENTG signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6ENTG , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6ENTG , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6ENTG , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6ENTC decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6ENTG target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6ENTG , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6ENTG that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6ENTG signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6ENTG ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6ENTG ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6ENTG signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6ENTG signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6ENTG signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6ENTG ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6ENTG and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6ENTG ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6ENTG signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6ENTG , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6ENTG , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6ENTG , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6ENTC on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6OTHER on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6ENTG target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6ENTG , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6ENTG that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6ENTG signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6ENTG ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6ENTG ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6ENTG signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6ENTG signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6ENTG signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6ENTG ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6ENTG and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6ENTG ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6ENTG signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6ENTG , BC6OTHER , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6ENTG , and BC6OTHER , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6ENTG , established canonical BC6OTHER target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	CPR:4
In support of the hypothesis that BC6OTHER decreases canonical BC6OTHER signaling , we identify inhibitory effects of BC6OTHER on multiple components of the canonical BC6OTHER signaling pathway in the UGS that temporally coincide with the inhibitory effect of BC6ENTC on prostatic bud formation: (1) expression of BC6OTHER ( BC6OTHER and BC6OTHER ) that promote canonical BC6OTHER signaling is reduced; (2) expression of BC6OTHER , BC6OTHER , and BC6OTHER , established canonical BC6ENTG target genes , is decreased; (3) expression of BC6OTHER , a BC6OTHER that activates canonical BC6OTHER signaling , is reduced; and (4) expression of BC6OTHER ( BC6OTHER ) , inhibitors of canonical BC6OTHER signaling , is not increased by BC6OTHER .	False
 BC6ENTC inhibition of canonical BC6ENTG signaling disrupts prostatic bud formation in mouse urogenital sinus.	CPR:4
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6ENTG oncoprotein that is flanked by BC6ENTC residues - was executed in order to determine its pharmacophore.	False
A structure - activity relationship (SAR) study of the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6ENTC residues - was executed in order to determine its pharmacophore.	False
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6ENTC residues - was executed in order to determine its pharmacophore.	False
Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the BC6ENTG - BC6OTHER heterodimer , BC6ENTC demonstrated excellent selectivity over BC6OTHER - BC6OTHER homodimers , with no apparent effect at 100 μM.	False
Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the BC6OTHER - BC6ENTG heterodimer , BC6ENTC demonstrated excellent selectivity over BC6OTHER - BC6OTHER homodimers , with no apparent effect at 100 μM.	False
Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the BC6OTHER - BC6OTHER heterodimer , BC6ENTC demonstrated excellent selectivity over BC6ENTG - BC6OTHER homodimers , with no apparent effect at 100 μM.	False
Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the BC6OTHER - BC6OTHER heterodimer , BC6ENTC demonstrated excellent selectivity over BC6OTHER - BC6ENTG homodimers , with no apparent effect at 100 μM.	False
Importantly , the CHEM of BC6ENTC improves the physicochemical properties of the lead compound , which will facilitate the incorporation of additional hydrophobicity that might enhance BC6ENTG inhibitory activity further still.	CPR:4
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6OTHER ) inhibitor BC6ENTC ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6ENTG oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	False
A structure - activity relationship (SAR) study of the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	CPR:4
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC ( BC6OTHER , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	CPR:4
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6OTHER ) inhibitor BC6OTHER ( BC6ENTC , 1) - which targets a hydrophobic domain of the BC6ENTG oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	False
A structure - activity relationship (SAR) study of the BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER ( BC6ENTC , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	CPR:4
A structure - activity relationship (SAR) study of the BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER ( BC6ENTC , 1) - which targets a hydrophobic domain of the BC6OTHER oncoprotein that is flanked by BC6OTHER residues - was executed in order to determine its pharmacophore.	CPR:4
Pharmacophore identification of BC6ENTG inhibitor BC6ENTC .	CPR:4
BC6ENTC also caused the phosphorylation of BC6ENTG and BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC also caused the phosphorylation of BC6OTHER and BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC also caused the phosphorylation of BC6OTHER and BC6OTHER ( BC6ENTG ).	CPR:3
In rats exposed to BC6ENTC , apoptosis was also observed in brain , as shown by the detection of cleaved BC6ENTG and BC6OTHER proteins and increased TUNEL positive staining.	False
In rats exposed to BC6ENTC , apoptosis was also observed in brain , as shown by the detection of cleaved BC6OTHER and BC6ENTG proteins and increased TUNEL positive staining.	False
PC12 cell apoptosis induced by BC6ENTC was confirmed by annexin V / BC6OTHER staining , and characterized by cleavage of BC6ENTG and BC6OTHER proteins.	False
PC12 cell apoptosis induced by BC6ENTC was confirmed by annexin V / BC6OTHER staining , and characterized by cleavage of BC6OTHER and BC6ENTG proteins.	False
PC12 cell apoptosis induced by BC6OTHER was confirmed by annexin V / BC6ENTC staining , and characterized by cleavage of BC6ENTG and BC6OTHER proteins.	False
PC12 cell apoptosis induced by BC6OTHER was confirmed by annexin V / BC6ENTC staining , and characterized by cleavage of BC6OTHER and BC6ENTG proteins.	False
BC6ENTC induced the release of BC6ENTG from the mitochondria to the cytosol and the generation of reactive BC6OTHER species.	False
BC6OTHER induced the release of BC6ENTG from the mitochondria to the cytosol and the generation of reactive BC6ENTC species.	False
BC6ENTC up - regulated the expression of BC6OTHER , down - regulated the expression of BC6OTHER , and significantly increased the ratio of BC6ENTG / BC6OTHER .	CPR:3
BC6ENTC up - regulated the expression of BC6OTHER , down - regulated the expression of BC6OTHER , and significantly increased the ratio of BC6OTHER / BC6ENTG .	CPR:3
BC6ENTC up - regulated the expression of BC6ENTG , down - regulated the expression of BC6OTHER , and significantly increased the ratio of BC6OTHER / BC6OTHER .	CPR:3
BC6ENTC up - regulated the expression of BC6OTHER , down - regulated the expression of BC6ENTG , and significantly increased the ratio of BC6OTHER / BC6OTHER .	CPR:4
BC6ENTG stimulated BC6ENTC incorporation in these end buds in the absence and presence of BC6OTHER .	False
BC6OTHER stimulated BC6ENTC incorporation in these end buds in the absence and presence of BC6ENTG .	False
The twigs of Cudrania tricuspidata were found to show strong BC6ENTG inhibitory activity , and further detailed component analysis resulted in the isolation of a new BC6ENTC , BC6OTHER (1) , plus twenty - seven known compounds (2 - 28).	False
The twigs of Cudrania tricuspidata were found to show strong BC6ENTG inhibitory activity , and further detailed component analysis resulted in the isolation of a new BC6OTHER , BC6ENTC (1) , plus twenty - seven known compounds (2 - 28).	False
Among the isolated compounds , BC6ENTC (8) , BC6OTHER (9) , and BC6OTHER (12) were found to exhibit significant BC6ENTG inhibition activities.	CPR:4
Among the isolated compounds , BC6OTHER (8) , BC6ENTC (9) , and BC6OTHER (12) were found to exhibit significant BC6ENTG inhibition activities.	CPR:4
Among the isolated compounds , BC6OTHER (8) , BC6OTHER (9) , and BC6ENTC (12) were found to exhibit significant BC6ENTG inhibition activities.	CPR:4
The immunosuppressive effects of T3 SCI were caused by BC6ENTC acting at BC6ENTG ( BC6OTHER ) and could be reversed using BC6OTHER blockers.	False
The immunosuppressive effects of T3 SCI were caused by BC6ENTC acting at BC6OTHER ( BC6ENTG ) and could be reversed using BC6OTHER blockers.	False
The immunosuppressive effects of T3 SCI were caused by BC6ENTC acting at BC6OTHER ( BC6OTHER ) and could be reversed using BC6ENTG blockers.	False
The up - regulation of BC6OTHER biosynthesis gene expression and BC6ENTG mRNA observed in non - treated grape is not enhanced in BC6ENTC - treated grapes , which presented low total decay.	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTG ( BC6OTHER ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6ENTC biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6ENTG ).	CPR:9
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTC BC6OTHER - lyase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTC BC6OTHER - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTC BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTC BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTG ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTC BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6ENTG ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6ENTC - lyase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6ENTC - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6ENTC - lyase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6ENTC - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTG ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6ENTC - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6ENTG ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTG ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6ENTG ) and BC6ENTC synthase ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6ENTC synthase ( BC6ENTG ) , and an antioxidant enzyme such as BC6OTHER ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTG ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) , and an antioxidant enzyme such as BC6OTHER ( BC6ENTG ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTC peroxidase ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTC peroxidase ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTC peroxidase ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and an antioxidant enzyme such as BC6ENTC peroxidase ( BC6OTHER ).	False
We isolated partial cDNAs that codified for enzymes implicated in the BC6OTHER biosynthesis such as l - CHEM BC6OTHER - lyase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and an antioxidant enzyme such as BC6ENTC peroxidase ( BC6ENTG ).	False
The up - regulation of BC6ENTC biosynthesis gene expression and BC6ENTG mRNA observed in non - treated grape is not enhanced in BC6OTHER - treated grapes , which presented low total decay.	False
Correlation between activation of BC6ENTG and BC6OTHER downregulation in a mouse adipocyte cell line by a series of BC6ENTC .	CPR:3
Correlation between activation of BC6OTHER and BC6ENTG downregulation in a mouse adipocyte cell line by a series of BC6ENTC .	CPR:4
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6ENTC (pKB = 8.40 + / - 0.09) were too low to account for BC6ENTG - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6ENTC (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6ENTG involvement.	False
The potency of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6ENTC (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6ENTC (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6ENTG agonist BC6ENTC (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	CPR:5
Selective protection of a putative BC6ENTG population against the irreversible action of BC6ENTC also failed to increase the potency of BC6OTHER (pA2 = 8.25 + / - 0.06 against A61603).	False
Selective protection of a putative BC6ENTG population against the irreversible action of BC6OTHER also failed to increase the potency of BC6ENTC (pA2 = 8.25 + / - 0.06 against A61603).	False
Combined concentration - ratio analysis demonstrated that BC6ENTC , which does not discriminate between BC6ENTG - and BC6OTHER , and BC6OTHER competed for binding at the same site in the SMA.	False
Combined concentration - ratio analysis demonstrated that BC6ENTC , which does not discriminate between BC6OTHER - and BC6ENTG , and BC6OTHER competed for binding at the same site in the SMA.	False
Combined concentration - ratio analysis demonstrated that BC6OTHER , which does not discriminate between BC6ENTG - and BC6OTHER , and BC6ENTC competed for binding at the same site in the SMA.	False
Combined concentration - ratio analysis demonstrated that BC6OTHER , which does not discriminate between BC6OTHER - and BC6ENTG , and BC6ENTC competed for binding at the same site in the SMA.	False
In summary , data obtained in our experiments in rat SMA indicate that the BC6ENTG mediating BC6ENTC - induced contraction displays a distinct BC6OTHER pharmacology.	False
In summary , data obtained in our experiments in rat SMA indicate that the BC6OTHER mediating BC6ENTC - induced contraction displays a distinct BC6ENTG pharmacology.	False
BC6ENTC antagonized all agonists with a low potency (pA2: 8.29 - 8.80) indicating the involvement of BC6ENTG - rather than BC6OTHER .	False
BC6ENTC antagonized all agonists with a low potency (pA2: 8.29 - 8.80) indicating the involvement of BC6OTHER - rather than BC6ENTG .	False
The putative BC6ENTG antagonist BC6ENTC , but not the BC6OTHER antagonist BC6OTHER (10 microM) antagonized BC6OTHER - induced contractions of SMA.	CPR:6
The putative BC6OTHER antagonist BC6ENTC , but not the BC6ENTG antagonist BC6OTHER (10 microM) antagonized BC6OTHER - induced contractions of SMA.	False
The putative BC6ENTG antagonist BC6OTHER , but not the BC6OTHER antagonist BC6ENTC (10 microM) antagonized BC6OTHER - induced contractions of SMA.	False
The putative BC6OTHER antagonist BC6OTHER , but not the BC6ENTG antagonist BC6ENTC (10 microM) antagonized BC6OTHER - induced contractions of SMA.	CPR:6
The putative BC6ENTG antagonist BC6OTHER , but not the BC6OTHER antagonist BC6OTHER (10 microM) antagonized BC6ENTC - induced contractions of SMA.	False
The putative BC6OTHER antagonist BC6OTHER , but not the BC6ENTG antagonist BC6OTHER (10 microM) antagonized BC6ENTC - induced contractions of SMA.	False
The potency of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6ENTG - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6ENTG involvement.	False
The potency of the selective BC6ENTG antagonist BC6ENTC against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	CPR:6
The potency of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6ENTG agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6ENTG - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6ENTG involvement.	False
The potency of the selective BC6ENTG antagonist BC6OTHER against BC6ENTC (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pA2 = 6.16 + / - 0.13) and of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6ENTG agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
To illuminate the controversy on BC6OTHER - or BC6OTHER involvement in BC6ENTC - mediated contractions of rat small mesenteric artery (SMA) , we have studied the effects of subtype - selective BC6ENTG agonists and antagonists under different experimental conditions.	False
To illuminate the controversy on BC6ENTG - or BC6OTHER involvement in BC6ENTC - mediated contractions of rat small mesenteric artery (SMA) , we have studied the effects of subtype - selective BC6OTHER agonists and antagonists under different experimental conditions.	False
To illuminate the controversy on BC6OTHER - or BC6ENTG involvement in BC6ENTC - mediated contractions of rat small mesenteric artery (SMA) , we have studied the effects of subtype - selective BC6OTHER agonists and antagonists under different experimental conditions.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6ENTG - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6ENTG involvement.	False
The potency of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6ENTG antagonist BC6ENTC against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	CPR:6
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6ENTC against BC6OTHER (pKB = 8.35 + / - 0.10) and against the selective BC6ENTG agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6ENTG - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6ENTG involvement.	False
The potency of the selective BC6ENTG antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6ENTG antagonist BC6OTHER against BC6ENTC (pKB = 8.35 + / - 0.10) and against the selective BC6OTHER agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
The potency of the selective BC6OTHER antagonist BC6OTHER against BC6OTHER (pA2 = 6.16 + / - 0.13) and of the selective BC6OTHER antagonist BC6OTHER against BC6ENTC (pKB = 8.35 + / - 0.10) and against the selective BC6ENTG agonist BC6OTHER (pKB = 8.40 + / - 0.09) were too low to account for BC6OTHER - and BC6OTHER involvement.	False
Hypoxic and BC6ENTG - deficient cells use BC6OTHER to generate BC6OTHER and lipids through reductive carboxylation (RC) of BC6ENTC .	False
Hypoxic and BC6ENTG - deficient cells use BC6ENTC to generate BC6OTHER and lipids through reductive carboxylation (RC) of BC6OTHER .	False
BC6ENTG expression drastically reduced intracellular BC6ENTC levels.	False
Feeding BC6ENTG - deficient RCC cells with BC6ENTC or BC6OTHER or knocking down BC6OTHER and BC6OTHER restored BC6OTHER levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6ENTC or BC6OTHER or knocking down BC6ENTG and BC6OTHER restored BC6OTHER levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6ENTC or BC6OTHER or knocking down BC6OTHER and BC6ENTG restored BC6OTHER levels and suppressed RC.	False
Feeding BC6ENTG - deficient RCC cells with BC6OTHER or BC6ENTC or knocking down BC6OTHER and BC6OTHER restored BC6OTHER levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6OTHER or BC6ENTC or knocking down BC6ENTG and BC6OTHER restored BC6OTHER levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6OTHER or BC6ENTC or knocking down BC6OTHER and BC6ENTG restored BC6OTHER levels and suppressed RC.	False
Feeding BC6ENTG - deficient RCC cells with BC6OTHER or BC6OTHER or knocking down BC6OTHER and BC6OTHER restored BC6ENTC levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6OTHER or BC6OTHER or knocking down BC6ENTG and BC6OTHER restored BC6ENTC levels and suppressed RC.	False
Feeding BC6OTHER - deficient RCC cells with BC6OTHER or BC6OTHER or knocking down BC6OTHER and BC6ENTG restored BC6ENTC levels and suppressed RC.	False
Hypoxic and BC6ENTG - deficient cells use BC6OTHER to generate BC6ENTC and lipids through reductive carboxylation (RC) of BC6OTHER .	False
These data suggest that BC6ENTG - induced low intracellular BC6ENTC levels promote the reductive flux by mass action to maintain lipogenesis.	False
Using BC6ENTC , we demonstrated in vivo RC activity in BC6ENTG - deficient tumors growing as xenografts in mice.	False
Lastly , BC6ENTG rendered BC6OTHER - deficient cells sensitive to BC6ENTC deprivation in vitro , and systemic administration of BC6OTHER inhibitors suppressed the growth of RCC cells as mice xenografts.	False
Lastly , BC6OTHER rendered BC6ENTG - deficient cells sensitive to BC6ENTC deprivation in vitro , and systemic administration of BC6OTHER inhibitors suppressed the growth of RCC cells as mice xenografts.	False
Lastly , BC6OTHER rendered BC6OTHER - deficient cells sensitive to BC6ENTC deprivation in vitro , and systemic administration of BC6ENTG inhibitors suppressed the growth of RCC cells as mice xenografts.	False
In vivo BC6ENTG - mediated reductive carboxylation is regulated by BC6OTHER levels and sensitizes BC6OTHER - deficient cells to BC6ENTC deprivation.	False
In vivo BC6OTHER - mediated reductive carboxylation is regulated by BC6OTHER levels and sensitizes BC6ENTG - deficient cells to BC6ENTC deprivation.	False
In vivo BC6ENTG - mediated reductive carboxylation is regulated by BC6ENTC levels and sensitizes BC6OTHER - deficient cells to BC6OTHER deprivation.	False
In vivo BC6OTHER - mediated reductive carboxylation is regulated by BC6ENTC levels and sensitizes BC6ENTG - deficient cells to BC6OTHER deprivation.	False
BC6ENTG ( BC6OTHER )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6OTHER ( BC6ENTG )is a BC6OTHER - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER )is a BC6ENTG - containing protein and one of the binding partners for several trans - membrane BC6ENTC - kinase receptors , including BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Recent studies have reported that BC6OTHER , a BC6OTHER inhibitor that targets the intracellular BC6ENTC kinase BC6ENTG - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	False
Recent studies have reported that BC6OTHER , a BC6OTHER inhibitor that targets the intracellular BC6ENTC kinase BC6OTHER - BC6ENTG and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	False
Recent studies have reported that BC6OTHER , a BC6OTHER inhibitor that targets the intracellular BC6ENTC kinase BC6OTHER - BC6OTHER and the BC6ENTG , is an effective inhibitor of the BC6OTHER , BC6OTHER .	False
Recent studies have reported that BC6OTHER , a BC6OTHER inhibitor that targets the intracellular BC6ENTC kinase BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6ENTG , BC6OTHER .	False
Recent studies have reported that BC6OTHER , a BC6OTHER inhibitor that targets the intracellular BC6ENTC kinase BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6ENTG .	False
Recent studies have reported that BC6OTHER , a BC6ENTG inhibitor that targets the intracellular BC6ENTC kinase BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6ENTG .	CPR:4
BC6OTHER was also found to inhibit BC6ENTG - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6OTHER was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6ENTG - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6ENTC may affect mature osteoclasts through the inhibition of BC6OTHER .	False
Taken together , these results suggest that BC6ENTC could be of clinical value in treating diseases where bone destruction can occur due to excessive BC6ENTG production such as osteoporosis , inflammatory - and tumor - induced osteolysis.	False
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6ENTG BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	CPR:4
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6OTHER BC6ENTG - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	CPR:4
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6OTHER BC6OTHER - BC6ENTG and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	CPR:4
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6OTHER BC6OTHER - BC6OTHER and the BC6ENTG , is an effective inhibitor of the BC6OTHER , BC6OTHER .	CPR:4
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6OTHER BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6ENTG , BC6OTHER .	CPR:4
Recent studies have reported that BC6ENTC , a BC6OTHER inhibitor that targets the intracellular BC6OTHER BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6ENTG .	CPR:4
Recent studies have reported that BC6ENTC , a BC6ENTG inhibitor that targets the intracellular BC6OTHER BC6OTHER - BC6OTHER and the BC6OTHER , is an effective inhibitor of the BC6OTHER , BC6OTHER .	CPR:4
Given that BC6ENTG signalling through BC6OTHER plays an important role in osteoclast biology , we speculated that blocking such a pathway with BC6ENTC may modulate osteoclast activity.	CPR:4
Given that BC6OTHER signalling through BC6ENTG plays an important role in osteoclast biology , we speculated that blocking such a pathway with BC6ENTC may modulate osteoclast activity.	CPR:4
Our findings demonstrate that BC6ENTC dose - dependently stimulates osteoclast apoptosis , a phenomenon which is blocked by the BC6ENTG inhibitor Z - VAD - fmk.	False
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	False
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6ENTG .	False
BC6ENTC was also found to inhibit BC6ENTG - induced osteoclast survival as well as BC6OTHER - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	CPR:4
BC6ENTC was also found to inhibit BC6OTHER - induced osteoclast survival as well as BC6ENTG - induced osteoclast bone resorbing activity , but was without effect on BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - induced inhibition of osteoclasts apoptosis , further supporting the hypothesis that BC6OTHER may affect mature osteoclasts through the inhibition of BC6OTHER .	CPR:4
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6ENTC decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6ENTG , BC6OTHER and BC6OTHER which were decreased by BC6OTHER .	CPR:3
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6ENTC decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6OTHER , BC6OTHER and BC6ENTG which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6ENTC level and increased amount of BC6ENTG , BC6OTHER and BC6OTHER which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6ENTC level and increased amount of BC6OTHER , BC6OTHER and BC6ENTG which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6ENTC dismutase , BC6OTHER and BC6ENTG which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6ENTG , BC6ENTC and BC6OTHER which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6OTHER , BC6ENTC and BC6ENTG which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6ENTG , BC6OTHER and BC6ENTC peroxidase which were decreased by BC6OTHER .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6ENTG , BC6OTHER and BC6OTHER which were decreased by BC6ENTC .	False
Cotreatments of 5 , 10 and 20 µg / mL concentrations of CHEM with BC6OTHER decreased the frequencies of SCE and the BC6OTHER level and increased amount of BC6OTHER , BC6OTHER and BC6ENTG which were decreased by BC6ENTC .	CPR:4
These effects were fully counteracted by dietary BC6ENTC which inhibited ROS overproduction and CHEM consumption , rendered the reactive transcription of BC6OTHER - associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of BC6ENTG signalling molecule.	CPR:4
These effects were fully counteracted by dietary BC6OTHER which inhibited ROS overproduction and CHEM consumption , rendered the reactive transcription of BC6ENTC - associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of BC6ENTG signalling molecule.	False
In this study , we investigated the alterations of the redox balance induced by the lipid fraction of BC6ENTG in Caco - 2 intestinal cells , and the effects of BC6ENTC and BC6OTHER , two dietary BC6OTHER compounds.	False
In this study , we investigated the alterations of the redox balance induced by the lipid fraction of BC6ENTG in Caco - 2 intestinal cells , and the effects of BC6OTHER and BC6ENTC , two dietary BC6OTHER compounds.	False
In this study , we investigated the alterations of the redox balance induced by the lipid fraction of BC6ENTG in Caco - 2 intestinal cells , and the effects of BC6OTHER and BC6OTHER , two dietary BC6ENTC compounds.	False
We found that oxidized lipids extracted from BC6ENTG ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6ENTG ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6ENTG vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6ENTG vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTG , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6ENTG and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6ENTC and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTG .	False
We found that oxidized lipids extracted from BC6ENTG ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6ENTG ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6ENTG vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6ENTG vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTG , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6ENTG and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6ENTC production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTG .	False
We found that oxidized lipids extracted from BC6ENTG ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6ENTG ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6ENTG vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6ENTG vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6OTHER and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6ENTG and BC6OTHER .	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTC dismutase , BC6OTHER and BC6ENTG .	False
We found that oxidized lipids extracted from BC6ENTG ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTC peroxidase.	False
We found that oxidized lipids extracted from BC6OTHER ( BC6ENTG ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTC peroxidase.	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6ENTG vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTC peroxidase.	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6ENTG vs. control) , and by impairing the activities of BC6OTHER , BC6OTHER and BC6ENTC peroxidase.	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6ENTG , BC6OTHER and BC6ENTC peroxidase.	False
We found that oxidized lipids extracted from BC6OTHER ( BC6OTHER ) induced oxidative stress by determining , 6 h after treatment , ROS overproduction (about a 100% and a 43% increase of BC6OTHER and BC6OTHER production , respectively , P<.05: BC6OTHER vs. control) and , 12 h after treatment , CHEM depletion (about a 26% decrease , P<.05: BC6OTHER vs. control) , and by impairing the activities of BC6OTHER , BC6ENTG and BC6ENTC peroxidase.	False
In response to the induced oxidative stress , we observed significant overexpression of BC6ENTC peroxidase (6 h after treatment: P<.05) , BC6ENTG and BC6OTHER (12 h after treatment: P<.05).	False
In response to the induced oxidative stress , we observed significant overexpression of BC6ENTC peroxidase (6 h after treatment: P<.05) , BC6OTHER and BC6ENTG (12 h after treatment: P<.05).	False
In response to the induced oxidative stress , we observed significant overexpression of BC6ENTG (6 h after treatment: P<.05) , BC6ENTC reductase and BC6OTHER (12 h after treatment: P<.05).	False
In response to the induced oxidative stress , we observed significant overexpression of BC6OTHER (6 h after treatment: P<.05) , BC6ENTC reductase and BC6ENTG (12 h after treatment: P<.05).	False
In response to the induced oxidative stress , we observed significant overexpression of BC6ENTG (6 h after treatment: P<.05) , BC6OTHER and BC6ENTC synthetase (12 h after treatment: P<.05).	False
In response to the induced oxidative stress , we observed significant overexpression of BC6OTHER (6 h after treatment: P<.05) , BC6ENTG and BC6ENTC synthetase (12 h after treatment: P<.05).	False
Apoptosis induced by oxidized lipids is associated with up - regulation of BC6ENTG in intestinal Caco - 2 cells: protective effects of BC6ENTC compounds.	False
As is the case for the bovine BC6ENTC - BC6OTHER - neurophysin II ( BC6ENTG ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6ENTC - BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6ENTG precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6ENTC - BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6ENTG by a BC6OTHER sequence.	False
As is the case for the bovine BC6ENTC - BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTG sequence.	False
As is the case for the bovine BC6OTHER - BC6ENTC - neurophysin II ( BC6ENTG ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6ENTC - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6ENTG precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6ENTC - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6ENTG by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6ENTC - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTG sequence.	False
As is the case for the BC6ENTG BC6ENTC - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6ENTC - NpII) precursor , the signal sequence of the BC6ENTG precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6ENTC - NpII) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6ENTG by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6ENTC - NpII) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTG sequence.	False
As is the case for the BC6ENTG BC6OTHER - neurophysin II ( BC6ENTC - NpII) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6OTHER sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6ENTG ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTC sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6ENTG precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTC sequence.	False
As is the case for the bovine BC6OTHER - BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6ENTG by a BC6ENTC sequence.	False
As is the case for the BC6ENTG BC6OTHER - neurophysin II ( BC6OTHER ) precursor , the signal sequence of the BC6OTHER precursor is immediately followed by the CHEM hormone which is connected to BC6OTHER by a BC6ENTC sequence.	False
A striking feature of the CHEM sequence is the 197 - nucleotide long perfect homology with the BC6ENTC - NpII precursor mRNA sequence encoding the conserved middle part of BC6ENTG .	False
The CHEM hormone BC6ENTC - like BC6ENTG ( BC6OTHER ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6ENTC - like CHEM - BC6OTHER ( BC6ENTG ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6ENTG - like BC6ENTC - BC6OTHER ( BC6OTHER ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6OTHER - like BC6ENTC - BC6OTHER ( BC6ENTG ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6ENTG - like CHEM - BC6ENTC ( BC6OTHER ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6OTHER - like CHEM - BC6ENTC ( BC6ENTG ) is synthesized as part of a larger precursor polypeptide.	False
A protein of molecular weight (Mr) approximately 20 , 000 has been isolated from supraoptic nuclei of rat hypothalami which , after CHEM cleavage , released a BC6ENTG - like molecule of Mr approximately 10 , 000 and an oligopeptide related to BC6ENTC .	False
The CHEM hormone BC6ENTG - like CHEM - BC6OTHER ( BC6ENTC ) is synthesized as part of a larger precursor polypeptide.	False
The CHEM hormone BC6OTHER - like BC6ENTG ( BC6ENTC ) is synthesized as part of a larger precursor polypeptide.	False
Among the primary translation products a single polypeptide of Mr approximately 16 , 500 was shown to contain antigenic determinants recognized by specific antisera against BC6ENTG and BC6ENTC .	False
Here we report the BC6ENTC sequence of the BC6ENTG which was derived from sequence analysis of the cloned cDNA.	False
Deduced BC6ENTC sequence from the BC6ENTG cDNA.	False
The lysosomal inhibitor BC6ENTC significantly increased BC6ENTG accumulation in + / + cells , consistent with the hypothesis that higher lysosomal pH impairs BC6OTHER degradation , leading to a higher BC6OTHER / BC6OTHER ratio and consequently BC6OTHER inhibition.	CPR:3
The lysosomal inhibitor BC6ENTC significantly increased BC6OTHER accumulation in + / + cells , consistent with the hypothesis that higher lysosomal pH impairs BC6ENTG degradation , leading to a higher BC6OTHER / BC6OTHER ratio and consequently BC6OTHER inhibition.	False
The lysosomal inhibitor BC6ENTC significantly increased BC6OTHER accumulation in + / + cells , consistent with the hypothesis that higher lysosomal pH impairs BC6OTHER degradation , leading to a higher BC6ENTG / BC6OTHER ratio and consequently BC6OTHER inhibition.	False
The lysosomal inhibitor BC6ENTC significantly increased BC6OTHER accumulation in + / + cells , consistent with the hypothesis that higher lysosomal pH impairs BC6OTHER degradation , leading to a higher BC6OTHER / BC6ENTG ratio and consequently BC6OTHER inhibition.	False
The lysosomal inhibitor BC6ENTC significantly increased BC6OTHER accumulation in + / + cells , consistent with the hypothesis that higher lysosomal pH impairs BC6OTHER degradation , leading to a higher BC6OTHER / BC6OTHER ratio and consequently BC6ENTG inhibition.	False
Vacuolar BC6ENTC - ATPase ( BC6ENTG ) , a multisubunit enzyme located at the ruffled border and in lysosomes of osteoclasts , is necessary for bone resorption.	False
A series of BC6ENTC incorporating BC6OTHER moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6ENTG ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6ENTC incorporating BC6OTHER moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6ENTG , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6ENTC incorporating BC6OTHER moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6ENTG ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6ENTC incorporating BC6OTHER moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6ENTG .	CPR:4
A series of BC6OTHER incorporating BC6ENTC moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6ENTG ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6ENTC moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6ENTG , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6ENTC moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6ENTG ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6ENTC moieties ( BC6OTHER analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6ENTG .	CPR:4
A series of BC6OTHER incorporating BC6OTHER moieties ( BC6ENTC analogs) were assayed as inhibitors of the BC6ENTG ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6OTHER moieties ( BC6ENTC analogs) were assayed as inhibitors of the BC6OTHER ( BC6ENTG , BC6OTHER ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6OTHER moieties ( BC6ENTC analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6ENTG ) from Saccharomyces cerevisiae , BC6OTHER .	CPR:4
A series of BC6OTHER incorporating BC6OTHER moieties ( BC6ENTC analogs) were assayed as inhibitors of the BC6OTHER ( BC6OTHER , BC6OTHER ) from Saccharomyces cerevisiae , BC6ENTG .	CPR:4
BC6ENTC incorporating BC6OTHER moieties strongly inhibit BC6ENTG .	CPR:4
BC6OTHER incorporating BC6ENTC moieties strongly inhibit BC6ENTG .	CPR:4
In mammalian cells , BC6ENTC ( BC6OTHER ) is synthesized through the action of the endoplasmic reticulum enzymes , BC6ENTG , and the decarboxylation of PtdSer accounts for the majority of BC6OTHER ( BC6OTHER ) synthesis.	False
In mammalian cells , BC6OTHER ( BC6OTHER ) is synthesized through the action of the endoplasmic reticulum enzymes , BC6ENTG , and the decarboxylation of PtdSer accounts for the majority of BC6ENTC ( BC6OTHER ) synthesis.	False
In mammalian cells , BC6OTHER ( BC6OTHER ) is synthesized through the action of the endoplasmic reticulum enzymes , BC6ENTG , and the decarboxylation of PtdSer accounts for the majority of BC6OTHER ( BC6ENTC ) synthesis.	False
In mammalian cells , BC6OTHER ( BC6ENTC ) is synthesized through the action of the endoplasmic reticulum enzymes , BC6ENTG , and the decarboxylation of PtdSer accounts for the majority of BC6OTHER ( BC6OTHER ) synthesis.	False
Taken together , we conclude that the BC6ENTC series of compounds share a similar cellular mechanism that includes interaction with BC6ENTG in addition to the well - characterized target BC6OTHER .	False
Taken together , we conclude that the BC6ENTC series of compounds share a similar cellular mechanism that includes interaction with BC6OTHER in addition to the well - characterized target BC6ENTG .	False
We previously employed a chemical genomic strategy to identify a novel small molecule , BC6ENTC , as a likely inhibitor of the BC6ENTG targeting BC6OTHER , BC6OTHER .	CPR:4
We previously employed a chemical genomic strategy to identify a novel small molecule , BC6ENTC , as a likely inhibitor of the BC6OTHER targeting BC6ENTG , BC6OTHER .	CPR:4
We previously employed a chemical genomic strategy to identify a novel small molecule , BC6ENTC , as a likely inhibitor of the BC6OTHER targeting BC6OTHER , BC6ENTG .	CPR:4
Herein , we demonstrate that the antibacterial activity of BC6ENTC and the BC6OTHER compounds are similar; these activities are suppressed or sensitized in response to increases or decreases of BC6ENTG copy number , respectively.	False
Herein , we demonstrate that the antibacterial activity of BC6OTHER and the BC6ENTC compounds are similar; these activities are suppressed or sensitized in response to increases or decreases of BC6ENTG copy number , respectively.	False
We provide STD NMR data which confirms a physical interaction between BC6ENTG and the BC6ENTC degradation product of BC6OTHER , with a Kd of ~150 μM.	False
We provide STD NMR data which confirms a physical interaction between BC6ENTG and the BC6OTHER degradation product of BC6ENTC , with a Kd of ~150 μM.	False
Degradation of BC6ENTC and studies of the interaction of resulting BC6OTHER compounds with the BC6OTHER targeting BC6ENTG BC6OTHER .	False
Degradation of BC6ENTC and studies of the interaction of resulting BC6OTHER compounds with the BC6OTHER targeting BC6OTHER BC6ENTG .	False
Degradation of BC6ENTC and studies of the interaction of resulting BC6OTHER compounds with the BC6ENTG targeting BC6OTHER BC6OTHER .	False
Degradation of BC6OTHER and studies of the interaction of resulting BC6ENTC compounds with the BC6OTHER targeting BC6ENTG BC6OTHER .	False
Degradation of BC6OTHER and studies of the interaction of resulting BC6ENTC compounds with the BC6OTHER targeting BC6OTHER BC6ENTG .	False
Degradation of BC6OTHER and studies of the interaction of resulting BC6ENTC compounds with the BC6ENTG targeting BC6OTHER BC6OTHER .	False
BC6OTHER is a new , orally active , selective inhibitor of BC6ENTG BC6ENTC receptor.	False
BC6ENTC is a new , orally active , selective inhibitor of BC6ENTG BC6OTHER .	CPR:4
BC6ENTC is a new , orally active , selective inhibitor of BC6OTHER BC6ENTG .	CPR:4
Clinical effects of BC6ENTC , an oral BC6ENTG antagonist , in mild - to - moderate asthma: a 4 week randomized multicentre controlled trial.	CPR:6
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6ENTG , BC6OTHER converts into a BC6OTHER robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6ENTG converts into a BC6OTHER robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6OTHER converts into a BC6ENTG robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6OTHER converts into a BC6OTHER robustly activating BC6ENTG and its downstream pro - inflammatory targets BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6OTHER converts into a BC6OTHER robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6ENTG , BC6OTHER , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6OTHER converts into a BC6OTHER robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6OTHER , BC6ENTG , and inducible BC6ENTC synthase ( BC6OTHER ).	False
Specifically , by using human DLD1 colon epithelial / carcinoma cells we demonstrate that , upon BC6OTHER , BC6OTHER converts into a BC6OTHER robustly activating BC6OTHER and its downstream pro - inflammatory targets BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase ( BC6ENTG ).	False
Using the viral mimic BC6ENTC and the BC6OTHER antagonist B18R we furthermore demonstrate the capability of endogenous BC6ENTG to promote BC6OTHER - induced BC6OTHER activation and expression of BC6OTHER .	False
Using the viral mimic BC6ENTC and the BC6OTHER antagonist B18R we furthermore demonstrate the capability of endogenous BC6OTHER to promote BC6ENTG - induced BC6OTHER activation and expression of BC6OTHER .	False
Using the viral mimic BC6ENTC and the BC6OTHER antagonist B18R we furthermore demonstrate the capability of endogenous BC6OTHER to promote BC6OTHER - induced BC6ENTG activation and expression of BC6OTHER .	False
Using the viral mimic BC6ENTC and the BC6OTHER antagonist B18R we furthermore demonstrate the capability of endogenous BC6OTHER to promote BC6OTHER - induced BC6OTHER activation and expression of BC6ENTG .	False
Using the viral mimic BC6ENTC and the BC6ENTG antagonist B18R we furthermore demonstrate the capability of endogenous BC6OTHER to promote BC6OTHER - induced BC6OTHER activation and expression of BC6OTHER .	False
Mutation of a single BC6ENTC residue in the potential BC6ENTG increased the secretion efficiency of BC6OTHER by threefold.	False
Mutation of a single BC6ENTC residue in the potential BC6OTHER increased the secretion efficiency of BC6ENTG by threefold.	False
We propose that BC6ENTC binds the BC6ENTG in the BC6OTHER and provides the essential requirement for a stable interaction between the heavy and light chains.	False
We propose that BC6ENTC binds the type - 1 BC6OTHER ion - binding site in the BC6ENTG and provides the essential requirement for a stable interaction between the heavy and light chains.	False
We propose that BC6OTHER binds the type - 1 BC6ENTC ion - binding site in the BC6ENTG and provides the essential requirement for a stable interaction between the heavy and light chains.	False
The BC6ENTG and BC6OTHER interaction with BC6OTHER occurs primarily through BC6ENTC - terminal linked CHEM within the heavily glycosylated BC6OTHER and this interaction appears to be required for BC6OTHER secretion.	False
The BC6OTHER and BC6ENTG interaction with BC6OTHER occurs primarily through BC6ENTC - terminal linked CHEM within the heavily glycosylated BC6OTHER and this interaction appears to be required for BC6OTHER secretion.	False
The BC6OTHER and BC6OTHER interaction with BC6ENTG occurs primarily through BC6ENTC - terminal linked CHEM within the heavily glycosylated BC6OTHER and this interaction appears to be required for BC6OTHER secretion.	False
The BC6OTHER and BC6OTHER interaction with BC6OTHER occurs primarily through BC6ENTC - terminal linked CHEM within the heavily glycosylated BC6ENTG and this interaction appears to be required for BC6OTHER secretion.	False
The BC6OTHER and BC6OTHER interaction with BC6OTHER occurs primarily through BC6ENTC - terminal linked CHEM within the heavily glycosylated BC6OTHER and this interaction appears to be required for BC6ENTG secretion.	False
The observations suggest a unique requirement for BC6ENTC processing and BC6ENTG / BC6OTHER interaction that may limit the productive secretion of BC6OTHER and have implications for approaches towards somatic cell gene therapy for hemophilia A.	False
The observations suggest a unique requirement for BC6ENTC processing and BC6OTHER / BC6ENTG interaction that may limit the productive secretion of BC6OTHER and have implications for approaches towards somatic cell gene therapy for hemophilia A.	False
The observations suggest a unique requirement for BC6ENTC processing and BC6OTHER / BC6OTHER interaction that may limit the productive secretion of BC6ENTG and have implications for approaches towards somatic cell gene therapy for hemophilia A.	False
This study also provides insight into the anticancer effects of BC6ENTC and suggests that BC6ENTG may be a potential target of cancer therapy.	False
Here , we identified BC6ENTG antagonist killer 1 ( BC6OTHER ) as a molecular target of BC6ENTC - induced apoptosis.	False
Here , we identified BC6OTHER antagonist killer 1 ( BC6ENTG ) as a molecular target of BC6ENTC - induced apoptosis.	False
BC6ENTC directly interacts with BC6ENTG and induces mitochondrial - mediated apoptosis.	False
Although BC6ENTG and BC6OTHER ( BC6OTHER ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6OTHER ) release and cell death.	False
Although BC6OTHER and BC6ENTG ( BC6OTHER ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6OTHER ) release and cell death.	False
Although BC6OTHER and BC6OTHER ( BC6ENTG ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6OTHER ) release and cell death.	False
Although BC6OTHER and BC6OTHER ( BC6OTHER ) , another member of the BC6ENTG family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6OTHER ) release and cell death.	False
Although BC6OTHER and BC6OTHER ( BC6OTHER ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6ENTG is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6OTHER ) release and cell death.	False
Although BC6OTHER and BC6OTHER ( BC6OTHER ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6ENTG ( BC6OTHER ) release and cell death.	CPR:3
Although BC6OTHER and BC6OTHER ( BC6OTHER ) , another member of the BC6OTHER family , are generally thought to be functionally redundant , only BC6OTHER is necessary and sufficient for BC6ENTC - induced BC6OTHER ( BC6ENTG ) release and cell death.	CPR:3
Moreover , BC6ENTC , an intracellular metabolite of BC6OTHER , was shown to covalently bind to the BC6OTHER - 166 residue of BC6ENTG .	False
Moreover , BC6OTHER , an intracellular metabolite of BC6ENTC , was shown to covalently bind to the BC6OTHER - 166 residue of BC6ENTG .	False
Moreover , BC6OTHER , an intracellular metabolite of BC6OTHER , was shown to covalently bind to the BC6ENTC - 166 residue of BC6ENTG .	False
 BC6ENTC covalently binds to BC6ENTG and induces BC6OTHER - mediated apoptosis.	False
 BC6ENTC covalently binds to BC6OTHER and induces BC6ENTG - mediated apoptosis.	False
BC6ENTC dehydratase ( BC6ENTG ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6OTHER or BC6OTHER .	False
BC6ENTG ( BC6OTHER ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6ENTC and BC6OTHER to yield BC6OTHER or BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6ENTC and BC6OTHER to yield BC6OTHER or BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6ENTC to yield BC6OTHER or BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6ENTC to yield BC6OTHER or BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6ENTC or BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6ENTC or BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6OTHER or BC6ENTC .	CPR:9
BC6OTHER ( BC6ENTG ) , a member of the beta - family of BC6OTHER - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6OTHER or BC6ENTC .	CPR:9
The crystal structure of BC6ENTC dehydratase from human liver ( BC6ENTG ) has been solved at 2.5 A - resolution by molecular replacement.	False
BC6ENTG ( BC6OTHER ) , a member of the beta - family of BC6ENTC - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6OTHER or BC6OTHER .	False
BC6OTHER ( BC6ENTG ) , a member of the beta - family of BC6ENTC - dependent (CHEM) enzymes , catalyzes the deamination of BC6OTHER and BC6OTHER to yield BC6OTHER or BC6OTHER .	False
Comparison with the BC6ENTG - (CHEM - OMS) holo - enzyme reveals a large structural difference in active sites caused by the artifical BC6ENTC .	False
Crystal structure of the BC6ENTC - dependent BC6ENTG from human liver.	False
Enzymes encoded by the BC6ENTC BC6OTHER - tranferase mu 1 ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
Enzymes encoded by the BC6ENTC BC6OTHER - tranferase mu 1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
Enzymes encoded by the BC6ENTC BC6OTHER - tranferase mu 1 ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
Enzymes encoded by the CHEM BC6ENTC - tranferase mu 1 ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
Enzymes encoded by the CHEM BC6ENTC - tranferase mu 1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
Enzymes encoded by the CHEM BC6ENTC - tranferase mu 1 ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes , which are expressed in breast tissue , catalyze the detoxification of endogenous and exogenous electrophiles.	False
BC6ENTC represents the first in a novel class of BC6ENTG inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.	CPR:4
Inhibitors of the BC6ENTG - BC6ENTC system (RAS) have proven to be successful treatments for hypertension.	False
This led to the discovery of BC6ENTC , a highly potent and selective inhibitor of BC6ENTG in vitro , and in vivo; once - daily oral doses of BC6OTHER inhibit BC6OTHER and lower blood pressure in BC6OTHER - depleted marmosets and hypertensive human patients.	CPR:4
This led to the discovery of BC6ENTC , a highly potent and selective inhibitor of BC6OTHER in vitro , and in vivo; once - daily oral doses of BC6OTHER inhibit BC6ENTG and lower blood pressure in BC6OTHER - depleted marmosets and hypertensive human patients.	False
This led to the discovery of BC6OTHER , a highly potent and selective inhibitor of BC6ENTG in vitro , and in vivo; once - daily oral doses of BC6ENTC inhibit BC6OTHER and lower blood pressure in BC6OTHER - depleted marmosets and hypertensive human patients.	False
This led to the discovery of BC6OTHER , a highly potent and selective inhibitor of BC6OTHER in vitro , and in vivo; once - daily oral doses of BC6ENTC inhibit BC6ENTG and lower blood pressure in BC6OTHER - depleted marmosets and hypertensive human patients.	CPR:4
This led to the discovery of BC6OTHER , a highly potent and selective inhibitor of BC6ENTG in vitro , and in vivo; once - daily oral doses of BC6OTHER inhibit BC6OTHER and lower blood pressure in BC6ENTC - depleted marmosets and hypertensive human patients.	False
This led to the discovery of BC6OTHER , a highly potent and selective inhibitor of BC6OTHER in vitro , and in vivo; once - daily oral doses of BC6OTHER inhibit BC6ENTG and lower blood pressure in BC6ENTC - depleted marmosets and hypertensive human patients.	False
Structure - based design of BC6ENTC , a novel orally effective BC6ENTG inhibitor.	CPR:4
BC6ENTC ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6OTHER secretion by closing the BC6ENTG BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	CPR:4
BC6ENTC ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the CHEM - sensitive BC6OTHER ( BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	CPR:3
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6ENTC to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6ENTC to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the BC6ENTC - sensitive BC6OTHER ( BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6ENTC , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6ENTC , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6ENTC , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6ENTC , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6ENTC , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6ENTC , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6ENTC binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6ENTC binding site.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the CHEM - sensitive BC6ENTC ( BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6OTHER secretion by closing the BC6ENTG BC6ENTC ( BC6OTHER )) channels in pancreatic beta - cells.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the CHEM - sensitive BC6OTHER ( BC6ENTC ( BC6OTHER )) channels in pancreatic beta - cells.	False
The BC6ENTG responses to BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6OTHER secretion by closing the BC6ENTG BC6OTHER ( BC6ENTC )) channels in pancreatic beta - cells.	False
BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the CHEM - sensitive BC6OTHER ( BC6OTHER ( BC6ENTC )) channels in pancreatic beta - cells.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
BC6OTHER ( BC6ENTC ) , a new anti - diabetic drug , is thought to stimulate BC6OTHER secretion by closing the BC6ENTG BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	CPR:4
BC6OTHER ( BC6ENTC ) , a new anti - diabetic drug , is thought to stimulate BC6ENTG secretion by closing the CHEM - sensitive BC6OTHER ( BC6OTHER ( BC6OTHER )) channels in pancreatic beta - cells.	CPR:3
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6ENTC , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6ENTC , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6ENTC treatment were comparable to those after chronic BC6OTHER and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6ENTC and BC6OTHER treatment.	False
The BC6ENTG responses to BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER in MIN6 cells after chronic BC6OTHER , BC6OTHER , or BC6OTHER treatment were comparable to those after chronic BC6OTHER and BC6ENTC treatment.	False
These results indicate that , similar to the BC6ENTC , BC6OTHER is highly specific to the BC6ENTG / BC6OTHER complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6ENTC , BC6OTHER is highly specific to the BC6OTHER / BC6ENTG complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6ENTC , BC6OTHER is highly specific to the BC6OTHER / BC6OTHER complex , i.e. , the pancreatic beta - cell BC6ENTG , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6ENTC is highly specific to the BC6ENTG / BC6OTHER complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6ENTC is highly specific to the BC6OTHER / BC6ENTG complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6ENTC is highly specific to the BC6OTHER / BC6OTHER complex , i.e. , the pancreatic beta - cell BC6ENTG , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6ENTG / BC6OTHER complex , i.e. , the pancreatic beta - cell BC6ENTC ( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6OTHER / BC6ENTG complex , i.e. , the pancreatic beta - cell BC6ENTC ( BC6OTHER ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6ENTG / BC6OTHER complex , i.e. , the pancreatic beta - cell K( BC6ENTC ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6OTHER / BC6ENTG complex , i.e. , the pancreatic beta - cell K( BC6ENTC ) channel , and suggest that BC6OTHER may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6ENTG / BC6OTHER complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6ENTC may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6OTHER / BC6ENTG complex , i.e. , the pancreatic beta - cell K( BC6OTHER ) channel , and suggest that BC6ENTC may be a clinically useful anti - diabetic drug.	False
These results indicate that , similar to the BC6OTHER , BC6OTHER is highly specific to the BC6OTHER / BC6OTHER complex , i.e. , the pancreatic beta - cell BC6ENTG , and suggest that BC6ENTC may be a clinically useful anti - diabetic drug.	CPR:5
In this study , we examined the effects of BC6ENTC on various cloned BC6ENTG ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6ENTG / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6ENTG , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6ENTG / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6ENTG , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTG / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6ENTC on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6ENTG ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6ENTG / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6OTHER / BC6ENTG , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6ENTG / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6ENTG , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTG / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTC ( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6ENTG ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6ENTG / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6OTHER / BC6ENTG , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6OTHER / BC6OTHER , BC6ENTG / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6ENTG , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTG / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6ENTC ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6ENTG ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTG ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6ENTG / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6ENTG , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6ENTG / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6ENTG , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTG / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6ENTG ) reconstituted in COS - 1 cells , and compared them to another BC6ENTC - related compound , BC6OTHER .	False
In this study , we examined the effects of BC6OTHER on various cloned BC6ENTG ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6ENTG / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6ENTG , BC6OTHER / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6ENTG / BC6OTHER , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6ENTG , and BC6OTHER / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6ENTG / BC6OTHER ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
In this study , we examined the effects of BC6OTHER on various cloned K( BC6OTHER ) channels ( BC6OTHER / BC6OTHER , BC6OTHER / BC6OTHER , and BC6OTHER / BC6ENTG ) reconstituted in COS - 1 cells , and compared them to another BC6OTHER - related compound , BC6ENTC .	False
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6ENTG / BC6OTHER channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER channel currents even at high doses (more than 10 microM).	CPR:4
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6OTHER / BC6ENTG channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER channel currents even at high doses (more than 10 microM).	CPR:4
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6OTHER / BC6OTHER channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6ENTG / BC6OTHER or BC6OTHER / BC6OTHER channel currents even at high doses (more than 10 microM).	False
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6OTHER / BC6OTHER channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6OTHER / BC6ENTG or BC6OTHER / BC6OTHER channel currents even at high doses (more than 10 microM).	False
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6OTHER / BC6OTHER channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6OTHER / BC6OTHER or BC6ENTG / BC6OTHER channel currents even at high doses (more than 10 microM).	False
Patch - clamp analysis using inside - out recording configuration showed that BC6ENTC inhibits the BC6OTHER / BC6OTHER channel currents in a dose - dependent manner (IC50 value , 100 nM) but does not significantly inhibit either BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTG channel currents even at high doses (more than 10 microM).	False
BC6ENTC inhibits BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER channels at 100 nM , and inhibits BC6OTHER / BC6OTHER channels at high concentrations (1 microM).	CPR:4
BC6ENTC inhibits BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER channels at 100 nM , and inhibits BC6OTHER / BC6OTHER channels at high concentrations (1 microM).	CPR:4
BC6ENTC inhibits BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER channels at 100 nM , and inhibits BC6OTHER / BC6OTHER channels at high concentrations (1 microM).	CPR:4
BC6ENTC inhibits BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG channels at 100 nM , and inhibits BC6OTHER / BC6OTHER channels at high concentrations (1 microM).	CPR:4
BC6ENTC inhibits BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER channels at 100 nM , and inhibits BC6ENTG / BC6OTHER channels at high concentrations (1 microM).	CPR:4
BC6ENTC inhibits BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER channels at 100 nM , and inhibits BC6OTHER / BC6ENTG channels at high concentrations (1 microM).	CPR:4
Binding experiments on BC6ENTC , BC6OTHER , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6ENTC , BC6OTHER , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6ENTC , and BC6OTHER to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6ENTC , and BC6OTHER to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6ENTC to BC6OTHER expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6ENTG (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
Binding experiments on BC6OTHER , BC6OTHER , and BC6ENTC to BC6ENTG expressed in COS - 1 cells revealed that they inhibit the binding of BC6OTHER to BC6OTHER (IC50 values: BC6OTHER , 280 nM; BC6OTHER , 8 microM; BC6OTHER , 1.6 microM) , suggesting that they all share a BC6OTHER binding site.	False
The effects of BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , on BC6ENTG and BC6OTHER secretion: comparison with the BC6ENTC and BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , on BC6OTHER and BC6ENTG secretion: comparison with the BC6ENTC and BC6OTHER .	False
The effects of BC6ENTC ( BC6OTHER ) , a new anti - diabetic drug , on BC6ENTG and BC6OTHER secretion: comparison with the BC6OTHER and BC6OTHER .	False
The effects of BC6ENTC ( BC6OTHER ) , a new anti - diabetic drug , on BC6OTHER and BC6ENTG secretion: comparison with the BC6OTHER and BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , on BC6ENTG and BC6OTHER secretion: comparison with the BC6OTHER and BC6ENTC .	False
The effects of BC6OTHER ( BC6OTHER ) , a new anti - diabetic drug , on BC6OTHER and BC6ENTG secretion: comparison with the BC6OTHER and BC6ENTC .	False
The effects of BC6OTHER ( BC6ENTC ) , a new anti - diabetic drug , on BC6ENTG and BC6OTHER secretion: comparison with the BC6OTHER and BC6OTHER .	False
The effects of BC6OTHER ( BC6ENTC ) , a new anti - diabetic drug , on BC6OTHER and BC6ENTG secretion: comparison with the BC6OTHER and BC6OTHER .	False
Results showed that CHEM alone exposure could trigger the significant increase of BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER and SBP and decrease of heart rate variability (HRV) , a marker of cardiac autonomic nervous system (ANS) function.	False
Results showed that CHEM alone exposure could trigger the significant increase of BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER and SBP and decrease of heart rate variability (HRV) , a marker of cardiac autonomic nervous system (ANS) function.	False
Results showed that CHEM alone exposure could trigger the significant increase of BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG and SBP and decrease of heart rate variability (HRV) , a marker of cardiac autonomic nervous system (ANS) function.	False
BC6ENTC plus PM(2.5) exposure , however , induced BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER increase , BC6OTHER and HRV decrease significantly in a dose - response way.	CPR:3
BC6ENTC plus PM(2.5) exposure , however , induced BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER increase , BC6OTHER and HRV decrease significantly in a dose - response way.	CPR:3
BC6ENTC plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER increase , BC6OTHER and HRV decrease significantly in a dose - response way.	CPR:3
BC6ENTC plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER increase , BC6OTHER and HRV decrease significantly in a dose - response way.	CPR:3
BC6ENTC plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER increase , BC6ENTG and HRV decrease significantly in a dose - response way.	CPR:4
BC6OTHER plus PM(2.5) exposure , however , induced BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC increase , BC6OTHER and HRV decrease significantly in a dose - response way.	False
BC6OTHER plus PM(2.5) exposure , however , induced BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC increase , BC6OTHER and HRV decrease significantly in a dose - response way.	False
BC6OTHER plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC increase , BC6OTHER and HRV decrease significantly in a dose - response way.	False
BC6OTHER plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC increase , BC6OTHER and HRV decrease significantly in a dose - response way.	False
BC6OTHER plus PM(2.5) exposure , however , induced BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC increase , BC6ENTG and HRV decrease significantly in a dose - response way.	False
Biomarkers of systemic inflammation and injuries ( BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6OTHER , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6OTHER , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6OTHER , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6OTHER , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6ENTG ) and endothelial function ( BC6OTHER , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6ENTG , BC6OTHER ) were analyzed after the 6th exposure.	False
Biomarkers of systemic inflammation and injuries ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) , heart oxidative stress ( BC6ENTC , BC6OTHER ) and endothelial function ( BC6OTHER , BC6ENTG ) were analyzed after the 6th exposure.	False
Endogenously produced asymmetrically methylated BC6OTHER residues are competitive inhibitors of all three isoforms of BC6ENTC synthase ( BC6ENTG ).	False
The enzyme BC6ENTC dimethylaminohydrolase ( BC6ENTG ) specifically hydrolyzes these asymmetrically methylated BC6OTHER residues to CHEM and CHEM.	False
The enzyme BC6ENTG ( BC6OTHER ) specifically hydrolyzes these asymmetrically methylated BC6ENTC residues to CHEM and CHEM.	CPR:9
The enzyme BC6OTHER ( BC6ENTG ) specifically hydrolyzes these asymmetrically methylated BC6ENTC residues to CHEM and CHEM.	CPR:9
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6ENTG may provide a novel mechanism for the regulation of BC6OTHER activity in vivo. Recently we reported the cloning of BC6OTHER and identified a novel BC6OTHER isoform ( BC6OTHER and BC6OTHER , respectively).	CPR:9
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6OTHER may provide a novel mechanism for the regulation of BC6ENTG activity in vivo. Recently we reported the cloning of BC6OTHER and identified a novel BC6OTHER isoform ( BC6OTHER and BC6OTHER , respectively).	False
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6OTHER may provide a novel mechanism for the regulation of BC6OTHER activity in vivo. Recently we reported the cloning of BC6ENTG and identified a novel BC6OTHER isoform ( BC6OTHER and BC6OTHER , respectively).	False
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6OTHER may provide a novel mechanism for the regulation of BC6OTHER activity in vivo. Recently we reported the cloning of BC6OTHER and identified a novel BC6ENTG isoform ( BC6OTHER and BC6OTHER , respectively).	False
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6OTHER may provide a novel mechanism for the regulation of BC6OTHER activity in vivo. Recently we reported the cloning of BC6OTHER and identified a novel BC6OTHER isoform ( BC6ENTG and BC6OTHER , respectively).	False
 Previously we have proposed that regulation of asymmetric BC6ENTC concentration by BC6OTHER may provide a novel mechanism for the regulation of BC6OTHER activity in vivo. Recently we reported the cloning of BC6OTHER and identified a novel BC6OTHER isoform ( BC6OTHER and BC6ENTG , respectively).	False
Endogenously produced asymmetrically methylated BC6ENTC residues are competitive inhibitors of all three isoforms of BC6ENTG ( BC6OTHER ).	CPR:4
Endogenously produced asymmetrically methylated BC6ENTC residues are competitive inhibitors of all three isoforms of BC6OTHER ( BC6ENTG ).	CPR:4
In addition to the BC6ENTC - terminal and BC6ENTG that mediate these interactions , BC6OTHER proteins contain a BC6OTHER - terminal BC6OTHER .	False
In addition to the BC6ENTC - terminal and BC6OTHER that mediate these interactions , BC6ENTG proteins contain a BC6OTHER - terminal BC6OTHER .	False
In addition to the BC6ENTC - terminal and BC6OTHER that mediate these interactions , BC6OTHER proteins contain a BC6OTHER - terminal BC6ENTG .	False
In addition to the BC6OTHER - terminal and BC6ENTG that mediate these interactions , BC6OTHER proteins contain a BC6ENTC - terminal BC6OTHER .	False
In addition to the BC6OTHER - terminal and BC6OTHER that mediate these interactions , BC6ENTG proteins contain a BC6ENTC - terminal BC6OTHER .	False
In addition to the BC6OTHER - terminal and BC6OTHER that mediate these interactions , BC6OTHER proteins contain a BC6ENTC - terminal BC6ENTG .	False
Using a proteomics approach , we demonstrate that BC6ENTC kinase B ( BC6ENTG ) interacts with BC6OTHER in a specific , BC6OTHER - independent manner.	False
Using a proteomics approach , we demonstrate that BC6ENTC kinase B ( BC6OTHER ) interacts with BC6ENTG in a specific , BC6OTHER - independent manner.	False
Using a proteomics approach , we demonstrate that BC6ENTC kinase B ( BC6OTHER ) interacts with BC6OTHER in a specific , BC6ENTG - independent manner.	False
 BC6ENTG repeat and suppressors of BC6OTHER BC6OTHER targets BC6ENTC kinase B for degradation.	False
 BC6OTHER repeat and suppressors of BC6ENTG BC6OTHER targets BC6ENTC kinase B for degradation.	False
 BC6OTHER repeat and suppressors of BC6OTHER BC6ENTG targets BC6ENTC kinase B for degradation.	False
BC6ENTC enhances excitatory parasympathetic activity by competing with BC6OTHER for attachment to BC6ENTG at sites of cholinergic transmission and enhancing cholinergic action.	False
BC6OTHER enhances excitatory parasympathetic activity by competing with BC6ENTC for attachment to BC6ENTG at sites of cholinergic transmission and enhancing cholinergic action.	False
BC6OTHER exhibited a significantly higher Vmax and Km values toward both BC6ENTC and BC6OTHER - BC6OTHER than the other BC6ENTG .	CPR:9
BC6ENTG exhibited a significantly higher Vmax and Km values toward both BC6ENTC and BC6OTHER - BC6OTHER than the other BC6OTHER .	CPR:9
BC6OTHER exhibited a significantly higher Vmax and Km values toward both BC6OTHER and BC6ENTC - BC6OTHER than the other BC6ENTG .	CPR:9
BC6ENTG exhibited a significantly higher Vmax and Km values toward both BC6OTHER and BC6ENTC - BC6OTHER than the other BC6OTHER .	CPR:9
BC6OTHER exhibited a significantly higher Vmax and Km values toward both BC6OTHER and BC6OTHER - BC6ENTC than the other BC6ENTG .	CPR:9
BC6ENTG exhibited a significantly higher Vmax and Km values toward both BC6OTHER and BC6OTHER - BC6ENTC than the other BC6OTHER .	CPR:9
This new method is particularly suitable for fast activity screenings of BC6ENTG and BC6ENTC glucuronidation activity determination from various samples.	False
BC6ENTC - glucuronosyltransferases ( BC6ENTG ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics.	False
We have developed a convenient quantitative multi - well plate assay to measure the glucuronidation rate of BC6ENTC ( BC6OTHER ) for several BC6ENTG .	CPR:9
We have developed a convenient quantitative multi - well plate assay to measure the glucuronidation rate of BC6OTHER ( BC6ENTC ) for several BC6ENTG .	CPR:9
We have used this method to screen 11 recombinant BC6ENTG for BC6ENTC glucuronidation activity and studied the reaction kinetics with the most active enzymes.	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6ENTG followed by BC6OTHER > BC6OTHER > BC6OTHER , whereas at 300 µM BC6OTHER was about 10 times better catalyst than the other recombinant BC6OTHER .	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6OTHER followed by BC6ENTG > BC6OTHER > BC6OTHER , whereas at 300 µM BC6OTHER was about 10 times better catalyst than the other recombinant BC6OTHER .	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6OTHER followed by BC6OTHER > BC6ENTG > BC6OTHER , whereas at 300 µM BC6OTHER was about 10 times better catalyst than the other recombinant BC6OTHER .	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6OTHER followed by BC6OTHER > BC6OTHER > BC6ENTG , whereas at 300 µM BC6OTHER was about 10 times better catalyst than the other recombinant BC6OTHER .	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6OTHER followed by BC6OTHER > BC6OTHER > BC6OTHER , whereas at 300 µM BC6ENTG was about 10 times better catalyst than the other recombinant BC6OTHER .	CPR:9
At a substrate concentration of 20 µM , the most active BC6ENTC glucuronidation catalysts were BC6OTHER followed by BC6OTHER > BC6OTHER > BC6OTHER , whereas at 300 µM BC6OTHER was about 10 times better catalyst than the other recombinant BC6ENTG .	CPR:9
The activities of BC6ENTG were low , whereas BC6OTHER and BC6OTHER exhibited no BC6ENTC glucuronidation activity.	False
The activities of BC6OTHER were low , whereas BC6ENTG and BC6OTHER exhibited no BC6ENTC glucuronidation activity.	False
The activities of BC6OTHER were low , whereas BC6OTHER and BC6ENTG exhibited no BC6ENTC glucuronidation activity.	False
A high throughput assay for the glucuronidation of BC6ENTC by recombinant BC6ENTG and liver microsomes.	CPR:9
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6ENTG ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6ENTG and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6ENTG have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6ENTC kinase U - type ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6ENTG and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6ENTG have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6ENTC abusers.	False
The data identify phosphoproteins differentially regulated by BC6ENTC treatment and / or the presence of endogenous BC6ENTG / BC6OTHER which may be relevant mediators of BC6OTHER / BC6OTHER neuroprotective effects against BC6OTHER - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6ENTC treatment and / or the presence of endogenous BC6OTHER / BC6ENTG which may be relevant mediators of BC6OTHER / BC6OTHER neuroprotective effects against BC6OTHER - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6ENTC treatment and / or the presence of endogenous BC6OTHER / BC6OTHER which may be relevant mediators of BC6ENTG / BC6OTHER neuroprotective effects against BC6OTHER - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6ENTC treatment and / or the presence of endogenous BC6OTHER / BC6OTHER which may be relevant mediators of BC6OTHER / BC6ENTG neuroprotective effects against BC6OTHER - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6OTHER treatment and / or the presence of endogenous BC6ENTG / BC6OTHER which may be relevant mediators of BC6OTHER / BC6OTHER neuroprotective effects against BC6ENTC - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6OTHER treatment and / or the presence of endogenous BC6OTHER / BC6ENTG which may be relevant mediators of BC6OTHER / BC6OTHER neuroprotective effects against BC6ENTC - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6OTHER treatment and / or the presence of endogenous BC6OTHER / BC6OTHER which may be relevant mediators of BC6ENTG / BC6OTHER neuroprotective effects against BC6ENTC - induced neurotoxicity.	False
The data identify phosphoproteins differentially regulated by BC6OTHER treatment and / or the presence of endogenous BC6OTHER / BC6OTHER which may be relevant mediators of BC6OTHER / BC6ENTG neuroprotective effects against BC6ENTC - induced neurotoxicity.	False
Accordingly , BC6ENTG - / - and BC6OTHER - / - mice show an increased vulnerability to BC6ENTC - induced neurotoxic effects.	False
Accordingly , BC6OTHER - / - and BC6ENTG - / - mice show an increased vulnerability to BC6ENTC - induced neurotoxic effects.	False
In an effort to uncover new pharmacological targets to prevent BC6ENTC neurotoxic effects , we have now used a proteomic approach to study protein phosphorylation , in which we combined phosphoprotein enrichment , by immobilized metal affinity chromatography (IMAC) , with two - dimensional gel electrophoresis and mass spectrometry , in order to identify the phosphoproteins regulated in the striatum of BC6ENTG - / - , BC6OTHER - / - and wild type (WT) mice treated with BC6OTHER .	False
In an effort to uncover new pharmacological targets to prevent BC6ENTC neurotoxic effects , we have now used a proteomic approach to study protein phosphorylation , in which we combined phosphoprotein enrichment , by immobilized metal affinity chromatography (IMAC) , with two - dimensional gel electrophoresis and mass spectrometry , in order to identify the phosphoproteins regulated in the striatum of BC6OTHER - / - , BC6ENTG - / - and wild type (WT) mice treated with BC6OTHER .	False
In an effort to uncover new pharmacological targets to prevent BC6OTHER neurotoxic effects , we have now used a proteomic approach to study protein phosphorylation , in which we combined phosphoprotein enrichment , by immobilized metal affinity chromatography (IMAC) , with two - dimensional gel electrophoresis and mass spectrometry , in order to identify the phosphoproteins regulated in the striatum of BC6ENTG - / - , BC6OTHER - / - and wild type (WT) mice treated with BC6ENTC .	False
In an effort to uncover new pharmacological targets to prevent BC6OTHER neurotoxic effects , we have now used a proteomic approach to study protein phosphorylation , in which we combined phosphoprotein enrichment , by immobilized metal affinity chromatography (IMAC) , with two - dimensional gel electrophoresis and mass spectrometry , in order to identify the phosphoproteins regulated in the striatum of BC6OTHER - / - , BC6ENTG - / - and wild type (WT) mice treated with BC6ENTC .	False
We identified 13 differentially expressed phosphoproteins that are judged to be relevant in the neuroprotective roles of BC6ENTG and BC6OTHER against BC6ENTC - induced neurotoxicity.	False
We identified 13 differentially expressed phosphoproteins that are judged to be relevant in the neuroprotective roles of BC6OTHER and BC6ENTG against BC6ENTC - induced neurotoxicity.	False
The neurotrophic factors BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) have been shown to modulate BC6ENTC - induced neurotoxicity.	False
The neurotrophic factors BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) have been shown to modulate BC6ENTC - induced neurotoxicity.	False
The neurotrophic factors BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) have been shown to modulate BC6ENTC - induced neurotoxicity.	False
The neurotrophic factors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) have been shown to modulate BC6ENTC - induced neurotoxicity.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6ENTG and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6ENTG have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
It is very interesting to note that 4 of these phosphoproteins , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC dehydrogenase family 1 member A1 ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , are known to be involved in Parkinson's disease , a result of significant importance since BC6OTHER and BC6OTHER have been also demonstrated to limit Parkinson's disease (PD) progress and have been suggested to be among the important genetic factors possibly preventing the development of PD in BC6OTHER abusers.	False
Differential phosphoproteome of the striatum from BC6ENTG knockout and BC6OTHER knockout mice treated with BC6ENTC : Correlations with BC6OTHER - induced neurotoxicity.	False
Differential phosphoproteome of the striatum from BC6OTHER knockout and BC6ENTG knockout mice treated with BC6ENTC : Correlations with BC6OTHER - induced neurotoxicity.	False
Differential phosphoproteome of the striatum from BC6ENTG knockout and BC6OTHER knockout mice treated with BC6OTHER : Correlations with BC6ENTC - induced neurotoxicity.	False
Differential phosphoproteome of the striatum from BC6OTHER knockout and BC6ENTG knockout mice treated with BC6OTHER : Correlations with BC6ENTC - induced neurotoxicity.	False
Their deduced BC6OTHER sequences show a high degree of conservation compared with orthologues from other mammalian species , with the notable exception of the BC6ENTC - terminus of BC6ENTG .	False
These differences were also present in BC6ENTG , whose BC6ENTC - terminal sequence we determined.	False
Expression in yeast allowed kinetic characterization of the two native enzymes , and of a chimaera in which the distinctive BC6ENTC - terminal segment of BC6ENTG was replaced with that from BC6OTHER .	False
Expression in yeast allowed kinetic characterization of the two native enzymes , and of a chimaera in which the distinctive BC6ENTC - terminal segment of BC6OTHER was replaced with that from BC6ENTG .	False
The ovine BC6ENTC - terminal segment influences the kinetics of the enzyme for both its substrates , such that the K (m) for BC6OTHER is decreased and that for BC6OTHER is increased for the chimaera , relative to the parental BC6ENTG .	False
The ovine BC6OTHER - terminal segment influences the kinetics of the enzyme for both its substrates , such that the K (m) for BC6ENTC is decreased and that for BC6OTHER is increased for the chimaera , relative to the parental BC6ENTG .	False
The ovine BC6OTHER - terminal segment influences the kinetics of the enzyme for both its substrates , such that the K (m) for BC6OTHER is decreased and that for BC6ENTC is increased for the chimaera , relative to the parental BC6ENTG .	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6ENTG and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6ENTG cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6ENTG and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6ENTG respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6ENTG clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6ENTG and BC6OTHER respectively.	False
The BC6ENTC sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6OTHER Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6ENTG respectively.	False
BC6ENTC palmitoyltransferase 1 ( BC6ENTG ) is the key locus for the control of long - chain BC6OTHER beta - oxidation and liver ketogenesis.	False
BC6ENTG ( BC6OTHER ) is the key locus for the control of long - chain BC6ENTC beta - oxidation and liver ketogenesis.	False
BC6OTHER ( BC6ENTG ) is the key locus for the control of long - chain BC6ENTC beta - oxidation and liver ketogenesis.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6ENTG and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6ENTG cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6ENTG and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6ENTG respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6ENTG clones have the accession numbers BC6OTHER and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6ENTG and BC6OTHER respectively.	False
The BC6OTHER sequence data reported will appear in DDBJ , EMBL , GenBank(R) and GSDB BC6ENTC Sequence Databases; the sequences of BC6OTHER and BC6OTHER cDNAs have the accession numbers BC6OTHER and BC6OTHER respectively and the partial adipose tissue and liver BC6OTHER clones have the accession numbers BC6OTHER and BC6ENTG respectively.	False
Their deduced BC6ENTC sequences show a high degree of conservation compared with orthologues from other mammalian species , with the notable exception of the BC6OTHER - terminus of BC6ENTG .	False
Cloning and expression of the liver and muscle isoforms of BC6ENTG : residues within the BC6ENTC - terminus of the muscle isoform influence the kinetic properties of the enzyme.	False
This vulnerability to BC6ENTC abuse was associated with a lower BC6ENTG immunoreactivity in the Nac and enduring alterations of the expression of BC6OTHER and BC6OTHER , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6OTHER and alcoholism.	False
This vulnerability to BC6ENTC abuse was associated with a lower BC6OTHER immunoreactivity in the Nac and enduring alterations of the expression of BC6ENTG and BC6OTHER , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6OTHER and alcoholism.	False
This vulnerability to BC6ENTC abuse was associated with a lower BC6OTHER immunoreactivity in the Nac and enduring alterations of the expression of BC6OTHER and BC6ENTG , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6OTHER and alcoholism.	False
This vulnerability to BC6OTHER abuse was associated with a lower BC6ENTG immunoreactivity in the Nac and enduring alterations of the expression of BC6OTHER and BC6OTHER , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6ENTC and alcoholism.	False
This vulnerability to BC6OTHER abuse was associated with a lower BC6OTHER immunoreactivity in the Nac and enduring alterations of the expression of BC6ENTG and BC6OTHER , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6ENTC and alcoholism.	False
This vulnerability to BC6OTHER abuse was associated with a lower BC6OTHER immunoreactivity in the Nac and enduring alterations of the expression of BC6OTHER and BC6ENTG , 2 neurotransmission - related genes that have been shown to play critical roles in the behavioral effects of BC6ENTC and alcoholism.	False
BC6ENTC , a unique cardioselective BC6ENTG blocker with a half - life of 9 minutes , can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta - blocking therapy.	CPR:4
Taken together , these findings suggest that BC6ENTC induces apoptosis in OLC odontoblasts through a BC6ENTG - dependent mitochondrial pathway.	False
Exposure of cells to 4mM BC6ENTC for 24h induced BC6ENTG activation , ultrastructural alterations , and resulted in the translocation of BC6OTHER to the mitochondria and the release of BC6OTHER from the mitochondrial inter - membrane space into the cytosol , indicating that BC6OTHER - mediated apoptosis is mitochondria - dependent.	CPR:3
Exposure of cells to 4mM BC6ENTC for 24h induced BC6OTHER activation , ultrastructural alterations , and resulted in the translocation of BC6ENTG to the mitochondria and the release of BC6OTHER from the mitochondrial inter - membrane space into the cytosol , indicating that BC6OTHER - mediated apoptosis is mitochondria - dependent.	False
Exposure of cells to 4mM BC6ENTC for 24h induced BC6OTHER activation , ultrastructural alterations , and resulted in the translocation of BC6OTHER to the mitochondria and the release of BC6ENTG from the mitochondrial inter - membrane space into the cytosol , indicating that BC6OTHER - mediated apoptosis is mitochondria - dependent.	False
Exposure of cells to 4mM BC6OTHER for 24h induced BC6ENTG activation , ultrastructural alterations , and resulted in the translocation of BC6OTHER to the mitochondria and the release of BC6OTHER from the mitochondrial inter - membrane space into the cytosol , indicating that BC6ENTC - mediated apoptosis is mitochondria - dependent.	False
Exposure of cells to 4mM BC6OTHER for 24h induced BC6OTHER activation , ultrastructural alterations , and resulted in the translocation of BC6ENTG to the mitochondria and the release of BC6OTHER from the mitochondrial inter - membrane space into the cytosol , indicating that BC6ENTC - mediated apoptosis is mitochondria - dependent.	False
Exposure of cells to 4mM BC6OTHER for 24h induced BC6OTHER activation , ultrastructural alterations , and resulted in the translocation of BC6OTHER to the mitochondria and the release of BC6ENTG from the mitochondrial inter - membrane space into the cytosol , indicating that BC6ENTC - mediated apoptosis is mitochondria - dependent.	False
BC6ENTC treatment also increased phosphorylation of BC6ENTG and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6OTHER was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	CPR:3
BC6ENTC treatment also increased phosphorylation of BC6OTHER and BC6ENTG , but not BC6OTHER , and apoptosis induced by BC6OTHER was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	CPR:3
BC6ENTC treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6ENTG , and apoptosis induced by BC6OTHER was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	False
BC6ENTC treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6OTHER was notably or partly suppressed by treatment with BC6ENTG or BC6OTHER inhibitors , respectively.	False
BC6ENTC treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6OTHER was notably or partly suppressed by treatment with BC6OTHER or BC6ENTG inhibitors , respectively.	False
BC6OTHER treatment also increased phosphorylation of BC6ENTG and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6ENTC was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	False
BC6OTHER treatment also increased phosphorylation of BC6OTHER and BC6ENTG , but not BC6OTHER , and apoptosis induced by BC6ENTC was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	False
BC6OTHER treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6ENTG , and apoptosis induced by BC6ENTC was notably or partly suppressed by treatment with BC6OTHER or BC6OTHER inhibitors , respectively.	False
BC6OTHER treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6ENTC was notably or partly suppressed by treatment with BC6ENTG or BC6OTHER inhibitors , respectively.	False
BC6OTHER treatment also increased phosphorylation of BC6OTHER and BC6OTHER , but not BC6OTHER , and apoptosis induced by BC6ENTC was notably or partly suppressed by treatment with BC6OTHER or BC6ENTG inhibitors , respectively.	False
 BC6ENTC induces apoptosis in odontoblasts via a BC6ENTG - dependent mechanism.	False
BC6OTHER and BC6OTHER ( BC6ENTC , BC6ENTG agonist) constricted MVs but not MAs.	CPR:5
The BC6ENTG agonist BC6ENTC ( BC6OTHER ) (0.001 - 0.1 μM) did not alter NE oxidation currents.	CPR:5
The BC6ENTG agonist BC6OTHER ( BC6ENTC ) (0.001 - 0.1 μM) did not alter NE oxidation currents.	CPR:5
We conclude that there are prejunctional BC6ENTG in arteries and both pre - and postjunctional BC6OTHER in veins; thus , BC6ENTC selectively constricts the veins.	False
We conclude that there are prejunctional BC6OTHER in arteries and both pre - and postjunctional BC6ENTG in veins; thus , BC6ENTC selectively constricts the veins.	False
Prejunctional BC6ENTG function is impaired in arteries , but not veins , from BC6ENTC - salt rats.	False
Sympathetic autoreceptor dysfunction is not specific to BC6ENTG , but there is a more general disruption of prejunctional mechanisms controlling sympathetic neurotransmitter release in BC6ENTC - salt hypertension.	False
NE acts at prejunctional BC6ENTG ( BC6OTHER ) to inhibit NE release , and BC6OTHER function is impaired in BC6ENTC - salt rats.	False
NE acts at prejunctional BC6OTHER ( BC6ENTG ) to inhibit NE release , and BC6OTHER function is impaired in BC6ENTC - salt rats.	False
NE acts at prejunctional BC6OTHER ( BC6OTHER ) to inhibit NE release , and BC6ENTG function is impaired in BC6ENTC - salt rats.	False
BC6ENTC , an enzymatic BC6OTHER degradation product , acts at prejunctional BC6ENTG ( BC6OTHER ) to inhibit NE release.	False
BC6ENTC , an enzymatic BC6OTHER degradation product , acts at prejunctional A1 BC6OTHER receptors ( BC6ENTG ) to inhibit NE release.	False
BC6OTHER , an enzymatic BC6ENTC degradation product , acts at prejunctional BC6ENTG ( BC6OTHER ) to inhibit NE release.	False
BC6OTHER , an enzymatic BC6ENTC degradation product , acts at prejunctional A1 BC6OTHER receptors ( BC6ENTG ) to inhibit NE release.	False
BC6OTHER , an enzymatic BC6OTHER degradation product , acts at prejunctional A1 BC6ENTC receptors ( BC6ENTG ) to inhibit NE release.	False
We tested the hypothesis that prejunctional BC6ENTG function is impaired in sympathetic nerves supplying mesenteric arteries (MAs) and veins (MVs) of BC6ENTC - salt rats.	False
Immunohistochemical methods were used to localize BC6ENTC hydroxylase ( BC6ENTG ) and BC6OTHER in perivascular sympathetic nerves.	False
Immunohistochemical methods were used to localize BC6ENTC hydroxylase ( BC6OTHER ) and BC6ENTG in perivascular sympathetic nerves.	False
BC6ENTC and BC6OTHER ( BC6OTHER , BC6ENTG agonist) constricted MVs but not MAs.	CPR:5
BC6OTHER and BC6ENTC ( BC6OTHER , BC6ENTG agonist) constricted MVs but not MAs.	CPR:5
Impaired function of prejunctional BC6ENTG expressed by perivascular sympathetic nerves in BC6ENTC - salt hypertensive rats.	False
BC6ENTG ( BC6OTHER ) is a highly conserved BC6ENTC metallopeptidase that is ubiquitously distributed in human tissues , and particularly abundant in the brain , liver , and muscles.	False
BC6OTHER ( BC6ENTG ) is a highly conserved BC6ENTC metallopeptidase that is ubiquitously distributed in human tissues , and particularly abundant in the brain , liver , and muscles.	False
Transient overexpression of the BC6ENTG isoform led to reduced vulnerability to the cytotoxicity of BC6OTHER with an increased activity of BC6ENTC accumulation in murine osteoblastic MC3T3 - E1 cells.	False
These results suggest that BC6ENTG may be functionally expressed by osteoblasts to play a pivotal role in mechanisms related to the cytoprotective property of BC6ENTC .	False
In the present study , we have evaluated possible participation of BC6ENTG ( BC6OTHER ) responsible for the bidirectional membrane transport of BC6ENTC in the cytoprotective property in osteoblasts.	CPR:9
In the present study , we have evaluated possible participation of BC6OTHER ( BC6ENTG ) responsible for the bidirectional membrane transport of BC6ENTC in the cytoprotective property in osteoblasts.	CPR:9
The accumulation of BC6ENTC occurred in a temperature - and pH - dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific BC6ENTG inhibitor , whereas BC6OTHER was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the BC6OTHER inhibitor.	False
The accumulation of BC6ENTC occurred in a temperature - and pH - dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific BC6OTHER inhibitor , whereas BC6OTHER was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the BC6ENTG inhibitor.	False
The accumulation of BC6OTHER occurred in a temperature - and pH - dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific BC6ENTG inhibitor , whereas BC6ENTC was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the BC6OTHER inhibitor.	False
The accumulation of BC6OTHER occurred in a temperature - and pH - dependent manner in osteoblasts cultured for 7 days with high sensitivity to a specific BC6OTHER inhibitor , whereas BC6ENTC was released into extracellular spaces from cultured osteoblasts in a fashion sensitive to the BC6ENTG inhibitor.	False
Transient overexpression of the BC6ENTG isoform led to reduced vulnerability to the cytotoxicity of BC6ENTC with an increased activity of BC6OTHER accumulation in murine osteoblastic MC3T3 - E1 cells.	False
BC6ENTG hydrolyze BC6OTHER , BC6OTHER , and BC6OTHER to produce BC6OTHER and resulting BC6ENTC , BC6OTHER , and BC6OTHER , respectively.	CPR:9
BC6ENTG hydrolyze BC6OTHER , BC6OTHER , and BC6OTHER to produce BC6OTHER and resulting BC6OTHER , BC6ENTC , and BC6OTHER , respectively.	CPR:9
BC6ENTG hydrolyze BC6OTHER , BC6OTHER , and BC6OTHER to produce BC6OTHER and resulting BC6OTHER , BC6OTHER , and BC6ENTC , respectively.	CPR:9
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER selectively inhibited BC6ENTG , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6OTHER .	CPR:4
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER selectively inhibited BC6OTHER , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6ENTG .	False
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER selectively inhibited BC6ENTG , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6OTHER .	CPR:4
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER selectively inhibited BC6OTHER , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6ENTG .	False
BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER selectively inhibited BC6ENTG , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6OTHER .	CPR:4
BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER selectively inhibited BC6OTHER , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6ENTG .	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER selectively inhibited BC6ENTG , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6OTHER .	CPR:4
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER selectively inhibited BC6OTHER , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6ENTG .	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC selectively inhibited BC6ENTG , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6OTHER .	CPR:4
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC selectively inhibited BC6OTHER , with Ki values of 4.32 ± 0.47 , 24.8 ± 4.2 , 355 ± 38 , 468 ± 21 , 707 ± 64 µM , respectively , but did not significantly inhibit BC6ENTG .	False
BC6ENTC - glucuronosyltransferases are colocalized with BC6ENTG and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6OTHER .	False
BC6ENTC - glucuronosyltransferases are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6ENTG .	False
BC6ENTC and BC6OTHER did not inhibit either BC6ENTG .	False
BC6OTHER and BC6ENTC did not inhibit either BC6ENTG .	False
Time - dependent inactivation of BC6ENTG by BC6ENTC was not observed.	False
Lastly , both BC6ENTG and BC6OTHER were shown not to catalyze the hydrolysis of the BC6ENTC studied.	False
Lastly , both BC6OTHER and BC6ENTG were shown not to catalyze the hydrolysis of the BC6ENTC studied.	False
Conclusion: Drug - drug interaction studies may be warranted for drugs that metabolize to BC6ENTC due to the potential inhibition of BC6ENTG .	CPR:4
BC6ENTG are colocalized with BC6OTHER and have the potential to further metabolize BC6ENTC to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6OTHER .	CPR:9
BC6OTHER are colocalized with BC6ENTG and have the potential to further metabolize BC6ENTC to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6OTHER .	CPR:9
BC6OTHER are colocalized with BC6OTHER and have the potential to further metabolize BC6ENTC to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6ENTG .	False
BC6ENTG hydrolyze BC6ENTC , BC6OTHER , and BC6OTHER to produce BC6OTHER and resulting BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	CPR:9
BC6ENTG are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6ENTC , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6OTHER .	CPR:9
BC6OTHER are colocalized with BC6ENTG and have the potential to further metabolize BC6OTHER to BC6ENTC , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6OTHER .	CPR:9
BC6OTHER are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6ENTC , but it is currently unknown if BC6OTHER , being BC6OTHER , also interact with BC6ENTG .	False
BC6ENTG are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6ENTC , being BC6OTHER , also interact with BC6OTHER .	CPR:9
BC6OTHER are colocalized with BC6ENTG and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6ENTC , being BC6OTHER , also interact with BC6OTHER .	False
BC6OTHER are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6ENTC , being BC6OTHER , also interact with BC6ENTG .	False
BC6ENTG hydrolyze BC6OTHER , BC6ENTC , and BC6OTHER to produce BC6OTHER and resulting BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	CPR:9
BC6ENTG are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6ENTC , also interact with BC6OTHER .	False
BC6OTHER are colocalized with BC6ENTG and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6ENTC , also interact with BC6OTHER .	False
BC6OTHER are colocalized with BC6OTHER and have the potential to further metabolize BC6OTHER to BC6OTHER , but it is currently unknown if BC6OTHER , being BC6ENTC , also interact with BC6ENTG .	False
Objective: This study explores the ability of BC6ENTC to act as substrates or inhibitors of BC6ENTG ( BC6OTHER ) and 2 ( BC6OTHER ).	CPR:9
Objective: This study explores the ability of BC6ENTC to act as substrates or inhibitors of BC6OTHER ( BC6ENTG ) and 2 ( BC6OTHER ).	CPR:9
Objective: This study explores the ability of BC6ENTC to act as substrates or inhibitors of BC6OTHER ( BC6OTHER ) and 2 ( BC6ENTG ).	CPR:9
BC6ENTG hydrolyze BC6OTHER , BC6OTHER , and BC6ENTC to produce BC6OTHER and resulting BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	CPR:9
Methods: The stability of six BC6ENTC in the presence of BC6ENTG , BC6OTHER , and buffer alone (100 mM BC6OTHER , pH 7.4 , 37°C) were investigated.	CPR:9
Methods: The stability of six BC6ENTC in the presence of BC6OTHER , BC6ENTG , and buffer alone (100 mM BC6OTHER , pH 7.4 , 37°C) were investigated.	CPR:9
Methods: The stability of six BC6OTHER in the presence of BC6ENTG , BC6OTHER , and buffer alone (100 mM BC6ENTC , pH 7.4 , 37°C) were investigated.	False
Methods: The stability of six BC6OTHER in the presence of BC6OTHER , BC6ENTG , and buffer alone (100 mM BC6ENTC , pH 7.4 , 37°C) were investigated.	False
BC6ENTG hydrolyze BC6OTHER , BC6OTHER , and BC6OTHER to produce BC6ENTC and resulting BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	CPR:9
Reversible inhibition of BC6ENTG by BC6ENTC .	CPR:4
Mitochondrial BC6ENTG activity and the BC6ENTC / BC6OTHER ratio were decreased by BC6OTHER , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6OTHER production , and increased production of the reactive BC6OTHER species (ROS) , BC6OTHER .	False
Mitochondrial BC6ENTG activity and the BC6OTHER / BC6ENTC ratio were decreased by BC6OTHER , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6OTHER production , and increased production of the reactive BC6OTHER species (ROS) , BC6OTHER .	False
Mitochondrial BC6ENTG activity and the BC6OTHER / BC6OTHER ratio were decreased by BC6ENTC , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6OTHER production , and increased production of the reactive BC6OTHER species (ROS) , BC6OTHER .	CPR:4
Mitochondrial BC6ENTG activity and the BC6OTHER / BC6OTHER ratio were decreased by BC6OTHER , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6ENTC production , and increased production of the reactive BC6OTHER species (ROS) , BC6OTHER .	False
Mitochondrial BC6ENTG activity and the BC6OTHER / BC6OTHER ratio were decreased by BC6OTHER , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6OTHER production , and increased production of the reactive BC6ENTC species (ROS) , BC6OTHER .	False
Mitochondrial BC6ENTG activity and the BC6OTHER / BC6OTHER ratio were decreased by BC6OTHER , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and BC6OTHER production , and increased production of the reactive BC6OTHER species (ROS) , BC6ENTC .	False
BC6ENTC receptor ( BC6ENTG ) antagonists blocked the response of many transcripts to BC6OTHER , and the endpoints of decreased BC6OTHER production and differentiation , suggesting regulation by the BC6OTHER .	False
BC6ENTC receptor ( BC6OTHER ) antagonists blocked the response of many transcripts to BC6OTHER , and the endpoints of decreased BC6OTHER production and differentiation , suggesting regulation by the BC6ENTG .	False
BC6ENTG ( BC6OTHER ) antagonists blocked the response of many transcripts to BC6ENTC , and the endpoints of decreased BC6OTHER production and differentiation , suggesting regulation by the BC6OTHER .	False
BC6OTHER ( BC6ENTG ) antagonists blocked the response of many transcripts to BC6ENTC , and the endpoints of decreased BC6OTHER production and differentiation , suggesting regulation by the BC6OTHER .	False
BC6OTHER ( BC6OTHER ) antagonists blocked the response of many transcripts to BC6ENTC , and the endpoints of decreased BC6OTHER production and differentiation , suggesting regulation by the BC6ENTG .	False
BC6ENTG ( BC6OTHER ) antagonists blocked the response of many transcripts to BC6OTHER , and the endpoints of decreased BC6ENTC production and differentiation , suggesting regulation by the BC6OTHER .	False
BC6OTHER ( BC6ENTG ) antagonists blocked the response of many transcripts to BC6OTHER , and the endpoints of decreased BC6ENTC production and differentiation , suggesting regulation by the BC6OTHER .	False
BC6OTHER ( BC6OTHER ) antagonists blocked the response of many transcripts to BC6OTHER , and the endpoints of decreased BC6ENTC production and differentiation , suggesting regulation by the BC6ENTG .	False
Cotreatment of cells with chemical antioxidants or the enzyme BC6ENTG blocked the BC6ENTC - mediated acceleration of keratinocyte cornified envelope formation , an endpoint of terminal differentiation.	False
BC6ENTC decreased the expression of the BC6ENTG , BC6OTHER , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including BC6OTHER .	CPR:4
BC6ENTC decreased the expression of the BC6OTHER , BC6ENTG , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including BC6OTHER .	CPR:4
BC6OTHER decreased the expression of the BC6ENTC transporter , BC6ENTG , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including BC6OTHER .	False
BC6OTHER decreased the expression of the BC6ENTG , BC6OTHER , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including BC6ENTC .	False
BC6OTHER decreased the expression of the BC6OTHER , BC6ENTG , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including BC6ENTC .	False
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6ENTG ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6ENTG ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6ENTG , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6ENTG ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6ENTG ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6ENTG ( BC6OTHER ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6ENTG ) BC6OTHER and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6ENTG and BC6OTHER subunits.	CPR:4
The molecular mechanism studies suggested that BC6ENTC may block the phosphorylation of BC6OTHER ( BC6OTHER ) molecule BC6OTHER , BC6OTHER ( BC6OTHER ) and nuclear translocation of BC6OTHER ( BC6OTHER ) BC6OTHER and BC6ENTG subunits.	CPR:4
In this study , focus was given to evaluate the ability of BC6ENTC , an BC6OTHER alkaloid isolated from marine - derived Microsporum sp. , to attenuate microglial activation by oligomeric BC6ENTG ( BC6OTHER ).	CPR:4
In this study , focus was given to evaluate the ability of BC6ENTC , an BC6OTHER alkaloid isolated from marine - derived Microsporum sp. , to attenuate microglial activation by oligomeric BC6OTHER ( BC6ENTG ).	CPR:4
In this study , focus was given to evaluate the ability of BC6OTHER , an BC6ENTC alkaloid isolated from marine - derived Microsporum sp. , to attenuate microglial activation by oligomeric BC6ENTG ( BC6OTHER ).	CPR:4
In this study , focus was given to evaluate the ability of BC6OTHER , an BC6ENTC alkaloid isolated from marine - derived Microsporum sp. , to attenuate microglial activation by oligomeric BC6OTHER ( BC6ENTG ).	CPR:4
BC6ENTC treatment significantly inhibited the generation of reactive BC6OTHER and BC6OTHER species in BC6ENTG - activated BV - 2 microglia cells.	CPR:4
BC6OTHER treatment significantly inhibited the generation of reactive BC6ENTC and BC6OTHER species in BC6ENTG - activated BV - 2 microglia cells.	False
BC6OTHER treatment significantly inhibited the generation of reactive BC6OTHER and BC6ENTC species in BC6ENTG - activated BV - 2 microglia cells.	False
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6ENTC significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in activated BV - 2 cells.	CPR:4
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6ENTC ( BC6OTHER ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
In addition , we found that BC6OTHER significantly suppressed the production of neurotoxic inflammatory mediator BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6ENTC ) in activated BV - 2 cells.	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER .	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER .	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER , BC6OTHER and BC6OTHER .	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER and BC6OTHER .	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG and BC6OTHER .	False
Moreover , the treatment downregulated the protein and gene expressions of inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6ENTG .	False
 BC6ENTC suppresses BC6ENTG oligomer - induced microglia activation and thereby protects PC - 12 cells from inflammation - mediated toxicity.	CPR:4
To complement these studies , we generated an endothelial - specific transgenic mouse overexpressing BC6ENTC transporter BC6ENTG .	False
The BC6ENTG transgenic mice exhibited significantly enhanced responses to the endothelium - dependent vasodilator BC6ENTC ( - log EC50 for wild - type versus BC6OTHER transgenic: 6.87+ / - 0.10 versus 7.56+ / - 0.13; P<0.001).	False
The BC6OTHER transgenic mice exhibited significantly enhanced responses to the endothelium - dependent vasodilator BC6ENTC ( - log EC50 for wild - type versus BC6ENTG transgenic: 6.87+ / - 0.10 versus 7.56+ / - 0.13; P<0.001).	False
METHODS AND RESULTS: We have identified a novel C / T polymorphism in the 3'UTR of the principal BC6ENTC transporter , solute carrier family 7 ( BC6OTHER transporter , y+ system) , member 1 gene ( BC6ENTG ).	False
METHODS AND RESULTS: We have identified a novel C / T polymorphism in the 3'UTR of the principal CHEM transporter , solute carrier family 7 ( BC6ENTC transporter , y+ system) , member 1 gene ( BC6ENTG ).	False
Identification of a novel polymorphism in the 3'UTR of the BC6ENTC transporter gene BC6ENTG : contribution to hypertension and endothelial dysfunction.	False
In medial striatum , BC6ENTG - ir decreased by 21% , and in hypothalamus BC6OTHER - ir increased by 10% in BC6ENTC - exposed rats.	CPR:4
In medial striatum , BC6OTHER - ir decreased by 21% , and in hypothalamus BC6ENTG - ir increased by 10% in BC6ENTC - exposed rats.	CPR:3
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6ENTC showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6ENTG ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6OTHER ) - ir density.	CPR:3
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6ENTC showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6OTHER ( BC6ENTG ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6OTHER ) - ir density.	CPR:3
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6ENTC showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6OTHER ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6ENTG ( BC6OTHER ) - ir density.	CPR:4
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6ENTC showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6OTHER ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6ENTG ) - ir density.	CPR:4
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6ENTC marker BC6ENTG ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6ENTC marker BC6OTHER ( BC6ENTG ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6ENTC marker BC6OTHER ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6ENTG ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6ENTC marker BC6OTHER ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6ENTG ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6ENTC hydroxylase ( BC6ENTG ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6ENTC hydroxylase ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6ENTG ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6ENTC hydroxylase ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6OTHER ( BC6ENTG ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6ENTG ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6ENTC transporter ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6OTHER ( BC6ENTG ) , 60% more Nissl - stained cells , and 40% less BC6ENTC transporter ( BC6OTHER ) - ir density.	False
At PND35 , the medial prefrontal cortex (mPFC) of rats given BC6OTHER showed 55% greater immunoreactivity ( - ir) for the BC6OTHER marker BC6OTHER ( BC6OTHER ) , 60% more Nissl - stained cells , and 40% less BC6ENTC transporter ( BC6ENTG ) - ir density.	False
In hippocampal dentate gyrus , BC6ENTC - receiving rats showed a 51% decrease in BC6OTHER - ir density and a 61% expanded distribution of the new - cell marker PSA - BC6OTHER (polysialylated form of BC6ENTG ).	CPR:3
In hippocampal dentate gyrus , BC6ENTC - receiving rats showed a 51% decrease in BC6ENTG - ir density and a 61% expanded distribution of the new - cell marker PSA - BC6OTHER (polysialylated form of BC6OTHER ).	CPR:4
In hippocampal dentate gyrus , BC6ENTC - receiving rats showed a 51% decrease in BC6OTHER - ir density and a 61% expanded distribution of the new - cell marker PSA - BC6ENTG (polysialylated form of BC6OTHER ).	CPR:3
CONCLUSION: The peptide sequences containing BC6ENTC , BC6OTHER conservative residues identified in this study can bind to cell surface BC6ENTG .	False
CONCLUSION: The peptide sequences containing BC6OTHER , BC6ENTC conservative residues identified in this study can bind to cell surface BC6ENTG .	False
Furthermore , RA significantly inhibited the BC6ENTC - induced apoptosis , which was evident from decreased cleavage of BC6ENTG .	CPR:4
BC6ENTC intoxication caused hepatic necrosis and increased serum BC6ENTG activity.	CPR:3
In the livers , oxidative / nitrosative stress was evidenced by increased BC6ENTC ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in BC6ENTG BC6OTHER dismutase ( BC6OTHER ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6ENTC ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in CHEM / BC6OTHER BC6OTHER dismutase ( BC6ENTG ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6ENTC ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in BC6ENTG BC6OTHER dismutase ( BC6OTHER ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6ENTC ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in CHEM / BC6OTHER BC6OTHER dismutase ( BC6ENTG ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6ENTC reactive substances (TBARS) formation and a significant decrease in BC6ENTG BC6OTHER dismutase ( BC6OTHER ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6ENTC reactive substances (TBARS) formation and a significant decrease in CHEM / BC6OTHER BC6OTHER dismutase ( BC6ENTG ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in BC6ENTC / BC6OTHER BC6OTHER dismutase ( BC6ENTG ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in CHEM / BC6ENTC BC6OTHER dismutase ( BC6ENTG ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in BC6ENTG BC6ENTC dismutase ( BC6OTHER ) activity.	False
In the livers , oxidative / nitrosative stress was evidenced by increased BC6OTHER ( BC6OTHER ) and BC6OTHER reactive substances (TBARS) formation and a significant decrease in CHEM / BC6OTHER BC6ENTC dismutase ( BC6ENTG ) activity.	False
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6ENTG ( BC6OTHER ) , which coincided with the induction of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6OTHER ( BC6ENTG ) , which coincided with the induction of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6OTHER ( BC6OTHER ) , which coincided with the induction of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6OTHER ( BC6OTHER ) , which coincided with the induction of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:3
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6OTHER ( BC6OTHER ) , which coincided with the induction of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC administration triggered inflammatory response in mice livers by activating BC6OTHER ( BC6OTHER ) , which coincided with the induction of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:3
BC6ENTC ( BC6OTHER ) depress neuronal excitability via positive allosteric modulation of inhibitory BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) depress neuronal excitability via positive allosteric modulation of inhibitory BC6OTHER ( BC6ENTG ).	False
BC6ENTG channels were less sensitive to BC6ENTC inhibition than BC6OTHER channels , similar to BC6OTHER ( BC6OTHER ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6ENTC inhibition than BC6ENTG channels , similar to BC6OTHER ( BC6OTHER ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6ENTC inhibition than BC6OTHER channels , similar to BC6OTHER ( BC6OTHER ) BC6ENTG antagonists.	False
BC6ENTG channels were less sensitive to BC6OTHER inhibition than BC6OTHER channels , similar to BC6ENTC ( BC6OTHER ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6OTHER inhibition than BC6ENTG channels , similar to BC6ENTC ( BC6OTHER ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6OTHER inhibition than BC6OTHER channels , similar to BC6ENTC ( BC6OTHER ) BC6ENTG antagonists.	CPR:6
BC6ENTG channels were less sensitive to BC6OTHER inhibition than BC6OTHER channels , similar to BC6OTHER ( BC6ENTC ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6OTHER inhibition than BC6ENTG channels , similar to BC6OTHER ( BC6ENTC ) BC6OTHER antagonists.	CPR:4
BC6OTHER channels were less sensitive to BC6OTHER inhibition than BC6OTHER channels , similar to BC6OTHER ( BC6ENTC ) BC6ENTG antagonists.	CPR:6
All BC6ENTG modulators induced a negative shift in the steady - state inactivation curve of BC6OTHER channels , but only BC6ENTC and BC6OTHER induced a negative shift in BC6OTHER channel inactivation.	False
All BC6OTHER modulators induced a negative shift in the steady - state inactivation curve of BC6ENTG channels , but only BC6ENTC and BC6OTHER induced a negative shift in BC6OTHER channel inactivation.	False
All BC6OTHER modulators induced a negative shift in the steady - state inactivation curve of BC6OTHER channels , but only BC6ENTC and BC6OTHER induced a negative shift in BC6ENTG channel inactivation.	CPR:4
All BC6ENTG modulators induced a negative shift in the steady - state inactivation curve of BC6OTHER channels , but only BC6OTHER and BC6ENTC induced a negative shift in BC6OTHER channel inactivation.	False
All BC6OTHER modulators induced a negative shift in the steady - state inactivation curve of BC6ENTG channels , but only BC6OTHER and BC6ENTC induced a negative shift in BC6OTHER channel inactivation.	False
All BC6OTHER modulators induced a negative shift in the steady - state inactivation curve of BC6OTHER channels , but only BC6OTHER and BC6ENTC induced a negative shift in BC6ENTG channel inactivation.	CPR:4
BC6ENTC and other positive BC6ENTG modulators , including BC6OTHER , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	False
BC6ENTC and other positive BC6OTHER modulators , including BC6OTHER , BC6OTHER , and BC6OTHER , can also inhibit BC6ENTG ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6ENTC and other positive BC6OTHER modulators , including BC6OTHER , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6ENTG ) , which could contribute to reduced neuronal excitability.	CPR:4
Mutation of the high - affinity BC6ENTC binding site ( BC6ENTG and BC6OTHER ) in BC6OTHER channels reduced BC6OTHER potency.	False
Mutation of the high - affinity BC6ENTC binding site ( BC6OTHER and BC6ENTG ) in BC6OTHER channels reduced BC6OTHER potency.	False
Mutation of the high - affinity BC6ENTC binding site ( BC6OTHER and BC6OTHER ) in BC6ENTG channels reduced BC6OTHER potency.	False
Mutation of the BC6ENTG ( BC6OTHER and BC6OTHER ) in BC6OTHER channels reduced BC6ENTC potency.	False
Mutation of the high - affinity BC6OTHER binding site ( BC6ENTG and BC6OTHER ) in BC6OTHER channels reduced BC6ENTC potency.	False
Mutation of the high - affinity BC6OTHER binding site ( BC6OTHER and BC6ENTG ) in BC6OTHER channels reduced BC6ENTC potency.	False
Mutation of the high - affinity BC6OTHER binding site ( BC6OTHER and BC6OTHER ) in BC6ENTG channels reduced BC6ENTC potency.	False
Despite the structural similarity between BC6ENTC and BC6OTHER , mutation of an BC6OTHER important for BC6OTHER potency ( BC6ENTG ) did not affect BC6OTHER potency.	False
Despite the structural similarity between BC6OTHER and BC6ENTC , mutation of an BC6OTHER important for BC6OTHER potency ( BC6ENTG ) did not affect BC6OTHER potency.	False
Despite the structural similarity between BC6OTHER and BC6OTHER , mutation of an BC6ENTC important for BC6OTHER potency ( BC6ENTG ) did not affect BC6OTHER potency.	False
Despite the structural similarity between BC6OTHER and BC6OTHER , mutation of an BC6OTHER important for BC6ENTC potency ( BC6ENTG ) did not affect BC6OTHER potency.	False
Despite the structural similarity between BC6OTHER and BC6OTHER , mutation of an BC6OTHER important for BC6OTHER potency ( BC6ENTG ) did not affect BC6ENTC potency.	CPR:4
Although BC6ENTG inhibition by BC6ENTC occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6OTHER during long - term treatment , BC6OTHER and CHEM inhibited BC6OTHER at clinically relevant concentrations.	CPR:4
Although BC6OTHER inhibition by BC6ENTC occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6ENTG during long - term treatment , BC6OTHER and CHEM inhibited BC6OTHER at clinically relevant concentrations.	False
Although BC6OTHER inhibition by BC6ENTC occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6OTHER during long - term treatment , BC6OTHER and CHEM inhibited BC6ENTG at clinically relevant concentrations.	False
BC6OTHER ( BC6ENTC ) depress neuronal excitability via positive allosteric modulation of inhibitory BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) depress neuronal excitability via positive allosteric modulation of inhibitory BC6OTHER ( BC6ENTG ).	False
Although BC6ENTG inhibition by BC6OTHER occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6OTHER during long - term treatment , BC6ENTC and CHEM inhibited BC6OTHER at clinically relevant concentrations.	False
Although BC6OTHER inhibition by BC6OTHER occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6ENTG during long - term treatment , BC6ENTC and CHEM inhibited BC6OTHER at clinically relevant concentrations.	False
Although BC6OTHER inhibition by BC6OTHER occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up - regulation of BC6OTHER during long - term treatment , BC6ENTC and CHEM inhibited BC6ENTG at clinically relevant concentrations.	CPR:4
BC6OTHER and other positive BC6ENTG modulators , including BC6ENTC , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	False
BC6OTHER and other positive BC6OTHER modulators , including BC6ENTC , BC6OTHER , and BC6OTHER , can also inhibit BC6ENTG ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6OTHER modulators , including BC6ENTC , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6ENTG ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6ENTG modulators , including BC6OTHER , BC6ENTC , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	False
BC6OTHER and other positive BC6OTHER modulators , including BC6OTHER , BC6ENTC , and BC6OTHER , can also inhibit BC6ENTG ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6OTHER modulators , including BC6OTHER , BC6ENTC , and BC6OTHER , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6ENTG ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6ENTG modulators , including BC6OTHER , BC6OTHER , and BC6ENTC , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	False
BC6OTHER and other positive BC6OTHER modulators , including BC6OTHER , BC6OTHER , and BC6ENTC , can also inhibit BC6ENTG ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6OTHER modulators , including BC6OTHER , BC6OTHER , and BC6ENTC , can also inhibit L - type voltage - gated BC6OTHER channels ( BC6ENTG ) , which could contribute to reduced neuronal excitability.	CPR:4
BC6OTHER and other positive BC6ENTG modulators , including BC6OTHER , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6ENTC channels ( BC6OTHER ) , which could contribute to reduced neuronal excitability.	False
BC6OTHER and other positive BC6OTHER modulators , including BC6OTHER , BC6OTHER , and BC6OTHER , can also inhibit L - type voltage - gated BC6ENTC channels ( BC6ENTG ) , which could contribute to reduced neuronal excitability.	False
The current studies assessed the effects of BC6ENTC ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6ENTC ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6ENTC ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6ENTC , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6ENTC , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6ENTC , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6ENTC , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6ENTC , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6ENTC , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTC ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTC ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTC ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6ENTC , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6ENTC , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6ENTC , BC6OTHER , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6ENTC , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6ENTC , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6ENTC , and BC6OTHER on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6ENTC on whole - cell BC6OTHER currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6ENTC on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6ENTC on whole - cell BC6OTHER currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6ENTC currents through recombinant neuronal BC6ENTG and BC6OTHER BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6ENTC currents through recombinant neuronal BC6OTHER and BC6ENTG BC6OTHER expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
The current studies assessed the effects of BC6OTHER ( BC6OTHER , BC6OTHER , and BC6OTHER ) , BC6OTHER , BC6OTHER , and BC6OTHER on whole - cell BC6ENTC currents through recombinant neuronal BC6OTHER and BC6OTHER BC6ENTG expressed with beta(3) and alpha(2)delta - 1 in HEK293T cells.	False
Inhibition of recombinant L - type voltage - gated BC6ENTC channels by positive allosteric modulators of BC6ENTG .	False
Mice overexpressing BC6ENTG exhibited at adult age impaired BC6ENTC tolerance associated with reduced insulin secretion , decreased β - cell mass , and β - cell hypotrophy.	False
In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the BC6ENTG BC6ENTC ) and the BC6OTHER transporters using the selective ligands BC6OTHER and BC6OTHER , respectively.	False
In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the BC6ENTG BC6OTHER ) and the BC6ENTC transporters using the selective ligands BC6OTHER and BC6OTHER , respectively.	False
In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the BC6ENTG BC6OTHER ) and the BC6OTHER transporters using the selective ligands BC6ENTC and BC6OTHER , respectively.	False
In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the BC6ENTG BC6OTHER ) and the BC6OTHER transporters using the selective ligands BC6OTHER and BC6ENTC , respectively.	False
The selective BC6ENTC reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6OTHER .	False
The selective BC6ENTC reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6OTHER , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6ENTC , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6OTHER .	False
The selective BC6OTHER reuptake inhibitors BC6ENTC , BC6OTHER and BC6OTHER displayed a high affinity for the BC6OTHER , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6ENTC and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6OTHER .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6ENTC and BC6OTHER displayed a high affinity for the BC6OTHER , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6ENTC displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6OTHER .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6ENTC displayed a high affinity for the BC6OTHER , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTC transporter , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6ENTC reuptake inhibitor BC6OTHER had a high affinity for the BC6OTHER .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6OTHER , whereas the BC6ENTC reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6ENTC had a high affinity for the BC6OTHER .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6OTHER , whereas the BC6OTHER reuptake inhibitor BC6ENTC had a high affinity for the BC6ENTG .	False
The selective BC6OTHER reuptake inhibitors BC6OTHER , BC6OTHER and BC6OTHER displayed a high affinity for the BC6ENTG , whereas the BC6OTHER reuptake inhibitor BC6OTHER had a high affinity for the BC6ENTC transporter.	False
BC6ENTC , a dual BC6OTHER and BC6OTHER reuptake inhibitor , displayed a high affinity for both the BC6ENTG .	False
BC6OTHER , a dual BC6ENTC and BC6OTHER reuptake inhibitor , displayed a high affinity for both the BC6ENTG .	False
BC6OTHER , a dual BC6OTHER and BC6ENTC reuptake inhibitor , displayed a high affinity for both the BC6ENTG .	False
Interestingly , BC6ENTC , a dual BC6OTHER and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6ENTG (Ki = 74 nM) and a very low affinity for the BC6OTHER (Ki = 1.26 microM).	False
Interestingly , BC6ENTC , a dual BC6OTHER and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6OTHER (Ki = 74 nM) and a very low affinity for the BC6ENTG (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6ENTC and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6ENTG (Ki = 74 nM) and a very low affinity for the BC6OTHER (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6ENTC and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6OTHER (Ki = 74 nM) and a very low affinity for the BC6ENTG (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6OTHER and BC6ENTC reuptake inhibitor , displayed only a moderate affinity for the BC6ENTG (Ki = 74 nM) and a very low affinity for the BC6OTHER (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6OTHER and BC6ENTC reuptake inhibitor , displayed only a moderate affinity for the BC6OTHER (Ki = 74 nM) and a very low affinity for the BC6ENTG (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6OTHER and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6ENTC transporter (Ki = 74 nM) and a very low affinity for the BC6ENTG (Ki = 1.26 microM).	False
Interestingly , BC6OTHER , a dual BC6OTHER and BC6OTHER reuptake inhibitor , displayed only a moderate affinity for the BC6ENTG (Ki = 74 nM) and a very low affinity for the BC6ENTC transporter (Ki = 1.26 microM).	False
Affinities of BC6ENTC and various reuptake inhibitors for the BC6ENTG .	False
BC6ENTC content , BC6ENTG activity and BC6OTHER mRNA expression in nasal mucosa were also significantly increased after BC6OTHER provocation.	False
BC6ENTC content , BC6OTHER activity and BC6ENTG mRNA expression in nasal mucosa were also significantly increased after BC6OTHER provocation.	False
BACKGROUND: BC6ENTC synthesized by BC6ENTG ( BC6OTHER ) from BC6OTHER is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.	CPR:9
BACKGROUND: BC6ENTC synthesized by BC6OTHER ( BC6ENTG ) from BC6OTHER is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.	CPR:9
BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA expression in nasal mucosa were also significantly increased after BC6ENTC provocation.	CPR:3
BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA expression in nasal mucosa were also significantly increased after BC6ENTC provocation.	CPR:3
Pretreatment with BC6ENTC significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA induced by BC6OTHER in BC6OTHER - sensitized rats.	CPR:4
Pretreatment with BC6ENTC significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA induced by BC6OTHER in BC6OTHER - sensitized rats.	CPR:4
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6ENTC content , BC6ENTG activity and BC6OTHER mRNA induced by BC6OTHER in BC6OTHER - sensitized rats.	False
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6ENTC content , BC6OTHER activity and BC6ENTG mRNA induced by BC6OTHER in BC6OTHER - sensitized rats.	False
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA induced by BC6ENTC in BC6OTHER - sensitized rats.	CPR:3
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA induced by BC6ENTC in BC6OTHER - sensitized rats.	CPR:3
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA induced by BC6OTHER in BC6ENTC - sensitized rats.	False
Pretreatment with BC6OTHER significantly suppressed nasal allergy - like behaviors , up - regulation of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA induced by BC6OTHER in BC6ENTC - sensitized rats.	CPR:3
CONCLUSIONS: These findings indicate that increased synthesis of BC6ENTC through up - regulation of BC6ENTG gene expression and BC6OTHER activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.	CPR:9
CONCLUSIONS: These findings indicate that increased synthesis of BC6ENTC through up - regulation of BC6OTHER gene expression and BC6ENTG activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.	CPR:9
Repression of BC6ENTG gene expression and BC6OTHER activity by BC6ENTC may underlie its therapeutic effect in the treatment of allergy.	CPR:4
Repression of BC6OTHER gene expression and BC6ENTG activity by BC6ENTC may underlie its therapeutic effect in the treatment of allergy.	CPR:4
However the regulatory mechanism of BC6ENTC synthesis by BC6ENTG remains to be elucidated.	CPR:9
The objectives of the present study were to examine the changes of BC6ENTC content , BC6ENTG activity and BC6OTHER mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6OTHER ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6ENTC content , BC6OTHER activity and BC6ENTG mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6OTHER ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
BACKGROUND: BC6OTHER synthesized by BC6ENTC decarboxylase ( BC6ENTG ) from BC6OTHER is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6ENTC ( BC6OTHER ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6ENTC ( BC6OTHER ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6ENTC ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6ENTC ) and to investigate the effect of BC6OTHER on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6ENTG activity and BC6OTHER mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6OTHER ) and to investigate the effect of BC6ENTC on the above mentioned allergic parameters.	False
The objectives of the present study were to examine the changes of BC6OTHER content , BC6OTHER activity and BC6ENTG mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to BC6OTHER ( BC6OTHER ) and to investigate the effect of BC6ENTC on the above mentioned allergic parameters.	False
BACKGROUND: BC6OTHER synthesized by BC6ENTG ( BC6OTHER ) from BC6ENTC is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.	CPR:9
BACKGROUND: BC6OTHER synthesized by BC6OTHER ( BC6ENTG ) from BC6ENTC is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.	CPR:9
BC6ENTC content and BC6ENTG activity in the nasal mucosa were determined using fluorometric high performance liquid chromatography.	False
 BC6ENTC suppresses BC6OTHER synthesis by repressing both transcription and activity of BC6ENTG in allergic rats.	CPR:4
 BC6OTHER suppresses BC6ENTC synthesis by repressing both transcription and activity of BC6ENTG in allergic rats.	False
Thereafter , the BC6ENTG hydrolysates were sequentially fractionated by ultra filtration membranes in cut - off molecular weight (MW) of 30 , 10 , and 1kDa , and tested their antioxidant activities in terms of RP ability , BC6ENTC radical scavenging ability , BC6OTHER radical scavenging ability , and FRAP assay.	False
Thereafter , the BC6ENTG hydrolysates were sequentially fractionated by ultra filtration membranes in cut - off molecular weight (MW) of 30 , 10 , and 1kDa , and tested their antioxidant activities in terms of RP ability , BC6OTHER radical scavenging ability , BC6ENTC radical scavenging ability , and FRAP assay.	False
CRE and EB treatment also recovered BC6ENTG immunopositive fibers and cells , respectively , from BC6ENTC toxicity.	False
Additionally , BC6ENTC significantly down - regulated BC6ENTG expression in the mitochondria of dopaminergic cells in the SN , followed by an increase in BC6OTHER expression , BC6OTHER translocation to the cytosol , andcleaved - BC6OTHER expression , whereas these were inhibited by CRE or EB treatment.	CPR:4
Additionally , BC6ENTC significantly down - regulated BC6OTHER expression in the mitochondria of dopaminergic cells in the SN , followed by an increase in BC6ENTG expression , BC6OTHER translocation to the cytosol , andcleaved - BC6OTHER expression , whereas these were inhibited by CRE or EB treatment.	CPR:3
Additionally , BC6ENTC significantly down - regulated BC6OTHER expression in the mitochondria of dopaminergic cells in the SN , followed by an increase in BC6OTHER expression , BC6ENTG translocation to the cytosol , andcleaved - BC6OTHER expression , whereas these were inhibited by CRE or EB treatment.	False
Additionally , BC6ENTC significantly down - regulated BC6OTHER expression in the mitochondria of dopaminergic cells in the SN , followed by an increase in BC6OTHER expression , BC6OTHER translocation to the cytosol , andcleaved - BC6ENTG expression , whereas these were inhibited by CRE or EB treatment.	CPR:3
MATERIALS AND METHODS: To determine the BC6ENTC - like effect of Cyperi Rhizoma extract (CRE) , we measured luciferase expression after transfection of a promoter construct containing an BC6ENTG ( BC6OTHER ) and treatment of CRE.	False
MATERIALS AND METHODS: To determine the BC6ENTC - like effect of Cyperi Rhizoma extract (CRE) , we measured luciferase expression after transfection of a promoter construct containing an BC6OTHER ( BC6ENTG ) and treatment of CRE.	False
MATERIALS AND METHODS: To determine the BC6OTHER - like effect of Cyperi Rhizoma extract (CRE) , we measured luciferase expression after transfection of a promoter construct containing an BC6ENTC response element ( BC6ENTG ) and treatment of CRE.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6ENTC , movement ability , BC6ENTG ( BC6OTHER ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6OTHER ( BC6OTHER ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6ENTC , movement ability , BC6OTHER ( BC6ENTG ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6OTHER ( BC6OTHER ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6OTHER , movement ability , BC6ENTC hydroxylase ( BC6ENTG ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6OTHER ( BC6OTHER ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6OTHER , movement ability , BC6ENTG ( BC6OTHER ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6ENTC ( BC6OTHER ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6OTHER , movement ability , BC6OTHER ( BC6ENTG ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6ENTC ( BC6OTHER ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6OTHER , movement ability , BC6ENTG ( BC6OTHER ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6OTHER ( BC6ENTC ) in ovariectomized female mice.	False
To evaluate the neuroprotective effect of CRE , we measured striatal BC6OTHER , movement ability , BC6OTHER ( BC6ENTG ) immunoreactivity , and apoptosis - related protein expression levels after treatment of CRE either with or without BC6OTHER ( BC6ENTC ) in ovariectomized female mice.	False
The BC6ENTG antagonists , on the other hand , reduce the dynamic component of obstruction - - relaxation of smooth muscle in the prostate , urethra and bladder neck - - and provide rapid symptom relief after only a few doses , relieving LUTS more effectively than BC6ENTC and irrespective of prostate size.	False
 Both the BC6ENTG inhibitor BC6ENTC and BC6OTHER antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:4
 Both the BC6OTHER inhibitor BC6ENTC and BC6ENTG antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6ENTG inhibitor BC6OTHER and BC6OTHER antagonists (e.g. BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6OTHER inhibitor BC6OTHER and BC6ENTG antagonists (e.g. BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:6
 Both the BC6ENTG inhibitor BC6OTHER and BC6OTHER antagonists (e.g. BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6OTHER inhibitor BC6OTHER and BC6ENTG antagonists (e.g. BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:6
 Both the BC6ENTG inhibitor BC6OTHER and BC6OTHER antagonists (e.g. BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6OTHER inhibitor BC6OTHER and BC6ENTG antagonists (e.g. BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:6
 Both the BC6ENTG inhibitor BC6OTHER and BC6OTHER antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6OTHER inhibitor BC6OTHER and BC6ENTG antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:6
 Both the BC6ENTG inhibitor BC6OTHER and BC6OTHER antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	False
 Both the BC6OTHER inhibitor BC6OTHER and BC6ENTG antagonists (e.g. BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) have been recommended as appropriate treatment options for patients with lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO) , and their efficacy has been proven in several placebo - controlled trials.	CPR:6
BC6ENTC are biosynthesised from BC6OTHER by the BC6ENTG enzyme complex called BC6OTHER .	CPR:9
BC6ENTC are biosynthesised from BC6OTHER by the BC6OTHER enzyme complex called BC6ENTG .	CPR:9
These third - generation BC6ENTG inhibitors are currently approved as first - line therapy for the treatment of postmenopausal women with metastatic BC6ENTC - dependent breast cancer.	False
The use of an BC6ENTG inhibitor as initial therapy , or after treatment with BC6ENTC , is now recommended as adjuvant hormonal therapy for postmenopausal women with hormone - dependent breast cancer.	False
In breast cancer , intratumoural BC6ENTG is the source for local BC6ENTC production in the tissue.	CPR:9
BC6OTHER are biosynthesised from BC6ENTC by the BC6ENTG enzyme complex called BC6OTHER .	False
BC6OTHER are biosynthesised from BC6ENTC by the BC6OTHER enzyme complex called BC6ENTG .	CPR:9
Inhibition of BC6ENTG is an important approach for reducing growth stimulatory effects of BC6ENTC in BC6OTHER - dependent breast cancer.	False
Inhibition of BC6ENTG is an important approach for reducing growth stimulatory effects of BC6OTHER in BC6ENTC - dependent breast cancer.	False
The potent and selective third - generation BC6ENTG inhibitors BC6ENTC , BC6OTHER and CHEM were introduced to the market as endocrine therapy in postmenopausal patients failing anti - BC6OTHER therapy alone , or multiple hormonal therapies.	CPR:4
The potent and selective third - generation BC6ENTG inhibitors BC6OTHER , BC6ENTC and CHEM were introduced to the market as endocrine therapy in postmenopausal patients failing anti - BC6OTHER therapy alone , or multiple hormonal therapies.	CPR:4
The potent and selective third - generation BC6ENTG inhibitors BC6OTHER , BC6OTHER and CHEM were introduced to the market as endocrine therapy in postmenopausal patients failing anti - BC6ENTC therapy alone , or multiple hormonal therapies.	False
BC6ENTC and BC6OTHER are both non - BC6OTHER BC6ENTG inhibitors that compete with the substrate for binding to the enzyme active site.	CPR:4
BC6OTHER and BC6ENTC are both non - BC6OTHER BC6ENTG inhibitors that compete with the substrate for binding to the enzyme active site.	CPR:4
BC6OTHER and BC6OTHER are both non - BC6ENTC BC6ENTG inhibitors that compete with the substrate for binding to the enzyme active site.	False
CHEM is a mechanism - based BC6ENTC inhibitor that mimics the substrate , is converted by the enzyme to a reactive intermediate , and results in inactivation of BC6ENTG .	False
The BC6OTHER - like BC6ENTC protease BC6ENTG is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss.	False
The BC6ENTG - like BC6ENTC protease BC6OTHER is a target for the development of antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce excessive blood loss.	False
The most potent inhibitor 8 binds to BC6ENTG with an inhibition constant of 0.2 nM , whereas K(i) values >1 μM were determined for nearly all other tested trypsin - like BC6ENTC proteases , with the exception of BC6OTHER , which is also inhibited in the nanomolar range.	False
The most potent inhibitor 8 binds to BC6OTHER with an inhibition constant of 0.2 nM , whereas K(i) values >1 μM were determined for nearly all other tested trypsin - like BC6ENTC proteases , with the exception of BC6ENTG , which is also inhibited in the nanomolar range.	False
The potent BC6ENTG antagonist BC6OTHER ( BC6OTHER ) is a racemic mixture of BC6OTHER (now available under the trademark BC6ENTC and BC6OTHER .	CPR:6
The potent BC6ENTG antagonist BC6OTHER ( BC6OTHER ) is a racemic mixture of BC6OTHER (now available under the trademark BC6OTHER and BC6ENTC .	CPR:6
The potent BC6ENTG antagonist BC6ENTC ( BC6OTHER ) is a racemic mixture of BC6OTHER (now available under the trademark BC6OTHER and BC6OTHER .	CPR:6
The potent BC6ENTG antagonist BC6OTHER ( BC6ENTC ) is a racemic mixture of BC6OTHER (now available under the trademark BC6OTHER and BC6OTHER .	CPR:6
The potent BC6ENTG antagonist BC6OTHER ( BC6OTHER ) is a racemic mixture of BC6ENTC (now available under the trademark BC6OTHER and BC6OTHER .	CPR:6
Compared pharmacological characteristics in humans of racemic BC6ENTC and BC6OTHER , two BC6ENTG antagonists.	CPR:6
Compared pharmacological characteristics in humans of racemic BC6OTHER and BC6ENTC , two BC6ENTG antagonists.	CPR:6
The chemistry , pharmacology , pharmacokinetics , clinical efficacy , adverse effects , and dosages of the nonsedating BC6ENTG antagonists BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER are reviewed.	CPR:6
The chemistry , pharmacology , pharmacokinetics , clinical efficacy , adverse effects , and dosages of the nonsedating BC6ENTG antagonists BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER are reviewed.	CPR:6
The chemistry , pharmacology , pharmacokinetics , clinical efficacy , adverse effects , and dosages of the nonsedating BC6ENTG antagonists BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER are reviewed.	CPR:6
The chemistry , pharmacology , pharmacokinetics , clinical efficacy , adverse effects , and dosages of the nonsedating BC6ENTG antagonists BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC are reviewed.	CPR:6
BC6ENTC and BC6OTHER are chemically unrelated to BC6ENTG antagonists such as BC6OTHER and BC6OTHER .	CPR:6
BC6OTHER and BC6ENTC are chemically unrelated to BC6ENTG antagonists such as BC6OTHER and BC6OTHER .	CPR:6
BC6OTHER and BC6OTHER are chemically unrelated to BC6ENTG antagonists such as BC6ENTC and BC6OTHER .	CPR:6
BC6OTHER and BC6OTHER are chemically unrelated to BC6ENTG antagonists such as BC6OTHER and BC6ENTC .	CPR:6
Like other BC6ENTC H1 - receptor antagonists , they competitively block BC6ENTG sites rather than inhibiting BC6OTHER release.	False
Like other BC6ENTG antagonists , they competitively block BC6ENTC receptor sites rather than inhibiting BC6OTHER release.	False
Like other BC6ENTG antagonists , they competitively block BC6OTHER sites rather than inhibiting BC6ENTC release.	False
Like other BC6OTHER antagonists , they competitively block BC6ENTG sites rather than inhibiting BC6ENTC release.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6OTHER , hepatic TG , and BC6OTHER , and in the expression levels of BC6OTHER , and BC6ENTG ; on the contrary , the levels of BC6ENTC increased.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6ENTG , hepatic TG , and BC6OTHER , and in the expression levels of BC6OTHER , and BC6OTHER ; on the contrary , the levels of BC6ENTC increased.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6OTHER , hepatic TG , and BC6OTHER , and in the expression levels of BC6ENTG , and BC6OTHER ; on the contrary , the levels of BC6ENTC increased.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6ENTG ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTC aminotransferase ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTG ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6ENTG ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6ENTC (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTG ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6ENTG ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTG ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6ENTG ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTG ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6ENTG ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6ENTG ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6ENTG ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6ENTG and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6ENTG ; and levels of BC6OTHER and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6ENTG and BC6OTHER / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6ENTG / BC6OTHER protein.	False
Hepatic function was assessed by evaluating the following parameters: liver histology; plasma levels of BC6OTHER ( BC6OTHER ) , BC6OTHER (TG) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ); expression levels of BC6OTHER and BC6OTHER ; and levels of BC6OTHER and BC6OTHER / BC6ENTG protein.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6OTHER , hepatic TG , and BC6ENTC , and in the expression levels of BC6OTHER , and BC6ENTG ; on the contrary , the levels of BC6OTHER increased.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6ENTG , hepatic TG , and BC6ENTC , and in the expression levels of BC6OTHER , and BC6OTHER ; on the contrary , the levels of BC6OTHER increased.	False
Moreover , EDL led to a significant decrease in the serum levels of BC6OTHER , hepatic TG , and BC6ENTC , and in the expression levels of BC6ENTG , and BC6OTHER ; on the contrary , the levels of BC6OTHER increased.	False
Competitive displacement binding assays using BC6ENTG / BVD15 - DO3A against BC6ENTC - BC6OTHER (4) - CHEM yielded an IC(50) value of 18 ± 0.7 nM for BC6OTHER in T - 47D cells , a human breast cancer cell line.	False
Competitive displacement binding assays using BC6OTHER / BVD15 - DO3A against BC6ENTC - BC6OTHER (4) - CHEM yielded an IC(50) value of 18 ± 0.7 nM for BC6ENTG in T - 47D cells , a human breast cancer cell line.	False
Competitive displacement binding assays using BC6ENTG / BVD15 - DO3A against CHEM yielded an IC(50) value of 18 ± 0.7 nM for BC6OTHER in T - 47D cells , a human breast cancer cell line.	False
Competitive displacement binding assays using BC6OTHER / BVD15 - DO3A against CHEM yielded an IC(50) value of 18 ± 0.7 nM for BC6ENTG in T - 47D cells , a human breast cancer cell line.	False
A similar assay using BC6ENTG / BVD15 - DO3A against porcine BC6ENTC - NPY showed IC(50) values of 80 ± 11 nM for BC6OTHER in CHEM cells , another human breast cancer cell line.	False
A similar assay using BC6OTHER / BVD15 - DO3A against porcine BC6ENTC - NPY showed IC(50) values of 80 ± 11 nM for BC6ENTG in CHEM cells , another human breast cancer cell line.	False
We describe here the design and development of a new heterobivalent peptide ligand , truncated BC6ENTC ( BC6ENTG ) / BVD15 - DO3A , for dual - targeting of BC6OTHER and BC6OTHER , and validation of its dual binding capability.	False
We describe here the design and development of a new heterobivalent peptide ligand , truncated BC6ENTC ( BC6OTHER ) / BVD15 - DO3A , for dual - targeting of BC6ENTG and BC6OTHER , and validation of its dual binding capability.	False
We describe here the design and development of a new heterobivalent peptide ligand , truncated BC6ENTC ( BC6OTHER ) / BVD15 - DO3A , for dual - targeting of BC6OTHER and BC6ENTG , and validation of its dual binding capability.	False
Second , BC6ENTC , an antiatherogenic compound reported to be an inactivator of BC6ENTG reduced hepatic BC6OTHER secretion.	CPR:4
Second , BC6OTHER , an antiatherogenic compound reported to be an inactivator of BC6ENTG reduced hepatic BC6ENTC secretion.	False
Third , BC6ENTG - RNAi suppressed hepatic BC6ENTC secretion.	CPR:9
These results strongly suggest that BC6ENTG is substantially involved in hepatic BC6ENTC secretion.	CPR:9
BC6OTHER ( BC6ENTG ) , the product of the gene responsible for familial isolated BC6ENTC deficiency , plays an important role in maintaining the plasma BC6OTHER level by mediating the secretion of BC6OTHER by the liver.	False
BC6ENTG ( BC6OTHER ) , the product of the gene responsible for familial isolated BC6ENTC deficiency , plays an important role in maintaining the plasma BC6OTHER level by mediating the secretion of BC6OTHER by the liver.	False
BC6OTHER ( BC6ENTG ) , the product of the gene responsible for familial isolated BC6OTHER deficiency , plays an important role in maintaining the plasma BC6ENTC level by mediating the secretion of BC6OTHER by the liver.	CPR:9
BC6ENTG ( BC6OTHER ) , the product of the gene responsible for familial isolated BC6OTHER deficiency , plays an important role in maintaining the plasma BC6ENTC level by mediating the secretion of BC6OTHER by the liver.	CPR:9
BC6OTHER ( BC6ENTG ) , the product of the gene responsible for familial isolated BC6OTHER deficiency , plays an important role in maintaining the plasma BC6OTHER level by mediating the secretion of BC6ENTC by the liver.	CPR:9
BC6ENTG ( BC6OTHER ) , the product of the gene responsible for familial isolated BC6OTHER deficiency , plays an important role in maintaining the plasma BC6OTHER level by mediating the secretion of BC6ENTC by the liver.	CPR:9
From in vitro experiments using BC6ENTC and McARH7777 cells that stably express BC6ENTG ( BC6OTHER ) , the following results were obtained.	False
From in vitro experiments using BC6ENTC and McARH7777 cells that stably express BC6OTHER ( BC6ENTG ) , the following results were obtained.	False
From in vitro experiments using BC6OTHER and McARH7777 cells that stably express BC6ENTC transfer protein ( BC6ENTG ) , the following results were obtained.	False
First , addition of BC6ENTG ( BC6OTHER ) , a direct acceptor of the BC6ENTC - binding cassette transporter A1 ( BC6OTHER ) - secreted lipids , increased BC6OTHER secretion in a dose - dependent manner.	False
First , addition of BC6OTHER ( BC6ENTG ) , a direct acceptor of the BC6ENTC - binding cassette transporter A1 ( BC6OTHER ) - secreted lipids , increased BC6OTHER secretion in a dose - dependent manner.	False
First , addition of BC6OTHER ( BC6OTHER ) , a direct acceptor of the BC6ENTC - binding cassette transporter A1 ( BC6ENTG ) - secreted lipids , increased BC6OTHER secretion in a dose - dependent manner.	False
BC6ENTC transfer protein ( BC6ENTG ) , the product of the gene responsible for familial isolated BC6OTHER deficiency , plays an important role in maintaining the plasma BC6OTHER level by mediating the secretion of BC6OTHER by the liver.	False
First , addition of BC6ENTG ( BC6OTHER ) , a direct acceptor of the BC6OTHER ( BC6OTHER ) - secreted lipids , increased BC6ENTC secretion in a dose - dependent manner.	CPR:9
First , addition of BC6OTHER ( BC6ENTG ) , a direct acceptor of the BC6OTHER ( BC6OTHER ) - secreted lipids , increased BC6ENTC secretion in a dose - dependent manner.	CPR:9
First , addition of BC6OTHER ( BC6OTHER ) , a direct acceptor of the BC6ENTG ( BC6OTHER ) - secreted lipids , increased BC6ENTC secretion in a dose - dependent manner.	CPR:9
First , addition of BC6OTHER ( BC6OTHER ) , a direct acceptor of the BC6OTHER ( BC6ENTG ) - secreted lipids , increased BC6ENTC secretion in a dose - dependent manner.	CPR:9
 BC6ENTG is involved in hepatic BC6ENTC secretion.	CPR:9
A recombinant chimeric molecule expressing the BC6ENTG sequence BC6OTHER within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6ENTG within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6OTHER within a BC6ENTG backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6OTHER within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6ENTG to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6OTHER within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6ENTG transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6OTHER within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6ENTG or plasma BC6OTHER had no effect.	False
A recombinant chimeric molecule expressing the BC6OTHER sequence BC6OTHER within a BC6OTHER backbone inhibited binding of BC6ENTC - BC6OTHER to HUVEC and BC6OTHER transfectants in a dose - dependent fashion , while recombinant BC6OTHER or plasma BC6ENTG had no effect.	False
Furthermore , binding of BC6ENTC - BC6ENTG to immobilized JC15 was inhibited by molar excess of unlabeled BC6OTHER , but not by comparable concentrations of BC6OTHER .	False
Furthermore , binding of BC6ENTC - BC6OTHER to immobilized JC15 was inhibited by molar excess of unlabeled BC6ENTG , but not by comparable concentrations of BC6OTHER .	False
Furthermore , binding of BC6ENTC - BC6OTHER to immobilized JC15 was inhibited by molar excess of unlabeled BC6OTHER , but not by comparable concentrations of BC6ENTG .	False
BC6ENTG or catalytically inactive BC6ENTC - BC6OTHER bound indistinguishably to HUVEC and BC6OTHER transfectants , and inhibited equally well the binding of CHEM - BC6OTHER to these cells.	False
BC6OTHER or catalytically inactive BC6ENTC - BC6ENTG bound indistinguishably to HUVEC and BC6OTHER transfectants , and inhibited equally well the binding of CHEM - BC6OTHER to these cells.	False
BC6OTHER or catalytically inactive BC6ENTC - BC6OTHER bound indistinguishably to HUVEC and BC6ENTG transfectants , and inhibited equally well the binding of CHEM - BC6OTHER to these cells.	False
BC6OTHER or catalytically inactive BC6ENTC - BC6OTHER bound indistinguishably to HUVEC and BC6OTHER transfectants , and inhibited equally well the binding of CHEM - BC6ENTG to these cells.	False
A BC6ENTG peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6ENTC ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6OTHER - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6ENTG CHEM83 - CHEM- ( BC6ENTC ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6OTHER - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6ENTC ) inhibited BC6ENTG - independent BC6OTHER activation by HUVEC and blocked binding of BC6OTHER - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6ENTC ) inhibited BC6OTHER - independent BC6ENTG activation by HUVEC and blocked binding of BC6OTHER - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6ENTC ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6OTHER - BC6ENTG to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6ENTG peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6OTHER ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6ENTC - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6ENTG CHEM83 - CHEM- ( BC6OTHER ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6ENTC - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER BC6ENTG inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6ENTC - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6OTHER ) inhibited BC6ENTG - independent BC6OTHER activation by HUVEC and blocked binding of BC6ENTC - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6OTHER ) inhibited BC6OTHER - independent BC6ENTG activation by HUVEC and blocked binding of BC6ENTC - BC6OTHER to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
A BC6OTHER peptide duplicating the BC6OTHER CHEM83 - CHEM- ( BC6OTHER ) inhibited BC6OTHER - independent BC6OTHER activation by HUVEC and blocked binding of BC6ENTC - BC6ENTG to these cells in a dose - dependent manner (IC50 approximately 20 - 40 microM).	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6ENTC - substrates , BC6OTHER ( BC6OTHER ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6ENTG , i.e. BC6OTHER .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6ENTC - substrates , BC6OTHER ( BC6OTHER ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6OTHER , i.e. BC6ENTG .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6ENTC ( BC6OTHER ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6ENTG , i.e. BC6OTHER .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6ENTC ( BC6OTHER ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6OTHER , i.e. BC6ENTG .	False
These interactions were studied by following BC6ENTG ( BC6OTHER ) release and by measuring intraplatelet BC6ENTC changes induced by BC6OTHER - BC6OTHER interaction.	False
These interactions were studied by following BC6OTHER ( BC6ENTG ) release and by measuring intraplatelet BC6ENTC changes induced by BC6OTHER - BC6OTHER interaction.	False
These interactions were studied by following BC6OTHER ( BC6OTHER ) release and by measuring intraplatelet BC6ENTC changes induced by BC6ENTG - BC6OTHER interaction.	False
These interactions were studied by following BC6OTHER ( BC6OTHER ) release and by measuring intraplatelet BC6ENTC changes induced by BC6OTHER - BC6ENTG interaction.	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6OTHER ( BC6ENTC ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6ENTG , i.e. BC6OTHER .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6OTHER ( BC6ENTC ) and BC6OTHER binding to the catalytic site of two proteolyzed forms of BC6OTHER , i.e. BC6ENTG .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6OTHER ( BC6OTHER ) and BC6ENTC binding to the catalytic site of two proteolyzed forms of BC6ENTG , i.e. BC6OTHER .	False
 An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of BC6OTHER - substrates , BC6OTHER ( BC6OTHER ) and BC6ENTC binding to the catalytic site of two proteolyzed forms of BC6OTHER , i.e. BC6ENTG .	False
Moreover , the values of delta Cp for BC6ENTG interaction with BC6ENTC were found to be linearly correlated to the free energy of activation for both BC6OTHER and BC6OTHER cleavage.	False
Moreover , the values of delta Cp for BC6OTHER interaction with BC6ENTC were found to be linearly correlated to the free energy of activation for both BC6ENTG and BC6OTHER cleavage.	False
Moreover , the values of delta Cp for BC6OTHER interaction with BC6ENTC were found to be linearly correlated to the free energy of activation for both BC6OTHER and BC6ENTG cleavage.	False
In conclusion , these data demonstrate that: (1) the CHEM144 - Gly150 loop and the BC6ENTG are both involved in the conformational transition linked to the binding of BC6ENTC to the BC6OTHER active site; (2) the extent of BC6OTHER capacity to undergo conformational transitions in alpha - , zeta - and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the BC6OTHER .	False
In conclusion , these data demonstrate that: (1) the CHEM144 - Gly150 loop and the BC6OTHER are both involved in the conformational transition linked to the binding of BC6ENTC to the BC6ENTG active site; (2) the extent of BC6OTHER capacity to undergo conformational transitions in alpha - , zeta - and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the BC6OTHER .	False
In conclusion , these data demonstrate that: (1) the CHEM144 - Gly150 loop and the BC6OTHER are both involved in the conformational transition linked to the binding of BC6ENTC to the BC6OTHER active site; (2) the extent of BC6ENTG capacity to undergo conformational transitions in alpha - , zeta - and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the BC6OTHER .	False
In conclusion , these data demonstrate that: (1) the CHEM144 - Gly150 loop and the BC6OTHER are both involved in the conformational transition linked to the binding of BC6ENTC to the BC6OTHER active site; (2) the extent of BC6OTHER capacity to undergo conformational transitions in alpha - , zeta - and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the BC6ENTG .	False
 A phenomenological analysis of thermodynamic data showed that the BC6ENTC substrates and BC6OTHER interactions with BC6ENTG were respectively , associated with a chemical compensation (i.e. the linear relationship between entropy and enthalpy of binding) and a hydrophobic phenomenon (i.e. a change in the standard heat capacity).	False
 A phenomenological analysis of thermodynamic data showed that the BC6OTHER substrates and BC6ENTC interactions with BC6ENTG were respectively , associated with a chemical compensation (i.e. the linear relationship between entropy and enthalpy of binding) and a hydrophobic phenomenon (i.e. a change in the standard heat capacity).	False
BACKGROUND: Systemic lupus erythematosus (SLE) is a complex genetic disease; the BC6ENTC H4 receptor ( BC6ENTG ) has been shown to be related to different kinds of autoimmune disorders; and copy number variations (CNVs) have been found to be associated with various types of diseases.	False
Despite normal binding , autoactivation of mutants BC6ENTG and BC6OTHER was not stimulated by BC6ENTC .	False
Despite normal binding , autoactivation of mutants BC6OTHER and BC6ENTG was not stimulated by BC6ENTC .	False
BC6ENTG stimulates trypsinogen autoactivation by processing the activation peptide to a shorter form but also promotes degradation by cleaving the BC6ENTC binding loop in trypsinogen.	False
The BC6ENTG in the trypsinogen activation peptide binds BC6ENTC (KD ~1.6 mM) , which stimulates autoactivation.	False
BACKGROUND AND AIMS: BC6ENTG ( BC6OTHER , BC6OTHER ) catalyses the conversion of BC6OTHER to BC6ENTC ( BC6OTHER ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6ENTG , BC6OTHER ) catalyses the conversion of BC6OTHER to BC6ENTC ( BC6OTHER ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6OTHER , BC6ENTG ) catalyses the conversion of BC6OTHER to BC6ENTC ( BC6OTHER ).	CPR:9
BACKGROUND AND AIMS: BC6ENTG ( BC6OTHER , BC6OTHER ) catalyses the conversion of BC6OTHER to BC6OTHER ( BC6ENTC ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6ENTG , BC6OTHER ) catalyses the conversion of BC6OTHER to BC6OTHER ( BC6ENTC ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6OTHER , BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER ( BC6ENTC ).	CPR:9
BACKGROUND AND AIMS: BC6ENTC decarboxylase ( BC6ENTG , BC6OTHER ) catalyses the conversion of BC6OTHER to BC6OTHER ( BC6OTHER ).	False
BACKGROUND AND AIMS: BC6ENTC decarboxylase ( BC6OTHER , BC6ENTG ) catalyses the conversion of BC6OTHER to BC6OTHER ( BC6OTHER ).	False
A hybrid cDNA was created by fusing a human cDNA for BC6ENTC 1 - 101 of BC6ENTG to a human cDNA for BC6OTHER 96 - 585 of BC6OTHER ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6OTHER with diabetes sera.	False
A hybrid cDNA was created by fusing a human cDNA for BC6ENTC 1 - 101 of BC6OTHER to a human cDNA for BC6OTHER 96 - 585 of BC6ENTG ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6OTHER with diabetes sera.	False
A hybrid cDNA was created by fusing a human cDNA for BC6ENTC 1 - 101 of BC6OTHER to a human cDNA for BC6OTHER 96 - 585 of BC6OTHER ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6ENTG with diabetes sera.	False
A hybrid cDNA was created by fusing a human cDNA for BC6OTHER 1 - 101 of BC6ENTG to a human cDNA for BC6ENTC 96 - 585 of BC6OTHER ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6OTHER with diabetes sera.	False
A hybrid cDNA was created by fusing a human cDNA for BC6OTHER 1 - 101 of BC6OTHER to a human cDNA for BC6ENTC 96 - 585 of BC6ENTG ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6OTHER with diabetes sera.	False
A hybrid cDNA was created by fusing a human cDNA for BC6OTHER 1 - 101 of BC6OTHER to a human cDNA for BC6ENTC 96 - 585 of BC6OTHER ; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to BC6ENTG with diabetes sera.	False
METHODS: Studies were performed on enzymatic activity of BC6ENTG by production of BC6ENTC from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6OTHER - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6OTHER by production of BC6ENTC from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6ENTG - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6ENTG by production of BC6OTHER from BC6ENTC , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6OTHER - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6OTHER by production of BC6OTHER from BC6ENTC , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6ENTG - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6ENTG by production of BC6OTHER from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6ENTC ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6OTHER - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6OTHER by production of BC6OTHER from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6ENTC ( BC6OTHER ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6ENTG - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6ENTG by production of BC6OTHER from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6ENTC ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6OTHER - specific antisera.	False
METHODS: Studies were performed on enzymatic activity of BC6OTHER by production of BC6OTHER from BC6OTHER , enzyme kinetics , binding to the enzyme cofactor BC6OTHER ( BC6ENTC ) , stability according to differences in pH , temperature and duration of storage , and antigenic reactivity with various BC6ENTG - specific antisera.	False
BACKGROUND AND AIMS: BC6ENTG ( BC6OTHER , BC6OTHER ) catalyses the conversion of BC6ENTC to BC6OTHER ( BC6OTHER ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6ENTG , BC6OTHER ) catalyses the conversion of BC6ENTC to BC6OTHER ( BC6OTHER ).	CPR:9
BACKGROUND AND AIMS: BC6OTHER ( BC6OTHER , BC6ENTG ) catalyses the conversion of BC6ENTC to BC6OTHER ( BC6OTHER ).	CPR:9
Enzymatic characterization of a recombinant isoform hybrid of BC6ENTC decarboxylase ( BC6ENTG ) expressed in yeast.	False
The high resolution NMR solution structure of the BC6ENTG - BC6OTHER - BC6ENTC ternary complex showed that BC6OTHER bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6ENTG - BC6ENTC ternary complex showed that BC6OTHER bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6ENTC ternary complex showed that BC6OTHER bound at the hydrophobic interface formed by BC6ENTG and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6ENTC ternary complex showed that BC6OTHER bound at the hydrophobic interface formed by BC6OTHER and BC6ENTG making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6ENTC ternary complex showed that BC6OTHER bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6ENTG .	False
The high resolution NMR solution structure of the BC6ENTG - BC6OTHER - BC6OTHER ternary complex showed that BC6ENTC bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6ENTG - BC6OTHER ternary complex showed that BC6ENTC bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6OTHER ternary complex showed that BC6ENTC bound at the hydrophobic interface formed by BC6ENTG and BC6OTHER making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6OTHER ternary complex showed that BC6ENTC bound at the hydrophobic interface formed by BC6OTHER and BC6ENTG making critical interactions with residues such as CHEM147 of BC6OTHER .	False
The high resolution NMR solution structure of the BC6OTHER - BC6OTHER - BC6OTHER ternary complex showed that BC6ENTC bound at the hydrophobic interface formed by BC6OTHER and BC6OTHER making critical interactions with residues such as CHEM147 of BC6ENTG .	False
In the absence of BC6ENTG , docking localized BC6ENTC to the same position in the hydrophobic groove of BC6OTHER .	False
In the absence of BC6OTHER , docking localized BC6ENTC to the same position in the hydrophobic groove of BC6ENTG .	False
The structural and functional data reveal that the BC6ENTC class of BC6OTHER - sensitizers work by binding to the regulatory domain of BC6ENTG and stabilizing the pivotal BC6OTHER - BC6OTHER regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The structural and functional data reveal that the BC6ENTC class of BC6OTHER - sensitizers work by binding to the regulatory domain of BC6OTHER and stabilizing the pivotal BC6ENTG - BC6OTHER regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The structural and functional data reveal that the BC6ENTC class of BC6OTHER - sensitizers work by binding to the regulatory domain of BC6OTHER and stabilizing the pivotal BC6OTHER - BC6ENTG regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The structural and functional data reveal that the BC6OTHER class of BC6ENTC - sensitizers work by binding to the regulatory domain of BC6ENTG and stabilizing the pivotal BC6OTHER - BC6OTHER regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The structural and functional data reveal that the BC6OTHER class of BC6ENTC - sensitizers work by binding to the regulatory domain of BC6OTHER and stabilizing the pivotal BC6ENTG - BC6OTHER regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The structural and functional data reveal that the BC6OTHER class of BC6ENTC - sensitizers work by binding to the regulatory domain of BC6OTHER and stabilizing the pivotal BC6OTHER - BC6ENTG regulatory unit via a network of hydrophobic and electrostatic interactions , in contrast to the destabilizing effects of antagonists such as W7 at the same interface.	False
The BC6ENTC dependent interaction between BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) triggers contraction in heart muscle.	False
The BC6ENTC dependent interaction between BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) triggers contraction in heart muscle.	False
The BC6ENTC dependent interaction between BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) triggers contraction in heart muscle.	False
The BC6ENTC dependent interaction between BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) triggers contraction in heart muscle.	False
The affinities of BC6ENTC and BC6OTHER for the regulatory domain of BC6ENTG were measured in the absence and presence of cTnI by NMR spectroscopy , and BC6OTHER was found to bind more strongly than BC6OTHER .	False
The affinities of BC6OTHER and BC6ENTC for the regulatory domain of BC6ENTG were measured in the absence and presence of cTnI by NMR spectroscopy , and BC6OTHER was found to bind more strongly than BC6OTHER .	False
The affinities of BC6OTHER and BC6OTHER for the regulatory domain of BC6ENTG were measured in the absence and presence of cTnI by NMR spectroscopy , and BC6ENTC was found to bind more strongly than BC6OTHER .	False
The affinities of BC6OTHER and BC6OTHER for the regulatory domain of BC6ENTG were measured in the absence and presence of cTnI by NMR spectroscopy , and BC6OTHER was found to bind more strongly than BC6ENTC .	False
BC6ENTC also increased the affinity of BC6ENTG for BC6OTHER .	False
BC6ENTC also increased the affinity of BC6OTHER for BC6ENTG .	False
A structural and functional perspective into the mechanism of BC6ENTC - sensitizers that target the cardiac BC6ENTG .	False
This is described in a case study of the expedited review and approval of BC6ENTC , a novel BC6ENTG inhibitor , in Japan in the context of the emergence of new strain of influenza in 2009.	CPR:4
Homer1a , the inducible member of the BC6ENTG family of PSD proteins that is implicated in glutamatergic signal transduction , is induced in striatum by antipsychotics with high BC6ENTC receptor affinity and in the cortex by antipsychotics with mixed serotonergic / dopaminergic profile.	False
Signaling molecules , such as BC6ENTG and BC6OTHER ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6ENTC , BC6OTHER , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6ENTG ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6ENTC , BC6OTHER , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6OTHER ( BC6ENTG ) , could be involved in the mechanism of action of antipsychotics , targeting BC6ENTC , BC6OTHER , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6ENTG and BC6OTHER ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6ENTC , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6ENTG ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6ENTC , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6OTHER ( BC6ENTG ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6ENTC , and BC6OTHER neurotransmission.	False
Signaling molecules , such as BC6ENTG and BC6OTHER ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6OTHER , and BC6ENTC neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6ENTG ( BC6OTHER ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6OTHER , and BC6ENTC neurotransmission.	False
Signaling molecules , such as BC6OTHER and BC6OTHER ( BC6ENTG ) , could be involved in the mechanism of action of antipsychotics , targeting BC6OTHER , BC6OTHER , and BC6ENTC neurotransmission.	False
Type II metabotropic BC6ENTC receptors ( BC6ENTG ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6ENTC receptors ( BC6OTHER ) and BC6OTHER BC6ENTG receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6ENTC receptors ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6ENTG - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6ENTC receptors ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6ENTG and BC6OTHER homomers.	False
Type II metabotropic BC6ENTC receptors ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTG homomers.	False
BC6ENTG ( BC6OTHER ) and BC6ENTC BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6ENTG ) and BC6ENTC BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6ENTC BC6ENTG receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6ENTC BC6OTHER receptors have been reported to form heterodimers that modulate BC6ENTG - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6ENTC BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6ENTG and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6ENTC BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTG homomers.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER BC6ENTC (2A) receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6ENTG ) and BC6OTHER BC6ENTC (2A) receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6ENTC (2A) receptors have been reported to form heterodimers that modulate BC6ENTG - mediated intracellular signaling differentially compared to BC6OTHER and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6ENTC (2A) receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6ENTG and BC6OTHER homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6ENTC (2A) receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTG homomers.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTC (2A) homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6ENTG ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTC (2A) homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6ENTG receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTC (2A) homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6ENTG - mediated intracellular signaling differentially compared to BC6OTHER and BC6ENTC (2A) homomers.	False
Type II metabotropic BC6OTHER receptors ( BC6OTHER ) and BC6OTHER BC6OTHER receptors have been reported to form heterodimers that modulate BC6OTHER - mediated intracellular signaling differentially compared to BC6ENTG and BC6ENTC (2A) homomers.	False
Moving from receptors to postsynaptic density (PSD) scenario , the scaffolding protein PSD - 95 is known to interact with BC6ENTG BC6ENTC (2) receptors , regulating their activation state.	False
BC6ENTC synthase reductase ( BC6ENTG ) is an enzyme involved in the conversion of BC6OTHER to BC6OTHER .	False
BC6ENTG ( BC6OTHER ) is an enzyme involved in the conversion of BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) is an enzyme involved in the conversion of BC6ENTC to BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) is an enzyme involved in the conversion of BC6OTHER to BC6ENTC .	CPR:9
BC6OTHER ( BC6ENTG ) is an enzyme involved in the conversion of BC6OTHER to BC6ENTC .	CPR:9
 BC6ENTC synthase reductase polymorphisms are associated with serum BC6ENTG levels in postmenopausal women.	False
We also find that BC6ENTG endogenous to HEK - 293 cells , ostensibly through inhibition of BC6ENTC cyclase , decreases intracellular levels of BC6OTHER .	False
We also find that BC6ENTG endogenous to HEK - 293 cells , ostensibly through inhibition of BC6OTHER , decreases intracellular levels of BC6ENTC .	False
We also find that BC6OTHER endogenous to HEK - 293 cells , ostensibly through inhibition of BC6ENTG , decreases intracellular levels of BC6ENTC .	False
In this regard , we evaluate here the efficacy of BC6ENTG as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6ENTC (1A) ( BC6OTHER ) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6ENTG , by comparing BC6OTHER with the BC6ENTC (1A) ( BC6OTHER ) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6ENTG with the BC6ENTC (1A) ( BC6OTHER ) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6ENTC (1A) ( BC6ENTG ) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6ENTC (1A) ( BC6OTHER ) receptor , a quintessential BC6ENTG .	False
In this regard , we evaluate here the efficacy of BC6ENTG as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6OTHER ( BC6ENTC (1A)) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6ENTG , by comparing BC6OTHER with the BC6OTHER ( BC6ENTC (1A)) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6ENTG with the BC6OTHER ( BC6ENTC (1A)) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6ENTG ( BC6ENTC (1A)) receptor , a quintessential BC6OTHER .	False
In this regard , we evaluate here the efficacy of BC6OTHER as it relates to the activation of BC6OTHER , by comparing BC6OTHER with the BC6OTHER ( BC6ENTC (1A)) receptor , a quintessential BC6ENTG .	False
We find that with use of BC6ENTC , first , with forms of BC6ENTG endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6OTHER receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6ENTC , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6ENTG fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6OTHER receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6ENTC , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6ENTG is equivalent to the BC6OTHER receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6ENTC , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6ENTG receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6ENTC , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6OTHER receptor in the assay as it relates to capacity to activate BC6ENTG .	False
We find that with use of BC6OTHER , first , with forms of BC6ENTG endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6ENTC (1A) receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6OTHER , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6ENTG fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6ENTC (1A) receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6OTHER , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6ENTG is equivalent to the BC6ENTC (1A) receptor in the assay as it relates to capacity to activate BC6OTHER .	False
We find that with use of BC6OTHER , first , with forms of BC6OTHER endogenous to human embryonic kidney (HEK) - 293 cells made to express epitope - tagged receptors and , second , with individual forms of BC6OTHER fused to the C terminus of each receptor , BC6OTHER is equivalent to the BC6ENTC (1A) receptor in the assay as it relates to capacity to activate BC6ENTG .	False
Few targets like BC6ENTG ( BC6OTHER ) mutations and BC6OTHER ( BC6OTHER ) gene rearrangements have successfully been targeted with BC6OTHER BC6OTHER inhibitors (TKIs) and BC6ENTC , respectively.	False
Few targets like BC6OTHER ( BC6ENTG ) mutations and BC6OTHER ( BC6OTHER ) gene rearrangements have successfully been targeted with BC6OTHER BC6OTHER inhibitors (TKIs) and BC6ENTC , respectively.	False
Few targets like BC6OTHER ( BC6OTHER ) mutations and BC6ENTG ( BC6OTHER ) gene rearrangements have successfully been targeted with BC6OTHER BC6OTHER inhibitors (TKIs) and BC6ENTC , respectively.	False
Few targets like BC6OTHER ( BC6OTHER ) mutations and BC6OTHER ( BC6ENTG ) gene rearrangements have successfully been targeted with BC6OTHER BC6OTHER inhibitors (TKIs) and BC6ENTC , respectively.	False
Few targets like BC6OTHER ( BC6OTHER ) mutations and BC6OTHER ( BC6OTHER ) gene rearrangements have successfully been targeted with BC6ENTG BC6OTHER inhibitors (TKIs) and BC6ENTC , respectively.	False
Few targets like BC6OTHER ( BC6OTHER ) mutations and BC6OTHER ( BC6OTHER ) gene rearrangements have successfully been targeted with BC6OTHER BC6ENTG inhibitors (TKIs) and BC6ENTC , respectively.	False
BC6ENTG encoded by the BC6OTHER gene converts BC6OTHER to inactive BC6OTHER , and alteration in this enzymatic activity might affect BC6ENTC homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	False
Type 2 BC6OTHER dehydrogenase encoded by the BC6ENTG gene converts BC6OTHER to inactive BC6OTHER , and alteration in this enzymatic activity might affect BC6ENTC homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	False
We investigated the association of BC6ENTG variant with BC6ENTC homeostasis.	False
Subjects with normal BC6ENTC tolerance (n=585) , impaired BC6OTHER tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic BC6ENTG polymorphism in the first intron of BC6OTHER .	False
Subjects with normal BC6ENTC tolerance (n=585) , impaired BC6OTHER tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic BC6OTHER polymorphism in the first intron of BC6ENTG .	False
Subjects with normal BC6OTHER tolerance (n=585) , impaired BC6ENTC tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic BC6ENTG polymorphism in the first intron of BC6OTHER .	False
Subjects with normal BC6OTHER tolerance (n=585) , impaired BC6ENTC tolerance (n=202) and type 2 diabetes (n=355) were genotyped for a highly polymorphic BC6OTHER polymorphism in the first intron of BC6ENTG .	False
Type 2 BC6ENTC dehydrogenase encoded by the BC6ENTG gene converts BC6OTHER to inactive BC6OTHER , and alteration in this enzymatic activity might affect BC6OTHER homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	False
BC6ENTG encoded by the BC6OTHER gene converts BC6ENTC to inactive BC6OTHER , and alteration in this enzymatic activity might affect BC6OTHER homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	CPR:9
Type 2 BC6OTHER dehydrogenase encoded by the BC6ENTG gene converts BC6ENTC to inactive BC6OTHER , and alteration in this enzymatic activity might affect BC6OTHER homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	CPR:9
Thus , subjects having more BC6OTHER are susceptible to developing abnormal BC6ENTC tolerance , whereas normal subjects carrying more BC6ENTG appeared to have frugal characteristics in BC6OTHER secretion.	False
Thus , subjects having more BC6OTHER are susceptible to developing abnormal BC6ENTC tolerance , whereas normal subjects carrying more BC6OTHER appeared to have frugal characteristics in BC6ENTG secretion.	False
Thus , subjects having more BC6ENTG are susceptible to developing abnormal BC6ENTC tolerance , whereas normal subjects carrying more BC6OTHER appeared to have frugal characteristics in BC6OTHER secretion.	False
BC6ENTG encoded by the BC6OTHER gene converts BC6OTHER to inactive BC6ENTC , and alteration in this enzymatic activity might affect BC6OTHER homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	CPR:9
Type 2 BC6OTHER dehydrogenase encoded by the BC6ENTG gene converts BC6OTHER to inactive BC6ENTC , and alteration in this enzymatic activity might affect BC6OTHER homeostasis by affecting circulating levels or tissue availability of glucocorticoids.	CPR:9
Longer BC6OTHER BC6ENTG in impaired BC6ENTC tolerance and type 2 diabetes.	False
Longer BC6ENTG BC6OTHER in impaired BC6ENTC tolerance and type 2 diabetes.	False
DISCUSSION: These results are consistent with previous studies that found that: (1) BC6ENTG had a very low activity in children with autism and (2) BC6ENTC ( BC6OTHER ) levels are unusually low in children with autism.	False
DISCUSSION: These results are consistent with previous studies that found that: (1) BC6ENTG had a very low activity in children with autism and (2) BC6OTHER ( BC6ENTC ) levels are unusually low in children with autism.	False
CONCLUSIONS: Total BC6ENTC is abnormally high in autism , consistent with previous reports of an impaired BC6ENTG for the conversion of BC6OTHER and BC6OTHER to BC6OTHER .	False
CONCLUSIONS: Total BC6OTHER is abnormally high in autism , consistent with previous reports of an impaired BC6ENTG for the conversion of BC6ENTC and BC6OTHER to BC6OTHER .	CPR:9
CONCLUSIONS: Total BC6OTHER is abnormally high in autism , consistent with previous reports of an impaired BC6ENTG for the conversion of BC6OTHER and BC6ENTC to BC6OTHER .	CPR:9
CONCLUSIONS: Total BC6OTHER is abnormally high in autism , consistent with previous reports of an impaired BC6ENTG for the conversion of BC6OTHER and BC6OTHER to BC6ENTC .	CPR:9
However , phosphorylation of the BC6ENTG / BC6OTHER subunit was clearly inhibited by BC6ENTC in stimulated cells.	CPR:4
However , phosphorylation of the BC6OTHER / BC6ENTG subunit was clearly inhibited by BC6ENTC in stimulated cells.	CPR:4
In addition , BC6ENTC inhibited the transcriptional activity of BC6ENTG without interfering with the BC6OTHER - induced BC6OTHER dephosphorylation event , which represents the major signaling pathway for its activation.	CPR:4
In addition , BC6ENTC inhibited the transcriptional activity of BC6OTHER without interfering with the BC6OTHER - induced BC6ENTG dephosphorylation event , which represents the major signaling pathway for its activation.	False
In addition , BC6OTHER inhibited the transcriptional activity of BC6ENTG without interfering with the BC6ENTC - induced BC6OTHER dephosphorylation event , which represents the major signaling pathway for its activation.	False
In addition , BC6OTHER inhibited the transcriptional activity of BC6OTHER without interfering with the BC6ENTC - induced BC6ENTG dephosphorylation event , which represents the major signaling pathway for its activation.	CPR:3
BC6ENTG cooperates with BC6OTHER , a compound of the BC6OTHER complex , to activate target genes , and we also found that BC6ENTC inhibited both BC6OTHER activation and BC6OTHER transcriptional activity.	False
BC6OTHER cooperates with BC6ENTG , a compound of the BC6OTHER complex , to activate target genes , and we also found that BC6ENTC inhibited both BC6OTHER activation and BC6OTHER transcriptional activity.	False
BC6OTHER cooperates with BC6OTHER , a compound of the BC6ENTG complex , to activate target genes , and we also found that BC6ENTC inhibited both BC6OTHER activation and BC6OTHER transcriptional activity.	False
BC6OTHER cooperates with BC6OTHER , a compound of the BC6OTHER complex , to activate target genes , and we also found that BC6ENTC inhibited both BC6ENTG activation and BC6OTHER transcriptional activity.	CPR:4
BC6OTHER cooperates with BC6OTHER , a compound of the BC6OTHER complex , to activate target genes , and we also found that BC6ENTC inhibited both BC6OTHER activation and BC6ENTG transcriptional activity.	CPR:4
We found that BC6ENTC inhibits BC6ENTG ( BC6OTHER ) and BC6OTHER - gene transcription in stimulated Jurkat cells , a human T - cell leukemia cell line.	CPR:4
We found that BC6ENTC inhibits BC6OTHER ( BC6ENTG ) and BC6OTHER - gene transcription in stimulated Jurkat cells , a human T - cell leukemia cell line.	CPR:4
We found that BC6ENTC inhibits BC6OTHER ( BC6OTHER ) and BC6ENTG - gene transcription in stimulated Jurkat cells , a human T - cell leukemia cell line.	CPR:3
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6ENTG - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6ENTG , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6ENTC at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6OTHER inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6ENTG or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6ENTG - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6OTHER or the DNA - binding activity.	CPR:4
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6ENTG , BC6OTHER or the DNA - binding activity.	False
To further characterize the inhibitory mechanisms of BC6OTHER at the transcriptional level , we examined the transcriptional activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) transcription factors and found that BC6ENTC inhibited BC6OTHER - dependent transcriptional activity without affecting either the phosphorylation , the degradation of the cytoplasmic BC6OTHER , BC6ENTG or the DNA - binding activity.	False
 BC6ENTC inhibits T - cell activation by targeting BC6ENTG , BC6OTHER and BC6OTHER signaling pathways.	CPR:4
 BC6ENTC inhibits T - cell activation by targeting BC6OTHER , BC6ENTG and BC6OTHER signaling pathways.	CPR:4
 BC6ENTC inhibits T - cell activation by targeting BC6OTHER , BC6OTHER and BC6ENTG signaling pathways.	CPR:4
Six children with BC6ENTC oxidase ( BC6ENTG ) deficiency presented with neonatal epileptic encephalopathy.	False
Prompt treatment with BC6ENTC in all neonates and infants with epileptic encephalopathy should become mandatory , permitting normal development in at least some of those affected with BC6ENTG deficiency.	False
These data are particularly important in light of the recent identification of CMT - associated mutations in another BC6ENTG gene [ BC6OTHER ( BC6ENTC - tRNA synthetase gene)].	False
These data are particularly important in light of the recent identification of CMT - associated mutations in another BC6OTHER gene [ BC6ENTG ( BC6ENTC - tRNA synthetase gene)].	False
We previously implicated mutations in the gene encoding BC6ENTC - tRNA synthetase ( BC6ENTG ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTC - tRNA synthetase ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6ENTG is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTC - tRNA synthetase ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTG responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTC - tRNA synthetase ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6ENTG ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTG ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTC - tRNA synthetases responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6ENTG ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTC - tRNA synthetases responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6ENTG is a member of the family of BC6ENTC - tRNA synthetases responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTC - tRNA synthetases responsible for charging tRNA with cognate BC6OTHER ; BC6ENTG ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTG ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6ENTC ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6ENTG ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6ENTC ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6ENTG is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6ENTC ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTG responsible for charging tRNA with cognate BC6ENTC ; BC6OTHER ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6ENTC ; BC6ENTG ligates BC6OTHER to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6ENTG ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6ENTC to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6ENTG ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6ENTC to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6ENTG is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6ENTC to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6ENTG responsible for charging tRNA with cognate BC6OTHER ; BC6OTHER ligates BC6ENTC to tRNA(Gly).	False
We previously implicated mutations in the gene encoding BC6OTHER ( BC6OTHER ) as the cause of CMT2D and dSMA - V. BC6OTHER is a member of the family of BC6OTHER responsible for charging tRNA with cognate BC6OTHER ; BC6ENTG ligates BC6ENTC to tRNA(Gly).	False
Functional analyses of BC6ENTC - tRNA synthetase mutations suggest a key role for BC6ENTG in peripheral axons.	False
We describe the function of BC6OTHER in BC6OTHER hydroxylation , and discuss the allosteric and structural effects that BC6ENTC exerts on BC6ENTG .	False
Finally , we illustrate how BC6ENTC might transform the BC6ENTG dimer into an efficient BC6OTHER , and briefly touch on some more speculative aspects of the role of BC6OTHER in BC6OTHER synthesis.	False
Finally , we illustrate how BC6ENTC might transform the BC6OTHER dimer into an efficient BC6ENTG , and briefly touch on some more speculative aspects of the role of BC6OTHER in BC6OTHER synthesis.	False
Finally , we illustrate how BC6OTHER might transform the BC6ENTG dimer into an efficient BC6ENTC synthase , and briefly touch on some more speculative aspects of the role of BC6OTHER in BC6OTHER synthesis.	False
Finally , we illustrate how BC6OTHER might transform the BC6ENTG dimer into an efficient BC6OTHER , and briefly touch on some more speculative aspects of the role of BC6ENTC in BC6OTHER synthesis.	False
Finally , we illustrate how BC6OTHER might transform the BC6OTHER dimer into an efficient BC6ENTG , and briefly touch on some more speculative aspects of the role of BC6ENTC in BC6OTHER synthesis.	False
Finally , we illustrate how BC6OTHER might transform the BC6ENTG dimer into an efficient BC6OTHER , and briefly touch on some more speculative aspects of the role of BC6OTHER in BC6ENTC synthesis.	False
Finally , we illustrate how BC6OTHER might transform the BC6OTHER dimer into an efficient BC6ENTG , and briefly touch on some more speculative aspects of the role of BC6OTHER in BC6ENTC synthesis.	False
Ever since the discovery that BC6ENTC ( BC6OTHER ) is a cofactor of BC6ENTG , its function has been the object of intense research and occasional controversy.	False
In this review we aim to provide an outline of the various ways in which BC6ENTC affects BC6ENTG catalysis.	False
First we give a brief general description of the structure and catalytic mechanism of BC6ENTG , with special emphasis on those aspects of catalysis that are actively debated , and that directly or indirectly involve BC6ENTC .	False
Ever since the discovery that BC6OTHER ( BC6ENTC ) is a cofactor of BC6ENTG , its function has been the object of intense research and occasional controversy.	False
 Foremost among those issues is uncoupled catalysis , i.e. the BC6ENTG - catalyzed oxidation of BC6ENTC in the absence of substrate or CHEM that does not result in BC6OTHER production.	False
 Foremost among those issues is uncoupled catalysis , i.e. the BC6ENTG - catalyzed oxidation of BC6OTHER in the absence of substrate or CHEM that does not result in BC6ENTC production.	False
We also shortly discuss the ongoing debate on whether BC6ENTC is the actual reaction product of BC6ENTG catalysis , as well as the phenomenon of BC6OTHER - mediated autoinhibition.	CPR:9
We also shortly discuss the ongoing debate on whether BC6OTHER is the actual reaction product of BC6ENTG catalysis , as well as the phenomenon of BC6ENTC - mediated autoinhibition.	False
We describe the function of BC6ENTC in BC6OTHER hydroxylation , and discuss the allosteric and structural effects that BC6OTHER exerts on BC6ENTG .	False
We describe the function of BC6OTHER in BC6ENTC hydroxylation , and discuss the allosteric and structural effects that BC6OTHER exerts on BC6ENTG .	False
BC6OTHER induced a higher level of secretion of the inflammatory BC6OTHER BC6ENTG compared with BC6ENTC in the WEHI - 231 cells and displayed a marked biphasic dose - response curve for the induction.	CPR:3
BC6OTHER induced a higher level of secretion of the inflammatory BC6ENTG BC6OTHER compared with BC6ENTC in the WEHI - 231 cells and displayed a marked biphasic dose - response curve for the induction.	CPR:3
BC6ENTC was unable to cause the same extent of association of the BC6ENTG of BC6OTHER with lipids , compared with BC6OTHER or the physiological regulator BC6OTHER , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
BC6ENTC was unable to cause the same extent of association of the BC6OTHER of BC6ENTG with lipids , compared with BC6OTHER or the physiological regulator BC6OTHER , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
BC6OTHER was unable to cause the same extent of association of the BC6ENTG of BC6OTHER with lipids , compared with BC6ENTC or the physiological regulator BC6OTHER , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
BC6OTHER was unable to cause the same extent of association of the BC6OTHER of BC6ENTG with lipids , compared with BC6ENTC or the physiological regulator BC6OTHER , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
BC6OTHER was unable to cause the same extent of association of the BC6ENTG of BC6OTHER with lipids , compared with BC6OTHER or the physiological regulator BC6ENTC , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
BC6OTHER was unable to cause the same extent of association of the BC6OTHER of BC6ENTG with lipids , compared with BC6OTHER or the physiological regulator BC6ENTC , and was able to partially block the association induced by these agents , measured by surface plasmon resonance.	False
The in vitro kinase activity of BC6ENTG induced by BC6ENTC was lower than that induced by BC6OTHER .	CPR:3
The in vitro kinase activity of BC6ENTG induced by BC6OTHER was lower than that induced by BC6ENTC .	CPR:3
Here , we report the initial characterization of BC6ENTC as a BC6ENTG ( BC6OTHER ) ligand.	False
Here , we report the initial characterization of BC6ENTC as a BC6OTHER ( BC6ENTG ) ligand.	False
BC6ENTC bound to BC6ENTG in the presence of BC6OTHER with high affinity; however , under these assay conditions , little BC6OTHER isoform selectivity was observed.	False
BC6ENTC bound to BC6OTHER in the presence of BC6OTHER with high affinity; however , under these assay conditions , little BC6ENTG isoform selectivity was observed.	False
BC6OTHER bound to BC6ENTG in the presence of BC6ENTC with high affinity; however , under these assay conditions , little BC6OTHER isoform selectivity was observed.	False
BC6OTHER bound to BC6OTHER in the presence of BC6ENTC with high affinity; however , under these assay conditions , little BC6ENTG isoform selectivity was observed.	False
BC6ENTG isoforms did show different sensitivity and selectivity for down - regulation by BC6ENTC and BC6OTHER ( BC6OTHER ) in WEHI - 231 , HOP - 92 , and Colo - 205 cells.	CPR:4
BC6ENTG isoforms did show different sensitivity and selectivity for down - regulation by BC6OTHER and BC6ENTC ( BC6OTHER ) in WEHI - 231 , HOP - 92 , and Colo - 205 cells.	CPR:4
BC6ENTG isoforms did show different sensitivity and selectivity for down - regulation by BC6OTHER and BC6OTHER ( BC6ENTC ) in WEHI - 231 , HOP - 92 , and Colo - 205 cells.	CPR:4
In intact CHO - K1 cells , BC6ENTC was able to translocate different BC6ENTG - tagged BC6OTHER isoforms , visualized by confocal microscopy , with equal or higher potency than BC6OTHER .	False
In intact CHO - K1 cells , BC6ENTC was able to translocate different BC6OTHER - tagged BC6ENTG isoforms , visualized by confocal microscopy , with equal or higher potency than BC6OTHER .	False
In intact CHO - K1 cells , BC6OTHER was able to translocate different BC6ENTG - tagged BC6OTHER isoforms , visualized by confocal microscopy , with equal or higher potency than BC6ENTC .	False
In intact CHO - K1 cells , BC6OTHER was able to translocate different BC6OTHER - tagged BC6ENTG isoforms , visualized by confocal microscopy , with equal or higher potency than BC6ENTC .	False
BC6ENTG in particular showed a different pattern of translocation in response to BC6ENTC and BC6OTHER .	False
BC6ENTG in particular showed a different pattern of translocation in response to BC6OTHER and BC6ENTC .	False
BC6ENTC induced a higher level of secretion of the inflammatory BC6OTHER BC6ENTG compared with BC6OTHER in the WEHI - 231 cells and displayed a marked biphasic dose - response curve for the induction.	CPR:3
BC6ENTC induced a higher level of secretion of the inflammatory BC6ENTG BC6OTHER compared with BC6OTHER in the WEHI - 231 cells and displayed a marked biphasic dose - response curve for the induction.	CPR:3
Characterization of the interaction of BC6ENTC with BC6ENTG .	False
BC6ENTC - containing BC6OTHER ( BC6OTHER - BC6OTHER ) induce apoptosis in tumor cells by inhibiting the prenylation of small BC6ENTG .	CPR:4
BC6OTHER - containing BC6ENTC ( BC6OTHER - BC6OTHER ) induce apoptosis in tumor cells by inhibiting the prenylation of small BC6ENTG .	CPR:4
BC6OTHER - containing BC6OTHER ( BC6ENTC - BC6OTHER ) induce apoptosis in tumor cells by inhibiting the prenylation of small BC6ENTG .	CPR:4
BC6OTHER - containing BC6OTHER ( BC6OTHER - BC6ENTC ) induce apoptosis in tumor cells by inhibiting the prenylation of small BC6ENTG .	CPR:4
Furthermore , BC6ENTC - BC6OTHER decreased the levels of BC6ENTG ( BC6OTHER ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6ENTC - BC6OTHER decreased the levels of BC6OTHER ( BC6ENTG ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6ENTC - BC6OTHER decreased the levels of BC6OTHER ( BC6OTHER ) and BC6ENTG via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6ENTC - BC6OTHER decreased the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER via suppression of BC6ENTG prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6ENTC - BC6OTHER decreased the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6ENTG expression.	CPR:3
Furthermore , BC6OTHER - BC6ENTC decreased the levels of BC6ENTG ( BC6OTHER ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6OTHER - BC6ENTC decreased the levels of BC6OTHER ( BC6ENTG ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6OTHER - BC6ENTC decreased the levels of BC6OTHER ( BC6OTHER ) and BC6ENTG via suppression of BC6OTHER prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6OTHER - BC6ENTC decreased the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER via suppression of BC6ENTG prenylation and enhanced BC6OTHER expression.	CPR:4
Furthermore , BC6OTHER - BC6ENTC decreased the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER via suppression of BC6OTHER prenylation and enhanced BC6ENTG expression.	CPR:3
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6ENTG and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6ENTG , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6ENTG expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6ENTG / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways.	CPR:4
The present results indicated that BC6ENTC - BC6OTHER induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG pathways.	CPR:4
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6ENTG and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6ENTG , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6ENTG expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:3
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6ENTG / BC6OTHER / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER pathways.	CPR:4
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER pathways.	CPR:4
The present results indicated that BC6OTHER - BC6ENTC induce apoptosis by decreasing the mitochondrial transmembrane potential , increasing the activation of BC6OTHER and BC6OTHER , and enhancing BC6OTHER expression through inhibition of the BC6OTHER / BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG pathways.	CPR:4
The accumulation of BC6ENTC - BC6OTHER in bones suggests that they may act more effectively on tumors that have spread to bones or on BC6ENTG - variable tumors.	False
The accumulation of BC6OTHER - BC6ENTC in bones suggests that they may act more effectively on tumors that have spread to bones or on BC6ENTG - variable tumors.	False
 BC6ENTC - containing BC6OTHER induce apoptosis of hematopoietic tumor cells via inhibition of BC6ENTG signaling pathways and BC6OTHER - mediated activation of the intrinsic apoptotic pathway.	CPR:4
 BC6ENTC - containing BC6OTHER induce apoptosis of hematopoietic tumor cells via inhibition of BC6OTHER signaling pathways and BC6ENTG - mediated activation of the intrinsic apoptotic pathway.	CPR:3
 BC6OTHER - containing BC6ENTC induce apoptosis of hematopoietic tumor cells via inhibition of BC6ENTG signaling pathways and BC6OTHER - mediated activation of the intrinsic apoptotic pathway.	CPR:4
 BC6OTHER - containing BC6ENTC induce apoptosis of hematopoietic tumor cells via inhibition of BC6OTHER signaling pathways and BC6ENTG - mediated activation of the intrinsic apoptotic pathway.	CPR:3
BC6ENTC synthetase ( BC6ENTG ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	False
BC6ENTG ( BC6OTHER ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6ENTC to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	False
BC6OTHER ( BC6ENTG ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6ENTC to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	False
BC6ENTC , a product of the reaction , was found to be a potent inhibitor of BC6ENTG showing biphasic inhibition of enzyme activity.	CPR:4
BC6ENTG ( BC6OTHER ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6ENTC , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6ENTC , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	CPR:9
BC6ENTG , like the mouse BC6ENTC isozyme , exhibits substrate inhibition , with IMP inhibiting enzyme activity at subsaturating BC6OTHER concentrations.	False
BC6ENTG , like the mouse BC6OTHER isozyme , exhibits substrate inhibition , with IMP inhibiting enzyme activity at subsaturating BC6ENTC concentrations.	False
BC6OTHER , like the BC6ENTG , exhibits substrate inhibition , with IMP inhibiting enzyme activity at subsaturating BC6ENTC concentrations.	False
BC6ENTG ( BC6OTHER ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6ENTC to BC6OTHER .	False
BC6OTHER ( BC6ENTG ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6ENTC to BC6OTHER .	False
BC6ENTG ( BC6OTHER ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6ENTC .	False
BC6OTHER ( BC6ENTG ) catalyzes the BC6OTHER dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6ENTC .	False
BC6ENTG from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6OTHER ) is 345 BC6ENTC long against an average length of 430 - 457 BC6OTHER for most mesophilic BC6OTHER .	False
BC6OTHER from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6ENTG ) is 345 BC6ENTC long against an average length of 430 - 457 BC6OTHER for most mesophilic BC6OTHER .	False
BC6OTHER from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6OTHER ) is 345 BC6ENTC long against an average length of 430 - 457 BC6OTHER for most mesophilic BC6ENTG .	False
BC6ENTG from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6OTHER ) is 345 BC6OTHER long against an average length of 430 - 457 BC6ENTC for most mesophilic BC6OTHER .	False
BC6OTHER from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6ENTG ) is 345 BC6OTHER long against an average length of 430 - 457 BC6ENTC for most mesophilic BC6OTHER .	False
BC6OTHER from the thermophilic archaea , Methanocaldococcus jannaschii ( BC6OTHER ) is 345 BC6OTHER long against an average length of 430 - 457 BC6ENTC for most mesophilic BC6ENTG .	False
This short BC6ENTG has two large deletions that map to the middle and BC6ENTC - terminus of the protein.	False
BC6ENTG ( BC6OTHER ) catalyzes the BC6ENTC dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	False
BC6OTHER ( BC6ENTG ) catalyzes the BC6ENTC dependent condensation of a molecule of IMP with BC6OTHER to form BC6OTHER , in a reaction driven by the hydrolysis of BC6OTHER to BC6OTHER .	CPR:9
The BC6ENTC sequence of BC6ENTG contains 649 bp , and the mature protein is predicted to have 131 BC6OTHER residues - 104 of which make up the large subunit , and 27 of which make up the small subunit.	False
The BC6OTHER sequence of BC6ENTG contains 649 bp , and the mature protein is predicted to have 131 BC6ENTC residues - 104 of which make up the large subunit , and 27 of which make up the small subunit.	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6ENTC 24 - BC6OTHER 34) , CHEM ( BC6OTHER 59 - BC6OTHER 71) , and h3 ( BC6OTHER 80 - BC6OTHER 89).	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6OTHER 24 - BC6ENTC 34) , CHEM ( BC6OTHER 59 - BC6OTHER 71) , and h3 ( BC6OTHER 80 - BC6OTHER 89).	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6OTHER 24 - BC6OTHER 34) , CHEM ( BC6ENTC 59 - BC6OTHER 71) , and h3 ( BC6OTHER 80 - BC6OTHER 89).	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6OTHER 24 - BC6OTHER 34) , CHEM ( BC6OTHER 59 - BC6ENTC 71) , and h3 ( BC6OTHER 80 - BC6OTHER 89).	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6OTHER 24 - BC6OTHER 34) , CHEM ( BC6OTHER 59 - BC6OTHER 71) , and h3 ( BC6ENTC 80 - BC6OTHER 89).	False
The 3D - structure of BC6ENTG consists of three conserved alpha - helices: h1 ( BC6OTHER 24 - BC6OTHER 34) , CHEM ( BC6OTHER 59 - BC6OTHER 71) , and h3 ( BC6OTHER 80 - BC6ENTC 89).	False
The beta - sheet consisted of a single stranded anti - parallel beta - sheet (b1.1 at BC6ENTC 43 - BC6OTHER 45 and b1.2 at BC6OTHER 48 - BC6OTHER 50) that was highly similar to the conserved sequences ( - CGXG - ,  - CCXXHDXC - and CXCEXXXXXC - ) of Apis mellifera (bee) BC6ENTG .	False
The beta - sheet consisted of a single stranded anti - parallel beta - sheet (b1.1 at BC6OTHER 43 - BC6ENTC 45 and b1.2 at BC6OTHER 48 - BC6OTHER 50) that was highly similar to the conserved sequences ( - CGXG - ,  - CCXXHDXC - and CXCEXXXXXC - ) of Apis mellifera (bee) BC6ENTG .	False
The beta - sheet consisted of a single stranded anti - parallel beta - sheet (b1.1 at BC6OTHER 43 - BC6OTHER 45 and b1.2 at BC6ENTC 48 - BC6OTHER 50) that was highly similar to the conserved sequences ( - CGXG - ,  - CCXXHDXC - and CXCEXXXXXC - ) of Apis mellifera (bee) BC6ENTG .	False
The beta - sheet consisted of a single stranded anti - parallel beta - sheet (b1.1 at BC6OTHER 43 - BC6OTHER 45 and b1.2 at BC6OTHER 48 - BC6ENTC 50) that was highly similar to the conserved sequences ( - CGXG - ,  - CCXXHDXC - and CXCEXXXXXC - ) of Apis mellifera (bee) BC6ENTG .	False
The inhibitory effects of BC6ENTG activation on BC6OTHER signaling were associated with a marked increase in BC6ENTC 792 phosphorylation on raptor.	False
The inhibitory effects of BC6OTHER activation on BC6ENTG signaling were associated with a marked increase in BC6ENTC 792 phosphorylation on raptor.	False
The objective of this study was to examine the effect of BC6ENTG ( BC6OTHER ) activation by BC6ENTC on protein synthesis and the mammalian target of BC6OTHER complex 1 ( BC6OTHER ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6OTHER ( BC6ENTG ) activation by BC6ENTC on protein synthesis and the mammalian target of BC6OTHER complex 1 ( BC6OTHER ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6OTHER ( BC6OTHER ) activation by BC6ENTC on protein synthesis and the BC6ENTG ( BC6OTHER ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6OTHER ( BC6OTHER ) activation by BC6ENTC on protein synthesis and the mammalian target of BC6OTHER complex 1 ( BC6ENTG ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6ENTG ( BC6OTHER ) activation by BC6OTHER on protein synthesis and the mammalian target of BC6ENTC complex 1 ( BC6OTHER ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6OTHER ( BC6ENTG ) activation by BC6OTHER on protein synthesis and the mammalian target of BC6ENTC complex 1 ( BC6OTHER ) signaling pathway in bovine mammary epithelial cells.	False
The objective of this study was to examine the effect of BC6OTHER ( BC6OTHER ) activation by BC6OTHER on protein synthesis and the mammalian target of BC6ENTC complex 1 ( BC6ENTG ) signaling pathway in bovine mammary epithelial cells.	False
Phosphorylation of BC6ENTG at BC6ENTC 172 increased by 1.4 - fold within 5 min , and remained elevated throughout a 30 - min time course , in response to BC6OTHER .	False
Phosphorylation of BC6ENTG at BC6OTHER 172 increased by 1.4 - fold within 5 min , and remained elevated throughout a 30 - min time course , in response to BC6ENTC .	CPR:3
Phosphorylation of ER - stress marker BC6ENTG was also increased but only at 30 min of BC6ENTC exposure.	CPR:3
BC6ENTC increased phosphorylation of BC6OTHER ( BC6ENTG ) on BC6OTHER consensus sites but did not change the amount of BC6OTHER bound to BC6OTHER .	CPR:3
BC6ENTC increased phosphorylation of BC6OTHER ( BC6OTHER ) on BC6ENTG consensus sites but did not change the amount of BC6OTHER bound to BC6OTHER .	CPR:3
BC6ENTC increased phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER consensus sites but did not change the amount of BC6ENTG bound to BC6OTHER .	False
BC6ENTC increased phosphorylation of BC6OTHER ( BC6OTHER ) on BC6OTHER consensus sites but did not change the amount of BC6OTHER bound to BC6ENTG .	CPR:3
BC6ENTC increased phosphorylation of BC6ENTG ( BC6OTHER ) on BC6OTHER consensus sites but did not change the amount of BC6OTHER bound to BC6OTHER .	CPR:3
Second , BC6OTHER mutant BC6OTHER , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6ENTC - sensitive but not BC6OTHER - insensitive BC6ENTG poisons.	False
Second , BC6ENTG mutant BC6OTHER , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6ENTC - sensitive but not BC6OTHER - insensitive BC6OTHER poisons.	False
Second , BC6OTHER mutant BC6ENTG , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6ENTC - sensitive but not BC6OTHER - insensitive BC6OTHER poisons.	False
Second , BC6OTHER mutant BC6OTHER , which exhibits reduced BC6ENTG activity , was shown to exhibit cross - resistance to all BC6ENTC - sensitive but not BC6OTHER - insensitive BC6OTHER poisons.	False
Second , BC6OTHER mutant BC6OTHER , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6OTHER - sensitive but not BC6ENTC - insensitive BC6ENTG poisons.	False
Second , BC6ENTG mutant BC6OTHER , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6OTHER - sensitive but not BC6ENTC - insensitive BC6OTHER poisons.	False
Second , BC6OTHER mutant BC6ENTG , which exhibits reduced BC6OTHER activity , was shown to exhibit cross - resistance to all BC6OTHER - sensitive but not BC6ENTC - insensitive BC6OTHER poisons.	False
Second , BC6OTHER mutant BC6OTHER , which exhibits reduced BC6ENTG activity , was shown to exhibit cross - resistance to all BC6OTHER - sensitive but not BC6ENTC - insensitive BC6OTHER poisons.	CPR:4
Third , using BC6ENTC competition assay , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6OTHER - insensitive poisons was shown to be antagonized by BC6OTHER .	False
Third , using BC6OTHER competition assay , BC6ENTG - mediated DNA cleavage induced by BC6ENTC - sensitive but not BC6OTHER - insensitive poisons was shown to be antagonized by BC6OTHER .	False
Third , using BC6OTHER competition assay , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6ENTC - insensitive poisons was shown to be antagonized by BC6OTHER .	False
Third , using BC6OTHER competition assay , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6OTHER - insensitive poisons was shown to be antagonized by BC6ENTC .	False
These results suggest that BC6ENTC - bound BC6ENTG may be the specific target of BC6OTHER - sensitive BC6OTHER poisons.	False
These results suggest that BC6ENTC - bound BC6OTHER may be the specific target of BC6OTHER - sensitive BC6ENTG poisons.	False
These results suggest that BC6OTHER - bound BC6ENTG may be the specific target of BC6ENTC - sensitive BC6OTHER poisons.	False
These results suggest that BC6OTHER - bound BC6OTHER may be the specific target of BC6ENTC - sensitive BC6ENTG poisons.	False
Using BC6ENTG as roadblocks , we show that BC6ENTC - bound BC6OTHER acts as a circular clamp capable of entering DNA ends and sliding on unobstructed duplex DNA.	False
Using BC6OTHER as roadblocks , we show that BC6ENTC - bound BC6ENTG acts as a circular clamp capable of entering DNA ends and sliding on unobstructed duplex DNA.	False
In the current studies , we show that two different classes ( BC6ENTC - sensitive and - insensitive) of BC6ENTG poisons can be identified based on their differential sensitivity to the BC6OTHER - bound conformation of BC6OTHER .	False
In the current studies , we show that two different classes ( BC6ENTC - sensitive and - insensitive) of BC6OTHER poisons can be identified based on their differential sensitivity to the BC6OTHER - bound conformation of BC6ENTG .	False
In the current studies , we show that two different classes ( BC6OTHER - sensitive and - insensitive) of BC6ENTG poisons can be identified based on their differential sensitivity to the BC6ENTC - bound conformation of BC6OTHER .	False
In the current studies , we show that two different classes ( BC6OTHER - sensitive and - insensitive) of BC6OTHER poisons can be identified based on their differential sensitivity to the BC6ENTC - bound conformation of BC6ENTG .	False
 First , in the presence of 1 mm BC6ENTC or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6ENTC or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6ENTC or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6ENTC , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6ENTC , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6ENTC , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6ENTC - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6ENTC - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6ENTC - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6ENTC - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6ENTC - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6ENTC - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6ENTC , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6ENTC , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6ENTC , BC6OTHER , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6ENTC , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6ENTC , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6ENTC , and BC6OTHER ) was only slightly (less than 3 - fold) affected.	CPR:4
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6ENTC ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , and BC6ENTC ) was only slightly (less than 3 - fold) affected.	False
 First , in the presence of 1 mm BC6OTHER or the nonhydrolyzable analog BC6OTHER , BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive BC6OTHER poisons (e.g. BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) was 30 - 100 - fold stimulated , whereas DNA cleavage induced by BC6OTHER - insensitive BC6ENTG poisons (e.g. BC6OTHER , BC6OTHER , and BC6ENTC ) was only slightly (less than 3 - fold) affected.	CPR:4
In addition , BC6ENTC was shown to strongly antagonize BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6OTHER - insensitive BC6OTHER poisons.	False
In addition , BC6ENTC was shown to strongly antagonize BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6OTHER - insensitive BC6ENTG poisons.	False
In addition , BC6OTHER was shown to strongly antagonize BC6ENTG - mediated DNA cleavage induced by BC6ENTC - sensitive but not BC6OTHER - insensitive BC6OTHER poisons.	CPR:3
In addition , BC6OTHER was shown to strongly antagonize BC6OTHER - mediated DNA cleavage induced by BC6ENTC - sensitive but not BC6OTHER - insensitive BC6ENTG poisons.	False
In addition , BC6OTHER was shown to strongly antagonize BC6ENTG - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6ENTC - insensitive BC6OTHER poisons.	False
In addition , BC6OTHER was shown to strongly antagonize BC6OTHER - mediated DNA cleavage induced by BC6OTHER - sensitive but not BC6ENTC - insensitive BC6ENTG poisons.	False
The 90% CI for the AUC0 - t ratio of BC6ENTC but not for BC6OTHER / BC6OTHER plasma ratio 3 hours post - dose or BC6OTHER / BC6OTHER AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6OTHER pharmacokinetics.	False
The 90% CI for the AUC0 - t ratio of BC6OTHER but not for BC6ENTC / BC6OTHER plasma ratio 3 hours post - dose or BC6OTHER / BC6OTHER AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6OTHER pharmacokinetics.	False
The 90% CI for the AUC0 - t ratio of BC6OTHER but not for BC6OTHER / BC6ENTC plasma ratio 3 hours post - dose or BC6OTHER / BC6OTHER AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6OTHER pharmacokinetics.	False
The 90% CI for the AUC0 - t ratio of BC6OTHER but not for BC6OTHER / BC6OTHER plasma ratio 3 hours post - dose or BC6ENTC / BC6OTHER AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6OTHER pharmacokinetics.	False
The 90% CI for the AUC0 - t ratio of BC6OTHER but not for BC6OTHER / BC6OTHER plasma ratio 3 hours post - dose or BC6OTHER / BC6ENTC AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6OTHER pharmacokinetics.	False
The 90% CI for the AUC0 - t ratio of BC6OTHER but not for BC6OTHER / BC6OTHER plasma ratio 3 hours post - dose or BC6OTHER / BC6OTHER AUC0 - t ratio (secondary BC6ENTG metrics) was above the predefined threshold of 1.43 , probably caused by the inherent high variability of BC6ENTC pharmacokinetics.	False
Additionally , on day 11 of both study periods , 150 mg BC6ENTC ( BC6ENTG ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6ENTC ( BC6OTHER ) , 125 mg BC6OTHER ( BC6ENTG ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6ENTC ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6ENTG ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6ENTC ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6ENTG ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6ENTC ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6ENTG ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6ENTG ) , 125 mg BC6ENTC ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6ENTC ( BC6ENTG ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6ENTC ( BC6OTHER ) , 20 mg BC6OTHER ( BC6ENTG ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6ENTC ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6ENTG ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6ENTC ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6ENTG ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6ENTG ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6ENTC ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6ENTG ) , 20 mg BC6ENTC ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6ENTC ( BC6ENTG ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6ENTC ( BC6OTHER ) , 30 mg BC6OTHER ( BC6ENTG ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6ENTC ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6ENTG ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6ENTG ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6ENTC ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6ENTG ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6ENTC ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6ENTG ) , 30 mg BC6ENTC ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6ENTC ( BC6ENTG ) , and 2 mg BC6OTHER ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6ENTC ( BC6OTHER ) , and 2 mg BC6OTHER ( BC6ENTG ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6ENTG ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6ENTC ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6ENTG ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6ENTC ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6ENTG ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6ENTC ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6ENTG ) , and 2 mg BC6ENTC ( BC6OTHER ) were administered orally.	False
Additionally , on day 11 of both study periods , 150 mg BC6OTHER ( BC6OTHER ) , 125 mg BC6OTHER ( BC6OTHER ) , 20 mg BC6OTHER ( BC6OTHER ) , 30 mg BC6OTHER ( BC6OTHER ) , and 2 mg BC6ENTC ( BC6ENTG ) were administered orally.	False
BC6ENTC dehydrogenase ( BC6ENTG ) and betaine - BC6OTHER methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6ENTC dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6ENTC dehydrogenase ( BC6OTHER ) and betaine - BC6OTHER methyltransferase ( BC6ENTG ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6ENTG ( BC6OTHER ) and betaine - BC6OTHER methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6ENTC oxidation.	CPR:9
BC6OTHER ( BC6ENTG ) and betaine - BC6OTHER methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6ENTC oxidation.	CPR:9
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) are 2 enzymes involved in BC6ENTC oxidation.	CPR:9
BC6OTHER ( BC6OTHER ) and betaine - BC6OTHER methyltransferase ( BC6ENTG ) are 2 enzymes involved in BC6ENTC oxidation.	CPR:9
Independent of dietary BC6ENTC , supplemental BC6OTHER increased hepatic BC6ENTG activity approximately 30%.	CPR:3
Independent of dietary BC6OTHER , supplemental BC6ENTC increased hepatic BC6ENTG activity approximately 30%.	CPR:3
BC6ENTG is expressed at high levels in rat liver and its expression is regulated by dietary BC6ENTC and BC6OTHER .	False
BC6ENTG is expressed at high levels in rat liver and its expression is regulated by dietary BC6OTHER and BC6ENTC .	False
BC6ENTG ( BC6OTHER ) and BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6OTHER ( BC6ENTG ) and BC6ENTC - BC6OTHER methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER methyltransferase ( BC6ENTG ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6ENTG is also found in rat kidney , albeit in substantially lower amounts , but it is not known whether kidney BC6OTHER expression is regulated by dietary BC6ENTC or BC6OTHER .	False
BC6OTHER is also found in rat kidney , albeit in substantially lower amounts , but it is not known whether kidney BC6ENTG expression is regulated by dietary BC6ENTC or BC6OTHER .	False
BC6ENTG is also found in rat kidney , albeit in substantially lower amounts , but it is not known whether kidney BC6OTHER expression is regulated by dietary BC6OTHER or BC6ENTC .	False
BC6OTHER is also found in rat kidney , albeit in substantially lower amounts , but it is not known whether kidney BC6ENTG expression is regulated by dietary BC6OTHER or BC6ENTC .	False
BC6ENTG ( BC6OTHER ) and betaine - BC6ENTC methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6OTHER ( BC6ENTG ) and betaine - BC6ENTC methyltransferase ( BC6OTHER ) are 2 enzymes involved in BC6OTHER oxidation.	False
BC6OTHER ( BC6OTHER ) and betaine - BC6ENTC methyltransferase ( BC6ENTG ) are 2 enzymes involved in BC6OTHER oxidation.	False
Liver BC6ENTG activity was 1.3 - fold higher in rats fed the BC6ENTC deficient diet containing BC6OTHER , which was reflected in corresponding increases in mRNA content and immunodetectable protein.	False
Liver BC6ENTG activity was 1.3 - fold higher in rats fed the BC6OTHER deficient diet containing BC6ENTC , which was reflected in corresponding increases in mRNA content and immunodetectable protein.	CPR:3
Liver BC6OTHER and kidney BC6ENTG expression are not affected by BC6ENTC or BC6OTHER intake in growing rats.	False
Liver BC6ENTG and kidney betaine - BC6OTHER methyltransferase expression are not affected by BC6ENTC or BC6OTHER intake in growing rats.	False
Liver BC6OTHER and kidney BC6ENTG expression are not affected by BC6OTHER or BC6ENTC intake in growing rats.	False
Liver BC6ENTG and kidney betaine - BC6OTHER methyltransferase expression are not affected by BC6OTHER or BC6ENTC intake in growing rats.	False
Liver BC6ENTG and kidney BC6ENTC - BC6OTHER methyltransferase expression are not affected by BC6OTHER or BC6OTHER intake in growing rats.	False
Liver BC6ENTG and kidney betaine - BC6ENTC methyltransferase expression are not affected by BC6OTHER or BC6OTHER intake in growing rats.	False
Liver BC6ENTC dehydrogenase and kidney BC6ENTG expression are not affected by BC6OTHER or BC6OTHER intake in growing rats.	False
A new inhibitor of BC6ENTG , BC6ENTC (1) , was isolated from the culture broth of Streptomyces sp.	CPR:4
 BC6ENTC , an Inhibitor of BC6ENTG Isolated from the Culture Broth of Streptomyces sp.	CPR:4
To confirm molecular recognition of BC6ENTC by BC6ENTG , a surface acoustic wave - biosensor was applied.	False
A BC6ENTG containing membrane preparation of MV3 cells was immobilised at the sensors to allow for detection of kinetic binding constants of BC6ENTC compared to BC6OTHER .	False
A BC6OTHER containing membrane preparation of MV3 cells was immobilised at the sensors to allow for detection of kinetic binding constants of BC6ENTC compared to BC6ENTG .	False
BC6ENTC binds to BC6ENTG with affinity in the low micromolar range (4.61 x 10( - 6) M) , which clearly indicates specific molecular recognition.	False
Furthermore , BC6ENTC displays a nearly identical k(off) compared to BC6ENTG (5.13 x 10( - 3) s( - 1) versus 3.44 x 10( - 3) s( - 1)) which is evident for interference with the ligand binding.	False
Isometric contraction induced by a submaximal concentration of BC6ENTG (10( - 7) mol / L) was reduced in a dose - dependent way by BC6ENTC (IC(50)=0.5+ / - 0.04 micromol / L).	CPR:4
Incubation of VSMCs with different concentrations of BC6ENTG (from 10( - 10) to 10( - 6) mol / L) resulted in a dose - dependent rise of [ BC6ENTC ](i) (pD(2)=7.5+ / - 0.3).	False
The stimulatory effect of [ BC6ENTC ](i) induced by a submaximal concentration of BC6ENTG (10( - 7) mol / L) was blocked by BC6OTHER (IC(50)=0.5+ / - 0.3 nmol / L).	False
The stimulatory effect of [ BC6OTHER ](i) induced by a submaximal concentration of BC6ENTG (10( - 7) mol / L) was blocked by BC6ENTC (IC(50)=0.5+ / - 0.3 nmol / L).	CPR:4
Our findings suggest that BC6ENTC blocks the vasoconstrictor action of BC6ENTG in vitro.	CPR:4
This action can be related to the ability of BC6ENTC to block the increase of [ BC6OTHER ](i) induced by BC6ENTG in VSMCs.	CPR:4
This action can be related to the ability of BC6OTHER to block the increase of [ BC6ENTC ](i) induced by BC6ENTG in VSMCs.	False
In the present study , the ability of different concentrations of BC6ENTC to modify BC6ENTG ( BC6OTHER ) - induced vascular responses was examined , with the use of an organ bath system , in endothelium - denuded aortic rings from spontaneously hypertensive rats.	False
In the present study , the ability of different concentrations of BC6ENTC to modify BC6OTHER ( BC6ENTG ) - induced vascular responses was examined , with the use of an organ bath system , in endothelium - denuded aortic rings from spontaneously hypertensive rats.	False
BC6ENTG - induced increases of intracellular free BC6ENTC concentration ([ BC6OTHER ](i)) were also examined by image analysis in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats.	False
BC6ENTG - induced increases of intracellular free BC6OTHER concentration ([ BC6ENTC ](i)) were also examined by image analysis in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats.	False
 BC6ENTC inhibits BC6ENTG - induced vasoconstriction and intracellular BC6OTHER increase in the aorta of spontaneously hypertensive rats.	CPR:4
 BC6OTHER inhibits BC6ENTG - induced vasoconstriction and intracellular BC6ENTC increase in the aorta of spontaneously hypertensive rats.	False
Both the BC6ENTG and BC6ENTC treatments protected the brain BC6OTHER activities measured 24 h after BC6OTHER exposure.	False
Both the BC6OTHER and BC6ENTC treatments protected the brain BC6ENTG activities measured 24 h after BC6OTHER exposure.	False
Both the BC6ENTG and BC6OTHER treatments protected the brain BC6OTHER activities measured 24 h after BC6ENTC exposure.	False
Both the BC6OTHER and BC6OTHER treatments protected the brain BC6ENTG activities measured 24 h after BC6ENTC exposure.	False
In BC6ENTG and BC6ENTC - treated mice , a 4 - and 2 - fold higher BC6OTHER dose , respectively , was needed to cause a 50% inhibition of brain BC6OTHER activity.	False
In BC6OTHER and BC6ENTC - treated mice , a 4 - and 2 - fold higher BC6OTHER dose , respectively , was needed to cause a 50% inhibition of brain BC6ENTG activity.	False
In BC6ENTG and BC6OTHER - treated mice , a 4 - and 2 - fold higher BC6ENTC dose , respectively , was needed to cause a 50% inhibition of brain BC6OTHER activity.	False
In BC6OTHER and BC6OTHER - treated mice , a 4 - and 2 - fold higher BC6ENTC dose , respectively , was needed to cause a 50% inhibition of brain BC6ENTG activity.	CPR:4
Moreover , the combination of BC6ENTG - BC6ENTC increased the LD50 value for BC6OTHER 4.3 - fold.	False
Moreover , the combination of BC6ENTG - BC6OTHER increased the LD50 value for BC6ENTC 4.3 - fold.	False
The animals pretreated with BC6ENTG - BC6ENTC tolerated four times the lethal dose in control animals , furthermore their survival time was 2 - 3 h in comparison to 20 min in controls.	False
In conclusion , BC6ENTG and BC6ENTC were the most effective treatments against BC6OTHER intoxication.	False
The acute toxicity of BC6OTHER (OP) compounds in mammals is due to their irreversible inhibition of BC6ENTG ( BC6OTHER ) in the nervous system , which leads to increased synaptic BC6ENTC levels.	CPR:9
The acute toxicity of BC6OTHER (OP) compounds in mammals is due to their irreversible inhibition of BC6OTHER ( BC6ENTG ) in the nervous system , which leads to increased synaptic BC6ENTC levels.	CPR:9
In conclusion , BC6ENTG and BC6OTHER were the most effective treatments against BC6ENTC intoxication.	False
The acute toxicity of BC6ENTC (OP) compounds in mammals is due to their irreversible inhibition of BC6ENTG ( BC6OTHER ) in the nervous system , which leads to increased synaptic BC6OTHER levels.	CPR:4
The acute toxicity of BC6ENTC (OP) compounds in mammals is due to their irreversible inhibition of BC6OTHER ( BC6ENTG ) in the nervous system , which leads to increased synaptic BC6OTHER levels.	CPR:4
administered BC6ENTC , BC6OTHER , BC6OTHER , and an BC6ENTG , BC6OTHER , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6ENTC , BC6OTHER , BC6OTHER , and an BC6OTHER , BC6ENTG , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6ENTC , BC6OTHER , and an BC6ENTG , BC6OTHER , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6ENTC , BC6OTHER , and an BC6OTHER , BC6ENTG , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6OTHER , BC6ENTC , and an BC6ENTG , BC6OTHER , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6OTHER , BC6ENTC , and an BC6OTHER , BC6ENTG , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6OTHER , BC6OTHER , and an BC6ENTC hydrolase , BC6ENTG , in acute BC6OTHER intoxication were studied in mice.	False
administered BC6OTHER , BC6OTHER , BC6OTHER , and an BC6ENTG , BC6OTHER , in acute BC6ENTC intoxication were studied in mice.	False
administered BC6OTHER , BC6OTHER , BC6OTHER , and an BC6OTHER , BC6ENTG , in acute BC6ENTC intoxication were studied in mice.	False
The mice received BC6ENTC (0.06 mg / kg body weight) , BC6OTHER (0.09 mg / kg body weight) , the BC6OTHER derivative BC6OTHER (0.90 mg / kg body weight) or BC6ENTG (104 U / g , 10.7 microg / g body weight) 10 min prior to the i.g.	False
The mice received BC6OTHER (0.06 mg / kg body weight) , BC6ENTC (0.09 mg / kg body weight) , the BC6OTHER derivative BC6OTHER (0.90 mg / kg body weight) or BC6ENTG (104 U / g , 10.7 microg / g body weight) 10 min prior to the i.g.	False
The mice received BC6OTHER (0.06 mg / kg body weight) , BC6OTHER (0.09 mg / kg body weight) , the BC6ENTC derivative BC6OTHER (0.90 mg / kg body weight) or BC6ENTG (104 U / g , 10.7 microg / g body weight) 10 min prior to the i.g.	False
The mice received BC6OTHER (0.06 mg / kg body weight) , BC6OTHER (0.09 mg / kg body weight) , the BC6OTHER derivative BC6ENTC (0.90 mg / kg body weight) or BC6ENTG (104 U / g , 10.7 microg / g body weight) 10 min prior to the i.g.	False
BC6ENTC was also administered with BC6ENTG .	False
BC6ENTG was the most effective antidote in BC6ENTC intoxication.	False
The LD50 value for BC6ENTC increased 3.4 - fold in mice receiving BC6ENTG .	False
Success of BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG treatments in acute BC6OTHER intoxication.	False
Success of BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG treatments in acute BC6OTHER intoxication.	False
Success of BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG treatments in acute BC6OTHER intoxication.	False
Success of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG treatments in acute BC6ENTC intoxication.	False
Local BC6ENTC administration prevented the increase of airway BC6ENTG and BC6OTHER and kept lung plasmacytoid dendritic cell counts close to baseline.	CPR:4
Local BC6ENTC administration prevented the increase of airway BC6OTHER and BC6ENTG and kept lung plasmacytoid dendritic cell counts close to baseline.	CPR:4
Lung inflammation , BC6ENTG production , and airway mast cell activity were also prevented under this early short - term treatment with BC6ENTC .	CPR:4
The enzyme BC6ENTG catalyses the oxygenation of BC6OTHER , leading to the formation of BC6ENTC .	CPR:9
The competitive inhibitor of BC6ENTG , BC6ENTC , also displayed competitive inhibition of BC6OTHER .	CPR:4
The competitive inhibitor of BC6OTHER , BC6ENTC , also displayed competitive inhibition of BC6ENTG .	CPR:4
BC6ENTG had a specific activity of 18.8 mumol of BC6ENTC / mg with a Km of 13.8 microM for BC6OTHER and Vmax.	False
The enzyme BC6ENTG catalyses the oxygenation of BC6ENTC , leading to the formation of BC6OTHER .	CPR:9
BC6ENTG had a specific activity of 18.8 mumol of BC6OTHER / mg with a Km of 13.8 microM for BC6ENTC and Vmax.	CPR:9
of 1500 nmol of CHEM / nmol of enzyme , whereas BC6ENTG had a specific activity of 12.2 mumol of BC6ENTC / mg with a Km of 8.7 microM for BC6OTHER and a Vmax.	False
of 1500 nmol of CHEM / nmol of enzyme , whereas BC6ENTG had a specific activity of 12.2 mumol of BC6OTHER / mg with a Km of 8.7 microM for BC6ENTC and a Vmax.	CPR:9
BC6ENTC inhibited both BC6ENTG and BC6OTHER , whereas BC6OTHER and BC6OTHER selectively inhibited BC6OTHER .	CPR:4
BC6ENTC inhibited both BC6OTHER and BC6ENTG , whereas BC6OTHER and BC6OTHER selectively inhibited BC6OTHER .	CPR:4
BC6ENTC inhibited both BC6OTHER and BC6OTHER , whereas BC6OTHER and BC6OTHER selectively inhibited BC6ENTG .	False
BC6OTHER inhibited both BC6ENTG and BC6OTHER , whereas BC6ENTC and BC6OTHER selectively inhibited BC6OTHER .	False
BC6OTHER inhibited both BC6OTHER and BC6ENTG , whereas BC6ENTC and BC6OTHER selectively inhibited BC6OTHER .	False
BC6OTHER inhibited both BC6OTHER and BC6OTHER , whereas BC6ENTC and BC6OTHER selectively inhibited BC6ENTG .	CPR:4
BC6OTHER inhibited both BC6ENTG and BC6OTHER , whereas BC6OTHER and BC6ENTC selectively inhibited BC6OTHER .	False
BC6OTHER inhibited both BC6OTHER and BC6ENTG , whereas BC6OTHER and BC6ENTC selectively inhibited BC6OTHER .	False
BC6OTHER inhibited both BC6OTHER and BC6OTHER , whereas BC6OTHER and BC6ENTC selectively inhibited BC6ENTG .	CPR:4
Both BC6ENTC and BC6OTHER exhibited time - dependent inactivation of BC6ENTG , as did BC6OTHER on both enzymes.	CPR:4
Both BC6OTHER and BC6ENTC exhibited time - dependent inactivation of BC6ENTG , as did BC6OTHER on both enzymes.	CPR:4
Both BC6OTHER and BC6OTHER exhibited time - dependent inactivation of BC6ENTG , as did BC6ENTC on both enzymes.	CPR:4
Additionally , BC6ENTG increased the apparent K(M) of BC6OTHER for BC6ENTC by 8 - fold and the apparent K(M) did not decrease to its original value when saturating concentrations of BC6OTHER were used.	False
Additionally , BC6OTHER increased the apparent K(M) of BC6ENTG for BC6ENTC by 8 - fold and the apparent K(M) did not decrease to its original value when saturating concentrations of BC6OTHER were used.	False
Additionally , BC6OTHER increased the apparent K(M) of BC6OTHER for BC6ENTC by 8 - fold and the apparent K(M) did not decrease to its original value when saturating concentrations of BC6ENTG were used.	False
The results show that BC6ENTG inhibits BC6OTHER - mediated metabolism of BC6ENTC ( BC6OTHER ) with a K(i) of 0.04 µM.	False
The results show that BC6OTHER inhibits BC6ENTG - mediated metabolism of BC6ENTC ( BC6OTHER ) with a K(i) of 0.04 µM.	CPR:9
The results show that BC6ENTG inhibits BC6OTHER - mediated metabolism of BC6OTHER ( BC6ENTC ) with a K(i) of 0.04 µM.	False
The results show that BC6OTHER inhibits BC6ENTG - mediated metabolism of BC6OTHER ( BC6ENTC ) with a K(i) of 0.04 µM.	CPR:9
However , BC6ENTG is not an inhibitor of BC6OTHER - mediated BC6ENTC hydroxylation.	False
However , BC6OTHER is not an inhibitor of BC6ENTG - mediated BC6ENTC hydroxylation.	CPR:9
When these inhibition studies were performed with the artificial oxidant BC6ENTC , BC6ENTG did not significantly inhibit BC6OTHER activity.	False
When these inhibition studies were performed with the artificial oxidant BC6ENTC , BC6OTHER did not significantly inhibit BC6ENTG activity.	False
Interactions between BC6ENTG and BC6OTHER : effects on affinity for BC6ENTC - cytochrome P450 reductase and substrate metabolism.	False
Interactions between BC6OTHER and BC6ENTG : effects on affinity for BC6ENTC - cytochrome P450 reductase and substrate metabolism.	False
BC6OTHER - induced antinociception was reversed by BC6OTHER , a BC6ENTG BC6ENTC ( BC6OTHER )) channel inhibitor.	False
BC6OTHER - induced antinociception was reversed by BC6OTHER , a BC6ENTG BC6OTHER ( BC6ENTC )) channel inhibitor.	False
Colonic BC6ENTG and BC6OTHER mRNA and spinal BC6OTHER mRNA expression were significantly down - regulated by BC6ENTC , but not by BC6OTHER .	CPR:4
Colonic BC6OTHER and BC6ENTG mRNA and spinal BC6OTHER mRNA expression were significantly down - regulated by BC6ENTC , but not by BC6OTHER .	CPR:4
Colonic BC6OTHER and BC6OTHER mRNA and spinal BC6ENTG mRNA expression were significantly down - regulated by BC6ENTC , but not by BC6OTHER .	CPR:4
Colonic BC6ENTG and BC6OTHER mRNA and spinal BC6OTHER mRNA expression were significantly down - regulated by BC6OTHER , but not by BC6ENTC .	False
Colonic BC6OTHER and BC6ENTG mRNA and spinal BC6OTHER mRNA expression were significantly down - regulated by BC6OTHER , but not by BC6ENTC .	False
Colonic BC6OTHER and BC6OTHER mRNA and spinal BC6ENTG mRNA expression were significantly down - regulated by BC6OTHER , but not by BC6ENTC .	False
Taken together , these data suggest that BC6ENTC inhibits hypersensitivity induced by CRD in both healthy and postcolitic , allodynic rats by a BC6ENTG - mediated mechanism.	False
In healthy rats , BC6ENTC dose dependently (25 , 50 , or 100 mg / kg) attenuated CRD - induced hypersensitivity and significantly inhibited CRD - induced overexpression of spinal BC6ENTG mRNA , whereas BC6OTHER had no effect.	CPR:4
In healthy rats , BC6OTHER dose dependently (25 , 50 , or 100 mg / kg) attenuated CRD - induced hypersensitivity and significantly inhibited CRD - induced overexpression of spinal BC6ENTG mRNA , whereas BC6ENTC had no effect.	False
BC6ENTC - induced antinociception was reversed by BC6OTHER , a BC6ENTG BC6OTHER ( BC6OTHER )) channel inhibitor.	False
BC6OTHER - induced antinociception was reversed by BC6ENTC , a BC6ENTG BC6OTHER ( BC6OTHER )) channel inhibitor.	CPR:4
Single dose and 7 - day AC administration at 0.125mg / kg had no effect on BC6ENTG activity since no change in the formation of BC6ENTC and BC6OTHER .	False
Single dose and 7 - day AC administration at 0.125mg / kg had no effect on BC6ENTG activity since no change in the formation of BC6OTHER and BC6ENTC .	False
Our study aims to explore the potent effects of AC , as a marker component of Aconitum , on BC6ENTG using the probe BC6ENTC in rats.	False
BC6ENTG activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro BC6ENTC metabolism and Western blot.	False
The exposure of highly toxic BC6OTHER does not significantly impact the activity and expression of BC6ENTG in rats determined by a novel ultra performance liquid chromatography - tandem mass spectrometric method of a specific probe BC6ENTC .	False
The exposure of highly toxic BC6ENTC does not significantly impact the activity and expression of BC6ENTG in rats determined by a novel ultra performance liquid chromatography - tandem mass spectrometric method of a specific probe BC6OTHER .	False
BC6ENTC reversed the inhibitory effect of the BC6OTHER agonist BC6OTHER on VTA DA neurons (ED50 = 61 mug / kg) , whereas it was ineffective when administered alone , indicating partial agonistic action on BC6ENTG .	False
BC6OTHER reversed the inhibitory effect of the BC6ENTC agonist BC6OTHER on VTA DA neurons (ED50 = 61 mug / kg) , whereas it was ineffective when administered alone , indicating partial agonistic action on BC6ENTG .	False
BC6OTHER reversed the inhibitory effect of the BC6OTHER agonist BC6ENTC on VTA DA neurons (ED50 = 61 mug / kg) , whereas it was ineffective when administered alone , indicating partial agonistic action on BC6ENTG .	CPR:5
Compared with BC6ENTC , which significantly inhibited the firing activity of VTA BC6OTHER neurons , BC6OTHER displayed less efficacy at BC6ENTG .	False
Compared with BC6OTHER , which significantly inhibited the firing activity of VTA BC6ENTC neurons , BC6OTHER displayed less efficacy at BC6ENTG .	False
Compared with BC6OTHER , which significantly inhibited the firing activity of VTA BC6OTHER neurons , BC6ENTC displayed less efficacy at BC6ENTG .	CPR:4
In the hippocampus , BC6ENTC acted as a full agonist at BC6ENTG receptors on pyramidal neurons.	CPR:5
Furthermore , it increased BC6ENTC release by terminal BC6ENTG but not BC6OTHER autoreceptor antagonism.	False
Furthermore , it increased BC6ENTC release by terminal BC6OTHER but not BC6ENTG autoreceptor antagonism.	False
In the lateral geniculate nucleus , BC6ENTC displayed BC6ENTG antagonistic action.	CPR:6
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on BC6ENTG subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on CHEM ( BC6OTHER ) receptor subtypes BC6ENTG , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6ENTG , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6ENTG ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTG , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6ENTC on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6ENTG .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTC ( BC6OTHER ) receptor subtypes BC6ENTG , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTC ( BC6OTHER ) receptor subtypes BC6OTHER , BC6ENTG , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTC ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6ENTG ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTC ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTG , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTC ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6ENTG .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6ENTC ) receptor subtypes BC6ENTG , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6ENTC ) receptor subtypes BC6OTHER , BC6ENTG , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6ENTC ) receptor subtypes BC6OTHER , BC6OTHER , and BC6ENTG ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6ENTC ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTG , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6ENTC ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6OTHER ) D2 autoreceptors , and BC6ENTG .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTG subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTC ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6ENTG , BC6OTHER , and BC6OTHER ; BC6ENTC ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6ENTG , and BC6OTHER ; BC6ENTC ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6ENTG ; BC6ENTC ( BC6OTHER ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTC ( BC6OTHER ) D2 autoreceptors , and BC6ENTG .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on BC6ENTG subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6ENTC ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6ENTG , BC6OTHER , and BC6OTHER ; CHEM ( BC6ENTC ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6ENTG , and BC6OTHER ; CHEM ( BC6ENTC ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6ENTG ; CHEM ( BC6ENTC ) D2 autoreceptors , and BC6OTHER .	False
Using electrophysiologic techniques , the present study assessed the in vivo action of BC6OTHER on CHEM ( BC6OTHER ) receptor subtypes BC6OTHER , BC6OTHER , and BC6OTHER ; CHEM ( BC6ENTC ) D2 autoreceptors , and BC6ENTG .	False
In addition , the effects on BC6ENTG autoreceptors in the dorsal raphe nucleus (DRN) and BC6OTHER in the ventral tegmental area (VTA) were compared with those of BC6ENTC , an agent in wide clinical use.	False
In addition , the effects on BC6OTHER autoreceptors in the dorsal raphe nucleus (DRN) and BC6ENTG in the ventral tegmental area (VTA) were compared with those of BC6ENTC , an agent in wide clinical use.	False
In the DRN , BC6ENTC completely inhibited the firing of BC6OTHER neurons via BC6ENTG agonism and was more potent than BC6OTHER (ED50 = 230 and 700 mug / kg , respectively).	CPR:5
In the DRN , BC6OTHER completely inhibited the firing of BC6ENTC neurons via BC6ENTG agonism and was more potent than BC6OTHER (ED50 = 230 and 700 mug / kg , respectively).	False
In the DRN , BC6OTHER completely inhibited the firing of BC6OTHER neurons via BC6ENTG agonism and was more potent than BC6ENTC (ED50 = 230 and 700 mug / kg , respectively).	CPR:5
In the locus coeruleus , BC6ENTC reversed the inhibitory effect of the preferential BC6OTHER receptor agonist BC6OTHER ( BC6OTHER ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6ENTG antagonistic action.	False
In the locus coeruleus , BC6ENTC reversed the inhibitory effect of the preferential BC6ENTG receptor agonist BC6OTHER ( BC6OTHER ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6OTHER antagonistic action.	False
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6OTHER receptor agonist BC6ENTC ( BC6OTHER ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6ENTG antagonistic action.	False
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6ENTG receptor agonist BC6ENTC ( BC6OTHER ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6OTHER antagonistic action.	CPR:5
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6OTHER receptor agonist BC6OTHER ( BC6ENTC ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6ENTG antagonistic action.	False
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6ENTG receptor agonist BC6OTHER ( BC6ENTC ) on BC6OTHER neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6OTHER antagonistic action.	CPR:5
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6OTHER receptor agonist BC6OTHER ( BC6OTHER ) on BC6ENTC neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6ENTG antagonistic action.	False
In the locus coeruleus , BC6OTHER reversed the inhibitory effect of the preferential BC6ENTG receptor agonist BC6OTHER ( BC6OTHER ) on BC6ENTC neuronal firing (ED50 = 110 mug / kg) , demonstrating BC6OTHER antagonistic action.	False
Inhibitors of BC6ENTG function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6ENTG , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6ENTG , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6ENTG antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6ENTG - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6ENTG BC6OTHER - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6ENTG - BC6OTHER ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6ENTG ) prevented aberrant BC6OTHER expression.	False
Inhibitors of BC6OTHER function( BC6ENTC , a dominant - negative form of BC6OTHER , BC6OTHER , and anti - BC6OTHER antibody M3 / 38) or BC6OTHER - mediated platelet adhesion(revacept , a dimeric BC6OTHER BC6OTHER - BC6OTHER ) prevented aberrant BC6ENTG expression.	False
Inhibition of platelet - cancer cell interaction by revacept was more effective than BC6ENTC in preventing platelet - induced mRNA changes of EMT markers suggesting that direct cell - cell contact and aberrant BC6ENTG expression synergistically induced gene expression modifications associated with EMT.	False
BC6ENTG - derived BC6ENTC can influence several processes that are linked to carcinogenesis.	CPR:9
Platelet - induced BC6ENTG - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	CPR:9
Platelet - induced BC6OTHER - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6ENTG ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6OTHER - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6ENTG / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6OTHER - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6ENTG ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6OTHER - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6ENTG , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6OTHER - dependent BC6ENTC synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6ENTG inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6ENTG - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6ENTC (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6ENTG ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6ENTC (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	CPR:3
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6ENTG / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6ENTC (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	CPR:3
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6ENTG ) and upregulation of BC6OTHER , since these effects were prevented by BC6ENTC (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	CPR:3
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6ENTG , since these effects were prevented by BC6ENTC (a selective BC6OTHER inhibitor) and rescued by exogenous BC6OTHER .	CPR:4
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6ENTC (a selective BC6ENTG inhibitor) and rescued by exogenous BC6OTHER .	CPR:4
Platelet - induced BC6ENTG - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6ENTC .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6ENTG ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6ENTC .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6ENTG / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6ENTC .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6ENTG ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6ENTC .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6ENTG , since these effects were prevented by BC6OTHER (a selective BC6OTHER inhibitor) and rescued by exogenous BC6ENTC .	False
Platelet - induced BC6OTHER - dependent BC6OTHER synthesis in HT29 cells was involved in downregulation of BC6OTHER ( BC6OTHER / BC6OTHER ) and upregulation of BC6OTHER , since these effects were prevented by BC6OTHER (a selective BC6ENTG inhibitor) and rescued by exogenous BC6ENTC .	False
The treatment has been varied and included BC6ENTC , BC6OTHER , BC6ENTG , and in some cases chemotherapy.	False
The treatment has been varied and included BC6OTHER , BC6ENTC , BC6ENTG , and in some cases chemotherapy.	False
On the basis of BC6ENTG - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6OTHER positive cases the BC6ENTC kinase inhibitor BC6OTHER (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6ENTG fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6OTHER positive cases the BC6ENTC kinase inhibitor BC6OTHER (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6ENTG - BC6OTHER positive cases the BC6ENTC kinase inhibitor BC6OTHER (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6ENTG positive cases the BC6ENTC kinase inhibitor BC6OTHER (CHEM) would be effective.	False
On the basis of BC6ENTG - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6OTHER positive cases the BC6OTHER inhibitor BC6ENTC (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6ENTG fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6OTHER positive cases the BC6OTHER inhibitor BC6ENTC (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6ENTG - BC6OTHER positive cases the BC6OTHER inhibitor BC6ENTC (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6ENTG positive cases the BC6OTHER inhibitor BC6ENTC (CHEM) would be effective.	False
On the basis of BC6OTHER - BC6OTHER fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the BC6OTHER - BC6OTHER positive cases the BC6ENTG inhibitor BC6ENTC (CHEM) would be effective.	CPR:4
BC6ENTC oxidase BC6ENTG is expressed in a wide range of tissues and plays a role in cellular signaling by providing reactive BC6OTHER species (ROS) as intracellular messengers.	False
BC6ENTG BC6OTHER is expressed in a wide range of tissues and plays a role in cellular signaling by providing reactive BC6ENTC species (ROS) as intracellular messengers.	False
BC6OTHER BC6ENTG is expressed in a wide range of tissues and plays a role in cellular signaling by providing reactive BC6ENTC species (ROS) as intracellular messengers.	False
Such model of BC6OTHER activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme , i.e. , its potential redox regulation , and could also define new therapeutic targets in diseases in which BC6ENTC and BC6ENTG are implicated.	False
Such model of BC6ENTG activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme , i.e. , its potential redox regulation , and could also define new therapeutic targets in diseases in which BC6ENTC and BC6OTHER are implicated.	CPR:3
BC6ENTG BC6OTHER activity is thought to be constitutive and regulated at the transcriptional level; however , we challenge this point of view and suggest that specific BC6ENTC derivatives could modulate this activity.	CPR:3
BC6OTHER BC6ENTG activity is thought to be constitutive and regulated at the transcriptional level; however , we challenge this point of view and suggest that specific BC6ENTC derivatives could modulate this activity.	CPR:3
In fact , we demonstrated a significant stimulation of BC6ENTG activity by 4 BC6ENTC derivatives ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ) observed in 3 different cellular models , HEK293E , T - REx™ , and chondrocyte cell lines.	CPR:3
In fact , we demonstrated a significant stimulation of BC6ENTG activity by 4 BC6OTHER derivatives ( BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) observed in 3 different cellular models , HEK293E , T - REx™ , and chondrocyte cell lines.	CPR:3
In fact , we demonstrated a significant stimulation of BC6ENTG activity by 4 BC6OTHER derivatives ( BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) observed in 3 different cellular models , HEK293E , T - REx™ , and chondrocyte cell lines.	CPR:3
In fact , we demonstrated a significant stimulation of BC6ENTG activity by 4 BC6OTHER derivatives ( BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) observed in 3 different cellular models , HEK293E , T - REx™ , and chondrocyte cell lines.	CPR:3
In fact , we demonstrated a significant stimulation of BC6ENTG activity by 4 BC6OTHER derivatives ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) observed in 3 different cellular models , HEK293E , T - REx™ , and chondrocyte cell lines.	CPR:3
Furthermore , we showed that BC6ENTC : BC6OTHER oxidoreductase ( BC6ENTG ) may participate in this stimulation.	False
Furthermore , we showed that CHEM: BC6ENTC oxidoreductase ( BC6ENTG ) may participate in this stimulation.	False
Interestingly , BC6ENTG activity is also stimulated by reducing agents that possibly act by reducing the BC6ENTC bridge ( BC6OTHER 226 , BC6OTHER 270) located in the BC6OTHER of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6ENTC bridge ( BC6OTHER 226 , BC6OTHER 270) located in the BC6ENTG of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6ENTC bridge ( BC6OTHER 226 , BC6OTHER 270) located in the BC6OTHER of BC6ENTG .	False
Interestingly , BC6ENTG activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6ENTC 226 , BC6OTHER 270) located in the BC6OTHER of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6ENTC 226 , BC6OTHER 270) located in the BC6ENTG of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6ENTC 226 , BC6OTHER 270) located in the BC6OTHER of BC6ENTG .	False
Interestingly , BC6ENTG activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6OTHER 226 , BC6ENTC 270) located in the BC6OTHER of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6OTHER 226 , BC6ENTC 270) located in the BC6ENTG of BC6OTHER .	False
Interestingly , BC6OTHER activity is also stimulated by reducing agents that possibly act by reducing the BC6OTHER bridge ( BC6OTHER 226 , BC6ENTC 270) located in the BC6OTHER of BC6ENTG .	False
 BC6ENTC compounds regulate the level of ROS production by the BC6ENTG BC6OTHER .	False
 BC6ENTC compounds regulate the level of ROS production by the BC6OTHER BC6ENTG .	False
 BC6OTHER compounds regulate the level of ROS production by the BC6ENTC oxidase BC6ENTG .	False
In catalytic properties , BC6ENTG is closest to BC6OTHER ; however , in inhibition by BC6ENTC , BC6OTHER , and BC6OTHER , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6ENTG ; however , in inhibition by BC6ENTC , BC6OTHER , and BC6OTHER , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6ENTC , BC6OTHER , and BC6OTHER , BC6ENTG is very similar to BC6OTHER .	CPR:4
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6ENTC , BC6OTHER , and BC6OTHER , BC6OTHER is very similar to BC6ENTG .	CPR:4
In catalytic properties , BC6ENTG is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6ENTC , and BC6OTHER , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6ENTG ; however , in inhibition by BC6OTHER , BC6ENTC , and BC6OTHER , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6ENTC , and BC6OTHER , BC6ENTG is very similar to BC6OTHER .	CPR:4
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6ENTC , and BC6OTHER , BC6OTHER is very similar to BC6ENTG .	CPR:4
In catalytic properties , BC6ENTG is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6OTHER , and BC6ENTC , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6ENTG ; however , in inhibition by BC6OTHER , BC6OTHER , and BC6ENTC , BC6OTHER is very similar to BC6OTHER .	False
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6OTHER , and BC6ENTC , BC6ENTG is very similar to BC6OTHER .	CPR:4
In catalytic properties , BC6OTHER is closest to BC6OTHER ; however , in inhibition by BC6OTHER , BC6OTHER , and BC6ENTC , BC6OTHER is very similar to BC6ENTG .	CPR:4
BC6ENTG has a CHEM at position 64 , where the highly active isozyme II has BC6ENTC serving as a proton shuttle in the catalytic pathway.	False
Investigation of a site - specific mutant of BC6ENTG containing the replacement CHEM64 - - > BC6ENTC showed that the unique kinetic properties of BC6OTHER are not due to the presence of BC6OTHER at position 64.	False
Investigation of a site - specific mutant of BC6OTHER containing the replacement CHEM64 - - > BC6ENTC showed that the unique kinetic properties of BC6ENTG are not due to the presence of BC6OTHER at position 64.	False
Investigation of a site - specific mutant of BC6ENTG containing the replacement CHEM64 - - > BC6OTHER showed that the unique kinetic properties of BC6OTHER are not due to the presence of BC6ENTC at position 64.	False
Investigation of a site - specific mutant of BC6OTHER containing the replacement BC6ENTG showed that the unique kinetic properties of BC6OTHER are not due to the presence of BC6ENTC at position 64.	False
Investigation of a site - specific mutant of BC6OTHER containing the replacement CHEM64 - - > BC6OTHER showed that the unique kinetic properties of BC6ENTG are not due to the presence of BC6ENTC at position 64.	False
BC6ENTG produced by a vector containing the full coding sequence , which includes a possible BC6ENTC - terminal mitochondrial targeting signal , was proteolytically processed by E. coli and contained several BC6OTHER - terminal ends.	False
BC6ENTG produced by a vector containing the full coding sequence , which includes a possible BC6OTHER - terminal mitochondrial targeting signal , was proteolytically processed by E. coli and contained several BC6ENTC - terminal ends.	False
The two BC6ENTC - terminal truncated vectors deleted , respectively , 1) the 29 - BC6OTHER putative targeting sequence and 2) 51 BC6OTHER , yielding a protein equivalent to a BC6ENTG isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.	False
The two BC6OTHER - terminal truncated vectors deleted , respectively , 1) the 29 - BC6ENTC putative targeting sequence and 2) 51 BC6OTHER , yielding a protein equivalent to a BC6ENTG isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.	False
The two BC6OTHER - terminal truncated vectors deleted , respectively , 1) the 29 - BC6OTHER putative targeting sequence and 2) 51 BC6ENTC , yielding a protein equivalent to a BC6ENTG isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.	False
These latter two forms of BC6ENTG had identical steady - state constants for the hydration of BC6ENTC , with maximal values of kcat / Km at 3 x 10(7) M CHEM with an apparent pKa for catalysis of 7.4 determined from kcat / Km.	False
BC6ENTC is a novel , orally active inhibitor of BC6OTHER BC6OTHER , the enzyme that degrades BC6ENTG ( BC6OTHER ).	False
BC6ENTC is a novel , orally active inhibitor of BC6OTHER BC6OTHER , the enzyme that degrades BC6OTHER ( BC6ENTG ).	False
BC6ENTC is a novel , orally active inhibitor of BC6ENTG BC6OTHER , the enzyme that degrades BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC is a novel , orally active inhibitor of BC6OTHER BC6ENTG , the enzyme that degrades BC6OTHER ( BC6OTHER ).	CPR:4
On study day 1 , BC6ENTC acutely increased plasma BC6ENTG levels , suppressed BC6OTHER and decreased right atrial and pulmonary capillary wedge pressures.	CPR:3
On study day 1 , BC6OTHER acutely increased plasma BC6ENTG levels , suppressed BC6ENTC and decreased right atrial and pulmonary capillary wedge pressures.	False
After 10 days of treatment , basal BC6ENTG was increased and basal BC6ENTC was decreased.	False
On study day 10 , the acute effects of BC6ENTC were similar to those on day 1 (i.e. , BC6ENTG was further increased , BC6OTHER was suppressed , and right and left ventricular filling pressures were decreased).	CPR:3
On study day 10 , the acute effects of BC6OTHER were similar to those on day 1 (i.e. , BC6ENTG was further increased , BC6ENTC was suppressed , and right and left ventricular filling pressures were decreased).	False
Effectiveness of BC6ENTG inhibition ( BC6ENTC ) in congestive heart failure.	CPR:4
Current research shows that the practice of swim training increases the BC6ENTC phosphorylation of BC6ENTG which can modulate the effect caused by obesity in BC6OTHER .	False
Current research shows that the practice of swim training increases the BC6ENTC phosphorylation of BC6OTHER which can modulate the effect caused by obesity in BC6ENTG .	False
The goal of the present study was to investigate changes on BC6OTHER homoeostasis and of the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) signalling in pancreatic islets from BC6ENTC - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6OTHER homoeostasis and of the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) signalling in pancreatic islets from BC6ENTC - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6OTHER homoeostasis and of the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) signalling in pancreatic islets from BC6ENTC - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6OTHER homoeostasis and of the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) signalling in pancreatic islets from BC6ENTC - obese mice submitted to or not submitted to swim training.	False
Swim training of 90 - day - old BC6ENTC mice was used to evaluate whether signalling pathways of the BC6ENTG and BC6OTHER in islets are involved with the BC6OTHER resistance and BC6OTHER intolerance observed in this obese animal model.	False
Swim training of 90 - day - old BC6ENTC mice was used to evaluate whether signalling pathways of the BC6OTHER and BC6ENTG in islets are involved with the BC6OTHER resistance and BC6OTHER intolerance observed in this obese animal model.	False
Swim training of 90 - day - old BC6ENTC mice was used to evaluate whether signalling pathways of the BC6OTHER and BC6OTHER in islets are involved with the BC6ENTG resistance and BC6OTHER intolerance observed in this obese animal model.	False
Swim training of 90 - day - old BC6OTHER mice was used to evaluate whether signalling pathways of the BC6ENTG and BC6OTHER in islets are involved with the BC6OTHER resistance and BC6ENTC intolerance observed in this obese animal model.	False
Swim training of 90 - day - old BC6OTHER mice was used to evaluate whether signalling pathways of the BC6OTHER and BC6ENTG in islets are involved with the BC6OTHER resistance and BC6ENTC intolerance observed in this obese animal model.	False
Swim training of 90 - day - old BC6OTHER mice was used to evaluate whether signalling pathways of the BC6OTHER and BC6OTHER in islets are involved with the BC6ENTG resistance and BC6ENTC intolerance observed in this obese animal model.	False
 The results showed that BC6ENTG BC6ENTC phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6ENTC phosphorylation ( BC6ENTG ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6ENTC phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6ENTG by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6ENTC - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) was reduced by 42 % in BC6ENTC - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6ENTC - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6ENTG by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6ENTC , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) was reduced by 42 % in BC6OTHER - obese mice ( BC6ENTC , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6ENTC , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6ENTG by 76 % in BC6OTHER mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
The goal of the present study was to investigate changes on BC6ENTC homoeostasis and of the BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) signalling in pancreatic islets from BC6OTHER - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6ENTC homoeostasis and of the BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) signalling in pancreatic islets from BC6OTHER - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6ENTC homoeostasis and of the BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) signalling in pancreatic islets from BC6OTHER - obese mice submitted to or not submitted to swim training.	False
The goal of the present study was to investigate changes on BC6ENTC homoeostasis and of the BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) signalling in pancreatic islets from BC6OTHER - obese mice submitted to or not submitted to swim training.	False
 The results showed that BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6ENTC mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6ENTC mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6ENTG by 76 % in BC6ENTC mice without affecting control mice ( BC6OTHER , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6ENTC , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	False
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6OTHER by 76 % in BC6OTHER mice without affecting control mice ( BC6ENTC , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 The results showed that BC6OTHER BC6OTHER phosphorylation ( BC6OTHER ) was reduced by 42 % in BC6OTHER - obese mice ( BC6OTHER , 6.7 ± 0.2 arbitrary units (a.u.); control , 11.5 ± 0.4 a.u.); on the other hand , exercise training increased BC6ENTG by 76 % in BC6OTHER mice without affecting control mice ( BC6ENTC , 11.8 ± 0.3; control , 12.8 ± 0.2 a.u.).	CPR:4
 Although the treatment with BC6ENTC increased BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	False
 Although the treatment with BC6ENTC increased BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	CPR:3
 Although the treatment with BC6OTHER increased BC6ENTG BC6ENTC phosphorylation ( BC6OTHER ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	False
 Although the treatment with BC6OTHER increased BC6OTHER BC6ENTC phosphorylation ( BC6ENTG ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	False
 Although the treatment with BC6OTHER increased BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) by 96 % ( BC6ENTC , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	False
 Although the treatment with BC6OTHER increased BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) by 96 % ( BC6ENTC , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6OTHER , 22.2 ± 1.1 a.u.).	CPR:3
 Although the treatment with BC6OTHER increased BC6ENTG BC6OTHER phosphorylation ( BC6OTHER ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6ENTC , 22.2 ± 1.1 a.u.).	False
 Although the treatment with BC6OTHER increased BC6OTHER BC6OTHER phosphorylation ( BC6ENTG ) by 96 % ( BC6OTHER , 17.02 ± 0.6; control , 8.7 ± 0.2 a.u.) , exercise training also increased it in both groups (control , 13.6 ± 0.1; BC6ENTC , 22.2 ± 1.1 a.u.).	CPR:3
Swim training of BC6ENTC - obese mice improves the impaired BC6ENTG BC6OTHER phosphorylation in pancreatic islets.	False
Swim training of BC6OTHER - obese mice improves the impaired BC6ENTG BC6ENTC phosphorylation in pancreatic islets.	False
These findings suggest that the anti - allodynia effect of BC6ENTC is ascribable to blockade of BC6ENTG receptors at the brain , but not at the spinal cord.	CPR:4
In contrast , intrathecal injection of a non - selective BC6ENTC antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTG antagonist and the BC6OTHER - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6ENTC antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6ENTG - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6ENTC antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6OTHER - specific BC6ENTG antagonist.	False
In contrast , intrathecal injection of a non - selective BC6ENTG antagonist , BC6ENTC , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6OTHER - specific BC6OTHER antagonist.	CPR:6
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6ENTC , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTG antagonist and the BC6OTHER - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6ENTC , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6ENTG - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6ENTC , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6OTHER - specific BC6ENTG antagonist.	False
In contrast , intrathecal injection of a non - selective BC6ENTG antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTC antagonist and the BC6OTHER - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTC antagonist and the BC6ENTG - specific BC6OTHER antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTC antagonist and the BC6OTHER - specific BC6ENTG antagonist.	False
In contrast , intrathecal injection of a non - selective BC6ENTG antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6OTHER - specific BC6ENTC antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6ENTG antagonist and the BC6OTHER - specific BC6ENTC antagonist.	False
In contrast , intrathecal injection of a non - selective BC6OTHER antagonist , BC6OTHER , significantly inhibited CCI - induced mechanical allodynia at a dose of 300 nmol , indicating the difference in the site of action between the non - selective BC6OTHER antagonist and the BC6ENTG - specific BC6ENTC antagonist.	False
In order to examine the site of action of an BC6ENTG subtype - selective BC6ENTC antagonist BC6OTHER , we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.	False
In order to examine the site of action of an BC6ENTG subtype - selective BC6OTHER antagonist BC6ENTC , we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.	CPR:6
In order to examine the site of action of an BC6OTHER subtype - selective BC6ENTG antagonist BC6ENTC , we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.	CPR:6
A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that BC6ENTC bound to the brain BC6ENTG receptor with a greater extent compared to the spinal cord one.	False
Brain but not spinal BC6ENTG receptor is responsible for the anti - allodynic effect of an BC6OTHER subunit - selective antagonist BC6ENTC in a rat chronic constriction injury model.	CPR:6
Brain but not spinal BC6OTHER receptor is responsible for the anti - allodynic effect of an BC6ENTG subunit - selective antagonist BC6ENTC in a rat chronic constriction injury model.	CPR:6
BC6ENTG and BC6OTHER BC6ENTC kinases are important targets for therapy of different types of leukemia.	False
BC6OTHER and BC6ENTG BC6ENTC kinases are important targets for therapy of different types of leukemia.	False
This effort led to the identification of five compounds that were confirmed to be active on additional BC6ENTG dependent cell lines (cellular EC50 values between 35 and 700 nM) , while having no significant effect on 24 other BC6ENTC kinases.	False
Treatment with BC6ENTC reversed both protein and mRNA of BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER to the baseline values.	CPR:4
Treatment with BC6ENTC reversed both protein and mRNA of BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG to the baseline values.	CPR:3
Increased immunohistochemical labeling of BC6ENTG , BC6OTHER , and BC6OTHER in the ventricular myocardium was observed in the shunt group and BC6ENTC again normalized the labeling.	CPR:4
Increased immunohistochemical labeling of BC6OTHER , BC6ENTG , and BC6OTHER in the ventricular myocardium was observed in the shunt group and BC6ENTC again normalized the labeling.	CPR:4
Increased immunohistochemical labeling of BC6OTHER , BC6OTHER , and BC6ENTG in the ventricular myocardium was observed in the shunt group and BC6ENTC again normalized the labeling.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6ENTG and BC6OTHER in the failing ventricular myocardium.	CPR:4
Treatment with BC6ENTC is associated with a reversal of abnormal regulation of BC6OTHER and BC6ENTG in the failing ventricular myocardium.	CPR:4
 BC6ENTC modulates the expression of BC6ENTG and BC6OTHER in a rat model of volume - overload heart failure.	False
 BC6ENTC modulates the expression of BC6OTHER and BC6ENTG in a rat model of volume - overload heart failure.	False
These mice had lower circulating active BC6ENTG levels after a BC6ENTC challenge as well as reduced distal ileum BC6OTHER content after insulin treatment.	False
These mice had lower circulating active BC6OTHER levels after a BC6ENTC challenge as well as reduced distal ileum BC6ENTG content after insulin treatment.	False
Finally , the BC6ENTG ( - / - ) mice exhibited reduced brainstem gcg level and abolished BC6OTHER BC6ENTC 675 phosphorylation in brain neurons after BC6OTHER treatment.	False
Finally , the BC6OTHER ( - / - ) mice exhibited reduced brainstem gcg level and abolished BC6ENTG BC6ENTC 675 phosphorylation in brain neurons after BC6OTHER treatment.	False
Finally , the BC6OTHER ( - / - ) mice exhibited reduced brainstem gcg level and abolished BC6OTHER BC6ENTC 675 phosphorylation in brain neurons after BC6ENTG treatment.	False
We suggest that BC6ENTG mediates the cross talk between BC6OTHER and BC6OTHER signaling pathways on gut and brain BC6OTHER expression , and its ablation impairs BC6ENTC homeostasis.	False
We suggest that BC6OTHER mediates the cross talk between BC6ENTG and BC6OTHER signaling pathways on gut and brain BC6OTHER expression , and its ablation impairs BC6ENTC homeostasis.	False
We suggest that BC6OTHER mediates the cross talk between BC6OTHER and BC6ENTG signaling pathways on gut and brain BC6OTHER expression , and its ablation impairs BC6ENTC homeostasis.	False
We suggest that BC6OTHER mediates the cross talk between BC6OTHER and BC6OTHER signaling pathways on gut and brain BC6ENTG expression , and its ablation impairs BC6ENTC homeostasis.	False
Here we determined the role of BC6ENTG in BC6OTHER expression and the effect of BC6OTHER deletion on BC6ENTC homeostasis.	False
Here we determined the role of BC6OTHER in BC6ENTG expression and the effect of BC6OTHER deletion on BC6ENTC homeostasis.	False
Here we determined the role of BC6OTHER in BC6OTHER expression and the effect of BC6ENTG deletion on BC6ENTC homeostasis.	False
BC6ENTG stimulated BC6OTHER activation through increasing its BC6ENTC 423 phosphorylation in gut BC6OTHER - expressing cell lines , associated with increased BC6OTHER mRNA levels.	False
BC6OTHER stimulated BC6ENTG activation through increasing its BC6ENTC 423 phosphorylation in gut BC6OTHER - expressing cell lines , associated with increased BC6OTHER mRNA levels.	False
BC6OTHER stimulated BC6OTHER activation through increasing its BC6ENTC 423 phosphorylation in gut BC6ENTG - expressing cell lines , associated with increased BC6OTHER mRNA levels.	False
BC6OTHER stimulated BC6OTHER activation through increasing its BC6ENTC 423 phosphorylation in gut BC6OTHER - expressing cell lines , associated with increased BC6ENTG mRNA levels.	False
This stimulation was attenuated by the BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) or dominant - negative BC6OTHER .	CPR:4
This stimulation was attenuated by the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) or dominant - negative BC6ENTG .	False
This stimulation was attenuated by the BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) or dominant - negative BC6OTHER .	CPR:4
This stimulation was attenuated by the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) or dominant - negative BC6ENTG .	False
Both BC6ENTG and BC6ENTC - promoting agents activated β - cat BC6OTHER 675 phosphorylation , which was attenuated by CHEM or BC6OTHER inhibition , respectively.	False
Both BC6OTHER and BC6ENTC - promoting agents activated β - cat BC6OTHER 675 phosphorylation , which was attenuated by CHEM or BC6ENTG inhibition , respectively.	False
Both BC6ENTG and BC6OTHER - promoting agents activated β - cat BC6ENTC 675 phosphorylation , which was attenuated by CHEM or BC6OTHER inhibition , respectively.	False
Both BC6OTHER and BC6OTHER - promoting agents activated β - cat BC6ENTC 675 phosphorylation , which was attenuated by CHEM or BC6ENTG inhibition , respectively.	False
Gut BC6ENTG levels were reduced in male BC6OTHER ( - / - ) mice , associated with impaired BC6ENTC tolerance after an ip or oral BC6OTHER challenge.	False
Gut BC6OTHER levels were reduced in male BC6ENTG ( - / - ) mice , associated with impaired BC6ENTC tolerance after an ip or oral BC6OTHER challenge.	False
Gut BC6ENTG levels were reduced in male BC6OTHER ( - / - ) mice , associated with impaired BC6OTHER tolerance after an ip or oral BC6ENTC challenge.	False
Gut BC6OTHER levels were reduced in male BC6ENTG ( - / - ) mice , associated with impaired BC6OTHER tolerance after an ip or oral BC6ENTC challenge.	False
 BC6ENTG ( BC6OTHER ) mediates the cross talk between BC6OTHER and BC6OTHER on BC6OTHER gene expression and its ablation affects BC6ENTC homeostasis in male C57BL / 6 mice.	False
 BC6OTHER ( BC6ENTG ) mediates the cross talk between BC6OTHER and BC6OTHER on BC6OTHER gene expression and its ablation affects BC6ENTC homeostasis in male C57BL / 6 mice.	False
 BC6OTHER ( BC6OTHER ) mediates the cross talk between BC6ENTG and BC6OTHER on BC6OTHER gene expression and its ablation affects BC6ENTC homeostasis in male C57BL / 6 mice.	False
 BC6OTHER ( BC6OTHER ) mediates the cross talk between BC6OTHER and BC6ENTG on BC6OTHER gene expression and its ablation affects BC6ENTC homeostasis in male C57BL / 6 mice.	False
 BC6OTHER ( BC6OTHER ) mediates the cross talk between BC6OTHER and BC6OTHER on BC6ENTG gene expression and its ablation affects BC6ENTC homeostasis in male C57BL / 6 mice.	False
CONCLUSIONS: Our results show that BC6ENTC , a known BC6ENTG ( BC6OTHER ) inhibitor , is also an activator of BC6OTHER .	CPR:4
CONCLUSIONS: Our results show that BC6ENTC , a known BC6OTHER ( BC6ENTG ) inhibitor , is also an activator of BC6OTHER .	CPR:4
CONCLUSIONS: Our results show that BC6ENTC , a known BC6OTHER ( BC6OTHER ) inhibitor , is also an activator of BC6ENTG .	CPR:3
Our data also prove that BC6ENTC is not only an activator of BC6ENTG but also antagonizes the effect of BC6OTHER , a specific inhibitor of this enzyme.	CPR:3
Our data also prove that BC6OTHER is not only an activator of BC6ENTG but also antagonizes the effect of BC6ENTC , a specific inhibitor of this enzyme.	CPR:4
OBJECTIVES: In this paper we investigated the effect of BC6OTHER , BC6OTHER and their combination in vitro and in vivo on BC6ENTC anhydrase ( BC6ENTG ) isozymes.	False
In view of the role of BC6ENTG in acid - base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra - and extracellular pH , our results suggest that: firstly , BC6OTHER activation induced by BC6ENTC might cause changes in BC6OTHER activity; secondly , PGs are synthetized as a consequence of the changes in BC6OTHER activity , a hypothesis that requires further study.	False
In view of the role of BC6OTHER in acid - base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra - and extracellular pH , our results suggest that: firstly , BC6ENTG activation induced by BC6ENTC might cause changes in BC6OTHER activity; secondly , PGs are synthetized as a consequence of the changes in BC6OTHER activity , a hypothesis that requires further study.	CPR:3
In view of the role of BC6OTHER in acid - base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra - and extracellular pH , our results suggest that: firstly , BC6OTHER activation induced by BC6ENTC might cause changes in BC6ENTG activity; secondly , PGs are synthetized as a consequence of the changes in BC6OTHER activity , a hypothesis that requires further study.	False
In view of the role of BC6OTHER in acid - base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra - and extracellular pH , our results suggest that: firstly , BC6OTHER activation induced by BC6ENTC might cause changes in BC6OTHER activity; secondly , PGs are synthetized as a consequence of the changes in BC6ENTG activity , a hypothesis that requires further study.	False
 The effects of single and combined administration of BC6ENTC and BC6OTHER on red cell BC6ENTG and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6OTHER activity.	False
 The effects of single and combined administration of BC6ENTC and BC6OTHER on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6ENTG and BC6OTHER activity.	False
 The effects of single and combined administration of BC6ENTC and BC6OTHER on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6ENTG activity.	False
 The effects of single and combined administration of BC6OTHER and BC6ENTC on red cell BC6ENTG and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6OTHER activity.	False
 The effects of single and combined administration of BC6OTHER and BC6ENTC on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6ENTG and BC6OTHER activity.	False
 The effects of single and combined administration of BC6OTHER and BC6ENTC on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6OTHER , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6ENTG activity.	False
OBJECTIVES: In this paper we investigated the effect of BC6ENTC , BC6OTHER and their combination in vitro and in vivo on BC6ENTG ( BC6OTHER ) isozymes.	False
OBJECTIVES: In this paper we investigated the effect of BC6ENTC , BC6OTHER and their combination in vitro and in vivo on BC6OTHER ( BC6ENTG ) isozymes.	False
 The effects of single and combined administration of BC6OTHER and BC6OTHER on red cell BC6ENTG and on gastric acid secretion were studied in vivo. RESULTS: BC6ENTC , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6OTHER activity.	False
 The effects of single and combined administration of BC6OTHER and BC6OTHER on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6ENTC , in vitro and in vivo. induces an increase in erythorcyte BC6ENTG and BC6OTHER activity.	CPR:3
 The effects of single and combined administration of BC6OTHER and BC6OTHER on red cell BC6OTHER and on gastric acid secretion were studied in vivo. RESULTS: BC6ENTC , in vitro and in vivo. induces an increase in erythorcyte BC6OTHER and BC6ENTG activity.	CPR:3
BC6ENTC , a specific inhibitor of BC6ENTG , reduces the activity of BC6OTHER and BC6OTHER from red cells.	CPR:4
BC6ENTC , a specific inhibitor of BC6OTHER , reduces the activity of BC6ENTG and BC6OTHER from red cells.	CPR:4
BC6ENTC , a specific inhibitor of BC6OTHER , reduces the activity of BC6OTHER and BC6ENTG from red cells.	CPR:4
OBJECTIVES: In this paper we investigated the effect of BC6OTHER , BC6ENTC and their combination in vitro and in vivo on BC6ENTG ( BC6OTHER ) isozymes.	False
OBJECTIVES: In this paper we investigated the effect of BC6OTHER , BC6ENTC and their combination in vitro and in vivo on BC6OTHER ( BC6ENTG ) isozymes.	False
 BC6ENTC completely antagonizes BC6ENTG activity , i.e. abolishes the inhibitory effect of BC6OTHER on BC6OTHER .	CPR:3
 BC6ENTC completely antagonizes BC6OTHER activity , i.e. abolishes the inhibitory effect of BC6OTHER on BC6ENTG .	CPR:3
 BC6OTHER completely antagonizes BC6ENTG activity , i.e. abolishes the inhibitory effect of BC6ENTC on BC6OTHER .	CPR:4
 BC6OTHER completely antagonizes BC6OTHER activity , i.e. abolishes the inhibitory effect of BC6ENTC on BC6ENTG .	CPR:4
 BC6ENTC activates BC6ENTG and antagonizes the effect of the specific BC6OTHER inhibitor BC6OTHER , by a direct mechanism of action.	CPR:3
 BC6ENTC activates BC6OTHER and antagonizes the effect of the specific BC6ENTG inhibitor BC6OTHER , by a direct mechanism of action.	CPR:3
 BC6OTHER activates BC6ENTG and antagonizes the effect of the specific BC6OTHER inhibitor BC6ENTC , by a direct mechanism of action.	CPR:4
 BC6OTHER activates BC6OTHER and antagonizes the effect of the specific BC6ENTG inhibitor BC6ENTC , by a direct mechanism of action.	CPR:4
 BC6OTHER activates BC6ENTC anhydrase and antagonizes the effect of the specific BC6ENTG inhibitor BC6OTHER , by a direct mechanism of action.	False
 BC6OTHER activates BC6ENTG and antagonizes the effect of the specific BC6ENTC anhydrase inhibitor BC6OTHER , by a direct mechanism of action.	False
BC6ENTC is synthesized from BC6OTHER by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6ENTC is synthesized from BC6OTHER by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6ENTC is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6ENTC is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6ENTC is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6ENTG through BC6OTHER .	False
BC6ENTC is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6ENTG .	False
BC6OTHER is synthesized from BC6ENTC by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6OTHER is synthesized from BC6ENTC by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6OTHER is synthesized from BC6ENTC by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6OTHER is synthesized from BC6ENTC by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	CPR:9
BC6OTHER is synthesized from BC6ENTC by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6ENTG through BC6OTHER .	False
BC6OTHER is synthesized from BC6ENTC by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6ENTG .	False
BC6OTHER is synthesized from BC6OTHER by BC6ENTG ( BC6OTHER ) and BC6ENTC synthases ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	False
BC6OTHER is synthesized from BC6OTHER by BC6OTHER ( BC6ENTG ) and BC6ENTC synthases ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	False
BC6OTHER is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6ENTC synthases ( BC6ENTG ) and mediates its biological activity through binding to the four BC6OTHER through BC6OTHER .	False
BC6OTHER is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6ENTC synthases ( BC6OTHER ) and mediates its biological activity through binding to the four BC6ENTG through BC6OTHER .	False
BC6OTHER is synthesized from BC6OTHER by BC6OTHER ( BC6OTHER ) and BC6ENTC synthases ( BC6OTHER ) and mediates its biological activity through binding to the four BC6OTHER through BC6ENTG .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6ENTG , microsomal BC6ENTC synthase - 1 , and BC6OTHER through BC6OTHER and secretes BC6OTHER .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6OTHER , microsomal BC6ENTC synthase - 1 , and BC6ENTG through BC6OTHER and secretes BC6OTHER .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6OTHER , microsomal BC6ENTC synthase - 1 , and BC6OTHER through BC6ENTG and secretes BC6OTHER .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6ENTG , microsomal BC6OTHER synthase - 1 , and BC6OTHER through BC6OTHER and secretes BC6ENTC .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6OTHER , BC6ENTG , and BC6OTHER through BC6OTHER and secretes BC6ENTC .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6OTHER , microsomal BC6OTHER synthase - 1 , and BC6ENTG through BC6OTHER and secretes BC6ENTC .	False
In this study , we show for the first time that medulloblastoma (MB) , the most common malignant childhood brain tumor , expresses high levels of BC6OTHER , microsomal BC6OTHER synthase - 1 , and BC6OTHER through BC6ENTG and secretes BC6ENTC .	False
BC6ENTC and the BC6ENTG agonist CHEM stimulated MB cell proliferation.	False
Treatment of MB cells with BC6ENTG inhibitors suppressed BC6ENTC production and induced BC6OTHER - dependent apoptosis.	False
Treatment of MB cells with BC6OTHER inhibitors suppressed BC6ENTC production and induced BC6ENTG - dependent apoptosis.	False
BC6OTHER and BC6OTHER antagonists BC6ENTC and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6ENTG and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6ENTC and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6ENTG but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6ENTC and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6ENTG for MB growth.	False
BC6ENTG and BC6OTHER antagonists BC6ENTC and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
BC6OTHER and BC6ENTG antagonists BC6ENTC and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
BC6OTHER and BC6OTHER antagonists BC6ENTC and BC6OTHER , but not the BC6ENTG antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6ENTC , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6ENTG and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6ENTC , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6ENTG but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6ENTC , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6ENTG for MB growth.	False
BC6ENTG and BC6OTHER antagonists BC6OTHER and BC6ENTC , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
BC6OTHER and BC6ENTG antagonists BC6OTHER and BC6ENTC , but not the BC6OTHER antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6ENTC , but not the BC6ENTG antagonists BC6OTHER and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6ENTG and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6ENTG but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6ENTG for MB growth.	False
BC6ENTG and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6ENTG antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6ENTG antagonists BC6ENTC and BC6OTHER , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6ENTG and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6ENTG but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6ENTG for MB growth.	False
BC6ENTG and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6ENTG antagonists BC6OTHER and BC6OTHER , but not the BC6OTHER antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	False
BC6OTHER and BC6OTHER antagonists BC6OTHER and BC6OTHER , but not the BC6ENTG antagonists BC6OTHER and BC6ENTC , inhibited tumor cell proliferation , indicating the significance of BC6OTHER and BC6OTHER but not BC6OTHER for MB growth.	CPR:6
Tumor - growth - promoting BC6ENTG BC6ENTC pathway provides medulloblastoma therapeutic targets.	CPR:9
Reactivators showed different activity in the reactivation of BC6ENTG after BC6ENTC , BC6OTHER and BC6OTHER inhibition.	CPR:4
Reactivators showed different activity in the reactivation of BC6ENTG after BC6OTHER , BC6ENTC and BC6OTHER inhibition.	CPR:4
Reactivators showed different activity in the reactivation of BC6ENTG after BC6OTHER , BC6OTHER and BC6ENTC inhibition.	CPR:4
BC6ENTG was easier reactivated after BC6ENTC treatment.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6ENTC , BC6OTHER and BC6OTHER from symmetric BC6OTHER , and BC6OTHER and BC6OTHER possessing asymmetric structure.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6OTHER , BC6ENTC and BC6OTHER from symmetric BC6OTHER , and BC6OTHER and BC6OTHER possessing asymmetric structure.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6OTHER , BC6OTHER and BC6ENTC from symmetric BC6OTHER , and BC6OTHER and BC6OTHER possessing asymmetric structure.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6OTHER , BC6OTHER and BC6OTHER from symmetric BC6ENTC , and BC6OTHER and BC6OTHER possessing asymmetric structure.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6OTHER , BC6OTHER and BC6OTHER from symmetric BC6OTHER , and BC6ENTC and BC6OTHER possessing asymmetric structure.	CPR:3
The reactivation of brain BC6ENTG inhibited with CHEM demonstrated better activity of new compound BC6OTHER , BC6OTHER and BC6OTHER from symmetric BC6OTHER , and BC6OTHER and BC6ENTC possessing asymmetric structure.	CPR:3
All compounds showed low activity toward inhibition of BC6ENTG caused by BC6ENTC .	CPR:4
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6ENTC , BC6OTHER and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6ENTC and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6OTHER and BC6ENTC ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6OTHER and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6OTHER and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6OTHER and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ).	False
The aim of the present study was to evaluate the efficacy of some BC6ENTG reactivators against OPC intoxication ( BC6OTHER , BC6OTHER and BC6OTHER ) in in vitro experiments and to compare their activity to that known for some currently used BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ).	False
We evaluated associations between mood , cognitive and cardiovascular responses to BC6ENTC and four polymorphisms in the BC6ENTG ( BC6OTHER ): rs460000 , rs3756450 , rs37022 and rs6869645.	False
We evaluated associations between mood , cognitive and cardiovascular responses to BC6ENTC and four polymorphisms in the BC6OTHER ( BC6ENTG ): rs460000 , rs3756450 , rs37022 and rs6869645.	False
We evaluated associations between mood , cognitive and cardiovascular responses to BC6OTHER and four polymorphisms in the BC6ENTC transporter ( BC6ENTG ): rs460000 , rs3756450 , rs37022 and rs6869645.	False
Polymorphisms in BC6ENTC transporter ( BC6ENTG ) are associated with stimulant effects of BC6OTHER : an exploratory pharmacogenetic study using healthy volunteers.	False
Polymorphisms in BC6ENTG ( BC6OTHER ) are associated with stimulant effects of BC6ENTC : an exploratory pharmacogenetic study using healthy volunteers.	CPR:3
Polymorphisms in BC6OTHER ( BC6ENTG ) are associated with stimulant effects of BC6ENTC : an exploratory pharmacogenetic study using healthy volunteers.	CPR:3
BC6ENTG abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing BC6ENTC treatment before the operation but not in the other 2 patients stopping BC6OTHER 1 month before operation.	CPR:4
BC6ENTG abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing BC6OTHER treatment before the operation but not in the other 2 patients stopping BC6ENTC 1 month before operation.	False
One of the mechanism of BC6ENTC action on decreasing leiomyomata volume may be related to suppression on expression of BC6ENTG .	CPR:4
OBJECTIVE: To determine the expression of BC6ENTG ( BC6OTHER ) mRNA and BC6OTHER levels in the myometrium and leiomyomata from untreated and BC6ENTC pretreated women with leiomyoma and to examine the mechanism of BC6OTHER treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6OTHER ( BC6ENTG ) mRNA and BC6OTHER levels in the myometrium and leiomyomata from untreated and BC6ENTC pretreated women with leiomyoma and to examine the mechanism of BC6OTHER treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6OTHER ( BC6OTHER ) mRNA and BC6ENTG levels in the myometrium and leiomyomata from untreated and BC6ENTC pretreated women with leiomyoma and to examine the mechanism of BC6OTHER treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6ENTG ( BC6OTHER ) mRNA and BC6OTHER levels in the myometrium and leiomyomata from untreated and BC6OTHER pretreated women with leiomyoma and to examine the mechanism of BC6ENTC treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6OTHER ( BC6ENTG ) mRNA and BC6OTHER levels in the myometrium and leiomyomata from untreated and BC6OTHER pretreated women with leiomyoma and to examine the mechanism of BC6ENTC treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6OTHER ( BC6OTHER ) mRNA and BC6ENTG levels in the myometrium and leiomyomata from untreated and BC6OTHER pretreated women with leiomyoma and to examine the mechanism of BC6ENTC treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6ENTC receptor ( BC6ENTG ) mRNA and BC6OTHER levels in the myometrium and leiomyomata from untreated and BC6OTHER pretreated women with leiomyoma and to examine the mechanism of BC6OTHER treatment on uterine leiomyomata.	False
OBJECTIVE: To determine the expression of BC6ENTC receptor ( BC6OTHER ) mRNA and BC6ENTG levels in the myometrium and leiomyomata from untreated and BC6OTHER pretreated women with leiomyoma and to examine the mechanism of BC6OTHER treatment on uterine leiomyomata.	False
METHODS: Expression of BC6ENTG and BC6OTHER were determined by Northern blot and HAP of single - dose saturated analysis in myometrium and leiomyomata (center and marginal area) from 27 untreated and 6 BC6ENTC pretreated women with leiomyomata.	False
METHODS: Expression of BC6OTHER and BC6ENTG were determined by Northern blot and HAP of single - dose saturated analysis in myometrium and leiomyomata (center and marginal area) from 27 untreated and 6 BC6ENTC pretreated women with leiomyomata.	False
[Effect of BC6ENTC on the expression of BC6ENTG messenger RNA and protein in uterine leiomyomata].	False
The efficacy of BC6ENTC , a new , long acting , oral BC6ENTG antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.	CPR:6
 BC6ENTC , a potent BC6ENTG antagonist: effect in allergic rhinoconjunctivitis , on antigen and BC6OTHER induced skin weal responses and relationship to serum levels.	CPR:6
 BC6OTHER , a potent BC6ENTG antagonist: effect in allergic rhinoconjunctivitis , on antigen and BC6ENTC induced skin weal responses and relationship to serum levels.	False
The neuropeptide BC6ENTG has been shown to attenuate BC6ENTC signaling in multiple cell types.	False
The current study demonstrates that acute BC6ENTG treatment blocks the consequences of increased BC6ENTC signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor BC6OTHER ( BC6OTHER ).	False
The current study demonstrates that acute BC6OTHER treatment blocks the consequences of increased BC6ENTC signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor BC6ENTG ( BC6OTHER ).	False
The current study demonstrates that acute BC6OTHER treatment blocks the consequences of increased BC6ENTC signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor BC6OTHER ( BC6ENTG ).	False
The current study demonstrates that acute BC6ENTG treatment blocks the consequences of increased BC6OTHER signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor BC6ENTC regulatory element - binding protein ( BC6OTHER ).	False
The current study demonstrates that acute BC6OTHER treatment blocks the consequences of increased BC6OTHER signaling following chronic opiate administration and withdrawal in Cath.a cells and primary cultures of striatal neurons as measured by phosphorylation of the transcription factor BC6ENTC regulatory element - binding protein ( BC6ENTG ).	False
 BC6ENTG attenuates BC6OTHER ( BC6OTHER ) phosphorylation induced by chronic BC6ENTC and BC6OTHER challenge in Cath.a cells and primary striatal cultures.	False
 BC6OTHER attenuates BC6ENTG ( BC6OTHER ) phosphorylation induced by chronic BC6ENTC and BC6OTHER challenge in Cath.a cells and primary striatal cultures.	CPR:3
 BC6OTHER attenuates BC6OTHER ( BC6ENTG ) phosphorylation induced by chronic BC6ENTC and BC6OTHER challenge in Cath.a cells and primary striatal cultures.	CPR:3
 BC6ENTG attenuates BC6OTHER ( BC6OTHER ) phosphorylation induced by chronic BC6OTHER and BC6ENTC challenge in Cath.a cells and primary striatal cultures.	False
 BC6OTHER attenuates BC6ENTG ( BC6OTHER ) phosphorylation induced by chronic BC6OTHER and BC6ENTC challenge in Cath.a cells and primary striatal cultures.	CPR:3
 BC6OTHER attenuates BC6OTHER ( BC6ENTG ) phosphorylation induced by chronic BC6OTHER and BC6ENTC challenge in Cath.a cells and primary striatal cultures.	CPR:3
 BC6ENTG attenuates BC6ENTC regulatory element - binding protein ( BC6OTHER ) phosphorylation induced by chronic BC6OTHER and BC6OTHER challenge in Cath.a cells and primary striatal cultures.	False
 BC6OTHER attenuates BC6ENTC regulatory element - binding protein ( BC6ENTG ) phosphorylation induced by chronic BC6OTHER and BC6OTHER challenge in Cath.a cells and primary striatal cultures.	False
Novel BC6ENTC were designed as potential inhibitiors of BC6ENTG .	CPR:4
Spiro heterocycles as potential inhibitors of BC6ENTG : BC6ENTC / BC6OTHER - mediated synthesis of novel BC6OTHER .	False
Spiro heterocycles as potential inhibitors of BC6ENTG : BC6OTHER / BC6ENTC - mediated synthesis of novel BC6OTHER .	False
Spiro heterocycles as potential inhibitors of BC6ENTG : BC6OTHER / BC6OTHER - mediated synthesis of novel BC6ENTC .	CPR:4
The BC6ENTG / gamma(c) interface itself exhibits the smallest buried surface and the fewest BC6ENTC bonds in the complex , which is consistent with its promiscuous use in other BC6OTHER complexes.	False
The BC6OTHER / gamma(c) interface itself exhibits the smallest buried surface and the fewest BC6ENTC bonds in the complex , which is consistent with its promiscuous use in other BC6ENTG complexes.	False
Conversely , severe hypoxia increased transcripts involved in extracellular matrix remodeling , those of BC6ENTG , and others involved in CHEM BC6ENTC synthesis and CHEM transport ( BC6OTHER ).	False
Conversely , severe hypoxia increased transcripts involved in extracellular matrix remodeling , those of BC6OTHER , and others involved in CHEM BC6ENTC synthesis and CHEM transport ( BC6ENTG ).	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTC 1 - hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6ENTG transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6ENTG ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6ENTG ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6ENTG ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , and BC6OTHER transcripts.	False
Normoxia was required for full expression of the proximal tubule - specific transcripts BC6OTHER ( BC6OTHER ) and BC6ENTC kinase ( BC6OTHER ) , transcripts involved in tissue cohesion such as BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , and BC6ENTG transcripts.	False
In the proximal tubule , BC6ENTG regulates volume and acid - base regulation through stimulation of the BC6ENTC / BC6OTHER exchanger BC6OTHER .	False
In the proximal tubule , BC6OTHER regulates volume and acid - base regulation through stimulation of the BC6ENTC / BC6OTHER exchanger BC6ENTG .	False
In the proximal tubule , BC6ENTG regulates volume and acid - base regulation through stimulation of the CHEM / BC6ENTC exchanger BC6OTHER .	False
In the proximal tubule , BC6OTHER regulates volume and acid - base regulation through stimulation of the CHEM / BC6ENTC exchanger BC6ENTG .	False
Chronic BC6ENTG (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6ENTG through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6ENTG ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6ENTG - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6ENTG ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6ENTG stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6ENTG phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6ENTG effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6ENTG inhibitor BC6OTHER or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTC 3 - kinase - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6OTHER or a dominant - negative BC6ENTG .	False
Chronic BC6ENTG (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6ENTG through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6ENTG - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	CPR:4
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6ENTG ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6ENTG - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	CPR:4
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTG ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6ENTG stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6ENTG phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6ENTG effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6OTHER .	False
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6ENTG inhibitor BC6ENTC or a dominant - negative BC6OTHER .	CPR:4
Chronic BC6OTHER (24 h) activates BC6OTHER through the classic BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) pathway as BC6OTHER stimulates BC6OTHER phosphorylation and the BC6OTHER effect can be blocked by the BC6OTHER inhibitor BC6ENTC or a dominant - negative BC6ENTG .	False
Characterization of the regulation of renal BC6ENTC / BC6OTHER exchanger BC6ENTG by BC6OTHER .	False
Characterization of the regulation of renal BC6ENTC / BC6OTHER exchanger BC6OTHER by BC6ENTG .	False
Characterization of the regulation of BC6ENTG BC6ENTC exchanger BC6OTHER by BC6OTHER .	False
Characterization of the regulation of renal BC6OTHER / BC6ENTC exchanger BC6ENTG by BC6OTHER .	False
Characterization of the regulation of renal BC6OTHER / BC6ENTC exchanger BC6OTHER by BC6ENTG .	False
Preclinical studies demonstrate that the therapeutic activity of BC6ENTC resides in the S - isomer and that BC6OTHER binds with high affinity to the BC6ENTG .	False
Preclinical studies demonstrate that the therapeutic activity of BC6OTHER resides in the S - isomer and that BC6ENTC binds with high affinity to the BC6ENTG .	False
In addition , BC6ENTC has negligible effects on BC6ENTG drug - metabolising enzymes in vitro , suggesting a low potential for drug - drug interactions.	False
The vascular protective effects of BC6OTHER were speculated to be attributed to oxidative stress inhibition and the reduction of BC6ENTG ( BC6OTHER ) mRNA expression levels in high BC6ENTC conditions.	False
The vascular protective effects of BC6OTHER were speculated to be attributed to oxidative stress inhibition and the reduction of BC6OTHER ( BC6ENTG ) mRNA expression levels in high BC6ENTC conditions.	False
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	CPR:4
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6ENTC (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTC dehydrogenase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6OTHER (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6ENTG - the BC6OTHER ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6ENTG ( BC6OTHER - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6ENTG - BC6OTHER P) system.	False
In the in vitro assay , BC6OTHER (20 and 50μg / mL) markedly inhibited changes in various biochemical substances ( BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER )) in human umbilical vein endothelial cells (HUVECs) damaged by high BC6ENTC (35mM) and restored vascular endothelial structure by balancing the BC6OTHER - the BC6OTHER ( BC6OTHER - BC6ENTG P) system.	False
The vascular protective effects of BC6ENTC were speculated to be attributed to oxidative stress inhibition and the reduction of BC6ENTG ( BC6OTHER ) mRNA expression levels in high BC6OTHER conditions.	CPR:4
The vascular protective effects of BC6ENTC were speculated to be attributed to oxidative stress inhibition and the reduction of BC6OTHER ( BC6ENTG ) mRNA expression levels in high BC6OTHER conditions.	CPR:4
Comparisons of the structures of the BC6OTHER : BC6OTHER complexes explain the biochemical mechanism by which BC6ENTC but not BC6OTHER permanently modify their BC6ENTG targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6ENTG : BC6OTHER complexes explain the biochemical mechanism by which BC6ENTC but not BC6OTHER permanently modify their BC6OTHER targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6OTHER : BC6ENTG complexes explain the biochemical mechanism by which BC6ENTC but not BC6OTHER permanently modify their BC6OTHER targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6OTHER : BC6OTHER complexes explain the biochemical mechanism by which BC6OTHER but not BC6ENTC permanently modify their BC6ENTG targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6ENTG : BC6OTHER complexes explain the biochemical mechanism by which BC6OTHER but not BC6ENTC permanently modify their BC6OTHER targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6OTHER : BC6ENTG complexes explain the biochemical mechanism by which BC6OTHER but not BC6ENTC permanently modify their BC6OTHER targets by covalent addition to an active site BC6OTHER residue.	False
Comparisons of the structures of the BC6OTHER : BC6OTHER complexes explain the biochemical mechanism by which BC6OTHER but not BC6OTHER permanently modify their BC6ENTG targets by covalent addition to an active site BC6ENTC residue.	False
Comparisons of the structures of the BC6ENTG : BC6OTHER complexes explain the biochemical mechanism by which BC6OTHER but not BC6OTHER permanently modify their BC6OTHER targets by covalent addition to an active site BC6ENTC residue.	False
Comparisons of the structures of the BC6OTHER : BC6ENTG complexes explain the biochemical mechanism by which BC6OTHER but not BC6OTHER permanently modify their BC6OTHER targets by covalent addition to an active site BC6ENTC residue.	False
A previous crystal structure of a BC6ENTC bound to the catalytic subunit of BC6ENTG ( BC6OTHER ) showed distinct changes in the active site region when compared with BC6OTHER structures bound to other toxins.	False
A previous crystal structure of a BC6ENTC bound to the catalytic subunit of BC6OTHER ( BC6ENTG ) showed distinct changes in the active site region when compared with BC6OTHER structures bound to other toxins.	False
A previous crystal structure of a BC6ENTC bound to the catalytic subunit of BC6OTHER ( BC6OTHER ) showed distinct changes in the active site region when compared with BC6ENTG structures bound to other toxins.	False
We have elucidated the crystal structures of the BC6ENTG , BC6ENTC ( BC6OTHER ) and BC6OTHER bound to BC6OTHER .	False
We have elucidated the crystal structures of the BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER bound to BC6ENTG .	False
We have elucidated the crystal structures of the BC6ENTG , BC6OTHER ( BC6ENTC ) and BC6OTHER bound to BC6OTHER .	False
We have elucidated the crystal structures of the BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER bound to BC6ENTG .	False
We have elucidated the crystal structures of the BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6ENTC bound to BC6OTHER .	False
We have elucidated the crystal structures of the BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC bound to BC6ENTG .	False
Crystal structures of BC6ENTG bound to BC6ENTC and BC6OTHER : elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.	False
Crystal structures of BC6ENTG bound to BC6OTHER and BC6ENTC : elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.	False
Moreover , in rat hepatoma H4 - II - E cells , the esterified - BC6ENTC failed to induce BC6ENTG , which is regulated by BC6OTHER - mediated transactivation activity.	False
Moreover , in rat hepatoma H4 - II - E cells , the esterified - BC6ENTC failed to induce BC6OTHER , which is regulated by BC6ENTG - mediated transactivation activity.	CPR:5
Moreover , in rat hepatoma H4 - II - E cells , the esterified - BC6OTHER failed to induce BC6ENTC aminotransferase , which is regulated by BC6ENTG - mediated transactivation activity.	False
Consistent with the weak transactivation activity of esterified - BC6ENTC mediated by BC6ENTG , there were few side effects , evaluated by thymus involution and body weight loss , in an antigen - induced asthmatic model in rats.	CPR:5
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and their esterified - derivatives had full transrepression agonistic activity in a reporter assay using CV - 1 cells transfected with either BC6ENTG .	CPR:5
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , and their esterified - derivatives had full transrepression agonistic activity in a reporter assay using CV - 1 cells transfected with either BC6ENTG .	CPR:5
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , and their esterified - derivatives had full transrepression agonistic activity in a reporter assay using CV - 1 cells transfected with either BC6ENTG .	CPR:5
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , and their esterified - derivatives had full transrepression agonistic activity in a reporter assay using CV - 1 cells transfected with either BC6ENTG .	CPR:5
The esterified - BC6ENTC , however , had only partial transactivation agonistic activity in cells transfected with BC6ENTG , whereas BC6OTHER and esterified - BC6OTHER had full transactivation agonistic activity.	CPR:5
The esterified - BC6OTHER , however , had only partial transactivation agonistic activity in cells transfected with BC6ENTG , whereas BC6ENTC and esterified - BC6OTHER had full transactivation agonistic activity.	CPR:5
The esterified - BC6OTHER , however , had only partial transactivation agonistic activity in cells transfected with BC6ENTG , whereas BC6OTHER and esterified - BC6ENTC had full transactivation agonistic activity.	CPR:5
Species - specific differences in the BC6ENTG transactivation function upon binding with BC6ENTC .	False
BC6ENTC ( BC6OTHER ) is a potent , selective BC6ENTG signaling pathway inhibitor that binds to BC6OTHER and is being developed for the treatment of cancer.	False
BC6ENTC ( BC6OTHER ) is a potent , selective BC6OTHER signaling pathway inhibitor that binds to BC6ENTG and is being developed for the treatment of cancer.	False
The IC50 values for BC6ENTG mRNA inhibition in the tumor and skin by BC6ENTC were estimated to be 0.0457 and 0.113 μg / ml , respectively.	CPR:4
BC6OTHER ( BC6ENTC ) is a potent , selective BC6ENTG signaling pathway inhibitor that binds to BC6OTHER and is being developed for the treatment of cancer.	CPR:4
BC6OTHER ( BC6ENTC ) is a potent , selective BC6OTHER signaling pathway inhibitor that binds to BC6ENTG and is being developed for the treatment of cancer.	False
The objectives of these studies were to explore the possibility of establishing of a link between the pharmacokinetics of BC6ENTC and the responses of BC6ENTG mRNA in tumor - associated stromal or skin cells and the antitumor effect of BC6OTHER inhibition.	False
The objectives of these studies were to explore the possibility of establishing of a link between the pharmacokinetics of BC6ENTC and the responses of BC6OTHER mRNA in tumor - associated stromal or skin cells and the antitumor effect of BC6ENTG inhibition.	False
To this end , we built pharmacokinetic and pharmacodynamic models that describe the relationship of the concentrations of BC6ENTC plasma to the responses of BC6ENTG mRNA in the tumor (target) and skin (surrogate) and to tumor growth inhibition in mice bearing xenografts of human pancreatic tumors (PAN - 04).	False
Pharmacokinetic and pharmacodynamic modeling of BC6ENTG inhibitor BC6ENTC for the inhibition of BC6OTHER messenger RNA expression and antitumor efficacy in xenografted tumor model mice.	CPR:4
Pharmacokinetic and pharmacodynamic modeling of BC6OTHER inhibitor BC6ENTC for the inhibition of BC6ENTG messenger RNA expression and antitumor efficacy in xenografted tumor model mice.	CPR:4
BC6ENTC is a potent and specific inhibitor of BC6ENTG , which is used for the treatment of rheumatoid arthritis , osteoarthritis , and the dysmenorrhea pain.	CPR:4
Disposition of a specific BC6ENTG inhibitor , BC6ENTC , in human.	CPR:4
A series of novel BC6ENTC were synthesized and evaluated for their anticancer effects involving induction of BC6ENTG .	False
In further evaluation , the representative compound BC6ENTC (3b) exhibited potent pro - apoptotic activity , through BC6ENTG activation , in HeLa cells.	CPR:3
The capacity of BC6ENTG inhibitors , with the exception of BC6ENTC and BC6OTHER , to displace bound BC6OTHER in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6OTHER .	CPR:4
The capacity of BC6OTHER inhibitors , with the exception of BC6ENTC and BC6OTHER , to displace bound BC6OTHER in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6ENTG .	False
The capacity of BC6ENTG inhibitors , with the exception of BC6OTHER and BC6ENTC , to displace bound BC6OTHER in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6OTHER .	CPR:4
The capacity of BC6OTHER inhibitors , with the exception of BC6OTHER and BC6ENTC , to displace bound BC6OTHER in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6ENTG .	False
The capacity of BC6ENTG inhibitors , with the exception of BC6OTHER and BC6OTHER , to displace bound BC6ENTC in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6OTHER .	False
The capacity of BC6OTHER inhibitors , with the exception of BC6OTHER and BC6OTHER , to displace bound BC6ENTC in preference to BC6OTHER predicts that the former compounds could act as potential agonists at BC6ENTG .	False
The capacity of BC6ENTG inhibitors , with the exception of BC6OTHER and BC6OTHER , to displace bound BC6OTHER in preference to BC6ENTC predicts that the former compounds could act as potential agonists at BC6OTHER .	False
The capacity of BC6OTHER inhibitors , with the exception of BC6OTHER and BC6OTHER , to displace bound BC6OTHER in preference to BC6ENTC predicts that the former compounds could act as potential agonists at BC6ENTG .	False
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6ENTC > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6ENTC > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6ENTC = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6ENTC = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6ENTC = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6ENTC = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6ENTC > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6ENTC > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6ENTC = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6ENTC = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6ENTC = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6ENTC = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6ENTC > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6ENTC > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6ENTC > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6ENTC ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6OTHER to the greatest extent.	CPR:4
Moreover , the rank order for potency in inhibiting BC6ENTG ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6OTHER also displaced BC6ENTC to the greatest extent.	False
Moreover , the rank order for potency in inhibiting BC6OTHER ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER > BC6OTHER ) indicated that the most effective inhibitors of BC6ENTG also displaced BC6ENTC to the greatest extent.	False
The capacity of these inhibitors to displace BC6ENTC - M binding preclude their utilisation for the prevention of BC6OTHER catabolism in rat brain membranes , the latter being required to estimate the binding of CHEM to BC6OTHER - labelled BC6ENTG .	False
The capacity of these inhibitors to displace BC6OTHER - M binding preclude their utilisation for the prevention of BC6ENTC catabolism in rat brain membranes , the latter being required to estimate the binding of CHEM to BC6OTHER - labelled BC6ENTG .	False
The capacity of these inhibitors to displace BC6OTHER - M binding preclude their utilisation for the prevention of BC6OTHER catabolism in rat brain membranes , the latter being required to estimate the binding of CHEM to BC6ENTC - labelled BC6ENTG .	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6ENTG (IC50 24 nM) , did prevent catabolism of BC6ENTC in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6OTHER - labelled BC6OTHER in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6OTHER (IC50 24 nM) , did prevent catabolism of BC6ENTC in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6OTHER - labelled BC6ENTG in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6ENTG (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6ENTC binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6OTHER - labelled BC6OTHER in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6OTHER (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6ENTC binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6OTHER - labelled BC6ENTG in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6ENTG (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6ENTC (Ki 85 nM) for BC6OTHER - labelled BC6OTHER in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6OTHER (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6ENTC (Ki 85 nM) for BC6OTHER - labelled BC6ENTG in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6ENTG (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6ENTC - labelled BC6OTHER in rat brain."	False
"However , CHEM - 2 , a potent peptide inhibitor of BC6OTHER (IC50 24 nM) , did prevent catabolism of BC6OTHER in rat brain membranes with an atypical inhibition isotherm of BC6OTHER binding , thus permitting an estimation of the ""global affinity"" of BC6OTHER (Ki 85 nM) for BC6ENTC - labelled BC6ENTG in rat brain."	False
In the present study , the capacity of BC6ENTG inhibitors to interact with BC6OTHER was assessed by their ability to displace both BC6ENTC and BC6OTHER binding in rat brain membranes.	False
In the present study , the capacity of BC6OTHER inhibitors to interact with BC6ENTG was assessed by their ability to displace both BC6ENTC and BC6OTHER binding in rat brain membranes.	False
In the present study , the capacity of BC6ENTG inhibitors to interact with BC6OTHER was assessed by their ability to displace both BC6OTHER and BC6ENTC binding in rat brain membranes.	False
In the present study , the capacity of BC6OTHER inhibitors to interact with BC6ENTG was assessed by their ability to displace both BC6OTHER and BC6ENTC binding in rat brain membranes.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6ENTC binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6ENTC > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6ENTC = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6ENTC = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6ENTC > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6ENTC > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6ENTC = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6ENTC > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6ENTC ) whereas only BC6OTHER and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6ENTC and BC6OTHER displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6ENTC displaced BC6OTHER binding.	False
A series of compounds , representative of the principal classes of BC6ENTG inhibitors , displaced BC6OTHER binding with high - to - moderate potency ( BC6OTHER > BC6OTHER = BC6OTHER = BC6OTHER > BC6OTHER > BC6OTHER = BC6OTHER > BC6OTHER ) whereas only BC6OTHER and BC6OTHER displaced BC6ENTC binding.	False
Differential inhibition of BC6ENTC and BC6OTHER binding to BC6OTHER in rat brain membranes with BC6ENTG inhibitors.	False
Differential inhibition of BC6ENTC and BC6OTHER binding to BC6ENTG in rat brain membranes with BC6OTHER inhibitors.	False
Differential inhibition of BC6OTHER and BC6ENTC binding to BC6OTHER in rat brain membranes with BC6ENTG inhibitors.	False
Differential inhibition of BC6OTHER and BC6ENTC binding to BC6ENTG in rat brain membranes with BC6OTHER inhibitors.	False
This led to the still controversial hypothesis that BC6ENTG influences bone formation indirectly by regulating the expression of BC6OTHER and as a consequence influencing the production of BC6ENTC in the gut.	False
This led to the still controversial hypothesis that BC6OTHER influences bone formation indirectly by regulating the expression of BC6ENTG and as a consequence influencing the production of BC6ENTC in the gut.	False
Gene expression studies showed that mice lacking BC6ENTG have increased expression of BC6OTHER , the rate limiting enzyme for the production of BC6ENTC in the gut.	False
Gene expression studies showed that mice lacking BC6OTHER have increased expression of BC6ENTG , the rate limiting enzyme for the production of BC6ENTC in the gut.	False
Furthermore mice lacking either BC6ENTG or BC6OTHER , the receptor for BC6ENTC on the osteoblasts , were reported to have an increased bone mass due to increased bone formation.	False
Furthermore mice lacking either BC6OTHER or BC6ENTG , the receptor for BC6ENTC on the osteoblasts , were reported to have an increased bone mass due to increased bone formation.	False
No mutations in the BC6ENTC related BC6ENTG and BC6OTHER genes in patients with monogenic sclerosing bone disorders.	False
No mutations in the BC6ENTC related BC6OTHER and BC6ENTG genes in patients with monogenic sclerosing bone disorders.	False
In this study , a bilayered BC6ENTC composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of BC6ENTG ( BC6OTHER ) with varying release kinetics and / or BC6OTHER ( BC6OTHER ) on osteochondral tissue regeneration in a rabbit full - thickness osteochondral defect model.	False
In this study , a bilayered BC6ENTC composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of BC6OTHER ( BC6ENTG ) with varying release kinetics and / or BC6OTHER ( BC6OTHER ) on osteochondral tissue regeneration in a rabbit full - thickness osteochondral defect model.	False
In this study , a bilayered BC6ENTC composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of BC6OTHER ( BC6OTHER ) with varying release kinetics and / or BC6ENTG ( BC6OTHER ) on osteochondral tissue regeneration in a rabbit full - thickness osteochondral defect model.	False
In this study , a bilayered BC6ENTC composite hydrogel that mimics the distinctive hierarchical structure of native osteochondral tissue was utilized to investigate the effect of BC6OTHER ( BC6OTHER ) with varying release kinetics and / or BC6OTHER ( BC6ENTG ) on osteochondral tissue regeneration in a rabbit full - thickness osteochondral defect model.	False
The four groups investigated included (i) a blank control (no GFs) , (ii) CHEM - loaded BC6ENTG alone , (iii) CHEM - loaded BC6OTHER and gel - loaded BC6OTHER , and (iv) CHEM - loaded BC6OTHER and CHEM - loaded BC6OTHER in BC6ENTC composite hydrogels.	False
The four groups investigated included (i) a blank control (no GFs) , (ii) CHEM - loaded BC6OTHER alone , (iii) CHEM - loaded BC6ENTG and gel - loaded BC6OTHER , and (iv) CHEM - loaded BC6OTHER and CHEM - loaded BC6OTHER in BC6ENTC composite hydrogels.	False
The four groups investigated included (i) a blank control (no GFs) , (ii) CHEM - loaded BC6OTHER alone , (iii) CHEM - loaded BC6OTHER and gel - loaded BC6ENTG , and (iv) CHEM - loaded BC6OTHER and CHEM - loaded BC6OTHER in BC6ENTC composite hydrogels.	False
The four groups investigated included (i) a blank control (no GFs) , (ii) CHEM - loaded BC6OTHER alone , (iii) CHEM - loaded BC6OTHER and gel - loaded BC6OTHER , and (iv) CHEM - loaded BC6ENTG and CHEM - loaded BC6OTHER in BC6ENTC composite hydrogels.	False
The four groups investigated included (i) a blank control (no GFs) , (ii) CHEM - loaded BC6OTHER alone , (iii) CHEM - loaded BC6OTHER and gel - loaded BC6OTHER , and (iv) CHEM - loaded BC6OTHER and CHEM - loaded BC6ENTG in BC6ENTC composite hydrogels.	False
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC dismutase ( BC6ENTG ) levels in renal homogenate , and urine protein excretion were measured.	False
The expression of mRNA for BC6ENTG , BC6ENTC oxidase subunits BC6OTHER and BC6OTHER in renal tissue was examined by realtime PCR.	False
The expression of mRNA for BC6OTHER , BC6ENTC oxidase subunits BC6ENTG and BC6OTHER in renal tissue was examined by realtime PCR.	False
The expression of mRNA for BC6OTHER , BC6ENTC oxidase subunits BC6OTHER and BC6ENTG in renal tissue was examined by realtime PCR.	False
There were significant increases in urine protein excretion , BC6ENTC levels and the expression of mRNA of BC6ENTG , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6ENTC levels and the expression of mRNA of BC6OTHER , BC6ENTG and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6ENTC levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6ENTG , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6ENTC levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6ENTG , BC6OTHER and BC6OTHER , and significant decreases in BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6ENTG and BC6OTHER , and significant decreases in BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6ENTG , and significant decreases in BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6OTHER , and significant decreases in BC6ENTC , BC6ENTG , BC6OTHER and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6ENTG , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6ENTG and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6ENTG , and significant decreases in BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6ENTG , BC6ENTC and BC6OTHER levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6ENTG , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6ENTG and BC6OTHER , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6ENTG , and significant decreases in BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC levels in the diabetic control group compared with the normal control group.	False
There were significant increases in urine protein excretion , BC6OTHER levels and the expression of mRNA of BC6OTHER , BC6OTHER and BC6OTHER , and significant decreases in BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC levels in the diabetic control group compared with the normal control group.	False
BC6ENTC (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTG , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6ENTC (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6ENTC (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6ENTC (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6ENTC (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
BC6ENTC (1) is a potent BC6ENTG agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	CPR:5
Compounds 4b - h were either inactive (4e , f) or weaker than 4a as affinity ligands for BC6OTHER and BC6ENTG with relative potencies comparable with those of the corresponding BC6ENTC analogues as BC6OTHER agonists.	False
Compounds 4b - h were either inactive (4e , f) or weaker than 4a as affinity ligands for BC6OTHER and BC6OTHER with relative potencies comparable with those of the corresponding BC6ENTC analogues as BC6ENTG agonists.	False
Compounds 4b - h were either inactive (4e , f) or weaker than 4a as affinity ligands for BC6ENTG and BC6OTHER with relative potencies comparable with those of the corresponding BC6ENTC analogues as BC6OTHER agonists.	False
Compounds 4b - h were either inactive (4e , f) or weaker than 4a as affinity ligands for BC6OTHER and BC6ENTG with relative potencies comparable with those of the corresponding BC6OTHER analogues as BC6ENTC receptor agonists.	False
Compounds 4b - h were either inactive (4e , f) or weaker than 4a as affinity ligands for BC6ENTG and BC6OTHER with relative potencies comparable with those of the corresponding BC6OTHER analogues as BC6ENTC receptor agonists.	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTC ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTC ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTC ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTC ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
BC6OTHER (1) is a potent BC6ENTG agonist with moderate affinity for native BC6ENTC ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6ENTC ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6ENTC ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6ENTC ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6ENTC ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
BC6OTHER (1) is a potent BC6ENTG agonist with moderate affinity for native CHEM ( BC6ENTC ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTG , whereas BC6ENTC (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6ENTC (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6ENTC (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6ENTC (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6ENTC (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
BC6OTHER (1) is a potent BC6ENTG agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6ENTC (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTG , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTC receptors and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6ENTC receptors and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTC receptors and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTC receptors and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
BC6OTHER (1) is a potent BC6ENTG agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTC receptors and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native BC6ENTG , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTC receptors.	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTC receptors.	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6ENTC receptors.	False
BC6OTHER (1) is a potent BC6OTHER agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6ENTC receptors.	False
BC6OTHER (1) is a potent BC6ENTG agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTC receptors.	False
As an attempt to develop new pharmacological tools for studies of BC6ENTG receptors , BC6ENTC (4a) was designed as a structural hybrid between 1 and 3.	False
4a was shown to be a potent BC6ENTG agonist and a high affinity ligand and to indiscriminately bind to the BC6ENTC receptor subtypes BC6OTHER with lower affinities.	False
4a was shown to be a potent BC6OTHER agonist and a high affinity ligand and to indiscriminately bind to the BC6ENTC receptor subtypes BC6ENTG with lower affinities.	False
BC6OTHER (1) is a potent BC6ENTC receptor agonist with moderate affinity for native BC6ENTG , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6ENTC receptor agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6ENTG subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6ENTC receptor agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6ENTG and much lower affinity for the BC6OTHER subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6ENTC receptor agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6ENTG subtype of BC6OTHER .	False
BC6OTHER (1) is a potent BC6ENTC receptor agonist with moderate affinity for native CHEM ( BC6OTHER ) receptors , whereas BC6OTHER (3) show high affinity for the BC6OTHER subtype of BC6OTHER and much lower affinity for the BC6OTHER subtype of BC6ENTG .	False
Synthesis and in vitro pharmacology at BC6ENTC and BC6OTHER preferring BC6ENTG of BC6OTHER analogues.	False
Synthesis and in vitro pharmacology at BC6OTHER and BC6ENTC preferring BC6ENTG of BC6OTHER analogues.	False
Synthesis and in vitro pharmacology at BC6OTHER and BC6OTHER preferring BC6ENTG of BC6ENTC analogues.	False
Regarding BC6ENTG inhibition , BC6ENTC was the most potent fraction (IC50: 97 µg / mL).	CPR:4
There was no significant difference in BC6ENTG , BC6OTHER , and BC6OTHER mRNA and proteins between BC6ENTC - treated and BC6OTHER - treated groups.	CPR:4
There was no significant difference in BC6OTHER , BC6ENTG , and BC6OTHER mRNA and proteins between BC6ENTC - treated and BC6OTHER - treated groups.	CPR:4
There was no significant difference in BC6OTHER , BC6OTHER , and BC6ENTG mRNA and proteins between BC6ENTC - treated and BC6OTHER - treated groups.	CPR:4
There was no significant difference in BC6ENTG , BC6OTHER , and BC6OTHER mRNA and proteins between BC6OTHER - treated and BC6ENTC - treated groups.	CPR:4
There was no significant difference in BC6OTHER , BC6ENTG , and BC6OTHER mRNA and proteins between BC6OTHER - treated and BC6ENTC - treated groups.	CPR:4
There was no significant difference in BC6OTHER , BC6OTHER , and BC6ENTG mRNA and proteins between BC6OTHER - treated and BC6ENTC - treated groups.	CPR:4
The anti - inflammatory actions of BC6ENTC on colitis may involve inhibition of the BC6ENTG / BC6OTHER signaling pathway and of BC6OTHER expression.	CPR:4
The anti - inflammatory actions of BC6ENTC on colitis may involve inhibition of the BC6OTHER / BC6ENTG signaling pathway and of BC6OTHER expression.	CPR:4
The anti - inflammatory actions of BC6ENTC on colitis may involve inhibition of the BC6OTHER / BC6OTHER signaling pathway and of BC6ENTG expression.	CPR:4
This study explored whether BC6ENTC improves colonic inflammation in a rat colitis model through inhibition of the BC6ENTG / BC6OTHER signaling pathway and BC6OTHER expression.	CPR:4
This study explored whether BC6ENTC improves colonic inflammation in a rat colitis model through inhibition of the BC6OTHER / BC6ENTG signaling pathway and BC6OTHER expression.	CPR:4
This study explored whether BC6ENTC improves colonic inflammation in a rat colitis model through inhibition of the BC6OTHER / BC6OTHER signaling pathway and BC6ENTG expression.	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6ENTG mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6OTHER BC6OTHER protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6ENTG mRNA , BC6OTHER protein , BC6OTHER BC6OTHER protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6ENTG protein , BC6OTHER BC6OTHER protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6ENTG BC6OTHER protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6OTHER BC6ENTG protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6OTHER BC6OTHER protein , and BC6ENTG BC6OTHER protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6OTHER activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6OTHER BC6OTHER protein , and BC6OTHER BC6ENTG protein (p < 0.05).	CPR:4
Compared with the untreated colitis group , the BC6ENTC - treated group showed significant decreases in the disease activity index , colonic mucosa damage index , histological score , BC6ENTG activity , and expressions of BC6OTHER mRNA , BC6OTHER mRNA , BC6OTHER protein , BC6OTHER BC6OTHER protein , and BC6OTHER BC6OTHER protein (p < 0.05).	CPR:4
 BC6ENTC improves CHEM - induced colitis in rats by inhibiting BC6ENTG expression via the BC6OTHER / BC6OTHER signaling pathway.	CPR:4
 BC6ENTC improves CHEM - induced colitis in rats by inhibiting BC6OTHER expression via the BC6ENTG / BC6OTHER signaling pathway.	CPR:4
 BC6ENTC improves CHEM - induced colitis in rats by inhibiting BC6OTHER expression via the BC6OTHER / BC6ENTG signaling pathway.	CPR:4
When the juice was mixed in an emulsion stabilised with BC6ENTG or phospholipids the maximum extraction decreased to 14.5 ± 0.2% and 18.5 ± 1.5% respectively , indicating that in addition to the saturation of the oil phase at low oil / tomato ratio and in addition to intrinsic properties of the tomato juice in non - saturating conditions , BC6ENTC diffusion was limited by the structure of the interface in emulsions.	False
Inhibition of BC6ENTG significantly increased vascular BC6ENTC production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6OTHER and BC6OTHER , which were prevented by BC6OTHER .	CPR:9
Inhibition of BC6OTHER significantly increased vascular BC6ENTC production , enhanced BC6ENTG activity , and mRNA expression of its subunits BC6OTHER and BC6OTHER , which were prevented by BC6OTHER .	False
Inhibition of BC6OTHER significantly increased vascular BC6ENTC production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6ENTG and BC6OTHER , which were prevented by BC6OTHER .	False
Inhibition of BC6OTHER significantly increased vascular BC6ENTC production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6OTHER and BC6ENTG , which were prevented by BC6OTHER .	False
Inhibition of BC6ENTG significantly increased vascular BC6OTHER production , enhanced BC6ENTC oxidase activity , and mRNA expression of its subunits BC6OTHER and BC6OTHER , which were prevented by BC6OTHER .	False
Inhibition of BC6OTHER significantly increased vascular BC6OTHER production , enhanced BC6ENTC oxidase activity , and mRNA expression of its subunits BC6ENTG and BC6OTHER , which were prevented by BC6OTHER .	False
Inhibition of BC6OTHER significantly increased vascular BC6OTHER production , enhanced BC6ENTC oxidase activity , and mRNA expression of its subunits BC6OTHER and BC6ENTG , which were prevented by BC6OTHER .	False
Inhibition of BC6ENTG significantly increased vascular BC6OTHER production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6OTHER and BC6OTHER , which were prevented by BC6ENTC .	False
Inhibition of BC6OTHER significantly increased vascular BC6OTHER production , enhanced BC6ENTG activity , and mRNA expression of its subunits BC6OTHER and BC6OTHER , which were prevented by BC6ENTC .	CPR:4
Inhibition of BC6OTHER significantly increased vascular BC6OTHER production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6ENTG and BC6OTHER , which were prevented by BC6ENTC .	CPR:4
Inhibition of BC6OTHER significantly increased vascular BC6OTHER production , enhanced BC6OTHER activity , and mRNA expression of its subunits BC6OTHER and BC6ENTG , which were prevented by BC6ENTC .	CPR:4
BC6ENTG ( BC6OTHER ) activation mimicked the effects of BC6ENTC while BC6OTHER inhibition prevented the effects of this BC6OTHER activator.	False
BC6OTHER ( BC6ENTG ) activation mimicked the effects of BC6ENTC while BC6OTHER inhibition prevented the effects of this BC6OTHER activator.	False
BC6OTHER ( BC6OTHER ) activation mimicked the effects of BC6ENTC while BC6ENTG inhibition prevented the effects of this BC6OTHER activator.	False
BC6OTHER ( BC6OTHER ) activation mimicked the effects of BC6ENTC while BC6OTHER inhibition prevented the effects of this BC6ENTG activator.	CPR:3
BC6ENTG co - precipitated with BC6OTHER and BC6ENTC increased the acetylation of the BC6OTHER coactivator BC6OTHER , which was suppressed by BC6OTHER .	False
BC6OTHER co - precipitated with BC6ENTG and BC6ENTC increased the acetylation of the BC6OTHER coactivator BC6OTHER , which was suppressed by BC6OTHER .	False
BC6OTHER co - precipitated with BC6OTHER and BC6ENTC increased the acetylation of the BC6ENTG coactivator BC6OTHER , which was suppressed by BC6OTHER .	False
BC6OTHER co - precipitated with BC6OTHER and BC6ENTC increased the acetylation of the BC6OTHER coactivator BC6ENTG , which was suppressed by BC6OTHER .	CPR:3
BC6ENTG co - precipitated with BC6OTHER and BC6OTHER increased the acetylation of the BC6OTHER coactivator BC6OTHER , which was suppressed by BC6ENTC .	False
BC6OTHER co - precipitated with BC6ENTG and BC6OTHER increased the acetylation of the BC6OTHER coactivator BC6OTHER , which was suppressed by BC6ENTC .	False
BC6OTHER co - precipitated with BC6OTHER and BC6OTHER increased the acetylation of the BC6ENTG coactivator BC6OTHER , which was suppressed by BC6ENTC .	False
BC6OTHER co - precipitated with BC6OTHER and BC6OTHER increased the acetylation of the BC6OTHER coactivator BC6ENTG , which was suppressed by BC6ENTC .	CPR:4
In conclusion , impaired activity of BC6ENTG induces endothelial dysfunction and up - regulates BC6ENTC oxidase - derived ROS production in the vascular wall , mimicking the vascular aging phenotype.	False
Moreover , a new mechanism for controlling endothelial function after BC6ENTG activation involves a decreased BC6OTHER acetylation and the subsequent BC6OTHER activation , resulting in both decreased BC6ENTC oxidase - driven ROS production and BC6OTHER inactivation.	False
Moreover , a new mechanism for controlling endothelial function after BC6OTHER activation involves a decreased BC6ENTG acetylation and the subsequent BC6OTHER activation , resulting in both decreased BC6ENTC oxidase - driven ROS production and BC6OTHER inactivation.	False
Moreover , a new mechanism for controlling endothelial function after BC6OTHER activation involves a decreased BC6OTHER acetylation and the subsequent BC6ENTG activation , resulting in both decreased BC6ENTC oxidase - driven ROS production and BC6OTHER inactivation.	False
Previous studies demonstrate that the activity of the evolutionarily conserved BC6ENTC - dependent deacetylase SIRT1 declines with age and that pharmacological activators of BC6ENTG confer significant anti - aging cardiovascular effects.	False
Moreover , a new mechanism for controlling endothelial function after BC6ENTG activation involves a decreased BC6OTHER acetylation and the subsequent BC6OTHER activation , resulting in both decreased BC6OTHER - driven ROS production and BC6ENTC inactivation.	False
Moreover , a new mechanism for controlling endothelial function after BC6OTHER activation involves a decreased BC6ENTG acetylation and the subsequent BC6OTHER activation , resulting in both decreased BC6OTHER - driven ROS production and BC6ENTC inactivation.	False
Moreover , a new mechanism for controlling endothelial function after BC6OTHER activation involves a decreased BC6OTHER acetylation and the subsequent BC6ENTG activation , resulting in both decreased BC6OTHER - driven ROS production and BC6ENTC inactivation.	False
Moreover , a new mechanism for controlling endothelial function after BC6OTHER activation involves a decreased BC6OTHER acetylation and the subsequent BC6OTHER activation , resulting in both decreased BC6ENTG - driven ROS production and BC6ENTC inactivation.	False
To determine whether dysregulation of BC6ENTG promotes BC6ENTC oxidase - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6ENTC oxidase - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6ENTG promotes BC6OTHER - dependent production of reactive BC6ENTC species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6ENTG - dependent production of reactive BC6ENTC species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	CPR:9
To determine whether dysregulation of BC6OTHER promotes BC6OTHER - dependent production of reactive BC6ENTC species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6ENTG promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6ENTG - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6ENTG ( BC6ENTC , BC6OTHER , BC6OTHER ) in aorta segments isolated from young Wistar rats.	CPR:4
To determine whether dysregulation of BC6ENTG promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6ENTG - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6ENTG ( BC6OTHER , BC6ENTC , BC6OTHER ) in aorta segments isolated from young Wistar rats.	CPR:4
To determine whether dysregulation of BC6ENTG promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6ENTG - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC ) in aorta segments isolated from young Wistar rats.	False
To determine whether dysregulation of BC6OTHER promotes BC6OTHER - dependent production of reactive BC6OTHER species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER , BC6ENTC ) in aorta segments isolated from young Wistar rats.	CPR:4
Inhibition of BC6ENTG induced endothelial dysfunction , as shown by the significantly reduced relaxation to the endothelium - dependent vasodilators BC6ENTC and the BC6OTHER ionophore BC6OTHER .	False
Inhibition of BC6ENTG induced endothelial dysfunction , as shown by the significantly reduced relaxation to the endothelium - dependent vasodilators BC6OTHER and the BC6ENTC ionophore BC6OTHER .	False
Inhibition of BC6ENTG induced endothelial dysfunction , as shown by the significantly reduced relaxation to the endothelium - dependent vasodilators BC6OTHER and the BC6OTHER ionophore BC6ENTC .	False
Endothelial dysfunction induced by BC6ENTG inhibition was prevented by treatment of the vessels with the BC6ENTC oxidase inhibitor BC6OTHER or BC6OTHER .	False
Endothelial dysfunction induced by BC6OTHER inhibition was prevented by treatment of the vessels with the BC6ENTC oxidase inhibitor BC6OTHER or BC6ENTG .	False
Endothelial dysfunction induced by BC6ENTG inhibition was prevented by treatment of the vessels with the BC6OTHER inhibitor BC6ENTC or BC6OTHER .	False
Endothelial dysfunction induced by BC6OTHER inhibition was prevented by treatment of the vessels with the BC6ENTG inhibitor BC6ENTC or BC6OTHER .	CPR:4
Endothelial dysfunction induced by BC6OTHER inhibition was prevented by treatment of the vessels with the BC6OTHER inhibitor BC6ENTC or BC6ENTG .	False
Endothelial dysfunction induced by BC6ENTG inhibition was prevented by treatment of the vessels with the BC6OTHER inhibitor BC6OTHER or BC6ENTC dismutase.	False
Endothelial dysfunction induced by BC6OTHER inhibition was prevented by treatment of the vessels with the BC6ENTG inhibitor BC6OTHER or BC6ENTC dismutase.	False
 BC6ENTG inhibits BC6ENTC oxidase activation and protects endothelial function in the rat aorta: Implications for vascular aging.	False
Neither the BC6ENTC radical scavenger , tiron , nor the inhibitor of the BC6ENTG , BC6OTHER , prevented the metabolites' toxicity.	False
Neither the BC6OTHER radical scavenger , tiron , nor the inhibitor of the BC6ENTG , BC6ENTC , prevented the metabolites' toxicity.	CPR:4
Cells exposed to BC6ENTC showed an increase in intracellular BC6OTHER ( BC6OTHER ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6ENTG ( BC6OTHER ) , revealing a possible transient effect.	False
Cells exposed to BC6ENTC showed an increase in intracellular BC6OTHER ( BC6OTHER ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6OTHER ( BC6ENTG ) , revealing a possible transient effect.	False
Cells exposed to BC6OTHER showed an increase in intracellular BC6ENTC ( BC6OTHER ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6ENTG ( BC6OTHER ) , revealing a possible transient effect.	False
Cells exposed to BC6OTHER showed an increase in intracellular BC6ENTC ( BC6OTHER ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6OTHER ( BC6ENTG ) , revealing a possible transient effect.	False
Cells exposed to BC6OTHER showed an increase in intracellular BC6OTHER ( BC6ENTC ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6ENTG ( BC6OTHER ) , revealing a possible transient effect.	False
Cells exposed to BC6OTHER showed an increase in intracellular BC6OTHER ( BC6ENTC ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6OTHER ( BC6ENTG ) , revealing a possible transient effect.	False
Cells exposed to BC6OTHER showed an increase in intracellular BC6OTHER ( BC6OTHER ) levels , which , at the 48 h time - point , was not dependent in the activity increase of BC6ENTC synthetase ( BC6ENTG ) , revealing a possible transient effect.	False
Importantly , pre - treatment with BC6ENTC ( BC6OTHER ) , an inhibitor of BC6ENTG , prevented BC6OTHER induced increase in BC6OTHER levels , but did not augment this metabolite cytotoxicity.	CPR:4
Importantly , pre - treatment with BC6OTHER ( BC6ENTC ) , an inhibitor of BC6ENTG , prevented BC6OTHER induced increase in BC6OTHER levels , but did not augment this metabolite cytotoxicity.	CPR:4
Importantly , pre - treatment with BC6OTHER ( BC6OTHER ) , an inhibitor of BC6ENTG , prevented BC6ENTC induced increase in BC6OTHER levels , but did not augment this metabolite cytotoxicity.	False
Importantly , pre - treatment with BC6OTHER ( BC6OTHER ) , an inhibitor of BC6ENTG , prevented BC6OTHER induced increase in BC6ENTC levels , but did not augment this metabolite cytotoxicity.	False
BC6ENTC BC6OTHER metabolites were neurotoxic to SH - SY5Y neurons , leading to BC6ENTG - independent cell death in a concentration - and time - dependent manner.	False
BC6OTHER BC6ENTC metabolites were neurotoxic to SH - SY5Y neurons , leading to BC6ENTG - independent cell death in a concentration - and time - dependent manner.	False
Based on these suggestions , the rational redesign of BC6ENTC 24 (clog P=7.41; BC6ENTG IC(50) =43 nM; HCT - 116 IC(50) =400 nM) led to the identification of BC6OTHER 67 (clog P=5.28; BC6OTHER IC(50) =25 nM; HCT - 116 IC(50) =23 nM).	CPR:4
Based on these suggestions , the rational redesign of BC6ENTC 24 (clog P=7.41; BC6OTHER IC(50) =43 nM; HCT - 116 IC(50) =400 nM) led to the identification of BC6OTHER 67 (clog P=5.28; BC6ENTG IC(50) =25 nM; HCT - 116 IC(50) =23 nM).	False
Based on these suggestions , the rational redesign of BC6OTHER 24 (clog P=7.41; BC6ENTG IC(50) =43 nM; HCT - 116 IC(50) =400 nM) led to the identification of BC6ENTC 67 (clog P=5.28; BC6OTHER IC(50) =25 nM; HCT - 116 IC(50) =23 nM).	False
Based on these suggestions , the rational redesign of BC6OTHER 24 (clog P=7.41; BC6OTHER IC(50) =43 nM; HCT - 116 IC(50) =400 nM) led to the identification of BC6ENTC 67 (clog P=5.28; BC6ENTG IC(50) =25 nM; HCT - 116 IC(50) =23 nM).	CPR:4
Three different 3D - QSAR models were built and validated by using a set of 66 BC6ENTC (Model I) and BC6OTHER (Model II) compounds with IC(50) values toward BC6ENTG ranging from 33 nM to 10.5 μM.	CPR:4
Three different 3D - QSAR models were built and validated by using a set of 66 BC6OTHER (Model I) and BC6ENTC (Model II) compounds with IC(50) values toward BC6ENTG ranging from 33 nM to 10.5 μM.	CPR:4
3D - QSAR - assisted drug design: identification of a potent BC6ENTC - based BC6ENTG inhibitor.	CPR:4
A major part of this processing requires endoproteolytic cleavage at specific pairs of basic BC6ENTC residues , an event necessary for the maturation of a variety of important biologically active proteins , such as BC6ENTG and BC6OTHER .	False
A major part of this processing requires endoproteolytic cleavage at specific pairs of basic BC6ENTC residues , an event necessary for the maturation of a variety of important biologically active proteins , such as BC6OTHER and BC6ENTG .	False
Knockdown of BC6ENTG BC6OTHER by BC6OTHER siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER BC6ENTG by BC6OTHER siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER BC6OTHER by BC6ENTG siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER BC6OTHER by BC6OTHER siRNA significantly decreased acid - induced increase in BC6ENTG expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTG BC6OTHER by BC6OTHER siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER BC6ENTG by BC6OTHER siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER BC6OTHER by BC6ENTG siRNA significantly decreased acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER BC6OTHER by BC6OTHER siRNA significantly decreased acid - induced increase in BC6ENTG expression , BC6OTHER incorporation , and BC6ENTC production.	False
BC6ENTG ( BC6OTHER ) - derived BC6ENTC ( BC6OTHER ) has been shown to be important in esophageal tumorigenesis.	CPR:9
BC6OTHER ( BC6ENTG ) - derived BC6ENTC ( BC6OTHER ) has been shown to be important in esophageal tumorigenesis.	CPR:9
We conclude that BC6ENTG mediates acid - induced increase in BC6ENTC production and cell proliferation.	CPR:9
BC6ENTG ( BC6OTHER ) - derived BC6OTHER ( BC6ENTC ) has been shown to be important in esophageal tumorigenesis.	CPR:9
BC6OTHER ( BC6ENTG ) - derived BC6OTHER ( BC6ENTC ) has been shown to be important in esophageal tumorigenesis.	CPR:9
We have shown that BC6ENTG mediates acid - induced BC6ENTC production.	CPR:9
The BC6ENTC synthase ( BC6ENTG ) responsible for acid - induced BC6OTHER production in BE , however , is not known.	False
The BC6ENTG ( BC6OTHER ) responsible for acid - induced BC6ENTC production in BE , however , is not known.	False
The BC6OTHER ( BC6ENTG ) responsible for acid - induced BC6ENTC production in BE , however , is not known.	False
Knockdown of BC6ENTG by BC6OTHER small interfering RNA (siRNA) blocked acid - induced increase in BC6ENTC production and BC6OTHER incorporation.	False
Knockdown of BC6OTHER by BC6ENTG small interfering RNA (siRNA) blocked acid - induced increase in BC6ENTC production and BC6OTHER incorporation.	False
Knockdown of BC6ENTG by BC6OTHER small interfering RNA (siRNA) blocked acid - induced increase in BC6OTHER production and BC6ENTC incorporation.	False
Knockdown of BC6OTHER by BC6ENTG small interfering RNA (siRNA) blocked acid - induced increase in BC6OTHER production and BC6ENTC incorporation.	False
Knockdown of BC6ENTC oxidase , BC6ENTG , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTC oxidase , BC6OTHER , a variant lacking BC6ENTG , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTC oxidase , BC6OTHER , a variant lacking BC6OTHER , by BC6ENTG siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTC oxidase , BC6OTHER , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6ENTG expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTG , BC6OTHER , a variant lacking BC6ENTC - binding domains , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6ENTG , a variant lacking BC6ENTC - binding domains , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6ENTC - binding domains , by BC6ENTG siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6ENTC - binding domains , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6ENTG expression , BC6OTHER incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTG , BC6OTHER , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6ENTG , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6ENTG , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6OTHER , by BC6ENTG siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6ENTG expression , BC6ENTC incorporation , and BC6OTHER production.	False
Knockdown of BC6ENTG , BC6OTHER , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER , BC6ENTG , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6ENTG , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6OTHER , by BC6ENTG siRNA significantly inhibited acid - induced increase in BC6OTHER expression , BC6OTHER incorporation , and BC6ENTC production.	False
Knockdown of BC6OTHER , BC6OTHER , a variant lacking BC6OTHER , by BC6OTHER siRNA significantly inhibited acid - induced increase in BC6ENTG expression , BC6OTHER incorporation , and BC6ENTC production.	False
 BC6ENTC Oxidase NOX5 - S and BC6ENTG Mediate Acid - Induced Microsomal BC6OTHER Synthase - 1 Expression in Barrett's Esophageal Adenocarcinoma Cells.	False
 BC6ENTC Oxidase NOX5 - S and BC6OTHER Mediate Acid - Induced BC6ENTG Expression in Barrett's Esophageal Adenocarcinoma Cells.	False
 BC6ENTG and BC6OTHER Mediate Acid - Induced Microsomal BC6ENTC Synthase - 1 Expression in Barrett's Esophageal Adenocarcinoma Cells.	False
 BC6OTHER and BC6ENTG Mediate Acid - Induced Microsomal BC6ENTC Synthase - 1 Expression in Barrett's Esophageal Adenocarcinoma Cells.	False
BC6ENTC is an allosteric inhibitor of BC6ENTG / BC6OTHER BC6OTHER .	False
BC6ENTC is an allosteric inhibitor of BC6OTHER / BC6ENTG BC6OTHER .	False
BC6ENTC is an allosteric inhibitor of BC6OTHER / BC6OTHER BC6ENTG .	False
We found distinct differences in the action of BC6ENTC at BC6ENTG / BC6OTHER in comparison with previous studies on the effect of BC6OTHER on BC6OTHER / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6ENTC at BC6OTHER / BC6ENTG in comparison with previous studies on the effect of BC6OTHER on BC6OTHER / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6ENTC at BC6OTHER / BC6OTHER in comparison with previous studies on the effect of BC6OTHER on BC6ENTG / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6ENTC at BC6OTHER / BC6OTHER in comparison with previous studies on the effect of BC6OTHER on BC6OTHER / BC6ENTG gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6OTHER at BC6ENTG / BC6OTHER in comparison with previous studies on the effect of BC6ENTC on BC6OTHER / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6OTHER at BC6OTHER / BC6ENTG in comparison with previous studies on the effect of BC6ENTC on BC6OTHER / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6OTHER at BC6OTHER / BC6OTHER in comparison with previous studies on the effect of BC6ENTC on BC6ENTG / BC6OTHER gating , which may arise due to their unique binding sites.	False
We found distinct differences in the action of BC6OTHER at BC6OTHER / BC6OTHER in comparison with previous studies on the effect of BC6ENTC on BC6OTHER / BC6ENTG gating , which may arise due to their unique binding sites.	False
At a low pH (pH 7.4) , but not pH 7.9 , BC6ENTC reduces the mean open time of BC6ENTG / BC6OTHER receptors , which may be responsible for its usefulness as a context - dependent inhibitor in conditions like ischemia and stroke , when the pH of the extracellular milieu becomes acidic.	CPR:4
At a low pH (pH 7.4) , but not pH 7.9 , BC6ENTC reduces the mean open time of BC6OTHER / BC6ENTG receptors , which may be responsible for its usefulness as a context - dependent inhibitor in conditions like ischemia and stroke , when the pH of the extracellular milieu becomes acidic.	CPR:4
Interestingly , recent crystallographic evidence identified that BC6ENTC unlike BC6OTHER , binds at the interface of the BC6ENTG / BC6OTHER BC6OTHER terminal domain dimer by an induced - fit mechanism.	False
Interestingly , recent crystallographic evidence identified that BC6ENTC unlike BC6OTHER , binds at the interface of the BC6OTHER / BC6ENTG BC6OTHER terminal domain dimer by an induced - fit mechanism.	False
Interestingly , recent crystallographic evidence identified that BC6OTHER unlike BC6ENTC , binds at the interface of the BC6ENTG / BC6OTHER BC6OTHER terminal domain dimer by an induced - fit mechanism.	False
Interestingly , recent crystallographic evidence identified that BC6OTHER unlike BC6ENTC , binds at the interface of the BC6OTHER / BC6ENTG BC6OTHER terminal domain dimer by an induced - fit mechanism.	False
Interestingly , recent crystallographic evidence identified that BC6OTHER unlike BC6OTHER , binds at the interface of the BC6ENTG / BC6OTHER BC6ENTC terminal domain dimer by an induced - fit mechanism.	False
Interestingly , recent crystallographic evidence identified that BC6OTHER unlike BC6OTHER , binds at the interface of the BC6OTHER / BC6ENTG BC6ENTC terminal domain dimer by an induced - fit mechanism.	False
BC6OTHER is an allosteric inhibitor of BC6ENTG / BC6OTHER BC6ENTC receptors.	False
BC6OTHER is an allosteric inhibitor of BC6OTHER / BC6ENTG BC6ENTC receptors.	False
Effect of BC6ENTC on BC6ENTG / BC6OTHER BC6OTHER gating.	False
Effect of BC6ENTC on BC6OTHER / BC6ENTG BC6OTHER gating.	False
Effect of BC6ENTC on BC6OTHER / BC6OTHER BC6ENTG gating.	False
Effect of BC6OTHER on BC6ENTG / BC6OTHER BC6ENTC receptor gating.	False
Effect of BC6OTHER on BC6OTHER / BC6ENTG BC6ENTC receptor gating.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6ENTC synthase ( BC6ENTG ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6ENTC synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6ENTG activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6ENTC synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6ENTG - resistant state.	False
The BC6OTHER treatment also partially improved the BC6ENTG sensitivity and blood pressure , as well as the serum BC6ENTC concentration , in the BC6OTHER - fed rats.	False
The BC6OTHER treatment also partially improved the BC6ENTG sensitivity and blood pressure , as well as the serum BC6OTHER concentration , in the BC6ENTC - fed rats.	False
Moreover , BC6ENTC treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6ENTG and BC6OTHER , which were increased in BC6OTHER - fed rats.	CPR:4
Moreover , BC6ENTC treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6OTHER and BC6ENTG , which were increased in BC6OTHER - fed rats.	CPR:4
Moreover , BC6OTHER treatment of the BC6ENTC - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6ENTG and BC6OTHER , which were increased in BC6OTHER - fed rats.	CPR:3
Moreover , BC6OTHER treatment of the BC6ENTC - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6OTHER and BC6ENTG , which were increased in BC6OTHER - fed rats.	CPR:3
Moreover , BC6OTHER treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6ENTC content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6ENTG and BC6OTHER , which were increased in BC6OTHER - fed rats.	False
Moreover , BC6OTHER treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6ENTC content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6OTHER and BC6ENTG , which were increased in BC6OTHER - fed rats.	False
Moreover , BC6OTHER treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6ENTG and BC6OTHER , which were increased in BC6ENTC - fed rats.	CPR:3
Moreover , BC6OTHER treatment of the BC6OTHER - fed rats markedly reduced the lipid BC6OTHER content of both aortic and cardiac tissues and inhibited the activation of 2 redox - sensitive transcription factors , BC6OTHER and BC6ENTG , which were increased in BC6ENTC - fed rats.	CPR:3
These results indicate that BC6ENTC augmentation is essential for the restoration of BC6ENTG function and the reduction of vascular oxidative stress in BC6OTHER - resistant rats.	False
These results indicate that BC6ENTC augmentation is essential for the restoration of BC6OTHER function and the reduction of vascular oxidative stress in BC6ENTG - resistant rats.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6ENTG ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6ENTC ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6ENTG activity and increased BC6ENTC ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6ENTC ( BC6OTHER ) generation in the BC6ENTG - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of BC6ENTG ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6ENTC ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6ENTG ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6ENTC ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6ENTG activity and increased BC6OTHER ( BC6ENTC ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6ENTC ) generation in the BC6ENTG - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6OTHER ) , an active cofactor of BC6ENTG ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6ENTC ) generation in the BC6OTHER - resistant state.	False
To further confirm this hypothesis , we investigated the effects of dietary treatment with BC6ENTC on endothelium - dependent arterial relaxation and vascular oxidative stress in the aortas of BC6ENTG - resistant rats.	False
We have reported that a deficiency of BC6ENTC ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6ENTG ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6ENTC ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6ENTG activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6ENTC ( BC6OTHER ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6ENTG - resistant state.	False
We have reported that a deficiency of BC6ENTC ( BC6OTHER ) , an active cofactor of BC6ENTG ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6ENTC ) , an active cofactor of endothelial BC6OTHER synthase ( BC6ENTG ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6ENTC ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6ENTG activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6ENTC ) , an active cofactor of endothelial BC6OTHER synthase ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6ENTG - resistant state.	False
We have reported that a deficiency of BC6OTHER ( BC6ENTC ) , an active cofactor of BC6ENTG ( BC6OTHER ) , contributes to the endothelial dysfunction through reduced BC6OTHER activity and increased BC6OTHER ( BC6OTHER ) generation in the BC6OTHER - resistant state.	False
The BC6ENTC treatment was associated with a 2 - fold increase in BC6ENTG activity as well as a 70% reduction in endothelial BC6OTHER production compared with those in BC6OTHER - fed rats.	CPR:3
The BC6OTHER treatment was associated with a 2 - fold increase in BC6ENTG activity as well as a 70% reduction in endothelial BC6ENTC production compared with those in BC6OTHER - fed rats.	False
The BC6OTHER treatment was associated with a 2 - fold increase in BC6ENTG activity as well as a 70% reduction in endothelial BC6OTHER production compared with those in BC6ENTC - fed rats.	False
The BC6ENTC treatment also partially improved the BC6ENTG sensitivity and blood pressure , as well as the serum BC6OTHER concentration , in the BC6OTHER - fed rats.	CPR:3
Oral administration of BC6ENTC prevents endothelial dysfunction and vascular oxidative stress in the aortas of BC6ENTG - resistant rats.	False
The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X - ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a BC6ENTC from the conserved BC6ENTG found in BC6OTHER .	False
The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X - ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a BC6ENTC from the conserved BC6OTHER found in BC6ENTG .	False
Although reducing BC6ENTG BC6ENTC ( BC6OTHER - c) levels decreases morbidity and mortality , this therapeutic intervention only translates into a 25 - 40% reduction in cardiovascular events.	False
Although reducing BC6OTHER BC6ENTC ( BC6ENTG - c) levels decreases morbidity and mortality , this therapeutic intervention only translates into a 25 - 40% reduction in cardiovascular events.	False
Repression of BC6ENTG ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6ENTC caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6OTHER transfer protein transgenes.	CPR:4
Repression of BC6OTHER ( BC6ENTG ) by siRNA and the enzyme inhibitor BC6ENTC caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6OTHER transfer protein transgenes.	CPR:4
Repression of BC6OTHER ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6ENTC caused elevation of BC6ENTG secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6OTHER transfer protein transgenes.	CPR:3
Repression of BC6OTHER ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6ENTC caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6ENTG and BC6OTHER transfer protein transgenes.	CPR:3
Repression of BC6ENTG ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6OTHER caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6ENTC transfer protein transgenes.	False
Repression of BC6OTHER ( BC6ENTG ) by siRNA and the enzyme inhibitor BC6OTHER caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6ENTC transfer protein transgenes.	False
Repression of BC6OTHER ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6OTHER caused elevation of BC6ENTG secretion from hepatocytes and from transgenic mice expressing BC6OTHER and BC6ENTC transfer protein transgenes.	False
Repression of BC6OTHER ( BC6OTHER ) by siRNA and the enzyme inhibitor BC6OTHER caused elevation of BC6OTHER secretion from hepatocytes and from transgenic mice expressing BC6ENTG and BC6ENTC transfer protein transgenes.	False
Epidemiological studies have shown that a high BC6ENTG L - c level is not the only risk factor for CAD; low BC6OTHER BC6ENTC ( BC6OTHER - c) is an independent risk factor for CAD.	False
Epidemiological studies have shown that a high BC6OTHER L - c level is not the only risk factor for CAD; low BC6ENTG BC6ENTC ( BC6OTHER - c) is an independent risk factor for CAD.	False
Epidemiological studies have shown that a high BC6OTHER L - c level is not the only risk factor for CAD; low BC6OTHER BC6ENTC ( BC6ENTG - c) is an independent risk factor for CAD.	False
BC6ENTG I ( BC6OTHER ) is the major protein component of BC6OTHER - c that mediates reverse BC6ENTC transport from tissues to the liver for excretion.	False
BC6OTHER I ( BC6ENTG ) is the major protein component of BC6OTHER - c that mediates reverse BC6ENTC transport from tissues to the liver for excretion.	False
BC6OTHER I ( BC6OTHER ) is the major protein component of BC6ENTG - c that mediates reverse BC6ENTC transport from tissues to the liver for excretion.	False
The inhibitor binds at the base of the active site gorge of BC6ENTG , interacting with both the BC6ENTC - binding site ( BC6OTHER - 84) and the BC6OTHER ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6ENTC - binding site ( BC6OTHER - 84) and the BC6ENTG ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6ENTG , interacting with both the BC6OTHER ( BC6ENTC - 84) and the BC6OTHER ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6ENTG ( BC6ENTC - 84) and the BC6OTHER ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6OTHER ( BC6ENTC - 84) and the BC6ENTG ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6ENTG , interacting with both the BC6OTHER ( BC6OTHER - 84) and the BC6ENTC - binding pocket ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6ENTG ( BC6OTHER - 84) and the BC6ENTC - binding pocket ( BC6OTHER - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6ENTG , interacting with both the BC6OTHER ( BC6OTHER - 84) and the BC6OTHER ( BC6ENTC - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6ENTG ( BC6OTHER - 84) and the BC6OTHER ( BC6ENTC - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6OTHER ( BC6OTHER - 84) and the BC6ENTG ( BC6ENTC - 288 , BC6OTHER - 290).	False
The inhibitor binds at the base of the active site gorge of BC6ENTG , interacting with both the BC6OTHER ( BC6OTHER - 84) and the BC6OTHER ( BC6OTHER - 288 , BC6ENTC - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6ENTG ( BC6OTHER - 84) and the BC6OTHER ( BC6OTHER - 288 , BC6ENTC - 290).	False
The inhibitor binds at the base of the active site gorge of BC6OTHER , interacting with both the BC6OTHER ( BC6OTHER - 84) and the BC6ENTG ( BC6OTHER - 288 , BC6ENTC - 290).	False
Structure of BC6ENTG complexed with BC6ENTC at 2.3 A resolution.	False
These results indicate that co - administration of CNF with BC6ENTC can alleviate BC6OTHER induced liver damage through preventing lipid formation , protecting antioxidant system and suppressing productions of pro - inflammatory BC6ENTG .	False
These results indicate that co - administration of CNF with BC6OTHER can alleviate BC6ENTC induced liver damage through preventing lipid formation , protecting antioxidant system and suppressing productions of pro - inflammatory BC6ENTG .	False
Consumption of BC6ENTC for 8weeks induced severe liver damage with increases in prognostic indicators such as BC6ENTG , BC6OTHER in serum whereas co - administration of CNF suppressed their increases.	CPR:3
Consumption of BC6ENTC for 8weeks induced severe liver damage with increases in prognostic indicators such as BC6OTHER , BC6ENTG in serum whereas co - administration of CNF suppressed their increases.	CPR:3
Consumption of BC6OTHER for 8weeks induced severe liver damage with increases in prognostic indicators such as BC6ENTC transaminase , BC6ENTG in serum whereas co - administration of CNF suppressed their increases.	False
CHEM - administration of CNF maintained BC6ENTG activity , BC6ENTC and BC6OTHER levels close to those of the normal diet group.	False
CHEM - administration of CNF maintained BC6ENTG activity , BC6OTHER and BC6ENTC levels close to those of the normal diet group.	False
Chronic consumption of BC6ENTC also stimulated abrupt increases in pro - inflammatory cytokines such as BC6ENTG , BC6OTHER and BC6OTHER in liver otherwise co - administration of CNF effectively suppressed production of these BC6OTHER dose - dependently.	CPR:3
Chronic consumption of BC6ENTC also stimulated abrupt increases in pro - inflammatory cytokines such as BC6OTHER , BC6ENTG and BC6OTHER in liver otherwise co - administration of CNF effectively suppressed production of these BC6OTHER dose - dependently.	CPR:3
Chronic consumption of BC6ENTC also stimulated abrupt increases in pro - inflammatory cytokines such as BC6OTHER , BC6OTHER and BC6ENTG in liver otherwise co - administration of CNF effectively suppressed production of these BC6OTHER dose - dependently.	CPR:3
Chronic consumption of BC6ENTC also stimulated abrupt increases in pro - inflammatory cytokines such as BC6OTHER , BC6OTHER and BC6OTHER in liver otherwise co - administration of CNF effectively suppressed production of these BC6ENTG dose - dependently.	False
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6ENTG and BC6OTHER , did not modify the BC6ENTC - induced antinociception.	False
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6ENTG , did not modify the BC6ENTC - induced antinociception.	False
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6ENTG , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6OTHER , did not modify the BC6ENTC - induced antinociception.	False
The aim of this study was to evaluate the effects of BC6ENTG ( BC6OTHER ) inhibitors on BC6ENTC - induced antinociception in the tail flick test in mice , and on BC6OTHER binding to the forebrain crude synaptosome fraction.	False
The aim of this study was to evaluate the effects of CHEM / BC6OTHER protein phosphatase ( BC6ENTG ) inhibitors on BC6ENTC - induced antinociception in the tail flick test in mice , and on BC6OTHER binding to the forebrain crude synaptosome fraction.	False
These results suggest that the activation of type 2A BC6ENTC / BC6OTHER protein phosphatases may play a role in the antinociceptive effect of BC6OTHER , and that BC6ENTG might counterbalace this activity.	False
These results suggest that the activation of BC6ENTG BC6ENTC protein phosphatases may play a role in the antinociceptive effect of BC6OTHER , and that BC6OTHER might counterbalace this activity.	False
These results suggest that the activation of type 2A BC6OTHER / BC6ENTC protein phosphatases may play a role in the antinociceptive effect of BC6OTHER , and that BC6ENTG might counterbalace this activity.	False
These results suggest that the activation of BC6ENTG BC6OTHER protein phosphatases may play a role in the antinociceptive effect of BC6ENTC , and that BC6OTHER might counterbalace this activity.	False
These results suggest that the activation of type 2A BC6OTHER / BC6OTHER protein phosphatases may play a role in the antinociceptive effect of BC6ENTC , and that BC6ENTG might counterbalace this activity.	False
The aim of this study was to evaluate the effects of BC6ENTG ( BC6OTHER ) inhibitors on BC6OTHER - induced antinociception in the tail flick test in mice , and on BC6ENTC binding to the forebrain crude synaptosome fraction.	False
The aim of this study was to evaluate the effects of CHEM / BC6OTHER protein phosphatase ( BC6ENTG ) inhibitors on BC6OTHER - induced antinociception in the tail flick test in mice , and on BC6ENTC binding to the forebrain crude synaptosome fraction.	False
Neither BC6ENTC nor BC6OTHER (1 - 10000 nM) displaced BC6OTHER from its specific binding sites , which indicates that they do not interact at the BC6ENTG level.	False
Neither BC6OTHER nor BC6ENTC (1 - 10000 nM) displaced BC6OTHER from its specific binding sites , which indicates that they do not interact at the BC6ENTG level.	False
Neither BC6OTHER nor BC6OTHER (1 - 10000 nM) displaced BC6ENTC from its specific binding sites , which indicates that they do not interact at the BC6ENTG level.	False
 The i.c.v. administration of very low doses of BC6ENTC (0.001 - 1 pg / mouse) and BC6OTHER (0.001 - 1 ng / mouse) , which inhibit BC6ENTG , produced a dose - dependent antagonism of the antinociception induced by BC6OTHER (s.c.).	CPR:4
 The i.c.v. administration of very low doses of BC6OTHER (0.001 - 1 pg / mouse) and BC6ENTC (0.001 - 1 ng / mouse) , which inhibit BC6ENTG , produced a dose - dependent antagonism of the antinociception induced by BC6OTHER (s.c.).	CPR:4
The aim of this study was to evaluate the effects of BC6ENTC / BC6OTHER protein phosphatase ( BC6ENTG ) inhibitors on BC6OTHER - induced antinociception in the tail flick test in mice , and on BC6OTHER binding to the forebrain crude synaptosome fraction.	False
The aim of this study was to evaluate the effects of CHEM / BC6ENTC protein phosphatase ( BC6ENTG ) inhibitors on BC6OTHER - induced antinociception in the tail flick test in mice , and on BC6OTHER binding to the forebrain crude synaptosome fraction.	False
 The i.c.v. administration of very low doses of BC6OTHER (0.001 - 1 pg / mouse) and BC6OTHER (0.001 - 1 ng / mouse) , which inhibit BC6ENTG , produced a dose - dependent antagonism of the antinociception induced by BC6ENTC (s.c.).	False
 However , BC6ENTC (0.001 pg / mouse - 1 ng / mouse , i.c.v.) , an analogue of BC6OTHER lacking activity against BC6ENTG , did not affect the antinociceptive effect of BC6OTHER .	False
 However , BC6OTHER (0.001 pg / mouse - 1 ng / mouse , i.c.v.) , an analogue of BC6ENTC lacking activity against BC6ENTG , did not affect the antinociceptive effect of BC6OTHER .	False
 However , BC6OTHER (0.001 pg / mouse - 1 ng / mouse , i.c.v.) , an analogue of BC6OTHER lacking activity against BC6ENTG , did not affect the antinociceptive effect of BC6ENTC .	False
 On the other hand , high doses of BC6ENTC (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6ENTG and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	False
 On the other hand , high doses of BC6ENTC (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6ENTG , did not modify the BC6OTHER - induced antinociception.	False
 On the other hand , high doses of BC6ENTC (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6ENTG , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	CPR:4
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6ENTC (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6ENTG and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	False
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6ENTC (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6ENTG , did not modify the BC6OTHER - induced antinociception.	False
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6ENTC (1 microg / mouse , i.c.v.) , which also block BC6ENTG , and BC6OTHER (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	CPR:4
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6ENTC (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6ENTG and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	CPR:4
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6OTHER , and BC6ENTC (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6ENTG , did not modify the BC6OTHER - induced antinociception.	CPR:4
 On the other hand , high doses of BC6OTHER (10 ng / mouse , i.c.v.) and BC6OTHER (1 microg / mouse , i.c.v.) , which also block BC6ENTG , and BC6ENTC (0.1 fg / mouse - 1 ng / mouse , i.c.v.) , which inhibits equally both BC6OTHER and BC6OTHER , did not modify the BC6OTHER - induced antinociception.	False
Effects of BC6ENTG inhibitors on BC6ENTC - induced antinociception in the tail flick test in mice.	False
A BC6ENTG inhibitor - BC6ENTC ( BC6OTHER ) - blocked RVD more in CHEM than RCEC.	CPR:4
A BC6ENTG inhibitor - BC6OTHER ( BC6ENTC ) - blocked RVD more in CHEM than RCEC.	CPR:4
Under isotonic conditions , BC6ENTC ( BC6OTHER ) produced BC6ENTG activation and transient cell shrinkage.	CPR:3
Under isotonic conditions , BC6OTHER ( BC6ENTC ) produced BC6ENTG activation and transient cell shrinkage.	CPR:3
The dependence of regulatory volume decrease (RVD) activity on BC6ENTC cotransporter ( BC6ENTG ) isoform expression was characterized in corneal epithelial cells (CEC).	False
Furthermore , BC6OTHER ( BC6OTHER inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6ENTG inhibitor or BC6ENTC ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6OTHER ( BC6OTHER inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6ENTC ( BC6ENTG inhibitor) , decreased apoptosis in U937 cells.	CPR:4
Furthermore , BC6OTHER ( BC6ENTG inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6ENTC ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
Taken together , our study for the first time suggests that BC6ENTC is able to enhance apoptosis of U937 cells , at least in part , through activation of BC6ENTG and downregulation of BC6OTHER .	CPR:3
Taken together , our study for the first time suggests that BC6ENTC is able to enhance apoptosis of U937 cells , at least in part , through activation of BC6OTHER and downregulation of BC6ENTG .	False
The current study determines the role of BC6ENTG ( BC6OTHER ) in human leukemic U937 cells apoptosis induced by BC6ENTC from H. diffusa.	False
The current study determines the role of BC6OTHER ( BC6ENTG ) in human leukemic U937 cells apoptosis induced by BC6ENTC from H. diffusa.	False
Our results showed that BC6ENTC decreased phosphorylation - BC6ENTG ( BC6OTHER ) , and increased BC6OTHER , but did not affect expressions of BC6OTHER in U937 cells.	False
Our results showed that BC6ENTC decreased phosphorylation - BC6OTHER ( BC6ENTG ) , and increased BC6OTHER , but did not affect expressions of BC6OTHER in U937 cells.	False
Our results showed that BC6ENTC decreased phosphorylation - BC6OTHER ( BC6OTHER ) , and increased BC6ENTG , but did not affect expressions of BC6OTHER in U937 cells.	CPR:3
Our results showed that BC6ENTC decreased phosphorylation - BC6OTHER ( BC6OTHER ) , and increased BC6OTHER , but did not affect expressions of BC6ENTG in U937 cells.	False
Moreover , treatment of U937 cells with BC6ENTC resulted in activation of BC6ENTG .	CPR:3
Furthermore , BC6ENTC ( BC6OTHER inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6ENTG inhibitor or BC6OTHER ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6ENTC ( BC6OTHER inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6OTHER ( BC6ENTG inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6ENTC ( BC6ENTG inhibitor) significantly enhanced BC6OTHER - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6OTHER ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6OTHER ( BC6OTHER inhibitor) significantly enhanced BC6ENTC - induced apoptosis in U937 cells , whereas BC6ENTG inhibitor or BC6OTHER ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6OTHER ( BC6OTHER inhibitor) significantly enhanced BC6ENTC - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6OTHER ( BC6ENTG inhibitor) , decreased apoptosis in U937 cells.	False
Furthermore , BC6OTHER ( BC6ENTG inhibitor) significantly enhanced BC6ENTC - induced apoptosis in U937 cells , whereas BC6OTHER inhibitor or BC6OTHER ( BC6OTHER inhibitor) , decreased apoptosis in U937 cells.	False
 BC6ENTC from Hedyotis diffusa Willd induces apoptosis in human leukemic U937 cells through modulation of BC6ENTG pathways.	False
These effects resemble those seen with BC6OTHER - terminal deletions (DeltaN) of BC6ENTG , and application of Ntp to DeltaNK( BC6ENTC ) channels decreased their P(O(max)) and apparent IC(50) for BC6OTHER in the absence of BC6OTHER .	False
These effects resemble those seen with BC6OTHER - terminal deletions (DeltaN) of BC6OTHER , and application of Ntp to BC6ENTG decreased their P(O(max)) and apparent IC(50) for BC6ENTC in the absence of BC6OTHER .	CPR:4
These effects resemble those seen with BC6OTHER - terminal deletions (DeltaN) of BC6ENTG , and application of Ntp to DeltaNK( BC6OTHER ) channels decreased their P(O(max)) and apparent IC(50) for BC6ENTC in the absence of BC6OTHER .	False
These effects resemble those seen with BC6OTHER - terminal deletions (DeltaN) of BC6OTHER , and application of Ntp to BC6ENTG decreased their P(O(max)) and apparent IC(50) for BC6OTHER in the absence of BC6ENTC .	False
These effects resemble those seen with BC6OTHER - terminal deletions (DeltaN) of BC6ENTG , and application of Ntp to DeltaNK( BC6OTHER ) channels decreased their P(O(max)) and apparent IC(50) for BC6OTHER in the absence of BC6ENTC .	False
The BC6ENTG BC6ENTC terminus and the TMD0 - L0 segment of BC6OTHER are known to control the P(O(max)).	False
The BC6OTHER BC6ENTC terminus and the TMD0 - L0 segment of BC6ENTG are known to control the P(O(max)).	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6ENTG / BC6OTHER BC6ENTC ( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6ENTG BC6ENTC ( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6ENTG , respectively , were used to probe gating of BC6OTHER / BC6OTHER BC6ENTC ( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6ENTG / BC6OTHER K( BC6ENTC ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6ENTG K( BC6ENTC ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6OTHER - terminal sequences of BC6ENTG , respectively , were used to probe gating of BC6OTHER / BC6OTHER K( BC6ENTC ) channels.	False
The L0 linker has been reported to be required for BC6ENTC binding , and BC6ENTG / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6ENTC binding , and BC6OTHER / BC6ENTG channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6ENTC binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6ENTG with BC6OTHER , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6ENTC binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6ENTG BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6ENTC binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6ENTG are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6ENTG / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6ENTC , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6ENTG channels exhibit reduced labeling of BC6OTHER with BC6ENTC , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6ENTG with BC6ENTC , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6ENTC , implying that the BC6ENTG BC6OTHER terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6ENTC , implying that the BC6OTHER BC6OTHER terminus and L0 of BC6ENTG are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6ENTG / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6ENTC terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6ENTG channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6ENTC terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6ENTG with BC6OTHER , implying that the BC6OTHER BC6ENTC terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6ENTG BC6ENTC terminus and L0 of BC6OTHER are in proximity.	False
The L0 linker has been reported to be required for BC6OTHER binding , and BC6OTHER / BC6OTHER channels exhibit reduced labeling of BC6OTHER with BC6OTHER , implying that the BC6OTHER BC6ENTC terminus and L0 of BC6ENTG are in proximity.	False
We hypothesize that L0 interacts with the BC6ENTG BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited BC6ENTG and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6ENTG , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6ENTG , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6ENTG channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6ENTG - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6ENTG with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6ENTC terminus in ligand - inhibited K( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6ENTG pore.	False
We hypothesize that L0 interacts with the BC6ENTG BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6ENTG , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6ENTG , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6ENTG channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6ENTG - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6ENTG with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited BC6ENTC ( BC6OTHER ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6ENTG pore.	False
We hypothesize that L0 interacts with the BC6ENTG BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6ENTG , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6ENTG , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6ENTG channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6ENTG - like core of BC6OTHER with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6ENTG with the BC6OTHER pore.	False
We hypothesize that L0 interacts with the BC6OTHER BC6OTHER terminus in ligand - inhibited K( BC6ENTC ) channels and put forward a model , based on the architecture of BC6OTHER , BC6OTHER , and the BC6OTHER channel , in which TMD0 - L0 links the BC6OTHER - like core of BC6OTHER with the BC6ENTG pore.	False
Micromolar Ntp dose - dependently increased the mean open channel probability in ligand - free solution (P(O(max))) and attenuated the BC6ENTC inhibition of BC6ENTG / BC6OTHER , but had no effect on homomeric BC6OTHER channels.	CPR:4
Micromolar Ntp dose - dependently increased the mean open channel probability in ligand - free solution (P(O(max))) and attenuated the BC6ENTC inhibition of BC6OTHER / BC6ENTG , but had no effect on homomeric BC6OTHER channels.	CPR:4
Micromolar Ntp dose - dependently increased the mean open channel probability in ligand - free solution (P(O(max))) and attenuated the BC6ENTC inhibition of BC6OTHER / BC6OTHER , but had no effect on homomeric BC6ENTG channels.	False
Ntp and Ctp , synthetic peptides based on the BC6ENTC - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6ENTG / BC6OTHER K( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6ENTC - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6ENTG K( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6ENTC - and BC6OTHER - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6OTHER BC6ENTG .	False
Ntp and Ctp , synthetic peptides based on the BC6ENTC - and BC6OTHER - terminal sequences of BC6ENTG , respectively , were used to probe gating of BC6OTHER / BC6OTHER K( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6ENTC - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6ENTG / BC6OTHER K( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6ENTC - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6ENTG K( BC6OTHER ) channels.	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6ENTC - terminal sequences of BC6OTHER , respectively , were used to probe gating of BC6OTHER / BC6OTHER BC6ENTG .	False
Ntp and Ctp , synthetic peptides based on the BC6OTHER - and BC6ENTC - terminal sequences of BC6ENTG , respectively , were used to probe gating of BC6OTHER / BC6OTHER K( BC6OTHER ) channels.	False
Ntp opened BC6ENTG / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6ENTC and attenuated the coupling of high - affinity BC6OTHER binding with K( BC6OTHER ) pore closure.	False
Ntp opened BC6OTHER / BC6ENTG channels normally silent in the absence of stimulatory CHEM - ) BC6ENTC and attenuated the coupling of high - affinity BC6OTHER binding with K( BC6OTHER ) pore closure.	False
Ntp opened BC6OTHER / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6ENTC and attenuated the coupling of high - affinity BC6OTHER binding with BC6ENTG pore closure.	False
Ntp opened BC6ENTG / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6ENTC binding with K( BC6OTHER ) pore closure.	False
Ntp opened BC6OTHER / BC6ENTG channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6ENTC binding with K( BC6OTHER ) pore closure.	False
Ntp opened BC6OTHER / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6ENTC binding with BC6ENTG pore closure.	False
Ntp opened BC6ENTG / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6OTHER binding with BC6ENTC ( BC6OTHER ) pore closure.	False
Ntp opened BC6OTHER / BC6ENTG channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6OTHER binding with BC6ENTC ( BC6OTHER ) pore closure.	False
Ntp opened BC6ENTG / BC6OTHER channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6OTHER binding with K( BC6ENTC ) pore closure.	False
Ntp opened BC6OTHER / BC6ENTG channels normally silent in the absence of stimulatory CHEM - ) BC6OTHER and attenuated the coupling of high - affinity BC6OTHER binding with K( BC6ENTC ) pore closure.	False
These effects resemble those seen with BC6ENTC - terminal deletions (DeltaN) of BC6OTHER , and application of Ntp to BC6ENTG decreased their P(O(max)) and apparent IC(50) for BC6OTHER in the absence of BC6OTHER .	False
These effects resemble those seen with BC6ENTC - terminal deletions (DeltaN) of BC6ENTG , and application of Ntp to DeltaNK( BC6OTHER ) channels decreased their P(O(max)) and apparent IC(50) for BC6OTHER in the absence of BC6OTHER .	False
 BC6ENTG - dependent modulation of BC6ENTC channels by an BC6OTHER - terminal BC6OTHER peptide.	False
 BC6OTHER - dependent modulation of BC6ENTC channels by an BC6OTHER - terminal BC6ENTG peptide.	False
 BC6ENTG - dependent modulation of BC6OTHER by an BC6ENTC - terminal BC6OTHER peptide.	False
 BC6OTHER - dependent modulation of BC6ENTG by an BC6ENTC - terminal BC6OTHER peptide.	False
 BC6OTHER - dependent modulation of BC6OTHER by an BC6ENTC - terminal BC6ENTG peptide.	False
In the asthmatic model , AHR to BC6ENTC was demonstrated in conscious , freely moving mice in vivo and in isolated trachea in vitro 24 and 72h after BC6ENTG challenge.	False
The contractions to BC6ENTC were inhibited by BC6OTHER and BC6OTHER indicating involvement of BC6ENTG and BC6OTHER receptors , respectively.	False
The contractions to BC6ENTC were inhibited by BC6OTHER and BC6OTHER indicating involvement of BC6OTHER and BC6ENTG receptors , respectively.	False
The contractions to BC6OTHER were inhibited by BC6ENTC and BC6OTHER indicating involvement of BC6ENTG and BC6OTHER receptors , respectively.	CPR:4
The contractions to BC6OTHER were inhibited by BC6ENTC and BC6OTHER indicating involvement of BC6OTHER and BC6ENTG receptors , respectively.	False
The contractions to BC6OTHER were inhibited by BC6OTHER and BC6ENTC indicating involvement of BC6ENTG and BC6OTHER receptors , respectively.	False
The contractions to BC6OTHER were inhibited by BC6OTHER and BC6ENTC indicating involvement of BC6OTHER and BC6ENTG receptors , respectively.	CPR:4
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6ENTG and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6ENTC , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	False
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6ENTG activator , BC6ENTC , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	CPR:3
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6ENTC , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6ENTG content were attenuated through improved redox balance.	False
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6ENTG and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6OTHER , and the results showed that BC6ENTC - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	False
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6ENTG activator , BC6OTHER , and the results showed that BC6ENTC - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	False
To confirm this novel mechanism of BC6OTHER - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6OTHER , and the results showed that BC6ENTC - induced fibroblast proliferation and BC6ENTG content were attenuated through improved redox balance.	False
Treatment of C57 BL / 6 mice with BC6ENTC increased fibroblast viability and BC6ENTG production and significantly downregulated BC6OTHER .	False
Treatment of C57 BL / 6 mice with BC6ENTC increased fibroblast viability and BC6OTHER production and significantly downregulated BC6ENTG .	CPR:4
In addition , prominent oxidative stress was indicated by changes in BC6ENTC dismutase , BC6ENTG activity , and BC6OTHER and BC6OTHER - reactive substance levels.	False
In addition , prominent oxidative stress was indicated by changes in BC6ENTG , BC6OTHER activity , and BC6ENTC and BC6OTHER - reactive substance levels.	False
In addition , prominent oxidative stress was indicated by changes in BC6OTHER , BC6ENTG activity , and BC6ENTC and BC6OTHER - reactive substance levels.	False
In addition , prominent oxidative stress was indicated by changes in BC6ENTG , BC6OTHER activity , and BC6OTHER and BC6ENTC - reactive substance levels.	False
In addition , prominent oxidative stress was indicated by changes in BC6OTHER , BC6ENTG activity , and BC6OTHER and BC6ENTC - reactive substance levels.	False
In a cell - based model , BC6ENTC suppressed BC6ENTG activation via BC6OTHER phosphorylation , enhancing intracellular reactive BC6OTHER species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.	CPR:4
In a cell - based model , BC6ENTC suppressed BC6OTHER activation via BC6ENTG phosphorylation , enhancing intracellular reactive BC6OTHER species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.	CPR:3
In a cell - based model , BC6OTHER suppressed BC6ENTG activation via BC6OTHER phosphorylation , enhancing intracellular reactive BC6ENTC species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.	False
In a cell - based model , BC6OTHER suppressed BC6OTHER activation via BC6ENTG phosphorylation , enhancing intracellular reactive BC6ENTC species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.	False
To confirm this novel mechanism of BC6ENTC - induced fibrogenesis , we attempted to upregulate BC6ENTG and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6OTHER , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	CPR:3
To confirm this novel mechanism of BC6ENTC - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6ENTG activator , BC6OTHER , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6OTHER content were attenuated through improved redox balance.	False
To confirm this novel mechanism of BC6ENTC - induced fibrogenesis , we attempted to upregulate BC6OTHER and related antioxidant proteins in CHEM - treated fibroblasts using a putative BC6OTHER activator , BC6OTHER , and the results showed that BC6OTHER - induced fibroblast proliferation and BC6ENTG content were attenuated through improved redox balance.	False
Suppression of BC6ENTG via BC6OTHER contributes to BC6ENTC - induced oxidative stress and fibrogenesis.	False
Suppression of BC6OTHER via BC6ENTG contributes to BC6ENTC - induced oxidative stress and fibrogenesis.	False
The present study was designed to test the hypothesis that BC6ENTC alters global DNA methylation , and modulates expression of the BC6ENTG ( BC6OTHER ) and various CHEM BC6OTHER .	False
The present study was designed to test the hypothesis that BC6ENTC alters global DNA methylation , and modulates expression of the BC6OTHER ( BC6ENTG ) and various CHEM BC6OTHER .	False
The present study was designed to test the hypothesis that BC6ENTC alters global DNA methylation , and modulates expression of the BC6OTHER ( BC6OTHER ) and various CHEM BC6ENTG .	False
The present study was designed to test the hypothesis that BC6OTHER alters global DNA methylation , and modulates expression of the BC6ENTG ( BC6OTHER ) and various BC6ENTC - binding proteins.	False
The present study was designed to test the hypothesis that BC6OTHER alters global DNA methylation , and modulates expression of the BC6OTHER ( BC6ENTG ) and various BC6ENTC - binding proteins.	False
In addition , BC6ENTC induced degradation of BC6ENTG ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6ENTG 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6ENTG , and BC6OTHER ) , as well as the BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6ENTG ) , as well as the BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6ENTC induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) , in MEF cells by the proteasomal pathway.	CPR:4
In addition , BC6OTHER induced degradation of BC6ENTG ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6ENTG 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6OTHER 1 , BC6ENTG , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6ENTG ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6ENTG , BC6OTHER and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6ENTG and BC6OTHER ) , in MEF cells by the proteasomal pathway.	False
In addition , BC6OTHER induced degradation of BC6OTHER ( BC6OTHER 1 , BC6OTHER , and BC6OTHER ) , as well as the BC6ENTC - binding proteins ( BC6OTHER , BC6OTHER and BC6ENTG ) , in MEF cells by the proteasomal pathway.	False
 BC6ENTC modulates expression of BC6ENTG and CHEM - / BC6OTHER domain - binding proteins in murine embryonic fibroblasts.	False
 BC6ENTC modulates expression of BC6OTHER and BC6ENTG in murine embryonic fibroblasts.	False
 BC6OTHER modulates expression of BC6ENTG and BC6ENTC - / BC6OTHER domain - binding proteins in murine embryonic fibroblasts.	False
 BC6OTHER modulates expression of BC6ENTG and CHEM - / BC6ENTC domain - binding proteins in murine embryonic fibroblasts.	False
In vitro BC6ENTG release studies were performed in BC6ENTC buffer pH 7.4 and also in BC6OTHER pH 2 with and without BC6OTHER .	False
In vitro BC6OTHER release studies were performed in BC6ENTC buffer pH 7.4 and also in BC6OTHER pH 2 with and without BC6ENTG .	False
In vitro BC6ENTG release studies were performed in BC6OTHER buffer pH 7.4 and also in BC6ENTC pH 2 with and without BC6OTHER .	False
In vitro BC6OTHER release studies were performed in BC6OTHER buffer pH 7.4 and also in BC6ENTC pH 2 with and without BC6ENTG .	False
BC6ENTC ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:9
BC6ENTC ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:9
BC6ENTC ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:9
BC6ENTC ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
Furthermore , BC6ENTG ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTG ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTG gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the primary receptor for BC6ENTC , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTG , are increased in secretagogue BC6ENTC - treated acinar cells.	False
Furthermore , BC6ENTG ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6ENTG ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTG gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6ENTC - treated acinar cells.	CPR:3
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6ENTG ) and BC6ENTC - beta - synthase ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6OTHER ) and BC6ENTC - beta - synthase ( BC6ENTG ).	False
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6ENTG ( BC6OTHER ) and BC6ENTC - beta - synthase ( BC6OTHER ).	False
Inhibition of endogenous production of BC6ENTC by BC6OTHER significantly suppressed BC6ENTG concentration , BC6OTHER expression and BC6OTHER expression in the acini.	CPR:4
Inhibition of endogenous production of BC6ENTC by BC6OTHER significantly suppressed BC6OTHER concentration , BC6ENTG expression and BC6OTHER expression in the acini.	CPR:4
Inhibition of endogenous production of BC6ENTC by BC6OTHER significantly suppressed BC6OTHER concentration , BC6OTHER expression and BC6ENTG expression in the acini.	CPR:4
Inhibition of endogenous production of BC6OTHER by BC6ENTC significantly suppressed BC6ENTG concentration , BC6OTHER expression and BC6OTHER expression in the acini.	False
Inhibition of endogenous production of BC6OTHER by BC6ENTC significantly suppressed BC6OTHER concentration , BC6ENTG expression and BC6OTHER expression in the acini.	False
Inhibition of endogenous production of BC6OTHER by BC6ENTC significantly suppressed BC6OTHER concentration , BC6OTHER expression and BC6ENTG expression in the acini.	False
Inhibition of endogenous production of BC6OTHER by BC6OTHER significantly suppressed BC6ENTC concentration , BC6ENTG expression and BC6OTHER expression in the acini.	False
Inhibition of endogenous production of BC6OTHER by BC6OTHER significantly suppressed BC6ENTC concentration , BC6OTHER expression and BC6ENTG expression in the acini.	False
To determine whether BC6ENTC itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTG concentration and expression of BC6OTHER and BC6OTHER in acinar cells.	False
To determine whether BC6ENTC itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6ENTG and BC6OTHER in acinar cells.	False
To determine whether BC6ENTC itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6OTHER and BC6ENTG in acinar cells.	False
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6ENTC donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTG concentration and expression of BC6OTHER and BC6OTHER in acinar cells.	False
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6ENTC donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6ENTG and BC6OTHER in acinar cells.	False
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6ENTC donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6OTHER and BC6ENTG in acinar cells.	False
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6ENTC ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTG concentration and expression of BC6OTHER and BC6OTHER in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6ENTC ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6ENTG and BC6OTHER in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6ENTC ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6OTHER and BC6ENTG in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6ENTC ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTG concentration and expression of BC6OTHER and BC6OTHER in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6ENTC ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6ENTG and BC6OTHER in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6ENTC ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6OTHER concentration and expression of BC6OTHER and BC6ENTG in acinar cells.	CPR:3
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTC concentration and expression of BC6ENTG and BC6OTHER in acinar cells.	False
To determine whether BC6OTHER itself provoked inflammation in acinar cells , the cells were treated with BC6OTHER donor drug , BC6OTHER ( BC6OTHER ) , (10 , 50 and 100 muM) , that resulted in a significant increase in BC6ENTC concentration and expression of BC6OTHER and BC6ENTG in acinar cells.	False
These results suggest that the pro - inflammatory effect of BC6ENTC may be mediated by BC6ENTG - BC6OTHER related pathway in mouse pancreatic acinar cells.	CPR:9
These results suggest that the pro - inflammatory effect of BC6ENTC may be mediated by BC6OTHER - BC6ENTG related pathway in mouse pancreatic acinar cells.	CPR:9
BC6OTHER ( BC6ENTC ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6ENTC ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6ENTC ) is synthesized from BC6OTHER via the action of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6ENTC ) is synthesized from BC6OTHER via the action of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
In this study , we investigated the presence of BC6ENTC and the expression of BC6OTHER synthesizing enzymes , BC6ENTG and BC6OTHER , in isolated mouse pancreatic acini.	False
In this study , we investigated the presence of BC6ENTC and the expression of BC6OTHER synthesizing enzymes , BC6OTHER and BC6ENTG , in isolated mouse pancreatic acini.	False
In this study , we investigated the presence of BC6OTHER and the expression of BC6ENTC synthesizing enzymes , BC6ENTG and BC6OTHER , in isolated mouse pancreatic acini.	CPR:9
In this study , we investigated the presence of BC6OTHER and the expression of BC6ENTC synthesizing enzymes , BC6OTHER and BC6ENTG , in isolated mouse pancreatic acini.	CPR:9
BC6OTHER ( BC6OTHER ) is synthesized from BC6ENTC via the action of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) is synthesized from BC6ENTC via the action of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) is synthesized from BC6ENTC via the action of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6OTHER ) is synthesized from BC6ENTC via the action of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
BC6ENTC increased the levels of BC6OTHER and BC6ENTG mRNA expression while BC6OTHER mRNA expression was decreased.	CPR:3
BC6ENTC increased the levels of BC6OTHER and BC6OTHER mRNA expression while BC6ENTG mRNA expression was decreased.	CPR:4
BC6OTHER increased the levels of BC6ENTC and BC6ENTG mRNA expression while BC6OTHER mRNA expression was decreased.	False
BC6OTHER increased the levels of BC6ENTC and BC6OTHER mRNA expression while BC6ENTG mRNA expression was decreased.	False
In addition , cells pre - treated with BC6ENTC ( BC6OTHER , 3 mM) , a BC6ENTG inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6OTHER may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	CPR:4
In addition , cells pre - treated with BC6ENTC ( BC6OTHER , 3 mM) , a BC6OTHER inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6ENTG may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6ENTC , 3 mM) , a BC6ENTG inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6OTHER may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	CPR:4
In addition , cells pre - treated with BC6OTHER ( BC6ENTC , 3 mM) , a BC6OTHER inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6ENTG may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6ENTG inhibitor , reduced the formation of BC6ENTC in BC6OTHER treated cells , suggesting that BC6OTHER may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6OTHER inhibitor , reduced the formation of BC6ENTC in BC6OTHER treated cells , suggesting that BC6ENTG may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6ENTG inhibitor , reduced the formation of BC6OTHER in BC6ENTC treated cells , suggesting that BC6OTHER may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6OTHER inhibitor , reduced the formation of BC6OTHER in BC6ENTC treated cells , suggesting that BC6ENTG may be the main enzyme involved in BC6OTHER formation in mouse acinar cells.	False
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6ENTC - gamma - lyase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6ENTC - gamma - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) is synthesized from BC6OTHER via the action of BC6ENTC - gamma - lyase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6ENTG inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6OTHER may be the main enzyme involved in BC6ENTC formation in mouse acinar cells.	False
In addition , cells pre - treated with BC6OTHER ( BC6OTHER , 3 mM) , a BC6OTHER inhibitor , reduced the formation of BC6OTHER in BC6OTHER treated cells , suggesting that BC6ENTG may be the main enzyme involved in BC6ENTC formation in mouse acinar cells.	CPR:9
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTG , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6ENTG ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6ENTG gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTC ( BC6OTHER ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTG , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTG ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6ENTG gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTC ) concentration in the acini and expression of BC6OTHER gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6ENTG , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6ENTG ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6ENTG ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6ENTG , BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
Furthermore , BC6OTHER ( BC6OTHER ) concentration in the acini and expression of BC6ENTC gene ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the primary receptor for BC6OTHER , are increased in secretagogue BC6OTHER - treated acinar cells.	False
BC6ENTC is a selective BC6ENTG blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.	CPR:4
BC6ENTC is a breakthrough in the therapy of hyponatremia as it directly combats elevated BC6ENTG levels associated with the syndrome of inappropriate secretion of BC6OTHER , congestive heart failure , and cirrhosis of the liver.	False
BC6ENTC is a breakthrough in the therapy of hyponatremia as it directly combats elevated BC6OTHER levels associated with the syndrome of inappropriate secretion of BC6ENTG , congestive heart failure , and cirrhosis of the liver.	False
BC6OTHER is a breakthrough in the therapy of hyponatremia as it directly combats elevated BC6ENTC levels associated with the syndrome of inappropriate secretion of BC6ENTG , congestive heart failure , and cirrhosis of the liver.	False
Prolonged use of BC6ENTC leads to increased endogenous levels of BC6ENTG and perhaps over - stimulation of BC6OTHER .	CPR:3
Prolonged use of BC6ENTC leads to increased endogenous levels of BC6OTHER and perhaps over - stimulation of BC6ENTG .	CPR:3
Prolonged use of BC6OTHER leads to increased endogenous levels of BC6ENTC and perhaps over - stimulation of BC6ENTG .	False
In addition , BC6ENTC is metabolized by the BC6ENTG system; thus physicians should be aware of the potential for increased interactions with other medications.	CPR:9
An investigation is detailed of the structure activity relationships (SAR) of two BC6OTHER side chains of compound ( - ) - 1a ( BC6ENTC ) , a potent , BC6ENTG - selective BC6OTHER inhibitor and clinical candidate for the treatment of Alzheimer's disease.	CPR:4
An investigation is detailed of the structure activity relationships (SAR) of two BC6OTHER side chains of compound ( - ) - 1a ( BC6ENTC ) , a potent , BC6OTHER - selective BC6ENTG inhibitor and clinical candidate for the treatment of Alzheimer's disease.	CPR:4
An investigation is detailed of the structure activity relationships (SAR) of two BC6ENTC side chains of compound ( - ) - 1a ( BC6OTHER ) , a potent , BC6ENTG - selective BC6OTHER inhibitor and clinical candidate for the treatment of Alzheimer's disease.	False
An investigation is detailed of the structure activity relationships (SAR) of two BC6ENTC side chains of compound ( - ) - 1a ( BC6OTHER ) , a potent , BC6OTHER - selective BC6ENTG inhibitor and clinical candidate for the treatment of Alzheimer's disease.	False
Structure activity relationship studies of BC6ENTC BC6ENTG inhibitors.	CPR:4
BC6ENTC and nonsteroidal BC6ENTG ( BC6OTHER ) agonists have been synthesized as well , although the latter are still in a very early stage of development.	False
BC6ENTC and nonsteroidal BC6OTHER ( BC6ENTG ) agonists have been synthesized as well , although the latter are still in a very early stage of development.	False
BC6OTHER and nonsteroidal BC6ENTC receptor ( BC6ENTG ) agonists have been synthesized as well , although the latter are still in a very early stage of development.	False
BC6ENTC was effective in blocking these sympathomimetic actions of BC6OTHER even in all 7 subjects who were homozygous for the CHEM polymorphism in the BC6ENTG , a loss - of - function mutation that is highly enriched in blacks.	False
BC6OTHER was effective in blocking these sympathomimetic actions of BC6ENTC even in all 7 subjects who were homozygous for the CHEM polymorphism in the BC6ENTG , a loss - of - function mutation that is highly enriched in blacks.	False
CONCLUSIONS: The data advance the novel hypothesis that central sympatholysis with BC6ENTC constitutes a highly effective countermeasure for CHEM's sympathomimetic actions on the human cardiovascular system , even in individuals carrying the BC6ENTG Del322 - 325 polymorphism.	False
OBJECTIVES: The aim of this study was to determine whether CHEM's sympathomimetic actions can be reversed by a potent centrally acting BC6ENTG ( BC6OTHER ) agonist ( BC6ENTC ).	CPR:5
OBJECTIVES: The aim of this study was to determine whether CHEM's sympathomimetic actions can be reversed by a potent centrally acting BC6OTHER ( BC6ENTG ) agonist ( BC6ENTC ).	CPR:5
BC6OTHER - stimulated phosphorylation of BC6OTHER and BC6OTHER is blocked by pretreatment with BC6ENTC , a selective BC6ENTG inhibitor.	CPR:4
BC6ENTG - stimulated phosphorylation of BC6OTHER and BC6OTHER is blocked by pretreatment with BC6ENTC , a selective BC6OTHER inhibitor.	CPR:4
BC6OTHER - stimulated phosphorylation of BC6ENTG and BC6OTHER is blocked by pretreatment with BC6ENTC , a selective BC6OTHER inhibitor.	CPR:4
BC6OTHER - stimulated phosphorylation of BC6OTHER and BC6ENTG is blocked by pretreatment with BC6ENTC , a selective BC6OTHER inhibitor.	CPR:4
Similarly , pretreatment with BC6ENTC blocks the ability of BC6ENTG to induce BC6OTHER and BC6OTHER phosphorylation , but also down - regulates total BC6OTHER but not BC6OTHER protein levels.	CPR:4
Similarly , pretreatment with BC6ENTC blocks the ability of BC6OTHER to induce BC6ENTG and BC6OTHER phosphorylation , but also down - regulates total BC6OTHER but not BC6OTHER protein levels.	False
Similarly , pretreatment with BC6ENTC blocks the ability of BC6OTHER to induce BC6OTHER and BC6ENTG phosphorylation , but also down - regulates total BC6OTHER but not BC6OTHER protein levels.	CPR:4
Similarly , pretreatment with BC6ENTC blocks the ability of BC6OTHER to induce BC6OTHER and BC6OTHER phosphorylation , but also down - regulates total BC6ENTG but not BC6OTHER protein levels.	CPR:4
Similarly , pretreatment with BC6ENTC blocks the ability of BC6OTHER to induce BC6OTHER and BC6OTHER phosphorylation , but also down - regulates total BC6OTHER but not BC6ENTG protein levels.	False
The ability of BC6ENTC to block BC6ENTG signaling by the BC6OTHER may account for at least part of its potent growth - inhibitory effects against cancer cells.	CPR:4
The ability of BC6ENTC to block BC6OTHER signaling by the BC6ENTG may account for at least part of its potent growth - inhibitory effects against cancer cells.	CPR:4
BC6ENTC and selective BC6ENTG inhibitors cause regression of colonic polyps in familial polyposis patients.	CPR:4
 BC6ENTC induces apoptotic cell death in cancer cells in vitro and in vivo. In tumor cells , activation of BC6ENTG results in phosphorylation of several BC6OTHER effectors , including the proapoptotic protein BC6OTHER .	False
 BC6ENTC induces apoptotic cell death in cancer cells in vitro and in vivo. In tumor cells , activation of BC6OTHER results in phosphorylation of several BC6ENTG effectors , including the proapoptotic protein BC6OTHER .	False
 BC6ENTC induces apoptotic cell death in cancer cells in vitro and in vivo. In tumor cells , activation of BC6OTHER results in phosphorylation of several BC6OTHER effectors , including the proapoptotic protein BC6ENTG .	False
Phosphorylation of BC6ENTC 112 by BC6ENTG inactivates BC6OTHER and protects the tumor cell from apoptosis.	False
Phosphorylation of BC6ENTC 112 by BC6OTHER inactivates BC6ENTG and protects the tumor cell from apoptosis.	False
BC6ENTC metabolites and other nonsteroidal anti - inflammatory drugs selectively inhibit BC6ENTG phosphorylation in human colon cancer cells.	CPR:4
 BC6ENTC inhibits BC6OTHER - induced phosphorylation of BC6OTHER and BC6ENTG in human colon cancer cells.	CPR:4
 BC6ENTC inhibits BC6ENTG - induced phosphorylation of BC6OTHER and BC6OTHER in human colon cancer cells.	CPR:4
 BC6ENTC inhibits BC6OTHER - induced phosphorylation of BC6ENTG and BC6OTHER in human colon cancer cells.	False
The results show that the decrease in LPS - induced BC6ENTC and pro - inflammatory BC6ENTG in RAW 264.7 macrophages through BC6OTHER induction was greater for FRGE compared with HRGE.	False
The results show that the decrease in LPS - induced BC6ENTC and pro - inflammatory BC6OTHER in RAW 264.7 macrophages through BC6ENTG induction was greater for FRGE compared with HRGE.	False
Treatment with FRGE and HRGE significantly reduced the LPS - induced increase in the pro - inflammatory BC6ENTG concentration ( BC6OTHER , BC6OTHER , and BC6OTHER ) and BC6ENTC through BC6OTHER upregulation in RAW 264.7 macrophages.	False
Treatment with FRGE and HRGE significantly reduced the LPS - induced increase in the pro - inflammatory BC6OTHER concentration ( BC6ENTG , BC6OTHER , and BC6OTHER ) and BC6ENTC through BC6OTHER upregulation in RAW 264.7 macrophages.	False
Treatment with FRGE and HRGE significantly reduced the LPS - induced increase in the pro - inflammatory BC6OTHER concentration ( BC6OTHER , BC6ENTG , and BC6OTHER ) and BC6ENTC through BC6OTHER upregulation in RAW 264.7 macrophages.	False
Treatment with FRGE and HRGE significantly reduced the LPS - induced increase in the pro - inflammatory BC6OTHER concentration ( BC6OTHER , BC6OTHER , and BC6ENTG ) and BC6ENTC through BC6OTHER upregulation in RAW 264.7 macrophages.	False
Treatment with FRGE and HRGE significantly reduced the LPS - induced increase in the pro - inflammatory BC6OTHER concentration ( BC6OTHER , BC6OTHER , and BC6OTHER ) and BC6ENTC through BC6ENTG upregulation in RAW 264.7 macrophages.	False
BC6ENTC treatment showed reduced production of pro - inflammatory BC6ENTG and BC6OTHER and increased BC6OTHER activity.	CPR:4
BC6ENTC treatment showed reduced production of pro - inflammatory BC6OTHER and BC6OTHER and increased BC6ENTG activity.	CPR:3
BC6OTHER treatment showed reduced production of pro - inflammatory BC6ENTG and BC6ENTC and increased BC6OTHER activity.	False
BC6OTHER treatment showed reduced production of pro - inflammatory BC6OTHER and BC6ENTC and increased BC6ENTG activity.	False
Short - term heating reduces the anti - inflammatory effects of fresh raw garlic extracts on the LPS - induced production of BC6ENTC and pro - inflammatory BC6ENTG by downregulating BC6OTHER activity in RAW 264.7 macrophages.	False
Short - term heating reduces the anti - inflammatory effects of fresh raw garlic extracts on the LPS - induced production of BC6OTHER and pro - inflammatory BC6ENTG by downregulating BC6ENTC activity in RAW 264.7 macrophages.	False
BC6ENTC is a peripheral opiate agonist able to inhibit BC6ENTG secretion.	CPR:4
BC6ENTG caused a rise in plasma BC6OTHER after both BC6OTHER (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6OTHER secretion was significantly lower after BC6ENTC .	False
BC6OTHER caused a rise in plasma BC6ENTG after both BC6OTHER (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6OTHER secretion was significantly lower after BC6ENTC .	False
BC6OTHER caused a rise in plasma BC6OTHER after both BC6OTHER (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6ENTG - induced BC6OTHER secretion was significantly lower after BC6ENTC .	CPR:4
BC6OTHER caused a rise in plasma BC6OTHER after both BC6OTHER (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6ENTG secretion was significantly lower after BC6ENTC .	CPR:4
These data demonstrate that BC6ENTC differently modifies the stimulatory action of BC6ENTG and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6ENTC differently modifies the stimulatory action of BC6OTHER and BC6ENTG on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6ENTC differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6ENTG secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6ENTC differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6ENTG and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6ENTC differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6ENTG and BC6OTHER interact in a non additive way.	False
In this work , the interactions between BC6ENTC and two BC6ENTG secretagogues , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6ENTC and two BC6OTHER secretagogues , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6ENTC and two BC6OTHER secretagogues , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6ENTC and two BC6OTHER secretagogues , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6ENTC and two BC6OTHER secretagogues , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , were investigated in patients with Addison's disease.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTC and BC6ENTG on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTC and BC6OTHER on BC6ENTG secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTC and BC6OTHER on BC6OTHER secretion: namely , BC6ENTG and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTC and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6ENTG and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTG and BC6OTHER on BC6OTHER secretion: namely , BC6ENTC and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6ENTG on BC6OTHER secretion: namely , BC6ENTC and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6ENTG secretion: namely , BC6ENTC and BC6OTHER act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6ENTC and BC6OTHER act in an additive manner , while BC6ENTG and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTG and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6ENTC act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6ENTG on BC6OTHER secretion: namely , BC6OTHER and BC6ENTC act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6ENTG secretion: namely , BC6OTHER and BC6ENTC act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6ENTG and BC6ENTC act in an additive manner , while BC6OTHER and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6ENTC act in an additive manner , while BC6ENTG and BC6OTHER interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6ENTG and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6ENTC interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6ENTG on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6ENTC interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6ENTG secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6OTHER and BC6ENTC interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6ENTG and BC6OTHER act in an additive manner , while BC6OTHER and BC6ENTC interact in a non additive way.	False
These data demonstrate that BC6OTHER differently modifies the stimulatory action of BC6OTHER and BC6OTHER on BC6OTHER secretion: namely , BC6OTHER and BC6OTHER act in an additive manner , while BC6ENTG and BC6ENTC interact in a non additive way.	False
Although these findings might be explained by the involvement of different intracellular BC6ENTG - secreting mechanisms , an influence of BC6ENTC on some suprapituitary factors modulating the BC6OTHER response is suggested.	False
Although these findings might be explained by the involvement of different intracellular BC6OTHER - secreting mechanisms , an influence of BC6ENTC on some suprapituitary factors modulating the BC6ENTG response is suggested.	False
In this work , the interactions between BC6OTHER and two BC6ENTG secretagogues , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6ENTC ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6ENTG secretagogues , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6ENTG ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) , were investigated in patients with Addison's disease.	False
In this work , the interactions between BC6OTHER and two BC6OTHER secretagogues , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) , were investigated in patients with Addison's disease.	False
 After BC6ENTC (16 mg orally) or placebo administration , 5 patients received BC6ENTG (0.06 IU / kg i.v. over 1 h) and 6 patients received BC6OTHER (1 micrograms / kg i.v. as bolus).	False
 After BC6ENTC (16 mg orally) or placebo administration , 5 patients received BC6OTHER (0.06 IU / kg i.v. over 1 h) and 6 patients received BC6ENTG (1 micrograms / kg i.v. as bolus).	False
 After BC6OTHER (16 mg orally) or placebo administration , 5 patients received BC6ENTC (0.06 IU / kg i.v. over 1 h) and 6 patients received BC6ENTG (1 micrograms / kg i.v. as bolus).	False
In all patients BC6ENTC induced a significant fall in plasma BC6ENTG levels.	CPR:4
BC6ENTC increased BC6ENTG levels after both BC6OTHER (from 48 + / - 17.3 to a peak of 95 + / - 21 pmol / l) and placebo (from 231 + / - 59.5 to 365 + / - 86.6 pmol / l): the interaction between treatments and time was not significant.	False
BC6ENTG increased BC6OTHER levels after both BC6ENTC (from 48 + / - 17.3 to a peak of 95 + / - 21 pmol / l) and placebo (from 231 + / - 59.5 to 365 + / - 86.6 pmol / l): the interaction between treatments and time was not significant.	False
BC6OTHER increased BC6ENTG levels after both BC6ENTC (from 48 + / - 17.3 to a peak of 95 + / - 21 pmol / l) and placebo (from 231 + / - 59.5 to 365 + / - 86.6 pmol / l): the interaction between treatments and time was not significant.	False
BC6ENTG caused a rise in plasma BC6OTHER after both BC6ENTC (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6OTHER secretion was significantly lower after BC6OTHER .	False
BC6OTHER caused a rise in plasma BC6ENTG after both BC6ENTC (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6OTHER secretion was significantly lower after BC6OTHER .	False
BC6OTHER caused a rise in plasma BC6OTHER after both BC6ENTC (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6ENTG - induced BC6OTHER secretion was significantly lower after BC6OTHER .	False
BC6OTHER caused a rise in plasma BC6OTHER after both BC6ENTC (from 30 + / - 16.6 to a peak of 108 + / - 31 pmol / l) and placebo (from 98.5 + / - 47 to 211 + / - 61.7 pmol / l): the interaction between treatments and time was significant , and the first phase of BC6OTHER - induced BC6ENTG secretion was significantly lower after BC6OTHER .	False
 BC6ENTC , an opiate analog , differently modifies the BC6OTHER responses to BC6OTHER and BC6ENTG in patients with Addison's disease.	False
 BC6ENTC , an opiate analog , differently modifies the BC6ENTG responses to BC6OTHER and BC6OTHER in patients with Addison's disease.	False
 BC6ENTC , an opiate analog , differently modifies the BC6OTHER responses to BC6ENTG and BC6OTHER in patients with Addison's disease.	False
 BC6OTHER , an opiate analog , differently modifies the BC6ENTG responses to BC6OTHER and BC6ENTC in patients with Addison's disease.	False
 BC6OTHER , an opiate analog , differently modifies the BC6OTHER responses to BC6ENTG and BC6ENTC in patients with Addison's disease.	False
Doses of BC6ENTC (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6OTHER ) and the BC6OTHER antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6ENTC (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6OTHER antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6ENTC (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6OTHER ) and the BC6OTHER antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6ENTC (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6OTHER antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6ENTC were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6OTHER ) and the BC6OTHER antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6ENTC were administered in combination with the BC6OTHER antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTC D1 receptor antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6ENTC ( BC6OTHER ) and the BC6OTHER antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	CPR:6
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6OTHER antagonist BC6ENTC ( BC6OTHER ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6ENTC ) and the BC6OTHER antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	CPR:6
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6OTHER antagonist BC6OTHER ( BC6ENTC ) and the BC6ENTG antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTC D2 receptor antagonist BC6OTHER (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6ENTG antagonist BC6OTHER ( BC6OTHER ) and the BC6OTHER antagonist BC6ENTC (both at 0.003 - 0.03 mg / kg).	False
Doses of BC6OTHER (1.7 mg / kg) and BC6OTHER (0.3 mg / kg) which produced full (> 80%) substitution for BC6OTHER were administered in combination with the BC6OTHER antagonist BC6OTHER ( BC6OTHER ) and the BC6ENTG antagonist BC6ENTC (both at 0.003 - 0.03 mg / kg).	CPR:6
The pharmacologic properties of BC6ENTC - including high lipophilicity , high selectivity and affinity for the BC6ENTG , low systemic absorption , and rapid metabolism and clearance - combine to give BC6OTHER a high therapeutic index.	False
The pharmacologic properties of BC6OTHER - including high lipophilicity , high selectivity and affinity for the BC6ENTG , low systemic absorption , and rapid metabolism and clearance - combine to give BC6ENTC a high therapeutic index.	False
BC6ENTG ( BC6OTHER ) are newly described BC6ENTC - rich proteins that share significant aminoterminal structural similarity with the conventional BC6OTHER and are involved in a diversity of biological functions , including growth regulation.	False
BC6OTHER ( BC6OTHER ) are newly described BC6ENTC - rich proteins that share significant aminoterminal structural similarity with the conventional BC6ENTG and are involved in a diversity of biological functions , including growth regulation.	False
BC6OTHER ( BC6ENTG ) are newly described BC6ENTC - rich proteins that share significant aminoterminal structural similarity with the conventional BC6OTHER and are involved in a diversity of biological functions , including growth regulation.	False
Moreover , BC6ENTG noticeably increased in response to BC6OTHER and BC6ENTC ( BC6OTHER ) in HPEC and PC - 3 cells , and it decreased in response to BC6OTHER in HPEC.	CPR:3
Moreover , BC6OTHER noticeably increased in response to BC6ENTG and BC6ENTC ( BC6OTHER ) in HPEC and PC - 3 cells , and it decreased in response to BC6OTHER in HPEC.	False
Moreover , BC6OTHER noticeably increased in response to BC6OTHER and BC6ENTC ( BC6OTHER ) in HPEC and PC - 3 cells , and it decreased in response to BC6ENTG in HPEC.	False
Moreover , BC6ENTG noticeably increased in response to BC6OTHER and BC6OTHER ( BC6ENTC ) in HPEC and PC - 3 cells , and it decreased in response to BC6OTHER in HPEC.	CPR:3
Moreover , BC6OTHER noticeably increased in response to BC6ENTG and BC6OTHER ( BC6ENTC ) in HPEC and PC - 3 cells , and it decreased in response to BC6OTHER in HPEC.	False
Moreover , BC6OTHER noticeably increased in response to BC6OTHER and BC6OTHER ( BC6ENTC ) in HPEC and PC - 3 cells , and it decreased in response to BC6ENTG in HPEC.	False
Although the data collected on BC6ENTG in prostate are modest , its role as a growth stimulator and / or protooncogene is supported by its preferential expression in cancerous cells and its down - regulation by BC6ENTC .	CPR:4
BC6ENTG ( BC6OTHER / BC6OTHER / BC6ENTC - stimulating factor) is a potential tumor - suppressor gene that is differentially expressed in meningiomas , mammary and prostatic cancers , compared with their malignant counterparts.	False
BC6OTHER ( BC6ENTG / BC6OTHER / BC6ENTC - stimulating factor) is a potential tumor - suppressor gene that is differentially expressed in meningiomas , mammary and prostatic cancers , compared with their malignant counterparts.	False
BC6OTHER ( BC6OTHER / BC6ENTG / BC6ENTC - stimulating factor) is a potential tumor - suppressor gene that is differentially expressed in meningiomas , mammary and prostatic cancers , compared with their malignant counterparts.	False
Interestingly , the increases in BC6ENTG and BC6OTHER levels , and BC6ENTC - O - deethylase , BC6OTHER , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6ENTG levels , and BC6ENTC - O - deethylase , BC6OTHER , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6ENTC - O - deethylase , BC6ENTG , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6ENTC - O - deethylase , BC6OTHER , and BC6ENTG activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6ENTG and BC6OTHER levels , and BC6OTHER , CHEM - depentylase , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6ENTG levels , and BC6OTHER , CHEM - depentylase , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6ENTG , CHEM - depentylase , and BC6OTHER activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6OTHER , CHEM - depentylase , and BC6ENTG activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6ENTG and BC6OTHER levels , and BC6OTHER , BC6OTHER , and BC6ENTC 6 - hydroxylase activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6ENTG levels , and BC6OTHER , BC6OTHER , and BC6ENTC 6 - hydroxylase activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6ENTG , BC6OTHER , and BC6ENTC 6 - hydroxylase activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Interestingly , the increases in BC6OTHER and BC6OTHER levels , and BC6OTHER , BC6ENTG , and BC6ENTC 6 - hydroxylase activities were attenuated by fermentation of GGT extract using Lactobacillus plantarum KFRI 402 , but not 144.	False
Hepatic activities of BC6ENTC - BC6OTHER - deethylase , BC6ENTG , and BC6OTHER , but not BC6OTHER were also elevated.	False
Hepatic activities of BC6ENTC - BC6OTHER - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6ENTG , but not BC6OTHER were also elevated.	False
Hepatic activities of BC6ENTC - BC6OTHER - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6OTHER , but not BC6ENTG were also elevated.	False
Hepatic activities of 7 - CHEM - BC6ENTC - deethylase , BC6ENTG , and BC6OTHER , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6ENTC - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6ENTG , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6ENTC - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6OTHER , but not BC6ENTG were also elevated.	False
Hepatic activities of BC6ENTG , BC6ENTC - BC6OTHER - depentylase , and BC6OTHER , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , BC6ENTC - BC6OTHER - depentylase , and BC6ENTG , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , BC6ENTC - BC6OTHER - depentylase , and BC6OTHER , but not BC6ENTG were also elevated.	False
Hepatic activities of BC6ENTG , 7 - CHEM - BC6ENTC - depentylase , and BC6OTHER , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , 7 - CHEM - BC6ENTC - depentylase , and BC6ENTG , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , 7 - CHEM - BC6ENTC - depentylase , and BC6OTHER , but not BC6ENTG were also elevated.	False
Hepatic activities of BC6ENTG , 7 - CHEM - BC6OTHER - depentylase , and BC6ENTC 6 - hydroxylase , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , BC6ENTG , and BC6ENTC 6 - hydroxylase , but not BC6OTHER were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6ENTC 6 - hydroxylase , but not BC6ENTG were also elevated.	False
Hepatic activities of BC6ENTG , 7 - CHEM - BC6OTHER - depentylase , and BC6OTHER , but not BC6ENTC hydroxylase were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , BC6ENTG , and BC6OTHER , but not BC6ENTC hydroxylase were also elevated.	False
Hepatic activities of 7 - CHEM - BC6OTHER - deethylase , 7 - CHEM - BC6OTHER - depentylase , and BC6ENTG , but not BC6ENTC hydroxylase were also elevated.	False
In summary , distinct and specific affinities of heparan BC6ENTC for different BC6ENTG were identified that may affect growth factor activation and local distribution.	False
BC6ENTG signal through transmembrane receptor BC6ENTC kinases , but heparan BC6OTHER is also required for signaling by members of the BC6OTHER family.	False
BC6OTHER signal through transmembrane receptor BC6ENTC kinases , but heparan BC6OTHER is also required for signaling by members of the BC6ENTG family.	False
BC6ENTG signal through transmembrane receptor BC6OTHER kinases , but heparan BC6ENTC is also required for signaling by members of the BC6OTHER family.	False
BC6OTHER signal through BC6ENTG , but heparan BC6ENTC is also required for signaling by members of the BC6OTHER family.	False
BC6OTHER signal through transmembrane receptor BC6OTHER kinases , but heparan BC6ENTC is also required for signaling by members of the BC6ENTG family.	False
Using biotinylated BC6ENTG and BC6OTHER ( BC6OTHER ) as probes , we have identified specific interactions between BC6OTHER and heparan BC6ENTC in human tissues.	False
Using biotinylated BC6OTHER and BC6ENTG ( BC6OTHER ) as probes , we have identified specific interactions between BC6OTHER and heparan BC6ENTC in human tissues.	False
Using biotinylated BC6OTHER and BC6OTHER ( BC6ENTG ) as probes , we have identified specific interactions between BC6OTHER and heparan BC6ENTC in human tissues.	False
Using biotinylated BC6OTHER and BC6OTHER ( BC6OTHER ) as probes , we have identified specific interactions between BC6ENTG and heparan BC6ENTC in human tissues.	False
Although BC6ENTG strongly binds to basement membrane heparan BC6ENTC in skin and most other tissue sites examined , BC6OTHER fails to bind to basement membrane heparan BC6OTHER in most locations.	False
Although BC6OTHER strongly binds to basement membrane heparan BC6ENTC in skin and most other tissue sites examined , BC6ENTG fails to bind to basement membrane heparan BC6OTHER in most locations.	False
Although BC6ENTG strongly binds to basement membrane heparan BC6OTHER in skin and most other tissue sites examined , BC6OTHER fails to bind to basement membrane heparan BC6ENTC in most locations.	False
Although BC6OTHER strongly binds to basement membrane heparan BC6OTHER in skin and most other tissue sites examined , BC6ENTG fails to bind to basement membrane heparan BC6ENTC in most locations.	False
Differential binding of BC6ENTG to basement membrane heparan BC6ENTC : comparison of normal and abnormal human tissues.	False
"Blockade of BC6ENTC receptors by BC6OTHER could theoretically confer disease - modifying activity in AD by inhibiting the ""weak"" BC6ENTG - dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia."	False
"Blockade of BC6ENTG by BC6ENTC could theoretically confer disease - modifying activity in AD by inhibiting the ""weak"" BC6OTHER - dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia."	CPR:4
"Blockade of BC6OTHER by BC6ENTC could theoretically confer disease - modifying activity in AD by inhibiting the ""weak"" BC6ENTG - dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia."	CPR:4
"Blockade of BC6ENTG by BC6OTHER could theoretically confer disease - modifying activity in AD by inhibiting the ""weak"" BC6ENTC receptor - dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia."	False
Moreover , recent in vitro studies suggest that BC6ENTC abrogates BC6ENTG ( BC6OTHER ) toxicity and possibly inhibits BC6OTHER production.	CPR:4
Moreover , recent in vitro studies suggest that BC6ENTC abrogates BC6OTHER ( BC6ENTG ) toxicity and possibly inhibits BC6OTHER production.	CPR:4
Moreover , recent in vitro studies suggest that BC6ENTC abrogates BC6OTHER ( BC6OTHER ) toxicity and possibly inhibits BC6ENTG production.	CPR:4
Considerable attention has focused on the investigation of theories to explain the better tolerability of BC6ENTC over other BC6ENTG antagonists , particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic - like agents ( BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
Considerable attention has focused on the investigation of theories to explain the better tolerability of BC6OTHER over other BC6ENTG antagonists , particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic - like agents ( BC6ENTC , BC6OTHER , BC6OTHER ).	False
Considerable attention has focused on the investigation of theories to explain the better tolerability of BC6OTHER over other BC6ENTG antagonists , particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic - like agents ( BC6OTHER , BC6ENTC , BC6OTHER ).	False
Considerable attention has focused on the investigation of theories to explain the better tolerability of BC6OTHER over other BC6ENTG antagonists , particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic - like agents ( BC6OTHER , BC6OTHER , BC6ENTC ).	False
While the neurobiological basis for the therapeutic activity of BC6ENTC is not fully understood , the drug is not a BC6ENTG inhibitor and , therefore , acts differently from current AD therapies.	False
BC6ENTC can interact with a variety of BC6ENTG .	False
However , BC6ENTG appear to be a key target of BC6ENTC at therapeutic concentrations.	False
BC6ENTC is an uncompetitive (channel blocking) BC6ENTG antagonist.	CPR:6
Like other BC6ENTG antagonists , BC6ENTC at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.	CPR:6
Conversely , BC6OTHER inhibitor BC6ENTC or BC6ENTG inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6OTHER in HepG2 cells.	False
Conversely , BC6OTHER inhibitor BC6ENTC or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6ENTG and BC6OTHER induced by BC6OTHER in HepG2 cells.	False
Conversely , BC6OTHER inhibitor BC6ENTC or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6ENTG induced by BC6OTHER in HepG2 cells.	CPR:4
Conversely , BC6ENTG inhibitor BC6ENTC or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6OTHER in HepG2 cells.	CPR:4
Conversely , BC6OTHER inhibitor BC6OTHER or BC6ENTG inhibitor BC6ENTC blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6OTHER in HepG2 cells.	CPR:4
Conversely , BC6OTHER inhibitor BC6OTHER or BC6OTHER inhibitor BC6ENTC blocked the cleavages of BC6ENTG and BC6OTHER induced by BC6OTHER in HepG2 cells.	False
Conversely , BC6OTHER inhibitor BC6OTHER or BC6OTHER inhibitor BC6ENTC blocked the cleavages of BC6OTHER and BC6ENTG induced by BC6OTHER in HepG2 cells.	CPR:4
Conversely , BC6ENTG inhibitor BC6OTHER or BC6OTHER inhibitor BC6ENTC blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6OTHER in HepG2 cells.	False
Conversely , BC6OTHER inhibitor BC6OTHER or BC6ENTG inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6ENTC in HepG2 cells.	False
Conversely , BC6OTHER inhibitor BC6OTHER or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6ENTG and BC6OTHER induced by BC6ENTC in HepG2 cells.	CPR:3
Conversely , BC6OTHER inhibitor BC6OTHER or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6ENTG induced by BC6ENTC in HepG2 cells.	CPR:3
Conversely , BC6ENTG inhibitor BC6OTHER or BC6OTHER inhibitor BC6OTHER blocked the cleavages of BC6OTHER and BC6OTHER induced by BC6ENTC in HepG2 cells.	False
Furthermore , proteosomal inhibitor BC6ENTC suppressed BC6ENTG activation , BC6OTHER phosphorylation , cleaved BC6OTHER and deceased BC6OTHER induced by BC6OTHER in HepG2 cells.	CPR:4
Furthermore , proteosomal inhibitor BC6ENTC suppressed BC6OTHER activation , BC6ENTG phosphorylation , cleaved BC6OTHER and deceased BC6OTHER induced by BC6OTHER in HepG2 cells.	CPR:4
Furthermore , proteosomal inhibitor BC6ENTC suppressed BC6OTHER activation , BC6OTHER phosphorylation , cleaved BC6ENTG and deceased BC6OTHER induced by BC6OTHER in HepG2 cells.	False
Furthermore , proteosomal inhibitor BC6ENTC suppressed BC6OTHER activation , BC6OTHER phosphorylation , cleaved BC6OTHER and deceased BC6ENTG induced by BC6OTHER in HepG2 cells.	CPR:3
Furthermore , proteosomal inhibitor BC6OTHER suppressed BC6ENTG activation , BC6OTHER phosphorylation , cleaved BC6OTHER and deceased BC6OTHER induced by BC6ENTC in HepG2 cells.	CPR:3
Furthermore , proteosomal inhibitor BC6OTHER suppressed BC6OTHER activation , BC6ENTG phosphorylation , cleaved BC6OTHER and deceased BC6OTHER induced by BC6ENTC in HepG2 cells.	CPR:3
Furthermore , proteosomal inhibitor BC6OTHER suppressed BC6OTHER activation , BC6OTHER phosphorylation , cleaved BC6ENTG and deceased BC6OTHER induced by BC6ENTC in HepG2 cells.	False
Furthermore , proteosomal inhibitor BC6OTHER suppressed BC6OTHER activation , BC6OTHER phosphorylation , cleaved BC6OTHER and deceased BC6ENTG induced by BC6ENTC in HepG2 cells.	CPR:4
Overall , our findings suggest that BC6ENTC induced apoptosis in HepG2 cells via BC6ENTG activation and BC6OTHER phosphorylation as a potent chemopreventive agent.	CPR:3
Overall , our findings suggest that BC6ENTC induced apoptosis in HepG2 cells via BC6OTHER activation and BC6ENTG phosphorylation as a potent chemopreventive agent.	CPR:3
Thus , in the present study , the roles of BC6ENTC - activated protein kinase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were examined in CHEM induced apoptosis in HepG2 hepatocellular carcinoma cells.	False
Thus , in the present study , the roles of BC6ENTC - activated protein kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were examined in CHEM induced apoptosis in HepG2 hepatocellular carcinoma cells.	False
Thus , in the present study , the roles of BC6ENTC - activated protein kinase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were examined in CHEM induced apoptosis in HepG2 hepatocellular carcinoma cells.	False
Also , CHEM enhanced the cleavages of BC6ENTC polymerase ( BC6ENTG ) and BC6OTHER , attenuated the expression of BC6OTHER ( BC6OTHER ) and BC6OTHER in HepG2 cells.	False
Also , CHEM enhanced the cleavages of BC6ENTC polymerase ( BC6OTHER ) and BC6ENTG , attenuated the expression of BC6OTHER ( BC6OTHER ) and BC6OTHER in HepG2 cells.	False
Also , CHEM enhanced the cleavages of BC6ENTC polymerase ( BC6OTHER ) and BC6OTHER , attenuated the expression of BC6ENTG ( BC6OTHER ) and BC6OTHER in HepG2 cells.	False
Also , CHEM enhanced the cleavages of BC6ENTC polymerase ( BC6OTHER ) and BC6OTHER , attenuated the expression of BC6OTHER ( BC6ENTG ) and BC6OTHER in HepG2 cells.	False
Also , CHEM enhanced the cleavages of BC6ENTC polymerase ( BC6OTHER ) and BC6OTHER , attenuated the expression of BC6OTHER ( BC6OTHER ) and BC6ENTG in HepG2 cells.	False
Interestingly , BC6ENTC increased the phosphorylation of BC6ENTG and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	CPR:3
Interestingly , BC6ENTC increased the phosphorylation of BC6OTHER and BC6ENTG and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	CPR:3
Interestingly , BC6ENTC increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6ENTG at inactive form BC6OTHER 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	CPR:3
Interestingly , BC6ENTC increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6OTHER attenuated the phosphorylation of BC6ENTG and BC6OTHER in HepG2 cells.	False
Interestingly , BC6ENTC increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6ENTG in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6ENTG and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6ENTC 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6ENTG and also enhanced phosphorylation of BC6OTHER at inactive form BC6ENTC 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6ENTG at inactive form BC6ENTC 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6ENTC 9 , whereas BC6OTHER attenuated the phosphorylation of BC6ENTG and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6ENTC 9 , whereas BC6OTHER attenuated the phosphorylation of BC6OTHER and BC6ENTG in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6ENTG and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6ENTC attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6ENTG and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6ENTC attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6ENTG at inactive form BC6OTHER 9 , whereas BC6ENTC attenuated the phosphorylation of BC6OTHER and BC6OTHER in HepG2 cells.	False
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6ENTC attenuated the phosphorylation of BC6ENTG and BC6OTHER in HepG2 cells.	CPR:4
Interestingly , BC6OTHER increased the phosphorylation of BC6OTHER and BC6OTHER and also enhanced phosphorylation of BC6OTHER at inactive form BC6OTHER 9 , whereas BC6ENTC attenuated the phosphorylation of BC6OTHER and BC6ENTG in HepG2 cells.	CPR:4
Activation of BC6ENTG and Phosphorylation of BC6OTHER Mediate BC6ENTC Induced Apoptosis in HepG2 Liver Cancer Cells.	CPR:3
Activation of BC6OTHER and Phosphorylation of BC6ENTG Mediate BC6ENTC Induced Apoptosis in HepG2 Liver Cancer Cells.	CPR:3
Activation of BC6ENTC - activated Protein Kinase and Phosphorylation of BC6ENTG Mediate BC6OTHER Induced Apoptosis in HepG2 Liver Cancer Cells.	False
The deduced BC6ENTC sequence contains 779 BC6OTHER , including a putative BC6ENTG in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6OTHER families.	False
The deduced BC6ENTC sequence contains 779 BC6OTHER , including a putative BC6OTHER in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6ENTG families.	False
The deduced BC6OTHER sequence contains 779 BC6ENTC , including a putative BC6ENTG in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6OTHER families.	False
The deduced BC6OTHER sequence contains 779 BC6ENTC , including a putative BC6OTHER in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6ENTG families.	False
The deduced BC6OTHER sequence contains 779 BC6OTHER , including a putative BC6ENTC binding sequence in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6ENTG families.	False
The deduced BC6OTHER sequence contains 779 BC6OTHER , including a putative BC6ENTG in the BC6ENTC - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6OTHER families.	False
The deduced BC6OTHER sequence contains 779 BC6OTHER , including a putative BC6OTHER in the BC6ENTC - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6OTHER sequence to those of other BC6ENTG families.	False
The deduced BC6OTHER sequence contains 779 BC6OTHER , including a putative BC6ENTG in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6ENTC sequence to those of other BC6OTHER families.	False
The deduced BC6OTHER sequence contains 779 BC6OTHER , including a putative BC6OTHER in the BC6OTHER - terminal portion of the molecule and a catalytic domain that is 16 - 47% identical in BC6ENTC sequence to those of other BC6ENTG families.	False
Recombinant BC6ENTG transfected and expressed in COS - 7 cells hydrolyzed BC6ENTC and BC6OTHER with Km values of 0.26 and 7.2 microM , respectively , and Vmax with BC6OTHER was almost twice that with BC6OTHER .	CPR:9
Recombinant BC6ENTG transfected and expressed in COS - 7 cells hydrolyzed BC6OTHER and BC6ENTC with Km values of 0.26 and 7.2 microM , respectively , and Vmax with BC6OTHER was almost twice that with BC6OTHER .	CPR:9
Recombinant BC6ENTG transfected and expressed in COS - 7 cells hydrolyzed BC6OTHER and BC6OTHER with Km values of 0.26 and 7.2 microM , respectively , and Vmax with BC6ENTC was almost twice that with BC6OTHER .	CPR:9
Recombinant BC6ENTG transfected and expressed in COS - 7 cells hydrolyzed BC6OTHER and BC6OTHER with Km values of 0.26 and 7.2 microM , respectively , and Vmax with BC6OTHER was almost twice that with BC6ENTC .	CPR:9
Of the BC6ENTG inhibitors tested , BC6ENTC was most effective , with IC50 values of 1.2 and 0.45 microM for inhibition of BC6OTHER and BC6OTHER hydrolysis , respectively.	CPR:4
Of the BC6ENTG inhibitors tested , BC6OTHER was most effective , with IC50 values of 1.2 and 0.45 microM for inhibition of BC6ENTC and BC6OTHER hydrolysis , respectively.	CPR:9
Of the BC6ENTG inhibitors tested , BC6OTHER was most effective , with IC50 values of 1.2 and 0.45 microM for inhibition of BC6OTHER and BC6ENTC hydrolysis , respectively.	CPR:9
Thus , BC6ENTG exhibited properties of a BC6ENTC PDE and a CHEM - inhibited BC6OTHER PDE.	False
Thus , BC6OTHER exhibited properties of a BC6ENTC PDE and a BC6ENTG .	False
Thus , BC6ENTG exhibited properties of a BC6OTHER and a BC6ENTC - inhibited BC6OTHER PDE.	False
Thus , BC6OTHER exhibited properties of a BC6ENTG and a BC6ENTC - inhibited BC6OTHER PDE.	False
Thus , BC6ENTG exhibited properties of a BC6OTHER and a CHEM - inhibited BC6ENTC PDE.	False
Thus , BC6OTHER exhibited properties of a BC6ENTG and a CHEM - inhibited BC6ENTC PDE.	False
Cloning and characterization of a novel BC6OTHER that hydrolyzes both BC6ENTC and BC6OTHER ( BC6ENTG ).	CPR:9
Cloning and characterization of a novel BC6ENTG that hydrolyzes both BC6ENTC and BC6OTHER ( BC6OTHER ).	CPR:9
Cloning and characterization of a novel BC6OTHER that hydrolyzes both BC6OTHER and BC6ENTC ( BC6ENTG ).	CPR:9
Cloning and characterization of a novel BC6ENTG that hydrolyzes both BC6OTHER and BC6ENTC ( BC6OTHER ).	CPR:9
BC6ENTC ( BC6OTHER ) is an endogenous BC6ENTG antagonist at the level of the different ionotropic BC6OTHER receptors.	CPR:6
BC6ENTC ( BC6OTHER ) is an endogenous BC6OTHER antagonist at the level of the different BC6ENTG .	CPR:6
BC6OTHER ( BC6OTHER ) is an endogenous BC6ENTG antagonist at the level of the different ionotropic BC6ENTC receptors.	False
BC6OTHER ( BC6ENTC ) is an endogenous BC6ENTG antagonist at the level of the different ionotropic BC6OTHER receptors.	CPR:6
BC6OTHER ( BC6ENTC ) is an endogenous BC6OTHER antagonist at the level of the different BC6ENTG .	CPR:6
The expression of several BC6ENTG mRNAs with different BC6OTHER represents an interesting example of transcriptional / translational control on the expression of BC6ENTC ( BC6OTHER ) - dependent aminotransferases.	False
The expression of several BC6OTHER mRNAs with different BC6ENTG represents an interesting example of transcriptional / translational control on the expression of BC6ENTC ( BC6OTHER ) - dependent aminotransferases.	False
The expression of several BC6ENTG mRNAs with different BC6OTHER represents an interesting example of transcriptional / translational control on the expression of CHEM ( BC6ENTC ) - dependent aminotransferases.	False
The expression of several BC6OTHER mRNAs with different BC6ENTG represents an interesting example of transcriptional / translational control on the expression of CHEM ( BC6ENTC ) - dependent aminotransferases.	False
One of the enzymes responsible for the production of BC6ENTC , BC6ENTG ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6ENTC , BC6OTHER ( BC6ENTG ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6ENTC , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
One of the enzymes responsible for the production of BC6ENTC , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
One of the enzymes responsible for the production of BC6OTHER , BC6ENTC aminotransferase I ( BC6ENTG ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6OTHER , BC6OTHER ).	False
One of the enzymes responsible for the production of BC6OTHER , BC6ENTC aminotransferase I ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6ENTG , BC6OTHER ).	False
One of the enzymes responsible for the production of BC6OTHER , BC6ENTC aminotransferase I ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
One of the enzymes responsible for the production of BC6OTHER , BC6ENTG ( BC6OTHER ) , also catalyses the reversible transamination of BC6ENTC to BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6ENTG ) , also catalyses the reversible transamination of BC6ENTC to BC6OTHER ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6ENTC to BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6ENTC to BC6OTHER ( BC6OTHER , BC6ENTG ).	False
One of the enzymes responsible for the production of BC6OTHER , BC6ENTG ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6ENTC ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6ENTG ) , also catalyses the reversible transamination of BC6OTHER to BC6ENTC ( BC6OTHER , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6ENTC ( BC6ENTG , BC6OTHER ).	CPR:9
One of the enzymes responsible for the production of BC6OTHER , BC6OTHER ( BC6OTHER ) , also catalyses the reversible transamination of BC6OTHER to BC6ENTC ( BC6OTHER , BC6ENTG ).	CPR:9
BC6OTHER ( BC6OTHER ) is an endogenous BC6ENTC receptor antagonist at the level of the different BC6ENTG .	False
Tissue expression and translational control of rat BC6ENTC aminotransferase / BC6ENTG mRNAs.	False
Tissue expression and translational control of BC6ENTG e / BC6ENTC transaminase K mRNAs.	False
Exposure to BC6ENTC NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of BC6OTHER , intracellular reactive BC6OTHER species and BC6ENTG that mirrored our findings from subacute in vivo inhalation studies in mice.	CPR:3
Exposure to BC6ENTC NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of BC6ENTG , intracellular reactive BC6OTHER species and BC6OTHER that mirrored our findings from subacute in vivo inhalation studies in mice.	CPR:3
Exposure to BC6OTHER NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of BC6ENTC dehydrogenase , intracellular reactive BC6OTHER species and BC6ENTG that mirrored our findings from subacute in vivo inhalation studies in mice.	False
Exposure to BC6OTHER NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of BC6OTHER , intracellular reactive BC6ENTC species and BC6ENTG that mirrored our findings from subacute in vivo inhalation studies in mice.	False
Exposure to BC6OTHER NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of BC6ENTG , intracellular reactive BC6ENTC species and BC6OTHER that mirrored our findings from subacute in vivo inhalation studies in mice.	False
When BC6ENTC was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment , BC6ENTG activity in both cornea and tear fluid was strongly inhibited.	CPR:4
In conclusion , early application of BC6ENTC inhibited BC6ENTG activity in UVB - irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.	CPR:4
Therefore , comparative histochemical and biochemical studies of BC6ENTG and the effects of BC6ENTC were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate BC6OTHER .	False
Therefore , comparative histochemical and biochemical studies of BC6ENTG and the effects of BC6OTHER were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate BC6ENTC .	CPR:9
The purpose of the present study was to test our hypothesis that BC6ENTC , a specific BC6OTHER inhibitor , effectively decreases BC6ENTG activity in cornea as well as in tear fluid and favourably affects corneal healing.	CPR:4
The purpose of the present study was to test our hypothesis that BC6ENTC , a specific BC6ENTG inhibitor , effectively decreases BC6OTHER activity in cornea as well as in tear fluid and favourably affects corneal healing.	CPR:4
Effects of inhibition of BC6ENTG ( BC6OTHER ) by BC6ENTC in the cornea and tear fluid of eyes irradiated with UVB.	CPR:4
Effects of inhibition of BC6OTHER ( BC6ENTG ) by BC6ENTC in the cornea and tear fluid of eyes irradiated with UVB.	CPR:4
Data from heterologous expression of wild - type and mutant BC6ENTG genes indicate the mutation causes a 20 - fold increase in IC50 of d - CHEM but only a 5.8 - fold increase in IC50 of BC6ENTC .	False
CONCLUSION: Oral BC6ENTC is effective in suppressing the gain of function in BC6ENTG responsible for some cases of short QT syndrome with a mutation in BC6OTHER and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia / ventricular fibrillation noninducible.	CPR:4
CONCLUSION: Oral BC6ENTC is effective in suppressing the gain of function in BC6OTHER responsible for some cases of short QT syndrome with a mutation in BC6ENTG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia / ventricular fibrillation noninducible.	False
"INTRODUCTION: The principal aim of this study was to assess the efficacy of BC6ENTC in suppressing BC6ENTG in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome."	CPR:4
Further insights into the effect of BC6ENTC in short QT syndrome caused by a mutation in BC6ENTG .	False
BC6ENTC causes lactic acidosis in clinical situations due to inhibition of BC6ENTG .	CPR:4
Inhibition by BC6OTHER of BC6ENTC consumption via BC6ENTG respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6OTHER on BC6OTHER respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	False
Inhibition by BC6OTHER of BC6ENTC consumption via BC6OTHER respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6OTHER on BC6ENTG respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	False
Inhibition by BC6OTHER of BC6OTHER consumption via BC6ENTG respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6ENTC on BC6OTHER respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	False
Inhibition by BC6OTHER of BC6OTHER consumption via BC6OTHER respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6ENTC on BC6ENTG respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	CPR:4
Lactic acidosis provoked by iv infusion of BC6ENTC was weaker in BC6ENTG ( - / - ) mice than that in wild - type mice.	False
These observations suggest that uptake of BC6ENTC into liver mitochondria is at least partly mediated by BC6ENTG and functionally relevant to its inhibition potential of BC6OTHER respiration.	CPR:9
These observations suggest that uptake of BC6ENTC into liver mitochondria is at least partly mediated by BC6OTHER and functionally relevant to its inhibition potential of BC6ENTG respiration.	CPR:4
In this study , uptake of BC6ENTC and BC6OTHER ( BC6OTHER ) and BC6ENTG inhibition by BC6OTHER were examined in isolated liver and heart mitochondria.	False
In this study , uptake of BC6OTHER and BC6ENTC ( BC6OTHER ) and BC6ENTG inhibition by BC6OTHER were examined in isolated liver and heart mitochondria.	False
In this study , uptake of BC6OTHER and BC6OTHER ( BC6ENTC ) and BC6ENTG inhibition by BC6OTHER were examined in isolated liver and heart mitochondria.	False
In this study , uptake of BC6OTHER and BC6OTHER ( BC6OTHER ) and BC6ENTG inhibition by BC6ENTC were examined in isolated liver and heart mitochondria.	CPR:4
Similar characteristics were also observed for uptake of BC6ENTC ; however , uptake of BC6OTHER into mitochondria of BC6ENTG ( BC6OTHER ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6OTHER was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6ENTC ; however , uptake of BC6OTHER into mitochondria of organic cation / BC6OTHER transporter 1 ( BC6ENTG ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6OTHER was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6OTHER ; however , uptake of BC6ENTC into mitochondria of BC6ENTG ( BC6OTHER ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6OTHER was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6OTHER ; however , uptake of BC6ENTC into mitochondria of organic cation / BC6OTHER transporter 1 ( BC6ENTG ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6OTHER was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6OTHER ; however , uptake of BC6OTHER into mitochondria of organic cation / BC6ENTC transporter 1 ( BC6ENTG ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6OTHER was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6OTHER ; however , uptake of BC6OTHER into mitochondria of BC6ENTG ( BC6OTHER ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6ENTC was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Similar characteristics were also observed for uptake of BC6OTHER ; however , uptake of BC6OTHER into mitochondria of organic cation / BC6OTHER transporter 1 ( BC6ENTG ) knockout mice was lower than that in wild - type mice , whereas uptake of BC6ENTC was comparable between the two strains , suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.	False
Inhibition by BC6ENTC of BC6OTHER consumption via BC6ENTG respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6OTHER on BC6OTHER respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	CPR:4
Inhibition by BC6ENTC of BC6OTHER consumption via BC6OTHER respiration in isolated rat liver mitochondria was greater than that in heart mitochondria , whereas inhibitory effect of BC6OTHER on BC6ENTG respiration was similar in inside - out structured submitochondrial particles prepared from rat livers and hearts.	False
Role of organic cation / BC6ENTC transporter 1 in uptake of BC6OTHER and inhibitory effect on BC6ENTG respiration in mitochondria.	False
Role of BC6ENTG in uptake of BC6ENTC and inhibitory effect on BC6OTHER respiration in mitochondria.	CPR:9
Role of organic cation / BC6OTHER transporter 1 in uptake of BC6ENTC and inhibitory effect on BC6ENTG respiration in mitochondria.	CPR:4
However , BC6ENTG - positive cells exhibited increased cell death with exposure to the BC6ENTC polymerase inhibitor that blocks single - strand DNA repair.	False
Although both intracellular and membrane BC6ENTG pools were markedly reduced in cells released from contact inhibition by BC6ENTC , siRNA - mediated BC6OTHER knock - down was not sufficient to stimulate proliferation in contact - inhibited cells.	CPR:4
Although both intracellular and membrane BC6OTHER pools were markedly reduced in cells released from contact inhibition by BC6ENTC , siRNA - mediated BC6ENTG knock - down was not sufficient to stimulate proliferation in contact - inhibited cells.	CPR:4
The BC6ENTC receptor ( BC6ENTG ) contributes to the control of cell - to - cell communication , cell adhesion , migration or proliferation.	False
Disruption of contact inhibition , which was induced by toxic BC6ENTG ligands BC6ENTC ( BC6OTHER ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	False
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6ENTC ( BC6OTHER ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6ENTG protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	CPR:4
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6ENTC ( BC6OTHER ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6ENTG - dependent manner.	False
Disruption of contact inhibition , which was induced by toxic BC6ENTG ligands BC6OTHER ( BC6ENTC ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	False
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6OTHER ( BC6ENTC ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6ENTG protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	CPR:4
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6OTHER ( BC6ENTC ) or BC6OTHER in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6ENTG - dependent manner.	False
Disruption of contact inhibition , which was induced by toxic BC6ENTG ligands BC6OTHER ( BC6OTHER ) or BC6ENTC in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	False
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6OTHER ( BC6OTHER ) or BC6ENTC in epithelial WB - F344 cells , reduced BC6ENTG protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6OTHER - dependent manner.	CPR:4
Disruption of contact inhibition , which was induced by toxic BC6OTHER ligands BC6OTHER ( BC6OTHER ) or BC6ENTC in epithelial WB - F344 cells , reduced BC6OTHER protein levels , possibly via enhanced proteasomal degradation , significantly decreased the amount of gap junction plaques and downregulated GJIC , in an BC6ENTG - dependent manner.	False
 BC6ENTC receptor - mediated disruption of contact inhibition is associated with BC6ENTG downregulation and inhibition of gap junctional intercellular communication.	False
BC6ENTG genes encode mitochondrial enzymes capable of metabolizing BC6OTHER and other biological BC6ENTC in the body.	False
BC6ENTG , another mitochondrial enzyme sharing 72% identity with BC6OTHER , is also capable of metabolizing BC6ENTC but has a tissue distribution and pattern of activity distinct from that of BC6OTHER .	CPR:9
BC6OTHER , another mitochondrial enzyme sharing 72% identity with BC6ENTG , is also capable of metabolizing BC6ENTC but has a tissue distribution and pattern of activity distinct from that of BC6OTHER .	CPR:9
BC6OTHER , another mitochondrial enzyme sharing 72% identity with BC6OTHER , is also capable of metabolizing BC6ENTC but has a tissue distribution and pattern of activity distinct from that of BC6ENTG .	False
Bioinformatic analyses of several vertebrate genomes were undertaken using known BC6ENTG and BC6OTHER BC6ENTC sequences.	False
Bioinformatic analyses of several vertebrate genomes were undertaken using known BC6OTHER and BC6ENTG BC6ENTC sequences.	False
BC6ENTG genes encode mitochondrial enzymes capable of metabolizing BC6ENTC and other biological BC6OTHER in the body.	False
BC6ENTC and BC6ENTG are involved in this inhibitory action.	False
In contrast , BC6ENTG potentiates contractile actions in mesenteric arteries via the release of endogeneous BC6ENTC from non - endothelial cells.	False
In basilar arteries , BC6ENTG reduces the contractions induced by BC6ENTC ( BC6OTHER ) , by the BC6OTHER agonist BC6OTHER , and by BC6OTHER .	False
In basilar arteries , BC6OTHER reduces the contractions induced by BC6ENTC ( BC6OTHER ) , by the BC6OTHER agonist BC6OTHER , and by BC6ENTG .	False
In basilar arteries , BC6ENTG reduces the contractions induced by BC6OTHER ( BC6ENTC ) , by the BC6OTHER agonist BC6OTHER , and by BC6OTHER .	False
In basilar arteries , BC6OTHER reduces the contractions induced by BC6OTHER ( BC6ENTC ) , by the BC6OTHER agonist BC6OTHER , and by BC6ENTG .	False
In basilar arteries , BC6ENTG reduces the contractions induced by BC6OTHER ( BC6OTHER ) , by the BC6ENTC agonist BC6OTHER , and by BC6OTHER .	False
In basilar arteries , BC6OTHER reduces the contractions induced by BC6OTHER ( BC6OTHER ) , by the BC6ENTC agonist BC6OTHER , and by BC6ENTG .	False
In basilar arteries , BC6ENTG reduces the contractions induced by BC6OTHER ( BC6OTHER ) , by the BC6OTHER agonist BC6ENTC , and by BC6OTHER .	False
In basilar arteries , BC6OTHER reduces the contractions induced by BC6OTHER ( BC6OTHER ) , by the BC6OTHER agonist BC6ENTC , and by BC6ENTG .	False
In basilar arteries , BC6ENTG reduces the contractions induced by BC6OTHER ( BC6OTHER ) , by the BC6OTHER agonist BC6OTHER , and by BC6ENTC .	False
The inhibitory effect of BC6ENTG on the contraction induced by BC6ENTC is abolished by deendothelialization , by the BC6OTHER antagonist BC6OTHER , by BC6OTHER , or by BC6OTHER .	False
The inhibitory effect of BC6OTHER on the contraction induced by BC6ENTC is abolished by deendothelialization , by the BC6ENTG antagonist BC6OTHER , by BC6OTHER , or by BC6OTHER .	False
The inhibitory effect of BC6ENTG on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6OTHER antagonist BC6ENTC , by BC6OTHER , or by BC6OTHER .	False
The inhibitory effect of BC6OTHER on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6ENTG antagonist BC6ENTC , by BC6OTHER , or by BC6OTHER .	CPR:6
The inhibitory effect of BC6ENTG on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6OTHER antagonist BC6OTHER , by BC6ENTC , or by BC6OTHER .	False
The inhibitory effect of BC6OTHER on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6ENTG antagonist BC6OTHER , by BC6ENTC , or by BC6OTHER .	False
The inhibitory effect of BC6ENTG on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6OTHER antagonist BC6OTHER , by BC6OTHER , or by BC6ENTC .	False
The inhibitory effect of BC6OTHER on the contraction induced by BC6OTHER is abolished by deendothelialization , by the BC6ENTG antagonist BC6OTHER , by BC6OTHER , or by BC6ENTC .	False
In mesenteric arteries , BC6ENTG potentiates the contractile effects of BC6ENTC , BC6OTHER , and BC6OTHER .	False
In mesenteric arteries , BC6OTHER potentiates the contractile effects of BC6ENTC , BC6OTHER , and BC6ENTG .	False
In mesenteric arteries , BC6ENTG potentiates the contractile effects of BC6OTHER , BC6ENTC , and BC6OTHER .	False
In mesenteric arteries , BC6OTHER potentiates the contractile effects of BC6OTHER , BC6ENTC , and BC6ENTG .	False
In mesenteric arteries , BC6ENTG potentiates the contractile effects of BC6OTHER , BC6OTHER , and BC6ENTC .	False
The potentiation of the contractile effect induced by BC6ENTC is only somewhat modified by deendothelialization , but abolished by the BC6ENTG antagonists BC6OTHER and BC6OTHER .	False
The potentiation of the contractile effect induced by BC6OTHER is only somewhat modified by deendothelialization , but abolished by the BC6ENTG antagonists BC6ENTC and BC6OTHER .	CPR:6
The potentiation of the contractile effect induced by BC6OTHER is only somewhat modified by deendothelialization , but abolished by the BC6ENTG antagonists BC6OTHER and BC6ENTC .	CPR:6
Threshold concentrations of BC6ENTG : the effects on contractions induced by BC6ENTC in isolated rat cerebral and mesenteric arteries.	False
As a consequence , under fasting conditions in which plasma BC6OTHER levels were identical , blood BC6ENTC levels were reduced in BC6ENTG KO mice , again consistent with human GWAS data.	False
As a consequence , under fasting conditions in which plasma BC6ENTG levels were identical , blood BC6ENTC levels were reduced in BC6OTHER KO mice , again consistent with human GWAS data.	False
BC6ENTC - 6 - phosphatase activity was reduced , whereas basal cytoplasmic BC6OTHER levels were elevated in islets isolated from BC6ENTG KO mice.	False
BC6ENTG activity was reduced , whereas basal cytoplasmic BC6ENTC levels were elevated in islets isolated from BC6OTHER KO mice.	False
BC6OTHER activity was reduced , whereas basal cytoplasmic BC6ENTC levels were elevated in islets isolated from BC6ENTG KO mice.	False
These data suggest that BC6ENTG represents a novel , negative regulator of basal GSIS that acts by hydrolyzing BC6ENTC , thereby reducing glycolytic flux.	CPR:9
Genome - wide association studies (GWAS) have linked polymorphisms in BC6ENTG with variations in FBG and body fat , although not BC6OTHER sensitivity or BC6ENTC tolerance.	False
Genome - wide association studies (GWAS) have linked polymorphisms in BC6OTHER with variations in FBG and body fat , although not BC6ENTG sensitivity or BC6ENTC tolerance.	False
BC6ENTG encodes an islet - specific , endoplasmic reticulum - resident BC6ENTC - 6 - phosphatase catalytic subunit.	False
BC6ENTG deletion had little effect on BC6OTHER sensitivity and BC6ENTC tolerance , whereas body fat was reduced in female BC6OTHER knockout (KO) mice on both a chow and high - fat diet , observations that are all consistent with human GWAS data.	False
BC6OTHER deletion had little effect on BC6ENTG sensitivity and BC6ENTC tolerance , whereas body fat was reduced in female BC6OTHER knockout (KO) mice on both a chow and high - fat diet , observations that are all consistent with human GWAS data.	False
BC6OTHER deletion had little effect on BC6OTHER sensitivity and BC6ENTC tolerance , whereas body fat was reduced in female BC6ENTG knockout (KO) mice on both a chow and high - fat diet , observations that are all consistent with human GWAS data.	False
BC6ENTG deletion resulted in a leftward shift in the dose - response curve for BC6ENTC - stimulated BC6OTHER secretion (GSIS).	False
BC6OTHER deletion resulted in a leftward shift in the dose - response curve for BC6ENTC - stimulated BC6ENTG secretion (GSIS).	CPR:3
 BC6ENTG : A Negative Regulator of Basal BC6ENTC - Stimulated BC6OTHER Secretion.	False
 BC6OTHER : A Negative Regulator of Basal BC6ENTC - Stimulated BC6ENTG Secretion.	CPR:3
At the enzymatic activity level , BC6OTHER started to suppress BC6ENTG activity at 5 mg / kg / day (P<0.001) , while BC6ENTC had an effect at a lower dose , 1 mg / kg / day (P<0.02).	False
We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the BC6ENTG inhibition by BC6ENTC .	CPR:4
In vitro , BC6ENTC , but not BC6OTHER , inhibits BC6ENTG , at least in part , via the BC6OTHER ( BC6OTHER ) - mediated pathway.	CPR:4
In vitro , BC6ENTC , but not BC6OTHER , inhibits BC6OTHER , at least in part , via the BC6ENTG ( BC6OTHER ) - mediated pathway.	False
In vitro , BC6ENTC , but not BC6OTHER , inhibits BC6OTHER , at least in part , via the BC6OTHER ( BC6ENTG ) - mediated pathway.	False
In vitro , BC6OTHER , but not BC6ENTC , inhibits BC6ENTG , at least in part , via the BC6OTHER ( BC6OTHER ) - mediated pathway.	CPR:4
In vitro , BC6OTHER , but not BC6ENTC , inhibits BC6OTHER , at least in part , via the BC6ENTG ( BC6OTHER ) - mediated pathway.	False
In vitro , BC6OTHER , but not BC6ENTC , inhibits BC6OTHER , at least in part , via the BC6OTHER ( BC6ENTG ) - mediated pathway.	False
This study provided the evidence that the BC6ENTC inhibit stimulated cerebral BC6ENTG at multiple levels and are effective at very low doses , offering great potential for therapeutic use.	CPR:4
BC6ENTC was shown to decrease cerebral BC6ENTG activities and angiogenesis induced by BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC was shown to decrease cerebral BC6OTHER activities and angiogenesis induced by BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC was shown to decrease cerebral BC6OTHER activities and angiogenesis induced by BC6OTHER ( BC6ENTG ).	CPR:4
In the present study , we determined the dose - response effects of BC6ENTC and BC6OTHER on cerebral BC6ENTG using our mouse model with BC6OTHER focal hyperstimulation delivered with adenoviral vector (Ad BC6OTHER ) in the brain.	False
In the present study , we determined the dose - response effects of BC6ENTC and BC6OTHER on cerebral BC6OTHER using our mouse model with BC6ENTG focal hyperstimulation delivered with adenoviral vector (Ad BC6OTHER ) in the brain.	False
In the present study , we determined the dose - response effects of BC6ENTC and BC6OTHER on cerebral BC6OTHER using our mouse model with BC6OTHER focal hyperstimulation delivered with adenoviral vector (Ad BC6ENTG ) in the brain.	False
In the present study , we determined the dose - response effects of BC6OTHER and BC6ENTC on cerebral BC6ENTG using our mouse model with BC6OTHER focal hyperstimulation delivered with adenoviral vector (Ad BC6OTHER ) in the brain.	False
In the present study , we determined the dose - response effects of BC6OTHER and BC6ENTC on cerebral BC6OTHER using our mouse model with BC6ENTG focal hyperstimulation delivered with adenoviral vector (Ad BC6OTHER ) in the brain.	False
In the present study , we determined the dose - response effects of BC6OTHER and BC6ENTC on cerebral BC6OTHER using our mouse model with BC6OTHER focal hyperstimulation delivered with adenoviral vector (Ad BC6ENTG ) in the brain.	False
Our results have shown that BC6ENTG messenger ribonucleic acid (mRNA) expression was inhibited by BC6ENTC starting at 10 mg / kg / day (P<0.02).	CPR:4
BC6ENTC showed more potent inhibition on BC6ENTG mRNA expression , starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg / kg / day.	CPR:4
At the enzymatic activity level , BC6ENTC started to suppress BC6ENTG activity at 5 mg / kg / day (P<0.001) , while BC6OTHER had an effect at a lower dose , 1 mg / kg / day (P<0.02).	CPR:4
Dose - response effect of BC6ENTC on cerebral BC6ENTG after BC6OTHER hyperstimulation.	False
Dose - response effect of BC6ENTC on cerebral BC6OTHER after BC6ENTG hyperstimulation.	False
BC6ENTC also increased BC6ENTG ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6OTHER , there was an increase in the BC6OTHER - dependent luciferase activity.	CPR:3
BC6ENTC also increased BC6OTHER ( BC6ENTG ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6OTHER , there was an increase in the BC6OTHER - dependent luciferase activity.	CPR:3
BC6ENTC also increased BC6OTHER ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6ENTG alone or in the presence of BC6OTHER , there was an increase in the BC6OTHER - dependent luciferase activity.	False
BC6ENTC also increased BC6OTHER ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6OTHER , there was an increase in the BC6ENTG - dependent luciferase activity.	False
BC6OTHER also increased BC6ENTG ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6ENTC , there was an increase in the BC6OTHER - dependent luciferase activity.	False
BC6OTHER also increased BC6OTHER ( BC6ENTG ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6ENTC , there was an increase in the BC6OTHER - dependent luciferase activity.	False
BC6OTHER also increased BC6OTHER ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6ENTG alone or in the presence of BC6ENTC , there was an increase in the BC6OTHER - dependent luciferase activity.	False
BC6OTHER also increased BC6OTHER ( BC6OTHER ) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with BC6OTHER alone or in the presence of BC6ENTC , there was an increase in the BC6ENTG - dependent luciferase activity.	CPR:3
When isolated hepatocytes were treated for 2 h with BC6ENTC in the presence of BC6OTHER , followed by replacement of the medium with new medium containing BC6ENTG , there was further potentiation to the BC6OTHER - mediated effect.	False
When isolated hepatocytes were treated for 2 h with BC6OTHER in the presence of BC6ENTC , followed by replacement of the medium with new medium containing BC6ENTG , there was further potentiation to the BC6OTHER - mediated effect.	False
When isolated hepatocytes were treated for 2 h with BC6OTHER in the presence of BC6OTHER , followed by replacement of the medium with new medium containing BC6ENTG , there was further potentiation to the BC6ENTC - mediated effect.	False
The present study demonstrates that there is a differential modulation of BC6ENTG by BC6ENTC in C57BL / 6 mice livers and isolated hepatocytes and demonstrates BC6OTHER as an in vivo specific modulator.	False
The present study demonstrates that there is a differential modulation of BC6OTHER by BC6ENTC in C57BL / 6 mice livers and isolated hepatocytes and demonstrates BC6ENTG as an in vivo specific modulator.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6ENTC (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6ENTC (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6ENTC (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6ENTC ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6ENTC ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6ENTC ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6ENTC ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6ENTC ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6ENTC ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6ENTC (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6ENTC (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6ENTC (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6ENTC (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6ENTC (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6ENTC (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6OTHER alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6ENTC alone did not significantly alter BC6ENTG , BC6OTHER , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6ENTC alone did not significantly alter BC6OTHER , BC6ENTG , or BC6OTHER mRNA , protein , or catalytic activity levels.	False
For this purpose , C57BL6 mice were injected intraperitoneally with BC6OTHER (5 mg / kg) in the absence and presence of BC6OTHER ( BC6OTHER ) (15 μg / kg) for 6 and 24 h. Furthermore , isolated hepatocytes from C57BL6 mice were treated with BC6OTHER (5 , 10 , and 20 μM) in the absence and presence of BC6OTHER (1 nM) for 3 , 6 , 12 , and 24 h. In vivo , BC6ENTC alone did not significantly alter BC6OTHER , BC6OTHER , or BC6ENTG mRNA , protein , or catalytic activity levels.	False
Upon co - exposure to BC6ENTC and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6ENTC and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6ENTC and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6ENTC and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6ENTC , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6ENTC , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6ENTC , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6ENTC , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6ENTC significantly potentiated the BC6OTHER - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6ENTC significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6ENTC significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6ENTC significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	False
The objective of the current study was to investigate the effect of BC6ENTC ( BC6OTHER ) on BC6ENTG expression and activity in C57BL / 6 mice liver and isolated hepatocytes.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6ENTC - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6ENTC - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6ENTC - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	CPR:3
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6ENTC - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6OTHER - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	False
The objective of the current study was to investigate the effect of BC6OTHER ( BC6ENTC ) on BC6ENTG expression and activity in C57BL / 6 mice liver and isolated hepatocytes.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6ENTC decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6ENTC decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6ENTC decreased the BC6OTHER - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6ENTC decreased the BC6OTHER - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	CPR:4
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6ENTG , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6ENTC - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6ENTG , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6ENTC - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6ENTG mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6ENTC - mediated induction of BC6OTHER mRNA , protein , and catalytic activity levels.	False
Upon co - exposure to BC6OTHER and BC6OTHER , BC6OTHER significantly potentiated the BC6OTHER - mediated induction of the BC6OTHER , BC6OTHER , and BC6OTHER mRNA , protein , and catalytic activity levels at 24 h. In vitro , BC6OTHER decreased the BC6ENTC - mediated induction of BC6ENTG mRNA , protein , and catalytic activity levels.	CPR:3
Furthermore , BC6ENTC significantly inhibited the BC6OTHER - induced BC6ENTG - dependent luciferase activity.	CPR:4
Furthermore , BC6OTHER significantly inhibited the BC6ENTC - induced BC6ENTG - dependent luciferase activity.	CPR:3
Modulation of BC6ENTG ( BC6OTHER ) by BC6ENTC in hepatic tissue and isolated hepatocyte of C57BL / 6 mice.	False
Modulation of BC6OTHER ( BC6ENTG ) by BC6ENTC in hepatic tissue and isolated hepatocyte of C57BL / 6 mice.	False
The demonstration that BC6ENTC exhibits potent target inhibition and efficacy in BC6ENTG - driven models suggests that this compound may have a therapeutic benefit for patients with BC6OTHER - driven leukemias.	CPR:4
The demonstration that BC6ENTC exhibits potent target inhibition and efficacy in BC6OTHER - driven models suggests that this compound may have a therapeutic benefit for patients with BC6ENTG - driven leukemias.	CPR:4
We show that BC6ENTC ( BC6OTHER , BC6OTHER ) potently inhibits BC6ENTG enzymatic and signaling activities.	CPR:4
We show that BC6OTHER ( BC6ENTC , BC6OTHER ) potently inhibits BC6ENTG enzymatic and signaling activities.	CPR:4
We show that BC6OTHER ( BC6OTHER , BC6ENTC ) potently inhibits BC6ENTG enzymatic and signaling activities.	CPR:4
In HEK293 cells stably transfected with BC6ENTG - WT or BC6OTHER - ITD , BC6ENTC blocked basal and ligand dependent BC6OTHER - mediated BC6OTHER autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6ENTG - ITD , BC6ENTC blocked basal and ligand dependent BC6OTHER - mediated BC6OTHER autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6ENTC blocked basal and ligand dependent BC6ENTG - mediated BC6OTHER autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	CPR:4
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6ENTC blocked basal and ligand dependent BC6OTHER - mediated BC6OTHER autophosphorylation as well as BC6ENTG and BC6OTHER phosphorylation.	CPR:4
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6ENTC blocked basal and ligand dependent BC6OTHER - mediated BC6OTHER autophosphorylation as well as BC6OTHER and BC6ENTG phosphorylation.	CPR:4
In HEK293 cells stably transfected with BC6ENTG - WT or BC6OTHER - ITD , BC6OTHER blocked basal and ligand dependent BC6OTHER - mediated BC6ENTC autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6ENTG - ITD , BC6OTHER blocked basal and ligand dependent BC6OTHER - mediated BC6ENTC autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6OTHER blocked basal and ligand dependent BC6ENTG - mediated BC6ENTC autophosphorylation as well as BC6OTHER and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6OTHER blocked basal and ligand dependent BC6OTHER - mediated BC6ENTC autophosphorylation as well as BC6ENTG and BC6OTHER phosphorylation.	False
In HEK293 cells stably transfected with BC6OTHER - WT or BC6OTHER - ITD , BC6OTHER blocked basal and ligand dependent BC6OTHER - mediated BC6ENTC autophosphorylation as well as BC6OTHER and BC6ENTG phosphorylation.	False
In leukemia cell lines MV4 - 11 and EOL - 1 , BC6ENTC treatment resulted in decreased cell proliferation and inhibition of BC6ENTG signaling.	CPR:4
The growth of the BC6ENTG - independent RS4 - 11 cell line was only weakly inhibited by BC6ENTC .	CPR:4
Activating internal tandem duplication (ITD) insertions in the BC6ENTG of the BC6OTHER BC6ENTC kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival.	False
Activating internal tandem duplication (ITD) insertions in the BC6OTHER of the BC6ENTG BC6ENTC kinase are found in about one fourth of patients with acute myeloid leukemia and have been shown to be an independent negative prognostic factor for survival.	False
Antitumor activity of BC6ENTC in BC6ENTG - driven leukemic cells.	CPR:4
This 40 kDa BC6ENTC - conjugated BC6ENTG (CHEM - BC6OTHER ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6OTHER side - chain of BC6OTHER .	False
This 40 kDa BC6ENTC - conjugated BC6OTHER (CHEM - BC6ENTG ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6OTHER side - chain of BC6OTHER .	False
This 40 kDa BC6ENTC - conjugated BC6OTHER (CHEM - BC6OTHER ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6OTHER side - chain of BC6ENTG .	False
This 40 kDa BC6OTHER - conjugated BC6ENTG (CHEM - BC6OTHER ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6ENTC side - chain of BC6OTHER .	False
This 40 kDa BC6OTHER - conjugated BC6OTHER (CHEM - BC6ENTG ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6ENTC side - chain of BC6OTHER .	False
This 40 kDa BC6OTHER - conjugated BC6OTHER (CHEM - BC6OTHER ) is obtained by the covalent binding of one 40 kDa branched CHEM - polymer to a BC6ENTC side - chain of BC6ENTG .	False
Structural , kinetic , and thermodynamic analysis of the binding of the 40 kDa BC6ENTC - BC6OTHER and its individual positional isomers to the extracellular domain of the receptor BC6ENTG .	False
Structural , kinetic , and thermodynamic analysis of the binding of the 40 kDa BC6ENTC - BC6ENTG and its individual positional isomers to the extracellular domain of the receptor BC6OTHER .	False
A critical role in organismal homeostatic functions is played by the BC6ENTC receptor ( BC6ENTG ) complex , which senses environmental and endogenous compounds , influences metabolic responses controlling phase I / II gene expression , and modulates vital phenomena such as development , inflammation and adaptive immunity.	False
The mouse BC6ENTG subfamily includes members that have wide tissue distribution and are active in the metabolism of BC6ENTC (AA) , BC6OTHER (LA) , and other lipids and xenobiotics.	CPR:9
The mouse BC6ENTG subfamily includes members that have wide tissue distribution and are active in the metabolism of BC6OTHER (AA) , BC6ENTC (LA) , and other lipids and xenobiotics.	CPR:9
The Turkish patient and her affected relatives all had a heterozygous BC6ENTG ( BC6OTHER ) of exon 10 of BC6OTHER that results in a replacement of BC6ENTC by BC6OTHER .	False
The Turkish patient and her affected relatives all had a heterozygous BC6OTHER ( BC6ENTG ) of exon 10 of BC6OTHER that results in a replacement of BC6ENTC by BC6OTHER .	False
The Turkish patient and her affected relatives all had a heterozygous BC6OTHER ( BC6OTHER ) of exon 10 of BC6ENTG that results in a replacement of BC6ENTC by BC6OTHER .	False
The Turkish patient and her affected relatives all had a heterozygous BC6ENTG ( BC6OTHER ) of exon 10 of BC6OTHER that results in a replacement of BC6OTHER by BC6ENTC .	False
The Turkish patient and her affected relatives all had a heterozygous BC6OTHER ( BC6ENTG ) of exon 10 of BC6OTHER that results in a replacement of BC6OTHER by BC6ENTC .	False
The Turkish patient and her affected relatives all had a heterozygous BC6OTHER ( BC6OTHER ) of exon 10 of BC6ENTG that results in a replacement of BC6OTHER by BC6ENTC .	False
The Chinese index patient and one of her siblings had a heterozygous mutation at codon 418 of exon 9 ( BC6ENTG ) that results in a substitution of BC6ENTC by BC6OTHER .	False
The Chinese index patient and one of her siblings had a heterozygous mutation at codon 418 of exon 9 ( BC6ENTG ) that results in a substitution of BC6OTHER by BC6ENTC .	False
BC6ENTC is a BC6ENTG inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.	CPR:4
High BC6ENTG protein levels , but not genetic or functional BC6OTHER status , were associated with increased BC6ENTC - induced DNA / BC6OTHER complex formation.	CPR:3
High BC6OTHER protein levels , but not genetic or functional BC6ENTG status , were associated with increased BC6ENTC - induced DNA / BC6OTHER complex formation.	False
High BC6OTHER protein levels , but not genetic or functional BC6OTHER status , were associated with increased BC6ENTC - induced DNA / BC6ENTG complex formation.	False
Neither functional BC6ENTG status , nor BC6OTHER protein levels , nor complex formation predicted BC6ENTC - induced growth inhibition.	False
Neither functional BC6OTHER status , nor BC6ENTG protein levels , nor complex formation predicted BC6ENTC - induced growth inhibition.	False
We thus confirm a possible role for BC6ENTG protein in modulating BC6OTHER activity but conclude that the major molecular determinants of BC6ENTC sensitivity in glioma cells await identification.	False
We thus confirm a possible role for BC6OTHER protein in modulating BC6ENTG activity but conclude that the major molecular determinants of BC6ENTC sensitivity in glioma cells await identification.	False
Glioma cell sensitivity to BC6ENTC : the role of BC6ENTG and BC6OTHER - induced DNA damage.	False
Glioma cell sensitivity to BC6OTHER : the role of BC6ENTG and BC6ENTC - induced DNA damage.	False
The BC6ENTG physically associates with these complexes to recruit them during transcription and mediates phosphorylation at BC6ENTC - 2 of the BC6OTHER - terminal domain (CTD) of BC6OTHER .	False
The BC6OTHER physically associates with these complexes to recruit them during transcription and mediates phosphorylation at BC6ENTC - 2 of the BC6OTHER - terminal domain (CTD) of BC6ENTG .	False
The BC6ENTG physically associates with these complexes to recruit them during transcription and mediates phosphorylation at BC6OTHER - 2 of the BC6ENTC - terminal domain (CTD) of BC6OTHER .	False
The BC6OTHER physically associates with these complexes to recruit them during transcription and mediates phosphorylation at BC6OTHER - 2 of the BC6ENTC - terminal domain (CTD) of BC6ENTG .	False
BC6ENTC , an effective competitive inhibitor of the BC6ENTG used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.	CPR:4
In the liver of rats given BC6ENTC as initiating agent at the dose of 500 mg / kg / week for 6 successive weeks , BC6ENTG - positive foci were detected only in 3 of 10 rats.	CPR:3
BC6ENTC products of BC6OTHER displayed significantly diminished BC6ENTG - dependent cleavage of DNA and cytotoxicity to human HL - 60 leukemia cells.	False
BC6OTHER products of BC6ENTC displayed significantly diminished BC6ENTG - dependent cleavage of DNA and cytotoxicity to human HL - 60 leukemia cells.	CPR:4
LPS - mediated induction of BC6ENTG in murine macrophages resulted in BC6ENTC resistance compared to Raw cells.	False
Furthermore , BC6ENTC products derived from BC6ENTG rapidly reacted with BC6OTHER leading to decreased DNA damage and cytotoxicity.	False
Furthermore , BC6OTHER products derived from BC6ENTG rapidly reacted with BC6ENTC leading to decreased DNA damage and cytotoxicity.	False
One of the most important transcription factors that activate the expression of BC6ENTC - regulated genes is BC6ENTG ( BC6OTHER ).	False
One of the most important transcription factors that activate the expression of BC6ENTC - regulated genes is BC6OTHER ( BC6ENTG ).	False
We investigated the effect of the clinically used CHEM BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We investigated the effect of the clinically used CHEM BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We investigated the effect of the clinically used CHEM BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We investigated the effect of the clinically used CHEM BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We investigated the effect of the clinically used CHEM BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We investigated the effect of the clinically used CHEM BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) on BC6ENTG - mediated transcriptional responses to hypoxia.	False
We demonstrate that among the three CHEM , only BC6ENTC inhibits BC6ENTG activation in response to hypoxia.	CPR:4
In contrast , BC6ENTC or BC6OTHER does not affect BC6ENTG activity.	False
In contrast , BC6OTHER or BC6ENTC does not affect BC6ENTG activity.	False
BC6ENTC inhibits the accumulation of BC6ENTG , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6OTHER or soluble BC6OTHER cyclase.	CPR:4
BC6ENTC inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6ENTG , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6OTHER or soluble BC6OTHER cyclase.	CPR:4
BC6ENTC inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6ENTG via a mechanism that is not dependent on either BC6OTHER or soluble BC6OTHER cyclase.	CPR:4
BC6ENTC inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6OTHER or BC6ENTG .	False
BC6OTHER inhibits the accumulation of BC6ENTG , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6ENTC or soluble BC6OTHER cyclase.	False
BC6OTHER inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6ENTG , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6ENTC or soluble BC6OTHER cyclase.	False
BC6OTHER inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6ENTG via a mechanism that is not dependent on either BC6ENTC or soluble BC6OTHER cyclase.	False
BC6OTHER inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6ENTC or BC6ENTG .	False
BC6OTHER inhibits the accumulation of BC6ENTG , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6OTHER or soluble BC6ENTC cyclase.	False
BC6OTHER inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6ENTG , and the transcriptional activation of BC6OTHER via a mechanism that is not dependent on either BC6OTHER or soluble BC6ENTC cyclase.	False
BC6OTHER inhibits the accumulation of BC6OTHER , the regulatory subunit of BC6OTHER , and the transcriptional activation of BC6ENTG via a mechanism that is not dependent on either BC6OTHER or soluble BC6ENTC cyclase.	False
The inhibitory effect of BC6OTHER on BC6ENTG activation is not dependent on BC6OTHER - soluble BC6ENTC cyclase pathway.	False
The inhibitory effect of BC6ENTC on BC6ENTG activation is not dependent on BC6OTHER - soluble BC6OTHER cyclase pathway.	CPR:4
The inhibitory effect of BC6ENTC on BC6OTHER activation is not dependent on BC6OTHER - BC6ENTG pathway.	False
The inhibitory effect of BC6OTHER on BC6ENTG activation is not dependent on BC6ENTC - soluble BC6OTHER cyclase pathway.	False
The inhibitory effect of BC6OTHER on BC6OTHER activation is not dependent on BC6ENTC - BC6ENTG pathway.	False
Here , we found that expression of the BC6ENTG - BC6OTHER mutant , which causes severe disease , depletes some ER chaperones with a BC6OTHER ( BC6ENTC ) motif , in HeLa cells , MO3.13 oligodendrocytic cells , and primary oligodendrocytes.	False
Here , we found that expression of the BC6OTHER - BC6ENTG mutant , which causes severe disease , depletes some ER chaperones with a BC6OTHER ( BC6ENTC ) motif , in HeLa cells , MO3.13 oligodendrocytic cells , and primary oligodendrocytes.	False
Here , we found that expression of the BC6OTHER - BC6OTHER mutant , which causes severe disease , depletes some ER chaperones with a BC6ENTG ( BC6ENTC ) motif , in HeLa cells , MO3.13 oligodendrocytic cells , and primary oligodendrocytes.	False
However , so far no information has been published on the BC6ENTG activity of the metabolites or degradation products of BC6ENTC .	False
In competition experiments with BC6ENTG we have determined the relative receptor affinities (RRA) of these substances with reference to BC6ENTC (RRA = 100).	False
Our results indicate that Salix extract 1520L inhibits BC6ENTG - mediated BC6ENTC release through compounds other than BC6OTHER or BC6OTHER .	CPR:9
Our results indicate that Salix extract 1520L inhibits BC6ENTG - mediated BC6OTHER release through compounds other than BC6ENTC or BC6OTHER .	False
Our results indicate that Salix extract 1520L inhibits BC6ENTG - mediated BC6OTHER release through compounds other than BC6OTHER or BC6ENTC .	False
The IC50 - values obtained for the inhibition of lipopolysaccharide (LPS) - induced release of BC6ENTC ( BC6OTHER ) reflecting BC6ENTG - mediated BC6OTHER release were 47 microg / ml and 0.6 microg / ml , for the Salix extract 1520L and BC6OTHER - like research compound BC6OTHER , respectively.	False
The IC50 - values obtained for the inhibition of lipopolysaccharide (LPS) - induced release of BC6OTHER ( BC6ENTC ) reflecting BC6ENTG - mediated BC6OTHER release were 47 microg / ml and 0.6 microg / ml , for the Salix extract 1520L and BC6OTHER - like research compound BC6OTHER , respectively.	False
The IC50 - values obtained for the inhibition of lipopolysaccharide (LPS) - induced release of BC6OTHER ( BC6OTHER ) reflecting BC6ENTG - mediated BC6ENTC release were 47 microg / ml and 0.6 microg / ml , for the Salix extract 1520L and BC6OTHER - like research compound BC6OTHER , respectively.	CPR:9
The IC50 - values obtained for the inhibition of lipopolysaccharide (LPS) - induced release of BC6OTHER ( BC6OTHER ) reflecting BC6ENTG - mediated BC6OTHER release were 47 microg / ml and 0.6 microg / ml , for the Salix extract 1520L and BC6ENTC - like research compound BC6OTHER , respectively.	False
The IC50 - values obtained for the inhibition of lipopolysaccharide (LPS) - induced release of BC6OTHER ( BC6OTHER ) reflecting BC6ENTG - mediated BC6OTHER release were 47 microg / ml and 0.6 microg / ml , for the Salix extract 1520L and BC6OTHER - like research compound BC6ENTC , respectively.	False
In approximately 20% of the cases BrS is caused by mutations in the BC6ENTG gene on chromosome 3p21 - 23 , encoding the cardiac BC6ENTC channel , a protein involved in the control of myocardial excitability.	False
The modulation of BC6ENTG surface expression by BC6OTHER can explain the decrease of circulating anti - MAb observed during BC6ENTC therapy in hypothyroid patients with Hashimoto's thyroiditis.	False
The modulation of BC6OTHER surface expression by BC6ENTG can explain the decrease of circulating anti - MAb observed during BC6ENTC therapy in hypothyroid patients with Hashimoto's thyroiditis.	False
Other agents , such as BC6ENTC and BC6OTHER , which influence thyroid cell function , do not directly interfere with the expression of BC6ENTG .	False
Other agents , such as BC6OTHER and BC6ENTC , which influence thyroid cell function , do not directly interfere with the expression of BC6ENTG .	False
Evidence has accumulated in the last few years that the expression of the BC6OTHER ( BC6ENTG ) in thyroid cells is induced by BC6OTHER , through pathways which involve intracellular BC6ENTC accumulation and protein synthesis.	CPR:3
Evidence has accumulated in the last few years that the expression of the BC6OTHER ( BC6OTHER ) in thyroid cells is induced by BC6ENTG , through pathways which involve intracellular BC6ENTC accumulation and protein synthesis.	False
Evidence has accumulated in the last few years that the expression of the BC6ENTG ( BC6OTHER ) in thyroid cells is induced by BC6OTHER , through pathways which involve intracellular BC6ENTC accumulation and protein synthesis.	CPR:3
BC6ENTG and BC6ENTC also increase the levels of the specific mRNA for BC6OTHER in thyroid cells from different species.	False
BC6OTHER and BC6ENTC also increase the levels of the specific mRNA for BC6ENTG in thyroid cells from different species.	CPR:3
BC6ENTC , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6ENTG inactivation of the BC6OTHER BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6ENTG BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6OTHER and BC6ENTG .	CPR:3
BC6ENTC , an oral BC6ENTG ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC , an oral BC6OTHER ( BC6ENTG ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6OTHER and BC6OTHER .	CPR:4
As add - on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment , BC6OTHER improved BC6ENTG to a significantly greater extent than placebo when added to BC6ENTC or BC6OTHER and was noninferior to BC6OTHER when added to BC6OTHER .	CPR:3
As add - on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment , BC6OTHER improved BC6ENTG to a significantly greater extent than placebo when added to BC6OTHER or BC6ENTC and was noninferior to BC6OTHER when added to BC6OTHER .	CPR:3
As add - on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment , BC6OTHER improved BC6ENTG to a significantly greater extent than placebo when added to BC6OTHER or BC6OTHER and was noninferior to BC6ENTC when added to BC6OTHER .	False
As add - on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment , BC6OTHER improved BC6ENTG to a significantly greater extent than placebo when added to BC6OTHER or BC6OTHER and was noninferior to BC6OTHER when added to BC6ENTC .	CPR:4
BC6OTHER , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6ENTG inactivation of the BC6OTHER BC6OTHER and BC6ENTC - dependent insulinotropic polypeptide.	False
BC6OTHER , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6ENTG BC6OTHER and BC6ENTC - dependent insulinotropic polypeptide.	False
BC6OTHER , an oral BC6OTHER ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6ENTG and BC6ENTC - dependent insulinotropic polypeptide.	False
BC6OTHER , an oral BC6ENTG ( BC6OTHER ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6OTHER and BC6ENTC - dependent insulinotropic polypeptide.	False
BC6OTHER , an oral BC6OTHER ( BC6ENTG ) inhibitor , improves glycaemic control by inhibiting BC6OTHER inactivation of the BC6OTHER BC6OTHER and BC6ENTC - dependent insulinotropic polypeptide.	False
This increases active BC6ENTG and BC6OTHER levels , and decreases BC6OTHER levels and post - BC6ENTC - load BC6OTHER excursion.	False
This increases active BC6OTHER and BC6ENTG levels , and decreases BC6OTHER levels and post - BC6ENTC - load BC6OTHER excursion.	False
This increases active BC6OTHER and BC6OTHER levels , and decreases BC6ENTG levels and post - BC6ENTC - load BC6OTHER excursion.	False
This increases active BC6ENTG and BC6OTHER levels , and decreases BC6OTHER levels and post - BC6OTHER - load BC6ENTC excursion.	False
This increases active BC6OTHER and BC6ENTG levels , and decreases BC6OTHER levels and post - BC6OTHER - load BC6ENTC excursion.	False
This increases active BC6OTHER and BC6OTHER levels , and decreases BC6ENTG levels and post - BC6OTHER - load BC6ENTC excursion.	False
In large , well designed phase III trials in patients with type 2 diabetes mellitus , BC6ENTC 100 or 200mg once daily alone or in combination with other antihyperglycaemics was associated with significant improvements relative to placebo in overall glycaemic control and indices for BC6ENTG response and beta - cell function.	False
Improvements from baseline in mean BC6ENTG ( BC6OTHER ) were significantly greater with BC6ENTC monotherapy than with placebo in patients with type 2 diabetes.	CPR:3
Improvements from baseline in mean BC6OTHER ( BC6ENTG ) were significantly greater with BC6ENTC monotherapy than with placebo in patients with type 2 diabetes.	CPR:3
As add - on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment , BC6ENTC improved BC6ENTG to a significantly greater extent than placebo when added to BC6OTHER or BC6OTHER and was noninferior to BC6OTHER when added to BC6OTHER .	CPR:3
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6ENTC ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6ENTC ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
Polyclonal antisera to either BC6ENTG or BC6OTHER significantly inhibited BC6ENTC ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:9
Polyclonal antisera to either BC6OTHER or BC6ENTG significantly inhibited BC6ENTC ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:9
Polyclonal antisera to either BC6ENTG or BC6OTHER significantly inhibited BC6OTHER ( BC6ENTC ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:9
Polyclonal antisera to either BC6OTHER or BC6ENTG significantly inhibited BC6OTHER ( BC6ENTC ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:9
Polyclonal antisera to either BC6ENTG or BC6OTHER significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Polyclonal antisera to either BC6OTHER or BC6ENTG significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Polyclonal antisera to either BC6ENTG or BC6OTHER significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Polyclonal antisera to either BC6OTHER or BC6ENTG significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Polyclonal antisera to either BC6ENTG or BC6OTHER significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Polyclonal antisera to either BC6OTHER or BC6ENTG significantly inhibited BC6OTHER ( BC6OTHER ) reduction by 95 and 89% , respectively , and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both BC6OTHER and BC6OTHER ( BC6ENTC ).	False
We conclude that BC6ENTG and BC6OTHER are together solely capable of the reduction of BC6ENTC carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6OTHER or BC6OTHER exposure.	False
We conclude that BC6OTHER and BC6ENTG are together solely capable of the reduction of BC6ENTC carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6OTHER or BC6OTHER exposure.	False
We conclude that BC6ENTG and BC6OTHER are together solely capable of the reduction of BC6OTHER carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6ENTC or BC6OTHER exposure.	False
We conclude that BC6OTHER and BC6ENTG are together solely capable of the reduction of BC6OTHER carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6ENTC or BC6OTHER exposure.	False
We conclude that BC6ENTG and BC6OTHER are together solely capable of the reduction of BC6OTHER carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6OTHER or BC6ENTC exposure.	False
We conclude that BC6OTHER and BC6ENTG are together solely capable of the reduction of BC6OTHER carcinogens , and we further hypothesize that this pathway may be a source of individual variability with respect to cancer susceptibility following BC6OTHER or BC6ENTC exposure.	False
On the basis of our findings with structurally similar BC6ENTC metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
On the basis of our findings with structurally similar BC6ENTC metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
On the basis of our findings with structurally similar BC6ENTC metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
On the basis of our findings with structurally similar BC6ENTC metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6ENTC carcinogens was catalyzed by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6ENTC carcinogens was catalyzed by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	CPR:9
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6ENTC carcinogens was catalyzed by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	CPR:9
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6ENTC carcinogens was catalyzed by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	CPR:9
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6ENTC cytochrome b5 reductase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6ENTC cytochrome b5 reductase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
On the basis of our findings with structurally similar BC6OTHER metabolites of therapeutic drugs , we hypothesized that the reductive detoxification of BC6OTHER carcinogens was catalyzed by BC6ENTC cytochrome b5 reductase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
We found that reduction of the carcinogenic BC6ENTC of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6ENTC of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6ENTC BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6ENTC BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6ENTC ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6ENTC ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6ENTC ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6ENTC ; found in cigarette smoke) and the BC6OTHER BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6ENTC BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6ENTC BC6OTHER ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6ENTC ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6ENTG and BC6OTHER .	CPR:9
We found that reduction of the carcinogenic BC6OTHER of the BC6OTHER BC6OTHER ( BC6OTHER ; found in cigarette smoke) and the BC6OTHER BC6ENTC ( BC6OTHER ; found in grilled meats) was indeed catalyzed by a purified system containing only BC6OTHER and BC6ENTG .	CPR:9
Reductive detoxification of BC6ENTC carcinogens by human BC6OTHER cytochrome b5 reductase and BC6ENTG .	CPR:9
Reductive detoxification of BC6ENTC carcinogens by BC6ENTG and BC6OTHER .	CPR:9
Reductive detoxification of BC6OTHER carcinogens by human BC6ENTC cytochrome b5 reductase and BC6ENTG .	False
BC6ENTC ( BC6OTHER ) , a potent , BC6OTHER BC6OTHER inhibitor , mimics the transition state of the BC6OTHER substrate , BC6ENTG .	False
BC6ENTC ( BC6OTHER ) , a potent , BC6OTHER BC6ENTG inhibitor , mimics the transition state of the BC6OTHER substrate , BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) , a potent , BC6OTHER BC6OTHER inhibitor , mimics the transition state of the BC6ENTG substrate , BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) , a potent , BC6OTHER BC6OTHER inhibitor , mimics the transition state of the BC6OTHER substrate , BC6ENTG .	False
BC6OTHER ( BC6ENTC ) , a potent , BC6OTHER BC6ENTG inhibitor , mimics the transition state of the BC6OTHER substrate , BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) , a potent , BC6OTHER BC6OTHER inhibitor , mimics the transition state of the BC6ENTG substrate , BC6OTHER .	CPR:4
The results of clinical trials with BC6ENTC are encouraging , and suggest that BC6ENTG inhibitors may be safe , useful therapeutic agents in the management of hypertension.	CPR:4
BC6ENTC has been shown to produce dose - related suppression of plasma BC6ENTG activity (PRA) and BC6OTHER when administered intravenously.	CPR:4
BC6ENTC has been shown to produce dose - related suppression of plasma BC6OTHER activity (PRA) and BC6ENTG when administered intravenously.	CPR:4
BC6OTHER has been shown to produce dose - related suppression of plasma BC6ENTG activity (PRA) and BC6ENTC when administered intravenously.	False
BC6OTHER ( BC6OTHER ) , a potent , BC6ENTC BC6OTHER inhibitor , mimics the transition state of the BC6OTHER substrate , BC6ENTG .	False
BC6OTHER ( BC6OTHER ) , a potent , BC6ENTC BC6ENTG inhibitor , mimics the transition state of the BC6OTHER substrate , BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) , a potent , BC6ENTC BC6OTHER inhibitor , mimics the transition state of the BC6ENTG substrate , BC6OTHER .	CPR:4
Clinical pharmacology of BC6ENTC , a novel , BC6OTHER BC6ENTG inhibitor.	CPR:4
Clinical pharmacology of BC6OTHER , a novel , BC6ENTC BC6ENTG inhibitor.	CPR:4
The BC6ENTG BC6OTHER ( BC6OTHER / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6ENTC and BC6OTHER .	False
The BC6OTHER BC6ENTG ( BC6OTHER / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6ENTC and BC6OTHER .	False
The BC6OTHER BC6OTHER ( BC6ENTG / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6ENTC and BC6OTHER .	False
The BC6OTHER BC6OTHER ( BC6OTHER / BC6ENTG ) can mediate resistance against the commonly used anticancer drugs BC6ENTC and BC6OTHER .	False
The BC6ENTG BC6OTHER ( BC6OTHER / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6ENTC .	False
The BC6OTHER BC6ENTG ( BC6OTHER / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6ENTC .	False
The BC6OTHER BC6OTHER ( BC6ENTG / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6ENTC .	False
The BC6OTHER BC6OTHER ( BC6OTHER / BC6ENTG ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6ENTC .	False
To overcome the BC6ENTG - depending drug resistance , two specific anti - BC6OTHER small interfering RNAs (siRNAs) were designed for transient triggering of the gene - silencing RNA interference (RNAi) pathway in the BC6ENTC - resistant human ovarian carcinoma cell line A2780RCIS.	False
To overcome the BC6OTHER - depending drug resistance , two specific anti - BC6ENTG small interfering RNAs (siRNAs) were designed for transient triggering of the gene - silencing RNA interference (RNAi) pathway in the BC6ENTC - resistant human ovarian carcinoma cell line A2780RCIS.	False
The BC6ENTC binding cassette (ABC) - transporter BC6ENTG ( BC6OTHER / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6OTHER .	False
The BC6ENTC binding cassette (ABC) - transporter BC6OTHER ( BC6ENTG / BC6OTHER ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6OTHER .	False
The BC6ENTC binding cassette (ABC) - transporter BC6OTHER ( BC6OTHER / BC6ENTG ) can mediate resistance against the commonly used anticancer drugs BC6OTHER and BC6OTHER .	False
RNA interference - triggered reversal of BC6ENTG - dependent BC6ENTC resistance in human cancer cells.	False
Methods: Stabilized anaplastic thyroid cancer cell lines (CHEM and CAL - 62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the BC6ENTG inhibitor BC6ENTC .	CPR:4
Results: Our results demonstrate that treatment with BC6ENTC leads to BC6ENTG RNA expression as shown by RT - PCR and luciferase assay , and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.	CPR:3
The resistance of anaplastic thyroid cancer to BC6ENTC treatment is principally due to the absence of expression of the BC6ENTG ( BC6OTHER ) , mainly due to epigenetic silencing.	False
The resistance of anaplastic thyroid cancer to BC6ENTC treatment is principally due to the absence of expression of the BC6OTHER ( BC6ENTG ) , mainly due to epigenetic silencing.	False
The resistance of anaplastic thyroid cancer to BC6OTHER treatment is principally due to the absence of expression of the BC6ENTC symporter ( BC6ENTG ) , mainly due to epigenetic silencing.	False
 BC6ENTG INHIBITION AFFECTS BC6ENTC SYMPORTER ( BC6OTHER ) EXPRESSION AND INDUCES BC6OTHER CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.	False
 BC6OTHER INHIBITION AFFECTS BC6ENTC SYMPORTER ( BC6ENTG ) EXPRESSION AND INDUCES BC6OTHER CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.	False
 BC6ENTG INHIBITION AFFECTS BC6OTHER ( BC6OTHER ) EXPRESSION AND INDUCES BC6ENTC CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.	False
 BC6OTHER INHIBITION AFFECTS BC6ENTG ( BC6OTHER ) EXPRESSION AND INDUCES BC6ENTC CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.	False
 BC6OTHER INHIBITION AFFECTS BC6OTHER ( BC6ENTG ) EXPRESSION AND INDUCES BC6ENTC CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.	False
To further validate the result , we examined sub - cellular distribution of BC6ENTG in lungs of CS - exposed guinea pigs treated or untreated with BC6ENTC .	False
Result showed that BC6ENTC treatment resulted in markedly reduced BC6ENTG nuclear translocation.	CPR:4
All these results demonstrate that BC6ENTC prevents CS(E) - induced BC6ENTG activation and thus it could be used for the prevention of CS - induced inflammatory diseases.	CPR:4
It is possible that BC6ENTC , an antioxidant , may prevent cigarette smoke (CS) - induced BC6ENTG activation that involves degradation of BC6OTHER and nuclear translocation of BC6OTHER / BC6OTHER in alveolar epithelial cells.	CPR:4
It is possible that BC6ENTC , an antioxidant , may prevent cigarette smoke (CS) - induced BC6OTHER activation that involves degradation of BC6ENTG and nuclear translocation of BC6OTHER / BC6OTHER in alveolar epithelial cells.	CPR:4
It is possible that BC6ENTC , an antioxidant , may prevent cigarette smoke (CS) - induced BC6OTHER activation that involves degradation of BC6OTHER and nuclear translocation of BC6ENTG / BC6OTHER in alveolar epithelial cells.	False
It is possible that BC6ENTC , an antioxidant , may prevent cigarette smoke (CS) - induced BC6OTHER activation that involves degradation of BC6OTHER and nuclear translocation of BC6OTHER / BC6ENTG in alveolar epithelial cells.	False
Therefore , to examine the hypothesis , we verified the effect of BC6ENTC on CS - induced expression of BC6ENTG driven luciferase reporter and BC6OTHER binding at its target DNA by EMSA in alveolar epithelial A549 cells.	False
Therefore , to examine the hypothesis , we verified the effect of BC6ENTC on CS - induced expression of BC6OTHER driven luciferase reporter and BC6ENTG binding at its target DNA by EMSA in alveolar epithelial A549 cells.	False
We also examined the level of BC6ENTG and sub - cellular distribution of BC6OTHER by western blotting and immunofluorescence respectively in CSE - treated A549 cells with or without BC6ENTC pretreatment.	False
We also examined the level of BC6OTHER and sub - cellular distribution of BC6ENTG by western blotting and immunofluorescence respectively in CSE - treated A549 cells with or without BC6ENTC pretreatment.	False
We observed a significant reduction in CSE induced luciferase expression , BC6ENTG DNA binding , BC6OTHER degradation and BC6OTHER nuclear translocation in cells pretreated with BC6ENTC .	False
We observed a significant reduction in CSE induced luciferase expression , BC6OTHER DNA binding , BC6ENTG degradation and BC6OTHER nuclear translocation in cells pretreated with BC6ENTC .	CPR:4
We observed a significant reduction in CSE induced luciferase expression , BC6OTHER DNA binding , BC6OTHER degradation and BC6ENTG nuclear translocation in cells pretreated with BC6ENTC .	False
 BC6ENTC forestalls cigarette smoke induced BC6ENTG activation in alveolar epithelial cells.	CPR:4
BC6ENTC (nonselective BC6ENTG antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:6
BC6ENTC (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6ENTC (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6ENTG antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6ENTG antagonist) , BC6ENTC (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6OTHER antagonist) , BC6ENTC (selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:6
BC6OTHER (nonselective BC6OTHER antagonist) , BC6ENTC (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6ENTG antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6ENTG antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6ENTG antagonist) and BC6ENTC ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6ENTC ( BC6OTHER ) (selective BC6ENTG antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:6
BC6OTHER (nonselective BC6ENTG antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6ENTG antagonist) and BC6OTHER ( BC6ENTC ) (selective BC6OTHER antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	False
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6ENTC ) (selective BC6ENTG antagonist) competitively antagonized the BC6OTHER - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:6
BC6OTHER (nonselective BC6ENTG antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6ENTC - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:5
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6ENTG antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6OTHER antagonist) competitively antagonized the BC6ENTC - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:5
BC6OTHER (nonselective BC6OTHER antagonist) , BC6OTHER (selective BC6OTHER antagonist) and BC6OTHER ( BC6OTHER ) (selective BC6ENTG antagonist) competitively antagonized the BC6ENTC - induced contraction (pA(2) values , 8.60+ / - 0.07 , 9.44+ / - 0.06 and 5.75+ / - 0.07 , respectively).	CPR:5
BC6ENTG antagonists were tested against the BC6ENTC ( BC6OTHER agonist) - induced contraction in isolated hamster ureteral preparations using a functional experimental approach.	False
BC6OTHER antagonists were tested against the BC6ENTC ( BC6ENTG agonist) - induced contraction in isolated hamster ureteral preparations using a functional experimental approach.	CPR:5
BC6ENTC and BC6OTHER ( BC6ENTG agonist) each produced a concentration - dependent tonic contraction , their pD(2) values being 6.87+ / - 0.08 and 6.10+ / - 0.05 , respectively.	CPR:5
BC6OTHER and BC6ENTC ( BC6ENTG agonist) each produced a concentration - dependent tonic contraction , their pD(2) values being 6.87+ / - 0.08 and 6.10+ / - 0.05 , respectively.	CPR:5
BC6ENTC depletion did not change the level of BC6ENTG protein.	False
Inhibition of BC6ENTC decarboxylase by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6ENTG .	False
Inhibition of BC6ENTG by a specific inhibitor [ BC6ENTC ; BC6OTHER ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6OTHER .	CPR:4
Inhibition of BC6OTHER by a specific inhibitor [ BC6ENTC ; BC6OTHER ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6ENTG .	False
Inhibition of BC6ENTG by a specific inhibitor [ BC6OTHER ; BC6ENTC ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6OTHER .	CPR:4
Inhibition of BC6OTHER by a specific inhibitor [ BC6OTHER ; BC6ENTC ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6ENTG .	False
Inhibition of BC6ENTG by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6ENTC and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6OTHER .	CPR:9
Inhibition of BC6OTHER by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6ENTC and BC6OTHER with a significant accumulation of BC6OTHER and induction of BC6ENTG .	False
Inhibition of BC6ENTG by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6OTHER and BC6ENTC with a significant accumulation of BC6OTHER and induction of BC6OTHER .	CPR:9
Inhibition of BC6OTHER by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6OTHER and BC6ENTC with a significant accumulation of BC6OTHER and induction of BC6ENTG .	False
Inhibition of BC6ENTG by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6ENTC and induction of BC6OTHER .	False
Inhibition of BC6OTHER by a specific inhibitor [ BC6OTHER ; BC6OTHER ] led to depletion of BC6OTHER and BC6OTHER with a significant accumulation of BC6ENTC and induction of BC6ENTG .	False
Addition of BC6ENTC to BC6OTHER - treated cell extracts did not increase BC6ENTG activity.	False
Addition of BC6OTHER to BC6ENTC - treated cell extracts did not increase BC6ENTG activity.	False
The above results indicate that BC6ENTC depletion delays the onset of apoptosis in IEC - 6 cells and confers protection against DNA damaging agents , suggesting that BC6OTHER might be involved in the BC6ENTG activating signal cascade.	False
The above results indicate that BC6OTHER depletion delays the onset of apoptosis in IEC - 6 cells and confers protection against DNA damaging agents , suggesting that BC6ENTC might be involved in the BC6ENTG activating signal cascade.	CPR:3
This study examines the involvement of BC6ENTC in the induction of apoptosis by the BC6ENTG inhibitor , CHEM.	False
Depletion of BC6ENTC , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6ENTC , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6OTHER , BC6ENTC , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6OTHER , BC6ENTC , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6OTHER , BC6OTHER , and BC6ENTC by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6OTHER , BC6OTHER , and BC6ENTC by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:9
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6ENTC ( BC6OTHER ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:4
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6ENTC ( BC6OTHER ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:4
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6ENTC ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:4
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6ENTC ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	CPR:4
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6ENTC decarboxylase ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6OTHER biosynthesis , decreased the apoptotic index.	False
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6ENTG ( BC6OTHER ) that is the CHEM - limiting enzyme for BC6ENTC biosynthesis , decreased the apoptotic index.	False
Depletion of BC6OTHER , BC6OTHER , and BC6OTHER by BC6OTHER ( BC6OTHER ) , a specific inhibitor of BC6OTHER ( BC6ENTG ) that is the CHEM - limiting enzyme for BC6ENTC biosynthesis , decreased the apoptotic index.	False
Delayed apoptosis was accompanied by a decrease in BC6ENTG activity in BC6ENTC - depleted cells.	False
Addition of BC6ENTC restored the induction of apoptosis as indicated by an increase in the number of detached cells and BC6ENTG activity.	CPR:3
BC6OTHER ( BC6OTHER ) decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6ENTG , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6ENTG , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6ENTC ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6ENTG , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6ENTG , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6ENTC ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
BC6ENTC and BC6OTHER attenuated the mRNA expression of BC6ENTG and BC6OTHER induced by the costimulation of BC6OTHER , BC6OTHER , and LPS.	CPR:4
BC6ENTC and BC6OTHER attenuated the mRNA expression of BC6OTHER and BC6ENTG induced by the costimulation of BC6OTHER , BC6OTHER , and LPS.	CPR:4
BC6ENTC and BC6OTHER attenuated the mRNA expression of BC6OTHER and BC6OTHER induced by the costimulation of BC6ENTG , BC6OTHER , and LPS.	False
BC6ENTC and BC6OTHER attenuated the mRNA expression of BC6OTHER and BC6OTHER induced by the costimulation of BC6OTHER , BC6ENTG , and LPS.	False
BC6OTHER and BC6ENTC attenuated the mRNA expression of BC6ENTG and BC6OTHER induced by the costimulation of BC6OTHER , BC6OTHER , and LPS.	CPR:4
BC6OTHER and BC6ENTC attenuated the mRNA expression of BC6OTHER and BC6ENTG induced by the costimulation of BC6OTHER , BC6OTHER , and LPS.	CPR:4
BC6OTHER and BC6ENTC attenuated the mRNA expression of BC6OTHER and BC6OTHER induced by the costimulation of BC6ENTG , BC6OTHER , and LPS.	False
BC6OTHER and BC6ENTC attenuated the mRNA expression of BC6OTHER and BC6OTHER induced by the costimulation of BC6OTHER , BC6ENTG , and LPS.	False
BC6ENTC and the BC6ENTG inhibitors may decrease pulmonary neutrophilia due , in part , to a direct inhibition of some of these factors.	False
BC6ENTG either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6ENTG ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6ENTG ( BC6OTHER ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6ENTG ) on BC6OTHER .	False
BC6OTHER either increased the expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , and inducible BC6ENTC synthase ( BC6OTHER ) , or potentiated the coeffects of lipopolysaccharide (LPS) and BC6OTHER ( BC6OTHER ) on BC6ENTG .	False
BC6ENTC ( BC6OTHER ) decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6ENTG , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6ENTG , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER .	False
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER .	False
BC6ENTC ( BC6OTHER ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG .	False
BC6OTHER ( BC6ENTC ) decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6ENTG , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6ENTG , decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6ENTG , BC6OTHER , and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6ENTG , and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) decreased the expression of BC6OTHER , BC6OTHER , and BC6OTHER induced by BC6OTHER , while BC6OTHER ( BC6OTHER ) , a selective inhibitor of BC6OTHER , decreased the expression of BC6OTHER , BC6OTHER , and BC6ENTG .	False
 BC6ENTG stimulates the expression of BC6OTHER , BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase mRNA by equine pulmonary artery endothelial cells.	False
 BC6OTHER stimulates the expression of BC6ENTG , BC6OTHER , BC6OTHER , and inducible BC6ENTC synthase mRNA by equine pulmonary artery endothelial cells.	False
 BC6OTHER stimulates the expression of BC6OTHER , BC6ENTG , BC6OTHER , and inducible BC6ENTC synthase mRNA by equine pulmonary artery endothelial cells.	False
 BC6OTHER stimulates the expression of BC6OTHER , BC6OTHER , BC6ENTG , and inducible BC6ENTC synthase mRNA by equine pulmonary artery endothelial cells.	False
 BC6ENTG agonist BC6ENTC enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.	CPR:5
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , together with the expression of BC6OTHER and BC6OTHER proteins.	CPR:3
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , together with the expression of BC6OTHER and BC6OTHER proteins.	CPR:3
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , together with the expression of BC6OTHER and BC6OTHER proteins.	CPR:3
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , together with the expression of BC6OTHER and BC6OTHER proteins.	CPR:3
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , together with the expression of BC6ENTG and BC6OTHER proteins.	CPR:3
In addition , BC6ENTC induces the DNA - binding activities of the transcription factor BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , together with the expression of BC6OTHER and BC6ENTG proteins.	CPR:3
Moreover , inhibitory experiments addressed a central role for BC6ENTG in the regulation of BC6ENTC - induced apoptosis of melanoma cells via mitochondrial and non - mitochondrial - dependent mechanisms.	False
In conclusion , the present study addresses for the first time a central role for BC6ENTG in the modulation of BC6ENTC - induced apoptosis of melanoma cells and thereby provides an insight into the molecular action of BC6OTHER in melanoma treatment.	False
In conclusion , the present study addresses for the first time a central role for BC6ENTG in the modulation of BC6OTHER - induced apoptosis of melanoma cells and thereby provides an insight into the molecular action of BC6ENTC in melanoma treatment.	False
In the present study , the exposure of melanoma cells to BC6ENTC was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6ENTG and BC6OTHER , activation of BC6OTHER , and cleavage of BC6OTHER .	False
In the present study , the exposure of melanoma cells to BC6ENTC was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6OTHER and BC6ENTG , activation of BC6OTHER , and cleavage of BC6OTHER .	False
In the present study , the exposure of melanoma cells to BC6ENTC was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6OTHER and BC6OTHER , activation of BC6ENTG , and cleavage of BC6OTHER .	False
In the present study , the exposure of melanoma cells to BC6ENTC was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6OTHER and BC6OTHER , activation of BC6OTHER , and cleavage of BC6ENTG .	False
In the present study , the exposure of melanoma cells to BC6OTHER was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6ENTG and BC6OTHER , activation of BC6OTHER , and cleavage of BC6ENTC - Polymerase.	False
In the present study , the exposure of melanoma cells to BC6OTHER was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6OTHER and BC6ENTG , activation of BC6OTHER , and cleavage of BC6ENTC - Polymerase.	False
In the present study , the exposure of melanoma cells to BC6OTHER was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential , the release of both BC6OTHER and BC6OTHER , activation of BC6ENTG , and cleavage of BC6ENTC - Polymerase.	False
Also , BC6ENTC enhances the phosphorylation of BC6ENTG , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6ENTG , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6ENTG , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6ENTG ( BC6OTHER ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6ENTG ) BC6OTHER , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6ENTG , and BC6OTHER .	CPR:3
Also , BC6ENTC enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTG .	CPR:3
Also , BC6OTHER enhances the phosphorylation of BC6ENTG , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6ENTG , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6ENTG , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6ENTG ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6ENTG ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6ENTG , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6ENTC species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTG .	False
Also , BC6OTHER enhances the phosphorylation of BC6ENTG , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6ENTG , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6ENTG , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6ENTG ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6ENTG ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6ENTG , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6ENTC , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTG .	False
Also , BC6OTHER enhances the phosphorylation of BC6ENTG , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6ENTG , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6ENTG , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6ENTG ( BC6OTHER ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6OTHER ( BC6ENTG ) BC6OTHER , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6ENTG , and BC6OTHER .	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6ENTC - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTG .	False
Also , BC6OTHER enhances the phosphorylation of BC6ENTG , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6ENTG , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6ENTG , BC6OTHER ( BC6OTHER ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6ENTG ( BC6OTHER ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6ENTG ) BC6OTHER , and BC6ENTC requiring enzyme 1α.	False
Also , BC6OTHER enhances the phosphorylation of BC6OTHER , the accumulation of reactive BC6OTHER species , the release of intracellular BC6OTHER , as well as the activation of BC6OTHER , c - jun - BC6OTHER - terminal kinase , BC6OTHER , BC6OTHER ( BC6OTHER ) BC6ENTG , and BC6ENTC requiring enzyme 1α.	False
 BC6ENTC - induced apoptosis of melanoma cells is mediated by BC6ENTG ( BC6OTHER ) via mitochondrial and non - mitochondrial - dependent mechanisms.	False
 BC6ENTC - induced apoptosis of melanoma cells is mediated by BC6OTHER ( BC6ENTG ) via mitochondrial and non - mitochondrial - dependent mechanisms.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6ENTG ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6ENTG , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6ENTG - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6ENTG ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6ENTG - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6ENTG , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
The increased activities of the most important intestinal efflux ( BC6OTHER - BC6OTHER , BC6ENTG - BC6OTHER , BC6OTHER - BC6OTHER ) and uptake ( BC6ENTC Transporter 1 - BC6OTHER , BC6OTHER - BC6OTHER , BC6OTHER - BC6OTHER ) transporters were caused by changes in electrophysiological membrane properties and by allosteric modifications.	False
Because clinical studies investigating interactions between garlic and BC6ENTG inhibitors BC6ENTC and BC6OTHER have already been performed , we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first - pass intestinal metabolism changes.	CPR:4
Because clinical studies investigating interactions between garlic and BC6ENTG inhibitors BC6OTHER and BC6ENTC have already been performed , we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first - pass intestinal metabolism changes.	CPR:4
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER binding and functional assays.	False
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG binding and functional assays.	False
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER binding and functional assays.	False
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER binding and functional assays.	False
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER binding and functional assays.	False
The four stereoisomers of BC6ENTC were synthesized and evaluated in BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER binding and functional assays.	False
The concomitantly administered effects of BC6ENTC on other drugs can result in their altered metabolism or transportation that are metabolised by BC6ENTG or transported by BC6OTHER in the gastrointestinal tract and liver.	CPR:9
The concomitantly administered effects of BC6ENTC on other drugs can result in their altered metabolism or transportation that are metabolised by BC6OTHER or transported by BC6ENTG in the gastrointestinal tract and liver.	CPR:9
In general , BC6ENTC can act on a pattern: BC6OTHER activates the BC6ENTG that in turn affects BC6OTHER , BC6OTHER and BC6OTHER activities.	CPR:5
In general , BC6ENTC can act on a pattern: BC6OTHER activates the nuclear BC6OTHER X receptor that in turn affects BC6ENTG , BC6OTHER and BC6OTHER activities.	False
In general , BC6ENTC can act on a pattern: BC6OTHER activates the nuclear BC6OTHER X receptor that in turn affects BC6OTHER , BC6ENTG and BC6OTHER activities.	False
In general , BC6ENTC can act on a pattern: BC6OTHER activates the nuclear BC6OTHER X receptor that in turn affects BC6OTHER , BC6OTHER and BC6ENTG activities.	False
In general , BC6OTHER can act on a pattern: BC6ENTC activates the BC6ENTG that in turn affects BC6OTHER , BC6OTHER and BC6OTHER activities.	CPR:3
In general , BC6OTHER can act on a pattern: BC6ENTC activates the nuclear BC6OTHER X receptor that in turn affects BC6ENTG , BC6OTHER and BC6OTHER activities.	False
In general , BC6OTHER can act on a pattern: BC6ENTC activates the nuclear BC6OTHER X receptor that in turn affects BC6OTHER , BC6ENTG and BC6OTHER activities.	False
In general , BC6OTHER can act on a pattern: BC6ENTC activates the nuclear BC6OTHER X receptor that in turn affects BC6OTHER , BC6OTHER and BC6ENTG activities.	False
In general , BC6OTHER can act on a pattern: BC6OTHER activates the nuclear BC6ENTC X receptor that in turn affects BC6ENTG , BC6OTHER and BC6OTHER activities.	False
In general , BC6OTHER can act on a pattern: BC6OTHER activates the nuclear BC6ENTC X receptor that in turn affects BC6OTHER , BC6ENTG and BC6OTHER activities.	False
In general , BC6OTHER can act on a pattern: BC6OTHER activates the nuclear BC6ENTC X receptor that in turn affects BC6OTHER , BC6OTHER and BC6ENTG activities.	False
Roles of BC6ENTC in drug - drug interactions: underlying molecular mechanisms involving the BC6ENTG .	False
Thus far , PHA1 has been attributed to mutations affecting the BC6ENTG or any of the three subunits assembling the BC6ENTC - sensitive epithelial BC6OTHER channel ( BC6OTHER ).	False
Thus far , PHA1 has been attributed to mutations affecting the BC6OTHER or any of the three subunits assembling the BC6ENTC - sensitive epithelial BC6OTHER channel ( BC6ENTG ).	False
Thus far , PHA1 has been attributed to mutations affecting the BC6ENTG or any of the three subunits assembling the CHEM - sensitive epithelial BC6ENTC channel ( BC6OTHER ).	False
Thus far , PHA1 has been attributed to mutations affecting the BC6OTHER or any of the three subunits assembling the CHEM - sensitive epithelial BC6ENTC channel ( BC6ENTG ).	False
Recent studies have elucidated additional participants ( BC6ENTG and members of the families of transmembrane BC6ENTC proteases , BC6OTHER , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6ENTC proteases , BC6ENTG , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6ENTC proteases , BC6OTHER , and BC6ENTG , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6ENTG and members of the families of transmembrane BC6OTHER proteases , BC6OTHER , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6ENTC retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of BC6ENTG , BC6OTHER , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6ENTC retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6OTHER proteases , BC6ENTG , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6ENTC retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6OTHER proteases , BC6OTHER , and BC6ENTG , respectively) regulating and / or interacting in the complex pathway of BC6ENTC retention in the BC6OTHER - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6ENTG and members of the families of transmembrane BC6OTHER proteases , BC6OTHER , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6ENTC - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of BC6ENTG , BC6OTHER , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6ENTC - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6OTHER proteases , BC6ENTG , and BC6OTHER , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6ENTC - sensitive distal nephron.	False
Recent studies have elucidated additional participants ( BC6OTHER and members of the families of transmembrane BC6OTHER proteases , BC6OTHER , and BC6ENTG , respectively) regulating and / or interacting in the complex pathway of BC6OTHER retention in the BC6ENTC - sensitive distal nephron.	False
BC6ENTC 2 , 3 - dioxygenase ( BC6ENTG ) , a BC6OTHER catabolizing enzyme , has been implicated in the pathogenesis of various neurological disorders.	False
BC6ENTG expression is induced by BC6OTHER and leads to neurotoxicity by generating BC6ENTC .	False
BC6OTHER expression is induced by BC6ENTG and leads to neurotoxicity by generating BC6ENTC .	False
BC6ENTG ( BC6OTHER ) , a BC6ENTC catabolizing enzyme , has been implicated in the pathogenesis of various neurological disorders.	CPR:9
BC6OTHER ( BC6ENTG ) , a BC6ENTC catabolizing enzyme , has been implicated in the pathogenesis of various neurological disorders.	CPR:9
However , BC6ENTC - tRNA synthetase ( BC6ENTG ) , which is coinduced with BC6OTHER by BC6OTHER , is downregulated by BC6OTHER and BC6OTHER .	False
However , BC6ENTC - tRNA synthetase ( BC6OTHER ) , which is coinduced with BC6ENTG by BC6OTHER , is downregulated by BC6OTHER and BC6OTHER .	False
However , BC6ENTC - tRNA synthetase ( BC6OTHER ) , which is coinduced with BC6OTHER by BC6ENTG , is downregulated by BC6OTHER and BC6OTHER .	False
However , BC6ENTC - tRNA synthetase ( BC6OTHER ) , which is coinduced with BC6OTHER by BC6OTHER , is downregulated by BC6ENTG and BC6OTHER .	False
However , BC6ENTC - tRNA synthetase ( BC6OTHER ) , which is coinduced with BC6OTHER by BC6OTHER , is downregulated by BC6OTHER and BC6ENTG .	False
The BC6ENTC 3 - kinase ( BC6OTHER ) pathway further differentiated the regulation of these two enzymes , as inhibiting the BC6ENTG pathway eliminated BC6OTHER induction of BC6OTHER , whereas such inhibition greatly enhanced BC6OTHER expression.	False
The BC6ENTC 3 - kinase ( BC6OTHER ) pathway further differentiated the regulation of these two enzymes , as inhibiting the BC6OTHER pathway eliminated BC6ENTG induction of BC6OTHER , whereas such inhibition greatly enhanced BC6OTHER expression.	False
The BC6ENTC 3 - kinase ( BC6OTHER ) pathway further differentiated the regulation of these two enzymes , as inhibiting the BC6OTHER pathway eliminated BC6OTHER induction of BC6ENTG , whereas such inhibition greatly enhanced BC6OTHER expression.	False
The BC6ENTC 3 - kinase ( BC6OTHER ) pathway further differentiated the regulation of these two enzymes , as inhibiting the BC6OTHER pathway eliminated BC6OTHER induction of BC6OTHER , whereas such inhibition greatly enhanced BC6ENTG expression.	False
The BC6ENTC 3 - kinase ( BC6ENTG ) pathway further differentiated the regulation of these two enzymes , as inhibiting the BC6OTHER pathway eliminated BC6OTHER induction of BC6OTHER , whereas such inhibition greatly enhanced BC6OTHER expression.	False
In addition , the number and area of BC6ENTG ( BC6OTHER ) positive foci and BC6OTHER ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6ENTC compared with the control animals.	CPR:3
In addition , the number and area of CHEM BC6OTHER - transferase placental form ( BC6ENTG ) positive foci and BC6OTHER ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6ENTC compared with the control animals.	CPR:3
In addition , the number and area of CHEM BC6OTHER - transferase placental form ( BC6OTHER ) positive foci and BC6ENTG ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6ENTC compared with the control animals.	CPR:3
In addition , the number and area of CHEM BC6OTHER - transferase placental form ( BC6OTHER ) positive foci and BC6OTHER ( BC6ENTG ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6ENTC compared with the control animals.	CPR:3
In this study , a BC6ENTG delta transgenic rat model was used to clarify whether genotoxic mechanisms are involved in BC6ENTC - induced hepatocarcinogenesis following medium - term exposure.	False
F344 BC6ENTG delta rats were subjected to repeated oral administration of BC6ENTC at dosages of 0 , 10 , 30 , or 100mg / kg (a carcinogenic dose) for 13 weeks.	False
In addition , the number and area of BC6ENTC BC6OTHER - transferase placental form ( BC6ENTG ) positive foci and BC6OTHER ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In addition , the number and area of BC6ENTC BC6OTHER - transferase placental form ( BC6OTHER ) positive foci and BC6ENTG ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In addition , the number and area of BC6ENTC BC6OTHER - transferase placental form ( BC6OTHER ) positive foci and BC6OTHER ( BC6ENTG ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In addition , the number and area of CHEM BC6ENTC - transferase placental form ( BC6ENTG ) positive foci and BC6OTHER ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In addition , the number and area of CHEM BC6ENTC - transferase placental form ( BC6OTHER ) positive foci and BC6ENTG ( BC6OTHER ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In addition , the number and area of CHEM BC6ENTC - transferase placental form ( BC6OTHER ) positive foci and BC6OTHER ( BC6ENTG ) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg / kg BC6OTHER compared with the control animals.	False
In vivo genotoxicity of BC6ENTC in BC6ENTG delta transgenic rats following medium - term exposure.	False
The activity of BC6ENTG in excised liver samples from rats following multiple BC6ENTC treatment was significantly decreased compared to that of the control group (P<0.05) , whereas multiple doses of BC6OTHER had no obvious effect on the activity of BC6OTHER .	CPR:4
The activity of BC6OTHER in excised liver samples from rats following multiple BC6ENTC treatment was significantly decreased compared to that of the control group (P<0.05) , whereas multiple doses of BC6OTHER had no obvious effect on the activity of BC6ENTG .	False
The activity of BC6ENTG in excised liver samples from rats following multiple BC6OTHER treatment was significantly decreased compared to that of the control group (P<0.05) , whereas multiple doses of BC6ENTC had no obvious effect on the activity of BC6OTHER .	False
The activity of BC6OTHER in excised liver samples from rats following multiple BC6OTHER treatment was significantly decreased compared to that of the control group (P<0.05) , whereas multiple doses of BC6ENTC had no obvious effect on the activity of BC6ENTG .	False
Taken together , these data demonstrate that BC6ENTC inhibits the metabolism of BC6OTHER in a concentration - dependent manner in rats , possibly through inhibiting hepatic BC6ENTG and BC6OTHER activities.	CPR:4
Taken together , these data demonstrate that BC6ENTC inhibits the metabolism of BC6OTHER in a concentration - dependent manner in rats , possibly through inhibiting hepatic BC6OTHER and BC6ENTG activities.	CPR:4
Taken together , these data demonstrate that BC6OTHER inhibits the metabolism of BC6ENTC in a concentration - dependent manner in rats , possibly through inhibiting hepatic BC6ENTG and BC6OTHER activities.	CPR:9
Taken together , these data demonstrate that BC6OTHER inhibits the metabolism of BC6ENTC in a concentration - dependent manner in rats , possibly through inhibiting hepatic BC6OTHER and BC6ENTG activities.	CPR:9
In the current study , we reveal the inhibitory effects of BC6ENTC on the metabolism of BC6OTHER ( BC6OTHER ) , a dual probe substrate of BC6ENTG and BC6OTHER , in rats.	CPR:4
In the current study , we reveal the inhibitory effects of BC6ENTC on the metabolism of BC6OTHER ( BC6OTHER ) , a dual probe substrate of BC6OTHER and BC6ENTG , in rats.	CPR:4
In the current study , we reveal the inhibitory effects of BC6OTHER on the metabolism of BC6ENTC ( BC6OTHER ) , a dual probe substrate of BC6ENTG and BC6OTHER , in rats.	CPR:9
In the current study , we reveal the inhibitory effects of BC6OTHER on the metabolism of BC6ENTC ( BC6OTHER ) , a dual probe substrate of BC6OTHER and BC6ENTG , in rats.	CPR:9
In the current study , we reveal the inhibitory effects of BC6OTHER on the metabolism of BC6OTHER ( BC6ENTC ) , a dual probe substrate of BC6ENTG and BC6OTHER , in rats.	CPR:9
In the current study , we reveal the inhibitory effects of BC6OTHER on the metabolism of BC6OTHER ( BC6ENTC ) , a dual probe substrate of BC6OTHER and BC6ENTG , in rats.	CPR:9
Lineweaver - Burk plots demonstrated that BC6ENTC inhibited the activities of BC6ENTG and BC6OTHER in a non - competitive manner in rat liver microsomes (RLMs).	CPR:4
Lineweaver - Burk plots demonstrated that BC6ENTC inhibited the activities of BC6OTHER and BC6ENTG in a non - competitive manner in rat liver microsomes (RLMs).	CPR:4
Concentration - dependent inhibitory effects of BC6ENTC on the metabolism of BC6OTHER , a dual probe of BC6ENTG and BC6OTHER , in rats.	CPR:4
Concentration - dependent inhibitory effects of BC6ENTC on the metabolism of BC6OTHER , a dual probe of BC6OTHER and BC6ENTG , in rats.	CPR:4
Concentration - dependent inhibitory effects of BC6OTHER on the metabolism of BC6ENTC , a dual probe of BC6ENTG and BC6OTHER , in rats.	CPR:9
Concentration - dependent inhibitory effects of BC6OTHER on the metabolism of BC6ENTC , a dual probe of BC6OTHER and BC6ENTG , in rats.	CPR:9
In GC patients , BC6ENTG expression was positively associated with the tumor stage and the nodal status , and inversely correlated with the response to ECF ( BC6ENTC , BC6OTHER , BC6OTHER ) chemotherapy.	False
In GC patients , BC6ENTG expression was positively associated with the tumor stage and the nodal status , and inversely correlated with the response to ECF ( BC6OTHER , BC6ENTC , BC6OTHER ) chemotherapy.	False
In GC patients , BC6ENTG expression was positively associated with the tumor stage and the nodal status , and inversely correlated with the response to ECF ( BC6OTHER , BC6OTHER , BC6ENTC ) chemotherapy.	False
These results showed that BC6ENTG and BC6OTHER are upregulated by chemotherapeutics and enhance the resistance of GC cells to BC6ENTC drugs.	CPR:3
These results showed that BC6OTHER and BC6ENTG are upregulated by chemotherapeutics and enhance the resistance of GC cells to BC6ENTC drugs.	CPR:3
BC6ENTG knock - down and overexpression experiments demonstrated that BC6OTHER increased the resistance to apoptotic cell death induced by the BC6ENTC chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER knock - down and overexpression experiments demonstrated that BC6ENTG increased the resistance to apoptotic cell death induced by the BC6ENTC chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6ENTG knock - down and overexpression experiments demonstrated that BC6OTHER increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER knock - down and overexpression experiments demonstrated that BC6ENTG increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
BC6ENTG knock - down and overexpression experiments demonstrated that BC6OTHER increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
BC6OTHER knock - down and overexpression experiments demonstrated that BC6ENTG increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
BC6ENTG knock - down and overexpression experiments demonstrated that BC6OTHER increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
BC6OTHER knock - down and overexpression experiments demonstrated that BC6ENTG increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
BC6ENTG knock - down and overexpression experiments demonstrated that BC6OTHER increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
BC6OTHER knock - down and overexpression experiments demonstrated that BC6ENTG increased the resistance to apoptotic cell death induced by the BC6OTHER chemotherapeutics BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
BC6ENTC increased the activity of the BC6ENTG through BC6OTHER - dependent binding of BC6OTHER to the proximal BC6OTHER .	CPR:3
BC6ENTC increased the activity of the BC6OTHER through BC6ENTG - dependent binding of BC6OTHER to the proximal BC6OTHER .	False
BC6ENTC increased the activity of the BC6OTHER through BC6OTHER - dependent binding of BC6ENTG to the proximal BC6OTHER .	False
BC6ENTC increased the activity of the BC6OTHER through BC6OTHER - dependent binding of BC6OTHER to the proximal BC6ENTG .	CPR:3
BC6ENTC increased both BC6ENTG / BC6OTHER and BC6OTHER expression in human GC cells and within the tumor area of a murine model of GC (CEA424 - SV40 TAg).	CPR:3
BC6ENTC increased both BC6OTHER / BC6ENTG and BC6OTHER expression in human GC cells and within the tumor area of a murine model of GC (CEA424 - SV40 TAg).	CPR:3
BC6ENTC increased both BC6OTHER / BC6OTHER and BC6ENTG expression in human GC cells and within the tumor area of a murine model of GC (CEA424 - SV40 TAg).	CPR:3
 BC6ENTG is a novel target gene of BC6OTHER promoting chemoresistance to BC6ENTC in human gastric cancer cells.	False
 BC6OTHER is a novel target gene of BC6ENTG promoting chemoresistance to BC6ENTC in human gastric cancer cells.	False
The aim of the present study was to evaluate the cardiac effects of the BC6OTHER agonist BC6ENTC , and determine whether BC6ENTG are involved in mediating chronotropic or inotropic responses in man.	False
The aim of the present study was to evaluate the cardiac effects of the BC6ENTG agonist BC6ENTC , and determine whether BC6OTHER are involved in mediating chronotropic or inotropic responses in man.	CPR:5
However , whereas N20 blocked these responses to BC6ENTC , a small but significant response occurred with BC6OTHER in comparison with placebo despite complete blockade of co - existing BC6ENTG - mediated effects.	False
However , whereas N20 blocked these responses to BC6OTHER , a small but significant response occurred with BC6ENTC in comparison with placebo despite complete blockade of co - existing BC6ENTG - mediated effects.	False
Eight normal males received single oral doses of BC6ENTC 8 mg ( BC6OTHER ) or the selective BC6ENTG agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6ENTC 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6ENTG antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6ENTC 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6ENTG .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6ENTC ) or the selective BC6ENTG agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6ENTC ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6ENTG antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6ENTC ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6ENTG .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6ENTG agonist BC6ENTC 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	CPR:5
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6ENTC 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6ENTG antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6ENTC 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6ENTG .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6ENTG agonist BC6OTHER 8 mg ( BC6ENTC ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	CPR:5
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6ENTC ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6ENTG antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6ENTC ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6ENTG .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6ENTG agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6ENTC 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6ENTC 5 mg (B5) as a selective BC6ENTG antagonist , or BC6OTHER 20 mg (N20) to block BC6OTHER .	CPR:6
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6ENTC 5 mg (B5) as a selective BC6OTHER antagonist , or BC6OTHER 20 mg (N20) to block BC6ENTG .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6ENTG agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6ENTC 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6ENTG antagonist , or BC6ENTC 20 mg (N20) to block BC6OTHER .	False
Eight normal males received single oral doses of BC6OTHER 8 mg ( BC6OTHER ) or the selective BC6OTHER agonist BC6OTHER 8 mg ( BC6OTHER ) , after pretreatment with either placebo (PL) , BC6OTHER 5 mg (B5) as a selective BC6OTHER antagonist , or BC6ENTC 20 mg (N20) to block BC6ENTG .	False
Both BC6ENTC and BC6OTHER produced a significant increase in postural finger tremor in keeping with BC6ENTG stimulation , and this response was totally abolished by pretreatment with N20.	CPR:3
Both BC6OTHER and BC6ENTC produced a significant increase in postural finger tremor in keeping with BC6ENTG stimulation , and this response was totally abolished by pretreatment with N20.	CPR:3
Significant increases in systolic blood pressure and Doppler stroke distance occurred with BC6ENTC and BC6OTHER which were unaffected by pretreatment with B5 and completely blocked by N20 , in keeping with BC6ENTG - mediated effects.	False
Significant increases in systolic blood pressure and Doppler stroke distance occurred with BC6OTHER and BC6ENTC which were unaffected by pretreatment with B5 and completely blocked by N20 , in keeping with BC6ENTG - mediated effects.	False
BC6ENTC and BC6OTHER produced significant chronotropic and minute distance responses which were unaffected by BC6ENTG blockade.	False
BC6OTHER and BC6ENTC produced significant chronotropic and minute distance responses which were unaffected by BC6ENTG blockade.	False
Cardiac effects of the BC6ENTG agonist BC6ENTC in man.	CPR:5
BC6OTHER and the BC6OTHER analogue inhibited BC6ENTC / BC6ENTG - dependent BC6OTHER with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	False
BC6OTHER and the BC6OTHER analogue inhibited BC6ENTC / BC6OTHER - dependent BC6ENTG with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	False
BC6OTHER and the BC6OTHER analogue inhibited BC6OTHER / BC6ENTG - dependent BC6OTHER with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6ENTC analogues caused no inhibition.	False
BC6OTHER and the BC6OTHER analogue inhibited BC6OTHER / BC6OTHER - dependent BC6ENTG with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6ENTC analogues caused no inhibition.	False
Similarly , BC6ENTC and the BC6OTHER analogue inhibited BC6ENTG activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact BC6OTHER (IC50 = 11.0 microM) was used as substrate.	CPR:4
Similarly , BC6ENTC and the BC6OTHER analogue inhibited BC6OTHER activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact BC6ENTG (IC50 = 11.0 microM) was used as substrate.	False
Similarly , BC6OTHER and the BC6ENTC analogue inhibited BC6ENTG activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact BC6OTHER (IC50 = 11.0 microM) was used as substrate.	CPR:4
Similarly , BC6OTHER and the BC6ENTC analogue inhibited BC6OTHER activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact BC6ENTG (IC50 = 11.0 microM) was used as substrate.	False
Finally , the effects of BC6ENTC and the three analogues on two processes which are dependent on BC6ENTG phosphorylation were examined , namely the BC6OTHER - activated BC6OTHER activity of BC6OTHER and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6ENTC and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6ENTG - activated BC6OTHER activity of BC6OTHER and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6ENTC and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6OTHER - activated BC6ENTG activity of BC6OTHER and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6ENTC and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6OTHER - activated BC6OTHER activity of BC6ENTG and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6ENTC and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6OTHER - activated BC6OTHER activity of BC6OTHER and the assembly of BC6ENTG filaments.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) of the BC6ENTC BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) of the BC6ENTC BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6ENTC BC6ENTG blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6ENTC BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) of the BC6ENTC BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
Finally , the effects of BC6OTHER and the three analogues on two processes which are dependent on BC6ENTG phosphorylation were examined , namely the BC6OTHER - activated BC6ENTC - ATPase activity of BC6OTHER and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6OTHER and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6ENTG - activated BC6ENTC - ATPase activity of BC6OTHER and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6OTHER and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6OTHER - activated BC6ENTC - ATPase activity of BC6ENTG and the assembly of BC6OTHER filaments.	False
Finally , the effects of BC6OTHER and the three analogues on two processes which are dependent on BC6OTHER phosphorylation were examined , namely the BC6OTHER - activated BC6ENTC - ATPase activity of BC6OTHER and the assembly of BC6ENTG filaments.	False
BC6ENTC and the BC6OTHER analogue inhibited the BC6ENTG - activated BC6OTHER activity of smooth muscle BC6OTHER (IC50 = 25.1 microM).	False
BC6ENTC and the BC6OTHER analogue inhibited the BC6OTHER - activated BC6ENTG activity of smooth muscle BC6OTHER (IC50 = 25.1 microM).	CPR:4
BC6ENTC and the BC6OTHER analogue inhibited the BC6OTHER - activated BC6OTHER activity of smooth muscle BC6ENTG (IC50 = 25.1 microM).	CPR:4
BC6OTHER and the BC6ENTC analogue inhibited the BC6ENTG - activated BC6OTHER activity of smooth muscle BC6OTHER (IC50 = 25.1 microM).	False
BC6OTHER and the BC6ENTC analogue inhibited the BC6OTHER - activated BC6ENTG activity of smooth muscle BC6OTHER (IC50 = 25.1 microM).	CPR:4
BC6OTHER and the BC6ENTC analogue inhibited the BC6OTHER - activated BC6OTHER activity of smooth muscle BC6ENTG (IC50 = 25.1 microM).	CPR:4
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) of the BC6OTHER BC6ENTC channel blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) of the BC6OTHER BC6ENTC channel blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTC channel blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTC channel blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
BC6OTHER and the BC6OTHER analogue inhibited the BC6ENTG - activated BC6ENTC - ATPase activity of smooth muscle BC6OTHER (IC50 = 25.1 microM).	False
BC6OTHER and the BC6OTHER analogue inhibited the BC6OTHER - activated BC6ENTC - ATPase activity of smooth muscle BC6ENTG (IC50 = 25.1 microM).	False
Similarly , BC6ENTC and the BC6OTHER analogue blocked BC6ENTG filament assembly induced by low concentrations of BC6OTHER , whereas the oxidized and BC6OTHER analogues did not.	CPR:4
Similarly , BC6ENTC and the BC6OTHER analogue blocked BC6OTHER filament assembly induced by low concentrations of BC6ENTG , whereas the oxidized and BC6OTHER analogues did not.	False
Similarly , BC6OTHER and the BC6ENTC analogue blocked BC6ENTG filament assembly induced by low concentrations of BC6OTHER , whereas the oxidized and BC6OTHER analogues did not.	CPR:4
Similarly , BC6OTHER and the BC6ENTC analogue blocked BC6OTHER filament assembly induced by low concentrations of BC6ENTG , whereas the oxidized and BC6OTHER analogues did not.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6ENTC and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) of the BC6OTHER BC6OTHER blocker BC6ENTC and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTG blocker BC6ENTC and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	CPR:4
We have examined the effects on the activities of three BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6ENTC and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6ENTC and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
Similarly , BC6OTHER and the BC6OTHER analogue blocked BC6ENTG filament assembly induced by low concentrations of BC6OTHER , whereas the oxidized and BC6ENTC analogues did not.	False
Similarly , BC6OTHER and the BC6OTHER analogue blocked BC6OTHER filament assembly induced by low concentrations of BC6ENTG , whereas the oxidized and BC6ENTC analogues did not.	False
Again , inhibition of the BC6ENTG - activated BC6OTHER BC6ENTC - ATPase and BC6OTHER filament assembly by BC6OTHER and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	False
Again , inhibition of the BC6OTHER - activated BC6ENTG BC6ENTC - ATPase and BC6OTHER filament assembly by BC6OTHER and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	False
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6ENTC - ATPase and BC6ENTG filament assembly by BC6OTHER and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	False
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6ENTC - ATPase and BC6OTHER filament assembly by BC6OTHER and the BC6OTHER analogue could be reversed by raising the BC6ENTG concentration.	False
Again , inhibition of the BC6ENTG - activated BC6OTHER BC6OTHER and BC6OTHER filament assembly by BC6ENTC and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	False
Again , inhibition of the BC6OTHER - activated BC6ENTG BC6OTHER and BC6OTHER filament assembly by BC6ENTC and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6ENTG and BC6OTHER filament assembly by BC6ENTC and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6OTHER and BC6ENTG filament assembly by BC6ENTC and the BC6OTHER analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6OTHER and BC6OTHER filament assembly by BC6ENTC and the BC6OTHER analogue could be reversed by raising the BC6ENTG concentration.	False
Again , inhibition of the BC6ENTG - activated BC6OTHER BC6OTHER and BC6OTHER filament assembly by BC6OTHER and the BC6ENTC analogue could be reversed by raising the BC6OTHER concentration.	False
Again , inhibition of the BC6OTHER - activated BC6ENTG BC6OTHER and BC6OTHER filament assembly by BC6OTHER and the BC6ENTC analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6ENTG and BC6OTHER filament assembly by BC6OTHER and the BC6ENTC analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6OTHER and BC6ENTG filament assembly by BC6OTHER and the BC6ENTC analogue could be reversed by raising the BC6OTHER concentration.	CPR:4
Again , inhibition of the BC6OTHER - activated BC6OTHER BC6OTHER and BC6OTHER filament assembly by BC6OTHER and the BC6ENTC analogue could be reversed by raising the BC6ENTG concentration.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6ENTC , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6ENTC , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTG blocker BC6OTHER and three analogues ( BC6ENTC , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6ENTC , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6ENTC , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
These observations suggest that some of the pharmacological actions of BC6ENTC on smooth muscle may involve inhibition of BC6ENTG which are functionally involved in the regulation of smooth muscle contraction.	CPR:4
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6ENTG and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6ENTC ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTG ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6ENTC ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTG blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6ENTC ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6ENTG ( BC6OTHER , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6ENTC ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTG , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6ENTC ) exhibiting different pharmacological potencies.	False
The BC6ENTG was inhibited completely by BC6ENTC and the BC6OTHER analogue with IC50 values of 3.7 and 1.5 microM respectively.	CPR:4
The BC6ENTG was inhibited completely by BC6OTHER and the BC6ENTC analogue with IC50 values of 3.7 and 1.5 microM respectively.	CPR:4
The oxidized and BC6ENTC analogues were relatively ineffective in inhibiting BC6ENTG .	False
BC6ENTC and the BC6OTHER analogue inhibited the basal ( BC6OTHER / calmodulin - independent) activity of BC6ENTG as well as the BC6OTHER - stimulated activity.	CPR:4
BC6ENTC and the BC6OTHER analogue inhibited the basal ( BC6OTHER / calmodulin - independent) activity of BC6OTHER as well as the BC6ENTG - stimulated activity.	CPR:4
BC6OTHER and the BC6ENTC analogue inhibited the basal ( BC6OTHER / calmodulin - independent) activity of BC6ENTG as well as the BC6OTHER - stimulated activity.	CPR:4
BC6OTHER and the BC6ENTC analogue inhibited the basal ( BC6OTHER / calmodulin - independent) activity of BC6OTHER as well as the BC6ENTG - stimulated activity.	CPR:4
BC6OTHER and the BC6OTHER analogue inhibited the basal ( BC6ENTC / calmodulin - independent) activity of BC6ENTG as well as the BC6OTHER - stimulated activity.	False
BC6OTHER and the BC6OTHER analogue inhibited the basal ( BC6ENTC / calmodulin - independent) activity of BC6OTHER as well as the BC6ENTG - stimulated activity.	False
BC6OTHER and the BC6OTHER analogue inhibited the basal ( BC6OTHER / calmodulin - independent) activity of BC6ENTC phosphodiesterase as well as the BC6ENTG - stimulated activity.	False
BC6ENTG was relatively ineffective in preventing inhibition of BC6ENTC phosphodiesterase by BC6OTHER and the BC6OTHER analogue.	False
BC6ENTG was relatively ineffective in preventing inhibition of BC6OTHER by BC6ENTC and the BC6OTHER analogue.	False
BC6OTHER was relatively ineffective in preventing inhibition of BC6ENTG by BC6ENTC and the BC6OTHER analogue.	CPR:4
BC6ENTG was relatively ineffective in preventing inhibition of BC6OTHER by BC6OTHER and the BC6ENTC analogue.	False
BC6OTHER was relatively ineffective in preventing inhibition of BC6ENTG by BC6OTHER and the BC6ENTC analogue.	CPR:4
We have examined the effects on the activities of three BC6OTHER ( BC6ENTC phosphodiesterase , BC6ENTG and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTC phosphodiesterase , BC6OTHER and BC6ENTG ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6OTHER ( BC6ENTC phosphodiesterase , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6ENTG blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
We have examined the effects on the activities of three BC6ENTG ( BC6ENTC phosphodiesterase , BC6OTHER and BC6OTHER ) of the BC6OTHER BC6OTHER blocker BC6OTHER and three analogues ( BC6OTHER , oxidized and BC6OTHER ) exhibiting different pharmacological potencies.	False
These observations suggest that BC6ENTC may act directly on the BC6ENTG as well as through BC6OTHER .	False
These observations suggest that BC6ENTC may act directly on the BC6OTHER as well as through BC6ENTG .	False
BC6ENTC and the BC6OTHER analogue inhibited BC6OTHER / BC6ENTG - dependent BC6OTHER with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	False
BC6ENTC and the BC6OTHER analogue inhibited BC6OTHER / BC6OTHER - dependent BC6ENTG with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	CPR:4
BC6OTHER and the BC6ENTC analogue inhibited BC6OTHER / BC6ENTG - dependent BC6OTHER with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	False
BC6OTHER and the BC6ENTC analogue inhibited BC6OTHER / BC6OTHER - dependent BC6ENTG with similar potencies (IC50 = 17.4 microM) , whereas the oxidized and BC6OTHER analogues caused no inhibition.	CPR:4
Effects of BC6ENTC (a BC6OTHER BC6ENTG blocker) and analogues on BC6OTHER .	CPR:4
Effects of BC6ENTC (a BC6OTHER BC6OTHER blocker) and analogues on BC6ENTG .	False
Effects of BC6OTHER (a BC6ENTC BC6ENTG blocker) and analogues on BC6OTHER .	CPR:4
Effects of BC6OTHER (a BC6ENTC BC6OTHER blocker) and analogues on BC6ENTG .	False
Effects of BC6OTHER (a BC6OTHER BC6ENTC channel blocker) and analogues on BC6ENTG .	False
In addition , the new compound BC6ENTC (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6OTHER (17) , showed significant BC6ENTG ( BC6OTHER ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6ENTC (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6OTHER (17) , showed significant BC6OTHER ( BC6ENTG ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6ENTC derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6OTHER (17) , showed significant BC6ENTG ( BC6OTHER ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6ENTC derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6OTHER (17) , showed significant BC6OTHER ( BC6ENTG ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6ENTC , BC6OTHER (17) , showed significant BC6ENTG ( BC6OTHER ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6ENTC , BC6OTHER (17) , showed significant BC6OTHER ( BC6ENTG ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6ENTC (17) , showed significant BC6ENTG ( BC6OTHER ) inhibitory activity in an ELISA assay.	CPR:4
In addition , the new compound BC6OTHER (2) , three known BC6OTHER derivatives (9 , 11 , 12) , and a known BC6OTHER , BC6ENTC (17) , showed significant BC6OTHER ( BC6ENTG ) inhibitory activity in an ELISA assay.	CPR:4
A model including BC6ENTG and BC6OTHER genotypes , age , sex , and body weight accounted for 61% of the variance in BC6ENTC daily maintenance dose.	False
A model including BC6OTHER and BC6ENTG genotypes , age , sex , and body weight accounted for 61% of the variance in BC6ENTC daily maintenance dose.	False
Higher plasma BC6ENTC concentrations corresponding to increased BC6OTHER maintenance dosages support a hypothesis for increased expression of the BC6ENTG - 1639G allele.	False
Higher plasma BC6OTHER concentrations corresponding to increased BC6ENTC maintenance dosages support a hypothesis for increased expression of the BC6ENTG - 1639G allele.	False
BC6ENTG and BC6OTHER genotypes , age , sex , and body weight account for the majority of variance in BC6ENTC dose among our study population.	False
BC6OTHER and BC6ENTG genotypes , age , sex , and body weight account for the majority of variance in BC6ENTC dose among our study population.	False
Decreased expression of BC6ENTG resulting from the BC6OTHER substitution has also been implicated in lower BC6ENTC dose requirements.	False
Decreased expression of BC6OTHER resulting from the BC6ENTG substitution has also been implicated in lower BC6ENTC dose requirements.	False
Plasma BC6ENTC concentrations and BC6OTHER maintenance dose were compared among patients on the basis of the BC6ENTG BC6OTHER genotype.	False
Plasma BC6ENTC concentrations and BC6OTHER maintenance dose were compared among patients on the basis of the BC6OTHER BC6ENTG genotype.	False
Plasma BC6OTHER concentrations and BC6ENTC maintenance dose were compared among patients on the basis of the BC6ENTG BC6OTHER genotype.	False
Plasma BC6OTHER concentrations and BC6ENTC maintenance dose were compared among patients on the basis of the BC6OTHER BC6ENTG genotype.	False
BACKGROUND: BC6ENTG polymorphisms are associated with decreased BC6ENTC clearance and lower maintenance dosage.	False
RESULTS: Eighty percent of BC6ENTG *1 / *1 patients stabilized on <4.0 mg / day BC6ENTC had at least 1 BC6OTHER - 1639A allele.	False
RESULTS: Eighty percent of BC6OTHER *1 / *1 patients stabilized on <4.0 mg / day BC6ENTC had at least 1 BC6ENTG - 1639A allele.	False
Mean BC6ENTC doses (SD) were 6.7 (3.3) , 4.3 (2.2) , and 2.7 (1.2) mg / day for patients with the BC6ENTG - 1639GG , GA , and AA genotypes , respectively.	False
Steady - state plasma concentrations of BC6ENTC were lowest in patients with the BC6OTHER - 1639AA genotype and demonstrated a positive association with the BC6ENTG - 1639G allele copy number (trend P = 0.012).	False
Steady - state plasma concentrations of BC6ENTC were lowest in patients with the BC6ENTG - 1639AA genotype and demonstrated a positive association with the BC6OTHER - 1639G allele copy number (trend P = 0.012).	False
Estimation of BC6ENTC maintenance dose based on BC6ENTG ( BC6OTHER ) and BC6OTHER genotypes.	False
Estimation of BC6ENTC maintenance dose based on BC6OTHER ( BC6ENTG ) and BC6OTHER genotypes.	False
Estimation of BC6ENTC maintenance dose based on BC6OTHER ( BC6OTHER ) and BC6ENTG genotypes.	False
The present study also shows that some of the biological activities of BC6ENTC / BC6ENTG in SCC - VII cells strongly depend on a functional BC6OTHER - binding site within domain 3 , thus providing further evidence for the non - redundant cellular functions of the individual BC6OTHER - binding domains of the receptor.	False
The present study also shows that some of the biological activities of BC6OTHER / BC6ENTG in SCC - VII cells strongly depend on a functional BC6ENTC - binding site within domain 3 , thus providing further evidence for the non - redundant cellular functions of the individual BC6OTHER - binding domains of the receptor.	False
The present study also shows that some of the biological activities of BC6OTHER / BC6ENTG in SCC - VII cells strongly depend on a functional BC6OTHER - binding site within domain 3 , thus providing further evidence for the non - redundant cellular functions of the individual BC6ENTC - binding domains of the receptor.	False
It has been shown that expression of wild - type BC6ENTC / BC6ENTG reduces the tumorigenic and invasive properties of receptor - deficient SCC - VII squamous cell carcinoma cells.	False
We have now used mutant forms of BC6ENTC / BC6ENTG to assess the relevance of the different ligand - binding sites of the receptor for its biological activities in this cellular system.	False
The BC6ENTC ( BC6OTHER ) / BC6ENTG ( BC6OTHER ) interacts with a variety of factors that impinge on tumour invasion and metastasis.	False
The BC6ENTC ( BC6OTHER ) / BC6OTHER ( BC6ENTG ) interacts with a variety of factors that impinge on tumour invasion and metastasis.	False
The results of the present study demonstrate that BC6ENTC / BC6ENTG does not require a functional binding site for BC6OTHER for inhibition of anchorage - independent growth and matrix invasion by SCC - VII cells.	False
The results of the present study demonstrate that BC6ENTC / BC6OTHER does not require a functional binding site for BC6ENTG for inhibition of anchorage - independent growth and matrix invasion by SCC - VII cells.	False
These findings highlight that the interaction between BC6ENTC / BC6ENTG and BC6OTHER - modified ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes , but is also crucial for the ability of the receptor to suppress SCC - VII growth and invasion.	False
The BC6OTHER ( BC6ENTC ) / BC6ENTG ( BC6OTHER ) interacts with a variety of factors that impinge on tumour invasion and metastasis.	False
The BC6OTHER ( BC6ENTC ) / BC6OTHER ( BC6ENTG ) interacts with a variety of factors that impinge on tumour invasion and metastasis.	False
These findings highlight that the interaction between BC6OTHER / BC6ENTG and BC6ENTC - modified ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes , but is also crucial for the ability of the receptor to suppress SCC - VII growth and invasion.	False
The BC6OTHER - binding sites of BC6ENTC / BC6ENTG determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.	False
The BC6ENTC - binding sites of BC6OTHER / BC6ENTG determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.	False
Diagnosis is made by measuring the concentration of different metabolites in the BC6ENTC cycle , enzyme activity and in BC6ENTG and BC6OTHER deficiency , also by mutation analysis.	False
Diagnosis is made by measuring the concentration of different metabolites in the BC6ENTC cycle , enzyme activity and in BC6OTHER and BC6ENTG deficiency , also by mutation analysis.	False
Diagnosis is made by measuring the concentration of different metabolites in the BC6OTHER cycle , enzyme activity and in BC6ENTC synthetase and BC6ENTG deficiency , also by mutation analysis.	False
Diagnosis is made by measuring the concentration of different metabolites in the BC6OTHER cycle , enzyme activity and in BC6ENTG and BC6ENTC synthetase deficiency , also by mutation analysis.	False
No treatment has been recommended for BC6ENTC transpeptidase , BC6ENTG and BC6OTHER deficiency.	False
No treatment has been recommended for BC6ENTC transpeptidase , BC6OTHER and BC6ENTG deficiency.	False
The BC6OTHER BC6OTHER - responsive site was restricted to a single BC6ENTC BC6OTHER located at - 381 to - 376 bp whose mutation impaired the specific BC6ENTG binding.	False
The BC6ENTG BC6OTHER - responsive site was restricted to a single BC6ENTC BC6OTHER located at - 381 to - 376 bp whose mutation impaired the specific BC6OTHER binding.	False
The BC6OTHER BC6OTHER - responsive site was restricted to a single BC6OTHER BC6ENTC located at - 381 to - 376 bp whose mutation impaired the specific BC6ENTG binding.	False
The BC6ENTG BC6OTHER - responsive site was restricted to a single BC6OTHER BC6ENTC located at - 381 to - 376 bp whose mutation impaired the specific BC6OTHER binding.	False
BC6ENTG ectopic expression activated the BC6OTHER gene transcription in absence of BC6ENTC , and its protein amount in nuclear extracts is 1.8 - fold increased by BC6OTHER treatment of adipocytes.	False
BC6OTHER ectopic expression activated the BC6ENTG gene transcription in absence of BC6ENTC , and its protein amount in nuclear extracts is 1.8 - fold increased by BC6OTHER treatment of adipocytes.	False
BC6ENTG ectopic expression activated the BC6OTHER gene transcription in absence of BC6OTHER , and its protein amount in nuclear extracts is 1.8 - fold increased by BC6ENTC treatment of adipocytes.	CPR:3
BC6OTHER ectopic expression activated the BC6ENTG gene transcription in absence of BC6OTHER , and its protein amount in nuclear extracts is 1.8 - fold increased by BC6ENTC treatment of adipocytes.	CPR:3
We show that BC6ENTG ( BC6OTHER ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6ENTC homeostasis by promoting BC6OTHER formation for BC6OTHER re - esterification during fasting.	False
We show that cytosolic BC6OTHER aminotransferase ( BC6ENTG ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6ENTC homeostasis by promoting BC6OTHER formation for BC6OTHER re - esterification during fasting.	False
Finally , the amounts of BC6ENTG and BC6OTHER mRNAs were similarly increased by BC6ENTC treatment of human adipose tissue explants , confirming coordinated regulation.	CPR:3
Finally , the amounts of BC6OTHER and BC6ENTG mRNAs were similarly increased by BC6ENTC treatment of human adipose tissue explants , confirming coordinated regulation.	CPR:3
Our data identify BC6ENTG as a new member of glyceroneogenesis , transcriptionally regulated by BC6ENTC via the control of BC6OTHER expression by BC6OTHER in adipocytes.	CPR:3
Our data identify BC6OTHER as a new member of glyceroneogenesis , transcriptionally regulated by BC6ENTC via the control of BC6ENTG expression by BC6OTHER in adipocytes.	False
Our data identify BC6OTHER as a new member of glyceroneogenesis , transcriptionally regulated by BC6ENTC via the control of BC6OTHER expression by BC6ENTG in adipocytes.	False
We show that BC6ENTG ( BC6OTHER ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6OTHER homeostasis by promoting BC6ENTC formation for BC6OTHER re - esterification during fasting.	False
We show that cytosolic BC6OTHER aminotransferase ( BC6ENTG ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6OTHER homeostasis by promoting BC6ENTC formation for BC6OTHER re - esterification during fasting.	False
We show that BC6ENTG ( BC6OTHER ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6OTHER homeostasis by promoting BC6OTHER formation for BC6ENTC re - esterification during fasting.	False
We show that cytosolic BC6OTHER aminotransferase ( BC6ENTG ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6OTHER homeostasis by promoting BC6OTHER formation for BC6ENTC re - esterification during fasting.	False
We show that cytosolic BC6ENTC aminotransferase ( BC6ENTG ) is involved in adipocyte glyceroneogenesis , a regulated pathway that controls BC6OTHER homeostasis by promoting BC6OTHER formation for BC6OTHER re - esterification during fasting.	False
BC6ENTG activity , as well as the incorporation of BC6ENTC into the neutral lipid fraction of 3T3 - BC6OTHER adipocytes was stimulated by the BC6OTHER ( BC6OTHER ) BC6OTHER .	False
BC6OTHER activity , as well as the incorporation of BC6ENTC into the neutral lipid fraction of 3T3 - BC6ENTG adipocytes was stimulated by the BC6OTHER ( BC6OTHER ) BC6OTHER .	False
BC6ENTG activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6OTHER adipocytes was stimulated by the BC6ENTC ( BC6OTHER ) BC6OTHER .	CPR:3
BC6OTHER activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6ENTG adipocytes was stimulated by the BC6ENTC ( BC6OTHER ) BC6OTHER .	False
BC6ENTG activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6OTHER adipocytes was stimulated by the BC6OTHER ( BC6ENTC ) BC6OTHER .	CPR:3
BC6OTHER activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6ENTG adipocytes was stimulated by the BC6OTHER ( BC6ENTC ) BC6OTHER .	False
BC6ENTG activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6OTHER adipocytes was stimulated by the BC6OTHER ( BC6OTHER ) BC6ENTC .	CPR:3
BC6OTHER activity , as well as the incorporation of BC6OTHER into the neutral lipid fraction of 3T3 - BC6ENTG adipocytes was stimulated by the BC6OTHER ( BC6OTHER ) BC6ENTC .	False
Nevertheless , BC6ENTG is indirectly necessary for both BC6OTHER basal expression and BC6ENTC responsiveness because they are , respectively , diminished and abolished by ectopic overexpression of a dominant negative BC6OTHER .	False
Nevertheless , BC6OTHER is indirectly necessary for both BC6ENTG basal expression and BC6ENTC responsiveness because they are , respectively , diminished and abolished by ectopic overexpression of a dominant negative BC6OTHER .	False
Nevertheless , BC6OTHER is indirectly necessary for both BC6OTHER basal expression and BC6ENTC responsiveness because they are , respectively , diminished and abolished by ectopic overexpression of a dominant negative BC6ENTG .	False
The BC6OTHER BC6ENTC - responsive site was restricted to a single BC6OTHER BC6OTHER located at - 381 to - 376 bp whose mutation impaired the specific BC6ENTG binding.	False
The BC6ENTG BC6ENTC - responsive site was restricted to a single BC6OTHER BC6OTHER located at - 381 to - 376 bp whose mutation impaired the specific BC6OTHER binding.	False
 BC6ENTG , a new partner in adipocyte glyceroneogenesis and an atypical target of BC6ENTC .	False
Some effects of BC6ENTC and BC6ENTG were mediated by BC6OTHER - derived PG.	False
Some effects of BC6ENTC and BC6OTHER were mediated by BC6ENTG - derived PG.	False
In study 2 , bred ewes received BC6ENTC or recombinant BC6ENTG and into the uterus from day 10 to day 14 after mating.	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6ENTG ( BC6OTHER ) and BC6OTHER via BC6OTHER ( BC6OTHER ).	CPR:9
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6OTHER ( BC6ENTG ) and BC6OTHER via BC6OTHER ( BC6OTHER ).	CPR:9
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6ENTG ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6OTHER ( BC6ENTG ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6ENTG ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6OTHER ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6ENTG ) and the conceptus as well as endometrial epithelia produce BC6ENTC (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6OTHER ( BC6OTHER ).	False
These results suggest that BC6ENTG - derived BC6ENTC mediates , in part , actions of ovarian BC6OTHER and the conceptus on endometrial function and support the hypothesis that BC6OTHER , PG , and BC6OTHER coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	CPR:9
These results suggest that BC6OTHER - derived BC6ENTC mediates , in part , actions of ovarian BC6OTHER and the conceptus on endometrial function and support the hypothesis that BC6ENTG , PG , and BC6OTHER coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	False
These results suggest that BC6ENTG - derived BC6OTHER mediates , in part , actions of ovarian BC6ENTC and the conceptus on endometrial function and support the hypothesis that BC6OTHER , PG , and BC6OTHER coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	False
These results suggest that BC6OTHER - derived BC6OTHER mediates , in part , actions of ovarian BC6ENTC and the conceptus on endometrial function and support the hypothesis that BC6ENTG , PG , and BC6OTHER coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	False
These results suggest that BC6ENTG - derived BC6OTHER mediates , in part , actions of ovarian BC6OTHER and the conceptus on endometrial function and support the hypothesis that BC6OTHER , PG , and BC6ENTC coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	False
These results suggest that BC6OTHER - derived BC6OTHER mediates , in part , actions of ovarian BC6OTHER and the conceptus on endometrial function and support the hypothesis that BC6ENTG , PG , and BC6ENTC coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6ENTG ( BC6OTHER ) and BC6ENTC via BC6OTHER ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6ENTG ) and BC6ENTC via BC6OTHER ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6ENTC via BC6ENTG ( BC6OTHER ).	CPR:9
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6ENTC via BC6OTHER ( BC6ENTG ).	CPR:9
During early pregnancy in sheep , the elongating conceptus secretes BC6ENTG ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6ENTC via BC6OTHER ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6ENTG ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6ENTC via BC6OTHER ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6ENTG ( BC6OTHER ) and BC6OTHER via BC6ENTC (11 - β) dehydrogenase 1 ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6ENTG ) and BC6OTHER via BC6ENTC (11 - β) dehydrogenase 1 ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6ENTC (11 - β) dehydrogenase 1 ( BC6ENTG ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6ENTG ( BC6OTHER ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6ENTC (11 - β) dehydrogenase 1 ( BC6OTHER ).	False
During early pregnancy in sheep , the elongating conceptus secretes BC6OTHER ( BC6ENTG ) and the conceptus as well as endometrial epithelia produce BC6OTHER (PG) via BC6OTHER ( BC6OTHER ) and BC6OTHER via BC6ENTC (11 - β) dehydrogenase 1 ( BC6OTHER ).	False
Ovarian BC6ENTC induces and PG and BC6ENTG stimulates endometrial BC6OTHER expression and BC6OTHER activity as well as many epithelial genes that govern trophectoderm proliferation , migration , and attachment during elongation.	False
Ovarian BC6ENTC induces and PG and BC6OTHER stimulates endometrial BC6ENTG expression and BC6OTHER activity as well as many epithelial genes that govern trophectoderm proliferation , migration , and attachment during elongation.	False
Ovarian BC6ENTC induces and PG and BC6OTHER stimulates endometrial BC6OTHER expression and BC6ENTG activity as well as many epithelial genes that govern trophectoderm proliferation , migration , and attachment during elongation.	False
Ovarian BC6OTHER induces and PG and BC6ENTG stimulates endometrial BC6OTHER expression and BC6ENTC - reductase activity as well as many epithelial genes that govern trophectoderm proliferation , migration , and attachment during elongation.	False
Ovarian BC6OTHER induces and PG and BC6OTHER stimulates endometrial BC6ENTG expression and BC6ENTC - reductase activity as well as many epithelial genes that govern trophectoderm proliferation , migration , and attachment during elongation.	False
The primary aim of these studies was to test the hypothesis that BC6ENTG - derived BC6ENTC has a biological role in endometrial function and conceptus development during early pregnancy in sheep.	CPR:9
In study 1 , cyclic ewes received vehicle , BC6ENTC , BC6OTHER (PF; a selective inhibitor of BC6ENTG ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6ENTC , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6ENTG ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6ENTC , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6ENTC , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6ENTC (PF; a selective inhibitor of BC6ENTG ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	CPR:4
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6ENTC (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6ENTG ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6ENTC (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6ENTC (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6ENTG ) , BC6ENTC and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6ENTC and PF , BC6OTHER (a selective inhibitor of BC6ENTG ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6ENTC and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6ENTC and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6ENTG ) , BC6OTHER and PF , BC6ENTC (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6ENTC (a selective inhibitor of BC6ENTG ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	CPR:4
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6ENTC (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6ENTC (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6OTHER , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6ENTG ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6ENTC and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6ENTG ) , BC6ENTC and BC6OTHER , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6ENTC and BC6OTHER , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6ENTC and BC6OTHER , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6ENTG ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6ENTC , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6ENTG ) , BC6OTHER and BC6ENTC , recombinant BC6OTHER , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6ENTC , recombinant BC6ENTG , or BC6OTHER and PF into the uterus from day 10 to day14 after estrus.	False
In study 1 , cyclic ewes received vehicle , BC6OTHER , BC6OTHER (PF; a selective inhibitor of BC6OTHER ) , BC6OTHER and PF , BC6OTHER (a selective inhibitor of BC6OTHER ) , BC6OTHER and BC6ENTC , recombinant BC6OTHER , or BC6ENTG and PF into the uterus from day 10 to day14 after estrus.	False
BC6ENTC and BC6OTHER stimulated endometrial BC6ENTG expression and activity , increased endometrial BC6OTHER activity and the amount of PG in the uterine lumen , and up - regulated many conceptus elongation - related genes in the endometrium.	CPR:3
BC6ENTC and BC6OTHER stimulated endometrial BC6OTHER expression and activity , increased endometrial BC6ENTG activity and the amount of PG in the uterine lumen , and up - regulated many conceptus elongation - related genes in the endometrium.	CPR:3
BC6ENTC and BC6ENTG stimulated endometrial BC6OTHER expression and activity , increased endometrial BC6OTHER activity and the amount of PG in the uterine lumen , and up - regulated many conceptus elongation - related genes in the endometrium.	False
In addition , BC6ENTG ( BC6OTHER ) and c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) signaling pathways activated by BC6OTHER treatment were prevented by the OPE pre - treatment.	False
In addition , BC6OTHER ( BC6ENTG ) and c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) signaling pathways activated by BC6OTHER treatment were prevented by the OPE pre - treatment.	False
In addition , BC6OTHER ( BC6OTHER ) and c - Jun BC6ENTC - terminal kinase ( BC6ENTG ) signaling pathways activated by BC6OTHER treatment were prevented by the OPE pre - treatment.	False
In addition , BC6OTHER ( BC6OTHER ) and c - Jun BC6ENTC - terminal kinase ( BC6OTHER ) signaling pathways activated by BC6ENTG treatment were prevented by the OPE pre - treatment.	False
BC6ENTC synthase ( BC6OTHER ) inhibitors interfere with BC6OTHER biosynthesis by inhibiting BC6ENTG .	False
BC6ENTC synthase ( BC6ENTG ) inhibitors interfere with BC6OTHER biosynthesis by inhibiting BC6OTHER .	False
Similarly , BC6ENTG and BC6OTHER genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode BC6ENTC BC6OTHER - acetyltransferase to detoxify BC6OTHER .	False
Similarly , BC6OTHER and BC6ENTG genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode BC6ENTC BC6OTHER - acetyltransferase to detoxify BC6OTHER .	False
Similarly , BC6ENTG and BC6OTHER genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode CHEM BC6ENTC - acetyltransferase to detoxify BC6OTHER .	False
Similarly , BC6OTHER and BC6ENTG genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode CHEM BC6ENTC - acetyltransferase to detoxify BC6OTHER .	False
Similarly , BC6OTHER and BC6OTHER genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode BC6ENTG to detoxify BC6ENTC .	False
Similarly , BC6ENTG and BC6OTHER genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode CHEM BC6OTHER - acetyltransferase to detoxify BC6ENTC .	False
Similarly , BC6OTHER and BC6ENTG genes isolated from Streptomyces hygroscopicus and S. viridochromogenes , respectively , have been inserted into plants to encode CHEM BC6OTHER - acetyltransferase to detoxify BC6ENTC .	False
BC6ENTC affects BC6OTHER biosynthesis by inhibiting BC6ENTG ( BC6OTHER ).	CPR:4
BC6ENTC affects BC6OTHER biosynthesis by inhibiting BC6OTHER ( BC6ENTG ).	CPR:4
BC6OTHER affects BC6ENTC biosynthesis by inhibiting BC6ENTG ( BC6OTHER ).	False
BC6OTHER affects BC6ENTC biosynthesis by inhibiting BC6OTHER ( BC6ENTG ).	False
BC6OTHER affects BC6OTHER biosynthesis by inhibiting BC6ENTC synthase ( BC6ENTG ).	False
BC6ENTC inhibits BC6ENTG and blocks biosynthesis of BC6OTHER .	CPR:4
BC6OTHER inhibits BC6ENTG and blocks biosynthesis of BC6ENTC .	CPR:9
BC6ENTC - tolerant crops have been commercialized based on these BC6ENTG gene variants.	False
BC6ENTG ( BC6OTHER ) inhibitors interfere with BC6ENTC biosynthesis by inhibiting BC6OTHER .	False
BC6OTHER ( BC6OTHER ) inhibitors interfere with BC6ENTC biosynthesis by inhibiting BC6ENTG .	False
BC6OTHER ( BC6ENTG ) inhibitors interfere with BC6ENTC biosynthesis by inhibiting BC6OTHER .	False
A BC6ENTG gene isolated from Ochrobactrum anthropi has also been employed to encode BC6ENTC oxidoreductase to detoxify BC6OTHER in plants.	False
A BC6ENTG gene isolated from Ochrobactrum anthropi has also been employed to encode BC6OTHER to detoxify BC6ENTC in plants.	False
A BC6OTHER gene isolated from Ochrobactrum anthropi has also been employed to encode BC6ENTG to detoxify BC6ENTC in plants.	False
BC6ENTC - tolerant crops with BC6ENTG transgene alone or both BC6OTHER and BC6OTHER transgenes have been commercialized.	False
BC6ENTC - tolerant crops with BC6OTHER transgene alone or both BC6ENTG and BC6OTHER transgenes have been commercialized.	False
BC6ENTC - tolerant crops with BC6OTHER transgene alone or both BC6OTHER and BC6ENTG transgenes have been commercialized.	False
However , we show that BC6ENTG is not the major entry route of BC6ENTC - drugs and that the BC6OTHER transporter is not internalized in response to extracellular drug.	False
However , we show that BC6ENTG is not the major entry route of BC6OTHER - drugs and that the BC6ENTC transporter is not internalized in response to extracellular drug.	False
If reduced drug uptake is a major factor in resistance , BC6ENTG is unlikely to be a productive target in attempts to enhance efficacy , although the proteins involved in BC6ENTC homeostasis may play a role.	False
It has been claimed that BC6ENTG , the human high affinity BC6ENTC transporter , is the major entry pathway for BC6OTHER and related drugs via a mechanism that mimics CHEM.	False
It has been claimed that BC6ENTG , the human high affinity BC6OTHER transporter , is the major entry pathway for BC6ENTC and related drugs via a mechanism that mimics CHEM.	CPR:9
It has been claimed that BC6OTHER , the BC6ENTG , is the major entry pathway for BC6ENTC and related drugs via a mechanism that mimics CHEM.	CPR:9
We compared the uptake rates of CHEM with CHEM (and several analogs) into HEK293 cells over - expressing wild - type or mutant BC6ENTG , mouse embryonic fibroblasts (mefs) that do or do not express BC6OTHER , and human ovarian tumor cells , sensitive or resistant to BC6ENTC .	False
We compared the uptake rates of CHEM with CHEM (and several analogs) into HEK293 cells over - expressing wild - type or mutant BC6OTHER , mouse embryonic fibroblasts (mefs) that do or do not express BC6ENTG , and human ovarian tumor cells , sensitive or resistant to BC6ENTC .	False
We have also compared the effects of extracellular BC6ENTC , which causes regulatory endocytosis of BC6ENTG , to those of BC6OTHER .	False
We have also compared the effects of extracellular BC6OTHER , which causes regulatory endocytosis of BC6ENTG , to those of BC6ENTC .	False
We confirm the correlation between higher BC6ENTG levels and higher BC6ENTC - drug uptake in tumor cells sensitive to the drug.	CPR:9
A Re - evaluation of the Role of BC6ENTG , the Human High Affinity BC6ENTC Transporter in BC6OTHER - Drug Entry into Human Cells.	False
A Re - evaluation of the Role of BC6ENTG , the Human High Affinity BC6OTHER Transporter in BC6ENTC - Drug Entry into Human Cells.	False
A Re - evaluation of the Role of BC6OTHER , the BC6ENTG in BC6ENTC - Drug Entry into Human Cells.	False
The assembly and activation of oligomeric complexes of BC6ENTG , the BC6OTHER ( BC6OTHER ) , and heparan BC6ENTC transmit intracellular signals regulating growth and function of cells.	False
The assembly and activation of oligomeric complexes of BC6OTHER , the BC6ENTG ( BC6OTHER ) , and heparan BC6ENTC transmit intracellular signals regulating growth and function of cells.	False
The assembly and activation of oligomeric complexes of BC6OTHER , the BC6OTHER ( BC6ENTG ) , and heparan BC6ENTC transmit intracellular signals regulating growth and function of cells.	False
Addition of a specific number of BC6ENTG sequences to the BC6ENTC - terminus of BC6OTHER resulted in a gain in affinity for BC6OTHER .	False
Addition of a specific number of BC6OTHER sequences to the BC6ENTC - terminus of BC6ENTG resulted in a gain in affinity for BC6OTHER .	False
Addition of a specific number of BC6OTHER sequences to the BC6ENTC - terminus of BC6OTHER resulted in a gain in affinity for BC6ENTG .	False
Several site - specific alterations in the BC6ENTC - terminus of full - length BC6ENTG , an isoform that otherwise absolutely rejects BC6OTHER , resulted in gain of BC6OTHER binding.	False
Several site - specific alterations in the BC6ENTC - terminus of full - length BC6OTHER , an isoform that otherwise absolutely rejects BC6ENTG , resulted in gain of BC6OTHER binding.	False
Several site - specific alterations in the BC6ENTC - terminus of full - length BC6OTHER , an isoform that otherwise absolutely rejects BC6OTHER , resulted in gain of BC6ENTG binding.	False
These results suggest that a complex of BC6ENTG and heparan BC6ENTC is the base common active core of the BC6OTHER and that flanking structural domains modify BC6OTHER affinity and determine specificity.	False
These results suggest that a complex of BC6OTHER and heparan BC6ENTC is the base common active core of the BC6ENTG and that flanking structural domains modify BC6OTHER affinity and determine specificity.	False
These results suggest that a complex of BC6OTHER and heparan BC6ENTC is the base common active core of the BC6OTHER and that flanking structural domains modify BC6ENTG affinity and determine specificity.	False
Previously , we reported that a primary heparin or heparan BC6ENTC binding site resides in a distinct sequence in BC6ENTG of the three modules of BC6OTHER .	False
Previously , we reported that a primary heparin or heparan BC6ENTC binding site resides in a distinct sequence in BC6OTHER of the three modules of BC6ENTG .	False
BC6ENTG and the BC6ENTC - terminus of BC6OTHER are dispensable for high - affinity binding of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER and the BC6ENTC - terminus of BC6ENTG are dispensable for high - affinity binding of BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6OTHER and the BC6ENTC - terminus of BC6OTHER are dispensable for high - affinity binding of BC6ENTG , BC6OTHER , and BC6OTHER .	False
BC6OTHER and the BC6ENTC - terminus of BC6OTHER are dispensable for high - affinity binding of BC6OTHER , BC6ENTG , and BC6OTHER .	False
BC6OTHER and the BC6ENTC - terminus of BC6OTHER are dispensable for high - affinity binding of BC6OTHER , BC6OTHER , and BC6ENTG .	False
The molecular bases for BC6ENTG ( BC6OTHER ) catalytic - site affinity for BC6OTHER ( BC6ENTC ) and potency of inhibitors are poorly understood.	False
The molecular bases for BC6OTHER ( BC6ENTG ) catalytic - site affinity for BC6OTHER ( BC6ENTC ) and potency of inhibitors are poorly understood.	False
Affinity of BC6ENTG for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was reduced 5.5 - , 23 - , 10 - , 3 - , and 12 - fold , respectively.	False
Affinity of BC6ENTG for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER was reduced 5.5 - , 23 - , 10 - , 3 - , and 12 - fold , respectively.	False
Affinity of BC6ENTG for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER was reduced 5.5 - , 23 - , 10 - , 3 - , and 12 - fold , respectively.	False
Affinity of BC6ENTG for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER was reduced 5.5 - , 23 - , 10 - , 3 - , and 12 - fold , respectively.	False
Affinity of BC6ENTG for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC was reduced 5.5 - , 23 - , 10 - , 3 - , and 12 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6ENTG or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6ENTG for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6ENTG or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6ENTG for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6ENTG or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6ENTG for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG was less , but affinity of BC6OTHER or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6ENTG or BC6OTHER for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6ENTG for BC6OTHER was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER was less , but affinity of BC6OTHER or BC6OTHER for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG was less , but affinity of BC6OTHER or BC6OTHER for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6ENTG or BC6OTHER for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
Change in affinity for BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER in BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER was less , but affinity of BC6OTHER or BC6ENTG for BC6ENTC was weakened 37 - and 17 - fold , respectively.	False
The results quantify the role of BC6ENTG catalytic - site residues for BC6ENTC and inhibitors , indicate that BC6OTHER - 612 , BC6OTHER - 817 , and BC6OTHER - 820 are the most important BC6OTHER or inhibitor contacts studied , and identify residues that contribute to selectivity among different classes of inhibitors.	False
The results quantify the role of BC6ENTG catalytic - site residues for BC6OTHER and inhibitors , indicate that BC6ENTC - 612 , BC6OTHER - 817 , and BC6OTHER - 820 are the most important BC6OTHER or inhibitor contacts studied , and identify residues that contribute to selectivity among different classes of inhibitors.	False
The results quantify the role of BC6ENTG catalytic - site residues for BC6OTHER and inhibitors , indicate that BC6OTHER - 612 , BC6ENTC - 817 , and BC6OTHER - 820 are the most important BC6OTHER or inhibitor contacts studied , and identify residues that contribute to selectivity among different classes of inhibitors.	False
The results quantify the role of BC6ENTG catalytic - site residues for BC6OTHER and inhibitors , indicate that BC6OTHER - 612 , BC6OTHER - 817 , and BC6ENTC - 820 are the most important BC6OTHER or inhibitor contacts studied , and identify residues that contribute to selectivity among different classes of inhibitors.	False
The results quantify the role of BC6ENTG catalytic - site residues for BC6OTHER and inhibitors , indicate that BC6OTHER - 612 , BC6OTHER - 817 , and BC6OTHER - 820 are the most important BC6ENTC or inhibitor contacts studied , and identify residues that contribute to selectivity among different classes of inhibitors.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6ENTC bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6ENTC - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6ENTC bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6ENTC - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6ENTC - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6ENTC - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6ENTC - 613 , BC6OTHER - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6ENTC - 765 , and BC6OTHER - 786 [Sung et al.	False
Cocrystal structures of BC6ENTG with inhibitors reveal a BC6OTHER bond and hydrophobic interactions with BC6OTHER - 612 , BC6OTHER bonds with BC6OTHER - 817 , a hydrophobic clamp formed by BC6OTHER - 820 and BC6OTHER - 782 , and contacts with BC6OTHER - 613 , BC6OTHER - 765 , and BC6ENTC - 786 [Sung et al.	False
Catalytic - site affinities for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
Catalytic - site affinities for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	CPR:9
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , or BC6OTHER ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTC ( BC6OTHER ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6ENTC ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6ENTG ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6ENTC ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6ENTG ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6OTHER .	False
Catalytic - site affinities for BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER ( BC6ENTC ) were respectively weakened 14 - , 123 - , 30 - , 51 - , and 43 - fold for BC6OTHER ; 63 - , 511 - , 43 - , 95 - and 61 - fold for BC6OTHER ; and 59 - , 448 - , 71 - , 137 - , and 93 - fold for BC6ENTG .	False
The molecular bases for BC6ENTG ( BC6OTHER ) catalytic - site affinity for BC6ENTC ( BC6OTHER ) and potency of inhibitors are poorly understood.	False
The molecular bases for BC6OTHER ( BC6ENTG ) catalytic - site affinity for BC6ENTC ( BC6OTHER ) and potency of inhibitors are poorly understood.	False
Critical BC6OTHER in BC6ENTG catalytic site that provide for high - affinity interaction with BC6ENTC and inhibitors.	False
Critical BC6ENTC in BC6ENTG catalytic site that provide for high - affinity interaction with BC6OTHER and inhibitors.	False
The data indicated that BC6ENTC could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6ENTG and BC6OTHER and inactivation of BC6OTHER , which may play a role in the pathogenesis of BC6OTHER - associated stomach cancer.	CPR:3
The data indicated that BC6ENTC could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6OTHER and BC6ENTG and inactivation of BC6OTHER , which may play a role in the pathogenesis of BC6OTHER - associated stomach cancer.	CPR:3
The data indicated that BC6ENTC could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6OTHER and BC6OTHER and inactivation of BC6ENTG , which may play a role in the pathogenesis of BC6OTHER - associated stomach cancer.	CPR:4
The data indicated that BC6OTHER could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6ENTG and BC6OTHER and inactivation of BC6OTHER , which may play a role in the pathogenesis of BC6ENTC - associated stomach cancer.	False
The data indicated that BC6OTHER could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6OTHER and BC6ENTG and inactivation of BC6OTHER , which may play a role in the pathogenesis of BC6ENTC - associated stomach cancer.	False
The data indicated that BC6OTHER could cause stomach injury , oxidative stress in rat stomachs as well as the activation of BC6OTHER and BC6OTHER and inactivation of BC6ENTG , which may play a role in the pathogenesis of BC6ENTC - associated stomach cancer.	False
To understand the possible mechanism of BC6ENTC - associated stomach cancer , the effects of BC6OTHER on morphology , oxidative stress , gene expression of BC6ENTG , BC6OTHER and BC6OTHER in rat stomachs were investigated.	False
To understand the possible mechanism of BC6ENTC - associated stomach cancer , the effects of BC6OTHER on morphology , oxidative stress , gene expression of BC6OTHER , BC6ENTG and BC6OTHER in rat stomachs were investigated.	False
To understand the possible mechanism of BC6ENTC - associated stomach cancer , the effects of BC6OTHER on morphology , oxidative stress , gene expression of BC6OTHER , BC6OTHER and BC6ENTG in rat stomachs were investigated.	False
To understand the possible mechanism of BC6OTHER - associated stomach cancer , the effects of BC6ENTC on morphology , oxidative stress , gene expression of BC6ENTG , BC6OTHER and BC6OTHER in rat stomachs were investigated.	False
To understand the possible mechanism of BC6OTHER - associated stomach cancer , the effects of BC6ENTC on morphology , oxidative stress , gene expression of BC6OTHER , BC6ENTG and BC6OTHER in rat stomachs were investigated.	False
To understand the possible mechanism of BC6OTHER - associated stomach cancer , the effects of BC6ENTC on morphology , oxidative stress , gene expression of BC6OTHER , BC6OTHER and BC6ENTG in rat stomachs were investigated.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6ENTG ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6ENTC induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6ENTG ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	CPR:4
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	CPR:4
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	CPR:4
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	CPR:4
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6ENTG ( BC6OTHER ) activity compared with the control.	CPR:3
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6ENTC (10 and / or 15mg / kg) significantly decreased BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6ENTG ) activity compared with the control.	CPR:3
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTC dismutase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTC dismutase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activities , while increased BC6OTHER ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6ENTG ( BC6OTHER ) activity compared with the control.	False
The results showed that (1) 15mg / kg body weight BC6OTHER induced obvious histopathological changes in gastric mucosa; (2) BC6OTHER (10 and / or 15mg / kg) significantly decreased BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activities , while increased BC6OTHER ( BC6ENTG ) activity compared with the control.	False
With the elevated doses of BC6ENTC , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6OTHER and BC6ENTG expression relative to control.	False
With the elevated doses of BC6ENTC , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6ENTG mRNA and protein expression , whereas enhanced BC6OTHER and BC6OTHER expression relative to control.	False
With the elevated doses of BC6ENTC , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6ENTG and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6ENTC ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6OTHER and BC6ENTG expression relative to control.	False
With the elevated doses of BC6OTHER , BC6ENTC ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6ENTG mRNA and protein expression , whereas enhanced BC6OTHER and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6ENTC ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6ENTG and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6ENTC ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6OTHER and BC6ENTG expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6ENTC ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6ENTG mRNA and protein expression , whereas enhanced BC6OTHER and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6ENTC ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6ENTG and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6ENTC (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6OTHER and BC6ENTG expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6ENTC (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6ENTG mRNA and protein expression , whereas enhanced BC6OTHER and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6ENTC (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6OTHER at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6ENTG and BC6OTHER expression relative to control.	False
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6ENTC at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6OTHER and BC6ENTG expression relative to control.	CPR:3
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6ENTC at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6ENTG mRNA and protein expression , whereas enhanced BC6OTHER and BC6OTHER expression relative to control.	CPR:4
With the elevated doses of BC6OTHER , BC6OTHER ( BC6OTHER ) contents , protein BC6OTHER (PCO) contents and DNA - protein crosslinks (DPC) coefficients were significantly raised in a dose - dependent manner; (3) BC6ENTC at the doses of 10mg / kg and / or 15mg / kg significantly inhibited BC6OTHER mRNA and protein expression , whereas enhanced BC6ENTG and BC6OTHER expression relative to control.	CPR:3
Effects of BC6ENTC ( BC6OTHER ) on histopathology , oxidative stress , and expression of BC6ENTG , BC6OTHER and BC6OTHER in rat stomachs.	False
Effects of BC6ENTC ( BC6OTHER ) on histopathology , oxidative stress , and expression of BC6OTHER , BC6ENTG and BC6OTHER in rat stomachs.	False
Effects of BC6ENTC ( BC6OTHER ) on histopathology , oxidative stress , and expression of BC6OTHER , BC6OTHER and BC6ENTG in rat stomachs.	False
Effects of BC6OTHER ( BC6ENTC ) on histopathology , oxidative stress , and expression of BC6ENTG , BC6OTHER and BC6OTHER in rat stomachs.	False
Effects of BC6OTHER ( BC6ENTC ) on histopathology , oxidative stress , and expression of BC6OTHER , BC6ENTG and BC6OTHER in rat stomachs.	False
Effects of BC6OTHER ( BC6ENTC ) on histopathology , oxidative stress , and expression of BC6OTHER , BC6OTHER and BC6ENTG in rat stomachs.	False
Sequential chromatin IP uncovered the BC6ENTG - BC6ENTC to bind BC6OTHER exponentially upon recruitment of BC6OTHER rather than BC6OTHER .	False
Sequential chromatin IP uncovered the BC6OTHER - BC6ENTC to bind BC6ENTG exponentially upon recruitment of BC6OTHER rather than BC6OTHER .	False
Sequential chromatin IP uncovered the BC6OTHER - BC6ENTC to bind BC6OTHER exponentially upon recruitment of BC6ENTG rather than BC6OTHER .	False
Sequential chromatin IP uncovered the BC6OTHER - BC6ENTC to bind BC6OTHER exponentially upon recruitment of BC6OTHER rather than BC6ENTG .	False
CHEM and coimmunolocalization confirmed that BC6ENTG associated with BC6OTHER and cotransfection with BC6OTHER - BC6ENTC in HT22 cells enhanced BC6OTHER transcription.	False
CHEM and coimmunolocalization confirmed that BC6OTHER associated with BC6ENTG and cotransfection with BC6OTHER - BC6ENTC in HT22 cells enhanced BC6OTHER transcription.	False
CHEM and coimmunolocalization confirmed that BC6OTHER associated with BC6OTHER and cotransfection with BC6ENTG - BC6ENTC in HT22 cells enhanced BC6OTHER transcription.	False
CHEM and coimmunolocalization confirmed that BC6OTHER associated with BC6OTHER and cotransfection with BC6OTHER - BC6ENTC in HT22 cells enhanced BC6ENTG transcription.	False
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6ENTG and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	CPR:4
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6ENTG separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	CPR:4
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6ENTG and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6ENTG binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6ENTG - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6ENTC pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6ENTG expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6ENTG and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	CPR:4
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6ENTG separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	CPR:4
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6ENTG and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6ENTG binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6ENTG - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6ENTC reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6ENTG expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6ENTG and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6OTHER and BC6ENTG separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6ENTG and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6ENTG binding of BC6OTHER - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6ENTG - BC6OTHER reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6ENTC and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6OTHER reduced BC6ENTG expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6ENTG and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6ENTC reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6ENTG separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6ENTC reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6ENTG and / or BC6OTHER binding of BC6OTHER - BC6ENTC reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6ENTG binding of BC6OTHER - BC6ENTC reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6ENTG - BC6ENTC reduced BC6OTHER expression in HT22 cells.	False
Separate BC6OTHER pretreatment or in combination with BC6OTHER reduced BC6OTHER and specific small interference RNAs targeting BC6OTHER and BC6OTHER separately or together depleting BC6OTHER and / or BC6OTHER binding of BC6OTHER - BC6ENTC reduced BC6ENTG expression in HT22 cells.	False
Recruitment of BC6ENTG - BC6OTHER by BC6OTHER - BC6ENTC contributes towards transactivation , formulating an escape from BC6OTHER - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6ENTG by BC6OTHER - BC6ENTC contributes towards transactivation , formulating an escape from BC6OTHER - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6OTHER by BC6ENTG - BC6ENTC contributes towards transactivation , formulating an escape from BC6OTHER - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6OTHER by BC6OTHER - BC6ENTC contributes towards transactivation , formulating an escape from BC6OTHER - induced gene suppression , and thereby promoting developmental neuronal BC6ENTG gene transcription and expression.	False
Recruitment of BC6ENTG - BC6OTHER by BC6OTHER - BC6OTHER contributes towards transactivation , formulating an escape from BC6ENTC - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6ENTG by BC6OTHER - BC6OTHER contributes towards transactivation , formulating an escape from BC6ENTC - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6OTHER by BC6ENTG - BC6OTHER contributes towards transactivation , formulating an escape from BC6ENTC - induced gene suppression , and thereby promoting developmental neuronal BC6OTHER gene transcription and expression.	False
Recruitment of BC6OTHER - BC6OTHER by BC6OTHER - BC6OTHER contributes towards transactivation , formulating an escape from BC6ENTC - induced gene suppression , and thereby promoting developmental neuronal BC6ENTG gene transcription and expression.	False
In the present study , we characterized a canonical BC6ENTC island spanning the 5' - flanking region of the BC6ENTG gene.	False
Methylation - specific PCR and BC6ENTC sequencing identified methylation of this BC6OTHER ( BC6OTHER ) island of the BC6ENTG gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6OTHER concentrations noted with advancing postnatal age (PN14 vs PN3).	False
Methylation - specific PCR and BC6ENTC sequencing identified methylation of this BC6OTHER ( BC6OTHER ) island of the BC6OTHER gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6ENTG concentrations noted with advancing postnatal age (PN14 vs PN3).	False
The murine neuronal facilitative BC6ENTC transporter isoform 3 ( BC6ENTG ) is developmentally regulated , peaking in expression at postnatal day (PN)14.	False
Methylation - specific PCR and BC6OTHER sequencing identified methylation of this BC6ENTC ( BC6OTHER ) island of the BC6ENTG gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6OTHER concentrations noted with advancing postnatal age (PN14 vs PN3).	False
Methylation - specific PCR and BC6OTHER sequencing identified methylation of this BC6ENTC ( BC6OTHER ) island of the BC6OTHER gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6ENTG concentrations noted with advancing postnatal age (PN14 vs PN3).	CPR:3
Methylation - specific PCR and BC6OTHER sequencing identified methylation of this BC6OTHER ( BC6ENTC ) island of the BC6ENTG gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6OTHER concentrations noted with advancing postnatal age (PN14 vs PN3).	False
Methylation - specific PCR and BC6OTHER sequencing identified methylation of this BC6OTHER ( BC6ENTC ) island of the BC6OTHER gene , frequency of methylation increasing 2.5 - fold with a 1.6 - fold increase in BC6ENTG concentrations noted with advancing postnatal age (PN14 vs PN3).	CPR:3
5' - flanking region of BC6ENTG - luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that BC6ENTC inhibit BC6OTHER transcription.	False
5' - flanking region of BC6OTHER - luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that BC6ENTC inhibit BC6ENTG transcription.	CPR:4
Contrary to this biological function , BC6ENTG expression rises synchronously with BC6ENTC in PN14 vs PN3 neurons.	False
Chromatin immunoprecipitation (IP) revealed that BC6ENTC - CpG binding protein 2 ( BC6ENTG ) bound the BC6OTHER - BC6OTHER .	False
Chromatin immunoprecipitation (IP) revealed that BC6ENTC - CpG binding protein 2 ( BC6OTHER ) bound the BC6ENTG - BC6OTHER .	False
Chromatin immunoprecipitation (IP) revealed that BC6ENTG ( BC6OTHER ) bound the BC6OTHER - BC6ENTC .	False
Chromatin immunoprecipitation (IP) revealed that BC6OTHER ( BC6ENTG ) bound the BC6OTHER - BC6ENTC .	False
Chromatin immunoprecipitation (IP) revealed that BC6OTHER ( BC6OTHER ) bound the BC6ENTG - BC6ENTC .	False
 BC6ENTG - BC6OTHER - BC6ENTC complex transactivates postnatal murine neuronal BC6OTHER expression.	False
 BC6OTHER - BC6ENTG - BC6ENTC complex transactivates postnatal murine neuronal BC6OTHER expression.	False
 BC6OTHER - BC6OTHER - BC6ENTC complex transactivates postnatal murine neuronal BC6ENTG expression.	False
 BC6ENTG - BC6OTHER - BC6OTHER complex transactivates postnatal murine neuronal BC6ENTC transporter isoform 3 expression.	False
 BC6OTHER - BC6ENTG - BC6OTHER complex transactivates postnatal murine neuronal BC6ENTC transporter isoform 3 expression.	False
BC6ENTC transporters ( BC6ENTG ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6OTHER , BC6OTHER , as well as BC6OTHER bodies.	False
BC6ENTG ( BC6OTHER ) are proton - linked membrane carriers involved in the transport of BC6ENTC such as BC6OTHER , BC6OTHER , as well as BC6OTHER bodies.	CPR:9
BC6OTHER ( BC6ENTG ) are proton - linked membrane carriers involved in the transport of BC6ENTC such as BC6OTHER , BC6OTHER , as well as BC6OTHER bodies.	CPR:9
BC6ENTG ( BC6OTHER ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6ENTC , BC6OTHER , as well as BC6OTHER bodies.	CPR:9
BC6OTHER ( BC6ENTG ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6ENTC , BC6OTHER , as well as BC6OTHER bodies.	CPR:9
BC6ENTG ( BC6OTHER ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6OTHER , BC6ENTC , as well as BC6OTHER bodies.	CPR:9
BC6OTHER ( BC6ENTG ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6OTHER , BC6ENTC , as well as BC6OTHER bodies.	CPR:9
BC6ENTG ( BC6OTHER ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6OTHER , BC6OTHER , as well as BC6ENTC bodies.	CPR:9
BC6OTHER ( BC6ENTG ) are proton - linked membrane carriers involved in the transport of BC6OTHER such as BC6OTHER , BC6OTHER , as well as BC6ENTC bodies.	CPR:9
By contrast , the predominant neuronal BC6ENTC transporter is BC6ENTG .	False
Interestingly , part of BC6ENTG immunoreactivity is located at postsynaptic sites , suggesting a particular role of BC6ENTC and their transporters in synaptic transmission.	CPR:9
Cells in which BC6ENTC was depleted had decreased BC6ENTG ( BC6OTHER ) abundance and increased BC6OTHER at the later stages of the DNA damage response.	False
Cells in which BC6ENTC was depleted had decreased BC6OTHER ( BC6ENTG ) abundance and increased BC6OTHER at the later stages of the DNA damage response.	False
Cells in which BC6ENTC was depleted had decreased BC6OTHER ( BC6OTHER ) abundance and increased BC6ENTG at the later stages of the DNA damage response.	False
BC6ENTC ( BC6OTHER ) , a BC6ENTG - targeting drug that stabilizes BC6OTHER - DNA covalent adducts , can induce S - phase - specific cytotoxicity due to the arrest of progressing replication forks.	False
BC6ENTC ( BC6OTHER ) , a BC6OTHER - targeting drug that stabilizes BC6ENTG - DNA covalent adducts , can induce S - phase - specific cytotoxicity due to the arrest of progressing replication forks.	False
Altogether , our findings support a model in which BC6ENTG deficiency promotes BC6ENTC - induced apoptosis in quiescent non - S - phase cells , possibly due to BC6OTHER depletion and BC6OTHER accumulation.	False
Altogether , our findings support a model in which BC6OTHER deficiency promotes BC6ENTC - induced apoptosis in quiescent non - S - phase cells , possibly due to BC6ENTG depletion and BC6OTHER accumulation.	CPR:4
Altogether , our findings support a model in which BC6OTHER deficiency promotes BC6ENTC - induced apoptosis in quiescent non - S - phase cells , possibly due to BC6OTHER depletion and BC6ENTG accumulation.	CPR:3
BC6OTHER ( BC6ENTC ) , a BC6ENTG - targeting drug that stabilizes BC6OTHER - DNA covalent adducts , can induce S - phase - specific cytotoxicity due to the arrest of progressing replication forks.	False
BC6OTHER ( BC6ENTC ) , a BC6OTHER - targeting drug that stabilizes BC6ENTG - DNA covalent adducts , can induce S - phase - specific cytotoxicity due to the arrest of progressing replication forks.	False
In this study , we have identified BC6ENTG ( BC6OTHER ) as a specific determinant for BC6ENTC sensitivity , but not for many other cytotoxic agents , in non - S - phase cells.	False
In this study , we have identified BC6OTHER ( BC6ENTG ) as a specific determinant for BC6ENTC sensitivity , but not for many other cytotoxic agents , in non - S - phase cells.	False
First , quiescent mouse embryonic fibroblasts (MEFs) lacking BC6ENTG were shown to be hypersensitive to BC6ENTC with prominent induction of apoptosis.	False
Second , BC6ENTC , a BC6ENTG catalytic inhibitor known to deplete BC6OTHER , specifically sensitized MEFs to BC6OTHER .	CPR:4
Second , BC6ENTC , a BC6OTHER catalytic inhibitor known to deplete BC6ENTG , specifically sensitized MEFs to BC6OTHER .	CPR:4
Second , BC6OTHER , a BC6ENTG catalytic inhibitor known to deplete BC6OTHER , specifically sensitized MEFs to BC6ENTC .	False
Second , BC6OTHER , a BC6OTHER catalytic inhibitor known to deplete BC6ENTG , specifically sensitized MEFs to BC6ENTC .	False
To explore the molecular basis for BC6ENTC hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6OTHER exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6ENTG - deficient cells.	False
To explore the molecular basis for BC6ENTC hypersensitivity in BC6ENTG - deficient cells , we found that upon BC6OTHER exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	False
To explore the molecular basis for BC6ENTC hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6OTHER exposure , the BC6ENTG ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	False
To explore the molecular basis for BC6ENTC hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6OTHER exposure , the BC6OTHER ( BC6ENTG ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	False
To explore the molecular basis for BC6ENTC hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6OTHER exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6ENTG remained depleted without recovery in BC6OTHER - deficient cells.	False
To explore the molecular basis for BC6OTHER hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6ENTC exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6ENTG - deficient cells.	False
To explore the molecular basis for BC6OTHER hypersensitivity in BC6ENTG - deficient cells , we found that upon BC6ENTC exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	False
To explore the molecular basis for BC6OTHER hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6ENTC exposure , the BC6ENTG ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	CPR:4
To explore the molecular basis for BC6OTHER hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6ENTC exposure , the BC6OTHER ( BC6ENTG ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6OTHER remained depleted without recovery in BC6OTHER - deficient cells.	CPR:4
To explore the molecular basis for BC6OTHER hypersensitivity in BC6OTHER - deficient cells , we found that upon BC6ENTC exposure , the BC6OTHER ( BC6OTHER ) became progressively depleted , followed by recovery to nearly the original level in wild - type MEFs , whereas BC6ENTG remained depleted without recovery in BC6OTHER - deficient cells.	CPR:4
 BC6ENTG deficiency enhances BC6ENTC - induced apoptosis.	False
Since plasma concentrations of BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6ENTG generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6ENTG , the effect is specific for BC6OTHER and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6ENTG and is not attributable to the BC6OTHER of all BC6ENTC - dependent proteins.	False
Since plasma concentrations of BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER did not by themselves potentiate BC6OTHER generation and did not interfere with the potentiation of the reaction of BC6OTHER , the effect is specific for BC6OTHER and is not attributable to the BC6ENTG of all BC6ENTC - dependent proteins.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6ENTG or BC6OTHER - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6ENTG showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6OTHER showed that the increased BC6ENTG activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6ENTG - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6ENTG and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6ENTG in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6ENTC - labeled BC6OTHER or BC6OTHER - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6ENTG in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6ENTG or BC6ENTC - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6ENTG showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6OTHER showed that the increased BC6ENTG activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6ENTG - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6ENTG and that there was increased cleavage of BC6OTHER in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6ENTG in the presence of BC6OTHER in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
Autoradiographs of PAGE - separated reactions containing either BC6OTHER - labeled BC6OTHER or BC6ENTC - labeled BC6OTHER showed that the increased BC6OTHER activation was not due to BC6OTHER - mediated feedback activation of BC6OTHER and that there was increased cleavage of BC6OTHER in the presence of BC6ENTG in comparison with control reactions but only in the presence of both the enzyme and the surface.	False
OBJECTIVETo determine the prevalence of people with diabetes who meet BC6OTHER ( BC6OTHER ) , blood pressure (BP) , and BC6ENTG BC6ENTC (ABC) recommendations , and their current CHEM use , factors associated with goal achievement , and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross - sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988 - 1994 , 1999 - 2002 , 2003 - 2006 , and 2007 - 2010.	False
OBJECTIVETo determine the prevalence of people with diabetes who meet BC6ENTG ( BC6OTHER ) , blood pressure (BP) , and BC6OTHER BC6ENTC (ABC) recommendations , and their current CHEM use , factors associated with goal achievement , and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross - sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988 - 1994 , 1999 - 2002 , 2003 - 2006 , and 2007 - 2010.	False
OBJECTIVETo determine the prevalence of people with diabetes who meet BC6OTHER ( BC6ENTG ) , blood pressure (BP) , and BC6OTHER BC6ENTC (ABC) recommendations , and their current CHEM use , factors associated with goal achievement , and changes in the proportion achieving goals between 1988 and 2010.RESEARCH AND DESIGN METHODSData were cross - sectional from the National Health and Nutrition Examination Surveys (NHANES) from 1988 - 1994 , 1999 - 2002 , 2003 - 2006 , and 2007 - 2010.	False
Main outcome measures were BC6ENTG , BP , and BC6OTHER BC6ENTC , in accordance with the American Diabetes Association recommendations , and current use of CHEM 2007 - 2010 , 52.5% of people with diabetes achieved BC6OTHER <7.0% (<53 mmol / mol) , 51.1% achieved BP <130 / 80 mmHg , 56.2% achieved BC6OTHER <100 mg / dL , and 18.8% achieved all three ABCs.	False
Main outcome measures were BC6OTHER , BP , and BC6ENTG BC6ENTC , in accordance with the American Diabetes Association recommendations , and current use of CHEM 2007 - 2010 , 52.5% of people with diabetes achieved BC6OTHER <7.0% (<53 mmol / mol) , 51.1% achieved BP <130 / 80 mmHg , 56.2% achieved BC6OTHER <100 mg / dL , and 18.8% achieved all three ABCs.	False
Main outcome measures were BC6OTHER , BP , and BC6OTHER BC6ENTC , in accordance with the American Diabetes Association recommendations , and current use of CHEM 2007 - 2010 , 52.5% of people with diabetes achieved BC6ENTG <7.0% (<53 mmol / mol) , 51.1% achieved BP <130 / 80 mmHg , 56.2% achieved BC6OTHER <100 mg / dL , and 18.8% achieved all three ABCs.	False
Main outcome measures were BC6OTHER , BP , and BC6OTHER BC6ENTC , in accordance with the American Diabetes Association recommendations , and current use of CHEM 2007 - 2010 , 52.5% of people with diabetes achieved BC6OTHER <7.0% (<53 mmol / mol) , 51.1% achieved BP <130 / 80 mmHg , 56.2% achieved BC6ENTG <100 mg / dL , and 18.8% achieved all three ABCs.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6ENTC 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6ENTC 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6ENTC 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6ENTC 152.	False
Saturated BC6ENTC increased BC6OTHER , up - regulated BC6ENTG , and had BC6OTHER and BC6OTHER phosphorylation at BC6OTHER 50 impaired.	CPR:3
Saturated BC6ENTC increased BC6OTHER , up - regulated BC6OTHER , and had BC6ENTG and BC6OTHER phosphorylation at BC6OTHER 50 impaired.	CPR:3
Saturated BC6ENTC increased BC6OTHER , up - regulated BC6OTHER , and had BC6OTHER and BC6ENTG phosphorylation at BC6OTHER 50 impaired.	CPR:3
Saturated BC6OTHER increased BC6ENTC , up - regulated BC6ENTG , and had BC6OTHER and BC6OTHER phosphorylation at BC6OTHER 50 impaired.	False
Saturated BC6OTHER increased BC6ENTC , up - regulated BC6OTHER , and had BC6ENTG and BC6OTHER phosphorylation at BC6OTHER 50 impaired.	False
Saturated BC6OTHER increased BC6ENTC , up - regulated BC6OTHER , and had BC6OTHER and BC6ENTG phosphorylation at BC6OTHER 50 impaired.	False
Saturated BC6OTHER increased BC6OTHER , up - regulated BC6ENTG , and had BC6OTHER and BC6OTHER phosphorylation at BC6ENTC 50 impaired.	False
Saturated BC6OTHER increased BC6OTHER , up - regulated BC6OTHER , and had BC6ENTG and BC6OTHER phosphorylation at BC6ENTC 50 impaired.	False
Saturated BC6OTHER increased BC6OTHER , up - regulated BC6OTHER , and had BC6OTHER and BC6ENTG phosphorylation at BC6ENTC 50 impaired.	False
Only FFAs that increased BC6ENTC caused impairment of BC6ENTG and BC6OTHER phosphorylation at BC6OTHER 50.	CPR:4
Only FFAs that increased BC6ENTC caused impairment of BC6OTHER and BC6ENTG phosphorylation at BC6OTHER 50.	CPR:4
Only FFAs that increased BC6OTHER caused impairment of BC6ENTG and BC6OTHER phosphorylation at BC6ENTC 50.	False
Only FFAs that increased BC6OTHER caused impairment of BC6OTHER and BC6ENTG phosphorylation at BC6ENTC 50.	False
A clear relationship between BC6ENTG phosphorylation levels at BC6ENTC 50 and its negative effect on BC6OTHER signaling is shown.	False
A clear relationship between BC6OTHER phosphorylation levels at BC6ENTC 50 and its negative effect on BC6ENTG signaling is shown.	False
Excess lipids in peripheral tissues - skeletal muscle , liver and adipose tissue - may attenuate BC6ENTG signaling through the BC6OTHER ( BC6OTHER ) pathway and up - regulate protein BC6ENTC phosphatase 1B ( BC6OTHER ) , a negative regulator of BC6OTHER signaling.	False
Excess lipids in peripheral tissues - skeletal muscle , liver and adipose tissue - may attenuate BC6OTHER signaling through the BC6ENTG ( BC6OTHER ) pathway and up - regulate protein BC6ENTC phosphatase 1B ( BC6OTHER ) , a negative regulator of BC6OTHER signaling.	False
Excess lipids in peripheral tissues - skeletal muscle , liver and adipose tissue - may attenuate BC6OTHER signaling through the BC6OTHER ( BC6ENTG ) pathway and up - regulate protein BC6ENTC phosphatase 1B ( BC6OTHER ) , a negative regulator of BC6OTHER signaling.	False
Excess lipids in peripheral tissues - skeletal muscle , liver and adipose tissue - may attenuate BC6OTHER signaling through the BC6OTHER ( BC6OTHER ) pathway and up - regulate protein BC6ENTC phosphatase 1B ( BC6ENTG ) , a negative regulator of BC6OTHER signaling.	False
Excess lipids in peripheral tissues - skeletal muscle , liver and adipose tissue - may attenuate BC6OTHER signaling through the BC6OTHER ( BC6OTHER ) pathway and up - regulate protein BC6ENTC phosphatase 1B ( BC6OTHER ) , a negative regulator of BC6ENTG signaling.	False
We studied accumulation of lipid metabolites [ BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER )] and BC6OTHER in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER )] and BC6OTHER in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC )] and BC6OTHER in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC )] and BC6OTHER in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6ENTC in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6ENTC in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6OTHER (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6ENTG signaling and expression and phosphorylation of BC6OTHER by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6ENTC (FFAs) (200 μM).	False
We studied accumulation of lipid metabolites [ BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER )] and BC6OTHER in relation to BC6OTHER signaling and expression and phosphorylation of BC6ENTG by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free BC6ENTC (FFAs) (200 μM).	False
Normal BC6ENTC regulation is achieved by having adequate BC6ENTG secretion and effective BC6OTHER uptake / disposal.	False
Cells were also evaluated in the presence of BC6ENTC , an inhibitor of BC6ENTG and thus BC6OTHER (0 - 100 nM).	CPR:4
Cells were also evaluated in the presence of BC6ENTC , an inhibitor of BC6OTHER and thus BC6ENTG (0 - 100 nM).	CPR:4
Cells were also evaluated in the presence of BC6OTHER , an inhibitor of BC6ENTC 3 - kinases and thus BC6ENTG (0 - 100 nM).	False
Unsaturated FFAs increased BC6ENTC , BC6OTHER and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6ENTC , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6ENTC , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6ENTC , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6ENTC and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6ENTC and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6ENTC and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6ENTC and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Normal BC6OTHER regulation is achieved by having adequate BC6ENTG secretion and effective BC6ENTC uptake / disposal.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6ENTC ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6ENTC ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6ENTC ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6ENTC ( BC6OTHER ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6ENTC ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6ENTC ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6OTHER ( BC6ENTC ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6OTHER ( BC6ENTC ) 50 , BC6OTHER 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6ENTG expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6ENTC 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6ENTG sensitive as assessed by robust BC6OTHER and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6ENTC 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6ENTG and BC6OTHER phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6ENTC 398 and BC6OTHER 152.	False
Unsaturated FFAs increased BC6OTHER , BC6OTHER and BC6OTHER expression significantly , but cells remained BC6OTHER sensitive as assessed by robust BC6OTHER and BC6ENTG phosphorylation at BC6OTHER ( BC6OTHER ) 50 , BC6ENTC 398 and BC6OTHER 152.	False
Circulating BC6ENTG peptide concentrations were unaffected , suggesting that the rapid BC6ENTC inhibitory effect specifically targeted ACTH secretion from pituitary corticotrophs.	False
BC6ENTC fast feedback was only reduced by BC6ENTG antagonist pretreatment and not by BC6OTHER antagonism , suggesting a BC6OTHER - mediated pathway.	False
BC6ENTC fast feedback was only reduced by BC6OTHER antagonist pretreatment and not by BC6ENTG antagonism , suggesting a BC6OTHER - mediated pathway.	False
BC6ENTC fast feedback was only reduced by BC6OTHER antagonist pretreatment and not by BC6OTHER antagonism , suggesting a BC6ENTG - mediated pathway.	False
We have investigated in normal human male subjects the importance , site of action , and receptor - mediated processes involved in rapid basal BC6ENTC feedback and its interaction with BC6ENTG ( BC6OTHER ) drive.	False
We have investigated in normal human male subjects the importance , site of action , and receptor - mediated processes involved in rapid basal BC6ENTC feedback and its interaction with BC6OTHER ( BC6ENTG ) drive.	False
BC6ENTC also inhibited ACTH and BC6OTHER secretion in response to exogenous BC6ENTG stimulation , inferring rapid feedback inhibition at the anterior pituitary.	CPR:4
BC6OTHER also inhibited ACTH and BC6ENTC secretion in response to exogenous BC6ENTG stimulation , inferring rapid feedback inhibition at the anterior pituitary.	CPR:9
BC6ENTC ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6ENTC hydroxylase , BC6ENTG ).	False
BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6ENTG ( BC6ENTC hydroxylase , BC6OTHER ).	False
The high - affinity of BC6ENTC to BC6ENTG is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6OTHER , which is purified as a stable BC6OTHER - BC6OTHER complex.	False
The high - affinity of BC6ENTC to BC6OTHER is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6ENTG , which is purified as a stable BC6OTHER - BC6OTHER complex.	False
The high - affinity of BC6OTHER to BC6ENTC hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6ENTG , which is purified as a stable BC6OTHER - BC6OTHER complex.	False
BC6OTHER ( BC6ENTC , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
The high - affinity of BC6OTHER to BC6ENTG is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6ENTC hydroxylase , which is purified as a stable BC6OTHER - BC6OTHER complex.	False
The high - affinity of BC6OTHER to BC6ENTG is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6OTHER , which is purified as a stable BC6ENTC - BC6OTHER complex.	False
The high - affinity of BC6OTHER to BC6OTHER is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6ENTG , which is purified as a stable BC6ENTC - BC6OTHER complex.	False
The high - affinity of BC6OTHER to BC6ENTG is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6OTHER , which is purified as a stable BC6OTHER - BC6ENTC complex.	False
The high - affinity of BC6OTHER to BC6OTHER is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme BC6ENTG , which is purified as a stable BC6OTHER - BC6ENTC complex.	False
BC6OTHER ( BC6OTHER , BC6ENTC and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC and BC6OTHER ) are potent inhibitors of BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC and BC6OTHER ) are potent inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTC ) are potent inhibitors of BC6OTHER ( BC6ENTG , BC6OTHER ).	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTC ) are potent inhibitors of BC6OTHER ( BC6OTHER , BC6ENTG ).	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER and BC6ENTC ) are potent inhibitors of BC6ENTG ( BC6OTHER , BC6OTHER ).	CPR:4
The high - affinity binding of BC6ENTC to BC6ENTG , as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically) , shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol BC6OTHER / mol subunit with a half - maximal binding (S50) at 0.25 microM BC6OTHER .	False
The high - affinity binding of BC6OTHER to BC6ENTG , as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically) , shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol BC6ENTC / mol subunit with a half - maximal binding (S50) at 0.25 microM BC6OTHER .	False
BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6ENTC 4 - monooxygenase ( BC6ENTG , BC6OTHER ).	False
BC6OTHER ( BC6OTHER , BC6OTHER and BC6OTHER ) are potent inhibitors of BC6ENTC 4 - monooxygenase ( BC6OTHER , BC6ENTG ).	False
The high - affinity binding of BC6OTHER to BC6ENTG , as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically) , shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol BC6OTHER / mol subunit with a half - maximal binding (S50) at 0.25 microM BC6ENTC .	False
Cooperative homotropic interaction of BC6ENTC with the catalytic site of BC6ENTG .	False
These data further demonstrate the high degree of specificity (nuclei - , sex - and hormone - specific effects) in this system , highlighting the complexity of the stress - BC6ENTG link and suggesting modes through which the nongenomic modulation of this enzyme can result in targeted , rapid changes in local BC6ENTC concentrations.	False
By examining the relative effects of BC6ENTC ( BC6OTHER ) , BC6ENTG ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6ENTG , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6ENTC ) , BC6ENTG ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6ENTG , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6ENTG , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER , the avian homologue to BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6ENTC , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC , the avian homologue to BC6ENTG ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC , the avian homologue to BC6OTHER ) and BC6ENTG ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC , the avian homologue to BC6OTHER ) and BC6OTHER ( BC6ENTG ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER , the avian homologue to BC6ENTC ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG , the avian homologue to BC6ENTC ) and BC6OTHER ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6ENTC ) and BC6ENTG ( BC6OTHER ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
By examining the relative effects of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER , the avian homologue to BC6ENTC ) and BC6OTHER ( BC6ENTG ) , the present study aimed to define the hormone profile regulating stress - induced increases in AA in the POM.	False
We found that BC6ENTC , BC6ENTG and BC6OTHER all appear to play some role in these changes in the male brain.	False
We found that BC6ENTC , BC6OTHER and BC6ENTG all appear to play some role in these changes in the male brain.	False
We found that BC6OTHER , BC6ENTC and BC6ENTG all appear to play some role in these changes in the male brain.	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6ENTC and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6ENTC and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6ENTC and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6ENTC and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
These findings suggest that BC6ENTC inhibits antigen - induced LT production in the BC6ENTG - sensitized RBL - 2H3 cells and BC6OTHER - stimulated rat peritoneal neutrophils by direct inhibition of BC6OTHER activity.	False
These findings suggest that BC6ENTC inhibits antigen - induced LT production in the BC6OTHER - sensitized RBL - 2H3 cells and BC6OTHER - stimulated rat peritoneal neutrophils by direct inhibition of BC6ENTG activity.	CPR:4
These findings suggest that BC6OTHER inhibits antigen - induced LT production in the BC6ENTG - sensitized RBL - 2H3 cells and BC6ENTC - stimulated rat peritoneal neutrophils by direct inhibition of BC6OTHER activity.	False
These findings suggest that BC6OTHER inhibits antigen - induced LT production in the BC6OTHER - sensitized RBL - 2H3 cells and BC6ENTC - stimulated rat peritoneal neutrophils by direct inhibition of BC6ENTG activity.	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6ENTC ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6ENTC ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6ENTC ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6ENTC ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6ENTC , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6ENTC , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6ENTC , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6ENTC , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6ENTC ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6ENTC ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6ENTC ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6ENTC ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6ENTC ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6ENTC ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6ENTC ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6ENTC ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6ENTC ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6ENTC ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6ENTC ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6ENTC ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6OTHER - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6ENTG ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6ENTC - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6ENTG ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6ENTC - conjugated BC6OTHER .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6OTHER - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6ENTC - conjugated BC6ENTG .	False
The effect of BC6OTHER , an anti - diabetic drug with BC6ENTG - sensitizing action , on antigen - induced production of BC6OTHER and BC6OTHER ( BC6OTHER ) was examined in BC6OTHER ( BC6OTHER ) - specific BC6OTHER ( BC6OTHER ) - sensitized RBL - 2H3 mast cells following stimulation by the antigen , BC6ENTC - conjugated BC6OTHER .	False
BC6ENTC inhibited the antigen - induced production of BC6OTHER , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6OTHER , a specific inhibitor of BC6ENTG ( BC6OTHER ) and a clinically used anti - asthmatic drug.	False
BC6ENTC inhibited the antigen - induced production of BC6OTHER , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6OTHER , a specific inhibitor of BC6OTHER ( BC6ENTG ) and a clinically used anti - asthmatic drug.	False
BC6OTHER inhibited the antigen - induced production of BC6ENTC , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6OTHER , a specific inhibitor of BC6ENTG ( BC6OTHER ) and a clinically used anti - asthmatic drug.	False
BC6OTHER inhibited the antigen - induced production of BC6ENTC , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6OTHER , a specific inhibitor of BC6OTHER ( BC6ENTG ) and a clinically used anti - asthmatic drug.	False
BC6OTHER inhibited the antigen - induced production of BC6OTHER , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6ENTC , a specific inhibitor of BC6ENTG ( BC6OTHER ) and a clinically used anti - asthmatic drug.	CPR:4
BC6OTHER inhibited the antigen - induced production of BC6OTHER , CHEM and E(4) and the potency of the inhibition was comparable to that of BC6ENTC , a specific inhibitor of BC6OTHER ( BC6ENTG ) and a clinically used anti - asthmatic drug.	CPR:4
BC6ENTC inhibited BC6OTHER production by the supernatant fraction of RBL - 2H3 cell lysate with similar potency to BC6OTHER , suggesting that BC6OTHER inhibits LT production by direct inhibition of BC6ENTG activity.	False
BC6OTHER inhibited BC6ENTC production by the supernatant fraction of RBL - 2H3 cell lysate with similar potency to BC6OTHER , suggesting that BC6OTHER inhibits LT production by direct inhibition of BC6ENTG activity.	False
BC6OTHER inhibited BC6OTHER production by the supernatant fraction of RBL - 2H3 cell lysate with similar potency to BC6ENTC , suggesting that BC6OTHER inhibits LT production by direct inhibition of BC6ENTG activity.	CPR:4
BC6OTHER inhibited BC6OTHER production by the supernatant fraction of RBL - 2H3 cell lysate with similar potency to BC6OTHER , suggesting that BC6ENTC inhibits LT production by direct inhibition of BC6ENTG activity.	CPR:4
Inhibition by BC6ENTC of the antigen - induced production of BC6OTHER in BC6ENTG - sensitized RBL - 2H3 cells.	False
Inhibition by BC6OTHER of the antigen - induced production of BC6ENTC in BC6ENTG - sensitized RBL - 2H3 cells.	False
Furthermore , a decreased CD11c(+) macrophage infiltration in colons and inactivation of BC6ENTG in peritoneal macrophages were detected in BC6ENTC - 2 - treated mice.	CPR:4
The mechanism of action of BC6ENTC was related to the inhibition of the cleavage of BC6ENTG , BC6OTHER and BC6OTHER which in turn suppressed the activation of BC6OTHER inflammasome.	CPR:4
The mechanism of action of BC6ENTC was related to the inhibition of the cleavage of BC6OTHER , BC6ENTG and BC6OTHER which in turn suppressed the activation of BC6OTHER inflammasome.	CPR:4
The mechanism of action of BC6ENTC was related to the inhibition of the cleavage of BC6OTHER , BC6OTHER and BC6ENTG which in turn suppressed the activation of BC6OTHER inflammasome.	CPR:4
The mechanism of action of BC6ENTC was related to the inhibition of the cleavage of BC6OTHER , BC6OTHER and BC6OTHER which in turn suppressed the activation of BC6ENTG inflammasome.	CPR:4
Taken together , our results demonstrate the ability of BC6ENTC to inhibit BC6ENTG inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.	CPR:4
In the present study , we aimed at examining the effect of BC6ENTC , a synthetic small molecular compound also named BC6OTHER , for the treatment of dextran BC6OTHER BC6OTHER (DSS) - induced experimental colitis in mice via targeting BC6ENTG inflammasome.	False
In the present study , we aimed at examining the effect of BC6OTHER , a synthetic small molecular compound also named BC6ENTC , for the treatment of dextran BC6OTHER BC6OTHER (DSS) - induced experimental colitis in mice via targeting BC6ENTG inflammasome.	False
In the present study , we aimed at examining the effect of BC6OTHER , a synthetic small molecular compound also named BC6OTHER , for the treatment of dextran BC6ENTC BC6OTHER (DSS) - induced experimental colitis in mice via targeting BC6ENTG inflammasome.	False
In the present study , we aimed at examining the effect of BC6OTHER , a synthetic small molecular compound also named BC6OTHER , for the treatment of dextran BC6OTHER BC6ENTC (DSS) - induced experimental colitis in mice via targeting BC6ENTG inflammasome.	False
In addition , the disease activity index , histopathologic scores and BC6ENTG activity were also significantly reduced by BC6ENTC treatment.	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6ENTG in colon , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , were markedly suppressed by BC6ENTC .	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6OTHER in colon , including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , were markedly suppressed by BC6ENTC .	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6OTHER in colon , including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , were markedly suppressed by BC6ENTC .	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6OTHER in colon , including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , were markedly suppressed by BC6ENTC .	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6OTHER in colon , including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , were markedly suppressed by BC6ENTC .	CPR:4
Moreover , protein and mRNA levels of DSS - induced proinflammatory BC6OTHER in colon , including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , were markedly suppressed by BC6ENTC .	CPR:4
A novel BC6OTHER derivate prevents the development of dextran CHEM BC6ENTC - induced murine experimental colitis via inhibition of BC6ENTG inflammasome.	False
A novel BC6ENTC derivate prevents the development of dextran CHEM BC6OTHER - induced murine experimental colitis via inhibition of BC6ENTG inflammasome.	CPR:4
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6ENTC ) interaction on BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6ENTC ) interaction on inducible BC6OTHER synthase ( BC6ENTG ) , BC6OTHER , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6ENTC ) interaction on inducible BC6OTHER synthase ( BC6OTHER ) , BC6ENTG , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6ENTC ) interaction on inducible BC6OTHER synthase ( BC6OTHER ) , BC6OTHER , and BC6ENTG mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on inducible BC6ENTC synthase ( BC6ENTG ) , BC6OTHER , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on inducible BC6ENTC synthase ( BC6OTHER ) , BC6ENTG , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on inducible BC6ENTC synthase ( BC6OTHER ) , BC6OTHER , and BC6ENTG mRNA levels.	False
BC6ENTC , a BC6ENTG antagonist , prevented (P < 0.01) the CHEM - induced BC6OTHER mRNA downregulation in HD11 cells.	CPR:6
BC6ENTC , a BC6OTHER antagonist , prevented (P < 0.01) the CHEM - induced BC6ENTG mRNA downregulation in HD11 cells.	CPR:3
We conclude that CHEM and BC6ENTC interact through the BC6ENTG and BC6OTHER pathways to modulate BC6OTHER mRNA.	False
We conclude that CHEM and BC6ENTC interact through the BC6OTHER and BC6ENTG pathways to modulate BC6OTHER mRNA.	False
We conclude that CHEM and BC6ENTC interact through the BC6OTHER and BC6OTHER pathways to modulate BC6ENTG mRNA.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6ENTC X receptor (RXR) alpha and gamma mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on inducible BC6OTHER synthase ( BC6ENTG ) , BC6OTHER , and BC6ENTC X receptor (RXR) alpha and gamma mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6OTHER ( BC6OTHER ) interaction on inducible BC6OTHER synthase ( BC6OTHER ) , BC6ENTG , and BC6ENTC X receptor (RXR) alpha and gamma mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6ENTC ( BC6OTHER ) interaction on BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6ENTC ( BC6OTHER ) interaction on inducible BC6OTHER synthase ( BC6ENTG ) , BC6OTHER , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6ENTC ( BC6OTHER ) interaction on inducible BC6OTHER synthase ( BC6OTHER ) , BC6ENTG , and BC6OTHER mRNA levels.	False
Two experiments were conducted to investigate the effect of CHEM and fat or BC6ENTC ( BC6OTHER ) interaction on inducible BC6OTHER synthase ( BC6OTHER ) , BC6OTHER , and BC6ENTG mRNA levels.	False
CHEM and BC6ENTC interact to modify BC6ENTG mRNA levels through the BC6OTHER / BC6OTHER pathway in chickens and HD11 cell lines.	False
CHEM and BC6ENTC interact to modify BC6OTHER mRNA levels through the BC6ENTG / BC6OTHER pathway in chickens and HD11 cell lines.	False
CHEM and BC6ENTC interact to modify BC6OTHER mRNA levels through the BC6OTHER / BC6ENTG pathway in chickens and HD11 cell lines.	False
Fasting and mean post - BC6ENTC plasma bioactive BC6ENTG were higher (P < 0.01) after S and M+S vs. M and P. Basal endogenous BC6OTHER production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg / kg ⋅ min , M 1.8 ± 0.2 mg / kg ⋅ min [both P < 0.05 vs. P) , and M+S 1.5 ± 0.1 mg / kg ⋅ min (P < 0.01 vs. P).	False
Fasting and mean post - BC6OTHER plasma bioactive BC6ENTG were higher (P < 0.01) after S and M+S vs. M and P. Basal endogenous BC6ENTC production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg / kg ⋅ min , M 1.8 ± 0.2 mg / kg ⋅ min [both P < 0.05 vs. P) , and M+S 1.5 ± 0.1 mg / kg ⋅ min (P < 0.01 vs. P).	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6ENTG , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6ENTG ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6ENTG secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6ENTG , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6ENTC (FPG) , fasting plasma BC6OTHER , BC6OTHER ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6ENTG , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6ENTG secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6ENTG , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
Fasting plasma BC6OTHER (FPG) , fasting plasma BC6OTHER , BC6ENTC - peptide ( BC6OTHER secretory rate [ISR]) , fasting plasma BC6OTHER , and bioactive BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) was measured.RESULTSFPG decreased from P , 160 ± 4 to M , 150 ± 4; S , 154 ± 4; and M+S , 125 ± 3 mg / dL.	False
The increase in mean post - BC6ENTC plasma BC6ENTG and in ISR was similar in P , M , and S and slightly greater in M+S.	False
Mechanisms of BC6OTHER Lowering of BC6ENTG Inhibitor BC6OTHER When Used Alone or With BC6ENTC in Type 2 Diabetes: A double - tracer study.	False
Mechanisms of BC6ENTC Lowering of BC6ENTG Inhibitor BC6OTHER When Used Alone or With BC6OTHER in Type 2 Diabetes: A double - tracer study.	False
Mechanisms of BC6OTHER Lowering of BC6ENTG Inhibitor BC6ENTC When Used Alone or With BC6OTHER in Type 2 Diabetes: A double - tracer study.	CPR:4
Conjugates of BC6ENTC - rich peptides with two BC6OTHER mimetic scaffolds were synthesized and tested as inhibitors of BC6ENTG .	False
Conjugates of BC6OTHER - rich peptides with two BC6ENTC mimetic scaffolds were synthesized and tested as inhibitors of BC6ENTG .	False
Potent and selective: The unique nature of the BC6ENTC binding pocket structure of BC6OTHER family BC6OTHER ( BC6ENTG ) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub - nanomolar affinity.	False
Potent and selective: The unique nature of the BC6ENTC binding pocket structure of BC6ENTG family BC6OTHER ( BC6OTHER ) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub - nanomolar affinity.	False
Potent and selective: The unique nature of the BC6ENTC binding pocket structure of BC6OTHER family BC6ENTG ( BC6OTHER ) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub - nanomolar affinity.	False
"These results demonstrate that this receptor corresponds to the previously called "" BC6ENTG "" BC6OTHER and show that the active metabolite of BC6ENTC binds in a covalent manner to this receptor , thus explaining how it blocks the aggregating effect of BC6OTHER on platelets."	False
"These results demonstrate that this receptor corresponds to the previously called "" BC6OTHER "" BC6ENTG and show that the active metabolite of BC6ENTC binds in a covalent manner to this receptor , thus explaining how it blocks the aggregating effect of BC6OTHER on platelets."	False
"These results demonstrate that this receptor corresponds to the previously called "" BC6ENTG "" BC6OTHER and show that the active metabolite of BC6OTHER binds in a covalent manner to this receptor , thus explaining how it blocks the aggregating effect of BC6ENTC on platelets."	False
"These results demonstrate that this receptor corresponds to the previously called "" BC6OTHER "" BC6ENTG and show that the active metabolite of BC6OTHER binds in a covalent manner to this receptor , thus explaining how it blocks the aggregating effect of BC6ENTC on platelets."	False
The antiaggregating effect of BC6ENTC is attributed to an irreversible inhibition of BC6OTHER binding to a BC6ENTG present at the platelet surface.	False
The antiaggregating effect of BC6OTHER is attributed to an irreversible inhibition of BC6ENTC binding to a BC6ENTG present at the platelet surface.	False
Several BC6ENTG have been described on platelets; BC6OTHER , a BC6ENTC channel , and BC6OTHER a BC6OTHER , have been found not to be antagonized by BC6OTHER .	False
Several BC6OTHER have been described on platelets; BC6ENTG , a BC6ENTC channel , and BC6OTHER a BC6OTHER , have been found not to be antagonized by BC6OTHER .	False
Several BC6OTHER have been described on platelets; BC6OTHER , a BC6ENTC channel , and BC6ENTG a BC6OTHER , have been found not to be antagonized by BC6OTHER .	False
Several BC6OTHER have been described on platelets; BC6OTHER , a BC6ENTC channel , and BC6OTHER a BC6ENTG , have been found not to be antagonized by BC6OTHER .	False
Several BC6ENTG have been described on platelets; BC6OTHER , a BC6OTHER , and BC6OTHER a BC6OTHER , have been found not to be antagonized by BC6ENTC .	False
Several BC6OTHER have been described on platelets; BC6ENTG , a BC6OTHER , and BC6OTHER a BC6OTHER , have been found not to be antagonized by BC6ENTC .	False
Several BC6OTHER have been described on platelets; BC6OTHER , a BC6ENTG , and BC6OTHER a BC6OTHER , have been found not to be antagonized by BC6ENTC .	False
Several BC6OTHER have been described on platelets; BC6OTHER , a BC6OTHER , and BC6ENTG a BC6OTHER , have been found not to be antagonized by BC6ENTC .	False
Several BC6OTHER have been described on platelets; BC6OTHER , a BC6OTHER , and BC6OTHER a BC6ENTG , have been found not to be antagonized by BC6ENTC .	False
 BC6ENTG , a new platelet BC6ENTC receptor , target of BC6OTHER .	False
 BC6ENTG , a new platelet BC6OTHER , target of BC6ENTC .	False
 BC6OTHER , a new platelet BC6ENTG , target of BC6ENTC .	False
The BC6OTHER ( BC6ENTG ) is a BC6ENTC hormone receptor that functions as a ligand - dependent transcriptional factor , which plays a key role in the development and progression of prostate cancer.	False
The BC6ENTG ( BC6OTHER ) is a BC6ENTC hormone receptor that functions as a ligand - dependent transcriptional factor , which plays a key role in the development and progression of prostate cancer.	False
Recent advancement in high throughput technologies including microarrays and deep - sequencing provides unbiased genome - wide knowledge on the BC6ENTG signaling including datasets for BC6ENTC - regulated gene expression and genomic binding sites for BC6OTHER .	False
Recent advancement in high throughput technologies including microarrays and deep - sequencing provides unbiased genome - wide knowledge on the BC6OTHER signaling including datasets for BC6ENTC - regulated gene expression and genomic binding sites for BC6ENTG .	False
The BC6ENTC receptor ( BC6ENTG ) is a BC6OTHER that functions as a ligand - dependent transcriptional factor , which plays a key role in the development and progression of prostate cancer.	False
The BC6ENTC receptor ( BC6OTHER ) is a BC6ENTG that functions as a ligand - dependent transcriptional factor , which plays a key role in the development and progression of prostate cancer.	False
In contrast , analogs with different para - substituents on the BC6ENTC ring had significantly different potencies for wild - type BC6ENTG block.	False
Binding sites for BC6ENTG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ( BC6ENTC - 652 , BC6OTHER - 656) and residues in the pore helix ( BC6OTHER - 623 , BC6OTHER - 624 , BC6OTHER - 625).	False
Binding sites for BC6ENTG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ( BC6OTHER - 652 , BC6ENTC - 656) and residues in the pore helix ( BC6OTHER - 623 , BC6OTHER - 624 , BC6OTHER - 625).	False
Binding sites for BC6ENTG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ( BC6OTHER - 652 , BC6OTHER - 656) and residues in the pore helix ( BC6ENTC - 623 , BC6OTHER - 624 , BC6OTHER - 625).	False
Binding sites for BC6ENTG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ( BC6OTHER - 652 , BC6OTHER - 656) and residues in the pore helix ( BC6OTHER - 623 , BC6ENTC - 624 , BC6OTHER - 625).	False
Binding sites for BC6ENTG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix ( BC6OTHER - 652 , BC6OTHER - 656) and residues in the pore helix ( BC6OTHER - 623 , BC6OTHER - 624 , BC6ENTC - 625).	False
We used mutagenesis of these residues , combined with an investigation of BC6ENTG block by close analogs of BC6ENTC and BC6OTHER , to assess how specific alterations in drug structure affected potency and binding interactions.	CPR:4
We used mutagenesis of these residues , combined with an investigation of BC6ENTG block by close analogs of BC6OTHER and BC6ENTC , to assess how specific alterations in drug structure affected potency and binding interactions.	CPR:4
Drug binding interactions in the inner cavity of BC6ENTG channels: molecular insights from structure - activity relationships of BC6ENTC and BC6OTHER analogs.	False
Drug binding interactions in the inner cavity of BC6ENTG channels: molecular insights from structure - activity relationships of BC6OTHER and BC6ENTC analogs.	False
A novel class of BC6ENTC has been discovered as antagonists of the BC6ENTG : BC6OTHER protein - protein interaction through optimization of a hit derived from a virtual ligand - based screen.	CPR:6
A novel class of BC6ENTC has been discovered as antagonists of the BC6OTHER : BC6ENTG protein - protein interaction through optimization of a hit derived from a virtual ligand - based screen.	CPR:6
The beneficial role of BC6ENTC on blood pressure , cardiac hypertrophy , vascular BC6ENTG expression , perivascular fibrosis , and impaired BC6OTHER - dependent relaxation of isolated aortic rings was completely abrogated by coadministration of BC6OTHER .	CPR:3
The beneficial role of BC6OTHER on blood pressure , cardiac hypertrophy , vascular BC6ENTG expression , perivascular fibrosis , and impaired BC6ENTC - dependent relaxation of isolated aortic rings was completely abrogated by coadministration of BC6OTHER .	False
Controversial results obtained from human and animal studies on the prevention of heart disease by BC6OTHER and BC6ENTC warrant a better understanding of BC6ENTG function and interaction.	False
The beneficial role of BC6OTHER on blood pressure , cardiac hypertrophy , vascular BC6ENTG expression , perivascular fibrosis , and impaired BC6OTHER - dependent relaxation of isolated aortic rings was completely abrogated by coadministration of BC6ENTC .	CPR:4
The current results support the hypothesis of complex interactions among BC6ENTG BC6ENTC , and mineralocorticoid receptor signaling in cardiovascular injury and inflammation.	False
To address this issue and taking into account that effects of synthetic BC6ENTC are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6ENTC are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTC receptor but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6ENTC receptors , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6ENTC salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6ENTC salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6ENTC , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6ENTC , BC6OTHER , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6ENTC , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6ENTC , and BC6OTHER , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6ENTC , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6ENTC , a new BC6OTHER exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6ENTG but may also be mediated by other BC6OTHER , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6ENTC exhibiting antimineralocorticoid activity.	False
To address this issue and taking into account that effects of synthetic BC6OTHER are not only referable to action through the BC6OTHER but may also be mediated by other BC6ENTG , we characterized cardiovascular function and inflammatory gene expression in BC6OTHER salt - treated rats on long - term administration of BC6OTHER , BC6OTHER , and BC6OTHER , a new BC6ENTC exhibiting antimineralocorticoid activity.	False
Controversial results obtained from human and animal studies on the prevention of heart disease by BC6ENTC and BC6OTHER warrant a better understanding of BC6ENTG function and interaction.	False
In this work , we utilized magnetic circular dichroism spectroscopy to explore how the electronic structure of the reduced B12 cofactor (i.e. , the post - homolysis product BC6ENTC ) is modulated by the enzyme BC6ENTG .	False
showed that when BC6ENTC is bound to the BC6ENTG active site , no enzymatic perturbation of the BC6OTHER electronic structure occurs , even in the presence of substrate (analogues).	False
showed that when BC6OTHER is bound to the BC6ENTG active site , no enzymatic perturbation of the BC6ENTC electronic structure occurs , even in the presence of substrate (analogues).	False
 BC6ENTC bond activation in BC6ENTG by stabilization of the post - homolysis product BC6OTHER BC6OTHER .	False
 BC6OTHER bond activation in BC6ENTG by stabilization of the post - homolysis product BC6OTHER BC6ENTC .	False
 BC6OTHER bond activation in BC6ENTG by stabilization of the post - homolysis product BC6ENTC BC6OTHER .	False
A series of BC6ENTC analogues of the muscarinic antagonist BC6OTHER bearing 1 - substituents of different lipophilic , electronic , and steric properties was synthesized and their affinity for the BC6ENTG subtypes was evaluated by functional tests.	False
This work showed that appropriate structural modification of BC6ENTC can lead to BC6ENTG - selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.	CPR:6
A series of BC6OTHER analogues of the muscarinic antagonist BC6ENTC bearing 1 - substituents of different lipophilic , electronic , and steric properties was synthesized and their affinity for the BC6ENTG subtypes was evaluated by functional tests.	CPR:6
Synthesis and antagonistic activity at BC6ENTG subtypes of some BC6OTHER derivatives of BC6ENTC .	CPR:6
Synthesis and antagonistic activity at BC6ENTG subtypes of some BC6ENTC derivatives of BC6OTHER .	CPR:6
In this report , we show that the hypolipidemic agent BC6ENTC is a competitive inhibitor of BC6ENTG in vitro , with K(i)=57.8+ / - 2.3 microM.	CPR:4
These results may have implications in the development of novel BC6ENTG inhibitors based on the use of BC6ENTC as a lead compound for the treatment of type 2 diabetes.	CPR:4
Inhibition of BC6ENTG ( BC6OTHER ) by BC6ENTC .	CPR:4
Inhibition of BC6OTHER ( BC6ENTG ) by BC6ENTC .	CPR:4
Pretreatment with BC6ENTC (1 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	CPR:6
Pretreatment with BC6ENTC (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6ENTC (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6ENTG antagonist , BC6ENTC (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6ENTC (10 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	CPR:6
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6ENTC (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6ENTC (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , BC6ENTC (10 microM) , a BC6OTHER antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6ENTC (10 microM) , a BC6ENTG antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	CPR:6
Pretreatment with BC6OTHER (1 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTC H3 antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6ENTC H3 antagonist , or BC6OTHER (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6ENTC (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , or BC6ENTC (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
Pretreatment with BC6OTHER (1 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6OTHER antagonist , BC6OTHER (10 microM) , a BC6ENTG antagonist , or BC6ENTC (10 microM) , an alpha - adrenergic antagonist , however , had no effect.	False
BC6ENTC (10 microM) , another BC6ENTG antagonist without significant BC6OTHER binding affinity , did not produce any inhibition of the eNANC contraction.	CPR:6
BC6ENTC (10 microM) , another BC6OTHER antagonist without significant BC6ENTG binding affinity , did not produce any inhibition of the eNANC contraction.	False
BC6OTHER (10 microM) , another BC6ENTC H1 receptor antagonist without significant BC6ENTG binding affinity , did not produce any inhibition of the eNANC contraction.	False
BC6OTHER (10 microM) , another BC6ENTG antagonist without significant BC6ENTC receptor binding affinity , did not produce any inhibition of the eNANC contraction.	False
BC6ENTC (100 microM) did not displace the dose - response curve to exogenously applied BC6ENTG (0.01 - 10 microM).	False
These results suggest that BC6ENTC , although identified as a BC6OTHER antagonist , acts as a BC6ENTG agonist and that it inhibits the noncholinergic contraction in guinea - pig airways through stimulation of a prejunctional BC6OTHER , located to sensory nerves.	CPR:5
These results suggest that BC6ENTC , although identified as a BC6OTHER antagonist , acts as a BC6OTHER agonist and that it inhibits the noncholinergic contraction in guinea - pig airways through stimulation of a prejunctional BC6ENTG , located to sensory nerves.	CPR:3
These results suggest that BC6OTHER , although identified as a BC6ENTC antagonist , acts as a BC6ENTG agonist and that it inhibits the noncholinergic contraction in guinea - pig airways through stimulation of a prejunctional BC6OTHER , located to sensory nerves.	False
These results suggest that BC6OTHER , although identified as a BC6ENTC antagonist , acts as a BC6OTHER agonist and that it inhibits the noncholinergic contraction in guinea - pig airways through stimulation of a prejunctional BC6ENTG , located to sensory nerves.	False
BC6ENTC ( BC6OTHER ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6ENTG and various CHEM ( BC6OTHER ) receptor subtypes.	False
BC6ENTC ( BC6OTHER ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6OTHER and various BC6ENTG subtypes.	False
BC6OTHER ( BC6ENTC ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6ENTG and various CHEM ( BC6OTHER ) receptor subtypes.	False
BC6OTHER ( BC6ENTC ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6OTHER and various BC6ENTG subtypes.	False
BC6OTHER ( BC6OTHER ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6ENTG and various BC6ENTC ( BC6OTHER ) receptor subtypes.	False
BC6OTHER ( BC6OTHER ) is an antihistaminic drug with binding affinity at certain other receptors , including BC6ENTG and various CHEM ( BC6ENTC ) receptor subtypes.	False
Pretreatment of the tissues with combined BC6ENTG / BC6OTHER antagonists , BC6ENTC (1 microM) or BC6OTHER (0.1 microM) , significantly attenuated the inhibitory effect of BC6OTHER on the noncholinergic contraction.	CPR:6
Pretreatment of the tissues with combined BC6OTHER / BC6ENTG antagonists , BC6ENTC (1 microM) or BC6OTHER (0.1 microM) , significantly attenuated the inhibitory effect of BC6OTHER on the noncholinergic contraction.	CPR:6
Pretreatment of the tissues with combined BC6ENTG / BC6OTHER antagonists , BC6OTHER (1 microM) or BC6ENTC (0.1 microM) , significantly attenuated the inhibitory effect of BC6OTHER on the noncholinergic contraction.	CPR:6
Pretreatment of the tissues with combined BC6OTHER / BC6ENTG antagonists , BC6OTHER (1 microM) or BC6ENTC (0.1 microM) , significantly attenuated the inhibitory effect of BC6OTHER on the noncholinergic contraction.	CPR:6
Pretreatment of the tissues with combined BC6ENTG / BC6OTHER antagonists , BC6OTHER (1 microM) or BC6OTHER (0.1 microM) , significantly attenuated the inhibitory effect of BC6ENTC on the noncholinergic contraction.	CPR:5
Pretreatment of the tissues with combined BC6OTHER / BC6ENTG antagonists , BC6OTHER (1 microM) or BC6OTHER (0.1 microM) , significantly attenuated the inhibitory effect of BC6ENTC on the noncholinergic contraction.	CPR:5
 BC6ENTC ( BC6OTHER ) modulates the noncholinergic contraction in guinea - pig airways in vitro by a prejunctional BC6ENTG .	False
 BC6OTHER ( BC6ENTC ) modulates the noncholinergic contraction in guinea - pig airways in vitro by a prejunctional BC6ENTG .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6ENTG ( BC6OTHER ) because BC6ENTC , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6ENTG ) because BC6ENTC , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6ENTC , a specific ligand of BC6ENTG , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6ENTC , a specific ligand of BC6OTHER , was unable to inhibit BC6ENTG induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6ENTC , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6ENTG - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6ENTC , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6ENTG .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6ENTG ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6ENTG ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6ENTG , was unable to inhibit BC6OTHER induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6ENTG induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6ENTG - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6ENTC nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6ENTG .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6ENTG ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6ENTG ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6ENTG , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6ENTG induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6ENTG - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6OTHER does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6ENTC could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6ENTG .	False
BC6ENTC did not block nuclear translocation or DNA - binding activity of the transcription factor BC6ENTG , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6OTHER may involve interference with BC6OTHER transcriptional activity in the nucleus.	False
BC6ENTC did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6ENTG reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6OTHER may involve interference with BC6OTHER transcriptional activity in the nucleus.	CPR:4
BC6ENTC did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6ENTG by BC6OTHER may involve interference with BC6OTHER transcriptional activity in the nucleus.	False
BC6ENTC did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6OTHER may involve interference with BC6ENTG transcriptional activity in the nucleus.	False
BC6OTHER did not block nuclear translocation or DNA - binding activity of the transcription factor BC6ENTG , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6ENTC may involve interference with BC6OTHER transcriptional activity in the nucleus.	False
BC6OTHER did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6ENTG reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6ENTC may involve interference with BC6OTHER transcriptional activity in the nucleus.	False
BC6OTHER did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6ENTG by BC6ENTC may involve interference with BC6OTHER transcriptional activity in the nucleus.	CPR:4
BC6OTHER did not block nuclear translocation or DNA - binding activity of the transcription factor BC6OTHER , but it did inhibit the activity of an BC6OTHER reporter construct , suggesting that the mechanism of suppression of microglial BC6OTHER by BC6ENTC may involve interference with BC6ENTG transcriptional activity in the nucleus.	False
As models of glial activation , production of inducible BC6ENTC synthase ( BC6ENTG ) was studied in lipopolysaccharide - stimulated rat microglia , a murine microglial cell line BV - 2 , and BC6OTHER - stimulated rat astrocytes.	False
As models of glial activation , production of inducible BC6ENTC synthase ( BC6OTHER ) was studied in lipopolysaccharide - stimulated rat microglia , a murine microglial cell line BV - 2 , and BC6ENTG - stimulated rat astrocytes.	False
BC6ENTC were potent inhibitors of BC6ENTG induction and were more effective than their precursors , BC6OTHER .	CPR:4
BC6OTHER were potent inhibitors of BC6ENTG induction and were more effective than their precursors , BC6ENTC .	CPR:4
In activated microglia , BC6ENTC suppressed BC6ENTG activity , BC6OTHER mRNA , and protein levels.	CPR:4
In activated microglia , BC6ENTC suppressed BC6OTHER activity , BC6ENTG mRNA , and protein levels.	CPR:4
The action of BC6ENTC does not appear to involve its nuclear receptor BC6ENTG ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6ENTC does not appear to involve its nuclear receptor BC6OTHER ( BC6ENTG ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6ENTC does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6ENTG , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6ENTC does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6ENTG induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6ENTC does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6ENTG - dependent promoter in the absence of cotransfected BC6OTHER .	False
The action of BC6ENTC does not appear to involve its nuclear receptor BC6OTHER ( BC6OTHER ) because BC6OTHER , a specific ligand of BC6OTHER , was unable to inhibit BC6OTHER induction , and neither BC6OTHER nor BC6OTHER could stimulate the activity of a BC6OTHER - dependent promoter in the absence of cotransfected BC6ENTG .	False
 BC6ENTC suppress activation of microglia: down - regulation of BC6ENTG by BC6OTHER .	CPR:4
 BC6OTHER suppress activation of microglia: down - regulation of BC6ENTG by BC6ENTC .	CPR:4
BC6OTHER , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6ENTC , while BC6OTHER induced BC6ENTG and BC6OTHER .	False
BC6OTHER , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6ENTC , while BC6OTHER induced BC6OTHER and BC6ENTG .	False
BC6ENTG , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6ENTC , while BC6OTHER induced BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER , BC6ENTG and BC6OTHER mRNA levels were significantly induced by BC6ENTC , while BC6OTHER induced BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER , BC6OTHER and BC6ENTG mRNA levels were significantly induced by BC6ENTC , while BC6OTHER induced BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6OTHER , while BC6ENTC induced BC6ENTG and BC6OTHER .	CPR:3
BC6OTHER , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6OTHER , while BC6ENTC induced BC6OTHER and BC6ENTG .	CPR:3
BC6ENTG , BC6OTHER and BC6OTHER mRNA levels were significantly induced by BC6OTHER , while BC6ENTC induced BC6OTHER and BC6OTHER .	False
BC6OTHER , BC6ENTG and BC6OTHER mRNA levels were significantly induced by BC6OTHER , while BC6ENTC induced BC6OTHER and BC6OTHER .	False
BC6OTHER , BC6OTHER and BC6ENTG mRNA levels were significantly induced by BC6OTHER , while BC6ENTC induced BC6OTHER and BC6OTHER .	False
Despite its ability to block the action of BC6ENTC on BC6ENTG , no demonstrable benefit from this action was noted in patients with chronic compensated heart failure and it is not approved for this indication.	False
Several fluid retentive states such as heart failure , cirrhosis of the liver , and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of BC6ENTC ( BC6ENTG ) , a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis.	False
Several fluid retentive states such as heart failure , cirrhosis of the liver , and syndrome of inappropriate antidiuretic hormone secretion are associated with inappropriate elevation in plasma levels of BC6ENTG ( BC6ENTC ) , a neuropeptide that is secreted by the hypothalamus and plays a critical role in the regulation of serum osmolality and in circulatory homeostasis.	False
BC6ENTC is a nonpeptide dual BC6ENTG antagonist.	CPR:6
 BC6ENTC : a dual BC6ENTG antagonist [corrected].	CPR:6
Previous reports have identified a role for the BC6ENTC kinase receptor BC6ENTG and its ligand , BC6OTHER , as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts.	False
Previous reports have identified a role for the BC6ENTC kinase receptor BC6OTHER and its ligand , BC6ENTG , as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts.	False
BC6ENTC (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6ENTG , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6ENTC (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6ENTG / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6ENTC (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6ENTG ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6ENTC (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6ENTG and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:3
BC6ENTC (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6ENTG to the cytosol induced by BC6OTHER .	CPR:4
BC6OTHER (25 and 50mg / kg) or BC6ENTC improved histopathological damages , decreased BC6OTHER and BC6ENTG , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6OTHER (25 and 50mg / kg) or BC6ENTC improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6ENTG / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6OTHER (25 and 50mg / kg) or BC6ENTC improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6ENTG ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:4
BC6OTHER (25 and 50mg / kg) or BC6ENTC improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6ENTG and release of BC6OTHER to the cytosol induced by BC6OTHER .	CPR:3
BC6OTHER (25 and 50mg / kg) or BC6ENTC improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6ENTG to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6ENTC and BC6ENTG , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6ENTC and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6ENTG / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6ENTC and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6ENTG ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6ENTC and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6ENTG and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6ENTC and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6ENTG to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6ENTG , increased BC6ENTC content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6ENTC content and attenuated the increase of BC6ENTG / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6ENTC content and attenuated the increase of BC6OTHER / BC6ENTG ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6ENTC content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6ENTG and release of BC6OTHER to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6ENTC content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6ENTG to the cytosol induced by BC6OTHER .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6ENTG , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6ENTC .	False
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6ENTG / BC6OTHER ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6ENTC .	CPR:3
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6ENTG ratio , activation of BC6OTHER and release of BC6OTHER to the cytosol induced by BC6ENTC .	CPR:4
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6ENTG and release of BC6OTHER to the cytosol induced by BC6ENTC .	CPR:3
BC6OTHER (25 and 50mg / kg) or BC6OTHER improved histopathological damages , decreased BC6OTHER and BC6OTHER , increased BC6OTHER content and attenuated the increase of BC6OTHER / BC6OTHER ratio , activation of BC6OTHER and release of BC6ENTG to the cytosol induced by BC6ENTC .	CPR:3
BC6ENTC phosphokinase MB ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6ENTG ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6OTHER ( BC6ENTG ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) levels were evaluated in heart tissue at the end of treatments.	False
BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels were evaluated in heart tissue at the end of treatments.	False
BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) levels were evaluated in heart tissue at the end of treatments.	False
RESULTS: BC6ENTC induced histophatological damages and elevated the level of cardiac marker BC6ENTG .	CPR:3
These effects were associated with increased BC6ENTC level , lower level of reduced BC6OTHER and induction of apoptosis through elevation of BC6ENTG / BC6OTHER ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6ENTC level , lower level of reduced BC6OTHER and induction of apoptosis through elevation of BC6OTHER / BC6ENTG ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6ENTC level , lower level of reduced BC6OTHER and induction of apoptosis through elevation of BC6OTHER / BC6OTHER ratio (both protein and mRNA levels) , BC6ENTG release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6ENTC level , lower level of reduced BC6OTHER and induction of apoptosis through elevation of BC6OTHER / BC6OTHER ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6ENTG in cardiac tissue.	False
These effects were associated with increased BC6OTHER level , lower level of reduced BC6ENTC and induction of apoptosis through elevation of BC6ENTG / BC6OTHER ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6OTHER level , lower level of reduced BC6ENTC and induction of apoptosis through elevation of BC6OTHER / BC6ENTG ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6OTHER level , lower level of reduced BC6ENTC and induction of apoptosis through elevation of BC6OTHER / BC6OTHER ratio (both protein and mRNA levels) , BC6ENTG release to the cytosol and activation BC6OTHER in cardiac tissue.	False
These effects were associated with increased BC6OTHER level , lower level of reduced BC6ENTC and induction of apoptosis through elevation of BC6OTHER / BC6OTHER ratio (both protein and mRNA levels) , BC6OTHER release to the cytosol and activation BC6ENTG in cardiac tissue.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6ENTC , and BC6OTHER and noninferior to BC6ENTG glargine and BC6OTHER CHEM at reducing BC6OTHER in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6ENTC , and BC6OTHER and noninferior to BC6OTHER glargine and BC6ENTG CHEM at reducing BC6OTHER in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6ENTC , and BC6OTHER and noninferior to BC6OTHER glargine and BC6OTHER CHEM at reducing BC6ENTG in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6ENTC , and BC6OTHER and noninferior to BC6OTHER glargine and BC6OTHER CHEM at reducing BC6OTHER in T2D patients , with BC6ENTG changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6OTHER , and BC6ENTC and noninferior to BC6ENTG glargine and BC6OTHER CHEM at reducing BC6OTHER in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6OTHER , and BC6ENTC and noninferior to BC6OTHER glargine and BC6ENTG CHEM at reducing BC6OTHER in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6OTHER , and BC6ENTC and noninferior to BC6OTHER glargine and BC6OTHER CHEM at reducing BC6ENTG in T2D patients , with BC6OTHER changes from baseline ranging from - 0.55% to - 0.9%.	False
Clinical studies have shown albiglutide to be superior to placebo , BC6OTHER , and BC6ENTC and noninferior to BC6OTHER glargine and BC6OTHER CHEM at reducing BC6OTHER in T2D patients , with BC6ENTG changes from baseline ranging from - 0.55% to - 0.9%.	False
DATA SYNTHESIS: Albiglutide is a long - acting BC6ENTG A that lowers BC6OTHER ( BC6OTHER ) and reduces weight by stimulating BC6ENTC - dependent BC6OTHER secretion , suppressing BC6OTHER secretion , delaying gastric emptying , and promoting satiety.	False
DATA SYNTHESIS: Albiglutide is a long - acting BC6OTHER A that lowers BC6ENTG ( BC6OTHER ) and reduces weight by stimulating BC6ENTC - dependent BC6OTHER secretion , suppressing BC6OTHER secretion , delaying gastric emptying , and promoting satiety.	False
DATA SYNTHESIS: Albiglutide is a long - acting BC6OTHER A that lowers BC6OTHER ( BC6ENTG ) and reduces weight by stimulating BC6ENTC - dependent BC6OTHER secretion , suppressing BC6OTHER secretion , delaying gastric emptying , and promoting satiety.	False
DATA SYNTHESIS: Albiglutide is a long - acting BC6OTHER A that lowers BC6OTHER ( BC6OTHER ) and reduces weight by stimulating BC6ENTC - dependent BC6ENTG secretion , suppressing BC6OTHER secretion , delaying gastric emptying , and promoting satiety.	False
DATA SYNTHESIS: Albiglutide is a long - acting BC6OTHER A that lowers BC6OTHER ( BC6OTHER ) and reduces weight by stimulating BC6ENTC - dependent BC6OTHER secretion , suppressing BC6ENTG secretion , delaying gastric emptying , and promoting satiety.	False
Albiglutide has been studied as monotherapy and add - on therapy to BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG glargine , and varying combinations of these agents.	False
Albiglutide has been studied as monotherapy and add - on therapy to BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG glargine , and varying combinations of these agents.	False
Albiglutide has been studied as monotherapy and add - on therapy to BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG glargine , and varying combinations of these agents.	False
 BC6OTHER efficiently activated BC6OTHER and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6ENTC and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6ENTG - deficient mice.	False
 BC6OTHER efficiently activated BC6ENTG and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6ENTC and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
 BC6OTHER efficiently activated BC6OTHER and induced BC6ENTG target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6ENTC and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
 BC6OTHER efficiently activated BC6OTHER and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6ENTC levels in wild - type mice , but not in BC6ENTG - deficient mice.	False
 BC6OTHER efficiently activated BC6ENTG and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6ENTC levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
 BC6OTHER efficiently activated BC6OTHER and induced BC6ENTG target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6ENTC levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
BC6ENTC - mediated BC6ENTG activation stimulated the expression of several key intestinal genes involved in lipid homeostasis.	CPR:3
Several PIs have been implicated to activate the nuclear receptor BC6ENTC X receptor ( BC6ENTG ) , which acts as a xenobiotic sensor to regulate xenobiotic metabolism in the liver and intestine.	False
In the present study , we identified BC6ENTC , a widely used HIV PI , as a potent BC6ENTG - selective agonist.	CPR:5
Computational docking studies combined with site - direct mutagenesis identified several key residues within the ligand binding pocket of BC6ENTG that constitute points of interaction with BC6ENTC .	False
 BC6ENTC efficiently activated BC6OTHER and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6ENTG - deficient mice.	False
 BC6ENTC efficiently activated BC6ENTG and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	CPR:3
 BC6ENTC efficiently activated BC6OTHER and induced BC6ENTG target gene expression in vitro and in vivo. Short - term exposure to BC6OTHER significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	CPR:3
 BC6OTHER efficiently activated BC6OTHER and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6ENTC significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6ENTG - deficient mice.	False
 BC6OTHER efficiently activated BC6ENTG and induced BC6OTHER target gene expression in vitro and in vivo. Short - term exposure to BC6ENTC significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
 BC6OTHER efficiently activated BC6OTHER and induced BC6ENTG target gene expression in vitro and in vivo. Short - term exposure to BC6ENTC significantly increased plasma total BC6OTHER and atherogenic low - density lipoprotein BC6OTHER levels in wild - type mice , but not in BC6OTHER - deficient mice.	False
 BC6ENTC X Receptor Mediates Dyslipidemia Induced by the BC6ENTG Inhibitor BC6OTHER in Mice.	False
 BC6ENTG Mediates Dyslipidemia Induced by the BC6OTHER Inhibitor BC6ENTC in Mice.	False
 BC6OTHER Mediates Dyslipidemia Induced by the BC6ENTG Inhibitor BC6ENTC in Mice.	CPR:4
In conclusion , of the seven NSAIDs investigated , BC6ENTC was the most potent inhibitor of recombinant BC6ENTG via 4 - MUG in a competitive manner.	CPR:4
The inhibitory potencies of non - BC6OTHER anti - inflammatory drugs (NSAIDs) on BC6OTHER activity were investigated in recombinant BC6ENTG using BC6ENTC ( BC6OTHER ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6OTHER anti - inflammatory drugs (NSAIDs) on BC6ENTG activity were investigated in recombinant BC6OTHER using BC6ENTC ( BC6OTHER ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6OTHER anti - inflammatory drugs (NSAIDs) on BC6OTHER activity were investigated in recombinant BC6ENTG using BC6OTHER ( BC6ENTC ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6OTHER anti - inflammatory drugs (NSAIDs) on BC6ENTG activity were investigated in recombinant BC6OTHER using BC6OTHER ( BC6ENTC ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6ENTC anti - inflammatory drugs (NSAIDs) on BC6OTHER activity were investigated in recombinant BC6ENTG using BC6OTHER ( BC6OTHER ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6ENTC anti - inflammatory drugs (NSAIDs) on BC6ENTG activity were investigated in recombinant BC6OTHER using BC6OTHER ( BC6OTHER ) as a substrate for glucuronidation.	False
The inhibitory potencies of non - BC6OTHER anti - inflammatory drugs (NSAIDs) on BC6ENTC - glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant BC6ENTG using BC6OTHER ( BC6OTHER ) as a substrate for glucuronidation.	False
In vitro inhibitory effects of non - BC6OTHER anti - inflammatory drugs on BC6OTHER glucuronidation in recombinant BC6ENTG - - potent inhibition by BC6ENTC .	CPR:4
In vitro inhibitory effects of non - BC6ENTC anti - inflammatory drugs on BC6OTHER glucuronidation in recombinant BC6ENTG - - potent inhibition by BC6OTHER .	False
In vitro inhibitory effects of non - BC6OTHER anti - inflammatory drugs on BC6ENTC glucuronidation in recombinant BC6ENTG - - potent inhibition by BC6OTHER .	False
"Low levels of BC6ENTC may reduce the density of the BC6ENTG ( BC6OTHER ) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response""."	CPR:4
"Low levels of BC6ENTC may reduce the density of the BC6OTHER ( BC6ENTG ) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response""."	CPR:4
To determine whether BC6ENTC ( BC6OTHER ) - induced reductions in BC6ENTG density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6OTHER and BC6OTHER density were measured.	CPR:4
To determine whether BC6ENTC ( BC6OTHER ) - induced reductions in BC6OTHER density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6OTHER and BC6ENTG density were measured.	False
To determine whether BC6OTHER ( BC6ENTC ) - induced reductions in BC6ENTG density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6OTHER and BC6OTHER density were measured.	CPR:4
To determine whether BC6OTHER ( BC6ENTC ) - induced reductions in BC6OTHER density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6OTHER and BC6ENTG density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6ENTG density could be related to such a mechanism , BC6ENTC or BC6OTHER was administered to rats , and brain BC6OTHER and BC6OTHER density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6OTHER density could be related to such a mechanism , BC6ENTC or BC6OTHER was administered to rats , and brain BC6OTHER and BC6ENTG density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6ENTG density could be related to such a mechanism , BC6OTHER or BC6ENTC was administered to rats , and brain BC6OTHER and BC6OTHER density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6OTHER density could be related to such a mechanism , BC6OTHER or BC6ENTC was administered to rats , and brain BC6OTHER and BC6ENTG density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6ENTG density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6ENTC and BC6OTHER density were measured.	False
To determine whether BC6OTHER ( BC6OTHER ) - induced reductions in BC6OTHER density could be related to such a mechanism , BC6OTHER or BC6OTHER was administered to rats , and brain BC6ENTC and BC6ENTG density were measured.	False
However , only BC6ENTC reduced BC6ENTG density.	CPR:4
"Low levels of BC6OTHER may reduce the density of the BC6ENTC transporter ( BC6ENTG ) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response""."	False
This observation suggests that BC6ENTC - induced reductions in BC6ENTG density do not represent neuroadaptive responses to decreased levels of brain BC6OTHER , but may occur in response to some other stimulus or to the neurotoxic effects of BC6OTHER .	CPR:4
This observation suggests that BC6OTHER - induced reductions in BC6ENTG density do not represent neuroadaptive responses to decreased levels of brain BC6ENTC , but may occur in response to some other stimulus or to the neurotoxic effects of BC6OTHER .	False
This observation suggests that BC6OTHER - induced reductions in BC6ENTG density do not represent neuroadaptive responses to decreased levels of brain BC6OTHER , but may occur in response to some other stimulus or to the neurotoxic effects of BC6ENTC .	False
 BC6ENTC - and BC6OTHER - induced reduction in BC6OTHER concentrations: effects on BC6ENTG densities.	False
 BC6OTHER - and BC6ENTC - induced reduction in BC6OTHER concentrations: effects on BC6ENTG densities.	False
 BC6OTHER - and BC6OTHER - induced reduction in BC6ENTC concentrations: effects on BC6ENTG densities.	False
BC6ENTG encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6ENTC [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6ENTG ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6ENTC [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6ENTG ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6ENTC [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6ENTG cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6ENTC [ BC6OTHER ].	False
BC6ENTG encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6ENTC ].	CPR:9
BC6OTHER encodes BC6ENTG ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6ENTC ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6ENTG ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6ENTC ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6ENTG cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6ENTC ].	False
Accordingly , loss of BC6ENTG function in FRDA cells was accompanied by decreased BC6ENTC levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.	CPR:9
BC6ENTG encodes BC6ENTC 5 - kinase β type I ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	False
BC6OTHER encodes BC6ENTC 5 - kinase β type I ( BC6ENTG ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	False
BC6OTHER encodes BC6ENTC 5 - kinase β type I ( BC6OTHER ) , an enzyme functionally linked to BC6ENTG cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	False
BC6ENTG encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6ENTC [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6ENTG ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6ENTC [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6ENTG ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6ENTC [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6ENTG cytoskeleton dynamics that phosphorylates BC6ENTC [ BC6OTHER ] to generate BC6OTHER [ BC6OTHER ].	False
BC6ENTG encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6ENTC ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6ENTG ( BC6OTHER ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6ENTC ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6ENTG ) , an enzyme functionally linked to BC6OTHER cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6ENTC ] to generate BC6OTHER [ BC6OTHER ].	CPR:9
BC6OTHER encodes BC6OTHER ( BC6OTHER ) , an enzyme functionally linked to BC6ENTG cytoskeleton dynamics that phosphorylates BC6OTHER [ BC6ENTC ] to generate BC6OTHER [ BC6OTHER ].	False
BC6ENTC treatment also induced abnormal BC6ENTG bridges , suggesting that cytokinesis was interfered within cells undergoing karyokinesis.	False
BC6ENTG gene deletion did not affect BC6OTHER expression or the ability of BC6ENTC to suppress BC6OTHER - induced lipolysis.	False
BC6OTHER gene deletion did not affect BC6ENTG expression or the ability of BC6ENTC to suppress BC6OTHER - induced lipolysis.	False
BC6ENTG gene deletion did not affect BC6OTHER expression or the ability of BC6OTHER to suppress BC6ENTC - induced lipolysis.	False
BC6OTHER gene deletion did not affect BC6ENTG expression or the ability of BC6OTHER to suppress BC6ENTC - induced lipolysis.	False
Collectively , these studies suggest that BC6ENTG supports aspects of adipose tissue mass and alters the sensitivity of epididymal adipose tissue to BC6ENTC , glucocorticoids , and LPS , thereby modulating lipolysis and BC6OTHER release.	False
Collectively , these studies suggest that BC6OTHER supports aspects of adipose tissue mass and alters the sensitivity of epididymal adipose tissue to BC6ENTC , glucocorticoids , and LPS , thereby modulating lipolysis and BC6ENTG release.	False
Epididymal tissue from wild - type mice responded in vitro to BC6ENTC and BC6OTHER with increased BC6OTHER release , reduced BC6ENTG release , and increased BC6OTHER accumulation.	CPR:4
Epididymal tissue from wild - type mice responded in vitro to BC6OTHER and BC6ENTC with increased BC6OTHER release , reduced BC6ENTG release , and increased BC6OTHER accumulation.	CPR:4
Epididymal tissue from wild - type mice responded in vitro to BC6OTHER and BC6OTHER with increased BC6ENTC release , reduced BC6ENTG release , and increased BC6OTHER accumulation.	False
Epididymal tissue from wild - type mice responded in vitro to BC6OTHER and BC6OTHER with increased BC6OTHER release , reduced BC6ENTG release , and increased BC6ENTC accumulation.	False
Qualitatively similar but significantly attenuated responses to the BC6ENTC were observed in tissue from BC6ENTG - null mice , an effect that was not associated with changes in BC6OTHER mRNA expression.	False
Qualitatively similar but significantly attenuated responses to the BC6ENTC were observed in tissue from BC6OTHER - null mice , an effect that was not associated with changes in BC6ENTG mRNA expression.	False
Our previous work , built on the early pioneering multikinase inhibitor BC6ENTC , resulted in the only BC6ENTG vascular - targeted BC6OTHER inhibitor prodrug , BC6OTHER , which has now completed Phase I clinical trials.	CPR:4
Our previous work , built on the early pioneering multikinase inhibitor BC6ENTC , resulted in the only BC6OTHER vascular - targeted BC6ENTG inhibitor prodrug , BC6OTHER , which has now completed Phase I clinical trials.	CPR:4
Our previous work , built on the early pioneering multikinase inhibitor BC6OTHER , resulted in the only BC6ENTG vascular - targeted BC6OTHER inhibitor prodrug , BC6ENTC , which has now completed Phase I clinical trials.	CPR:4
Our previous work , built on the early pioneering multikinase inhibitor BC6OTHER , resulted in the only BC6OTHER vascular - targeted BC6ENTG inhibitor prodrug , BC6ENTC , which has now completed Phase I clinical trials.	CPR:4
This work resulted in the discovery of the BC6ENTC system as the foundation of a new compound class of potential BC6ENTG inhibitors having improved potency toward BC6OTHER .	CPR:4
This work resulted in the discovery of the BC6ENTC system as the foundation of a new compound class of potential BC6OTHER inhibitors having improved potency toward BC6ENTG .	CPR:4
Synthesis and cancer stem cell - based activity of substituted BC6ENTC designed as next generation BC6ENTG inhibitors.	CPR:4
The authors investigated (a) the association of BC6ENTC - oxidative stress and endothelial function with myocardial deformation , (b) the effects of CHEM , an BC6ENTG antagonist on myocardial deformation in patients with rheumatoid arthritis (RA).	False
Chronic inhibition of BC6ENTG improves LV deformation in parallel with endothelial function and BC6ENTC - oxidative stress.	False
OBJECTIVE: Inhibition of BC6ENTG activity improves BC6ENTC - oxidative stress , endothelial and coronary function.	False
One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of BC6ENTG inhibitors to delay the breakdown of BC6ENTC released into synaptic clefts.	False
BC6ENTC , the first of the BC6ENTG inhibitors to undergo extensive trials for this purpose , was associated with significant adverse effects including hepatotoxicity.	CPR:4
Other BC6ENTG inhibitors , including BC6ENTC , with superior properties in terms of specificity of action and low risk of adverse effects , have now been introduced.	CPR:4
BC6ENTC , a BC6ENTG inhibitor , arrests cell division and causes apoptosis in non - small lung cancer cells [283660].	CPR:4
In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia , dose - dependent BC6ENTG inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of BC6ENTC .	CPR:4
BC6ENTC inhibits BC6ENTG with an IC50 value of 0.4 mM [285707].	CPR:4
These findings lend support to a role for BC6ENTG as a BC6ENTC donor for basal adrenal steroidogenesis in humans.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTG ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6ENTG ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , BC6ENTG ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6ENTG ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6ENTG BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6ENTG - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6ENTG / BC6OTHER mutations.	False
To study this , BC6ENTC profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6ENTG mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6ENTG ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , BC6ENTG ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6ENTG ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6ENTG BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6ENTG - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6ENTG / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTC binding cassette transporter A1 ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6ENTG mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTG ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6ENTG ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6ENTG ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6ENTG BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6ENTG - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6ENTG / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6ENTC acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6OTHER ( BC6OTHER - C) without BC6OTHER / BC6ENTG mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6ENTG ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6ENTG ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , BC6ENTG ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6ENTG ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6ENTG BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6ENTG - C) without BC6OTHER / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6ENTG / BC6OTHER mutations.	False
To study this , BC6OTHER profiles in urine were assessed in male subjects suffering from functional mutations in BC6OTHER ( BC6OTHER ) (n = 24) , CHEM: BC6OTHER acyltransferase ( BC6OTHER ) (n = 40) , as well as in 11 subjects with low BC6OTHER BC6ENTC ( BC6OTHER - C) without BC6OTHER / BC6ENTG mutations.	False
 BC6OTHER as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6ENTG - derived BC6ENTC to the adrenals for BC6OTHER production in humans.	False
 BC6ENTG as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6OTHER - derived BC6ENTC to the adrenals for BC6OTHER production in humans.	False
 BC6OTHER as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6ENTG - C. Few studies have addressed the delivery of BC6OTHER - derived BC6ENTC to the adrenals for BC6OTHER production in humans.	False
In all groups with low BC6ENTG - C levels , urinary excretion of BC6ENTC was reduced by 33% , 27% , and 32% compared with controls (all P < 0.04).	False
 BC6OTHER as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6ENTG - derived BC6OTHER to the adrenals for BC6ENTC production in humans.	False
 BC6ENTG as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6OTHER - derived BC6OTHER to the adrenals for BC6ENTC production in humans.	False
 BC6OTHER as a source of BC6OTHER for adrenal steroidogenesis: a study in individuals with low plasma BC6ENTG - C. Few studies have addressed the delivery of BC6OTHER - derived BC6OTHER to the adrenals for BC6ENTC production in humans.	False
 BC6OTHER as a source of BC6ENTC for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6ENTG - derived BC6OTHER to the adrenals for BC6OTHER production in humans.	False
 BC6ENTG as a source of BC6ENTC for adrenal steroidogenesis: a study in individuals with low plasma BC6OTHER - C. Few studies have addressed the delivery of BC6OTHER - derived BC6OTHER to the adrenals for BC6OTHER production in humans.	False
 BC6OTHER as a source of BC6ENTC for adrenal steroidogenesis: a study in individuals with low plasma BC6ENTG - C. Few studies have addressed the delivery of BC6OTHER - derived BC6OTHER to the adrenals for BC6OTHER production in humans.	False
Inhibition of BC6OTHER BC6ENTC kinase signaling with CHEM , or with the selective BC6OTHER scavenger BC6OTHER - Fc , both inhibited MF - LTP to the same extent as observed in BC6ENTG + / - mice.	False
Inhibition of BC6ENTG BC6ENTC kinase signaling with CHEM , or with the selective BC6OTHER scavenger BC6OTHER - Fc , both inhibited MF - LTP to the same extent as observed in BC6OTHER + / - mice.	False
Inhibition of BC6OTHER BC6ENTC kinase signaling with CHEM , or with the selective BC6ENTG scavenger BC6OTHER - Fc , both inhibited MF - LTP to the same extent as observed in BC6OTHER + / - mice.	False
Inhibition of BC6OTHER BC6ENTC kinase signaling with CHEM , or with the selective BC6OTHER scavenger BC6ENTG - Fc , both inhibited MF - LTP to the same extent as observed in BC6OTHER + / - mice.	False
Pretreatment with lysosomal enzyme inhibitors BC6ENTC or BC6ENTG inhibitors ( BC6OTHER inhibitor I , BC6OTHER , or BC6OTHER ) decreased the extent of BC6OTHER - induced down - regulation.	False
Pretreatment with lysosomal enzyme inhibitors BC6ENTC or BC6OTHER inhibitors ( BC6ENTG inhibitor I , BC6OTHER , or BC6OTHER ) decreased the extent of BC6OTHER - induced down - regulation.	False
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6ENTG inhibitors ( BC6OTHER inhibitor I , BC6ENTC , or BC6OTHER ) decreased the extent of BC6OTHER - induced down - regulation.	False
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6OTHER inhibitors ( BC6ENTG inhibitor I , BC6ENTC , or BC6OTHER ) decreased the extent of BC6OTHER - induced down - regulation.	CPR:4
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6ENTG inhibitors ( BC6OTHER inhibitor I , BC6OTHER , or BC6ENTC ) decreased the extent of BC6OTHER - induced down - regulation.	False
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6OTHER inhibitors ( BC6ENTG inhibitor I , BC6OTHER , or BC6ENTC ) decreased the extent of BC6OTHER - induced down - regulation.	CPR:4
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6ENTG inhibitors ( BC6OTHER inhibitor I , BC6OTHER , or BC6OTHER ) decreased the extent of BC6ENTC - induced down - regulation.	False
Pretreatment with lysosomal enzyme inhibitors BC6OTHER or BC6OTHER inhibitors ( BC6ENTG inhibitor I , BC6OTHER , or BC6OTHER ) decreased the extent of BC6ENTC - induced down - regulation.	False
A combination of BC6ENTC and BC6ENTG inhibitor I abolished BC6OTHER - induced down - regulation.	False
A combination of BC6OTHER and BC6ENTG inhibitor I abolished BC6ENTC - induced down - regulation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6ENTG involves BC6OTHER - , BC6OTHER - , BC6OTHER - , BC6OTHER - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	CPR:4
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6ENTG - , BC6OTHER - , BC6OTHER - , BC6OTHER - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6OTHER - , BC6ENTG - , BC6OTHER - , BC6OTHER - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6OTHER - , BC6OTHER - , BC6ENTG - , BC6OTHER - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6OTHER - , BC6OTHER - , BC6OTHER - , BC6ENTG - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6OTHER - , BC6OTHER - , BC6OTHER - , BC6OTHER - , and BC6ENTG - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6OTHER for degradation.	False
These results indicate that BC6ENTC - induced down - regulation of the BC6OTHER involves BC6OTHER - , BC6OTHER - , BC6OTHER - , BC6OTHER - , and BC6OTHER - dependent mechanisms and receptors seem to be trafficked to lysosomes and BC6ENTG for degradation.	False
Thus , BC6ENTC - induced internalization and down - regulation of the BC6ENTG share initial common mechanisms.	CPR:4
Previously , we showed that the BC6ENTG ( BC6OTHER ) stably expressed in Chinese hamster ovary (CHO) cells underwent down - regulation after prolonged BC6ENTC treatment.	CPR:4
Previously , we showed that the BC6OTHER ( BC6ENTG ) stably expressed in Chinese hamster ovary (CHO) cells underwent down - regulation after prolonged BC6ENTC treatment.	CPR:4
BC6ENTC caused a significant down - regulation of the BC6ENTG , although BC6OTHER did not.	CPR:4
BC6OTHER caused a significant down - regulation of the BC6ENTG , although BC6ENTC did not.	False
Neither BC6ENTC nor BC6OTHER caused down - regulation of the BC6ENTG .	False
Neither BC6OTHER nor BC6ENTC caused down - regulation of the BC6ENTG .	False
Expression of the dominant negative mutants BC6ENTG (319 - 418) or BC6OTHER - BC6OTHER significantly reduced BC6ENTC - induced down - regulation of the BC6OTHER .	False
Expression of the dominant negative mutants BC6OTHER (319 - 418) or BC6ENTG - BC6OTHER significantly reduced BC6ENTC - induced down - regulation of the BC6OTHER .	False
Expression of the dominant negative mutants BC6OTHER (319 - 418) or BC6OTHER - BC6ENTG significantly reduced BC6ENTC - induced down - regulation of the BC6OTHER .	False
Expression of the dominant negative mutants BC6OTHER (319 - 418) or BC6OTHER - BC6OTHER significantly reduced BC6ENTC - induced down - regulation of the BC6ENTG .	CPR:4
Coexpression of BC6ENTG or BC6OTHER and BC6OTHER permitted BC6ENTC to induce down - regulation of the BC6OTHER , although expression of BC6OTHER or BC6OTHER alone did not.	False
Coexpression of BC6OTHER or BC6ENTG and BC6OTHER permitted BC6ENTC to induce down - regulation of the BC6OTHER , although expression of BC6OTHER or BC6OTHER alone did not.	False
Coexpression of BC6OTHER or BC6OTHER and BC6ENTG permitted BC6ENTC to induce down - regulation of the BC6OTHER , although expression of BC6OTHER or BC6OTHER alone did not.	False
Coexpression of BC6OTHER or BC6OTHER and BC6OTHER permitted BC6ENTC to induce down - regulation of the BC6ENTG , although expression of BC6OTHER or BC6OTHER alone did not.	CPR:4
Coexpression of BC6OTHER or BC6OTHER and BC6OTHER permitted BC6ENTC to induce down - regulation of the BC6OTHER , although expression of BC6ENTG or BC6OTHER alone did not.	False
Coexpression of BC6OTHER or BC6OTHER and BC6OTHER permitted BC6ENTC to induce down - regulation of the BC6OTHER , although expression of BC6OTHER or BC6ENTG alone did not.	False
Expression of the dominant negative mutants BC6ENTG - BC6OTHER or BC6OTHER - BC6OTHER blunted BC6ENTC - induced down - regulation.	CPR:4
Expression of the dominant negative mutants BC6OTHER - BC6ENTG or BC6OTHER - BC6OTHER blunted BC6ENTC - induced down - regulation.	CPR:4
Expression of the dominant negative mutants BC6OTHER - BC6OTHER or BC6ENTG - BC6OTHER blunted BC6ENTC - induced down - regulation.	CPR:4
Expression of the dominant negative mutants BC6OTHER - BC6OTHER or BC6OTHER - BC6ENTG blunted BC6ENTC - induced down - regulation.	CPR:4
BC6ENTC suppressed the expression of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC suppressed the expression of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC suppressed the expression of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC suppressed the expression of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC suppressed the expression of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC suppressed the expression of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG at the mRNA and protein level , and inhibited the adhesion of leukocytes to A549 cells.	CPR:4
BC6ENTC treatment also decreased BC6ENTG BC6OTHER nuclear translocation and inhibited the phosphorylation of BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ).	CPR:4
BC6ENTC treatment also decreased BC6OTHER BC6ENTG nuclear translocation and inhibited the phosphorylation of BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ).	CPR:4
BC6ENTC treatment also decreased BC6OTHER BC6OTHER nuclear translocation and inhibited the phosphorylation of BC6ENTG BC6OTHER ( BC6OTHER BC6OTHER ).	CPR:4
BC6ENTC treatment also decreased BC6OTHER BC6OTHER nuclear translocation and inhibited the phosphorylation of BC6OTHER BC6ENTG ( BC6OTHER BC6OTHER ).	CPR:4
BC6ENTC treatment also decreased BC6OTHER BC6OTHER nuclear translocation and inhibited the phosphorylation of BC6OTHER BC6OTHER ( BC6ENTG BC6OTHER ).	CPR:4
BC6ENTC treatment also decreased BC6OTHER BC6OTHER nuclear translocation and inhibited the phosphorylation of BC6OTHER BC6OTHER ( BC6OTHER BC6ENTG ).	CPR:4
The BC6ENTC 790 side chain of the BC6ENTG / BC6OTHER double mutant , in the apo form and BC6OTHER - and CHEM - bound forms , adopts different conformations that explain the accommodation of these ligands.	False
The BC6ENTC 790 side chain of the BC6OTHER / BC6ENTG double mutant , in the apo form and BC6OTHER - and CHEM - bound forms , adopts different conformations that explain the accommodation of these ligands.	False
The BC6OTHER 790 side chain of the BC6ENTG / BC6OTHER double mutant , in the apo form and BC6ENTC - and CHEM - bound forms , adopts different conformations that explain the accommodation of these ligands.	False
The BC6OTHER 790 side chain of the BC6OTHER / BC6ENTG double mutant , in the apo form and BC6ENTC - and CHEM - bound forms , adopts different conformations that explain the accommodation of these ligands.	False
In the BC6ENTG mutant structure , the active - site cleft is expanded by the repositioning of BC6ENTC 723 within the P - loop.	False
Notably , the introduction of the BC6ENTG mutation greatly enhanced the BC6ENTC sensitivity of the wild - type BC6OTHER in vivo , supporting our hypothesis that the expansion of the active - site cleft results in enhanced BC6OTHER sensitivity.	False
Notably , the introduction of the BC6OTHER mutation greatly enhanced the BC6ENTC sensitivity of the wild - type BC6ENTG in vivo , supporting our hypothesis that the expansion of the active - site cleft results in enhanced BC6OTHER sensitivity.	False
Notably , the introduction of the BC6ENTG mutation greatly enhanced the BC6OTHER sensitivity of the wild - type BC6OTHER in vivo , supporting our hypothesis that the expansion of the active - site cleft results in enhanced BC6ENTC sensitivity.	False
Notably , the introduction of the BC6OTHER mutation greatly enhanced the BC6OTHER sensitivity of the wild - type BC6ENTG in vivo , supporting our hypothesis that the expansion of the active - site cleft results in enhanced BC6ENTC sensitivity.	False
The BC6OTHER ( BC6ENTG ) has an essential role in multiple signaling pathways , including cell proliferation and migration , through extracellular ligand binding and subsequent activation of its intracellular BC6ENTC kinase (TK) domain.	False
The BC6ENTG ( BC6OTHER ) has an essential role in multiple signaling pathways , including cell proliferation and migration , through extracellular ligand binding and subsequent activation of its intracellular BC6ENTC kinase (TK) domain.	False
They display sensitivity to BC6ENTG inhibitors , including BC6ENTC and BC6OTHER .	CPR:4
They display sensitivity to BC6ENTG inhibitors , including BC6OTHER and BC6ENTC .	CPR:4
In this study , our biochemical analyses revealed that the introduction of the BC6ENTG mutation confers BC6ENTC resistance on the BC6OTHER mutant.	False
In this study , our biochemical analyses revealed that the introduction of the BC6OTHER mutation confers BC6ENTC resistance on the BC6ENTG mutant.	False
The BC6ENTG / BC6OTHER double mutant has enhanced activity and retains high BC6ENTC - binding affinity.	False
The BC6OTHER / BC6ENTG double mutant has enhanced activity and retains high BC6ENTC - binding affinity.	False
The BC6ENTG mutation increases the BC6ENTC affinity of the BC6OTHER mutant , explaining the acquired drug resistance of the double mutant.	False
The BC6OTHER mutation increases the BC6ENTC affinity of the BC6ENTG mutant , explaining the acquired drug resistance of the double mutant.	False
The attenuated proliferation , migration , invasion and BC6ENTC - evoked BC6OTHER entry was mimicked by overexpressing a non - conducting , truncated BC6ENTG ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6ENTC - evoked BC6OTHER entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6ENTG - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6ENTC - evoked BC6OTHER entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6ENTG - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6ENTC - evoked BC6OTHER entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6ENTG cells.	False
The attenuated proliferation , migration , invasion and BC6OTHER - evoked BC6ENTC entry was mimicked by overexpressing a non - conducting , truncated BC6ENTG ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6OTHER - evoked BC6ENTC entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6ENTG - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6OTHER - evoked BC6ENTC entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6ENTG - GFP in sh BC6OTHER cells.	False
The attenuated proliferation , migration , invasion and BC6OTHER - evoked BC6ENTC entry was mimicked by overexpressing a non - conducting , truncated BC6OTHER ( BC6OTHER - DN) in wild type cells , and was reversed by overexpression of BC6OTHER - GFP in sh BC6ENTG cells.	False
The electrostatic potential of BC6ENTC cleft of BC6ENTG / mutants and their heterodimerization with BC6OTHER ( BC6OTHER ) were computationally evaluated.	False
The electrostatic potential of BC6ENTC cleft of BC6OTHER / mutants and their heterodimerization with BC6ENTG ( BC6OTHER ) were computationally evaluated.	False
The electrostatic potential of BC6ENTC cleft of BC6OTHER / mutants and their heterodimerization with BC6OTHER ( BC6ENTG ) were computationally evaluated.	False
BC6ENTG , an BC6ENTC - dependent deacetylase , was identified as a molecule necessary for caloric restriction - related anti - aging strategies.	False
BC6ENTG functions as an intracellular energy sensor to detect the concentration of BC6ENTC , and controls in vivo metabolic changes under caloric restriction and starvation through its BC6OTHER activity to many targets including BC6OTHER , nuclear transcriptional factors , and enzymes.	False
BC6OTHER functions as an intracellular energy sensor to detect the concentration of BC6ENTC , and controls in vivo metabolic changes under caloric restriction and starvation through its BC6ENTG activity to many targets including BC6OTHER , nuclear transcriptional factors , and enzymes.	False
BC6OTHER functions as an intracellular energy sensor to detect the concentration of BC6ENTC , and controls in vivo metabolic changes under caloric restriction and starvation through its BC6OTHER activity to many targets including BC6ENTG , nuclear transcriptional factors , and enzymes.	False
This study also investigated the effect of BC6ENTC on cortical and hippocampal monoaminergic neurotransmitters' levels together with BC6ENTG enzyme ( BC6OTHER ) activity , both of which are known to be important in control of cognitive function.	False
This study also investigated the effect of BC6ENTC on cortical and hippocampal monoaminergic neurotransmitters' levels together with BC6OTHER enzyme ( BC6ENTG ) activity , both of which are known to be important in control of cognitive function.	False
neither affected BC6ENTC ( BC6OTHER ) level nor BC6ENTG activity in rat cortex and hippocampus.	False
neither affected BC6OTHER ( BC6ENTC ) level nor BC6ENTG activity in rat cortex and hippocampus.	False
BC6ENTC treatment also results in modest improvements in total BC6OTHER , BC6ENTG , blood pressure , and fasting BC6OTHER and BC6OTHER concentrations.	CPR:3
BC6ENTC treatment also results in modest improvements in total BC6OTHER , BC6OTHER , blood pressure , and fasting BC6OTHER and BC6ENTG concentrations.	CPR:3
BC6OTHER treatment also results in modest improvements in total BC6ENTC , BC6ENTG , blood pressure , and fasting BC6OTHER and BC6OTHER concentrations.	False
BC6OTHER treatment also results in modest improvements in total BC6ENTC , BC6OTHER , blood pressure , and fasting BC6OTHER and BC6ENTG concentrations.	False
BC6OTHER treatment also results in modest improvements in total BC6OTHER , BC6ENTG , blood pressure , and fasting BC6ENTC and BC6OTHER concentrations.	False
BC6OTHER treatment also results in modest improvements in total BC6OTHER , BC6OTHER , blood pressure , and fasting BC6ENTC and BC6ENTG concentrations.	False
 BC6ENTC , a new BC6ENTG inhibitor for the management of obesity.	CPR:4
A BC6OTHER residue in place of the catalytic BC6OTHER or BC6OTHER residues found in other BC6ENTG was shown to form a mixed BC6OTHER with BC6ENTC .	False
BC6ENTG have BC6OTHER and BC6OTHER activities and also catalyze the reduction of BC6ENTC , an intermediate in the pathway of BC6OTHER biotransformation.	CPR:9
BC6OTHER have BC6ENTG and BC6OTHER activities and also catalyze the reduction of BC6ENTC , an intermediate in the pathway of BC6OTHER biotransformation.	False
BC6OTHER have BC6OTHER and BC6ENTG activities and also catalyze the reduction of BC6ENTC , an intermediate in the pathway of BC6OTHER biotransformation.	False
BC6ENTG have BC6OTHER and BC6OTHER activities and also catalyze the reduction of BC6OTHER , an intermediate in the pathway of BC6ENTC biotransformation.	False
BC6OTHER have BC6ENTG and BC6OTHER activities and also catalyze the reduction of BC6OTHER , an intermediate in the pathway of BC6ENTC biotransformation.	False
BC6OTHER have BC6OTHER and BC6ENTG activities and also catalyze the reduction of BC6OTHER , an intermediate in the pathway of BC6ENTC biotransformation.	False
Other diverse actions of BC6ENTG include modulation of BC6ENTC receptors and interaction with BC6OTHER release inhibitory drugs.	False
Other diverse actions of BC6OTHER include modulation of BC6ENTC receptors and interaction with BC6ENTG release inhibitory drugs.	False
A BC6ENTC residue in place of the catalytic BC6OTHER or BC6OTHER residues found in other BC6ENTG was shown to form a mixed BC6OTHER with BC6OTHER .	False
A BC6OTHER residue in place of the catalytic BC6ENTC or BC6OTHER residues found in other BC6ENTG was shown to form a mixed BC6OTHER with BC6OTHER .	False
A BC6OTHER residue in place of the catalytic BC6OTHER or BC6ENTC residues found in other BC6ENTG was shown to form a mixed BC6OTHER with BC6OTHER .	False
A BC6OTHER residue in place of the catalytic BC6OTHER or BC6OTHER residues found in other BC6ENTG was shown to form a mixed BC6ENTC with BC6OTHER .	False
BC6OTHER (5 mg / kg) also increased blood and brain BC6ENTC concentrations that were generally higher in Tg - BC6ENTG mice.	False
The in vivo inhibitory effect of BC6ENTC on BC6ENTG - catalyzed BC6OTHER formation was confirmed by in vitro study using purified BC6OTHER .	CPR:4
The in vivo inhibitory effect of BC6ENTC on BC6OTHER - catalyzed BC6OTHER formation was confirmed by in vitro study using purified BC6ENTG .	CPR:4
The in vivo inhibitory effect of BC6OTHER on BC6ENTG - catalyzed BC6ENTC formation was confirmed by in vitro study using purified BC6OTHER .	CPR:9
The in vivo inhibitory effect of BC6OTHER on BC6OTHER - catalyzed BC6ENTC formation was confirmed by in vitro study using purified BC6ENTG .	CPR:9
Given these findings , a unified PK model including the inhibition of BC6ENTG - and BC6OTHER - catalyzed BC6ENTC metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6ENTG - catalyzed BC6ENTC metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6OTHER - catalyzed BC6ENTC metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6ENTG mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6ENTG - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6ENTC was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6ENTG - catalyzed BC6OTHER metabolism by BC6ENTC was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6ENTC was developed to describe blood BC6OTHER , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6ENTG mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6ENTG - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6ENTC , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6ENTG - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6ENTC , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6ENTC , BC6OTHER , and BC6OTHER PK profiles in both wild - type and Tg - BC6ENTG mouse models.	CPR:4
Given these findings , a unified PK model including the inhibition of BC6ENTG - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6ENTC , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6ENTG - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6ENTC , and BC6OTHER PK profiles in both wild - type and Tg - BC6OTHER mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6ENTC , and BC6OTHER PK profiles in both wild - type and Tg - BC6ENTG mouse models.	CPR:9
Given these findings , a unified PK model including the inhibition of BC6ENTG - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6ENTC PK profiles in both wild - type and Tg - BC6OTHER mouse models.	False
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6ENTG - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6ENTC PK profiles in both wild - type and Tg - BC6OTHER mouse models.	False
Given these findings , a unified PK model including the inhibition of BC6OTHER - and BC6OTHER - catalyzed BC6OTHER metabolism by BC6OTHER was developed to describe blood BC6OTHER , BC6OTHER , and BC6ENTC PK profiles in both wild - type and Tg - BC6ENTG mouse models.	False
This PK model may be further employed to predict BC6ENTC and BC6OTHER PK interactions at various doses , define the impact of BC6ENTG status , and drive BC6OTHER - BC6OTHER pharmacodynamics.	False
This PK model may be further employed to predict BC6OTHER and BC6ENTC PK interactions at various doses , define the impact of BC6ENTG status , and drive BC6OTHER - BC6OTHER pharmacodynamics.	False
This PK model may be further employed to predict BC6OTHER and BC6OTHER PK interactions at various doses , define the impact of BC6ENTG status , and drive BC6ENTC - BC6OTHER pharmacodynamics.	False
This PK model may be further employed to predict BC6OTHER and BC6OTHER PK interactions at various doses , define the impact of BC6ENTG status , and drive BC6OTHER - BC6ENTC pharmacodynamics.	False
Our recent study has demonstrated that coadministration of BC6ENTC oxidase A ( BC6ENTG ) inhibitor BC6OTHER (5 mg / kg) increases systemic exposure to BC6OTHER (2 mg / kg) and active metabolite CHEM.	False
Our recent study has demonstrated that coadministration of BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC (5 mg / kg) increases systemic exposure to BC6OTHER (2 mg / kg) and active metabolite CHEM.	CPR:4
Our recent study has demonstrated that coadministration of BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC (5 mg / kg) increases systemic exposure to BC6OTHER (2 mg / kg) and active metabolite CHEM.	CPR:4
Our recent study has demonstrated that coadministration of BC6ENTG ( BC6OTHER ) inhibitor BC6OTHER (5 mg / kg) increases systemic exposure to BC6ENTC (2 mg / kg) and active metabolite CHEM.	False
Our recent study has demonstrated that coadministration of BC6OTHER ( BC6ENTG ) inhibitor BC6OTHER (5 mg / kg) increases systemic exposure to BC6ENTC (2 mg / kg) and active metabolite CHEM.	False
This study is aimed at delineating BC6ENTC and BC6OTHER pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6OTHER PK and determines BC6OTHER BC6OTHER - demethylation to produce BC6OTHER .	False
This study is aimed at delineating BC6OTHER and BC6ENTC pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6OTHER PK and determines BC6OTHER BC6OTHER - demethylation to produce BC6OTHER .	False
This study is aimed at delineating BC6OTHER and BC6OTHER pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6ENTC PK and determines BC6OTHER BC6OTHER - demethylation to produce BC6OTHER .	False
This study is aimed at delineating BC6OTHER and BC6OTHER pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6OTHER PK and determines BC6ENTC BC6OTHER - demethylation to produce BC6OTHER .	False
This study is aimed at delineating BC6OTHER and BC6OTHER pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6OTHER PK and determines BC6OTHER BC6ENTC - demethylation to produce BC6OTHER .	False
This study is aimed at delineating BC6OTHER and BC6OTHER pharmacokinetic (PK) interactions at multiple dose levels , as well as the impact of BC6ENTG that affects BC6OTHER PK and determines BC6OTHER BC6OTHER - demethylation to produce BC6ENTC .	False
Our data revealed that inhibition of BC6ENTG - mediated metabolic elimination by BC6ENTC (2 , 5 , and 15 mg / kg) led to a sharp increase in systemic and cerebral exposure to BC6OTHER (2 and 10 mg / kg) at all dose combinations.	CPR:4
Our data revealed that inhibition of BC6ENTG - mediated metabolic elimination by BC6OTHER (2 , 5 , and 15 mg / kg) led to a sharp increase in systemic and cerebral exposure to BC6ENTC (2 and 10 mg / kg) at all dose combinations.	False
A more pronounced effect on BC6ENTC PK was associated with greater exposure to BC6OTHER in wild - type mice than BC6ENTG - humanized (Tg - BC6OTHER ) mice.	False
A more pronounced effect on BC6ENTC PK was associated with greater exposure to BC6OTHER in wild - type mice than BC6OTHER - humanized (Tg - BC6ENTG ) mice.	False
A more pronounced effect on BC6OTHER PK was associated with greater exposure to BC6ENTC in wild - type mice than BC6ENTG - humanized (Tg - BC6OTHER ) mice.	False
A more pronounced effect on BC6OTHER PK was associated with greater exposure to BC6ENTC in wild - type mice than BC6OTHER - humanized (Tg - BC6ENTG ) mice.	False
BC6ENTC (5 mg / kg) also increased blood and brain BC6OTHER concentrations that were generally higher in Tg - BC6ENTG mice.	False
Pharmacokinetic Interactions between BC6ENTC Oxidase A Inhibitor BC6OTHER and BC6OTHER , and the Impact of BC6ENTG Status.	False
Pharmacokinetic Interactions between BC6OTHER Inhibitor BC6ENTC and BC6OTHER , and the Impact of BC6ENTG Status.	False
Pharmacokinetic Interactions between BC6ENTG Inhibitor BC6ENTC and BC6OTHER , and the Impact of BC6OTHER Status.	CPR:4
Pharmacokinetic Interactions between BC6OTHER Inhibitor BC6OTHER and BC6ENTC , and the Impact of BC6ENTG Status.	False
Pharmacokinetic Interactions between BC6ENTG Inhibitor BC6OTHER and BC6ENTC , and the Impact of BC6OTHER Status.	False
It is not yet clear whether BC6ENTC can reduce breast cancer incidence in women with BC6ENTG and BC6OTHER mutations , although preliminary evidence favors benefit for at least those with a BC6OTHER mutation.	False
It is not yet clear whether BC6ENTC can reduce breast cancer incidence in women with BC6OTHER and BC6ENTG mutations , although preliminary evidence favors benefit for at least those with a BC6OTHER mutation.	CPR:4
It is not yet clear whether BC6ENTC can reduce breast cancer incidence in women with BC6OTHER and BC6OTHER mutations , although preliminary evidence favors benefit for at least those with a BC6ENTG mutation.	CPR:4
BC6ENTC is a selective BC6ENTG modulator with less uterine BC6OTHER agonist activity than BC6OTHER , and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer.	False
BC6OTHER is a selective BC6ENTG modulator with less uterine BC6ENTC agonist activity than BC6OTHER , and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer.	False
BC6OTHER is a selective BC6ENTG modulator with less uterine BC6OTHER agonist activity than BC6ENTC , and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer.	False
BC6ENTC does not reduce the incidence of BC6ENTG - negative cancers , nor does it appear to be effective in preventing the appearance of one third of BC6OTHER - positive cancers.	False
BC6ENTC does not reduce the incidence of BC6OTHER - negative cancers , nor does it appear to be effective in preventing the appearance of one third of BC6ENTG - positive cancers.	False
Priorities in prevention research are to develop (a) biomarkers to refine short - term risk assessments based on epidemiologic models , (b) biomarkers predictive of response to specific classes of preventive agents , (c) drugs with fewer side - effects and / or effective in BC6ENTG - negative or BC6OTHER - positive BC6ENTC - resistant precancerous disease , and (d) efficient clinical trial models to assess new agent efficacy.	False
Priorities in prevention research are to develop (a) biomarkers to refine short - term risk assessments based on epidemiologic models , (b) biomarkers predictive of response to specific classes of preventive agents , (c) drugs with fewer side - effects and / or effective in BC6OTHER - negative or BC6ENTG - positive BC6ENTC - resistant precancerous disease , and (d) efficient clinical trial models to assess new agent efficacy.	False
A number of agents are being developed that target molecular abnormalities in IEN , have fewer or different side effects than BC6ENTC , and may be effective in BC6ENTG - negative or BC6OTHER - resistant disease.	False
A number of agents are being developed that target molecular abnormalities in IEN , have fewer or different side effects than BC6OTHER , and may be effective in BC6ENTG - negative or BC6ENTC - resistant disease.	False
Individuals in whom BC6ENTC - associated breast cancer risk reduction appears to outweigh risk of serious side - effects include women with prior in situ or BC6ENTG ( BC6OTHER ) - positive invasive cancer , atypical hyperplasia , and / or women ages 35 - 49 with a calculated Gail 5 - year risk of > or =1.7% , hysterectomized women aged 50 and older with a 5 - year Gail risk of > or =2.5% , and nonhysterectomized women aged 50 and older with a 5 - year Gail risk of >5.0%.	False
Individuals in whom BC6ENTC - associated breast cancer risk reduction appears to outweigh risk of serious side - effects include women with prior in situ or BC6OTHER ( BC6ENTG ) - positive invasive cancer , atypical hyperplasia , and / or women ages 35 - 49 with a calculated Gail 5 - year risk of > or =1.7% , hysterectomized women aged 50 and older with a 5 - year Gail risk of > or =2.5% , and nonhysterectomized women aged 50 and older with a 5 - year Gail risk of >5.0%.	False
Individuals in whom BC6OTHER - associated breast cancer risk reduction appears to outweigh risk of serious side - effects include women with prior in situ or BC6ENTC receptor ( BC6ENTG ) - positive invasive cancer , atypical hyperplasia , and / or women ages 35 - 49 with a calculated Gail 5 - year risk of > or =1.7% , hysterectomized women aged 50 and older with a 5 - year Gail risk of > or =2.5% , and nonhysterectomized women aged 50 and older with a 5 - year Gail risk of >5.0%.	False
A head - to - head comparison between BC6OTHER detemir and NPH BC6OTHER in women with type 1 diabetes showed that while foetal outcomes did not differ , fasting plasma BC6ENTC improved with BC6ENTG detemir without an increased incidence of hypoglycaemia.	CPR:3
A head - to - head comparison between BC6ENTG detemir and NPH BC6OTHER in women with type 1 diabetes showed that while foetal outcomes did not differ , fasting plasma BC6ENTC improved with BC6OTHER detemir without an increased incidence of hypoglycaemia.	False
A head - to - head comparison between BC6OTHER detemir and NPH BC6ENTG in women with type 1 diabetes showed that while foetal outcomes did not differ , fasting plasma BC6ENTC improved with BC6OTHER detemir without an increased incidence of hypoglycaemia.	False
BC6ENTC increased the mRNA levels of the BC6ENTG and decreased the mRNA levels of BC6OTHER and BC6OTHER in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:3
BC6ENTC increased the mRNA levels of the BC6OTHER and decreased the mRNA levels of BC6ENTG and BC6OTHER in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
BC6ENTC increased the mRNA levels of the BC6OTHER and decreased the mRNA levels of BC6OTHER and BC6ENTG in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:4
BC6ENTC increased the mRNA levels of the BC6OTHER and decreased the mRNA levels of BC6OTHER and BC6OTHER in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6ENTG , BC6OTHER , or BC6OTHER .	False
BC6ENTC increased the mRNA levels of the BC6OTHER and decreased the mRNA levels of BC6OTHER and BC6OTHER in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6OTHER , BC6ENTG , or BC6OTHER .	False
BC6ENTC increased the mRNA levels of the BC6OTHER and decreased the mRNA levels of BC6OTHER and BC6OTHER in a dose - dependent manner; no significant effect was found in the mRNA levels of the BC6OTHER , BC6OTHER , or BC6ENTG .	False
In this study , we performed live imaging analyses of Neuro - 2a cells expressing SCAT3 , a BC6ENTG cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus , to determine whether BC6ENTC ( BC6OTHER ; 0 , 1 , 5 , or 10 μM) affects both neurite outgrowth and / or induces apoptosis with the same doses and in the same cell cultures.	False
In this study , we performed live imaging analyses of Neuro - 2a cells expressing SCAT3 , a BC6ENTG cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus , to determine whether BC6OTHER ( BC6ENTC ; 0 , 1 , 5 , or 10 μM) affects both neurite outgrowth and / or induces apoptosis with the same doses and in the same cell cultures.	False
We observed that the area ratio of neurite to cell body in SCAT3 - expressing cells was significantly reduced by 5 and 10 μM BC6ENTC , but not by 1 μM , although the emission ratio of ECFP to Venus , an endpoint of BC6ENTG activity , was not changed.	False
The cellular BC6ENTG consists of two domains - - a flexible BC6OTHER - terminal domain , which participates in BC6ENTC and BC6OTHER regulation , and a largely helical BC6OTHER - terminal domain that converts to β sheet in the course of prion disease.	False
The cellular BC6ENTG consists of two domains - - a flexible BC6OTHER - terminal domain , which participates in BC6OTHER and BC6ENTC regulation , and a largely helical BC6OTHER - terminal domain that converts to β sheet in the course of prion disease.	False
The cellular BC6ENTG consists of two domains - - a flexible BC6OTHER - terminal domain , which participates in BC6OTHER and BC6OTHER regulation , and a largely helical BC6ENTC - terminal domain that converts to β sheet in the course of prion disease.	False
Here , we identify a BC6ENTC - driven BC6OTHER - terminal to BC6OTHER - terminal tertiary interaction in BC6ENTG .	False
Here , we identify a BC6OTHER - driven BC6ENTC - terminal to BC6OTHER - terminal tertiary interaction in BC6ENTG .	False
Here , we identify a BC6OTHER - driven BC6OTHER - terminal to BC6ENTC - terminal tertiary interaction in BC6ENTG .	False
The cellular BC6ENTG consists of two domains - - a flexible BC6ENTC - terminal domain , which participates in BC6OTHER and BC6OTHER regulation , and a largely helical BC6OTHER - terminal domain that converts to β sheet in the course of prion disease.	False
 BC6ENTC drives a tertiary fold in the BC6ENTG with familial disease mutation sites at the interface.	False
In many renal diseases , BC6OTHER ( BC6OTHER ) - stimulated canonical BC6OTHER and noncanonical mechanistic target of BC6ENTC ( BC6ENTG ) promote increased protein synthesis and mesangial cell hypertrophy.	False
In many renal diseases , BC6ENTG ( BC6OTHER ) - stimulated canonical BC6OTHER and noncanonical mechanistic target of BC6ENTC ( BC6OTHER ) promote increased protein synthesis and mesangial cell hypertrophy.	False
In many renal diseases , BC6OTHER ( BC6ENTG ) - stimulated canonical BC6OTHER and noncanonical mechanistic target of BC6ENTC ( BC6OTHER ) promote increased protein synthesis and mesangial cell hypertrophy.	False
In many renal diseases , BC6OTHER ( BC6OTHER ) - stimulated canonical BC6ENTG and noncanonical mechanistic target of BC6ENTC ( BC6OTHER ) promote increased protein synthesis and mesangial cell hypertrophy.	False
Using the BC6ENTG inhibitor BC6ENTC we found that BC6OTHER - induced both early and sustained activation of BC6OTHER and BC6OTHER was necessary for BC6OTHER suppression.	CPR:4
Using the BC6OTHER inhibitor BC6ENTC we found that BC6ENTG - induced both early and sustained activation of BC6OTHER and BC6OTHER was necessary for BC6OTHER suppression.	False
Using the BC6OTHER inhibitor BC6ENTC we found that BC6OTHER - induced both early and sustained activation of BC6ENTG and BC6OTHER was necessary for BC6OTHER suppression.	False
Using the BC6OTHER inhibitor BC6ENTC we found that BC6OTHER - induced both early and sustained activation of BC6OTHER and BC6ENTG was necessary for BC6OTHER suppression.	False
Using the BC6OTHER inhibitor BC6ENTC we found that BC6OTHER - induced both early and sustained activation of BC6OTHER and BC6OTHER was necessary for BC6ENTG suppression.	False
BC6ENTC - induced reversal of BC6OTHER suppression by BC6OTHER was associated with a significant inhibition of BC6ENTG - stimulated protein synthesis and hypertrophy.	False
BC6ENTC - induced reversal of BC6ENTG suppression by BC6OTHER was associated with a significant inhibition of BC6OTHER - stimulated protein synthesis and hypertrophy.	CPR:3
BC6ENTC - induced reversal of BC6OTHER suppression by BC6ENTG was associated with a significant inhibition of BC6OTHER - stimulated protein synthesis and hypertrophy.	False
 BC6ENTG integrates BC6OTHER to mechanistic target of BC6ENTC complexes to arrest BC6OTHER abundance for glomerular mesangial cell hypertrophy.	False
 BC6OTHER integrates BC6OTHER to mechanistic target of BC6ENTC complexes to arrest BC6ENTG abundance for glomerular mesangial cell hypertrophy.	False
 BC6OTHER integrates BC6ENTG to mechanistic target of BC6ENTC complexes to arrest BC6OTHER abundance for glomerular mesangial cell hypertrophy.	False
RESULTS: Fractionated bulb extracts and the two isolated BC6ENTC (1) and (2) induced BC6OTHER production and BC6ENTG mRNA expression in fibroblast cell culture.	CPR:3
RESULTS: Fractionated bulb extracts and the two isolated BC6OTHER (1) and (2) induced BC6ENTC production and BC6ENTG mRNA expression in fibroblast cell culture.	False
To gain insight into the mode of action of the BC6ENTC , BC6OTHER ( BC6OTHER ) production , and expression of genes for BC6ENTG ( BC6OTHER ) and its receptors were evaluated.	False
To gain insight into the mode of action of the BC6ENTC , BC6OTHER ( BC6OTHER ) production , and expression of genes for BC6OTHER ( BC6ENTG ) and its receptors were evaluated.	False
To gain insight into the mode of action of the BC6OTHER , BC6ENTC ( BC6OTHER ) production , and expression of genes for BC6ENTG ( BC6OTHER ) and its receptors were evaluated.	False
To gain insight into the mode of action of the BC6OTHER , BC6ENTC ( BC6OTHER ) production , and expression of genes for BC6OTHER ( BC6ENTG ) and its receptors were evaluated.	False
To gain insight into the mode of action of the BC6OTHER , BC6OTHER ( BC6ENTC ) production , and expression of genes for BC6ENTG ( BC6OTHER ) and its receptors were evaluated.	False
To gain insight into the mode of action of the BC6OTHER , BC6OTHER ( BC6ENTC ) production , and expression of genes for BC6OTHER ( BC6ENTG ) and its receptors were evaluated.	False
Thus BC6ENTG and or BC6ENTC oxidase inhibition may represent a therapeutic modality of diabetic kidney disease.	False
Pharmacological doses of the BC6ENTG inhibitor BC6ENTC reduce albuminura in diabetes.	CPR:4
High BC6ENTC (HG) induces apoptosis of podocytes , inhibits BC6ENTG activation , inactivates BC6OTHER and activates BC6OTHER .	CPR:4
High BC6ENTC (HG) induces apoptosis of podocytes , inhibits BC6OTHER activation , inactivates BC6ENTG and activates BC6OTHER .	CPR:4
High BC6ENTC (HG) induces apoptosis of podocytes , inhibits BC6OTHER activation , inactivates BC6OTHER and activates BC6ENTG .	CPR:3
HG also increases the levels of BC6ENTG and BC6OTHER and BC6ENTC oxidase activity.	False
HG also increases the levels of BC6OTHER and BC6ENTG and BC6ENTC oxidase activity.	False
Inhibition of BC6ENTG by low dose BC6ENTC decreases HG - induced BC6OTHER and BC6OTHER , BC6OTHER activity and podocyte apoptosis.	CPR:4
Inhibition of BC6OTHER by low dose BC6ENTC decreases HG - induced BC6ENTG and BC6OTHER , BC6OTHER activity and podocyte apoptosis.	CPR:4
Inhibition of BC6OTHER by low dose BC6ENTC decreases HG - induced BC6OTHER and BC6ENTG , BC6OTHER activity and podocyte apoptosis.	CPR:4
Inhibition of BC6OTHER by low dose BC6ENTC decreases HG - induced BC6OTHER and BC6OTHER , BC6ENTG activity and podocyte apoptosis.	CPR:4
Inhibition of BC6ENTG by low dose BC6OTHER decreases HG - induced BC6OTHER and BC6OTHER , BC6ENTC oxidase activity and podocyte apoptosis.	False
Inhibition of BC6OTHER by low dose BC6OTHER decreases HG - induced BC6ENTG and BC6OTHER , BC6ENTC oxidase activity and podocyte apoptosis.	False
Inhibition of BC6OTHER by low dose BC6OTHER decreases HG - induced BC6OTHER and BC6ENTG , BC6ENTC oxidase activity and podocyte apoptosis.	False
In isolated glomeruli of OVE26 mice , there is similar decrease in the activation of BC6ENTG and BC6OTHER and activation of BC6OTHER with increase in BC6OTHER and BC6ENTC oxidase activity.	False
In isolated glomeruli of OVE26 mice , there is similar decrease in the activation of BC6OTHER and BC6ENTG and activation of BC6OTHER with increase in BC6OTHER and BC6ENTC oxidase activity.	False
In isolated glomeruli of OVE26 mice , there is similar decrease in the activation of BC6OTHER and BC6OTHER and activation of BC6ENTG with increase in BC6OTHER and BC6ENTC oxidase activity.	False
In isolated glomeruli of OVE26 mice , there is similar decrease in the activation of BC6OTHER and BC6OTHER and activation of BC6OTHER with increase in BC6ENTG and BC6ENTC oxidase activity.	False
Inhibition of BC6ENTG by small dose of BC6ENTC reduces podocyte apoptosis , attenuates glomerular injury and albuminuria.	CPR:4
In this study , we employed virtual screening and chemical synthesis to identify a series of BC6ENTC derivatives as potent BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
In this study , we employed virtual screening and chemical synthesis to identify a series of BC6ENTC derivatives as potent BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
Identification and synthesis of BC6ENTC derivatives as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Identification and synthesis of BC6ENTC derivatives as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
BC6ENTC - induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells , rupture of the smooth muscle cell layer , loss of BC6ENTG , and high BC6OTHER staining.	CPR:4
BC6ENTC - induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells , rupture of the smooth muscle cell layer , loss of BC6OTHER , and high BC6ENTG staining.	CPR:3
BC6OTHER and BC6OTHER also partially inhibited BC6OTHER - mediated BC6OTHER release induced by BC6ENTC or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6ENTG substrate.	False
BC6OTHER and BC6OTHER also partially inhibited BC6ENTG - mediated BC6OTHER release induced by BC6ENTC or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6OTHER substrate.	False
BC6OTHER and BC6OTHER also partially inhibited BC6OTHER - mediated BC6OTHER release induced by BC6OTHER or BC6ENTC , demonstrating that the observed partial inhibition is not specific for a particular BC6ENTG substrate.	False
BC6OTHER and BC6OTHER also partially inhibited BC6ENTG - mediated BC6OTHER release induced by BC6OTHER or BC6ENTC , demonstrating that the observed partial inhibition is not specific for a particular BC6OTHER substrate.	False
BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6ENTC and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6ENTC and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6ENTC ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6ENTC ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6ENTC ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6ENTC ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6ENTC - induced BC6ENTG - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6ENTC - induced BC6OTHER - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6ENTC release and 2) BC6OTHER uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6ENTC release and 2) BC6OTHER uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6OTHER release and 2) BC6ENTC uptake and BC6OTHER - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6OTHER release and 2) BC6ENTC uptake and BC6OTHER - induced BC6ENTG - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6ENTG - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6ENTC - induced BC6OTHER - mediated efflux can be separately modulated."	False
"The two major findings of this study are 1) the identification of both ""agonist"" ( BC6OTHER and BC6OTHER ) and ""antagonist"" ( BC6OTHER ) allosteric modulators of BC6OTHER - induced BC6OTHER - mediated BC6OTHER release and 2) BC6OTHER uptake and BC6ENTC - induced BC6ENTG - mediated efflux can be separately modulated."	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTC ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6ENTC ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6ENTC ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6ENTC from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6ENTC uptake.	False
"In the present study , we report that BC6ENTC and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6ENTC and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6ENTC , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6ENTC , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
Recent studies identified novel allosteric modulators of the BC6ENTC ( BC6OTHER ) transporter ( BC6ENTG ).	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6ENTC - induced BC6ENTG - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6ENTC - induced BC6OTHER - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6ENTC ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6ENTC ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6OTHER ( BC6ENTC )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6OTHER ( BC6ENTC )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6OTHER ( BC6OTHER )or BC6ENTC from striatal synaptosomes ("" BC6OTHER - mediated BC6OTHER release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6OTHER ( BC6OTHER )or BC6ENTC from striatal synaptosomes ("" BC6ENTG - mediated BC6OTHER release"") in a dose - dependent manner."	False
Recent studies identified novel allosteric modulators of the CHEM ( BC6ENTC ) transporter ( BC6ENTG ).	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6ENTG - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6OTHER - mediated BC6ENTC release"") in a dose - dependent manner."	False
"In the present study , we report that BC6OTHER and BC6OTHER , at doses that do not alter release , partially inhibited BC6OTHER - induced BC6OTHER - mediated release of BC6OTHER ( BC6OTHER )or BC6OTHER from striatal synaptosomes ("" BC6ENTG - mediated BC6ENTC release"") in a dose - dependent manner."	False
BC6ENTC , which does not alter BC6ENTG - mediated BC6OTHER release measured with BC6OTHER , reversed the effect of BC6OTHER .	False
BC6OTHER , which does not alter BC6ENTG - mediated BC6ENTC release measured with BC6OTHER , reversed the effect of BC6OTHER .	False
BC6OTHER , which does not alter BC6ENTG - mediated BC6OTHER release measured with BC6ENTC , reversed the effect of BC6OTHER .	False
BC6OTHER , which does not alter BC6ENTG - mediated BC6OTHER release measured with BC6OTHER , reversed the effect of BC6ENTC .	False
BC6ENTC and BC6OTHER also partially inhibited BC6OTHER - mediated BC6OTHER release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6ENTG substrate.	False
BC6ENTC and BC6OTHER also partially inhibited BC6ENTG - mediated BC6OTHER release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6OTHER substrate.	False
BC6OTHER and BC6ENTC also partially inhibited BC6OTHER - mediated BC6OTHER release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6ENTG substrate.	False
BC6OTHER and BC6ENTC also partially inhibited BC6ENTG - mediated BC6OTHER release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6OTHER substrate.	False
BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) partially inhibited BC6OTHER ( BC6OTHER ) binding , slowed the dissociation rate of BC6OTHER from the BC6ENTG , and partially inhibited BC6OTHER uptake.	False
BC6OTHER and BC6OTHER also partially inhibited BC6OTHER - mediated BC6ENTC release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6ENTG substrate.	False
BC6OTHER and BC6OTHER also partially inhibited BC6ENTG - mediated BC6ENTC release induced by BC6OTHER or BC6OTHER , demonstrating that the observed partial inhibition is not specific for a particular BC6OTHER substrate.	False
Significant differences were observed in a different region (loop B93 - B101) , that we identified as binding site of BC6ENTC to the BC6ENTG ( BC6OTHER ).	False
Significant differences were observed in a different region (loop B93 - B101) , that we identified as binding site of BC6ENTC to the BC6OTHER ( BC6ENTG ).	False
BC6ENTC is a specific inhibitor of BC6ENTG but does not inhibit BC6OTHER .	CPR:4
BC6ENTC is a specific inhibitor of BC6OTHER but does not inhibit BC6ENTG .	False
By theoretical calculations we have determined most probable structure of BC6ENTC / BC6ENTG complexes.	False
Binding site of BC6ENTC to BC6ENTG depends on species.	False
BC6ENTC , a selective BC6OTHER reuptake inhibitor , exhibits high affinity and selectivity for the BC6ENTG .	CPR:4
BC6OTHER , a selective BC6ENTC reuptake inhibitor , exhibits high affinity and selectivity for the BC6ENTG .	False
PURPOSE: BC6OTHER - to - BC6OTHER ratio levels in infertile men improve during treatment with the BC6ENTG inhibitor , BC6ENTC , and resulting changes in semen parameters.	CPR:4
We evaluated the effect of BC6ENTC , a more selective BC6ENTG inhibitor , on the hormonal and semen profiles of infertile men with abnormal baseline BC6OTHER - to - BC6OTHER ratios.	CPR:4
PURPOSE: BC6OTHER - to - BC6ENTC ratio levels in infertile men improve during treatment with the BC6ENTG inhibitor , BC6OTHER , and resulting changes in semen parameters.	False
CONCLUSIONS: Men who are infertile with a low serum BC6ENTC - to - BC6OTHER ratio can be treated with an BC6ENTG inhibitor.	False
CONCLUSIONS: Men who are infertile with a low serum BC6OTHER - to - BC6ENTC ratio can be treated with an BC6ENTG inhibitor.	False
We evaluated the effect of BC6OTHER , a more selective BC6ENTG inhibitor , on the hormonal and semen profiles of infertile men with abnormal baseline BC6ENTC - to - BC6OTHER ratios.	False
We evaluated the effect of BC6OTHER , a more selective BC6ENTG inhibitor , on the hormonal and semen profiles of infertile men with abnormal baseline BC6OTHER - to - BC6ENTC ratios.	False
PURPOSE: BC6ENTC - to - BC6OTHER ratio levels in infertile men improve during treatment with the BC6ENTG inhibitor , BC6OTHER , and resulting changes in semen parameters.	False
In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of BC6ENTC , higher fold change of BC6ENTG and BC6OTHER mRNA levels were observed in rs7903146 - TT cells than that in rs7903146 - CC cells (P = 0.02 for BC6OTHER ; P = 0.004 for BC6OTHER ) , suggesting ER stress plays a role in PDR pathogenesis.	False
In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of BC6ENTC , higher fold change of BC6OTHER and BC6ENTG mRNA levels were observed in rs7903146 - TT cells than that in rs7903146 - CC cells (P = 0.02 for BC6OTHER ; P = 0.004 for BC6OTHER ) , suggesting ER stress plays a role in PDR pathogenesis.	False
In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of BC6ENTC , higher fold change of BC6OTHER and BC6OTHER mRNA levels were observed in rs7903146 - TT cells than that in rs7903146 - CC cells (P = 0.02 for BC6ENTG ; P = 0.004 for BC6OTHER ) , suggesting ER stress plays a role in PDR pathogenesis.	False
In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of BC6ENTC , higher fold change of BC6OTHER and BC6OTHER mRNA levels were observed in rs7903146 - TT cells than that in rs7903146 - CC cells (P = 0.02 for BC6OTHER ; P = 0.004 for BC6ENTG ) , suggesting ER stress plays a role in PDR pathogenesis.	False
Retinas of BC6ENTC - induced retinopathy (OIR) mice (a model for PDR) had higher BC6OTHER and BC6ENTG mRNA levels than controls (P = 2.9E - 04 for BC6OTHER ; P = 1.9E - 07 for BC6OTHER ).	False
Retinas of BC6ENTC - induced retinopathy (OIR) mice (a model for PDR) had higher BC6OTHER and BC6OTHER mRNA levels than controls (P = 2.9E - 04 for BC6ENTG ; P = 1.9E - 07 for BC6OTHER ).	False
Retinas of BC6ENTC - induced retinopathy (OIR) mice (a model for PDR) had higher BC6OTHER and BC6OTHER mRNA levels than controls (P = 2.9E - 04 for BC6OTHER ; P = 1.9E - 07 for BC6ENTG ).	False
Retinas of BC6ENTC - induced retinopathy (OIR) mice (a model for PDR) had higher BC6ENTG and BC6OTHER mRNA levels than controls (P = 2.9E - 04 for BC6OTHER ; P = 1.9E - 07 for BC6OTHER ).	False
A combination of a BC6ENTG or BC6OTHER inhibitor (10 microM) with BC6ENTC (100 nM) further delayed eosinophil apoptosis maximally by 42 - 49%.	False
A combination of a BC6OTHER or BC6ENTG inhibitor (10 microM) with BC6ENTC (100 nM) further delayed eosinophil apoptosis maximally by 42 - 49%.	False
Inhibitor of BC6ENTG ( BC6ENTC ; 0.1 - 10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.	CPR:4
The effect of BC6ENTC on apoptosis was not significantly modulated by a BC6ENTG inhibitor in eosinophils or neutrophils.	False
The present results show that selective inhibitors of BC6ENTC - hydrolyzing PDEs ( BC6ENTG and BC6OTHER ) delay eosinophil apoptosis and , thus , increase their survival in vitro.	False
The present results show that selective inhibitors of BC6ENTC - hydrolyzing PDEs ( BC6OTHER and BC6ENTG ) delay eosinophil apoptosis and , thus , increase their survival in vitro.	False
We also evaluated whether a BC6ENTG inhibitor could modulate the effect of a BC6ENTC on eosinophil and neutrophil apoptosis.	False
Inhibitors of BC6ENTG ( BC6ENTC ; 0.1 - 10 microM) and BC6OTHER ( BC6OTHER ; 0.1 - 10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15% , respectively.	CPR:4
Inhibitors of BC6OTHER ( BC6ENTC ; 0.1 - 10 microM) and BC6ENTG ( BC6OTHER ; 0.1 - 10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15% , respectively.	False
Inhibitors of BC6ENTG ( BC6OTHER ; 0.1 - 10 microM) and BC6OTHER ( BC6ENTC ; 0.1 - 10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15% , respectively.	False
Inhibitors of BC6OTHER ( BC6OTHER ; 0.1 - 10 microM) and BC6ENTG ( BC6ENTC ; 0.1 - 10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15% , respectively.	CPR:4
 BC6ENTG inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of BC6ENTC .	False
A series of BC6ENTC derivatives in which a BC6OTHER was inserted at position 8 of BC6OTHER scaffold was synthesized and evaluated as inhibitors of BC6ENTG ( BC6OTHER ) for the treatment of type 2 diabetes.	CPR:4
A series of BC6ENTC derivatives in which a BC6OTHER was inserted at position 8 of BC6OTHER scaffold was synthesized and evaluated as inhibitors of BC6OTHER ( BC6ENTG ) for the treatment of type 2 diabetes.	CPR:4
A series of BC6OTHER derivatives in which a BC6ENTC was inserted at position 8 of BC6OTHER scaffold was synthesized and evaluated as inhibitors of BC6ENTG ( BC6OTHER ) for the treatment of type 2 diabetes.	False
A series of BC6OTHER derivatives in which a BC6ENTC was inserted at position 8 of BC6OTHER scaffold was synthesized and evaluated as inhibitors of BC6OTHER ( BC6ENTG ) for the treatment of type 2 diabetes.	False
A series of BC6OTHER derivatives in which a BC6OTHER was inserted at position 8 of BC6ENTC scaffold was synthesized and evaluated as inhibitors of BC6ENTG ( BC6OTHER ) for the treatment of type 2 diabetes.	CPR:4
A series of BC6OTHER derivatives in which a BC6OTHER was inserted at position 8 of BC6ENTC scaffold was synthesized and evaluated as inhibitors of BC6OTHER ( BC6ENTG ) for the treatment of type 2 diabetes.	CPR:4
Synthesis and biological evaluation of BC6ENTC derivatives on BC6ENTG .	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6ENTC , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6ENTC , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6ENTC , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6ENTC , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6ENTC , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6ENTC levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6ENTC levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6ENTC levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6ENTC levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6ENTC levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTC dismutase , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTC dismutase , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTC dismutase , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTC dismutase , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6ENTC peroxidase and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6ENTC peroxidase and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTC peroxidase and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTC peroxidase and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC reductase) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC reductase) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC reductase) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC reductase) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6ENTC anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6ENTC anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6ENTC anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6ENTC anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6ENTC anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6ENTC , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6ENTC , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6ENTC , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6ENTC , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6ENTC , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6ENTC ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6ENTC ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6ENTC ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6ENTC ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6ENTC ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6ENTC ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6ENTC ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6ENTC ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6ENTC ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6OTHER , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6ENTC ) NSAIDs.	False
BC6ENTC treatment led to an increase in lipid peroxidation , BC6ENTG and BC6OTHER activities and to a decrease in BC6OTHER activity and BC6OTHER levels in gastric mucosa.	CPR:3
BC6ENTC treatment led to an increase in lipid peroxidation , BC6OTHER and BC6ENTG activities and to a decrease in BC6OTHER activity and BC6OTHER levels in gastric mucosa.	CPR:3
BC6ENTC treatment led to an increase in lipid peroxidation , BC6OTHER and BC6OTHER activities and to a decrease in BC6ENTG activity and BC6OTHER levels in gastric mucosa.	CPR:4
BC6OTHER treatment led to an increase in lipid peroxidation , BC6ENTC peroxidase and BC6ENTG activities and to a decrease in BC6OTHER activity and BC6OTHER levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6ENTC peroxidase and BC6OTHER activities and to a decrease in BC6ENTG activity and BC6OTHER levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6ENTG and BC6ENTC dehydrogenase activities and to a decrease in BC6OTHER activity and BC6OTHER levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6OTHER and BC6ENTC dehydrogenase activities and to a decrease in BC6ENTG activity and BC6OTHER levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6ENTG and BC6OTHER activities and to a decrease in BC6OTHER activity and BC6ENTC levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6OTHER and BC6ENTG activities and to a decrease in BC6OTHER activity and BC6ENTC levels in gastric mucosa.	False
BC6OTHER treatment led to an increase in lipid peroxidation , BC6OTHER and BC6OTHER activities and to a decrease in BC6ENTG activity and BC6ENTC levels in gastric mucosa.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6ENTC , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6ENTC , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6ENTC , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6ENTC , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6OTHER selective ( BC6OTHER ) NSAIDs.	False
The in vivo effects of the non - BC6OTHER anti - inflammatory drug (NSAID) BC6ENTC , a pro - drug of the NSAID BC6OTHER , on lipid peroxidation , BC6OTHER levels and activity of antioxidant enzymes ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) in rat gastric mucosa , colon mucosa and liver , were compared with the effects of non - selective ( BC6OTHER , BC6OTHER ) and BC6ENTG selective ( BC6OTHER ) NSAIDs.	False
BC6ENTC was also shown to decrease DA uptake and BC6OTHER - induced DA efflux in BC6ENTG containing cells.	False
BC6OTHER was also shown to decrease DA uptake and BC6ENTC - induced DA efflux in BC6ENTG containing cells.	False
Time - lapsed confocal microscopy indicates that BC6ENTC can promote trafficking of cell surface BC6ENTG into intracellular compartments which may account for the decrease in DA uptake and DA efflux in these cells.	False
BC6ENTC - induced internalization of BC6ENTG may provide an explanation for disruption in DA transmission previously reported in the striatum.	False
Although dopaminergic neurons within the nigrostriatal pathway appear intact , BC6ENTC - induced irregularities in DA transmission have been observed including decreased BC6OTHER - induced DA release and loss of the BC6ENTG ( BC6OTHER ).	False
Although dopaminergic neurons within the nigrostriatal pathway appear intact , BC6ENTC - induced irregularities in DA transmission have been observed including decreased BC6OTHER - induced DA release and loss of the BC6OTHER ( BC6ENTG ).	False
Although dopaminergic neurons within the nigrostriatal pathway appear intact , BC6OTHER - induced irregularities in DA transmission have been observed including decreased BC6ENTC - induced DA release and loss of the BC6ENTG ( BC6OTHER ).	False
Although dopaminergic neurons within the nigrostriatal pathway appear intact , BC6OTHER - induced irregularities in DA transmission have been observed including decreased BC6ENTC - induced DA release and loss of the BC6OTHER ( BC6ENTG ).	False
Although dopaminergic neurons within the nigrostriatal pathway appear intact , BC6OTHER - induced irregularities in DA transmission have been observed including decreased BC6OTHER - induced DA release and loss of the BC6ENTC transporter ( BC6ENTG ).	False
Results of studies to evaluate the effect of BC6ENTC and DA on cell viability in control and BC6ENTG - transfected HEK cells reveal that BC6OTHER is equally toxic to both cell lines whereas DA was only toxic to cells containing BC6OTHER .	False
Results of studies to evaluate the effect of BC6ENTC and DA on cell viability in control and BC6OTHER - transfected HEK cells reveal that BC6OTHER is equally toxic to both cell lines whereas DA was only toxic to cells containing BC6ENTG .	False
Results of studies to evaluate the effect of BC6OTHER and DA on cell viability in control and BC6ENTG - transfected HEK cells reveal that BC6ENTC is equally toxic to both cell lines whereas DA was only toxic to cells containing BC6OTHER .	False
Results of studies to evaluate the effect of BC6OTHER and DA on cell viability in control and BC6OTHER - transfected HEK cells reveal that BC6ENTC is equally toxic to both cell lines whereas DA was only toxic to cells containing BC6ENTG .	False
When BC6ENTC and DA were added simultaneously to the media , cell toxicity was similar to that produced by BC6OTHER alone suggesting that BC6OTHER may suppress DA uptake in the BC6ENTG containing cells.	False
When BC6OTHER and DA were added simultaneously to the media , cell toxicity was similar to that produced by BC6ENTC alone suggesting that BC6OTHER may suppress DA uptake in the BC6ENTG containing cells.	False
When BC6OTHER and DA were added simultaneously to the media , cell toxicity was similar to that produced by BC6OTHER alone suggesting that BC6ENTC may suppress DA uptake in the BC6ENTG containing cells.	False
The effect of BC6ENTC on BC6OTHER toxicity and BC6ENTG ( BC6OTHER ) in control and BC6OTHER transfected HEK cells.	False
The effect of BC6ENTC on BC6OTHER toxicity and BC6OTHER ( BC6ENTG ) in control and BC6OTHER transfected HEK cells.	False
The effect of BC6ENTC on BC6OTHER toxicity and BC6OTHER ( BC6OTHER ) in control and BC6ENTG transfected HEK cells.	False
The effect of BC6OTHER on BC6ENTC toxicity and BC6ENTG ( BC6OTHER ) in control and BC6OTHER transfected HEK cells.	False
The effect of BC6OTHER on BC6ENTC toxicity and BC6OTHER ( BC6ENTG ) in control and BC6OTHER transfected HEK cells.	False
The effect of BC6OTHER on BC6ENTC toxicity and BC6OTHER ( BC6OTHER ) in control and BC6ENTG transfected HEK cells.	False
The effect of BC6OTHER on BC6OTHER toxicity and BC6ENTC transporter ( BC6ENTG ) in control and BC6OTHER transfected HEK cells.	False
The effect of BC6OTHER on BC6OTHER toxicity and BC6ENTC transporter ( BC6OTHER ) in control and BC6ENTG transfected HEK cells.	False
In the BC6OTHER + BC6OTHER group , activities of BC6ENTG , BC6OTHER in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6ENTC accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6OTHER , BC6ENTG in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6ENTC accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6ENTG , BC6OTHER in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6ENTC - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6OTHER , BC6ENTG in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6ENTC - treated group.	False
In the BC6ENTC + BC6OTHER group , activities of BC6ENTG , BC6OTHER in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6ENTC + BC6OTHER group , activities of BC6OTHER , BC6ENTG in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6ENTC group , activities of BC6ENTG , BC6OTHER in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6ENTC group , activities of BC6OTHER , BC6ENTG in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6ENTC dismutase , BC6ENTG in serum and BC6OTHER / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6ENTG , BC6OTHER in serum and BC6ENTC / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6OTHER , BC6ENTG in serum and BC6ENTC / BC6OTHER were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6ENTG , BC6OTHER in serum and BC6OTHER / BC6ENTC were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
In the BC6OTHER + BC6OTHER group , activities of BC6OTHER , BC6ENTG in serum and BC6OTHER / BC6ENTC were significantly increased , histopathological effects were reduced , and BC6OTHER accumulation markedly decreased in the liver , compared with the BC6OTHER - treated group.	False
The disease has been associated with mutations in the BC6ENTC receptor subunit genes BC6ENTG and BC6OTHER .	False
The disease has been associated with mutations in the BC6ENTC receptor subunit genes BC6OTHER and BC6ENTG .	False
Here , we describe mutations within the neuronal BC6ENTC transporter 2 gene ( BC6ENTG , or BC6OTHER , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6OTHER mutations.	False
Here , we describe mutations within the neuronal BC6ENTC transporter 2 gene ( BC6OTHER , or BC6ENTG , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6OTHER mutations.	False
Here , we describe mutations within the neuronal BC6ENTC transporter 2 gene ( BC6OTHER , or BC6OTHER , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6ENTG mutations.	False
Here , we describe mutations within the neuronal BC6ENTG gene ( BC6OTHER , or BC6OTHER , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6ENTC receptor mutations.	False
Here , we describe mutations within the neuronal BC6OTHER gene ( BC6ENTG , or BC6OTHER , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6ENTC receptor mutations.	False
Here , we describe mutations within the neuronal BC6OTHER gene ( BC6OTHER , or BC6ENTG , ) of hyperekplexia patients , whose symptoms cannot be attributed to BC6ENTC receptor mutations.	False
BC6ENTG plays a role in BC6OTHER salvage by catalyzing the direct conversion of BC6ENTC to BC6OTHER .	CPR:9
BC6ENTG plays a role in BC6OTHER salvage by catalyzing the direct conversion of BC6OTHER to BC6ENTC .	CPR:9
The involvement of the BC6ENTC salvage pathway in tumor proliferation and angiogenesis makes BC6ENTG a potential target for oncology drug discovery.	False
We have expressed and characterized recombinant , BC6ENTC - terminally BC6OTHER - tagged BC6ENTG .	False
We have expressed and characterized recombinant , BC6OTHER - terminally BC6ENTC - tagged BC6ENTG .	False
BC6ENTG plays a role in BC6ENTC salvage by catalyzing the direct conversion of BC6OTHER to BC6OTHER .	False
FCEO significantly inhibited BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of BC6ENTG ( BC6OTHER ) and BC6OTHER , respectively.	CPR:4
FCEO significantly inhibited BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER , respectively.	CPR:4
FCEO significantly inhibited BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of BC6ENTG ( BC6OTHER ) and BC6OTHER , respectively.	CPR:4
FCEO significantly inhibited BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER , respectively.	CPR:4
FCEO significantly inhibited BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) by suppressing the protein expression of BC6ENTG ( BC6OTHER ) and BC6OTHER , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG , respectively.	CPR:4
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) by suppressing the protein expression of BC6ENTG ( BC6OTHER ) and BC6OTHER , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) by suppressing the protein expression of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG , respectively.	CPR:4
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6ENTC synthase ( BC6ENTG ) and BC6OTHER , respectively.	False
FCEO significantly inhibited BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) by suppressing the protein expression of inducible BC6ENTC synthase ( BC6OTHER ) and BC6ENTG , respectively.	False
Both drugs target the alpha - subunit of the BC6ENTC channel , encoded by the BC6ENTG family of genes.	False
BC6ENTC is principally metabolized by BC6ENTG , and both are probable substrates of the BC6OTHER BC6OTHER .	CPR:9
BC6ENTC is principally metabolized by BC6OTHER , and both are probable substrates of the BC6ENTG BC6OTHER .	CPR:9
BC6ENTC is principally metabolized by BC6OTHER , and both are probable substrates of the BC6OTHER BC6ENTG .	CPR:9
We report that a known functional polymorphism in BC6ENTG is highly associated with the maximum dose of BC6ENTC (P = 0.0066).	False
We also show that an intronic polymorphism in the BC6ENTG gene shows significant association with maximum doses in regular usage of both BC6ENTC and BC6OTHER (P = 0.0051 and P = 0.014 , respectively).	False
We also show that an intronic polymorphism in the BC6ENTG gene shows significant association with maximum doses in regular usage of both BC6OTHER and BC6ENTC (P = 0.0051 and P = 0.014 , respectively).	False
Dietary soy protein isolate (SPI) reduces hepatic lipogenesis by suppressing gene expression of lipogenic enzymes , including BC6ENTC carboxylase ( BC6ENTG ).	False
Rats were fed experimental diets containing SPI or BC6ENTG as a BC6ENTC source.	CPR:9
SPI feeding decreased the hepatic contents of total BC6ENTG mRNA as well as BC6ENTC ( BC6OTHER ) content , but dietary SPI affected the amount of BC6OTHER mRNA and protein very little.	False
SPI feeding decreased the hepatic contents of total BC6OTHER mRNA as well as BC6ENTC ( BC6OTHER ) content , but dietary SPI affected the amount of BC6ENTG mRNA and protein very little.	False
SPI feeding decreased the hepatic contents of total BC6ENTG mRNA as well as BC6OTHER ( BC6ENTC ) content , but dietary SPI affected the amount of BC6OTHER mRNA and protein very little.	False
SPI feeding decreased the hepatic contents of total BC6OTHER mRNA as well as BC6OTHER ( BC6ENTC ) content , but dietary SPI affected the amount of BC6ENTG mRNA and protein very little.	False
Soy protein suppresses gene expression of BC6ENTC carboxylase alpha from BC6ENTG in rat liver.	False
In membranes from HEK293 cells transfected with BC6ENTG , BC6ENTC inhibited binding of the alpha2 - antagonist , BC6OTHER , with higher potency from BC6OTHER than from BC6OTHER (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	False
In membranes from HEK293 cells transfected with BC6OTHER , BC6ENTC inhibited binding of the alpha2 - antagonist , BC6OTHER , with higher potency from BC6ENTG than from BC6OTHER (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	False
In membranes from HEK293 cells transfected with BC6OTHER , BC6ENTC inhibited binding of the alpha2 - antagonist , BC6OTHER , with higher potency from BC6OTHER than from BC6ENTG (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	False
In membranes from HEK293 cells transfected with BC6ENTG , BC6OTHER inhibited binding of the alpha2 - antagonist , BC6ENTC , with higher potency from BC6OTHER than from BC6OTHER (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	CPR:6
In membranes from HEK293 cells transfected with BC6OTHER , BC6OTHER inhibited binding of the alpha2 - antagonist , BC6ENTC , with higher potency from BC6ENTG than from BC6OTHER (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	False
In membranes from HEK293 cells transfected with BC6OTHER , BC6OTHER inhibited binding of the alpha2 - antagonist , BC6ENTC , with higher potency from BC6OTHER than from BC6ENTG (Ki alpha2A 208 microm , alpha2B 26 microm , alpha2C 56 microm).	CPR:6
BACKGROUND: The intravenous anesthetic BC6OTHER exhibits structural similarities to specific BC6ENTG agonists of the type such as BC6ENTC .	CPR:5
In BC6ENTG - expressing HEK293 cells , BC6ENTC rapidly increased phosphorylation of the BC6OTHER BC6OTHER .	False
In BC6OTHER - expressing HEK293 cells , BC6ENTC rapidly increased phosphorylation of the BC6ENTG BC6OTHER .	CPR:3
In BC6OTHER - expressing HEK293 cells , BC6ENTC rapidly increased phosphorylation of the BC6OTHER BC6ENTG .	CPR:3
CONCLUSIONS: These results indicate that BC6ENTC acts as an agonist at BC6ENTG , which appears in vivo primarily as an BC6OTHER - mediated increase in blood pressure.	CPR:5
CONCLUSIONS: These results indicate that BC6ENTC acts as an agonist at BC6OTHER , which appears in vivo primarily as an BC6ENTG - mediated increase in blood pressure.	False
The current study was performed to elucidate the possible interaction of BC6ENTC with BC6ENTG in mice lacking individual BC6OTHER subtypes (alpha2 - KO).	False
The current study was performed to elucidate the possible interaction of BC6ENTC with BC6OTHER in mice lacking individual BC6ENTG subtypes (alpha2 - KO).	False
METHODS: Sedative and cardiovascular responses to BC6ENTC and the alpha2 - agonist , BC6OTHER , were determined in mice deficient in BC6ENTG subtypes.	False
BACKGROUND: The intravenous anesthetic BC6ENTC exhibits structural similarities to specific BC6ENTG agonists of the type such as BC6OTHER .	False
METHODS: Sedative and cardiovascular responses to BC6OTHER and the alpha2 - agonist , BC6ENTC , were determined in mice deficient in BC6ENTG subtypes.	CPR:5
Inhibition of binding of the BC6ENTG antagonist BC6ENTC to recombinant BC6OTHER by BC6OTHER was tested in human embryonic kidney (HEK293) cells in vitro.	CPR:6
Inhibition of binding of the BC6OTHER antagonist BC6ENTC to recombinant BC6ENTG by BC6OTHER was tested in human embryonic kidney (HEK293) cells in vitro.	CPR:6
Inhibition of binding of the BC6ENTG antagonist BC6OTHER to recombinant BC6OTHER by BC6ENTC was tested in human embryonic kidney (HEK293) cells in vitro.	False
Inhibition of binding of the BC6OTHER antagonist BC6OTHER to recombinant BC6ENTG by BC6ENTC was tested in human embryonic kidney (HEK293) cells in vitro.	False
RESULTS: In vivo , loss and recovery of the righting reflex required similar times after intraperitoneal injection of BC6ENTC in wild - type and in BC6ENTG - deficient mice , indicating that the hypnotic effect of BC6OTHER in mice does not require the BC6OTHER subtype.	False
RESULTS: In vivo , loss and recovery of the righting reflex required similar times after intraperitoneal injection of BC6ENTC in wild - type and in BC6OTHER - deficient mice , indicating that the hypnotic effect of BC6OTHER in mice does not require the BC6ENTG subtype.	False
RESULTS: In vivo , loss and recovery of the righting reflex required similar times after intraperitoneal injection of BC6OTHER in wild - type and in BC6ENTG - deficient mice , indicating that the hypnotic effect of BC6ENTC in mice does not require the BC6OTHER subtype.	False
RESULTS: In vivo , loss and recovery of the righting reflex required similar times after intraperitoneal injection of BC6OTHER in wild - type and in BC6OTHER - deficient mice , indicating that the hypnotic effect of BC6ENTC in mice does not require the BC6ENTG subtype.	False
Activation of BC6ENTG mediates the cardiovascular effects of BC6ENTC .	CPR:3
Overexpression of BC6ENTG by adenoviral transfer rescued BC6OTHER proteins from elimination by BC6ENTC or BC6OTHER .	False
Overexpression of BC6OTHER by adenoviral transfer rescued BC6ENTG proteins from elimination by BC6ENTC or BC6OTHER .	False
Overexpression of BC6ENTG by adenoviral transfer rescued BC6OTHER proteins from elimination by BC6OTHER or BC6ENTC .	False
Overexpression of BC6OTHER by adenoviral transfer rescued BC6ENTG proteins from elimination by BC6OTHER or BC6ENTC .	False
To determine the role of BC6OTHER in colorectal cancer apoptosis induced by nonsteroidal anti - inflammatory drugs (NSAIDs) , we evaluated the effects of BC6ENTC on BC6ENTG expression in colorectal cancer cells.	False
To determine the role of BC6ENTG in colorectal cancer apoptosis induced by nonsteroidal anti - inflammatory drugs (NSAIDs) , we evaluated the effects of BC6ENTC on BC6OTHER expression in colorectal cancer cells.	False
BC6ENTC inhibited BC6ENTG in HT - 29 and DLD - 1 cells in a time - and concentration - dependent manner.	CPR:4
BC6ENTC and BC6OTHER , a selective BC6ENTG ( BC6OTHER ) inhibitor , exerted a similar effect as BC6OTHER .	CPR:4
BC6ENTC and BC6OTHER , a selective BC6OTHER ( BC6ENTG ) inhibitor , exerted a similar effect as BC6OTHER .	CPR:4
BC6OTHER and BC6ENTC , a selective BC6ENTG ( BC6OTHER ) inhibitor , exerted a similar effect as BC6OTHER .	CPR:4
BC6OTHER and BC6ENTC , a selective BC6OTHER ( BC6ENTG ) inhibitor , exerted a similar effect as BC6OTHER .	CPR:4
BC6OTHER and BC6OTHER , a selective BC6ENTG ( BC6OTHER ) inhibitor , exerted a similar effect as BC6ENTC .	False
BC6OTHER and BC6OTHER , a selective BC6OTHER ( BC6ENTG ) inhibitor , exerted a similar effect as BC6ENTC .	False
BC6ENTC inhibited BC6ENTG protein expression and BC6OTHER transcriptional activity.	CPR:4
BC6ENTC inhibited BC6OTHER protein expression and BC6ENTG transcriptional activity.	CPR:4
BC6ENTC is a T - type BC6OTHER channel antagonist with reported cross - reactivity with other classes of ion channels , including BC6ENTG BC6OTHER channels.	False
BC6ENTC is a BC6ENTG antagonist with reported cross - reactivity with other classes of ion channels , including CHEM , BC6OTHER , and BC6OTHER channels.	CPR:6
In addition , inhibiting the binding of the fast inactivation lid ( BC6ENTG ICM + CHEM) did not alter BC6ENTC block , confirming that the drug does not preferentially interact with the fast - inactivated state.	CPR:4
BC6OTHER is a BC6ENTG antagonist with reported cross - reactivity with other classes of ion channels , including BC6ENTC , BC6OTHER , and BC6OTHER channels.	False
BC6OTHER is a BC6ENTG antagonist with reported cross - reactivity with other classes of ion channels , including CHEM , BC6ENTC , and BC6OTHER channels.	False
BC6OTHER is a T - type BC6OTHER channel antagonist with reported cross - reactivity with other classes of ion channels , including BC6ENTG BC6ENTC channels.	False
BC6OTHER is a BC6ENTG antagonist with reported cross - reactivity with other classes of ion channels , including CHEM , BC6OTHER , and BC6ENTC channels.	False
When selectively applied to channels after inducing slow inactivation with a 60 - s pulse to - 10 mV , BC6ENTC (1 microM) produced 45% fractional block in BC6ENTG and greater block (88%) in an isoform ( BC6OTHER ) that slow - inactivates more completely.	CPR:4
When selectively applied to channels after inducing slow inactivation with a 60 - s pulse to - 10 mV , BC6ENTC (1 microM) produced 45% fractional block in BC6OTHER and greater block (88%) in an isoform ( BC6ENTG ) that slow - inactivates more completely.	CPR:4
Our results suggest that BC6ENTC blocks BC6ENTG in a state - dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow - inactivated state(s).	CPR:4
Using whole - cell voltage clamp , we examined BC6ENTC block of four BC6ENTG isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6OTHER (skeletal muscle) , BC6OTHER (brain) , and BC6OTHER (peripheral nerve).	CPR:4
Using whole - cell voltage clamp , we examined BC6ENTC block of four BC6OTHER isoforms expressed in human embryonic kidney cells: BC6ENTG (cardiac) , BC6OTHER (skeletal muscle) , BC6OTHER (brain) , and BC6OTHER (peripheral nerve).	CPR:4
Using whole - cell voltage clamp , we examined BC6ENTC block of four BC6OTHER isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6ENTG (skeletal muscle) , BC6OTHER (brain) , and BC6OTHER (peripheral nerve).	CPR:4
Using whole - cell voltage clamp , we examined BC6ENTC block of four BC6OTHER isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6OTHER (skeletal muscle) , BC6ENTG (brain) , and BC6OTHER (peripheral nerve).	CPR:4
Using whole - cell voltage clamp , we examined BC6ENTC block of four BC6OTHER isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6OTHER (skeletal muscle) , BC6OTHER (brain) , and BC6ENTG (peripheral nerve).	CPR:4
Using whole - cell voltage clamp , we examined BC6OTHER block of four BC6ENTC channel isoforms expressed in human embryonic kidney cells: BC6ENTG (cardiac) , BC6OTHER (skeletal muscle) , BC6OTHER (brain) , and BC6OTHER (peripheral nerve).	False
Using whole - cell voltage clamp , we examined BC6OTHER block of four BC6ENTC channel isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6ENTG (skeletal muscle) , BC6OTHER (brain) , and BC6OTHER (peripheral nerve).	False
Using whole - cell voltage clamp , we examined BC6OTHER block of four BC6ENTC channel isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6OTHER (skeletal muscle) , BC6ENTG (brain) , and BC6OTHER (peripheral nerve).	False
Using whole - cell voltage clamp , we examined BC6OTHER block of four BC6ENTC channel isoforms expressed in human embryonic kidney cells: BC6OTHER (cardiac) , BC6OTHER (skeletal muscle) , BC6OTHER (brain) , and BC6ENTG (peripheral nerve).	False
BC6OTHER is a T - type BC6ENTC channel antagonist with reported cross - reactivity with other classes of ion channels , including BC6ENTG BC6OTHER channels.	False
BC6ENTC blocked BC6ENTG in a use / frequency - dependent manner , indicating preferential binding to states visited during depolarization.	CPR:4
BC6ENTC blocked currents of all BC6ENTG isoforms with similar affinity and a dependence on holding potential , and drug off - rate was slowed at depolarized potentials (k(off) was 0.024 / s at - 130 mV and 0.007 / s at - 100 mV for BC6OTHER ).	CPR:4
BC6ENTC blocked currents of all BC6OTHER isoforms with similar affinity and a dependence on holding potential , and drug off - rate was slowed at depolarized potentials (k(off) was 0.024 / s at - 130 mV and 0.007 / s at - 100 mV for BC6ENTG ).	CPR:4
BC6OTHER blocked currents of all BC6ENTC channel isoforms with similar affinity and a dependence on holding potential , and drug off - rate was slowed at depolarized potentials (k(off) was 0.024 / s at - 130 mV and 0.007 / s at - 100 mV for BC6ENTG ).	False
We further probed the interaction of BC6ENTC with inactivated BC6ENTG channels.	False
State - dependent BC6ENTC block of BC6ENTG .	CPR:4
The CHEM / BC6ENTC exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	False
Existing BC6ENTG blockers , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , have been found to have an BC6OTHER inhibitory action.	CPR:4
Existing BC6OTHER blockers , such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , have been found to have an BC6ENTG inhibitory action.	CPR:4
Existing BC6ENTG blockers , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , have been found to have an BC6OTHER inhibitory action.	CPR:4
Existing BC6OTHER blockers , such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , have been found to have an BC6ENTG inhibitory action.	CPR:4
Existing BC6ENTG blockers , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , have been found to have an BC6OTHER inhibitory action.	CPR:4
Existing BC6OTHER blockers , such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , have been found to have an BC6ENTG inhibitory action.	CPR:4
Existing BC6ENTG blockers , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , have been found to have an BC6OTHER inhibitory action.	CPR:4
Existing BC6OTHER blockers , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , have been found to have an BC6ENTG inhibitory action.	CPR:4
Existing BC6ENTG blockers , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , have been found to have an BC6OTHER inhibitory action.	CPR:4
Existing BC6OTHER blockers , such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , have been found to have an BC6ENTG inhibitory action.	CPR:4
The CHEM / BC6OTHER exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6ENTC into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	False
The BC6ENTG ( BC6OTHER ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6ENTC into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	CPR:9
This article presents the characteristics of selective and non - selective BC6ENTG inhibitors and their therapeutic potential as a new BC6ENTC regulator.	False
The CHEM / BC6OTHER exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6ENTC ( BC6OTHER (i)) accumulation or membrane depolarization.	False
The BC6ENTG ( BC6OTHER ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6ENTC ( BC6OTHER (i)) accumulation or membrane depolarization.	False
The CHEM / BC6OTHER exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6ENTC (i)) accumulation or membrane depolarization.	False
The BC6ENTG ( BC6OTHER ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6ENTC (i)) accumulation or membrane depolarization.	False
The BC6ENTC / BC6OTHER exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6OTHER from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	False
The pharmacology of BC6ENTG inhibitors has been studied extensively since the development of BC6ENTC , a prototype BC6OTHER BC6OTHER inhibitor , in 1996.	False
The pharmacology of BC6OTHER inhibitors has been studied extensively since the development of BC6ENTC , a prototype BC6OTHER BC6ENTG inhibitor , in 1996.	CPR:4
The pharmacology of BC6ENTG inhibitors has been studied extensively since the development of BC6OTHER , a prototype BC6ENTC BC6OTHER inhibitor , in 1996.	False
The pharmacology of BC6OTHER inhibitors has been studied extensively since the development of BC6OTHER , a prototype BC6ENTC BC6ENTG inhibitor , in 1996.	CPR:4
Intriguingly , the inhibitory potency of BC6ENTC BC6ENTG inhibitors is directly coupled to the rate of BC6OTHER (i) - dependent inactivation.	CPR:4
Intriguingly , the inhibitory potency of BC6OTHER BC6ENTG inhibitors is directly coupled to the rate of BC6ENTC (i) - dependent inactivation.	False
The CHEM / BC6OTHER exchanger ( BC6ENTG ) is a bidirectional transporter that normally extrudes BC6ENTC from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	False
The BC6ENTG ( BC6OTHER ) is a bidirectional transporter that normally extrudes BC6ENTC from the cell (forward mode) , but also brings BC6OTHER into the cell (reverse mode) under special conditions such as intracellular BC6OTHER ( BC6OTHER (i)) accumulation or membrane depolarization.	CPR:9
The isolated BC6ENTG protein underwent reduction in the presence of either BC6ENTC - cytochrome P450 reductase or BC6OTHER but did not exhibit BC6OTHER activity.	False
The isolated BC6OTHER protein underwent reduction in the presence of either BC6ENTC - cytochrome P450 reductase or BC6ENTG but did not exhibit BC6OTHER activity.	False
The isolated BC6OTHER protein underwent reduction in the presence of either BC6ENTC - cytochrome P450 reductase or BC6OTHER but did not exhibit BC6ENTG activity.	False
The isolated BC6ENTG protein underwent reduction in the presence of either BC6OTHER or BC6ENTC - putidaredoxin - putidaredoxin reductase but did not exhibit BC6OTHER activity.	False
The isolated BC6OTHER protein underwent reduction in the presence of either BC6ENTG or BC6ENTC - putidaredoxin - putidaredoxin reductase but did not exhibit BC6OTHER activity.	False
The isolated BC6OTHER protein underwent reduction in the presence of either BC6OTHER or BC6ENTC - putidaredoxin - putidaredoxin reductase but did not exhibit BC6ENTG activity.	False
The protein exhibited modest BC6ENTC - dependent BC6ENTG activities with BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ).	CPR:3
The protein exhibited modest BC6OTHER - dependent BC6ENTG activities with BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER ).	CPR:9
The protein exhibited modest BC6OTHER - dependent BC6ENTG activities with BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER ).	CPR:9
The protein exhibited modest BC6OTHER - dependent BC6ENTG activities with BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER ).	CPR:9
The protein exhibited modest BC6OTHER - dependent BC6ENTG activities with BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC ).	CPR:9
As predicted , BC6OTHER enhanced the production of both BC6OTHER precursors (i.e. , BC6OTHER and BC6OTHER ) , and BC6ENTG was identified as the likely source of BC6ENTC - stimulated BC6OTHER production.	CPR:9
As predicted , BC6OTHER enhanced the production of both BC6OTHER precursors (i.e. , BC6OTHER and BC6OTHER ) , and BC6ENTG was identified as the likely source of BC6OTHER - stimulated BC6ENTC production.	CPR:9
Functional and biochemical studies indicated that BC6ENTC signaling involved activity of the BC6ENTG - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6ENTC signaling involved activity of the BC6OTHER - BC6ENTG ( BC6OTHER ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6ENTC signaling involved activity of the BC6OTHER - BC6OTHER ( BC6ENTG ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6ENTC signaling involved activity of the BC6OTHER - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6ENTG and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	CPR:3
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6ENTC 3 (PI3) kinase - BC6ENTG ( BC6OTHER ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6ENTC 3 (PI3) kinase - BC6OTHER ( BC6ENTG ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6ENTC 3 (PI3) kinase - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6ENTG and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6ENTG - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6ENTC receptor and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6OTHER - BC6ENTG ( BC6OTHER ) cascade initiated by activation of the BC6ENTC receptor and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6OTHER - BC6OTHER ( BC6ENTG ) cascade initiated by activation of the BC6ENTC receptor and culminated in enhanced production of BC6OTHER and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6ENTG - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6ENTC and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6OTHER - BC6ENTG ( BC6OTHER ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6ENTC and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6OTHER - BC6OTHER ( BC6ENTG ) cascade initiated by activation of the BC6OTHER and culminated in enhanced production of BC6ENTC and microvascular vasodilation.	False
Functional and biochemical studies indicated that BC6OTHER signaling involved activity of the BC6OTHER - BC6OTHER ( BC6OTHER ) cascade initiated by activation of the BC6ENTG and culminated in enhanced production of BC6ENTC and microvascular vasodilation.	False
These findings , derived from a variety of analytical and functional approaches , provide evidence for a novel nongenomic signaling mechanism for BC6ENTC action in the microvasculature: BC6OTHER - stimulated vasodilation mediated primarily by BC6OTHER formed from BC6ENTG - generated BC6OTHER and BC6OTHER .	False
These findings , derived from a variety of analytical and functional approaches , provide evidence for a novel nongenomic signaling mechanism for BC6OTHER action in the microvasculature: BC6ENTC - stimulated vasodilation mediated primarily by BC6OTHER formed from BC6ENTG - generated BC6OTHER and BC6OTHER .	False
These findings , derived from a variety of analytical and functional approaches , provide evidence for a novel nongenomic signaling mechanism for BC6OTHER action in the microvasculature: BC6OTHER - stimulated vasodilation mediated primarily by BC6ENTC formed from BC6ENTG - generated BC6OTHER and BC6OTHER .	CPR:9
These findings , derived from a variety of analytical and functional approaches , provide evidence for a novel nongenomic signaling mechanism for BC6OTHER action in the microvasculature: BC6OTHER - stimulated vasodilation mediated primarily by BC6OTHER formed from BC6ENTG - generated BC6ENTC and BC6OTHER .	CPR:9
These findings , derived from a variety of analytical and functional approaches , provide evidence for a novel nongenomic signaling mechanism for BC6OTHER action in the microvasculature: BC6OTHER - stimulated vasodilation mediated primarily by BC6OTHER formed from BC6ENTG - generated BC6OTHER and BC6ENTC .	CPR:9
This response was associated with activation of the BC6ENTG - BC6OTHER signaling cascade initiated by activation of the BC6ENTC receptor.	False
This response was associated with activation of the BC6OTHER - BC6ENTG signaling cascade initiated by activation of the BC6ENTC receptor.	False
As predicted , BC6ENTC enhanced the production of both BC6OTHER precursors (i.e. , BC6OTHER and BC6OTHER ) , and BC6ENTG was identified as the likely source of BC6OTHER - stimulated BC6OTHER production.	False
As predicted , BC6OTHER enhanced the production of both BC6ENTC precursors (i.e. , BC6OTHER and BC6OTHER ) , and BC6ENTG was identified as the likely source of BC6OTHER - stimulated BC6OTHER production.	False
As predicted , BC6OTHER enhanced the production of both BC6OTHER precursors (i.e. , BC6ENTC and BC6OTHER ) , and BC6ENTG was identified as the likely source of BC6OTHER - stimulated BC6OTHER production.	False
As predicted , BC6OTHER enhanced the production of both BC6OTHER precursors (i.e. , BC6OTHER and BC6ENTC ) , and BC6ENTG was identified as the likely source of BC6OTHER - stimulated BC6OTHER production.	False
BC6ENTC ( BC6OTHER ) exhibits moderate dual BC6ENTG - inhibitory activity and promises as a combined bronchodilatory / anti - inflammatory agent.	CPR:4
BC6OTHER ( BC6ENTC ) exhibits moderate dual BC6ENTG - inhibitory activity and promises as a combined bronchodilatory / anti - inflammatory agent.	CPR:4
BC6ENTC - alkylation of the BC6OTHER ring markedly enhances potency against BC6ENTG but suppresses BC6OTHER inhibition.	CPR:4
BC6ENTC - alkylation of the BC6OTHER ring markedly enhances potency against BC6OTHER but suppresses BC6ENTG inhibition.	CPR:4
BC6OTHER - alkylation of the BC6ENTC ring markedly enhances potency against BC6ENTG but suppresses BC6OTHER inhibition.	CPR:4
BC6OTHER - alkylation of the BC6ENTC ring markedly enhances potency against BC6OTHER but suppresses BC6ENTG inhibition.	CPR:4
Addition of a BC6ENTC extension to the BC6OTHER - CHEM group facilitates both enhancement of BC6ENTG - inhibitory activity and restoration of potent BC6OTHER inhibition.	CPR:4
Addition of a BC6ENTC extension to the BC6OTHER - CHEM group facilitates both enhancement of BC6OTHER - inhibitory activity and restoration of potent BC6ENTG inhibition.	CPR:4
Addition of a BC6OTHER extension to the BC6ENTC - CHEM group facilitates both enhancement of BC6ENTG - inhibitory activity and restoration of potent BC6OTHER inhibition.	CPR:4
Addition of a BC6OTHER extension to the BC6ENTC - CHEM group facilitates both enhancement of BC6OTHER - inhibitory activity and restoration of potent BC6ENTG inhibition.	CPR:4
In combination , these modifications afford potent dual BC6ENTG inhibitors that suppress BC6ENTC - induced bronchoconstriction in vivo and exhibit promising anti - inflammatory activity via intratracheal administration.	False
BC6OTHER and BC6ENTC at 10CHEM( - 7) , and 10( - 6) M inhibited the cardiac stimulation response slightly , which is indicative of membrane - stabilizing activity independent of BC6ENTG blockade.	CPR:4
BC6ENTC and BC6OTHER also caused surmountable antagonism of BC6OTHER responses , and this BC6ENTG antagonism was slowly reversible.	CPR:6
BC6OTHER and BC6ENTC also caused surmountable antagonism of BC6OTHER responses , and this BC6ENTG antagonism was slowly reversible.	CPR:6
BC6OTHER and BC6OTHER also caused surmountable antagonism of BC6ENTC responses , and this BC6ENTG antagonism was slowly reversible.	CPR:5
We conclude that BC6ENTC and BC6OTHER are competitive slowly reversible BC6ENTG antagonists on rat left atria.	CPR:6
We conclude that BC6OTHER and BC6ENTC are competitive slowly reversible BC6ENTG antagonists on rat left atria.	CPR:6
BC6ENTC and BC6OTHER at 10CHEM( - 7) , and 10( - 6) M inhibited the cardiac stimulation response slightly , which is indicative of membrane - stabilizing activity independent of BC6ENTG blockade.	CPR:4
 BC6ENTC and BC6OTHER are competitive slowly reversible antagonists at the BC6ENTG of rat left atria.	CPR:6
 BC6OTHER and BC6ENTC are competitive slowly reversible antagonists at the BC6ENTG of rat left atria.	CPR:6
In fact , the plasma BC6ENTC concentration is more than doubled 6 hr after the administration of 10 mg of BC6OTHER while plasma BC6ENTG and BC6OTHER levels are increased by 7 - and 17 - fold , respectively , after 14 days of similar daily treatment.	False
In fact , the plasma BC6OTHER concentration is more than doubled 6 hr after the administration of 10 mg of BC6ENTC while plasma BC6ENTG and BC6OTHER levels are increased by 7 - and 17 - fold , respectively , after 14 days of similar daily treatment.	False
In fact , the plasma BC6OTHER concentration is more than doubled 6 hr after the administration of 10 mg of BC6OTHER while plasma BC6ENTG and BC6ENTC levels are increased by 7 - and 17 - fold , respectively , after 14 days of similar daily treatment.	False
Although inhibition of BC6ENTG release can be achieved by BC6ENTC and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	CPR:4
Although inhibition of BC6OTHER release can be achieved by BC6ENTC and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6ENTG agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6ENTC and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6ENTG responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6ENTC and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6ENTG .	False
Although inhibition of BC6ENTG release can be achieved by BC6OTHER and BC6ENTC , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	CPR:4
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6ENTC , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6ENTG agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6ENTC , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6ENTG responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6ENTC , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6OTHER biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6ENTG .	False
Although inhibition of BC6ENTG release can be achieved by BC6OTHER and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6ENTC biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6ENTG agonist that causes a specific blockage of testicular BC6ENTC biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6ENTC biosynthesis as well as an inhibition of the BC6ENTG responsiveness to BC6OTHER .	False
Although inhibition of BC6OTHER release can be achieved by BC6OTHER and BC6OTHER , an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an BC6OTHER agonist that causes a specific blockage of testicular BC6ENTC biosynthesis as well as an inhibition of the BC6OTHER responsiveness to BC6ENTG .	False
The nonsteroidal antiandrogen BC6ENTC ( BC6OTHER ) weakly interacts with the prostatic cytosolic BC6ENTG and shows a fast dissociation rate.	False
The nonsteroidal antiandrogen BC6OTHER ( BC6ENTC ) weakly interacts with the prostatic cytosolic BC6ENTG and shows a fast dissociation rate.	False
This is due to the property of the pure antiandrogen to neutralize the inhibitory feedback effect of BC6ENTC at the pituitary level on the BC6ENTG responsiveness to BC6OTHER , as illustrated in vitro in rat anterior pituitary cells in culture as well as in vivo in intact and castrated animals.	False
This is due to the property of the pure antiandrogen to neutralize the inhibitory feedback effect of BC6ENTC at the pituitary level on the BC6OTHER responsiveness to BC6ENTG , as illustrated in vitro in rat anterior pituitary cells in culture as well as in vivo in intact and castrated animals.	False
In intact animals , neutralization of the inhibitory feedback action of endogenous BC6ENTC leads to an increased BC6ENTG and BC6OTHER secretion , which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles.	False
In intact animals , neutralization of the inhibitory feedback action of endogenous BC6OTHER leads to an increased BC6ENTG and BC6ENTC secretion , which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles.	False
The active compounds reduced both serum BC6ENTG and mucosal BC6ENTC levels.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6ENTG BC6OTHER ( BC6OTHER ) , in addition to reduction of colonic BC6ENTC ( BC6OTHER ) contents.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6OTHER BC6ENTG ( BC6OTHER ) , in addition to reduction of colonic BC6ENTC ( BC6OTHER ) contents.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6OTHER BC6OTHER ( BC6ENTG ) , in addition to reduction of colonic BC6ENTC ( BC6OTHER ) contents.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6ENTG BC6OTHER ( BC6OTHER ) , in addition to reduction of colonic BC6OTHER ( BC6ENTC ) contents.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6OTHER BC6ENTG ( BC6OTHER ) , in addition to reduction of colonic BC6OTHER ( BC6ENTC ) contents.	False
The anti - UC activity of these compounds may be explained by reducing the pro - inflammatory BC6OTHER BC6OTHER ( BC6ENTG ) , in addition to reduction of colonic BC6OTHER ( BC6ENTC ) contents.	False
The BC6ENTC channel gene BC6ENTG is mutated in the heritable long QT (LQT) syndrome.	False
Functional consequences of the arrhythmogenic BC6ENTG BC6OTHER BC6ENTC channel mutant probed by viral gene transfer in cardiomyocytes.	False
Functional consequences of the arrhythmogenic BC6OTHER BC6ENTG BC6ENTC channel mutant probed by viral gene transfer in cardiomyocytes.	False
The effects of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6OTHER storage , BC6OTHER .	False
The effects of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6OTHER storage , BC6ENTG .	False
The effects of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6OTHER storage , BC6OTHER .	False
The effects of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6OTHER storage , BC6ENTG .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6OTHER storage , BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6OTHER storage , BC6ENTG .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6OTHER storage , BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6OTHER storage , BC6ENTG .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6ENTC in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6OTHER storage , BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6ENTC in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6OTHER storage , BC6ENTG .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6ENTG or the vesicular transporter for BC6ENTC storage , BC6OTHER .	False
The effects of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , for example , depend on the ability to increase BC6OTHER in the synapse , by effects on either the plasma membrane transporter BC6OTHER or the vesicular transporter for BC6ENTC storage , BC6ENTG .	False
The potential role of BC6ENTG as a target for BC6ENTC and BC6OTHER has been reviewed extensively.	False
The potential role of BC6ENTG as a target for BC6OTHER and BC6ENTC has been reviewed extensively.	False
The presence of BC6ENTG in noradrenergic , serotoninergic , histaminergic , and potentially trace aminergic neurons invites consideration of a wider role for aminergic neurotransmission in BC6ENTC and BC6OTHER abuse and addiction.	False
The presence of BC6ENTG in noradrenergic , serotoninergic , histaminergic , and potentially trace aminergic neurons invites consideration of a wider role for aminergic neurotransmission in BC6OTHER and BC6ENTC abuse and addiction.	False
Analysis of defined heparin fragment pools shows a size dependence for interaction , with BC6ENTC showing easily detectable binding to BC6ENTG affinity columns.	False
BC6ENTG binding fragments include more heavily sulfated and epimerized regions and , as with the endothelial HS chains , they are enriched in BC6ENTC groups.	False
The BC6OTHER are BC6ENTC - dependent BC6ENTG that bind certain sialylated , fucosylated , sulfated glycoprotein ligands.	False
The BC6ENTG are BC6ENTC - dependent BC6OTHER that bind certain sialylated , fucosylated , sulfated glycoprotein ligands.	False
BC6ENTG also recognizes endothelial proteoglycans in a BC6ENTC - dependent manner , via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted BC6OTHER units.	False
BC6ENTG also recognizes endothelial proteoglycans in a BC6OTHER - dependent manner , via heparan sulfate (HS) glycosaminoglycan chains enriched in unsubstituted BC6ENTC units.	False
Despite this , HS chains bound to BC6ENTG are eluted by BC6ENTC ( BC6OTHER ) , but only at high concentrations.	False
Despite this , HS chains bound to BC6ENTG are eluted by BC6OTHER ( BC6ENTC ) , but only at high concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6ENTG , BC6ENTC - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6ENTC - dependent binding of a subfraction to BC6ENTG and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6ENTC - dependent binding of a subfraction to BC6OTHER and to BC6ENTG , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6ENTC - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6ENTG , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6ENTG , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6ENTC - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6ENTG and to BC6OTHER , and BC6ENTC - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6ENTG , and BC6ENTC - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6ENTC - independent binding of a larger fraction to BC6ENTG , the latter being disrupted by high BC6OTHER concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6ENTG , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6ENTC concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6ENTG and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6ENTC concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6ENTG , and BC6OTHER - independent binding of a larger fraction to BC6OTHER , the latter being disrupted by high BC6ENTC concentrations.	False
Porcine intestinal mucosal (mast cell - derived) heparin (PIM - heparin) shows similar properties , with no binding to BC6OTHER , BC6OTHER - dependent binding of a subfraction to BC6OTHER and to BC6OTHER , and BC6OTHER - independent binding of a larger fraction to BC6ENTG , the latter being disrupted by high BC6ENTC concentrations.	False
BC6ENTC , an antihypertensive drug , binds to BC6ENTG .	False
The endogenous ligand for BC6ENTG may be a BC6ENTC - displacing substance , a small molecule isolated from bovine brain.	False
BC6ENTC binds to BC6ENTG and stimulates release of BC6OTHER from adrenal chromaffin cells.	False
BC6OTHER binds to BC6ENTG and stimulates release of BC6ENTC from adrenal chromaffin cells.	False
BC6ENTC , locally synthesized , is an endogenous agonist at BC6ENTG , a BC6OTHER ligand at BC6OTHER and may act as a neurotransmitter.	CPR:5
BC6ENTC , locally synthesized , is an endogenous agonist at BC6OTHER , a BC6OTHER ligand at BC6ENTG and may act as a neurotransmitter.	False
BC6OTHER , locally synthesized , is an endogenous agonist at BC6ENTC receptors , a BC6OTHER ligand at BC6ENTG and may act as a neurotransmitter.	False
BC6OTHER , locally synthesized , is an endogenous agonist at BC6ENTG , a BC6ENTC ligand at BC6OTHER and may act as a neurotransmitter.	False
BC6OTHER , locally synthesized , is an endogenous agonist at BC6OTHER , a BC6ENTC ligand at BC6ENTG and may act as a neurotransmitter.	False
The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic BC6ENTG subfamily - mediated metabolism (21.9% decrease) of BC6ENTC .	CPR:9
BC6ENTC is mainly excreted into the bile via BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in hepatobiliary route and metabolized via BC6OTHER subfamily.	CPR:9
BC6ENTC is mainly excreted into the bile via BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in hepatobiliary route and metabolized via BC6OTHER subfamily.	CPR:9
BC6ENTC is mainly excreted into the bile via BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in hepatobiliary route and metabolized via BC6OTHER subfamily.	CPR:9
BC6ENTC is mainly excreted into the bile via BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in hepatobiliary route and metabolized via BC6OTHER subfamily.	CPR:9
BC6ENTC is mainly excreted into the bile via BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in hepatobiliary route and metabolized via BC6ENTG subfamily.	CPR:9
BC6ENTC acts at vascular BC6ENTG (postsynaptically) and at presynaptic BC6OTHER , where it inhibits sympathetically stimulated BC6OTHER release.	False
BC6ENTC acts at vascular BC6OTHER (postsynaptically) and at presynaptic BC6ENTG , where it inhibits sympathetically stimulated BC6OTHER release.	False
BC6OTHER acts at vascular BC6ENTG (postsynaptically) and at presynaptic BC6OTHER , where it inhibits sympathetically stimulated BC6ENTC release.	False
BC6OTHER acts at vascular BC6OTHER (postsynaptically) and at presynaptic BC6ENTG , where it inhibits sympathetically stimulated BC6ENTC release.	False
In clinical trials , BC6ENTC has been demonstrated to be at least as effective in reducing blood pressure as the BC6ENTG inhibitor BC6OTHER , and has significantly lower side effects.	False
In clinical trials , BC6OTHER has been demonstrated to be at least as effective in reducing blood pressure as the BC6ENTG inhibitor BC6ENTC , and has significantly lower side effects.	CPR:4
BC6ENTC ( BC6OTHER ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6ENTG , and reduce the pressor effects of BC6OTHER in the vasculature.	False
BC6ENTC ( BC6OTHER ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6OTHER , and reduce the pressor effects of BC6ENTG in the vasculature.	False
CHEM ( BC6ENTC ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6ENTG , and reduce the pressor effects of BC6OTHER in the vasculature.	False
CHEM ( BC6ENTC ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6OTHER , and reduce the pressor effects of BC6ENTG in the vasculature.	False
BC6ENTG antagonists are a relatively new class of antihypertensive agent that block BC6ENTC Type 1 (AT(1)) receptors , and reduce the pressor effects of BC6OTHER in the vasculature.	False
CHEM ( BC6OTHER ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6ENTC Type 1 (AT(1)) receptors , and reduce the pressor effects of BC6ENTG in the vasculature.	False
BC6ENTG antagonists are a relatively new class of antihypertensive agent that block BC6OTHER , and reduce the pressor effects of BC6ENTC in the vasculature.	False
CHEM ( BC6OTHER ) receptor antagonists are a relatively new class of antihypertensive agent that block BC6ENTG , and reduce the pressor effects of BC6ENTC in the vasculature.	False
By this mechanism , they induce similar pharmacological effects compared with BC6ENTC - converting enzyme ( BC6ENTG ) inhibitors , resulting in a lowering of blood pressure.	False
However , BC6ENTC receptor blockers differ from BC6ENTG inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6OTHER or other mediators such as s BC6OTHER .	False
However , BC6ENTC receptor blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6ENTG or other mediators such as s BC6OTHER .	False
However , BC6ENTC receptor blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6OTHER or other mediators such as s BC6ENTG .	False
However , BC6ENTG blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6ENTC or other mediators such as s BC6OTHER .	False
However , BC6OTHER blockers differ from BC6ENTG inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6ENTC or other mediators such as s BC6OTHER .	False
However , BC6OTHER blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6ENTC or other mediators such as s BC6ENTG .	False
However , BC6ENTG blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6OTHER or other mediators such as BC6ENTC .	False
However , BC6OTHER blockers differ from BC6ENTG inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6OTHER or other mediators such as BC6ENTC .	False
However , BC6OTHER blockers differ from BC6OTHER inhibitors with respect to side effects , and induce less cough , a side effect which may be related to BC6ENTG or other mediators such as BC6ENTC .	False
Within the class of BC6ENTG blockers , BC6ENTC differs from other currently available agents in terms of chemical structure , as it is a non - BC6OTHER , non - BC6OTHER , non - peptide antagonist with a dual pharmacological mode of action.	CPR:4
Within the class of BC6ENTG blockers , BC6OTHER differs from other currently available agents in terms of chemical structure , as it is a non - BC6ENTC , non - BC6OTHER , non - peptide antagonist with a dual pharmacological mode of action.	False
Within the class of BC6ENTG blockers , BC6OTHER differs from other currently available agents in terms of chemical structure , as it is a non - BC6OTHER , non - BC6ENTC , non - peptide antagonist with a dual pharmacological mode of action.	False
Antibodies to either the BC6ENTC - or BC6OTHER - terminus of BC6ENTG detected two proteins (73 and 55 kD) in transfected COS - 1 cells.	False
Antibodies to either the BC6OTHER - or BC6ENTC - terminus of BC6ENTG detected two proteins (73 and 55 kD) in transfected COS - 1 cells.	False
The BC6ENTC - terminal antibodies detected both proteins in extracts of mouse medulla / pons , cortex , hypothalamus , and cerebellum but only the 73 kD protein and higher molecular weight immunoreactive proteins in mouse adrenal and rat PC12 cells , which are positive controls for BC6ENTG .	False
OBJECTIVE: Vesicular BC6ENTC transporter 1 ( BC6OTHER ) mRNA and protein were examined (1) to determine whether adult mouse brain expresses full - length BC6ENTG mRNA that can be translated to functional transporter protein and (2) to compare immunoreactive BC6OTHER proteins in brain and adrenal.	False
OBJECTIVE: Vesicular BC6ENTC transporter 1 ( BC6OTHER ) mRNA and protein were examined (1) to determine whether adult mouse brain expresses full - length BC6OTHER mRNA that can be translated to functional transporter protein and (2) to compare immunoreactive BC6ENTG proteins in brain and adrenal.	False
OBJECTIVE: Vesicular BC6ENTC transporter 1 ( BC6ENTG ) mRNA and protein were examined (1) to determine whether adult mouse brain expresses full - length BC6OTHER mRNA that can be translated to functional transporter protein and (2) to compare immunoreactive BC6OTHER proteins in brain and adrenal.	False
Transfection of the brain cDNA into COS - 1 cells resulted in transporter activity that was blocked by the BC6ENTG inhibitor BC6ENTC and a proton ionophore , but not by BC6OTHER , which has a high affinity for BC6OTHER .	CPR:4
Transfection of the brain cDNA into COS - 1 cells resulted in transporter activity that was blocked by the BC6OTHER inhibitor BC6ENTC and a proton ionophore , but not by BC6OTHER , which has a high affinity for BC6ENTG .	False
Transfection of the brain cDNA into COS - 1 cells resulted in transporter activity that was blocked by the BC6ENTG inhibitor BC6OTHER and a proton ionophore , but not by BC6ENTC , which has a high affinity for BC6OTHER .	False
Transfection of the brain cDNA into COS - 1 cells resulted in transporter activity that was blocked by the BC6OTHER inhibitor BC6OTHER and a proton ionophore , but not by BC6ENTC , which has a high affinity for BC6ENTG .	False
Vesicular BC6ENTC transporter - 1 ( BC6ENTG ) mRNA and immunoreactive proteins in mouse brain.	False
These results suggest that BC6OTHER inhibited the activity of BC6OTHER by a mechanism different from that of BC6ENTC and did not directly interact with the active site of BC6ENTG .	False
These results suggest that BC6OTHER inhibited the activity of BC6ENTG by a mechanism different from that of BC6ENTC and did not directly interact with the active site of BC6OTHER .	CPR:4
The BC6ENTG ( BC6OTHER ) is the target molecule of action of some psychostimulants , such as BC6ENTC and BC6OTHER ( BC6OTHER ).	False
The neuronal vesicular BC6OTHER transporter ( BC6ENTG ) is the target molecule of action of some psychostimulants , such as BC6ENTC and BC6OTHER ( BC6OTHER ).	False
The BC6ENTG ( BC6OTHER ) is the target molecule of action of some psychostimulants , such as BC6OTHER and BC6ENTC ( BC6OTHER ).	False
The neuronal vesicular BC6OTHER transporter ( BC6ENTG ) is the target molecule of action of some psychostimulants , such as BC6OTHER and BC6ENTC ( BC6OTHER ).	False
The BC6ENTG ( BC6OTHER ) is the target molecule of action of some psychostimulants , such as BC6OTHER and BC6OTHER ( BC6ENTC ).	False
The neuronal vesicular BC6OTHER transporter ( BC6ENTG ) is the target molecule of action of some psychostimulants , such as BC6OTHER and BC6OTHER ( BC6ENTC ).	False
The neuronal vesicular BC6ENTC transporter ( BC6ENTG ) is the target molecule of action of some psychostimulants , such as BC6OTHER and BC6OTHER ( BC6OTHER ).	False
The present study examined the effect of antidepressants , such as selective BC6ENTC reuptake inhibitors (SSRIs) , on BC6ENTG activity by measuring BC6OTHER - dependent BC6OTHER uptake into synaptic vesicles prepared from rat striatum.	False
The present study examined the effect of antidepressants , such as selective BC6OTHER reuptake inhibitors (SSRIs) , on BC6ENTG activity by measuring BC6ENTC - dependent BC6OTHER uptake into synaptic vesicles prepared from rat striatum.	False
The present study examined the effect of antidepressants , such as selective BC6OTHER reuptake inhibitors (SSRIs) , on BC6ENTG activity by measuring BC6OTHER - dependent BC6ENTC uptake into synaptic vesicles prepared from rat striatum.	CPR:9
Moreover , kinetic analysis revealed that inhibition by BC6ENTC , a typical BC6ENTG inhibitor , was uncompetitive , decreasing maximum velocity and affinity for BC6OTHER .	CPR:4
Moreover , kinetic analysis revealed that inhibition by BC6OTHER , a typical BC6ENTG inhibitor , was uncompetitive , decreasing maximum velocity and affinity for BC6ENTC .	CPR:9
These results suggest that BC6ENTC inhibited the activity of BC6OTHER by a mechanism different from that of BC6OTHER and did not directly interact with the active site of BC6ENTG .	CPR:4
These results suggest that BC6ENTC inhibited the activity of BC6ENTG by a mechanism different from that of BC6OTHER and did not directly interact with the active site of BC6OTHER .	CPR:4
Inhibitory effect of selective BC6ENTC reuptake inhibitors on the BC6ENTG .	False
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6ENTG ( BC6OTHER ) in rats using BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:3
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6ENTG ) in rats using BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:3
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6OTHER ) in rats using BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6ENTG , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6ENTG ( BC6OTHER ) in rats using BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:3
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6ENTG ) in rats using BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:3
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6OTHER ) in rats using BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) as an inducer and a substrate to BC6ENTG , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6ENTG ( BC6OTHER ) in rats using BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6ENTG ) in rats using BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6OTHER ) in rats using BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) as an inducer and a substrate to BC6ENTG , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6ENTG ( BC6OTHER ) in rats using BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) as an inducer and a substrate to BC6OTHER , respectively.	False
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6ENTG ) in rats using BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) as an inducer and a substrate to BC6OTHER , respectively.	CPR:9
We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal BC6OTHER ( BC6OTHER ) in rats using BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) as an inducer and a substrate to BC6ENTG , respectively.	CPR:9
The number of times BC6ENTC was administered was not a significant factor in the induction of either hepatic or intestinal BC6ENTG ; however , administration of BC6OTHER multiple times markedly decreased the bioavailability of BC6OTHER by self - induction of BC6OTHER .	False
The number of times BC6ENTC was administered was not a significant factor in the induction of either hepatic or intestinal BC6OTHER ; however , administration of BC6OTHER multiple times markedly decreased the bioavailability of BC6OTHER by self - induction of BC6ENTG .	False
The number of times BC6OTHER was administered was not a significant factor in the induction of either hepatic or intestinal BC6ENTG ; however , administration of BC6ENTC multiple times markedly decreased the bioavailability of BC6OTHER by self - induction of BC6OTHER .	False
The number of times BC6OTHER was administered was not a significant factor in the induction of either hepatic or intestinal BC6OTHER ; however , administration of BC6ENTC multiple times markedly decreased the bioavailability of BC6OTHER by self - induction of BC6ENTG .	False
The number of times BC6OTHER was administered was not a significant factor in the induction of either hepatic or intestinal BC6ENTG ; however , administration of BC6OTHER multiple times markedly decreased the bioavailability of BC6ENTC by self - induction of BC6OTHER .	False
The number of times BC6OTHER was administered was not a significant factor in the induction of either hepatic or intestinal BC6OTHER ; however , administration of BC6OTHER multiple times markedly decreased the bioavailability of BC6ENTC by self - induction of BC6ENTG .	False
BC6ENTG induction in the liver increased depending on the dose of BC6ENTC , whereas that in intestine showed a mild increase , but the induction level was almost constant regardless of the dose of BC6OTHER .	CPR:3
BC6ENTG induction in the liver increased depending on the dose of BC6OTHER , whereas that in intestine showed a mild increase , but the induction level was almost constant regardless of the dose of BC6ENTC .	CPR:3
Administration of a single dose of BC6ENTC showed a temporal increase in BC6ENTG activity in both tissues and the induction ratios reached maximum values at 12 h after BC6OTHER administration.	CPR:3
Administration of a single dose of BC6OTHER showed a temporal increase in BC6ENTG activity in both tissues and the induction ratios reached maximum values at 12 h after BC6ENTC administration.	CPR:3
Time - dependent changes in hepatic and intestinal induction of BC6ENTG after administration of BC6ENTC to rats.	CPR:3
Recent studies have provided consistent evidence that treatment with CHEM results in a rapid onset of efficacy that is maintained over the course of treatment in patients with inadequate response to BC6ENTC and anti - BC6ENTG therapies.	False
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6ENTG inhibitor , BC6ENTC .	CPR:4
It was also antagonized by the non - specific BC6ENTG ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6ENTC .	False
It was also antagonized by the non - specific BC6OTHER ( BC6ENTG ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6ENTC .	False
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6ENTG inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6ENTC .	False
Both the non - specific BC6ENTG inhibitor , BC6ENTC , and an inhibitor of BC6OTHER and BC6OTHER , AACOF3 , counteracted the effect; in contrast , a selective BC6OTHER inhibitor , BEL , and a selective BC6OTHER inhibitor , TAPC , were ineffective.	CPR:4
Both the non - specific BC6OTHER inhibitor , BC6ENTC , and an inhibitor of BC6ENTG and BC6OTHER , AACOF3 , counteracted the effect; in contrast , a selective BC6OTHER inhibitor , BEL , and a selective BC6OTHER inhibitor , TAPC , were ineffective.	False
Both the non - specific BC6OTHER inhibitor , BC6ENTC , and an inhibitor of BC6OTHER and BC6ENTG , AACOF3 , counteracted the effect; in contrast , a selective BC6OTHER inhibitor , BEL , and a selective BC6OTHER inhibitor , TAPC , were ineffective.	False
Both the non - specific BC6OTHER inhibitor , BC6ENTC , and an inhibitor of BC6OTHER and BC6OTHER , AACOF3 , counteracted the effect; in contrast , a selective BC6ENTG inhibitor , BEL , and a selective BC6OTHER inhibitor , TAPC , were ineffective.	False
Both the non - specific BC6OTHER inhibitor , BC6ENTC , and an inhibitor of BC6OTHER and BC6OTHER , AACOF3 , counteracted the effect; in contrast , a selective BC6OTHER inhibitor , BEL , and a selective BC6ENTG inhibitor , TAPC , were ineffective.	False
We have earlier demonstrated that CHEM stimulates the liberation of the BC6OTHER ( BC6OTHER ) precursor , BC6ENTC , in Chinese hamster ovary cells transfected with the BC6ENTG , also without concomitant administration of a BC6OTHER - releasing agent [Nilsson et al. , CHEM J CHEM;124:1651 - 8].	False
The results reinforce previous assumptions that BC6ENTC may interact with BC6OTHER metabolism by means of BC6ENTG activation , and implicate an involvement of BC6OTHER and BC6OTHER in this effect.	CPR:3
The results reinforce previous assumptions that BC6ENTC may interact with BC6OTHER metabolism by means of BC6OTHER activation , and implicate an involvement of BC6ENTG and BC6OTHER in this effect.	False
The results reinforce previous assumptions that BC6ENTC may interact with BC6OTHER metabolism by means of BC6OTHER activation , and implicate an involvement of BC6OTHER and BC6ENTG in this effect.	False
The results reinforce previous assumptions that BC6OTHER may interact with BC6ENTC metabolism by means of BC6ENTG activation , and implicate an involvement of BC6OTHER and BC6OTHER in this effect.	False
The results reinforce previous assumptions that BC6OTHER may interact with BC6ENTC metabolism by means of BC6OTHER activation , and implicate an involvement of BC6ENTG and BC6OTHER in this effect.	False
The results reinforce previous assumptions that BC6OTHER may interact with BC6ENTC metabolism by means of BC6OTHER activation , and implicate an involvement of BC6OTHER and BC6ENTG in this effect.	False
It is suggested that measurement of BC6ENTC - induced CHEM production may serve as a convenient way to study BC6ENTG function in vitro.	False
We have earlier demonstrated that CHEM stimulates the liberation of the BC6OTHER ( BC6OTHER ) precursor , BC6OTHER , in Chinese hamster ovary cells transfected with the BC6ENTG , also without concomitant administration of a BC6ENTC - releasing agent [Nilsson et al. , CHEM J CHEM;124:1651 - 8].	False
The effect was counteracted by the BC6ENTG antagonist BC6ENTC , BC6OTHER , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	CPR:6
The effect was counteracted by the BC6OTHER antagonist BC6ENTC , BC6ENTG , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6OTHER antagonist BC6ENTC , BC6OTHER , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6ENTG desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6ENTG antagonist BC6OTHER , BC6OTHER , the inhibitor of intracellular BC6ENTC release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6OTHER antagonist BC6OTHER , BC6ENTG , the inhibitor of intracellular BC6ENTC release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6OTHER antagonist BC6OTHER , BC6OTHER , the inhibitor of intracellular BC6ENTC release CHEM - 8 , incubation in BC6OTHER - free experimental medium , and BC6ENTG desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6ENTG antagonist BC6OTHER , BC6OTHER , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6ENTC - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6OTHER antagonist BC6OTHER , BC6ENTG , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6ENTC - free experimental medium , and BC6OTHER desensitization obtained by chronic pretreatment with the CHEM.	False
The effect was counteracted by the BC6OTHER antagonist BC6OTHER , BC6OTHER , the inhibitor of intracellular BC6OTHER release CHEM - 8 , incubation in BC6ENTC - free experimental medium , and BC6ENTG desensitization obtained by chronic pretreatment with the CHEM.	False
We have earlier demonstrated that CHEM stimulates the liberation of the BC6ENTC ( BC6OTHER ) precursor , BC6OTHER , in Chinese hamster ovary cells transfected with the BC6ENTG , also without concomitant administration of a BC6OTHER - releasing agent [Nilsson et al. , CHEM J CHEM;124:1651 - 8].	False
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6ENTC , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6ENTG inhibitor , BC6OTHER .	False
It was also antagonized by the non - specific BC6ENTG ( BC6OTHER ) inhibitor , BC6ENTC , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6OTHER .	CPR:4
It was also antagonized by the non - specific BC6OTHER ( BC6ENTG ) inhibitor , BC6ENTC , and by the selective BC6OTHER inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6OTHER .	CPR:4
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6ENTC , and by the selective BC6ENTG inhibitor , BC6OTHER , but not by the specific BC6OTHER inhibitor , BC6OTHER .	False
We have earlier demonstrated that CHEM stimulates the liberation of the BC6OTHER ( BC6ENTC ) precursor , BC6OTHER , in Chinese hamster ovary cells transfected with the BC6ENTG , also without concomitant administration of a BC6OTHER - releasing agent [Nilsson et al. , CHEM J CHEM;124:1651 - 8].	False
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6ENTC , but not by the specific BC6ENTG inhibitor , BC6OTHER .	False
It was also antagonized by the non - specific BC6ENTG ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6ENTC , but not by the specific BC6OTHER inhibitor , BC6OTHER .	False
It was also antagonized by the non - specific BC6OTHER ( BC6ENTG ) inhibitor , BC6OTHER , and by the selective BC6OTHER inhibitor , BC6ENTC , but not by the specific BC6OTHER inhibitor , BC6OTHER .	False
It was also antagonized by the non - specific BC6OTHER ( BC6OTHER ) inhibitor , BC6OTHER , and by the selective BC6ENTG inhibitor , BC6ENTC , but not by the specific BC6OTHER inhibitor , BC6OTHER .	CPR:4
 BC6ENTC D(2) receptor - induced BC6ENTG - mediated production of BC6OTHER in BC6OTHER - transfected Chinese hamster ovary cells without simultaneous administration of a BC6OTHER - mobilizing agent.	False
 BC6ENTC D(2) receptor - induced BC6OTHER - mediated production of BC6OTHER in BC6ENTG - transfected Chinese hamster ovary cells without simultaneous administration of a BC6OTHER - mobilizing agent.	False
 BC6ENTG - induced BC6OTHER - mediated production of BC6OTHER in BC6OTHER - transfected Chinese hamster ovary cells without simultaneous administration of a BC6ENTC - mobilizing agent.	False
 BC6OTHER - induced BC6ENTG - mediated production of BC6OTHER in BC6OTHER - transfected Chinese hamster ovary cells without simultaneous administration of a BC6ENTC - mobilizing agent.	False
 BC6OTHER - induced BC6OTHER - mediated production of BC6OTHER in BC6ENTG - transfected Chinese hamster ovary cells without simultaneous administration of a BC6ENTC - mobilizing agent.	False
 BC6ENTG - induced BC6OTHER - mediated production of BC6ENTC in BC6OTHER - transfected Chinese hamster ovary cells without simultaneous administration of a BC6OTHER - mobilizing agent.	False
 BC6OTHER - induced BC6ENTG - mediated production of BC6ENTC in BC6OTHER - transfected Chinese hamster ovary cells without simultaneous administration of a BC6OTHER - mobilizing agent.	CPR:9
 BC6OTHER - induced BC6OTHER - mediated production of BC6ENTC in BC6ENTG - transfected Chinese hamster ovary cells without simultaneous administration of a BC6OTHER - mobilizing agent.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of BC6ENTC - BC6OTHER - demethylase and BC6ENTG activity and BC6OTHER , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of BC6ENTC - BC6OTHER - demethylase and BC6OTHER activity and BC6ENTG , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6ENTC - demethylase and BC6ENTG activity and BC6OTHER , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6ENTC - demethylase and BC6OTHER activity and BC6ENTG , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of BC6ENTG and BC6ENTC 4 - hydroxylase activity and BC6OTHER , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6ENTC 4 - hydroxylase activity and BC6ENTG , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of BC6ENTG and BC6OTHER activity and BC6OTHER , compared to the BC6ENTC only group.	CPR:3
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6ENTG activity and BC6OTHER , compared to the BC6ENTC only group.	CPR:3
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6OTHER activity and BC6ENTG , compared to the BC6ENTC only group.	CPR:3
A significant decrease of BC6ENTC aminotransferase , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTC aminotransferase , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTC aminotransferase , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6ENTC aminotransferase , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTC aminotransferase , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTC aminotransferase , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6ENTC dehydrogenase ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTG , BC6ENTC dehydrogenase ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) activities and BC6ENTC ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6ENTC ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6ENTC ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6ENTC ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6ENTC ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6ENTC ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6ENTC ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6ENTC ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6ENTC ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6ENTC ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6ENTC ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6ENTC ( BC6OTHER ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6ENTC ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6ENTC ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6ENTC ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6ENTC ) quantity was observed after BC6OTHER and PC administration alone.	False
A significant decrease of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6ENTC and PC administration alone.	CPR:4
A significant decrease of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6ENTC and PC administration alone.	CPR:4
A significant decrease of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6ENTC and PC administration alone.	CPR:4
A significant decrease of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) activities and BC6OTHER ( BC6OTHER ) levels and an increase of BC6OTHER ( BC6OTHER ) quantity was observed after BC6ENTC and PC administration alone.	CPR:4
PSM pre - treatment decreased BC6ENTG and BC6OTHER activities and BC6ENTC levels and increased the levels of cell protector BC6OTHER .	False
PSM pre - treatment decreased BC6OTHER and BC6ENTG activities and BC6ENTC levels and increased the levels of cell protector BC6OTHER .	False
PSM pre - treatment decreased BC6ENTG and BC6OTHER activities and BC6OTHER levels and increased the levels of cell protector BC6ENTC .	False
PSM pre - treatment decreased BC6OTHER and BC6ENTG activities and BC6OTHER levels and increased the levels of cell protector BC6ENTC .	False
In the BC6ENTC hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of BC6ENTG and BC6OTHER activity and BC6OTHER , compared to the BC6OTHER only group.	False
In the BC6ENTC hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6ENTG activity and BC6OTHER , compared to the BC6OTHER only group.	False
In the BC6ENTC hepatotoxicity model , pre - treatment with PSM or BC6OTHER resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6OTHER activity and BC6ENTG , compared to the BC6OTHER only group.	False
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6ENTC resulted in significantly increased activities of BC6ENTG and BC6OTHER activity and BC6OTHER , compared to the BC6OTHER only group.	CPR:3
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6ENTC resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6ENTG activity and BC6OTHER , compared to the BC6OTHER only group.	CPR:3
In the BC6OTHER hepatotoxicity model , pre - treatment with PSM or BC6ENTC resulted in significantly increased activities of CHEM - BC6OTHER - demethylase and BC6OTHER activity and BC6ENTG , compared to the BC6OTHER only group.	CPR:3
In a recent study using protein - specific anti - CHEM BC6OTHER antibodies and immunological methods , we demonstrated the ability of BC6ENTC to acetylate the BC6ENTG .	CPR:3
Although the inhibition of BC6ENTG by BC6ENTC , which leads to its anti - inflammatory / analgesic properties , has been well studied , the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill - defined.	CPR:4
Studies over the past decades suggest that , besides BC6ENTG , BC6ENTC acetylates other cellular proteins.	False
In a recent study using protein - specific anti - CHEM BC6ENTC antibodies and immunological methods , we demonstrated the ability of BC6OTHER to acetylate the BC6ENTG .	False
Taken together , this study demonstrated for the first time that BC6ENTG antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6OTHER ( - / - ) mice and lowered serum BC6ENTC and BC6OTHER levels in nondiabetic BC6OTHER ( - / - ) mice.	False
Taken together , this study demonstrated for the first time that BC6OTHER antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6ENTG ( - / - ) mice and lowered serum BC6ENTC and BC6OTHER levels in nondiabetic BC6OTHER ( - / - ) mice.	False
Taken together , this study demonstrated for the first time that BC6OTHER antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6OTHER ( - / - ) mice and lowered serum BC6ENTC and BC6OTHER levels in nondiabetic BC6ENTG ( - / - ) mice.	False
Taken together , this study demonstrated for the first time that BC6ENTG antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6OTHER ( - / - ) mice and lowered serum BC6OTHER and BC6ENTC levels in nondiabetic BC6OTHER ( - / - ) mice.	False
Taken together , this study demonstrated for the first time that BC6OTHER antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6ENTG ( - / - ) mice and lowered serum BC6OTHER and BC6ENTC levels in nondiabetic BC6OTHER ( - / - ) mice.	False
Taken together , this study demonstrated for the first time that BC6OTHER antagonist inhibited vascular inflammation and atherogenesis in diabetic BC6OTHER ( - / - ) mice and lowered serum BC6OTHER and BC6ENTC levels in nondiabetic BC6ENTG ( - / - ) mice.	False
In this study , we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs - LPS) , an established BC6ENTG antagonist , on early - stage atherosclerosis in nondiabetic and BC6ENTC - induced diabetic BC6OTHER - deficient ( BC6OTHER ( - / - )) mice.	False
In this study , we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs - LPS) , an established BC6OTHER antagonist , on early - stage atherosclerosis in nondiabetic and BC6ENTC - induced diabetic BC6ENTG - deficient ( BC6OTHER ( - / - )) mice.	False
In this study , we determined the effect of Rhodobacter sphaeroides lipopolysaccharide (Rs - LPS) , an established BC6OTHER antagonist , on early - stage atherosclerosis in nondiabetic and BC6ENTC - induced diabetic BC6OTHER - deficient ( BC6ENTG ( - / - )) mice.	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6ENTC - induced BC6OTHER influx by BC6OTHER imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6ENTG and BC6OTHER .	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6ENTC - induced BC6OTHER influx by BC6OTHER imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6OTHER and BC6ENTG .	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6OTHER - induced BC6ENTC influx by BC6OTHER imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6ENTG and BC6OTHER .	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6OTHER - induced BC6ENTC influx by BC6OTHER imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6OTHER and BC6ENTG .	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6OTHER - induced BC6OTHER influx by BC6ENTC imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6ENTG and BC6OTHER .	False
The previously developed probe was found to display the greatest activity in the inhibition of BC6OTHER - induced BC6OTHER influx by BC6ENTC imaging experiments on HEK293 cells transfected with the cDNA encoding for BC6OTHER and BC6ENTG .	False
BC6ENTG - containing BC6ENTC receptors are involved in many important physiological functions and play a pivotal role in mediating pain as well as in several neurodegenerative disorders.	False
BC6ENTC , known as the BC6ENTG antagonist of reference , was chosen as the template for the elaboration of probes.	CPR:6
We had previously reported a BC6ENTC conjugate that was shown (by confocal microscopy imaging of DS - red - labelled cortical neurons) to bind specifically to BC6ENTG .	False
Synthesis and in Vitro Characterisation of BC6ENTC - Based BC6OTHER Conjugates as BC6ENTG / BC6OTHER BC6OTHER Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6ENTC - Based BC6OTHER Conjugates as BC6OTHER / BC6ENTG BC6OTHER Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6ENTC - Based BC6OTHER Conjugates as BC6OTHER / BC6OTHER BC6ENTG Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6OTHER - Based BC6ENTC Conjugates as BC6ENTG / BC6OTHER BC6OTHER Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6OTHER - Based BC6ENTC Conjugates as BC6OTHER / BC6ENTG BC6OTHER Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6OTHER - Based BC6ENTC Conjugates as BC6OTHER / BC6OTHER BC6ENTG Antagonists.	CPR:6
Synthesis and in Vitro Characterisation of BC6OTHER - Based BC6OTHER Conjugates as BC6ENTG / BC6OTHER BC6ENTC Receptor Antagonists.	False
Synthesis and in Vitro Characterisation of BC6OTHER - Based BC6OTHER Conjugates as BC6OTHER / BC6ENTG BC6ENTC Receptor Antagonists.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6ENTG ( BC6OTHER ) activity , BC6OTHER ( BC6OTHER ) , total BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6ENTG ) activity , BC6OTHER ( BC6OTHER ) , total BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6ENTG ( BC6OTHER ) , total BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6OTHER ( BC6ENTG ) , total BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6OTHER ( BC6OTHER ) , total BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6OTHER ( BC6OTHER ) , total BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6OTHER ( BC6OTHER ) , total BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) were estimated.	False
Levels of brain BC6ENTC (Ach) , serum and brain BC6OTHER ( BC6OTHER ) activity , BC6OTHER ( BC6OTHER ) , total BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) were estimated.	False
The results showed that administration of BC6ENTC resulted in a significant elevation in the levels of BC6ENTG activity , BC6OTHER , BC6OTHER , and BC6OTHER accompanied with a significant depletion in the Ach level.	CPR:3
The results showed that administration of BC6ENTC resulted in a significant elevation in the levels of BC6OTHER activity , BC6ENTG , BC6OTHER , and BC6OTHER accompanied with a significant depletion in the Ach level.	CPR:3
The results showed that administration of BC6ENTC resulted in a significant elevation in the levels of BC6OTHER activity , BC6OTHER , BC6ENTG , and BC6OTHER accompanied with a significant depletion in the Ach level.	CPR:3
The results showed that administration of BC6ENTC resulted in a significant elevation in the levels of BC6OTHER activity , BC6OTHER , BC6OTHER , and BC6ENTG accompanied with a significant depletion in the Ach level.	CPR:3
Several inhibitors of BC6ENTG have been described , including BC6ENTC , which is currently in phase 3 clinical development for the treatment of atherosclerosis.	CPR:4
The selectivity that BC6ENTC and other BC6ENTG inhibitors display across the larger BC6OTHER family has not , however , been reported.	False
The selectivity that BC6ENTC and other BC6OTHER inhibitors display across the larger BC6ENTG family has not , however , been reported.	False
The selectivity that BC6OTHER and other BC6ENTG inhibitors display across the larger BC6ENTC hydrolase family has not , however , been reported.	False
We show that both BC6ENTC and a novel class of structurally distinct BC6OTHER inhibitors inactivate BC6ENTG in mouse tissues and human cell lines with high selectivity.	CPR:4
We show that both BC6OTHER and a novel class of structurally distinct BC6ENTC inhibitors inactivate BC6ENTG in mouse tissues and human cell lines with high selectivity.	CPR:4
Inhibition of BC6ENTG with BC6ENTC induces apoptosis but fails to activate BC6OTHER phosphorylation or down - regulate BC6OTHER protein expression.	False
Inhibition of BC6OTHER with BC6ENTC induces apoptosis but fails to activate BC6ENTG phosphorylation or down - regulate BC6OTHER protein expression.	False
Inhibition of BC6OTHER with BC6ENTC induces apoptosis but fails to activate BC6OTHER phosphorylation or down - regulate BC6ENTG protein expression.	False
Cotreatment with BC6ENTC and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6ENTG , BC6OTHER , and BC6OTHER .	False
Cotreatment with BC6ENTC and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:3
Cotreatment with BC6ENTC and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Cotreatment with BC6OTHER and BC6ENTC synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6ENTG , BC6OTHER , and BC6OTHER .	False
Cotreatment with BC6OTHER and BC6ENTC synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:3
Cotreatment with BC6OTHER and BC6ENTC synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6OTHER treatment on BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Cotreatment with BC6OTHER and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6ENTC treatment on BC6ENTG , BC6OTHER , and BC6OTHER .	False
Cotreatment with BC6OTHER and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6ENTC treatment on BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:3
Cotreatment with BC6OTHER and BC6OTHER synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of BC6ENTC treatment on BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
These results indicate that BC6ENTC metabolites modulate BC6ENTG and BC6OTHER pathways independently in colon cancer cells and suggest that the full apoptotic effect of BC6OTHER is mediated by more than one pathway.	False
These results indicate that BC6ENTC metabolites modulate BC6OTHER and BC6ENTG pathways independently in colon cancer cells and suggest that the full apoptotic effect of BC6OTHER is mediated by more than one pathway.	False
These results indicate that BC6OTHER metabolites modulate BC6ENTG and BC6OTHER pathways independently in colon cancer cells and suggest that the full apoptotic effect of BC6ENTC is mediated by more than one pathway.	False
These results indicate that BC6OTHER metabolites modulate BC6OTHER and BC6ENTG pathways independently in colon cancer cells and suggest that the full apoptotic effect of BC6ENTC is mediated by more than one pathway.	False
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTG ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	CPR:3
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6ENTG ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	CPR:3
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate BC6ENTG ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	CPR:4
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6ENTG ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	CPR:4
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6ENTG ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6ENTG ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6ENTC metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6ENTG protein expression at times and doses consistent with apoptosis.	CPR:4
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6ENTG ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6ENTG ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate BC6ENTG ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6ENTG ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6ENTG ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6ENTG ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6ENTC and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6ENTG protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6ENTG ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6OTHER ); (b) activate BC6ENTG ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6ENTG ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6ENTG ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6ENTG ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTC - dependent protein kinase ( BC6OTHER ); (b) activate c - jun BC6OTHER - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6ENTG protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6ENTG ( BC6OTHER ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6ENTG ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6ENTG ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6OTHER ); (c) inhibit BC6ENTG ( BC6OTHER ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6ENTG ); and (d) decrease BC6OTHER protein expression at times and doses consistent with apoptosis.	False
BC6OTHER metabolites simultaneously (a) increase cellular BC6OTHER and subsequently activate BC6OTHER ( BC6OTHER ); (b) activate c - jun BC6ENTC - terminal kinase ( BC6OTHER ); (c) inhibit BC6OTHER ( BC6OTHER ); and (d) decrease BC6ENTG protein expression at times and doses consistent with apoptosis.	False
The purpose of this study was to determine if BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER are independent targets for BC6ENTC in vitro.	False
The purpose of this study was to determine if BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER are independent targets for BC6ENTC in vitro.	False
The purpose of this study was to determine if BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER are independent targets for BC6ENTC in vitro.	False
The purpose of this study was to determine if BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG are independent targets for BC6ENTC in vitro.	False
Pharmacologic activation of BC6OTHER with BC6ENTC increases BC6OTHER phosphorylation and induces apoptosis in colon cancer cells without modulating BC6ENTG phosphorylation or BC6OTHER protein expression.	False
Pharmacologic activation of BC6OTHER with BC6ENTC increases BC6OTHER phosphorylation and induces apoptosis in colon cancer cells without modulating BC6OTHER phosphorylation or BC6ENTG protein expression.	False
Pharmacologic activation of BC6ENTG with BC6ENTC increases BC6OTHER phosphorylation and induces apoptosis in colon cancer cells without modulating BC6OTHER phosphorylation or BC6OTHER protein expression.	False
Pharmacologic activation of BC6OTHER with BC6ENTC increases BC6ENTG phosphorylation and induces apoptosis in colon cancer cells without modulating BC6OTHER phosphorylation or BC6OTHER protein expression.	False
 BC6ENTC independently modulates BC6ENTG and BC6OTHER signaling pathways.	False
 BC6ENTC independently modulates BC6OTHER and BC6ENTG signaling pathways.	False
 BC6OTHER independently modulates BC6ENTG and BC6ENTC - dependent protein kinase signaling pathways.	False
BC6ENTC - associated protein ( BC6ENTG ) was found to be one of the major BC6OTHER in human serum and in liver , brain , and prostate tissues.	False
BC6ENTC - associated protein ( BC6OTHER ) was found to be one of the major BC6ENTG in human serum and in liver , brain , and prostate tissues.	False
BC6ENTG ( BC6OTHER ) was found to be one of the major BC6ENTC binding proteins in human serum and in liver , brain , and prostate tissues.	False
BC6OTHER ( BC6ENTG ) was found to be one of the major BC6ENTC binding proteins in human serum and in liver , brain , and prostate tissues.	False
Alteration of BC6ENTC - associated protein ( BC6ENTG ) expression in human breast epithelial cells during breast cancer development.	False
These data provided a novel insight to the mechanisms of BC6ENTC protective effects on BC6ENTG - induced endothelial cells apoptosis , suggesting that BC6OTHER - BC6OTHER signaling pathway might play an important role in it.	CPR:4
These data provided a novel insight to the mechanisms of BC6ENTC protective effects on BC6OTHER - induced endothelial cells apoptosis , suggesting that BC6ENTG - BC6OTHER signaling pathway might play an important role in it.	False
These data provided a novel insight to the mechanisms of BC6ENTC protective effects on BC6OTHER - induced endothelial cells apoptosis , suggesting that BC6OTHER - BC6ENTG signaling pathway might play an important role in it.	False
Present study attempted to evaluate the potential mechanisms of BC6ENTG - mediated insult and the protective effects of BC6ENTC on human endothelial cells.	False
BC6ENTC attenuated the BC6ENTG - associated mitochondrial apoptotic events , accompanied by inhibiting BC6OTHER expression followed by intracellular reactive BC6OTHER species generation , and protein nitrotyrosination.	CPR:4
BC6ENTC attenuated the BC6OTHER - associated mitochondrial apoptotic events , accompanied by inhibiting BC6ENTG expression followed by intracellular reactive BC6OTHER species generation , and protein nitrotyrosination.	CPR:4
BC6OTHER attenuated the BC6ENTG - associated mitochondrial apoptotic events , accompanied by inhibiting BC6OTHER expression followed by intracellular reactive BC6ENTC species generation , and protein nitrotyrosination.	False
BC6OTHER attenuated the BC6OTHER - associated mitochondrial apoptotic events , accompanied by inhibiting BC6ENTG expression followed by intracellular reactive BC6ENTC species generation , and protein nitrotyrosination.	False
These protective effects were abolished by BC6ENTG ( BC6OTHER ) antagonist BC6ENTC or BC6OTHER inhibitor BC6OTHER rather than BC6OTHER antagonist BC6OTHER .	CPR:6
These protective effects were abolished by BC6OTHER ( BC6ENTG ) antagonist BC6ENTC or BC6OTHER inhibitor BC6OTHER rather than BC6OTHER antagonist BC6OTHER .	CPR:6
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6ENTC or BC6ENTG inhibitor BC6OTHER rather than BC6OTHER antagonist BC6OTHER .	False
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6ENTC or BC6OTHER inhibitor BC6OTHER rather than BC6ENTG antagonist BC6OTHER .	False
These protective effects were abolished by BC6ENTG ( BC6OTHER ) antagonist BC6OTHER or BC6OTHER inhibitor BC6ENTC rather than BC6OTHER antagonist BC6OTHER .	False
These protective effects were abolished by BC6OTHER ( BC6ENTG ) antagonist BC6OTHER or BC6OTHER inhibitor BC6ENTC rather than BC6OTHER antagonist BC6OTHER .	False
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6OTHER or BC6ENTG inhibitor BC6ENTC rather than BC6OTHER antagonist BC6OTHER .	CPR:4
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6OTHER or BC6OTHER inhibitor BC6ENTC rather than BC6ENTG antagonist BC6OTHER .	False
These protective effects were abolished by BC6ENTG ( BC6OTHER ) antagonist BC6OTHER or BC6OTHER inhibitor BC6OTHER rather than BC6ENTC receptor α antagonist BC6OTHER .	False
These protective effects were abolished by BC6OTHER ( BC6ENTG ) antagonist BC6OTHER or BC6OTHER inhibitor BC6OTHER rather than BC6ENTC receptor α antagonist BC6OTHER .	False
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6OTHER or BC6ENTG inhibitor BC6OTHER rather than BC6ENTC receptor α antagonist BC6OTHER .	False
These protective effects were abolished by BC6ENTG ( BC6OTHER ) antagonist BC6OTHER or BC6OTHER inhibitor BC6OTHER rather than BC6OTHER antagonist BC6ENTC .	False
These protective effects were abolished by BC6OTHER ( BC6ENTG ) antagonist BC6OTHER or BC6OTHER inhibitor BC6OTHER rather than BC6OTHER antagonist BC6ENTC .	False
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6OTHER or BC6ENTG inhibitor BC6OTHER rather than BC6OTHER antagonist BC6ENTC .	False
These protective effects were abolished by BC6OTHER ( BC6OTHER ) antagonist BC6OTHER or BC6OTHER inhibitor BC6OTHER rather than BC6ENTG antagonist BC6ENTC .	CPR:6
Taken together , our results suggested that BC6ENTC protected against BC6ENTG - induced apoptosis at least in part by two complementary BC6OTHER - dependent BC6OTHER phosphorylation pathways: (1) down - regulating BC6OTHER initiated protein nitrotyrosination , and (2) inhibiting mitochondrial apoptotic cascades.	CPR:4
Taken together , our results suggested that BC6ENTC protected against BC6OTHER - induced apoptosis at least in part by two complementary BC6ENTG - dependent BC6OTHER phosphorylation pathways: (1) down - regulating BC6OTHER initiated protein nitrotyrosination , and (2) inhibiting mitochondrial apoptotic cascades.	False
Taken together , our results suggested that BC6ENTC protected against BC6OTHER - induced apoptosis at least in part by two complementary BC6OTHER - dependent BC6ENTG phosphorylation pathways: (1) down - regulating BC6OTHER initiated protein nitrotyrosination , and (2) inhibiting mitochondrial apoptotic cascades.	CPR:3
Taken together , our results suggested that BC6ENTC protected against BC6OTHER - induced apoptosis at least in part by two complementary BC6OTHER - dependent BC6OTHER phosphorylation pathways: (1) down - regulating BC6ENTG initiated protein nitrotyrosination , and (2) inhibiting mitochondrial apoptotic cascades.	CPR:4
Activating BC6OTHER - BC6OTHER signaling pathway contributes to BC6ENTC protection against BC6ENTG - induced human endothelial cells apoptosis.	CPR:4
Activating BC6ENTG - BC6OTHER signaling pathway contributes to BC6ENTC protection against BC6OTHER - induced human endothelial cells apoptosis.	CPR:3
Activating BC6OTHER - BC6ENTG signaling pathway contributes to BC6ENTC protection against BC6OTHER - induced human endothelial cells apoptosis.	CPR:3
In conclusion , in this study we showed that BC6ENTG and BC6OTHER genotypes may be an important predictor of time to progression in GIST patients receiving BC6ENTC therapy.	False
In conclusion , in this study we showed that BC6OTHER and BC6ENTG genotypes may be an important predictor of time to progression in GIST patients receiving BC6ENTC therapy.	False
Response to BC6ENTC mainly depends from BC6ENTG and BC6OTHER mutational status.	False
Response to BC6ENTC mainly depends from BC6OTHER and BC6ENTG mutational status.	False
The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and BC6ENTC , a selective BC6ENTG inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable / metastatic GIST.	CPR:4
Polymorphisms in BC6ENTG and BC6OTHER transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with BC6ENTC therapy.	False
Polymorphisms in BC6OTHER and BC6ENTG transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with BC6ENTC therapy.	False
Previously , we have found that BC6ENTC , a BC6OTHER derivative , inhibits BC6OTHER ( BC6ENTG ) - mediated angiogenesis signaling in human endothelial cells.	CPR:4
Previously , we have found that BC6ENTC , a BC6OTHER derivative , inhibits BC6ENTG ( BC6OTHER ) - mediated angiogenesis signaling in human endothelial cells.	CPR:4
Previously , we have found that BC6OTHER , a BC6ENTC derivative , inhibits BC6OTHER ( BC6ENTG ) - mediated angiogenesis signaling in human endothelial cells.	CPR:4
Previously , we have found that BC6OTHER , a BC6ENTC derivative , inhibits BC6ENTG ( BC6OTHER ) - mediated angiogenesis signaling in human endothelial cells.	CPR:4
Furthermore , BC6ENTC inhibited the BC6ENTG - induced phosphorylation and intracellular BC6OTHER activity of BC6OTHER ( BC6OTHER ) and the activation of its downstream BC6OTHER pathway.	CPR:4
Furthermore , BC6ENTC inhibited the BC6OTHER - induced phosphorylation and intracellular BC6ENTG activity of BC6OTHER ( BC6OTHER ) and the activation of its downstream BC6OTHER pathway.	CPR:4
Furthermore , BC6ENTC inhibited the BC6OTHER - induced phosphorylation and intracellular BC6OTHER activity of BC6ENTG ( BC6OTHER ) and the activation of its downstream BC6OTHER pathway.	CPR:4
Furthermore , BC6ENTC inhibited the BC6OTHER - induced phosphorylation and intracellular BC6OTHER activity of BC6OTHER ( BC6ENTG ) and the activation of its downstream BC6OTHER pathway.	CPR:4
Furthermore , BC6ENTC inhibited the BC6OTHER - induced phosphorylation and intracellular BC6OTHER activity of BC6OTHER ( BC6OTHER ) and the activation of its downstream BC6ENTG pathway.	CPR:4
Furthermore , BC6OTHER inhibited the BC6ENTG - induced phosphorylation and intracellular BC6ENTC kinase activity of BC6OTHER ( BC6OTHER ) and the activation of its downstream BC6OTHER pathway.	False
Furthermore , BC6OTHER inhibited the BC6OTHER - induced phosphorylation and intracellular BC6ENTC kinase activity of BC6ENTG ( BC6OTHER ) and the activation of its downstream BC6OTHER pathway.	False
Furthermore , BC6OTHER inhibited the BC6OTHER - induced phosphorylation and intracellular BC6ENTC kinase activity of BC6OTHER ( BC6ENTG ) and the activation of its downstream BC6OTHER pathway.	False
Furthermore , BC6OTHER inhibited the BC6OTHER - induced phosphorylation and intracellular BC6ENTC kinase activity of BC6OTHER ( BC6OTHER ) and the activation of its downstream BC6ENTG pathway.	False
The effects of BC6OTHER on both BC6OTHER and their BC6OTHER were blocked by pre - treatment with the BC6ENTG inhibitor BC6ENTC .	CPR:4
The effects of BC6OTHER on both BC6OTHER and their BC6ENTG were blocked by pre - treatment with the BC6OTHER inhibitor BC6ENTC .	CPR:4
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTC oxidase ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
This pretreament had no effect on the inhibition of BC6ENTG or the elevation of brain BC6ENTC levels produced by BC6OTHER .	False
This pretreament had no effect on the inhibition of BC6ENTG or the elevation of brain BC6OTHER levels produced by BC6ENTC .	CPR:4
CONCLUSIONS: At the doses studied , BC6ENTC was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6ENTG and BC6OTHER (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6ENTC was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6OTHER and BC6ENTG (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6ENTC at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6ENTG and BC6OTHER (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6ENTC at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6OTHER and BC6ENTG (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6ENTC levels , but , unlike BC6OTHER , also inhibited BC6ENTG and BC6OTHER (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6ENTC levels , but , unlike BC6OTHER , also inhibited BC6OTHER and BC6ENTG (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6ENTC , also inhibited BC6ENTG and BC6OTHER (and increased brain BC6OTHER levels).	CPR:4
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6ENTC , also inhibited BC6OTHER and BC6ENTG (and increased brain BC6OTHER levels).	CPR:4
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6ENTG and BC6ENTC - T (and increased brain BC6OTHER levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6ENTG and BC6OTHER (and increased brain BC6ENTC levels).	False
CONCLUSIONS: At the doses studied , BC6OTHER was as effective as BC6OTHER at elevating brain BC6OTHER levels , but , unlike BC6OTHER , also inhibited BC6OTHER and BC6ENTG (and increased brain BC6ENTC levels).	False
Pretreatment of rats with the BC6ENTG inhibitor BC6ENTC prevented the increase in brain BC6OTHER and BC6OTHER levels with BC6OTHER , but did not block the effect of BC6OTHER on BC6OTHER .	CPR:4
Pretreatment of rats with the BC6ENTG inhibitor BC6OTHER prevented the increase in brain BC6ENTC and BC6OTHER levels with BC6OTHER , but did not block the effect of BC6OTHER on BC6OTHER .	False
Pretreatment of rats with the BC6ENTG inhibitor BC6OTHER prevented the increase in brain BC6OTHER and BC6ENTC levels with BC6OTHER , but did not block the effect of BC6OTHER on BC6OTHER .	False
Pretreatment of rats with the BC6ENTG inhibitor BC6OTHER prevented the increase in brain BC6OTHER and BC6OTHER levels with BC6ENTC , but did not block the effect of BC6OTHER on BC6OTHER .	False
Pretreatment of rats with the BC6ENTG inhibitor BC6OTHER prevented the increase in brain BC6OTHER and BC6OTHER levels with BC6OTHER , but did not block the effect of BC6ENTC on BC6OTHER .	False
Pretreatment of rats with the BC6ENTG inhibitor BC6OTHER prevented the increase in brain BC6OTHER and BC6OTHER levels with BC6OTHER , but did not block the effect of BC6OTHER on BC6ENTC .	False
These observations with BC6ENTC and BC6OTHER support the hypothesis that an active metabolite of BC6OTHER produced by the actions of BC6ENTG on this drug plays a major role in its BC6OTHER - and BC6OTHER - elevating actions.	False
These observations with BC6OTHER and BC6ENTC support the hypothesis that an active metabolite of BC6OTHER produced by the actions of BC6ENTG on this drug plays a major role in its BC6OTHER - and BC6OTHER - elevating actions.	False
These observations with BC6OTHER and BC6OTHER support the hypothesis that an active metabolite of BC6ENTC produced by the actions of BC6ENTG on this drug plays a major role in its BC6OTHER - and BC6OTHER - elevating actions.	False
These observations with BC6OTHER and BC6OTHER support the hypothesis that an active metabolite of BC6OTHER produced by the actions of BC6ENTG on this drug plays a major role in its BC6ENTC - and BC6OTHER - elevating actions.	False
These observations with BC6OTHER and BC6OTHER support the hypothesis that an active metabolite of BC6OTHER produced by the actions of BC6ENTG on this drug plays a major role in its BC6OTHER - and BC6ENTC - elevating actions.	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6ENTC ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6ENTC ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6ENTC ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6ENTC ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6ENTC by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTC transaminase ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6ENTC ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTC - T) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6ENTC and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6ENTC and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6ENTC - T and BC6OTHER ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6ENTG ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTC - T and BC6OTHER ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6ENTC transaminase ( BC6OTHER ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTC transaminase ( BC6ENTG ).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6ENTG ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6ENTG ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6ENTG ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6ENTG ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6ENTG , BC6OTHER and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6ENTG and BC6OTHER ( BC6ENTC - T).	False
PURPOSE: To compare BC6OTHER ( BC6OTHER ) , an antidepressant drug with anxiolytic properties which inhibits BC6OTHER ( BC6OTHER ) but also elevates rat brain levels of the BC6OTHER ? - BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) , with BC6OTHER ( BC6OTHER ) , an anticonvulsant which elevates brain BC6OTHER by inhibition of BC6OTHER ( BC6OTHER ) , with regard to their actions on brain levels of BC6OTHER and BC6OTHER and on activities of BC6OTHER , BC6OTHER and BC6ENTG ( BC6ENTC - T).	False
METHODS: Male rats were administered BC6ENTC (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6OTHER and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6ENTC (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTG and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6ENTC (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6OTHER and BC6ENTG (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6ENTC (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6OTHER and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6ENTC (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTG and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6ENTC (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6OTHER and BC6ENTG (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6ENTC and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6OTHER and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6ENTC and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTG and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6ENTC and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6OTHER and BC6ENTG (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6ENTC (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6OTHER and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6ENTC (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTG and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6ENTC (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6OTHER and BC6ENTG (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6ENTC - T and BC6OTHER (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTC - T and BC6ENTG (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6ENTG , BC6OTHER and BC6ENTC - T (radiochemical assays).	False
METHODS: Male rats were administered BC6OTHER (10 mg / kg) or BC6OTHER (1 , 000 mg / kg) i.p. , and the rats were euthanized 4 hours later and the brains removed for analysis of levels of BC6OTHER and BC6OTHER (by electron capture gas chromatography after derivatization) and activities of BC6OTHER , BC6ENTG and BC6ENTC - T (radiochemical assays).	False
RESULTS: Both BC6ENTC and BC6OTHER inhibited BC6ENTG and elevated BC6OTHER levels.	CPR:4
RESULTS: Both BC6OTHER and BC6ENTC inhibited BC6ENTG and elevated BC6OTHER levels.	CPR:4
RESULTS: Both BC6OTHER and BC6OTHER inhibited BC6ENTG and elevated BC6ENTC levels.	False
Only BC6ENTC inhibited BC6ENTG and BC6OTHER and elevated BC6OTHER levels.	CPR:4
Only BC6ENTC inhibited BC6OTHER and BC6ENTG and elevated BC6OTHER levels.	CPR:4
Only BC6OTHER inhibited BC6ENTG and BC6ENTC - T and elevated BC6OTHER levels.	False
Only BC6OTHER inhibited BC6ENTG and BC6OTHER and elevated BC6ENTC levels.	False
Only BC6OTHER inhibited BC6OTHER and BC6ENTG and elevated BC6ENTC levels.	False
The effects of BC6ENTC on both BC6OTHER and their BC6OTHER were blocked by pre - treatment with the BC6ENTG inhibitor BC6OTHER .	False
The effects of BC6ENTC on both BC6OTHER and their BC6ENTG were blocked by pre - treatment with the BC6OTHER inhibitor BC6OTHER .	False
The effects of BC6OTHER on both BC6ENTC and their BC6OTHER were blocked by pre - treatment with the BC6ENTG inhibitor BC6OTHER .	False
The effects of BC6OTHER on both BC6ENTC and their BC6ENTG were blocked by pre - treatment with the BC6OTHER inhibitor BC6OTHER .	False
Neurochemical effects of the BC6ENTG inhibitor BC6OTHER on brain BC6OTHER and BC6OTHER : A comparison with BC6ENTC .	False
Neurochemical effects of the BC6ENTG inhibitor BC6ENTC on brain BC6OTHER and BC6OTHER : A comparison with BC6OTHER .	CPR:4
Neurochemical effects of the BC6ENTG inhibitor BC6OTHER on brain BC6ENTC and BC6OTHER : A comparison with BC6OTHER .	False
Neurochemical effects of the BC6ENTG inhibitor BC6OTHER on brain BC6OTHER and BC6ENTC : A comparison with BC6OTHER .	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6ENTG , BC6ENTC peroxidase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTC peroxidase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTC peroxidase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTC peroxidase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6ENTG , BC6OTHER ( BC6ENTC - Px) and BC6OTHER ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTG ( BC6ENTC - Px) and BC6OTHER ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6ENTC - Px) and BC6ENTG ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6ENTC - Px) and BC6OTHER ( BC6ENTG ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6ENTC reductase ( BC6OTHER ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6ENTG ) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Rd) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Rd) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC - Rd) in the liver.	False
Moreover , green tea extract administration significantly increased (p<0.05) the activities of BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6ENTC - Rd) in the liver.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6ENTG cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6ENTG ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6ENTG ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6ENTG ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6ENTG (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG BC6OTHER ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6ENTG ( BC6OTHER ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
SF levels of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER BC6OTHER ( BC6ENTG ) (reflecting BC6OTHER cleavage of cartilage BC6OTHER ) , BC6OTHER ( BC6OTHER ) (a biosynthesis marker) , CHEM BC6ENTC (KS) , and the 846 epitope of BC6OTHER (turnover) were measured by enzyme - linked immunosorbent assay or radioimmunoassay.	False
No effects were observed when BC6ENTC was assessed for BC6ENTG - dependent and BC6OTHER - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6OTHER enzymes , inhibition of the biliary BC6OTHER BC6OTHER and BC6OTHER or mitochondrial toxicity to THLE or HepG2 cells.	False
No effects were observed when BC6ENTC was assessed for BC6OTHER - dependent and BC6ENTG - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6OTHER enzymes , inhibition of the biliary BC6OTHER BC6OTHER and BC6OTHER or mitochondrial toxicity to THLE or HepG2 cells.	False
No effects were observed when BC6ENTC was assessed for BC6OTHER - dependent and BC6OTHER - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6ENTG enzymes , inhibition of the biliary BC6OTHER BC6OTHER and BC6OTHER or mitochondrial toxicity to THLE or HepG2 cells.	CPR:4
No effects were observed when BC6ENTC was assessed for BC6OTHER - dependent and BC6OTHER - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6OTHER enzymes , inhibition of the biliary BC6ENTG BC6OTHER and BC6OTHER or mitochondrial toxicity to THLE or HepG2 cells.	CPR:4
No effects were observed when BC6ENTC was assessed for BC6OTHER - dependent and BC6OTHER - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6OTHER enzymes , inhibition of the biliary BC6OTHER BC6ENTG and BC6OTHER or mitochondrial toxicity to THLE or HepG2 cells.	CPR:4
No effects were observed when BC6ENTC was assessed for BC6OTHER - dependent and BC6OTHER - independent cytotoxicity to THLE cell lines , time - dependent inhibition of five major BC6OTHER enzymes , inhibition of the biliary BC6OTHER BC6OTHER and BC6ENTG or mitochondrial toxicity to THLE or HepG2 cells.	CPR:4
BC6ENTG activity was significantly higher in survivors (238.8±51.5) than non - survivors (166.4±40.2; p=0.005) , while protein BC6ENTC levels were significantly lower in survivors (0.32±0.09) than non - survivors (0.48±0.16; p=0.036) on the 1stday.	False
Synergistic cytotoxicity was demonstrated , and BC6ENTC significantly decreased the amount of BC6ENTG , enhanced apoptosis , and increased the expression of BC6OTHER in A549 and Calu - 6 cells , as well as the expression of the human BC6OTHER equilibrative transporter 1 ( BC6OTHER ) in all cell lines.	CPR:4
Synergistic cytotoxicity was demonstrated , and BC6ENTC significantly decreased the amount of BC6OTHER , enhanced apoptosis , and increased the expression of BC6ENTG in A549 and Calu - 6 cells , as well as the expression of the human BC6OTHER equilibrative transporter 1 ( BC6OTHER ) in all cell lines.	CPR:3
Synergistic cytotoxicity was demonstrated , and BC6ENTC significantly decreased the amount of BC6OTHER , enhanced apoptosis , and increased the expression of BC6OTHER in A549 and Calu - 6 cells , as well as the expression of the BC6ENTG ( BC6OTHER ) in all cell lines.	CPR:3
Synergistic cytotoxicity was demonstrated , and BC6ENTC significantly decreased the amount of BC6OTHER , enhanced apoptosis , and increased the expression of BC6OTHER in A549 and Calu - 6 cells , as well as the expression of the human BC6OTHER equilibrative transporter 1 ( BC6ENTG ) in all cell lines.	CPR:3
Synergistic cytotoxicity was demonstrated , and BC6OTHER significantly decreased the amount of BC6ENTG , enhanced apoptosis , and increased the expression of BC6OTHER in A549 and Calu - 6 cells , as well as the expression of the human BC6ENTC equilibrative transporter 1 ( BC6OTHER ) in all cell lines.	False
Synergistic cytotoxicity was demonstrated , and BC6OTHER significantly decreased the amount of BC6OTHER , enhanced apoptosis , and increased the expression of BC6ENTG in A549 and Calu - 6 cells , as well as the expression of the human BC6ENTC equilibrative transporter 1 ( BC6OTHER ) in all cell lines.	False
Synergistic cytotoxicity was demonstrated , and BC6OTHER significantly decreased the amount of BC6OTHER , enhanced apoptosis , and increased the expression of BC6OTHER in A549 and Calu - 6 cells , as well as the expression of the human BC6ENTC equilibrative transporter 1 ( BC6ENTG ) in all cell lines.	False
PCR demonstrated a correlation between BC6ENTG expression and BC6ENTC sensitivity , whereas expression of BC6OTHER , BC6OTHER , and BC6OTHER was predictive of BC6OTHER chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6ENTC sensitivity , whereas expression of BC6ENTG , BC6OTHER , and BC6OTHER was predictive of BC6OTHER chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6ENTC sensitivity , whereas expression of BC6OTHER , BC6ENTG , and BC6OTHER was predictive of BC6OTHER chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6ENTC sensitivity , whereas expression of BC6OTHER , BC6OTHER , and BC6ENTG was predictive of BC6OTHER chemosensitivity.	False
PCR demonstrated a correlation between BC6ENTG expression and BC6OTHER sensitivity , whereas expression of BC6OTHER , BC6OTHER , and BC6OTHER was predictive of BC6ENTC chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6OTHER sensitivity , whereas expression of BC6ENTG , BC6OTHER , and BC6OTHER was predictive of BC6ENTC chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6OTHER sensitivity , whereas expression of BC6OTHER , BC6ENTG , and BC6OTHER was predictive of BC6ENTC chemosensitivity.	False
PCR demonstrated a correlation between BC6OTHER expression and BC6OTHER sensitivity , whereas expression of BC6OTHER , BC6OTHER , and BC6ENTG was predictive of BC6ENTC chemosensitivity.	False
These data demonstrated that 1) BC6ENTC and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6ENTG phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6OTHER and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	CPR:4
These data demonstrated that 1) BC6ENTC and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6ENTG and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	False
These data demonstrated that 1) BC6ENTC and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6OTHER and BC6ENTG expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	False
These data demonstrated that 1) BC6OTHER and BC6ENTC synergistically interact against NSCLC cells through the suppression of BC6ENTG phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6OTHER and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	CPR:4
These data demonstrated that 1) BC6OTHER and BC6ENTC synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6ENTG and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	False
These data demonstrated that 1) BC6OTHER and BC6ENTC synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6OTHER enhances BC6OTHER and BC6ENTG expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	False
These data demonstrated that 1) BC6OTHER and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6ENTG phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6ENTC enhances BC6OTHER and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	False
These data demonstrated that 1) BC6OTHER and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6ENTC enhances BC6ENTG and BC6OTHER expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	CPR:3
These data demonstrated that 1) BC6OTHER and BC6OTHER synergistically interact against NSCLC cells through the suppression of BC6OTHER phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) BC6ENTC enhances BC6OTHER and BC6ENTG expression , thus suggesting the role of gene - expression modulation for rational development of chemotherapy combinations.	CPR:3
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6ENTC cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6ENTG ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6ENTG , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6ENTG , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTC deaminase , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTC synthase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTG ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6ENTG ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTC reductase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6ENTC formyltransferase ( BC6OTHER ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The role of drug metabolism in BC6OTHER cytotoxicity was examined with inhibitors of BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER , whereas the role of CHEM targets , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC formyltransferase ( BC6ENTG ) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.	False
The effect of BC6ENTC and CHEM on BC6ENTG phosphorylation was investigated with enzyme - linked immunosorbent assay , whereas quantitative polymerase chain reaction (PCR) was used to study target gene - expression profiles and its modulation by each drug.	False
Agonist competition assays with BC6ENTC showed the following rank order of potency: BC6OTHER > BC6OTHER > BC6OTHER , consistent with BC6ENTG interaction.	False
Agonist competition assays with BC6OTHER showed the following rank order of potency: BC6ENTC > BC6OTHER > BC6OTHER , consistent with BC6ENTG interaction.	False
Agonist competition assays with BC6OTHER showed the following rank order of potency: BC6OTHER > BC6ENTC > BC6OTHER , consistent with BC6ENTG interaction.	False
Agonist competition assays with BC6OTHER showed the following rank order of potency: BC6OTHER > BC6OTHER > BC6ENTC , consistent with BC6ENTG interaction.	False
Receptor trafficking demonstrated surface expression of BC6ENTG with vehicle treatment and internalization following BC6ENTC treatment.	False
BC6ENTG density measured with BC6ENTC ( BC6OTHER ) increased either 13 - or 77 - fold in infected cells compared to mock infected controls depending on the culture conditions used.	False
BC6ENTG density measured with BC6OTHER ( BC6ENTC ) increased either 13 - or 77 - fold in infected cells compared to mock infected controls depending on the culture conditions used.	False
The BC6ENTC binding was to a single receptor population with a dissociation constant of 0.42 nM , as would be expected for wild - type BC6ENTG .	False
BC6ENTC , which has high affinity for BC6ENTG and BC6OTHER subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6OTHER .	False
BC6ENTC , which has high affinity for BC6OTHER and BC6ENTG subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6OTHER .	False
BC6ENTC , which has high affinity for BC6OTHER and BC6OTHER subtypes but not for BC6ENTG , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6OTHER .	False
BC6OTHER , which has high affinity for BC6ENTG and BC6OTHER subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6ENTC and BC6OTHER .	False
BC6OTHER , which has high affinity for BC6OTHER and BC6ENTG subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6ENTC and BC6OTHER .	False
BC6OTHER , which has high affinity for BC6OTHER and BC6OTHER subtypes but not for BC6ENTG , shows efficacy similar to the nonsubtype selective agents BC6ENTC and BC6OTHER .	False
BC6OTHER , which has high affinity for BC6ENTG and BC6OTHER subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6ENTC .	False
BC6OTHER , which has high affinity for BC6OTHER and BC6ENTG subtypes but not for BC6OTHER , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6ENTC .	False
BC6OTHER , which has high affinity for BC6OTHER and BC6OTHER subtypes but not for BC6ENTG , shows efficacy similar to the nonsubtype selective agents BC6OTHER and BC6ENTC .	False
We used BC6ENTC - Pdots to track the dynamics of BC6ENTG on a breast cancer cell - line , determining the diffusion characteristics and showing BC6OTHER - containing membrane nanodomains were important for receptor mobility at the plasma membrane.	False
We used BC6OTHER - Pdots to track the dynamics of BC6ENTG on a breast cancer cell - line , determining the diffusion characteristics and showing BC6ENTC - containing membrane nanodomains were important for receptor mobility at the plasma membrane.	False
 BC6ENTC - terminated conjugated polymer nanoparticles have near - unity bright fraction and reveal BC6OTHER - dependence of BC6ENTG .	False
 BC6OTHER - terminated conjugated polymer nanoparticles have near - unity bright fraction and reveal BC6ENTC - dependence of BC6ENTG .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6ENTG ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6ENTG ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6ENTC was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6ENTG ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6ENTG ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6ENTC group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6ENTG ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6ENTG ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6ENTC residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6ENTG ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6ENTG ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6ENTC and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6ENTG ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6OTHER ( BC6ENTG ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6ENTC - BC6OTHER ( BC6OTHER ) and BC6OTHER - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6ENTG ( BC6OTHER ) and BC6ENTC - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6ENTG ) and BC6ENTC - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6ENTG ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER ( BC6ENTG ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6ENTG or BC6OTHER .	False
An intermediate BC6OTHER was first synthesized by activating the BC6OTHER group of the 2nd and 8th BC6OTHER residues with three different BC6OTHER and two artificial complete antigens BC6OTHER - BC6OTHER ( BC6OTHER ) and BC6ENTC - BC6OTHER ( BC6OTHER ) were then prepared by cross - linking the intermediate with BC6OTHER or BC6ENTG .	False
Furthermore , BC6OTHER significantly reversed the up - regulation of BC6ENTG and inhibited the BC6ENTC overload in the cultured neurons after challenging the BC6OTHER .	False
Furthermore , BC6OTHER significantly reversed the up - regulation of BC6ENTG and inhibited the BC6OTHER overload in the cultured neurons after challenging the BC6ENTC .	False
BC6ENTC showed partial protection in the cortical neurons via down - regulation of BC6ENTG containing BC6OTHER and up - regulation of BC6OTHER family.	CPR:4
BC6ENTC showed partial protection in the cortical neurons via down - regulation of BC6OTHER containing BC6ENTG and up - regulation of BC6OTHER family.	CPR:4
BC6ENTC showed partial protection in the cortical neurons via down - regulation of BC6OTHER containing BC6OTHER and up - regulation of BC6ENTG family.	CPR:3
BC6OTHER showed partial protection in the cortical neurons via down - regulation of BC6ENTG containing BC6ENTC receptors and up - regulation of BC6OTHER family.	False
BC6OTHER showed partial protection in the cortical neurons via down - regulation of BC6OTHER containing BC6ENTC receptors and up - regulation of BC6ENTG family.	False
Western blot analysis revealed that BC6ENTC decreased the expression of BC6ENTG and repaired the balance of pro - and anti - apoptotic proteins.	CPR:4
Furthermore , BC6ENTC significantly reversed the up - regulation of BC6ENTG and inhibited the BC6OTHER overload in the cultured neurons after challenging the BC6OTHER .	CPR:4
Neuroprotective effects of BC6OTHER against excitotoxicity partially through down - regulation of BC6ENTG - containing BC6ENTC receptors.	False
Neuroprotective effects of BC6ENTC against excitotoxicity partially through down - regulation of BC6OTHER - containing BC6ENTG .	False
Neuroprotective effects of BC6ENTC against excitotoxicity partially through down - regulation of BC6ENTG - containing BC6OTHER .	False
BC6ENTC polymerase - 1 ( BC6ENTG ) enzyme is involved in the repair of DNA damages made by certain anticancer agents.	False
It is suggested that BC6ENTG inhibitors potentiate the cytotoxic effects and circumvent the resistance of DNA - modifying anticancer agents such as BC6ENTC .	False
We then examined the chemosensitization of BC6ENTC by pre - treatment of BC6ENTG inhibitors in BC6OTHER - resistant human gastric cancer cells.	False
We then examined the chemosensitization of BC6OTHER by pre - treatment of BC6ENTG inhibitors in BC6ENTC - resistant human gastric cancer cells.	False
Our results show that BC6ENTG inhibitors suppress the formation of BC6ENTC and enhance the cytotoxicity of BC6OTHER .	False
Our results show that BC6ENTG inhibitors suppress the formation of BC6OTHER and enhance the cytotoxicity of BC6ENTC .	False
In silico identification of BC6ENTG inhibitors and their chemosensitizing effects against BC6ENTC - resistant human gastric cancer cells.	False
BC6ENTC - induced apoptotic changes were evaluated by BC6ENTG BC6OTHER nick end labeling (TUNEL) assay and its related mechanism was confirmed by Western blot analysis and colorimetric assay.	False
BC6OTHER - induced apoptotic changes were evaluated by BC6ENTG BC6ENTC nick end labeling (TUNEL) assay and its related mechanism was confirmed by Western blot analysis and colorimetric assay.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6ENTG activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6ENTG BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6ENTG and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6ENTG expression.	False
However , BC6ENTG BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6ENTG ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6ENTG BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6ENTG ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6ENTG ) expression increased at 8 - 24 h. BC6OTHER and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
However , BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) and CHEM BC6ENTC - terminal kinase ( BC6OTHER ) expression increased at 8 - 24 h. BC6ENTG and BC6OTHER activities also increased at 8 - 48 h and 12 - 48 h , respectively , in the same manner as BC6OTHER BC6OTHER and BC6OTHER expression.	False
BC6ENTC , an inhibitor of BC6ENTG ( BC6OTHER and BC6OTHER , respectively) , is a standard treatment for ADHD.	CPR:4
BC6ENTC , an inhibitor of CHEM and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively) , is a standard treatment for ADHD.	CPR:4
BC6ENTC , an inhibitor of CHEM and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively) , is a standard treatment for ADHD.	CPR:4
In both OFC and mPFC , no strain differences in Vmax or Km for BC6ENTC uptake into synaptosomes were found between vehicle - treated SHR , WKY and WIS. BC6OTHER increased BC6ENTG Vmax in SHR mPFC and decreased BC6OTHER Vmax in WKY OFC.	False
In both OFC and mPFC , no strain differences in Vmax or Km for BC6ENTC uptake into synaptosomes were found between vehicle - treated SHR , WKY and WIS. BC6OTHER increased BC6OTHER Vmax in SHR mPFC and decreased BC6ENTG Vmax in WKY OFC.	False
In both OFC and mPFC , no strain differences in Vmax or Km for BC6OTHER uptake into synaptosomes were found between vehicle - treated SHR , WKY and WIS. BC6ENTC increased BC6ENTG Vmax in SHR mPFC and decreased BC6OTHER Vmax in WKY OFC.	CPR:3
In both OFC and mPFC , no strain differences in Vmax or Km for BC6OTHER uptake into synaptosomes were found between vehicle - treated SHR , WKY and WIS. BC6ENTC increased BC6OTHER Vmax in SHR mPFC and decreased BC6ENTG Vmax in WKY OFC.	CPR:4
Also , BC6ENTC decreased BC6ENTG Km in WIS OFC.	CPR:4
Further , BC6ENTC did not alter BC6ENTG cellular localization , indicating that BC6OTHER treatment during adolescence regulated BC6OTHER function in SHR mPFC in a trafficking - independent manner.	False
Further , BC6ENTC did not alter BC6OTHER cellular localization , indicating that BC6OTHER treatment during adolescence regulated BC6ENTG function in SHR mPFC in a trafficking - independent manner.	False
Further , BC6OTHER did not alter BC6ENTG cellular localization , indicating that BC6ENTC treatment during adolescence regulated BC6OTHER function in SHR mPFC in a trafficking - independent manner.	False
Further , BC6OTHER did not alter BC6OTHER cellular localization , indicating that BC6ENTC treatment during adolescence regulated BC6ENTG function in SHR mPFC in a trafficking - independent manner.	False
BC6OTHER , an inhibitor of BC6ENTC and BC6OTHER transporters ( BC6ENTG and BC6OTHER , respectively) , is a standard treatment for ADHD.	False
BC6OTHER , an inhibitor of BC6ENTC and BC6OTHER transporters ( BC6OTHER and BC6ENTG , respectively) , is a standard treatment for ADHD.	False
BC6OTHER , an inhibitor of CHEM and BC6ENTC transporters ( BC6ENTG and BC6OTHER , respectively) , is a standard treatment for ADHD.	False
BC6OTHER , an inhibitor of CHEM and BC6ENTC transporters ( BC6OTHER and BC6ENTG , respectively) , is a standard treatment for ADHD.	False
Thus , the increase in mPFC BC6ENTG function was an SHR - specific long term consequence of BC6ENTC treatment during adolescence , which may be responsible for the treatment - induced alterations in behavior including the observed increases in BC6OTHER self - administration.	CPR:3
Thus , the increase in mPFC BC6ENTG function was an SHR - specific long term consequence of BC6OTHER treatment during adolescence , which may be responsible for the treatment - induced alterations in behavior including the observed increases in BC6ENTC self - administration.	False
Our previous results showed that BC6ENTC treatment in adolescent SHR enhanced BC6OTHER self - administration during adulthood , and alterations in BC6ENTG function in prefrontal cortex play a role in this response.	False
Our previous results showed that BC6OTHER treatment in adolescent SHR enhanced BC6ENTC self - administration during adulthood , and alterations in BC6ENTG function in prefrontal cortex play a role in this response.	False
Adolescence BC6ENTC treatment in a rodent model of attention deficit / hyperactivity disorder: BC6ENTG function and cellular distribution in adulthood.	False
Previously , 3 BC6ENTC / insulin response elements were identified in the 5' - flanking region of the BC6ENTG gene up to bp - 170.	False
Expression of L - type BC6ENTC kinase ( BC6ENTG ) is upregulated in the liver by dietary BC6OTHER .	False
Expression of BC6ENTG ( BC6OTHER ) is upregulated in the liver by dietary BC6ENTC .	CPR:3
Expression of L - type BC6OTHER kinase ( BC6ENTG ) is upregulated in the liver by dietary BC6ENTC .	CPR:3
BC6ENTC ( BC6OTHER ) is made in mammalian cells by two BC6ENTG , BC6OTHER and BC6OTHER .	CPR:9
BC6ENTC ( BC6OTHER ) is made in mammalian cells by two BC6OTHER , BC6ENTG and BC6OTHER .	CPR:9
BC6ENTC ( BC6OTHER ) is made in mammalian cells by two BC6OTHER , BC6OTHER and BC6ENTG .	CPR:9
Cells that were deficient in either BC6ENTG or BC6OTHER , as well as cells that were deficient in both BC6OTHER and BC6OTHER , externalized normal amounts of BC6ENTC .	False
Cells that were deficient in either BC6OTHER or BC6ENTG , as well as cells that were deficient in both BC6OTHER and BC6OTHER , externalized normal amounts of BC6ENTC .	False
Cells that were deficient in either BC6OTHER or BC6OTHER , as well as cells that were deficient in both BC6ENTG and BC6OTHER , externalized normal amounts of BC6ENTC .	False
Cells that were deficient in either BC6OTHER or BC6OTHER , as well as cells that were deficient in both BC6OTHER and BC6ENTG , externalized normal amounts of BC6ENTC .	False
Moreover , a normal level of expression of BC6ENTG and / or BC6OTHER is not required for generating the pool of BC6ENTC externalized during apoptosis.	CPR:9
Moreover , a normal level of expression of BC6OTHER and / or BC6ENTG is not required for generating the pool of BC6ENTC externalized during apoptosis.	CPR:9
BC6OTHER ( BC6ENTC ) is made in mammalian cells by two BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) is made in mammalian cells by two BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER ( BC6ENTC ) is made in mammalian cells by two BC6OTHER , BC6OTHER and BC6ENTG .	False
We induced apoptosis with BC6ENTC in four Chinese hamster ovary (CHO) cell lines that are deficient in BC6ENTG and / or BC6OTHER to determine if BC6OTHER generated by either of these enzymes is required for externalization on the cell surface during apoptosis.	False
We induced apoptosis with BC6ENTC in four Chinese hamster ovary (CHO) cell lines that are deficient in BC6OTHER and / or BC6ENTG to determine if BC6OTHER generated by either of these enzymes is required for externalization on the cell surface during apoptosis.	False
We induced apoptosis with BC6OTHER in four Chinese hamster ovary (CHO) cell lines that are deficient in BC6ENTG and / or BC6OTHER to determine if BC6ENTC generated by either of these enzymes is required for externalization on the cell surface during apoptosis.	False
We induced apoptosis with BC6OTHER in four Chinese hamster ovary (CHO) cell lines that are deficient in BC6OTHER and / or BC6ENTG to determine if BC6ENTC generated by either of these enzymes is required for externalization on the cell surface during apoptosis.	False
BC6OTHER ( BC6OTHER ) is made in mammalian cells by two BC6ENTC synthases , BC6ENTG and BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is made in mammalian cells by two BC6ENTC synthases , BC6OTHER and BC6ENTG .	False
Externalization of BC6ENTC during apoptosis does not specifically require either isoform of BC6ENTG .	False
These results suggest that BC6ENTG genotype is the most important patient variable for predicting the level of BC6OTHER activity in women , when measured by the metabolism of BC6ENTC .	CPR:9
These results suggest that BC6OTHER genotype is the most important patient variable for predicting the level of BC6ENTG activity in women , when measured by the metabolism of BC6ENTC .	CPR:9
The BC6ENTC metabolic ratio appears to detect known differences in BC6ENTG activity associated with genetic polymorphism , across different ethnic groups.	CPR:9
To identify important covariates associated with interindividual variation in BC6ENTG activity in vivo , we evaluated these effects in healthy volunteers using BC6ENTC ( BC6OTHER GlaxoSmithKline , Research Triangle Park , NC) as a BC6OTHER probe substrate.	False
To identify important covariates associated with interindividual variation in BC6OTHER activity in vivo , we evaluated these effects in healthy volunteers using BC6ENTC ( BC6OTHER GlaxoSmithKline , Research Triangle Park , NC) as a BC6ENTG probe substrate.	CPR:9
To identify important covariates associated with interindividual variation in BC6ENTG activity in vivo , we evaluated these effects in healthy volunteers using BC6OTHER ( BC6ENTC GlaxoSmithKline , Research Triangle Park , NC) as a BC6OTHER probe substrate.	False
To identify important covariates associated with interindividual variation in BC6OTHER activity in vivo , we evaluated these effects in healthy volunteers using BC6OTHER ( BC6ENTC GlaxoSmithKline , Research Triangle Park , NC) as a BC6ENTG probe substrate.	CPR:9
The influence of sex , ethnicity , and BC6OTHER genotype on BC6ENTC metabolism as an index of hepatic BC6ENTG activity in humans.	False
The influence of sex , ethnicity , and BC6ENTG genotype on BC6ENTC metabolism as an index of hepatic BC6OTHER activity in humans.	CPR:9
Weekly subcutaneous BC6ENTC produces cumulative increases in BC6ENTG and total BC6OTHER through a noncytotoxic mechanism of action.	CPR:3
Weekly subcutaneous BC6ENTC produces cumulative increases in BC6OTHER and total BC6ENTG through a noncytotoxic mechanism of action.	CPR:3
The BC6ENTC analog BC6OTHER ( BC6OTHER ) hypomethylates DNA by inhibiting BC6ENTG .	CPR:4
The BC6OTHER analog BC6ENTC ( BC6OTHER ) hypomethylates DNA by inhibiting BC6ENTG .	CPR:4
The BC6OTHER analog BC6OTHER ( BC6ENTC ) hypomethylates DNA by inhibiting BC6ENTG .	CPR:4
We examined if subcutaneous BC6ENTC could increase BC6ENTG levels and improve SSD pathophysiology without cytotoxicity.	CPR:3
Effects of BC6ENTC on BC6ENTG levels , red cell adhesion , and hematopoietic differentiation in patients with sickle cell disease.	False
We evaluated the clinical effectiveness of BC6ENTC , an ultra - short - acting BC6ENTG blocking drug , to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6ENTG isozymes involved in important physiological processes , BC6OTHER , and BC6OTHER , of the same order of magnitude as the clinically used drugs BC6ENTC and BC6OTHER .	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6OTHER isozymes involved in important physiological processes , BC6ENTG , and BC6OTHER , of the same order of magnitude as the clinically used drugs BC6ENTC and BC6OTHER .	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6OTHER isozymes involved in important physiological processes , BC6OTHER , and BC6ENTG , of the same order of magnitude as the clinically used drugs BC6ENTC and BC6OTHER .	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6ENTG isozymes involved in important physiological processes , BC6OTHER , and BC6OTHER , of the same order of magnitude as the clinically used drugs BC6OTHER and BC6ENTC .	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6OTHER isozymes involved in important physiological processes , BC6ENTG , and BC6OTHER , of the same order of magnitude as the clinically used drugs BC6OTHER and BC6ENTC .	CPR:4
Some of these derivatives showed good inhibitory potency against two BC6OTHER isozymes involved in important physiological processes , BC6OTHER , and BC6ENTG , of the same order of magnitude as the clinically used drugs BC6OTHER and BC6ENTC .	CPR:4
 BC6ENTG inhibitors: BC6ENTC incorporating BC6OTHER moieties with strong anticonvulsant activity.	CPR:4
 BC6ENTG inhibitors: BC6OTHER incorporating BC6ENTC moieties with strong anticonvulsant activity.	CPR:4
BACKGROUND: BC6ENTC is a BC6OTHER drug designed to inhibit both BC6ENTG and BC6OTHER by reversibly covalently bonding to these enzymes.	CPR:4
BACKGROUND: BC6ENTC is a BC6OTHER drug designed to inhibit both BC6OTHER and BC6ENTG by reversibly covalently bonding to these enzymes.	CPR:4
BACKGROUND: BC6OTHER is a BC6ENTC drug designed to inhibit both BC6ENTG and BC6OTHER by reversibly covalently bonding to these enzymes.	CPR:4
BACKGROUND: BC6OTHER is a BC6ENTC drug designed to inhibit both BC6OTHER and BC6ENTG by reversibly covalently bonding to these enzymes.	CPR:4
 BC6ENTC inhibits BC6OTHER - induced inflammatory responses in vitro and in vivo. BC6ENTG ( BC6OTHER ) protein acts as a potent proinflammatory BC6OTHER and is involved in the pathogenesis of several vascular diseases , such as , systemic vasculitis and sepsis.	False
 BC6ENTC inhibits BC6OTHER - induced inflammatory responses in vitro and in vivo. BC6OTHER ( BC6ENTG ) protein acts as a potent proinflammatory BC6OTHER and is involved in the pathogenesis of several vascular diseases , such as , systemic vasculitis and sepsis.	False
 BC6ENTC inhibits BC6OTHER - induced inflammatory responses in vitro and in vivo. BC6OTHER ( BC6OTHER ) protein acts as a potent proinflammatory BC6ENTG and is involved in the pathogenesis of several vascular diseases , such as , systemic vasculitis and sepsis.	False
 BC6ENTC inhibits BC6ENTG - induced inflammatory responses in vitro and in vivo. BC6OTHER ( BC6OTHER ) protein acts as a potent proinflammatory BC6OTHER and is involved in the pathogenesis of several vascular diseases , such as , systemic vasculitis and sepsis.	CPR:4
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6ENTG / BC6ENTC cartridges; ii) by collagen and BC6OTHER (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6OTHER , to generate BC6OTHER concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6OTHER / BC6ENTC cartridges; ii) by collagen and BC6OTHER (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6ENTG , to generate BC6OTHER concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6OTHER / BC6ENTC cartridges; ii) by collagen and BC6OTHER (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6OTHER , to generate BC6ENTG concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6ENTG / BC6OTHER cartridges; ii) by collagen and BC6ENTC (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6OTHER , to generate BC6OTHER concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6OTHER / BC6OTHER cartridges; ii) by collagen and BC6ENTC (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6ENTG , to generate BC6OTHER concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
"Citrated blood from healthy subjects was stimulated: i) from passage through the ""Platelet Function Analyzer"" (CHEM - 100) , a device that exposes blood to standardized high shear flow through BC6OTHER / BC6OTHER cartridges; ii) by collagen and BC6ENTC (2 and 50 mug / ml , respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant BC6OTHER , to generate BC6ENTG concentrations able to activate platelets without inducing blood clotting , or iv) the Thrombin Receptor Activating Peptide - 6 (CHEM - 6)."	False
BC6ENTC inhibits BC6ENTG secretion via pertussis toxin - sensitive mechanisms.	CPR:4
Since voltage - dependent BC6ENTC currents play a key role in BC6ENTG secretion , we examined whether BC6OTHER modulates voltage - dependent BC6OTHER currents of the rat insulinoma cell line , RINm5F.	False
In membranes of control but not of BC6ENTG - treated cells , BC6ENTC via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6ENTC via BC6ENTG stimulated incorporation of the photo - reactive BC6OTHER analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6ENTC via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6ENTG , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6ENTC via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6ENTG , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6ENTC via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6ENTG subtype.	False
In membranes of control but not of BC6ENTG - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6ENTC analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6ENTG stimulated incorporation of the photo - reactive BC6ENTC analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6ENTC analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6ENTG , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6ENTC analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6ENTG , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6ENTC analog BC6OTHER into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6ENTG subtype.	False
In membranes of control but not of BC6ENTG - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6ENTC into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6ENTG stimulated incorporation of the photo - reactive BC6OTHER analog BC6ENTC into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6ENTC into pertussis toxin substrates comigrating with the alpha - subunits of BC6ENTG , BC6OTHER , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6ENTC into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6ENTG , and the not further identified BC6OTHER subtype.	False
In membranes of control but not of BC6OTHER - treated cells , BC6OTHER via BC6OTHER stimulated incorporation of the photo - reactive BC6OTHER analog BC6ENTC into pertussis toxin substrates comigrating with the alpha - subunits of BC6OTHER , BC6OTHER , and the not further identified BC6ENTG subtype.	False
These BC6ENTG are likely to be involved in the BC6ENTC - induced inhibition of BC6OTHER - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6OTHER secretion.	False
These BC6OTHER are likely to be involved in the BC6ENTC - induced inhibition of BC6OTHER - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6ENTG secretion.	False
Since voltage - dependent BC6OTHER currents play a key role in BC6ENTG secretion , we examined whether BC6ENTC modulates voltage - dependent BC6OTHER currents of the rat insulinoma cell line , RINm5F.	False
These BC6ENTG are likely to be involved in the BC6OTHER - induced inhibition of BC6ENTC - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6OTHER secretion.	False
These BC6OTHER are likely to be involved in the BC6OTHER - induced inhibition of BC6ENTC - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6ENTG secretion.	False
These BC6ENTG are likely to be involved in the BC6OTHER - induced inhibition of BC6OTHER - sensitive BC6ENTC currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6OTHER secretion.	False
These BC6OTHER are likely to be involved in the BC6OTHER - induced inhibition of BC6OTHER - sensitive BC6ENTC currents and in other signal transduction pathways contributing to the BC6OTHER - induced inhibition of BC6ENTG secretion.	False
These BC6ENTG are likely to be involved in the BC6OTHER - induced inhibition of BC6OTHER - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6ENTC - induced inhibition of BC6OTHER secretion.	False
These BC6OTHER are likely to be involved in the BC6OTHER - induced inhibition of BC6OTHER - sensitive BC6OTHER currents and in other signal transduction pathways contributing to the BC6ENTC - induced inhibition of BC6ENTG secretion.	CPR:4
Since voltage - dependent BC6OTHER currents play a key role in BC6ENTG secretion , we examined whether BC6OTHER modulates voltage - dependent BC6ENTC currents of the rat insulinoma cell line , RINm5F.	False
BC6ENTC via BC6ENTG inhibited the BC6OTHER currents by about 50%.	False
BC6OTHER via BC6ENTG inhibited the BC6ENTC currents by about 50%.	False
BC6ENTC which also inhibits BC6ENTG secretion was less efficient (inhibition by 20%).	CPR:4
The hormonal inhibition of BC6ENTC currents was not affected by intracellularly applied BC6OTHER but blocked by the intracellularly applied BC6OTHER analog BC6OTHER and by pretreatment of cells with BC6ENTG .	False
The hormonal inhibition of BC6OTHER currents was not affected by intracellularly applied BC6ENTC but blocked by the intracellularly applied BC6OTHER analog BC6OTHER and by pretreatment of cells with BC6ENTG .	False
The hormonal inhibition of BC6OTHER currents was not affected by intracellularly applied BC6OTHER but blocked by the intracellularly applied BC6ENTC analog BC6OTHER and by pretreatment of cells with BC6ENTG .	False
The hormonal inhibition of BC6OTHER currents was not affected by intracellularly applied BC6OTHER but blocked by the intracellularly applied BC6OTHER analog BC6ENTC and by pretreatment of cells with BC6ENTG .	False
In contrast to BC6ENTC and BC6ENTG , BC6OTHER , another inhibitor of BC6OTHER secretion , reduced BC6OTHER currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6ENTC and BC6OTHER , BC6ENTG , another inhibitor of BC6OTHER secretion , reduced BC6OTHER currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6ENTC and BC6OTHER , BC6OTHER , another inhibitor of BC6ENTG secretion , reduced BC6OTHER currents by about 40% in a BC6OTHER - insensitive manner.	CPR:4
In contrast to BC6ENTC and BC6OTHER , BC6OTHER , another inhibitor of BC6OTHER secretion , reduced BC6OTHER currents by about 40% in a BC6ENTG - insensitive manner.	False
In contrast to BC6OTHER and BC6ENTC , BC6ENTG , another inhibitor of BC6OTHER secretion , reduced BC6OTHER currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6OTHER and BC6ENTC , BC6OTHER , another inhibitor of BC6ENTG secretion , reduced BC6OTHER currents by about 40% in a BC6OTHER - insensitive manner.	CPR:4
In contrast to BC6OTHER and BC6ENTC , BC6OTHER , another inhibitor of BC6OTHER secretion , reduced BC6OTHER currents by about 40% in a BC6ENTG - insensitive manner.	False
In contrast to BC6OTHER and BC6ENTG , BC6OTHER , another inhibitor of BC6OTHER secretion , reduced BC6ENTC currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6OTHER and BC6OTHER , BC6ENTG , another inhibitor of BC6OTHER secretion , reduced BC6ENTC currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6OTHER and BC6OTHER , BC6OTHER , another inhibitor of BC6ENTG secretion , reduced BC6ENTC currents by about 40% in a BC6OTHER - insensitive manner.	False
In contrast to BC6OTHER and BC6OTHER , BC6OTHER , another inhibitor of BC6OTHER secretion , reduced BC6ENTC currents by about 40% in a BC6ENTG - insensitive manner.	False
Involvement of BC6OTHER - sensitive BC6OTHER in the hormonal inhibition of BC6OTHER - sensitive BC6ENTC currents in an BC6ENTG - secreting cell line (RINm5F).	False
Involvement of BC6ENTG - sensitive BC6OTHER in the hormonal inhibition of BC6OTHER - sensitive BC6ENTC currents in an BC6OTHER - secreting cell line (RINm5F).	False
Involvement of BC6OTHER - sensitive BC6ENTG in the hormonal inhibition of BC6OTHER - sensitive BC6ENTC currents in an BC6OTHER - secreting cell line (RINm5F).	False
Involvement of BC6OTHER - sensitive BC6OTHER in the hormonal inhibition of BC6ENTC - sensitive BC6OTHER currents in an BC6ENTG - secreting cell line (RINm5F).	False
Involvement of BC6ENTG - sensitive BC6OTHER in the hormonal inhibition of BC6ENTC - sensitive BC6OTHER currents in an BC6OTHER - secreting cell line (RINm5F).	False
Involvement of BC6OTHER - sensitive BC6ENTG in the hormonal inhibition of BC6ENTC - sensitive BC6OTHER currents in an BC6OTHER - secreting cell line (RINm5F).	False
BC6ENTC ( BC6OTHER ) are BC6ENTG sensitizers used for treatment of diabetes.	False
BC6ENTC effects on osteoblast viability , CHEM uptake , BC6ENTG and BC6OTHER production are independent of their effects on BC6OTHER .	False
BC6ENTC effects on osteoblast viability , CHEM uptake , BC6OTHER and BC6ENTG production are independent of their effects on BC6OTHER .	False
BC6ENTC effects on osteoblast viability , CHEM uptake , BC6OTHER and BC6OTHER production are independent of their effects on BC6ENTG .	CPR:4
We have previously reported that BC6ENTC reduce BC6OTHER synthesis by inhibiting BC6ENTG activity in human granulosa cells (HGC).	CPR:4
We have previously reported that BC6OTHER reduce BC6ENTC synthesis by inhibiting BC6ENTG activity in human granulosa cells (HGC).	CPR:9
BC6OTHER ( BC6ENTC ) are BC6ENTG sensitizers used for treatment of diabetes.	False
We studied mouse osteoblasts alone or in a co - culture with HGC to determine whether BC6ENTC inhibition of BC6ENTG plays a role in their effects on bone metabolism.	CPR:4
BC6ENTC also inhibited BC6ENTG activity (58 - 75% , p<0.046) and BC6OTHER production (52 - 75% , p<0.031).	CPR:4
BC6ENTC also inhibited BC6OTHER activity (58 - 75% , p<0.046) and BC6ENTG production (52 - 75% , p<0.031).	CPR:4
 BC6ENTC ( BC6OTHER ) affect osteoblast viability and biomarkers independently of the BC6OTHER effects on BC6ENTG .	False
 BC6OTHER ( BC6ENTC ) affect osteoblast viability and biomarkers independently of the BC6OTHER effects on BC6ENTG .	False
 BC6OTHER ( BC6OTHER ) affect osteoblast viability and biomarkers independently of the BC6ENTC effects on BC6ENTG .	False
CHEM is a BC6OTHER (gene encoding BC6ENTC / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the BC6ENTG substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding BC6ENTC / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6ENTG ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding BC6ENTC / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6OTHER ( BC6ENTG )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6ENTG (gene encoding BC6ENTC / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
 In vivo , the ratio of area under the concentration - time curve (AUC)(brain) to AUC(plasma) (K(p)) of BC6ENTC after an i.v. dose (2.5 mg / kg) was 0.023 , which increased by 18 - fold in BC6ENTG ( - / - ) BC6OTHER ( - / - ) mice to 0.42.	False
 In vivo , the ratio of area under the concentration - time curve (AUC)(brain) to AUC(plasma) (K(p)) of BC6ENTC after an i.v. dose (2.5 mg / kg) was 0.023 , which increased by 18 - fold in BC6OTHER ( - / - ) BC6ENTG ( - / - ) mice to 0.42.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6ENTC - protein kinase B - Raf) inhibitor that has been developed to selectively target the BC6ENTG substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6ENTC - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6ENTG ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6ENTC - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6OTHER ( BC6ENTG )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6ENTG (gene encoding CHEM / BC6ENTC - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6OTHER substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
BC6ENTC plasma exposure was ∼2 - fold greater in BC6ENTG ( - / - ) BC6OTHER ( - / - ) mice as compared with wild - type with an oral dose (25 mg / kg); however , the brain distribution was increased by ~10 - fold with a resulting K(p) of 0.25.	False
BC6ENTC plasma exposure was ∼2 - fold greater in BC6OTHER ( - / - ) BC6ENTG ( - / - ) mice as compared with wild - type with an oral dose (25 mg / kg); however , the brain distribution was increased by ~10 - fold with a resulting K(p) of 0.25.	False
Further , compared with BC6ENTC , another BC6ENTG ( BC6OTHER ) inhibitor , BC6OTHER showed greater brain penetration with a similar dose.	CPR:4
Further , compared with BC6ENTC , another BC6OTHER ( BC6ENTG ) inhibitor , BC6OTHER showed greater brain penetration with a similar dose.	CPR:4
Further , compared with BC6OTHER , another BC6ENTG ( BC6OTHER ) inhibitor , BC6ENTC showed greater brain penetration with a similar dose.	False
Further , compared with BC6OTHER , another BC6OTHER ( BC6ENTG ) inhibitor , BC6ENTC showed greater brain penetration with a similar dose.	False
CHEM is a BC6OTHER (gene encoding BC6ENTG ) inhibitor that has been developed to selectively target the BC6ENTC 600 to BC6OTHER substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the BC6ENTC 600 to BC6OTHER substitution ( BC6ENTG ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the BC6ENTC 600 to BC6OTHER substitution ( BC6OTHER ( BC6ENTG )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6ENTG (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the BC6ENTC 600 to BC6OTHER substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding BC6ENTG ) inhibitor that has been developed to selectively target the CHEM 600 to BC6ENTC substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6ENTC substitution ( BC6ENTG ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6OTHER (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6ENTC substitution ( BC6OTHER ( BC6ENTG )) , which is commonly found in metastatic melanoma.	False
CHEM is a BC6ENTG (gene encoding CHEM / BC6OTHER - protein kinase B - Raf) inhibitor that has been developed to selectively target the CHEM 600 to BC6ENTC substitution ( BC6OTHER ( BC6OTHER )) , which is commonly found in metastatic melanoma.	False
Thus , the objective of the current study was to evaluate the brain distribution of BC6ENTC in mice , and to see whether active efflux by BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) restricts its delivery across the blood - brain barrier (BBB).	False
Thus , the objective of the current study was to evaluate the brain distribution of BC6ENTC in mice , and to see whether active efflux by BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) restricts its delivery across the blood - brain barrier (BBB).	False
Thus , the objective of the current study was to evaluate the brain distribution of BC6ENTC in mice , and to see whether active efflux by BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) restricts its delivery across the blood - brain barrier (BBB).	False
Thus , the objective of the current study was to evaluate the brain distribution of BC6ENTC in mice , and to see whether active efflux by BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) restricts its delivery across the blood - brain barrier (BBB).	False
In vitro accumulation studies conducted in Madin - Darby canine kidney II cells indicate that BC6ENTC is an avid substrate for both BC6ENTG and BC6OTHER .	CPR:9
In vitro accumulation studies conducted in Madin - Darby canine kidney II cells indicate that BC6ENTC is an avid substrate for both BC6OTHER and BC6ENTG .	CPR:9
Mechanisms limiting distribution of the BC6ENTC - protein kinase B - RaF( BC6ENTG ) inhibitor BC6OTHER to the brain: implications for the treatment of melanoma brain metastases.	False
Mechanisms limiting distribution of the BC6ENTG ( BC6OTHER ) inhibitor BC6ENTC to the brain: implications for the treatment of melanoma brain metastases.	CPR:4
Mechanisms limiting distribution of the BC6OTHER ( BC6ENTG ) inhibitor BC6ENTC to the brain: implications for the treatment of melanoma brain metastases.	CPR:4
Also , BC6ENTC showed anti - angiogenic activity by decreasing the expression of BC6ENTG and BC6OTHER .	CPR:4
Also , BC6ENTC showed anti - angiogenic activity by decreasing the expression of BC6OTHER and BC6ENTG .	CPR:4
 When further examined for its anticancer mechanism , BC6ENTC effectively suppressed the BC6ENTG / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6OTHER inhibits the BC6OTHER / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	CPR:4
 When further examined for its anticancer mechanism , BC6ENTC effectively suppressed the BC6OTHER / BC6ENTG pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6OTHER inhibits the BC6OTHER / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	CPR:4
 When further examined for its anticancer mechanism , BC6ENTC effectively suppressed the BC6OTHER / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6OTHER inhibits the BC6ENTG / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	False
 When further examined for its anticancer mechanism , BC6ENTC effectively suppressed the BC6OTHER / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6OTHER inhibits the BC6OTHER / BC6ENTG pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	False
 When further examined for its anticancer mechanism , BC6OTHER effectively suppressed the BC6ENTG / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6ENTC inhibits the BC6OTHER / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	False
 When further examined for its anticancer mechanism , BC6OTHER effectively suppressed the BC6OTHER / BC6ENTG pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6ENTC inhibits the BC6OTHER / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	False
 When further examined for its anticancer mechanism , BC6OTHER effectively suppressed the BC6OTHER / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6ENTC inhibits the BC6ENTG / BC6OTHER pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	CPR:4
 When further examined for its anticancer mechanism , BC6OTHER effectively suppressed the BC6OTHER / BC6OTHER pathway both in vitro and in vivo. Taken together , our study demonstrated that BC6ENTC inhibits the BC6OTHER / BC6ENTG pathway , leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.	CPR:4
 BC6ENTC , BC6OTHER suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the BC6ENTG / BC6OTHER signalling pathway.	False
 BC6ENTC , BC6OTHER suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the BC6OTHER / BC6ENTG signalling pathway.	False
 BC6OTHER , BC6ENTC suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the BC6ENTG / BC6OTHER signalling pathway.	False
 BC6OTHER , BC6ENTC suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the BC6OTHER / BC6ENTG signalling pathway.	False
A similar signature is associated with the persistence of BC6ENTC ( BC6OTHER ) in DNA , and it also depends on BC6ENTG activity.	False
A similar signature is associated with the persistence of BC6OTHER ( BC6ENTC ) in DNA , and it also depends on BC6ENTG activity.	False
There is only partial overlap , however , between BC6ENTG - dependent deletion hotspots identified in highly transcribed DNA and those associated with BC6ENTC , suggesting the existence of both BC6OTHER - dependent and BC6OTHER - independent events.	False
There is only partial overlap , however , between BC6ENTG - dependent deletion hotspots identified in highly transcribed DNA and those associated with BC6OTHER , suggesting the existence of both BC6ENTC - dependent and BC6OTHER - independent events.	False
There is only partial overlap , however , between BC6ENTG - dependent deletion hotspots identified in highly transcribed DNA and those associated with BC6OTHER , suggesting the existence of both BC6OTHER - dependent and BC6ENTC - independent events.	False
Data suggest a novel model in which BC6ENTC - dependent hotspots are generated by sequential BC6ENTG reactions and are consistent with BC6OTHER - independent hotspots reflecting processing of a trapped BC6OTHER cleavage complex.	False
Data suggest a novel model in which BC6ENTC - dependent hotspots are generated by sequential BC6OTHER reactions and are consistent with BC6OTHER - independent hotspots reflecting processing of a trapped BC6ENTG cleavage complex.	False
Data suggest a novel model in which BC6OTHER - dependent hotspots are generated by sequential BC6ENTG reactions and are consistent with BC6ENTC - independent hotspots reflecting processing of a trapped BC6OTHER cleavage complex.	False
Data suggest a novel model in which BC6OTHER - dependent hotspots are generated by sequential BC6OTHER reactions and are consistent with BC6ENTC - independent hotspots reflecting processing of a trapped BC6ENTG cleavage complex.	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTC activity in liver , which was found to represent 98% of the observed BC6ENTG activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTC activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6ENTG inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6ENTG activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTC activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTG activity in liver , which was found to represent 98% of the observed BC6ENTC activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6ENTC activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6ENTG inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6ENTG activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6ENTC activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Little is known in terms of multi - matrix BC6ENTG activity induction under repeated oral exposure to planar BC6ENTC (PHH , BC6OTHER ).	CPR:3
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTG activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6ENTC .	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6ENTG activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6ENTC .	False
Correlations between matrices made it possible to conclude that BC6OTHER activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6ENTG inducing CHEM and BC6ENTC .	False
Correlations between matrices made it possible to conclude that BC6ENTG activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6ENTC .	False
Little is known in terms of multi - matrix BC6ENTG activity induction under repeated oral exposure to planar BC6OTHER (PHH , BC6ENTC ).	CPR:3
BC6ENTC activity , reflecting almost exclusively BC6ENTG and BC6OTHER activities , was measured in brain and liver microsomes as well as in peripheral blood lymphocytes (PBLs).	False
BC6ENTC activity , reflecting almost exclusively BC6OTHER and BC6ENTG activities , was measured in brain and liver microsomes as well as in peripheral blood lymphocytes (PBLs).	False
Correlations between matrices made it possible to conclude that BC6ENTC activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6ENTG activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6ENTC activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6ENTG activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6OTHER inducing CHEM and BC6OTHER .	False
Correlations between matrices made it possible to conclude that BC6ENTC activity in PBL should be considered as a sensitive , convenient and non - destructive approach for (i) evaluating BC6OTHER activity in liver , which was found to represent 98% of the observed BC6OTHER activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race , diet) to BC6ENTG inducing CHEM and BC6OTHER .	False
 BC6ENTG activity induction in peripheral blood lymphocytes , liver and brain tissues of rats orally exposed to BC6ENTC .	CPR:3
Suppression of BC6ENTG by the pharmacological inhibitor ( BC6ENTC ) markedly reduced BC6OTHER release by HFL - 1 in response to CSE and this effect was confirmed by BC6OTHER siRNA.	CPR:4
Suppression of BC6OTHER by the pharmacological inhibitor ( BC6ENTC ) markedly reduced BC6ENTG release by HFL - 1 in response to CSE and this effect was confirmed by BC6OTHER siRNA.	CPR:4
Suppression of BC6OTHER by the pharmacological inhibitor ( BC6ENTC ) markedly reduced BC6OTHER release by HFL - 1 in response to CSE and this effect was confirmed by BC6ENTG siRNA.	False
BC6ENTC does not account for the CHEM stimulation of BC6ENTG in HFL - 1.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6ENTC (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6ENTC (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6ENTC (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6ENTC (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6ENTC (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The study showed that BC6ENTC did not attenuate increased blood pressure induced by PE , BC6ENTG and BC6OTHER but caused enhanced vasodilation by BC6OTHER , BC6OTHER and BC6OTHER .	False
The study showed that BC6ENTC did not attenuate increased blood pressure induced by PE , BC6OTHER and BC6ENTG but caused enhanced vasodilation by BC6OTHER , BC6OTHER and BC6OTHER .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6ENTG and BC6OTHER but caused enhanced vasodilation by BC6ENTC , BC6OTHER and BC6OTHER .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6OTHER and BC6ENTG but caused enhanced vasodilation by BC6ENTC , BC6OTHER and BC6OTHER .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6ENTG and BC6OTHER but caused enhanced vasodilation by BC6OTHER , BC6ENTC and BC6OTHER .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6OTHER and BC6ENTG but caused enhanced vasodilation by BC6OTHER , BC6ENTC and BC6OTHER .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6ENTG and BC6OTHER but caused enhanced vasodilation by BC6OTHER , BC6OTHER and BC6ENTC .	False
The study showed that BC6OTHER did not attenuate increased blood pressure induced by PE , BC6OTHER and BC6ENTG but caused enhanced vasodilation by BC6OTHER , BC6OTHER and BC6ENTC .	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were evaluated in BC6OTHER - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6ENTC - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6ENTC - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6ENTC - induced acute kidney injury in rats.	False
The modulating effect of BC6OTHER ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6ENTC - induced acute kidney injury in rats.	False
The modulating effect of BC6ENTG ligand on haemodynamic effects of BC6OTHER (PE) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were evaluated in BC6ENTC - induced acute kidney injury in rats.	False
For BC6ENTG and BC6OTHER , MAP was also increased for the BC6ENTC group but not in a dose - dependent fashion.	CPR:3
For BC6OTHER and BC6ENTG , MAP was also increased for the BC6ENTC group but not in a dose - dependent fashion.	CPR:3
On the medullary blood flow (MBF) , while the lower doses of PE and BC6ENTG increased the perfusion unit on the BC6ENTC - treated group , the higher doses decreased the perfusion unit.	False
The effects of PE and BC6ENTG on the cortical blood flow (CBF) of BC6ENTC - treated group is similar to that of MBF for the same group but not for BC6OTHER .	False
The effects of PE and BC6OTHER on the cortical blood flow (CBF) of BC6ENTC - treated group is similar to that of MBF for the same group but not for BC6ENTG .	False
Effects of BC6ENTC , a BC6ENTG ligand , on the haemodynamics of BC6OTHER - induced renal failure in rats.	False
Effects of BC6OTHER , a BC6ENTG ligand , on the haemodynamics of BC6ENTC - induced renal failure in rats.	False
The mechanisms by which BC6ENTC may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6ENTG , by binding to BC6OTHER , BC6OTHER and BC6OTHER .	False
The mechanisms by which BC6ENTC may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6OTHER , by binding to BC6ENTG , BC6OTHER and BC6OTHER .	False
The mechanisms by which BC6ENTC may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6OTHER , by binding to BC6OTHER , BC6ENTG and BC6OTHER .	False
The mechanisms by which BC6ENTC may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6OTHER , by binding to BC6OTHER , BC6OTHER and BC6ENTG .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6ENTC synthesis , BC6ENTG , by binding to BC6OTHER , BC6OTHER and BC6OTHER .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6ENTC synthesis , BC6OTHER , by binding to BC6ENTG , BC6OTHER and BC6OTHER .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6ENTC synthesis , BC6OTHER , by binding to BC6OTHER , BC6ENTG and BC6OTHER .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6ENTC synthesis , BC6OTHER , by binding to BC6OTHER , BC6OTHER and BC6ENTG .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6ENTC reductase , by binding to BC6ENTG , BC6OTHER and BC6OTHER .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6ENTC reductase , by binding to BC6OTHER , BC6ENTG and BC6OTHER .	False
The mechanisms by which BC6OTHER may influence proliferation are manifold: they control the transcription and the turnover of the key enzyme in BC6OTHER synthesis , BC6ENTC reductase , by binding to BC6OTHER , BC6OTHER and BC6ENTG .	False
BC6ENTC uptake from BC6ENTG , intracellular vesicle transport and lipid transfer are also modified by BC6OTHER .	CPR:9
BC6OTHER uptake from BC6ENTG , intracellular vesicle transport and lipid transfer are also modified by BC6ENTC .	False
BC6ENTC interfere with BC6ENTG , BC6OTHER and BC6OTHER pathways of proliferation and differentiation.	False
BC6ENTC interfere with BC6OTHER , BC6ENTG and BC6OTHER pathways of proliferation and differentiation.	False
BC6ENTC interfere with BC6OTHER , BC6OTHER and BC6ENTG pathways of proliferation and differentiation.	False
BC6ENTG ( BC6OTHER ) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of BC6ENTC based BC6OTHER inhibitors.	False
BC6OTHER ( BC6OTHER ) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of BC6ENTC based BC6ENTG inhibitors.	CPR:4
BC6OTHER ( BC6ENTG ) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of BC6ENTC based BC6OTHER inhibitors.	False
Enzyme kinetic analyses using human liver microsomes revealed inhibition of BC6ENTG activity by BC6ENTC (IC50 78 μM) and BC6OTHER (IC50 33 μM).	CPR:4
Enzyme kinetic analyses using human liver microsomes revealed inhibition of BC6ENTG activity by BC6OTHER (IC50 78 μM) and BC6ENTC (IC50 33 μM).	CPR:4
Overall , although most BC6ENTC had no effects on BC6ENTG - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6ENTC had no effects on BC6OTHER - BC6ENTG signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6ENTC had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6ENTG and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6ENTC had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6ENTG - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6ENTC had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6ENTG catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6ENTG - BC6OTHER signaling , BC6ENTC can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6ENTG signaling , BC6ENTC can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6ENTC can bind to and activate the BC6ENTG and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	CPR:3
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6ENTC can bind to and activate the BC6OTHER and BC6ENTG - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6ENTC can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6OTHER inhibit the BC6ENTG catalytic activity.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTC receptor ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTC receptor ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
Overall , although most BC6OTHER had no effects on BC6ENTG - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6ENTC and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6ENTG signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6ENTC and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6ENTG and BC6OTHER - dependent gene expression , and BC6ENTC and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6ENTG - dependent gene expression , and BC6ENTC and BC6OTHER inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6ENTC and BC6OTHER inhibit the BC6ENTG catalytic activity.	CPR:4
Overall , although most BC6OTHER had no effects on BC6ENTG - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6ENTC inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6ENTG signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6ENTC inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6ENTG and BC6OTHER - dependent gene expression , and BC6OTHER and BC6ENTC inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6ENTG - dependent gene expression , and BC6OTHER and BC6ENTC inhibit the BC6OTHER catalytic activity.	False
Overall , although most BC6OTHER had no effects on BC6OTHER - BC6OTHER signaling , BC6OTHER can bind to and activate the BC6OTHER and BC6OTHER - dependent gene expression , and BC6OTHER and BC6ENTC inhibit the BC6ENTG catalytic activity.	CPR:4
We examined the effects of BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
BC6ENTG - dependent reporter gene expression in transfected HepG2 cells was increased by BC6ENTC in a concentration - dependent manner at 24h.	CPR:3
Similarly , BC6ENTC induced the expression of BC6ENTG mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6OTHER ( BC6OTHER ) , the most potent activator of BC6OTHER .	CPR:3
Similarly , BC6ENTC induced the expression of BC6OTHER mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6OTHER ( BC6OTHER ) , the most potent activator of BC6ENTG .	False
We examined the effects of BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
Similarly , BC6OTHER induced the expression of BC6ENTG mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6ENTC ( BC6OTHER ) , the most potent activator of BC6OTHER .	CPR:3
Similarly , BC6OTHER induced the expression of BC6OTHER mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6ENTC ( BC6OTHER ) , the most potent activator of BC6ENTG .	CPR:3
We examined the effects of BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
Similarly , BC6OTHER induced the expression of BC6ENTG mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6OTHER ( BC6ENTC ) , the most potent activator of BC6OTHER .	CPR:3
Similarly , BC6OTHER induced the expression of BC6OTHER mRNA up to 5 - fold in HepG2 and LS174T cells relative to the induction by 5 nM BC6OTHER ( BC6ENTC ) , the most potent activator of BC6ENTG .	CPR:3
BC6ENTG and BC6OTHER mRNAs were also increased by BC6ENTC in three primary human hepatocytes cultures (approximately 5% of BC6OTHER potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6ENTG mRNAs were also increased by BC6ENTC in three primary human hepatocytes cultures (approximately 5% of BC6OTHER potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6OTHER mRNAs were also increased by BC6ENTC in three primary human hepatocytes cultures (approximately 5% of BC6OTHER potency) and the increase in BC6ENTG protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6OTHER mRNAs were also increased by BC6ENTC in three primary human hepatocytes cultures (approximately 5% of BC6OTHER potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6ENTG enzyme.	CPR:3
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
BC6ENTG and BC6OTHER mRNAs were also increased by BC6OTHER in three primary human hepatocytes cultures (approximately 5% of BC6ENTC potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6ENTG mRNAs were also increased by BC6OTHER in three primary human hepatocytes cultures (approximately 5% of BC6ENTC potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6OTHER mRNAs were also increased by BC6OTHER in three primary human hepatocytes cultures (approximately 5% of BC6ENTC potency) and the increase in BC6ENTG protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6OTHER enzyme.	CPR:3
BC6OTHER and BC6OTHER mRNAs were also increased by BC6OTHER in three primary human hepatocytes cultures (approximately 5% of BC6ENTC potency) and the increase in BC6OTHER protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of BC6ENTG enzyme.	CPR:3
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
Ligand binding analysis demonstrated that BC6ENTC was a weak ligand of BC6ENTG .	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) on the BC6ENTG ( BC6OTHER ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) on the BC6OTHER ( BC6ENTG ) - BC6OTHER signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
We examined the effects of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) on the BC6OTHER ( BC6OTHER ) - BC6ENTG signaling pathway in human hepatocytes , hepatic HepG2 and intestinal LS174T cancer cells.	False
 BC6ENTC activates the BC6ENTG and induces BC6OTHER in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.	CPR:3
 BC6ENTC activates the BC6OTHER and induces BC6ENTG in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.	False
Experimental as well as clinical reports support the hypothesis that BC6ENTG blockers such as BC6ENTC may be an appropriate therapeutic approach in LQTS.	CPR:4
METHODS AND RESULTS: In 8 Langendorff - perfused rabbit hearts , BC6ENTC (0.1 microM) , an inhibitor of BC6ENTG inactivation , led to a marked increase in QT - interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.	CPR:4
RESULTS: BC6ENTC was six times more active against BC6ENTG (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6OTHER was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	False
RESULTS: BC6ENTC was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6ENTG (IC(50) = 0.12 microM) while BC6OTHER was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	False
RESULTS: BC6ENTC was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6OTHER was approximately 32 times more active against BC6ENTG (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	CPR:4
RESULTS: BC6ENTC was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6OTHER was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6ENTG (IC(50) = 0.210 microM).	CPR:4
RESULTS: BC6OTHER was six times more active against BC6ENTG (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6ENTC was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	CPR:4
RESULTS: BC6OTHER was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6ENTG (IC(50) = 0.12 microM) while BC6ENTC was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	CPR:4
RESULTS: BC6OTHER was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6ENTC was approximately 32 times more active against BC6ENTG (IC(50) = 0.0066 microM) than BC6OTHER (IC(50) = 0.210 microM).	False
RESULTS: BC6OTHER was six times more active against BC6OTHER (IC(50) = 0.02 microM) than BC6OTHER (IC(50) = 0.12 microM) while BC6ENTC was approximately 32 times more active against BC6OTHER (IC(50) = 0.0066 microM) than BC6ENTG (IC(50) = 0.210 microM).	False
OBJECTIVE: To compare the BC6ENTG ( BC6OTHER ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
OBJECTIVE: To compare the BC6OTHER ( BC6ENTG ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
OBJECTIVE: To compare the BC6ENTG ( BC6OTHER ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
OBJECTIVE: To compare the BC6OTHER ( BC6ENTG ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
OBJECTIVE: To compare the BC6ENTG ( BC6OTHER ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
OBJECTIVE: To compare the BC6OTHER ( BC6ENTG ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
CONCLUSIONS: BC6ENTC is relatively BC6ENTG selective while BC6OTHER is potently selective for BC6OTHER over BC6OTHER .	False
CONCLUSIONS: BC6ENTC is relatively BC6OTHER selective while BC6OTHER is potently selective for BC6ENTG over BC6OTHER .	False
CONCLUSIONS: BC6ENTC is relatively BC6OTHER selective while BC6OTHER is potently selective for BC6OTHER over BC6ENTG .	False
CONCLUSIONS: BC6OTHER is relatively BC6ENTG selective while BC6ENTC is potently selective for BC6OTHER over BC6OTHER .	False
CONCLUSIONS: BC6OTHER is relatively BC6OTHER selective while BC6ENTC is potently selective for BC6ENTG over BC6OTHER .	False
CONCLUSIONS: BC6OTHER is relatively BC6OTHER selective while BC6ENTC is potently selective for BC6OTHER over BC6ENTG .	False
OBJECTIVE: To compare the BC6ENTG ( BC6OTHER ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
OBJECTIVE: To compare the BC6OTHER ( BC6ENTG ) activity and anti - inflammatory effects of the nonsteroidal anti - inflammatory drugs (NSAIDs) BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
METHODS: BC6ENTG activity and selectivity was determined in vitro by measuring BC6ENTC ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6OTHER and BC6OTHER .	CPR:9
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6ENTC ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6ENTG or BC6OTHER and BC6OTHER .	False
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6ENTC ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6ENTG and BC6OTHER .	False
METHODS: BC6ENTG activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6ENTC ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6OTHER and BC6OTHER .	CPR:9
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6ENTC ) production following incubation of varying concentrations of NSAID with BC6ENTG or BC6OTHER and BC6OTHER .	False
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6ENTC ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6ENTG and BC6OTHER .	False
METHODS: BC6ENTG activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6OTHER and BC6ENTC .	False
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6ENTG or BC6OTHER and BC6ENTC .	False
METHODS: BC6OTHER activity and selectivity was determined in vitro by measuring BC6OTHER ( BC6OTHER ) production following incubation of varying concentrations of NSAID with BC6OTHER or BC6ENTG and BC6ENTC .	False
Comparison of BC6ENTG inhibitory activity and ocular anti - inflammatory effects of BC6OTHER and BC6ENTC .	CPR:4
Comparison of BC6ENTG inhibitory activity and ocular anti - inflammatory effects of BC6ENTC and BC6OTHER .	CPR:4
The cardiostimulant effects of BC6ENTC were enhanced by CHEM ( BC6ENTG inhibitor) and decreased by BC6OTHER ( BC6OTHER antagonist).	False
The cardiostimulant effects of BC6OTHER were enhanced by CHEM ( BC6ENTG inhibitor) and decreased by BC6ENTC ( BC6OTHER antagonist).	False
The cardiostimulant effects of BC6OTHER were enhanced by CHEM ( BC6ENTG inhibitor) and decreased by BC6OTHER ( BC6ENTC antagonist).	False
BC6ENTC but not BC6OTHER initiated arrhythmias at lower concentrations following BC6ENTG overexpression.	CPR:3
BC6OTHER but not BC6ENTC initiated arrhythmias at lower concentrations following BC6ENTG overexpression.	False
BC6ENTC saturation binding in Adv.beta(1) myocytes demonstrated approximately 18 - fold increase in BC6ENTG .	CPR:3
BC6ENTC saturation binding , in the presence of BC6OTHER , increased approximately 5 - fold following overexpression of BC6ENTG .	CPR:3
BC6OTHER saturation binding , in the presence of BC6ENTC , increased approximately 5 - fold following overexpression of BC6ENTG .	CPR:3
This study demonstrates enhanced cardiostimulation by BC6ENTC (in the presence of BC6OTHER ) in rat ventricular myocytes overexpressing BC6ENTG , mediated by a BC6OTHER / BC6OTHER signalling pathway.	False
This study demonstrates enhanced cardiostimulation by BC6ENTC (in the presence of BC6OTHER ) in rat ventricular myocytes overexpressing BC6OTHER , mediated by a BC6ENTG / BC6OTHER signalling pathway.	False
This study demonstrates enhanced cardiostimulation by BC6OTHER (in the presence of BC6ENTC ) in rat ventricular myocytes overexpressing BC6ENTG , mediated by a BC6OTHER / BC6OTHER signalling pathway.	False
This study demonstrates enhanced cardiostimulation by BC6OTHER (in the presence of BC6ENTC ) in rat ventricular myocytes overexpressing BC6OTHER , mediated by a BC6ENTG / BC6OTHER signalling pathway.	False
This study demonstrates enhanced cardiostimulation by BC6OTHER (in the presence of BC6OTHER ) in rat ventricular myocytes overexpressing BC6ENTG , mediated by a BC6OTHER / BC6ENTC signalling pathway.	False
This study demonstrates enhanced cardiostimulation by BC6OTHER (in the presence of BC6OTHER ) in rat ventricular myocytes overexpressing BC6OTHER , mediated by a BC6ENTG / BC6ENTC signalling pathway.	False
BC6ENTC mediates cardiostimulation by activation of the 'putative' BC6OTHER ; however , it has recently been reported that disruption of the BC6ENTG gene abolishes this effect.	CPR:3
BC6ENTC mediates cardiostimulation by activation of the 'putative' BC6ENTG ; however , it has recently been reported that disruption of the BC6OTHER gene abolishes this effect.	CPR:3
We have adenovirally overexpressed BC6ENTG in isolated , cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of BC6ENTC and BC6OTHER (in the presence of 1 microm BC6OTHER ).	False
We have adenovirally overexpressed BC6ENTG in isolated , cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of BC6OTHER and BC6ENTC (in the presence of 1 microm BC6OTHER ).	False
We have adenovirally overexpressed BC6ENTG in isolated , cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of BC6OTHER and BC6OTHER (in the presence of 1 microm BC6ENTC ).	False
BC6ENTG overexpression enhanced the inotropic potency of BC6ENTC by 11.7 - fold (pD(2) 8.76+ / - 0.14) and CHEM by 5.9 - fold (7.11+ / - 0.10) , respectively.	False
Overexpression of BC6OTHER in adult rat ventricular myocytes enhances BC6ENTC cardiostimulation: implications for 'putative' BC6ENTG pharmacology.	False
Overexpression of BC6ENTG in adult rat ventricular myocytes enhances BC6ENTC cardiostimulation: implications for 'putative' BC6OTHER pharmacology.	False
BC6ENTC ( BC6OTHER ; BC6OTHER BC6OTHER ) is a novel BC6ENTG receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.	CPR:5
These actions are consistent with a pre - junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve , as confirmed by independent studies showing that BC6ENTC blocks elevations of BC6ENTG in jugular venous blood during electrical stimulation of the trigeminal ganglion.	CPR:4
BC6OTHER ( BC6ENTC ; BC6OTHER BC6OTHER ) is a novel BC6ENTG receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.	CPR:5
BC6OTHER ( BC6OTHER ; BC6ENTC BC6OTHER ) is a novel BC6ENTG receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.	False
BC6OTHER ( BC6OTHER ; BC6OTHER BC6ENTC ) is a novel BC6ENTG receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.	CPR:5
Consistent with its selectivity for BC6ENTG receptors , BC6ENTC produces constriction of various isolated blood vessels , most notably cranial arteries.	False
Pre - clinical pharmacology of BC6ENTC ( BC6OTHER ; BC6OTHER BC6OTHER ) , a centrally and peripherally acting BC6ENTG agonist for migraine.	CPR:5
Pre - clinical pharmacology of BC6OTHER ( BC6ENTC ; BC6OTHER BC6OTHER ) , a centrally and peripherally acting BC6ENTG agonist for migraine.	CPR:5
Pre - clinical pharmacology of BC6OTHER ( BC6OTHER ; BC6ENTC BC6OTHER ) , a centrally and peripherally acting BC6ENTG agonist for migraine.	False
Pre - clinical pharmacology of BC6OTHER ( BC6OTHER ; BC6OTHER BC6ENTC ) , a centrally and peripherally acting BC6ENTG agonist for migraine.	CPR:5
BC6ENTG is a BC6ENTC - CpG - binding protein that is a main component of brain chromatin in vertebrates.	False
In vitro studies have determined that in addition to its specific BC6ENTC - CpG - binding domain ( BC6ENTG ) BC6OTHER also has several BC6OTHER .	False
In vitro studies have determined that in addition to its specific BC6ENTC - CpG - binding domain ( BC6OTHER ) BC6ENTG also has several BC6OTHER .	False
In vitro studies have determined that in addition to its specific BC6ENTC - CpG - binding domain ( BC6OTHER ) BC6OTHER also has several BC6ENTG .	False
)(1)(Jae)) in which exon 3 deletion results in an BC6ENTC - terminal truncation of the protein , including most of the BC6ENTG .	False
Impaired in vivo binding of BC6ENTG to chromatin in the absence of its DNA BC6ENTC - binding domain.	False
 BC6ENTC is transported into adrenergic neurons and radiolabeled BC6OTHER has been employed in positron emission tomography (PET) to image adrenergic neurons in vivo. To extend structure - activity analyses of binding sites within BC6ENTG and to determine which stereoisomer displayed the best selectivity for PET imaging applications , we tested the BC6OTHER compounds for their abilities to inhibit [ BC6OTHER ]neurotransmitter uptake into platelets , transfected cells , and chromaffin vesicles.	False
 BC6OTHER is transported into adrenergic neurons and radiolabeled BC6ENTC has been employed in positron emission tomography (PET) to image adrenergic neurons in vivo. To extend structure - activity analyses of binding sites within BC6ENTG and to determine which stereoisomer displayed the best selectivity for PET imaging applications , we tested the BC6OTHER compounds for their abilities to inhibit [ BC6OTHER ]neurotransmitter uptake into platelets , transfected cells , and chromaffin vesicles.	False
 BC6OTHER is transported into adrenergic neurons and radiolabeled BC6OTHER has been employed in positron emission tomography (PET) to image adrenergic neurons in vivo. To extend structure - activity analyses of binding sites within BC6ENTG and to determine which stereoisomer displayed the best selectivity for PET imaging applications , we tested the BC6ENTC compounds for their abilities to inhibit [ BC6OTHER ]neurotransmitter uptake into platelets , transfected cells , and chromaffin vesicles.	CPR:4
 BC6OTHER is transported into adrenergic neurons and radiolabeled BC6OTHER has been employed in positron emission tomography (PET) to image adrenergic neurons in vivo. To extend structure - activity analyses of binding sites within BC6ENTG and to determine which stereoisomer displayed the best selectivity for PET imaging applications , we tested the BC6OTHER compounds for their abilities to inhibit [ BC6ENTC ]neurotransmitter uptake into platelets , transfected cells , and chromaffin vesicles.	False
We hypothesized that the BC6ENTC compounds would be most potent at the BC6ENTG ( BC6OTHER ) compared to the CHEM or BC6OTHER transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	CPR:4
We hypothesized that the BC6ENTC compounds would be most potent at the BC6OTHER ( BC6ENTG ) compared to the CHEM or BC6OTHER transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	CPR:4
We hypothesized that the BC6ENTC compounds would be most potent at the BC6OTHER ( BC6OTHER ) compared to the BC6ENTG and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6ENTC transporter ( BC6ENTG ) compared to the CHEM or BC6OTHER transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6ENTC transporter ( BC6OTHER ) compared to the BC6ENTG and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6ENTG ( BC6OTHER ) compared to the BC6ENTC or BC6OTHER transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6OTHER ( BC6ENTG ) compared to the BC6ENTC or BC6OTHER transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6ENTG ( BC6OTHER ) compared to the CHEM or BC6ENTC transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	False
We hypothesized that the BC6OTHER compounds would be most potent at the BC6OTHER ( BC6ENTG ) compared to the CHEM or BC6ENTC transporters and that the 1R diastereomers would be more effective than 1S diastereomers.	False
Stereospecific inhibition of BC6ENTG by BC6ENTC isomers.	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6ENTC ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6ENTC ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTC acyltransferase ( BC6ENTG ).	False
Four BC6OTHER , BC6ENTC ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6ENTC ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
The BC6ENTC inhibited BC6ENTG activity in a dose - dependent manner with IC50 values of 10.9 microM ( 1) , 9.8 microM ( 2) , 8.6 microM ( 3) , 142.0 microM ( 4) and 250 microM ( 5).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6ENTC of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6ENTC of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
Four BC6ENTC , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6ENTC , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6ENTC ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6ENTC ( 2) , BC6OTHER ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6ENTC ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6ENTC ( 3) , BC6OTHER ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
These data suggest that the BC6ENTC side chain and the position of the BC6OTHER group are important for high BC6ENTG inhibitory activity.	CPR:4
These data suggest that the BC6OTHER side chain and the position of the BC6ENTC group are important for high BC6ENTG inhibitory activity.	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6ENTC ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6ENTG ( BC6OTHER ).	CPR:4
Four BC6OTHER , BC6OTHER ( 1) , a BC6OTHER of 1 , BC6OTHER ( 2) , BC6OTHER ( 3) , BC6ENTC ( 4) and BC6OTHER ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on BC6OTHER ( BC6ENTG ).	CPR:4
In vitro inhibition of BC6ENTG by BC6ENTC from Sophora flavescens.	CPR:4
Moreover , cells not expressing BC6ENTG were insensitive to the growth - inhibitory and effects on BC6OTHER of BC6ENTC .	False
Moreover , cells not expressing BC6OTHER were insensitive to the growth - inhibitory and effects on BC6ENTG of BC6ENTC .	False
In our mouse xenograft model of OVCAR - 3 and HCT - 8 , we found that BC6ENTC could decrease intratumoral microvessel density in both tumors; it exerted antitumor effects only on OVCAR - 3 expressing BC6ENTG but did not on HCT - 8 not expressing BC6OTHER .	False
In our mouse xenograft model of OVCAR - 3 and HCT - 8 , we found that BC6ENTC could decrease intratumoral microvessel density in both tumors; it exerted antitumor effects only on OVCAR - 3 expressing BC6OTHER but did not on HCT - 8 not expressing BC6ENTG .	False
Effect of BC6ENTC on BC6ENTG and BC6OTHER in vivo was consistent with that of in vitro.	False
Effect of BC6ENTC on BC6OTHER and BC6ENTG in vivo was consistent with that of in vitro.	False
These results demonstrated that BC6ENTC might inhibit growth of tumors through BC6ENTG degradation independent of antiangiogenesis.	CPR:4
We evaluated the effects of BC6ENTC on the growth of human tumor cells expressing (MCF - 7 and HL - 60) or not expressing (HeLa and K562) BC6ENTG in vitro.	False
We also studied the effects of BC6ENTC on BC6ENTG , BC6OTHER or BC6OTHER expression , BC6OTHER , BC6OTHER , CHEM and BC6OTHER in these cells.	False
We also studied the effects of BC6ENTC on BC6OTHER , BC6ENTG or BC6OTHER expression , BC6OTHER , BC6OTHER , CHEM and BC6OTHER in these cells.	False
We also studied the effects of BC6ENTC on BC6OTHER , BC6OTHER or BC6ENTG expression , BC6OTHER , BC6OTHER , CHEM and BC6OTHER in these cells.	False
We also studied the effects of BC6ENTC on BC6OTHER , BC6OTHER or BC6OTHER expression , BC6ENTG , BC6OTHER , CHEM and BC6OTHER in these cells.	False
We also studied the effects of BC6ENTC on BC6OTHER , BC6OTHER or BC6OTHER expression , BC6OTHER , BC6ENTG , CHEM and BC6OTHER in these cells.	False
We also studied the effects of BC6ENTC on BC6OTHER , BC6OTHER or BC6OTHER expression , BC6OTHER , BC6OTHER , CHEM and BC6ENTG in these cells.	False
BC6ENTC reduced BC6OTHER expression accompanied by a decrease of BC6OTHER protein , BC6OTHER , BC6OTHER , CHEM and an increased BC6ENTG , but had no effect on that of BC6OTHER , in MCF - 7 and HL - 60.	CPR:3
BC6ENTC reduced BC6OTHER expression accompanied by a decrease of BC6OTHER protein , BC6OTHER , BC6OTHER , CHEM and an increased BC6OTHER , but had no effect on that of BC6ENTG , in MCF - 7 and HL - 60.	False
BC6ENTC reduced BC6ENTG expression accompanied by a decrease of BC6OTHER protein , BC6OTHER , BC6OTHER , CHEM and an increased BC6OTHER , but had no effect on that of BC6OTHER , in MCF - 7 and HL - 60.	CPR:4
BC6ENTC reduced BC6OTHER expression accompanied by a decrease of BC6ENTG protein , BC6OTHER , BC6OTHER , CHEM and an increased BC6OTHER , but had no effect on that of BC6OTHER , in MCF - 7 and HL - 60.	CPR:4
BC6ENTC reduced BC6OTHER expression accompanied by a decrease of BC6OTHER protein , BC6ENTG , BC6OTHER , CHEM and an increased BC6OTHER , but had no effect on that of BC6OTHER , in MCF - 7 and HL - 60.	CPR:4
BC6ENTC reduced BC6OTHER expression accompanied by a decrease of BC6OTHER protein , BC6OTHER , BC6ENTG , CHEM and an increased BC6OTHER , but had no effect on that of BC6OTHER , in MCF - 7 and HL - 60.	CPR:4
 BC6ENTC inhibits growth of tumors through BC6ENTG degradation independent of antiangiogenesis.	CPR:4
In multivariate regression tests including age , gender , albumin ratio , number of the BC6ENTG alleles , and diagnosis , BC6OTHER levels independently predicted the CSF BC6ENTC , BC6OTHER and BC6OTHER concentrations.	False
In multivariate regression tests including age , gender , albumin ratio , number of the BC6OTHER alleles , and diagnosis , BC6ENTG levels independently predicted the CSF BC6ENTC , BC6OTHER and BC6OTHER concentrations.	False
In multivariate regression tests including age , gender , albumin ratio , number of the BC6ENTG alleles , and diagnosis , BC6OTHER levels independently predicted the CSF BC6OTHER , BC6ENTC and BC6OTHER concentrations.	False
In multivariate regression tests including age , gender , albumin ratio , number of the BC6OTHER alleles , and diagnosis , BC6ENTG levels independently predicted the CSF BC6OTHER , BC6ENTC and BC6OTHER concentrations.	False
In multivariate regression tests including age , gender , albumin ratio , number of the BC6ENTG alleles , and diagnosis , BC6OTHER levels independently predicted the CSF BC6OTHER , BC6OTHER and BC6ENTC concentrations.	False
In multivariate regression tests including age , gender , albumin ratio , number of the BC6OTHER alleles , and diagnosis , BC6ENTG levels independently predicted the CSF BC6OTHER , BC6OTHER and BC6ENTC concentrations.	False
The results suggest that alterations of CNS BC6ENTC de novo genesis and metabolism are related to neurodegeneration and in particular to the cerebral accumulation of BC6ENTG .	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6ENTC , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6ENTC , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6ENTC precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6ENTC precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6ENTC , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6ENTC , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6ENTC and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6ENTC and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6ENTC , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6ENTC , and the BC6OTHER elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6ENTC elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6ENTC elimination products BC6OTHER and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6ENTC and BC6OTHER , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6ENTC and BC6OTHER , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6ENTC , and the CSF markers for AD pathology BC6ENTG and BC6OTHER in 86 subjects with normal cognition and in 107 AD patients.	False
We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of BC6OTHER , the BC6OTHER precursors BC6OTHER , BC6OTHER and BC6OTHER , and the BC6OTHER elimination products BC6OTHER and BC6ENTC , and the CSF markers for AD pathology BC6OTHER and BC6ENTG in 86 subjects with normal cognition and in 107 AD patients.	False
CSF BC6ENTC , BC6OTHER and BC6OTHER in the AD group , and CSF BC6OTHER in the control group correlated with the BC6ENTG levels.	False
CSF BC6OTHER , BC6ENTC and BC6OTHER in the AD group , and CSF BC6OTHER in the control group correlated with the BC6ENTG levels.	False
CSF BC6OTHER , BC6OTHER and BC6ENTC in the AD group , and CSF BC6OTHER in the control group correlated with the BC6ENTG levels.	False
CSF BC6OTHER , BC6OTHER and BC6OTHER in the AD group , and CSF BC6ENTC in the control group correlated with the BC6ENTG levels.	False
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6ENTG and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6ENTC significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6ENTG genes with and / or without BC6OTHER ( BC6OTHER ).	CPR:4
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTC receptor ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTC receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6ENTG and BC6OTHER genes with and / or without BC6OTHER ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTC receptor ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6ENTG genes with and / or without BC6OTHER ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6ENTG and BC6OTHER genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6ENTG genes with and / or without BC6ENTC ( BC6OTHER ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6ENTC ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6ENTC ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6ENTC ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6OTHER genes with and / or without BC6OTHER ( BC6ENTC ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6ENTG and BC6OTHER genes with and / or without BC6OTHER ( BC6ENTC ).	False
Moreover , we found that BC6OTHER significantly inhibited the expression levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in a dose - dependent manner , as well as abrogated up - regulation of BC6OTHER and BC6ENTG genes with and / or without BC6OTHER ( BC6ENTC ).	False
Take together , our results demonstrated that BC6ENTC might induce the apoptosis in LNCaP cell via down - regulation of BC6ENTG expression.	CPR:4
 BC6ENTC , isolated from Juglans mandshurica Maxim , induces apoptosis via down - regulation of BC6ENTG expression in human prostate cancer LNCaP cells.	CPR:4
These and other data have generated a working hypothesis that activation of the terminal BC6OTHER enhances the kinetics of BC6ENTC uptake through an effect on the BC6ENTG .	CPR:9
These and other data have generated a working hypothesis that activation of the terminal BC6ENTG enhances the kinetics of BC6ENTC uptake through an effect on the BC6OTHER .	CPR:9
These and other data have generated a working hypothesis that activation of the terminal BC6ENTG enhances the kinetics of BC6OTHER uptake through an effect on the BC6ENTC transporter.	False
From these data , it is inferred that both the BC6ENTG and BC6OTHER contribute to the active clearance of exogenously applied BC6ENTC in the dentate gyrus.	CPR:9
From these data , it is inferred that both the BC6OTHER and BC6ENTG contribute to the active clearance of exogenously applied BC6ENTC in the dentate gyrus.	CPR:9
In another experiment , BC6ENTC , an antagonist of the BC6ENTG , also prolonged the clearance of BC6OTHER from the CA3 region.	CPR:6
In another experiment , BC6OTHER , an antagonist of the BC6ENTG , also prolonged the clearance of BC6ENTC from the CA3 region.	False
These and other data have generated a working hypothesis that activation of the terminal BC6ENTC autoreceptor enhances the kinetics of BC6OTHER uptake through an effect on the BC6ENTG .	False
BC6ENTG reduce CHEM to the corresponding BC6ENTC by means of BC6OTHER ( BC6OTHER ).	CPR:9
BC6ENTG reduce CHEM to the corresponding BC6OTHER by means of BC6ENTC ( BC6OTHER ).	False
BC6ENTG reduce CHEM to the corresponding BC6OTHER by means of BC6OTHER ( BC6ENTC ).	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6ENTG , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6ENTG ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6ENTG ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6ENTG , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6ENTG ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6ENTG ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6ENTG , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6ENTG ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6ENTG ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6ENTG , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6ENTG ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6ENTG , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6ENTG ) in mammals: BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
Analysis of the selenoproteome identified five BC6ENTC peroxidases ( BC6OTHER ) in mammals: BC6ENTG ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) , BC6OTHER ( BC6OTHER , BC6OTHER ) and , in BC6OTHER , which is restricted to the olfactory system.	False
BC6ENTG specifically interferes with BC6OTHER activation by BC6OTHER , reduces BC6ENTC and BC6OTHER biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6ENTG activation by BC6OTHER , reduces BC6ENTC and BC6OTHER biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6OTHER activation by BC6ENTG , reduces BC6ENTC and BC6OTHER biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6OTHER activation by BC6OTHER , reduces BC6ENTC and BC6OTHER biosynthesis , prevents BC6ENTG expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6ENTG specifically interferes with BC6OTHER activation by BC6OTHER , reduces BC6OTHER and BC6ENTC biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6ENTG activation by BC6OTHER , reduces BC6OTHER and BC6ENTC biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6OTHER activation by BC6ENTG , reduces BC6OTHER and BC6ENTC biosynthesis , prevents BC6OTHER expression , and is indispensable for sperm maturation and embryogenesis.	False
BC6OTHER specifically interferes with BC6OTHER activation by BC6OTHER , reduces BC6OTHER and BC6ENTC biosynthesis , prevents BC6ENTG expression , and is indispensable for sperm maturation and embryogenesis.	False
The BC6ENTC moiety of the BC6ENTG fragment , markedly increases the half - life of CZP and confers to the drug a unique structure that differs from the other anti - BC6OTHER agents tested for the treatment of Crohn's disease , rheumatoid arthritis , ankylosing spondylitis , axial spondyloarthritis , nonradiographic spondyloarthritis , CHEM , and PsA.	False
The BC6ENTC moiety of the BC6OTHER fragment , markedly increases the half - life of CZP and confers to the drug a unique structure that differs from the other anti - BC6ENTG agents tested for the treatment of Crohn's disease , rheumatoid arthritis , ankylosing spondylitis , axial spondyloarthritis , nonradiographic spondyloarthritis , CHEM , and PsA.	False
An earlier study showed that BC6ENTG negatively regulates the functional activity of BC6ENTC - activated protein kinase ( BC6OTHER ) in vitro by binding directly to the BC6OTHER complex.	False
An earlier study showed that BC6OTHER negatively regulates the functional activity of BC6ENTC - activated protein kinase ( BC6ENTG ) in vitro by binding directly to the BC6OTHER complex.	False
An earlier study showed that BC6OTHER negatively regulates the functional activity of BC6ENTC - activated protein kinase ( BC6OTHER ) in vitro by binding directly to the BC6ENTG complex.	False
Moreover , BC6ENTC alleviated BC6ENTG expression , and reversely raised BC6OTHER expression in neurons treated with hyperglycaemia.	CPR:3
Moreover , BC6ENTC alleviated BC6OTHER expression , and reversely raised BC6ENTG expression in neurons treated with hyperglycaemia.	CPR:3
It was found that expression of BC6ENTG protein in cortical neurons was increased in BC6ENTC - induced diabetes mellitus rat model.	CPR:3
The expression pattern of BC6ENTG and BC6OTHER correspond to 50mmol / L BC6ENTC (hyperglycaemia) was also found in primary cultured neurons.	False
The expression pattern of BC6OTHER and BC6ENTG correspond to 50mmol / L BC6ENTC (hyperglycaemia) was also found in primary cultured neurons.	False
Collectively , these results suggest that besides its classical proteolytic activity , BC6ENTG acts as a BC6OTHER that binds to the cell membrane receptor BC6OTHER , induces its BC6ENTC phosphorylation , and triggers intracellular signal transduction , thereby inducing specific gene expression in renal interstitial fibroblasts.	False
Collectively , these results suggest that besides its classical proteolytic activity , BC6OTHER acts as a BC6ENTG that binds to the cell membrane receptor BC6OTHER , induces its BC6ENTC phosphorylation , and triggers intracellular signal transduction , thereby inducing specific gene expression in renal interstitial fibroblasts.	False
Collectively , these results suggest that besides its classical proteolytic activity , BC6OTHER acts as a BC6OTHER that binds to the cell membrane receptor BC6ENTG , induces its BC6ENTC phosphorylation , and triggers intracellular signal transduction , thereby inducing specific gene expression in renal interstitial fibroblasts.	False
BC6ENTG ( BC6OTHER ) , a BC6ENTC protease well known for generating BC6OTHER , has been demonstrated to induce BC6OTHER ( BC6OTHER ) gene expression and protein secretion in renal interstitial fibroblasts.	False
BC6OTHER ( BC6OTHER ) , a BC6ENTC protease well known for generating BC6OTHER , has been demonstrated to induce BC6ENTG ( BC6OTHER ) gene expression and protein secretion in renal interstitial fibroblasts.	CPR:3
BC6OTHER ( BC6OTHER ) , a BC6ENTC protease well known for generating BC6OTHER , has been demonstrated to induce BC6OTHER ( BC6ENTG ) gene expression and protein secretion in renal interstitial fibroblasts.	False
BC6OTHER ( BC6ENTG ) , a BC6ENTC protease well known for generating BC6OTHER , has been demonstrated to induce BC6OTHER ( BC6OTHER ) gene expression and protein secretion in renal interstitial fibroblasts.	False
BC6OTHER ( BC6OTHER ) , a BC6ENTC protease well known for generating BC6ENTG , has been demonstrated to induce BC6OTHER ( BC6OTHER ) gene expression and protein secretion in renal interstitial fibroblasts.	CPR:3
Furthermore , BC6OTHER induced rapid BC6ENTC phosphorylation on the beta subunit of BC6ENTG , which was followed by the activation of BC6OTHER and its downstream BC6OTHER .	False
Furthermore , BC6OTHER induced rapid BC6ENTC phosphorylation on the beta subunit of BC6OTHER , which was followed by the activation of BC6ENTG and its downstream BC6OTHER .	CPR:3
Furthermore , BC6OTHER induced rapid BC6ENTC phosphorylation on the beta subunit of BC6OTHER , which was followed by the activation of BC6OTHER and its downstream BC6ENTG .	CPR:3
Furthermore , BC6ENTG induced rapid BC6ENTC phosphorylation on the beta subunit of BC6OTHER , which was followed by the activation of BC6OTHER and its downstream BC6OTHER .	False
BACKGROUND: Synergistic neuromuscular blocking effects have been observed clinically with certain pairs of nicotinic BC6ENTC receptor ( BC6ENTG ) competitive antagonists.	False
Ex vivo IC(50) values ( BC6ENTG : 105.2 micromol / L; BC6OTHER : 26.3 micromol / L) of BC6ENTC compared favorably with its in vitro IC(50) values.	CPR:4
Ex vivo IC(50) values ( BC6OTHER : 105.2 micromol / L; BC6ENTG : 26.3 micromol / L) of BC6ENTC compared favorably with its in vitro IC(50) values.	CPR:4
In contrast to previous concepts , BC6ENTC inhibited BC6ENTG by more than 80% , i.e. , to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective BC6OTHER inhibitors.	CPR:4
In contrast to previous concepts , BC6ENTC inhibited BC6OTHER by more than 80% , i.e. , to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective BC6ENTG inhibitors.	False
In view of its substantial BC6ENTG inhibition , recently defined cardiovascular warnings for use of BC6OTHER inhibitors should also be considered for BC6ENTC .	CPR:4
In view of its substantial BC6OTHER inhibition , recently defined cardiovascular warnings for use of BC6ENTG inhibitors should also be considered for BC6ENTC .	False
The fact that BC6ENTC acts functionally as a selective BC6ENTG inhibitor led us to investigate the hypothesis of whether it works via preferential BC6OTHER blockade.	CPR:4
The fact that BC6ENTC acts functionally as a selective BC6OTHER inhibitor led us to investigate the hypothesis of whether it works via preferential BC6ENTG blockade.	False
Ex vivo BC6ENTG inhibition and pharmacokinetics of BC6ENTC were assessed in 5 volunteers receiving single 1000 mg doses orally.	CPR:4
Coagulation - induced BC6ENTC and lipopolysaccharide - induced BC6OTHER were measured ex vivo and in vitro in human whole blood as indices of BC6ENTG and BC6OTHER activity.	CPR:9
Coagulation - induced BC6ENTC and lipopolysaccharide - induced BC6OTHER were measured ex vivo and in vitro in human whole blood as indices of BC6OTHER and BC6ENTG activity.	False
Coagulation - induced BC6OTHER and lipopolysaccharide - induced BC6ENTC were measured ex vivo and in vitro in human whole blood as indices of BC6ENTG and BC6OTHER activity.	False
Coagulation - induced BC6OTHER and lipopolysaccharide - induced BC6ENTC were measured ex vivo and in vitro in human whole blood as indices of BC6OTHER and BC6ENTG activity.	CPR:9
In vitro , BC6ENTC elicited a 4.4 - fold selectivity toward BC6ENTG inhibition (IC(50)=113.7 micromol / L for BC6OTHER ; IC(50)=25.8 micromol / L for BC6OTHER ).	CPR:4
In vitro , BC6ENTC elicited a 4.4 - fold selectivity toward BC6OTHER inhibition (IC(50)=113.7 micromol / L for BC6ENTG ; IC(50)=25.8 micromol / L for BC6OTHER ).	CPR:4
In vitro , BC6ENTC elicited a 4.4 - fold selectivity toward BC6OTHER inhibition (IC(50)=113.7 micromol / L for BC6OTHER ; IC(50)=25.8 micromol / L for BC6ENTG ).	CPR:4
BC6ENTC plasma concentrations remained above the in vitro IC(50) for BC6ENTG for at least 5 h postadministration.	CPR:4
 BC6ENTC ( BC6OTHER ) is a selective BC6ENTG inhibitor in man.	CPR:4
 BC6OTHER ( BC6ENTC ) is a selective BC6ENTG inhibitor in man.	CPR:4
The BC6OTHER ( BC6OTHER ) is a multi - subunit enzyme that transfers electrons from BC6ENTG to molecular BC6ENTC , yielding water.	False
The BC6ENTG ( BC6OTHER ) is a multi - subunit enzyme that transfers electrons from BC6OTHER to molecular BC6ENTC , yielding water.	CPR:9
The BC6OTHER ( BC6ENTG ) is a multi - subunit enzyme that transfers electrons from BC6OTHER to molecular BC6ENTC , yielding water.	CPR:9
BC6ENTC sequencing also demonstrated the presence of BC6ENTG around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6ENTG in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6ENTG genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6ENTG for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6ENTG ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6ENTG ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6ENTG ; and - 122 and +216 for BC6OTHER were differentially methylated among the liver , kidney , and cerebrum.	False
BC6ENTC sequencing also demonstrated the presence of BC6OTHER around the BC6OTHER in other BC6OTHER genes: CpG CHEM at +149 relative to the BC6OTHER for BC6OTHER ; - 48 , +101 , and +356 for BC6OTHER ; - 572 and - 550 for BC6OTHER ; and - 122 and +216 for BC6ENTG were differentially methylated among the liver , kidney , and cerebrum.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6ENTC and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6ENTC and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTG and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6ENTC and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTG , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6ENTC and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTG were found to accumulate intracellular BC6ENTC and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	CPR:9
These results suggest that the altered BC6ENTC kinase results in stabilization of the complex or has an indirect effect on BC6ENTG activity , which leads to an increase in BC6OTHER production in Saccharomyces cerevisiae.	False
These results suggest that the altered BC6ENTG results in stabilization of the complex or has an indirect effect on BC6ENTC reductase activity , which leads to an increase in BC6OTHER production in Saccharomyces cerevisiae.	False
These results suggest that the altered BC6ENTG results in stabilization of the complex or has an indirect effect on BC6OTHER activity , which leads to an increase in BC6ENTC production in Saccharomyces cerevisiae.	CPR:9
These results suggest that the altered BC6OTHER results in stabilization of the complex or has an indirect effect on BC6ENTG activity , which leads to an increase in BC6ENTC production in Saccharomyces cerevisiae.	CPR:9
By introducing the mutant - derived genomic library into a non - BC6ENTC - utilizing strain , the mutant was found to carry an allele of the wild - type BC6ENTG gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6ENTC - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTG , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6ENTC - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6ENTG ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6ENTC - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6ENTG ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6ENTG gene encoding BC6ENTC kinase , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTC kinase , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6ENTG ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTC kinase , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6ENTG ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6ENTG gene encoding BC6OTHER , which resulted in a single BC6ENTC replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTG , which resulted in a single BC6ENTC replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6ENTC replacement; BC6OTHER ( BC6ENTG ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6ENTC replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6ENTG ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6ENTG gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6ENTC ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTG , which resulted in a single BC6OTHER replacement; BC6ENTC ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6ENTC ( BC6ENTG ) at position 154 was replaced by BC6OTHER ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6ENTC ( BC6OTHER ) at position 154 was replaced by BC6OTHER ( BC6ENTG ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6ENTG gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6ENTC ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6ENTG , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6ENTC ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6ENTG ) at position 154 was replaced by BC6ENTC ( BC6OTHER ).	False
By introducing the mutant - derived genomic library into a non - BC6OTHER - utilizing strain , the mutant was found to carry an allele of the wild - type BC6OTHER gene encoding BC6OTHER , which resulted in a single BC6OTHER replacement; BC6OTHER ( BC6OTHER ) at position 154 was replaced by BC6ENTC ( BC6ENTG ).	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTC kinase and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6ENTC kinase and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTC kinase and BC6ENTG , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTC kinase and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTG were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTC reductase , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6OTHER and BC6ENTC reductase , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTG and BC6ENTC reductase , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTC reductase , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTG were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6ENTC synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6ENTC synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTG and BC6OTHER , both of which catalyze the first two steps of BC6ENTC synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	CPR:9
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTG , both of which catalyze the first two steps of BC6ENTC synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	CPR:9
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6ENTC synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTG were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6ENTC and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6ENTC and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTG and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6ENTC and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	CPR:9
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTG , both of which catalyze the first two steps of BC6OTHER synthesis from BC6ENTC and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6OTHER were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	CPR:9
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6ENTC and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTG were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTC kinase were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6ENTG gene.	False
 Interestingly , the allele of BC6ENTG was shown to enhance the activities of BC6OTHER and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTC kinase were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6ENTG and BC6OTHER , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTC kinase were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 Interestingly , the allele of BC6OTHER was shown to enhance the activities of BC6OTHER and BC6ENTG , both of which catalyze the first two steps of BC6OTHER synthesis from BC6OTHER and which together may form a complex in vivo. When cultured in liquid minimal medium , yeast cells expressing the mutated BC6ENTC kinase were found to accumulate intracellular BC6OTHER and showed a prominent increase in cell viability after freezing at - 20 degrees C compared to the viability of cells harboring the wild - type BC6OTHER gene.	False
 BC6ENTC accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the BC6ENTG gene encoding BC6OTHER .	False
 BC6ENTC accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the BC6OTHER gene encoding BC6ENTG .	CPR:9
 BC6OTHER accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the BC6ENTG gene encoding BC6ENTC kinase.	False
BC6ENTC kinase - 1 ( BC6ENTG and BC6OTHER ( BC6OTHER ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
BC6ENTC kinase - 1 ( BC6OTHER and BC6ENTG ( BC6OTHER ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
BC6ENTC kinase - 1 ( BC6OTHER and BC6OTHER ( BC6ENTG ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high BC6ENTG expression , indicating activation of BC6ENTC synthesis through both the salvage and de novo pathways.	CPR:9
These results led us to consider that BC6ENTC may also be effective for esophageal and uterine squamous cell carcinomas , as well as for gastrointestinal adenocarcinomas , even in BC6OTHER - resistant cases with high BC6ENTG expression.	False
These results led us to consider that BC6OTHER may also be effective for esophageal and uterine squamous cell carcinomas , as well as for gastrointestinal adenocarcinomas , even in BC6ENTC - resistant cases with high BC6ENTG expression.	False
In contrast , thyroid papillary carcinomas , lung adenocarcinomas , hepatocellular carcinomas , pancreatic ductal carcinomas , and renal cell carcinomas , which exhibit low BC6ENTG expression , may be resistant to BC6ENTC .	False
Our results indicate that administration of BC6ENTC could be selected on the basis of the immunohistochemical evaluation of BC6ENTG and BC6OTHER .	False
Our results indicate that administration of BC6ENTC could be selected on the basis of the immunohistochemical evaluation of BC6OTHER and BC6ENTG .	False
Numerous studies have suggested that increased BC6ENTG levels are associated closely with resistance to BC6ENTC - based chemotherapy.	False
BC6ENTC is a novel drug containing BC6OTHER , which is phosphorylated by BC6ENTG to its active monophosphated form , that in turn can inhibit BC6OTHER .	CPR:9
BC6ENTC is a novel drug containing BC6OTHER , which is phosphorylated by BC6OTHER to its active monophosphated form , that in turn can inhibit BC6ENTG .	CPR:4
BC6OTHER is a novel drug containing BC6ENTC , which is phosphorylated by BC6ENTG to its active monophosphated form , that in turn can inhibit BC6OTHER .	CPR:9
BC6OTHER is a novel drug containing BC6ENTC , which is phosphorylated by BC6OTHER to its active monophosphated form , that in turn can inhibit BC6ENTG .	False
BC6ENTG ( BC6OTHER and BC6ENTC synthase ( BC6OTHER ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
BC6OTHER ( BC6ENTG and BC6ENTC synthase ( BC6OTHER ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
BC6OTHER ( BC6OTHER and BC6ENTC synthase ( BC6ENTG ) are key enzymes for salvage and de novo BC6OTHER synthesis , respectively.	False
BC6ENTG ( BC6OTHER and BC6OTHER ( BC6OTHER ) are key enzymes for salvage and de novo BC6ENTC synthesis , respectively.	CPR:9
BC6OTHER ( BC6ENTG and BC6OTHER ( BC6OTHER ) are key enzymes for salvage and de novo BC6ENTC synthesis , respectively.	CPR:9
BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) are key enzymes for salvage and de novo BC6ENTC synthesis , respectively.	CPR:9
BC6OTHER ( BC6OTHER and BC6OTHER ( BC6ENTG ) are key enzymes for salvage and de novo BC6ENTC synthesis , respectively.	CPR:9
Immunohistochemical characterization of BC6ENTC synthetic enzymes , BC6ENTG and BC6OTHER , in various types of cancer.	CPR:9
Immunohistochemical characterization of BC6ENTC synthetic enzymes , BC6OTHER and BC6ENTG , in various types of cancer.	CPR:9
Immunohistochemical characterization of BC6OTHER synthetic enzymes , BC6ENTC kinase - 1 and BC6ENTG , in various types of cancer.	False
In preclinical studies , the mammalian target of BC6ENTC ( BC6ENTG ) in the medial prefrontal cortex and the BC6OTHER ( BC6OTHER ) in the hippocampus have been proposed as critical mediators of BC6OTHER 's rapid antidepressant actions.	False
In preclinical studies , the mammalian target of BC6ENTC ( BC6OTHER ) in the medial prefrontal cortex and the BC6ENTG ( BC6OTHER ) in the hippocampus have been proposed as critical mediators of BC6OTHER 's rapid antidepressant actions.	False
In preclinical studies , the mammalian target of BC6ENTC ( BC6OTHER ) in the medial prefrontal cortex and the BC6OTHER ( BC6ENTG ) in the hippocampus have been proposed as critical mediators of BC6OTHER 's rapid antidepressant actions.	False
In preclinical studies , the BC6ENTG ( BC6OTHER ) in the medial prefrontal cortex and the BC6OTHER ( BC6OTHER ) in the hippocampus have been proposed as critical mediators of BC6ENTC 's rapid antidepressant actions.	False
In preclinical studies , the mammalian target of BC6OTHER ( BC6ENTG ) in the medial prefrontal cortex and the BC6OTHER ( BC6OTHER ) in the hippocampus have been proposed as critical mediators of BC6ENTC 's rapid antidepressant actions.	False
In preclinical studies , the mammalian target of BC6OTHER ( BC6OTHER ) in the medial prefrontal cortex and the BC6ENTG ( BC6OTHER ) in the hippocampus have been proposed as critical mediators of BC6ENTC 's rapid antidepressant actions.	False
In preclinical studies , the mammalian target of BC6OTHER ( BC6OTHER ) in the medial prefrontal cortex and the BC6OTHER ( BC6ENTG ) in the hippocampus have been proposed as critical mediators of BC6ENTC 's rapid antidepressant actions.	False
In our hands , the increased sensitivity of female rats to a low dose of BC6ENTC was not mediated through phosphorylation of BC6ENTG or BC6OTHER .	False
In our hands , the increased sensitivity of female rats to a low dose of BC6ENTC was not mediated through phosphorylation of BC6OTHER or BC6ENTG .	False
However , recent clinical studies have shown that a single low - dose injection of BC6ENTC , an BC6ENTG ( BC6OTHER ) antagonist , has rapid antidepressant effects that are observed within hours and are long lasting.	CPR:6
However , recent clinical studies have shown that a single low - dose injection of BC6ENTC , an BC6OTHER ( BC6ENTG ) antagonist , has rapid antidepressant effects that are observed within hours and are long lasting.	CPR:6
However , recent clinical studies have shown that a single low - dose injection of BC6OTHER , an BC6ENTC receptor ( BC6ENTG ) antagonist , has rapid antidepressant effects that are observed within hours and are long lasting.	False
BC6ENTG antagonism (10 mg kg( - 1) BC6ENTC ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists , but BC6OTHER - induced apoptosis could also be prevented by 96% (P < 0.05) by BC6OTHER antagonism (10 mg kg( - 1) CHEM).	CPR:6
BC6OTHER antagonism (10 mg kg( - 1) BC6ENTC ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists , but BC6OTHER - induced apoptosis could also be prevented by 96% (P < 0.05) by BC6ENTG antagonism (10 mg kg( - 1) CHEM).	False
BC6ENTG antagonism (10 mg kg( - 1) BC6OTHER ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists , but BC6ENTC - induced apoptosis could also be prevented by 96% (P < 0.05) by BC6OTHER antagonism (10 mg kg( - 1) CHEM).	False
BC6OTHER antagonism (10 mg kg( - 1) BC6OTHER ) prevented 92% (P < 0.05) of apoptosis induced by all three agonists , but BC6ENTC - induced apoptosis could also be prevented by 96% (P < 0.05) by BC6ENTG antagonism (10 mg kg( - 1) CHEM).	False
The BC6OTHER ( BC6ENTG ) agonists BC6ENTC and BC6OTHER have similar beneficial effects in animal models of heart failure.	CPR:5
The BC6ENTG ( BC6OTHER ) agonists BC6ENTC and BC6OTHER have similar beneficial effects in animal models of heart failure.	CPR:5
The BC6OTHER ( BC6ENTG ) agonists BC6OTHER and BC6ENTC have similar beneficial effects in animal models of heart failure.	CPR:5
The BC6ENTG ( BC6OTHER ) agonists BC6OTHER and BC6ENTC have similar beneficial effects in animal models of heart failure.	CPR:5
We describe here the isolation and biochemical characterization of the marine natural BC6ENTC BC6OTHER as a BC6ENTG inhibitor.	CPR:4
We describe here the isolation and biochemical characterization of the marine natural BC6OTHER BC6ENTC as a BC6ENTG inhibitor.	CPR:4
Experimental studies performed for characterizing the inhibitory mechanism indicate that BC6ENTG inhibition by BC6ENTC cannot be competed out by BC6OTHER nor peptide substrate.	CPR:4
Experimental studies performed for characterizing the inhibitory mechanism indicate that BC6ENTG inhibition by BC6OTHER cannot be competed out by BC6ENTC nor peptide substrate.	False
Moreover , molecular dynamics simulations have identified an allosteric mechanism by which binding of BC6ENTC leads to BC6ENTG inhibition.	CPR:4
Evidence for a new binding mode to BC6ENTG : allosteric regulation by the marine compound BC6ENTC .	False
BC6ENTC alpha - BC6OTHER - Acetylglucosaminidase ( BC6ENTG ; BC6OTHER ) catalyzes the second step in the synthesis of the BC6OTHER determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	False
BC6ENTC alpha - BC6OTHER - Acetylglucosaminidase ( BC6OTHER ; BC6ENTG ) catalyzes the second step in the synthesis of the BC6OTHER determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	False
The data indicate that bovine BC6ENTG is a 272 , 000 - Da complex of four identical 68 , 000 - Da glycoprotein subunits arranged as two BC6ENTC - linked homodimers.	False
Both forms of the enzyme reacted with a rabbit antibody raised to the BC6ENTC - terminal peptide of the liver enzyme , suggesting that BC6ENTG is a BC6OTHER with its BC6OTHER terminus in the lumen of the Golgi apparatus.	False
Both forms of the enzyme reacted with a rabbit antibody raised to the BC6ENTC - terminal peptide of the liver enzyme , suggesting that BC6OTHER is a BC6ENTG with its BC6OTHER terminus in the lumen of the Golgi apparatus.	False
Both forms of the enzyme reacted with a rabbit antibody raised to the BC6OTHER - terminal peptide of the liver enzyme , suggesting that BC6ENTG is a BC6OTHER with its BC6ENTC terminus in the lumen of the Golgi apparatus.	False
Both forms of the enzyme reacted with a rabbit antibody raised to the BC6OTHER - terminal peptide of the liver enzyme , suggesting that BC6OTHER is a BC6ENTG with its BC6ENTC terminus in the lumen of the Golgi apparatus.	False
BC6ENTG ( BC6OTHER ; BC6OTHER ) catalyzes the second step in the synthesis of the BC6ENTC determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	CPR:9
CHEM- BC6OTHER - Acetylglucosaminidase ( BC6ENTG ; BC6OTHER ) catalyzes the second step in the synthesis of the BC6ENTC determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	CPR:9
CHEM- BC6OTHER - Acetylglucosaminidase ( BC6OTHER ; BC6ENTG ) catalyzes the second step in the synthesis of the BC6ENTC determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	CPR:9
CHEM- BC6ENTC - Acetylglucosaminidase ( BC6ENTG ; BC6OTHER ) catalyzes the second step in the synthesis of the BC6OTHER determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	False
CHEM- BC6ENTC - Acetylglucosaminidase ( BC6OTHER ; BC6ENTG ) catalyzes the second step in the synthesis of the BC6OTHER determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.	False
The purified BC6ENTG has a specific activity of 498 micromol of BC6ENTC cleaved per h per mg of protein using 0.5 mM BC6OTHER as substrate.	CPR:9
The purified BC6ENTG has a specific activity of 498 micromol of BC6OTHER cleaved per h per mg of protein using 0.5 mM BC6ENTC as substrate.	CPR:9
BC6ENTC plays a direct and causal role in diabetes pathogenesis mediated both by β cell failure and BC6ENTG resistance.	False
BACKGROUND: BC6ENTG ( BC6OTHER ) are involved in the detoxification of xenobiotics by conjugation with BC6ENTC .	False
BACKGROUND: BC6OTHER ( BC6ENTG ) are involved in the detoxification of xenobiotics by conjugation with BC6ENTC .	False
BACKGROUND: BC6ENTC S - transferases ( BC6ENTG ) are involved in the detoxification of xenobiotics by conjugation with BC6OTHER .	False
Using a transient heterologous cell expression system , we find that the transport activities of the BC6ENTG variant towards substrates BC6ENTC and BC6OTHER are similar to the well - characterized full length variant.	CPR:9
Using a transient heterologous cell expression system , we find that the transport activities of the BC6ENTG variant towards substrates BC6OTHER and BC6ENTC are similar to the well - characterized full length variant.	CPR:9
These variants are expected to encode either a full length ( BC6ENTG ) or shortened protein lacking 22 BC6ENTC - terminus BC6OTHER ( BC6OTHER ).	False
These variants are expected to encode either a full length ( BC6OTHER ) or shortened protein lacking 22 BC6ENTC - terminus BC6OTHER ( BC6ENTG ).	False
These variants are expected to encode either a full length ( BC6ENTG ) or shortened protein lacking 22 BC6OTHER - terminus BC6ENTC ( BC6OTHER ).	False
These variants are expected to encode either a full length ( BC6OTHER ) or shortened protein lacking 22 BC6OTHER - terminus BC6ENTC ( BC6ENTG ).	False
Little is known regarding the transport activity and regulation of BC6ENTG variants with BC6ENTC - terminus truncation.	False
In contrast , mutation BC6ENTG results in an BC6ENTC substitution ( BC6OTHER ) , which abolishes signal transduction due to structural changes.	False
In contrast , mutation BC6OTHER results in an BC6ENTC substitution ( BC6ENTG ) , which abolishes signal transduction due to structural changes.	False
Interestingly , disruption of the BC6ENTG - BC6OTHER pathway prevented the inhibitory effect of BC6ENTC on BC6OTHER activation by BC6OTHER .	False
Interestingly , disruption of the BC6OTHER - BC6ENTG pathway prevented the inhibitory effect of BC6ENTC on BC6OTHER activation by BC6OTHER .	False
Interestingly , disruption of the BC6OTHER - BC6OTHER pathway prevented the inhibitory effect of BC6ENTC on BC6ENTG activation by BC6OTHER .	CPR:4
Interestingly , disruption of the BC6OTHER - BC6OTHER pathway prevented the inhibitory effect of BC6ENTC on BC6OTHER activation by BC6ENTG .	False
Lastly , we found that BC6ENTG activation by BC6ENTC is mediated by reactive BC6OTHER species (ROS).	CPR:3
Lastly , we found that BC6ENTG activation by BC6OTHER is mediated by reactive BC6ENTC species (ROS).	False
The ROS scavenger BC6ENTC and the mitochondrial antioxidant Mito - CHEM rescued the inhibitory effect of BC6OTHER on BC6ENTG activation.	CPR:3
The ROS scavenger BC6OTHER and the mitochondrial antioxidant Mito - CHEM rescued the inhibitory effect of BC6ENTC on BC6ENTG activation.	CPR:4
Moreover , they established that the inhibitory effect of BC6ENTC on BC6ENTG activity involves the alteration of the balance between BC6OTHER and BC6OTHER .	CPR:4
Moreover , they established that the inhibitory effect of BC6ENTC on BC6OTHER activity involves the alteration of the balance between BC6ENTG and BC6OTHER .	False
Moreover , they established that the inhibitory effect of BC6ENTC on BC6OTHER activity involves the alteration of the balance between BC6OTHER and BC6ENTG .	False
Previous studies established that stimulation of BC6ENTG receptors in breast cancer cells activates BC6OTHER and enhances motility via the Rac - BC6ENTC exchange factor BC6OTHER .	False
Previous studies established that stimulation of BC6OTHER receptors in breast cancer cells activates BC6ENTG and enhances motility via the Rac - BC6ENTC exchange factor BC6OTHER .	False
Previous studies established that stimulation of BC6OTHER receptors in breast cancer cells activates BC6OTHER and enhances motility via the Rac - BC6ENTC exchange factor BC6ENTG .	False
As the Janus BC6ENTC kinase 2 ( BC6ENTG ) / BC6OTHER ( BC6OTHER ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6OTHER / BC6OTHER activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6ENTG ( BC6OTHER ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6OTHER / BC6OTHER activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6OTHER ( BC6ENTG ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6OTHER / BC6OTHER activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) pathway has been shown to be functionally associated with BC6ENTG receptors , we asked if this pathway could mediate BC6OTHER / BC6OTHER activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6ENTG / BC6OTHER activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6OTHER / BC6ENTG activation in response to BC6OTHER ligands.	False
As the Janus BC6ENTC kinase 2 ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) pathway has been shown to be functionally associated with BC6OTHER receptors , we asked if this pathway could mediate BC6OTHER / BC6OTHER activation in response to BC6ENTG ligands.	False
Here we found that the anticancer agent BC6ENTC , a BC6ENTG inhibitor , reduced the activation of BC6OTHER and motility in response to the BC6OTHER ligand BC6OTHER in breast cancer cells.	CPR:4
Here we found that the anticancer agent BC6ENTC , a BC6OTHER inhibitor , reduced the activation of BC6ENTG and motility in response to the BC6OTHER ligand BC6OTHER in breast cancer cells.	CPR:4
Here we found that the anticancer agent BC6ENTC , a BC6OTHER inhibitor , reduced the activation of BC6OTHER and motility in response to the BC6ENTG ligand BC6OTHER in breast cancer cells.	False
Here we found that the anticancer agent BC6ENTC , a BC6OTHER inhibitor , reduced the activation of BC6OTHER and motility in response to the BC6OTHER ligand BC6ENTG in breast cancer cells.	False
However , BC6ENTG activation was not affected by BC6OTHER or BC6OTHER RNA interference , suggesting that the effect of BC6ENTC occurs through a BC6OTHER - independent mechanism.	False
However , BC6OTHER activation was not affected by BC6ENTG or BC6OTHER RNA interference , suggesting that the effect of BC6ENTC occurs through a BC6OTHER - independent mechanism.	False
However , BC6OTHER activation was not affected by BC6OTHER or BC6ENTG RNA interference , suggesting that the effect of BC6ENTC occurs through a BC6OTHER - independent mechanism.	False
However , BC6OTHER activation was not affected by BC6OTHER or BC6OTHER RNA interference , suggesting that the effect of BC6ENTC occurs through a BC6ENTG - independent mechanism.	False
BC6ENTC also failed to affect the activation of BC6ENTG by BC6OTHER .	False
BC6ENTC also failed to affect the activation of BC6OTHER by BC6ENTG .	False
Subsequent analysis revealed that BC6ENTC strongly activates BC6ENTG and the BC6OTHER effector BC6OTHER ( BC6OTHER ) in breast cancer cells and induces the formation of stress fibers.	CPR:3
Subsequent analysis revealed that BC6ENTC strongly activates BC6OTHER and the BC6ENTG effector BC6OTHER ( BC6OTHER ) in breast cancer cells and induces the formation of stress fibers.	CPR:3
Subsequent analysis revealed that BC6ENTC strongly activates BC6OTHER and the BC6OTHER effector BC6ENTG ( BC6OTHER ) in breast cancer cells and induces the formation of stress fibers.	CPR:3
Subsequent analysis revealed that BC6ENTC strongly activates BC6OTHER and the BC6OTHER effector BC6OTHER ( BC6ENTG ) in breast cancer cells and induces the formation of stress fibers.	CPR:3
 BC6ENTC inhibits BC6OTHER activation in breast cancer cells by a reactive BC6OTHER species - mediated mechanism and independently of BC6ENTG and BC6OTHER .	False
 BC6ENTC inhibits BC6OTHER activation in breast cancer cells by a reactive BC6OTHER species - mediated mechanism and independently of janus BC6OTHER kinase 2 and BC6ENTG .	False
 BC6ENTC inhibits BC6ENTG activation in breast cancer cells by a reactive BC6OTHER species - mediated mechanism and independently of janus BC6OTHER kinase 2 and BC6OTHER .	CPR:4
 BC6OTHER inhibits BC6OTHER activation in breast cancer cells by a reactive BC6OTHER species - mediated mechanism and independently of janus BC6ENTC kinase 2 and BC6ENTG .	False
 BC6OTHER inhibits BC6ENTG activation in breast cancer cells by a reactive BC6OTHER species - mediated mechanism and independently of janus BC6ENTC kinase 2 and BC6OTHER .	False
 BC6OTHER inhibits BC6OTHER activation in breast cancer cells by a reactive BC6ENTC species - mediated mechanism and independently of BC6ENTG and BC6OTHER .	False
 BC6OTHER inhibits BC6OTHER activation in breast cancer cells by a reactive BC6ENTC species - mediated mechanism and independently of janus BC6OTHER kinase 2 and BC6ENTG .	False
 BC6OTHER inhibits BC6ENTG activation in breast cancer cells by a reactive BC6ENTC species - mediated mechanism and independently of janus BC6OTHER kinase 2 and BC6OTHER .	False
 There is , however , much information on the direct (acute and chronic) effects of BC6ENTC on the binding properties of BC6ENTG , as well as modulation of BC6OTHER synthesis and secretion (e.g. a suggested increase in BC6OTHER release).	False
 There is , however , much information on the direct (acute and chronic) effects of BC6ENTC on the binding properties of BC6OTHER , as well as modulation of BC6ENTG synthesis and secretion (e.g. a suggested increase in BC6OTHER release).	False
 There is , however , much information on the direct (acute and chronic) effects of BC6ENTC on the binding properties of BC6OTHER , as well as modulation of BC6OTHER synthesis and secretion (e.g. a suggested increase in BC6ENTG release).	CPR:3
Conversely , opioid antagonists such as BC6ENTC and BC6OTHER (which bind to non - selectively BC6ENTG ) have been shown to decrease BC6OTHER consumption under various experimental conditions.	CPR:6
Conversely , opioid antagonists such as BC6OTHER and BC6ENTC (which bind to non - selectively BC6ENTG ) have been shown to decrease BC6OTHER consumption under various experimental conditions.	CPR:3
Conversely , opioid antagonists such as BC6OTHER and BC6OTHER (which bind to non - selectively BC6ENTG ) have been shown to decrease BC6ENTC consumption under various experimental conditions.	False
Three types of BC6ENTG represent the respective targets of the major BC6OTHER ( BC6OTHER , BC6ENTC and BC6OTHER , respectively).	False
Three types of BC6OTHER represent the respective targets of the major BC6ENTG ( BC6OTHER , BC6ENTC and BC6OTHER , respectively).	False
Three types of BC6OTHER represent the respective targets of the major BC6OTHER ( BC6ENTG , BC6ENTC and BC6OTHER , respectively).	False
Three types of BC6OTHER represent the respective targets of the major BC6OTHER ( BC6OTHER , BC6ENTC and BC6ENTG , respectively).	False
BC6ENTC treatment had no significant effect on adipogenesis , or the mRNA expression of BC6ENTG and BC6OTHER ; however , there was a significant increase in the mRNA expression of BC6OTHER .	False
BC6ENTC treatment had no significant effect on adipogenesis , or the mRNA expression of BC6OTHER and BC6ENTG ; however , there was a significant increase in the mRNA expression of BC6OTHER .	False
BC6ENTC treatment had no significant effect on adipogenesis , or the mRNA expression of BC6OTHER and BC6OTHER ; however , there was a significant increase in the mRNA expression of BC6ENTG .	CPR:3
On the other hand , treatment with BC6ENTC significantly increased adipogenesis , which was associated with a significant increase in the mRNA expression of BC6ENTG , BC6OTHER and BC6OTHER .	CPR:3
On the other hand , treatment with BC6ENTC significantly increased adipogenesis , which was associated with a significant increase in the mRNA expression of BC6OTHER , BC6ENTG and BC6OTHER .	CPR:3
On the other hand , treatment with BC6ENTC significantly increased adipogenesis , which was associated with a significant increase in the mRNA expression of BC6OTHER , BC6OTHER and BC6ENTG .	CPR:3
Anti - diabetic Activity of BC6ENTC is due to an Active Metabolite , BC6OTHER , that Upregulates BC6ENTG Gene Expression in 3T3 - L1 cells.	False
Anti - diabetic Activity of BC6OTHER is due to an Active Metabolite , BC6ENTC , that Upregulates BC6ENTG Gene Expression in 3T3 - L1 cells.	CPR:3
Specifically , light microscopy revealed a decrease in BC6ENTG - expressing ( BC6ENTC ) neurons in the midbrain of BC6OTHER - exposed fetuses and electron microscopy identified a reduction in spine synapses in the CA1 region of hippocampus.	False
Specifically , light microscopy revealed a decrease in BC6ENTG - expressing ( BC6OTHER ) neurons in the midbrain of BC6ENTC - exposed fetuses and electron microscopy identified a reduction in spine synapses in the CA1 region of hippocampus.	False
BC6OTHER acts at vascular BC6OTHER (postsynaptically) and at presynaptic BC6ENTG , where it inhibits BC6ENTC release.	False
BC6OTHER acts at vascular BC6ENTG (postsynaptically) and at presynaptic BC6OTHER , where it inhibits BC6ENTC release.	False
In clinical studies , BC6ENTC has been shown to significantly reduce cardiovascular and cerebrovascular events , whilst avoiding the persistent cough that commonly occurs with the use of BC6ENTG inhibitors.	False
Both the BC6ENTG - BC6ENTC system and the sympathetic nervous system are involved in hypertension , hence targeting these systems is likely to be of benefit in the treatment of hypertension.	False
The ARB BC6ENTC is a CHEM BC6ENTG ( BC6OTHER ) antagonist , which acts to decrease total peripheral resistance.	CPR:6
The ARB BC6ENTC is a CHEM BC6OTHER ( BC6ENTG ) antagonist , which acts to decrease total peripheral resistance.	CPR:6
The ARB BC6OTHER is a CHEM BC6ENTC type 1 receptor ( BC6ENTG ) antagonist , which acts to decrease total peripheral resistance.	False
BC6ENTC acts at vascular BC6OTHER (postsynaptically) and at presynaptic BC6ENTG , where it inhibits BC6OTHER release.	False
BC6ENTC acts at vascular BC6ENTG (postsynaptically) and at presynaptic BC6OTHER , where it inhibits BC6OTHER release.	False
The BC6ENTC - gated channel P2X1 and the 2 BC6ENTG and BC6OTHER BC6OTHER selectively contribute to platelet aggregation.	False
The BC6ENTC - gated channel P2X1 and the 2 BC6OTHER and BC6ENTG BC6OTHER selectively contribute to platelet aggregation.	False
The BC6ENTC - gated channel P2X1 and the 2 BC6OTHER and BC6OTHER BC6ENTG selectively contribute to platelet aggregation.	False
Platelet activation by BC6ENTC and BC6OTHER plays a crucial role in haemostasis and thrombosis , and their so - called BC6ENTG are potential targets for antithrombotic drugs.	False
Platelet activation by BC6OTHER and BC6ENTC plays a crucial role in haemostasis and thrombosis , and their so - called BC6ENTG are potential targets for antithrombotic drugs.	False
The BC6ENTG receptor is responsible for BC6ENTC - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6ENTC - induced shape change and weak and transient aggregation , while the BC6ENTG receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6ENTC - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6ENTC - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG .	False
The BC6ENTG receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6ENTC and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6ENTG receptor is responsible for the completion and amplification of the response to BC6ENTC and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6ENTC and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6ENTC and to all platelet agonists , including BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG .	False
The BC6ENTG receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6ENTC ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6ENTG receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6ENTC ( BC6OTHER ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6ENTC ( BC6OTHER ) , BC6ENTG , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6ENTC ( BC6OTHER ) , BC6OTHER , and BC6ENTG .	False
The BC6ENTG receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6ENTC ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6ENTG receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6ENTC ) , BC6OTHER , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6ENTC ) , BC6ENTG , and BC6OTHER .	False
The BC6OTHER receptor is responsible for BC6OTHER - induced shape change and weak and transient aggregation , while the BC6OTHER receptor is responsible for the completion and amplification of the response to BC6OTHER and to all platelet agonists , including BC6OTHER ( BC6ENTC ) , BC6OTHER , and BC6ENTG .	False
Due to its central role in the formation and stabilization of a thrombus , the BC6ENTG receptor is a well - established target of antithrombotic drugs like BC6ENTC or BC6OTHER , which have proved efficacy in many clinical trials and experimental models of thrombosis.	False
Due to its central role in the formation and stabilization of a thrombus , the BC6ENTG receptor is a well - established target of antithrombotic drugs like BC6OTHER or BC6ENTC , which have proved efficacy in many clinical trials and experimental models of thrombosis.	False
In the long term , BC6ENTC has been shown to be more effective than placebo in reducing body weight and serum total and BC6ENTG BC6OTHER levels.	CPR:4
In the long term , BC6OTHER has been shown to be more effective than placebo in reducing body weight and serum total and BC6ENTG BC6ENTC levels.	False
Along with weight loss , BC6ENTC also favourably affects blood pressure and BC6OTHER and BC6ENTG levels in obese individuals and in obese type 2 diabetic patients.	False
Along with weight loss , BC6OTHER also favourably affects blood pressure and BC6ENTC and BC6ENTG levels in obese individuals and in obese type 2 diabetic patients.	False
BC6ENTC is a new inhibitor of BC6ENTG enzyme.	CPR:4
Pretreatment of human breast carcinoma MCF - 7 cells for 24 h with the groundnut extract and soybean BC6ENTC increased gene expression of BC6ENTG ( BC6OTHER ) , a major antioxidative stress enzyme.	CPR:3
Pretreatment of human breast carcinoma MCF - 7 cells for 24 h with the groundnut extract and soybean BC6ENTC increased gene expression of BC6OTHER ( BC6ENTG ) , a major antioxidative stress enzyme.	CPR:3
The BC6ENTG binding affinities of a series of synthetic BC6ENTC have been measured with the aims of dissecting individual group contributions and obtaining a rationale for the design of novel compounds with the ability to overcome drug resistance.	False
Insight into the structural basis for this improvement was gained with molecular modeling and NMR data obtained for BC6ENTG - bound BC6ENTC .	False
BC6ENTC with affinities for BC6ENTG well above their affinities for BC6OTHER are shown not to be affected by multidrug resistance.	False
BC6ENTC with affinities for BC6OTHER well above their affinities for BC6ENTG are shown not to be affected by multidrug resistance.	False
Optimization of BC6OTHER binding to BC6ENTG : binding affinity dissection and incremental construction of a high - affinity analog of BC6ENTC .	False
Optimization of BC6ENTC binding to BC6ENTG : binding affinity dissection and incremental construction of a high - affinity analog of BC6OTHER .	False
The discovery of an inducible BC6ENTG whose apparent substrate preference is BC6OTHER indicates that BC6ENTC catabolism is more complex than that originally proposed.	False
To facilitate the study of this enzyme , the purification and characterization of the recombinant BC6ENTG / BC6OTHER BC6ENTC oxidase are reported.	False
To facilitate the study of this enzyme , the purification and characterization of the recombinant BC6OTHER / BC6ENTG BC6ENTC oxidase are reported.	False
Purified BC6ENTG / BC6OTHER oxidizes both BC6ENTC (K(m)=1.6 microM) and BC6OTHER (K(m)=51 microM) , but does not oxidize BC6OTHER .	CPR:9
Purified BC6OTHER / BC6ENTG oxidizes both BC6ENTC (K(m)=1.6 microM) and BC6OTHER (K(m)=51 microM) , but does not oxidize BC6OTHER .	CPR:9
Purified BC6ENTG / BC6OTHER oxidizes both BC6OTHER (K(m)=1.6 microM) and BC6ENTC (K(m)=51 microM) , but does not oxidize BC6OTHER .	CPR:9
Purified BC6OTHER / BC6ENTG oxidizes both BC6OTHER (K(m)=1.6 microM) and BC6ENTC (K(m)=51 microM) , but does not oxidize BC6OTHER .	CPR:9
Purified BC6ENTG / BC6OTHER oxidizes both BC6OTHER (K(m)=1.6 microM) and BC6OTHER (K(m)=51 microM) , but does not oxidize BC6ENTC .	False
Purified BC6OTHER / BC6ENTG oxidizes both BC6OTHER (K(m)=1.6 microM) and BC6OTHER (K(m)=51 microM) , but does not oxidize BC6ENTC .	False
The purified human enzyme also does not oxidize eight representative antitumor BC6ENTC analogues; however , specific CHEM analogues were found to be potent inhibitors of the oxidation of BC6OTHER by BC6ENTG / BC6OTHER .	False
The purified human enzyme also does not oxidize eight representative antitumor BC6ENTC analogues; however , specific CHEM analogues were found to be potent inhibitors of the oxidation of BC6OTHER by BC6OTHER / BC6ENTG .	False
The purified human enzyme also does not oxidize eight representative antitumor BC6OTHER analogues; however , specific CHEM analogues were found to be potent inhibitors of the oxidation of BC6ENTC by BC6ENTG / BC6OTHER .	CPR:9
The purified human enzyme also does not oxidize eight representative antitumor BC6OTHER analogues; however , specific CHEM analogues were found to be potent inhibitors of the oxidation of BC6ENTC by BC6OTHER / BC6ENTG .	CPR:9
The results of these studies are consistent with the hypothesis that BC6ENTG / BC6OTHER represents a new addition to the BC6ENTC metabolic pathway that may represent a new target for antineoplastic drug development.	False
The results of these studies are consistent with the hypothesis that BC6OTHER / BC6ENTG represents a new addition to the BC6ENTC metabolic pathway that may represent a new target for antineoplastic drug development.	False
The discovery of an inducible BC6ENTG whose apparent substrate preference is BC6ENTC indicates that BC6OTHER catabolism is more complex than that originally proposed.	CPR:9
Properties of purified recombinant human BC6ENTC oxidase , BC6ENTG / BC6OTHER .	False
Properties of purified recombinant human BC6ENTC oxidase , BC6OTHER / BC6ENTG .	False
These results confirm the selective BC6ENTG agonist and BC6OTHER antagonist actions of BC6ENTC .	CPR:5
These results confirm the selective BC6OTHER agonist and BC6ENTG antagonist actions of BC6ENTC .	CPR:6
BC6ENTC was claimed from BC6ENTG expressed in non - neuronal cells to be a selective orthosteric BC6OTHER agonist and BC6OTHER antagonist.	False
BC6ENTC was claimed from BC6OTHER expressed in non - neuronal cells to be a selective orthosteric BC6ENTG agonist and BC6OTHER antagonist.	CPR:5
BC6ENTC was claimed from BC6OTHER expressed in non - neuronal cells to be a selective orthosteric BC6OTHER agonist and BC6ENTG antagonist.	CPR:6
Field excitatory post - synaptic potentials (fEPSPs) evoked by stimulation of the temporo - ammonic path (TAP) input to CA1 stratum lacunosum moleculare (SLM) were inhibited by BC6ENTC in BC6ENTG - / - mice (EC(50) 38 nM) and wild - type littermates (EC(50) 42 nM) to a similar extent but were not significantly affected in BC6OTHER - / - mice.	False
Field excitatory post - synaptic potentials (fEPSPs) evoked by stimulation of the temporo - ammonic path (TAP) input to CA1 stratum lacunosum moleculare (SLM) were inhibited by BC6ENTC in BC6OTHER - / - mice (EC(50) 38 nM) and wild - type littermates (EC(50) 42 nM) to a similar extent but were not significantly affected in BC6ENTG - / - mice.	False
Despite the potential therapeutic relevance of group II metabotropic BC6ENTC (mGlu) receptors , there has been a lack of pharmacological tools for separating the roles of BC6ENTG and BC6OTHER receptor subtypes.	False
Despite the potential therapeutic relevance of group II metabotropic BC6ENTC (mGlu) receptors , there has been a lack of pharmacological tools for separating the roles of BC6OTHER and BC6ENTG receptor subtypes.	False
CHEM - application of DCG - IV and BC6ENTC in BC6ENTG - / - and wild - type littermates resulted in an additive effect , whereas in BC6OTHER - / - mice , BC6OTHER reversed the inhibitory action of DCG - IV.	False
CHEM - application of DCG - IV and BC6ENTC in BC6OTHER - / - and wild - type littermates resulted in an additive effect , whereas in BC6ENTG - / - mice , BC6OTHER reversed the inhibitory action of DCG - IV.	False
CHEM - application of DCG - IV and BC6OTHER in BC6ENTG - / - and wild - type littermates resulted in an additive effect , whereas in BC6OTHER - / - mice , BC6ENTC reversed the inhibitory action of DCG - IV.	False
CHEM - application of DCG - IV and BC6OTHER in BC6OTHER - / - and wild - type littermates resulted in an additive effect , whereas in BC6ENTG - / - mice , BC6ENTC reversed the inhibitory action of DCG - IV.	False
Differentiating the roles of BC6ENTG and BC6OTHER receptors using BC6ENTC , an BC6OTHER agonist / BC6OTHER antagonist.	False
Differentiating the roles of BC6OTHER and BC6ENTG receptors using BC6ENTC , an BC6OTHER agonist / BC6OTHER antagonist.	False
Differentiating the roles of BC6OTHER and BC6OTHER receptors using BC6ENTC , an BC6ENTG agonist / BC6OTHER antagonist.	CPR:5
Differentiating the roles of BC6OTHER and BC6OTHER receptors using BC6ENTC , an BC6OTHER agonist / BC6ENTG antagonist.	CPR:6
The values of mean corpuscular BC6OTHER concentration and mean corpuscular BC6ENTG increased in the BC6ENTC group.	CPR:3
The values of mean corpuscular BC6ENTG concentration and mean corpuscular BC6OTHER increased in the BC6ENTC group.	CPR:3
The results suggested the generation of reactive BC6ENTC species , with increased activity of BC6ENTG and concentrations of LPO and BC6OTHER ; whereas the specific activity of BC6OTHER decreased.	False
The results suggested the generation of reactive BC6ENTC species , with increased activity of BC6OTHER and concentrations of LPO and BC6OTHER ; whereas the specific activity of BC6ENTG decreased.	False
The results suggested the generation of reactive BC6OTHER species , with increased activity of BC6ENTG and concentrations of LPO and BC6ENTC ; whereas the specific activity of BC6OTHER decreased.	False
The results suggested the generation of reactive BC6OTHER species , with increased activity of BC6OTHER and concentrations of LPO and BC6ENTC ; whereas the specific activity of BC6ENTG decreased.	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC S - transferase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC S - transferase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6ENTC peroxidase ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6ENTG ) , and concentrations of BC6OTHER ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) , and concentrations of BC6ENTC ( BC6OTHER ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
The animal's liver was assessed using biomarkers as activities of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) , and concentrations of BC6OTHER ( BC6ENTC ) and lipoperoxidation (LPO) and protein carbonylation (PCO).	False
These findings demonstrate that BC6ENTG is the primary transporter responsible for BC6ENTC uptake in the choroid plexus.	CPR:9
At normal pH (7.4) and temperature (37 degrees C) , the uptake of 1 microM BC6ENTC was reduced by 83% in BC6ENTG ( - / - ) mice as compared with BC6OTHER (+ / +) mice (p < 0.001).	CPR:9
At normal pH (7.4) and temperature (37 degrees C) , the uptake of 1 microM BC6ENTC was reduced by 83% in BC6OTHER ( - / - ) mice as compared with BC6ENTG (+ / +) mice (p < 0.001).	CPR:9
The choroid plexus uptake of BC6ENTC was studied in BC6ENTG ( BC6OTHER ) wild - type and null mice as a function of temperature , transport inhibitors , pH , and saturability.	CPR:9
The choroid plexus uptake of BC6ENTC was studied in BC6OTHER ( BC6ENTG ) wild - type and null mice as a function of temperature , transport inhibitors , pH , and saturability.	CPR:9
BC6ENTC coadministration could inhibit the uptake of BC6OTHER in BC6ENTG (+ / +) mice (p < 0.01) but not BC6OTHER ( - / - ) mice.	False
BC6ENTC coadministration could inhibit the uptake of BC6OTHER in BC6OTHER (+ / +) mice (p < 0.01) but not BC6ENTG ( - / - ) mice.	False
BC6OTHER coadministration could inhibit the uptake of BC6ENTC in BC6ENTG (+ / +) mice (p < 0.01) but not BC6OTHER ( - / - ) mice.	CPR:9
BC6OTHER coadministration could inhibit the uptake of BC6ENTC in BC6OTHER (+ / +) mice (p < 0.01) but not BC6ENTG ( - / - ) mice.	CPR:9
Although a proton - stimulated uptake of BC6ENTC was demonstrated in BC6ENTG (+ / +) mice (pH 6.5 versus pH 7.4; p < 0.01) , no pH dependence was observed in BC6OTHER ( - / - ) mice.	CPR:9
Although a proton - stimulated uptake of BC6ENTC was demonstrated in BC6OTHER (+ / +) mice (pH 6.5 versus pH 7.4; p < 0.01) , no pH dependence was observed in BC6ENTG ( - / - ) mice.	CPR:9
Mechanisms of BC6ENTC uptake in the choroid plexus: studies in wild - type and BC6ENTG knockout mice.	CPR:9
The treatment of mice with BC6ENTC alone enhances BC6ENTG activity to 4.6 folds , protein BC6OTHER formation increased up to 2.9 folds and DNA synthesis expressed in terms of BC6OTHER incorporation increased to 3.2 folds , and antioxidants and antioxidant enzymes decreased to 1.8 - 2.5 folds , compared with the corresponding saline - treated controls.	CPR:3
The treatment of mice with BC6OTHER alone enhances BC6ENTG activity to 4.6 folds , protein BC6ENTC formation increased up to 2.9 folds and DNA synthesis expressed in terms of BC6OTHER incorporation increased to 3.2 folds , and antioxidants and antioxidant enzymes decreased to 1.8 - 2.5 folds , compared with the corresponding saline - treated controls.	False
The treatment of mice with BC6OTHER alone enhances BC6ENTG activity to 4.6 folds , protein BC6OTHER formation increased up to 2.9 folds and DNA synthesis expressed in terms of BC6ENTC incorporation increased to 3.2 folds , and antioxidants and antioxidant enzymes decreased to 1.8 - 2.5 folds , compared with the corresponding saline - treated controls.	False
This paper aims to review briefly the literature on the BC6ENTC hypothesis of depression with a major focus on the possible role of BC6ENTG in this disorder , while highlighting how recent data are more oriented on dimensional rather than nosological involvement of this structure in different conditions spanning from normality to pathology.	False
Moreover , when the BC6ENTG - coregulator binding profiles were hierarchically clustered using Euclidian cluster distance , the structurally related compounds were found to cluster together , whereas the BC6ENTC test compounds having an CHEM - ring were separated from those with a BC6OTHER A - ring.	False
Moreover , when the BC6ENTG - coregulator binding profiles were hierarchically clustered using Euclidian cluster distance , the structurally related compounds were found to cluster together , whereas the BC6OTHER test compounds having an CHEM - ring were separated from those with a BC6ENTC A - ring.	False
Testing chemicals for their endocrine - disrupting potential , including interference with BC6ENTC receptor ( BC6ENTG ) signaling , is an important aspect of chemical safety testing.	False
In Alexander cells , only when they were transfected with BC6ENTG + BC6OTHER , BC6ENTC caused up - regulation of BC6OTHER and BC6OTHER , and a down - regulation of BC6OTHER .	False
In Alexander cells , only when they were transfected with BC6OTHER + BC6ENTG , BC6ENTC caused up - regulation of BC6OTHER and BC6OTHER , and a down - regulation of BC6OTHER .	False
In Alexander cells , only when they were transfected with BC6OTHER + BC6OTHER , BC6ENTC caused up - regulation of BC6ENTG and BC6OTHER , and a down - regulation of BC6OTHER .	CPR:3
In Alexander cells , only when they were transfected with BC6OTHER + BC6OTHER , BC6ENTC caused up - regulation of BC6OTHER and BC6ENTG , and a down - regulation of BC6OTHER .	CPR:3
In Alexander cells , only when they were transfected with BC6OTHER + BC6OTHER , BC6ENTC caused up - regulation of BC6OTHER and BC6OTHER , and a down - regulation of BC6ENTG .	CPR:4
Moreover , GCs have a synergistic effect on BC6ENTC - induced BC6ENTG activation , whereas BC6OTHER and BC6OTHER have an additive effect.	CPR:3
Moreover , GCs have a synergistic effect on BC6OTHER - induced BC6ENTG activation , whereas BC6ENTC and BC6OTHER have an additive effect.	False
Moreover , GCs have a synergistic effect on BC6OTHER - induced BC6ENTG activation , whereas BC6OTHER and BC6ENTC have an additive effect.	False
In HepG2 cells , GCs induced a decreased expression of BC6ENTG and BC6OTHER , and inhibited the regulatory effect of BC6ENTC on BC6OTHER - target genes.	False
In HepG2 cells , GCs induced a decreased expression of BC6OTHER and BC6ENTG , and inhibited the regulatory effect of BC6ENTC on BC6OTHER - target genes.	False
In HepG2 cells , GCs induced a decreased expression of BC6OTHER and BC6OTHER , and inhibited the regulatory effect of BC6ENTC on BC6ENTG - target genes.	False
 BC6ENTG - dependent and - independent interaction of glucocorticoids with the regulatory pathways involved in the control of BC6ENTC handling by the liver.	False
This study examined the effect of BC6ENTC on the gene expression of secretory proteins and BC6ENTG in the submaxillary gland.	False
Multiple exposure to BC6ENTC , a BC6ENTG ( BC6OTHER ) inhibitor , induces acinar hypertrophy in the salivary gland.	CPR:4
Multiple exposure to BC6ENTC , a BC6OTHER ( BC6ENTG ) inhibitor , induces acinar hypertrophy in the salivary gland.	CPR:4
The gene expressions for the secretory protein , cystatin BC6ENTC ( BC6ENTG ) , and BC6OTHER in the submaxillary gland were quantified using RT - PCR.	False
The gene expressions for the secretory protein , cystatin BC6ENTC ( BC6OTHER ) , and BC6ENTG in the submaxillary gland were quantified using RT - PCR.	False
BC6ENTC exposure resulted in a sustained increase in mRNA expression for BC6ENTG and BC6OTHER , but BC6OTHER gene expression was unchanged.	CPR:3
BC6ENTC exposure resulted in a sustained increase in mRNA expression for BC6OTHER and BC6ENTG , but BC6OTHER gene expression was unchanged.	CPR:3
BC6ENTC exposure resulted in a sustained increase in mRNA expression for BC6OTHER and BC6OTHER , but BC6ENTG gene expression was unchanged.	False
The upregulation of BC6ENTG , BC6OTHER and BC6OTHER activity were further inhibited by treatment with BC6OTHER in the presence of BC6ENTC .	CPR:3
The upregulation of BC6OTHER , BC6ENTG and BC6OTHER activity were further inhibited by treatment with BC6OTHER in the presence of BC6ENTC .	CPR:3
The upregulation of BC6OTHER , BC6OTHER and BC6ENTG activity were further inhibited by treatment with BC6OTHER in the presence of BC6ENTC .	CPR:3
Additionally , BC6ENTG levels in the cytosol decreased due to BC6ENTC but not due to BC6OTHER .	CPR:4
Additionally , BC6ENTG levels in the cytosol decreased due to BC6OTHER but not due to BC6ENTC .	False
Furthermore , treatment with BC6ENTC not only attenuated the pro - apoptotic effect of BC6OTHER but reversed the BC6OTHER - induced increase of BC6ENTG and BC6OTHER levels.	CPR:4
Furthermore , treatment with BC6ENTC not only attenuated the pro - apoptotic effect of BC6OTHER but reversed the BC6OTHER - induced increase of BC6OTHER and BC6ENTG levels.	CPR:4
Furthermore , treatment with BC6OTHER not only attenuated the pro - apoptotic effect of BC6ENTC but reversed the BC6OTHER - induced increase of BC6ENTG and BC6OTHER levels.	False
Furthermore , treatment with BC6OTHER not only attenuated the pro - apoptotic effect of BC6ENTC but reversed the BC6OTHER - induced increase of BC6OTHER and BC6ENTG levels.	False
Furthermore , treatment with BC6OTHER not only attenuated the pro - apoptotic effect of BC6OTHER but reversed the BC6ENTC - induced increase of BC6ENTG and BC6OTHER levels.	CPR:3
Furthermore , treatment with BC6OTHER not only attenuated the pro - apoptotic effect of BC6OTHER but reversed the BC6ENTC - induced increase of BC6OTHER and BC6ENTG levels.	CPR:3
In this study , BC6ENTC ( BC6OTHER ) - induced apoptosis of cardiomyocyte was evaluated based on the previous studies , and the roles of BC6ENTG signaling were clarified.	CPR:3
In this study , BC6OTHER ( BC6ENTC ) - induced apoptosis of cardiomyocyte was evaluated based on the previous studies , and the roles of BC6ENTG signaling were clarified.	CPR:3
Cardiomyocytes that were injured by BC6ENTC were assayed by the BC6OTHER and BC6ENTG leakage ratio.	False
Cardiomyocytes that were injured by BC6OTHER were assayed by the BC6ENTC and BC6ENTG leakage ratio.	False
BC6ENTC increased BC6ENTG expression and BC6OTHER activity and promoted Bid cleavage.	CPR:3
BC6ENTC increased BC6OTHER expression and BC6ENTG activity and promoted Bid cleavage.	CPR:3
The upregulation of BC6ENTG , BC6OTHER and BC6OTHER activity were further inhibited by treatment with BC6ENTC in the presence of BC6OTHER .	CPR:4
The upregulation of BC6OTHER , BC6ENTG and BC6OTHER activity were further inhibited by treatment with BC6ENTC in the presence of BC6OTHER .	CPR:4
The upregulation of BC6OTHER , BC6OTHER and BC6ENTG activity were further inhibited by treatment with BC6ENTC in the presence of BC6OTHER .	CPR:4
Activation of an apoptotic signal transduction pathway involved in the upregulation of BC6ENTG and BC6OTHER in BC6ENTC - induced primary cultured cardiomyocytes.	CPR:3
Activation of an apoptotic signal transduction pathway involved in the upregulation of BC6OTHER and BC6ENTG in BC6ENTC - induced primary cultured cardiomyocytes.	CPR:3
These results provide the first evidence for the existence of a BC6ENTC channel family with four TMS and two BC6ENTG in the nervous system of mammals.	False
Here we report the structural and functional properties of BC6ENTG , a mammalian TWIK - 1 - related BC6ENTC channel.	False
Despite a low BC6ENTC identity between BC6ENTG and BC6OTHER (approximately 28%) , both channel proteins share the same overall structural arrangement consisting of two BC6OTHER and four transmembrane segments (TMS).	False
Despite a low BC6ENTC identity between BC6OTHER and BC6ENTG (approximately 28%) , both channel proteins share the same overall structural arrangement consisting of two BC6OTHER and four transmembrane segments (TMS).	False
Despite a low BC6ENTC identity between BC6OTHER and BC6OTHER (approximately 28%) , both channel proteins share the same overall structural arrangement consisting of two BC6ENTG and four transmembrane segments (TMS).	False
BC6ENTC currents generated by BC6ENTG are inwardly rectifying while BC6OTHER currents generated by BC6OTHER are outwardly rectifying.	False
BC6ENTC currents generated by BC6OTHER are inwardly rectifying while BC6OTHER currents generated by BC6ENTG are outwardly rectifying.	False
BC6OTHER currents generated by BC6ENTG are inwardly rectifying while BC6ENTC currents generated by BC6OTHER are outwardly rectifying.	False
BC6OTHER currents generated by BC6OTHER are inwardly rectifying while BC6ENTC currents generated by BC6ENTG are outwardly rectifying.	False
BC6ENTG currents are insensitive to pharmacological agents that block BC6OTHER activity such as BC6ENTC and BC6OTHER .	False
BC6OTHER currents are insensitive to pharmacological agents that block BC6ENTG activity such as BC6ENTC and BC6OTHER .	CPR:4
BC6ENTG currents are insensitive to pharmacological agents that block BC6OTHER activity such as BC6OTHER and BC6ENTC .	False
BC6OTHER currents are insensitive to pharmacological agents that block BC6ENTG activity such as BC6OTHER and BC6ENTC .	CPR:4
BC6ENTG currents are sensitive to extracellular BC6ENTC and BC6OTHER .	False
BC6ENTG currents are sensitive to extracellular BC6OTHER and BC6ENTC .	False
BC6ENTG , which has been cloned recently , is a new structural type of weak inward rectifier BC6ENTC channel.	False
There was a significant overlap (42 genes) between the 3 and 30 ppb differentially expressed gene lists , with two of these genes ( BC6ENTG and BC6OTHER ) present in all three BC6ENTC treatments.	False
There was a significant overlap (42 genes) between the 3 and 30 ppb differentially expressed gene lists , with two of these genes ( BC6OTHER and BC6ENTG ) present in all three BC6ENTC treatments.	False
Though BC6ENTC alone obviously induced endoplasmic reticulum stress , this signaling pathway may not contribute to the synergetic anti - proliferative effect as the protein expression of BC6ENTG and BC6OTHER was similar in BC6OTHER alone and combined treatment group.	False
Though BC6ENTC alone obviously induced endoplasmic reticulum stress , this signaling pathway may not contribute to the synergetic anti - proliferative effect as the protein expression of BC6OTHER and BC6ENTG was similar in BC6OTHER alone and combined treatment group.	False
Though BC6OTHER alone obviously induced endoplasmic reticulum stress , this signaling pathway may not contribute to the synergetic anti - proliferative effect as the protein expression of BC6ENTG and BC6OTHER was similar in BC6ENTC alone and combined treatment group.	False
Though BC6OTHER alone obviously induced endoplasmic reticulum stress , this signaling pathway may not contribute to the synergetic anti - proliferative effect as the protein expression of BC6OTHER and BC6ENTG was similar in BC6ENTC alone and combined treatment group.	False
 BC6ENTC Presents Synergistic Anti - proliferative Activity With BC6OTHER Via Altering Cell Cycle and BC6ENTG Signaling in 95 - D Lung Cancer Cells.	False
 BC6OTHER Presents Synergistic Anti - proliferative Activity With BC6ENTC Via Altering Cell Cycle and BC6ENTG Signaling in 95 - D Lung Cancer Cells.	False
One of the BC6ENTG agonists , BC6ENTC (19 ,  - logEC(50)=7.5 , E(max)=255%) was selected for further development.	CPR:5
As far as we are aware , the compound's BC6ENTC scaffold represents a new core structure for BC6ENTG agonists.	CPR:5
Discovery of novel BC6OTHER ligands by a virtual screening approach: further development of BC6ENTC as BC6ENTG agonists.	CPR:5
Discovery of novel BC6ENTG ligands by a virtual screening approach: further development of BC6ENTC as BC6OTHER agonists.	False
The kinetic parameters indicate that the main effect of the mutation of CHEM228 to BC6ENTC is on the k(cat) of BC6ENTG , which increases 3 - 4 - fold , both in the absence and in the presence of LA; simultaneously , the k(cat) for the BC6OTHER reaction is reduced 30 - fold.	False
The kinetic parameters indicate that the main effect of the mutation of CHEM228 to BC6ENTC is on the k(cat) of BC6OTHER , which increases 3 - 4 - fold , both in the absence and in the presence of LA; simultaneously , the k(cat) for the BC6ENTG reaction is reduced 30 - fold.	False
The kinetic parameters indicate that the main effect of the mutation of CHEM228 to BC6OTHER is on the k(cat) of BC6ENTC - T , which increases 3 - 4 - fold , both in the absence and in the presence of LA; simultaneously , the k(cat) for the BC6ENTG reaction is reduced 30 - fold.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6ENTC ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6ENTC ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6ENTC ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6ENTC ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
The kinetic parameters indicate that the main effect of the mutation of CHEM228 to BC6OTHER is on the k(cat) of BC6ENTG , which increases 3 - 4 - fold , both in the absence and in the presence of LA; simultaneously , the k(cat) for the BC6ENTC - T reaction is reduced 30 - fold.	False
The crystal structure of BC6ENTG - BC6ENTC - T1 complexed with LA , BC6OTHER , and BC6OTHER determined at 1.9 A resolution shows that the CHEM318 side chain exhibits a minor alternate conformation , compared to that in the wild type.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTC - T activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTC - T activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTC - T activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
The crystal structure of BC6ENTG - BC6OTHER complexed with LA , BC6ENTC , and BC6OTHER determined at 1.9 A resolution shows that the CHEM318 side chain exhibits a minor alternate conformation , compared to that in the wild type.	False
The crystal structure of BC6OTHER - BC6ENTG complexed with LA , BC6ENTC , and BC6OTHER determined at 1.9 A resolution shows that the CHEM318 side chain exhibits a minor alternate conformation , compared to that in the wild type.	False
The crystal structure of BC6ENTG - BC6OTHER complexed with LA , BC6OTHER , and BC6ENTC determined at 1.9 A resolution shows that the CHEM318 side chain exhibits a minor alternate conformation , compared to that in the wild type.	False
The crystal structure of BC6OTHER - BC6ENTG complexed with LA , BC6OTHER , and BC6ENTC determined at 1.9 A resolution shows that the CHEM318 side chain exhibits a minor alternate conformation , compared to that in the wild type.	False
This alternate conformation now causes a steric hindrance to the BC6ENTC group of the BC6OTHER moiety of BC6OTHER , probably causing the dissociation of BC6OTHER and the reduced k(cat) of the BC6ENTG reaction.	False
This alternate conformation now causes a steric hindrance to the BC6OTHER group of the BC6ENTC moiety of BC6OTHER , probably causing the dissociation of BC6OTHER and the reduced k(cat) of the BC6ENTG reaction.	False
This alternate conformation now causes a steric hindrance to the BC6OTHER group of the BC6OTHER moiety of BC6ENTC , probably causing the dissociation of BC6OTHER and the reduced k(cat) of the BC6ENTG reaction.	False
This alternate conformation now causes a steric hindrance to the BC6OTHER group of the BC6OTHER moiety of BC6OTHER , probably causing the dissociation of BC6ENTC and the reduced k(cat) of the BC6ENTG reaction.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6ENTC from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6ENTC from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6ENTC from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6ENTC from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6ENTC to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6ENTC to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6ENTC to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	CPR:9
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6ENTC to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6ENTC ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6ENTC ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6ENTC ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6ENTC ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTC - T activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTC - T activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTC - T activity) , albeit at only 0.3% efficiency.	False
In addition , BC6ENTG ( BC6OTHER ) enhances this BC6ENTC - T activity more than 25 times.	False
In addition , BC6OTHER ( BC6ENTG ) enhances this BC6ENTC - T activity more than 25 times.	False
Comparison of the crystal structures of BC6ENTC - and BC6OTHER - bound BC6ENTG reveals that the BC6OTHER group in both BC6OTHER and BC6OTHER moieties forms a BC6OTHER bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6ENTC - bound BC6ENTG reveals that the BC6OTHER group in both BC6OTHER and BC6OTHER moieties forms a BC6OTHER bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6OTHER - bound BC6ENTG reveals that the BC6ENTC group in both BC6OTHER and BC6OTHER moieties forms a BC6OTHER bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6OTHER - bound BC6ENTG reveals that the BC6OTHER group in both BC6ENTC and BC6OTHER moieties forms a BC6OTHER bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6OTHER - bound BC6ENTG reveals that the BC6OTHER group in both BC6OTHER and BC6ENTC moieties forms a BC6OTHER bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6OTHER - bound BC6ENTG reveals that the BC6OTHER group in both BC6OTHER and BC6OTHER moieties forms a BC6ENTC bond with the side chain BC6OTHER group of CHEM317.	False
Comparison of the crystal structures of BC6OTHER - and BC6OTHER - bound BC6ENTG reveals that the BC6OTHER group in both BC6OTHER and BC6OTHER moieties forms a BC6OTHER bond with the side chain BC6ENTC group of CHEM317.	False
The orientation of the BC6ENTC causes a steric hindrance to the side chain BC6OTHER group of CHEM317 , accounting for the enzyme's low BC6ENTG activity.	False
The orientation of the BC6OTHER causes a steric hindrance to the side chain BC6ENTC group of CHEM317 , accounting for the enzyme's low BC6ENTG activity.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6ENTC from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6ENTC from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6ENTC from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6ENTC from BC6OTHER to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6ENTC to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	CPR:9
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6ENTC to BC6OTHER in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	CPR:9
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6ENTC to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6ENTC to BC6OTHER in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	CPR:9
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6ENTC ( BC6ENTG - BC6OTHER ) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6ENTC ( BC6OTHER - BC6ENTG ) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6ENTC ( BC6OTHER - BC6OTHER ) results in a 15 - fold higher BC6ENTG activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6ENTC ( BC6OTHER - BC6OTHER ) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6ENTG activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6ENTG - BC6ENTC - T1) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6ENTC - T1) results in a 15 - fold higher BC6ENTG activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6ENTC - T1) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6ENTG activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6ENTG - BC6OTHER ) results in a 15 - fold higher BC6ENTC - T activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6ENTG ) results in a 15 - fold higher BC6ENTC - T activity , which is further enhanced by LA to nearly 25% of the BC6OTHER activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6OTHER ) results in a 15 - fold higher BC6ENTC - T activity , which is further enhanced by LA to nearly 25% of the BC6ENTG activity of the wild type.	False
BC6ENTG ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6ENTC in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6ENTC in the presence of BC6OTHER ion ( BC6ENTG activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6OTHER ) normally transfers BC6OTHER from BC6OTHER to BC6ENTC in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6ENTG activity) , albeit at only 0.3% efficiency.	False
BC6OTHER ( BC6ENTG ) normally transfers BC6OTHER from BC6OTHER to BC6ENTC in the presence of BC6OTHER ion ( BC6OTHER activity) and also transfers BC6OTHER from BC6OTHER to BC6OTHER ( BC6OTHER activity) , albeit at only 0.3% efficiency.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6ENTG - BC6OTHER ) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6ENTC - T activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6ENTG ) results in a 15 - fold higher BC6OTHER activity , which is further enhanced by LA to nearly 25% of the BC6ENTC - T activity of the wild type.	False
In this study , we show that mutation of CHEM228 , a residue in the vicinity of CHEM317 , to BC6OTHER ( BC6OTHER - BC6OTHER ) results in a 15 - fold higher BC6ENTG activity , which is further enhanced by LA to nearly 25% of the BC6ENTC - T activity of the wild type.	False
Mutation of BC6ENTC 228 to BC6OTHER enhances the BC6ENTG activity of BC6OTHER .	False
Mutation of BC6ENTC 228 to BC6OTHER enhances the BC6OTHER activity of BC6ENTG .	False
Mutation of BC6OTHER 228 to BC6ENTC enhances the BC6ENTG activity of BC6OTHER .	CPR:3
Mutation of BC6OTHER 228 to BC6ENTC enhances the BC6OTHER activity of BC6ENTG .	False
The binding of BC6OTHER to BC6OTHER in the cerebral cortex of BC6ENTG - / - mice was also decreased , most probably as an adaptive response to the sustained elevation of extracellular BC6ENTC levels observed in these mice.	False
The binding of BC6OTHER to BC6ENTG in the cerebral cortex of BC6OTHER - / - mice was also decreased , most probably as an adaptive response to the sustained elevation of extracellular BC6ENTC levels observed in these mice.	False
A pronounced BC6ENTG knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6OTHER - inhibiting ADs such as BC6ENTC , BC6OTHER , and BC6OTHER .	False
A pronounced BC6OTHER knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6ENTG - inhibiting ADs such as BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:4
A pronounced BC6ENTG knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6OTHER - inhibiting ADs such as BC6OTHER , BC6ENTC , and BC6OTHER .	False
A pronounced BC6OTHER knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6ENTG - inhibiting ADs such as BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:4
A pronounced BC6ENTG knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6OTHER - inhibiting ADs such as BC6OTHER , BC6OTHER , and BC6ENTC .	False
A pronounced BC6OTHER knockout - induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by BC6ENTG - inhibiting ADs such as BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:4
BC6ENTC , which is devoid of affinity for the BC6ENTG , exerted a significant reduction of immobility time in the BC6OTHER - / - mice.	False
BC6ENTC , which is devoid of affinity for the BC6OTHER , exerted a significant reduction of immobility time in the BC6ENTG - / - mice.	False
In the FST , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6ENTG knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6OTHER - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6OTHER knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6ENTG - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6ENTG knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6OTHER - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6OTHER knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6ENTG - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6ENTG knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6OTHER - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6OTHER knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6ENTG - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC administered acutely did not reduce any further the immobility time shortened by BC6ENTG knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6OTHER - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC administered acutely did not reduce any further the immobility time shortened by BC6OTHER knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6OTHER was observed in BC6ENTG - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6ENTG knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6ENTC was observed in BC6OTHER - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
In the FST , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER administered acutely did not reduce any further the immobility time shortened by BC6OTHER knockout itself (ca 25%); however , antidepressant - like action of repeatedly (7 days) administered BC6ENTC was observed in BC6ENTG - / - mice , indicating that the chronic presence of this drug may also affect other neurochemical targets involved in the behavioral reactions monitored by this test.	False
From the present study , it may be concluded that mice lacking the BC6ENTG may represent a good model of some aspects of depression - resistant behavior , paralleled with alterations in the expression of BC6OTHER , which result as an adaptation to elevated levels of extracellular BC6ENTC .	False
From the present study , it may be concluded that mice lacking the BC6OTHER may represent a good model of some aspects of depression - resistant behavior , paralleled with alterations in the expression of BC6ENTG , which result as an adaptation to elevated levels of extracellular BC6ENTC .	False
Using mice lacking BC6ENTC transporter ( BC6ENTG - / - ) we examined their baseline phenotype as well as the response in the forced swim test (FST) and in the tail suspension test (TST) upon treatment with ADs that display different pharmacological profiles.	False
Autoradiographic studies showed decreased binding of the beta - adrenergic ligand BC6ENTC in the cerebral cortex of BC6ENTG - / - mice , indicating the changes at the level of BC6OTHER similar to those obtained with ADs treatment.	False
Autoradiographic studies showed decreased binding of the beta - adrenergic ligand BC6ENTC in the cerebral cortex of BC6OTHER - / - mice , indicating the changes at the level of BC6ENTG similar to those obtained with ADs treatment.	False
The binding of BC6ENTC to BC6OTHER in the cerebral cortex of BC6ENTG - / - mice was also decreased , most probably as an adaptive response to the sustained elevation of extracellular BC6OTHER levels observed in these mice.	False
The binding of BC6ENTC to BC6ENTG in the cerebral cortex of BC6OTHER - / - mice was also decreased , most probably as an adaptive response to the sustained elevation of extracellular BC6OTHER levels observed in these mice.	False
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6OTHER ( BC6OTHER ) and the BC6ENTC - converting enzyme inhibitor , BC6OTHER , on BC6ENTG activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6ENTG inhibitor , BC6OTHER ( BC6OTHER ) and the BC6ENTC - converting enzyme inhibitor , BC6OTHER , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6OTHER ( BC6OTHER ) and the BC6ENTG inhibitor , BC6ENTC , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	CPR:4
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6OTHER ( BC6OTHER ) and the BC6OTHER inhibitor , BC6ENTC , on BC6ENTG activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6ENTG inhibitor , BC6OTHER ( BC6OTHER ) and the BC6OTHER inhibitor , BC6ENTC , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
Moreover , blockade of invasion , angiogenesis and other processes mediated by BC6ENTG may underlie the anti - tumor and anti - metastatic effect of BC6ENTC and BC6OTHER and their combination.	False
Moreover , blockade of invasion , angiogenesis and other processes mediated by BC6ENTG may underlie the anti - tumor and anti - metastatic effect of BC6OTHER and BC6ENTC and their combination.	False
Here we report that BC6ENTC treatment resulted in decreased transcription and protein levels of BC6ENTG by 3LL cells.	CPR:4
Both BC6ENTC and CHEM also prevented substrate degradation by BC6ENTG released in conditioned medium by cultured cells.	CPR:4
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6ENTC ( BC6OTHER ) and the BC6ENTG inhibitor , BC6OTHER , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6ENTC ( BC6OTHER ) and the BC6OTHER inhibitor , BC6OTHER , on BC6ENTG activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6ENTG inhibitor , BC6ENTC ( BC6OTHER ) and the BC6OTHER inhibitor , BC6OTHER , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	CPR:4
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6OTHER ( BC6ENTC ) and the BC6ENTG inhibitor , BC6OTHER , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6OTHER inhibitor , BC6OTHER ( BC6ENTC ) and the BC6OTHER inhibitor , BC6OTHER , on BC6ENTG activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	False
We have examined the effects of the synthetic BC6ENTG inhibitor , BC6OTHER ( BC6ENTC ) and the BC6OTHER inhibitor , BC6OTHER , on BC6OTHER activity of murine Lewis - lung - carcinoma cells (3LL) in vitro , and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL / 6 mice.	CPR:4
Inhibition of BC6ENTG ( BC6OTHER ) by BC6ENTC and BC6OTHER reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.	CPR:4
Inhibition of BC6OTHER ( BC6ENTG ) by BC6ENTC and BC6OTHER reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.	CPR:4
Inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER and BC6ENTC reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.	CPR:4
Inhibition of BC6OTHER ( BC6ENTG ) by BC6OTHER and BC6ENTC reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.	CPR:4
Massive urinary excretion of BC6ENTC , BC6OTHER and BC6OTHER , known as CHEM or hydroxykynureninuria , in a young Somali boy suggested BC6ENTG deficiency.	False
Mutation analysis of BC6ENTG encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a BC6ENTC - to - BC6OTHER ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6ENTG of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a BC6ENTC - to - BC6OTHER ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6ENTG substitution leading to a BC6ENTC - to - BC6OTHER ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a BC6ENTC - to - BC6OTHER ( BC6ENTG ) shift.	False
Mutation analysis of BC6ENTG encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a CHEM - to - BC6ENTC ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6ENTG of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a CHEM - to - BC6ENTC ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6ENTG substitution leading to a CHEM - to - BC6ENTC ( BC6OTHER ) shift.	False
Mutation analysis of BC6OTHER encoding BC6OTHER of the index case revealed homozygosity for a c.593 BC6OTHER substitution leading to a CHEM - to - BC6ENTC ( BC6ENTG ) shift.	False
Massive urinary excretion of BC6OTHER , BC6ENTC and BC6OTHER , known as CHEM or hydroxykynureninuria , in a young Somali boy suggested BC6ENTG deficiency.	False
Massive urinary excretion of BC6OTHER , BC6OTHER and BC6ENTC , known as CHEM or hydroxykynureninuria , in a young Somali boy suggested BC6ENTG deficiency.	False
In many countries , a BC6ENTG antagonist BC6ENTC has been used in the treatment of BC6OTHER dependence.	CPR:6
In many countries , a BC6ENTG antagonist BC6OTHER has been used in the treatment of BC6ENTC dependence.	False
The endogenous CHEM agonists , such as BC6ENTG , increase the activity of the mesolimbic dopaminergic system through the inhibition of the BC6ENTC ( BC6OTHER ) - containing inhibitory interneurons in the ventral tegmental area , resulting in the expression of BC6OTHER reinforcement and / or rewarding effect.	False
The endogenous CHEM agonists , such as BC6ENTG , increase the activity of the mesolimbic dopaminergic system through the inhibition of the BC6OTHER ( BC6ENTC ) - containing inhibitory interneurons in the ventral tegmental area , resulting in the expression of BC6OTHER reinforcement and / or rewarding effect.	False
The endogenous CHEM agonists , such as BC6ENTG , increase the activity of the mesolimbic dopaminergic system through the inhibition of the BC6OTHER ( BC6OTHER ) - containing inhibitory interneurons in the ventral tegmental area , resulting in the expression of BC6ENTC reinforcement and / or rewarding effect.	False
[Pharmacological effects of a BC6ENTG antagonist BC6ENTC on BC6OTHER dependence].	CPR:6
[Pharmacological effects of a BC6ENTG antagonist BC6OTHER on BC6ENTC dependence].	False
Sixty - four female mice (ICR) were injected with BC6ENTC (0 , 7.5 , 15 and 30 µg / d) for 3 d starting from the day of BC6ENTG treatment.	False
Nevertheless , coperfusion with 0.1 and 0.3 mM BC6OTHER , which inhibits the BC6ENTG ( BC6OTHER ) , dose dependently inhibited BC6ENTC - induced DBS.	False
Nevertheless , coperfusion with 0.1 and 0.3 mM BC6OTHER , which inhibits the BC6OTHER ( BC6ENTG ) , dose dependently inhibited BC6ENTC - induced DBS.	False
In conclusion , only specific apical BC6ENTG inhibition increased DBS , whereas BC6ENTC synthesis , CHEM - BC6OTHER - cotransporter activation , or intracellular BC6OTHER - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6ENTC synthesis , BC6ENTG activation , or intracellular BC6OTHER - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6ENTC synthesis , CHEM - BC6OTHER - cotransporter activation , or intracellular BC6OTHER - formation by BC6ENTG was not involved.	False
In conclusion , only specific apical BC6ENTG inhibition increased DBS , whereas BC6OTHER synthesis , BC6ENTC - BC6OTHER - cotransporter activation , or intracellular BC6OTHER - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6OTHER synthesis , BC6ENTC - BC6OTHER - cotransporter activation , or intracellular BC6OTHER - formation by BC6ENTG was not involved.	False
In conclusion , only specific apical BC6ENTG inhibition increased DBS , whereas BC6OTHER synthesis , CHEM - BC6ENTC - cotransporter activation , or intracellular BC6OTHER - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6OTHER synthesis , CHEM - BC6ENTC - cotransporter activation , or intracellular BC6OTHER - formation by BC6ENTG was not involved.	False
In conclusion , only specific apical BC6ENTG inhibition increased DBS , whereas BC6OTHER synthesis , CHEM - BC6OTHER - cotransporter activation , or intracellular BC6ENTC - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6OTHER synthesis , BC6ENTG activation , or intracellular BC6ENTC - formation by BC6OTHER was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6OTHER synthesis , CHEM - BC6OTHER - cotransporter activation , or intracellular BC6ENTC - formation by BC6ENTG was not involved.	CPR:9
In conclusion , only specific apical BC6ENTG inhibition increased DBS , whereas BC6OTHER synthesis , CHEM - BC6OTHER - cotransporter activation , or intracellular BC6OTHER - formation by BC6ENTC anhydrase was not involved.	False
In conclusion , only specific apical BC6OTHER inhibition increased DBS , whereas BC6OTHER synthesis , BC6ENTG activation , or intracellular BC6OTHER - formation by BC6ENTC anhydrase was not involved.	False
BC6ENTC (50 microM; BC6OTHER ) , a concentration that selectively inhibits the BC6ENTG isoforms BC6OTHER and BC6OTHER , but not BC6OTHER , did not affect DBS.	CPR:4
BC6ENTC (50 microM; BC6OTHER ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6ENTG and BC6OTHER , but not BC6OTHER , did not affect DBS.	CPR:4
BC6ENTC (50 microM; BC6OTHER ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6OTHER and BC6ENTG , but not BC6OTHER , did not affect DBS.	CPR:4
BC6ENTC (50 microM; BC6OTHER ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6OTHER and BC6OTHER , but not BC6ENTG , did not affect DBS.	CPR:4
BC6OTHER (50 microM; BC6ENTC ) , a concentration that selectively inhibits the BC6ENTG isoforms BC6OTHER and BC6OTHER , but not BC6OTHER , did not affect DBS.	CPR:4
BC6OTHER (50 microM; BC6ENTC ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6ENTG and BC6OTHER , but not BC6OTHER , did not affect DBS.	CPR:4
BC6OTHER (50 microM; BC6ENTC ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6OTHER and BC6ENTG , but not BC6OTHER , did not affect DBS.	CPR:4
BC6OTHER (50 microM; BC6ENTC ) , a concentration that selectively inhibits the BC6OTHER isoforms BC6OTHER and BC6OTHER , but not BC6ENTG , did not affect DBS.	CPR:4
We examined the effect of inhibition of BC6ENTC / BC6OTHER exchange ( BC6ENTG ) on duodenal CHEM secretion (DBS) in rats to further understand DBS regulation.	False
Nevertheless , 3 mM BC6ENTC , a higher concentration that inhibits BC6ENTG , BC6OTHER , and BC6OTHER , significantly increased DBS.	CPR:4
Nevertheless , 3 mM BC6ENTC , a higher concentration that inhibits BC6OTHER , BC6ENTG , and BC6OTHER , significantly increased DBS.	CPR:4
Nevertheless , 3 mM BC6ENTC , a higher concentration that inhibits BC6OTHER , BC6OTHER , and BC6ENTG , significantly increased DBS.	CPR:4
We examined the effect of inhibition of CHEM / BC6ENTC exchange ( BC6ENTG ) on duodenal CHEM secretion (DBS) in rats to further understand DBS regulation.	False
Moreover , BC6ENTC and BC6OTHER , both specific inhibitors of BC6ENTG only , or perfusion with BC6OTHER - free solutions , dose dependently increased DBS , as measured by pH - stat and BC6OTHER - sensitive electrode , without affecting intracellular pH.	CPR:4
Moreover , BC6OTHER and BC6ENTC , both specific inhibitors of BC6ENTG only , or perfusion with BC6OTHER - free solutions , dose dependently increased DBS , as measured by pH - stat and BC6OTHER - sensitive electrode , without affecting intracellular pH.	CPR:4
Moreover , BC6OTHER and BC6OTHER , both specific inhibitors of BC6ENTG only , or perfusion with BC6ENTC - free solutions , dose dependently increased DBS , as measured by pH - stat and BC6OTHER - sensitive electrode , without affecting intracellular pH.	False
Moreover , BC6OTHER and BC6OTHER , both specific inhibitors of BC6ENTG only , or perfusion with BC6OTHER - free solutions , dose dependently increased DBS , as measured by pH - stat and BC6ENTC - sensitive electrode , without affecting intracellular pH.	False
Nevertheless , coperfusion with 0.1 and 0.3 mM BC6ENTC , which inhibits the BC6ENTG ( BC6OTHER ) , dose dependently inhibited BC6OTHER - induced DBS.	CPR:4
Nevertheless , coperfusion with 0.1 and 0.3 mM BC6ENTC , which inhibits the BC6OTHER ( BC6ENTG ) , dose dependently inhibited BC6OTHER - induced DBS.	CPR:4
Taken together , the data provide evidence that the synergistic antiproliferative effect of BC6ENTC and BC6OTHER is linked to the inhibition of BC6ENTG and BC6OTHER activities , and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.	CPR:4
Taken together , the data provide evidence that the synergistic antiproliferative effect of BC6ENTC and BC6OTHER is linked to the inhibition of BC6OTHER and BC6ENTG activities , and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.	CPR:4
Taken together , the data provide evidence that the synergistic antiproliferative effect of BC6OTHER and BC6ENTC is linked to the inhibition of BC6ENTG and BC6OTHER activities , and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.	CPR:4
Taken together , the data provide evidence that the synergistic antiproliferative effect of BC6OTHER and BC6ENTC is linked to the inhibition of BC6OTHER and BC6ENTG activities , and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.	CPR:4
In combination with BC6ENTC , the ability of BC6OTHER to reduce the contents of BC6ENTG and its target gene products was also evident in a time - and dose - dependent experiment.	CPR:4
In combination with BC6OTHER , the ability of BC6ENTC to reduce the contents of BC6ENTG and its target gene products was also evident in a time - and dose - dependent experiment.	CPR:4
The inhibition of BC6ENTC 3 - kinase using BC6OTHER augmented a decrease in the BC6OTHER level induced by their combination , but it showed no significant effects on expression of BC6ENTG and BC6OTHER .	False
The inhibition of BC6ENTC 3 - kinase using BC6OTHER augmented a decrease in the BC6OTHER level induced by their combination , but it showed no significant effects on expression of BC6OTHER and BC6ENTG .	False
The inhibition of BC6ENTC 3 - kinase using BC6OTHER augmented a decrease in the BC6ENTG level induced by their combination , but it showed no significant effects on expression of BC6OTHER and BC6OTHER .	False
The inhibition of BC6OTHER using BC6ENTC augmented a decrease in the BC6OTHER level induced by their combination , but it showed no significant effects on expression of BC6ENTG and BC6OTHER .	False
The inhibition of BC6OTHER using BC6ENTC augmented a decrease in the BC6OTHER level induced by their combination , but it showed no significant effects on expression of BC6OTHER and BC6ENTG .	False
The inhibition of BC6ENTG using BC6ENTC augmented a decrease in the BC6OTHER level induced by their combination , but it showed no significant effects on expression of BC6OTHER and BC6OTHER .	CPR:4
The inhibition of BC6OTHER using BC6ENTC augmented a decrease in the BC6ENTG level induced by their combination , but it showed no significant effects on expression of BC6OTHER and BC6OTHER .	CPR:4
Some BC6ENTG gene polymorphisms have been associated with BC6OTHER - BC6ENTC ( BC6OTHER - C) concentrations.	False
Some BC6OTHER gene polymorphisms have been associated with BC6ENTG - BC6ENTC ( BC6OTHER - C) concentrations.	False
Some BC6OTHER gene polymorphisms have been associated with BC6OTHER - BC6ENTC ( BC6ENTG - C) concentrations.	False
The BC6ENTC - binding cassette A1 ( BC6ENTG ) gene plays a key role in reverse BC6OTHER transport.	False
The BC6ENTG ( BC6OTHER ) gene plays a key role in reverse BC6ENTC transport.	False
The BC6OTHER ( BC6ENTG ) gene plays a key role in reverse BC6ENTC transport.	False
 BC6ENTG single BC6ENTC polymorphisms on BC6OTHER - BC6OTHER and overweight: the D.E.S.I.R.	False
 BC6OTHER single BC6ENTC polymorphisms on BC6ENTG - BC6OTHER and overweight: the D.E.S.I.R.	False
 BC6ENTG single BC6OTHER polymorphisms on BC6OTHER - BC6ENTC and overweight: the D.E.S.I.R.	False
 BC6OTHER single BC6OTHER polymorphisms on BC6ENTG - BC6ENTC and overweight: the D.E.S.I.R.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6ENTG and BC6OTHER BC6ENTC , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6OTHER and BC6ENTG BC6ENTC , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6ENTG and BC6OTHER BC6OTHER , BC6ENTC , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6OTHER and BC6ENTG BC6OTHER , BC6ENTC , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6ENTG and BC6OTHER BC6OTHER , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6ENTC and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6OTHER measurement , BC6OTHER and BC6ENTG BC6OTHER , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6ENTC and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6ENTC measurement , BC6ENTG and BC6OTHER BC6OTHER , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
A multivariable model adjusted for age , sex , population group , immigrant status , BMI , season of BC6ENTC measurement , BC6OTHER and BC6ENTG BC6OTHER , BC6OTHER , estimated glomerular filtration rate , history of hypertension or cardiovascular disease , Charlson comorbidity index , smoking , and socioeconomic status revealed an inverse association between BC6OTHER and the risk of progression to IFG and diabetes.	False
The effect of BC6ENTC on plasma BC6ENTG ( BC6OTHER ) in non - stressed and immobilization - stressed mice were investigated.	False
The effect of BC6ENTC on plasma BC6OTHER ( BC6ENTG ) in non - stressed and immobilization - stressed mice were investigated.	False
Ginseng total BC6ENTC , BC6OTHER administered intraperitoneally attenuated the immobilization stress - induced increase in plasma BC6ENTG level.	CPR:4
Ginseng total BC6OTHER , BC6ENTC administered intraperitoneally attenuated the immobilization stress - induced increase in plasma BC6ENTG level.	CPR:4
But , intracerebroventricular injection of each BC6ENTC did not affect plasma BC6ENTG level induced by immobilization stress.	False
BC6ENTC significantly decreased BC6OTHER and / or BC6OTHER - induced increase of BC6ENTG level in macrophage cell line (RAW 264.7).	CPR:4
BC6OTHER significantly decreased BC6ENTC and / or BC6OTHER - induced increase of BC6ENTG level in macrophage cell line (RAW 264.7).	CPR:3
BC6OTHER significantly decreased BC6OTHER and / or BC6ENTC - induced increase of BC6ENTG level in macrophage cell line (RAW 264.7).	CPR:3
Thus , it can be suggested that the inhibitory action of BC6ENTC against the immobilization stress - induced increase of plasma BC6ENTG level would be in periphery; at least in part , mediated by blocking BC6OTHER - and / or BC6OTHER - induced increase of BC6OTHER level in macrophage rather than in the brain.	CPR:4
Thus , it can be suggested that the inhibitory action of BC6ENTC against the immobilization stress - induced increase of plasma BC6OTHER level would be in periphery; at least in part , mediated by blocking BC6OTHER - and / or BC6OTHER - induced increase of BC6ENTG level in macrophage rather than in the brain.	CPR:4
Thus , it can be suggested that the inhibitory action of BC6OTHER against the immobilization stress - induced increase of plasma BC6ENTG level would be in periphery; at least in part , mediated by blocking BC6ENTC - and / or BC6OTHER - induced increase of BC6OTHER level in macrophage rather than in the brain.	False
Thus , it can be suggested that the inhibitory action of BC6OTHER against the immobilization stress - induced increase of plasma BC6OTHER level would be in periphery; at least in part , mediated by blocking BC6ENTC - and / or BC6OTHER - induced increase of BC6ENTG level in macrophage rather than in the brain.	CPR:3
Thus , it can be suggested that the inhibitory action of BC6OTHER against the immobilization stress - induced increase of plasma BC6ENTG level would be in periphery; at least in part , mediated by blocking BC6OTHER - and / or BC6ENTC - induced increase of BC6OTHER level in macrophage rather than in the brain.	False
Thus , it can be suggested that the inhibitory action of BC6OTHER against the immobilization stress - induced increase of plasma BC6OTHER level would be in periphery; at least in part , mediated by blocking BC6OTHER - and / or BC6ENTC - induced increase of BC6ENTG level in macrophage rather than in the brain.	CPR:3
The inhibitory effect of BC6ENTC on the stress - induced plasma BC6ENTG level in mice.	CPR:4
BC6ENTC was previously identified in mammalian brain and was shown to be a co - agonist at the ' BC6OTHER ' site of the BC6ENTG .	CPR:5
Racemization of BC6ENTC is catalyzed by BC6ENTG , a BC6OTHER - dependent enzyme expressed mainly in brain and liver.	CPR:9
Racemization of BC6OTHER is catalyzed by BC6ENTG , a BC6ENTC - dependent enzyme expressed mainly in brain and liver.	False
BC6ENTC receptor overactivation has been implicated in a number of pathological conditions and inhibitors of BC6ENTG are thus potentially interesting targets for therapy.	False
BC6ENTG overactivation has been implicated in a number of pathological conditions and inhibitors of BC6ENTC racemase are thus potentially interesting targets for therapy.	False
BC6OTHER was previously identified in mammalian brain and was shown to be a co - agonist at the ' BC6ENTC ' site of the BC6ENTG .	False
 BC6ENTG catalyzes specific elimination of BC6ENTC to BC6OTHER .	CPR:9
 BC6ENTG catalyzes specific elimination of BC6OTHER to BC6ENTC .	CPR:9
A series of BC6ENTC (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6ENTC (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6ENTC group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6ENTC group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6ENTC ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6ENTC ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6ENTC , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6ENTC , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6ENTC groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6ENTC groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6ENTC group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6ENTC group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6ENTC (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTG ( BC6OTHER ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6ENTC (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6OTHER ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
A series of BC6OTHER (2) and BC6OTHER (3) analogues with a variety of electron - donating and electron - withdrawing groups in the pendant BC6OTHER group and the BC6OTHER ring C , as well as CHEM , BC6OTHER , and BC6OTHER groups replacing the BC6OTHER group were synthesized , and their binding affinities at the BC6ENTC transporter ( BC6ENTG ) on rat or guinea pig striatal membranes were determined.	False
Several active analogues were also evaluated for their ability to block uptake of BC6ENTC , BC6OTHER , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6ENTG , HEK - BC6OTHER , and HEK - BC6OTHER cells.	CPR:9
Several active analogues were also evaluated for their ability to block uptake of BC6ENTC , BC6OTHER , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6ENTG , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6ENTC , BC6OTHER , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6OTHER , and HEK - BC6ENTG cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6ENTC , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6ENTG , HEK - BC6OTHER , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6ENTC , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6ENTG , and HEK - BC6OTHER cells.	CPR:9
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6ENTC , and BC6OTHER and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6OTHER , and HEK - BC6ENTG cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6ENTC and inhibit binding of BC6OTHER at HEK - BC6ENTG , HEK - BC6OTHER , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6ENTC and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6ENTG , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6ENTC and inhibit binding of BC6OTHER at HEK - BC6OTHER , HEK - BC6OTHER , and HEK - BC6ENTG cells.	CPR:9
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6OTHER and inhibit binding of BC6ENTC at HEK - BC6ENTG , HEK - BC6OTHER , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6OTHER and inhibit binding of BC6ENTC at HEK - BC6OTHER , HEK - BC6ENTG , and HEK - BC6OTHER cells.	False
Several active analogues were also evaluated for their ability to block uptake of BC6OTHER , BC6OTHER , and BC6OTHER and inhibit binding of BC6ENTC at HEK - BC6OTHER , HEK - BC6OTHER , and HEK - BC6ENTG cells.	False
BC6ENTC (26) was found to be a pro - drug , oxidizing ( BC6OTHER - - > BC6OTHER ) to BC6OTHER on rat striatal membranes and HEK - BC6ENTG cells.	False
BC6OTHER (26) was found to be a pro - drug , oxidizing ( BC6ENTC - - > BC6OTHER ) to BC6OTHER on rat striatal membranes and HEK - BC6ENTG cells.	False
BC6OTHER (26) was found to be a pro - drug , oxidizing ( BC6OTHER - - > BC6ENTC ) to BC6OTHER on rat striatal membranes and HEK - BC6ENTG cells.	False
BC6OTHER (26) was found to be a pro - drug , oxidizing ( BC6OTHER - - > BC6OTHER ) to BC6ENTC on rat striatal membranes and HEK - BC6ENTG cells.	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6ENTG cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6ENTG K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6ENTG / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6ENTG = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6ENTG / BC6OTHER = 38).	False
The BC6ENTC analogue (38) of BC6OTHER was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6ENTG = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6ENTG cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6ENTG K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6ENTG / BC6OTHER = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6ENTG = 1283 and BC6OTHER / BC6OTHER = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6ENTG / BC6OTHER = 38).	False
The BC6OTHER analogue (38) of BC6ENTC was the most potent and selective ligand for HEK - BC6OTHER cells ( BC6OTHER K(i) = 1.1 nM; BC6OTHER / BC6OTHER = 1283 and BC6OTHER / BC6ENTG = 38).	False
 BC6ENTC analogues as potential inhibitors of the BC6ENTG at the BC6OTHER .	CPR:4
 BC6ENTC analogues as potential inhibitors of the BC6OTHER at the BC6ENTG .	CPR:4
 BC6OTHER analogues as potential inhibitors of the BC6ENTC binding site at the BC6ENTG .	False
 BC6OTHER analogues as potential inhibitors of the BC6ENTG at the BC6ENTC transporter.	False
We describe the discovery of several BC6ENTC as potent and selective BC6ENTG inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.	CPR:4
 BC6ENTC as Selective BC6ENTG Inhibitors.	CPR:4
In vitro data show comparable affinity to BC6ENTC D(2) , BC6ENTG and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6ENTC D(2) , BC6OTHER and BC6ENTG and recently , BC6OTHER showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6ENTC D(2) , BC6OTHER and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6ENTG and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6ENTC D(2) , BC6OTHER and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6ENTG .	False
CONCLUSIONS: We were able to demonstrate a moderate BC6ENTG and BC6OTHER occupancy under clinically relevant doses of BC6ENTC , albeit lower than expected from in vitro data and clearly below saturation.	False
CONCLUSIONS: We were able to demonstrate a moderate BC6OTHER and BC6ENTG occupancy under clinically relevant doses of BC6ENTC , albeit lower than expected from in vitro data and clearly below saturation.	False
In vitro data show comparable affinity to BC6ENTG , BC6OTHER and BC6OTHER and recently , BC6ENTC showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6ENTG and BC6OTHER and recently , BC6ENTC showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6ENTG and recently , BC6ENTC showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6OTHER and recently , BC6ENTC showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6ENTG and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6OTHER and recently , BC6ENTC showed to be not inferior to BC6OTHER in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6ENTG .	False
In vitro data show comparable affinity to BC6ENTG , BC6OTHER and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6ENTC in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6ENTG and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6ENTC in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6ENTG and recently , BC6OTHER showed to be not inferior to BC6ENTC in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6ENTC in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6ENTG and / or BC6OTHER .	False
In vitro data show comparable affinity to BC6OTHER , BC6OTHER and BC6OTHER and recently , BC6OTHER showed to be not inferior to BC6ENTC in schizophrenic patients with predominant negative symptomatology , which was implicated with CHEM's interaction with BC6OTHER and / or BC6ENTG .	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6ENTC (target: frontal BC6ENTG ) , BC6OTHER (striatal BC6OTHER ) or BC6OTHER (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6ENTC (target: frontal BC6OTHER ) , BC6OTHER (striatal BC6ENTG ) or BC6OTHER (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6ENTC (target: frontal BC6OTHER ) , BC6OTHER (striatal BC6OTHER ) or BC6OTHER (striatal BC6ENTG ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6ENTG ) , BC6ENTC (striatal BC6OTHER ) or BC6OTHER (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6OTHER ) , BC6ENTC (striatal BC6ENTG ) or BC6OTHER (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6OTHER ) , BC6ENTC (striatal BC6OTHER ) or BC6OTHER (striatal BC6ENTG ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6ENTG ) , BC6OTHER (striatal BC6OTHER ) or BC6ENTC (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6OTHER ) , BC6OTHER (striatal BC6ENTG ) or BC6ENTC (striatal BC6OTHER ).	False
MATERIALS AND METHODS: Each patient underwent two PET scans with BC6OTHER (target: frontal BC6OTHER ) , BC6OTHER (striatal BC6OTHER ) or BC6ENTC (striatal BC6ENTG ).	False
Occupancy of BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER in schizophrenic patients treated with BC6ENTC in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER in schizophrenic patients treated with BC6ENTC in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG in schizophrenic patients treated with BC6ENTC in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6ENTC BC6ENTG , BC6OTHER and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6ENTC BC6OTHER , BC6ENTG and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6ENTC BC6OTHER , BC6OTHER and BC6ENTG in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6ENTC and BC6OTHER .	False
Occupancy of BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6ENTC and BC6OTHER .	False
Occupancy of BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG in schizophrenic patients treated with BC6OTHER in comparison with BC6ENTC and BC6OTHER .	False
Occupancy of BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6ENTC .	False
Occupancy of BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6ENTC .	False
Occupancy of BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6ENTC .	False
Occupancy of BC6OTHER BC6ENTG , BC6OTHER and BC6ENTC (2A) receptors in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6OTHER .	False
Occupancy of BC6OTHER BC6OTHER , BC6ENTG and BC6ENTC (2A) receptors in schizophrenic patients treated with BC6OTHER in comparison with BC6OTHER and BC6OTHER .	False
Since the original discovery of BC6ENTC analogs as BC6ENTG antagonists , we have preliminarily defined an important BC6OTHER antagonist pharmacophore and developed less - toxic BC6OTHER antagonists.	CPR:6
Since the original discovery of BC6ENTC analogs as BC6OTHER antagonists , we have preliminarily defined an important BC6ENTG antagonist pharmacophore and developed less - toxic BC6OTHER antagonists.	CPR:6
Since the original discovery of BC6ENTC analogs as BC6OTHER antagonists , we have preliminarily defined an important BC6OTHER antagonist pharmacophore and developed less - toxic BC6ENTG antagonists.	CPR:6
Adopted BC6OTHER ( BC6ENTG ) , BC6ENTC X receptor ( BC6OTHER ) , plays a central role in the regulation of xeno - and endobiotic metabolism.	False
Adopted BC6OTHER ( BC6OTHER ) , BC6ENTC X receptor ( BC6ENTG ) , plays a central role in the regulation of xeno - and endobiotic metabolism.	False
Adopted BC6ENTG ( BC6OTHER ) , BC6ENTC X receptor ( BC6OTHER ) , plays a central role in the regulation of xeno - and endobiotic metabolism.	False
However , more recently , it is clear that BC6ENTG is also an important mediator of adverse xeno - (e.g. , enhances BC6ENTC toxicity) and endobiotic (e.g. , hepatic steatosis) metabolic phenotypes.	False
The baseline BC6OTHER and BC6ENTG levels were identified as factors that predicted the response to add - on therapy with BC6ENTC .	False
The baseline BC6ENTG and BC6OTHER levels were identified as factors that predicted the response to add - on therapy with BC6ENTC .	False
Stratified analysis based on the BC6ENTG regimen revealed a stronger antidiabetic effect and a high efficacy of BC6ENTC when it was added to basal BC6OTHER therapy.	False
Stratified analysis based on the BC6OTHER regimen revealed a stronger antidiabetic effect and a high efficacy of BC6ENTC when it was added to basal BC6ENTG therapy.	False
The results of this investigation confirmed that add - on therapy with BC6ENTC to various BC6ENTG regimens could improve glycemic control without severe hypoglycemia and / or weight gain.	False
The effect of add - on therapy with BC6ENTC on glycemic control was prospectively investigated in patients with type 2 diabetes mellitus (T2DM) receiving BC6ENTG alone or BC6OTHER combined with oral antidiabetic drugs.	False
The effect of add - on therapy with BC6ENTC on glycemic control was prospectively investigated in patients with type 2 diabetes mellitus (T2DM) receiving BC6OTHER alone or BC6ENTG combined with oral antidiabetic drugs.	False
Concomitant oral drugs included BC6ENTC , BC6ENTG inhibitors and BC6OTHER .	False
Concomitant oral drugs included BC6OTHER , BC6ENTG inhibitors and BC6ENTC .	False
The BC6ENTG ( BC6OTHER ) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add - on therapy with BC6ENTC (p<0.01) , and the BC6OTHER dosage was reduced from 27.3±15.8 U / day to 24.5±16.5 U / day (p<0.001).	CPR:3
The BC6OTHER ( BC6ENTG ) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add - on therapy with BC6ENTC (p<0.01) , and the BC6OTHER dosage was reduced from 27.3±15.8 U / day to 24.5±16.5 U / day (p<0.001).	CPR:3
The BC6OTHER ( BC6OTHER ) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add - on therapy with BC6ENTC (p<0.01) , and the BC6ENTG dosage was reduced from 27.3±15.8 U / day to 24.5±16.5 U / day (p<0.001).	False
Add - on therapy with the BC6ENTG inhibitor BC6ENTC improves glycemic control in BC6OTHER - treated Japanese patients with type 2 diabetes mellitus.	CPR:4
Add - on therapy with the BC6OTHER inhibitor BC6ENTC improves glycemic control in BC6ENTG - treated Japanese patients with type 2 diabetes mellitus.	False
One exception is BC6ENTC ( BC6OTHER ) , which , as a BC6OTHER mimetic , inhibits binding of BC6ENTG to BC6OTHER .	CPR:4
One exception is BC6ENTC ( BC6OTHER ) , which , as a BC6OTHER mimetic , inhibits binding of BC6OTHER to BC6ENTG .	CPR:4
One exception is BC6OTHER ( BC6ENTC ) , which , as a BC6OTHER mimetic , inhibits binding of BC6ENTG to BC6OTHER .	CPR:4
One exception is BC6OTHER ( BC6ENTC ) , which , as a BC6OTHER mimetic , inhibits binding of BC6OTHER to BC6ENTG .	CPR:4
One exception is BC6OTHER ( BC6OTHER ) , which , as a BC6ENTC mimetic , inhibits binding of BC6ENTG to BC6OTHER .	CPR:4
One exception is BC6OTHER ( BC6OTHER ) , which , as a BC6ENTC mimetic , inhibits binding of BC6OTHER to BC6ENTG .	CPR:4
Coupling this computational technique with a high - quality low - throughput screen identified BC6ENTC ( BC6OTHER ) as a potent BC6ENTG binding inhibitor with the potential for the treatment of various bleeding disorders.	CPR:4
Coupling this computational technique with a high - quality low - throughput screen identified BC6OTHER ( BC6ENTC ) as a potent BC6ENTG binding inhibitor with the potential for the treatment of various bleeding disorders.	CPR:4
BC6ENTC is a canonical allosteric inhibitor of the BC6ENTG BC6OTHER with immunosuppressive and pro - apoptotic activities.	False
BC6ENTC is a canonical allosteric inhibitor of the BC6OTHER BC6ENTG with immunosuppressive and pro - apoptotic activities.	False
Interestingly , we showed that BC6OTHER shares all the BC6ENTG targeting properties not only with other two - domain , closed - ring analogs (rapalogs) , but also with its single domain mimics , and with BC6ENTC .	False
The latter is the first in vivo open - ring metabolite of BC6ENTC that does not affect BC6ENTG .	False
We hypothesize that the BC6ENTC and related compounds bind to the α face and allosterically impact the BC6ENTG function.	False
The implications of our finding for mechanism of in vivo actions of BC6ENTC and for design of novel allosteric drugs targeting the BC6ENTG are discussed.	False
We found that in vitro BC6ENTC also regulates the BC6ENTG , an essential intracellular protease of the BC6OTHER - BC6OTHER pathway.	False
We found that in vitro BC6ENTC also regulates the BC6OTHER , an essential intracellular protease of the BC6ENTG - BC6OTHER pathway.	False
We found that in vitro BC6ENTC also regulates the BC6OTHER , an essential intracellular protease of the BC6OTHER - BC6ENTG pathway.	False
BC6ENTC inhibits BC6ENTG and selected BC6OTHER activities of the catalytic core BC6OTHER at low micromolar concentrations.	CPR:4
BC6ENTC inhibits BC6OTHER and selected BC6ENTG activities of the catalytic core BC6OTHER at low micromolar concentrations.	CPR:4
BC6ENTC inhibits BC6OTHER and selected BC6OTHER activities of the catalytic core BC6ENTG at low micromolar concentrations.	CPR:4
Interestingly , we showed that BC6ENTC shares all the BC6ENTG targeting properties not only with other two - domain , closed - ring analogs (rapalogs) , but also with its single domain mimics , and with BC6OTHER .	False
 BC6ENTC allosterically inhibits the BC6ENTG .	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6ENTG ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6ENTG ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6ENTG CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6ENTG (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6ENTG (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6ENTG synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6ENTG ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6ENTG ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6ENTG ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6ENTC bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6ENTG ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6ENTG ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6ENTG CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6ENTG (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6ENTG (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6ENTG synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6ENTG ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6ENTG ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6ENTG ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6ENTC bioavailability (retention , transport and uptake of BC6OTHER ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6ENTG ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6ENTG ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6ENTG CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6ENTG (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6ENTG (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6ENTG synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6ENTG ( BC6OTHER ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6ENTG ) obtained from BC6OTHER ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
A study has been made of the influence of two pools of BC6OTHER ( BC6OTHER ) obtained from BC6ENTG ( BC6OTHER ) fractions , and of three specific BC6OTHER ( BC6OTHER CHEM , BC6OTHER (64 - 74)4P and BC6OTHER (1 - 19)4P) , on BC6OTHER bioavailability ( BC6OTHER synthesis) and BC6OTHER bioavailability (retention , transport and uptake of BC6ENTC ) in Caco - 2 cells.	False
BC6ENTG and BC6OTHER pools did not improve BC6OTHER synthesis , but the three specific BC6OTHER showed an increase in BC6OTHER synthesis in Caco - 2 cells versus BC6ENTC , BC6OTHER CHEM being the most effective.	False
BC6OTHER and BC6ENTG pools did not improve BC6OTHER synthesis , but the three specific BC6OTHER showed an increase in BC6OTHER synthesis in Caco - 2 cells versus BC6ENTC , BC6OTHER CHEM being the most effective.	False
BC6OTHER and BC6OTHER pools did not improve BC6ENTG synthesis , but the three specific BC6OTHER showed an increase in BC6OTHER synthesis in Caco - 2 cells versus BC6ENTC , BC6OTHER CHEM being the most effective.	False
BC6OTHER and BC6OTHER pools did not improve BC6OTHER synthesis , but the three specific BC6ENTG showed an increase in BC6OTHER synthesis in Caco - 2 cells versus BC6ENTC , BC6OTHER CHEM being the most effective.	False
BC6OTHER and BC6OTHER pools did not improve BC6OTHER synthesis , but the three specific BC6OTHER showed an increase in BC6ENTG synthesis in Caco - 2 cells versus BC6ENTC , BC6OTHER CHEM being the most effective.	False
BC6OTHER and BC6OTHER pools did not improve BC6OTHER synthesis , but the three specific BC6OTHER showed an increase in BC6OTHER synthesis in Caco - 2 cells versus BC6ENTC , BC6ENTG CHEM being the most effective.	False
In relation to BC6ENTC bioavailability , BC6ENTG , BC6OTHER , BC6OTHER (64 - 74)4P and BC6OTHER CHEM increased BC6OTHER uptake.	False
In relation to BC6ENTC bioavailability , BC6OTHER , BC6ENTG , BC6OTHER (64 - 74)4P and BC6OTHER CHEM increased BC6OTHER uptake.	False
In relation to BC6ENTC bioavailability , BC6OTHER , BC6OTHER , BC6ENTG (64 - 74)4P and BC6OTHER CHEM increased BC6OTHER uptake.	False
In relation to BC6ENTC bioavailability , BC6OTHER , BC6OTHER , BC6OTHER (64 - 74)4P and BC6ENTG CHEM increased BC6OTHER uptake.	False
In relation to BC6OTHER bioavailability , BC6ENTG , BC6OTHER , BC6OTHER (64 - 74)4P and BC6OTHER CHEM increased BC6ENTC uptake.	CPR:9
In relation to BC6OTHER bioavailability , BC6OTHER , BC6ENTG , BC6OTHER (64 - 74)4P and BC6OTHER CHEM increased BC6ENTC uptake.	CPR:9
In relation to BC6OTHER bioavailability , BC6OTHER , BC6OTHER , BC6ENTG (64 - 74)4P and BC6OTHER CHEM increased BC6ENTC uptake.	CPR:9
In relation to BC6OTHER bioavailability , BC6OTHER , BC6OTHER , BC6OTHER (64 - 74)4P and BC6ENTG CHEM increased BC6ENTC uptake.	CPR:9
 BC6ENTC and BC6OTHER bioavailability in Caco - 2 cells: influence of BC6ENTG .	False
 BC6OTHER and BC6ENTC bioavailability in Caco - 2 cells: influence of BC6ENTG .	False
BC6ENTC was found to be unselective; BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
BC6OTHER was found to be unselective; BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
The potency of the antipsychotic drug , BC6ENTC , to antagonize BC6OTHER - mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney , and BC6ENTG - mediated contractions in spleen from guinea - pig and mouse was evaluated and compared to that of BC6OTHER subtype - discriminating antagonists.	CPR:6
The potency of the antipsychotic drug , BC6ENTC , to antagonize BC6OTHER - mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney , and BC6OTHER - mediated contractions in spleen from guinea - pig and mouse was evaluated and compared to that of BC6ENTG subtype - discriminating antagonists.	CPR:6
The potency of the antipsychotic drug , BC6ENTC , to antagonize BC6ENTG - mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney , and BC6OTHER - mediated contractions in spleen from guinea - pig and mouse was evaluated and compared to that of BC6OTHER subtype - discriminating antagonists.	CPR:6
BC6OTHER was found to be unselective; BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
BC6OTHER was found to be unselective; BC6OTHER ( BC6OTHER ) , BC6ENTC , BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
BC6OTHER was found to be unselective; BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTC and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
BC6OTHER was found to be unselective; BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6ENTC were confirmed as selective for the BC6ENTG , whereas BC6OTHER was weakly alpha 1B - selective.	False
BC6OTHER was found to be unselective; BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER and BC6OTHER were confirmed as selective for the BC6ENTG , whereas BC6ENTC was weakly alpha 1B - selective.	False
BC6ENTC was equipotent to BC6OTHER at BC6ENTG in rat vas deferens and kidney.	False
BC6OTHER was equipotent to BC6ENTC at BC6ENTG in rat vas deferens and kidney.	False
However , at BC6ENTG , the affinity values of BC6ENTC were 10 - fold lower than those of BC6OTHER .	False
However , at BC6ENTG , the affinity values of BC6OTHER were 10 - fold lower than those of BC6ENTC .	False
Thus , in functional experiments the presumed high selectivity of BC6ENTC for the B subtype of BC6ENTG could not be confirmed , the drug instead appears to be moderately selective (10 - fold) for the A subtype.	False
In functional experiments , BC6ENTC is selective , not for the B , but for the A subtype of BC6ENTG .	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6ENTG , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	CPR:3
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6ENTG in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	CPR:3
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER were recorded.	False
Results: The administration of BC6ENTC 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6ENTG , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6ENTG in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6ENTG , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6ENTG in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , and BC6OTHER were recorded.	False
Results: The administration of BC6OTHER 1.6% w / w created significant increased changes in the levels of total WBC , lymphocytes , RBC , BC6OTHER , packed cell volume , platelets , mean corpuscular volume , and mean corpuscular BC6OTHER in rats after 24 , 48 , and 72 h of continuous inhalation; however , there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6ENTG were recorded.	False
It is also concluded that BC6ENTC group of insecticide may cause hematological , biochemical , BC6ENTG disturbances and possible mutagenic damage to the tissues.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6ENTC kinase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTC ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6OTHER and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTG and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTC ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6OTHER ( BC6ENTG ) were assayed.	False
Total blood count , blood indices of BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6ENTG ( BC6OTHER ) were assayed.	False
Total blood count , blood indices of BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ) , BC6ENTC antigen (CA) 19.9 and BC6OTHER ( BC6ENTG ) were assayed.	False
BC6ENTC type A receptors ( BC6ENTG ) are important for BC6OTHER actions and it is of interest to link individual subunits with specific BC6OTHER behaviors.	False
BC6ENTG ( BC6OTHER ) are important for BC6OTHER actions and it is of interest to link individual subunits with specific BC6ENTC behaviors.	False
BC6OTHER ( BC6ENTG ) are important for BC6OTHER actions and it is of interest to link individual subunits with specific BC6ENTC behaviors.	False
BC6ENTG ( BC6ENTC (A) - R) are important for BC6OTHER actions and it is of interest to link individual subunits with specific BC6OTHER behaviors.	False
BC6ENTG ( BC6OTHER ) are important for BC6ENTC actions and it is of interest to link individual subunits with specific BC6OTHER behaviors.	False
BC6OTHER ( BC6ENTG ) are important for BC6ENTC actions and it is of interest to link individual subunits with specific BC6OTHER behaviors.	False
All together , they indicate that aversive property of BC6ENTC is dependent on BC6OTHER action on BC6ENTG .	False
All together , they indicate that aversive property of BC6OTHER is dependent on BC6ENTC action on BC6ENTG .	False
Linking BC6ENTG subunits to BC6OTHER - induced conditioned taste aversion and recovery from acute BC6ENTC intoxication.	False
Linking BC6ENTG subunits to BC6ENTC - induced conditioned taste aversion and recovery from acute BC6OTHER intoxication.	False
Effect of BC6ENTC ( BC6OTHER , BC6OTHER ) , a selective BC6ENTG agonist , on motor coordination was studied using rota - rod performance in mice.	CPR:5
BC6ENTC and BC6OTHER ( BC6OTHER ) , a ligand of BC6ENTG biding site , also had no impairment on the performance , per se.	False
BC6OTHER and BC6ENTC ( BC6OTHER ) , a ligand of BC6ENTG biding site , also had no impairment on the performance , per se.	False
BC6OTHER and BC6OTHER ( BC6ENTC ) , a ligand of BC6ENTG biding site , also had no impairment on the performance , per se.	False
Effect of BC6OTHER ( BC6ENTC , BC6OTHER ) , a selective BC6ENTG agonist , on motor coordination was studied using rota - rod performance in mice.	CPR:5
Effect of BC6OTHER ( BC6OTHER , BC6ENTC ) , a selective BC6ENTG agonist , on motor coordination was studied using rota - rod performance in mice.	CPR:5
Effect of BC6ENTC ( BC6OTHER ) , a selective BC6ENTG agonist , on motor performance in mice.	CPR:5
Effect of BC6OTHER ( BC6ENTC ) , a selective BC6ENTG agonist , on motor performance in mice.	CPR:5
All three mutations affect the structure and the function of the BC6ENTC channel BC6ENTG .	False
Based on these studies , the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal BC6ENTG expression and activity - was significantly higher following exposure to BC6ENTC concentrations as low as 31.2 nM.	CPR:3
Overall , our data suggest that (1) normal BC6ENTG activity is not required for secondary motoneuron development and (2) spontaneous tail contractions at 26 hpf are sensitive to BC6ENTC exposure , an effect that may be independent of BC6OTHER inhibition.	False
Overall , our data suggest that (1) normal BC6OTHER activity is not required for secondary motoneuron development and (2) spontaneous tail contractions at 26 hpf are sensitive to BC6ENTC exposure , an effect that may be independent of BC6ENTG inhibition.	False
We then showed that static exposure of embryos to BC6ENTC (31.2 - 500 nM) from 5 to 96 hpf resulted in significant stage - and concentration - dependent BC6ENTG inhibition , albeit these effects were fully reversible within 48 h following transfer to clean water.	CPR:4
Using BC6ENTC as a reference BC6ENTG ( BC6OTHER ) inhibitor , the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.	CPR:4
Using BC6ENTC as a reference BC6OTHER ( BC6ENTG ) inhibitor , the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.	CPR:4
However , even in the presence of significant BC6ENTG inhibition , exposure to non - teratogenic BC6ENTC concentrations (≤250 nM) did not adversely impact secondary motoneuron development at 96 hpf.	False
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of BC6ENTG a series of BC6ENTC derivatives of BC6OTHER were synthesized and evaluated for their inhibitory potencies against BC6OTHER .	False
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of BC6OTHER a series of BC6ENTC derivatives of BC6OTHER were synthesized and evaluated for their inhibitory potencies against BC6ENTG .	CPR:4
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of BC6ENTG a series of BC6OTHER derivatives of BC6ENTC were synthesized and evaluated for their inhibitory potencies against BC6OTHER .	False
To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of BC6OTHER a series of BC6OTHER derivatives of BC6ENTC were synthesized and evaluated for their inhibitory potencies against BC6ENTG .	CPR:4
The slightly serrated pattern that emerged as the BC6ENTC tether increased from three to six CHEM units suggests that inhibitory potency is not simply correlated to increased hydrophobicity imparted by the BC6OTHER chain , but rather that one or more hydrophobic binding registers may exist remote from the substrate recognition architecture in the active site of BC6ENTG .	False
The slightly serrated pattern that emerged as the BC6OTHER tether increased from three to six CHEM units suggests that inhibitory potency is not simply correlated to increased hydrophobicity imparted by the BC6ENTC chain , but rather that one or more hydrophobic binding registers may exist remote from the substrate recognition architecture in the active site of BC6ENTG .	False
Probing for a hydrophobic a binding register in BC6ENTG with BC6ENTC .	False
This was independent of age , sex , BC6ENTG inhibitors , BC6ENTC use , components of the metabolic syndrome , or homeostasis model CHEM conclusion , fasting BC6OTHER is strongly associated with NODAT development in RTR.	False
This was independent of age , sex , BC6OTHER inhibitors , BC6ENTC use , components of the metabolic syndrome , or homeostasis model CHEM conclusion , fasting BC6ENTG is strongly associated with NODAT development in RTR.	False
Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of BC6ENTC binding similar to that of the kidney BC6ENTG ( BC6OTHER greater than BC6OTHER greater than BC6OTHER ).	False
Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of BC6OTHER binding similar to that of the kidney BC6ENTG ( BC6ENTC greater than BC6OTHER greater than BC6OTHER ).	False
Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of BC6OTHER binding similar to that of the kidney BC6ENTG ( BC6OTHER greater than BC6ENTC greater than BC6OTHER ).	False
Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of BC6OTHER binding similar to that of the kidney BC6ENTG ( BC6OTHER greater than BC6OTHER greater than BC6ENTC ).	False
 It is concluded that the high affinity BC6ENTC receptor of rat brain , which had been identified in preliminary studies as a BC6ENTG , may bind either BC6OTHER or BC6OTHER in vivo.	False
 It is concluded that the high affinity BC6ENTG of rat brain , which had been identified in preliminary studies as a BC6OTHER , may bind either BC6ENTC or BC6OTHER in vivo.	False
 It is concluded that the high affinity BC6OTHER of rat brain , which had been identified in preliminary studies as a BC6ENTG , may bind either BC6ENTC or BC6OTHER in vivo.	False
 It is concluded that the high affinity BC6ENTG of rat brain , which had been identified in preliminary studies as a BC6OTHER , may bind either BC6OTHER or BC6ENTC in vivo.	False
 It is concluded that the high affinity BC6OTHER of rat brain , which had been identified in preliminary studies as a BC6ENTG , may bind either BC6OTHER or BC6ENTC in vivo.	False
However , due to the very high affinity of BC6ENTG for BC6ENTC at 4 C , this slight contamination resulted in significant alterations in the apparent affinity of BC6OTHER competing for BC6OTHER - binding sites.	False
However , due to the very high affinity of BC6ENTG for BC6OTHER at 4 C , this slight contamination resulted in significant alterations in the apparent affinity of BC6ENTC competing for BC6OTHER - binding sites.	False
However , due to the very high affinity of BC6ENTG for BC6OTHER at 4 C , this slight contamination resulted in significant alterations in the apparent affinity of BC6OTHER competing for BC6ENTC - binding sites.	False
Selective precipitation of cytosol receptors with 36% BC6ENTC reduced BC6ENTG concentrations to negligible levels.	CPR:4
Characterization of BC6ENTG reveals high affinity for BC6ENTC .	False
Moreover , overexpressed BC6ENTG and BC6ENTC inhibited BC6OTHER - induced macrophage migration in a VSMC - macrophage coculture system.	False
Moreover , overexpressed BC6OTHER and BC6ENTC inhibited BC6ENTG - induced macrophage migration in a VSMC - macrophage coculture system.	CPR:4
BC6ENTG ( BC6OTHER ) metabolizes BC6OTHER to form BC6OTHER ( BC6ENTC ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
BC6OTHER ( BC6ENTG ) metabolizes BC6OTHER to form BC6OTHER ( BC6ENTC ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
Taken together , these results provide evidence that rAAV - mediated BC6ENTG overexpression prevents AAA development which is likely via BC6OTHER activation and anti - inflammatory action , suggesting that increasing BC6ENTC levels could be considered as a potential strategy to prevent and treat AAA.	False
Taken together , these results provide evidence that rAAV - mediated BC6OTHER overexpression prevents AAA development which is likely via BC6ENTG activation and anti - inflammatory action , suggesting that increasing BC6ENTC levels could be considered as a potential strategy to prevent and treat AAA.	False
However , whether increasing BC6ENTC production by BC6ENTG overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.	CPR:9
BC6ENTG ( BC6OTHER ) metabolizes BC6ENTC to form BC6OTHER ( BC6OTHER ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
BC6OTHER ( BC6ENTG ) metabolizes BC6ENTC to form BC6OTHER ( BC6OTHER ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
rAAV - BC6ENTG delivery led to an abundant aortic BC6OTHER expression and increased BC6ENTC generation.	False
rAAV - BC6OTHER delivery led to an abundant aortic BC6ENTG expression and increased BC6ENTC generation.	False
BC6ENTG ( BC6OTHER ) metabolizes BC6OTHER to form BC6ENTC ( BC6OTHER ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
BC6OTHER ( BC6ENTG ) metabolizes BC6OTHER to form BC6ENTC ( BC6OTHER ) , which possess various beneficial effects on the cardiovascular system.	CPR:9
In cultured vascular smooth muscle cells (VSMCs) , rAAV - mediated BC6ENTG overexpression and BC6ENTC markedly suppressed BC6OTHER - induced inflammatory BC6OTHER expression.	False
In cultured vascular smooth muscle cells (VSMCs) , rAAV - mediated BC6OTHER overexpression and BC6ENTC markedly suppressed BC6ENTG - induced inflammatory BC6OTHER expression.	CPR:4
In cultured vascular smooth muscle cells (VSMCs) , rAAV - mediated BC6OTHER overexpression and BC6ENTC markedly suppressed BC6OTHER - induced inflammatory BC6ENTG expression.	CPR:4
 BC6ENTG overexpression increases BC6ENTC and protects against BC6OTHER - induced abdominal aortic aneurysm in mice.	False
 BC6OTHER overexpression increases BC6ENTC and protects against BC6ENTG - induced abdominal aortic aneurysm in mice.	False
Using temperature block , BC6ENTC , and recovery from each , we found that the cytoplasmic tail of BC6ENTG causes the recruitment of BC6OTHER and BC6OTHER to recycling endosomes and not at the Golgi , as predicted by steady state staining profiles.	False
Using temperature block , BC6ENTC , and recovery from each , we found that the cytoplasmic tail of BC6OTHER causes the recruitment of BC6ENTG and BC6OTHER to recycling endosomes and not at the Golgi , as predicted by steady state staining profiles.	False
Using temperature block , BC6ENTC , and recovery from each , we found that the cytoplasmic tail of BC6OTHER causes the recruitment of BC6OTHER and BC6ENTG to recycling endosomes and not at the Golgi , as predicted by steady state staining profiles.	False
We examined the specificity and initial sites of recruitment of BC6ENTG - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6ENTG ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6ENTG and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6ENTG ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6ENTG ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6ENTG , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6ENTG ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6ENTG lacking a BC6OTHER - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTC receptor ( BC6OTHER ) and BC6OTHER lacking a BC6OTHER - terminal domain BC6ENTG ).	False
We examined the specificity and initial sites of recruitment of BC6ENTG - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6ENTG ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6ENTG and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6ENTG ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6ENTG ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6ENTG , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6ENTG ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6ENTG lacking a BC6ENTC - terminal domain BC6OTHER ).	False
We examined the specificity and initial sites of recruitment of BC6OTHER - dependent BC6OTHER ( BC6OTHER and BC6OTHER ) in response to the Golgi or endosomal localization of specific BC6OTHER ( BC6OTHER , BC6OTHER ( BC6OTHER ) and BC6OTHER lacking a BC6ENTC - terminal domain BC6ENTG ).	False
A Role for BC6ENTG in the Activation of BC6ENTC - Ribosylation Factors ( BC6OTHER ) and BC6OTHER Recruitment.	False
A Role for BC6OTHER in the Activation of BC6ENTC - Ribosylation Factors ( BC6ENTG ) and BC6OTHER Recruitment.	False
A Role for BC6OTHER in the Activation of BC6ENTC - Ribosylation Factors ( BC6OTHER ) and BC6ENTG Recruitment.	False
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC appeared to act as competitive antagonists of BC6OTHER - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	CPR:6
BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER appeared to act as competitive antagonists of BC6ENTC - mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned BC6ENTG .	False
The profile of a range of BC6OTHER antagonists was determined in vitro against cloned BC6ENTG and against BC6ENTC - mediated contractions of rat aorta and human prostate.	False
The profile of a range of BC6ENTG antagonists was determined in vitro against cloned BC6OTHER and against BC6ENTC - mediated contractions of rat aorta and human prostate.	False
The affinity estimate for BC6ENTC on human prostate was lower than the corresponding binding affinity determined at BC6ENTG and BC6OTHER was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned BC6OTHER .	False
The affinity estimate for BC6ENTC on human prostate was lower than the corresponding binding affinity determined at BC6OTHER and BC6OTHER was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned BC6ENTG .	False
The affinity estimate for BC6OTHER on human prostate was lower than the corresponding binding affinity determined at BC6ENTG and BC6ENTC was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned BC6OTHER .	False
The affinity estimate for BC6OTHER on human prostate was lower than the corresponding binding affinity determined at BC6OTHER and BC6ENTC was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned BC6ENTG .	False
Data in this study suggest that the BC6ENTG mediating BC6ENTC - induced contractions of human prostate , whilst having some of the characteristics of an BC6OTHER , cannot be satisfactorily aligned with cloned BC6OTHER .	False
Data in this study suggest that the BC6OTHER mediating BC6ENTC - induced contractions of human prostate , whilst having some of the characteristics of an BC6ENTG , cannot be satisfactorily aligned with cloned BC6OTHER .	False
Data in this study suggest that the BC6OTHER mediating BC6ENTC - induced contractions of human prostate , whilst having some of the characteristics of an BC6OTHER , cannot be satisfactorily aligned with cloned BC6ENTG .	False
In addition , studies in the anaesthetized dog have shown that agents having high affinity and selectivity for prostatic BC6ENTG , particularly over the BC6OTHER , appear to inhibit BC6ENTC - induced increases in prostatic pressure selectively compared to blood pressure.	False
In addition , studies in the anaesthetized dog have shown that agents having high affinity and selectivity for prostatic BC6OTHER , particularly over the BC6ENTG , appear to inhibit BC6ENTC - induced increases in prostatic pressure selectively compared to blood pressure.	False
The BC6ENTC antagonists , BC6OTHER , BC6OTHER and BC6OTHER displayed high affinity but were non selective for the three cloned BC6ENTG .	False
The BC6OTHER antagonists , BC6ENTC , BC6OTHER and BC6OTHER displayed high affinity but were non selective for the three cloned BC6ENTG .	False
The BC6OTHER antagonists , BC6OTHER , BC6ENTC and BC6OTHER displayed high affinity but were non selective for the three cloned BC6ENTG .	False
The BC6OTHER antagonists , BC6OTHER , BC6OTHER and BC6ENTC displayed high affinity but were non selective for the three cloned BC6ENTG .	False
BC6ENTC and BC6OTHER showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6ENTC and BC6OTHER showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6OTHER and BC6ENTC showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6OTHER and BC6ENTC showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC showed selectivity for BC6ENTG relative to the BC6OTHER .	False
BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC showed selectivity for BC6OTHER relative to the BC6ENTG .	False
BC6ENTC showed high affinity and selectivity for BC6OTHER (pKi 8.6) relative to BC6OTHER (pKi = 7.3) and BC6ENTG (pKi = 7.1) subtypes.	False
BC6ENTC showed high affinity and selectivity for BC6ENTG (pKi 8.6) relative to BC6OTHER (pKi = 7.3) and BC6OTHER (pKi = 7.1) subtypes.	False
BC6ENTC showed high affinity and selectivity for BC6OTHER (pKi 8.6) relative to BC6ENTG (pKi = 7.3) and BC6OTHER (pKi = 7.1) subtypes.	False
BC6ENTC (1) was previously reported to be a potent and specific noncompetitive inhibitor of BC6ENTG - induced human PMNs chemotaxis.	CPR:4
 BC6ENTC BC6ENTG ( BC6OTHER ) ligands as novel noncompetitive BC6OTHER inhibitors.	False
 BC6ENTC BC6OTHER ( BC6ENTG ) ligands as novel noncompetitive BC6OTHER inhibitors.	False
 BC6ENTC BC6OTHER ( BC6OTHER ) ligands as novel noncompetitive BC6ENTG inhibitors.	CPR:4
BC6ENTC is a BC6OTHER and irreversible BC6ENTG inhibitor used for the treatment of Parkinson's disease (PD).	CPR:4
The results support a role for BC6ENTC in protecting dopaminergic cells against free radical mediated damage and apoptosis in the presence of BC6ENTG over - expression.	False
BC6OTHER is a BC6ENTC and irreversible BC6ENTG inhibitor used for the treatment of Parkinson's disease (PD).	CPR:4
We have used a combination of BC6ENTG and free radical mediated toxicity in a dopaminergic cell line to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that mediate BC6ENTC protection.	False
We demonstrate that BC6ENTC protects against cell death induced by the combination of free radicals generated by BC6OTHER and either wild - type or BC6ENTG mutant BC6OTHER over - expression.	False
We demonstrate that BC6ENTC protects against cell death induced by the combination of free radicals generated by BC6OTHER and either wild - type or BC6OTHER mutant BC6ENTG over - expression.	False
We demonstrate that BC6OTHER protects against cell death induced by the combination of free radicals generated by BC6ENTC and either wild - type or BC6ENTG mutant BC6OTHER over - expression.	False
We demonstrate that BC6OTHER protects against cell death induced by the combination of free radicals generated by BC6ENTC and either wild - type or BC6OTHER mutant BC6ENTG over - expression.	False
This protection was associated with a reduction in BC6ENTG activation , a reduction in BC6ENTC generation and a trend to ameliorate the fall in mitochondrial membrane potential.	False
 BC6ENTC protects against BC6ENTG induced sensitivity to oxidative stress in dopaminergic cells.	False
Among the [ BC6ENTC ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6ENTG ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6OTHER ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6ENTC ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6OTHER ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6ENTG ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6ENTC - dependent enzyme ( BC6ENTG ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6OTHER ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6ENTC - dependent enzyme ( BC6OTHER ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6ENTG ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6ENTG ) that is involved in the activation of BC6ENTC from BC6OTHER , and a molecular scaffold protein ( BC6OTHER ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6OTHER ) that is involved in the activation of BC6ENTC from BC6OTHER , and a molecular scaffold protein ( BC6ENTG ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6ENTG ) that is involved in the activation of BC6OTHER from BC6ENTC , and a molecular scaffold protein ( BC6OTHER ) upon which [ BC6OTHER ] cluster precursors are formed.	CPR:9
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6OTHER ) that is involved in the activation of BC6OTHER from BC6ENTC , and a molecular scaffold protein ( BC6ENTG ) upon which [ BC6OTHER ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6ENTG ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6OTHER ) upon which [ BC6ENTC ] cluster precursors are formed.	False
Among the [ BC6OTHER ] cluster biosynthetic proteins are included a BC6OTHER - dependent enzyme ( BC6OTHER ) that is involved in the activation of BC6OTHER from BC6OTHER , and a molecular scaffold protein ( BC6ENTG ) upon which [ BC6ENTC ] cluster precursors are formed.	False
db / db mice treated with BC6ENTC showed 5 - and 3.6 - fold inhibition in BC6ENTG and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6OTHER , respectively.	CPR:4
db / db mice treated with BC6ENTC showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6ENTG activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6OTHER , respectively.	CPR:4
db / db mice treated with BC6ENTC showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTG and BC6OTHER , respectively.	CPR:3
db / db mice treated with BC6ENTC showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6ENTG , respectively.	CPR:3
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTC carboxykinase and BC6ENTG activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTC carboxykinase and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTG and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTC carboxykinase and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6ENTG , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTG and BC6ENTC 6 - phosphatase activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6ENTC 6 - phosphatase activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTG and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6ENTC 6 - phosphatase activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6ENTG , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTG and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTC palmitoyltransferase and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6ENTG activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTC palmitoyltransferase and BC6OTHER , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTC palmitoyltransferase and BC6ENTG , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6ENTG and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6ENTC acetyltransferase , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6ENTG activity and 651% and 77% increases in the beta - oxidation enzymes BC6OTHER and BC6ENTC acetyltransferase , respectively.	False
db / db mice treated with BC6OTHER showed 5 - and 3.6 - fold inhibition in BC6OTHER and BC6OTHER activity and 651% and 77% increases in the beta - oxidation enzymes BC6ENTG and BC6ENTC acetyltransferase , respectively.	False
OBJECTIVE: Preclinical evaluation of BC6ENTC , a BC6OTHER ( BC6OTHER ) and BC6ENTG agonist , as a body - weight lowering , hypolipidemic and euglycemic agent.	CPR:5
OBJECTIVE: Preclinical evaluation of BC6ENTC , a BC6ENTG ( BC6OTHER ) and BC6OTHER agonist , as a body - weight lowering , hypolipidemic and euglycemic agent.	CPR:5
OBJECTIVE: Preclinical evaluation of BC6ENTC , a BC6OTHER ( BC6ENTG ) and BC6OTHER agonist , as a body - weight lowering , hypolipidemic and euglycemic agent.	CPR:5
RESULTS: BC6ENTC showed concentration - dependent transactivation of BC6ENTG and BC6OTHER .	CPR:5
RESULTS: BC6ENTC showed concentration - dependent transactivation of BC6OTHER and BC6ENTG .	CPR:5
To clarify the cause of age differences on BC6ENTC cataract formation in rats , mRNA expression of BC6ENTG , BC6OTHER and BC6OTHER , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6OTHER and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6ENTC cataract formation in rats , mRNA expression of BC6OTHER , BC6ENTG and BC6OTHER , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6OTHER and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6ENTC cataract formation in rats , mRNA expression of BC6OTHER , BC6OTHER and BC6ENTG , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6OTHER and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6ENTC cataract formation in rats , mRNA expression of BC6OTHER , BC6OTHER and BC6OTHER , as well as BC6ENTG activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6OTHER and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6OTHER cataract formation in rats , mRNA expression of BC6ENTG , BC6OTHER and BC6OTHER , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6ENTC and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6OTHER cataract formation in rats , mRNA expression of BC6OTHER , BC6ENTG and BC6OTHER , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6ENTC and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6OTHER cataract formation in rats , mRNA expression of BC6OTHER , BC6OTHER and BC6ENTG , as well as BC6OTHER activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6ENTC and barricade function of blood - CHEM barrier (BRB) were investigated.	False
To clarify the cause of age differences on BC6OTHER cataract formation in rats , mRNA expression of BC6OTHER , BC6OTHER and BC6OTHER , as well as BC6ENTG activity in Wistar rat lens at different ages were assayed , level of lipid peroxidation , extent of lens damage induced by BC6ENTC and barricade function of blood - CHEM barrier (BRB) were investigated.	False
The stimulation of transcription by BC6ENTC depletion requires activation of BC6ENTG BC6OTHER , which phosphorylates BC6OTHER .	False
The stimulation of transcription by BC6ENTC depletion requires activation of BC6OTHER BC6ENTG , which phosphorylates BC6OTHER .	False
The stimulation of transcription by BC6ENTC depletion requires activation of BC6OTHER BC6OTHER , which phosphorylates BC6ENTG .	False
BC6ENTG , the transporter for the essential BC6ENTC , BC6OTHER and BC6OTHER , is one of the up - regulated genes.	CPR:9
BC6ENTG , the transporter for the essential BC6OTHER , BC6ENTC and BC6OTHER , is one of the up - regulated genes.	CPR:9
BC6ENTG , the transporter for the essential BC6OTHER , BC6OTHER and BC6ENTC , is one of the up - regulated genes.	CPR:9
This induction is triggered by BC6ENTC depletion and the BC6ENTG ( BC6OTHER ) , which is caused by unfolded proteins in the endoplasmic reticulum.	False
This induction is triggered by BC6ENTC depletion and the BC6OTHER ( BC6ENTG ) , which is caused by unfolded proteins in the endoplasmic reticulum.	False
Transcriptional control of the BC6ENTC / BC6OTHER transporter , BC6ENTG , by physiological stress.	False
Transcriptional control of the CHEM / BC6ENTC transporter , BC6ENTG , by physiological stress.	False
BC6ENTC and CHEM block the BC6OTHER BC6OTHER / BC6OTHER , causing membrane depolarization and stimulating BC6ENTG secretion in pancreatic beta cells.	CPR:3
BC6ENTC and CHEM block the BC6ENTG BC6OTHER / BC6OTHER , causing membrane depolarization and stimulating BC6OTHER secretion in pancreatic beta cells.	CPR:4
BC6ENTC and CHEM block the BC6OTHER BC6ENTG / BC6OTHER , causing membrane depolarization and stimulating BC6OTHER secretion in pancreatic beta cells.	CPR:4
BC6ENTC and CHEM block the BC6OTHER BC6OTHER / BC6ENTG , causing membrane depolarization and stimulating BC6OTHER secretion in pancreatic beta cells.	CPR:4
BC6ENTC alone (5 μM) did not stimulate BC6ENTG secretion , but did increase intracellular BC6OTHER concentration significantly , and this activity was inhibited by 25 μM BC6OTHER ( BC6OTHER ) or the removal of extracellular BC6OTHER .	False
BC6OTHER alone (5 μM) did not stimulate BC6ENTG secretion , but did increase intracellular BC6ENTC concentration significantly , and this activity was inhibited by 25 μM BC6OTHER ( BC6OTHER ) or the removal of extracellular BC6OTHER .	False
BC6OTHER alone (5 μM) did not stimulate BC6ENTG secretion , but did increase intracellular BC6OTHER concentration significantly , and this activity was inhibited by 25 μM BC6ENTC ( BC6OTHER ) or the removal of extracellular BC6OTHER .	False
BC6OTHER alone (5 μM) did not stimulate BC6ENTG secretion , but did increase intracellular BC6OTHER concentration significantly , and this activity was inhibited by 25 μM BC6OTHER ( BC6ENTC ) or the removal of extracellular BC6OTHER .	False
BC6OTHER alone (5 μM) did not stimulate BC6ENTG secretion , but did increase intracellular BC6OTHER concentration significantly , and this activity was inhibited by 25 μM BC6OTHER ( BC6OTHER ) or the removal of extracellular BC6ENTC .	False
BC6ENTC potentiation of BC6ENTG secretion stimulated by BC6OTHER was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6OTHER inhibitor BC6OTHER (1 μM).	CPR:3
BC6ENTC potentiation of BC6OTHER secretion stimulated by BC6OTHER was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6ENTG inhibitor BC6OTHER (1 μM).	False
BC6OTHER potentiation of BC6ENTG secretion stimulated by BC6ENTC was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6OTHER inhibitor BC6OTHER (1 μM).	CPR:3
BC6OTHER potentiation of BC6OTHER secretion stimulated by BC6ENTC was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6ENTG inhibitor BC6OTHER (1 μM).	False
BC6OTHER potentiation of BC6ENTG secretion stimulated by BC6OTHER was markedly inhibited by BC6ENTC (25 μM) and enhanced by the BC6OTHER inhibitor BC6OTHER (1 μM).	CPR:4
BC6OTHER potentiation of BC6OTHER secretion stimulated by BC6OTHER was markedly inhibited by BC6ENTC (25 μM) and enhanced by the BC6ENTG inhibitor BC6OTHER (1 μM).	False
BC6OTHER potentiation of BC6ENTG secretion stimulated by BC6OTHER was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6OTHER inhibitor BC6ENTC (1 μM).	CPR:3
BC6OTHER potentiation of BC6OTHER secretion stimulated by BC6OTHER was markedly inhibited by BC6OTHER (25 μM) and enhanced by the BC6ENTG inhibitor BC6ENTC (1 μM).	CPR:4
Our data demonstrate that the actions of both BC6ENTC and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6ENTC and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6ENTC are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6ENTC are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6ENTC , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6ENTC , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6ENTC can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	CPR:3
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6ENTC can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6ENTC potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6ENTC potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6ENTC - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6ENTC - sensitive BC6OTHER influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6ENTG activity via a partially BC6OTHER - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6ENTC influx.	False
Our data demonstrate that the actions of both BC6OTHER and BC6OTHER are strongly potentiated by BC6OTHER , that BC6OTHER can stimulate BC6OTHER activity via a partially BC6ENTG - sensitive mechanism , and that BC6OTHER potentiation of CHEM action may involve activation of a BC6OTHER - sensitive BC6ENTC influx.	False
We examined the ability of the BC6ENTG - selective BC6ENTC analog BC6OTHER to potentiate the action of these drugs and the mechanism that might account for it.	False
We examined the ability of the BC6ENTG - selective BC6OTHER analog BC6ENTC to potentiate the action of these drugs and the mechanism that might account for it.	False
BC6ENTG secretion stimulated by both 200 μM BC6ENTC and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the L - type BC6OTHER channel blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	CPR:3
BC6OTHER secretion stimulated by both 200 μM BC6ENTC and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the BC6ENTG blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	False
BC6ENTG secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6ENTC , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the L - type BC6OTHER channel blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	CPR:3
BC6OTHER secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6ENTC , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the BC6ENTG blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	False
BC6ENTG secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6ENTC (1 μM) or the L - type BC6OTHER channel blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	CPR:4
BC6OTHER secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6ENTC (1 μM) or the BC6ENTG blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	False
BC6ENTG secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the L - type BC6ENTC channel blocker BC6OTHER (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	False
BC6ENTG secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the L - type BC6OTHER channel blocker BC6ENTC (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	CPR:4
BC6OTHER secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the BC6ENTG blocker BC6ENTC (2 μM) and was potentiated by BC6OTHER at concentrations ≥2 μM in INS - 1 cells.	CPR:4
BC6ENTG secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the L - type BC6OTHER channel blocker BC6OTHER (2 μM) and was potentiated by BC6ENTC at concentrations ≥2 μM in INS - 1 cells.	CPR:3
BC6OTHER secretion stimulated by both 200 μM BC6OTHER and 20 μM BC6OTHER , concentrations that had equivalent effects on membrane potential , was inhibited by BC6OTHER (1 μM) or the BC6ENTG blocker BC6OTHER (2 μM) and was potentiated by BC6ENTC at concentrations ≥2 μM in INS - 1 cells.	False
Both BC6ENTC and BC6OTHER stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6ENTG .	False
Both BC6ENTC and BC6OTHER stimulated BC6ENTG activity; however , only BC6OTHER did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6OTHER .	CPR:3
Both BC6ENTC and BC6OTHER stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at BC6ENTG , and this activity was partially inhibited by BC6OTHER .	False
Both BC6OTHER and BC6ENTC stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6ENTG .	False
Both BC6OTHER and BC6ENTC stimulated BC6ENTG activity; however , only BC6OTHER did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6OTHER .	CPR:3
Both BC6OTHER and BC6ENTC stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at BC6ENTG , and this activity was partially inhibited by BC6OTHER .	False
Both BC6OTHER and BC6OTHER stimulated BC6OTHER activity; however , only BC6ENTC did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6ENTG .	False
Both BC6OTHER and BC6OTHER stimulated BC6ENTG activity; however , only BC6ENTC did so independently of its activity at K( BC6OTHER ) channels , and this activity was partially inhibited by BC6OTHER .	False
Both BC6OTHER and BC6OTHER stimulated BC6OTHER activity; however , only BC6ENTC did so independently of its activity at BC6ENTG , and this activity was partially inhibited by BC6OTHER .	CPR:3
Both BC6OTHER and BC6OTHER stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at BC6ENTC ( BC6OTHER ) channels , and this activity was partially inhibited by BC6ENTG .	False
Both BC6OTHER and BC6OTHER stimulated BC6ENTG activity; however , only BC6OTHER did so independently of its activity at BC6ENTC ( BC6OTHER ) channels , and this activity was partially inhibited by BC6OTHER .	False
Both BC6OTHER and BC6OTHER stimulated BC6OTHER activity; however , only BC6OTHER did so independently of its activity at K( BC6ENTC ) channels , and this activity was partially inhibited by BC6ENTG .	False
Both BC6OTHER and BC6OTHER stimulated BC6ENTG activity; however , only BC6OTHER did so independently of its activity at K( BC6ENTC ) channels , and this activity was partially inhibited by BC6OTHER .	False
Potentiation of BC6OTHER action by an BC6OTHER - selective BC6OTHER analog in INS - 1 cells: comparison of BC6OTHER and BC6ENTC and a potential role for BC6ENTG activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6OTHER action by an BC6ENTG - selective BC6OTHER analog in INS - 1 cells: comparison of BC6OTHER and BC6ENTC and a potential role for BC6OTHER activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6ENTC action by an BC6OTHER - selective BC6OTHER analog in INS - 1 cells: comparison of BC6OTHER and BC6OTHER and a potential role for BC6ENTG activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6ENTC action by an BC6ENTG - selective BC6OTHER analog in INS - 1 cells: comparison of BC6OTHER and BC6OTHER and a potential role for BC6OTHER activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6OTHER action by an BC6OTHER - selective BC6ENTC analog in INS - 1 cells: comparison of BC6OTHER and BC6OTHER and a potential role for BC6ENTG activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6OTHER action by an BC6ENTG - selective BC6ENTC analog in INS - 1 cells: comparison of BC6OTHER and BC6OTHER and a potential role for BC6OTHER activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6OTHER action by an BC6OTHER - selective BC6OTHER analog in INS - 1 cells: comparison of BC6ENTC and BC6OTHER and a potential role for BC6ENTG activation of a 2 - APB - sensitive CHEM influx.	False
Potentiation of BC6OTHER action by an BC6ENTG - selective BC6OTHER analog in INS - 1 cells: comparison of BC6ENTC and BC6OTHER and a potential role for BC6OTHER activation of a 2 - APB - sensitive CHEM influx.	False
To characterise further the relationship between BC6ENTG and torpor , we profiled BC6OTHER expression in mice during prolonged fasting , cold exposure , and BC6ENTC - induced hypometabolism , as well as in naturally occurring torpor bouts in the Siberian hamster.	False
To characterise further the relationship between BC6OTHER and torpor , we profiled BC6ENTG expression in mice during prolonged fasting , cold exposure , and BC6ENTC - induced hypometabolism , as well as in naturally occurring torpor bouts in the Siberian hamster.	False
PURPOSE: BC6OTHER ( BC6OTHER ) , a potent oral multi - targeted BC6ENTG inhibitor against BC6OTHER and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6ENTC - acquired resistance and intolerance.	False
PURPOSE: BC6OTHER ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6ENTG and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6ENTC - acquired resistance and intolerance.	False
PURPOSE: BC6OTHER ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6ENTG - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6ENTC - acquired resistance and intolerance.	False
PURPOSE: BC6OTHER ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6OTHER - BC6ENTG , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6ENTC - acquired resistance and intolerance.	False
PURPOSE: BC6OTHER ( BC6ENTC ) , a potent oral multi - targeted BC6ENTG inhibitor against BC6OTHER and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6ENTG and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6ENTG - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6OTHER - BC6ENTG , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
However , in vivo studies in BC6ENTG knockout mice versus wild - type mice showed no difference in the amount of BC6ENTC remaining unabsorbed in the gastrointestinal tract , suggesting that BC6OTHER may not be responsible for the incomplete bioavailability.	False
However , in vivo studies in BC6OTHER knockout mice versus wild - type mice showed no difference in the amount of BC6ENTC remaining unabsorbed in the gastrointestinal tract , suggesting that BC6ENTG may not be responsible for the incomplete bioavailability.	False
PURPOSE: BC6ENTC ( BC6OTHER ) , a potent oral multi - targeted BC6ENTG inhibitor against BC6OTHER and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6ENTG and BC6OTHER - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6ENTG - BC6OTHER , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) , a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6OTHER - BC6ENTG , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in BC6OTHER - acquired resistance and intolerance.	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6ENTC ( BC6OTHER ): a potent oral multi - targeted BC6ENTG inhibitor against BC6OTHER and BC6OTHER - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6ENTC ( BC6OTHER ): a potent oral multi - targeted BC6OTHER inhibitor against BC6ENTG and BC6OTHER - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6ENTC ( BC6OTHER ): a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6ENTG - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6ENTC ( BC6OTHER ): a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6OTHER - BC6ENTG .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6OTHER ( BC6ENTC ): a potent oral multi - targeted BC6ENTG inhibitor against BC6OTHER and BC6OTHER - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6OTHER ( BC6ENTC ): a potent oral multi - targeted BC6OTHER inhibitor against BC6ENTG and BC6OTHER - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6OTHER ( BC6ENTC ): a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6ENTG - BC6OTHER .	CPR:4
Preclinical pharmacokinetics and in vitro metabolism of BC6OTHER ( BC6ENTC ): a potent oral multi - targeted BC6OTHER inhibitor against BC6OTHER and BC6OTHER - BC6ENTG .	CPR:4
Although the mechanism of heparin binding involves covalent BC6ENTC formation , it can be completely reversed by protamine addition , similar to heparin's complex formation with BC6ENTG .	False
This study assessed changes in myocardial BC6OTHER expression in the diabetic rat , in particular the diabetic rat pretreated with BC6ENTG activator BC6ENTC ( BC6OTHER ).	CPR:3
This study assessed changes in myocardial BC6ENTG expression in the diabetic rat , in particular the diabetic rat pretreated with BC6OTHER activator BC6ENTC ( BC6OTHER ).	False
This study assessed changes in myocardial BC6OTHER expression in the diabetic rat , in particular the diabetic rat pretreated with BC6ENTG activator BC6OTHER ( BC6ENTC ).	CPR:3
This study assessed changes in myocardial BC6ENTG expression in the diabetic rat , in particular the diabetic rat pretreated with BC6OTHER activator BC6OTHER ( BC6ENTC ).	False
Compared with control group , fasting blood BC6ENTC (FBG) and BC6ENTG ( BC6OTHER ) levels were increased in DM groups.	False
Compared with control group , fasting blood BC6ENTC (FBG) and BC6OTHER ( BC6ENTG ) levels were increased in DM groups.	False
BC6ENTG level in DM12W group was higher than in DM4W group , BC6OTHER level in BC6ENTC +DM8W group was lower than in DM8W group.	False
BC6OTHER level in DM12W group was higher than in DM4W group , BC6ENTG level in BC6ENTC +DM8W group was lower than in DM8W group.	CPR:4
In DM groups , BC6ENTG activity , BC6OTHER mRNA and protein levels were reduced , BC6ENTC content was increased compared with control group; which decreased further as diabetes progressed.	False
In DM groups , BC6OTHER activity , BC6ENTG mRNA and protein levels were reduced , BC6ENTC content was increased compared with control group; which decreased further as diabetes progressed.	False
Compared with DM8W group , BC6ENTG and BC6OTHER in BC6ENTC +DM8W group was increased , BC6OTHER was decreased.	CPR:3
Compared with DM8W group , BC6OTHER and BC6ENTG in BC6ENTC +DM8W group was increased , BC6OTHER was decreased.	CPR:3
Compared with DM8W group , BC6ENTG and BC6OTHER in BC6OTHER +DM8W group was increased , BC6ENTC was decreased.	False
Compared with DM8W group , BC6OTHER and BC6ENTG in BC6OTHER +DM8W group was increased , BC6ENTC was decreased.	False
Activation of BC6ENTG with BC6ENTC attenuates diabetes induced myocardial injury in rats.	CPR:3
Using a mouse peptidergic ( BC6OTHER , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6ENTG is present in BC6ENTC cells.	False
Using a mouse peptidergic ( BC6ENTG , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6ENTC cells.	False
Using a mouse peptidergic ( BC6OTHER , BC6ENTG ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6ENTC cells.	False
Using a mouse peptidergic ( BC6OTHER , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6ENTG with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6ENTC cells.	False
In COS cells transfected with BC6ENTG cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6ENTC was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6ENTG , BC6ENTC was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6ENTC was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6ENTG adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6ENTG cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6ENTC in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6ENTG , BC6OTHER was displaced by unlabelled BC6ENTC in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6ENTC in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6ENTG adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6ENTG cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6ENTC paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6ENTG , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6ENTC paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6ENTC paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6ENTG adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6ENTG cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6ENTC was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6ENTG , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6ENTC was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6ENTC was displaced likewise by a series of BC6ENTG adrenergic agonists , none of which increased the binding of BC6OTHER .	False
In COS cells transfected with BC6ENTG cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6ENTC .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6ENTG , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6OTHER adrenergic agonists , none of which increased the binding of BC6ENTC .	False
In COS cells transfected with BC6OTHER cDNA and in CHEM MF - 2 cells which express native BC6OTHER , BC6OTHER was displaced by unlabelled BC6OTHER in a normal equilibrium process , with no BC6OTHER paradox in concentrations up to 10( - 6) M. In CHEM MF - 2 cells , BC6OTHER was displaced likewise by a series of BC6ENTG adrenergic agonists , none of which increased the binding of BC6ENTC .	False
Hence , the BC6ENTC paradox is not due to some function of BC6ENTG , such as internalization of ligand - receptor complexes.	False
In neurones which possess Transport - P , transfection with BC6ENTG cDNA resulted in over - expression of BC6OTHER , but the BC6ENTC paradox was unaltered.	False
In neurones which possess Transport - P , transfection with BC6OTHER cDNA resulted in over - expression of BC6ENTG , but the BC6ENTC paradox was unaltered.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6ENTC in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6ENTC , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6ENTC which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Peptidergic neurones accumulate BC6ENTC via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6ENTC via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6OTHER binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6ENTC concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
Using a mouse peptidergic ( BC6ENTC , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6ENTG is present in BC6OTHER cells.	False
Using a mouse peptidergic ( BC6ENTC , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6ENTG cells.	False
Using a mouse peptidergic ( BC6ENTC , BC6ENTG ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6OTHER cells.	False
Using a mouse peptidergic ( BC6ENTC , BC6OTHER ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6ENTG with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6OTHER cells.	False
Using a mouse peptidergic ( BC6OTHER , BC6ENTC ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6ENTG is present in BC6OTHER cells.	False
Using a mouse peptidergic ( BC6OTHER , BC6ENTC ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6ENTG cells.	False
Using a mouse peptidergic ( BC6ENTG , BC6ENTC ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6OTHER with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6OTHER cells.	False
Using a mouse peptidergic ( BC6OTHER , BC6ENTC ) neuronal cell line which possesses Transport - P , we have studied the interaction of BC6ENTG with Transport - P. Polymerase chain reactions and DNA sequencing of the products demonstrated that only the BC6OTHER is present in BC6OTHER cells.	False
Peptidergic neurones accumulate BC6OTHER via an unusual uptake process , designated Transport - P. BC6ENTC binds to BC6ENTG on these cells and is displaceable by unlabelled BC6OTHER in concentrations up to 10( - 7) M. However , at greater concentrations of BC6OTHER , there is a paradoxical accumulation of BC6OTHER which we have attributed to Transport - P. Uptake of BC6OTHER via Transport - P is detectable at 10( - 10) M BC6OTHER concentration , is linear up to 10( - 7) M and at greater concentrations becomes non - linear.	False
 BC6ENTG in BC6ENTC neurones: relation to Transport - P. 1.	False
Among these differentially expressed lncRNAs , the greatest change was noted for BC6ENTG , which had more than 300 folds induction upon BC6ENTC treatment.	CPR:3
BC6ENTC selectively induced BC6ENTG in four studied HCC cell lines.	CPR:3
The BC6ENTC - induced BC6ENTG expression was positively correlated with the apoptotic effect of BC6OTHER in HCC cells.	CPR:3
The BC6OTHER - induced BC6ENTG expression was positively correlated with the apoptotic effect of BC6ENTC in HCC cells.	False
In addition , knockdown the expression of BC6ENTG significantly reduced BC6ENTC - induced apoptosis of Huh7cells.	False
Therefore , BC6ENTC - induced apoptosis of HCC cells is BC6ENTG dependent and reduced expression of BC6OTHER may be associated with liver carcinogenesis.	False
Therefore , BC6ENTC - induced apoptosis of HCC cells is BC6OTHER dependent and reduced expression of BC6ENTG may be associated with liver carcinogenesis.	False
Considerable attention has focused on the antitumor effect of BC6ENTG inhibitor ( BC6ENTC , BC6OTHER ) as well as the coding gene expression - induced apoptosis of cancer cells.	CPR:4
Considerable attention has focused on the antitumor effect of BC6ENTG inhibitor ( BC6OTHER , BC6ENTC ) as well as the coding gene expression - induced apoptosis of cancer cells.	CPR:4
Induction of the liver cancer - down - regulated long noncoding RNA BC6ENTG mediates BC6ENTC - induced apoptosis of liver cancer cells.	False
 The expression of BC6ENTG is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6OTHER utilization and lipid production in liver cells with BC6ENTC supplementation in vitro.	False
 The expression of BC6OTHER is stimulated through the action of BC6ENTG in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6OTHER utilization and lipid production in liver cells with BC6ENTC supplementation in vitro.	False
 The expression of BC6OTHER is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6ENTG stimulates BC6OTHER utilization and lipid production in liver cells with BC6ENTC supplementation in vitro.	False
 Deficiency of BC6ENTG induces an impairment of BC6ENTC tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6OTHER has been shown to decrease BC6OTHER , total BC6OTHER and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
 Deficiency of BC6OTHER induces an impairment of BC6ENTC tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6ENTG has been shown to decrease BC6OTHER , total BC6OTHER and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
 Deficiency of BC6ENTG induces an impairment of BC6OTHER tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6OTHER has been shown to decrease BC6ENTC , total BC6OTHER and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
 Deficiency of BC6OTHER induces an impairment of BC6OTHER tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6ENTG has been shown to decrease BC6ENTC , total BC6OTHER and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
 Deficiency of BC6ENTG induces an impairment of BC6OTHER tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6OTHER has been shown to decrease BC6OTHER , total BC6ENTC and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
 Deficiency of BC6OTHER induces an impairment of BC6OTHER tolerance and lipid accumulation in the liver of mice in vivo. Overexpression of endogenous BC6ENTG has been shown to decrease BC6OTHER , total BC6ENTC and glycogen contents in the liver of rats , inducing hyperlipidemia.	False
BC6ENTG ( BC6OTHER / BC6OTHER ) was originally discovered in 1978 as a unique BC6OTHER - binding protein that does not contain the BC6OTHER of BC6ENTC - binding domain.	False
BC6OTHER ( BC6OTHER / BC6OTHER ) was originally discovered in 1978 as a unique BC6OTHER - binding protein that does not contain the BC6ENTG of BC6ENTC - binding domain.	False
BC6OTHER ( BC6ENTG / BC6OTHER ) was originally discovered in 1978 as a unique BC6OTHER - binding protein that does not contain the BC6OTHER of BC6ENTC - binding domain.	False
BC6OTHER ( BC6OTHER / BC6ENTG ) was originally discovered in 1978 as a unique BC6OTHER - binding protein that does not contain the BC6OTHER of BC6ENTC - binding domain.	False
BC6ENTG has been shown to play a multifunctional role in cell regulation; maintaining of intracellular BC6ENTC homeostasis and suppressing of signal transduction , translational protein synthesis , nuclear deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis , proliferation , and apoptosis in many cell types.	False
BC6ENTG ( BC6OTHER / BC6OTHER ) was originally discovered in 1978 as a unique BC6ENTC - binding protein that does not contain the BC6OTHER of BC6OTHER .	False
BC6OTHER ( BC6OTHER / BC6OTHER ) was originally discovered in 1978 as a unique BC6ENTC - binding protein that does not contain the BC6ENTG of BC6OTHER .	False
BC6OTHER ( BC6ENTG / BC6OTHER ) was originally discovered in 1978 as a unique BC6ENTC - binding protein that does not contain the BC6OTHER of BC6OTHER .	False
BC6OTHER ( BC6OTHER / BC6OTHER ) was originally discovered in 1978 as a unique BC6ENTC - binding protein that does not contain the BC6OTHER of BC6ENTG .	False
BC6OTHER ( BC6OTHER / BC6ENTG ) was originally discovered in 1978 as a unique BC6ENTC - binding protein that does not contain the BC6OTHER of BC6OTHER .	False
 The expression of BC6ENTG is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6ENTC administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6OTHER utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	CPR:4
 The expression of BC6OTHER is stimulated through the action of BC6ENTG in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6ENTC administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6OTHER utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	False
 The expression of BC6OTHER is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6ENTC administration in vivo. Overexpression of endogenous BC6ENTG stimulates BC6OTHER utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	False
 The expression of BC6ENTG is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6ENTC utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	False
 The expression of BC6OTHER is stimulated through the action of BC6ENTG in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6OTHER stimulates BC6ENTC utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	False
 The expression of BC6OTHER is stimulated through the action of BC6OTHER in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by BC6OTHER administration in vivo. Overexpression of endogenous BC6ENTG stimulates BC6ENTC utilization and lipid production in liver cells with BC6OTHER supplementation in vitro.	False
BC6ENTC ( BC6OTHER ) receptors are BC6ENTG whose function is critical for normal excitatory synaptic transmission in the brain and whose dysfunction has been implicated in several neurologic conditions.	False
These results suggest a novel site of action for potentiation of BC6ENTC receptors by small molecules and implicate the pre - M1 region in BC6ENTG gating.	False
These results suggest a novel site of action for potentiation of BC6ENTG by small molecules and implicate the pre - M1 region in BC6ENTC receptor gating.	False
CHEM ( BC6ENTC ) receptors are BC6ENTG whose function is critical for normal excitatory synaptic transmission in the brain and whose dysfunction has been implicated in several neurologic conditions.	False
We show that BC6ENTC does not bind to the BC6OTHER - terminal domain of the BC6ENTG and does not share structural determinants with modulators acting at the agonist - binding domain dimer interface or BC6OTHER pore.	False
We show that BC6ENTC does not bind to the BC6OTHER - terminal domain of the BC6OTHER and does not share structural determinants with modulators acting at the agonist - binding domain dimer interface or BC6ENTG pore.	False
We show that BC6OTHER does not bind to the BC6ENTC - terminal domain of the BC6ENTG and does not share structural determinants with modulators acting at the agonist - binding domain dimer interface or BC6OTHER pore.	False
We show that BC6OTHER does not bind to the BC6ENTC - terminal domain of the BC6OTHER and does not share structural determinants with modulators acting at the agonist - binding domain dimer interface or BC6ENTG pore.	False
We show that BC6OTHER does not bind to the BC6OTHER - terminal domain of the BC6ENTC receptor and does not share structural determinants with modulators acting at the agonist - binding domain dimer interface or BC6ENTG pore.	False
For determination of BC6ENTG activity , 10 microL thereof was incubated with 150 microL 1.5 M BC6ENTC , pH 8.7 , and 100 microL 20 mM BC6OTHER preoxidized (15 minutes 37 degrees C) pooled normal BC6OTHER buffered BC6OTHER - plasma for 30 minutes (37 degrees C).	CPR:9
For determination of BC6ENTG activity , 10 microL thereof was incubated with 150 microL 1.5 M BC6OTHER , pH 8.7 , and 100 microL 20 mM BC6ENTC preoxidized (15 minutes 37 degrees C) pooled normal BC6OTHER buffered BC6OTHER - plasma for 30 minutes (37 degrees C).	False
For determination of BC6ENTG activity , 10 microL thereof was incubated with 150 microL 1.5 M BC6OTHER , pH 8.7 , and 100 microL 20 mM BC6OTHER preoxidized (15 minutes 37 degrees C) pooled normal BC6ENTC buffered BC6OTHER - plasma for 30 minutes (37 degrees C).	False
For determination of BC6ENTG activity , 10 microL thereof was incubated with 150 microL 1.5 M BC6OTHER , pH 8.7 , and 100 microL 20 mM BC6OTHER preoxidized (15 minutes 37 degrees C) pooled normal BC6OTHER buffered BC6ENTC - plasma for 30 minutes (37 degrees C).	False
For determination of [ BC6ENTG + BC6OTHER ] - activity , BC6ENTC was added after this incubation.	CPR:9
For determination of [ BC6OTHER + BC6ENTG ] - activity , BC6ENTC was added after this incubation.	CPR:9
Ten IU / mL BC6ENTG was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6ENTC ( BC6OTHER ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6OTHER .	False
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6ENTC ( BC6OTHER ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6ENTG and alpha2 - anti BC6OTHER .	CPR:4
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6ENTC ( BC6OTHER ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6ENTG .	False
Ten IU / mL BC6ENTG was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6ENTC ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6OTHER .	False
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6ENTC ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6ENTG and alpha2 - anti BC6OTHER .	CPR:4
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6ENTC ) donor BC6OTHER ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6ENTG .	False
Ten IU / mL BC6ENTG was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6ENTC ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6OTHER .	False
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6ENTC ( BC6OTHER ) , to destroy BC6ENTG and alpha2 - anti BC6OTHER .	CPR:4
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6ENTC ( BC6OTHER ) , to destroy BC6OTHER and alpha2 - anti BC6ENTG .	CPR:4
Ten IU / mL BC6ENTG was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6OTHER ( BC6ENTC ) , to destroy BC6OTHER and alpha2 - anti BC6OTHER .	False
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6OTHER ( BC6ENTC ) , to destroy BC6ENTG and alpha2 - anti BC6OTHER .	CPR:4
Ten IU / mL BC6OTHER was also incubated with pooled plasma of stroke patients , that was previously oxidized with the BC6OTHER ( BC6OTHER ) donor BC6OTHER ( BC6ENTC ) , to destroy BC6OTHER and alpha2 - anti BC6ENTG .	CPR:4
The results showed that BC6ENTC increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6ENTC increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6ENTC increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6ENTC increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6ENTC ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6ENTC ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6ENTC ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6ENTC ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6ENTC ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6ENTC ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6ENTC ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6ENTC ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6ENTC addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6ENTC addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6ENTC addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6ENTC addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTC receptor ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTC receptor ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTC receptor ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6ENTC receptor ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6ENTC receptor ( BC6OTHER ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTC receptor ( BC6ENTG ) antagonist did not increase [ BC6OTHER ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6ENTG ( BC6OTHER ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6ENTC ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6ENTG ) antagonist and an BC6OTHER ( BC6OTHER ) antagonist did not increase [ BC6ENTC ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6ENTG ( BC6OTHER ) antagonist did not increase [ BC6ENTC ](i).	False
The results showed that BC6OTHER increased [ BC6OTHER ](i) and decreased [ BC6OTHER ](ER) linearly in a time - and concentration - dependant manner , and BC6OTHER addition after the applying of a BC6OTHER ( BC6OTHER ) antagonist and an BC6OTHER ( BC6ENTG ) antagonist did not increase [ BC6ENTC ](i).	False
However , when CHEM was administered concurrently with BC6ENTC treatment , it antagonized the down - regulation of BC6ENTG protein in the nucleus accumbens (142 %) of rats exposed to BC6OTHER .	CPR:4
However , when CHEM was administered concurrently with BC6OTHER treatment , it antagonized the down - regulation of BC6ENTG protein in the nucleus accumbens (142 %) of rats exposed to BC6ENTC .	CPR:4
CONCLUSION: A long - term intake of BC6ENTC solution down - regulates the phosphorylation of BC6ENTG in the nucleus accumbens , and those changes can be reversed by BC6OTHER , which may be one kind of the molecular mechanisms associated with BC6OTHER dependence.	CPR:4
CONCLUSION: A long - term intake of BC6OTHER solution down - regulates the phosphorylation of BC6ENTG in the nucleus accumbens , and those changes can be reversed by BC6ENTC , which may be one kind of the molecular mechanisms associated with BC6OTHER dependence.	CPR:3
CONCLUSION: A long - term intake of BC6OTHER solution down - regulates the phosphorylation of BC6ENTG in the nucleus accumbens , and those changes can be reversed by BC6OTHER , which may be one kind of the molecular mechanisms associated with BC6ENTC dependence.	False
AIM: To study the changes in the expression and phosphorylation of BC6OTHER ( BC6ENTG ) in the rat nucleus accumbens after chronic BC6ENTC intake and its withdrawal.	False
AIM: To study the changes in the expression and phosphorylation of BC6ENTG ( BC6OTHER ) in the rat nucleus accumbens after chronic BC6ENTC intake and its withdrawal.	False
RESULTS: BC6ENTC given to rats in drinking water decreased the level of BC6ENTG protein in the nucleus accumbens ( - 75 %) at the time of exposure to BC6OTHER .	CPR:4
RESULTS: BC6OTHER given to rats in drinking water decreased the level of BC6ENTG protein in the nucleus accumbens ( - 75 %) at the time of exposure to BC6ENTC .	False
AIM: To study the changes in the expression and phosphorylation of BC6ENTC response element binding protein ( BC6ENTG ) in the rat nucleus accumbens after chronic BC6OTHER intake and its withdrawal.	False
The decrement of BC6ENTG protein in the nucleus accumbens remained at 24 h ( - 35 %) and 72 h ( - 28 %) of BC6ENTC withdrawal , which recovered toward control level after 7 d of BC6OTHER withdrawal.	CPR:4
The decrement of BC6ENTG protein in the nucleus accumbens remained at 24 h ( - 35 %) and 72 h ( - 28 %) of BC6OTHER withdrawal , which recovered toward control level after 7 d of BC6ENTC withdrawal.	CPR:4
However , chronic BC6ENTC , as well as BC6OTHER withdrawal failed to produce any significant alteration in the level of BC6ENTG protein in the nucleus accumbens.	False
However , chronic BC6OTHER , as well as BC6ENTC withdrawal failed to produce any significant alteration in the level of BC6ENTG protein in the nucleus accumbens.	False
BC6ENTC (alone) treatment of rats had no effect on the levels of BC6OTHER and BC6ENTG protein in the nucleus accumbens.	False
BC6ENTC (alone) treatment of rats had no effect on the levels of BC6ENTG and BC6OTHER protein in the nucleus accumbens.	False
Changes of phosphorylation of BC6ENTG in rat nucleus accumbens after chronic BC6ENTC intake: BC6OTHER reversal.	False
Changes of phosphorylation of BC6ENTG in rat nucleus accumbens after chronic BC6OTHER intake: BC6ENTC reversal.	False
 Pre - treatment of animals with BC6ENTC or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6ENTG pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6OTHER protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6ENTC or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6OTHER pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6ENTG protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6ENTC reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6ENTG pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6OTHER protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6ENTC reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6OTHER pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6ENTG protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6ENTC and BC6ENTG pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6OTHER protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6ENTC and BC6OTHER pathways in vivo. Furthermore , experiments showed that treatment with BC6OTHER results in a reduction in the amount of BC6ENTG protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6ENTG pathways in vivo. Furthermore , experiments showed that treatment with BC6ENTC results in a reduction in the amount of BC6OTHER protein in peritoneal exudate cells.	False
 Pre - treatment of animals with BC6OTHER or BC6OTHER reduced DEC's efficacy by almost 90% or 56% , respectively , supporting a role for the BC6OTHER and BC6OTHER pathways in vivo. Furthermore , experiments showed that treatment with BC6ENTC results in a reduction in the amount of BC6ENTG protein in peritoneal exudate cells.	CPR:4
Additionally , in BC6ENTG - / - mice infected with B. malayi microfilariae , BC6ENTC showed no activity , whereas the efficacy of another antifilarial drug , BC6OTHER , was unaffected.	False
Additionally , in BC6ENTG - / - mice infected with B. malayi microfilariae , BC6OTHER showed no activity , whereas the efficacy of another antifilarial drug , BC6ENTC , was unaffected.	False
CONCLUSION: These results confirm the important role of the BC6ENTC metabolic pathway in DEC's mechanism of action in vivo and show that in addition to its effects on the BC6ENTG pathway , it targets the BC6OTHER pathway and BC6OTHER .	False
CONCLUSION: These results confirm the important role of the BC6ENTC metabolic pathway in DEC's mechanism of action in vivo and show that in addition to its effects on the BC6OTHER pathway , it targets the BC6ENTG pathway and BC6OTHER .	False
CONCLUSION: These results confirm the important role of the BC6ENTC metabolic pathway in DEC's mechanism of action in vivo and show that in addition to its effects on the BC6OTHER pathway , it targets the BC6OTHER pathway and BC6ENTG .	False
Here we have investigated the contribution of the BC6ENTC and BC6ENTG ( BC6OTHER ) pathways to the activity of BC6OTHER against B. malayi microfilariae in mice.	False
Here we have investigated the contribution of the BC6ENTC and BC6OTHER ( BC6ENTG ) pathways to the activity of BC6OTHER against B. malayi microfilariae in mice.	False
Here we have investigated the contribution of the BC6OTHER and BC6ENTG ( BC6OTHER ) pathways to the activity of BC6ENTC against B. malayi microfilariae in mice.	False
Here we have investigated the contribution of the BC6OTHER and BC6OTHER ( BC6ENTG ) pathways to the activity of BC6ENTC against B. malayi microfilariae in mice.	False
To investigate a role for inducible BC6ENTC in DEC's activity , BC6OTHER and BC6OTHER were administered to microfilaraemic BC6ENTG - / - mice and their background strain (129 / SV).	False
To investigate a role for inducible BC6OTHER in DEC's activity , BC6ENTC and BC6OTHER were administered to microfilaraemic BC6ENTG - / - mice and their background strain (129 / SV).	False
To investigate a role for inducible BC6OTHER in DEC's activity , BC6OTHER and BC6ENTC were administered to microfilaraemic BC6ENTG - / - mice and their background strain (129 / SV).	False
Western blot analysis was used to determine any effect of BC6ENTC on the production of BC6ENTG and inducible BC6OTHER ( BC6OTHER ) proteins.	False
Western blot analysis was used to determine any effect of BC6ENTC on the production of BC6OTHER and inducible BC6ENTG ( BC6OTHER ) proteins.	False
Western blot analysis was used to determine any effect of BC6ENTC on the production of BC6OTHER and inducible BC6OTHER ( BC6ENTG ) proteins.	False
Western blot analysis was used to determine any effect of BC6OTHER on the production of BC6ENTG and inducible BC6ENTC synthase ( BC6OTHER ) proteins.	False
Western blot analysis was used to determine any effect of BC6OTHER on the production of BC6OTHER and inducible BC6ENTC synthase ( BC6ENTG ) proteins.	False
 BC6ENTC activity against Brugia malayi microfilariae is dependent on inducible BC6OTHER synthase and the BC6ENTG pathway.	False
 BC6ENTC activity against Brugia malayi microfilariae is dependent on BC6ENTG and the BC6OTHER pathway.	False
 BC6OTHER activity against Brugia malayi microfilariae is dependent on inducible BC6ENTC synthase and the BC6ENTG pathway.	False
This study investigated the anti - glycative activity of LSOPC in a BC6ENTG ( BC6OTHER ) - BC6ENTC model.	False
This study investigated the anti - glycative activity of LSOPC in a BC6OTHER ( BC6ENTG ) - BC6ENTC model.	False
It has been reported that oligomeric BC6ENTC of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and BC6ENTG - potentiating activities.	CPR:3
Also in contrast to effects of multiple BC6OTHER injections , 1) BC6OTHER caused little or no decrease in binding of the BC6ENTG ligand BC6OTHER , and 2) neither prevention of hyperthermia nor prior depletion of BC6OTHER prevented the BC6OTHER - induced reduction in plasmalemmal BC6ENTC transport.	CPR:9
However , a role for phosphorylation was suggested because pretreatment with BC6ENTG inhibitors attenuated the deficit caused by BC6ENTC in an in vitro model system.	False
In addition to affecting BC6ENTG function , BC6ENTC rapidly decreased vesicular BC6OTHER transport as assessed in striatal vesicles prepared from treated rats.	False
In addition to affecting BC6ENTG function , BC6OTHER rapidly decreased vesicular BC6ENTC transport as assessed in striatal vesicles prepared from treated rats.	CPR:9
Taken together , these results reveal several differences between effects of BC6ENTC and previously reported BC6OTHER on BC6ENTG and BC6OTHER ; differences that may underlie the dissimilar neurotoxic profile of these agents.	False
Taken together , these results reveal several differences between effects of BC6ENTC and previously reported BC6OTHER on BC6OTHER and BC6ENTG ; differences that may underlie the dissimilar neurotoxic profile of these agents.	False
Taken together , these results reveal several differences between effects of BC6OTHER and previously reported BC6ENTC on BC6ENTG and BC6OTHER ; differences that may underlie the dissimilar neurotoxic profile of these agents.	False
Taken together , these results reveal several differences between effects of BC6OTHER and previously reported BC6ENTC on BC6OTHER and BC6ENTG ; differences that may underlie the dissimilar neurotoxic profile of these agents.	False
To determine whether these responses were common to other BC6ENTC of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6ENTG ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6ENTC of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6ENTG ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6ENTC of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6ENTC of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6ENTG ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6ENTC ( BC6OTHER ) on the plasmalemmal BC6ENTG ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6ENTC ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6ENTG ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6ENTC ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6ENTC ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6ENTG ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6ENTC ) on the plasmalemmal BC6ENTG ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6ENTC ) on the plasmalemmal BC6OTHER ( BC6ENTG ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6ENTC ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6ENTC ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6ENTG ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6ENTC transporter ( BC6ENTG ) and vesicular BC6OTHER transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6ENTC transporter ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6ENTC transporter ( BC6OTHER ) and vesicular BC6OTHER transporter - 2 ( BC6ENTG ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6ENTG ( BC6OTHER ) and vesicular BC6ENTC transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6ENTG ) and vesicular BC6ENTC transporter - 2 ( BC6OTHER ) were assessed.	False
To determine whether these responses were common to other BC6OTHER of abuse , effects of BC6OTHER ( BC6OTHER ) on the plasmalemmal BC6OTHER ( BC6OTHER ) and vesicular BC6ENTC transporter - 2 ( BC6ENTG ) were assessed.	False
Also in contrast to effects of multiple BC6ENTC injections , 1) BC6OTHER caused little or no decrease in binding of the BC6ENTG ligand BC6OTHER , and 2) neither prevention of hyperthermia nor prior depletion of BC6OTHER prevented the BC6OTHER - induced reduction in plasmalemmal BC6OTHER transport.	CPR:4
Also in contrast to effects of multiple BC6OTHER injections , 1) BC6ENTC caused little or no decrease in binding of the BC6ENTG ligand BC6OTHER , and 2) neither prevention of hyperthermia nor prior depletion of BC6OTHER prevented the BC6OTHER - induced reduction in plasmalemmal BC6OTHER transport.	False
Also in contrast to effects of multiple BC6OTHER injections , 1) BC6OTHER caused little or no decrease in binding of the BC6ENTG ligand BC6ENTC , and 2) neither prevention of hyperthermia nor prior depletion of BC6OTHER prevented the BC6OTHER - induced reduction in plasmalemmal BC6OTHER transport.	False
Also in contrast to effects of multiple BC6OTHER injections , 1) BC6OTHER caused little or no decrease in binding of the BC6ENTG ligand BC6OTHER , and 2) neither prevention of hyperthermia nor prior depletion of BC6ENTC prevented the BC6OTHER - induced reduction in plasmalemmal BC6OTHER transport.	CPR:9
Also in contrast to effects of multiple BC6OTHER injections , 1) BC6OTHER caused little or no decrease in binding of the BC6ENTG ligand BC6OTHER , and 2) neither prevention of hyperthermia nor prior depletion of BC6OTHER prevented the BC6ENTC - induced reduction in plasmalemmal BC6OTHER transport.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6ENTC , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6ENTC , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6ENTC ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6ENTC ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Administration of a concentration (100 microM) of BC6ENTC that blocks BC6ENTG inhibited ecto - BC6OTHER activity (by 44%).	CPR:4
Administration of a concentration (100 microM) of BC6ENTC that blocks BC6OTHER inhibited ecto - BC6ENTG activity (by 44%).	CPR:4
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6ENTG , and metabolism of BC6ENTC to BC6OTHER by BC6OTHER .	False
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6ENTC to BC6OTHER by BC6ENTG .	CPR:9
In kidneys , stimulation of BC6ENTG causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6ENTC to BC6OTHER by BC6OTHER .	False
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6ENTG , and metabolism of BC6OTHER to BC6ENTC by BC6OTHER .	False
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6ENTC by BC6ENTG .	CPR:9
In kidneys , stimulation of BC6ENTG causes egress of BC6OTHER , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6ENTC by BC6OTHER .	False
However , a lower concentration of BC6ENTC (3 microM) that blocks BC6ENTG , BC6OTHER , and BC6OTHER , but not BC6OTHER , did not inhibit ecto - BC6OTHER activity.	CPR:4
However , a lower concentration of BC6ENTC (3 microM) that blocks BC6OTHER , BC6ENTG , and BC6OTHER , but not BC6OTHER , did not inhibit ecto - BC6OTHER activity.	CPR:4
However , a lower concentration of BC6ENTC (3 microM) that blocks BC6OTHER , BC6OTHER , and BC6ENTG , but not BC6OTHER , did not inhibit ecto - BC6OTHER activity.	CPR:4
However , a lower concentration of BC6ENTC (3 microM) that blocks BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6ENTG , did not inhibit ecto - BC6OTHER activity.	False
However , a lower concentration of BC6ENTC (3 microM) that blocks BC6OTHER , BC6OTHER , and BC6OTHER , but not BC6OTHER , did not inhibit ecto - BC6ENTG activity.	False
These data support the conclusion that renal ecto - BC6ENTG activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	CPR:4
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , or BC6OTHER and is inhibited by high concentrations of BC6ENTC .	False
These data support the conclusion that renal ecto - BC6OTHER activity is not mediated by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , or BC6ENTG and is inhibited by high concentrations of BC6ENTC .	False
In kidneys , stimulation of BC6OTHER causes egress of BC6ENTC , conversion of BC6OTHER to BC6OTHER by ecto - BC6ENTG , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	False
In kidneys , stimulation of BC6OTHER causes egress of BC6ENTC , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6ENTG .	False
In kidneys , stimulation of BC6ENTG causes egress of BC6ENTC , conversion of BC6OTHER to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	False
A broad - spectrum BC6ENTG ( BC6OTHER ) inhibitor ( BC6ENTC , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6OTHER secretion by 60 and 74% , respectively.	CPR:4
A broad - spectrum BC6OTHER ( BC6ENTG ) inhibitor ( BC6ENTC , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6OTHER secretion by 60 and 74% , respectively.	CPR:4
A broad - spectrum BC6ENTG ( BC6OTHER ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6ENTC , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6OTHER secretion by 60 and 74% , respectively.	False
A broad - spectrum BC6OTHER ( BC6ENTG ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6ENTC , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6OTHER secretion by 60 and 74% , respectively.	False
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6ENTC to BC6OTHER by ecto - BC6ENTG , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	CPR:9
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6ENTC to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6ENTG .	False
In kidneys , stimulation of BC6ENTG causes egress of BC6OTHER , conversion of BC6ENTC to BC6OTHER by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	False
A broad - spectrum BC6ENTG ( BC6OTHER ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6ENTC - induced BC6OTHER secretion by 60 and 74% , respectively.	False
A broad - spectrum BC6OTHER ( BC6ENTG ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6ENTC - induced BC6OTHER secretion by 60 and 74% , respectively.	False
A broad - spectrum BC6ENTG ( BC6OTHER ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6ENTC secretion by 60 and 74% , respectively.	False
A broad - spectrum BC6OTHER ( BC6ENTG ) inhibitor ( BC6OTHER , 300 microM , n=6) and an ecto - phosphodiesterase inhibitor ( BC6OTHER , 1 mM , n=6) significantly attenuated BC6OTHER - induced BC6ENTC secretion by 60 and 74% , respectively.	False
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6ENTC by ecto - BC6ENTG , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	CPR:9
In kidneys , stimulation of BC6OTHER causes egress of BC6OTHER , conversion of BC6OTHER to BC6ENTC by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6ENTG .	False
In kidneys , stimulation of BC6ENTG causes egress of BC6OTHER , conversion of BC6OTHER to BC6ENTC by ecto - BC6OTHER , and metabolism of BC6OTHER to BC6OTHER by BC6OTHER .	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6ENTC , 100 microM) , BC6OTHER [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
Blockade of BC6OTHER ( BC6ENTC , 100 microM) , BC6ENTG [ BC6OTHER , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6ENTG ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6ENTG (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6ENTG and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6ENTG ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6ENTG [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6ENTG activity.	False
Blockade of BC6ENTG ( BC6OTHER , 100 microM) , BC6OTHER [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	False
Blockade of BC6OTHER ( BC6OTHER , 100 microM) , BC6ENTG [ BC6ENTC , 30 microM] , BC6OTHER ( BC6OTHER , 10 microM; CHEM , 10 microM) , BC6OTHER (CHEM [ BC6OTHER ] , 100 microM) , BC6OTHER and BC6OTHER ( BC6OTHER , 30 microM) , and BC6OTHER [ BC6OTHER ( BC6OTHER ) , 10 microM] did not alter renal ecto - BC6OTHER activity.	CPR:4
BC6ENTC reductase ( BC6ENTG ) is the key enzyme in BC6OTHER respiration induced by anaerobic growth of bacteria.	False
Given that BC6ENTG , present in all H. pylori strains , is immunogenic in H. pylori - infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ( BC6ENTC , BC6OTHER and BC6OTHER ) , this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.	CPR:4
Given that BC6ENTG , present in all H. pylori strains , is immunogenic in H. pylori - infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ( BC6OTHER , BC6ENTC and BC6OTHER ) , this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.	CPR:4
Given that BC6ENTG , present in all H. pylori strains , is immunogenic in H. pylori - infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics ( BC6OTHER , BC6OTHER and BC6ENTC ) , this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.	CPR:4
BC6ENTG ( BC6OTHER ) is the key enzyme in BC6ENTC respiration induced by anaerobic growth of bacteria.	CPR:9
BC6OTHER ( BC6ENTG ) is the key enzyme in BC6ENTC respiration induced by anaerobic growth of bacteria.	CPR:9
The BC6ENTG gene coding for BC6OTHER , and two control genes , BC6OTHER and BC6OTHER associated with the export of BC6ENTC out of H. pylori , were inactivated by insertion of the BC6OTHER acetyltransferase cassette into these individual genes.	False
The BC6OTHER gene coding for BC6ENTG , and two control genes , BC6OTHER and BC6OTHER associated with the export of BC6ENTC out of H. pylori , were inactivated by insertion of the BC6OTHER acetyltransferase cassette into these individual genes.	False
The BC6OTHER gene coding for BC6OTHER , and two control genes , BC6ENTG and BC6OTHER associated with the export of BC6ENTC out of H. pylori , were inactivated by insertion of the BC6OTHER acetyltransferase cassette into these individual genes.	CPR:9
The BC6OTHER gene coding for BC6OTHER , and two control genes , BC6OTHER and BC6ENTG associated with the export of BC6ENTC out of H. pylori , were inactivated by insertion of the BC6OTHER acetyltransferase cassette into these individual genes.	CPR:9
The BC6ENTG gene coding for BC6OTHER , and two control genes , BC6OTHER and BC6OTHER associated with the export of BC6OTHER out of H. pylori , were inactivated by insertion of the BC6ENTC acetyltransferase cassette into these individual genes.	False
The BC6OTHER gene coding for BC6ENTG , and two control genes , BC6OTHER and BC6OTHER associated with the export of BC6OTHER out of H. pylori , were inactivated by insertion of the BC6ENTC acetyltransferase cassette into these individual genes.	False
The BC6OTHER gene coding for BC6OTHER , and two control genes , BC6ENTG and BC6OTHER associated with the export of BC6OTHER out of H. pylori , were inactivated by insertion of the BC6ENTC acetyltransferase cassette into these individual genes.	False
The BC6OTHER gene coding for BC6OTHER , and two control genes , BC6OTHER and BC6ENTG associated with the export of BC6OTHER out of H. pylori , were inactivated by insertion of the BC6ENTC acetyltransferase cassette into these individual genes.	False
The data show that BC6ENTC is less potent at inducing BC6ENTG gene expression in rainbow trout than BC6OTHER ( BC6OTHER ) , a well - known Ah - receptor agonist.	CPR:3
The data show that BC6OTHER is less potent at inducing BC6ENTG gene expression in rainbow trout than BC6ENTC ( BC6OTHER ) , a well - known Ah - receptor agonist.	CPR:3
The data show that BC6OTHER is less potent at inducing BC6ENTG gene expression in rainbow trout than BC6OTHER ( BC6ENTC ) , a well - known Ah - receptor agonist.	CPR:3
Interestingly , the BC6ENTC dependent up - regulation of BC6ENTG mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.	CPR:3
BC6ENTC has , comparably to BC6OTHER , a potential to repress expression of BC6ENTG , in the head kidney of rainbow trout.	CPR:4
BC6OTHER has , comparably to BC6ENTC , a potential to repress expression of BC6ENTG , in the head kidney of rainbow trout.	CPR:4
Furthermore , BC6ENTC responsive genes in fish liver , BC6ENTG and BC6OTHER , are not induced by BC6OTHER , suggesting that the compound has no endocrine disrupting potential.	False
Furthermore , BC6ENTC responsive genes in fish liver , BC6OTHER and BC6ENTG , are not induced by BC6OTHER , suggesting that the compound has no endocrine disrupting potential.	False
Furthermore , BC6OTHER responsive genes in fish liver , BC6ENTG and BC6OTHER , are not induced by BC6ENTC , suggesting that the compound has no endocrine disrupting potential.	False
Furthermore , BC6OTHER responsive genes in fish liver , BC6OTHER and BC6ENTG , are not induced by BC6ENTC , suggesting that the compound has no endocrine disrupting potential.	False
BC6ENTC (CHEM - BC6ENTG ) binds the BC6OTHER to significantly increase the eumelanin content of human skin cells.	False
BC6ENTC (CHEM - BC6OTHER ) binds the BC6ENTG to significantly increase the eumelanin content of human skin cells.	False
BC6OTHER ( BC6ENTC ) binds the BC6ENTG to significantly increase the eumelanin content of human skin cells.	False
In this study of 77 Caucasian individuals , we investigated the effects of BC6ENTC in individuals with variant BC6ENTG genotypes , as it has been suggested through in vitro studies that variant alleles decrease BC6OTHER binding efficacy , which would subsequently affect the synthesis of melanin.	False
In this study of 77 Caucasian individuals , we investigated the effects of BC6OTHER in individuals with variant BC6ENTG genotypes , as it has been suggested through in vitro studies that variant alleles decrease BC6ENTC binding efficacy , which would subsequently affect the synthesis of melanin.	False
This study demonstrates that BC6ENTC effectively increases the melanin content of skin in those individuals with BC6ENTG variant alleles and therefore , those most in need of photoprotection.	False
Effect of BC6ENTC , CHEM , on melanin synthesis in humans with BC6OTHER variant alleles.	False
Effect of BC6ENTC , CHEM , on melanin synthesis in humans with BC6ENTG variant alleles.	False
Effect of BC6OTHER , BC6ENTC , on melanin synthesis in humans with BC6ENTG variant alleles.	False
These include the BC6ENTC , as well as selective BC6ENTG antagonists.	False
The identification of the BC6ENTC receptor BC6ENTG in platelets is of particular interest , because physiologically relevant concentrations of BC6OTHER were shown to potentiate the effect of low doses of a variety of platelet agonists.	False
The identification of the BC6ENTG BC6OTHER in platelets is of particular interest , because physiologically relevant concentrations of BC6ENTC were shown to potentiate the effect of low doses of a variety of platelet agonists.	CPR:5
The identification of the BC6OTHER BC6ENTG in platelets is of particular interest , because physiologically relevant concentrations of BC6ENTC were shown to potentiate the effect of low doses of a variety of platelet agonists.	CPR:5
In addition , we found that BC6ENTG transcription and translation was completely inhibited by BC6ENTC , while BC6OTHER transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.	CPR:4
In addition , we found that BC6OTHER transcription and translation was completely inhibited by BC6ENTC , while BC6ENTG transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.	CPR:4
BC6ENTG and BC6OTHER was tested after 1 , 10 , 20 , 30 , and 40 days post inoculation , before and after BC6ENTC treatment.	False
BC6OTHER and BC6ENTG was tested after 1 , 10 , 20 , 30 , and 40 days post inoculation , before and after BC6ENTC treatment.	False
Inhibition of BC6ENTG and BC6OTHER transcription and translation by BC6ENTC in muscle tissue infected with the parasite Trichinella spiralis.	CPR:4
Inhibition of BC6OTHER and BC6ENTG transcription and translation by BC6ENTC in muscle tissue infected with the parasite Trichinella spiralis.	CPR:4
In addition , BC6OTHER ( BC6OTHER ) , a specific BC6ENTG inducer , predominantly suppressed LPS - induced BC6ENTC production.	False
In contrast , BC6ENTC ( BC6OTHER ) , a specific BC6ENTG inhibitor , showed a partial suppressive effect of BC6OTHER on LPS - induced BC6OTHER production.	CPR:4
In contrast , BC6OTHER ( BC6ENTC ) , a specific BC6ENTG inhibitor , showed a partial suppressive effect of BC6OTHER on LPS - induced BC6OTHER production.	CPR:4
In contrast , BC6OTHER ( BC6OTHER ) , a specific BC6ENTG inhibitor , showed a partial suppressive effect of BC6ENTC on LPS - induced BC6OTHER production.	False
In contrast , BC6OTHER ( BC6OTHER ) , a specific BC6ENTG inhibitor , showed a partial suppressive effect of BC6OTHER on LPS - induced BC6ENTC production.	False
Further , BC6ENTC increased specific DNA - binding activity of BC6ENTG , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6OTHER - induced BC6OTHER inhibition , which was followed by suppression of BC6OTHER activity.	CPR:3
Further , BC6ENTC increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6ENTG siRNA subsequently reversed BC6OTHER - induced BC6OTHER inhibition , which was followed by suppression of BC6OTHER activity.	CPR:3
Further , BC6ENTC increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6OTHER - induced BC6OTHER inhibition , which was followed by suppression of BC6ENTG activity.	CPR:3
Further , BC6OTHER increased specific DNA - binding activity of BC6ENTG , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6ENTC - induced BC6OTHER inhibition , which was followed by suppression of BC6OTHER activity.	CPR:3
Further , BC6OTHER increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6ENTG siRNA subsequently reversed BC6ENTC - induced BC6OTHER inhibition , which was followed by suppression of BC6OTHER activity.	CPR:3
Further , BC6OTHER increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6ENTC - induced BC6OTHER inhibition , which was followed by suppression of BC6ENTG activity.	CPR:4
Further , BC6OTHER increased specific DNA - binding activity of BC6ENTG , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6OTHER - induced BC6ENTC inhibition , which was followed by suppression of BC6OTHER activity.	False
Further , BC6OTHER increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6ENTG siRNA subsequently reversed BC6OTHER - induced BC6ENTC inhibition , which was followed by suppression of BC6OTHER activity.	False
Further , BC6OTHER increased specific DNA - binding activity of BC6OTHER , and transient knockdown with BC6OTHER siRNA subsequently reversed BC6OTHER - induced BC6ENTC inhibition , which was followed by suppression of BC6ENTG activity.	CPR:4
Taken together , our findings indicate that BC6ENTC suppresses BC6OTHER production through modulation of BC6ENTG , consequently suppressing BC6OTHER activity and induction of BC6OTHER - dependent BC6OTHER activity.	False
Taken together , our findings indicate that BC6ENTC suppresses BC6OTHER production through modulation of BC6OTHER , consequently suppressing BC6ENTG activity and induction of BC6OTHER - dependent BC6OTHER activity.	CPR:4
Taken together , our findings indicate that BC6ENTC suppresses BC6OTHER production through modulation of BC6OTHER , consequently suppressing BC6OTHER activity and induction of BC6ENTG - dependent BC6OTHER activity.	CPR:3
Taken together , our findings indicate that BC6ENTC suppresses BC6OTHER production through modulation of BC6OTHER , consequently suppressing BC6OTHER activity and induction of BC6OTHER - dependent BC6ENTG activity.	CPR:3
Taken together , our findings indicate that BC6OTHER suppresses BC6ENTC production through modulation of BC6ENTG , consequently suppressing BC6OTHER activity and induction of BC6OTHER - dependent BC6OTHER activity.	False
Taken together , our findings indicate that BC6OTHER suppresses BC6ENTC production through modulation of BC6OTHER , consequently suppressing BC6ENTG activity and induction of BC6OTHER - dependent BC6OTHER activity.	CPR:4
Taken together , our findings indicate that BC6OTHER suppresses BC6ENTC production through modulation of BC6OTHER , consequently suppressing BC6OTHER activity and induction of BC6ENTG - dependent BC6OTHER activity.	CPR:4
Taken together , our findings indicate that BC6OTHER suppresses BC6ENTC production through modulation of BC6OTHER , consequently suppressing BC6OTHER activity and induction of BC6OTHER - dependent BC6ENTG activity.	CPR:4
In this study , we found that BC6OTHER ( BC6OTHER ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6ENTC production by suppressing the expression of BC6ENTG ( BC6OTHER ) in BV2 microglia.	False
In this study , we found that BC6OTHER ( BC6OTHER ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6ENTC production by suppressing the expression of inducible BC6OTHER synthase ( BC6ENTG ) in BV2 microglia.	False
In this study , we found that BC6OTHER ( BC6OTHER ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6OTHER production by suppressing the expression of inducible BC6ENTC synthase ( BC6ENTG ) in BV2 microglia.	False
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6ENTG , resulting in suppression of the nuclear translocation of BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER and BC6OTHER , which are important molecules involved in the regulation of BC6OTHER expression.	CPR:4
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6OTHER , resulting in suppression of the nuclear translocation of BC6ENTG ( BC6OTHER ) subunits , namely BC6OTHER and BC6OTHER , which are important molecules involved in the regulation of BC6OTHER expression.	CPR:4
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6OTHER , resulting in suppression of the nuclear translocation of BC6OTHER ( BC6ENTG ) subunits , namely BC6OTHER and BC6OTHER , which are important molecules involved in the regulation of BC6OTHER expression.	CPR:4
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6OTHER , resulting in suppression of the nuclear translocation of BC6OTHER ( BC6OTHER ) subunits , namely BC6ENTG and BC6OTHER , which are important molecules involved in the regulation of BC6OTHER expression.	CPR:4
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6OTHER , resulting in suppression of the nuclear translocation of BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER and BC6ENTG , which are important molecules involved in the regulation of BC6OTHER expression.	CPR:4
In addition , BC6ENTC blocked LPS - induced phosphorylation of BC6OTHER , resulting in suppression of the nuclear translocation of BC6OTHER ( BC6OTHER ) subunits , namely BC6OTHER and BC6OTHER , which are important molecules involved in the regulation of BC6ENTG expression.	False
In this study , we found that BC6ENTC ( BC6OTHER ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6OTHER production by suppressing the expression of BC6ENTG ( BC6OTHER ) in BV2 microglia.	CPR:4
In this study , we found that BC6ENTC ( BC6OTHER ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6OTHER production by suppressing the expression of inducible BC6OTHER synthase ( BC6ENTG ) in BV2 microglia.	CPR:4
BC6ENTC ( BC6OTHER ) , a specific BC6ENTG inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	CPR:4
BC6ENTC ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6ENTG inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	False
BC6ENTC ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6ENTG expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	CPR:4
BC6ENTC ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6ENTG expression by suppressing BC6OTHER activity.	False
BC6ENTC ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6ENTG activity.	False
BC6OTHER ( BC6ENTC ) , a specific BC6ENTG inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	CPR:4
BC6OTHER ( BC6ENTC ) , a specific BC6OTHER inhibitor , along with BC6ENTG inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	False
BC6OTHER ( BC6ENTC ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6ENTG expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6OTHER activity.	CPR:4
BC6OTHER ( BC6ENTC ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6ENTG expression by suppressing BC6OTHER activity.	False
BC6OTHER ( BC6ENTC ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6OTHER downregulated BC6OTHER expression by suppressing BC6ENTG activity.	False
BC6OTHER ( BC6OTHER ) , a specific BC6ENTG inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6ENTC downregulated BC6OTHER expression by suppressing BC6OTHER activity.	False
BC6OTHER ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6ENTG inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6ENTC downregulated BC6OTHER expression by suppressing BC6OTHER activity.	False
BC6OTHER ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6ENTG expression , which indirectly suggested that BC6ENTC downregulated BC6OTHER expression by suppressing BC6OTHER activity.	False
BC6OTHER ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6ENTC downregulated BC6ENTG expression by suppressing BC6OTHER activity.	CPR:4
BC6OTHER ( BC6OTHER ) , a specific BC6OTHER inhibitor , along with BC6OTHER inhibitor (PSI) significantly inhibited LPS - induced BC6OTHER expression , which indirectly suggested that BC6ENTC downregulated BC6OTHER expression by suppressing BC6ENTG activity.	CPR:4
In this study , we found that BC6OTHER ( BC6ENTC ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6OTHER production by suppressing the expression of BC6ENTG ( BC6OTHER ) in BV2 microglia.	CPR:4
In this study , we found that BC6OTHER ( BC6ENTC ) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS) - stimulated BC6OTHER production by suppressing the expression of inducible BC6OTHER synthase ( BC6ENTG ) in BV2 microglia.	CPR:4
Thus , we found that BC6ENTC enhances BC6ENTG ( BC6OTHER ) expression via BC6OTHER ( BC6OTHER ) activation.	CPR:3
Thus , we found that BC6ENTC enhances BC6OTHER ( BC6ENTG ) expression via BC6OTHER ( BC6OTHER ) activation.	CPR:3
Thus , we found that BC6ENTC enhances BC6OTHER ( BC6OTHER ) expression via BC6ENTG ( BC6OTHER ) activation.	CPR:3
Thus , we found that BC6ENTC enhances BC6OTHER ( BC6OTHER ) expression via BC6OTHER ( BC6ENTG ) activation.	CPR:3
In addition , BC6ENTC ( BC6OTHER ) , a specific BC6ENTG inducer , predominantly suppressed LPS - induced BC6OTHER production.	CPR:3
In addition , BC6OTHER ( BC6ENTC ) , a specific BC6ENTG inducer , predominantly suppressed LPS - induced BC6OTHER production.	CPR:3
 BC6ENTC inhibits BC6OTHER production in lipopolysaccharide - stimulated BV2 microglia via BC6ENTG suppression and BC6OTHER - dependent BC6OTHER induction.	CPR:4
 BC6ENTC inhibits BC6OTHER production in lipopolysaccharide - stimulated BV2 microglia via BC6OTHER suppression and BC6ENTG - dependent BC6OTHER induction.	CPR:3
 BC6ENTC inhibits BC6OTHER production in lipopolysaccharide - stimulated BV2 microglia via BC6OTHER suppression and BC6OTHER - dependent BC6ENTG induction.	CPR:3
 BC6OTHER inhibits BC6ENTC production in lipopolysaccharide - stimulated BV2 microglia via BC6ENTG suppression and BC6OTHER - dependent BC6OTHER induction.	False
 BC6OTHER inhibits BC6ENTC production in lipopolysaccharide - stimulated BV2 microglia via BC6OTHER suppression and BC6ENTG - dependent BC6OTHER induction.	False
 BC6OTHER inhibits BC6ENTC production in lipopolysaccharide - stimulated BV2 microglia via BC6OTHER suppression and BC6OTHER - dependent BC6ENTG induction.	False
The BC6OTHER activity of BC6ENTG was little inhibited by BC6ENTC in a cell - free system.	CPR:4
The BC6ENTG activity of BC6OTHER was little inhibited by BC6ENTC in a cell - free system.	CPR:4
BC6ENTC and anti - BC6ENTG (anti - BC6OTHER ) were antagonistic to each other in inhibiting the cell cycle progression of SC - 6 from G0 / G1 to S , suggesting that the two compounds share the same target , BC6OTHER .	False
BC6ENTC and anti - BC6OTHER (anti - BC6ENTG ) were antagonistic to each other in inhibiting the cell cycle progression of SC - 6 from G0 / G1 to S , suggesting that the two compounds share the same target , BC6OTHER .	False
BC6ENTC and anti - BC6OTHER (anti - BC6OTHER ) were antagonistic to each other in inhibiting the cell cycle progression of SC - 6 from G0 / G1 to S , suggesting that the two compounds share the same target , BC6ENTG .	False
Effect of BC6ENTC , an BC6OTHER antibiotic , on the function of BC6ENTG in human stomach tumor cells.	False
Effect of BC6OTHER , an BC6ENTC antibiotic , on the function of BC6ENTG in human stomach tumor cells.	False
Recent studies of hereditary renal tubular disorders have facilitated the identification and roles of BC6ENTG in the regulation of the most abundant anion , BC6ENTC , in the ECF.	False
Thus , mutations that result in a loss of function of the voltage - gated BC6ENTC channel , BC6ENTG , are associated with Dent's disease , which is characterized by low - molecular weight proteinuria , hypercalciuria , nephrolithiasis , and renal failure.	False
Mutations of another voltage - gated BC6ENTC channel , BC6ENTG , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6ENTC channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTG ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6ENTC channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6ENTG ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6ENTC channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6ENTG , BC6OTHER .	False
Mutations of another voltage - gated BC6ENTC channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6OTHER , BC6ENTG .	False
Mutations of another BC6ENTG , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6ENTG , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6ENTG ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6ENTG , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6OTHER , BC6ENTG .	False
Mutations of another BC6ENTG , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6ENTC cotransporter ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6ENTG , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6ENTC cotransporter ( BC6OTHER ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6ENTC cotransporter ( BC6ENTG ) and the BC6OTHER , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6ENTC cotransporter ( BC6OTHER ) and the BC6ENTG , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6ENTC cotransporter ( BC6OTHER ) and the BC6OTHER , BC6ENTG .	False
Mutations of another BC6ENTG , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6ENTC channel , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6ENTG , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6ENTC channel , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the BC6ENTG ( BC6OTHER ) and the BC6ENTC channel , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6ENTG ) and the BC6ENTC channel , BC6OTHER .	False
Mutations of another voltage - gated BC6OTHER channel , BC6OTHER , are associated with a form of Bartter's syndrome , whereas other forms of Bartter's syndrome are caused by mutations in the bumetanide - sensitive BC6OTHER cotransporter ( BC6OTHER ) and the BC6ENTC channel , BC6ENTG .	False
Finally , mutations of the BC6ENTC - sensitive BC6OTHER cotransporter ( BC6ENTG ) are associated with Gitelman's syndrome.	False
Finally , mutations of the CHEM - sensitive BC6ENTC cotransporter ( BC6ENTG ) are associated with Gitelman's syndrome.	False
Sepracor in the US is developing BC6OTHER [ BC6OTHER ] , a single isomer form of the BC6ENTG agonist BC6ENTC [ BC6OTHER ].	CPR:5
Sepracor in the US is developing BC6OTHER [ BC6OTHER ] , a single isomer form of the BC6ENTG agonist BC6OTHER [ BC6ENTC ].	CPR:5
Sepracor in the US is developing BC6ENTC [ BC6OTHER ] , a single isomer form of the BC6ENTG agonist BC6OTHER [ BC6OTHER ].	False
Sepracor in the US is developing BC6OTHER [ BC6ENTC ] , a single isomer form of the BC6ENTG agonist BC6OTHER [ BC6OTHER ].	False
This effect was potentiated by BC6ENTC , an inhibitor of BC6ENTG .	CPR:4
The inhibitory effects of CHEM on BC6ENTG expression were also potentiated by BC6ENTC and mimicked by BC6OTHER and d BC6OTHER but not BC6OTHER .	CPR:4
The inhibitory effects of CHEM on BC6ENTG expression were also potentiated by BC6OTHER and mimicked by BC6ENTC and d BC6OTHER but not BC6OTHER .	CPR:4
The inhibitory effects of CHEM on BC6ENTG expression were also potentiated by BC6OTHER and mimicked by BC6OTHER and d BC6ENTC but not BC6OTHER .	CPR:4
The inhibitory effects of CHEM on BC6ENTG expression were also potentiated by BC6OTHER and mimicked by BC6OTHER and d BC6OTHER but not BC6ENTC .	False
These results suggest that BC6ENTC may play a role in downregulating BC6ENTG expression in monocytes , at least in part via elevation of intracellular levels of BC6OTHER .	CPR:4
These results suggest that BC6OTHER may play a role in downregulating BC6ENTG expression in monocytes , at least in part via elevation of intracellular levels of BC6ENTC .	CPR:4
The present studies were undertaken to determine whether stable analogues of BC6ENTC , a potent endothelium - derived platelet inhibitor and vasodilator , could inhibit BC6ENTG expression by human monocytic cells.	CPR:4
Preincubation for 30 minutes with BC6ENTC , BC6OTHER , and BC6OTHER led to a dose - dependent inhibition of BC6ENTG expression induced by all three challenging agents.	CPR:4
Preincubation for 30 minutes with BC6OTHER , BC6ENTC , and BC6OTHER led to a dose - dependent inhibition of BC6ENTG expression induced by all three challenging agents.	CPR:4
Preincubation for 30 minutes with BC6OTHER , BC6OTHER , and BC6ENTC led to a dose - dependent inhibition of BC6ENTG expression induced by all three challenging agents.	CPR:4
BC6ENTC was the most potent: 50% inhibition occurred at 5 nM , a concentration close to the reported dissociation constant for BC6OTHER binding to the platelet BC6ENTG .	False
BC6OTHER was the most potent: 50% inhibition occurred at 5 nM , a concentration close to the reported dissociation constant for BC6ENTC binding to the platelet BC6ENTG .	False
An orally active analogue , BC6ENTC , was equally effective against endotoxin - induced BC6ENTG expression.	False
 BC6ENTC analogues inhibit BC6ENTG expression in the human monocytic cell line THP - 1 via a BC6OTHER - dependent mechanism.	CPR:4
 BC6OTHER analogues inhibit BC6ENTG expression in the human monocytic cell line THP - 1 via a BC6ENTC - dependent mechanism.	False
Blockade of BC6ENTC transporters , especially the BC6ENTG ( BC6OTHER ) in the prefrontal cortex (PFC) , may contribute to pharmacological improvement of impulsivity in these mice.	False
Blockade of BC6ENTC transporters , especially the BC6OTHER ( BC6ENTG ) in the prefrontal cortex (PFC) , may contribute to pharmacological improvement of impulsivity in these mice.	False
Blockade of BC6ENTG , especially the BC6ENTC transporter ( BC6OTHER ) in the prefrontal cortex (PFC) , may contribute to pharmacological improvement of impulsivity in these mice.	False
Blockade of BC6OTHER , especially the BC6ENTC transporter ( BC6ENTG ) in the prefrontal cortex (PFC) , may contribute to pharmacological improvement of impulsivity in these mice.	False
BC6ENTC transporter knockout ( BC6ENTG - KO) mice display features of ADHD and are candidates in which to test other impulsive phenotypes.	False
Treatment with BC6ENTC or BC6OTHER ameliorated CAR impairments in BC6ENTG - KO mice.	False
Treatment with BC6OTHER or BC6ENTC ameliorated CAR impairments in BC6ENTG - KO mice.	False
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6OTHER into BC6OTHER in the presence of BC6ENTC , facilitating the entry of BC6OTHER into mitochondria.	False
BC6OTHER ( BC6ENTG ) catalyses the conversion of BC6OTHER into BC6OTHER in the presence of BC6ENTC , facilitating the entry of BC6OTHER into mitochondria.	False
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6OTHER into BC6OTHER in the presence of BC6OTHER , facilitating the entry of BC6ENTC into mitochondria.	False
BC6OTHER ( BC6ENTG ) catalyses the conversion of BC6OTHER into BC6OTHER in the presence of BC6OTHER , facilitating the entry of BC6ENTC into mitochondria.	False
We propose a CHEM (three - dimensional) structural model for BC6ENTG ( BC6OTHER ) , based on the similarity of this enzyme to the recently crystallized mouse BC6ENTC acetyltransferase.	False
We propose a CHEM (three - dimensional) structural model for BC6OTHER ( BC6ENTG ) , based on the similarity of this enzyme to the recently crystallized mouse BC6ENTC acetyltransferase.	False
The model includes 607 of the 773 BC6ENTC of BC6ENTG , and the positions of BC6OTHER , BC6OTHER and the BC6OTHER group were assigned by superposition and docking analysis.	False
The model includes 607 of the 773 BC6OTHER of BC6ENTG , and the positions of BC6ENTC , BC6OTHER and the BC6OTHER group were assigned by superposition and docking analysis.	False
The model includes 607 of the 773 BC6OTHER of BC6ENTG , and the positions of BC6OTHER , BC6ENTC and the BC6OTHER group were assigned by superposition and docking analysis.	False
The model includes 607 of the 773 BC6OTHER of BC6ENTG , and the positions of BC6OTHER , BC6OTHER and the BC6ENTC group were assigned by superposition and docking analysis.	False
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6ENTC into BC6OTHER in the presence of BC6OTHER , facilitating the entry of BC6OTHER into mitochondria.	CPR:9
BC6OTHER ( BC6ENTG ) catalyses the conversion of BC6ENTC into BC6OTHER in the presence of BC6OTHER , facilitating the entry of BC6OTHER into mitochondria.	CPR:9
BC6ENTG ( BC6ENTC palmitoyltransferase I) catalyses the conversion of BC6OTHER into BC6OTHER in the presence of BC6OTHER , facilitating the entry of BC6OTHER into mitochondria.	False
In addition , individual mutation of BC6ENTC forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6ENTG and BC6OTHER A and altered K(m) and the catalytic efficiency for BC6OTHER in mutant BC6OTHER .	False
In addition , individual mutation of BC6ENTC forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6OTHER and BC6ENTG A and altered K(m) and the catalytic efficiency for BC6OTHER in mutant BC6OTHER .	False
In addition , individual mutation of BC6ENTC forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6OTHER and BC6OTHER A and altered K(m) and the catalytic efficiency for BC6OTHER in mutant BC6ENTG .	False
BC6ENTG ( BC6OTHER ) catalyses the conversion of BC6OTHER into BC6ENTC in the presence of BC6OTHER , facilitating the entry of BC6OTHER into mitochondria.	CPR:9
BC6OTHER ( BC6ENTG ) catalyses the conversion of BC6OTHER into BC6ENTC in the presence of BC6OTHER , facilitating the entry of BC6OTHER into mitochondria.	CPR:9
In addition , individual mutation of BC6OTHER forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6ENTG and BC6OTHER A and altered K(m) and the catalytic efficiency for BC6ENTC in mutant BC6OTHER .	False
In addition , individual mutation of BC6OTHER forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6OTHER and BC6ENTG A and altered K(m) and the catalytic efficiency for BC6ENTC in mutant BC6OTHER .	False
In addition , individual mutation of BC6OTHER forming the conserved CHEM685 - CHEM686 - CHEM687 motif abolished enzyme activity in mutants BC6OTHER and BC6OTHER A and altered K(m) and the catalytic efficiency for BC6ENTC in mutant BC6ENTG .	False
Structural model of BC6ENTC palmitoyltransferase I based on the BC6ENTG crystal.	False
Structural model of BC6ENTG based on the BC6ENTC acetyltransferase crystal.	False
Ka values for BC6ENTC and BC6OTHER , drugs distinguishing the CHEM from the BC6ENTG subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6OTHER subtype mediates BC6OTHER - induced relaxation in rat arteries.	False
Ka values for BC6ENTC and BC6OTHER , drugs distinguishing the CHEM from the BC6OTHER subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6ENTG subtype mediates BC6OTHER - induced relaxation in rat arteries.	False
Ka values for BC6OTHER and BC6ENTC , drugs distinguishing the CHEM from the BC6ENTG subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6OTHER subtype mediates BC6OTHER - induced relaxation in rat arteries.	False
Ka values for BC6OTHER and BC6ENTC , drugs distinguishing the CHEM from the BC6OTHER subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6ENTG subtype mediates BC6OTHER - induced relaxation in rat arteries.	False
Ka values for BC6OTHER and BC6OTHER , drugs distinguishing the CHEM from the BC6ENTG subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6OTHER subtype mediates BC6ENTC - induced relaxation in rat arteries.	False
Ka values for BC6OTHER and BC6OTHER , drugs distinguishing the CHEM from the BC6OTHER subtype , were significantly higher in blocking relaxation of rat arteries compared with pig arteries , suggesting the BC6ENTG subtype mediates BC6ENTC - induced relaxation in rat arteries.	False
We used BC6ENTC to oppose BC6ENTG - mediated inhibition of BC6OTHER formation by directly stimulating BC6OTHER formation in endothelium.	False
We used BC6OTHER to oppose BC6ENTG - mediated inhibition of BC6ENTC formation by directly stimulating BC6OTHER formation in endothelium.	False
We used BC6OTHER to oppose BC6ENTG - mediated inhibition of BC6OTHER formation by directly stimulating BC6ENTC formation in endothelium.	False
BC6ENTC did not affect the relaxant response to BC6OTHER , suggesting that BC6OTHER is not involved in the coupling of BC6ENTG to BC6OTHER - induced vascular relaxation.	False
BC6OTHER did not affect the relaxant response to BC6ENTC , suggesting that BC6OTHER is not involved in the coupling of BC6ENTG to BC6OTHER - induced vascular relaxation.	False
BC6OTHER did not affect the relaxant response to BC6OTHER , suggesting that BC6ENTC is not involved in the coupling of BC6ENTG to BC6OTHER - induced vascular relaxation.	False
BC6OTHER did not affect the relaxant response to BC6OTHER , suggesting that BC6OTHER is not involved in the coupling of BC6ENTG to BC6ENTC - induced vascular relaxation.	False
Ka values in nM for BC6ENTC (19) , BC6OTHER (265) , BC6OTHER (197) , BC6OTHER (128) , and BC6OTHER (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the BC6ENTG subtype.	False
Ka values in nM for BC6OTHER (19) , BC6ENTC (265) , BC6OTHER (197) , BC6OTHER (128) , and BC6OTHER (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the BC6ENTG subtype.	False
Ka values in nM for BC6OTHER (19) , BC6OTHER (265) , BC6ENTC (197) , BC6OTHER (128) , and BC6OTHER (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the BC6ENTG subtype.	False
Ka values in nM for BC6OTHER (19) , BC6OTHER (265) , BC6OTHER (197) , BC6ENTC (128) , and BC6OTHER (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the BC6ENTG subtype.	False
Ka values in nM for BC6OTHER (19) , BC6OTHER (265) , BC6OTHER (197) , BC6OTHER (128) , and BC6ENTC (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the BC6ENTG subtype.	False
 BC6ENTG subtype causing BC6ENTC - mediated vascular relaxation in rats.	False
BC6ENTC H4 receptor ( BC6ENTG ) perturbation has previously been shown to modify acute inflammation and BC6OTHER production in a murine model of asthma.	False
BC6ENTC H4 receptor ( BC6OTHER ) perturbation has previously been shown to modify acute inflammation and BC6ENTG production in a murine model of asthma.	False
After inflammation was established mice were dosed with the BC6ENTG antagonist , BC6ENTC , or anti - BC6OTHER antibody for comparison.	CPR:6
After inflammation was established mice were dosed with the BC6OTHER antagonist , BC6ENTC , or anti - BC6ENTG antibody for comparison.	False
 BC6ENTC H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of BC6ENTG .	False
BC6ENTC ( BC6OTHER ) is a specific antifolate - based BC6ENTG inhibitor active in a variety of solid tumor malignancies.	CPR:4
The studies with dThyd rescue from BC6ENTG - BC6OTHER protein overexpression and growth inhibition by BC6ENTC indicate that increased BC6OTHER - BC6OTHER protein expression is associated with effective inhibition of BC6OTHER and resultant CHEM pool imbalance.	CPR:4
The studies with dThyd rescue from BC6OTHER - BC6ENTG protein overexpression and growth inhibition by BC6ENTC indicate that increased BC6OTHER - BC6OTHER protein expression is associated with effective inhibition of BC6OTHER and resultant CHEM pool imbalance.	CPR:4
The studies with dThyd rescue from BC6OTHER - BC6OTHER protein overexpression and growth inhibition by BC6ENTC indicate that increased BC6ENTG - BC6OTHER protein expression is associated with effective inhibition of BC6OTHER and resultant CHEM pool imbalance.	CPR:3
The studies with dThyd rescue from BC6OTHER - BC6OTHER protein overexpression and growth inhibition by BC6ENTC indicate that increased BC6OTHER - BC6ENTG protein expression is associated with effective inhibition of BC6OTHER and resultant CHEM pool imbalance.	CPR:3
The studies with dThyd rescue from BC6OTHER - BC6OTHER protein overexpression and growth inhibition by BC6ENTC indicate that increased BC6OTHER - BC6OTHER protein expression is associated with effective inhibition of BC6ENTG and resultant CHEM pool imbalance.	CPR:4
The studies with dThyd rescue from BC6ENTG - BC6OTHER protein overexpression and growth inhibition by BC6OTHER indicate that increased BC6OTHER - BC6OTHER protein expression is associated with effective inhibition of BC6ENTC synthase and resultant CHEM pool imbalance.	False
The studies with dThyd rescue from BC6OTHER - BC6ENTG protein overexpression and growth inhibition by BC6OTHER indicate that increased BC6OTHER - BC6OTHER protein expression is associated with effective inhibition of BC6ENTC synthase and resultant CHEM pool imbalance.	False
The studies with dThyd rescue from BC6OTHER - BC6OTHER protein overexpression and growth inhibition by BC6OTHER indicate that increased BC6ENTG - BC6OTHER protein expression is associated with effective inhibition of BC6ENTC synthase and resultant CHEM pool imbalance.	False
The studies with dThyd rescue from BC6OTHER - BC6OTHER protein overexpression and growth inhibition by BC6OTHER indicate that increased BC6OTHER - BC6ENTG protein expression is associated with effective inhibition of BC6ENTC synthase and resultant CHEM pool imbalance.	False
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6ENTC synthase by BC6OTHER and kilobase DNA fragmentation may correlate with the reduction of BC6ENTG expression and the increase in BC6OTHER and BC6OTHER BC6OTHER activities.	False
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6ENTC synthase by BC6OTHER and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6ENTG and BC6OTHER BC6OTHER activities.	False
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6ENTC synthase by BC6OTHER and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6OTHER and BC6ENTG BC6OTHER activities.	False
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6ENTC synthase by BC6OTHER and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6OTHER and BC6OTHER BC6ENTG activities.	False
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6ENTG by BC6ENTC and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6OTHER and BC6OTHER BC6OTHER activities.	CPR:4
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6OTHER by BC6ENTC and kilobase DNA fragmentation may correlate with the reduction of BC6ENTG expression and the increase in BC6OTHER and BC6OTHER BC6OTHER activities.	CPR:4
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6OTHER by BC6ENTC and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6ENTG and BC6OTHER BC6OTHER activities.	CPR:3
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6OTHER by BC6ENTC and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6OTHER and BC6ENTG BC6OTHER activities.	CPR:3
These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of BC6OTHER by BC6ENTC and kilobase DNA fragmentation may correlate with the reduction of BC6OTHER expression and the increase in BC6OTHER and BC6OTHER BC6ENTG activities.	CPR:3
The changes in cell cycle regulatory proteins associated with growth inhibition and DNA damage by BC6ENTC are not BC6ENTG dependent.	False
Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of BC6ENTG by BC6ENTC .	CPR:4
Twenty - four hours following the initial 2 - h treatment with BC6ENTC , human A253 head and neck squamous carcinoma cells , not expressing BC6ENTG and BC6OTHER ( BC6OTHER ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2 / M phases.	False
Twenty - four hours following the initial 2 - h treatment with BC6ENTC , human A253 head and neck squamous carcinoma cells , not expressing BC6OTHER and BC6ENTG ( BC6OTHER ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2 / M phases.	False
Twenty - four hours following the initial 2 - h treatment with BC6ENTC , human A253 head and neck squamous carcinoma cells , not expressing BC6OTHER and BC6OTHER ( BC6ENTG ) , were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2 / M phases.	False
BC6ENTC treatment resulted in the decrease in BC6ENTG expression , with an increase in BC6OTHER and BC6OTHER protein expression and BC6OTHER activities 24 h after a 2 - h exposure.	CPR:4
BC6ENTC treatment resulted in the decrease in BC6OTHER expression , with an increase in BC6ENTG and BC6OTHER protein expression and BC6OTHER activities 24 h after a 2 - h exposure.	CPR:3
BC6ENTC treatment resulted in the decrease in BC6OTHER expression , with an increase in BC6OTHER and BC6ENTG protein expression and BC6OTHER activities 24 h after a 2 - h exposure.	CPR:3
BC6ENTC treatment resulted in the decrease in BC6OTHER expression , with an increase in BC6OTHER and BC6OTHER protein expression and BC6ENTG activities 24 h after a 2 - h exposure.	CPR:3
BC6OTHER ( BC6ENTC ) is a specific antifolate - based BC6ENTG inhibitor active in a variety of solid tumor malignancies.	False
 BC6ENTG - BC6OTHER activation is associated with cell cycle arrest and inhibition of DNA replication induced by the BC6ENTC synthase inhibitor BC6OTHER .	False
 BC6OTHER - BC6ENTG activation is associated with cell cycle arrest and inhibition of DNA replication induced by the BC6ENTC synthase inhibitor BC6OTHER .	False
 BC6ENTG - BC6OTHER activation is associated with cell cycle arrest and inhibition of DNA replication induced by the BC6OTHER inhibitor BC6ENTC .	False
 BC6OTHER - BC6OTHER activation is associated with cell cycle arrest and inhibition of DNA replication induced by the BC6ENTG inhibitor BC6ENTC .	CPR:4
 BC6OTHER - BC6ENTG activation is associated with cell cycle arrest and inhibition of DNA replication induced by the BC6OTHER inhibitor BC6ENTC .	False
BC6ENTC was tested in a patch clamp assay to determine its effect on selected BC6ENTG .	False
BC6ENTC also inhibited other channels including BC6ENTG , BC6OTHER , and BC6OTHER ; however , the BC6OTHER ( BC6OTHER ) channel was minimally affected.	CPR:4
BC6ENTC also inhibited other channels including BC6OTHER , BC6ENTG , and BC6OTHER ; however , the BC6OTHER ( BC6OTHER ) channel was minimally affected.	CPR:4
BC6ENTC also inhibited other channels including BC6OTHER , BC6OTHER , and BC6ENTG ; however , the BC6OTHER ( BC6OTHER ) channel was minimally affected.	CPR:4
BC6ENTC also inhibited other channels including BC6OTHER , BC6OTHER , and BC6OTHER ; however , the BC6ENTG ( BC6OTHER ) channel was minimally affected.	False
BC6ENTC also inhibited other channels including BC6OTHER , BC6OTHER , and BC6OTHER ; however , the BC6OTHER ( BC6ENTG ) channel was minimally affected.	False
The effects of BC6ENTC on human cardiomyocyte function and BC6ENTG activity.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6ENTG in OO; BC6OTHER , BC6OTHER and BC6ENTC in SO); BC6OTHER - BC6OTHER , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6ENTG , BC6OTHER and BC6ENTC in SO); BC6OTHER - BC6OTHER , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6ENTG and BC6ENTC in SO); BC6OTHER - BC6OTHER , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6ENTC in SO); BC6ENTG - BC6OTHER , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6ENTC in SO); BC6OTHER - BC6OTHER , BC6ENTG and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6ENTC in SO); BC6OTHER - BC6OTHER , BC6OTHER and BC6ENTG ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6ENTG in OO; BC6OTHER , BC6OTHER and BC6OTHER in SO); BC6OTHER - BC6ENTC , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6ENTG , BC6OTHER and BC6OTHER in SO); BC6OTHER - BC6ENTC , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6ENTG and BC6OTHER in SO); BC6OTHER - BC6ENTC , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6OTHER in SO); BC6ENTG - BC6ENTC , BC6OTHER and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6OTHER in SO); BC6OTHER - BC6ENTC , BC6ENTG and BC6OTHER ratio increased in both groups.	False
Significant changes were observed from day 0 to day 35 (P<0.05): nutritional criteria improved ( BC6OTHER in OO; BC6OTHER , BC6OTHER and BC6OTHER in SO); BC6OTHER - BC6ENTC , BC6OTHER and BC6ENTG ratio increased in both groups.	False
BC6ENTG - BC6ENTC decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6ENTC decreased in OO; BC6ENTG increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6ENTC decreased in OO; BC6OTHER increased and BC6ENTG decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6ENTC decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6ENTG increased in both groups.	False
BC6ENTG - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6ENTC / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6ENTG increased and BC6OTHER decreased in SO; BC6ENTC / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6ENTG decreased in SO; BC6ENTC / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6ENTC / BC6OTHER ratio increased in OO; BC6OTHER decreased in both groups; BC6ENTG increased in both groups.	False
BC6ENTG - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6ENTC ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6ENTG increased and BC6OTHER decreased in SO; BC6OTHER / BC6ENTC ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6ENTG decreased in SO; BC6OTHER / BC6ENTC ratio increased in OO; BC6OTHER decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6ENTC ratio increased in OO; BC6OTHER decreased in both groups; BC6ENTG increased in both groups.	False
BC6ENTG - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6ENTC decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6ENTG increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6ENTC decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6ENTG decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6ENTC decreased in both groups; BC6OTHER increased in both groups.	False
BC6OTHER - BC6OTHER decreased in OO; BC6OTHER increased and BC6OTHER decreased in SO; BC6OTHER / BC6OTHER ratio increased in OO; BC6ENTC decreased in both groups; BC6ENTG increased in both groups.	False
The between - group comparison only showed the following differences: BC6ENTC / BC6OTHER increased in OO; BC6ENTG decreased in SO.	False
The between - group comparison only showed the following differences: BC6OTHER / BC6ENTC increased in OO; BC6ENTG decreased in SO.	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6ENTC , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6ENTC , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6ENTC , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC peroxidase , BC6OTHER and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6ENTG and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6ENTG ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6ENTG - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6ENTG - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6ENTG and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6ENTG ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
On days 0 and 35 , patients' nutritional status was assessed by BMI , normalized protein catabolic rate , predialytic BC6OTHER , BC6OTHER and BC6OTHER ; lipid metabolism by plasma BC6OTHER - and BC6OTHER - BC6OTHER , BC6OTHER , CHEM , BC6OTHER and BC6OTHER ; oxidative status by BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and advanced oxidized protein products; inflammatory status by serum BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
BC6ENTC binds to the BC6OTHER site on BC6ENTG and potentiates BC6OTHER - mediated responses in both recombinant and native systems.	False
BC6ENTC binds to the BC6OTHER site on BC6OTHER and potentiates BC6ENTG - mediated responses in both recombinant and native systems.	CPR:3
BC6OTHER binds to the BC6ENTC site on BC6ENTG and potentiates BC6OTHER - mediated responses in both recombinant and native systems.	False
BC6OTHER binds to the BC6ENTC site on BC6OTHER and potentiates BC6ENTG - mediated responses in both recombinant and native systems.	False
However , BC6ENTC provides greater BC6ENTG subtype selectivity than does BC6OTHER , making it more suitable for studies of effects on BC6OTHER in CNS preparations.	False
However , BC6ENTC provides greater BC6OTHER subtype selectivity than does BC6OTHER , making it more suitable for studies of effects on BC6ENTG in CNS preparations.	False
However , BC6OTHER provides greater BC6ENTG subtype selectivity than does BC6ENTC , making it more suitable for studies of effects on BC6OTHER in CNS preparations.	False
However , BC6OTHER provides greater BC6OTHER subtype selectivity than does BC6ENTC , making it more suitable for studies of effects on BC6ENTG in CNS preparations.	False
Metabotropic BC6ENTC receptor 5 ( BC6ENTG ) is a target for the treatment of central nervous system (CNS) disorders , such as schizophrenia and Alzheimer's disease.	False
Previous work has extensively characterized a common allosteric site on BC6ENTG , termed the BC6ENTC ( BC6OTHER ) binding site.	False
Previous work has extensively characterized a common allosteric site on BC6ENTG , termed the BC6OTHER ( BC6ENTC ) binding site.	False
However , one BC6ENTG PAM , BC6ENTC ( BC6OTHER ) , interacts with a separate allosteric site on BC6OTHER .	False
However , one BC6OTHER PAM , BC6ENTC ( BC6OTHER ) , interacts with a separate allosteric site on BC6ENTG .	False
However , one BC6ENTG PAM , BC6OTHER ( BC6ENTC ) , interacts with a separate allosteric site on BC6OTHER .	False
However , one BC6OTHER PAM , BC6OTHER ( BC6ENTC ) , interacts with a separate allosteric site on BC6ENTG .	False
Using cell - based assays and brain slice preparations , we characterized the interaction of a potent and efficacious BC6ENTG PAM from the BC6ENTC series termed BC6OTHER ( BC6OTHER ).	False
Using cell - based assays and brain slice preparations , we characterized the interaction of a potent and efficacious BC6ENTG PAM from the BC6OTHER series termed BC6ENTC ( BC6OTHER ).	False
Using cell - based assays and brain slice preparations , we characterized the interaction of a potent and efficacious BC6ENTG PAM from the BC6OTHER series termed BC6OTHER ( BC6ENTC ).	False
A novel metabotropic BC6ENTC receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to BC6ENTG signaling.	False
Therefore , the objective of the present study was to investigate the effects of BC6ENTG inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6ENTG inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) on BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) on BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) on BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) on BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) on BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) on BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	False
Therefore , the objective of the present study was to investigate the effects of BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) on BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	False
Pretreatment of the splenocytes with both BC6ENTC and BC6OTHER suppressed BC6OTHER plus CHEM - induced BC6ENTG secretion in a concentration - dependent manner.	CPR:4
Pretreatment of the splenocytes with both BC6OTHER and BC6ENTC suppressed BC6OTHER plus CHEM - induced BC6ENTG secretion in a concentration - dependent manner.	CPR:4
Pretreatment of the splenocytes with both BC6OTHER and BC6OTHER suppressed BC6ENTC plus CHEM - induced BC6ENTG secretion in a concentration - dependent manner.	CPR:3
Inhibition > 90% of BC6ENTG secretion was observed at 1 microM BC6ENTC and 10 microM BC6OTHER compared to the respective vehicle control.	CPR:4
Inhibition > 90% of BC6ENTG secretion was observed at 1 microM BC6OTHER and 10 microM BC6ENTC compared to the respective vehicle control.	CPR:4
Likewise , BC6ENTG steady - state mRNA expression was inhibited by both BC6OTHER inhibitors in a concentration - dependent fashion with > 90% inhibition at 1 microM BC6ENTC and 20 microM BC6OTHER .	CPR:4
Likewise , BC6OTHER steady - state mRNA expression was inhibited by both BC6ENTG inhibitors in a concentration - dependent fashion with > 90% inhibition at 1 microM BC6ENTC and 20 microM BC6OTHER .	CPR:4
Likewise , BC6ENTG steady - state mRNA expression was inhibited by both BC6OTHER inhibitors in a concentration - dependent fashion with > 90% inhibition at 1 microM BC6OTHER and 20 microM BC6ENTC .	CPR:4
Likewise , BC6OTHER steady - state mRNA expression was inhibited by both BC6ENTG inhibitors in a concentration - dependent fashion with > 90% inhibition at 1 microM BC6OTHER and 20 microM BC6ENTC .	CPR:4
Taken together , these data demonstrated that BC6ENTG inhibitors BC6ENTC and BC6OTHER are robust inhibitors of BC6OTHER expression at both the mRNA and protein levels in murine splenocytes.	CPR:4
Taken together , these data demonstrated that BC6OTHER inhibitors BC6ENTC and BC6OTHER are robust inhibitors of BC6ENTG expression at both the mRNA and protein levels in murine splenocytes.	CPR:4
Taken together , these data demonstrated that BC6ENTG inhibitors BC6OTHER and BC6ENTC are robust inhibitors of BC6OTHER expression at both the mRNA and protein levels in murine splenocytes.	CPR:4
Taken together , these data demonstrated that BC6OTHER inhibitors BC6OTHER and BC6ENTC are robust inhibitors of BC6ENTG expression at both the mRNA and protein levels in murine splenocytes.	CPR:4
 BC6ENTG inhibitors BC6ENTC and BC6OTHER suppressed BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:3
 BC6OTHER inhibitors BC6ENTC and BC6OTHER suppressed BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
 BC6OTHER inhibitors BC6ENTC and BC6OTHER suppressed BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	CPR:4
 BC6ENTG inhibitors BC6OTHER and BC6ENTC suppressed BC6OTHER ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
 BC6OTHER inhibitors BC6OTHER and BC6ENTC suppressed BC6ENTG ( BC6OTHER ) expression in murine primary splenocytes.	CPR:4
 BC6OTHER inhibitors BC6OTHER and BC6ENTC suppressed BC6OTHER ( BC6ENTG ) expression in murine primary splenocytes.	CPR:4
Pretreatment of rats with BC6ENTC ( BC6OTHER ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6ENTC ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6ENTC or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6OTHER or BC6ENTC ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6ENTC and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6ENTC , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6ENTC - oxidized BC6OTHER was without effect.	False
Pretreatment of rats with BC6OTHER ( BC6OTHER ) depletors ( BC6OTHER or BC6OTHER ) delayed the elimination of BC6OTHER and the accumulation of RBC - bound BC6OTHER , whereas the indirect BC6ENTG inhibitor BC6OTHER - oxidized BC6ENTC was without effect.	CPR:4
Although BC6ENTG ( BC6OTHER ) inhibitors ( BC6ENTC and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	CPR:4
Although BC6OTHER ( BC6ENTG ) inhibitors ( BC6ENTC and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	CPR:4
Although BC6OTHER ( BC6OTHER ) inhibitors ( BC6ENTC and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6ENTG plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER and BC6ENTC ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	CPR:4
Although BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER and BC6ENTC ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	CPR:4
Although BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER and BC6ENTC ) inhibited cytosolic BC6OTHER reduction , recombinant BC6ENTG plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6ENTC reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6ENTC reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6ENTC reduction , recombinant BC6ENTG plus BC6OTHER , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6ENTC , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6ENTC , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6ENTG plus BC6ENTC , alone or when added to the cytosol , failed to support BC6OTHER reduction.	False
Although BC6ENTG ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6ENTC reduction.	False
Although BC6OTHER ( BC6ENTG ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6OTHER plus BC6OTHER , alone or when added to the cytosol , failed to support BC6ENTC reduction.	False
Although BC6OTHER ( BC6OTHER ) inhibitors ( BC6OTHER and BC6OTHER ) inhibited cytosolic BC6OTHER reduction , recombinant BC6ENTG plus BC6OTHER , alone or when added to the cytosol , failed to support BC6ENTC reduction.	False
Although BC6ENTC BC6OTHER - transferase omega 1 ( BC6ENTG ) and BC6OTHER have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although BC6ENTC BC6OTHER - transferase omega 1 ( BC6OTHER ) and BC6ENTG have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6ENTC - transferase omega 1 ( BC6ENTG ) and BC6OTHER have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6ENTC - transferase omega 1 ( BC6OTHER ) and BC6ENTG have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although BC6ENTG ( BC6OTHER ) and BC6ENTC methyltransferase have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6OTHER - transferase omega 1 ( BC6ENTG ) and BC6ENTC methyltransferase have been shown or thought to catalyze BC6OTHER reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although BC6ENTG ( BC6OTHER ) and BC6OTHER have been shown or thought to catalyze BC6ENTC reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	CPR:9
Although CHEM BC6OTHER - transferase omega 1 ( BC6ENTG ) and BC6OTHER have been shown or thought to catalyze BC6ENTC reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6OTHER - transferase omega 1 ( BC6OTHER ) and BC6ENTG have been shown or thought to catalyze BC6ENTC reduction , their role in BC6OTHER reduction in vivo , or in cell extracts is uncertain.	CPR:9
Although BC6ENTG ( BC6OTHER ) and BC6OTHER have been shown or thought to catalyze BC6OTHER reduction , their role in BC6ENTC reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6OTHER - transferase omega 1 ( BC6ENTG ) and BC6OTHER have been shown or thought to catalyze BC6OTHER reduction , their role in BC6ENTC reduction in vivo , or in cell extracts is uncertain.	False
Although CHEM BC6OTHER - transferase omega 1 ( BC6OTHER ) and BC6ENTG have been shown or thought to catalyze BC6OTHER reduction , their role in BC6ENTC reduction in vivo , or in cell extracts is uncertain.	False
The interaction of BC6ENTC ( BC6OTHER ) with various BC6ENTG types was studied in vitro.	False
The interaction of BC6OTHER ( BC6ENTC ) with various BC6ENTG types was studied in vitro.	False
A BC6ENTC with selective and long - acting CHEM antagonism at BC6ENTG in vitro.	CPR:6
In animals , the BC6ENTC causes a significant reduction in intraocular pressure but had only 1 / 80 the activity of the CHEM at BC6ENTG .	False
The BC6ENTG blocking properties of orally administered BC6ENTC were compared in a double - blind placebo controlled trial in two groups of healthy men.	False
A dose of 25 microg kg( - 1) day( - 1) of BC6ENTC elicited greater EDL and soleus hypertrophy than BC6OTHER , but resulted in similar BC6ENTG downregulation.	CPR:4
A dose of 25 microg kg( - 1) day( - 1) of BC6OTHER elicited greater EDL and soleus hypertrophy than BC6ENTC , but resulted in similar BC6ENTG downregulation.	CPR:4
Two beta(2) - agonists , BC6ENTC and BC6OTHER , are approved for treating asthma and have an extended duration of action and increased safety , associated with greater BC6ENTG selectivity.	CPR:5
Two beta(2) - agonists , BC6OTHER and BC6ENTC , are approved for treating asthma and have an extended duration of action and increased safety , associated with greater BC6ENTG selectivity.	CPR:5
Systemic administration of BC6ENTG agonists , BC6ENTC and BC6OTHER , elicit skeletal muscle hypertrophy in rats at micromolar doses.	CPR:5
Systemic administration of BC6ENTG agonists , BC6OTHER and BC6ENTC , elicit skeletal muscle hypertrophy in rats at micromolar doses.	CPR:5
Although no comparisons have been made between BC6ENTC and other BC6ENTG analogues , this drug has been shown to have efficacy in the control of acute variceal bleeding as well as reducing the risk of recurrent bleeding and death , especially when started prior to endoscopy.	False
 BC6ENTC : a BC6ENTG analog for the treatment of acute variceal bleeding.	False
Two BC6ENTC transporters ( BC6ENTG and BC6OTHER ) mRNA and protein expression were also studied under hypoxia.	False
Two BC6ENTC transporters ( BC6OTHER and BC6ENTG ) mRNA and protein expression were also studied under hypoxia.	False
We previously reported that the enzyme BC6ENTC dehydrogenase ( BC6ENTG ) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM , Zheng J , Xu F , Kay HH.	False
Of the two BC6ENTC transporters studied , BC6ENTG mRNA and protein level are increased under hypoxia.	False
Differential expression of BC6ENTC dehydrogenase isozymes ( BC6ENTG ) in human placenta with high expression of BC6OTHER isozyme in the endothelial cells of pre - eclampsia villi.	False
Differential expression of BC6ENTC dehydrogenase isozymes ( BC6OTHER ) in human placenta with high expression of BC6ENTG isozyme in the endothelial cells of pre - eclampsia villi.	False
BC6ENTG is responsible for BC6ENTC conversion to BC6OTHER through glycolysis.	CPR:9
BC6ENTG is responsible for BC6OTHER conversion to BC6ENTC through glycolysis.	CPR:9
In this study , we further investigated the role of hypoxia in primary trophoblast cells and a cultured cell line , JEG3 cells , to obtain a better understanding of how it affects the activities of BC6ENTG , BC6ENTC production and regulatory genes , as a possible model for preeclampsia.	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6ENTC and BC6OTHER staining , Th1 / Th2 , BC6ENTG - specific serum , and BALF BC6OTHER levels and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6ENTC and BC6OTHER staining , Th1 / Th2 , BC6OTHER - specific serum , and BALF BC6ENTG levels and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6ENTC and BC6OTHER staining , Th1 / Th2 , BC6OTHER - specific serum , and BALF BC6OTHER levels and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6OTHER and BC6ENTC staining , Th1 / Th2 , BC6ENTG - specific serum , and BALF BC6OTHER levels and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6OTHER and BC6ENTC staining , Th1 / Th2 , BC6OTHER - specific serum , and BALF BC6ENTG levels and Th17 BC6OTHER were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
Airway resistance (RI) and lung compliance (Cdyn) were measured , histological studies were evaluated by the BC6OTHER and BC6ENTC staining , Th1 / Th2 , BC6OTHER - specific serum , and BALF BC6OTHER levels and Th17 BC6ENTG were evaluated by enzyme - linked immunosorbent assay , and Th17 cells was evaluated by flow cytometry (FCM).	False
BC6ENTC ( BC6OTHER ) is a novel BC6OTHER - containing antibiotic that inhibits BC6ENTG , and that has been in development for the treatment of serious Gram - negative infections.	CPR:4
BC6OTHER ( BC6OTHER ) is a novel BC6ENTC - containing antibiotic that inhibits BC6ENTG , and that has been in development for the treatment of serious Gram - negative infections.	False
A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor BC6ENTC provided strong evidence that BC6ENTG , potentially in association with BC6OTHER , is the primary enzyme involved in the formation of the M3 metabolite.	CPR:4
A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor BC6ENTC provided strong evidence that BC6OTHER , potentially in association with BC6ENTG , is the primary enzyme involved in the formation of the M3 metabolite.	False
A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor BC6OTHER provided strong evidence that BC6ENTC dehydrogenase , potentially in association with BC6ENTG , is the primary enzyme involved in the formation of the M3 metabolite.	False
A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor BC6OTHER provided strong evidence that BC6ENTG , potentially in association with BC6ENTC dehydrogenase , is the primary enzyme involved in the formation of the M3 metabolite.	False
BC6OTHER ( BC6ENTC ) is a novel BC6OTHER - containing antibiotic that inhibits BC6ENTG , and that has been in development for the treatment of serious Gram - negative infections.	CPR:4
BC6OTHER abolished the inhibitory effect of BC6ENTC on BC6ENTG and BC6OTHER .	CPR:4
BC6OTHER abolished the inhibitory effect of BC6ENTC on BC6OTHER and BC6ENTG .	CPR:4
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6OTHER ) E1 , E2 and I2 inhibit BC6ENTG ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6ENTC .	False
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6OTHER ) E1 , E2 and I2 inhibit BC6OTHER ( BC6ENTG ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6ENTC .	False
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6OTHER ) E1 , E2 and I2 inhibit BC6OTHER ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6ENTG in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6ENTC .	False
Previous studies by this research team proved that vasodilating BC6ENTC ( BC6OTHER ) E1 , E2 and I2 inhibit BC6ENTG ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	CPR:4
Previous studies by this research team proved that vasodilating BC6ENTC ( BC6OTHER ) E1 , E2 and I2 inhibit BC6OTHER ( BC6ENTG ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	CPR:4
Previous studies by this research team proved that vasodilating BC6ENTC ( BC6OTHER ) E1 , E2 and I2 inhibit BC6OTHER ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6ENTG in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	False
The results show that the NSAIDs used here , which reduce the activity of BC6ENTG and BC6ENTC production , activated BC6OTHER and BC6OTHER in a dose - dependent manner by a mechanism of the noncompetitive type.	False
The results show that the NSAIDs used here , which reduce the activity of BC6OTHER and BC6ENTC production , activated BC6ENTG and BC6OTHER in a dose - dependent manner by a mechanism of the noncompetitive type.	False
The results show that the NSAIDs used here , which reduce the activity of BC6OTHER and BC6ENTC production , activated BC6OTHER and BC6ENTG in a dose - dependent manner by a mechanism of the noncompetitive type.	False
BC6ENTC and BC6OTHER added to NSAIDs amplified the activating effect of the latter on BC6ENTG .	False
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6ENTC ) E1 , E2 and I2 inhibit BC6ENTG ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	CPR:4
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6ENTC ) E1 , E2 and I2 inhibit BC6OTHER ( BC6ENTG ) in vitro and in vivo , which suggested involvement of BC6OTHER in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	CPR:4
Previous studies by this research team proved that vasodilating BC6OTHER ( BC6ENTC ) E1 , E2 and I2 inhibit BC6OTHER ( BC6OTHER ) in vitro and in vivo , which suggested involvement of BC6ENTG in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of BC6OTHER .	False
BC6OTHER and BC6ENTC added to NSAIDs amplified the activating effect of the latter on BC6ENTG .	CPR:3
Association of CHEM or BC6ENTC to NSAIDs reduced NSAID - induced activation of BC6ENTG and BC6OTHER .	CPR:4
Association of CHEM or BC6ENTC to NSAIDs reduced NSAID - induced activation of BC6OTHER and BC6ENTG .	CPR:4
BC6ENTC abolished the inhibitory effect of BC6OTHER on BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC abolished the inhibitory effect of BC6OTHER on BC6OTHER and BC6ENTG .	CPR:3
In fact , while elimination of testicular BC6OTHER by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6ENTC ( BC6ENTG ) agonist) with a pure anti - BC6OTHER has been the first treatment shown to prolong life.	False
In fact , while elimination of testicular BC6OTHER by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6ENTG ( BC6ENTC ) agonist) with a pure anti - BC6OTHER has been the first treatment shown to prolong life.	False
In fact , while elimination of testicular BC6OTHER by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6ENTG ( BC6OTHER ) agonist) with a pure anti - BC6ENTC has been the first treatment shown to prolong life.	False
In fact , while elimination of testicular BC6OTHER by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6OTHER ( BC6ENTG ) agonist) with a pure anti - BC6ENTC has been the first treatment shown to prolong life.	False
While the role of BC6ENTC was believed to have become non - significant in cancer progressing under any form of BC6OTHER blockade , recent data have shown increased expression of the BC6ENTG ( BC6OTHER ) in treatment - resistant disease with a benefit of further BC6OTHER blockade.	False
While the role of BC6ENTC was believed to have become non - significant in cancer progressing under any form of BC6OTHER blockade , recent data have shown increased expression of the BC6OTHER ( BC6ENTG ) in treatment - resistant disease with a benefit of further BC6OTHER blockade.	False
While the role of BC6OTHER was believed to have become non - significant in cancer progressing under any form of BC6ENTC blockade , recent data have shown increased expression of the BC6ENTG ( BC6OTHER ) in treatment - resistant disease with a benefit of further BC6OTHER blockade.	False
While the role of BC6OTHER was believed to have become non - significant in cancer progressing under any form of BC6ENTC blockade , recent data have shown increased expression of the BC6OTHER ( BC6ENTG ) in treatment - resistant disease with a benefit of further BC6OTHER blockade.	False
While the role of BC6OTHER was believed to have become non - significant in cancer progressing under any form of BC6OTHER blockade , recent data have shown increased expression of the BC6ENTC receptor ( BC6ENTG ) in treatment - resistant disease with a benefit of further BC6OTHER blockade.	False
While the role of BC6OTHER was believed to have become non - significant in cancer progressing under any form of BC6OTHER blockade , recent data have shown increased expression of the BC6ENTG ( BC6OTHER ) in treatment - resistant disease with a benefit of further BC6ENTC blockade.	False
While the role of BC6OTHER was believed to have become non - significant in cancer progressing under any form of BC6OTHER blockade , recent data have shown increased expression of the BC6OTHER ( BC6ENTG ) in treatment - resistant disease with a benefit of further BC6ENTC blockade.	False
Since the available anti - BC6ENTC have low affinity for BC6ENTG and cannot block BC6OTHER action completely , especially in the presence of increased BC6OTHER levels , it becomes important to discover more potent and purely antagonistic blockers of BC6OTHER .	False
Since the available anti - BC6ENTC have low affinity for BC6OTHER and cannot block BC6OTHER action completely , especially in the presence of increased BC6ENTG levels , it becomes important to discover more potent and purely antagonistic blockers of BC6OTHER .	False
Since the available anti - BC6ENTC have low affinity for BC6OTHER and cannot block BC6OTHER action completely , especially in the presence of increased BC6OTHER levels , it becomes important to discover more potent and purely antagonistic blockers of BC6ENTG .	False
Since the available anti - BC6OTHER have low affinity for BC6ENTG and cannot block BC6ENTC action completely , especially in the presence of increased BC6OTHER levels , it becomes important to discover more potent and purely antagonistic blockers of BC6OTHER .	False
Since the available anti - BC6OTHER have low affinity for BC6OTHER and cannot block BC6ENTC action completely , especially in the presence of increased BC6ENTG levels , it becomes important to discover more potent and purely antagonistic blockers of BC6OTHER .	False
Since the available anti - BC6OTHER have low affinity for BC6OTHER and cannot block BC6ENTC action completely , especially in the presence of increased BC6OTHER levels , it becomes important to discover more potent and purely antagonistic blockers of BC6ENTG .	False
In fact , while elimination of testicular BC6ENTC by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6ENTG ( BC6OTHER ) agonist) with a pure anti - BC6OTHER has been the first treatment shown to prolong life.	False
In fact , while elimination of testicular BC6ENTC by castration alone has never been shown to prolong life in metastatic prostate cancer , combination of castration (surgical or medical with a BC6OTHER ( BC6ENTG ) agonist) with a pure anti - BC6OTHER has been the first treatment shown to prolong life.	False
The BC6ENTG antagonist CHEM and the BC6OTHER antagonist BC6ENTC enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6ENTG antagonist BC6ENTC enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	CPR:6
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6ENTC enhanced BC6OTHER - induced hyperglycemia , while the BC6ENTG antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6ENTC enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6ENTG antagonist BC6OTHER did not affect it.	False
The BC6ENTG antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6ENTC - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6ENTG antagonist BC6OTHER enhanced BC6ENTC - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6ENTC - induced hyperglycemia , while the BC6ENTG antagonist BC6OTHER and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6ENTC - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6ENTG antagonist BC6OTHER did not affect it.	False
The BC6ENTG antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6ENTC and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6ENTG antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6ENTC and the BC6OTHER antagonist BC6OTHER did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6ENTG antagonist BC6ENTC and the BC6OTHER antagonist BC6OTHER did not affect it.	CPR:6
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6ENTC and the BC6ENTG antagonist BC6OTHER did not affect it.	False
The BC6ENTG antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6ENTC did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6ENTG antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6OTHER antagonist BC6ENTC did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6ENTG antagonist BC6OTHER and the BC6OTHER antagonist BC6ENTC did not affect it.	False
The BC6OTHER antagonist CHEM and the BC6OTHER antagonist BC6OTHER enhanced BC6OTHER - induced hyperglycemia , while the BC6OTHER antagonist BC6OTHER and the BC6ENTG antagonist BC6ENTC did not affect it.	CPR:6
The BC6ENTG antagonist BC6ENTC facilitated hyperglycemia induced by BC6OTHER , although the BC6OTHER - receptor antagonist BC6OTHER was without effect.	CPR:6
The BC6OTHER antagonist BC6ENTC facilitated hyperglycemia induced by BC6OTHER , although the BC6ENTG - receptor antagonist BC6OTHER was without effect.	False
The BC6ENTG antagonist BC6OTHER facilitated hyperglycemia induced by BC6ENTC , although the BC6OTHER - receptor antagonist BC6OTHER was without effect.	False
The BC6OTHER antagonist BC6OTHER facilitated hyperglycemia induced by BC6ENTC , although the BC6ENTG - receptor antagonist BC6OTHER was without effect.	False
The BC6ENTG antagonist BC6OTHER facilitated hyperglycemia induced by BC6OTHER , although the BC6OTHER - receptor antagonist BC6ENTC was without effect.	False
The BC6OTHER antagonist BC6OTHER facilitated hyperglycemia induced by BC6OTHER , although the BC6ENTG - receptor antagonist BC6ENTC was without effect.	CPR:6
These results suggest that BC6ENTC induces hyperglycemia in mice by blocking the BC6ENTG and / or BC6OTHER receptors , which results in facilitation of BC6OTHER release.	CPR:4
These results suggest that BC6ENTC induces hyperglycemia in mice by blocking the BC6OTHER and / or BC6ENTG receptors , which results in facilitation of BC6OTHER release.	CPR:4
These results suggest that BC6OTHER induces hyperglycemia in mice by blocking the BC6ENTG and / or BC6OTHER receptors , which results in facilitation of BC6ENTC release.	False
These results suggest that BC6OTHER induces hyperglycemia in mice by blocking the BC6OTHER and / or BC6ENTG receptors , which results in facilitation of BC6ENTC release.	False
BC6OTHER and BC6ENTC have similar affinities for 60 - kDa BC6ENTG isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6OTHER BC6OTHER blockers.	False
BC6OTHER and BC6ENTC have similar affinities for 60 - kDa BC6OTHER isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6OTHER BC6ENTG blockers.	False
BC6OTHER and BC6OTHER have similar affinities for 60 - kDa BC6ENTG isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6ENTC BC6OTHER blockers.	CPR:4
BC6OTHER and BC6OTHER have similar affinities for 60 - kDa BC6OTHER isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6ENTC BC6ENTG blockers.	CPR:4
BC6OTHER and BC6OTHER have similar affinities for 60 - kDa BC6ENTG isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6OTHER BC6ENTC - channel blockers.	False
BC6ENTG ( BC6OTHER ) is one of the key enzymes involved in the complex interaction between the cyclic BC6ENTC and BC6OTHER second - messenger systems.	False
Calmodulin - dependent cyclic BC6OTHER phosphodiesterase ( BC6ENTG ) is one of the key enzymes involved in the complex interaction between the cyclic BC6ENTC and BC6OTHER second - messenger systems.	False
BC6ENTG ( BC6OTHER ) is one of the key enzymes involved in the complex interaction between the cyclic BC6OTHER and BC6ENTC second - messenger systems.	False
Calmodulin - dependent cyclic BC6OTHER phosphodiesterase ( BC6ENTG ) is one of the key enzymes involved in the complex interaction between the cyclic BC6OTHER and BC6ENTC second - messenger systems.	False
Calmodulin - dependent cyclic BC6ENTC phosphodiesterase ( BC6ENTG ) is one of the key enzymes involved in the complex interaction between the cyclic BC6OTHER and BC6OTHER second - messenger systems.	False
A variety of pharmacological agents have been used to inhibit BC6ENTG , and this inhibition occurs mostly via BC6ENTC - dependent association with the proteins.	False
We have examined the effect of BC6ENTC BC6ENTG blockers BC6OTHER and BC6OTHER on BC6OTHER .	CPR:4
We have examined the effect of BC6ENTC BC6OTHER blockers BC6OTHER and BC6OTHER on BC6ENTG .	False
We have examined the effect of BC6OTHER BC6ENTC - channel blockers BC6OTHER and BC6OTHER on BC6ENTG .	False
We have examined the effect of BC6OTHER BC6ENTG blockers BC6ENTC and BC6OTHER on BC6OTHER .	CPR:4
We have examined the effect of BC6OTHER BC6OTHER blockers BC6ENTC and BC6OTHER on BC6ENTG .	False
We have examined the effect of BC6OTHER BC6ENTG blockers BC6OTHER and BC6ENTC on BC6OTHER .	CPR:4
We have examined the effect of BC6OTHER BC6OTHER blockers BC6OTHER and BC6ENTC on BC6ENTG .	False
The results suggest that the 63 - kDa ( BC6ENTG ) and 60 - kDa ( BC6OTHER ) BC6OTHER isozymes are inhibited by BC6ENTC and BC6OTHER by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6ENTG ) BC6OTHER isozymes are inhibited by BC6ENTC and BC6OTHER by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6OTHER ) BC6ENTG isozymes are inhibited by BC6ENTC and BC6OTHER by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6ENTG ) and 60 - kDa ( BC6OTHER ) BC6OTHER isozymes are inhibited by BC6OTHER and BC6ENTC by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6ENTG ) BC6OTHER isozymes are inhibited by BC6OTHER and BC6ENTC by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6OTHER ) BC6ENTG isozymes are inhibited by BC6OTHER and BC6ENTC by partial competitive inhibition and that these two BC6OTHER antagonists appear to counteract each other.	CPR:4
The results suggest that the 63 - kDa ( BC6ENTG ) and 60 - kDa ( BC6OTHER ) BC6OTHER isozymes are inhibited by BC6OTHER and BC6OTHER by partial competitive inhibition and that these two BC6ENTC antagonists appear to counteract each other.	False
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6ENTG ) BC6OTHER isozymes are inhibited by BC6OTHER and BC6OTHER by partial competitive inhibition and that these two BC6ENTC antagonists appear to counteract each other.	False
The results suggest that the 63 - kDa ( BC6OTHER ) and 60 - kDa ( BC6OTHER ) BC6ENTG isozymes are inhibited by BC6OTHER and BC6OTHER by partial competitive inhibition and that these two BC6ENTC antagonists appear to counteract each other.	False
BC6ENTC and BC6OTHER have similar affinities for 60 - kDa BC6ENTG isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6OTHER BC6OTHER blockers.	False
BC6ENTC and BC6OTHER have similar affinities for 60 - kDa BC6OTHER isozymes but bring about different levels of enzyme inhibition , suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by BC6OTHER BC6ENTG blockers.	False
In BC6OTHER wild - type mice , BC6OTHER dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6OTHER at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6ENTG is involved , at least in part , with the activity of BC6ENTC .	False
In BC6ENTG wild - type mice , BC6OTHER dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6OTHER at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6OTHER is involved , at least in part , with the activity of BC6ENTC .	False
These results suggest that BC6ENTG mediates the antipsychotic effects of BC6ENTC in CAR and that the BC6OTHER - regulated BC6OTHER signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.	False
These results suggest that BC6OTHER mediates the antipsychotic effects of BC6ENTC in CAR and that the BC6ENTG - regulated BC6OTHER signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.	False
These results suggest that BC6ENTG mediates the antipsychotic effects of BC6OTHER in CAR and that the BC6OTHER - regulated BC6ENTC signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.	False
These results suggest that BC6OTHER mediates the antipsychotic effects of BC6OTHER in CAR and that the BC6ENTG - regulated BC6ENTC signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.	CPR:9
RATIONALE: Recent studies provide evidence for reduced BC6OTHER ( BC6OTHER ) as a genetic susceptibility factor as well as suggesting an association of several single BC6ENTC polymorphisms (SNPs) in BC6ENTG that are associated with an increased incidence of schizophrenia.	False
RATIONALE: Recent studies provide evidence for reduced BC6ENTG ( BC6OTHER ) as a genetic susceptibility factor as well as suggesting an association of several single BC6ENTC polymorphisms (SNPs) in BC6OTHER that are associated with an increased incidence of schizophrenia.	False
RATIONALE: Recent studies provide evidence for reduced BC6OTHER ( BC6ENTG ) as a genetic susceptibility factor as well as suggesting an association of several single BC6ENTC polymorphisms (SNPs) in BC6OTHER that are associated with an increased incidence of schizophrenia.	False
OBJECTIVES: The aim of the current study was to assess the activity of BC6ENTC , a nonsubtype - selective BC6ENTG inhibitor , in several animal models predictive of antipsychotic - like efficacy and side - effect liability and to use BC6OTHER wild - type and knockout mice to begin to understand the subtypes involved in the activity of BC6OTHER .	CPR:4
OBJECTIVES: The aim of the current study was to assess the activity of BC6ENTC , a nonsubtype - selective BC6OTHER inhibitor , in several animal models predictive of antipsychotic - like efficacy and side - effect liability and to use BC6ENTG wild - type and knockout mice to begin to understand the subtypes involved in the activity of BC6OTHER .	False
OBJECTIVES: The aim of the current study was to assess the activity of BC6OTHER , a nonsubtype - selective BC6ENTG inhibitor , in several animal models predictive of antipsychotic - like efficacy and side - effect liability and to use BC6OTHER wild - type and knockout mice to begin to understand the subtypes involved in the activity of BC6ENTC .	False
OBJECTIVES: The aim of the current study was to assess the activity of BC6OTHER , a nonsubtype - selective BC6OTHER inhibitor , in several animal models predictive of antipsychotic - like efficacy and side - effect liability and to use BC6ENTG wild - type and knockout mice to begin to understand the subtypes involved in the activity of BC6ENTC .	False
In BC6OTHER wild - type mice , BC6ENTC dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6OTHER at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6ENTG is involved , at least in part , with the activity of BC6OTHER .	False
In BC6ENTG wild - type mice , BC6ENTC dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6OTHER at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6OTHER is involved , at least in part , with the activity of BC6OTHER .	False
In BC6OTHER wild - type mice , BC6OTHER dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6ENTC at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6ENTG is involved , at least in part , with the activity of BC6OTHER .	False
In BC6ENTG wild - type mice , BC6OTHER dose - dependently suppressed CAR (ED(50) = 2.4 mg / kg); however , in knockout mice , their sensitivity to BC6ENTC at the higher doses (1.0 and 3.2 mg / kg) was reduced , resulting in a threefold shift in the ED(50) (7.3 mg / kg) , suggesting BC6OTHER is involved , at least in part , with the activity of BC6OTHER .	False
Antipsychotic profile of BC6ENTC : efficacy in rats and reduced sensitivity in mice deficient in the BC6ENTG ( BC6OTHER ) enzyme.	False
Antipsychotic profile of BC6ENTC : efficacy in rats and reduced sensitivity in mice deficient in the BC6OTHER ( BC6ENTG ) enzyme.	False
Transduction with constitutively active forms of BC6ENTG could protect against the downregulation of BC6OTHER and upregulation of cleaved - BC6OTHER that are induced by BC6ENTC treatment.	False
Transduction with constitutively active forms of BC6OTHER could protect against the downregulation of BC6ENTG and upregulation of cleaved - BC6OTHER that are induced by BC6ENTC treatment.	CPR:4
Transduction with constitutively active forms of BC6OTHER could protect against the downregulation of BC6OTHER and upregulation of cleaved - BC6ENTG that are induced by BC6ENTC treatment.	CPR:3
However , combined treatment with BC6ENTC and BC6OTHER resulted in a significant reduction in BC6ENTG and an increase in cleaved - BC6OTHER in U2OS cells.	CPR:4
However , combined treatment with BC6ENTC and BC6OTHER resulted in a significant reduction in BC6OTHER and an increase in cleaved - BC6ENTG in U2OS cells.	CPR:3
However , combined treatment with BC6OTHER and BC6ENTC resulted in a significant reduction in BC6ENTG and an increase in cleaved - BC6OTHER in U2OS cells.	CPR:4
However , combined treatment with BC6OTHER and BC6ENTC resulted in a significant reduction in BC6OTHER and an increase in cleaved - BC6ENTG in U2OS cells.	CPR:3
These studies are the first to reveal the involvement of the BC6ENTG / BC6OTHER pathway in BC6ENTC - induced apoptosis.	False
These studies are the first to reveal the involvement of the BC6OTHER / BC6ENTG pathway in BC6ENTC - induced apoptosis.	False
Furthermore , we validated the inhibition of BC6ENTG / BC6OTHER signaling following BC6ENTC treatment.	CPR:4
Furthermore , we validated the inhibition of BC6OTHER / BC6ENTG signaling following BC6ENTC treatment.	CPR:4
Western blots showed a decrease in nuclear BC6OTHER protein expression after exposure to different concentrations of BC6ENTC , while the phosphorylation of BC6ENTG was simultaneously increased.	CPR:3
Western blots showed a decrease in nuclear BC6ENTG protein expression after exposure to different concentrations of BC6ENTC , while the phosphorylation of BC6OTHER was simultaneously increased.	CPR:4
The BC6OTHER / BC6ENTG pathway is involved in BC6ENTC - induced apoptosis in cultured osteosarcoma cells.	False
The BC6ENTG / BC6OTHER pathway is involved in BC6ENTC - induced apoptosis in cultured osteosarcoma cells.	False
Despite the weak effect of these compounds at the BC6ENTG and BC6OTHER receptors , these substituted BC6ENTC do possess intrinsic activity which may contribute to their neurotoxic effects when administered at high doses.	False
Despite the weak effect of these compounds at the BC6OTHER and BC6ENTG receptors , these substituted BC6ENTC do possess intrinsic activity which may contribute to their neurotoxic effects when administered at high doses.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6OTHER ( BC6ENTC ) on BC6OTHER accumulation was studied in cells expressing either BC6ENTG or BC6OTHER receptors.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6OTHER ( BC6ENTC ) on BC6OTHER accumulation was studied in cells expressing either BC6OTHER or BC6ENTG receptors.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6OTHER ( BC6OTHER ) on BC6ENTC accumulation was studied in cells expressing either BC6ENTG or BC6OTHER receptors.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6OTHER ( BC6OTHER ) on BC6ENTC accumulation was studied in cells expressing either BC6OTHER or BC6ENTG receptors.	False
The effect of the BC6ENTC ( BC6OTHER ) and its BC6OTHER ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6ENTG or BC6OTHER receptors.	False
The effect of the BC6ENTC ( BC6OTHER ) and its BC6OTHER ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6OTHER or BC6ENTG receptors.	False
The isomers of BC6ENTC produced a concentration dependent increase in BC6OTHER ( BC6OTHER ) hydrolysis at the BC6ENTG receptors , with the BC6OTHER being more potent than the CHEM at the BC6OTHER receptor.	False
The isomers of BC6ENTC produced a concentration dependent increase in BC6OTHER ( BC6OTHER ) hydrolysis at the BC6OTHER receptors , with the BC6OTHER being more potent than the CHEM at the BC6ENTG receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6ENTC ( BC6OTHER ) hydrolysis at the BC6ENTG receptors , with the BC6OTHER being more potent than the CHEM at the BC6OTHER receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6ENTC ( BC6OTHER ) hydrolysis at the BC6OTHER receptors , with the BC6OTHER being more potent than the CHEM at the BC6ENTG receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6OTHER ( BC6ENTC ) hydrolysis at the BC6ENTG receptors , with the BC6OTHER being more potent than the CHEM at the BC6OTHER receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6OTHER ( BC6ENTC ) hydrolysis at the BC6OTHER receptors , with the BC6OTHER being more potent than the CHEM at the BC6ENTG receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6OTHER ( BC6OTHER ) hydrolysis at the BC6ENTG receptors , with the BC6ENTC being more potent than the CHEM at the BC6OTHER receptor.	False
The isomers of BC6OTHER produced a concentration dependent increase in BC6OTHER ( BC6OTHER ) hydrolysis at the BC6OTHER receptors , with the BC6ENTC being more potent than the CHEM at the BC6ENTG receptor.	False
The BC6ENTC were significantly less efficacious at the BC6ENTG receptor as compared to BC6OTHER ; BC6OTHER had no effect.	False
The BC6OTHER were significantly less efficacious at the BC6ENTG receptor as compared to BC6ENTC ; BC6OTHER had no effect.	False
The BC6OTHER were significantly less efficacious at the BC6ENTG receptor as compared to BC6OTHER ; BC6ENTC had no effect.	False
At the BC6ENTG receptor , both BC6ENTC were equipotent at stimulating BC6OTHER hydrolysis , with the BC6OTHER being more efficacious at the BC6OTHER receptor compared with the R( - ) isomer.	False
At the BC6OTHER receptor , both BC6ENTC were equipotent at stimulating BC6OTHER hydrolysis , with the BC6OTHER being more efficacious at the BC6ENTG receptor compared with the R( - ) isomer.	False
At the BC6ENTG receptor , both BC6OTHER were equipotent at stimulating BC6ENTC hydrolysis , with the BC6OTHER being more efficacious at the BC6OTHER receptor compared with the R( - ) isomer.	False
At the BC6OTHER receptor , both BC6OTHER were equipotent at stimulating BC6ENTC hydrolysis , with the BC6OTHER being more efficacious at the BC6ENTG receptor compared with the R( - ) isomer.	False
At the BC6ENTG receptor , both BC6OTHER were equipotent at stimulating BC6OTHER hydrolysis , with the BC6ENTC being more efficacious at the BC6OTHER receptor compared with the R( - ) isomer.	False
At the BC6OTHER receptor , both BC6OTHER were equipotent at stimulating BC6OTHER hydrolysis , with the BC6ENTC being more efficacious at the BC6ENTG receptor compared with the R( - ) isomer.	False
The effect of the BC6OTHER ( BC6ENTC ) and its BC6OTHER ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6ENTG or BC6OTHER receptors.	False
The effect of the BC6OTHER ( BC6ENTC ) and its BC6OTHER ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6OTHER or BC6ENTG receptors.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6ENTC ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6ENTG or BC6OTHER receptors.	False
The effect of the BC6OTHER ( BC6OTHER ) and its BC6ENTC ( BC6OTHER ) on BC6OTHER accumulation was studied in cells expressing either BC6OTHER or BC6ENTG receptors.	False
In all cases at both the BC6ENTG and BC6OTHER receptors , the affinities of the isomers of BC6ENTC and BC6OTHER were at least 2 - 3 orders of magnitude less than BC6OTHER .	False
In all cases at both the BC6OTHER and BC6ENTG receptors , the affinities of the isomers of BC6ENTC and BC6OTHER were at least 2 - 3 orders of magnitude less than BC6OTHER .	False
In all cases at both the BC6ENTG and BC6OTHER receptors , the affinities of the isomers of BC6OTHER and BC6ENTC were at least 2 - 3 orders of magnitude less than BC6OTHER .	False
In all cases at both the BC6OTHER and BC6ENTG receptors , the affinities of the isomers of BC6OTHER and BC6ENTC were at least 2 - 3 orders of magnitude less than BC6OTHER .	False
In all cases at both the BC6ENTG and BC6OTHER receptors , the affinities of the isomers of BC6OTHER and BC6OTHER were at least 2 - 3 orders of magnitude less than BC6ENTC .	False
In all cases at both the BC6OTHER and BC6ENTG receptors , the affinities of the isomers of BC6OTHER and BC6OTHER were at least 2 - 3 orders of magnitude less than BC6ENTC .	False
Effect of the BC6ENTC and BC6OTHER on BC6OTHER turnover in cultured cells expressing BC6ENTG or BC6OTHER receptors.	False
Effect of the BC6ENTC and BC6OTHER on BC6OTHER turnover in cultured cells expressing BC6OTHER or BC6ENTG receptors.	False
Effect of the BC6OTHER and BC6ENTC on BC6OTHER turnover in cultured cells expressing BC6ENTG or BC6OTHER receptors.	False
Effect of the BC6OTHER and BC6ENTC on BC6OTHER turnover in cultured cells expressing BC6OTHER or BC6ENTG receptors.	False
Effect of the BC6OTHER and BC6OTHER on BC6ENTC turnover in cultured cells expressing BC6ENTG or BC6OTHER receptors.	False
Effect of the BC6OTHER and BC6OTHER on BC6ENTC turnover in cultured cells expressing BC6OTHER or BC6ENTG receptors.	False
The anti - inflammatory mechanism of AGT might be related to the decrease in the level of BC6ENTC in the edema paw via increasing the activities of BC6ENTG , BC6OTHER and BC6OTHER in the liver.	False
The anti - inflammatory mechanism of AGT might be related to the decrease in the level of BC6ENTC in the edema paw via increasing the activities of BC6OTHER , BC6ENTG and BC6OTHER in the liver.	False
The anti - inflammatory mechanism of AGT might be related to the decrease in the level of BC6ENTC in the edema paw via increasing the activities of BC6OTHER , BC6OTHER and BC6ENTG in the liver.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTC peroxidase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTC peroxidase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTC peroxidase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTG ( BC6OTHER ) and BC6ENTC reductase ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6ENTG ) and BC6ENTC reductase ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6ENTC reductase ( BC6ENTG ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6ENTC ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6ENTC ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in the liver and the levels of BC6ENTC ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in the liver and the levels of BC6ENTC ( BC6OTHER ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6ENTC ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6ENTC ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6ENTC ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in the liver and the levels of BC6OTHER ( BC6ENTC ) and BC6OTHER in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6ENTC in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6ENTC in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6ENTC in the edema paw.	False
In order to investigate the anti - inflammatory mechanism of AGT , we have detected the activities of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in the liver and the levels of BC6OTHER ( BC6OTHER ) and BC6ENTC in the edema paw.	False
In the anti - inflammatory test , AGT (0.5 and 1.0 g / kg) decreased the paw edema at the third , fourth , fifth and sixth hour after lambda - carrageenan administration , and increased the activities of BC6ENTG , BC6OTHER and BC6OTHER in the liver tissue and decreased the BC6ENTC level in the edema paw at the third hour after lambda - carrageenan injection.	False
In the anti - inflammatory test , AGT (0.5 and 1.0 g / kg) decreased the paw edema at the third , fourth , fifth and sixth hour after lambda - carrageenan administration , and increased the activities of BC6OTHER , BC6ENTG and BC6OTHER in the liver tissue and decreased the BC6ENTC level in the edema paw at the third hour after lambda - carrageenan injection.	False
In the anti - inflammatory test , AGT (0.5 and 1.0 g / kg) decreased the paw edema at the third , fourth , fifth and sixth hour after lambda - carrageenan administration , and increased the activities of BC6OTHER , BC6OTHER and BC6ENTG in the liver tissue and decreased the BC6ENTC level in the edema paw at the third hour after lambda - carrageenan injection.	False
BC6ENTC , a BC6ENTG antagonist used for the treatment of glaucoma , is known to be neuroprotective in paradigms of ischaemia / excitotoxicity.	CPR:6
The ability of BC6ENTC to interact with neurotoxin site 2 of the BC6ENTG and inhibit BC6OTHER influx may have a role in its neuroprotective action in paradigms of excitotoxicity / ischaemia and in its therapeutic effect in glaucoma.	False
The ability of BC6OTHER to interact with neurotoxin site 2 of the BC6ENTG and inhibit BC6ENTC influx may have a role in its neuroprotective action in paradigms of excitotoxicity / ischaemia and in its therapeutic effect in glaucoma.	False
In this study , we examined whether BC6ENTC and other BC6ENTG antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage - sensitive BC6OTHER channel ( BC6OTHER ) in rat cerebrocortical synaptosomes.	CPR:6
In this study , we examined whether BC6ENTC and other BC6OTHER antagonists interact directly with neurotoxin binding to sites 1 and 2 of the BC6ENTG ( BC6OTHER ) in rat cerebrocortical synaptosomes.	False
In this study , we examined whether BC6ENTC and other BC6OTHER antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage - sensitive BC6OTHER channel ( BC6ENTG ) in rat cerebrocortical synaptosomes.	False
In this study , we examined whether BC6OTHER and other BC6ENTG antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage - sensitive BC6ENTC channel ( BC6OTHER ) in rat cerebrocortical synaptosomes.	False
In this study , we examined whether BC6OTHER and other BC6OTHER antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage - sensitive BC6ENTC channel ( BC6ENTG ) in rat cerebrocortical synaptosomes.	False
In this study , we examined whether BC6OTHER and other BC6ENTG antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage - sensitive BC6OTHER channel ( BC6ENTC channel) in rat cerebrocortical synaptosomes.	False
In this study , we examined whether BC6OTHER and other BC6OTHER antagonists interact directly with neurotoxin binding to sites 1 and 2 of the BC6ENTG ( BC6ENTC channel) in rat cerebrocortical synaptosomes.	False
BC6ENTC inhibited specific BC6OTHER ( BC6OTHER ) binding to BC6ENTG in a concentration - dependent manner with an IC(50) value of 9.8 microM.	False
BC6OTHER inhibited specific BC6ENTC ( BC6OTHER ) binding to BC6ENTG in a concentration - dependent manner with an IC(50) value of 9.8 microM.	False
BC6OTHER inhibited specific BC6OTHER ( BC6ENTC ) binding to BC6ENTG in a concentration - dependent manner with an IC(50) value of 9.8 microM.	False
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6ENTC > BC6OTHER approximately BC6OTHER > BC6OTHER approximately BC6OTHER > / = BC6OTHER > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6ENTC approximately BC6OTHER > BC6OTHER approximately BC6OTHER > / = BC6OTHER > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6OTHER approximately BC6ENTC > BC6OTHER approximately BC6OTHER > / = BC6OTHER > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6OTHER approximately BC6OTHER > BC6ENTC approximately BC6OTHER > / = BC6OTHER > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6OTHER approximately BC6OTHER > BC6OTHER approximately BC6ENTC > / = BC6OTHER > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6OTHER approximately BC6OTHER > BC6OTHER approximately BC6OTHER > / = BC6ENTC > BC6OTHER .	CPR:6
Comparison of all the BC6ENTG antagonists tested revealed a potency order of BC6OTHER > BC6OTHER approximately BC6OTHER > BC6OTHER approximately BC6OTHER > / = BC6OTHER > BC6ENTC .	CPR:6
None of the drugs caused a significant inhibition of BC6ENTC binding to BC6ENTG , even at concentrations as high as 250 microM.	False
 BC6ENTC , a BC6OTHER antagonist , reduces BC6OTHER influx into cortical synaptosomes by direct interaction with BC6ENTG : comparison with other BC6OTHER antagonists.	False
 BC6ENTC , a BC6ENTG antagonist , reduces BC6OTHER influx into cortical synaptosomes by direct interaction with BC6OTHER : comparison with other BC6OTHER antagonists.	CPR:6
 BC6ENTC , a BC6OTHER antagonist , reduces BC6OTHER influx into cortical synaptosomes by direct interaction with BC6OTHER : comparison with other BC6ENTG antagonists.	CPR:6
 BC6OTHER , a BC6ENTG antagonist , reduces BC6OTHER influx into cortical synaptosomes by direct interaction with BC6ENTC channels: comparison with other BC6OTHER antagonists.	False
 BC6OTHER , a BC6OTHER antagonist , reduces BC6OTHER influx into cortical synaptosomes by direct interaction with BC6ENTC channels: comparison with other BC6ENTG antagonists.	False
 BC6OTHER , a BC6OTHER antagonist , reduces BC6ENTC influx into cortical synaptosomes by direct interaction with BC6ENTG : comparison with other BC6OTHER antagonists.	False
 BC6OTHER , a BC6ENTG antagonist , reduces BC6ENTC influx into cortical synaptosomes by direct interaction with BC6OTHER : comparison with other BC6OTHER antagonists.	False
 BC6OTHER , a BC6OTHER antagonist , reduces BC6ENTC influx into cortical synaptosomes by direct interaction with BC6OTHER : comparison with other BC6ENTG antagonists.	False
BC6ENTC - tRNA synthetase ( BC6ENTG ) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria.	False
In striking contrast , deletion of the corresponding BC6OTHER - terminal domain of BC6ENTG abolished aminoacylation of CHEM and also BC6ENTC editing of mischarged tRNA molecules.	False
We propose that the secondary role of BC6ENTG in RNA splicing has impacted the functional evolution of this critical BC6ENTC - terminal domain.	False
 Deletions of the BC6ENTC terminus differentially impact the two functions of the enzyme in splicing and aminoacylation in vivo. Herein , we determined that a BC6OTHER BC6OTHER - terminal deletion of BC6ENTG , which does not complement a null strain , can form a ternary complex with the bI4 intron and its maturase splicing partner.	False
 Deletions of the BC6OTHER terminus differentially impact the two functions of the enzyme in splicing and aminoacylation in vivo. Herein , we determined that a BC6ENTC BC6OTHER - terminal deletion of BC6ENTG , which does not complement a null strain , can form a ternary complex with the bI4 intron and its maturase splicing partner.	False
 Deletions of the BC6OTHER terminus differentially impact the two functions of the enzyme in splicing and aminoacylation in vivo. Herein , we determined that a BC6OTHER BC6ENTC - terminal deletion of BC6ENTG , which does not complement a null strain , can form a ternary complex with the bI4 intron and its maturase splicing partner.	False
The x - ray co - crystal structure of BC6ENTG showed that a BC6ENTC - terminal extension of about 60 BC6OTHER forms a discrete domain , which is unique among the BC6OTHER and interacts with the corner of the L - shaped CHEM.	False
The x - ray co - crystal structure of BC6OTHER showed that a BC6ENTC - terminal extension of about 60 BC6OTHER forms a discrete domain , which is unique among the BC6ENTG and interacts with the corner of the L - shaped CHEM.	False
The x - ray co - crystal structure of BC6ENTG showed that a BC6OTHER - terminal extension of about 60 BC6ENTC forms a discrete domain , which is unique among the BC6OTHER and interacts with the corner of the L - shaped CHEM.	False
The x - ray co - crystal structure of BC6OTHER showed that a BC6OTHER - terminal extension of about 60 BC6ENTC forms a discrete domain , which is unique among the BC6ENTG and interacts with the corner of the L - shaped CHEM.	False
Interestingly , deletion of the entire BC6ENTG BC6ENTC - terminal domain enhanced its aminoacylation and BC6OTHER editing activities.	False
Interestingly , deletion of the entire BC6ENTG BC6OTHER - terminal domain enhanced its aminoacylation and BC6ENTC editing activities.	False
In striking contrast , deletion of the corresponding BC6ENTC - terminal domain of BC6ENTG abolished aminoacylation of CHEM and also BC6OTHER editing of mischarged tRNA molecules.	False
Functional divergence of a unique BC6ENTC - terminal domain of BC6ENTG to accommodate its splicing and aminoacylation roles.	False
Enhancement of BC6ENTG BC6ENTC currents may provide an important target for antiepileptic drug development.	False
Here , we show that BC6ENTC ( BC6OTHER ) and BC6OTHER , two related molecules previously used as anti - inflammatory drugs , act as novel BC6ENTG channel openers.	False
Here , we show that BC6OTHER ( BC6ENTC ) and BC6OTHER , two related molecules previously used as anti - inflammatory drugs , act as novel BC6ENTG channel openers.	False
Here , we show that BC6OTHER ( BC6OTHER ) and BC6ENTC , two related molecules previously used as anti - inflammatory drugs , act as novel BC6ENTG channel openers.	False
Extracellular application of BC6ENTC (EC(50) = 25 microM) and BC6OTHER (EC(50) = 2.6 microM) resulted in the activation of BC6ENTG CHEM currents , heterologously expressed in Chinese hamster ovary cells.	CPR:3
Extracellular application of BC6OTHER (EC(50) = 25 microM) and BC6ENTC (EC(50) = 2.6 microM) resulted in the activation of BC6ENTG CHEM currents , heterologously expressed in Chinese hamster ovary cells.	CPR:3
 BC6ENTC and BC6OTHER , novel templates of BC6ENTG BC6OTHER openers , depress cortical neuron activity and exhibit anticonvulsant properties.	False
 BC6ENTC and BC6OTHER , novel templates of BC6OTHER BC6ENTG openers , depress cortical neuron activity and exhibit anticonvulsant properties.	False
 BC6OTHER and BC6ENTC , novel templates of BC6ENTG BC6OTHER openers , depress cortical neuron activity and exhibit anticonvulsant properties.	False
 BC6OTHER and BC6ENTC , novel templates of BC6OTHER BC6ENTG openers , depress cortical neuron activity and exhibit anticonvulsant properties.	False
 BC6OTHER and BC6OTHER , novel templates of BC6ENTG BC6ENTC channel openers , depress cortical neuron activity and exhibit anticonvulsant properties.	False
In addition , BC6ENTG and BC6OTHER mutants have reduced levels of BC6ENTC - MPK - 1 / BC6OTHER in their germ cells , indicating that the BC6OTHER / BC6OTHER pathway promotes BC6OTHER signaling in the germline.	False
In addition , BC6OTHER and BC6ENTG mutants have reduced levels of BC6ENTC - MPK - 1 / BC6OTHER in their germ cells , indicating that the BC6OTHER / BC6OTHER pathway promotes BC6OTHER signaling in the germline.	False
In addition , BC6OTHER and BC6OTHER mutants have reduced levels of BC6ENTC - MPK - 1 / BC6ENTG in their germ cells , indicating that the BC6OTHER / BC6OTHER pathway promotes BC6OTHER signaling in the germline.	False
In addition , BC6OTHER and BC6OTHER mutants have reduced levels of BC6ENTC - MPK - 1 / BC6OTHER in their germ cells , indicating that the BC6ENTG / BC6OTHER pathway promotes BC6OTHER signaling in the germline.	False
In addition , BC6OTHER and BC6OTHER mutants have reduced levels of BC6ENTC - MPK - 1 / BC6OTHER in their germ cells , indicating that the BC6OTHER / BC6ENTG pathway promotes BC6OTHER signaling in the germline.	False
In addition , BC6OTHER and BC6OTHER mutants have reduced levels of BC6ENTC - MPK - 1 / BC6OTHER in their germ cells , indicating that the BC6OTHER / BC6OTHER pathway promotes BC6ENTG signaling in the germline.	False
Here , we report unexpected rearrangements to the BC6ENTG / BC6OTHER pathway , whereby the BC6OTHER BC6OTHER and 3 - BC6ENTC - dependent protein kinase PDK - 1 oppose BC6OTHER to promote DNA damage - induced apoptosis.	False
Here , we report unexpected rearrangements to the BC6OTHER / BC6ENTG pathway , whereby the BC6OTHER BC6OTHER and 3 - BC6ENTC - dependent protein kinase PDK - 1 oppose BC6OTHER to promote DNA damage - induced apoptosis.	False
Here , we report unexpected rearrangements to the BC6OTHER / BC6OTHER pathway , whereby the BC6ENTG BC6OTHER and 3 - BC6ENTC - dependent protein kinase PDK - 1 oppose BC6OTHER to promote DNA damage - induced apoptosis.	False
Here , we report unexpected rearrangements to the BC6OTHER / BC6OTHER pathway , whereby the BC6OTHER BC6ENTG and 3 - BC6ENTC - dependent protein kinase PDK - 1 oppose BC6OTHER to promote DNA damage - induced apoptosis.	False
Here , we report unexpected rearrangements to the BC6OTHER / BC6OTHER pathway , whereby the BC6OTHER BC6OTHER and 3 - BC6ENTC - dependent protein kinase PDK - 1 oppose BC6ENTG to promote DNA damage - induced apoptosis.	False
While DNA damage does not affect phosphorylation at the BC6ENTG site BC6OTHER of BC6OTHER , it increased phosphorylation at BC6ENTC 517 / BC6OTHER 473.	False
While DNA damage does not affect phosphorylation at the BC6OTHER site BC6ENTG of BC6OTHER , it increased phosphorylation at BC6ENTC 517 / BC6OTHER 473.	False
While DNA damage does not affect phosphorylation at the BC6OTHER site BC6OTHER of BC6ENTG , it increased phosphorylation at BC6ENTC 517 / BC6OTHER 473.	False
While DNA damage does not affect phosphorylation at the BC6ENTG site BC6OTHER of BC6OTHER , it increased phosphorylation at CHEM517 / BC6ENTC 473.	False
While DNA damage does not affect phosphorylation at the BC6OTHER site BC6ENTG of BC6OTHER , it increased phosphorylation at CHEM517 / BC6ENTC 473.	False
While DNA damage does not affect phosphorylation at the BC6OTHER site BC6OTHER of BC6ENTG , it increased phosphorylation at CHEM517 / BC6ENTC 473.	False
However , a lid conformation was induced by [ BC6ENTC (1) , BC6OTHER (2) , BC6OTHER (8)] BC6ENTG , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6ENTC (1) , BC6OTHER (2) , BC6OTHER (8)] BC6OTHER , a specific analog that binds to the BC6ENTG mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6ENTC (1) , BC6OTHER (2) , BC6OTHER (8)] BC6OTHER , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6ENTG .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6ENTC (2) , BC6OTHER (8)] BC6ENTG , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6ENTC (2) , BC6OTHER (8)] BC6OTHER , a specific analog that binds to the BC6ENTG mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6ENTC (2) , BC6OTHER (8)] BC6OTHER , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6ENTG .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6OTHER (2) , BC6ENTC (8)] BC6ENTG , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6OTHER (2) , BC6ENTC (8)] BC6OTHER , a specific analog that binds to the BC6ENTG mutant with better affinity than BC6OTHER .	False
However , a lid conformation was induced by [ BC6OTHER (1) , BC6OTHER (2) , BC6ENTC (8)] BC6OTHER , a specific analog that binds to the BC6OTHER mutant with better affinity than BC6ENTG .	False
"Binding of the agonist BC6ENTG ( BC6OTHER ) and inverse agonist BC6ENTC in wild - type BC6OTHER changed the accessibility of reporter BC6OTHER , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	False
"Binding of the agonist BC6OTHER ( BC6ENTG ) and inverse agonist BC6ENTC in wild - type BC6OTHER changed the accessibility of reporter BC6OTHER , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	False
"Binding of the agonist BC6OTHER ( BC6OTHER ) and inverse agonist BC6ENTC in wild - type BC6ENTG changed the accessibility of reporter BC6OTHER , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	CPR:5
"Binding of the agonist BC6ENTG ( BC6OTHER ) and inverse agonist BC6OTHER in wild - type BC6OTHER changed the accessibility of reporter BC6ENTC , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	False
"Binding of the agonist BC6OTHER ( BC6ENTG ) and inverse agonist BC6OTHER in wild - type BC6OTHER changed the accessibility of reporter BC6ENTC , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	False
"Binding of the agonist BC6OTHER ( BC6OTHER ) and inverse agonist BC6OTHER in wild - type BC6ENTG changed the accessibility of reporter BC6ENTC , and the pattern was consistent with ligand - specific ""lid"" conformations of ECL2."	False
The effects of BC6ENTC (unspecific BC6ENTG inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	CPR:4
The effects of BC6ENTC (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6ENTG inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6ENTC (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6ENTG inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6ENTC (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6ENTG inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6ENTG inhibitor) , BC6ENTC ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6ENTC ( BC6ENTG inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	CPR:4
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6ENTC ( BC6OTHER inhibitor) , CHEM ( BC6ENTG inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6ENTC ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6ENTG inhibitors BC6OTHER and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6ENTG inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6ENTC and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6ENTG inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6ENTC and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6ENTG inhibitor) and the BC6OTHER inhibitors BC6ENTC and BC6OTHER were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6ENTG inhibitors BC6ENTC and BC6OTHER were weak.	CPR:4
The effects of BC6OTHER (unspecific BC6ENTG inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6ENTC were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6ENTG inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6ENTC were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6ENTG inhibitor) and the BC6OTHER inhibitors BC6OTHER and BC6ENTC were weak.	False
The effects of BC6OTHER (unspecific BC6OTHER inhibitor) , BC6OTHER ( BC6OTHER inhibitor) , CHEM ( BC6OTHER inhibitor) and the BC6ENTG inhibitors BC6OTHER and BC6ENTC were weak.	CPR:4
In human blood , the tested glucocorticoids BC6ENTC , BC6OTHER and BC6OTHER inhibited the LPS induced BC6ENTG release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6OTHER release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6ENTC , BC6OTHER and BC6OTHER inhibited the LPS induced BC6OTHER release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6ENTG release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6OTHER , BC6ENTC and BC6OTHER inhibited the LPS induced BC6ENTG release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6OTHER release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6OTHER , BC6ENTC and BC6OTHER inhibited the LPS induced BC6OTHER release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6ENTG release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6OTHER , BC6OTHER and BC6ENTC inhibited the LPS induced BC6ENTG release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6OTHER release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6OTHER , BC6OTHER and BC6ENTC inhibited the LPS induced BC6OTHER release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6ENTG release , with the exception of BC6OTHER , was much less pronounced.	CPR:4
In human blood , the tested glucocorticoids BC6OTHER , BC6OTHER and BC6OTHER inhibited the LPS induced BC6ENTG release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6OTHER release , with the exception of BC6ENTC , was much less pronounced.	False
In human blood , the tested glucocorticoids BC6OTHER , BC6OTHER and BC6OTHER inhibited the LPS induced BC6OTHER release potently in a concentration dependent manner , whereas in dispersed human nasal polyp cells , the effect of the glucocorticoids on allergically induced BC6ENTG release , with the exception of BC6ENTC , was much less pronounced.	False
The selective BC6ENTG inhibitors , and to a certain extent the BC6OTHER inhibitors BC6ENTC and BC6OTHER , reduced the BC6OTHER release in a concentration dependent manner.	CPR:4
The selective BC6OTHER inhibitors , and to a certain extent the BC6ENTG inhibitors BC6ENTC and BC6OTHER , reduced the BC6OTHER release in a concentration dependent manner.	CPR:4
The selective BC6OTHER inhibitors , and to a certain extent the BC6OTHER inhibitors BC6ENTC and BC6OTHER , reduced the BC6ENTG release in a concentration dependent manner.	CPR:4
The selective BC6ENTG inhibitors , and to a certain extent the BC6OTHER inhibitors BC6OTHER and BC6ENTC , reduced the BC6OTHER release in a concentration dependent manner.	CPR:4
The selective BC6OTHER inhibitors , and to a certain extent the BC6ENTG inhibitors BC6OTHER and BC6ENTC , reduced the BC6OTHER release in a concentration dependent manner.	CPR:4
The selective BC6OTHER inhibitors , and to a certain extent the BC6OTHER inhibitors BC6OTHER and BC6ENTC , reduced the BC6ENTG release in a concentration dependent manner.	CPR:4
BC6ENTC and BC6OTHER , selective BC6ENTG inhibitors , suppressed BC6OTHER secretion to a lesser extent.	CPR:4
BC6ENTC and BC6OTHER , selective BC6OTHER inhibitors , suppressed BC6ENTG secretion to a lesser extent.	CPR:4
BC6OTHER and BC6ENTC , selective BC6ENTG inhibitors , suppressed BC6OTHER secretion to a lesser extent.	CPR:4
BC6OTHER and BC6ENTC , selective BC6OTHER inhibitors , suppressed BC6ENTG secretion to a lesser extent.	CPR:4
We report here that BC6ENTC , an antidepressant drug , directly binds BC6ENTG and BC6OTHER and triggers their dimerization and activation.	False
We report here that BC6ENTC , an antidepressant drug , directly binds BC6OTHER and BC6ENTG and triggers their dimerization and activation.	False
BC6ENTC , but not any other BC6OTHER or selective BC6OTHER reuptake inhibitor antidepressants , promotes BC6ENTG autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.	CPR:3
BC6OTHER , but not any other BC6ENTC or selective BC6OTHER reuptake inhibitor antidepressants , promotes BC6ENTG autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.	False
BC6OTHER , but not any other BC6OTHER or selective BC6ENTC reuptake inhibitor antidepressants , promotes BC6ENTG autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.	False
BC6ENTC binds the extracellular domain of both BC6ENTG and BC6OTHER and promotes BC6OTHER - BC6OTHER receptor heterodimerization.	False
BC6ENTC binds the extracellular domain of both BC6OTHER and BC6ENTG and promotes BC6OTHER - BC6OTHER receptor heterodimerization.	False
BC6ENTC binds the extracellular domain of both BC6OTHER and BC6OTHER and promotes BC6ENTG - BC6OTHER receptor heterodimerization.	False
BC6ENTC binds the extracellular domain of both BC6OTHER and BC6OTHER and promotes BC6OTHER - BC6ENTG receptor heterodimerization.	False
Truncation of BC6ENTC binding motif on BC6ENTG abrogates the receptor dimerization by BC6OTHER .	False
Truncation of BC6OTHER binding motif on BC6ENTG abrogates the receptor dimerization by BC6ENTC .	False
Thus , BC6ENTC acts as a BC6OTHER and BC6ENTG agonist and possesses marked neurotrophic activity.	CPR:5
Thus , BC6ENTC acts as a BC6ENTG and BC6OTHER agonist and possesses marked neurotrophic activity.	CPR:5
 BC6ENTC is a BC6ENTG and BC6OTHER receptor agonist that promotes BC6OTHER / BC6OTHER heterodimerization and has potent neurotrophic activity.	CPR:5
 BC6ENTC is a BC6OTHER and BC6ENTG receptor agonist that promotes BC6OTHER / BC6OTHER heterodimerization and has potent neurotrophic activity.	CPR:5
 BC6ENTC is a BC6OTHER and BC6OTHER receptor agonist that promotes BC6ENTG / BC6OTHER heterodimerization and has potent neurotrophic activity.	False
 BC6ENTC is a BC6OTHER and BC6OTHER receptor agonist that promotes BC6OTHER / BC6ENTG heterodimerization and has potent neurotrophic activity.	False
Preincubating hMSC with BC6ENTG prevented 90% of the suppressive effect of BC6ENTC .	False
Selective competitive antagonists of BC6ENTG - coupled BC6OTHER were ~60% effective in blocking BC6ENTC inhibition and combination of antagonists to both receptors were 85% effective.	False
Selective competitive antagonists of BC6OTHER - coupled BC6ENTG were ~60% effective in blocking BC6ENTC inhibition and combination of antagonists to both receptors were 85% effective.	False
In contrast , antagonists to the BC6ENTC type 1 receptor (previously shown to mediate BC6OTHER vascular effects) or the BC6ENTG were ineffective in blocking BC6OTHER effects.	False
In contrast , antagonists to the BC6ENTG (previously shown to mediate BC6ENTC vascular effects) or the BC6OTHER were ineffective in blocking BC6OTHER effects.	False
In contrast , antagonists to the BC6OTHER (previously shown to mediate BC6ENTC vascular effects) or the BC6ENTG were ineffective in blocking BC6OTHER effects.	False
In contrast , antagonists to the BC6ENTG (previously shown to mediate BC6OTHER vascular effects) or the BC6OTHER were ineffective in blocking BC6ENTC effects.	False
In contrast , antagonists to the BC6OTHER (previously shown to mediate BC6OTHER vascular effects) or the BC6ENTG were ineffective in blocking BC6ENTC effects.	False
These studies suggest a majority of BC6ENTC - inhibited adipocyte differentiation , and metabolism requires BC6ENTG BC6OTHER and that BC6OTHER effects on BC6OTHER signaling are tissue and context specific.	False
These studies suggest a majority of BC6ENTC - inhibited adipocyte differentiation , and metabolism requires BC6OTHER BC6ENTG and that BC6OTHER effects on BC6OTHER signaling are tissue and context specific.	False
These studies suggest a majority of BC6ENTC - inhibited adipocyte differentiation , and metabolism requires BC6OTHER BC6OTHER and that BC6OTHER effects on BC6ENTG signaling are tissue and context specific.	False
These studies suggest a majority of BC6OTHER - inhibited adipocyte differentiation , and metabolism requires BC6ENTG BC6OTHER and that BC6ENTC effects on BC6OTHER signaling are tissue and context specific.	False
These studies suggest a majority of BC6OTHER - inhibited adipocyte differentiation , and metabolism requires BC6OTHER BC6ENTG and that BC6ENTC effects on BC6OTHER signaling are tissue and context specific.	False
These studies suggest a majority of BC6OTHER - inhibited adipocyte differentiation , and metabolism requires BC6OTHER BC6OTHER and that BC6ENTC effects on BC6ENTG signaling are tissue and context specific.	False
We hypothesized that BC6ENTC signals through the BC6ENTG ( BC6OTHER ) sensitive , BC6OTHER ( BC6OTHER ) to impair adipogenesis , as previously demonstrated for its stimulation of vascular oxidant generation , angiogenesis , and remodeling.	False
We hypothesized that BC6ENTC signals through the BC6OTHER ( BC6ENTG ) sensitive , BC6OTHER ( BC6OTHER ) to impair adipogenesis , as previously demonstrated for its stimulation of vascular oxidant generation , angiogenesis , and remodeling.	False
We hypothesized that BC6ENTC signals through the BC6OTHER ( BC6OTHER ) sensitive , BC6ENTG ( BC6OTHER ) to impair adipogenesis , as previously demonstrated for its stimulation of vascular oxidant generation , angiogenesis , and remodeling.	False
We hypothesized that BC6ENTC signals through the BC6OTHER ( BC6OTHER ) sensitive , BC6OTHER ( BC6ENTG ) to impair adipogenesis , as previously demonstrated for its stimulation of vascular oxidant generation , angiogenesis , and remodeling.	False
Because both BC6ENTC and BC6ENTG ligands inhibit progenitor cell differentiation into adipocytes , we investigated the hypothesis in a model of low - passage human mesenchymal stem cells (hMSC).	False
BC6ENTC (0.1 - 1.0 µM) suppressed BC6OTHER / insulin - induced hMSC adipogenesis , as indicated by decreased transcriptional promoters of differentiation , decreased fat droplet formation , and decreased expression of differentiated adipocyte markers , such as BC6ENTG and BC6OTHER .	False
BC6ENTC (0.1 - 1.0 µM) suppressed BC6OTHER / insulin - induced hMSC adipogenesis , as indicated by decreased transcriptional promoters of differentiation , decreased fat droplet formation , and decreased expression of differentiated adipocyte markers , such as BC6OTHER and BC6ENTG .	False
BC6OTHER (0.1 - 1.0 µM) suppressed BC6ENTC / insulin - induced hMSC adipogenesis , as indicated by decreased transcriptional promoters of differentiation , decreased fat droplet formation , and decreased expression of differentiated adipocyte markers , such as BC6ENTG and BC6OTHER .	False
BC6OTHER (0.1 - 1.0 µM) suppressed BC6ENTC / insulin - induced hMSC adipogenesis , as indicated by decreased transcriptional promoters of differentiation , decreased fat droplet formation , and decreased expression of differentiated adipocyte markers , such as BC6OTHER and BC6ENTG .	False
 BC6ENTC activates BC6ENTG BC6OTHER signaling to inhibit stem cell differentiation in adipogenesis.	False
 BC6ENTC activates BC6OTHER BC6ENTG signaling to inhibit stem cell differentiation in adipogenesis.	False
 BC6ENTC has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6OTHER on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6ENTG ( BC6OTHER ) - BC6OTHER pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6ENTC has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6OTHER on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6OTHER ( BC6ENTG ) - BC6OTHER pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6ENTC has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6OTHER on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6OTHER ( BC6OTHER ) - BC6ENTG pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6OTHER has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6ENTC on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6ENTG ( BC6OTHER ) - BC6OTHER pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6OTHER has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6ENTC on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6OTHER ( BC6ENTG ) - BC6OTHER pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6OTHER has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6ENTC on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6OTHER ( BC6OTHER ) - BC6ENTG pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6OTHER has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6OTHER on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6ENTC 3 - kinase ( BC6ENTG ) - BC6OTHER pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
 BC6OTHER has been shown to hold potent anti - proliferative and apoptosis induction properties in vitro and in vivo. To investigate the effects of BC6OTHER on apoptosis initiation and its possible mechanisms of action , we qualified cell apoptosis , proteins related to apoptosis and a BC6ENTC 3 - kinase ( BC6OTHER ) - BC6ENTG pathway in human gastric adenocarcinoma cancer SGC - 7901 cells.	False
The results demonstrated that BC6ENTC - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6OTHER (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6OTHER was also shown to induce the expression of cleaved - BC6ENTG and inhibit BC6OTHER expression in SGC - 7901 cells in a dose - dependent manner.	False
The results demonstrated that BC6ENTC - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6OTHER (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6OTHER was also shown to induce the expression of cleaved - BC6OTHER and inhibit BC6ENTG expression in SGC - 7901 cells in a dose - dependent manner.	False
The results demonstrated that BC6OTHER - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6ENTC (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6OTHER was also shown to induce the expression of cleaved - BC6ENTG and inhibit BC6OTHER expression in SGC - 7901 cells in a dose - dependent manner.	False
The results demonstrated that BC6OTHER - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6ENTC (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6OTHER was also shown to induce the expression of cleaved - BC6OTHER and inhibit BC6ENTG expression in SGC - 7901 cells in a dose - dependent manner.	False
The results demonstrated that BC6OTHER - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6OTHER (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6ENTC was also shown to induce the expression of cleaved - BC6ENTG and inhibit BC6OTHER expression in SGC - 7901 cells in a dose - dependent manner.	CPR:3
The results demonstrated that BC6OTHER - induced apoptosis in a dose - dependent manner in SGC - 7901 cells treated with BC6OTHER (25 , 50 , 100 and 200 μmol / L) for 24 h. BC6ENTC was also shown to induce the expression of cleaved - BC6OTHER and inhibit BC6ENTG expression in SGC - 7901 cells in a dose - dependent manner.	CPR:4
The significantly decreased levels of BC6ENTG and BC6OTHER expression were observed in SGC - 7901 cells after BC6ENTC treatments in a time - and dose - dependent manner (P < 0.01).	CPR:4
The significantly decreased levels of BC6OTHER and BC6ENTG expression were observed in SGC - 7901 cells after BC6ENTC treatments in a time - and dose - dependent manner (P < 0.01).	CPR:4
Thus , the apoptosis induction in SGC - 7901 cells by BC6ENTC may be regulated through a BC6ENTG - BC6OTHER pathway.	False
Thus , the apoptosis induction in SGC - 7901 cells by BC6ENTC may be regulated through a BC6OTHER - BC6ENTG pathway.	False
Apoptosis initiation of BC6ENTC in SGC - 7901 gastric carcinoma cancer cells via a BC6ENTG - BC6OTHER pathway.	False
Apoptosis initiation of BC6ENTC in SGC - 7901 gastric carcinoma cancer cells via a BC6OTHER - BC6ENTG pathway.	False
BC6ENTC was significantly less potent in the BC6ENTG BC6OTHER mutant compared with wild - type BC6OTHER , whereas BC6OTHER was affected less.	False
BC6ENTC was significantly less potent in the BC6OTHER BC6ENTG mutant compared with wild - type BC6OTHER , whereas BC6OTHER was affected less.	False
BC6ENTC was significantly less potent in the BC6OTHER BC6OTHER mutant compared with wild - type BC6ENTG , whereas BC6OTHER was affected less.	False
BC6OTHER was significantly less potent in the BC6ENTG BC6OTHER mutant compared with wild - type BC6OTHER , whereas BC6ENTC was affected less.	False
BC6OTHER was significantly less potent in the BC6OTHER BC6ENTG mutant compared with wild - type BC6OTHER , whereas BC6ENTC was affected less.	False
BC6OTHER was significantly less potent in the BC6OTHER BC6OTHER mutant compared with wild - type BC6ENTG , whereas BC6ENTC was affected less.	False
Studies with the BC6ENTG BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6ENTC , which was further supported by BC6OTHER reactivity on the BC6OTHER BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6ENTG mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6ENTC , which was further supported by BC6OTHER reactivity on the BC6OTHER BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6ENTC , which was further supported by BC6OTHER reactivity on the BC6ENTG BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6ENTC , which was further supported by BC6OTHER reactivity on the BC6OTHER BC6ENTG BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6ENTC , which was further supported by BC6OTHER reactivity on the BC6OTHER BC6OTHER BC6ENTG .	False
Studies with the BC6ENTG BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6OTHER , which was further supported by BC6ENTC reactivity on the BC6OTHER BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6ENTG mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6OTHER , which was further supported by BC6ENTC reactivity on the BC6OTHER BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6OTHER , which was further supported by BC6ENTC reactivity on the BC6ENTG BC6OTHER BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6OTHER , which was further supported by BC6ENTC reactivity on the BC6OTHER BC6ENTG BC6OTHER .	False
Studies with the BC6OTHER BC6OTHER mutant showed that the R - and CHEM - enantiomers tolerated the inward - facing conformation better than BC6OTHER , which was further supported by BC6ENTC reactivity on the BC6OTHER BC6OTHER BC6ENTG .	False
METHODS: BC6ENTC and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6OTHER ) uptake and BC6OTHER binding in BC6ENTG ( BC6OTHER ) wild - type and mutants with altered conformational equilibria.	False
METHODS: BC6ENTC and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6OTHER ) uptake and BC6OTHER binding in human BC6OTHER transporter ( BC6ENTG ) wild - type and mutants with altered conformational equilibria.	False
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6ENTC ( BC6OTHER ) uptake and BC6OTHER binding in BC6ENTG ( BC6OTHER ) wild - type and mutants with altered conformational equilibria.	CPR:9
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6ENTC ( BC6OTHER ) uptake and BC6OTHER binding in human BC6OTHER transporter ( BC6ENTG ) wild - type and mutants with altered conformational equilibria.	CPR:9
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6ENTC ) uptake and BC6OTHER binding in BC6ENTG ( BC6OTHER ) wild - type and mutants with altered conformational equilibria.	CPR:9
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6ENTC ) uptake and BC6OTHER binding in human BC6OTHER transporter ( BC6ENTG ) wild - type and mutants with altered conformational equilibria.	CPR:9
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6OTHER ) uptake and BC6ENTC binding in BC6ENTG ( BC6OTHER ) wild - type and mutants with altered conformational equilibria.	False
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6OTHER ) uptake and BC6ENTC binding in human BC6OTHER transporter ( BC6ENTG ) wild - type and mutants with altered conformational equilibria.	False
METHODS: BC6OTHER and its R - ( - ) - and CHEM - (+) - enantiomers were synthesized and tested for inhibition of BC6OTHER ( BC6OTHER ) uptake and BC6OTHER binding in human BC6ENTC transporter ( BC6ENTG ) wild - type and mutants with altered conformational equilibria.	False
RESULTS: BC6ENTC bind to the BC6ENTG and inhibit BC6OTHER uptake less potently than BC6OTHER , with BC6OTHER having approximately threefold higher affinity than its S - enantiomer.	False
RESULTS: BC6OTHER bind to the BC6ENTG and inhibit BC6ENTC uptake less potently than BC6OTHER , with BC6OTHER having approximately threefold higher affinity than its S - enantiomer.	CPR:9
RESULTS: BC6OTHER bind to the BC6ENTG and inhibit BC6OTHER uptake less potently than BC6ENTC , with BC6OTHER having approximately threefold higher affinity than its S - enantiomer.	False
RESULTS: BC6OTHER bind to the BC6ENTG and inhibit BC6OTHER uptake less potently than BC6OTHER , with BC6ENTC having approximately threefold higher affinity than its S - enantiomer.	False
We found a substantial metabolism of the tested substrates , ranging from 26% ( BC6ENTC - glucuronosyltransferase 1A1) , 47% ( BC6ENTG ) , to 240% ( BC6OTHER ) of primary human hepatocytes.	False
We found a substantial metabolism of the tested substrates , ranging from 26% ( BC6ENTC - glucuronosyltransferase 1A1) , 47% ( BC6OTHER ) , to 240% ( BC6ENTG ) of primary human hepatocytes.	False
The BC6ENTG activity could be induced 2 - fold by BC6ENTC , whereas BC6OTHER activity remained equally high.	CPR:3
The BC6OTHER activity could be induced 2 - fold by BC6ENTC , whereas BC6ENTG activity remained equally high.	CPR:3
The fact that the response of the cells to the teratogen was clearly BC6ENTG - dependent implicates this molecule to be involved in the response of the embryonic cells to BC6ENTC .	False
Therefore , we tried to assess the involvement of the BC6ENTG subunit of BC6OTHER in the embryonic response to the anti - cancer drug BC6ENTC ( BC6OTHER ).	False
Therefore , we tried to assess the involvement of the BC6OTHER subunit of BC6ENTG in the embryonic response to the anti - cancer drug BC6ENTC ( BC6OTHER ).	False
Therefore , we tried to assess the involvement of the BC6ENTG subunit of BC6OTHER in the embryonic response to the anti - cancer drug BC6OTHER ( BC6ENTC ).	False
Therefore , we tried to assess the involvement of the BC6OTHER subunit of BC6ENTG in the embryonic response to the anti - cancer drug BC6OTHER ( BC6ENTC ).	False
Thus , exposure of BC6ENTG knockout ( BC6OTHER ( - / - )) or wild type (WT) mouse embryonic fibroblasts (MEFs) to BC6ENTC resulted in a decrease in cell survival , culture density and cell proliferation , which was found to be more prominent in BC6OTHER ( - / - ) MEFs.	False
Thus , exposure of BC6OTHER knockout ( BC6ENTG ( - / - )) or wild type (WT) mouse embryonic fibroblasts (MEFs) to BC6ENTC resulted in a decrease in cell survival , culture density and cell proliferation , which was found to be more prominent in BC6OTHER ( - / - ) MEFs.	False
Thus , exposure of BC6OTHER knockout ( BC6OTHER ( - / - )) or wild type (WT) mouse embryonic fibroblasts (MEFs) to BC6ENTC resulted in a decrease in cell survival , culture density and cell proliferation , which was found to be more prominent in BC6ENTG ( - / - ) MEFs.	False
Those phenomena were accompanied by a BC6ENTC - induced increase in the proportion of apoptotic cells , which was demonstrated only in BC6ENTG ( - / - ) cells and a G2 / M arrest , which was found to be more prominent in WT cells.	False
Furthermore , BC6ENTC - treated WT and BC6OTHER ( - / - ) MEFs differed in their expression of various apoptosis - associated molecules , when the former demonstrated a decrease in the percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells , while a decreased percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6ENTG - positive cells was detected among the latter.	False
Furthermore , BC6ENTC - treated WT and BC6ENTG ( - / - ) MEFs differed in their expression of various apoptosis - associated molecules , when the former demonstrated a decrease in the percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells , while a decreased percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells was detected among the latter.	False
Furthermore , BC6ENTC - treated WT and BC6OTHER ( - / - ) MEFs differed in their expression of various apoptosis - associated molecules , when the former demonstrated a decrease in the percentage of BC6ENTG - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells , while a decreased percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells was detected among the latter.	CPR:4
Furthermore , BC6ENTC - treated WT and BC6OTHER ( - / - ) MEFs differed in their expression of various apoptosis - associated molecules , when the former demonstrated a decrease in the percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6ENTG - positive cells , while a decreased percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells was detected among the latter.	False
Furthermore , BC6ENTC - treated WT and BC6OTHER ( - / - ) MEFs differed in their expression of various apoptosis - associated molecules , when the former demonstrated a decrease in the percentage of BC6OTHER - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells , while a decreased percentage of BC6ENTG - positive and a more prominent decrease in the percentage of BC6OTHER - positive cells was detected among the latter.	False
 BC6ENTG - associated mechanisms underlying the response of embryonic cells to BC6ENTC .	False
BC6ENTC block of BC6OTHER current (I( BC6OTHER )) was investigated in wild - type (WT) or the long QT syndrome 3 (LQT3) BC6OTHER channel alpha subunit mutation with three BC6OTHER deleted ( BC6ENTG ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	CPR:4
BC6ENTC block of BC6OTHER current (I( BC6OTHER )) was investigated in wild - type (WT) or the BC6ENTG subunit mutation with three BC6OTHER deleted ( BC6OTHER ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	CPR:4
For BC6ENTG , UDB of late I( BC6ENTC ) was greater than for peak I( BC6OTHER ).	False
For BC6ENTG , UDB of late I( BC6OTHER ) was greater than for peak I( BC6ENTC ).	False
BC6OTHER block of BC6OTHER current (I( BC6OTHER )) was investigated in wild - type (WT) or the long QT syndrome 3 (LQT3) BC6ENTC channel alpha subunit mutation with three BC6OTHER deleted ( BC6ENTG ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
We conclude that BC6ENTG interacts differently with BC6ENTC than with WT , leading to increased block and slowed recovery , especially for late I( BC6OTHER ).	CPR:4
We conclude that BC6ENTG interacts differently with BC6OTHER than with WT , leading to increased block and slowed recovery , especially for late I( BC6ENTC ).	False
BC6OTHER block of BC6OTHER current (I( BC6OTHER )) was investigated in wild - type (WT) or the long QT syndrome 3 (LQT3) BC6OTHER channel alpha subunit mutation with three BC6ENTC deleted ( BC6ENTG ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
BC6OTHER block of BC6OTHER current (I( BC6OTHER )) was investigated in wild - type (WT) or the BC6ENTG subunit mutation with three BC6ENTC deleted ( BC6OTHER ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
BC6OTHER block of BC6ENTC current (I( BC6OTHER )) was investigated in wild - type (WT) or the long QT syndrome 3 (LQT3) BC6OTHER channel alpha subunit mutation with three BC6OTHER deleted ( BC6ENTG ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
BC6OTHER block of BC6ENTC current (I( BC6OTHER )) was investigated in wild - type (WT) or the BC6ENTG subunit mutation with three BC6OTHER deleted ( BC6OTHER ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
BC6OTHER block of BC6OTHER current (I( BC6ENTC )) was investigated in wild - type (WT) or the long QT syndrome 3 (LQT3) BC6OTHER channel alpha subunit mutation with three BC6OTHER deleted ( BC6ENTG ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
BC6OTHER block of BC6OTHER current (I( BC6ENTC )) was investigated in wild - type (WT) or the BC6ENTG subunit mutation with three BC6OTHER deleted ( BC6OTHER ) stably transfected into human embryonic kidney 293 cells using whole - cell , patch - clamp recordings.	False
Compared with WT , BC6ENTG I( BC6ENTC ) was more sensitive to BC6OTHER , and BC6OTHER preferentially inhibited late I( BC6OTHER ) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( BC6OTHER ).	False
Compared with WT , BC6ENTG I( BC6OTHER ) was more sensitive to BC6ENTC , and BC6OTHER preferentially inhibited late I( BC6OTHER ) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( BC6OTHER ).	CPR:4
Compared with WT , BC6ENTG I( BC6OTHER ) was more sensitive to BC6OTHER , and BC6ENTC preferentially inhibited late I( BC6OTHER ) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( BC6OTHER ).	CPR:4
Compared with WT , BC6ENTG I( BC6OTHER ) was more sensitive to BC6OTHER , and BC6OTHER preferentially inhibited late I( BC6ENTC ) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( BC6OTHER ).	False
Compared with WT , BC6ENTG I( BC6OTHER ) was more sensitive to BC6OTHER , and BC6OTHER preferentially inhibited late I( BC6OTHER ) (mean current between 20 and 23.5 ms after depolarization) compared with peak I( BC6ENTC ).	False
The IC(50) value of peak and late I( BC6ENTC ) for WT was 127 + / - 6 and 44 + / - 2 microM (n = 20) and for BC6ENTG was 80 + / - 9 and 19 + / - 2 microM (n = 31) respectively.	False
UDB of peak I( BC6ENTC ) was greater and developed more slowly during pulse trains for BC6ENTG than for WT.	False
Preferential block of late BC6OTHER current in the BC6ENTG by the class I(C) antiarrhythmic BC6ENTC .	CPR:4
Preferential block of late BC6ENTC current in the BC6ENTG by the class I(C) antiarrhythmic BC6OTHER .	False
That observation , together with previous demonstrations of numerous lipid - synthesizing enzymes in myelin , suggests utilization of BC6ENTC groups liberated by myelin - localized BC6ENTG for lipid synthesis within the myelin sheath.	False
The latter reaction , catalyzed by BC6ENTG ( BC6OTHER ) , produces BC6ENTC groups plus BC6OTHER and has been proposed to occur in both soluble and membranous subfractions of white matter.	CPR:9
The latter reaction , catalyzed by BC6OTHER ( BC6ENTG ) , produces BC6ENTC groups plus BC6OTHER and has been proposed to occur in both soluble and membranous subfractions of white matter.	CPR:9
The latter reaction , catalyzed by BC6ENTG ( BC6OTHER ) , produces BC6OTHER groups plus BC6ENTC and has been proposed to occur in both soluble and membranous subfractions of white matter.	CPR:9
The latter reaction , catalyzed by BC6OTHER ( BC6ENTG ) , produces BC6OTHER groups plus BC6ENTC and has been proposed to occur in both soluble and membranous subfractions of white matter.	CPR:9
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6ENTC (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6ENTC (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6ENTC (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6ENTC (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6ENTC (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6ENTC (300 microg / kg; alpha2C).	False
Thus , the cranio - selective vasoconstriction elicited by BC6ENTC in dogs is predominantly mediated by BC6ENTG receptors as well as BC6OTHER subtypes and , to a lesser extent , by BC6OTHER .	False
Thus , the cranio - selective vasoconstriction elicited by BC6ENTC in dogs is predominantly mediated by BC6OTHER receptors as well as BC6ENTG subtypes and , to a lesser extent , by BC6OTHER .	False
Thus , the cranio - selective vasoconstriction elicited by BC6ENTC in dogs is predominantly mediated by BC6OTHER receptors as well as BC6OTHER subtypes and , to a lesser extent , by BC6ENTG .	False
It has previously been suggested that BC6ENTC produces external carotid vasoconstriction in vagosympathectomised dogs via BC6ENTG receptors and BC6OTHER .	False
It has previously been suggested that BC6ENTC produces external carotid vasoconstriction in vagosympathectomised dogs via BC6OTHER receptors and BC6ENTG .	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6ENTC (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	CPR:6
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6ENTC (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6ENTC (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6ENTC (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	CPR:6
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6ENTC (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6ENTC (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6ENTC (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6ENTC (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6ENTC (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6ENTC (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 The animals were divided into thirteen groups (n=4 each) receiving an i.v. bolus injection of , either physiological saline (0.3 ml / kg; control) , or the antagonists BC6OTHER (300 microg / kg; BC6OTHER ) , BC6OTHER (300 microg / kg; BC6ENTG ) , BC6OTHER (300 microg / kg; alpha2) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER + BC6OTHER (300 microg / kg each) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg; alpha1) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6OTHER (300 microg / kg) + BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) , BC6ENTC (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (1 , 000 microg / kg; alpha2A) , BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg)+ BC6OTHER (1 , 000 microg / kg; alpha2B) , or BC6OTHER (300 microg / kg) + BC6OTHER (100 microg / kg) + BC6OTHER (300 microg / kg; alpha2C).	False
 BC6ENTG receptors , alpha2A / 2C - and , to a lesser extent , BC6OTHER mediate the external carotid vasoconstriction to BC6ENTC in vagosympathectomised dogs.	False
 BC6OTHER receptors , alpha2A / 2C - and , to a lesser extent , BC6ENTG mediate the external carotid vasoconstriction to BC6ENTC in vagosympathectomised dogs.	False
CONCLUSIONS: We suggest that the additional effects of BC6ENTC on the BC6ENTG explain the different responses to these glucocorticoids in the same depressed patients.	False
BC6ENTC probes BC6ENTG ( BC6OTHER ) function , while BC6OTHER probes both BC6OTHER and BC6OTHER ( BC6OTHER ) function.	False
BC6ENTC probes BC6OTHER ( BC6ENTG ) function , while BC6OTHER probes both BC6OTHER and BC6OTHER ( BC6OTHER ) function.	False
BC6ENTC probes BC6OTHER ( BC6OTHER ) function , while BC6OTHER probes both BC6ENTG and BC6OTHER ( BC6OTHER ) function.	False
BC6ENTC probes BC6OTHER ( BC6OTHER ) function , while BC6OTHER probes both BC6OTHER and BC6ENTG ( BC6OTHER ) function.	False
BC6ENTC probes BC6OTHER ( BC6OTHER ) function , while BC6OTHER probes both BC6OTHER and BC6OTHER ( BC6ENTG ) function.	False
BC6OTHER probes BC6ENTG ( BC6OTHER ) function , while BC6ENTC probes both BC6OTHER and BC6OTHER ( BC6OTHER ) function.	False
BC6OTHER probes BC6OTHER ( BC6ENTG ) function , while BC6ENTC probes both BC6OTHER and BC6OTHER ( BC6OTHER ) function.	False
BC6OTHER probes BC6OTHER ( BC6OTHER ) function , while BC6ENTC probes both BC6ENTG and BC6OTHER ( BC6OTHER ) function.	False
BC6OTHER probes BC6OTHER ( BC6OTHER ) function , while BC6ENTC probes both BC6OTHER and BC6ENTG ( BC6OTHER ) function.	False
BC6OTHER probes BC6OTHER ( BC6OTHER ) function , while BC6ENTC probes both BC6OTHER and BC6OTHER ( BC6ENTG ) function.	False
BC6ENTC ( BC6OTHER ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several BC6ENTG ( BC6OTHER ) isoforms.	CPR:9
BC6ENTC ( BC6OTHER ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several CHEM BC6OTHER - transferase ( BC6ENTG ) isoforms.	CPR:9
Specifically , BC6ENTG cells had significantly higher BC6ENTC concentrations when exposed to 5 - 15 microM BC6OTHER , but not at 20 microM BC6OTHER , suggesting extensive BC6OTHER utilization at high concentrations of BC6OTHER .	False
Specifically , BC6ENTG cells had significantly higher BC6OTHER concentrations when exposed to 5 - 15 microM BC6ENTC , but not at 20 microM BC6OTHER , suggesting extensive BC6OTHER utilization at high concentrations of BC6OTHER .	CPR:9
Specifically , BC6ENTG cells had significantly higher BC6OTHER concentrations when exposed to 5 - 15 microM BC6OTHER , but not at 20 microM BC6ENTC , suggesting extensive BC6OTHER utilization at high concentrations of BC6OTHER .	CPR:9
Specifically , BC6ENTG cells had significantly higher BC6OTHER concentrations when exposed to 5 - 15 microM BC6OTHER , but not at 20 microM BC6OTHER , suggesting extensive BC6ENTC utilization at high concentrations of BC6OTHER .	False
Specifically , BC6ENTG cells had significantly higher BC6OTHER concentrations when exposed to 5 - 15 microM BC6OTHER , but not at 20 microM BC6OTHER , suggesting extensive BC6OTHER utilization at high concentrations of BC6ENTC .	False
The BC6ENTG cells exhibited a significant growth advantage relative to control cells in the absence of BC6ENTC , and a trend towards increased growth at low dose exposures to BC6OTHER .	False
The BC6ENTG cells exhibited a significant growth advantage relative to control cells in the absence of BC6OTHER , and a trend towards increased growth at low dose exposures to BC6ENTC .	False
BC6OTHER ( BC6OTHER ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several BC6ENTC BC6OTHER - transferase ( BC6ENTG ) isoforms.	False
However , the BC6ENTG cells did not exhibit a growth advantage relative to control cells at higher BC6ENTC exposures associated with increased BC6OTHER utilization.	False
BC6OTHER ( BC6OTHER ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several CHEM BC6ENTC - transferase ( BC6ENTG ) isoforms.	False
However , the BC6ENTG cells did not exhibit a growth advantage relative to control cells at higher BC6OTHER exposures associated with increased BC6ENTC utilization.	False
As expected , the BC6ENTG cells showed resistance to BC6ENTC stimulated lipid peroxidation at all BC6OTHER doses.	False
As expected , the BC6ENTG cells showed resistance to BC6OTHER stimulated lipid peroxidation at all BC6ENTC doses.	False
In summary , our data indicates that over - expression of BC6ENTG at levels conferring high BC6OTHER - BC6ENTC conjugating activity confers a partial growth advantage to HepG2 cells and protects against BC6OTHER oxidative injury.	False
In summary , our data indicates that over - expression of BC6OTHER at levels conferring high BC6ENTG - BC6ENTC conjugating activity confers a partial growth advantage to HepG2 cells and protects against BC6OTHER oxidative injury.	CPR:9
In summary , our data indicates that over - expression of BC6ENTG at levels conferring high BC6OTHER - BC6OTHER conjugating activity confers a partial growth advantage to HepG2 cells and protects against BC6ENTC oxidative injury.	False
In summary , our data indicates that over - expression of BC6OTHER at levels conferring high BC6ENTG - BC6OTHER conjugating activity confers a partial growth advantage to HepG2 cells and protects against BC6ENTC oxidative injury.	False
BC6OTHER ( BC6ENTC ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several BC6ENTG ( BC6OTHER ) isoforms.	CPR:9
BC6OTHER ( BC6ENTC ) is a mutagenic BC6OTHER produced during oxidative injury that is conjugated by several CHEM BC6OTHER - transferase ( BC6ENTG ) isoforms.	CPR:9
However , the loss of proliferative capacity of BC6ENTG cells challenged with levels of BC6ENTC associated with severe oxidative stress indicates a role of other BC6OTHER metabolizing enzymes , and / or BC6OTHER - electrophile transporter proteins , in providing full cellular protection against BC6OTHER toxicity.	CPR:9
However , the loss of proliferative capacity of BC6ENTG cells challenged with levels of BC6OTHER associated with severe oxidative stress indicates a role of other BC6ENTC metabolizing enzymes , and / or BC6OTHER - electrophile transporter proteins , in providing full cellular protection against BC6OTHER toxicity.	False
However , the loss of proliferative capacity of BC6ENTG cells challenged with levels of BC6OTHER associated with severe oxidative stress indicates a role of other BC6OTHER metabolizing enzymes , and / or BC6ENTC - electrophile transporter proteins , in providing full cellular protection against BC6OTHER toxicity.	False
However , the loss of proliferative capacity of BC6ENTG cells challenged with levels of BC6OTHER associated with severe oxidative stress indicates a role of other BC6OTHER metabolizing enzymes , and / or BC6OTHER - electrophile transporter proteins , in providing full cellular protection against BC6ENTC toxicity.	False
The alpha class BC6ENTG enzyme ( BC6OTHER ) has a particularly high catalytic efficiency toward BC6ENTC conjugation.	CPR:9
The alpha class BC6OTHER enzyme ( BC6ENTG ) has a particularly high catalytic efficiency toward BC6ENTC conjugation.	CPR:9
However , BC6ENTG expression is low in most human cells and there are other BC6ENTC metabolizing enzymes that detoxify BC6OTHER .	False
BC6OTHER ( BC6OTHER ) is a mutagenic BC6ENTC produced during oxidative injury that is conjugated by several BC6ENTG ( BC6OTHER ) isoforms.	CPR:9
BC6OTHER ( BC6OTHER ) is a mutagenic BC6ENTC produced during oxidative injury that is conjugated by several CHEM BC6OTHER - transferase ( BC6ENTG ) isoforms.	CPR:9
However , BC6ENTG expression is low in most human cells and there are other BC6OTHER metabolizing enzymes that detoxify BC6ENTC .	False
In the current study , we determined the effect of over - expression of BC6ENTG mRNA on the sensitivity of HepG2 cells to BC6ENTC injury.	False
HepG2 cells transfected with an BC6ENTG vector construct exhibited high steady - state BC6OTHER mRNA , high GST - BC6ENTC catalytic activities , but lower basal BC6OTHER ( BC6OTHER ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6OTHER vector construct exhibited high steady - state BC6ENTG mRNA , high GST - BC6ENTC catalytic activities , but lower basal BC6OTHER ( BC6OTHER ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6ENTG vector construct exhibited high steady - state BC6OTHER mRNA , high GST - BC6OTHER catalytic activities , but lower basal BC6ENTC ( BC6OTHER ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6OTHER vector construct exhibited high steady - state BC6ENTG mRNA , high GST - BC6OTHER catalytic activities , but lower basal BC6ENTC ( BC6OTHER ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6OTHER vector construct exhibited high steady - state BC6OTHER mRNA , high BC6ENTG - HNE catalytic activities , but lower basal BC6ENTC ( BC6OTHER ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6ENTG vector construct exhibited high steady - state BC6OTHER mRNA , high GST - BC6OTHER catalytic activities , but lower basal BC6OTHER ( BC6ENTC ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6OTHER vector construct exhibited high steady - state BC6ENTG mRNA , high GST - BC6OTHER catalytic activities , but lower basal BC6OTHER ( BC6ENTC ) concentrations relative to insert - free vector (control) cells.	False
HepG2 cells transfected with an BC6OTHER vector construct exhibited high steady - state BC6OTHER mRNA , high BC6ENTG - HNE catalytic activities , but lower basal BC6OTHER ( BC6ENTC ) concentrations relative to insert - free vector (control) cells.	False
Exposure to BC6ENTC elicited an increase in BC6OTHER concentrations in the control and BC6ENTG cells , although the dose - response of BC6OTHER induction differed among the two cell types.	False
Exposure to BC6OTHER elicited an increase in BC6ENTC concentrations in the control and BC6ENTG cells , although the dose - response of BC6OTHER induction differed among the two cell types.	False
Exposure to BC6OTHER elicited an increase in BC6OTHER concentrations in the control and BC6ENTG cells , although the dose - response of BC6ENTC induction differed among the two cell types.	False
Transfection of HepG2 cells with BC6ENTG provides protection against BC6ENTC - mediated oxidative injury.	False
In the presence of BC6OTHER blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6ENTC > BC6OTHER = BC6OTHER .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6ENTC > BC6OTHER = BC6OTHER .	False
In the presence of BC6OTHER blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6OTHER > BC6ENTC = BC6OTHER .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6OTHER > BC6ENTC = BC6OTHER .	False
In the presence of BC6OTHER blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6ENTC .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6OTHER suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6ENTC .	False
The selective BC6ENTG antagonists BC6ENTC and BC6OTHER blocked BC6OTHER - induced enhancement , with apparent K(b) values of 85 + / - 36 and 3.9 + / - 1.7 nM , respectively.	CPR:6
The selective BC6ENTG antagonists BC6OTHER and BC6ENTC blocked BC6OTHER - induced enhancement , with apparent K(b) values of 85 + / - 36 and 3.9 + / - 1.7 nM , respectively.	CPR:6
The selective BC6ENTG antagonists BC6OTHER and BC6OTHER blocked BC6ENTC - induced enhancement , with apparent K(b) values of 85 + / - 36 and 3.9 + / - 1.7 nM , respectively.	CPR:5
In higher cortical structures such as the hippocampus , BC6ENTC , via BC6ENTG ( BC6OTHER ) activation , has been shown to reinforce the cognitive processes of attention and memory.	False
In higher cortical structures such as the hippocampus , BC6ENTC , via BC6OTHER ( BC6ENTG ) activation , has been shown to reinforce the cognitive processes of attention and memory.	False
In contrast , the selective BC6ENTG antagonists BC6ENTC and BC6OTHER inhibited BC6OTHER - mediated enhancement with apparent low affinities (K(b) of 222 + / - 61 and 9268 + / - 512 nM , respectively).	CPR:6
In contrast , the selective BC6ENTG antagonists BC6OTHER and BC6ENTC inhibited BC6OTHER - mediated enhancement with apparent low affinities (K(b) of 222 + / - 61 and 9268 + / - 512 nM , respectively).	CPR:6
In contrast , the selective BC6ENTG antagonists BC6OTHER and BC6OTHER inhibited BC6ENTC - mediated enhancement with apparent low affinities (K(b) of 222 + / - 61 and 9268 + / - 512 nM , respectively).	CPR:5
Together , this pharmacological profile of subtype - selective BC6ENTG antagonists indicates that in this model , BC6OTHER activation is responsible for the enhanced hippocampal CA3 network activity initiated by BC6ENTC .	False
Together , this pharmacological profile of subtype - selective BC6OTHER antagonists indicates that in this model , BC6ENTG activation is responsible for the enhanced hippocampal CA3 network activity initiated by BC6ENTC .	CPR:5
The selective BC6ENTG agonist BC6ENTC caused an enhancement of hippocampal CA3 network activity , as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.	CPR:5
In the presence of BC6OTHER blockade , concentration - response curves for BC6ENTC , BC6OTHER , and BC6OTHER suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6ENTC , BC6OTHER , and BC6OTHER suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
In the presence of BC6OTHER blockade , concentration - response curves for BC6OTHER , BC6ENTC , and BC6OTHER suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6OTHER , BC6ENTC , and BC6OTHER suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
In the presence of BC6OTHER blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6ENTC suggested that a BC6ENTG was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
In the presence of BC6ENTG blockade , concentration - response curves for BC6OTHER , BC6OTHER , and BC6ENTC suggested that a BC6OTHER was involved in this response , and the rank order of potency was BC6OTHER > BC6OTHER = BC6OTHER .	False
Combining in vivo and in vitro findings , we identified nine BC6ENTG agonists , six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration , including BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:5
Combining in vivo and in vitro findings , we identified nine BC6ENTG agonists , six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration , including BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:5
Combining in vivo and in vitro findings , we identified nine BC6ENTG agonists , six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration , including BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:5
Expression of BC6OTHER and its related enzyme activity have long been used as a biomarker for BC6OTHER ( BC6ENTG ) activation and a warning of BC6ENTC - like toxicity.	False
Expression of BC6ENTG and its related enzyme activity have long been used as a biomarker for BC6OTHER ( BC6OTHER ) activation and a warning of BC6ENTC - like toxicity.	False
Expression of BC6OTHER and its related enzyme activity have long been used as a biomarker for BC6ENTG ( BC6OTHER ) activation and a warning of BC6ENTC - like toxicity.	False
These data demonstrate that induction of BC6ENTG is a nonspecific biomarker of direct BC6OTHER affinity and activation and lend further support to the hypothesis that BC6OTHER induction and / or BC6OTHER activation is not synonymous with BC6ENTC - like toxicity.	False
These data demonstrate that induction of BC6OTHER is a nonspecific biomarker of direct BC6ENTG affinity and activation and lend further support to the hypothesis that BC6OTHER induction and / or BC6OTHER activation is not synonymous with BC6ENTC - like toxicity.	False
These data demonstrate that induction of BC6OTHER is a nonspecific biomarker of direct BC6OTHER affinity and activation and lend further support to the hypothesis that BC6ENTG induction and / or BC6OTHER activation is not synonymous with BC6ENTC - like toxicity.	False
These data demonstrate that induction of BC6OTHER is a nonspecific biomarker of direct BC6OTHER affinity and activation and lend further support to the hypothesis that BC6OTHER induction and / or BC6ENTG activation is not synonymous with BC6ENTC - like toxicity.	False
Expression of BC6OTHER and its related enzyme activity have long been used as a biomarker for BC6ENTC receptor ( BC6ENTG ) activation and a warning of BC6OTHER - like toxicity.	False
Expression of BC6ENTG and its related enzyme activity have long been used as a biomarker for BC6ENTC receptor ( BC6OTHER ) activation and a warning of BC6OTHER - like toxicity.	False
Induction of BC6ENTG is a nonspecific biomarker of BC6ENTC receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro.	False
Absorption and secretion of BC6OTHER increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a BC6ENTG or a BC6ENTC / BC6OTHER antiporter.	False
Absorption and secretion of BC6OTHER increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a BC6ENTG or a F( - ) / BC6ENTC antiporter.	False
Absorption and secretion of BC6ENTC increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a F( - ) / BC6OTHER cotransporter or a BC6ENTG .	CPR:9
Absorption and secretion of BC6ENTC increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a BC6ENTG or a F( - ) / BC6OTHER antiporter.	CPR:9
Absorption and secretion of BC6OTHER increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a BC6ENTC / BC6OTHER cotransporter or a BC6ENTG .	False
Absorption and secretion of BC6OTHER increase at acid pH levels , possibly because of its non - ionized state at these pHs and / or because of participation of a F( - ) / BC6ENTC cotransporter or a BC6ENTG .	False
Moreover , activities of BC6ENTG and BC6OTHER enzymes were also significantly higher in both kinds of cells exposed to BC6ENTC NPs.	CPR:3
Moreover , activities of BC6OTHER and BC6ENTG enzymes were also significantly higher in both kinds of cells exposed to BC6ENTC NPs.	CPR:3
BC6ENTC NPs (concentration range 25 - 200 µg / ml) induced dose - dependent cytotoxicity in both types of cells , which was demonstrated by cell viability ( BC6OTHER ) and BC6ENTG leakage assays.	False
BC6OTHER NPs (concentration range 25 - 200 µg / ml) induced dose - dependent cytotoxicity in both types of cells , which was demonstrated by cell viability ( BC6ENTC ) and BC6ENTG leakage assays.	False
Quantitative real - time polymerase chain reaction analysis showed that following the exposure of cells to BC6ENTC NPs , the messenger RNA level of apoptotic genes ( BC6ENTG and BC6OTHER ) were upregulated in a dose - dependent manner.	CPR:3
Quantitative real - time polymerase chain reaction analysis showed that following the exposure of cells to BC6ENTC NPs , the messenger RNA level of apoptotic genes ( BC6OTHER and BC6ENTG ) were upregulated in a dose - dependent manner.	CPR:3
BC6ENTG binding affinity and activity were assessed using BC6ENTC binding , BC6OTHER ( BC6OTHER ) binding and isolated guinea - pig ileum.	False
BC6ENTG binding affinity and activity were assessed using BC6OTHER binding , BC6ENTC ( BC6OTHER ) binding and isolated guinea - pig ileum.	False
BC6ENTG binding affinity and activity were assessed using BC6OTHER binding , BC6OTHER ( BC6ENTC ) binding and isolated guinea - pig ileum.	False
Both BC6ENTC and BC6OTHER had high affinity for BC6OTHER (K (i) 1.36 ± 0.98 and 0.27 ± 0.08 , respectively) and were revealed as potent κ - antagonists (pA(2) 7.43 and 8.18 , respectively) and BC6ENTG antagonists (pA(2) 7.62 and 7.85 , respectively) in the ileum.	CPR:6
Both BC6ENTC and BC6OTHER had high affinity for BC6ENTG (K (i) 1.36 ± 0.98 and 0.27 ± 0.08 , respectively) and were revealed as potent κ - antagonists (pA(2) 7.43 and 8.18 , respectively) and BC6OTHER antagonists (pA(2) 7.62 and 7.85 , respectively) in the ileum.	False
Both BC6OTHER and BC6ENTC had high affinity for BC6OTHER (K (i) 1.36 ± 0.98 and 0.27 ± 0.08 , respectively) and were revealed as potent κ - antagonists (pA(2) 7.43 and 8.18 , respectively) and BC6ENTG antagonists (pA(2) 7.62 and 7.85 , respectively) in the ileum.	CPR:6
Both BC6OTHER and BC6ENTC had high affinity for BC6ENTG (K (i) 1.36 ± 0.98 and 0.27 ± 0.08 , respectively) and were revealed as potent κ - antagonists (pA(2) 7.43 and 8.18 , respectively) and BC6OTHER antagonists (pA(2) 7.62 and 7.85 , respectively) in the ileum.	False
In vivo and in vitro characterization of BC6ENTC - derived ligands at the BC6ENTG .	False
The anorexigenic effects of centrally injected BC6OTHER or BC6ENTG agonist were suppressed by blockade of the BC6OTHER , suggesting that BC6ENTC sensing involves endozepinergic control of the BC6OTHER pathway.	False
The anorexigenic effects of centrally injected BC6OTHER or BC6OTHER agonist were suppressed by blockade of the BC6ENTG , suggesting that BC6ENTC sensing involves endozepinergic control of the BC6OTHER pathway.	False
The anorexigenic effects of centrally injected BC6OTHER or BC6OTHER agonist were suppressed by blockade of the BC6OTHER , suggesting that BC6ENTC sensing involves endozepinergic control of the BC6ENTG pathway.	False
Finally , we found that brain BC6ENTG modulate blood BC6ENTC levels , suggesting their involvement in a feedback loop controlling whole - body BC6OTHER homeostasis.	False
Finally , we found that brain BC6ENTG modulate blood BC6OTHER levels , suggesting their involvement in a feedback loop controlling whole - body BC6ENTC homeostasis.	False
Collectively , these data indicate that BC6ENTG are a critical relay in brain BC6ENTC sensing and potentially new targets in treatment of metabolic disorders.	False
BC6ENTC - binding inhibitor ( BC6ENTG ) and its processing product the BC6OTHER ( BC6OTHER ) , collectively named BC6OTHER , are secreted by astroglia , and BC6OTHER is a potent anorexigenic factor.	False
BC6ENTC - binding inhibitor ( BC6OTHER ) and its processing product the BC6ENTG ( BC6OTHER ) , collectively named BC6OTHER , are secreted by astroglia , and BC6OTHER is a potent anorexigenic factor.	False
BC6ENTC - binding inhibitor ( BC6OTHER ) and its processing product the BC6OTHER ( BC6ENTG ) , collectively named BC6OTHER , are secreted by astroglia , and BC6OTHER is a potent anorexigenic factor.	False
BC6ENTC - binding inhibitor ( BC6OTHER ) and its processing product the BC6OTHER ( BC6OTHER ) , collectively named BC6ENTG , are secreted by astroglia , and BC6OTHER is a potent anorexigenic factor.	False
BC6ENTC - binding inhibitor ( BC6OTHER ) and its processing product the BC6OTHER ( BC6OTHER ) , collectively named BC6OTHER , are secreted by astroglia , and BC6ENTG is a potent anorexigenic factor.	False
First , we showed that intracerebroventricular administration of BC6ENTC in rats increases BC6ENTG expression in hypothalamic glial - like tanycytes.	CPR:3
Feeding experiments indicate that the anorexigenic effect of central administration of BC6ENTC was blunted by coinjection of an BC6ENTG antagonist.	False
The anorexigenic effects of centrally injected BC6ENTC or BC6ENTG agonist were suppressed by blockade of the BC6OTHER , suggesting that BC6OTHER sensing involves endozepinergic control of the BC6OTHER pathway.	False
The anorexigenic effects of centrally injected BC6ENTC or BC6OTHER agonist were suppressed by blockade of the BC6ENTG , suggesting that BC6OTHER sensing involves endozepinergic control of the BC6OTHER pathway.	False
The anorexigenic effects of centrally injected BC6ENTC or BC6OTHER agonist were suppressed by blockade of the BC6OTHER , suggesting that BC6OTHER sensing involves endozepinergic control of the BC6ENTG pathway.	False
Gliotransmission and brain BC6ENTC sensing: critical role of BC6ENTG .	False
The anti - inflammatory drugs BC6ENTC and BC6OTHER inhibited the activation of BC6ENTG , which further explains the mechanism of action of these drugs.	CPR:4
The anti - inflammatory drugs BC6OTHER and BC6ENTC inhibited the activation of BC6ENTG , which further explains the mechanism of action of these drugs.	CPR:4
BC6ENTC and BC6OTHER also inhibited BC6ENTG - dependent transcription from the BC6OTHER enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	CPR:4
BC6ENTC and BC6OTHER also inhibited BC6OTHER - dependent transcription from the BC6ENTG enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	CPR:4
BC6OTHER and BC6ENTC also inhibited BC6ENTG - dependent transcription from the BC6OTHER enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	CPR:4
BC6OTHER and BC6ENTC also inhibited BC6OTHER - dependent transcription from the BC6ENTG enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	CPR:4
After adjusting for age , sex , total BC6ENTC , BC6ENTG - CHEM and BC6OTHER , max - IMT was significantly increased in the highest tertile of BC6OTHER (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm , respectively; P=0.026).	False
After adjusting for age , sex , total BC6ENTC , BC6OTHER - CHEM and BC6OTHER , max - IMT was significantly increased in the highest tertile of BC6ENTG (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm , respectively; P=0.026).	False
After adjusting for age , sex , total BC6OTHER , BC6ENTG - CHEM and BC6ENTC , max - IMT was significantly increased in the highest tertile of BC6OTHER (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm , respectively; P=0.026).	False
After adjusting for age , sex , total BC6OTHER , BC6OTHER - CHEM and BC6ENTC , max - IMT was significantly increased in the highest tertile of BC6ENTG (0.969±0.033 vs 0.959±0.033 vs 1.077±0.033mm , respectively; P=0.026).	False
BC6ENTC , a lipid - lowering drug , inhibited BC6OTHER - induced production of BC6OTHER and the expression of BC6ENTG ( BC6OTHER ) in human U373MG astroglial cells and primary astrocytes.	CPR:4
BC6ENTC , a lipid - lowering drug , inhibited BC6OTHER - induced production of BC6OTHER and the expression of inducible BC6OTHER synthase ( BC6ENTG ) in human U373MG astroglial cells and primary astrocytes.	CPR:4
BC6ENTC , a lipid - lowering drug , inhibited BC6ENTG - induced production of BC6OTHER and the expression of inducible BC6OTHER synthase ( BC6OTHER ) in human U373MG astroglial cells and primary astrocytes.	CPR:4
BC6OTHER , a lipid - lowering drug , inhibited BC6OTHER - induced production of BC6OTHER and the expression of inducible BC6ENTC synthase ( BC6ENTG ) in human U373MG astroglial cells and primary astrocytes.	CPR:9
BC6OTHER , a lipid - lowering drug , inhibited BC6ENTG - induced production of BC6OTHER and the expression of inducible BC6ENTC synthase ( BC6OTHER ) in human U373MG astroglial cells and primary astrocytes.	False
The BC6ENTG contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6ENTG ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6ENTG ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
The BC6OTHER contains consensus sequences for the binding of transcription factors , including BC6OTHER ( BC6OTHER ) binding to BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) binding to gamma - activation site (GAS) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ); therefore , we investigated the effect of BC6ENTC on the activation of these transcription factors.	False
Interestingly , BC6ENTC strongly inhibited the activation of BC6ENTG , BC6OTHER , and BC6OTHER but not that of GAS in BC6OTHER - stimulated astroglial cells.	CPR:4
Interestingly , BC6ENTC strongly inhibited the activation of BC6OTHER , BC6ENTG , and BC6OTHER but not that of GAS in BC6OTHER - stimulated astroglial cells.	CPR:4
Interestingly , BC6ENTC strongly inhibited the activation of BC6OTHER , BC6OTHER , and BC6ENTG but not that of GAS in BC6OTHER - stimulated astroglial cells.	CPR:4
Interestingly , BC6ENTC strongly inhibited the activation of BC6OTHER , BC6OTHER , and BC6OTHER but not that of GAS in BC6ENTG - stimulated astroglial cells.	False
These results suggest that BC6ENTC inhibits the induction of BC6ENTG probably by inhibiting the activation of BC6OTHER , BC6OTHER , and BC6OTHER and that BC6OTHER , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	CPR:4
These results suggest that BC6ENTC inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6ENTG , BC6OTHER , and BC6OTHER and that BC6OTHER , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	CPR:4
These results suggest that BC6ENTC inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6OTHER , BC6ENTG , and BC6OTHER and that BC6OTHER , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	CPR:4
These results suggest that BC6ENTC inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6OTHER , BC6OTHER , and BC6ENTG and that BC6OTHER , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	CPR:4
Similar to BC6ENTC , BC6OTHER , another BC6OTHER drug , also inhibited the expression of BC6ENTG .	CPR:4
These results suggest that BC6OTHER inhibits the induction of BC6ENTG probably by inhibiting the activation of BC6OTHER , BC6OTHER , and BC6OTHER and that BC6ENTC , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	False
These results suggest that BC6OTHER inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6ENTG , BC6OTHER , and BC6OTHER and that BC6ENTC , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	False
These results suggest that BC6OTHER inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6OTHER , BC6ENTG , and BC6OTHER and that BC6ENTC , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	False
These results suggest that BC6OTHER inhibits the induction of BC6OTHER probably by inhibiting the activation of BC6OTHER , BC6OTHER , and BC6ENTG and that BC6ENTC , a prescribed drug for humans , may further find its therapeutic use in neuroinflammatory diseases.	False
Similar to BC6OTHER , BC6ENTC , another BC6OTHER drug , also inhibited the expression of BC6ENTG .	CPR:4
Similar to BC6OTHER , BC6OTHER , another BC6ENTC drug , also inhibited the expression of BC6ENTG .	CPR:4
Inhibition of BC6ENTG - driven luciferase activity by BC6ENTC in BC6OTHER - stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of BC6OTHER .	CPR:4
Inhibition of BC6OTHER - driven luciferase activity by BC6ENTC in BC6ENTG - stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of BC6OTHER .	False
Inhibition of BC6OTHER - driven luciferase activity by BC6ENTC in BC6OTHER - stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of BC6ENTG .	CPR:4
Since BC6ENTC is known to activate BC6ENTG ( BC6OTHER ) , we investigated the role of BC6OTHER in BC6OTHER - mediated inhibition of BC6OTHER .	CPR:3
Since BC6ENTC is known to activate BC6OTHER ( BC6ENTG ) , we investigated the role of BC6OTHER in BC6OTHER - mediated inhibition of BC6OTHER .	CPR:3
Since BC6ENTC is known to activate BC6OTHER ( BC6OTHER ) , we investigated the role of BC6ENTG in BC6OTHER - mediated inhibition of BC6OTHER .	False
Since BC6ENTC is known to activate BC6OTHER ( BC6OTHER ) , we investigated the role of BC6OTHER in BC6OTHER - mediated inhibition of BC6ENTG .	False
Since BC6OTHER is known to activate BC6ENTG ( BC6OTHER ) , we investigated the role of BC6OTHER in BC6ENTC - mediated inhibition of BC6OTHER .	False
Since BC6OTHER is known to activate BC6OTHER ( BC6ENTG ) , we investigated the role of BC6OTHER in BC6ENTC - mediated inhibition of BC6OTHER .	False
Since BC6OTHER is known to activate BC6OTHER ( BC6OTHER ) , we investigated the role of BC6ENTG in BC6ENTC - mediated inhibition of BC6OTHER .	CPR:3
Since BC6OTHER is known to activate BC6OTHER ( BC6OTHER ) , we investigated the role of BC6OTHER in BC6ENTC - mediated inhibition of BC6ENTG .	CPR:4
BC6ENTC induced BC6ENTG ( BC6OTHER ) - dependent luciferase activity , which was inhibited by the expression of BC6OTHER , the dominant - negative mutant of BC6OTHER .	CPR:3
BC6ENTC induced BC6OTHER ( BC6ENTG ) - dependent luciferase activity , which was inhibited by the expression of BC6OTHER , the dominant - negative mutant of BC6OTHER .	CPR:3
BC6ENTC induced BC6OTHER ( BC6OTHER ) - dependent luciferase activity , which was inhibited by the expression of BC6ENTG , the dominant - negative mutant of BC6OTHER .	False
BC6ENTC induced BC6OTHER ( BC6OTHER ) - dependent luciferase activity , which was inhibited by the expression of BC6OTHER , the dominant - negative mutant of BC6ENTG .	False
BC6OTHER , a lipid - lowering drug , inhibited BC6OTHER - induced production of BC6ENTC and the expression of BC6ENTG ( BC6OTHER ) in human U373MG astroglial cells and primary astrocytes.	CPR:9
BC6OTHER , a lipid - lowering drug , inhibited BC6OTHER - induced production of BC6ENTC and the expression of inducible BC6OTHER synthase ( BC6ENTG ) in human U373MG astroglial cells and primary astrocytes.	CPR:9
BC6OTHER , a lipid - lowering drug , inhibited BC6ENTG - induced production of BC6ENTC and the expression of inducible BC6OTHER synthase ( BC6OTHER ) in human U373MG astroglial cells and primary astrocytes.	False
However , BC6OTHER was unable to abrogate BC6ENTC - mediated inhibition of BC6OTHER suggesting that BC6OTHER inhibits BC6ENTG independent of BC6OTHER .	False
However , BC6OTHER was unable to abrogate BC6ENTC - mediated inhibition of BC6OTHER suggesting that BC6OTHER inhibits BC6OTHER independent of BC6ENTG .	False
However , BC6ENTG was unable to abrogate BC6ENTC - mediated inhibition of BC6OTHER suggesting that BC6OTHER inhibits BC6OTHER independent of BC6OTHER .	False
However , BC6OTHER was unable to abrogate BC6ENTC - mediated inhibition of BC6ENTG suggesting that BC6OTHER inhibits BC6OTHER independent of BC6OTHER .	CPR:4
However , BC6OTHER was unable to abrogate BC6OTHER - mediated inhibition of BC6OTHER suggesting that BC6ENTC inhibits BC6ENTG independent of BC6OTHER .	CPR:4
However , BC6OTHER was unable to abrogate BC6OTHER - mediated inhibition of BC6OTHER suggesting that BC6ENTC inhibits BC6OTHER independent of BC6ENTG .	False
However , BC6ENTG was unable to abrogate BC6OTHER - mediated inhibition of BC6OTHER suggesting that BC6ENTC inhibits BC6OTHER independent of BC6OTHER .	False
However , BC6OTHER was unable to abrogate BC6OTHER - mediated inhibition of BC6ENTG suggesting that BC6ENTC inhibits BC6OTHER independent of BC6OTHER .	False
 BC6ENTC , a lipid - lowering drug , inhibits the induction of BC6ENTG in human astrocytes.	CPR:4
 BC6ENTC receptors / BC6ENTG genes in human cancer.	False
Potentiation was prevented by BC6ENTG , the BC6OTHER / BC6OTHER mimetic BC6OTHER and the BC6ENTC oxidase inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6ENTG / BC6OTHER mimetic BC6OTHER and the BC6ENTC oxidase inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6ENTG mimetic BC6OTHER and the BC6ENTC oxidase inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6OTHER mimetic BC6OTHER and the BC6ENTG inhibitor BC6ENTC .	CPR:4
Potentiation was prevented by BC6ENTG , the BC6OTHER / BC6OTHER mimetic BC6OTHER and the BC6OTHER inhibitor BC6ENTC .	False
Potentiation was prevented by BC6OTHER , the BC6ENTG / BC6OTHER mimetic BC6OTHER and the BC6OTHER inhibitor BC6ENTC .	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6ENTG mimetic BC6OTHER and the BC6OTHER inhibitor BC6ENTC .	False
Our results suggest that BC6ENTC can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6ENTG can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6OTHER activity.	False
Our results suggest that BC6ENTC can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6OTHER can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6ENTG activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6ENTC , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6ENTG can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6OTHER activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6ENTC , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6OTHER can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6ENTG activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6ENTC anion generated by BC6ENTG can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6OTHER activity.	CPR:9
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6ENTC anion generated by BC6OTHER can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6ENTG activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6ENTC oxidase can potentially offset loss of BC6OTHER bioavailability under conditions of reduced BC6ENTG activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6ENTG can potentially offset loss of BC6ENTC bioavailability under conditions of reduced BC6OTHER activity.	False
Our results suggest that BC6OTHER can potentiate EDHF - type relaxations via a mechanism that is dependent on BC6OTHER , thus demonstrating that dismutation of the BC6OTHER anion generated by BC6OTHER can potentially offset loss of BC6ENTC bioavailability under conditions of reduced BC6ENTG activity.	False
Endothelium - dependent relaxations , BC6ENTC ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	False
Endothelium - dependent relaxations , BC6ENTC ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6ENTC ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6ENTC ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6ENTC ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	CPR:5
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6ENTC ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6ENTC ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	CPR:5
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6ENTC ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6OTHER ) and by BC6ENTC ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6OTHER ) and by BC6ENTC ( BC6OTHER ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	CPR:4
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6ENTC ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6OTHER pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6ENTC ) , which promotes store - operated BC6OTHER entry by inhibiting the endothelial BC6ENTG pump.	CPR:4
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6ENTG agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6ENTC entry by inhibiting the endothelial BC6OTHER pump.	False
Endothelium - dependent relaxations , BC6OTHER ( BC6OTHER ) and endothelium derived hyperpolarizing factor (EDHF) - type , were studied in rabbit iliac artery and aortic rings using the BC6OTHER agonist BC6OTHER ( BC6OTHER ) and by BC6OTHER ( BC6OTHER ) , which promotes store - operated BC6ENTC entry by inhibiting the endothelial BC6ENTG pump.	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6ENTC dismutase mimetic BC6OTHER and the BC6ENTG inhibitor BC6OTHER .	False
Potentiation was prevented by BC6ENTG , the BC6OTHER / BC6ENTC dismutase mimetic BC6OTHER and the BC6OTHER inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6ENTG / BC6ENTC dismutase mimetic BC6OTHER and the BC6OTHER inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6OTHER mimetic BC6ENTC and the BC6ENTG inhibitor BC6OTHER .	False
Potentiation was prevented by BC6ENTG , the BC6OTHER / BC6OTHER mimetic BC6ENTC and the BC6OTHER inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6ENTG / BC6OTHER mimetic BC6ENTC and the BC6OTHER inhibitor BC6OTHER .	False
Potentiation was prevented by BC6OTHER , the BC6OTHER / BC6ENTG mimetic BC6ENTC and the BC6OTHER inhibitor BC6OTHER .	False
The effect of inorganic BC6ENTC on endothelium - dependent relaxation: Role of BC6ENTG and BC6OTHER .	False
The effect of inorganic BC6OTHER on endothelium - dependent relaxation: Role of BC6ENTG and BC6ENTC .	False
BC6ENTC esterase ( BC6ENTG ) induced surface erosion of BC6OTHER ( BC6OTHER ) and drug release from BC6OTHER under mild physiological environment was investigated.	False
BC6ENTG ( BC6OTHER ) induced surface erosion of BC6OTHER ( BC6OTHER ) and drug release from BC6ENTC under mild physiological environment was investigated.	False
BC6OTHER ( BC6ENTG ) induced surface erosion of BC6OTHER ( BC6OTHER ) and drug release from BC6ENTC under mild physiological environment was investigated.	False
BC6ENTG ( BC6OTHER ) induced surface erosion of BC6ENTC ( BC6OTHER ) and drug release from BC6OTHER under mild physiological environment was investigated.	CPR:9
BC6OTHER ( BC6ENTG ) induced surface erosion of BC6ENTC ( BC6OTHER ) and drug release from BC6OTHER under mild physiological environment was investigated.	CPR:9
By this mechanism , BC6ENTG - responsive drug in vitro release from BC6ENTC in situ forming depots (ISFD) was conducted successfully.	False
As expected , less BC6ENTG ( BC6OTHER ) was released from BC6ENTC 41 compared with that of BC6OTHER 200 in the same time period.	False
As expected , less BC6OTHER ( BC6ENTG ) was released from BC6ENTC 41 compared with that of BC6OTHER 200 in the same time period.	False
BC6ENTG ( BC6OTHER ) induced surface erosion of BC6OTHER ( BC6ENTC ) and drug release from BC6OTHER under mild physiological environment was investigated.	CPR:9
BC6OTHER ( BC6ENTG ) induced surface erosion of BC6OTHER ( BC6ENTC ) and drug release from BC6OTHER under mild physiological environment was investigated.	CPR:9
As expected , less BC6ENTG ( BC6OTHER ) was released from BC6OTHER 41 compared with that of BC6ENTC 200 in the same time period.	False
As expected , less BC6OTHER ( BC6ENTG ) was released from BC6OTHER 41 compared with that of BC6ENTC 200 in the same time period.	False
BC6ENTC ( BC6OTHER ) , is a naturally occurring potent reversible BC6ENTG inhibitor that penetrates the blood - brain barrier.	CPR:4
BC6OTHER ( BC6ENTC ) , is a naturally occurring potent reversible BC6ENTG inhibitor that penetrates the blood - brain barrier.	CPR:4
The synthetic stereoisomer , BC6ENTC , is less toxic due to poor BC6ENTG inhibition and is suitable for both pre - / post - exposure treatments of nerve agent toxicity.	CPR:4
These results support the hypothesis that apoplastic BC6ENTC acting through heteromeric BC6ENTG / BC6OTHER channels affect lateral root development via BC6OTHER signaling in the phloem.	False
These results support the hypothesis that apoplastic BC6ENTC acting through heteromeric BC6OTHER / BC6ENTG channels affect lateral root development via BC6OTHER signaling in the phloem.	False
These results support the hypothesis that apoplastic BC6OTHER acting through heteromeric BC6ENTG / BC6OTHER channels affect lateral root development via BC6ENTC signaling in the phloem.	False
These results support the hypothesis that apoplastic BC6OTHER acting through heteromeric BC6OTHER / BC6ENTG channels affect lateral root development via BC6ENTC signaling in the phloem.	False
Molecular , genetic , and electrophysiological evidence indicates that at least one of the plant BC6OTHER - like molecules , BC6ENTG , functions as an BC6ENTC - gated BC6OTHER channel at the plasma membrane.	False
Molecular , genetic , and electrophysiological evidence indicates that at least one of the plant BC6ENTG - like molecules , BC6OTHER , functions as an BC6ENTC - gated BC6OTHER channel at the plasma membrane.	False
Molecular , genetic , and electrophysiological evidence indicates that at least one of the plant BC6OTHER - like molecules , BC6ENTG , functions as an CHEM - gated BC6ENTC channel at the plasma membrane.	False
Molecular , genetic , and electrophysiological evidence indicates that at least one of the plant BC6ENTG - like molecules , BC6OTHER , functions as an CHEM - gated BC6ENTC channel at the plasma membrane.	False
The replacement of the conserved BC6OTHER residues in e2 of BC6OTHER by BC6OTHER also eliminated BC6ENTC binding , but replacement of those in BC6ENTG resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
The replacement of the conserved BC6OTHER residues in e2 of BC6ENTG by BC6OTHER also eliminated BC6ENTC binding , but replacement of those in BC6OTHER resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
The BC6ENTG thus plays some role in BC6ENTC binding but none in BC6OTHER recognition , binding of the latter clearly implicating residues in the adjoining transmembrane helices.	False
The BC6ENTG thus plays some role in BC6OTHER binding but none in BC6ENTC recognition , binding of the latter clearly implicating residues in the adjoining transmembrane helices.	False
The antagonist BC6ENTC has a high specificity for the central BC6OTHER BC6OTHER and negligeable affinity for the peripheral BC6ENTG receptor , making it an excellent tool for probing receptor structure - activity relationships.	False
The antagonist BC6ENTC has a high specificity for the central BC6ENTG BC6OTHER and negligeable affinity for the peripheral BC6OTHER receptor , making it an excellent tool for probing receptor structure - activity relationships.	False
The antagonist BC6ENTC has a high specificity for the central BC6OTHER BC6ENTG and negligeable affinity for the peripheral BC6OTHER receptor , making it an excellent tool for probing receptor structure - activity relationships.	False
From binding experiments with mutated BC6ENTG and with chimeric BC6OTHER / BC6OTHER receptors we have begun to identify the domains of BC6OTHER implicated in the recognition of BC6ENTC .	False
From binding experiments with mutated BC6OTHER and with chimeric BC6ENTG / BC6OTHER receptors we have begun to identify the domains of BC6OTHER implicated in the recognition of BC6ENTC .	False
From binding experiments with mutated BC6OTHER and with chimeric BC6OTHER / BC6ENTG receptors we have begun to identify the domains of BC6OTHER implicated in the recognition of BC6ENTC .	False
From binding experiments with mutated BC6OTHER and with chimeric BC6OTHER / BC6OTHER receptors we have begun to identify the domains of BC6ENTG implicated in the recognition of BC6ENTC .	False
The antagonist BC6OTHER has a high specificity for the central BC6OTHER BC6ENTC receptor and negligeable affinity for the peripheral BC6ENTG receptor , making it an excellent tool for probing receptor structure - activity relationships.	False
The antagonist BC6OTHER has a high specificity for the central BC6ENTG BC6ENTC receptor and negligeable affinity for the peripheral BC6OTHER receptor , making it an excellent tool for probing receptor structure - activity relationships.	False
The region delineated by the fourth and fifth transmembrane helices of BC6ENTG proved to be crucial for high affinity binding of BC6ENTC .	False
The BC6ENTG and BC6OTHER second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6ENTC binding in the BC6OTHER variant but that eliminated BC6OTHER binding in both mutants.	False
The BC6OTHER and BC6ENTG second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6ENTC binding in the BC6OTHER variant but that eliminated BC6OTHER binding in both mutants.	False
The BC6OTHER and BC6OTHER second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6ENTC binding in the BC6ENTG variant but that eliminated BC6OTHER binding in both mutants.	False
The BC6ENTG and BC6OTHER second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6OTHER binding in the BC6OTHER variant but that eliminated BC6ENTC binding in both mutants.	False
The BC6OTHER and BC6ENTG second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6OTHER binding in the BC6OTHER variant but that eliminated BC6ENTC binding in both mutants.	False
The BC6OTHER and BC6OTHER second extracellular loops , e2 , were exchanged , modifications that had no effect on BC6OTHER binding in the BC6ENTG variant but that eliminated BC6ENTC binding in both mutants.	False
The replacement of the conserved BC6ENTC residues in e2 of BC6OTHER by BC6OTHER also eliminated BC6OTHER binding , but replacement of those in BC6ENTG resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
The replacement of the conserved BC6ENTC residues in e2 of BC6ENTG by BC6OTHER also eliminated BC6OTHER binding , but replacement of those in BC6OTHER resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
The replacement of the conserved BC6OTHER residues in e2 of BC6OTHER by BC6ENTC also eliminated BC6OTHER binding , but replacement of those in BC6ENTG resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
The replacement of the conserved BC6OTHER residues in e2 of BC6ENTG by BC6ENTC also eliminated BC6OTHER binding , but replacement of those in BC6OTHER resulted in the sequestration of the mutated receptors in the cell cytoplasm.	False
Structural features of the central BC6OTHER BC6OTHER receptor involved in the binding of the specific BC6ENTG antagonist BC6ENTC .	CPR:6
Structural features of the central BC6OTHER BC6ENTG receptor involved in the binding of the specific BC6OTHER antagonist BC6ENTC .	False
Structural features of the central BC6ENTC BC6OTHER receptor involved in the binding of the specific BC6ENTG antagonist BC6OTHER .	False
Structural features of the central BC6ENTC BC6ENTG receptor involved in the binding of the specific BC6OTHER antagonist BC6OTHER .	False
Some of the most commonly affected assays were BC6ENTG ( BC6OTHER , BC6OTHER ) , transporters (mitochondrial TSPO , BC6ENTC , dopaminergic) , and BC6OTHER (aminergic).	False
Some of the most commonly affected assays were BC6OTHER ( BC6ENTG , BC6OTHER ) , transporters (mitochondrial TSPO , BC6ENTC , dopaminergic) , and BC6OTHER (aminergic).	False
Some of the most commonly affected assays were BC6OTHER ( BC6OTHER , BC6ENTG ) , transporters (mitochondrial TSPO , BC6ENTC , dopaminergic) , and BC6OTHER (aminergic).	False
Some of the most commonly affected assays were BC6OTHER ( BC6OTHER , BC6OTHER ) , transporters (mitochondrial TSPO , BC6ENTC , dopaminergic) , and BC6ENTG (aminergic).	False
Heavy metals , surfactants , and BC6ENTC fungicides showed promiscuous , but distinctly different patterns of activity whereas many of the pharma compounds showed promiscuous activity across BC6ENTG .	False
INTRODUCTION: In this study , we examined the effects of the BC6ENTG inhibitors BC6OTHER and BC6ENTC on postprandial plasma BC6OTHER and serum CHEM levels in patients with type 2 diabetes mellitus.	CPR:4
INTRODUCTION: In this study , we examined the effects of the BC6ENTG inhibitors BC6OTHER and BC6OTHER on postprandial plasma BC6ENTC and serum CHEM levels in patients with type 2 diabetes mellitus.	CPR:4
No significant changes in serum high - density lipoprotein BC6ENTC levels were observed in either group , whereas serum BC6ENTG BC6OTHER levels decreased significantly from 3.20+ / - 0.25 to 2.65+ / - 0.18 mmol / L (P=0.04) , only in the high - dose group.	False
No significant changes in serum high - density lipoprotein BC6OTHER levels were observed in either group , whereas serum BC6ENTG BC6ENTC levels decreased significantly from 3.20+ / - 0.25 to 2.65+ / - 0.18 mmol / L (P=0.04) , only in the high - dose group.	False
INTRODUCTION: In this study , we examined the effects of the BC6ENTG inhibitors BC6ENTC and BC6OTHER on postprandial plasma BC6OTHER and serum CHEM levels in patients with type 2 diabetes mellitus.	CPR:4
Furthermore , the BC6OTHER channel blockers BC6ENTC and BC6OTHER were less effective in inhibiting BC6ENTG currents when BC6OTHER was co - expressed.	False
Furthermore , the BC6OTHER channel blockers BC6ENTC and BC6OTHER were less effective in inhibiting BC6OTHER currents when BC6ENTG was co - expressed.	False
Furthermore , the BC6ENTG channel blockers BC6ENTC and BC6OTHER were less effective in inhibiting BC6OTHER currents when BC6OTHER was co - expressed.	CPR:4
Furthermore , the BC6OTHER channel blockers BC6OTHER and BC6ENTC were less effective in inhibiting BC6ENTG currents when BC6OTHER was co - expressed.	False
Furthermore , the BC6OTHER channel blockers BC6OTHER and BC6ENTC were less effective in inhibiting BC6OTHER currents when BC6ENTG was co - expressed.	False
Furthermore , the BC6ENTG channel blockers BC6OTHER and BC6ENTC were less effective in inhibiting BC6OTHER currents when BC6OTHER was co - expressed.	CPR:4
A candidate regulatory protein of BC6ENTG is the BC6ENTC channel subunit Kvbeta3 , previously identified by bacterial two - hybrid strategies.	False
BC6ENTG is known to accelerate inactivation of otherwise slowly inactivating BC6ENTC channels under reducing conditions.	False
The BC6ENTC channel subunit Kvbeta3 interacts with BC6ENTG and attenuates its sensitivity to changes in redox potentials.	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6ENTG in the BC6ENTC mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6OTHER in the BC6ENTC mediated stimulation of BC6ENTG subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	CPR:3
In addition to this evidence (for the involvement of BC6ENTG ) , evidence for the involvement of BC6OTHER in the BC6ENTC mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6ENTG in the BC6OTHER mediated stimulation of BC6ENTC , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6ENTG ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of BC6ENTC , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6ENTG in the BC6OTHER mediated stimulation of CHEM , BC6ENTC - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6ENTG ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of CHEM , BC6ENTC - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6ENTG in the BC6OTHER mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6ENTC , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of BC6ENTG subunit gene transcription includes the stimulatory effect of BC6ENTC , as well as the inhibitory effects of BC6OTHER .	CPR:3
In addition to this evidence (for the involvement of BC6ENTG ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6ENTC , as well as the inhibitory effects of BC6OTHER .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6ENTG in the BC6OTHER mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6ENTC .	False
In addition to this evidence (for the involvement of BC6OTHER ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of BC6ENTG subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6ENTC .	CPR:4
In addition to this evidence (for the involvement of BC6ENTG ) , evidence for the involvement of BC6OTHER in the BC6OTHER mediated stimulation of CHEM , BC6OTHER - ATPase beta subunit gene transcription includes the stimulatory effect of BC6OTHER , as well as the inhibitory effects of BC6ENTC .	False
Also consistent with the involvement of BC6ENTG coupled BC6OTHER , the BC6ENTC stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6ENTG , the BC6ENTC stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6ENTC stimulation is inhibited by the BC6ENTG vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6ENTC stimulation is inhibited by the BC6OTHER vector (encoding the BC6ENTG ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6ENTC stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6ENTG inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6ENTC stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6ENTG antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6ENTG coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6ENTC , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6ENTG , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6ENTC , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6ENTG vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6ENTC , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6ENTG ) , the BC6OTHER inhibitor BC6ENTC , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6ENTG inhibitor BC6ENTC , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	CPR:4
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6ENTC , BC6OTHER , as well as the BC6ENTG antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6ENTG coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6ENTC , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6ENTG , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6ENTC , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6ENTG vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6ENTC , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6ENTG ) , the BC6OTHER inhibitor BC6OTHER , BC6ENTC , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6ENTG inhibitor BC6OTHER , BC6ENTC , as well as the BC6OTHER antagonists BC6OTHER and BC6OTHER .	CPR:4
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6ENTC , as well as the BC6ENTG antagonists BC6OTHER and BC6OTHER .	False
Also consistent with the involvement of BC6ENTG coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6ENTC and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6ENTG , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6ENTC and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6ENTG vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6ENTC and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6ENTG ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6ENTC and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6ENTG inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6ENTC and BC6OTHER .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6ENTG antagonists BC6ENTC and BC6OTHER .	CPR:6
Also consistent with the involvement of BC6ENTG coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6ENTC .	False
Also consistent with the involvement of BC6OTHER coupled BC6ENTG , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6ENTC .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6ENTG vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6ENTC .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6ENTG ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6ENTC .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6ENTG inhibitor BC6OTHER , BC6OTHER , as well as the BC6OTHER antagonists BC6OTHER and BC6ENTC .	False
Also consistent with the involvement of BC6OTHER coupled BC6OTHER , the BC6OTHER stimulation is inhibited by the BC6OTHER vector (encoding the BC6OTHER ) , the BC6OTHER inhibitor BC6OTHER , BC6OTHER , as well as the BC6ENTG antagonists BC6OTHER and BC6ENTC .	CPR:6
The involvement of BC6ENTG and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6ENTC , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6ENTG is indicated by studies with the BC6OTHER selective agonist BC6ENTC , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6ENTG selective agonist BC6ENTC , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6ENTC , and the BC6ENTG selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6ENTC , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6ENTG and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6ENTC , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6ENTG specific).	False
The involvement of BC6ENTG and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6ENTG is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6ENTG selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6ENTG selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6ENTG and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6ENTC (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6OTHER ( BC6OTHER and BC6ENTG specific).	False
The involvement of BC6ENTG and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6ENTG is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6ENTG selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6ENTG selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6OTHER and BC6OTHER specific).	False
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6ENTG and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6ENTC (EP1 specific) and BC6OTHER ( BC6OTHER and BC6ENTG specific).	False
The involvement of BC6ENTG and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6ENTG is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6ENTG selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6ENTG selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6OTHER and BC6OTHER specific).	CPR:5
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6ENTG and BC6OTHER specific).	CPR:6
The involvement of BC6OTHER and BC6OTHER is indicated by studies with the BC6OTHER selective agonist BC6OTHER , and the BC6OTHER selective agonist BC6OTHER (which stimulate) , as well as by studies with the antagonists BC6OTHER (EP1 specific) and BC6ENTC ( BC6OTHER and BC6ENTG specific).	CPR:6
Consistent with the involvement of BC6ENTG coupled BC6OTHER , is that the BC6ENTC stimulation is inhibited by the BC6OTHER expression vector (encoding the BC6OTHER ) , as well as by the BC6OTHER PKI.	False
Consistent with the involvement of BC6OTHER coupled BC6ENTG , is that the BC6ENTC stimulation is inhibited by the BC6OTHER expression vector (encoding the BC6OTHER ) , as well as by the BC6OTHER PKI.	False
Consistent with the involvement of BC6OTHER coupled BC6OTHER , is that the BC6ENTC stimulation is inhibited by the BC6ENTG expression vector (encoding the BC6OTHER ) , as well as by the BC6OTHER PKI.	False
Consistent with the involvement of BC6OTHER coupled BC6OTHER , is that the BC6ENTC stimulation is inhibited by the BC6OTHER expression vector (encoding the BC6ENTG ) , as well as by the BC6OTHER PKI.	False
Consistent with the involvement of BC6OTHER coupled BC6OTHER , is that the BC6ENTC stimulation is inhibited by the BC6OTHER expression vector (encoding the BC6OTHER ) , as well as by the BC6ENTG PKI.	False
Involvement of BC6ENTG and BC6OTHER in the regulation of the BC6ENTC , BC6OTHER - ATPase by BC6OTHER in MDCK cells.	False
Involvement of BC6OTHER and BC6ENTG in the regulation of the BC6ENTC , BC6OTHER - ATPase by BC6OTHER in MDCK cells.	False
Involvement of BC6ENTG and BC6OTHER in the regulation of the CHEM , BC6ENTC - ATPase by BC6OTHER in MDCK cells.	False
Involvement of BC6OTHER and BC6ENTG in the regulation of the CHEM , BC6ENTC - ATPase by BC6OTHER in MDCK cells.	False
Involvement of BC6ENTG and BC6OTHER in the regulation of the CHEM , BC6OTHER - ATPase by BC6ENTC in MDCK cells.	False
Involvement of BC6OTHER and BC6ENTG in the regulation of the CHEM , BC6OTHER - ATPase by BC6ENTC in MDCK cells.	False
Involvement of BC6OTHER and BC6OTHER in the regulation of the BC6ENTG by BC6ENTC in MDCK cells.	False
Finally , molecular modeling and BC6OTHER - and BC6OTHER - NMR studies performed on compounds 6c , d , 9c , and 10b allowed the right conformation of BC6ENTC side chain of these molecules within the BC6ENTG active site to be assessed.	False
New classes of BC6ENTC - derived BC6OTHER inverse BC6OTHER , BC6OTHER , and BC6OTHER (7 - 10) as BC6ENTG selective inhibitors and BC6OTHER donors were synthesized and are herein reported.	CPR:4
New classes of BC6OTHER - derived BC6ENTC inverse BC6OTHER , BC6OTHER , and BC6OTHER (7 - 10) as BC6ENTG selective inhibitors and BC6OTHER donors were synthesized and are herein reported.	CPR:4
New classes of BC6OTHER - derived BC6OTHER inverse BC6ENTC , BC6OTHER , and BC6OTHER (7 - 10) as BC6ENTG selective inhibitors and BC6OTHER donors were synthesized and are herein reported.	CPR:4
New classes of BC6OTHER - derived BC6OTHER inverse BC6OTHER , BC6ENTC , and BC6OTHER (7 - 10) as BC6ENTG selective inhibitors and BC6OTHER donors were synthesized and are herein reported.	CPR:4
New classes of BC6OTHER - derived BC6OTHER inverse BC6OTHER , BC6OTHER , and BC6ENTC (7 - 10) as BC6ENTG selective inhibitors and BC6OTHER donors were synthesized and are herein reported.	CPR:4
New classes of BC6OTHER - derived BC6OTHER inverse BC6OTHER , BC6OTHER , and BC6OTHER (7 - 10) as BC6ENTG selective inhibitors and BC6ENTC donors were synthesized and are herein reported.	False
BC6ENTC derivatives showed BC6OTHER - dependent vasorelaxing properties , while most of the compounds proved to be very potent and selective BC6ENTG inhibitors in in vitro experimental models.	CPR:4
BC6OTHER derivatives showed BC6ENTC - dependent vasorelaxing properties , while most of the compounds proved to be very potent and selective BC6ENTG inhibitors in in vitro experimental models.	False
Finally , molecular modeling and BC6ENTC - and BC6OTHER - NMR studies performed on compounds 6c , d , 9c , and 10b allowed the right conformation of BC6OTHER side chain of these molecules within the BC6ENTG active site to be assessed.	False
Finally , molecular modeling and BC6OTHER - and BC6ENTC - NMR studies performed on compounds 6c , d , 9c , and 10b allowed the right conformation of BC6OTHER side chain of these molecules within the BC6ENTG active site to be assessed.	False
Novel analgesic / anti - inflammatory agents: BC6OTHER and related compounds as BC6ENTG inhibiting BC6ENTC donors.	CPR:4
Novel analgesic / anti - inflammatory agents: BC6ENTC and related compounds as BC6ENTG inhibiting BC6OTHER donors.	CPR:4
The anti - inflammatory effects of WOE were closely attributed to decreased levels of tissue BC6ENTC and BC6ENTG ( BC6OTHER ).	False
The anti - inflammatory effects of WOE were closely attributed to decreased levels of tissue BC6ENTC and BC6OTHER ( BC6ENTG ).	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6ENTG ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6ENTG ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTC dismutase ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6ENTC peroxidase ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTC peroxidase ( BC6ENTG ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in vivo. Further , WOE also decreased the number of BC6ENTC - induced writhing responses and BC6OTHER - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , and BC6OTHER ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6ENTG ( BC6OTHER ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
 Further evidence for WOE's protection is shown in the reduction of lipid oxidation and the increase of antioxidant enzyme activities , including BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , and BC6OTHER ( BC6ENTG ) in vivo. Further , WOE also decreased the number of BC6OTHER - induced writhing responses and BC6ENTC - induced pain in the late phase in mice.	False
It increased both renal reduced BC6ENTC ( BC6OTHER ) content and BC6ENTG gene expression.	False
It increased both renal reduced BC6OTHER ( BC6ENTC ) content and BC6ENTG gene expression.	False
In conclusion , these results suggested that BC6ENTC protected against BC6OTHER - induced nephrotoxicity through its interaction with BC6ENTG receptors and antioxidant effects.	False
In conclusion , these results suggested that BC6OTHER protected against BC6ENTC - induced nephrotoxicity through its interaction with BC6ENTG receptors and antioxidant effects.	False
BC6ENTC , BC6OTHER , BC6OTHER , IP injected ( BC6ENTG ( BC6OTHER ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6ENTC , BC6OTHER , BC6OTHER , IP injected ( BC6OTHER ( BC6ENTG ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6OTHER , BC6ENTC , BC6OTHER , IP injected ( BC6ENTG ( BC6OTHER ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6OTHER , BC6ENTC , BC6OTHER , IP injected ( BC6OTHER ( BC6ENTG ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6OTHER , BC6OTHER , BC6ENTC , IP injected ( BC6ENTG ( BC6OTHER ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6OTHER , BC6OTHER , BC6ENTC , IP injected ( BC6OTHER ( BC6ENTG ) antagonist) , or their combination were administered to rats one hour before BC6OTHER injection.	False
BC6OTHER , BC6OTHER , BC6OTHER , IP injected ( BC6ENTG ( BC6OTHER ) antagonist) , or their combination were administered to rats one hour before BC6ENTC injection.	False
BC6OTHER , BC6OTHER , BC6OTHER , IP injected ( BC6OTHER ( BC6ENTG ) antagonist) , or their combination were administered to rats one hour before BC6ENTC injection.	False
The obtained results showed that BC6ENTC improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	CPR:3
The obtained results showed that BC6ENTC improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	CPR:3
The obtained results showed that BC6ENTC improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) genes expression in BC6OTHER injected rats.	CPR:3
The obtained results showed that BC6ENTC improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) genes expression in BC6OTHER injected rats.	CPR:3
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6ENTC ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6ENTC ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6ENTC ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6ENTC ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) genes expression in BC6OTHER injected rats.	False
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) genes expression in BC6ENTC injected rats.	CPR:4
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) , BC6OTHER ( BC6OTHER ) genes expression in BC6ENTC injected rats.	CPR:4
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6ENTG ( BC6OTHER ) genes expression in BC6ENTC injected rats.	CPR:4
The obtained results showed that BC6OTHER improved the renal function , structural changes , renal BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6OTHER ) , BC6OTHER ( BC6ENTG ) genes expression in BC6ENTC injected rats.	CPR:4
BC6ENTC reductases ( BC6ENTG ) metabolize a wide range of substrates , including BC6OTHER ( BC6OTHER ) , generating metabolites ( BC6OTHER ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	False
In the smoker group , there is a statistically significant positive association between BC6ENTG , BC6OTHER , and BC6OTHER mRNA induction and urine BC6ENTC levels in individuals with a body mass index (BMI) less than 25.	False
In the smoker group , there is a statistically significant positive association between BC6OTHER , BC6ENTG , and BC6OTHER mRNA induction and urine BC6ENTC levels in individuals with a body mass index (BMI) less than 25.	False
In the smoker group , there is a statistically significant positive association between BC6OTHER , BC6OTHER , and BC6ENTG mRNA induction and urine BC6ENTC levels in individuals with a body mass index (BMI) less than 25.	False
BC6ENTG ( BC6OTHER ) metabolize a wide range of substrates , including BC6OTHER ( BC6ENTC ) , generating metabolites ( BC6OTHER ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
BC6OTHER ( BC6ENTG ) metabolize a wide range of substrates , including BC6OTHER ( BC6ENTC ) , generating metabolites ( BC6OTHER ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
These results suggest that BC6ENTG induction by BC6ENTC in smokers' PBLs is associated with BMI; therefore , the role of adipose tissue accumulation in BC6OTHER ' effects needs further investigation.	False
These results suggest that BC6ENTG induction by BC6OTHER in smokers' PBLs is associated with BMI; therefore , the role of adipose tissue accumulation in BC6ENTC ' effects needs further investigation.	False
BC6ENTG ( BC6OTHER ) metabolize a wide range of substrates , including BC6OTHER ( BC6OTHER ) , generating metabolites ( BC6ENTC ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
BC6OTHER ( BC6ENTG ) metabolize a wide range of substrates , including BC6OTHER ( BC6OTHER ) , generating metabolites ( BC6ENTC ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
BC6ENTG ( BC6OTHER ) metabolize a wide range of substrates , including BC6OTHER ( BC6OTHER ) , generating metabolites ( BC6OTHER ) and reactive BC6ENTC species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
BC6OTHER ( BC6ENTG ) metabolize a wide range of substrates , including BC6OTHER ( BC6OTHER ) , generating metabolites ( BC6OTHER ) and reactive BC6ENTC species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
Exposure to BC6ENTC , their metabolites , and ROS further increase BC6ENTG isoform expression that may amplify oxidative damage.	CPR:3
Despite the importance of BC6ENTG in BC6ENTC metabolism , there are no studies that evaluate , in general human populations , the effect of BC6OTHER on BC6OTHER expression in peripheral blood lymphocytes (PBLs).	CPR:9
Despite the importance of BC6OTHER in BC6ENTC metabolism , there are no studies that evaluate , in general human populations , the effect of BC6OTHER on BC6ENTG expression in peripheral blood lymphocytes (PBLs).	False
Despite the importance of BC6ENTG in BC6OTHER metabolism , there are no studies that evaluate , in general human populations , the effect of BC6ENTC on BC6OTHER expression in peripheral blood lymphocytes (PBLs).	False
Despite the importance of BC6OTHER in BC6OTHER metabolism , there are no studies that evaluate , in general human populations , the effect of BC6ENTC on BC6ENTG expression in peripheral blood lymphocytes (PBLs).	False
BC6ENTG ( BC6OTHER ) metabolize a wide range of substrates , including BC6ENTC ( BC6OTHER ) , generating metabolites ( BC6OTHER ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
BC6OTHER ( BC6ENTG ) metabolize a wide range of substrates , including BC6ENTC ( BC6OTHER ) , generating metabolites ( BC6OTHER ) and reactive BC6OTHER species (ROS) , which are capable of initiating and promoting carcinogenesis.	CPR:9
There was also an increase in BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	False
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and mutant BC6OTHER protein expression in the BC6ENTC - treated cells.	CPR:3
There was also an increase in BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and mutant BC6ENTG protein expression in the BC6ENTC - treated cells.	CPR:3
BC6ENTC is a BC6ENTG inhibitor that induces the hydrolysis of body BC6OTHER , including BC6OTHER at cholinergic synapses.	CPR:4
BC6OTHER is a BC6ENTG inhibitor that induces the hydrolysis of body BC6ENTC , including BC6OTHER at cholinergic synapses.	False
BC6OTHER is a BC6ENTG inhibitor that induces the hydrolysis of body BC6OTHER , including BC6ENTC at cholinergic synapses.	False
On the other hand , in patients with a mean serum BC6ENTC level (Cmin) of less than 2.5 nmol / l up to 2 weeks after the start of BC6OTHER therapy , the degree of reduction in the BC6ENTG value after the 3rd month was significantly larger , relative to the patient group with Cmin over 2.5 nmol / l.	CPR:4
On the other hand , in patients with a mean serum BC6OTHER level (Cmin) of less than 2.5 nmol / l up to 2 weeks after the start of BC6ENTC therapy , the degree of reduction in the BC6ENTG value after the 3rd month was significantly larger , relative to the patient group with Cmin over 2.5 nmol / l.	CPR:4
OBJECTIVE: To examine the influence of BC6ENTC dose and concentration in serum on plasma BC6OTHER ( BC6ENTG ) , a measure of heart failure progression.	False
OBJECTIVE: To examine the influence of BC6ENTC dose and concentration in serum on plasma BC6ENTG ( BC6OTHER ) , a measure of heart failure progression.	False
The degree of improvement in heart failure was assessed from the ratio of change in the plasma BC6ENTG concentration , 2 weeks , 1 month and 3 months after the commencement of BC6ENTC administration.	False
Serum BC6ENTC concentration and its relation to change in plasma BC6ENTG level in the treatment of heart failure: a preliminary study.	False
BC6ENTC treatment prevents the formation of activated BC6ENTG , a known effector of apoptosis , as well as the appearance of a BC6OTHER cleaved substrate , a marker of excitotoxic / necrotic cell death.	CPR:4
BC6ENTC treatment prevents the formation of activated BC6OTHER , a known effector of apoptosis , as well as the appearance of a BC6ENTG cleaved substrate , a marker of excitotoxic / necrotic cell death.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6ENTG , fasting blood BC6ENTC , 2 - h oral BC6OTHER tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6ENTC , 2 - h oral BC6OTHER tolerance test , BC6ENTG sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6ENTC , 2 - h oral BC6OTHER tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6ENTG , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6ENTG , fasting blood BC6OTHER , 2 - h oral BC6ENTC tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6OTHER , 2 - h oral BC6ENTC tolerance test , BC6ENTG sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6OTHER , 2 - h oral BC6ENTC tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6ENTG , fasting blood CHEM and 2 - h oral BC6OTHER tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6ENTG , fasting blood BC6OTHER , 2 - h oral BC6OTHER tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6ENTC tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6OTHER , 2 - h oral BC6OTHER tolerance test , BC6ENTG sensitivity and screen - positive diabetes according to BC6OTHER , fasting blood CHEM and 2 - h oral BC6ENTC tolerance test were assessed.	False
METHODS: Using data from adult participants of the National Health and Nutrition Examination Survey (NHANES , 2005 - 2010) , the association of antidepressant use with continuous measures of BC6OTHER , fasting blood BC6OTHER , 2 - h oral BC6OTHER tolerance test , BC6OTHER sensitivity and screen - positive diabetes according to BC6ENTG , fasting blood CHEM and 2 - h oral BC6ENTC tolerance test were assessed.	False
RESULTS: Antidepressant use was not associated with increased levels of BC6ENTG , fasting blood BC6ENTC , 2 - h oral BC6OTHER tolerance test , reduced BC6OTHER sensitivity or increased prevalence of screen - positive diabetes.	False
RESULTS: Antidepressant use was not associated with increased levels of BC6OTHER , fasting blood BC6ENTC , 2 - h oral BC6OTHER tolerance test , reduced BC6ENTG sensitivity or increased prevalence of screen - positive diabetes.	False
RESULTS: Antidepressant use was not associated with increased levels of BC6ENTG , fasting blood BC6OTHER , 2 - h oral BC6ENTC tolerance test , reduced BC6OTHER sensitivity or increased prevalence of screen - positive diabetes.	False
RESULTS: Antidepressant use was not associated with increased levels of BC6OTHER , fasting blood BC6OTHER , 2 - h oral BC6ENTC tolerance test , reduced BC6ENTG sensitivity or increased prevalence of screen - positive diabetes.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6ENTC and BC6ENTG antagonist , alone and in combination , in order to manipulate brain BC6OTHER functioning and to assess their behavioral response to an intruder.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6ENTC and BC6OTHER antagonist , alone and in combination , in order to manipulate brain BC6ENTG functioning and to assess their behavioral response to an intruder.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6ENTG and BC6ENTC receptor antagonist , alone and in combination , in order to manipulate brain BC6OTHER functioning and to assess their behavioral response to an intruder.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6OTHER and BC6ENTC receptor antagonist , alone and in combination , in order to manipulate brain BC6ENTG functioning and to assess their behavioral response to an intruder.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6ENTG and BC6OTHER antagonist , alone and in combination , in order to manipulate brain BC6ENTC functioning and to assess their behavioral response to an intruder.	False
METHODS: Resident animals were intracerebroventricularly (icv) administered with different doses of synthetic BC6OTHER and BC6ENTG antagonist , alone and in combination , in order to manipulate brain BC6ENTC functioning and to assess their behavioral response to an intruder.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6ENTG ) , BC6ENTC - PLB , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC - PLB , and BC6ENTG are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6ENTG ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC - PLB , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6ENTG ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTC - PLB , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6ENTC - PLB , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6ENTG ( BC6OTHER ) , BC6ENTC - PLB , and BC6OTHER are important for contraction and relaxation.	False
BC6ENTG expression was increased in all BC6ENTC males and BC6OTHER 0.5 females and reduced in BC6OTHER 200 females.	CPR:3
BC6ENTG expression was increased in all BC6OTHER males and BC6ENTC 0.5 females and reduced in BC6OTHER 200 females.	CPR:3
BC6ENTG expression was increased in all BC6OTHER males and BC6OTHER 0.5 females and reduced in BC6ENTC 200 females.	CPR:4
BC6ENTC induced sex - specific altered DNA methylation in specific BC6OTHER pairs in the BC6ENTG CpG island.	False
BC6OTHER induced sex - specific altered DNA methylation in specific BC6ENTC pairs in the BC6ENTG CpG island.	False
The BC6ENTC homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6ENTG ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6OTHER ( BC6ENTG ) , CHEM BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTG , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6ENTC homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6OTHER exchanger - 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	CPR:9
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTC BC6OTHER exchanger - 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTC BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTC BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6ENTG ( BC6OTHER ) , BC6ENTC BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6ENTG ) , BC6ENTC BC6OTHER exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , BC6ENTC BC6OTHER exchanger - 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6ENTC exchanger - 1 , BC6OTHER ( BC6ENTG ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6ENTC exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6ENTG , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6ENTC exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6ENTG are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6ENTG ( BC6OTHER ) , CHEM BC6ENTC exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6ENTG ) , CHEM BC6ENTC exchanger - 1 , BC6OTHER ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
The BC6OTHER homeostasis proteins BC6OTHER ( BC6OTHER ) , CHEM BC6ENTC exchanger - 1 , BC6ENTG ( BC6OTHER ) , BC6OTHER , and BC6OTHER are important for contraction and relaxation.	False
Increasing the cellular concentration of BC6OTHER in yeast by expressing constitutively a plasmid - borne BC6ENTG gene encoding the enzyme greatly increases the sensitivity of the cells to BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Increasing the cellular concentration of BC6ENTG in yeast by expressing constitutively a plasmid - borne BC6OTHER gene encoding the enzyme greatly increases the sensitivity of the cells to BC6ENTC and BC6OTHER ( BC6OTHER ).	False
Increasing the cellular concentration of BC6OTHER in yeast by expressing constitutively a plasmid - borne BC6ENTG gene encoding the enzyme greatly increases the sensitivity of the cells to BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Increasing the cellular concentration of BC6ENTG in yeast by expressing constitutively a plasmid - borne BC6OTHER gene encoding the enzyme greatly increases the sensitivity of the cells to BC6OTHER and BC6ENTC ( BC6OTHER ).	False
Increasing the cellular concentration of BC6OTHER in yeast by expressing constitutively a plasmid - borne BC6ENTG gene encoding the enzyme greatly increases the sensitivity of the cells to BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Increasing the cellular concentration of BC6ENTG in yeast by expressing constitutively a plasmid - borne BC6OTHER gene encoding the enzyme greatly increases the sensitivity of the cells to BC6OTHER and BC6OTHER ( BC6ENTC ).	False
 BC6ENTC and BC6OTHER hypersensitivity of yeast cells overexpressing BC6ENTG .	False
 BC6OTHER and BC6ENTC hypersensitivity of yeast cells overexpressing BC6ENTG .	False
The treatment with BC6ENTC exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6OTHER , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	CPR:3
The treatment with BC6ENTC exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	CPR:3
The treatment with BC6ENTC exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	CPR:3
The treatment with BC6ENTC exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	CPR:3
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTC aminotransferase , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTC aminotransferase , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTC aminotransferase , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6ENTC aminotransferase , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTC aminotransferase , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTC aminotransferase , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6OTHER , BC6OTHER , total protein , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6OTHER , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6OTHER , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6ENTG , BC6OTHER , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6ENTG , BC6OTHER , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6ENTG , total protein , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ).	False
The treatment with BC6OTHER exhibited a significant increase in some serum hepatic and renal biochemical parameters ( BC6OTHER , BC6OTHER , BC6OTHER , total protein , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ).	False
In contrast to parenteral delivery of BC6OTHER , which currently requires posttranslational modification for good plasma stability , an unmodified aer - BC6ENTG pretreatment given 1 - 40h prior to >1 LD50 of aer - BC6ENTC (Px) was able to prevent inhibition of circulating BC6OTHER in a dose - dependent manner.	False
In contrast to parenteral delivery of BC6OTHER , which currently requires posttranslational modification for good plasma stability , an unmodified aer - BC6OTHER pretreatment given 1 - 40h prior to >1 LD50 of aer - BC6ENTC (Px) was able to prevent inhibition of circulating BC6ENTG in a dose - dependent manner.	CPR:3
In contrast to parenteral delivery of BC6ENTG , which currently requires posttranslational modification for good plasma stability , an unmodified aer - BC6OTHER pretreatment given 1 - 40h prior to >1 LD50 of aer - BC6ENTC (Px) was able to prevent inhibition of circulating BC6OTHER in a dose - dependent manner.	False
These studies are the first to show protection by BC6ENTG against a pesticide such as BC6ENTC when delivered directly into the lung and bode well for the use of a non - invasive and consumer friendly method of BC6OTHER delivery as a human treatment to counteract OP toxicity.	False
These studies are the first to show protection by BC6OTHER against a pesticide such as BC6ENTC when delivered directly into the lung and bode well for the use of a non - invasive and consumer friendly method of BC6ENTG delivery as a human treatment to counteract OP toxicity.	False
BC6ENTG ( BC6OTHER ) is the leading pretreatment candidate against exposure to BC6ENTC (OPs) , which pose an ever increasing public and military health.	False
BC6OTHER ( BC6ENTG ) is the leading pretreatment candidate against exposure to BC6ENTC (OPs) , which pose an ever increasing public and military health.	False
Pulmonary delivery of an aerosolized recombinant BC6ENTG pretreatment protects against aerosolized BC6ENTC in macaques.	False
In this article , the action of BC6ENTC ( BC6OTHER ) is contrasted with that of BC6OTHER , a BC6ENTG inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.	CPR:4
In this article , the action of BC6OTHER ( BC6ENTC ) is contrasted with that of BC6OTHER , a BC6ENTG inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.	CPR:4
In this article , the action of BC6OTHER ( BC6OTHER ) is contrasted with that of BC6ENTC , a BC6ENTG inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.	CPR:4
Both pharmacologic inhibitors target several BC6ENTC kinases , including BC6ENTG - BC6OTHER and the BC6OTHER ( BC6OTHER ).	False
Both pharmacologic inhibitors target several BC6ENTC kinases , including BC6OTHER - BC6ENTG and the BC6OTHER ( BC6OTHER ).	False
Both pharmacologic inhibitors target several BC6ENTC kinases , including BC6OTHER - BC6OTHER and the BC6ENTG ( BC6OTHER ).	False
Both pharmacologic inhibitors target several BC6ENTC kinases , including BC6OTHER - BC6OTHER and the BC6OTHER ( BC6ENTG ).	False
The work of Chen and colleagues shows that BC6ENTC is a particularly potent inhibitor of BC6ENTG and that the compound also targets BC6OTHER .	CPR:4
The work of Chen and colleagues shows that BC6ENTC is a particularly potent inhibitor of BC6OTHER and that the compound also targets BC6ENTG .	CPR:4
Importantly , the oral dose of these stimulants , which produce BC6ENTC - type subjective effects in humans , correlated with the their potency in releasing BC6OTHER , not BC6OTHER , and did not decrease plasma BC6ENTG , an effect mediated by BC6OTHER release.	False
Importantly , the oral dose of these stimulants , which produce BC6OTHER - type subjective effects in humans , correlated with the their potency in releasing BC6ENTC , not BC6OTHER , and did not decrease plasma BC6ENTG , an effect mediated by BC6OTHER release.	False
Importantly , the oral dose of these stimulants , which produce BC6OTHER - type subjective effects in humans , correlated with the their potency in releasing BC6OTHER , not BC6ENTC , and did not decrease plasma BC6ENTG , an effect mediated by BC6OTHER release.	False
Importantly , the oral dose of these stimulants , which produce BC6OTHER - type subjective effects in humans , correlated with the their potency in releasing BC6OTHER , not BC6OTHER , and did not decrease plasma BC6ENTG , an effect mediated by BC6ENTC release.	False
This effect requires cold - induced , BC6ENTG - mediated BC6ENTC influx and a BC6OTHER - sensitive BC6OTHER that signals to the transcription factor BC6OTHER / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6ENTC influx and a BC6OTHER - sensitive BC6ENTG that signals to the transcription factor BC6OTHER / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6ENTC influx and a BC6OTHER - sensitive BC6OTHER that signals to the transcription factor BC6ENTG / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6ENTC influx and a BC6OTHER - sensitive BC6OTHER that signals to the transcription factor BC6OTHER / BC6ENTG .	False
This effect requires cold - induced , BC6ENTG - mediated BC6OTHER influx and a BC6ENTC - sensitive BC6OTHER that signals to the transcription factor BC6OTHER / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6OTHER influx and a BC6ENTC - sensitive BC6ENTG that signals to the transcription factor BC6OTHER / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6OTHER influx and a BC6ENTC - sensitive BC6OTHER that signals to the transcription factor BC6ENTG / BC6OTHER .	False
This effect requires cold - induced , BC6OTHER - mediated BC6OTHER influx and a BC6ENTC - sensitive BC6OTHER that signals to the transcription factor BC6OTHER / BC6ENTG .	False
Our results reveal a previously unrecognized function for BC6ENTG , link BC6ENTC signaling to longevity , and , importantly , demonstrate that genetic programs contribute to lifespan extension at cold temperatures.	False
Overall , higher BC6ENTC production was reduced by BC6OTHER supplementation , and this can be correlated with a general downregulation of genes encoding BC6ENTG and BC6OTHER of the BC6OTHER .	False
Overall , higher BC6ENTC production was reduced by BC6OTHER supplementation , and this can be correlated with a general downregulation of genes encoding BC6OTHER and BC6ENTG of the BC6OTHER .	False
Overall , higher BC6ENTC production was reduced by BC6OTHER supplementation , and this can be correlated with a general downregulation of genes encoding BC6OTHER and BC6OTHER of the BC6ENTG .	False
Overall , higher BC6OTHER production was reduced by BC6ENTC supplementation , and this can be correlated with a general downregulation of genes encoding BC6ENTG and BC6OTHER of the BC6OTHER .	CPR:4
Overall , higher BC6OTHER production was reduced by BC6ENTC supplementation , and this can be correlated with a general downregulation of genes encoding BC6OTHER and BC6ENTG of the BC6OTHER .	CPR:4
Overall , higher BC6OTHER production was reduced by BC6ENTC supplementation , and this can be correlated with a general downregulation of genes encoding BC6OTHER and BC6OTHER of the BC6ENTG .	False
The BC6ENTC could be correlated with expression of BC6ENTG and the BC6OTHER .	False
The BC6ENTC could be correlated with expression of CHEM BC6OTHER - transferase EEB1 and the BC6ENTG .	False
The BC6OTHER could be correlated with expression of BC6ENTC BC6OTHER - transferase EEB1 and the BC6ENTG .	False
The BC6OTHER could be correlated with expression of CHEM BC6ENTC - transferase EEB1 and the BC6ENTG .	False
The BC6OTHER could be correlated with expression of BC6ENTG and the BC6ENTC esterase IAH1.	False
BC6ENTC ( BC6OTHER (®)) is a new subcutaneous BC6OTHER analogue that acts via BC6OTHER to inhibit the secretion of BC6ENTG from the pituitary adenoma in patients with Cushing's disease.	CPR:4
BC6ENTC ( BC6OTHER (®)) is a new subcutaneous BC6ENTG analogue that acts via BC6OTHER to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
BC6ENTC ( BC6OTHER (®)) is a new subcutaneous BC6OTHER analogue that acts via BC6ENTG to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
BC6ENTC has a generally similar tolerability profile to that of other BC6ENTG analogues , but is associated with a relatively high incidence of hyperglycaemia , requiring the addition or intensification of BC6OTHER - lowering medication in a substantial proportion of patients.	False
BC6OTHER ( BC6ENTC (®)) is a new subcutaneous BC6OTHER analogue that acts via BC6OTHER to inhibit the secretion of BC6ENTG from the pituitary adenoma in patients with Cushing's disease.	CPR:4
BC6OTHER ( BC6ENTC (®)) is a new subcutaneous BC6ENTG analogue that acts via BC6OTHER to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
BC6OTHER ( BC6ENTC (®)) is a new subcutaneous BC6OTHER analogue that acts via BC6ENTG to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
BC6OTHER has a generally similar tolerability profile to that of other BC6ENTG analogues , but is associated with a relatively high incidence of hyperglycaemia , requiring the addition or intensification of BC6ENTC - lowering medication in a substantial proportion of patients.	False
BC6ENTC has a receptor binding profile that is distinct from that of other BC6ENTG analogues , binding with high affinity to BC6OTHER , which is strongly over expressed in corticotroph adenoma cells.	False
BC6ENTC has a receptor binding profile that is distinct from that of other BC6OTHER analogues , binding with high affinity to BC6ENTG , which is strongly over expressed in corticotroph adenoma cells.	False
BC6OTHER has a receptor binding profile that is distinct from that of other BC6ENTC analogues , binding with high affinity to BC6ENTG , which is strongly over expressed in corticotroph adenoma cells.	False
BC6OTHER has a receptor binding profile that is distinct from that of other BC6ENTG analogues , binding with high affinity to BC6ENTC receptor subtype 5 , which is strongly over expressed in corticotroph adenoma cells.	False
BC6OTHER ( BC6OTHER (®)) is a new subcutaneous BC6ENTC analogue that acts via BC6OTHER to inhibit the secretion of BC6ENTG from the pituitary adenoma in patients with Cushing's disease.	False
BC6OTHER ( BC6OTHER (®)) is a new subcutaneous BC6ENTC analogue that acts via BC6ENTG to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
BC6OTHER ( BC6OTHER (®)) is a new subcutaneous BC6OTHER analogue that acts via BC6ENTC receptors to inhibit the secretion of BC6ENTG from the pituitary adenoma in patients with Cushing's disease.	False
BC6OTHER ( BC6OTHER (®)) is a new subcutaneous BC6ENTG analogue that acts via BC6ENTC receptors to inhibit the secretion of BC6OTHER from the pituitary adenoma in patients with Cushing's disease.	False
Despite more than a decade of research in the field of endocrine active compounds targeting the BC6OTHER ( BC6ENTG ) , and although suitable cell lines can be obtained , no validated human stably transfected BC6ENTC sensitive transactivation assay is available.	False
Despite more than a decade of research in the field of endocrine active compounds targeting the BC6ENTG ( BC6OTHER ) , and although suitable cell lines can be obtained , no validated human stably transfected BC6ENTC sensitive transactivation assay is available.	False
A few compounds , BC6ENTC ( BC6OTHER ) , BC6OTHER and BC6OTHER , were studied using a real world scenario , i.e. , assuming that their interaction with the BC6ENTG was not known: A prescreening for agonism and true , competitive antagonism was used to select conditions such as the appropriate mode of action , and the working range excluding cytotoxicity for the final screening.	False
Despite more than a decade of research in the field of endocrine active compounds targeting the BC6ENTC receptor ( BC6ENTG ) , and although suitable cell lines can be obtained , no validated human stably transfected BC6OTHER sensitive transactivation assay is available.	False
A few compounds , BC6OTHER ( BC6ENTC ) , BC6OTHER and BC6OTHER , were studied using a real world scenario , i.e. , assuming that their interaction with the BC6ENTG was not known: A prescreening for agonism and true , competitive antagonism was used to select conditions such as the appropriate mode of action , and the working range excluding cytotoxicity for the final screening.	False
A few compounds , BC6OTHER ( BC6OTHER ) , BC6ENTC and BC6OTHER , were studied using a real world scenario , i.e. , assuming that their interaction with the BC6ENTG was not known: A prescreening for agonism and true , competitive antagonism was used to select conditions such as the appropriate mode of action , and the working range excluding cytotoxicity for the final screening.	False
A few compounds , BC6OTHER ( BC6OTHER ) , BC6OTHER and BC6ENTC , were studied using a real world scenario , i.e. , assuming that their interaction with the BC6ENTG was not known: A prescreening for agonism and true , competitive antagonism was used to select conditions such as the appropriate mode of action , and the working range excluding cytotoxicity for the final screening.	False
Transcription factors , such as the BC6ENTG ( BC6OTHER ) , regulate both BC6ENTC and BC6OTHER metabolism in several tissues including the nervous system.	False
Transcription factors , such as the BC6OTHER ( BC6ENTG ) , regulate both BC6ENTC and BC6OTHER metabolism in several tissues including the nervous system.	False
Transcription factors , such as the BC6ENTG ( BC6OTHER ) , regulate both BC6OTHER and BC6ENTC metabolism in several tissues including the nervous system.	False
Transcription factors , such as the BC6OTHER ( BC6ENTG ) , regulate both BC6OTHER and BC6ENTC metabolism in several tissues including the nervous system.	False
Mass spectroscopy has revealed that ubiquitination of BC6ENTG consists of polyubiquitin chains , primarily through BC6ENTC 48 linkage.	False
Transfection of cells with the dominant negative mutant of ubiquitin Ub - K48R , which prevents the formation of BC6ENTC 48 - linked polyubiquitin chains , abolishes BC6ENTG - stimulated BC6OTHER ubiquitination and internalization.	False
Transfection of cells with the dominant negative mutant of ubiquitin Ub - K48R , which prevents the formation of BC6ENTC 48 - linked polyubiquitin chains , abolishes BC6OTHER - stimulated BC6ENTG ubiquitination and internalization.	False
Together , our findings demonstrate for the first time that BC6ENTC 48 - linked polyubiquitination is essential for BC6ENTG - regulated BC6OTHER trafficking.	False
Together , our findings demonstrate for the first time that BC6ENTC 48 - linked polyubiquitination is essential for BC6OTHER - regulated BC6ENTG trafficking.	False
 BC6ENTC 48 - linked polyubiquitination of BC6ENTG is essential for its BC6OTHER - regulated endocytosis.	False
 BC6ENTC 48 - linked polyubiquitination of BC6OTHER is essential for its BC6ENTG - regulated endocytosis.	False
Cosinor analysis indicated no diurnal rhythm of BC6ENTG expression in the livers of diabetic BC6ENTC or Iddm rats or in those of BC6OTHER - substituted Iddm rats.	False
Cosinor analysis indicated no diurnal rhythm of BC6OTHER expression in the livers of diabetic BC6ENTC or Iddm rats or in those of BC6ENTG - substituted Iddm rats.	False
We investigated the diurnal expression of BC6ENTG genes and BC6OTHER ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6ENTC ( BC6OTHER ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6ENTG ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6ENTC ( BC6OTHER ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6OTHER ( BC6ENTG ) in 3 - hour intervals for a 24 - h period in the livers of male BC6ENTC ( BC6OTHER ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6OTHER ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6ENTC ( BC6OTHER ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6ENTG .	False
We investigated the diurnal expression of BC6ENTG genes and BC6OTHER ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6OTHER ( BC6ENTC ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6ENTG ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6OTHER ( BC6ENTC ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6OTHER ( BC6ENTG ) in 3 - hour intervals for a 24 - h period in the livers of male BC6OTHER ( BC6ENTC ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6OTHER .	False
We investigated the diurnal expression of BC6OTHER genes and BC6OTHER ( BC6OTHER ) in 3 - hour intervals for a 24 - h period in the livers of male BC6OTHER ( BC6ENTC ) - treated rats , male spontaneous type 1 diabetic CHEM (Iddm) rats , and Iddm rats treated for 10 days with BC6ENTG .	False
Diabetic BC6ENTC and Iddm rats , as well as BC6ENTG - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6OTHER genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6OTHER , BC6OTHER , and BC6OTHER transcript expression was altered in Iddm and BC6OTHER - substituted Iddm rats.	False
Diabetic BC6ENTC and Iddm rats , as well as BC6OTHER - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6ENTG genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6OTHER , BC6OTHER , and BC6OTHER transcript expression was altered in Iddm and BC6OTHER - substituted Iddm rats.	False
Diabetic BC6ENTC and Iddm rats , as well as BC6OTHER - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6OTHER genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6ENTG , BC6OTHER , and BC6OTHER transcript expression was altered in Iddm and BC6OTHER - substituted Iddm rats.	False
Diabetic BC6ENTC and Iddm rats , as well as BC6OTHER - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6OTHER genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6OTHER , BC6ENTG , and BC6OTHER transcript expression was altered in Iddm and BC6OTHER - substituted Iddm rats.	False
Diabetic BC6ENTC and Iddm rats , as well as BC6OTHER - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6OTHER genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6OTHER , BC6OTHER , and BC6ENTG transcript expression was altered in Iddm and BC6OTHER - substituted Iddm rats.	False
Diabetic BC6ENTC and Iddm rats , as well as BC6OTHER - substituted Iddm rats , exhibited a significant diurnal expression pattern of BC6OTHER genes as determined by Cosinor analysis; however , the MESOR (midline estimating statistic of rhythm) of BC6OTHER , BC6OTHER , and BC6OTHER transcript expression was altered in Iddm and BC6ENTG - substituted Iddm rats.	False
 BC6ENTG Gene Expression in the Liver of BC6ENTC - induced and Spontaneous Type 1 Diabetic Rats.	False
In addition , BC6ENTG toxin , like diphtheria toxin itself , must pass through an acidic compartment in order to deliver its BC6ENTC BC6OTHER transferase activity to the cytosol of target T cells.	False
In addition , BC6ENTG toxin , like diphtheria toxin itself , must pass through an acidic compartment in order to deliver its CHEM BC6ENTC transferase activity to the cytosol of target T cells.	False
Hepatocellular carcinoma (HCC) is believed to be auxotrophic for BC6OTHER through the lack of expression of BC6ENTC synthetase ( BC6ENTG ).	False
This surprising correlation between the lack of BC6ENTG expression and sensitivity of BC6OTHER - positive HCC cells shows that BC6OTHER - deficient HCCs are sensitive to BC6OTHER - mediated BC6ENTC depletion.	False
This surprising correlation between the lack of BC6OTHER expression and sensitivity of BC6ENTG - positive HCC cells shows that BC6OTHER - deficient HCCs are sensitive to BC6OTHER - mediated BC6ENTC depletion.	False
This surprising correlation between the lack of BC6OTHER expression and sensitivity of BC6OTHER - positive HCC cells shows that BC6ENTG - deficient HCCs are sensitive to BC6OTHER - mediated BC6ENTC depletion.	False
This surprising correlation between the lack of BC6OTHER expression and sensitivity of BC6OTHER - positive HCC cells shows that BC6OTHER - deficient HCCs are sensitive to BC6ENTG - mediated BC6ENTC depletion.	CPR:9
Therefore , pretreatment tumor gene expression profiling of BC6ENTG and BC6OTHER could aid in predicting tumor response to BC6ENTC depletion with BC6OTHER .	False
Therefore , pretreatment tumor gene expression profiling of BC6OTHER and BC6ENTG could aid in predicting tumor response to BC6ENTC depletion with BC6OTHER .	False
Therefore , pretreatment tumor gene expression profiling of BC6OTHER and BC6OTHER could aid in predicting tumor response to BC6ENTC depletion with BC6ENTG .	CPR:9
Therefore , pretreatment tumor gene expression profiling of BC6ENTG and BC6OTHER could aid in predicting tumor response to BC6OTHER depletion with BC6ENTC - depleting enzymes.	False
Therefore , pretreatment tumor gene expression profiling of BC6OTHER and BC6ENTG could aid in predicting tumor response to BC6OTHER depletion with BC6ENTC - depleting enzymes.	False
The successful use of the BC6ENTC - depleting enzyme BC6ENTG ( BC6OTHER ) to treat BC6OTHER - deficient tumors has opened up new possibilities for effective cancer therapy.	False
The successful use of the BC6ENTC - depleting enzyme BC6OTHER ( BC6ENTG ) to treat BC6OTHER - deficient tumors has opened up new possibilities for effective cancer therapy.	False
The successful use of the BC6ENTC - depleting enzyme BC6OTHER ( BC6OTHER ) to treat BC6ENTG - deficient tumors has opened up new possibilities for effective cancer therapy.	False
Furthermore , the growth of the BC6ENTG - deficient Hep3B tumor cells ( BC6OTHER - positive and BC6OTHER - resistant) in mice was inhibited by treatment with BC6OTHER - peg(5 , 000mw) , which is active alone and is synergistic in combination with BC6ENTC .	False
Furthermore , the growth of the BC6OTHER - deficient Hep3B tumor cells ( BC6ENTG - positive and BC6OTHER - resistant) in mice was inhibited by treatment with BC6OTHER - peg(5 , 000mw) , which is active alone and is synergistic in combination with BC6ENTC .	False
Furthermore , the growth of the BC6OTHER - deficient Hep3B tumor cells ( BC6OTHER - positive and BC6ENTG - resistant) in mice was inhibited by treatment with BC6OTHER - peg(5 , 000mw) , which is active alone and is synergistic in combination with BC6ENTC .	False
Furthermore , the growth of the BC6OTHER - deficient Hep3B tumor cells ( BC6OTHER - positive and BC6OTHER - resistant) in mice was inhibited by treatment with BC6ENTG - peg(5 , 000mw) , which is active alone and is synergistic in combination with BC6ENTC .	False
The successful use of the BC6ENTG BC6ENTC deiminase ( BC6OTHER ) to treat BC6OTHER - deficient tumors has opened up new possibilities for effective cancer therapy.	False
The successful use of the BC6OTHER BC6ENTC deiminase ( BC6ENTG ) to treat BC6OTHER - deficient tumors has opened up new possibilities for effective cancer therapy.	False
The successful use of the BC6OTHER BC6ENTC deiminase ( BC6OTHER ) to treat BC6ENTG - deficient tumors has opened up new possibilities for effective cancer therapy.	False
Nevertheless , many BC6ENTG - positive HCC cell lines are found to be resistant to BC6OTHER treatment , although most require BC6ENTC for proliferation.	False
Nevertheless , many BC6OTHER - positive HCC cell lines are found to be resistant to BC6ENTG treatment , although most require BC6ENTC for proliferation.	False
Thus far , an BC6ENTC - depleting enzyme for killing BC6ENTG - positive tumors has not been reported.	False
Hepatocellular carcinoma (HCC) is believed to be auxotrophic for BC6ENTC through the lack of expression of BC6ENTG ( BC6OTHER ).	False
Hepatocellular carcinoma (HCC) is believed to be auxotrophic for BC6ENTC through the lack of expression of BC6OTHER ( BC6ENTG ).	False
They all expressed BC6ENTG , but not BC6ENTC transcarbamylase ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTC transcarbamylase ( BC6ENTG ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTC transcarbamylase ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6ENTG , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTC transcarbamylase ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6ENTG .	False
They all expressed BC6ENTG , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6ENTC , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTG ( BC6OTHER ) , the enzyme that converts BC6ENTC , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	CPR:9
They all expressed BC6OTHER , but not BC6OTHER ( BC6ENTG ) , the enzyme that converts BC6ENTC , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	CPR:9
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6ENTC , the product of degradation of BC6OTHER with BC6ENTG , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6ENTC , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6ENTG .	False
They all expressed BC6ENTG , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6ENTC with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTG ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6ENTC with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6ENTG ) , the enzyme that converts BC6OTHER , the product of degradation of BC6ENTC with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6ENTC with BC6ENTG , to BC6OTHER , which is converted back to BC6OTHER via BC6OTHER .	CPR:9
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6ENTC with BC6OTHER , to BC6OTHER , which is converted back to BC6OTHER via BC6ENTG .	False
They all expressed BC6ENTG , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6ENTC , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTG ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6ENTC , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6ENTG ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6ENTC , which is converted back to BC6OTHER via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6ENTG , to BC6ENTC , which is converted back to BC6OTHER via BC6OTHER .	CPR:9
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6ENTC , which is converted back to BC6OTHER via BC6ENTG .	False
They all expressed BC6ENTG , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6ENTC via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6ENTG ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6ENTC via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6ENTG ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6ENTC via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6ENTG , to BC6OTHER , which is converted back to BC6ENTC via BC6OTHER .	False
They all expressed BC6OTHER , but not BC6OTHER ( BC6OTHER ) , the enzyme that converts BC6OTHER , the product of degradation of BC6OTHER with BC6OTHER , to BC6OTHER , which is converted back to BC6ENTC via BC6ENTG .	CPR:9
 BC6ENTG ( BC6OTHER - peg5 , 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through BC6ENTC depletion.	False
 BC6OTHER ( BC6ENTG - peg5 , 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through BC6ENTC depletion.	False
